<SEC-DOCUMENT>0001493152-24-045971.txt : 20241114
<SEC-HEADER>0001493152-24-045971.hdr.sgml : 20241114
<ACCEPTANCE-DATETIME>20241114164029
ACCESSION NUMBER:		0001493152-24-045971
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241114
DATE AS OF CHANGE:		20241114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AIM ImmunoTech Inc.
		CENTRAL INDEX KEY:			0000946644
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				520845822
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-27072
		FILM NUMBER:		241463534

	BUSINESS ADDRESS:	
		STREET 1:		2117 SW HIGHWAY 484
		CITY:			OCALA
		STATE:			FL
		ZIP:			32801
		BUSINESS PHONE:		352-448-7797

	MAIL ADDRESS:	
		STREET 1:		2117 SW HIGHWAY 484
		CITY:			OCALA
		STATE:			FL
		ZIP:			32801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEMISPHERX BIOPHARMA INC
		DATE OF NAME CHANGE:	19950614
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:AIM="http://aimimmuno.com/20240930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_AIM_aimimmuno.com_20240930 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20240101_20240930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0000946644 -->
<!-- Field: Set; Name: xdx; ID: xdx_070_XDX_form10%2Dq.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_form10%2Dq.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000005" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000006" name="dei:EntityCentralIndexKey">0000946644</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-09-30" id="xdx2ixbrl0052" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2023-12-31" id="xdx2ixbrl0104" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-09-30" id="xdx2ixbrl0109" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0115" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0134" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0247" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:GainLossOnWarrantIssuance" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:GainLossOnWarrantIssuance" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:GainLossOnWarrantIssuance" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0255" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:GainFromSaleOfIncomeTaxOperatingLoss" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:GainFromSaleOfIncomeTaxOperatingLoss" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl0259" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCommittedShares" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCommittedShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCommittedShares" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCommittedShares" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCommittedShares" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCommittedShares" contextRef="From2024-01-012024-03-31" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValuePreferredSharesExpired" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValuePreferredSharesExpired" contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValuePreferredSharesExpired" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValuePreferredSharesExpired" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValuePreferredSharesExpired" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValuePreferredSharesExpired" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValuePreferredSharesExpired" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValuePreferredSharesExpired" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValuePreferredSharesExpired" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:StockIssuedDuringPeriodValuePreferredSharesExpired" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0522" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0528" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0546" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0555" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0556" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0570" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="xdx2ixbrl0575" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0576" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0577" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0578" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0585" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0594" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:GainFromSaleOfIncomeTaxOperatingLoss" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl0621" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0631" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0634" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl0639" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0652" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0688" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:ProceedsFromIssuanceOfEquityWarrants" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0691" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:ConversionOfSeriesBPreferred" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl0714" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:ConversionOfNotePayableInterestIntoShares" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl0718" unitRef="USD" xs:nil="true"/>
  <ix:nonNumeric contextRef="AsOf2024-09-30_srt_MinimumMember" id="xdx2ixbrl0753" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0851" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl0997" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl0999" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1001" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1003" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1005" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1007" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1009" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1013" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1015" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1023" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1031" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1039" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1052" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1054" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1056" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1058" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1062" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1064" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1072" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1080" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1092" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1094" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1096" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1098" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1100" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1102" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1104" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1108" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1110" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1118" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1126" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1134" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1147" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1149" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1151" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1153" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1157" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1159" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1167" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1175" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1187" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1189" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1191" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1193" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1195" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1197" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1199" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1203" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1205" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1213" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1221" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1229" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1237" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1239" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1241" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1243" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1247" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1249" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1257" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="xdx2ixbrl1265" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1273" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1275" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1277" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1279" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1281" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1283" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1285" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1289" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1291" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1299" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1307" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1315" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1323" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1325" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1327" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1329" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1333" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1335" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1343" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="xdx2ixbrl1351" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_ClassAWarrantMember" id="xdx2ixbrl1550" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_ClassAWarrantMember" id="xdx2ixbrl1554" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassAWarrantMember" id="xdx2ixbrl1558" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassAWarrantMember" id="xdx2ixbrl1564" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassAWarrantMember" id="xdx2ixbrl1566" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassAWarrantMember" id="xdx2ixbrl1568" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_ClassBWarrantMember" id="xdx2ixbrl1572" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_ClassBWarrantMember" id="xdx2ixbrl1576" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassBWarrantMember" id="xdx2ixbrl1580" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassBWarrantMember" id="xdx2ixbrl1586" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassBWarrantMember" id="xdx2ixbrl1588" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassBWarrantMember" id="xdx2ixbrl1590" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1608" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1610" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1616" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1618" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1624" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1626" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1632" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1634" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="AIM:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" contextRef="AsOf2024-09-30" id="xdx2ixbrl1707" unitRef="USD" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aim-20240930.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-162024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:NotePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">AIM:StreetervilleCapitalLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-16</xbrli:startDate>
        <xbrli:endDate>2024-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:NotePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">AIM:StreetervilleCapitalLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-09-122018-09-12_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-09-12</xbrli:startDate>
        <xbrli:endDate>2018-09-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-12_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-12_custom_RestatedTwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:RestatedTwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-03_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_OfficerMember_srt_MaximumMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_OfficerMember_srt_MaximumMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_OfficerMember_srt_MinimumMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_OfficerMember_srt_MaximumMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-09_custom_SeriesAJuniorParticipatingPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-10_custom_SeriesAJuniorParticipatingPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_RightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_RightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-072020-07-07_custom_DirectorsOfficersAndEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AIM:DirectorsOfficersAndEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-07</xbrli:startDate>
        <xbrli:endDate>2020-07-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_CommonStockMember62774140">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_CommonStockMember62774171">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-26</xbrli:startDate>
        <xbrli:endDate>2019-09-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:RepresentativeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-27_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-27_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-252019-09-25_custom_AllianceGlobalPartnersLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-25</xbrli:startDate>
        <xbrli:endDate>2019-09-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:RepresentativeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-302020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-30</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:RepresentativeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:RepresentativeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-192023-04-19_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EquityDistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-19</xbrli:startDate>
        <xbrli:endDate>2023-04-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EquityDistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EquityDistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EquityDistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-282024-03-28_us-gaap_CommonStockMember_custom_AtlasSciencesLlcMember_custom_PurchaseAndRegistrationRightsAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AtlasSciencesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAndRegistrationRightsAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-28</xbrli:startDate>
        <xbrli:endDate>2024-03-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AtlasSciencesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-282024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AtlasSciencesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-28</xbrli:startDate>
        <xbrli:endDate>2024-03-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember62774609">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AIM:AtlasSciencesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-04-30_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-04-30_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AtlasSciencesLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-032024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-03</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-032024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-03</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-032024-06-03_custom_SecuritiesPurchaseAgreementMember_custom_ClassBCommonWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBCommonWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-03</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-03_custom_SecuritiesPurchaseAgreementMember_custom_ClassBCommonWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBCommonWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-05-31_custom_PlacementAgentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">AIM:PlacementAgentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_MeasurementInputSharePriceMember_custom_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_MeasurementInputExercisePriceMember_custom_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassAWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_MeasurementInputSharePriceMember_custom_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_MeasurementInputExercisePriceMember_custom_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassBWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_ClinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ClinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_ManufacturingAndEngineeringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ManufacturingAndEngineeringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_QualityControlMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:QualityControlMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_RegulatoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:RegulatoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_ClinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ClinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_ManufacturingAndEngineeringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ManufacturingAndEngineeringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_QualityControlMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:QualityControlMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_RegulatoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:RegulatoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_ClinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ClinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_ManufacturingAndEngineeringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ManufacturingAndEngineeringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_QualityControlMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:QualityControlMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_RegulatoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:RegulatoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ClinicalStudiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ClinicalStudiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ManufacturingAndEngineeringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ManufacturingAndEngineeringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_QualityControlMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:QualityControlMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_RegulatoryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:RegulatoryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_AmarexClinicalResearchLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_AmarexClinicalResearchLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_AmarexClinicalResearchLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AdvancedPancreaticCancerStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AdvancedPancreaticCancerStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AdvancedPancreaticCancerStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AdvancedPancreaticCancerStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PostCOVIDStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PostCOVIDStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PostCOVIDStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PostCOVIDStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-12-31_custom_JubilantHollisterStierMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_JubilantHollisterStierMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AmpligenManufacturingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AmpligenManufacturingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AmpligenManufacturingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AmpligenManufacturingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:SterlingPharmaSolutionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:MasterServiceAgreementAndQualityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:SterlingPharmaSolutionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:MasterServiceAgreementAndQualityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:SterlingPharmaSolutionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:MasterServiceAgreementAndQualityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:SterlingPharmaSolutionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:MasterServiceAgreementAndQualityAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-04-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusUniversityMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JointClinicalStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusUniversityMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JointClinicalStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusUniversityMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JointClinicalStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusUniversityMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JointClinicalStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusUniversityMedicalCenterMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JointClinicalStudyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31_custom_AzenovaLLCMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-08-31_custom_AzenovaLLCMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-30_custom_AlcamiCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_AlcamiCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_AlcamiCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_AlcamiCorporationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiCorporationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-10-01_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-01_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassCCommonWarrantMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassCCommonWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassCCommonWarrantMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassCCommonWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassDCommonWarrantMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassDCommonWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassDCommonWarrantMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassDCommonWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-10-01_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>AIM:Integer</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_906_edei--DocumentType_c20240101__20240930_zeHu3S3zE6B9"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000014" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--DocumentQuarterlyReport_c20240101__20240930_zyNucQnjA9K8"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt:booleantrue" id="Fact000015" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
Quarterly Report Pursuant to Section 13 or 15(d)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
the Securities Exchange Act of 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_901_edei--DocumentTransitionReport_c20240101__20240930_zPXurAobeVv"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Quarterly Period Ended <span id="xdx_90F_edei--DocumentPeriodEndDate_c20240101__20240930_zqC0Jwz9En7a"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt:datemonthdayyearen" id="Fact000017" name="dei:DocumentPeriodEndDate">September 30, <span id="xdx_904_edei--DocumentFiscalYearFocus_c20240101__20240930_z0gHcScjZr0e"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000018" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: <span id="xdx_902_edei--EntityFileNumber_c20240101__20240930_zBBiLwHKU0t1"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000019" name="dei:EntityFileNumber">001-27072</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityRegistrantName_c20240101__20240930_znW1fDprgDqf"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000020" name="dei:EntityRegistrantName">AIM
IMMUNOTECH INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20240101__20240930_zfHCsy1FSx7b"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt-sec:stateprovnameen" id="Fact000021" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20240101__20240930_zZUta0mhIs88"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000022" name="dei:EntityTaxIdentificationNumber">52-0845822</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_906_edei--EntityAddressAddressLine1_c20240101__20240930_zKx6nHhvCWrh"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000023" name="dei:EntityAddressAddressLine1">2117
SW Highway 484</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressCityOrTown_c20240101__20240930_z2kVSLyaimbi"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000024" name="dei:EntityAddressCityOrTown">Ocala</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20240101__20240930_zgQHYSxgZTqc"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000025" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20240101__20240930_zhaokdM5dbdi"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000026" name="dei:EntityAddressPostalZipCode">34473</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_90C_edei--CityAreaCode_c20240101__20240930_zRyMoGaJIcuh"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000027" name="dei:CityAreaCode">(352)</ix:nonNumeric></span>
<span id="xdx_904_edei--LocalPhoneNumber_c20240101__20240930_ztyjTeBOLQzf"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000028" name="dei:LocalPhoneNumber">448-7797</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 27.8pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 43%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--Security12bTitle_c20240101__20240930_z8y2KTrOdiX3"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000029" name="dei:Security12bTitle">Common
    Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--TradingSymbol_c20240101__20240930_zg4Mifziz31j"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000030" name="dei:TradingSymbol">AIM</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SecurityExchangeName_c20240101__20240930_zLqG7aa0ti2j"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">NYSE
    American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#9746;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<span id="xdx_906_edei--EntityCurrentReportingStatus_c20240101__20240930_z7OGCE4CwLdi"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000032" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9744;   No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was
required to submit and post such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#9746; <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<span id="xdx_90C_edei--EntityInteractiveDataCurrent_c20240101__20240930_zz8ZGuHSgeva"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000033" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9744; No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; padding-right: 0.8pt; text-align: justify">&#9744;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     Large accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; padding-right: 0.8pt; text-align: justify">&#9744;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     Accelerated filer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&#9746;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    <span id="xdx_906_edei--EntityFilerCategory_c20240101__20240930_zRJiabEJbzk3"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt-sec:entityfilercategoryen" id="Fact000034" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span id="xdx_902_edei--EntitySmallBusiness_c20240101__20240930_zZOF9FIdMv4j"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt:booleantrue" id="Fact000035" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Smaller reporting company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span id="xdx_903_edei--EntityEmergingGrowthCompany_c20240101__20240930_zk98XFrOTnZe"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt:booleanfalse" id="Fact000036" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     Emerging growth company</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#9744; Yes
<span id="xdx_906_edei--EntityShellCompany_dbF_c20240101__20240930_zSxCgQosa7Ga"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt:booleanfalse" id="Fact000037" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span> No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityCommonStockSharesOutstanding_iI_c20241111_zgyl1qHy86f5"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-11-11" id="Fact000038" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,706,446</ix:nonFraction></span>
shares of common stock were outstanding, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and no shares
of series B preferred stock were outstanding as of November 11, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
I- FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1</b>: <b>Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AIM
IMMUNOTECH INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
thousands, except for share and per share amounts)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited
September 30, 2024 and Audited December 31, 2023)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_111_pn3n3_zWEwjoROypV5" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_495_20240930_zZEUwWtnBabh" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_490_20231231_zunHwNasKMT9" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td>&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zdbhsV2ecM4c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrentAbstract_i01B_zXop8nrcV4Rh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzBzE_zXwyMfWne4Oi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-09-30" id="Fact000046" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">915</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000047" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,439</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MarketableSecuritiesCurrent_i02I_maACzBzE_zcOLcq40hPY6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2024-09-30" id="Fact000049" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact000050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,631</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzBzE_zUr5bdailzs4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Funds receivable from New Jersey net operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0052">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="Fact000053" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,184</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzBzE_zBayyQEW2R3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-09-30" id="Fact000055" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">368</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">302</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsCurrent_i02TI_mtACzBzE_maAzaH9_zHDoLB3Wu4Bh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-09-30" id="Fact000058" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,570</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000059" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,556</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzaH9_zHmJiYn2XoG1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-09-30" id="Fact000061" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000062" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzaH9_zV7uG18QHXL3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Right of use asset, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-09-30" id="Fact000064" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">653</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_maAzaH9_ztfqxEy2PGnb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patent and trademark rights, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-09-30" id="Fact000067" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000068" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,313</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherAssetsNoncurrent_i01I_maAzaH9_zwEBmOzG79gk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-09-30" id="Fact000070" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,688</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_i01TI_mtAzaH9_zX0TCRLzLMU4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total assets</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-09-30" id="Fact000073" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,588</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,381</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zwE66XD3ANXh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesCurrentAbstract_i01B_zYTO69XolAEf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_i02I_maLCz0DT_zvRPvm62eXJc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-09-30" id="Fact000082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,264</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,443</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCz0DT_z8WKIAEzK6A5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,011</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,986</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCz0DT_zYjjDuCjEIH8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current portion of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-09-30" id="Fact000088" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">232</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NotesPayableCurrent_i02I_maLCz0DT_zHeY6iRwKMJh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current portion of note payable, net</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-09-30" id="Fact000091" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i02TI_mtLCz0DT_maLzdlm_zO4yENHgmtDf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,652</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zzHydCKx9zOe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Long-term liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLzdlm_z2nSDum9SF5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-09-30" id="Fact000100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">437</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">495</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LongTermNotesPayable_i02I_maLzdlm_zOmNHIvBKxC7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Note payable, net</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2024-09-30" id="Fact000103" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0104">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Liabilities_i02TI_mtLzdlm_maLASEz1HN_zjUDXdDCQ8Tl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-09-30" id="Fact000106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,676</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,147</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommitmentsAndContingencies_i01I_maLASEz1HN_zOgRuJ6lFZZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and contingencies (Notes 13 and 14)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0109">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_iB_zg51vpJIoUl5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_z0AOiqVMrjej" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series A Junior Participating Preferred Stock, $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zubRdqu9Th33" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zqJDVVfqRW6j" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000118" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000120" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_z2LkBqS64Hpj" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000122" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span> and <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zvd97ayROy94" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000124" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares authorized as of September 30, 2024, and December 31, 2023, respectively: issued and outstanding &#8211; <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zJ6EOD9qL67e" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zfvQr76o3Ugd" title="Preferred stock, shares outstanding"><span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zGJhovfP0icd" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_z3Hwi32wRhhg" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000126" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000128" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000130" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact000132" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0115">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0116">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_maSEzTaZ_z3jpMz1OeURj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series B Convertible Preferred Stock, stated value $<span id="xdx_90D_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zT0qUK0mUwo9" title="Preferred stock, stated value"><span id="xdx_909_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zp7aRzG9RW0d" title="Preferred stock, stated value"><ix:nonFraction name="AIM:PreferredStockStatedValuePerShare" contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="AIM:PreferredStockStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></ix:nonFraction></span></span> per share, <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zoU8wkpoypC1" title="Preferred stock, shares authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zqI1lhLHs4k8" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zdVBiq9nMj7k" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zdriLECdacXd" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000145" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact000147" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as of September 30, 2024 and <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zI6CPnWxrrS9" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z03RoVvzdnt2" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000149" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000151" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">689</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0134">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockValue_i01I_hus-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zQeqAXWLRmR2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible preferred stock, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0153">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember" id="Fact000154" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--CommonStockValue_i01I_maSEzTaZ_zkgueuEesJ2i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Common Stock, $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240930_zMkXU37mzmxi" title="Common stock, par value"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zMtP68Q88Tab" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" id="Fact000159" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, authorized shares - <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_zgZ7fQYxUAdd" title="Common stock, shares authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_zPiqh0krZWc3" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact000163" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></ix:nonFraction></span></span>; issued and outstanding shares <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_pid_c20240930_zO0CfKxovYQd" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240930_zbZzz5iDDSXa" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-30" id="Fact000167" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-09-30" id="Fact000169" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,668,647</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zpKaIaP9lsR2" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zxk0AH80RfP6" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,102,484</ix:nonFraction></ix:nonFraction></span></span> as of September 30, 2024 and December 31, 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-09-30" id="Fact000156" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdditionalPaidInCapital_i01I_maSEzTaZ_zMO5x0BwRKK1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-09-30" id="Fact000175" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">423,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">419,004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzTaZ_zLoJatbgruue" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-09-30" id="Fact000178" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">420,861</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">409,508</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquity_i01TI_mtSEzTaZ_maLASEz1HN_zIDelEOPhlXk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total stockholders&#8217; equity</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000181" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,912</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,234</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEz1HN_zIhpNV2gTGRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total liabilities and stockholders&#8217; equity</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000184" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,588</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000185" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,381</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AIM
IMMUNOTECH INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Comprehensive Loss </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
thousands, except share and per share data)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 314.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 314.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_pn3n3_zoFHUgpCRj75" summary="xdx: Statement - Consolidated Statements of Comprehensive Loss (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_495_20240701__20240930_zrEH0HedXxJ8" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49E_20230701__20230930_zQIdNRiDrDs9" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49C_20240101__20240930_zZPA1sZ0bra4" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49D_20230101__20230930_z52tXt8kgZD6" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three months ended September 30,</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Nine months ended September 30,</td><td style="text-align: center; padding-bottom: 1pt; font-size: 11pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenuesAbstract_iB_zsIFzJdxXy96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Revenues:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_maCz44Y_z9uakRAtsHC4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt; width: 36%; text-align: left">Clinical treatment programs - US</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-07-012024-09-30" id="Fact000192" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30" id="Fact000193" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-09-30" id="Fact000194" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">125</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-09-30" id="Fact000195" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">137</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Revenues_i01T_mtCz44Y_maCzA9M_zti3CfDZDa2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Total Revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-07-012024-09-30" id="Fact000197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012023-09-30" id="Fact000198" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-01-01to2024-09-30" id="Fact000199" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">125</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-09-30" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">137</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CostsAndExpensesAbstract_iB_zrfKc4jru4pf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Costs and Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ManufacturingCosts_i01_maCz18U_zFOoTMRS8481" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Production costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ManufacturingCosts" contextRef="From2024-07-012024-09-30" id="Fact000207" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ManufacturingCosts" contextRef="From2023-07-012023-09-30" id="Fact000208" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ManufacturingCosts" contextRef="From2024-01-01to2024-09-30" id="Fact000209" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ManufacturingCosts" contextRef="From2023-01-012023-09-30" id="Fact000210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maCz18U_zhP3d2N5uLhj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30" id="Fact000212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,437</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30" id="Fact000213" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-09-30" id="Fact000214" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30" id="Fact000215" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,739</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GeneralAndAdministrativeExpense_i01_maCz18U_zlrLfcxGtgfl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-012024-09-30" id="Fact000217" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,079</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012023-09-30" id="Fact000218" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,439</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-09-30" id="Fact000219" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,485</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-09-30" id="Fact000220" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,280</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostsAndExpenses_i01T_mtCz18U_msCzA9M_zzOky6lz5m3b" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Total Costs and Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2024-07-012024-09-30" id="Fact000222" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,524</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-07-012023-09-30" id="Fact000223" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,203</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2024-01-01to2024-09-30" id="Fact000224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,042</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostsAndExpenses" contextRef="From2023-01-012023-09-30" id="Fact000225" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,049</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_iT_mtCzA9M_maNILz0wW_zLSnClw3cx21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000227" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,489</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012023-09-30" id="Fact000228" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,157</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-09-30" id="Fact000229" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,917</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,912</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--GainLossOnInvestments_maNILz0wW_zd8lAhSShN8l" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Gain (loss) on investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2024-07-012024-09-30" id="Fact000232" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2023-07-012023-09-30" id="Fact000233" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">310</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2024-01-01to2024-09-30" id="Fact000234" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2023-01-012023-09-30" id="Fact000235" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">201</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_maNILz0wW_zCdVHRg7vYgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest and other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-07-012024-09-30" id="Fact000237" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">718</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-07-012023-09-30" id="Fact000238" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">294</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-09-30" id="Fact000239" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,379</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-09-30" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">811</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InterestExpense_iN_di_msNILz0wW_zAv58ldaH9if" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense and other finance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-07-012024-09-30" id="Fact000242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">202</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0243">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-09-30" id="Fact000244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">453</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_maNILz0wW_znJIHS7iJCSf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on sale of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0247">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-07-012023-09-30" id="Fact000248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-01-012023-09-30" id="Fact000250" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--GainLossOnWarrantIssuance_maNILz0wW_zv2FCbCgBME8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">(Loss) on warrant issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AIM:GainLossOnWarrantIssuance" contextRef="From2024-01-01to2024-09-30" id="Fact000254" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">458</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0255">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--GainFromSaleOfIncomeTaxOperatingLoss_iN_di_msNILz0wW_ziBptUIRzpQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Gain from sale of income tax operating losses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0257">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="AIM:GainFromSaleOfIncomeTaxOperatingLoss" contextRef="From2023-07-012023-09-30" id="Fact000258" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">318</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0259">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="AIM:GainFromSaleOfIncomeTaxOperatingLoss" contextRef="From2023-01-012023-09-30" id="Fact000260" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">900</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtNILz0wW_zvE6r5hqu2Ei" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Net Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact000262" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,700</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" id="Fact000263" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,816</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-09-30" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,353</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact000265" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,386</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted loss per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_pid_c20240701__20240930_zdPmC5D4yDke" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_pid_c20240701__20240930_zpBrJTSynjze" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-012024-09-30" id="Fact000267" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-012024-09-30" id="Fact000269" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.06</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20230701__20230930_ztnSPDTCY0h2" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_pid_c20230701__20230930_z9xdMiIMLMq5" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-012023-09-30" id="Fact000271" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012023-09-30" id="Fact000273" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.16</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="margin-top: 0; margin-bottom: 0"></p>
                                                                     <p style="margin-top: 0; margin-bottom: 0"><span>&#160;<span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20240101__20240930_zG503WHqAj8f" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20240930_z8SXg2TPrUwf" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-09-30" id="Fact000275" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-09-30" id="Fact000277" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.21</ix:nonFraction></ix:nonFraction></span></span></span></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230930_zRqLrhQaLCA4" title="Basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230930_zFwA1AF8sE7a" title="Diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-09-30" id="Fact000279" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-09-30" id="Fact000281" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.34</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average shares outstanding basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240701__20240930_z7jYgapGxTKg" title="Weighted average shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240701__20240930_zfQDeoZRd1X1" title="Weighted average shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012024-09-30" id="Fact000283" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012024-09-30" id="Fact000285" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,677,016</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zbAJAvncoV4f" title="Weighted average shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_zNTI3w5b08n4" title="Weighted average shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-09-30" id="Fact000287" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-09-30" id="Fact000289" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,635,165</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20240930_zfRbpSPrVRQ3" title="Weighted average shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20240930_z4qgtmsTReb3" title="Weighted average shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-09-30" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-09-30" id="Fact000293" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">53,351,467</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_zVyrJ9x15dQ6" title="Weighted average shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zsLNcSGXrTP8" title="Weighted average shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgQ29tcHJlaGVuc2l2ZSBMb3NzIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-09-30" id="Fact000295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-09-30" id="Fact000297" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,483,802</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 314.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 314.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AIM
IMMUNOTECH INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Changes in Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Nine Months Ended September 30, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
thousands except share data)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_114_pn3n3_zgLsT7phkRf8" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesBPreferredStockMember_zR1zbscFCC7k" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zhnvQkZ8c9B9" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zMvpwqoo3gy5" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zuyPSGNrADX9" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zqTjsrbTY394" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td id="xdx_4BE_zG3sWAc3Nm77" style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Series B <br/>Preferred</p>
                                               <p style="text-align: center; margin-top: 0; margin-bottom: 0">Shares</p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Common <br/>Stock <br/>Shares</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Common <br/>Stock .001 <br/>Par Value</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Additional <br/>Paid-in <br/>Capital</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Accumulated other</p>
                                               <p style="text-align: center; margin-top: 0; margin-bottom: 0">Comprehensive <br/>Income (Loss)</p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated <br/>Deficit</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Total <br/>Stockholders&#8217;</p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Equity</p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_43C_c20240101__20240331_eus-gaap--StockholdersEquity_iS_z9wtrz5iqIr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; width: 18%">Balance December 31, 2023</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000299" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right; width: 1%"/><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgpsLjmFODV" title="Balance, shares" style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,102,484</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000300" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000301" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">419,004</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000303" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">409,508</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,234</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zkZr3oSIz9fh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issuance, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6fQNF4qIlxj" title="Common stock issuance, net of costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000315" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">807,577</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000309" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000310" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-03-31" id="Fact000313" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">329</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_zhoKJGYCewhk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cashless exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhcNPgXsWGu6" title="Cashless Exercise of Warrants, shares" style="text-align: right"><ix:nonFraction name="AIM:StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000324" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,272</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zklU4nVQiLK6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000328" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31" id="Fact000331" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueCommittedShares_z9LBhOkIE1F5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Committed shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesCommittedShares_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbEbdwBdpT74" title="Committed Shares, shares" style="text-align: right"><ix:nonFraction name="AIM:StockIssuedDuringPeriodSharesCommittedShares" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">338,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ComprehensiveIncomeNetOfTax_zO8DYxZxPLVj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Net comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000346" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,817</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-012024-03-31" id="Fact000347" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,817</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_436_c20240401__20240630_eus-gaap--StockholdersEquity_iS_z2i7glbz2Tr" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance March 31, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000349" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLZfnwq7v7oj" title="Balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000356" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,251,933</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000350" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000351" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">419,412</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000353" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">415,325</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000354" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,826</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zBX9fNCc3CX2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issuance, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQYBw78i5dlj" title="Common stock issuance, net of costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000365" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,884,747</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact000359" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000360" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-04-012024-06-30" id="Fact000363" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">532</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_z4b6vECOXNj1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000369" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2024-04-012024-06-30" id="Fact000372" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zK0sZtX65WV" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000376" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30" id="Fact000379" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValuePreferredSharesExpired_zDTSiqYMHrag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B preferred shares expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AIM:StockIssuedDuringPeriodValuePreferredSharesExpired" contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000381" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">689</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AIM:StockIssuedDuringPeriodValuePreferredSharesExpired" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000383" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ComprehensiveIncomeNetOfTax_zrGCBB4YBuId" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Net comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact000392" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,836</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-04-012024-06-30" id="Fact000393" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,836</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_434_c20240701__20240930_eus-gaap--StockholdersEquity_iS_znBs19dRGuoi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance June 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlE3yCETRu61" title="Balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000402" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,136,680</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000396" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000397" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">423,206</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000399" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">417,161</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000400" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,102</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zfLkttdv3tqe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issuance, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpte1shHWQBh" title="Common stock issuance, net of costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000411" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">653,430</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000405" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000406" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">179</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-07-012024-09-30" id="Fact000409" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">180</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zRtzEQzXljN3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueOther_zmWDmy6p0QNb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuWYzTggVGDi" title="Equity-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000427" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">878,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact000421" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000422" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">329</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-07-012024-09-30" id="Fact000425" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">330</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValuePreferredSharesExpired_zFDBzQw8sM98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B preferred shares expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ComprehensiveIncomeNetOfTax_zbhPNsRuJFfi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Net comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="Fact000440" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,700</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-07-012024-09-30" id="Fact000441" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,700</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_432_c20240701__20240930_eus-gaap--StockholdersEquity_iE_zhNPuTN62RNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRZV73HU9yE3" title="Balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000450" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,668,647</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact000444" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">423,714</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact000447" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">420,861</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact000448" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,912</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center; font-size: 11pt">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Series B <br/>Preferred</p>
                    <p style="text-align: center; margin-top: 0; margin-bottom: 0">Shares</p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Common <br/>Stock <br/>Shares</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Common <br/>Stock .001 <br/>Par Value</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Additional <br/>Paid-in <br/>Capital</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated other <br/>Comprehensive <br/>Income (Loss)</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Accumulated <br/>Deficit</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Total <br/>Stockholders&#8217; <br/></p>
                                                                               <p style="margin-top: 0; margin-bottom: 0">Equity</p></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_435_c20230101__20230331_eus-gaap--StockholdersEquity_iS_z5LRE02rankh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; width: 18%">Balance December 31, 2022</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000452" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"/><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6rPeA4Dyzc4" title="Balance, shares" style="border-bottom: Black 1pt solid; width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000459" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,084,287</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000454" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418,270</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right; width: 8%"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#8212;</span></td><td style="padding-bottom: 1pt; width: 1%; text-align: left"/><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000456" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">380,546</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1pt; width: 2%; font-size: 11pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 11pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; font-size: 11pt; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000457" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,468</ix:nonFraction></td><td style="padding-bottom: 1pt; width: 1%; font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zisri3QXw5Wg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issuance, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zh93Dkix3RI9" title="Common stock issuance, net of costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000468" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">322,583</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000463" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31" id="Fact000466" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueOther_zXARFDVPafr6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000472" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0474">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-03-31" id="Fact000475" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_z0pLaWv9uhj3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series B preferred shares converted to common shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoEg0qfUAom8" title="Series B preferred shares converted to common shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="Fact000484" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">456</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000479" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ComprehensiveIncomeNetOfTax_zOtLftkvELV8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Net comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="Fact000490" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,661</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-03-31" id="Fact000491" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,661</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_433_c20230401__20230630_eus-gaap--StockholdersEquity_iS_zZGdZoRF3rk3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Balance March 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000493" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">692</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znG8tbs70Prk" title="Balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000500" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,407,326</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000494" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000495" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418,456</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" id="Fact000497" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">384,207</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" id="Fact000498" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,989</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zxY38Ox6zJAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issuance, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0502">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6cVlLst5fDd" title="Common stock issuance, net of costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact000509" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,937</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000504" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012023-06-30" id="Fact000507" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_zrtE50JTFhCh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0512">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-04-012023-06-30" id="Fact000516" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zOoOqMXoeDda" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series B preferred shares converted to common shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000518" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zogUKZUx1jya" title="Series B preferred shares converted to common shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact000525" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">228</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000520" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0522">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ComprehensiveIncomeNetOfTax_zXkRYJj9JzQb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Net Comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0528">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0529">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="Fact000531" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,909</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-04-012023-06-30" id="Fact000532" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,909</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_432_c20230701__20230930_eus-gaap--StockholdersEquity_iS_zHqNm6rfx07g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance June 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000534" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">690</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zX11kZhMefW2" title="Balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000541" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,419,491</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000535" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000536" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418,513</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" id="Fact000538" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">389,116</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000539" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,135</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20230701__20230930_eus-gaap--StockholdersEquity_iS_zrcor7OTmNBa" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000543" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">690</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zL1USyAVPwO1" title="Balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000550" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,419,491</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000544" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000545" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418,513</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0546">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" id="Fact000547" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">389,116</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000548" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,135</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z4JTvPfDOup4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issuance, net of costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn1JyuzLotX" title="Common stock issuance, net of costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="Fact000559" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">377,959</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000554" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">233</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-07-012023-09-30" id="Fact000557" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">233</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_z61iYgJBu0r5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000563" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30" id="Fact000566" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zZAZwRaD8Era" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series B preferred shares converted to common shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0570">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0572">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ComprehensiveIncomeNetOfTax_z7gL7QmFkfo5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Net Comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0575">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0577">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0578">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="Fact000579" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,816</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-07-012023-09-30" id="Fact000580" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,816</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_437_c20230701__20230930_eus-gaap--StockholdersEquity_iE_zzoe2e1SR9v2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Balance September 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000582" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">690</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zE0eNFdnR8Xc" title="Balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000589" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,797,450</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000583" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000584" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418,796</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" id="Fact000586" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">396,932</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact000587" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,602</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43E_c20230701__20230930_eus-gaap--StockholdersEquity_iE_zVw2TxhNYfe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Balance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember" id="Fact000591" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">690</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z17BLde2Lcsf" title="Balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000598" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,797,450</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact000592" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000593" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418,796</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0594">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" id="Fact000595" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">396,932</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact000596" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,602</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AIM
IMMUNOTECH INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Nine Months Ended September 30, 2024 and 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
thousands)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_112_pn3n3_zVrSsJoFpOp8" summary="xdx: Statement - Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_490_20240101__20240930_zaiZW0f65s91" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_496_20230101__20230930_zkUoEb974On5" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zZdjR0O3vmh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_i01_maNCPBUzAja_ztm8tug57SHj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-09-30" id="Fact000603" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,353</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact000604" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,386</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zp4z49dyBnrl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Depreciation_i02_maNCPBUzAja_zzZSQfQzKik6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-09-30" id="Fact000609" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-09-30" id="Fact000610" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AbandonmentOfPatentAndTrademarkRights_i02_maNCPBUzAja_z5GLVXUm8TP6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Abandonment of patent and trademark rights</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AIM:AbandonmentOfPatentAndTrademarkRights" contextRef="From2024-01-01to2024-09-30" id="Fact000612" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AIM:AbandonmentOfPatentAndTrademarkRights" contextRef="From2023-01-012023-09-30" id="Fact000613" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AmortizationOfIntangibleAssets_i02_maNCPBUzAja_zFx6qR62mvZc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of patent, trademark rights</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-09-30" id="Fact000615" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-09-30" id="Fact000616" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ChangesInRouAssets_i02_maNCPBUzAja_zjOr6HHBG8a3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Changes in right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AIM:ChangesInRouAssets" contextRef="From2024-01-01to2024-09-30" id="Fact000618" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">226</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AIM:ChangesInRouAssets" contextRef="From2023-01-012023-09-30" id="Fact000619" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--GainFromSaleOfIncomeTaxOperatingLoss_i02_maNCPBUzAja_zSbecd4Gttw7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Gain from sale of income tax operating losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AIM:GainFromSaleOfIncomeTaxOperatingLoss" contextRef="From2023-01-012023-09-30" id="Fact000622" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">900</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensation_i02_maNCPBUzAja_zMC3xCihkkf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Equity-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-09-30" id="Fact000624" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30" id="Fact000625" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">182</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_i02N_di_msNCPBUzAja_z6bFqA7UyfK9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">(Gain) loss on sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2024-01-01to2024-09-30" id="Fact000627" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-01-012023-09-30" id="Fact000628" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">201</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GainLossOnSaleOfDerivatives_i02N_di_msNCPBUzAja_zb1uOxAIlqXa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="From2024-01-01to2024-09-30" id="Fact000630" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">458</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0631">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AmortizationOfFinancingCosts_i02_maNCPBUzAja_zHjoOuR4R8N" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of financial obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2024-01-01to2024-09-30" id="Fact000633" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">232</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0634">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_z39OvlqNy77c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOtherReceivables_i02N_di_msNCPBUzAja_zPlFIV8pH79e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2023-01-012023-09-30" id="Fact000640" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzAja_zSAj3iklWNnc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Funds receivable from New Jersey net operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-01to2024-09-30" id="Fact000642" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-09-30" id="Fact000643" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,676</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzAja_zVuANN7Wcjnh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets and other non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-09-30" id="Fact000645" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-09-30" id="Fact000646" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">192</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzAja_z5gQCUq0tQg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-09-30" id="Fact000648" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">231</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-09-30" id="Fact000649" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">136</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i03N_di_msNCPBUzAja_z6KOrM7pUfv" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2024-01-01to2024-09-30" id="Fact000651" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,028</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0652">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzAja_zPDzqWQP7699" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-09-30" id="Fact000654" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">179</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-09-30" id="Fact000655" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,411</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maNCPBUzAja_zHcbrImb4HE9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-01-01to2024-09-30" id="Fact000657" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">799</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-012023-09-30" id="Fact000658" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">915</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzAja_maCCERCzTcr_zQYd2fUY7yVe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash used in operating activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-09-30" id="Fact000660" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,933</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-09-30" id="Fact000661" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,509</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zuXFUWnNKf7i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromSaleOfInvestmentProjects_i01_maNCPBUzmPv_zh6Ro3mgyHL1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfInvestmentProjects" contextRef="From2024-01-01to2024-09-30" id="Fact000666" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,597</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfInvestmentProjects" contextRef="From2023-01-012023-09-30" id="Fact000667" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">924</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsToAcquireInvestments_i01N_di_msNCPBUzmPv_zaZGFUu39OU5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Purchase of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2024-01-01to2024-09-30" id="Fact000669" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2023-01-012023-09-30" id="Fact000670" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,155</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzmPv_zKrsB7DL6Tvg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">(Purchase of)  property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-09-30" id="Fact000672" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-09-30" id="Fact000673" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msNCPBUzmPv_zID9fVzkZB11" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Purchase of patent and trademark rights</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2024-01-01to2024-09-30" id="Fact000675" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">419</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-012023-09-30" id="Fact000676" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">377</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzmPv_maCCERCzTcr_zu3j7gyt44S7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-09-30" id="Fact000678" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,002</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-09-30" id="Fact000679" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">618</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zoDFBqmbC08j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_i01_maNCPBUzuGK_zXtXiLfuzEU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-01-01to2024-09-30" id="Fact000684" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">860</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-01-012023-09-30" id="Fact000685" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromNotesPayable_i01_maNCPBUzuGK_zYvBlqZSwygk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from note payable, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-01-01to2024-09-30" id="Fact000687" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0688">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ProceedsFromIssuanceOfEquityWarrants_i01_maNCPBUzuGK_z29sYeqc3Nof" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of equity warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="AIM:ProceedsFromIssuanceOfEquityWarrants" contextRef="From2024-01-01to2024-09-30" id="Fact000690" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,047</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0691">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzuGK_maCCERCzTcr_z67BP7qCNnP8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-09-30" id="Fact000693" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,407</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-09-30" id="Fact000694" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">338</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzTcr_z76lQx8VI9E8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-09-30" id="Fact000696" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,524</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-09-30" id="Fact000697" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,789</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zT6nENY303M4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash and cash equivalents at beginning of period</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000699" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,439</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000700" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,053</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zVV6rF61HP2e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents at end of period</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-09-30" id="Fact000702" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">915</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-09-30" id="Fact000703" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zmr1YWj3yL66" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental disclosures of non-cash investing and financing cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--OperatingLeaserightOfUseAssets_i01_zdtCAUFTemyj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating lease-Right of Use Assets</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="AIM:OperatingLeaserightOfUseAssets" contextRef="From2024-01-01to2024-09-30" id="Fact000708" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AIM:OperatingLeaserightOfUseAssets" contextRef="From2023-01-012023-09-30" id="Fact000709" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--UnrealizedGainLossOnMarketableInvestments_i01_zHJmJg9PESjd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Unrealized gain (loss) on marketable securities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AIM:UnrealizedGainLossOnMarketableInvestments" contextRef="From2024-01-01to2024-09-30" id="Fact000711" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">373</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="AIM:UnrealizedGainLossOnMarketableInvestments" contextRef="From2023-01-012023-09-30" id="Fact000712" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">71</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--ConversionOfSeriesBPreferred_i01_zjaeOFhc4shc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Conversion of Series B preferred</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0714">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AIM:ConversionOfSeriesBPreferred" contextRef="From2023-01-012023-09-30" id="Fact000715" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ConversionOfNotePayableInterestIntoShares_i01_zgnh3kkRna48" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Conversion of note payable interest into shares</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AIM:ConversionOfNotePayableInterestIntoShares" contextRef="From2024-01-01to2024-09-30" id="Fact000717" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">175</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0718">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AIM
IMMUNOTECH INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000720" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_808_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zvXrSbojjZ67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1: <span id="xdx_825_znFavMe4BT99">Business and Basis of Presentation</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
ImmunoTech Inc. and its subsidiaries (collectively, &#8220;AIM&#8221;, &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;) are
an immuno-pharma company headquartered in Ocala, Florida,  focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical
and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system
of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM&#8217;s
flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (&#8220;dsRNA&#8221;)
molecule being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has not been approved
by the FDA or marketed in the United States but is approved for commercial sale in the Argentine Republic for the treatment of severe
Chronic Fatigue Syndrome (&#8220;CFS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently proceeding primarily in four areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
                                            clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic
                                            cancer.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating
                                            Ampligen across multiple cancers as a potential therapy that modifies the tumor microenvironment
                                            with the goal of increasing anti-tumor responses to checkpoint inhibitors.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exploring
                                            Ampligen&#8217;s antiviral activities and potential use as a prophylactic or treatment for
                                            existing viruses, new viruses and mutated viruses thereof.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating
                                            Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (&#8220;ME/CFS&#8221;)
                                            and fatigue and/or the Post-COVID condition of fatigue.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic
cancer, ME/CFS and Post-COVID conditions having priority over antiviral experimentation. The Company intends that priority clinical work
be conducted in trials authorized by the FDA or European Medicines Agency (&#8220;EMA&#8221;), which trials support a potential future
NDA. However, AIM&#8217;s antiviral experimentation is designed to accumulate additional preliminary data supporting their hypothesis
that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection.
Accordingly, AIM will conduct antiviral programs in those venues most readily available and able to generate valid proof-of-concept data,
including foreign venues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM&#8217;s
business plan requires one or more Contract Manufacturing Organizations (&#8220;CMO&#8221;) to produce Ampligen and its Active Pharmaceutical
Ingredients (APIs). This includes utilizing Jubilant HollisterStier and Sterling for the manufacture of Ampligen and our Poly I and Poly
C12U polynucleotides, respectively. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, all adjustments necessary for a fair presentation of its consolidated financial statements have been included.
Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (&#8220;SEC&#8221;),
and do not contain certain information which will be included in the Company&#8217;s annual consolidated financial statements and notes
thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements for the years
ended December 31, 2023, and 2022, contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023,
filed on April 1, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (&#8220;GAAP&#8221;)
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the
reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use
of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent
and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern.
The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements
are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Financial Accounting Standards Board&#8217;s (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 205-40, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern, management must evaluate whether
there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue
as a going concern for one year from the date these financial statements are issued. This evaluation does not take into consideration
the potential mitigating effect of management&#8217;s plans that have not been fully implemented or are not within control of the Company
as of the date the financial statements are issued. When substantial doubt about the Company&#8217;s ability to continue as a going concern
exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt. The mitigating
effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented
within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will
mitigate the relevant conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the financial statements are issued. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s principal source of liquidity is its cash and cash equivalents, marketable securities, and proceeds from financing
activities to provide the necessary funding to meet our obligations as they become due. The Company has suffered losses from
operations and net cash used on operating activities for the nine-month period ended September 30, 2024, and has a working capital
deficit as of September 30, 2024. Additionally, the Company&#8217;s stockholders&#8217; equity was below the minimum requirements
for continued listing on the New York Stock Exchange American (&#8220;NYSE American&#8221;). These conditions raise substantial
doubt regarding the Company&#8217;s ability to continue as a going concern for a period of at least one year from the date of
issuance of these unaudited condensed consolidated financial statements. Management evaluated the conditions, and the significance
of these conditions related to the Company&#8217;s ability to meet its obligations and determined that the primary cause of the
deficit was related to certain accounts payable which the Company is currently in negotiations with the vendor. These negotiations
are ongoing and could result in significant amounts which could partially alleviate the negative working capital. There is no assurance as to the timing or outcome of these efforts. If the Company is unable to implement
sufficient mitigation efforts, the Company may be forced to limit its business activities or be unable to continue as a going
concern, which would have a material adverse effect on its results of operations and financial condition.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000722" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zSSHZ6DUZhN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2</b>: <b><span id="xdx_829_z2nryRywse58">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
includes bank deposits maintained at several financial institutions. The Company considers highly liquid instruments with an original
maturity of three months or less to be cash equivalents. At various times throughout the nine months ended September 30, 2024, some accounts
held at financial institutions were in excess of the federally insured limit of $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20240930_ze3nab0wDKN1" title="Federlly insured limit"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-09-30" id="Fact000724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>. The Company has not experienced any losses
on these accounts and believes credit risk to be minimal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000726" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zFfeajKKv4L6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3: <span id="xdx_829_zM8Uaj60oD13">Marketable Securities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
securities consist of mutual funds. At September 30, 2024 and December
31, 2023, it was determined that none of the marketable securities had an other-than-temporary impairment. At September 30, 2024 and December
31, 2023, all securities were measured as Level 1 instruments of the fair value measurements standard (See Note 12: Fair Value). At September
30, 2024, and December 31, 2023 the Company held $<span id="xdx_902_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_c20240930_zGPiXdFoGmFd" title="Held value of marketable securities"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="AsOf2024-09-30" id="Fact000728" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,287,000</ix:nonFraction></span>
and $<span id="xdx_906_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_c20231231_zSQimBV7QZEd" title="Held value of marketable securities"><ix:nonFraction name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="AsOf2023-12-31" id="Fact000730" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,631,000</ix:nonFraction></span> respectively, in mutual funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutual Funds classified as available for sale consisted of $<span id="xdx_902_eus-gaap--MarketableSecuritiesCurrent_iI_c20240930_zBmGron1f3Si" title="Marketable securities"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2024-09-30" id="Fact000732" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,287,000</ix:nonFraction></span> at September 30, 2024. <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleTypeOfEquitySecurity_c20240101__20240930_zFGH0MtdGcjg" title="Equity securities description"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000734" name="us-gaap:DebtInstrumentConvertibleTypeOfEquitySecurity">The net gain recognized for the three-month
period ended September 30, 2024 on equity securities was $273,000. The net losses recognized for the three-month period ended September
30, 2024 on equity securities sold during the period were ($59,000). The unrealized gains recognized for the three-month period
ended September 30, 2024 on equity securities still held was $332,000. The net gain recognized for the nine-month period ended September
30, 2024 on equity securities was $96,000. The net losses recognized for the nine-month period ended September 30, 2024 on equity
securities sold during the period were ($277,000). The unrealized gains recognized for the nine-month period ended September 30,
2024 on equity securities still held was $373,000.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutual Funds classified as available for sale consisted of $<span id="xdx_900_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_z6a3a5ZWvIY2" title="Marketable securities"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact000736" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,631,000</ix:nonFraction></span> at December 31, 2023. <span id="xdx_908_eus-gaap--DebtInstrumentConvertibleTypeOfEquitySecurity_c20230101__20231231_z6EMBUekZ2D3" title="Equity securities description"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact000738" name="us-gaap:DebtInstrumentConvertibleTypeOfEquitySecurity">The net loss recognized for the three-month
period ended September 30, 2023 on equity securities was ($309,000).&#160; The net losses recognized for the three-month period ended
September 30, 2023 on equity securities sold during the period were ($42,000). The unrealized losses recognized during the three-month
period ended September 30, 2023 on equity securities still held was ($267,000). The net losses recognized for the nine-month
period ended September 30, 2023 on equity securities was ($201,000). The net losses recognized for the nine-month period ended
September 30, 2023 on equity securities sold during the period were ($130,000). The unrealized losses recognized during the nine-month
period ended September 30, 2023 on equity securities still held was ($71,000).</ix:nonNumeric></span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000740" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zCggWfUlxyhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4: <span id="xdx_826_zuXooo4pXdGc">Property and Equipment, net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000742" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zRGGwIRYWFyb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8B1_zCYYYn4y7eL1">Schedule
of Property and Equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_494_20240930_z5hFwuCCDQ9f" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49B_20231231_zBpvQnD47La7" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENztUG_zMy3sLzXGS6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Furniture, fixtures, and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-09-30" id="Fact000744" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,466</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000745" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,448</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENztUG_zQo49N7TPXn1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-09-30" id="Fact000747" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,349</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,321</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENztUG_zFFesyhVHXMa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-09-30" id="Fact000750" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">117</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000751" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_z4fpO1sgVRZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful
lives of the respective assets, ranging from <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20240930__srt--RangeAxis__srt--MinimumMember_z7CckCeoYvx8" title="Estimated useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0753">three</span></span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20240930__srt--RangeAxis__srt--MaximumMember_zZJtA53jY7E3" title="Estimated useful life"><ix:nonNumeric contextRef="AsOf2024-09-30_srt_MaximumMember" format="ixt-sec:durwordsen" id="Fact000755" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">ten years</ix:nonNumeric></span>. Depreciation expense for the nine months ending September 30, 2024 and
September 30, 2023 was $<span id="xdx_902_eus-gaap--Depreciation_c20240101__20240930_zfY7dvT8xSP6" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-09-30" id="Fact000757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--Depreciation_c20230101__20230930_zOpQXeIXQdDb" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-09-30" id="Fact000759" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000761" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_z4UG7EhRAl92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5: <span id="xdx_826_zXFFyQk49l5d">Patents, and Trademark Rights, Net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000763" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zBCDvBpBjFmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
and trademark rights consist of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt"><span id="xdx_8BB_zAa7JNWy89tb">Schedule
of Patent and Trademark Rights</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Gross Carrying Value</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated Amortization</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net Carrying Value</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Gross Carrying Value</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated Amortization</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net Carrying Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zbUICxw1Xj8c" title="Gross carrying value" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-09-30_us-gaap_PatentsMember" id="Fact000765" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,315</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zpwzsHMhXvG4" title="Accumulated amortization" style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-09-30_us-gaap_PatentsMember" id="Fact000767" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">887</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zEPpi2tMxpDa" title="Net carrying value" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-09-30_us-gaap_PatentsMember" id="Fact000769" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,428</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzxSZR35aLli" title="Gross carrying value" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact000771" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,947</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8J54CytraFk" title="Accumulated amortization" style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact000773" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">750</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAGxijkjvRf" title="Net carrying value" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact000775" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Trademarks</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zvfvEdCm6oY3" title="Gross carrying value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-09-30_us-gaap_TrademarksMember" id="Fact000777" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">232</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z33LHiL2D1bg" title="Accumulated amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-09-30_us-gaap_TrademarksMember" id="Fact000779" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">128</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zQvo28Jaoe61" title="Net carrying value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-09-30_us-gaap_TrademarksMember" id="Fact000781" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zjJM7f8pmrPd" title="Gross carrying value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" id="Fact000783" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">229</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zoBAV3VSrXfk" title="Accumulated amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" id="Fact000785" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">113</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSX6Kv6qQrbl" title="Net carrying value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" id="Fact000787" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">116</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net amortizable patents and trademarks rights</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930_zwH2Yy8CWW62" title="Gross carrying value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-09-30" id="Fact000789" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,547</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930_zxHNsNce0g53" title="Accumulated amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-09-30" id="Fact000791" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,015</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930_zUBZJdMlSL8b" title="Net carrying value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-09-30" id="Fact000793" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zXvptjERIbih" title="Gross carrying value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31" id="Fact000795" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,176</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zheFoTKFHNB6" title="Accumulated amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31" id="Fact000797" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">863</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zL8AbrNZtT67" title="Net carrying value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000799" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,313</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zhTQpzAtb0vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000801" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zGqBFECNpEW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
and trademark rights acquisitions, abandonments and amortization:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8B7_zkcpxAOiTA8">Schedule of Changes in
Patents, Trademark Rights</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20240101__20240930_zYazcw4FAWm1" title="Balance" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000803" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,313</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Acquisitions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20240930_zQkkLOeVr6Pl" title="Acquisitions" style="text-align: right"><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="From2024-01-01to2024-09-30" id="Fact000805" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">419</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Abandonments and expirations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20240101__20240930_z1PWeAKfCbvg" title="Abandonments" style="text-align: right">(<ix:nonFraction name="AIM:FinitelivedIntangibleAssetsAbandonments" contextRef="From2024-01-01to2024-09-30" id="Fact000807" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">46</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20240101__20240930_zbcdeHtCc1fd" title="Accumulated Amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-09-30" id="Fact000809" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">154</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20240101__20240930_zCEi51a2i4Qc" title="Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-09-30" id="Fact000811" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,532</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zp0yeFhg8wCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over an estimated useful life
of <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zqy5tcBpRkbc" title="Finite lived intangible assets, estimated useful life"><ix:nonNumeric contextRef="AsOf2024-09-30_us-gaap_PatentsMember" format="ixt-sec:durwordsen" id="Fact000813" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">17 years</ix:nonNumeric></span> for patents and <span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zbUxrGLdmBZa" title="Finite lived intangible assets, estimated useful life"><ix:nonNumeric contextRef="AsOf2024-09-30_us-gaap_TrademarksMember" format="ixt-sec:durwordsen" id="Fact000815" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10 years</ix:nonNumeric></span> for trademarks. The weighted remaining average amortization period is approximately <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_c20240101__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvpKWnMvDxb4" title="Finite lived intangible assets, weighted average amortization"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_PatentsMember" format="ixt-sec:durwordsen" id="Fact000817" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension">12 years</ix:nonNumeric></span> for
patents and <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_c20240101__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVS9hQqXWWUe" title="Finite lived intangible assets, weighted average amortization"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_TrademarksMember" format="ixt-sec:durwordsen" id="Fact000819" name="us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension">6 years</ix:nonNumeric></span> for trademarks, respectively. The company expenses annuity costs related to its trademarks and patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000821" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zFn3Ia1SZmGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of patents and trademarks for each of the next five years and thereafter is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8BF_zgAqJXpNuYmj">Schedule
of Amortization of Patents and Trademarks</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Year Ending December 31,</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20240930_z1tIYpVuM4Xe" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzzOp_zwjhISSXC6c7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: justify">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 24%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2024-09-30" id="Fact000823" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">72</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zTsNY3ua6BM7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2024-09-30" id="Fact000825" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">268</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zoOVx8HtnVqi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2024-09-30" id="Fact000827" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">265</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zd5hADRcvfP4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2024-09-30" id="Fact000829" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">239</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zrSd1XdSTIfk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2024-09-30" id="Fact000831" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzzOp_zJfUCy3CpjH1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="AIM:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" contextRef="AsOf2024-09-30" id="Fact000833" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,469</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zWhqaolA3oN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-09-30" id="Fact000835" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,532</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z68D5vV7JGv" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000837" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zDu3gHvXqICe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6: <span id="xdx_82F_zcgvTu96dolf">Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000839" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zQi5554CwUCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8B1_zCZ86rKhvOt7">Schedule
of Accrued Expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_493_20240930_zpvTaGPeAyEl" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_492_20231231_zyfNm3w9hjBi" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zxZUuEaIXWSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000841" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000842" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">414</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zErRAiIuwHzd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-09-30" id="Fact000844" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">790</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" id="Fact000845" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,352</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_z8kZCQ7m4g52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Clinical trial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AIM:AccruedClinicalTrialExpensesCurrent" contextRef="AsOf2024-09-30" id="Fact000847" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132</ix:nonFraction></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AIM:AccruedClinicalTrialExpensesCurrent" contextRef="AsOf2023-12-31" id="Fact000848" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">184</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzYmu_zxpeMg9SgGIi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-09-30" id="Fact000850" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ziLMURobsHek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000853" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000854" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zFlkF5q6M6L8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact000856" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,011</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000857" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,986</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zs0RdJN0aHGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000859" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_zYKkX7jA2XU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7: <span id="xdx_820_z1itmEsEwwC5">Unsecured Promissory Note</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2024, the Company (&#8220;Borrower&#8221;) entered into a Note Purchase Agreement with Streeterville Capital LLC
(&#8220;Streeterville&#8221; or the &#8220;Lender&#8221;). Under the terms of the agreement, Streeterville paid the Company $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zWAjx8pvr3e9" title="Exchange of unsecured promissory notes"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2024-02-162024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember" id="Fact000861" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span>
in exchange for an unsecured promissory Note with an Original Issue Discount of $<span id="xdx_900_eus-gaap--DebtConversionOriginalDebtAmount1_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zSDdVIlvnB4a" title="Unsecured debt original issue discount"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2024-02-162024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember" id="Fact000863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">781,250</ix:nonFraction></span>.
The Company will pay $<span id="xdx_90C_eus-gaap--LongTermDebt_iI_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zJpVZkQMLegi" title="Long term debt"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember" id="Fact000865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,301,250</ix:nonFraction></span>
consisting of the principal amount of the Note, together with the original issue discount and $<span id="xdx_901_eus-gaap--DeferredFinanceCostsGross_iI_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zqKMVPANOnc3" title="Debt issuance costs"><ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="AsOf2024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember" id="Fact000867" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></span>
of lender transaction fees, no later than February 16, 2026. The stated interest rate of the note is <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_z7D8T6ZrVfm3" title="Debt instrument stated interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember" id="Fact000869" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%.</span>
There was <span id="xdx_905_eus-gaap--UnsecuredDebt_iI_do_c20231231_zZMrBphQAdud" title="Unsecured debt"><ix:nonFraction name="us-gaap:UnsecuredDebt" contextRef="AsOf2023-12-31" id="Fact000871" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> debt at December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000873" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_z8qR51yTaila" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span><span id="xdx_8B3_zzL1KXT6vYW6">Schedule of Long Term Debt</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240930_znIPEbSifguf" style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Debt schedule at September 30, 2024 (in thousands)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: right"/><td style="padding-bottom: 1pt">&#160;</td>
    </tr>
  <tr id="xdx_40F_eus-gaap--LongTermDebt_iI_pn3n3_z5Qzrbi8hhlh" style="vertical-align: bottom; background-color: White">
    <td style="width: 77%; text-align: left">Long-term debt</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2024-09-30" id="Fact000875" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,301</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_zme2jc2Cl9lc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unamortized Original issue discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" contextRef="AsOf2024-09-30" id="Fact000877" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">555</ix:nonFraction></td><td style="text-align: left">)</td>
    </tr>
  <tr id="xdx_40C_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_zEzzylzYJd6g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Unamortized Financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2024-09-30" id="Fact000879" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td>
    </tr>
  <tr id="xdx_400_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn3n3_z1sjpi9zFbp3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Unamortized discount and debt issuance costs</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2024-09-30" id="Fact000881" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,732</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_z3tDTtSH1sf1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less current portion of long-term debt, net <span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="AsOf2024-09-30" id="Fact000883" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,593</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zfrhvPyY2899" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt, net <span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-09-30" id="Fact000885" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    </tr>
</table>

</ix:nonNumeric><p id="xdx_8A0_zNlZ4r61hy0a" style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Interest expense related to long-term debt was $<span id="xdx_906_eus-gaap--InterestExpenseDebtExcludingAmortization_c20240101__20240930_zPBg5i4epKn" title="Interest expense debt excluding amortization"><ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="From2024-01-01to2024-09-30" id="Fact000887" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,000</ix:nonFraction></span> at
September 30, 2024. Amortization expenses related to long-term debt was $<span id="xdx_905_eus-gaap--AdjustmentForAmortization_c20240101__20240930_zYRX6B9Jm1b6" title="Amortization expenses of long term debt"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2024-01-01to2024-09-30" id="Fact000889" format="ixt:numdotdecimal" decimals="0" unitRef="USD">232,000</ix:nonFraction></span> at September 30, 2024. This consisted of $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20240101__20240930_zL3PbyesAp83" title="Original issue discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-01to2024-09-30" id="Fact000891" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,000</ix:nonFraction></span> in
original issue discount and $<span id="xdx_900_eus-gaap--LoanProcessingFee_c20240101__20240930_z2VnrXySTJX" title="Loan fee amortization"><ix:nonFraction name="us-gaap:LoanProcessingFee" contextRef="From2024-01-01to2024-09-30" id="Fact000893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span> for loan fee amortization. Future maturities of long-term debt at September 30, 2024 were $<span id="xdx_90C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_c20240930_zZweHYSlJ3j5" title="Future maturities of long term debt"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" contextRef="AsOf2024-09-30" id="Fact000895" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></span>
for fiscal years ending December 31, 2024 and $<span id="xdx_90E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20240930_zPHus6N6Alqd" title="Future maturities of long term debt"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="AsOf2024-09-30" id="Fact000897" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,551,000</ix:nonFraction></span> for fiscal years ending December 31, 2025.</p>

<p style="display: none; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
                                            portion of long-term debt of approximately $3,000,000 is net of the current portion of debt
                                            discount of approximately $397,000 and the current portion of debt origination costs of approximately
                                            $10,000 as of September 30, 2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
                                            portion of debt of approximately $301,000 is net of the long-term portion of debt discount
                                            of approximately $159,000 and the unamortized debt origination costs of approximately $3,000
                                            as of September 30, 2024.</span></td></tr></table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current portion of long-term debt of approximately $<span id="xdx_90F_eus-gaap--DeferredFinanceCostsCurrentGross_iI_c20240930_zNYv0YVPyoB9" title="Long-term debt, current"><ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentGross" contextRef="AsOf2024-09-30" id="Fact000899" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span> is net of the current portion of debt discount of approximately $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20240930_zBDxCiJYsPK2" title="Debt discount, current"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextRef="AsOf2024-09-30" id="Fact000901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">397,000</ix:nonFraction></span> and the current portion of debt origination costs of approximately $<span id="xdx_904_eus-gaap--DeferredFinanceCostsCurrentNet_iI_c20240930_zNKvXoyp7qsg" title="Debt origination costs, current"><ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2024-09-30" id="Fact000903" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> as of September 30, 2024.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term portion of debt of approximately $<span id="xdx_904_eus-gaap--DeferredFinanceCostsNoncurrentGross_iI_c20240930_zEs4B5YzXbf9" title="Long-term debt, non current"><ix:nonFraction name="us-gaap:DeferredFinanceCostsNoncurrentGross" contextRef="AsOf2024-09-30" id="Fact000905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,000</ix:nonFraction></span> is net of the long-term portion of debt discount of approximately $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20240930_zC0vbMLiyli1" title="Debt discount, non current"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" contextRef="AsOf2024-09-30" id="Fact000907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,000</ix:nonFraction></span> and the unamortized debt origination costs of approximately $<span id="xdx_909_eus-gaap--DeferredFinanceCostsNoncurrentNet_iI_c20240930_zaA5Ts4qZz5c" title="Debt origination costs, non current"><ix:nonFraction name="us-gaap:DeferredFinanceCostsNoncurrentNet" contextRef="AsOf2024-09-30" id="Fact000909" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></span> as of September 30, 2024.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentRedemptionDescription_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zdzkBdvHSll3" title="Redemption description"><ix:nonNumeric contextRef="From2024-02-162024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember" id="Fact000911" name="us-gaap:DebtInstrumentRedemptionDescription">The
agreement allows the Lender to redeem up to $250,000 per calendar month beginning in August 2024, upon providing written notice to Borrower.</ix:nonNumeric></span>
The Note further contains triggering events which can be remedied by the Lender requiring the Borrower to correct the triggering event,
increasing the outstanding balance by applying the triggering effect, or making the Note immediately due and payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact000913" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zh3Get3u1WJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8: <span id="xdx_826_zl4NLBGUAcmb">Equity-Based Compensation </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2018 Equity Incentive Plan, effective September 12, 2018, as amended and restated on August 19, 2019 (the &#8220;2018 Equity
Incentive Plan&#8221;) authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock
Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii)
Performance Cash Awards, and (viii) Other Stock Awards. After taking into account the <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20180912__20180912__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z5Ns7upVg8jl" title="Stockholders equity reverse stock split"><ix:nonNumeric contextRef="From2018-09-122018-09-12_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000915" name="us-gaap:StockholdersEquityReverseStockSplit">44:1 reverse stock split</ix:nonNumeric></span> which was effected in
June 2019, initially, a maximum of <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20180912__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zM5eWYs3gOz9" title="Number of stock is reserved for potential issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2018-09-12_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000917" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">230,390</ix:nonFraction></span>
shares of common stock were reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan. When the plan
was amended and restated, an additional <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20180912__us-gaap--PlanNameAxis__custom--RestatedTwoThousandEighteenEquityIncentivePlanMember_zepBZ2X2JJ91" title="Number of stock is reserved for potential issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2018-09-12_custom_RestatedTwoThousandEighteenEquityIncentivePlanMember" id="Fact000919" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span>
shares were reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan. The number of shares of the
Company&#8217;s common stock available for grant and issuance under the 2018 Equity Incentive Plan is subject to an annual increase
on July 1 of each calendar year, by an amount equal to two percent (2%) of the then outstanding shares of the Company&#8217;s common
stock (the &#8220;2018 Plan Evergreen Provision&#8221;). On August 3, 2020, and July 1, 2021, 2022, 2023 and 2024, the number of
shares of the Company&#8217;s common stock available for grant and issuance under the 2018 Equity Incentive Plan increased by <span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20200803__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zSpUj2Db4E4b" title="Number of stock is reserved for potential issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-08-03_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000921" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">685,012</ix:nonFraction></span>
shares, <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zf33XvYiGk97" title="Number of stock is reserved for potential issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000923" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">956,660</ix:nonFraction></span>
shares, <span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zBbAwwsEjpd5" title="Number of stock is reserved for potential issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000925" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">960,976</ix:nonFraction></span>
shares, <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKsli0FMfluf" title="Number of stock is reserved for potential issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000927" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">968,389</ix:nonFraction></span>
and <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zBPGcH9fZNL5" title="Number of stock is reserved for potential issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000929" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,142,733</ix:nonFraction></span>
shares, respectively. As a result of the 2018 Plan Evergreen Provisions, a maximum of <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zVScmBNLTND9" title="Number of stock is reserved for potential issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2024-09-30_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000931" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,167,160</ix:nonFraction></span>
shares of common stock is reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan as of September
30, 2024. Unless sooner terminated, the 2018 Equity Incentive Plan will continue in effect for a period of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20180912__20180912__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_znPFYVH4i0Sa" title="Option vested years"><ix:nonNumeric contextRef="From2018-09-122018-09-12_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact000933" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">10</ix:nonNumeric></span>
years from its effective date. During the fiscal year ended December 31, 2018, the Board of Directors issued <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20180101__20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zWJLKt2DDjY2" title="Number of options issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2018-01-012018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember" id="Fact000935" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,189,284</ix:nonFraction></span>
options to each employee, the officers and directors at the exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20180101__20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zCcvL9Kb4Xnb" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2018-01-012018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember" id="Fact000937" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></span>
expiring in <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20180101__20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zGI9O7TGMhKe" title="Expiration period"><ix:nonNumeric contextRef="From2018-01-012018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember" format="ixt-sec:duryear" id="Fact000939" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">10</ix:nonNumeric></span>
years <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20180101__20181231_znVg4dNtEGU5" title="Stockholders equity reverse stock split"><ix:nonNumeric contextRef="From2018-01-012018-12-31" id="Fact000941" name="us-gaap:StockholdersEquityReverseStockSplit">(27,028 options post reverse split)</ix:nonNumeric></span>. During the fiscal year ending December 31, 2019, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zeW3j5Ztk5Cj" title="Number of options issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-01-012019-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember" id="Fact000943" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,727,756</ix:nonFraction></span>
options were issued to each of these officers with an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zcUoNv9gWtJ8" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember" id="Fact000945" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.68</ix:nonFraction></span>
for a period of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20190101__20191231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zPXJcKkMOhde" title="Expiration period"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember" format="ixt-sec:durwordsen" id="Fact000947" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten
years</ix:nonNumeric></span> with a vesting period of <span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20190101__20191231_z2xit69fxrcb" title="Stockholders equity reverse stock split"><ix:nonNumeric contextRef="From2019-01-012019-12-31" id="Fact000949" name="us-gaap:StockholdersEquityReverseStockSplit">one year (39,266 options post reverse split).</ix:nonNumeric></span> During the fiscal year ending December 31, 2020, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zmeg4dVDRNm3" title="Number of options issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,025,000</ix:nonFraction></span>
options were issued to each of these officers and directors with an exercise price range of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zTVwL4ez8rTl" title="Exercise price range"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_MinimumMember" id="Fact000953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.77</ix:nonFraction></span>
to $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z713DIxSEuT3" title="Option exercise price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_srt_OfficerMember_srt_MaximumMember_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.07</ix:nonFraction></span>
for a period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200101__20201231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z5uk8Bere3nb" title="Expiration period"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember" format="ixt-sec:durwordsen" id="Fact000957" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten
years</ix:nonNumeric></span> with a vesting period of one year. During the fiscal year ending December 31, 2021, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zsCDxuA8GMLg" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000959" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">613,512</ix:nonFraction></span>
options were issued to officers, directors and consultants with an exercise price range of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_z4RfXftsVTMi" title="Exercise price range"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_MinimumMember" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.11</ix:nonFraction></span>
to $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zxTnbndBT9Gj" title="Option exercise price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-12-31_srt_OfficerMember_srt_MaximumMember_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.71</ix:nonFraction></span>
for a period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKybHGnE7cKh" title="Expiration period"><ix:nonNumeric contextRef="From2021-01-012021-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt-sec:durwordsen" id="Fact000965" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten
years</ix:nonNumeric></span> with a vesting period of one year. During the fiscal year ending December 31, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zzlmhdaSrfYh" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">850,000</ix:nonFraction></span>
options were issued to officers, directors and consultants with an exercise price range of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKAhZBMvT4m4" title="Option exercise price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_srt_OfficerMember_srt_MinimumMember_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000969" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></span>
to $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zSdfv7msygx6" title="Option exercise price per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_srt_OfficerMember_srt_MaximumMember_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000971" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.71</ix:nonFraction></span>
for a period of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zA0GtgA6Paga" title="Expiration period"><ix:nonNumeric contextRef="From2022-01-012022-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt-sec:durwordsen" id="Fact000973" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten
years</ix:nonNumeric></span> with a vesting period of one year. During the fiscal year ending December 31, 2023, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zbza9FnqKFl9" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000975" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,000</ix:nonFraction></span>
options were issued to officers with an exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zTLR2sRmaCzc" title="Exercise price range"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000977" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.47</ix:nonFraction></span>
for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zIvzsvbAwMue" title="Expiration period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember" format="ixt-sec:durwordsen" id="Fact000979" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten
years</ix:nonNumeric></span> with a vesting period of one year. During the nine months ended September 30, 2024 there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20240101__20240930__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zY288SslhGRk" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-09-30_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000981" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span>
options issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation
model. Expected volatility is based on the historical volatility of the price of the Company&#8217;s stock. The risk-free interest rate
is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical
data to estimate expected dividend yield, expected life and forfeiture rates. During the nine months ended September 30, 2024, and 2023,
there were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20240101__20240930__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zJZRsp0gA9hk" title="Number of options granted"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20230101__20230930__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zxe4UkvTeVB1" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-09-30_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000983" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-09-30_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact000985" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> options granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options activity during the three months ended September 30, 2024, was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" continuedAt="ConU000989-01" escape="true" id="Fact000989" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SOSBCSOASA-KMP_zh7fODkBMfI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zELmZh9E6l79" style="display: none">Schedule
of Stock Option Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/> Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding June 30, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjyD49yckon5" title="Number of options outstanding, beginning of year" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact000991" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,407,775</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUDZ6B9tPuhk" title="Weighted Average Exercise Price Outstanding, Beginning of Period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact000993" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zA6WtLyZASid" title="Weighted Average Remaining Contracted Term (years) Outstanding"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact000995" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.70</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsI90ptM0jv6" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl0997">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlJOUT20gvv" title="Number of options, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHLE9He70K7f" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1001">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUqxUDPKGHFg" title="Aggregate Intrinsic Value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1003">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9AaJcEwgYJh" title="Number of Options, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1005">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7JJEhxpI8t1" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1007">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zH3aSRizWyMk" title="Aggregate Intrinsic Value, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1009">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIJ6I7oTvk64" title="Number of Options, Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001011" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7AT3mlVDgFa" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1013">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zaxovopTHiic" title="Aggregate Intrinsic Value, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1015">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSb3FI5Sl4P9" title="Number of Options Outstanding, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001017" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,407,680</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziURHvTtM7Wk" title="Weighted Average Exercise Price Outstanding, End of Period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001019" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.44</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7nelISYhCrd" title="Weighted Average Remaining Contracted Term (years)"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001021" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">8.70</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zqhlUrLQeYt5" title="Aggregate Intrinsic Value Outstanding, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1023">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoXN9PEJ5iLk" title="Number of Options, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001025" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,407,680</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCF6ICTITSrg" title="Weighted Average Exercise Price, Vested and Expected to Vest"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001027" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.44</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjEemedfkDJ3" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001029" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">8.70</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNwglLCnLnB1" title="Aggregate Intrinsic Value, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1031">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbhf65Q8YFt7" title="Number of Options Exercisable, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001033" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,341,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl7Tc0AMcUah" title="Weighted Average Exercise Price Exercisable, Ending of Period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001035" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.66</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSKGKa98BCnd" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001037" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.17</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zb7jfHMAqa5e" title="Aggregate Intrinsic Value, Exercisable at End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1039">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zrU2qa2FTRGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" continuedAt="ConU001044-01" escape="true" id="Fact001044" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SONSATTB-QOTKSOK_zQj05qtEmQE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
stock option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z9DxytPfegse" style="display: none">Schedule
of Unvested Stock Option Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/>Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/> Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Unvested June 30, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z84haaRrIaI6" title="Number of Options Unvested, Beginning of Period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001046" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">166,666</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOPx0OQtrqJb" title="Weighted Average Exercise Price Unvested, Beginning of Period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001048" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.11</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhcjV7bPlK7e" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001050" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">18.87</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbJjxQA7vjk4" title="Aggregate Intrinsic Value Unvested, Beginning of Period" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMg0PpIF6h3c" title="Number of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOG76PIF5jX9" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1056">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zytehApLdBq6" title="Aggregate Intrinsic Value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl4AwqJtOUXg" title="Number of Options, Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001060" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVvGzMWc26n8" title="Weighted Average Exercise Price, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z702F2nVWw5l" title="Aggregate Intrinsic Value, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRGMkXjIjQIh" title="Number of Options, Vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001066" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">99,905</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z5W5LUTZBwu2" title="Weighted Average Exercise Price, Vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001068" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zGhlSXfeXe6d" title="Weighted Average Remaining Contracted Term (years) Vested"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001070" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm">7.17</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTPUpqtwN4og" title="Aggregate Intrinsic Value, Vested" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjiOohm1j9rd" title="Number of Options Unvested, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001074" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbnRsZ3Zcdk5" title="Weighted Average Exercise Price Unvested, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001076" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.61</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV3ToK6T3u89" title="Average Remaining Contractual Term (years) Unvested, End of Period"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001078" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2">36.22</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUafxgzWlok5" title="Aggregate Intrinsic Value Unvested, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1080">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zuH4ZGrHpM0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" continuedAt="ConU001084-01" escape="true" id="Fact001084" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SOSBCSOASA-DNQVA_zuXh3tppq76j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zx8D0sBXYWv9" style="display: none">Schedule
of Stock Option Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding June 30, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaF5yDYcOZA7" title="Number of Options Outstanding, Beginning of Period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001086" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">885,055</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z7kZUofcgBYe" title="Weighted Average Exercise Price Outstanding, Beginning of Period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001088" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zftq24OTTlz7" title="Weighted Average Remaining Contracted Term (years) Outstanding"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001090" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.23</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcJElAxfvgD6" title="Aggregate Intrinsic Value Outstanding, Beginning of Period" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1092">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdySOjgFrc5a" title="Number of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1094">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCvgHS82Mkwi" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1096">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z2s1Nfh7zpJe" title="Aggregate Intrinsic Value Outstanding, Beginning of Period" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMpaDHJEvhw2" title="Number of Options, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1100">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeKE3oa92K1f" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhjdzz3wNJak" title="Aggregate Intrinsic Value, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1104">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z710pkk0K0uh" title="Number of Options, Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001106" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabMb2JSrqdd" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztqKFXx2XeCd" title="Aggregate Intrinsic Value, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1110">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeAutH3C3k71" title="Number of Options Outstanding, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">884,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z30GS8sFl1ak" title="Weighted Average Exercise Price Outstanding, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001114" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9ABWbeWmxz3" title="Weighted Average Remaining Contracted Term (years) Outstanding"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001116" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">9.23</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfXx2BNnCGS4" title="Aggregate Intrinsic Value, Expired" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zz9QdZSHTZuj" title="Number of Options, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001120" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">884,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhLvrb2naeBe" title="Weighted Average Exercise Price, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXLoaRrf9Nvi" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001124" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">9.23</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAnWbQZRLmYk" title="Aggregate Intrinsic Value, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRESdE1Et5lh" title="Number of Options Exercisable, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">729,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zl9srwqwk9kc" title="Weighted Average Exercise Price Exercisable, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001130" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.87</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zu2ni2MpRR0a" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001132" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">10.06</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFkhX2aFesW2" title="Aggregate Intrinsic Value, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1134">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zNrthgPuYDXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" continuedAt="ConU001139-01" escape="true" id="Fact001139" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SONSATTB-BWM_z7TXuu6oUU0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
stock option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zXrhTt3hW8sd" style="display: none">Schedule
of Unvested Stock Option Activity</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/>Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Unvested June 30, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjsXfy3G7EIc" title="Number of Options Unvested, Beginning of Period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">155,001</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zng86shSyV5i" title="Weighted Average Exercise Price Unvested, Beginning of Period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001143" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.42</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zyzkdqaqA9La" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001145" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">11.30</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUSMNti8XCE7" title="Aggregate Intrinsic Value Unvested, Beginning of Period" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1147">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZW30cPwV71a" title="Number of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1149">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFNQl2tfVz83" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1151">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zo7fYGT9D579" title="Aggregate Intrinsic Value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0n4X6iePLti" title="Number of Options, Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001155" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zr8ObjoHO3b4" title="Weighted Average Exercise Price, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1157">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRzwbedcMbrf" title="Aggregate Intrinsic Value, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1159">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYIPol713VB9" title="Number of Options, Vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001161" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcCNSfs1wMbi" title="Weighted Average Exercise Price, Vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001163" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwaIDvMMIrt5" title="Average Remaining Contractual Term Vested"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001165" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm">10.18</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMTvchDc45Of" title="Aggregate Intrinsic Value, Vested" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zE2w3bbv2uFl" title="Number of Options Unvested, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001169" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">155,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zyZlk7DeOZ6" title="Weighted Average Exercise Price Unvested, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001171" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUOg3jQg6uz8" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"><ix:nonNumeric contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001173" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2">11.31</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBQ8EF5Zv8ui" title="Aggregate Intrinsic Value Unvested, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1175">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zQqB44N6O36d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense was approximately $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20240701__20240930_zlWx30wz2pFi" title="Share based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012024-09-30" id="Fact001177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20230701__20230930_zBP7qd56yUj8" title="Share based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012023-09-30" id="Fact001179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> for the three months ended September 30, 2024, and 2023, resulting in an increase
in general and administrative expenses, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
stock option activity during the nine months ended September 30, 2024, was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div id="xdx_C06_gL3SOSBCSOASA-KMP_zFYpVLRmIcz5"><ix:continuation continuedAt="ConU000989-02" id="ConU000989-01"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_134_zbpFI8KrQIwe" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/> Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWsKzf9ySWcd" title="Number of options outstanding, beginning of year" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,408,438</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrvicYzwmdP5" title="Weighted Average Exercise Price Outstanding, Beginning of Period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001183" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.50</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zN11clVZ5eVd" title="Weighted Average Remaining Contracted Term (years) Outstanding"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001185" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.70</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zS9HesshdjB8" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1187">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zy6V6T5rRRN" title="Number of options, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1189">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWJ8tezMnSG9" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1191">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhNtAfhE9CKc" title="Aggregate Intrinsic Value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1193">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUJy01uAGkja" title="Number of Options, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1195">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z4k29IU5MeS8" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1197">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZ3INBtll8s8" title="Aggregate Intrinsic Value, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3RLPP1Z58l5" title="Number of Options, Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001201" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">758</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z5a9p87y7Nvl" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1203">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7rBX5pcldNj" title="Aggregate Intrinsic Value, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1205">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9PiyYO55108" title="Number of Options Outstanding, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001207" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,407,680</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zgiaI51Yf8Ud" title="Weighted Average Exercise Price Outstanding, End of Period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001209" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.44</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV7PHskuC1te" title="Weighted Average Remaining Contracted Term (years)"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001211" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">8.70</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziTI4BvTbXZd" title="Aggregate Intrinsic Value Outstanding, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1213">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9jbdJ1UeeN2" title="Number of Options, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001215" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,407,680</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrwk3sPKL9r7" title="Weighted Average Exercise Price, Vested and Expected to Vest"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001217" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.44</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zISzyz1ExvRd" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001219" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">8.70</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8k63vScsNze" title="Aggregate Intrinsic Value, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1221">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8jCkn80oLDd" title="Number of Options Exercisable, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001223" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,341,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zm7FjiaJ5nX1" title="Weighted Average Exercise Price Exercisable, Ending of Period"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001225" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.66</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlpZTqTiXH5" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001227" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.17</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNuy0VHkTDIi" title="Aggregate Intrinsic Value, Exercisable at End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1229">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0E_gL3SOSBCSOASA-KMP_zZkor6JBlWQd"><ix:continuation id="ConU000989-02">&#160;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
stock option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_C0A_gL3SONSATTB-QOTKSOK_zBTuXomo6wV6"><ix:continuation continuedAt="ConU001044-02" id="ConU001044-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></ix:continuation></span></p>

<div id="xdx_C06_gL3SONSATTB-QOTKSOK_zZpy4ve80s04"><ix:continuation continuedAt="ConU001044-03" id="ConU001044-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_134_zAZ64rbchUKi" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/>Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/> Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Unvested January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrsbidNc06B2" title="Number of Options Unvested, Beginning of Period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001231" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">366,666</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zStSkwQd2cG2" title="Weighted Average Exercise Price Unvested, Beginning of Period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001233" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.13</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zheVkcZA5wN6" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001235" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">12.44</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0qY0UsmBYE8" title="Aggregate Intrinsic Value Unvested, Beginning of Period" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1237">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zudH9uJhIe6a" title="Number of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSLDdwvQEmd1" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1241">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z27QE6z6S5j5" title="Aggregate Intrinsic Value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1243">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zorokXUxmwrj" title="Number of Options, Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">758</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zKpUHgKinFYd" title="Weighted Average Exercise Price, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRFXpXaqQykh" title="Aggregate Intrinsic Value, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1249">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zu3UHcuxfiG2" title="Number of Options, Vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">299,242</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXQeItkxToq4" title="Weighted Average Exercise Price, Vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001253" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zh9JpIprSBu" title="Weighted Average Remaining Contracted Term (years) Vested"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001255" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm">7.17</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zucRbwQeqIJg" title="Aggregate Intrinsic Value, Vested" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1257">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zouqYb3AJvB7" title="Number of Options Unvested, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001259" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziPvgbO0hBaa" title="Weighted Average Exercise Price Unvested, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" id="Fact001261" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.61</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJpG8ywn1Zi" title="Average Remaining Contractual Term (years) Unvested, End of Period"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember" format="ixt-sec:duryear" id="Fact001263" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2">36.22</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRctqqO8TGzl" title="Aggregate Intrinsic Value Unvested, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0C_gL3SONSATTB-QOTKSOK_zgDqFqbCeDhd"><ix:continuation id="ConU001044-03">&#160;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div id="xdx_C04_gL3SOSBCSOASA-DNQVA_z9pVz8jZzuFk"><ix:continuation continuedAt="ConU001084-02" id="ConU001084-01"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_134_z5EIUSL00SQj" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAx9aZk5OJy1" title="Number of Options Outstanding, Beginning of Period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001267" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">885,055</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8Yy6kGEQ4gb" title="Weighted Average Exercise Price Outstanding, Beginning of Period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001269" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.02</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zveAC0DMk4z8" title="Weighted Average Remaining Contracted Term (years) Outstanding"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001271" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.23</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWf50mYIhqz3" title="Aggregate Intrinsic Value Outstanding, Beginning of Period" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1273">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWvZ5bQsiAw5" title="Number of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1275">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfVgCh1XgInb" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGBxQLenuel9" title="Aggregate Intrinsic Value Outstanding, Beginning of Period" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1279">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zLhHJxFeAAWb" title="Number of Options, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1281">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIBK4GHzRX4" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1283">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPHXTzz1QA24" title="Aggregate Intrinsic Value, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1285">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMBcS49SknKb" title="Number of Options, Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001287" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUTYNo2XeF6b" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1289">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwxBMmTX69k8" title="Aggregate Intrinsic Value, Expired" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1291">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zg8oTRGTPnQh" title="Number of Options Outstanding, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001293" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">884,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMuWMj8NH6ef" title="Weighted Average Exercise Price Outstanding, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001295" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzu1hl5CNjUc" title="Weighted Average Remaining Contracted Term (years) Outstanding"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001297" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">9.23</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztMrm84L0PBa" title="Aggregate Intrinsic Value, Expired" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1299">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpinr46l4aYf" title="Number of Options, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001301" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">884,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zM7xY4RRunc5" title="Weighted Average Exercise Price, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001303" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsq7ABwkucle" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001305" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">9.23</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUPo1PxB47Df" title="Aggregate Intrinsic Value, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1307">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpXb0qGCGuW6" title="Number of Options Exercisable, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">729,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHk8CF75wanf" title="Weighted Average Exercise Price Exercisable, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001311" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.87</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuXm6S64XwJj" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001313" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">10.06</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZvKwcanEdFa" title="Aggregate Intrinsic Value, Vested and Expected to Vest" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1315">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C08_gL3SOSBCSOASA-DNQVA_zzy3q39sC92l"><ix:continuation id="ConU001084-02">&#160;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
stock option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0B_gL3SONSATTB-BWM_zfB4RMT3VGs"><ix:continuation continuedAt="ConU001139-02" id="ConU001139-01">&#160;</ix:continuation></span></span></p>

<div id="xdx_C01_gL3SONSATTB-BWM_zOhQk7WcFAvi"><ix:continuation continuedAt="ConU001139-03" id="ConU001139-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_134_zi3j29Bqb4l" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/>Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Exercise <br/> Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/> Intrinsic <br/>Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Unvested January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztMKYaa2HcQ7" title="Number of Options Unvested, Beginning of Period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001317" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">335,001</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwWwzRJl4Fs4" title="Weighted Average Exercise Price Unvested, Beginning of Period" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001319" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.83</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvt3P0Xidfej" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001321" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">10.70</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoypW4H5aJF" title="Aggregate Intrinsic Value Unvested, Beginning of Period" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1323">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKQZKbADmTGg" title="Number of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1325">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIn40faYM6ml" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zedKPVdPJhJb" title="Aggregate Intrinsic Value, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1329">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z1CmUEv6YRF2" title="Number of Options, Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001331" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">95</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zItSoXu7NGHb" title="Weighted Average Exercise Price, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zN47RSNjmyNe" title="Aggregate Intrinsic Value, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1335">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTJT17NtE8M4" title="Number of Options, Vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,905</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zbPwr0p8XMQ" title="Weighted Average Exercise Price, Vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001339" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhOprlOO2tMk" title="Average Remaining Contractual Term Vested"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001341" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm">10.18</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcKVg4IKRwBk" title="Aggregate Intrinsic Value, Vested" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqPrUzeBm0jc" title="Number of Options Unvested, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001345" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">155,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVCsCim7RUvc" title="Weighted Average Exercise Price Unvested, Ending of Period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" id="Fact001347" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeugZ61eatxh" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" format="ixt-sec:duryear" id="Fact001349" name="AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2">11.31</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzEf8hRTmQY7" title="Aggregate Intrinsic Value Unvested, End of Period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1351">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_C09_gL3SONSATTB-BWM_z5foyejtwwn7"><ix:continuation id="ConU001139-03"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense was approximately $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240930_zl13KkQhH6r1" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-09-30" id="Fact001353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930_z40MJp1EWLu5" title="Share based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30" id="Fact001355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,000</ix:nonFraction></span> for the nine months ended September 30, 2024, and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Company&#8217;s cash conservation strategy, the Company issued common stock as a substitute for cash salaries to certain
executives. For the three and nine months ended September 30, 2024, stock issued as payroll totaled $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20240701__20240930_z2yi3uNrBDij" title="Stock issued as payroll, value"><span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20240101__20240930_zaXVnXiACW1l" title="Stock issued as payroll, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-012024-09-30" id="Fact001357" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-09-30" id="Fact001359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></ix:nonFraction></span></span>, which is included in the
overall equity-based compensation expense. There was no stock issued as payroll for the three and nine months ended September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, and 2023, respectively, there was approximately $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20240930_zKS25oHb6946"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-09-30" id="Fact001360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,400</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230930_zgb2CZZ4zs42"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2023-09-30" id="Fact001361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of unrecognized equity-based compensation cost
related to options granted under the Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001363" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgmcER7ZoG6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9: <span id="xdx_825_zvWLU1z6KInl">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930_zOqRZT6lrsj3" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact001365" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> shares of $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240930_zyGSvb1nsSxi" title="Preferred stock stated value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" id="Fact001367" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> par value preferred stock with such designations, rights and preferences as
may be determined by the Board. Of our authorized preferred stock, <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zRTeQtHLu6kk" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact001369" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span> shares have been designated as Series A Junior Participating
Preferred Stock and <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zhMAyH0nNXuk" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact001371" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares have been designated as Series B Convertible Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A Junior Participating Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series
A Junior Participating Preferred Stock to <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230509__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zfxXoYbt2Aqj" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-05-09_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact001373" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000,000</ix:nonFraction></span> from <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zKWhsVN7Y272" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-05-10_custom_SeriesAJuniorParticipatingPreferredStockMember" id="Fact001375" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares. As of September 30, 2024, there were no Series A Junior Participating
Preferred Stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
B Convertible Preferred Stock </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has designated <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zI3n7ruFUJ8d"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact001376" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares of its preferred stock as Series B Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;).
Each share of Preferred Stock has a par value of $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zs73uTZx61vb" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact001378" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share and a stated value equal to $<span id="xdx_90C_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zA0Fuo8Eh4c" title="Preferred stock, stated value"><ix:nonFraction name="AIM:PreferredStockStatedValuePerShare" contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact001380" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span> (the &#8220;Stated Value&#8221;).
The shares of Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository
Trust Company or its nominee (&#8220;DTC&#8221;) shall initially be the sole registered holder of the shares of Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option
of the Holder thereof or at any time and from time to time on or after the second anniversary of the Original Issue Date at the option
of the Corporation, into that number of shares of common stock (subject in each case to the limitations determined by dividing the Stated
Value of such share of Preferred Stock by the Conversion Price). The conversion price for the Preferred Stock shall be equal to $<span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20240930_zR3DqConzAKj" title="Preferred stock conversion price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2024-09-30" id="Fact001382" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.20</ix:nonFraction></span>,
subject to adjustment herein (the &#8220;Conversion Price&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a registration statement relating to a rights offering (the &#8220;Rights Offering&#8221;) declared effective by the SEC on February
14, 2019, AIM distributed to its holders of common stock and to holders of certain options and redeemable warrants as of February 14,
2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each
right entitled the holder to purchase one unit, at a subscription price of $<span id="xdx_906_eus-gaap--CommonStockSharesSubscriptions_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zKFSenSQuSh3" title="Subscription price"><ix:nonFraction name="us-gaap:CommonStockSharesSubscriptions" contextRef="AsOf2024-09-30_us-gaap_RightsMember" id="Fact001384" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span> per unit, consisting of one share of Series B Convertible
Preferred Stock with a face value of $<span id="xdx_909_ecustom--ConvertiblePreferredStockFaceValue_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zqxI7z5v5fZ6" title="Convertible preferred stock face value"><ix:nonFraction name="AIM:ConvertiblePreferredStockFaceValue" contextRef="AsOf2024-09-30_us-gaap_RightsMember" id="Fact001386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction> </span>(and immediately convertible into common stock at an assumed conversion price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN3mPLUCoTSa" title="Conversion price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact001388" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.80</ix:nonFraction></span>) and
<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240930_zmqXhS7lPcxe" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-09-30" id="Fact001390" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">114</ix:nonFraction></span> warrants with an assumed exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930_zCFqUw37Tfm9" title="Subscription/exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-30" id="Fact001392" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.80</ix:nonFraction></span>. The redeemable warrants are exercisable for five years after the date of issuance.
The net proceeds realized from the rights offering were approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zJ5uCOPkTQP4" title="Net proceeds from warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-09-30_us-gaap_RightsMember" id="Fact001394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,700,000</ix:nonFraction></span>. As of September 30, 2024, <span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_pid_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zAzKca2mMK04" title="Conversion of shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2024-01-012024-09-30_custom_SeriesBConvertiblePreferredStockMember" id="Fact001396" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">689</ix:nonFraction></span> shares of Series B Convertible
Preferred Stock had expired, and none were converted prior to expiration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Common Stock and Equity Finances</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has authorized shares of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_zKV0ggF1L197" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact001398" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></span> with specific limitations and restrictions on the usage of <span id="xdx_90D_ecustom--CommonStockSharesWithLimitationsAndRestrictionsOnUsage_iI_pid_c20240930_zHeSxRoLoD11" title="Common stock specific limitations and restrictions on usage"><ix:nonFraction name="AIM:CommonStockSharesWithLimitationsAndRestrictionsOnUsage" contextRef="AsOf2024-09-30" id="Fact001400" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></span> of the <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_zOLECR8Uf3c8" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact001402" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></span>
authorized shares. <span style="background-color: white">As of September 30, 2024, and December 31, 2023, there were <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20240930_z5s2RDcpK1Ng" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240930_z3VuKo6Z0eh3" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-30" id="Fact001404" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-09-30" id="Fact001406" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,668,647</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zLy7uy3idNR7" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zGzCzttgT758" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact001408" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact001410" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,102,484</ix:nonFraction></ix:nonFraction></span></span>
shares of common stock issued and outstanding, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Employee
Stock Purchase Plan (Not equity compensation)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to
an aggregate of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200707__20200707__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsOfficersAndEmployeesMember_zpDOzkNs9kNe" title="Common stock shares issued, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-07-072020-07-07_custom_DirectorsOfficersAndEmployeesMember" id="Fact001412" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> worth of shares at the market price (including subsequent plans, the &#8220;Employee Stock Purchase Plan&#8221;).
Pursuant to NYSE American rules, this plan was effective for a sixty-day period commencing upon the date that the NYSE American approved
the Company&#8217;s Supplemental Listing Application. The Company created successive new plans following the expiration of the July 7,
2020 plan. The latest plan was approved by the Board on October 21, 2024 and expires in December 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2024, the Company did <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_do_c20240701__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zJNGUQY8NQi3" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember62774140" id="Fact001414" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span>t issue any shares of its common stock as part of the employee stock purchase
plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2024, the Company issued a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_za44fl9EQlw8" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact001416" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">335,603</ix:nonFraction></span> shares of its common stock at a price ranging from $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zixXXzTxGMTa" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember_srt_MinimumMember" id="Fact001418" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.33</ix:nonFraction></span>
to $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zd2pavd939oa" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember_srt_MaximumMember" id="Fact001420" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.41</ix:nonFraction></span> for total proceeds of approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zPotQyhb5qZ7" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember" id="Fact001422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> as part of the employee stock purchase plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023, the Company issued a total of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zBJQFnmATZ73" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember62774171" id="Fact001424" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,841</ix:nonFraction></span> shares of its common stock at a price ranging from $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zEP0jVJQ2aF5" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember_srt_MinimumMember" id="Fact001426" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.44</ix:nonFraction></span>
to $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zQ6VeuTyZU68" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember_srt_MaximumMember" id="Fact001428" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.67</ix:nonFraction></span> for total proceeds of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zeyu7mvaf40i" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember62774171" id="Fact001430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,500</ix:nonFraction></span> as part of the employee stock purchase plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the nine months ended September
30, 2023, the Company issued a total of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zzN3cXNuqCf" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="Fact001432" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">385,424</ix:nonFraction></span> shares of its common stock at a price ranging from $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zy0tzmCUB1i6" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember_srt_MinimumMember" id="Fact001434" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></span> to $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_z6XHYrdt27K3" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember_srt_MaximumMember" id="Fact001436" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.67</ix:nonFraction></span> for total proceeds of
approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zgJMA0cJubDi" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="Fact001438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,000</ix:nonFraction></span> as part of the employee stock purchase plan.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Rights
Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer &amp; Trust Company as
Rights Agent (the &#8220;Rights Plan&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants
(Rights offering)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the &#8220;Offering&#8221;)
of (i) <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20190926__20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zBg7vwwbMv06" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember" id="Fact001440" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,740,550</ix:nonFraction></span> shares of common stock; (ii) pre-funded warrants exercisable for <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zzFUxZG6TFE9" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember" id="Fact001442" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,148,310</ix:nonFraction></span> shares of common stock (the &#8220;Pre-funded
Warrants&#8221;), and (iii) warrants to purchase up to an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zk06vIxeMAvj" title="Number of warrant to purchase shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_WarrantsMember" id="Fact001444" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,888,860</ix:nonFraction></span> shares of common stock (the &#8220;Warrants&#8221;).
In conjunction with the Offering, we issued </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Representative&#8217;s
Warrant to purchase up to an aggregate of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zpn7ey1dppSj" title="Number of warrant to purchase shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember" id="Fact001446" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">266,665</ix:nonFraction></span> shares of common stock (the &#8220;Representative&#8217;s Warrant&#8221;)<span style="background-color: white">.
The shares of common stock and Warrants were sold at a combined Offering price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zxpcFYlkmU31" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_PreFundedWarrantsMember" id="Fact001448" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.90</ix:nonFraction></span>, less underwriting discounts and commissions.
Each Warrant sold with the shares of common stock represents the right to purchase one share of common stock at an exercise price of
$<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Ahw2qUTV0f" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-09-27_us-gaap_WarrantMember" id="Fact001450" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.99</ix:nonFraction></span> per share. The Pre-Funded Warrants and Warrants were sold at a combined Offering price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zr7VaKtovb9i" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember" id="Fact001452" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.899</ix:nonFraction></span>, less underwriting discounts and
commissions. The Pre-Funded Warrants were sold to purchasers whose purchase of shares of common stock in the Offering would otherwise
result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than <span id="xdx_90B_ecustom--PercentageOfOutstandingStock_iI_pid_dp_uPure_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zedz8pMBZfjc" title="Percentage of outstanding stock"><ix:nonFraction name="AIM:PercentageOfOutstandingStock" contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember" id="Fact001454" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span>% of the Company&#8217;s
outstanding common stock immediately following the consummation of the Offering, in lieu of shares of common stock. Each Pre-Funded Warrant
represents the right to purchase one share of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zz4bJv3T8bt8" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember" id="Fact001456" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. The Pre-Funded Warrants are exercisable
immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full. A registration statement on Form S-1,
relating to the Offering was filed with the SEC and was declared effective on September 25, 2019, the net proceeds were approximately
$<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190925__20190925__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_z0ASZUL2lSYa" title="Proceeds from issuance or sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2019-09-252019-09-25_custom_AllianceGlobalPartnersLLCMember" id="Fact001458" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,200,000</ix:nonFraction></span>. During the year ended </span>December 31<span style="background-color: white">, 2020, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zYmSzHIwGVuj" title="Stock issued during period shares other"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-01-012020-12-31_custom_PreFundedWarrantsMember" id="Fact001460" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">1,870,000</ix:nonFraction></span> of the Pre-funded Warrants
were exercised and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zctQaPregbB1" title="Pre-funded warrants exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" id="Fact001462" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,873,960</ix:nonFraction></span> Warrants were exercised. </span>In addition, on March 25, 2020, the Representative&#8217;s Warrant was amended
to permit exercise of such warrant to commence on March 30, 2020. These warrants were exercised on March 31, 2020, and an aggregate of
<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200331__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zLqkg4B09CUi" title="Warrants exercised aggregate"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-03-31_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember" id="Fact001464" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">266,665</ix:nonFraction></span> shares were issued upon exercise of this warrant for gross proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200330__20200331_zh9jjVbDpWwg" title="Warrant gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-03-302020-03-31" id="Fact001466" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">264,000</ix:nonFraction></span> and a $<span id="xdx_907_ecustom--WarrantModifications_pp0p0_c20200330__20200331_zhlfJIMnyV66" title="Warrant modification"><ix:nonFraction name="AIM:WarrantModifications" contextRef="From2020-03-302020-03-31" id="Fact001468" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,000</ix:nonFraction></span> expense for the warrant
modification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2024, there were <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_do_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMLHdojv32bi"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-07-012024-09-30_us-gaap_WarrantMember" id="Fact001469" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> warrants exercised and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240701__20240930__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember_zHNu2Pq7YRr7" title="Warrants expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-07-012024-09-30_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember" id="Fact001471" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></span> warrants expired unexercised. During the nine
months ended September 30, 2024, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh9Mlm1aHhB"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember" id="Fact001472" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">205,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants were exercised, and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20240930__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember_zoUWDRKMyD7l" title="Warrants expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-01-012024-09-30_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember" id="Fact001474" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,830,028</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants expired unexercised. As of September
30, 2024 there were <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_do_c20240930_z89reMuARwi6"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-09-30" id="Fact001475" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> warrants outstanding and December 31, 2023 there were <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_zX4TJjnw8aLe"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31" id="Fact001476" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">152,160</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-split
warrants outstanding, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity
Distribution Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 19, 2023, the Company entered into an Equity Distribution Agreement (the &#8220;EDA&#8221;) with Maxim Group LLC (&#8220;Maxim&#8221;),
pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate offering price of up to $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230419__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zMEtwbeO6O05" title="Issuance of common stoc, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-192023-04-19_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001478" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,500,000</ix:nonFraction></span> through Maxim, as agent (the &#8220;Offering&#8221;). Sales under the EDA were registered under the S-3 Shelf Registration Statement.
Under the terms of the EDA, Maxim will be entitled to a transaction fee at a fixed rate of <span id="xdx_908_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230419__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zGKFVuUhU4M1"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2023-04-192023-04-19_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001479" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross sales price of shares sold
under the EDA. During the year ended December 31, 2023, the Company sold <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zOJlSDZcgXu4" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001481" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">598,114</ix:nonFraction></span> shares under the EDA for total gross proceeds of approximately
$<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z3ggv6RmBjze"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001482" format="ixt:numdotdecimal" decimals="0" unitRef="USD">344,000</ix:nonFraction></span>, which includes a <span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zhWfTBAG9ojb"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001483" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% fee to Maxim of $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zMIXKv7gdpsi"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,326</ix:nonFraction></span>. For the three months ended September 30, 2024, the Company sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zCHh2hYi6Ji5" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-07-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001486" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,975</ix:nonFraction></span> shares
under the EDA for total gross proceeds of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zr2xUwumO2Yd"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-07-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,110</ix:nonFraction></span>, which includes a <span id="xdx_901_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zhodRipzm8lg"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2024-07-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001488" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% fee to Maxim of $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zFuh0L88Yfz9"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-07-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123</ix:nonFraction></span>. For the nine months ended
September 30, 2024, the Company sold <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z8NOpmnjpGOa" title="Sale of stock, number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-01-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001491" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,305,653</ix:nonFraction></span> shares under the EDA for total gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z90Up4udVZB9"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">630,204</ix:nonFraction> </span>which includes
a <span id="xdx_90D_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z61pkh309uQi"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2024-01-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001493" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% fee to Maxim of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zy8xvhzKMFqd"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-01-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember" id="Fact001494" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,906</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity
Purchase Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2024, the Company entered into a purchase agreement and a registration rights agreement with Atlas Sciences, LLC (&#8220;Atlas&#8221;),
pursuant to which Atlas committed to purchase up to $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240328__20240328__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAndRegistrationRightsAgreementMember_z6Qmmo76xiK6" title="Issuance of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-03-282024-03-28_us-gaap_CommonStockMember_custom_AtlasSciencesLlcMember_custom_PurchaseAndRegistrationRightsAgreementMember" id="Fact001496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000,000</ix:nonFraction> </span>of common stock of the Company for a period of 24 months from the date
of the purchase agreement. No assurance can be given as to the actual amount that will be raised pursuant to the purchase agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the purchase agreement, the Company, at its sole discretion, shall have the right to issue Put shares to the Investor
at <span id="xdx_90B_ecustom--MarketPricePercentage_iI_pid_dp_uPure_c20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zd08R2QALC9e" title="Market price, percentage"><ix:nonFraction name="AIM:MarketPricePercentage" contextRef="AsOf2024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember" id="Fact001498" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95</ix:nonFraction></span>%
of the Market Price of the shares on the day of trade. Sales under the purchase agreement are limited to a daily maximum of the
lessor of: $<span id="xdx_902_ecustom--TradingDailyMaximumLessorAmount_c20240328__20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z3GK5yc5iheb" title="Trading maximum lessor amount"><ix:nonFraction name="AIM:TradingDailyMaximumLessorAmount" contextRef="From2024-03-282024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember" id="Fact001500" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span>,
the Median Daily Trading volume, and a beneficial ownership limitation of <span id="xdx_90C_ecustom--BeneficialOwnershipPercentage_iI_dp_uPure_c20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zc2r96719jHl" title="Beneficial ownership percentage"><ix:nonFraction name="AIM:BeneficialOwnershipPercentage" contextRef="AsOf2024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember" id="Fact001502" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span>%
and a maximum of <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240328__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z8iLdsFcRGO7" title="Equity investment ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember62774609" id="Fact001504" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.99</ix:nonFraction></span>%
of the outstanding shares at the time of the purchase agreement. In April 2024, the Company filed a registration statement with the
SEC on Form S-1 registering a total of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z0e2Ittf2D41" title="Number of stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-04-012024-04-30_custom_PurchaseAgreementMember" id="Fact001506" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,975,000</ix:nonFraction></span>
shares for resale pursuant to the Atlas Agreements, consisting of <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240401__20240430__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zpx0vsEx6u2j" title="Stock sold by the company"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-04-012024-04-30_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember" id="Fact001508" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,636,400</ix:nonFraction></span>
shares that can be sold by the Company to Atlas and <span id="xdx_906_ecustom--StockIssuedDuringPeriodValueCommitmentShares_pid_c20240401__20240430__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ze5ADbNSqO0c" title="Commitment shares issued"><ix:nonFraction name="AIM:StockIssuedDuringPeriodValueCommitmentShares" contextRef="From2024-04-012024-04-30_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember" id="Fact001510" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">338,600</ix:nonFraction></span>
shares that were issued to Atlas as Commitment Shares. The registration statement was declared effective on May 1, 2024. There were
no shares issued for the three months ended September 30, 2024. As of September 30, 2024, a total of <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_znhEJEEFbAF4" title="Number of stock sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-01-012024-09-30_custom_PurchaseAgreementMember" id="Fact001512" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">759,685</ix:nonFraction></span>
shares have been issued pursuant to the purchase agreement for a total of approximately $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pid_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z0YJkGyaGQYf" title="Amount of stock sold"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-01-012024-09-30_custom_PurchaseAgreementMember" id="Fact001514" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">128,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Securities
Purchase Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) to complete an offering
(the &#8220;Transactions&#8221;) with a single accredited investor (the &#8220;Purchaser&#8221;), pursuant to which, on June 3, 2024, the Company
issued to the Purchaser, (i) in a registered direct offering, <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zvsNQakMz1Dk" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-06-032024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact001516" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,640,958</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;),
par value $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zjHrPc0hk8Df" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" id="Fact001518" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (&#8220;common stock&#8221;) and (ii) in a concurrent private placement, the Company  issued to the Purchaser
Class A common warrants to purchase an aggregate of up to <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_z0WsGfhJuftl" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-06-032024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember" id="Fact001520" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,640,958</ix:nonFraction></span> shares of its common stock (the &#8220;A Warrants&#8221;) at an exercise
price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zvOT7C0I7JFf" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember" id="Fact001522" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.363</ix:nonFraction></span> per share and Class B common warrants to purchase an aggregate of up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonWarrantMember_zEJtUG87iYxd" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-06-032024-06-03_custom_SecuritiesPurchaseAgreementMember_custom_ClassBCommonWarrantMember" id="Fact001524" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,640,958</ix:nonFraction></span> shares of its common stock (the &#8220;B
&#8220;Warrants&#8221; and, along with the A Warrants, the &#8220;Common Warrants&#8221;) at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonWarrantMember_zwuJnVqAau9e" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-03_custom_SecuritiesPurchaseAgreementMember_custom_ClassBCommonWarrantMember" id="Fact001526" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.363</ix:nonFraction></span> per share. The
A Warrants and B Warrants are  not  exercisable for six months after the issuance date and  expire, respectively, 24 months and
five years and six months after the issuance date. The Common Warrants and the shares of common stock issuable upon the exercise of such
warrants are offered pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of
the Securities Act and Rule 506(b) promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares were  offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared
effective on February 4, 2022 (as amended from time to time, the &#8220;Registration Statement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Purchase Agreement, subject to certain exceptions, the Company could not issue any equity securities for 60 days following
the issuance date, provided that the Company was able to utilize its at-the-market offering program with the Placement Agent after
30 days. Additionally, the Company cannot enter into a variable rate transaction (other than the ATM program with the Placement Agent)
for 120 days after the issuance date. In addition, the Company&#8217;s executive officers and each of the Company&#8217;s directors have
entered into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 90 days from the closing
of the Transactions, offer, sell, transfer or otherwise dispose of the Company&#8217;s securities, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The exercise price of the Common Warrants, and the number of Common Warrant
Shares, are subject to adjustment in the event of any stock dividend or split, reverse stock split, recapitalization, reorganization or
similar transaction, as described in the Common Warrants. If a Fundamental Transaction (as defined in the Common Warrants) occurs, then
the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the Company may
exercise and will assume all of its obligations under the Common Warrants with the same effect as if such successor entity had been named
in the warrant itself. Common Warrant Holders will have additional rights defined in the Common Warrants. The Common Warrants are exercisable
on a &#8220;cashless&#8221; basis only if there is not a current registration statement permitting public resale. In this regard, the Company
filed a registration statement to register the resale of the Common Warrant Shares providing for the resale of the Shares issued and issuable
upon exercise of the Common Warrants. That registration statement was declared effective by the SEC on July 11, 2024. The Company has
agreed to use commercially reasonable efforts to cause such registration statement to keep such registration statement effective at all
times until no Purchaser owns any Warrants or Warrant Shares issuable upon exercise thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maxim
Group LLC acted as the placement agent (the &#8220;Placement Agent&#8221;) on a &#8220;commercially reasonable best efforts&#8221; basis,
in connection with the Transactions pursuant to the Placement Agency Agreement, dated May 31, 2024 (the &#8220;Placement Agency Agreement&#8221;),
by and between the Company and the Placement Agent. Pursuant to the Placement Agency Agreement, the Placement Agent was paid a cash fee of <span id="xdx_900_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240501__20240531__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_znAyC7lznWWi" title="Aggregate gross proceeds, percentage"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2024-05-012024-05-31_custom_PlacementAgentMember" id="Fact001528" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% of the aggregate gross proceeds paid to the Company for the securities sold in the Transactions and reimbursement
of certain out-of-pocket expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the Common Warrants under the guidance of ASC 480 &#8211; Distinguishing Liabilities from Equity and determined that
they were in scope under the guidance as freestanding financial instruments but did not meet the criteria for liability classification
and are classified as equity within the condensed consolidated financial statements. Proceeds allocated to such warrants totaled approximately
$<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20240930_zRbP2wp9At8k" title="Proceeds from warrants"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2024-09-30" id="Fact001530" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million. For the nine months ended September 30,2024, no Common Warrants were exercised, and all remain outstanding on September
30, 2024 related to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, the Company entered into a Securities Purchase Agreement to complete an offering with a single accredited investor.
For more information see Note 15: Subsequent Events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001532" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zQ16CfIusnze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10: <span id="xdx_822_zMey225KA1Dd">Net Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period.
Equivalent common shares, consisting of stock options and warrants which amounted to <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z0jmiCxJTYMe" title="Net loss per share, antidilutive"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_us-gaap_StockOptionMember" id="Fact001534" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,574,557</ix:nonFraction></span> and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z7URUNwRkmuh" title="Net loss per share, antidilutive"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_us-gaap_StockOptionMember" id="Fact001536" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,763,020</ix:nonFraction></span> shares for the nine months
ended September 30, 2024 and 2023, respectively, are excluded from the calculation of diluted net loss per share since their effect is
anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001538" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"><p id="xdx_80A_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zqKxGYvluOn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11: <span id="xdx_82F_zzidmEODBJMb">Recent Accounting Pronouncements </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on
the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements
that have been issued that might have a material impact on its financial position or results of operations. Accounting pronouncements
issued by the FASB since filing the <span style="text-decoration: underline">Annual Report on Form 10-K for the year ended December 31, 2023</span> did not or are not believed
by management to have a material impact on the Company&#8217;s present or future financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001540" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_zWqt4sq0Z5s5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12: <span id="xdx_828_zF9MURIPxiUh">Fair Value</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the provisions of FASB ASC 820 &#8220;Fair Value Measurements&#8221; for its financial and non-financial assets
and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset
and liability category measured at fair value on either a recurring or nonrecurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to
the short-term maturities of these items and are considered a Level 1 instrument of the fair value measurements standard. The Company
also has certain warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair value of the warrants
(&#8220;June 2024 Warrants&#8221;) related to the Company&#8217;s June 2024 common stock and warrant issuance, are calculated using a
Monte Carlo Simulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also had certain redeemable warrants in the Rights Offering with a cash settlement feature in the occurrence of a Fundamental
Transaction. No Fundamental Transaction occurred. In March 2024, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240331_zpLyvAzh0wVj" title="Conversion of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2024-03-31" id="Fact001542" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">205,000</ix:nonFraction></span> of these warrants converted on a cashless basis and <span id="xdx_902_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired_iI_pid_c20240331_zEh3F7bf07v7" title="Cashless basis, expired"><ix:nonFraction name="AIM:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired" contextRef="AsOf2024-03-31" id="Fact001544" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,830,028</ix:nonFraction></span>
expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimated the fair value of the June 2024 Warrants using the Black-Scholes Model, which uses multiple inputs including the Company&#8217;s
stock price, the exercise price of the warrant, volatility of the Company&#8217;s stock price, the risk-free interest rate and the expected
term of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001546" name="AIM:ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock_zDgvahFw0swl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilized the following assumptions to estimate the fair value of the Class A Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zsQidJVgfr37" style="display: none">Schedule of Assumptions to
Estimate the Fair Value</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Underlying price per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zD97ws5Uj1Gf" title="Underlying price per share"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-09-30_us-gaap_MeasurementInputSharePriceMember_custom_ClassAWarrantMember" id="Fact001548" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.350</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zehpniDao4D1" title="Underlying price per share"><span style="-sec-ix-hidden: xdx2ixbrl1550">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zjz2yccjPuc7" title="Exercise price per share"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-09-30_us-gaap_MeasurementInputExercisePriceMember_custom_ClassAWarrantMember" id="Fact001552" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.363</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zsLb2u8NbOT4" title="Exercise price per share"><span style="-sec-ix-hidden: xdx2ixbrl1554">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z7chJrnIJQE7" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassAWarrantMember" id="Fact001556" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.42</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zPjaVxg5CK5d" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1558">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expected holding period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zKeOpE0BWuQ6" title="Expected holding period"><ix:nonNumeric contextRef="AsOf2024-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_ClassAWarrantMember" format="ixt-sec:duryear" id="Fact001560" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zNudCoGdbWBf" title="Expected volatility"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassAWarrantMember" id="Fact001562" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">110</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zGaYNRsqxF3i" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1564">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z1vSOtTunSqa" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1566">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zsbSz68ay1yc" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1568">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilized the following assumptions to estimate the fair value of the Class B Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Underlying price per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zY6l4IrI6hpg" title="Underlying price per share"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-09-30_us-gaap_MeasurementInputSharePriceMember_custom_ClassBWarrantMember" id="Fact001570" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.350</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zGWPwsoNbCb3" title="Underlying price per share"><span style="-sec-ix-hidden: xdx2ixbrl1572">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zHle8bqMekBg" title="Exercise price per share"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-09-30_us-gaap_MeasurementInputExercisePriceMember_custom_ClassBWarrantMember" id="Fact001574" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.363</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zvs0Pb7XXGH6" title="Exercise price per share"><span style="-sec-ix-hidden: xdx2ixbrl1576">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zO3kY87vtQM1" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassBWarrantMember" id="Fact001578" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.82</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zZS7CsO8Cih7" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1580">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expected holding period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zRFXnPoLRT89" title="Expected holding period"><ix:nonNumeric contextRef="AsOf2024-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_ClassBWarrantMember" format="ixt-sec:duryear" id="Fact001582" name="us-gaap:WarrantsAndRightsOutstandingTerm">2</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zhSJz61mkdKd" title="Expected volatility"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassBWarrantMember" id="Fact001584" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">89</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zczDmWDxJonc" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1586">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_z4dFcP95gwc" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1588">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zBmcWKIhTX0l" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1590">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zcMvkDWRsSjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
                                            Interest Rate</i>. The risk-free interest rates for the Warrants are based on U.S. Treasury
                                            constant maturities for periods commensurate with the remaining expected holding periods
                                            of the warrants.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Holding Period</i>. The expected holding period represents the period of time that the Warrants
                                            are expected to be outstanding until they are exercised. The Company utilizes the remaining
                                            contractual term of the Warrants at each valuation date as the expected holding period.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Volatility</i>. Expected stock volatility is based on daily observations of the Company&#8217;s
                                            historical stock values for a period commensurate with the remaining expected holding period
                                            on the last day of the period for which the computation is made.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Dividend Yield</i>. The expected dividend yield is based on the Company&#8217;s anticipated
                                            dividend payments over the remaining expected holding period. As the Company has never issued
                                            dividends, the expected dividend yield is 0% and this assumption will be continued in future
                                            calculations unless the Company changes its dividend policy.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Probability of a Fundamental Transaction.</i> Put rights arise if a Fundamental Transaction
                                            1) is an all cash transaction; (2) results in the Company going private; or (3) is a transaction
                                            involving a person or entity not traded on a national securities exchange. The Company believes
                                            such an occurrence is unlikely because:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company only has one product that is FDA approved but is currently not available for commercial
                                            sales.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company will have to perform additional clinical trials for FDA approval of its flagship
                                            product.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry
                                            and market conditions continue to include uncertainty, adding risk to any transaction.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            nature of a life sciences company is heavily dependent on future funding and high fixed costs,
                                            including Research &amp; Development.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has minimal revenues streams which are insufficient to meet the funding needs for
                                            the cost of operations or construction at their manufacturing facility; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company&#8217;s Rights Agreement and Executive Agreements make it less attractive to a potential
                                            buyer.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001592" name="AIM:ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_z1oSiJHN4Lh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the above factors utilized in analysis of the likelihood of the Put&#8217;s potential Liability, the Company estimated the range of probabilities
related to a Put right being triggered as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zh1FKqV7mGub" style="display: none">Schedule of Potential
Liability</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Probability</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: center; padding-left: 3pt">Low</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--LowRangeOfProbability_pid_dp_uPure_c20240101__20240930_zkvLgwu2uHej" title="Low range, rate"><ix:nonFraction name="AIM:LowRangeOfProbability" contextRef="From2024-01-01to2024-09-30" id="Fact001594" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.5</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 3pt">Medium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--MediumRangeOfProbability_pid_dp_uPure_c20240101__20240930_zATLeRfk5Hnf" title="Medium range, rate"><ix:nonFraction name="AIM:MediumRangeOfProbability" contextRef="From2024-01-01to2024-09-30" id="Fact001596" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 3pt">High</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--HighRangeOfProbability_pid_dp_uPure_c20240101__20240930_zVtQC9DS1mZj" title="High range, rate"><ix:nonFraction name="AIM:HighRangeOfProbability" contextRef="From2024-01-01to2024-09-30" id="Fact001598" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zyFa61NFGg14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Monte Carlo Simulation has incorporated a <span id="xdx_903_ecustom--HighRangeOfProbability_pid_dp_uPure_c20240101__20240930_zK5LHEzjENPa" title="Probability, rate"><ix:nonFraction name="AIM:HighRangeOfProbability" contextRef="From2024-01-01to2024-09-30" id="Fact001600" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>% probability of a Fundamental Transaction to date for the life of the securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Timing of Announcement of a Fundamental Transaction.</i> As the Company has no specific expectation
                                            of a Fundamental Transaction, for reasons elucidated above, the Company utilized a discrete
                                            uniform probability distribution over the Expected Holding Period to model in the potential
                                            announcement of a Fundamental Transaction occurring during the Expected Holding Period.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            100 Day Volatility at Announcement of a Fundamental Transaction</i>. An estimate of future
                                            volatility is necessary as there is no mechanism for directly measuring future stock price
                                            movements. Daily observations of the Company&#8217;s historical stock values for the 100
                                            days immediately prior to the Warrants&#8217; grant dates, with a floor of 100%, were utilized
                                            as a proxy for future volatility estimates.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Risk-Free Interest Rate at Announcement of a Fundamental Transaction</i>. The Company utilized
                                            a risk-free interest rate corresponding to the forward U.S. Treasury rate for the period
                                            equal to the time between the date forecast for the public announcement of a Fundamental
                                            Transaction and the Warrant expiration date for each simulation.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"/><td style="font: 10pt Times New Roman, Times, Serif; width: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ix)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Time Between Announcement and Consummation of a Fundamental Transaction.</i> The expected
                                            time between the announcement and the consummation of a Fundamental Transaction is based
                                            on the Company&#8217;s experience with the due diligence process performed by acquirers and
                                            is estimated to be six months. The Monte Carlo Simulation approach incorporates this additional
                                            period to reflect the delay Warrant Holders would experience in receiving the proceeds of
                                            the Put.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the actual historical prices input
for the relevant period input change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the
extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements
in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These
levels are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 &#8211; Quoted prices are available in active markets for identical assets or liabilities
                                            at the reporting date. Generally, this includes debt and equity securities that are traded
                                            in an active market.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 &#8211; Observable inputs other than Level 1 prices such as quote prices for similar assets
                                            or liabilities; quoted prices in markets that are not active; or other inputs that are observable
                                            or can be corroborated by observable market data for substantially the full term of the assets
                                            or liabilities. Generally, this includes debt and equity securities that are not traded in
                                            an active market.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 &#8211; Unobservable inputs that are supported by little or no market activity and that
                                            are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities
                                            include financial instruments whose value is determined using pricing models, discounted
                                            cash flow methodologies, or other valuation techniques, as well as instruments for which
                                            the determination of fair value requires significant management judgment or estimation. As
                                            of September 30, 2024, the Company has classified the warrants with cash settlement features as
                                            Level 3. Management evaluates a variety of inputs and then estimates fair value based on
                                            those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in
                                            valuing the warrants.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001602" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3JfoMmGwGK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy
as (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_z9N8VFqklMWa" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxI1fwhW7vZh" title="Cash equivalents-Marketable investments" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2024-09-30_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001604" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">67</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zo0YJhRvvtb9" title="Cash equivalents-Marketable investments" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001606" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">67</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYjPFy5GJxAk" title="Cash equivalents-Marketable investments" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1608">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2eiI3hcGQT3" title="Cash equivalents-Marketable investments" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1610">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQt1FjptGw6" title="Marketable securities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-09-30_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001612" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziVXcJcvj0gl" title="Marketable securities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001614" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zBULbOALFRw8" title="Marketable securities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1616">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8u55ydix3j5" title="Marketable securities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1618">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left; padding-bottom: 1pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zP7N3paE1grj" title="Cash equivalents-Marketable investments" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001620" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,805</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zW1g7juGpFkb" title="Cash equivalents-Marketable investments" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001622" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,805</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeQ27myYYqe5" title="Cash equivalents-Marketable investments" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1624">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVkicbnuFTJj" title="Cash equivalents-Marketable investments" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1626">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCfaO7iLt9a6" title="Marketable securities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001628" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,631</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zf9yCE8hz1x2" title="Marketable securities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001630" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,631</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zOKyfcRFHeS7" title="Marketable securities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1632">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zN7gLJdiHbEa" title="Marketable securities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1634">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z6H1m7PmFMPk" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001636" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zgKnSyBHpoMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13: <span id="xdx_821_zOwjbGkph6b8">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging
from <span id="xdx_906_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20240930__srt--RangeAxis__srt--MinimumMember_zqwBK1mnUDV8" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2024-09-30_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001638" name="us-gaap:LesseeOperatingLeaseRenewalTerm">1</ix:nonNumeric></span> to <span id="xdx_908_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20240930__srt--RangeAxis__srt--MaximumMember_zDUrzhch49s4" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2024-09-30_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001640" name="us-gaap:LesseeOperatingLeaseRenewalTerm">5</ix:nonNumeric></span> years, expiring at various dates during 2024 through 2027, and requiring monthly payments ranging from less than $<span id="xdx_90B_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_z0n4pZ8k0RBi" title="Operating lease Payment"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-012024-09-30_srt_MinimumMember" id="Fact001642" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000</ix:nonFraction></span> to
$<span id="xdx_904_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zn6gAKjYwXZa" title="Operating lease Payment"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-012024-09-30_srt_MaximumMember" id="Fact001644" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,000</ix:nonFraction></span>. Certain leases include additional renewal options ranging from <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20240930__srt--RangeAxis__srt--MinimumMember_zLNbeWAp0ADe" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2024-09-30_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001646" name="us-gaap:LesseeOperatingLeaseRenewalTerm">1</ix:nonNumeric></span> to <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20240930__srt--RangeAxis__srt--MaximumMember_z7z7Q1pL5c9f" title="Operating lease term"><ix:nonNumeric contextRef="AsOf2024-09-30_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001648" name="us-gaap:LesseeOperatingLeaseRenewalTerm">5</ix:nonNumeric></span> years. AIM has classified all of its leases as operating
leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2024 and December 31, 2023, the balance of the right of use assets was $<span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20240930_zRALP3AZf36j" title="Right of use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-09-30" id="Fact001650" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">653,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_zFPuPCMI2857" title="Right of use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact001652" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">697,000</ix:nonFraction></span>, respectively, and the corresponding
operating lease liability balance was $<span id="xdx_906_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20240930_zEzgo2kCuqyb" title="Lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-09-30" id="Fact001654" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">669,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20231231_zXwnqwpVXCwc" title="Lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" id="Fact001656" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">718,000</ix:nonFraction></span>, respectively. Right of use assets are recorded net of accumulated amortization
of $<span id="xdx_90D_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_pp0p0_c20240930_zWZmwuKDzSwh" title="Accumulated amortization"><ix:nonFraction name="AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization" contextRef="AsOf2024-09-30" id="Fact001658" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">404,000</ix:nonFraction></span> and $<span id="xdx_907_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_pp0p0_c20231231_z8FNm7i71c9i" title="Accumulated amortization"><ix:nonFraction name="AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization" contextRef="AsOf2023-12-31" id="Fact001660" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">363,000</ix:nonFraction> </span>as of September 30, 2024 and December 31, 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001662" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zjz1PFbiezc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
recognized rent expense associated with these leases are follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zun1HQhN8Be1" style="display: none">Schedule of AIM Recognized Rent Expense Associated with Operating Lease</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930_zTI3OTTC3hs3" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930_zDEerU0nJsUd" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2023</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2023</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_z4nmxel6skb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseCost_pn3n3_maLCzBan_zsdk9W45uZG6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-01to2024-09-30" id="Fact001667" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">226</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-09-30" id="Fact001668" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">214</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzBan_zvageJeGouK4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Short-term and variable lease costs</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2024-01-01to2024-09-30" id="Fact001670" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">205</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2023-01-012023-09-30" id="Fact001671" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">253</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_mtLCzBan_zZ6TvucId2ae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total lease costs</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-09-30" id="Fact001673" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">431</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-09-30" id="Fact001674" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">467</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Classification of lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3pRw35uNfzi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research &amp; development</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001676" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">358</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001677" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0Zk0RR1SeEd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">General and administrative</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001679" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001680" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">67</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_zpv8JbELhHWh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total lease costs</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-09-30" id="Fact001682" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">431</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-09-30" id="Fact001683" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">467</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zP1336Ol7TIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s leases have remaining lease terms between <span id="xdx_908_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20240930__srt--RangeAxis__srt--MinimumMember_zHehfpZopOj9" title="Lessee, operating lease, remaining lease term"><ix:nonNumeric contextRef="AsOf2024-09-30_srt_MinimumMember" format="ixt-sec:durmonth" id="Fact001685" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">6</ix:nonNumeric></span> and <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20240930__srt--RangeAxis__srt--MaximumMember_zXMllmtef8j9" title="Lessee, operating lease, remaining lease term"><ix:nonNumeric contextRef="AsOf2024-09-30_srt_MaximumMember" format="ixt-sec:durmonth" id="Fact001687" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">35</ix:nonNumeric></span> months. At September 30, 2024, the weighted-average remaining term
was <span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240930_zduiQC1TIYp4" title="Operating lease, weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2024-09-30" format="ixt-sec:durmonth" id="Fact001689" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">32</ix:nonNumeric></span> months. At December 31, 2023, the weighted-average remaining term was <span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231_ze6WAzQMLW97" title="Lessee, operating lease, remaining lease term"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:durmonth" id="Fact001691" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">41</ix:nonNumeric></span> months. The Company&#8217;s weighted average incremental
borrowing rate for its leases was <span id="xdx_90B_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20240930_zvandRUOlQn7" title="Debt, weighted average interest rate"><ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="AsOf2024-09-30" id="Fact001693" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.2</ix:nonFraction></span>% at September 30, 2024 and <span id="xdx_90B_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20231231_zaCkvHD1PB38" title="Debt, weighted average interest rate"><ix:nonFraction name="us-gaap:DebtWeightedAverageInterestRate" contextRef="AsOf2023-12-31" id="Fact001695" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001697" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zK8RbzJr9QNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments as of September 30, 2024, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zttuDYqICJa1" style="display: none">Schedule of Operating Lease Future Payments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Year Ending December 31, <br/>
(in thousands)</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20240930_zfOCBbh5b624" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_zo2ACskIj2Qi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2024-09-30" id="Fact001699" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">78</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zS98VF0BHrU2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-09-30" id="Fact001701" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">276</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zdqBlEQ5CUp8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-09-30" id="Fact001703" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">244</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_zNiQ2sSMMXGg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-09-30" id="Fact001705" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">159</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pn3n3_zCshRWIxwxm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1707">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_di_z50YeeiL5h9e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-09-30" id="Fact001709" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">88</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zCm8nqEVfErg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-09-30" id="Fact001711" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">669</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AB_zAxPU8YUGbll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001713" name="AIM:ResearchConsultingAndSupplyAgreementsTextBlock"><p id="xdx_80F_ecustom--ResearchConsultingAndSupplyAgreementsTextBlock_z4IcQw1sEmy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14: <span id="xdx_829_zWLDangXpff6">Research, Consulting and Supply Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into research, consulting and supply agreements with third party service providers to perform research and development
activities on therapeutics, including clinical trials. The identification of research and development costs involves reviewing open contracts
and purchase orders, communicating with applicable company and third-party personnel to identify services that have been performed, and
corroborating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced
or otherwise notified of actual expenses. The Company expenses these research and development costs when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2024, research and development expenses were comprised of: clinical studies ($<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zTk3z4c27k03" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_ClinicalStudiesMember" id="Fact001715" format="ixt:numdotdecimal" decimals="0" unitRef="USD">582,000</ix:nonFraction></span>), manufacturing
and engineering ($<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zACVIeWesRCb" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_ManufacturingAndEngineeringMember" id="Fact001717" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306,000</ix:nonFraction></span>), quality control ($<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__srt--ProductOrServiceAxis__custom--QualityControlMember_zivZgJJgb9ob" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_QualityControlMember" id="Fact001719" format="ixt:numdotdecimal" decimals="0" unitRef="USD">398,000</ix:nonFraction></span>) and regulatory ($<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__srt--ProductOrServiceAxis__custom--RegulatoryMember_zkQFYesVWaq6" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_RegulatoryMember" id="Fact001721" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,000</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023, research and development expenses were comprised of: clinical studies ($<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zQNh5kq4Z2e7" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_ClinicalStudiesMember" id="Fact001723" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,916,000</ix:nonFraction></span>), manufacturing
and engineering ($<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zupUCNY2Trl5" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_ManufacturingAndEngineeringMember" id="Fact001725" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,000</ix:nonFraction></span>), quality control ($<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__srt--ProductOrServiceAxis__custom--QualityControlMember_z8P3FwA2w4Gh" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_QualityControlMember" id="Fact001727" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,000</ix:nonFraction></span>) and regulatory ($<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__srt--ProductOrServiceAxis__custom--RegulatoryMember_zpuXm6pGKq38" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_RegulatoryMember" id="Fact001729" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,000</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2024, research and development expenses were comprised of: clinical studies ($<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_z2D4Vsoc5GVb" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_ClinicalStudiesMember" id="Fact001731" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,880,000</ix:nonFraction></span>), manufacturing
and engineering ($<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zQpvr0yAVnCl" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_ManufacturingAndEngineeringMember" id="Fact001733" format="ixt:numdotdecimal" decimals="0" unitRef="USD">882,000</ix:nonFraction></span>), quality control ($<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__srt--ProductOrServiceAxis__custom--QualityControlMember_zR24LXVpVcKd" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_QualityControlMember" id="Fact001735" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,232,000</ix:nonFraction></span>) and regulatory ($<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__srt--ProductOrServiceAxis__custom--RegulatoryMember_znM5pgBoWe8g" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_RegulatoryMember" id="Fact001737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">540,000</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2023, research and development expenses were comprised of: clinical studies ($<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zFVEJM3kuco8" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_ClinicalStudiesMember" id="Fact001739" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,845,000</ix:nonFraction></span>), manufacturing
and engineering ($<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zMC20vz8K0Hb" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_ManufacturingAndEngineeringMember" id="Fact001741" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,783,000</ix:nonFraction></span>), quality control ($<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__srt--ProductOrServiceAxis__custom--QualityControlMember_zaikd6VzLOz3" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_QualityControlMember" id="Fact001743" format="ixt:numdotdecimal" decimals="0" unitRef="USD">752,000</ix:nonFraction></span>) and regulatory ($<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__srt--ProductOrServiceAxis__custom--RegulatoryMember_zXXJOCSDxS4a" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_RegulatoryMember" id="Fact001745" format="ixt:numdotdecimal" decimals="0" unitRef="USD">359,000</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the most substantial of our contracts relating to research, consulting, and supply costs for AIM as they related
to research and development costs for the nine months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amarex
Clinical Research LLC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amarex
is the principal administrator of several of AIM&#8217;s largest clinical studies. AIM has multiple contracts with Amarex Clinical Research
LLC (&#8220;Amarex&#8221;). During the three months ended September 30, 2024 and 2023, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zJTgqcLWvxHc" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember" id="Fact001747" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">275,400</ix:nonFraction></span> and
$<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zNE78m7aQYr6" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_AmarexClinicalResearchLLCMember" id="Fact001749" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">516,284</ix:nonFraction></span>, respectively, related to these ongoing agreements. During the nine months ended September 30, 2024 and 2023, the Company
incurred approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zXqFOIS9xQR3" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_AmarexClinicalResearchLLCMember" id="Fact001751" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">881,987</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zj1X3YFg2Lyg" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_AmarexClinicalResearchLLCMember" id="Fact001753" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,294,265</ix:nonFraction></span>, respectively, related to these ongoing agreements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic
                                            Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is
                                            managing a Phase 2 clinical trial in locally advanced pancreatic cancer patients designated
                                            AMP-270. Per the work order, AIM anticipates that Amarex&#8217;s management of the study
                                            will cost approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pp0p0_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z5DzZbNvoecl" title="Research and development expense excluding acquired in process cost"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember" id="Fact001755" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,400,000</ix:nonFraction></span>. This estimate includes pass-through costs of approximately
                                            $<span id="xdx_902_eus-gaap--DevelopmentCosts_pp0p0_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zLIDOqZK9X77" title="Development cost"><ix:nonFraction name="us-gaap:DevelopmentCosts" contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember" id="Fact001757" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></span> and excludes certain third-party and investigator costs and escalations necessary
                                            for study completion. AIM anticipates that the study will take approximately <span id="xdx_904_ecustom--ResearchAndDevelopmentExpenseCostEstimatedLives_dtY_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zzyuOSUiuroh" title="Estimated lives"><ix:nonNumeric contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember" format="ixt-sec:duryear" id="Fact001759" name="AIM:ResearchAndDevelopmentExpenseCostEstimatedLives">4.6</ix:nonNumeric></span> years to
                                            complete.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_zPMxjNbFMZJh" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember" id="Fact001761" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">129,000</ix:nonFraction></span> related
                                            to this agreement. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2023, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_zfeeqhHOLYG5" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember" id="Fact001763" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">82,600</ix:nonFraction></span> related
                                            to this agreement.</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_zG31AwmZq5P3" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember" id="Fact001765" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">141,100</ix:nonFraction></span> related
                                            to this agreement. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_z1q1nkd6jsp5" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember" id="Fact001767" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">350,600</ix:nonFraction></span> related
                                            to this agreement.</span></span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-COVID
                                            Conditions - In September 2022, AIM executed a work order with Amarex, pursuant to which
                                            Amarex is managing a Phase 2 trial in patients with Post-COVID Conditions. AIM is sponsoring
                                            the study. AIM anticipates that the study will cost approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pp0p0_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zfZAe3tyMpIh"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember" id="Fact001768" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,400,000</ix:nonFraction></span>, which includes
                                            pass through costs of approximately $<span id="xdx_900_eus-gaap--DevelopmentCosts_pp0p0_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zEBQi3GwnBJ7" title="Development cost"><ix:nonFraction name="us-gaap:DevelopmentCosts" contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember" id="Fact001770" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,000</ix:nonFraction></span>, investigator costs estimated at about $<span id="xdx_902_eus-gaap--CostMaintenance_pp0p0_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zxvPX41gZc06" title="Invigilators cost"><ix:nonFraction name="us-gaap:CostMaintenance" contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember" id="Fact001772" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,400,000</ix:nonFraction></span>
                                            and excludes certain other third-party costs and escalations. During 2023, the original work
                                            order increased to approximately $<span id="xdx_90C_eus-gaap--DevelopmentCosts_pp0p0_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zqNQf0sVXvN7" title="Development cost"><ix:nonFraction name="us-gaap:DevelopmentCosts" contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember" id="Fact001774" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,600,000</ix:nonFraction></span> for the addition of patient reported outcome
                                            (PRO) electronic questionnaires (devices/tablets for patients to complete); services associated
                                            with the ePRO system and additional safety monitoring services as well as changes to study
                                            documentation (such as protocol amendments) which resulted in additional IND submissions
                                            to FDA. This study was completed in 2023, although certain activities are still ongoing.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2024, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zzwC0omYI5Fk" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember" id="Fact001776" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,500</ix:nonFraction></span> related
                                            to this agreement. During
                                            the three months ended September 30, 2023, the Company incurred approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zKfmtSA1QyB7" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember" id="Fact001778" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">447,600</ix:nonFraction></span> related
                                            to this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zUAvqKyWhV9d" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember" id="Fact001780" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">195,800</ix:nonFraction></span> related
                                            to this agreement. During
                                            the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zkZx6pQrBXF9" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember" id="Fact001782" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">783,400</ix:nonFraction></span> related
                                            to this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Jubilant HollisterStier</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Jubilant HollisterStier (&#8220;Jubilant&#8221;)
is AIM&#8217;s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company entered into an agreement with Jubilant
pursuant to which Jubilant will manufacture batches of Ampligen&#174; for the Company. Since the 2017 engagement of Jubilant, two lots
of Ampligen consisting of more than <span id="xdx_906_ecustom--UnitsManufactured_uInteger_c20170101__20171231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zUcdr5GVZmk8" title="Number of units manufactured"><ix:nonFraction name="AIM:UnitsManufactured" contextRef="From2017-01-012017-12-31_custom_JubilantHollisterStierMember" id="Fact001784" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">16,000</ix:nonFraction></span> units were manufactured and released in the year 2018. The first lot was designated for human
use in the United States in the cost recovery CFS program and for expanded oncology clinical trials. The second lot has been designated
for these programs in addition to commercial distribution in Argentina for the treatment of CFS. Jubilant manufactured additional two
lots of Ampligen in December 2019 and January 2020. In December 2023, Jubilant completed manufacturing of <span id="xdx_901_ecustom--NumberOfVials_uInteger_c20230101__20231231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_z4T5Sy2GSRu4" title="Additional number of vials"><ix:nonFraction name="AIM:NumberOfVials" contextRef="From2023-01-012023-12-31_custom_JubilantHollisterStierMember" id="Fact001786" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">9,042</ix:nonFraction></span> vials of Ampligen for
clinical use.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2024, the Company did <span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20240701__20240930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zd7Xy1vOyrR6" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember" id="Fact001788" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span>t incur any expense related
                                            to this agreement. During
                                            the three months ended September 30, 2023, the Company did <span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zT4YJsfc8UBf" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember" id="Fact001790" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span>t incur any expense related
                                            to this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zr5aN8UyKlA2" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember" id="Fact001792" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,200</ix:nonFraction></span> related
                                            to this agreement.</span> During
                                            the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zA9ohgAhx0ck" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember" id="Fact001794" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,432,000</ix:nonFraction></span> related
                                            to this agreement.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sterling
Pharma Solutions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (&#8220;Sterling&#8221;)
for the manufacture of the Company&#8217;s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling&#8217;s
Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_z7DbKXwdCOX4" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember" id="Fact001796" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">133,000</ix:nonFraction></span> related
                                            to this agreement. During
                                            the three months ended September 30, 2023, the Company did <span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zE56Y1J9FBpf" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember" id="Fact001798" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span>t incur any expense related
                                            to this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_z5JuugVYuFfk" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember" id="Fact001800" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">261,600</ix:nonFraction></span> related
                                            to this agreement. During
                                            the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zuA6kpr77eg2" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember" id="Fact001802" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">357,000</ix:nonFraction></span> related
                                            to this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Erasmus</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2022, the Company entered into a joint clinical study agreement with Erasmus University Medical Center Rotterdam to conduct
a Phase II study: Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic
pancreatic ductal adenocarcinoma for therapy efficacy. This is a study in collaboration with AstraZeneca. AIM&#8217;s limited responsibilities
are limited to providing Ampligen. Additionally, in April 2023 AIM agreed to provide to Erasmus MC an unrestricted grant of $<span id="xdx_903_eus-gaap--SuppliesExpense_pp0p0_c20230401__20230430__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_z7O3hYhkXxHk" title="Unrestricted grants"><ix:nonFraction name="us-gaap:SuppliesExpense" contextRef="From2023-04-012023-04-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember" id="Fact001804" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span>
for immune monitoring in pancreatic cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2024, the Company did <span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20240701__20240930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_ziXn8oDJb23l" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember" id="Fact001806" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span>t incur any expense related
                                            to this agreement. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2023, the Company did <span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zaxmqBcY8vRl" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember" id="Fact001808" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span>t incur any expense related
                                            to this agreement.</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zk7nDOkwB5Zg" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember" id="Fact001810" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">79,000</ix:nonFraction></span> related
                                            to this agreement. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zajwWSFsXS9g" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember" id="Fact001812" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> related
                                            to this agreement.</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Azenova
Sales International</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, the Company entered into a consulting agreement with Azenova, LLC whereas Azenova will provide business development
services for AIM&#8217;s Ampligen product for solid tumors for a 12-month term that is extendable upon the agreement of the parties.
In exchange for its services, Azenova will receive a fixed monthly retainer of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pp0p0_c20231031__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zERemEyApHXh" title="Stock options, aggregate intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2023-10-31_custom_AzenovaLLCMember_custom_ConsultingAgreementMember" id="Fact001814" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000</ix:nonFraction></span>
per month in addition to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pp0p0_c20231031__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z5z9qgncyonk" title="Stock options, vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-10-31_custom_AzenovaLLCMember_custom_ConsultingAgreementMember" id="Fact001816" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">360,000</ix:nonFraction></span>
stock options that vest monthly. In August 2024, an agreement was made to reduce the fixed monthly retainer fee to $<span id="xdx_906_ecustom--MonthlyRetainerFee_pp0p0_c20240801__20240831__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zIfgDHoAayy7" title="Monthly retainer fee"><ix:nonFraction name="AIM:MonthlyRetainerFee" contextRef="From2024-08-012024-08-31_custom_AzenovaLLCMember_custom_ConsultingAgreementMember" id="Fact001818" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zw3TeYRvVbif" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember" id="Fact001820" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span> related
                                            to this agreement. During
                                            the three months ended September 30, 2023, the Company did <span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zHDu2ilh8y6l" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember" id="Fact001822" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span>t incur any expense related
                                            to this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zyLJ2J5JZ1sg" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember" id="Fact001824" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">230,000</ix:nonFraction></span> related
                                            to this agreement. During
                                            the nine months ended September 30, 2023, the Company did <span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230101__20230930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zPsV8praX1a3" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember" id="Fact001826" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span>t incur any expense related to
                                            this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alcami</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, the Company entered into an agreement with Alcami Corporation to perform an extractables study for a primary packaging
component. The agreement called for fixed costs of approximately $<span id="xdx_903_eus-gaap--ProductionCosts_pp0p0_c20230901__20230930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_zWWl9oaMHjB7" title="Research and development expense"><ix:nonFraction name="us-gaap:ProductionCosts" contextRef="From2023-09-012023-09-30_custom_AlcamiCorporationMember" id="Fact001828" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000</ix:nonFraction></span> upon completion of the study and issue of the final report,
along with solvent costs, and pass through items to be billed on a per activity basis. The final bill for the initial study was received
in December 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9675;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During
the three months ended September 30, 2024, the Company did <span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_zJ6NGjhJCKs6">no</span>t
incur any expense for lab services from Alcami. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2023, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_zjdPb2zWY2n7" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_AlcamiCorporationMember" id="Fact001831" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,800</ix:nonFraction></span> of lab
                                            services from Alcami.</span></td></tr>
                                                                                  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_ztSYpQQ3uOOc" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_AlcamiCorporationMember" id="Fact001833" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,000</ix:nonFraction></span> of lab
                                            services from Alcami. During
                                            the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_zo2yiiwwdb8g" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_AlcamiCorporationMember" id="Fact001835" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span> of lab
                                            services from Alcami.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact001837" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zaJ6SoNeqCx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
15: <span id="xdx_82B_zbBx8nigwpTe">Subsequent Events</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;<span style="text-decoration: underline">Purchase Agreement</span>&#8221;) to complete
an offering (the &#8220;<span style="text-decoration: underline">Transactions</span>&#8221;) with a single accredited investor (the &#8220;<span style="text-decoration: underline">Purchaser</span>&#8221;). The Transactions
closed on October 1, 2024. Pursuant to the Purchase Agreement, at closing, the Company issued to the Purchaser, (i) in a registered
direct offering, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx00GvBaYtf8" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-012024-10-01_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001839" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,653,036</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;), par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoVgIkZB8Qn1" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-10-01_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember" id="Fact001841" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (&#8220;<span style="text-decoration: underline">Common
Stock</span>&#8221;); and (ii) in a concurrent private placement, the Company issued to the Purchaser Class C common warrants to purchase
an aggregate of up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2scs6y8z3O1" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-012024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassCCommonWarrantMember_us-gaap_SubsequentEventMember" id="Fact001843" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,653,036</ix:nonFraction></span> shares of its Common Stock (the &#8220;<span style="text-decoration: underline">C Warrants</span>&#8221;) at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGzc24PkOgwj" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassCCommonWarrantMember_us-gaap_SubsequentEventMember" id="Fact001845" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share
and Class D common warrants to purchase an aggregate of up to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassDCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOmoY0HHQ79h" title="Number of shares issued upon transaction"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-012024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassDCommonWarrantMember_us-gaap_SubsequentEventMember" id="Fact001847" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,653,036</ix:nonFraction></span> shares of its Common Stock (the &#8220;<span style="text-decoration: underline">D Warrants</span>&#8221;
and, along with the C Warrants, the &#8220;<span style="text-decoration: underline">Common Warrants</span>&#8221;) at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassDCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpvPwH27tzRc" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassDCommonWarrantMember_us-gaap_SubsequentEventMember" id="Fact001849" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share. The C Warrants and
D Warrants will not be exercisable for six months after the issuance date and will expire, respectively, 24 months and five years and
six months after the issuance date. The Common Warrants and the shares of Common Stock issuable upon the exercise of such warrants were
offered pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities
Act</span>&#8221;), provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received aggregate gross proceeds from the Transactions of approximately $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_pn4n6_c20241001__20241001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhwL3YQEkmcf" title="Grosss proceeds"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-10-012024-10-01_us-gaap_SubsequentEventMember" id="Fact001851" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">1.26</ix:nonFraction></span> million, before deducting fees to the Placement
Agent and other estimated offering expenses payable by the Company. The shares underlying the Common Warrants are being offered by the
Company pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared effective on February 4, 2022
(as amended from time to time, the &#8220;<span style="text-decoration: underline">Registration Statement</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Purchase Agreement, subject to certain exceptions, the Company cannot issue any equity securities for 60 days following
the closing of the Transactions (the &#8220;<span style="text-decoration: underline">Closing Date</span>&#8221;), provided that the Company will be able to utilize it&#8217;s
at-the-market offering (the &#8220;<span style="text-decoration: underline">ATM</span>&#8221;) program with the Placement Agent after 30 days. Additionally, the Company cannot
enter into a variable rate transaction (other than the ATM program with the Placement Agent) for 120 days after the Closing Date. In
addition, the Company&#8217;s executive officers and each of the Company&#8217;s directors have entered into lock-up agreements with
the Company pursuant to which each of them has agreed not to, for a period of 90 days from the Closing Date, offer, sell, transfer or
otherwise dispose of the Company&#8217;s securities, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of the Common Warrants, and the number of shares of Common Stock underling the Common Warrant (the &#8220;<span style="text-decoration: underline">Common Warrant
Shares</span>&#8221;) will be subject to adjustment in the event of any stock dividend or split, reverse stock split, recapitalization,
reorganization or similar transaction, as described in the Common Warrants. If a Fundamental Transaction (as defined in the Common Warrants)
occurs, then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the
Company may exercise and will assume all of its obligations under the Common Warrants with the same effect as if such successor entity
had been named in the warrant itself. Common Warrant Holders will have additional rights defined in the Common Warrants. The Common Warrants
will be exercisable on a &#8220;cashless&#8221; basis only if there is not a current registration statement permitting public resale.
In this regard, the Company has agreed to file a registration statement to register the resale of the Common Warrant Shares as soon as
practicable (and in any event within 45 calendar days of the date of the Purchase Agreement) providing for the resale of the Shares issued
and issuable upon exercise of the Common Warrants. The Company has agreed to use commercially reasonable efforts to cause such registration statement to become effective within 181 days
following the Closing Date and to keep such registration statement effective at all times
until no Purchaser owns any Common Warrants or Common Warrant Shares issuable upon exercise thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently evaluating the Common Warrants under the guidance of ASC 480 &#8211; Distinguishing Liabilities from Equity</span></p>

</ix:nonNumeric><p id="xdx_813_zSpB1fjT1iH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
2: Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Special
Note Regarding Forward-Looking Statements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E
of the Exchange Act. All statements, other than statements of historical fact, included or incorporated herein regarding our
strategy, future operations, financial position, future revenues, projected costs, plans, prospects and objectives are
forward-looking statements. Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221;
&#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;think,&#8221; &#8220;may,&#8221; &#8220;could,&#8221;
&#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221;
&#8220;likely,&#8221; &#8220;opportunity&#8221; and similar expressions or variations of such words are intended to identify
forward-looking statements but are not the exclusive means of identifying forward-looking statements and their absence does not mean
that a statement is not forward-looking. Our forward-looking statements are not guarantees of performance, and actual results could
vary materially from those contained in or expressed by such statements due to risks and uncertainties. These statements are based
on our management&#8217;s current beliefs, expectations and assumptions about future events, conditions and results and on
information currently available to us. Discussions containing these forward-looking statements may be found, among other places,
below in this Item 2: &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and
in Part II: Other information: Item 1A: &#8220;Risk Factors&#8221; of this report, and the following sections of our Annual Report
on Form 10-K for the year ended December 31, 2023: Part I; Item 1. &#8220;Business&#8221;, Part I; Item 1A. &#8220;Risk
Factors&#8221;, Part I; Item 3. &#8220;Legal Proceedings&#8221;, and Part I; Item 2. &#8220;Management&#8217;s Discussion and
Analysis of Financial Condition and Results of Operations&#8221; of this Report. Among other things, for those statements, we claim
the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not undertake to
update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. We are in
various stages of seeking to determine whether Ampligen&#174; will be effective in the treatment of multiple types of viral diseases,
cancers, and immune-deficiency disorders and the presentation sets forth our current and anticipated future activities. These
activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine
whether Ampligen&#174; will be effective in the treatment of these conditions. Results obtained in animal models do
not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen&#174; will be
efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield
favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change
in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, we cannot assure that the
clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials
that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies
will prove true or that the study or studies will yield favorable results. Some of the world&#8217;s largest pharmaceutical
companies and medical institutions are working on a treatment for COVID-19. Even if Ampligen&#174; proves effective in combating the
virus, no assurance can be given that our actions toward proving this will be given first priority or that another treatment that
eventually proves capable will not make our efforts ultimately unproductive, as multiple vaccines, and some treatments, are now
available and major pharma companies are working to develop their own disease treatments. Some of the world&#8217;s largest
pharmaceutical companies are also working on treatments and cures for different types of cancers. No assurance can be given that the
use of Ampligen with these proposed treatments and cures will prove effective. No assurance can be given that future studies will
not result in findings that are different from those reported in the studies referenced or incorporated by reference herein.
Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual
property rights. In addition, many countries, including Argentina, are still dealing with COVID-19 outbreaks and have made that
their primary focus. We believe that this may be delaying our commercialization of Ampligen&#174; in Argentina until COVID-19 is more
under control. We cannot assure that our potential foreign operations will not be adversely affected by these risks. No assurance can be given that we will be able to raise additional equity or other financing pursuant to the ATM,
Atlas Equity Line or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
filings are available at www.aimimmuno.com. The information found on our website is not incorporated by reference into this Report and
is included for reference purposes only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for our management
to predict all risk factors and uncertainties, nor are we able to assess the impact of all of these risk factors on our business or the
extent to which any risk factor, or combination of risk factors, may cause actual results to differ materially from those contained in
any forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
these uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein
to reflect future events or developments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Overview</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">General</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
ImmunoTech Inc. and its subsidiaries (collectively, &#8220;AIM&#8221;, &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;)
are an immuno-pharma company headquartered in Ocala, Florida,  focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical
and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system
of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (&#8220;dsRNA&#8221;)
molecule being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has not been approved
by the FDA or marketed in the United States but is approved for commercial sale in the Argentine Republic for the treatment of severe
Chronic Fatigue Syndrome (&#8220;CFS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently proceeding primarily in four areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
                                            clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic
                                            cancer.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating
                                            Ampligen across multiple cancers as a potential therapy that modifies the tumor microenvironment
                                            with the goal of increasing anti-tumor responses to checkpoint inhibitors.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exploring
                                            Ampligen&#8217;s antiviral activities and potential use as a prophylactic or treatment for
                                            existing viruses, new viruses and mutated viruses thereof.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating
                                            Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (&#8220;ME/CFS&#8221;)
                                            and fatigue and/or the Post-COVID condition of fatigue.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer,
ME/CFS and Post-COVID conditions having priority over antiviral experimentation. We intend that priority clinical work be conducted in
trials authorized by the Food and Drug Administration (&#8220;FDA&#8221;) or European Medicines Agency (&#8220;EMA&#8221;), which trials
support a potential future NDA. However, our antiviral experimentation is designed to accumulate additional preliminary data supporting
their hypothesis that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity
and cross-protection. Accordingly, we will conduct antiviral programs in those venues most readily available and able to generate valid
proof-of-concept data, including foreign venues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see &#8220;Immuno-Oncology&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Immuno-Oncology</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are focused on pancreatic cancer because testing results, to date, primarily conducted in the Netherlands, have been very promising.
The Netherlands study generated statistically significant data indicating that Ampligen extended survival well beyond the Standard of
Care (&#8220;SOC&#8221;), when compared to well-matched historical controls. These data support the proposition that Ampligen, when administered
to either patients with locally advanced or metastatic pancreatic cancer after systemic chemotherapy showed a statistically significant
increase in survival rate. In October 2021, we and our Contract Research Organization, Amarex, submitted an Investigational New Drug
(&#8220;IND&#8221;) application to the FDA for a planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage
pancreatic cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the differences in the scale of necessary trials, our initial primary focus when it comes to pancreatic cancer will be cases that
are locally advanced, rather than metastatic. The number of different approaches to treating metastatic pancreatic cancer &#8212; approaches
which would be determined by treating physicians &#8212; would require a much larger, far more expensive trial than  a trial for
locally advanced pancreatic cancer. Therefore, we are focusing on patients who have completed FOLFIRINOX and have stable disease. In
August 2022, we received Institutional Review Board (&#8220;IRB&#8221;) approval of the trial protocol in locally advanced pancreatic
cancer and  announced the trial&#8217;s commencement. The study is recruiting patients. Assuming this trial and subsequent planned
clinical trials confirm the existing data, our goal is to then submit an NDA for use of Ampligen in pancreatic cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ampligen
has also demonstrated in the clinic the potential for standalone efficacy in a number of other solid tumors. We have also seen success
in increasing survival rates and efficacy in the treatment of animal tumors when Ampligen is used in combination with checkpoint blockade
therapies. In fact, in March 2022 we announced interim data from an investigator-initiated, Phase 2, single-arm, efficacy/safety trial
to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP Ampligen
(TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab for patients with recurrent platinum-sensitive ovarian cancer.
We believe that data from the study, which is being conducted by the University of Pittsburgh Medical Center and funded by a Merck grant,
demonstrated that when combining three drugs &#8211; Ampligen and pembrolizumab, which are both immune therapies, with cisplatin, a chemotherapy
&#8211; evidence of increased biomarkers associated with T cell chemotaxis and cytolytic function has been seen. Importantly, increases
of these biomarkers in the tumor microenvironment have been correlated with favorable tumor responses. These successes in the field of
immuno-oncology have guided our efforts toward the potential use of Ampligen as a combinational therapy for the treatment of a variety
of solid tumor types. The first of our patent applications in this space was granted by the Netherlands on March 15, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see &#8220;<i>Immuno-Oncology</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Ampligen
as a Potential Antiviral</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a research and pre-clinical history that indicates broad-spectrum antiviral capability of Ampligen in animals. We hope to demonstrate
that it has the same effect in humans. To do this, among other things, we need a population infected with a virus. That is why we have
spent significant resources on COVID-19 (the disease caused by SARS-CoV-2) which is active and still infecting many subjects. While much
would need to be done to get Ampligen to market as a broad-spectrum antiviral, we believe that it is important to focus our efforts first
and foremost on thoroughly proving the concept, especially while there is still a large COVID-19-infected population. Previously, animal
studies were conducted that yielded positive results utilizing Ampligen to treat numerous viruses, such as Western Equine Encephalitis
Virus, Ebola, Vaccinia Virus (which is used in the manufacture of smallpox vaccine) and SARS-CoV-1. We have conducted experiments in
SARS-CoV-2 showing Ampligen has a powerful impact on viral replication. The prior studies of Ampligen in SARS-CoV-1 animal experimentation
may predict similar protective effects against SARS-CoV-2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has requested that we provide additional data to assist the agency in evaluating the potential risks and benefits of administering
Ampligen to asymptomatic and mild COVID-19 individuals. However, as discussed in more detail below, where the threat to the patient from
COVID-19 is high, the FDA has already authorized Ampligen in a clinical trial of patients with COVID-19 who have a pre-existing cancer, although this study is currently suspended.
We have also elected to explore studies (initially with healthy volunteers) outside the United States and have already conducted a study
in the Netherlands to determine the safety profile of the intranasal delivery of Ampligen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this regard, CHDR, a foundation located in Leiden in the Netherlands, managed a Phase 1 randomized, double-blind study for us to evaluate
the safety, tolerability, and biological activity of repeated administration of Ampligen intranasally. A total of 40 healthy subjects
received either Ampligen or a placebo in the trial, with the Ampligen given at four escalating dosages across four cohorts, to a maximum
level of 1,250 micrograms. The study was completed, and the Final Safety Report reported no Serious or Severe Adverse Events at any dosage
level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
there are approved therapies for COVID-19, we believe that, if Ampligen has the broad-spectrum antiviral properties that we believe that
it has, it could be a very valuable tool in treating variants of existing viral diseases, including COVID-19, or novel ones that arise
in the future. Unlike most developing therapeutics which attack the virus, Ampligen works differently. We believe that it activates antiviral
immune system pathways that fight not just a particular virus or viral variant, but other similar viruses as well.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see &#8220;<i>Ampligen as a Potential Antiviral</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Ampligen
as a Treatment for Post-COVID Conditions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen&#174; as a potential therapeutic for people
with post-COVID conditions (&#8220;AMP-518&#8221;). We announced in August 2023 that the study had met the planned enrollment of 80 subjects
ages 18 to 60 years who have been randomized 1:1 to receive twice-weekly intravenous infusions of Ampligen or placebo for 12 weeks, with
a follow-up phase of two weeks. All patients have completed the study, with topline data reported in February 2024 and an analysis of
complete patient clinical data reported in January 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white">Please see &#8220;Ampligen as a Treatment for Post-COVID Conditions&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Ampligen
as a treatment for ME/CFS and Post-COVID Conditions</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have long been focused on seeking the FDA&#8217;s approval for the use of Ampligen to treat myalgic encephalomyelitis/chronic fatigue
syndrome (&#8220;ME/CFS&#8221;). In fact, in February 2013, we received a Complete Response letter (&#8220;CRL&#8221;) from the FDA for
our Ampligen NDA for ME/CFS, stating that we should conduct at least one additional clinical trial, complete various nonclinical studies
and perform a number of data analyses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
developing a comprehensive response to the FDA and a plan for a confirmatory trial for the FDA NDA, we proceeded independently in Argentina
and, in August 2016, we received approval of an NDA from ANMAT for commercial sale of Ampligen in the Argentine Republic for the treatment
of severe CFS. In September 2019, we received clearance from the FDA to ship Ampligen to Argentina for the commercial launch and subsequent
sales. On June 10, 2020, we received import clearance from ANMAT to import the first shipment of commercial grade vials of Ampligen into
Argentina. The next steps in the commercial launch of Ampligen include ANMAT conducting a final inspection of the product and release
tests before granting final approval to begin commercial sales. This testing and approval process is ongoing due to ANMAT&#8217;s internal
processes. Once final approval by ANMAT is obtained, GP Pharm will be responsible for distributing Ampligen in Argentina.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA authorized an open-label treatment protocol (&#8220;AMP-511&#8221;) allowing patient access to Ampligen for treatment in a study
under which severely debilitated CFS patients have the opportunity to be on Ampligen to treat this very serious and chronic
condition. The data collected from the AMP-511 protocol through a consortium group of clinical sites provide safety information
regarding the use of Ampligen in patients with CFS. The AMP-511 protocol is ongoing. In October 2020, we received IRB approval for
the expansion of the AMP-511 protocol to include patients previously diagnosed with SARS-CoV-2 following clearance of the virus, but
who still demonstrate chronic fatigue-like symptoms that we refer to as Post-COVID conditions. As of September 30, 2024, there were
7 patients enrolled in this open-label, expanded access treatment protocol (including two patients with Post-COVID Conditions). To
date, there have been eight such Post-COVID patients treated in the study. AIM previously reported positive preliminary results
based on data from the first four Post-COVID Condition patients enrolled in the study. The data show that, by week 12, compared to
baseline, there was what the investigators considered a clinically significant decrease in fatigue-related measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan on a comprehensive follow through with the FDA regarding the use of Ampligen as a treatment for ME/CFS. We have learned a great
deal since the FDA&#8217;s CRL and plan to adjust our approach to concentrate on specific ME/CFS symptoms. Responses to the CRL and a
proposed confirmatory trial are being worked on now by our R&amp;D team and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see &#8220;<i>Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Atlas
Equity Line of Credit</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2024, we entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the
&#8220;Registration Rights Agreement&#8221;) with Atlas Sciences, LLC, a Utah limited liability company (&#8220;Atlas&#8221;), pursuant
to which Atlas has committed to purchase up to $15 million of our common stock. No assurance can be given as to the actual amount that will be raised pursuant to the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms and subject to the conditions of the Purchase Agreement, we have the right, but not the obligation, to sell to Atlas, and Atlas
is obligated to purchase up to $15 million of our common stock (the &#8220;Commitment Amount&#8221;). Such sales by us, if any, will
be subject to certain limitations, and may occur from time to time, at our sole discretion, over the 24-month period commencing on the
date that a registration statement covering the resale of shares that have been and may be issued under the Purchase Agreement. We agreed
to file the registration statement with the SEC pursuant to the Registration Rights Agreement. Sales could not commence until the registration
statement was declared effective by the SEC and a final prospectus in connection therewith is filed and the other conditions set forth
in the Purchase Agreement are satisfied. The registration statement was declared effective and the final prospectus was filed on May
1, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atlas
has no right to require us to sell any shares to Atlas, but Atlas is obligated to make purchases as we direct, subject to certain conditions.
There are no upper limits on the price per share that Atlas must pay for shares of common stock. Actual sales of shares to Atlas will
depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price
of the common stock and determinations by us as to the appropriate sources of funding for us and our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds under the Purchase Agreement will depend on the frequency and prices at which we sell shares to Atlas. We expect that any
proceeds received by us will be used for working capital and general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot sell shares below the Minimum Price (as defined by the NYSE American) under the Purchase Agreement that would represent, in the
aggregate, more than 19.99% of the outstanding shares on the date that the Purchase Agreement was executed. Before we could do that,
we would need to obtain stockholder approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed with Atlas that we will not enter into any &#8220;variable rate&#8221; transactions with any third party for a period
defined in the Purchase Agreement. Atlas has covenanted not to cause or engage in any manner whatsoever, any direct or indirect
short selling or hedging of our shares. Pursuant to the purchase agreement, our ATM with Maxim Group is not deemed to be a variable
rate transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for Atlas&#8217;s irrevocable commitment to purchase shares upon the terms of and subject to satisfaction of the conditions
set forth in the Purchase Agreement, upon execution of the Purchase Agreement, we agreed to pay Atlas an initial commitment fee in shares
equal to 1.0% of the Commitment Amount. The initial commitment fee was paid upon execution of the Purchase Agreement through the issuance
of 338,600 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, conditions and indemnification
obligations of the parties. We have the right to terminate the Purchase Agreement at any time, at no cost or penalty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
any period where bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for
relief under any bankruptcy law or any law for the relief of debtors shall be instituted or anticipated by or against us or any of our
subsidiaries, and in the case of such a proceeding being involuntary or commenced against us, which is not dismissed within 60 days,
we may not initiate any purchase of shares by Atlas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific
dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting
parties. The foregoing descriptions of the Agreements are qualified in their entirety by reference to the full text of these Agreements
which were filed as exhibits 10.104 and 10.105 to our 2023 Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Securities
Purchase Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2024, we entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) to complete an offering (the &#8220;Transactions&#8221;)
with a single accredited investor (the &#8220;Purchaser&#8221;), pursuant to which we  issued to the Purchaser, (i) in a registered
direct offering, 5,640,958 shares of our common stock (the &#8220;Shares&#8221;), par value $0.001 per share (&#8220;Common Stock&#8221;)
and (ii) in a concurrent private placement, we  issued to the Purchaser Class A common warrants to purchase an aggregate of up to
5,640,958 shares of its common stock (the &#8220;A Warrants&#8221;) at an exercise price of $0.363 per share and Class B common warrants
to purchase an aggregate of up to 5,640,958 shares of its common stock (the &#8220;B &#8220;Warrants&#8221; and, along with the A Warrants,
the &#8220;Common Warrants&#8221;) at an exercise price of $0.363 per share. The A Warrants and B Warrants will not be exercisable for
six months after the issuance date and will expire, respectively, 24 months and five years and six months after the issuance date. The
Common Warrants and the shares of common stock issuable upon the exercise of such warrants are offered pursuant to an exemption from
the registration requirements of the Securities Act provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
received aggregate gross proceeds from the Transactions of approximately $2,047,688, before deducting fees to the Placement Agent and
other estimated offering expenses payable by us. The Shares are being offered by us pursuant to a shelf registration statement on Form
S-3 (File No. 333-262280), which was declared effective on February 4, 2022 (as amended from time to time, the &#8220;Registration Statement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Purchase Agreement, subject to certain exceptions, we could not issue any equity securities for 60 days following the
issuance date, provided that we are able to utilize the at-the-market offering program with the Placement Agent after 30 days.
Additionally, we cannot enter into a variable rate transaction (other than the ATM program with the Placement Agent) for 120 days after
the issuance date. In addition, our executive officers and each of our directors have entered into lock-up agreements with us pursuant
to which each of them has agreed not to, for a period of 90 days from the closing of the Transactions, offer, sell, transfer or otherwise
dispose of our securities, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of the Common Warrants, and the number of Common Warrant Shares, are subject to adjustment in the event of any stock
dividend or split, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Common
Warrants. If a Fundamental Transaction (as defined in the Common Warrants) occurs, then the successor entity will succeed to, and be
substituted for us, and may exercise every right and power that we may exercise and will assume all of its obligations under the
Common Warrants with the same effect as if such successor entity had been named in the warrant itself. Common Warrant Holders will
have additional rights defined in the Common Warrants. The Common Warrants are exercisable on a &#8220;cashless&#8221; basis only if
there is not a current registration statement permitting public resale. In this regard, the Company filed a registration statement
to register the resale of the Common Warrant Shares. That registration statement was
declared effective by the SEC on July 11, 2024. The Company has agreed to use commercially reasonable efforts to keep such
registration statement effective at all times until no Purchaser owns any Warrants or Warrant Shares issuable upon exercise
thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maxim
Group LLC acted as the placement agent (the &#8220;Placement Agent&#8221;) on a &#8220;commercially reasonable best efforts&#8221;
basis, in connection with the Transactions pursuant to the Placement Agency Agreement, dated May 31, 2024 (the &#8220;Placement
Agency Agreement&#8221;), by and between us and the Placement Agent. Pursuant to the Placement Agency Agreement, the Placement Agent was paid a cash fee of 8% of the aggregate gross proceeds paid to the Company for the securities sold in
the Transactions and reimbursement of certain out-of-pocket expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, the Company entered into a Securities Purchase Agreement to complete an offering with a single accredited investor.
For more information see Note 15: Subsequent Events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">OUR
PRODUCTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary pharmaceutical product platform consists of Ampligen (rintatolimod), a first-in-class drug of large macromolecular double-stranded
(ds) RNA (ribonucleic acid) molecules, and our FDA-approved natural alpha-interferon product, Alferon N Injection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ampligen
is approved for sale in Argentina (to 2026) for severe CFS and is an experimental drug in the United States currently undergoing
clinical development for the treatment of certain cancers, ME/CFS and Post-COVID Conditions. Over its developmental history, Ampligen has received various
designations, including Orphan Drug Product Designation (FDA and EMA), Treatment protocol (e.g., &#8220;Expanded Access&#8221; or
&#8220;Compassionate&#8221; use authorization) with Cost Recovery Authorization (FDA) and &#8220;promising&#8221; clinical outcome
recognition based on the evaluation of certain summary clinical reports (&#8220;AHRQ&#8221; or Agency for Healthcare Research and
Quality). Based on the results of published, peer-reviewed pre-clinical studies and clinical trials, we believe that Ampligen may
have broad-spectrum antiviral and anti-cancer properties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that nucleic acid compounds represent a potential new class of pharmaceutical products designed to act at the molecular level
for treatment of many human diseases. Ampligen represents the first drug in the class of large (macromolecular) dsRNA molecules to apply
for NDA review. There are two forms of nucleic acids: deoxyribonucleic acid (&#8220;DNA&#8221;) and ribonucleic acid (&#8220;RNA&#8221;).
DNA is a group of naturally occurring molecules found in chromosomes, the cell&#8217;s genetic machinery. RNA is a group of naturally
occurring informational molecules which orchestrate a cell&#8217;s behavior which, in turn, regulates the action of groups of cells,
including the cells which comprise the body&#8217;s immune system. RNA directs the production of proteins and regulates certain cell
activities including the activation of an otherwise dormant cellular defense against viruses and tumors. Our drug technology utilizes
specifically configured RNA and is a selective Toll-like Receptor 3 (&#8220;TLR3&#8221;) agonist that can be administered intravenously,
intranasally and intraperitoneally. Ampligen has been assigned the generic name rintatolimod by the United States Adopted Names Council
(&#8220;USANC&#8221;) and has the chemical designation poly(I):poly(C12U).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expanded
Access Program/Early Access Programs/clinical trials of Ampligen that have been conducted or that are ongoing include studies of the
potential treatment of patients with pancreatic cancer, renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian
cancer, breast cancer, colorectal cancer, prostate cancer, ME/CFS, Hepatitis B, HIV, COVID-19 and Post-COVID conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received approval of our NDA from ANMAT for the commercial sale of Ampligen in the Argentine Republic for the treatment of severe
CFS. The product will be marketed by GP Pharm, our commercial partner in Latin America. Shipment of the drug product to Argentina was
initiated in 2018 to complete the release testing by ANMAT needed for commercial distribution. In September 2019, we received clearance
from the FDA to ship Ampligen to Argentina for the commercial launch and subsequent sales. In June 2020, we received import clearance
from ANMAT to import the first shipment of commercial grade vials of Ampligen into Argentina. We are currently working with GP Pharm
on the commercial launch of Ampligen in Argentina. Commercialization in Argentina will require, among other things, GP Pharm to establish
disease awareness, medical education, creation of an appropriate reimbursement level, design of marketing strategies and completion of
manufacturing preparations for launch and ANMAT conducting a final inspection of the product and release tests before granting final
approval to begin commercial sales. AIM has supplied GP Pharm with the Ampligen required for testing and ANMAT release. This testing
and approval process is ongoing due to ANMAT&#8217;s internal processes. Once final approval by ANMAT is obtained, GP Pharm will begin
distributing Ampligen in Argentina. Argentina has experienced hyper-inflation and recently devalued its currency to the U.S. dollar by
50%. Contracts with GP Pharm are U.S. dollar contracts and the parties must evaluate the impact of the recent devaluation on its relationship.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has authorized an open-label expanded access treatment protocol (AMP-511) allowing patient access to Ampligen in a study under which
severely debilitated CFS patients have the opportunity to be on Ampligen to treat this serious and chronic condition. The AMP-511 protocol
started in the 1990s and is ongoing. The data collected from the AMP-511 protocol through clinical sites provide safety information regarding
the use of Ampligen in patients with CFS. We are establishing an enlarged database of clinical safety information which we believe will
provide further documentation regarding the absence of autoimmune disease associated with Ampligen treatment. We believe that continued
efforts to understand existing data, and to advance the development of new data and information, will ultimately support our future filings
for Ampligen and/or the design of future clinical studies that the FDA requested in a CRL. The FDA approved an increased reimbursement
level from $200 to $345 per 200 mg vial of Ampligen, due to increased production costs; which was re-authorized in 2021, 2022, 2023 and
2024. At this time, we do not plan on passing this adjustment along to the patients in this program. In October 2020, we received IRB
approval for the expansion of the AMP-511 Expanded Access Program clinical trial for ME/CFS to include patients previously diagnosed
with SARS-CoV-2 following clearance of the virus, but who still demonstrate chronic fatigue-like symptoms that we refer to as Post-COVID
conditions. As of September 30, 2024, there were 7 patients enrolled in this open-label expanded access treatment protocol. In July 2022, AIM
reported positive preliminary results based on data from the first four Post-COVID Condition patients enrolled in the study. The data
show that, by week 12, compared to baseline, the investigators observed what they considered a clinically significant decrease in fatigue-related
measures. To date, there have been eight such Post-COVID patients treated in this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2016, we entered into a five-year agreement with myTomorrows, a Netherlands based company, for the commencement and management of
an Early Access Program (&#8220;EAP&#8221;) in Europe and Turkey related to ME/CFS. Pursuant to the agreement, as amended, myTomorrows
also is managing all Early Access Programs and Special Access Programs in Europe, Canada, and Turkey to treat pancreatic cancer and ME/CFS
patients. The agreement was automatically extended for a period of 12 months on May 20, 2021; has been automatically extended for 12
months on each subsequent May 20; and will continue to be automatically extended for periods of 12 months every May 20 until terminated
or the terms of the agreement are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2018, Ampligen was cited as outperforming two other TLR3 agonists &#8212; poly IC and natural double stranded RNA &#8212; in creating
an enhanced tumor microenvironment for checkpoint blockade therapy in the journal of Cancer Research . In a head-to-head study in explant
culture models, Ampligen activated the TLR3 pathway and promoted an accumulation of killer T cells but, unlike the other two TLR3 agonists,
it did so without causing regulatory T cell (Treg) attraction. These findings were considered important because they indicate that Ampligen
selectively reprograms the tumor microenvironment by inducing the beneficial aspects of tumor inflammation (attracting killer T cells),
without amplifying immune-suppressive elements such as regulatory T cells. The study was conducted at the University of Pittsburgh and
Roswell Park as a part of the NIH-funded P01 CA132714 and Ovarian Cancer Specialized Program of Research Excellence (&#8220;SPORE&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2018, we completed production of two commercial-size batches of more than 16,000 vials of Ampligen, following its &#8220;Fill &amp; Finish&#8221;
at Jubilant HollisterStier, the Contract Manufacturing Organization. These lots passed all required testing for regulatory release for
human use and are being used for multiple programs, including: the treatment of ME/CFS; the pancreatic cancer EAP in the Netherlands;
and will continue to be used for ongoing and future clinical studies in oncology. Lots of Ampligen were manufactured in December 2019,
January 2020 and December 2023. Additionally, in December 2020, we added Pharmaceutics International Inc. (&#8220;Pii&#8221;) as a &#8220;Fill
&amp; Finish&#8221; provider to enhance our capacity to produce Ampligen. This addition amplifies our manufacturing capability by providing
redundancy and cost savings. The contracts augment our active and in-process fill and finish capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Immuno-Oncology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potential of Ampligen as an immuno-oncology therapeutic has been a major focus of AIM since our current leadership took over in 2016.
We have been working with the University of Pittsburgh&#8217;s chemokine modulation research initiative, which includes the use of Ampligen
as a potential adjuvant to modify the tumor microenvironment (&#8220;TME&#8221;) with the goal of increasing anti-tumor responses to
check point inhibitors (&#8220;CPI&#8221;). As part of this collaboration, we have supplied Ampligen to the University. The study, under
the leadership of Robert P. Edwards, MD, chair of gynecologic services at Magee-Women&#8217;s Hospital of the University of Pittsburgh
School of Medicine, and Professor of Surgery Pawel Kalinski, M.D., Ph.D., at Roswell Park, Buffalo, N.Y., involved the chemokine modulatory
regimen developed by Dr. Kalinski&#8217;s group and successfully completed the Phase 1 dose escalation in patients with resectable colorectal
cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
Ampligen clinical trials are underway or recently completed at major university cancer centers testing whether tumor microenvironments
can be reprogrammed to increase the effectiveness of cancer immunotherapy, including checkpoint inhibitors. The underway trials include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pancreatic
                                            Cancer Trial</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Phase 2 AMP-270 clinical trial is a randomized, open-label, controlled, parallel-arm study
                                            with the primary objective of comparing the efficacy of Ampligen versus a no treatment control
                                            group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma.
                                            Secondary objectives include comparing safety and tolerability. AMP-270 is expected to enroll
                                            approximately 90 subjects in up to 30 centers across the U.S. and Europe. In March 2022,
                                            the FDA granted clearance to proceed with the study. In April 2022, we executed a work order
                                            with Amarex to manage the clinical trial. In August 2022, we received IRB approval of the
                                            trial protocol and so announced the trial&#8217;s commencement. The authorization to proceed
                                            with the Phase 2 pancreatic cancer clinical trial has been received with potential sites
                                            in the Netherlands at Erasmus MC, and also at major cancer research centers in the United
                                            States such as The Buffett Cancer Center at the University of Nebraska Medical Center (UNMC).
                                            A Type D meeting package seeking the FDA guidance on expansion of inclusion criteria and
                                            treatment arms to be included was submitted to the FDA. In June 2024, a written response
                                            to that meeting package was received from the FDA. The study protocol
                                            was amended  and resubmitted to the FDA in October 2024. The study is still recruiting patients under the current
                                            protocol. (<span style="text-decoration: underline">https://clinicaltrials.gov/ct2/show/NCT05494697</span>).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            DURIPANC Study is a Phase 1b/2 clinical trial combining Ampligen with AstraZeneca&#8217;s
                                            anti-PD-L1 immune checkpoint inhibitor Imfinzi&#174; (durvalumab) for the treatment of late-stage
                                            pancreatic cancer. The primary objective of the Phase 1b portion is to determine the safety
                                            of combination therapy. Investigators at Erasmus Medical Center (&#8220;Erasmus MC&#8221;)
                                            in the Netherlands had completed the safety evaluation of subjects enrolled in the first
                                            dose level of the dose escalation design, finding the combination therapy to be generally
                                            well-tolerated with no severe adverse events or dose-limiting toxicities. That first cohort
                                            has now reached the pre-determined 6-month stability assessment timepoint and AIM is pleased
                                            to announce that two of the three subjects remain stable. The subjects will continue to be
                                            treated and receive formal assessment of progression every three months. The standard for
                                            calculating median progression-free survival (&#8220;PFS&#8221;) requires that 50% or more
                                            of the subjects have seen disease progression. Because 67% of the patients in the cohort
                                            evaluated at 6 months have remained stable, AIM cannot yet report on PFS. Two of the three
                                            subjects in the higher-dose second cohort of subjects also have stable disease, although
                                            they have not yet reached the 6-month stability assessment timepoint. Investigators continue
                                            to treat and monitor these subjects.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Advanced
                                            Recurrent Ovarian Cancer</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
                                            of the Phase 1 portion of a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced
                                            recurrent ovarian cancer were published in the American Association for Cancer Research publication,
                                            Clinical Cancer Research (Clin Cancer Res January 19, 2022 DOI: 10.1158/1078-0432.CCR-21-3659).
                                            The study results represent an important extension of prior studies using human tumor explants
                                            that showed Ampligen&#8217;s potentially important role as a TLR3 agonist acting synergistically
                                            with high-dose IFN&#945; and celecoxib to selectively enhance Teff cell-attractants while
                                            suppressing Treg-attractants in the tumor microenvironment with a concomitant increase in
                                            the Teff/Treg ratio. The importance of boosting the Teff/Treg ratio in the tumor microenvironment
                                            is that it is associated with the conversion of &#8216;cold&#8217; tumors into &#8216;hot&#8217;
                                            tumors, which have an increased sensitivity to chemo-immunotherapy and an improved chance
                                            of showing tumor regression. The Phase 1 portion was designed to establish intraperitoneal
                                            safety. The Phase 2 portion of the study is recruiting subjects. <span style="text-decoration: underline">https://clinicaltrials.gov/ct2/show/NCT02432378</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            Phase 2 study of advanced recurrent ovarian cancer using cisplatin, pembrolizumab, plus Ampligen;
                                            up to 45 patients to be enrolled; enrollment has commenced, and numerous patients have commenced
                                            treatment. In April 2024, researchers released topline data that saw an Objective Response
                                            Rate (&#8220;ORR&#8221;) of 45% in platinum-sensitive subjects with recurrent ovarian cancer.
                                            ORR includes complete response (&#8220;CR&#8221;) and partial response (&#8220;PR&#8221;)
                                            to treatment. There was a total Clinical Benefit Rate (&#8220;CBR&#8221;) of 55% when including
                                            patients who experienced stable disease (&#8220;SD&#8221;). Researchers also reported a median
                                            Progression-Free Survival (&#8220;PFS&#8221;) of 7.8 months. Based on these results and other
                                            research suggesting a similar effect in other solid tumor types, AIM sees an Ampligen combination
                                            therapy as having potential across multiple types of cancers. Additional clinical studies
                                            are underway and planned in many of these types of tumors to further confirm these effects.&#8221;
                                            https://clinicaltrials.gov/ct2/show/NCT03734692</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, we were granted a patent by the Netherlands Patent Office with granted patent claims that include, but are not limited to,
the use of Ampligen as a combination cancer therapy with checkpoint blockade inhibitors (e.g. pembrolizumab, nivolumab). We believe that
the above positive data makes this patent have heightened potential. Similar patents are pending in other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stage
                                            4 Metastatic Triple Negative Breast Cancer</b> - Phase 1 study of metastatic triple-negative
                                            breast cancer using chemokine modulation therapy, including Ampligen and pembrolizumab. Eight
                                            patients were enrolled and 6 patients were evaluable. <span style="text-decoration: underline">https://www.clinicaltrials.gov/ct2/show/NCT03599453</span>.
                                            The key findings announced first in April 2022, and later published in November 2023, included:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            pre-determined primary endpoint of efficacy was met (increase in CD8 in TME).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uniform
                                            increase of immune markers upon treatment was observed: CD8 mRNA (6.1-fold; p-0.034), GZMB
                                            mRNA (3.5-fold; p=0.058), ratios of CD8 /FOXP3 and GZMB/FOXP3 (5.7-fold; p=0.036, and 7.6-fold;
                                            p=0.024 respectively), thus successfully meeting the pre-determined primary endpoint in the
                                            study (increase in CD8 in TME).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition, an increase in CTL attractants CXCL10 (2.6-fold; p=0.104) and CCL5 (3.3-fold; p=0.019)
                                            was observed. In contrast, Treg marker FOXP3 or Treg attractants CCL22 or CXCL12 were not
                                            enhanced.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
                                            patients had stable disease lasting 2.4, 2.5 and 3.8 months, as of data cut off September
                                            1, 2021.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            additional patient (non-evaluable) had a partial response (breast tumor autoamputation) with
                                            massive tumor necrosis in the post-CKM biopsy.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stage
                                            4 Colorectal Cancer Metastatic to the Liver</b> - Phase 2a study of Ampligen as a component
                                            of chemokine modulatory regimen on colorectal cancer metastatic to liver; recruitment has
                                            been completed; 19 patients were enrolled and 12 patients were evaluable for the primary
                                            endpoint <span style="text-decoration: underline">https://clinicaltrials.gov/ct2/show/NCT03403634</span>. The key findings announced
                                            in April 2022 included:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            study&#8217;s primary endpoint was met, evidenced by increased CD8a expression post-treatment
                                            (p=0.046).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Saw
                                            increase in the CD8a/CD4 (p=0.03), CD8a/FOXP3 (p&lt;0.01) and GZMB/FOXP3 (p&lt;0.01) ratios.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            expression of CTL-attracting chemokines CCL5 (p=0.08), CXCL9 (p=0.05), and CXCL10 (p=0.06)
                                            were increased, while expression of the Treg/MDSC attractant CXCL12 (p=0.07) was decreased
                                            post-treatment.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median
                                            OS was 10.5 (90% CI 2.2-15.2) months, and the median PFS was 1.5 (90% CI 1.4, 1.8) months.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            tumor responses were seen. The treatment was well tolerated. Of all enrolled patients (N=19),
                                            adverse events were noted in 74% of patients, with the most common being fatigue (58%). Grade
                                            3 or higher adverse events were rare (5%).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Early-Stage
                                            Prostate Cancer</b> - Phase 2 study investigating the effectiveness and safety of aspirin
                                            and Ampligen with or without interferon-alpha 2b (Intron A) compared to no drug treatments
                                            in a randomized three-arm study of patients with prostate cancer before undergoing radical
                                            prostatectomy. Patient enrollment has been initiated in this study designed for up to 45
                                            patients. The study is temporarily suspended due to the Merck discontinuation of Intron-A
                                            production. Roswell Park has had a Type-C meeting with the FDA and is currently performing
                                            the necessary experiments to replace Intron-A with a generic alpha-interferon. We expect
                                            this trial to resume in the near future. <span style="text-decoration: underline">https://clinicaltrials.gov/ct2/show/NCT03899987</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Early-Stage
                                            Triple Negative Breast Cancer</b> - The objective of this Phase 1 study is to evaluate the
                                            safety and tolerability of a combination of Ampligen, celecoxib with or without Intron A,
                                            when given along with chemotherapy in patients with early-stage triple negative breast cancer.
                                            The now completed (as of September 2022) topline results from the study confirm the positive
                                            findings that were previously presented at the <span style="text-decoration: underline">2022 Society for Immunotherapy of Cancer
                                            (SITC) 37th Annual Meeting</span> in a poster presentation titled <i>Safety and efficacy of
                                            de-escalated neoadjuvant chemoimmunotherapy of triple negative breast cancer (TNBC) using
                                            chemokine-modulating regimen (rintatolimod, IFN-&#945;2b, celecoxib)</i>. The primary endpoint
                                            of the study was safety and tolerability. The results demonstrated that treatment was well-tolerated
                                            with mostly grade 1 or 2 treatment-related adverse events (TRAEs) without dose-limiting toxicities
                                            (DLTs) or delayed or immune-related toxicities. DLT was defined as grade 3 or higher toxicities
                                            within the first 3 weeks. Secondary endpoints included pCR rate where 5/9 (56%) of patients
                                            attained pCR and 1 more patient attained ypTmic. Tumor and blood biomarkers were also analyzed
                                            in exploratory studies. <span style="text-decoration: underline">https://clinicaltrials.gov/ct2/show/NCT04081389</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Refractory
                                            Melanoma</b> &#8212; Roswell Park Comprehensive Cancer Center (&#8220;Roswell Park&#8221;),
                                            in a clinical trial fully funded by the National Cancer Institute (NCI), has commenced patient
                                            enrollment in its Phase 2 study in subjects with primary PD-1/PD-L1 resistant melanoma. The
                                            Phase 2 study will evaluate type-1 polarized dendritic cell (&#945;DC1) vaccine in combination
                                            with tumor-selective chemokine modulation (&#8220;CKM&#8221;) comprised of Interferon alpha
                                            2b, Ampligen (rintatolimod) and Celecoxib. Up to 24 patients are to be enrolled. The study
                                            was temporarily suspended due to the Merck discontinuation of Intron-A production but has
                                            since resumed recruitment (See: <span style="text-decoration: underline">https://www.clinicaltrials.gov/show/NCT04093323</span>).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Metastatic
                                            or Unresectable Triple Negative Breast Cancer &#8211; </b>This phase 1/2a trial tests the
                                            safety, side effects, and best dose of chemokine modulation therapy (CKM) (rintatolimod,
                                            celecoxib, and interferon alpha 2b) in combination with pembrolizumab for the treatment of
                                            patients with triple negative breast cancer that has spread from where it first started (primary
                                            site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable).
                                            The study is recruiting subjects.</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">https://clinicaltrials.gov/study/NCT05756166</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Additional
Progress and Analysis Related to Pancreatic Cancer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2017, the EAP established under our agreement with myTomorrows to enable access of Ampligen to ME/CFS patients was extended to
pancreatic cancer patients beginning in the Netherlands. myTomorrows is our exclusive service provider in Europe and Turkey and will
manage all EAP activities relating to the pancreatic cancer extension of the program. In February 2018, the agreement with myTomorrows
was extended to cover Canada to treat pancreatic cancer patients, pending government approval. There have been no physician requests
to date that would cause the program to move forward with the approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 42 pancreatic cancer patients initially received treatment with Ampligen immuno-oncology therapy under the EAP program at Erasmus
MC in the Netherlands; that initial program has since continued to expand and proceed with additional patients to be treated with Ampligen
supervised by Prof. C.H.J. van Eijck, MD. In March 2024, the team at Erasmus MC published a thorough data analysis in an article titled
&#8220;<i><span style="text-decoration: underline">Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses</span></i>&#8221;
in the journal <i>Clinical Cancer Research</i>. The positive clinical findings relate to changes in the tumor microenvironment after
Ampligen use. We are working with our Contract Research Organization, Amarex Clinical Research LLC, to seek FDA &#8220;fast-track.&#8221;
We have applied for fast-track status; have received denials to date; and are currently working through the FDA process to provide all
the materials and information required to achieve fast-track status.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
manuscript titled &#8220;<i><span style="text-decoration: underline">Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated
T Cell Responses</span></i>,&#8221; was published in the print version of the journal <i>Clinical Cancer Research</i> in August 2024. Researchers
at the Erasmus University Medical Center (&#8220;Erasmus MC&#8221;) found that Ampligen treatment in pancreatic cancer patients enhances
peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1s)
and T cells. Post-Ampligen, the increased peripheral abundance of BTLA+XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical
outcomes. Patients with stable disease exhibited pronounced overexpression of genes related to DC and T cell activation. Notably, the
expression of immune checkpoints PD-L1 and PD-L2 decreased post-Ampligen across all patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            December 2020, the FDA granted Ampligen Orphan Drug Designation status for the treatment
                                            of pancreatic cancer. The Orphan Drug Designation program provides orphan status to drugs
                                            and biologics which are defined as those intended for the treatment, prevention or diagnosis
                                            of a rare disease or condition, which is one that affects less than 200,000 persons in the
                                            United States or meets cost recovery provisions of the act. The status helps incentivize
                                            the treatment of therapies to treat unmet medical needs by providing a company with seven
                                            years of exclusivity rights once a drug reaches market.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            February 2021, our subsidiary, NV Hemispherx Biopharma Europe, received formal notification
                                            from the European Commission (&#8220;EC&#8221;) granting Orphan Medicinal Product Designation
                                            for Ampligen as a treatment for pancreatic cancer. Orphan products, once commercially approved
                                            in the European Union (&#8220;EU&#8221;), receive benefits including up to ten years of protection
                                            from market competition from similar medicines with similar active component and indication
                                            for use that are not shown to be clinically superior.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2021, Ampligen was featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal <span style="text-decoration: underline">Cancers
</span>as a potential treatment option for cancer patients who are infected with SARS-CoV-2. The study&#8217;s authors stated that Ampligen
has the potential to reduce the severity of the deadly respiratory disease COVID-19. According to laboratory data presented in the publication,
&#8220;Rintatolimod [Ampligen] activated the innate and the adaptive immune systems by activating a cascade of actions in human pancreatic
cancer cells&#8221;, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stimulation
                                            of interferon regulatory factors and activation of the interferon signaling pathway,</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Production
                                            of immunomodulatory activity and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Induction
                                            of the expression of MHC class I and II histocompatibility</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
full journal article is titled: &#8220;<span style="text-decoration: underline">Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an
Anti-COVID-19 Opportunity in Cancer Patients?</span>&#8221; <i>Cancers</i> is a peer-reviewed, open access journal of oncology published
semimonthly online by MDPI. The study&#8217;s authors include Prof. C.H.J. van Eijck, MD, PhD, the lead investigator at Erasmus Medical
Center in the Netherlands.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, we and Amarex submitted an IND application with the FDA for a planned Phase 2 study of Ampligen as a therapy for locally
advanced or metastatic late-stage pancreatic cancer. In December 2021, the FDA responded with a Clinical Hold on the proposed study.
We submitted our response to the FDA in February 2022. In March 2022, we received notification from the FDA that the Clinical Hold was
released and cleared, meaning that we are now able to proceed with the study specifically to treat locally advanced pancreatic cancer
patients. In August 2022, we received IRB approval of the trial protocol and so announced the trial&#8217;s commencement. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A Type D meeting package seeking
the FDA guidance on expansion of inclusion criteria and treatment arms to be included was submitted to the FDA. In June 2024, a written
response to that meeting package was received from the FDA. The study protocol was amended and resubmitted to the FDA in October 2024.
The study is still recruiting patients under the current protocol.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Positive
data was published in March 2022 in a manuscript titled, <span style="text-decoration: underline">&#8220;Rintatolimod (Ampligen&#174;) enhances numbers of peripheral B cells
and is associated with longer survival in patients with locally advanced and metastasized pancreatic cancer pre-treated with FOLFIRINOX:
a single-center named patient program</span>,&#8221; in <i>Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer</i>.
In the single-center, named-patient program, patients with locally advanced pancreatic cancer (LAPC) or metastatic disease were treated
with Ampligen for 6 weeks, at 2 doses per week with 400 mg per infusion. The study found that Ampligen improved the median survival of
these patients. The study&#8217;s primary endpoints were the Systemic Immune-Inflammation Index (SIII), the Neutrophils to Lymphocyte
Ratio (NLR), and absolute counts of 18 different populations of circulating immune cells as measured by flow cytometry. Secondary endpoints
were progression-free survival (PFS) and overall survival (OS). The median overall survival in the Ampligen group was 19 months, compared
to a historical control group and subgroup (7.5 and 12.5, respectively) that did not receive Ampligen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
in March 2022, we announced that study data evaluating the direct effects of Ampligen on human pancreatic ductal adenocarcinoma (PDAC)
cells was accepted for presentation at the 15th Annual International Hepato-Pancreato-Biliary Association World Congress in New York,
NY. For the study, three PDAC cell lines (CFPAC-1, MIAPaCa-2, and PANC-1) were treated with various concentrations of Ampligen and their
corresponding vehicle control. The proliferation and migration effects were examined using in-vitro assays and the molecular effect was
examined by targeted gene expression profiling. Additionally human PDAC samples were used to validate the expression of toll-like receptor
3 (TLR3) by immunohistochemistry. Results from the study demonstrated Ampligen decreased the proliferation and migration ability of CFPAC-1
cells. In addition, it decreased the proliferation of MIAPaCa-2 cells and the migration of PANC-1 cells. However, it did not have a dual
effect in MIAPaCa-2 and PANC-1 cells. Interestingly, TLR3 was highly expressed in CFPAC-1 cells, low expressed in MIAPaCa-2 and not expressed
in PANC-1. Gene expression analysis revealed the upregulation of interferon-related genes, chemokines, interleukins and cell cycle regulatory
genes. The heterogeneity of TLR3 expression was confirmed in human PDAC samples. Based on these results, treating pancreatic cancer with
Ampligen may have a direct anti-tumor effect in pancreatic cancer cells expressing TLR-3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ampligen
as a Potential Antiviral</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the SARS-CoV-1 outbreak in 2002-03, Ampligen exhibited excellent antiviral properties and protective survival effect in NIH-contracted
studies of SARS-CoV-1-infected mice, which is very similar to SARS-CoV-2, the novel virus that causes COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Barnard 2006 study (<span style="text-decoration: underline">https://journals.sagepub.com/doi/abs/10.1177/095632020601700505</span>)
                                            found that Ampligen reduced virus lung levels to below detectable limits.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Day 2009 study (<span style="text-decoration: underline">https://www.sciencedirect.com/science/article/pii/S0042682209005832</span>)
                                            found that, instead of 100% mortality, there was 100% protective survival using Ampligen.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compared key transcription regulatory sequences of SARS-CoV-1 to SARS-CoV-2 and found significant similarities, suggesting highly probable
extension of the antiviral effects of Ampligen in the earlier NIH-contracted SARS experiments to COVID-19. The SARS-CoV-2 virus &#8211;
which causes COVID-19 &#8211; shares important genomic and pathogenic similarities with SARS-CoV-1 (hence its name). Since Ampligen has
shown antiviral activity against more distantly related coronaviruses, there was a reasonable probability that the antiviral effects
of Ampligen against SARS-CoV-1 will likely extend to SARS-CoV-2, and as discussed below, recently, Ampligen has demonstrated ex vivo
antiviral activity against SARS-CoV-2. We believe that this creates a compelling case for clinical trials to evaluate Ampligen as a potential
tool in the fight against COVID-19.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the late 2019 outbreak of SARS-CoV-2, we have been actively engaged in determining whether Ampligen could be an effective treatment for
this virus or could be part of a vaccine. We believe that Ampligen has the potential to be both an early-onset treatment for and prophylaxis
against SARS-CoV-2. We believe that prior studies of Ampligen in SARS-CoV-1 animal experimentation may predict similar protective effects
against the new virus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2020, we filed three provisional patent applications related to Ampligen in our efforts toward joining the global health community
in the fight against the deadly coronavirus (See: https://aimimmuno.com/press-release/aim-immunotech-files-provisional-patent-application-for-the-use-of-ampligenr-as-a-potential-therapy-for-covid-19-induced-chronic-fatigue/).
Our three provisional patent applications include: 1) Ampligen as a therapy for the coronavirus; 2) Ampligen as part of a proposed intranasal
universal coronavirus vaccine that combines Ampligen with inactivated coronavirus, conveying immunity and cross-protection and; 3) a
high-volume manufacturing process for Ampligen. Under the Patent Cooperation Treaty of 1970, which provides international protections
for patents, these three provisional patent applications were converted into two international patent applications based on the date
of their filings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, we contracted Amarex to act as our Clinical Research Organization and provide regulatory support with regard to a possible
clinical trial testing Ampligen&#8217;s potential as a COVID-19 prophylaxis via intranasal delivery.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in April 2020, we entered into confidentiality and non-disclosure agreements with numerous companies for the potential outsourcing of
the production of polymer, enzyme, placebo as well as Ampligen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, the FDA authorized an IND for Roswell Park to conduct a Phase 1/2a study of a regimen of Ampligen and interferon alpha in cancer
patients with COVID-19 infections. This clinical trial, sponsored by Roswell Park in collaboration with us, will test the safety of this
combination regimen in patients with cancer and COVID-19, and the extent to which this therapy will promote clearance of the SARS-CoV-2
virus from the upper airway. Several subjects have been treated. It is planned that the phase 1/2a study will enroll up to 44 patients
in two stages. Phase 1 will see 12-24 patients receiving both Ampligen and interferon alpha-2b at escalating doses. Once that initial
phase is complete, further study participants will be randomized to two arms: one receiving the two-drug combination and a control group
who will not receive Ampligen or interferon alpha but will receive best available care. We are a financial sponsor of the study and will
provide Ampligen at no charge for this study. In November 2020, the first patient in the study had been enrolled and treated. This study
was amended to add 20 patients, with 10 randomized to receive a single dose of Ampligen and 10 patients to receive current best therapies.
(See <span style="text-decoration: underline">clinicaltrials.gov/NCT04379518</span>). Due to a shortage of qualifying subjects with COVID-19 and cancer as a result of the positive
impact of vaccinations and treatments for COVID-19, Roswell is seeking approval to expand the qualifying subject criteria to include
other diseases lethal to immuno-compromised cancer patients, such as influenza. Accordingly, the study is temporarily suspended while
seeking said approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also entered into a specialized services agreement with Utah State University and have supplied Ampligen to support the University&#8217;s
Institute for Viral Research in its research into SARS-CoV-2. The Utah State results show that Ampligen was able to decrease SARS-CoV-2
infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, we received IRB approval for the expansion of the AMP-511 Expanded Access Program clinical trial for ME/CFS to include
patients previously diagnosed with SARS-CoV-2, but who still demonstrate chronic fatigue-like symptoms. Patients in the trial are treated
with our flagship pipeline drug Ampligen. In January 2021, we commenced with the treatment of the first previously diagnosed COVID-19
patient with long-COVID symptoms (i.e., Long Hauler) also known as Post-COVID Conditions in the AMP-511 study. Enrollment of post-COVID
patients continues in the study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, we entered into a Sponsor Agreement with CHDR to manage a Phase 1 randomized, double-blind study to evaluate the safety
and activity of repeated intranasal administration of Ampligen. AIM funded and sponsored the study. This study was designed to assess
the safety, tolerability and biological activity of repeated administration of Ampligen intranasally. A total of 40 healthy subjects
received either Ampligen or a placebo in the trial, with the Ampligen given at four escalating dosages across four cohorts, to a maximum
level of 1,250 micrograms. The study was completed, and the Final Safety Report reported no Serious or Severe Adverse Events at any dosage
level. We believe that the trial is a critical step in our ongoing efforts to develop Ampligen as a potential prophylaxis or treatment
for COVID-19 and other respiratory viral diseases. Amarex provided us with monitoring support during the trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we filed two COVID-19-related provisional patent applications in the third quarter of 2021. In August, we filed an application for Ampligen
as both an intranasal and an intravenous therapy for what we describe as Post-COVID conditions. The people suffering from Post-COVID
conditions, including some young adults, can be afflicted with severe difficulties in concentrating; serious memory problems; and the
inability to live an active lifestyle, to work and even to perform everyday tasks. Early data has demonstrated that patients with symptoms
of Post-COVID conditions being treated with Ampligen in the ongoing AMP-511 Expanded Access Program have reported improvements in fatigue
symptoms. Similarly, in ME/CFS, data supports the claim that Ampligen improves fatigue symptoms. Then in September 2022, we filed a patent
application for Ampligen as a potential early-onset intranasal therapy designed to enhance and expand infection-induced immunity, epitope
spreading, cross-reactivity and cross-protection in patients exposed to a wide range of RNA respiratory viruses, such as influenza, Rhinoviruses
and SARS-CoV-2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to securing these two provisional patent applications, we also moved forward with proposed studies in these areas and with Pre-Investigational
New Drug Applications in September 2021. One pre-IND was for a Phase 2, two-arm, randomized, double-blind, placebo-controlled, multicenter
study to evaluate the efficacy and safety of Ampligen in patients experiencing Post-COVID conditions (originally referred to as Post-COVID
Cognitive Dysfunction (PCCD) and has been revised to Post-COVID conditions).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ampligen
as a Treatment for Post-COVID Conditions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, we enrolled and dosed the first patient in our Phase 2 study evaluating Ampligen&#174; as a potential therapeutic for people
with post-COVID conditions (&#8220;AMP-518&#8221;). We announced in August 2023 that the study had met the planned enrollment of 80 subjects
ages 18 to 60 years who have been randomized 1:1 to receive twice-weekly intravenous infusions of Ampligen or placebo for 12 weeks, with
a follow-up phase of two weeks. All patients have completed the study and topline data was reported in February 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2024, we announced that an analysis of the complete clinical patient data from the AMP-518 clinical trial supported our belief
in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would be
the likely subject population for AIM&#8217;s planned follow-up clinical trial. Study subjects with Long COVID were, on average, able
to walk farther in a Six-Minute Walk Test (&#8220;6MWT&#8221;) when compared to subjects who received a placebo. The 6MWT measured the
distance a subject was able to walk in six minutes as a baseline and then again at 13 weeks. A clear signal of significant potential
(p &lt;0.02, two-tailed T-test) was observed in Ampligen-treated subjects with a baseline 6MWT less than 205 meters, who saw a mean improvement
of 139 meters, compared to a mean improvement of 91 meters in the corresponding part of the group who received the placebo. AIM therefore
believes that any future trial design should focus on Ampligen&#8217;s therapeutic potential for subjects whose Long COVID-related fatigue
can be categorized as moderate or worse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)	</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), also known as Chronic Fatigue Immune Dysfunction Syndrome (&#8220;CFIDS&#8221;)
and Chronic Fatigue Syndrome (CFS), is a serious and debilitating chronic illness and a major public health problem. ME/CFS is recognized
by both the government and private sector as a significant unmet medical need, including the U.S. National Institutes of Health (&#8220;NIH&#8221;),
FDA and the CDC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
severe ME/CFS patients become completely disabled or totally bedridden and are afflicted with severe pain and mental confusion even at
rest. ME/CFS is characterized by incapacitating fatigue with profound exhaustion and extremely poor stamina, sleep difficulties and problems
with concentration and short-term memory. It is also accompanied by flu-like symptoms, pain in the joints and muscles, tender lymph nodes,
sore throat and new headaches. A distinctive characteristic of the illness is a worsening of symptoms following physical or mental exertion,
which do not subside with rest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
high number of younger people being hospitalized for COVID-19 suggests considerable numbers of people in the prime of their lives may
have a COVID-induced ME/CFS-like illness in their future. According to a 2016 journal article, the estimated annual cost of lost productivity
related to ME/CFS was $9-37 billion in the United States, and for direct medical costs it was $9-14 billion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June of 2020, we filed a provisional patent application for, among other discoveries, the use of Ampligen as a potential early-onset
therapy for the treatment of COVID-19-induced chronic fatigue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
survivors of the first SARS-CoV-1 epidemic in 2003 continued to report chronic fatigue, difficulty sleeping and shortness of breath months
after recovering from the acute illness. &#8220;After one year, 17% of patients had not returned to work and 9% more had not returned
to their pre-SARS work levels,&#8221; according to Simmaron Research. Now there is increasing evidence that patients with COVID-19 can
develop a similar, ME/CFS-like illness. These patients are commonly referred to as &#8220;Long Haulers.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, we received IRB approval for the expansion of the AMP-511 Expanded Access Program clinical trial for ME/CFS to include
patients previously diagnosed with SARS-CoV-2 following clearance of the virus, but who still demonstrate chronic fatigue-like symptoms.
For more information on our AMP-511 Expanded Access Program, please see &#8220;<i>OUR PRODUCTS: Ampligen</i>&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2020, we announced the publication of statistically significant data detailing how Ampligen could have a considerable positive
impact on people living with ME/CFS when administered in the early stages of the disease. The data were published in <i>PLOS ONE</i>,
a peer-reviewed open access scientific journal published by the Public Library of Science. AIM researchers found that the TLR3 agonist
Ampligen substantially improved physical performance in a subset of ME/CFS patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above in <i>Overview; General; Ampligen as a treatment for ME/CFS</i>, we have long been focused on seeking the FDA&#8217;s approval
for the use of Ampligen to treat ME/CFS. In fact, in February 2013, we received a CRL from the FDA for our Ampligen NDA for ME/CFS, stating
that we should conduct at least one additional clinical trial, complete various nonclinical studies and perform a number of data analyses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
developing a comprehensive response to the FDA and a plan for a confirmatory trial for the FDA NDA, we proceeded independently in Argentina
and, in August 2016, we received approval of an NDA from ANMAT for commercial sale of Ampligen in the Argentine Republic for the treatment
of severe CFS. In September 2019, we received clearance from the FDA to ship Ampligen to Argentina for the commercial launch and subsequent
sales. On June 10, 2020, we received import clearance from ANMAT to import the first shipment of commercial grade vials of Ampligen into
Argentina. The next steps in the commercial launch of Ampligen include ANMAT conducting a final inspection of the product and release
tests before granting final approval to begin commercial sales. This testing and approval process is currently delayed due to ANMAT&#8217;s
internal processes. Once final approval by ANMAT is obtained, GP Pharm will begin distributing Ampligen in Argentina.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan on a comprehensive follow through with the FDA regarding the use of Ampligen as a treatment for ME/CFS. We have learned a great
deal since the FDA&#8217;s CRL and plan to adjust our approach to concentrate on specific ME/CFS symptoms. Responses to the CRL and a
proposed confirmatory trial are being worked on now by our R&amp;D team and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Diseases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Europe, the EMA has approved the Orphan Medicinal Products Designation for Ampligen as a potential treatment of Ebola virus disease and
for Alferon N Injection as a potential treatment of MERS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
concluded our series of collaborations designed to determine the potential effectiveness of Ampligen and Alferon N Injection as potential
preventive and/or therapeutic treatments for Ebola-related disorders. Although we believe that the threat of both MERS and Ebola globally
may reemerge in the future, it appears that the spread of these disorders has diminished.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2021, we entered into an MTA with the University of Cagliari Dipartimento di Scienze della Vita e dell&#8217;Ambiente (&#8220;UNICA&#8221;),
an educational institution, under the laws of Italy, located in Monserrato (Cagliari), Italy. The MTA relates to the research and development
of the effects of Ampligen and its ability to induce interferon production in several cell lines, and also on the ability of the Ebola
virus protein VP35 to bind to viral dsRNA and impede interferon&#8217;s upregulation and activity, and on Ampligen&#8217;s ability to
reverse VP35 inhibition of interferon production in biological systems. The data analysis was published in the peer-reviewed journal
<i>Antiviral Research</i>, in a manuscript titled &#8220;Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3
agonist rintatolimod and its mechanism of action.&#8221; We believe that the analysis supports a dual mechanism of action when Ampligen
is used as a prophylactic therapy against Ebola Virus Disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, we filed a U.S. Provisional Patent Application for Ampligen as a potential therapeutic to possibly slow, halt, or reverse the
progression of Alzheimer&#8217;s disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2022, we received notice that the FDA had granted Orphan Drug Designation to Ampligen for the treatment of Ebola virus disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2024, we were granted U.S. patent No. 12,102,649, covering both compositions and methods comprising Ampligen&#160;in the treatment
of endometriosis, a painful chronic condition in which tissue similar to the lining of the uterus grows outside the uterus, causing severe
pelvic pain and making it difficult or impossible to become pregnant. The patented method involves the administration of a therapeutically
effective amount of a pharmaceutical composition containing our proprietary double-stranded RNA products. The versatile administration
options offer flexibility for patient-specific needs and care. The patent also covers treatments targeting recurrent endometriosis and
includes options for co-administration with interferons, including well-known types such as alpha and beta interferons.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alferon
N Injection&#174;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alferon
N Injection is the registered trademark for our injectable formulation of natural alpha interferon. Alferon N Injection is the only natural-source,
multi-species alpha interferon currently approved for sale in the United States and Argentina for the intralesional (within lesions)
treatment of refractory (resistant to other treatment) or recurring external genital warts in patients 18 years of age or older. Alferon
N Injection is also approved in Argentina for the treatment of refractory patients that failed or were intolerant to treatment with recombinant
interferons. Argentina has experienced hyper-inflation and recently devalued its currency to the U.S. dollar by 50%. Contracts with GP
Pharm are U.S. dollar contracts and the parties must evaluate the impact of the recent devaluation on its relationship. Certain types
of human papilloma viruses (&#8220;HPV&#8221;) cause genital warts, a sexually transmitted disease (&#8220;STD&#8221;). According to
the CDC, HPV is the most common sexually transmitted infection, with approximately 79 million Americans &#8212; most in their late teens
and early 20s &#8212; infected with HPV. In fact, the CDC states that &#8220;HPV is so common that nearly all sexually active men and
women get the virus at some point in their lives.&#8221; Although they do not usually result in death, genital warts commonly recur,
causing significant morbidity and entail substantial health care costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interferons
are a group of proteins produced and secreted by cells to combat diseases. Researchers have identified four major classes of human interferon:
alpha, beta, gamma and omega. Alferon N Injection contains a multi-species form of alpha interferon. The worldwide market for injectable
alpha interferon-based products has experienced rapid growth and various alpha interferon injectable products are approved for many major
medical uses worldwide. Alpha interferons are manufactured commercially in three ways: by genetic engineering, by cell culture, and from
human white blood cells. All three of these types of alpha interferon are or were approved for commercial sale in the United States.
Our natural alpha interferon is produced from human white blood cells. The potential advantages of natural alpha interferon over recombinant
(i.e., synthetic) interferon produced and marketed by other pharmaceutical firms may be based upon their respective molecular compositions.
Natural alpha interferon is composed of a family of proteins containing many molecular species of interferon. In contrast, commercial
recombinant alpha interferon products each contain only a single species. Researchers have reported that the various species of interferons
may have differing antiviral activity depending upon the type of virus. Natural alpha interferon presents a broad complement of species,
which we believe may account for its higher activity in laboratory studies. Natural alpha interferon is also glycosylated (i.e., partially
covered with sugar molecules). Such glycosylation is not present on the currently U.S.-marketed recombinant alpha interferons. We believe
that the absence of glycosylation may be in part responsible for the production of interferon-neutralizing antibodies seen in patients
treated with recombinant alpha interferon. Although cell culture-derived interferon is also composed of multiple glycosylated alpha interferon
species, the types and relative quantity of these species are different from our natural alpha interferon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alferon
N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon
product. There are essentially no neutralizing antibodies observed against Alferon N Injection to date and the product has a relatively
low side-effect profile. The recombinant DNA derived alpha interferon formulations have been reported to have decreased effectiveness
after one year of treatment, probably due to neutralizing antibody formation (See &#8220;Manufacturing&#8221; and &#8220;Marketing/Distribution&#8221;
sections below for more details on the manufacture and marketing/distribution of Alferon N Injection). The production of new Alferon
N Injection Active Pharmaceutical Ingredient, or API, is currently on hold. We do not know when, if ever, our products will be generally
available for commercial sale for any indication. Additionally, on May 9, 2023, we were granted a U.S. Patent for a method for preventing
or reducing antigenic drift or viral reassortment in a host animal comprising determining if a host animal has been exposed to or infected
by an avian influenza virus and administering to the exposed host animal alpha-interferon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">MANUFACTURING</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANMAT
in Argentina approved Ampligen for commercial distribution for the treatment of CFS in 2016. Shipment of the drug product to Argentina
was initiated in 2018 to complete the release testing by ANMAT needed for commercial distribution. In September 2019, we received clearance
from the FDA to ship Ampligen to Argentina for the commercial launch and subsequent sales. In June 2020, we received import clearance
from ANMAT to import the first shipment of commercial grade vials of Ampligen into Argentina. We are currently working with GP Pharm
on the commercial launch of Ampligen in Argentina (See &#8220;Our Products; Ampligen&#8221; above).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
our approval in Argentina, in 2017 we engaged Jubilant HollisterStier (&#8220;Jubilant&#8221;) to be our authorized CMO for
Ampligen. Two lots of Ampligen consisting of more than 16,000 units were manufactured and released in 2018; these lots have been
designated for human use in the United States in the cost recovery CFS program and for expanded oncology clinical trials. The
production of additional polymer (Ampligen intermediates) took place in 2019 at our New Brunswick facility. Additionally, Jubilant
manufactured three more lots of Ampligen in December 2019, January 2020 and December 2023. In addition, we have supplied GP Pharm
with the Ampligen required for testing and ANMAT release. Once final approval by ANMAT is obtained, we anticipate that GP Pharm will
begin distributing Ampligen in Argentina.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, we added Pii as a &#8220;Fill &amp; Finish&#8221; provider to enhance our capacity to produce Ampligen. This addition
amplifies our manufacturing capability by providing redundancy and cost savings. The contracts augment our existing fill and finish capacity.
We are prepared to initiate the production of additional Ampligen when and if needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2022 we entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square-foot, state-of-the-art
R&amp;D facility at the New Jersey Bioscience Center (NJBC), primarily consisting of two separate laboratory suites. The lease commenced
on July 1, 2022, and runs through August 31, 2027, but can be extended for an additional five-year period. The facility is AIM&#8217;s
operations, research and development center.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business plan calls for the utilization of one or more CMOs to produce Ampligen API. While we believe we have sufficient Ampligen API
to meet our current needs, we are also continually exploring new efficiencies so as to maximize our ability to fulfill future obligations.
In this regard, on December 5, 2022, we entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions
(&#8220;Sterling&#8221;) for the manufacture of our Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling&#8217;s
Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen. We are utilizing Sterling&#8217;s expertise to
refine our approach to polymer production. In March 2023, we submitted a purchase order for a total of $1,432,257 to manufacture additional
lots of Ampligen at Jubilant. An additional lot was manufactured by Jubilant in December 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
second product, Alferon N Injection, is approved by the FDA for commercial sales in the United States for the treatment of genital warts.
It is also approved by ANMAT in Argentina for commercial sales for the treatment of genital warts and in patients who are refractory
to treatment with recombinant interferons. Commercial sales of Alferon N Injection in the United States will not resume until new batches
of commercial filled and finished product are produced and released by the FDA. We will need the FDA&#8217;s approval to release commercial
product once we have identified our new manufacturing approach and submitted satisfactory stability and quality release data. Currently,
we are not manufacturing Alferon N Injection and there is no definitive timetable to resume production.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span style="text-decoration: underline">LICENSING/COLLABORATIONS/JOINT
VENTURES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
enable potential availability of Ampligen to patients on a worldwide basis, we have embarked on a strategy to license the product and/or
to collaborate and/or create a joint venture with companies that have the demonstrated capabilities and commitment to successfully gain
approval and commercialize Ampligen in their respective global territories of the world. Ideal partners would have the following characteristics:
well-established global and regional experience and coverage; robust commercial infrastructure; a strong track record of successful development
and registration of in-licensed products; and a therapeutic area fit (e.g., ME/CFS, immuno-oncology).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">MARKETING/DISTRIBUTION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2016, we entered into a five-year, exclusive Renewed Sales, Marketing, Distribution and Supply Agreement (the
&#8220;Agreement&#8221;) with GP Pharm. Under this Agreement, GP Pharm was responsible for gaining regulatory approval in Argentina
for Ampligen to treat severe CFS in Argentina and for commercializing Ampligen for this indication in Argentina. We granted GP Pharm
the right to expand rights to sell this experimental therapeutic into other Latin America countries based upon GP Pharm achieving
certain performance milestones. We also granted GP Pharm an option to market Alferon N Injection in Argentina and other Latin
America countries (See &#8220;Our Products; Ampligen&#8221; above). The GP Pharm contract was extended in May 2021 with an end date
of May 24, 2024. While we are in discussions with GP Pharm to extend the agreement, we are also open to the possibility of looking for a new partner. In August 2021, ANMAT
granted a five-year extension to a previous approval to sell and distribute Ampligen to treat severe CFS in Argentina. This extends
the approval until 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2016, we entered into a five-year agreement (the &#8220;Impatients Agreement&#8221;) with Impatients, N.V. (&#8220;myTomorrows&#8221;),
a Netherlands-based company, for the commencement and management of an EAP in Europe and Turkey (the &#8220;Territory&#8221;) related
to ME/CFS. Pursuant to the agreement, myTomorrows, as our exclusive service provider and distributor in the Territory, is performing
EAP activities. These activities will be directed to (a) the education of physicians and patients regarding the possibility of early
access to innovative medical treatments not yet the subject of a Marketing Authorization (regulatory approval) through named-patient
use, compassionate use, expanded access and hospital exemption, (b) patient and physician outreach related to a patient-physician platform,
(c) the securing of Early Access Approvals (exemptions and/or waivers required by regulatory authorities for medical treatments prior
to Marketing Authorization) for the use of such treatments, (d) the distribution and sale of such treatments pursuant to such Early Access
Approvals, (e) pharmacovigilance (drug safety) activities and/or (f) the collection of data such as patient-reported outcomes, doctor-reported
experiences and registry data. We are supporting these efforts and supplying Ampligen to myTomorrows at a predetermined transfer price.
In the event that we receive Marketing Authorization in any country in the Territory, we will pay myTomorrows a royalty on products sold.
Pursuant to the Impatients Agreement, the royalty would be a percentage of Net Sales (as defined in the Impatients Agreement) of Ampligen
sold in the Territory where Marketing Authorization was obtained. The formula to determine the percentage of Net Sales will be based
on the number of patients that are entered into the EAP. We believe that disclosure of the exact maximum royalty rate and royalty termination
date could cause competitive harm. However, to assist the public in gauging these terms, the actual maximum royalty rate is somewhere
between 2% and 10% and the royalty termination date is somewhere between five and fifteen years from the First Commercial Sale of a product
within a specific country. The parties established a Joint Steering Committee comprised of representatives of both parties to oversee
the EAP. No assurance can be given that activities under the EAP will result in Marketing Authorization or the sale of substantial amounts
of Ampligen in the Territory. The agreement was automatically extended for a period of 12 months on May 20, 2021; has been automatically
extended for 12 months on each subsequent May 20; and will continue to be automatically extended for periods of 12 months every May 20
until terminated or the terms of the agreement are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2017, ANMAT granted a five-year extension to a previous approval to sell and distribute Alferon N Injection (under the brand
name &#8220;Naturaferon&#8221;) in Argentina. This extended the approval until 2022. A request to extend the approval beyond 2022 has
been filed and is still under review. In February 2013, we received ANMAT approval for the treatment of refractory patients that failed
or were intolerant to treatment with recombinant interferon, with Naturaferon in Argentina.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2017, the EAP through our agreement with myTomorrows designed to enable access of Ampligen to ME/CFS patients was extended to
pancreatic cancer patients beginning in the Netherlands. myTomorrows is our exclusive service provider in the Territory and will manage
all EAP activities relating to the pancreatic cancer extension of the program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2017, we extended our agreement with Asembia LLC, formerly Armada Healthcare, LLC, to undertake the marketing, education and sales
of Alferon N Injection throughout the United States. This agreement has expired. We were in discussions with Asembia about the possibility
of continuing the relationship, while also exploring the possibility of working with other, similar companies. However, we still do not
foresee an immediate need for this service and continue to push this search further out in our expected timeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2018, we signed an amendment to the EAP with myTomorrows. This amendment extended the Territory to cover Canada to treat pancreatic
cancer patients, pending government approval. In March 2018, we signed an amendment to the EAP with myTomorrows, pursuant to which myTomorrows
will be our exclusive service provider for special access activities in Canada for the supply of Ampligen for the treatment of ME/CFS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2020, we entered into a signed Letter of Agreement with myTomorrows for the delivery of Ampligen for the treatment of up to
16 pancreatic cancer patients. In November 2021, we entered into a signed Letter of Agreement with myTomorrows for the delivery of Ampligen
for the treatment of up to an additional 5 pancreatic cancer patients. In March 2022, we entered into a signed Letter of Agreement with
myTomorrows for the delivery of Ampligen for the treatment of up to an additional 10 pancreatic cancer patients. In November 2022, we
entered into a signed Letter of Agreement with myTomorrows for the delivery of Ampligen for the treatment of up to an additional 10 pancreatic
cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">401(k)
Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a defined contribution plan, entitled the AIM ImmunoTech Employees 401(k) Plan and Trust Agreement (the &#8220;401(k) Plan&#8221;).
Our full-time employees are eligible to participate in the 401(k) Plan following 61 days of employment. Subject to certain limitations
imposed by federal tax laws, participants are eligible to contribute up to 15% of their salary (including bonuses and/or commissions)
per annum. Participants&#8217; contributions to the 401(k) Plan may be matched by us at a rate determined annually by the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
participant immediately vests in his or her deferred salary contributions as well as our safe harbor contributions. A 6% safe harbor
matching contribution by us was reinstated effective January 1, 2021. For the nine months ending September 30, 2024 we made approximately
$134,200 in contributions, and for the year ending December 31, 2023 approximately $162,000 in contributions were made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">New
Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
<b>&#8220;</b>Note 10: Recent Accounting Pronouncements&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Critical
Accounting Policies and Use of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no material changes in our critical accounting policies and estimates from those disclosed in Part II; Item 7: &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations; Critical Accounting Policies&#8221; contained in our Annual
Report on Form 10-K for the year ended December 31, 2023 except for the policies regarding &#8220;Distinguishing Liabilities from Equity&#8221;
and &#8220;Derivative Instruments&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distinguishing
Liabilities from Equity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted the guidance of ASC 480 in evaluating how it classifies and measures in its statement of financial position certain
financial instruments with characteristics of both liabilities and equity. Under this guidance the Company evaluates free-standing financial
instruments to determine whether the instruments are classified as liabilities or equity. The evaluation includes determining whether
the instruments are mandatorily redeemable, whether redemption includes a transfer of assets, and whether the redemption feature is conditional.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
Instruments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives requiring bifurcation in accordance with ASC Topic 815, Derivatives and Hedging. Derivative instruments are measured at fair
value at issuance and at each reporting date in accordance with ASC 820 with changes in fair value recognized in the period of change
in the consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESULTS
OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Three
months ended September 30, 2024 versus three months ended September 30, 2023</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Net
Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net loss was approximately $3,700,000 and $7,816,000 for the three months ended September 30, 2024, and 2023, respectively, representing
a decrease in loss of approximately $4,116,000 or 53%. This decrease in loss was primarily due to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            decrease in research and development expenses of $1,297,000,</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            decrease in general and administrative expenses of $2,360,000,</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            decrease in production costs of $22,000,</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            increase in gain on investments of $583,000,</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            increase in interest and other income of $424,000; offset by</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            decrease in gain from sale of Income tax operating of $318,000, and an</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
                                            in interest expense of $202,000.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share was $ (0.06) and $(0.16) for the three months ended September 30, 2024, and 2023, respectively. The weighted average number
of shares of our common stock outstanding as of September 30, 2024, was 57,677,016 as compared to 48,635,165 as of September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Revenues</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from our Ampligen&#174; Cost Recovery Program were $35,000 and $46,000 for the three months ended September 30, 2024, and 2023, respectively,
representing a decrease of $11,000 which is primarily related to the fluctuation of patient participation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended September 30, 2024 and 2023, we had no Alferon N Injection&#174; Finished Good product to commercially sell and
all revenue was generated from the EAP and our FDA approved open-label treatment protocol, (&#8220;AMP 511&#8221;), that allows patient
access to Ampligen&#174; for treatment in an open-label safety study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Interest
and Other Income</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
and other income for the three months ended September 30, 2024, and 2023 was approximately $718,000 and $294,000, respectively,
reflecting an increase of approximately $424,000. The increase was primarily due to an amendment in September 2024 to an original
agreement that was executed by us and Amarex clarifying and changing the nature of a remaining execution fee of $725,437. The
amendment allowed that the remainder would not be exclusive to the original agreement, that the nature of the payment changed from
an execution fee to a fully refundable deposit, and that it could be applied to any invoice upon mutual agreement of the parties,
removed the threshold contingencies, and if such invoices were not sufficient to exhaust the balance, that the refund would be
refunded in cash. Therefore, the nature of the payment changed to deposit status and outstanding invoices were applied against the
deposit resulting in an overall increase in other income of $657,300 for the three months ended September 30, 2024. The increase in
other income was offset by decreased interest income for the three months ended September 30, 2024 of approximately $233,000 interest  income was $61,000 and $294,000, for the three months ended September 30, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Gain
(loss) on Investments, net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
(loss) on investments for the three months ended September 30, 2024, and 2023 was approximately $273,000 and ($310,000), respectively,
reflecting an increase in gain on investments of approximately $583,000. The increase in gain was due to the change in the fair value
of equity investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Production
Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Production
costs were approximately $8,000 and $30,000, respectively, for the three months ended September 30, 2024, and 2023, representing a decrease
of $22,000 in production costs. This decrease was due to an increase in production costs for the three months ended 2023 due to production
starting in that quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Gain
(loss) from sale of income tax operating loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
quarterly income tax benefit for the three months ended September 30, 2024, was $0 compared to a gain of $318,000 for the three months
ended September 30, 2023. This was due to the lifetime limit of $20,000,000 for the sale of the New Jersey NOL being reached and therefore
no tax provision was calculated in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Research
and Development Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall
Research and Development (&#8220;R&amp;D&#8221;) costs for the three months ended September 30, 2024, were approximately $1,437,000,
as compared to $2,734,000 for the same period a year ago, reflecting a decrease of approximately $1,297,000. The primary reason for the
decrease in R&amp;D costs was a decrease in clinical expenses of $1,384,000 as well as a decrease in outside contractors of $20,000 offset
by an increase in patent and trademark expenses of approximately $44,000, salaries of $18,000, rent expense of $16,000, computer &amp;
information services expense of $16,000 as well as consultant fees of $13,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">General
and Administrative Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and Administrative (&#8220;G&amp;A&#8221;) expenses for the three months ended September 30, 2024, and 2023, were approximately $3,079,000
and $5,439,000, respectively, reflecting a decrease of approximately $2,360,000. The decrease in G&amp;A expenses for the three months
ended September 30, 2024 was due primarily to approximate decreases of professional fees of $2,395,000, public relation expenses of $138,000,
insurance expense of $55,000, rent expense of $33,000, office expenses of $30,000, salaries of $27,000 offset by increases of stock compensation
of $280,000, and license and taxes of $44,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Interest
Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expenses for the three months ended September 30, 2024 was approximately $202,000 and there was no interest expense for the three months
ended September 30, 2023. The increase in interest expense for the three months ended September 30, 2024 was due to the interest expense
incurred related to the Note Purchase Agreement entered into on February 16, 2024 with Streeterville.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Nine
months ended September 30, 2024 versus nine months ended September 30, 2023</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Net
Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net loss was approximately $11,353,000 and $16,386,000 for the nine months ended September 30, 2024, and 2023, respectively, representing
a decrease in loss of approximately $5,033,000 or 31%. This decrease in loss was primarily due to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            decrease in research and development expenses of $3,206,000,</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            decrease in general and administrative expenses of $795,000,</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            decrease in production costs of $6,000,</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            increase in gain on investments of $297,000,</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            increase in interest and other income of $2,568,000; offset by</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            decrease in gain from sale of Income tax operating of $900,000,</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            increase in warrant valuation of $458,000, and an</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
                                            in interest expense of $453,000.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share was $ (0.21) and $(0.34) for the nine months ended September 30, 2024, and 2023, respectively. The weighted average number
of shares of our common stock outstanding as of September 30, 2024, was 53,351,467 as compared to 48,483,802 as of September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Revenues</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from our Ampligen&#174; Cost Recovery Program were $125,000 and $137,000 for the nine months ended September 30, 2024, and 2023, respectively,
representing a decrease of $12,000 which is primarily related to the fluctuation of patient participation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the nine months ended September
30, 2024 and 2023, we had no Alferon N Injection&#174; Finished Good product to commercially sell and all revenue was generated from the
EAP and our FDA approved open-label treatment protocol, (&#8220;AMP 511&#8221;), that allows patient access to Ampligen&#174; for treatment
in an open-label safety study.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Interest
and Other Income</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
and other income for the nine months ended September 30, 2024, and 2023 was approximately $3,379,000 and $811,000, respectively, reflecting
an increase of approximately $2,568,000. The increase was primarily due to a recovery of $2,500,000 from the primary level of the Director and Officer (D&amp;O)
insurance proceeds during the nine months ended September 30, 2024 related to legal costs recovered related to shareholder
litigation matters in addition to an amendment in September 2024 to an original agreement that was executed by us and Amarex clarifying
and changing the nature of a remaining execution fee of $725,437. The amendment allowed that the remainder would not be exclusive to
the original agreement, that the nature of the payment changed from an execution fee to a fully refundable deposit, and that it could
be applied to any invoice upon mutual agreement of the parties, removed the threshold contingencies, and if such invoices were not sufficient
to exhaust the balance, that the refund would be refunded in cash. Therefore, the nature of the payment changed to deposit status and
outstanding invoices were applied against the deposit. These changes resulted in an approximate overall increase in interest and other
income of $3,379,000 for the nine months ended September 30, 2024. During the nine months ended September 30, 2023, interest earnings
were $811,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Gain
(loss) on Investments, net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
(loss) on investments for the nine months ended September 30, 2024, and 2023 was approximately $96,000 and ($201,000), respectively,
reflecting an increase in the gain on investments of approximately $297,000. The increase in gain was due to the change in the fair value
of equity investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Production
Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Production
costs were approximately $24,000 and $30,000, respectively, for the nine months ended September 30, 2024, and 2023, representing a decrease
of $6,000 in production costs. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Gain
(loss) from sale of income tax operating loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
quarterly income tax benefit for the nine months ended September 30, 2024, was $0 compared to a gain of $900,000 for the nine months
ended September 30, 2023. This was due to the lifetime limit of $20,000,000 for the sale of the New Jersey NOL being reached and therefore
no tax provision was calculated in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Research
and Development Costs</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall
Research and Development (&#8220;R&amp;D&#8221;) costs for the nine months ended September 30, 2024, were approximately $4,533,000, as
compared to $7,739,000 for September 30, 2023, reflecting a decrease of approximately $3,206,000. The primary reason for the
decrease in R&amp;D costs were approximate decreases in outside contractors of $1,770,000, clinical expenses of $1,738,000, computer
and IT services of $111,000 offset by an increase in salaries of $270,000, patent and trademark expenses of $34,000, rent expense of
$30,000, consulting fees of $27,000, manufacturing expenses of $24,000, insurance of $18,000 and maintenance expense of $17,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">General
and Administrative Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and Administrative (&#8220;G&amp;A&#8221;) expenses for the nine months ended September 30, 2024, and 2023, were approximately $9,485,000
and $10,280,000, respectively, reflecting a decrease of approximately $795,000. The decrease in G&amp;A expenses for the nine months
ended September 30, 2024 was due primarily to approximate decreases in legal professional fees of approximately $968,000, insurance
expense of $208,000, public relations fees of $141,000, travel expenses of $58,000, interest expense of $23,000, rent expense of $19,000
offset by an increase in investment banker fees of $314,000 and stock compensation of $308,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Interest
Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expenses for the nine months ended September 30, 2024 was approximately $453,000 and there was no interest expense for the nine months
ended September 30, 2023. The increase in interest expense for the nine months ended September 30, 2024 was due to the interest expense
incurred related to the Note Purchase Agreement entered into on February 16, 2024 with Streeterville.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Liquidity
and Capital Resources</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in operating activities for the nine months ended September 30, 2024, was approximately $10,933,000 compared to approximately $11,509,000
for the same period in 2023, a decrease of $576,000. The primary reasons for this decrease were a decrease in net loss during the nine
months of $5,033,000 as well as a decrease in gain from sale of income tax operating losses of $900,000, an increase in equity-based
compensation of $308,000 and an increase in loss on issuance of warrants of $458,000. This is partially offset by an increase in cash
utilized for accounts payable of $2,590,000, an increase in accrued expenses of $1,714,000, prepaid expenses of $255,000 as well as a
decrease in funds received from the 2023 sale of New Jersey net operating loss and received in 2024 of $495,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by investing activities for the nine months ended September 30, 2024, was approximately $1,002,000 compared to cash used in
investing activities for the nine months ended September 30, 2023, of approximately $618,000, representing a change of $1,620,000. The
primary reason for the change was the cash provided by the net purchase and sale of marketable securities activity of $1,439,000 compared
to cash used in the net purchase and sale of marketable securities of $231,000 for the same period in 2023, the loss on sale of property
and equipment of $0 in the current period in 2024, compared with $10,000 in the same period in 2023 as well as the net purchase and abandonment
of patents in the current period in 2024 of $417,000 compared with the net purchase and abandonment of patents in the same period in
2023 of $377,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for the nine months ended September 30, 2024, was approximately $5,407,000 compared to approximately
$338,000 for the same period in 2023, representing an increase of $5,069,000. The primary reason for this increase was the receipt of
$2,367,000 in net proceeds from the notes payable, net of issuance cost, an increase in the sale of shares in the current period in 2024
of $860,000 compared to $338,000 in the same period in 2023 as well as an increase in warrant valuation of $2,047,000 in the current
period in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our principal source of
liquidity is our cash and cash equivalents, marketable securities, and proceeds from financing activities to provide the necessary
funding to meet our obligations as they become due. As noted above, as of September 30, 2024, we had approximately $7,202,000 in
cash, cash equivalents and marketable securities, inclusive of approximately $6,287,000 in marketable securities, representing a
decrease of approximately $5,868,000 from December 31, 2023. In addition, we have suffered losses from operations and net cash used
on operating activities for the three-month period ended September 30, 2024, and have a working capital deficit. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
conditions raise substantial doubt regarding our ability to continue as a going concern for a period of at least one year from the
date of issuance of these unaudited condensed consolidated financial statements. See Note 1 to our Unaudited Condensed Consolidated Financial Statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as
a going concern. On September 30, 2024, our current liabilities exceeded our current assets by $2,530,000 which raised doubt our ability to continue as a going concern. Additionally, at September 30, 2024, our stockholders&#8217; equity was
below the minimum requirements for continued listing on the NYSE American.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Management
evaluated the conditions, and their significance of those conditions related to our ability to meet our obligations and determined
that the primary cause of the working capital deficit was related to an accounts payable balance of $6,300,000. This balance
includes $4,900,000 of legal fees related to litigation. We are currently negotiating with the law firm to reduce prior billings.
These negotiations are ongoing and could, if resolved favorably to us, partially alleviate the  working capital deficit. Further we are continuing to negotiate the recovery of an additional $2.5
million from our secondary director and officer coverage. There is no
assurance as to the timing or outcome of our efforts. If we are unable to implement sufficient mitigation efforts, we may be
forced to limit our business activities or be unable to continue as a going concern, which would have a material adverse effect on our
results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 6, 2024, an amendment to an agreement dated April 7, 2022, was executed by us and Amarex clarifying
and changing the nature of the remaining execution fee of $725,437. The amendment allowed that the remainder would not be exclusive to
the agreement dated on April 7, 2022, that the nature of the payment changed from an execution fee to a fully refundable deposit, and
that it could be applied to any invoice upon mutual agreement of the parties, removed the threshold contingencies, and if such invoices
were not sufficient to exhaust the balance, that the refund would be refunded in cash. Due to the changes brought about by the amendment,
the nature of the payment changed to deposit status. At September 30, 2024, we had an outstanding deposit of $653,000 which may be used
to offset future clinical research expenditures. This deposit is listed as a non-current asset on the balance sheet but could provide
working capital if the timing of expenditures are realized within the next 15 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, we received $2.5 million of insurance recoveries under the first layer of our director and officer
insurance policy during the quarter ended June 30, 2024. We believe, but cannot assure, that an additional $2.5 million will be recovered under the second
layer of our director and officer insurance policy, however, the insurer has initially denied our claim for the additional $2.5 million.
We continue to pursue the collection of $2.5 million. If received, these proceeds would alleviate the negative working capital. There
is no assurance as to the timing or outcome of our efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a research and development company, we are conducting research necessary to bring our product, Ampligen, to market. As such, we primarily
rely on financing activities to provide the necessary funding to meet our obligations as they become due. AIM has a long and demonstrated
history of success in these efforts, however, there is no assurance that we will be successful in attaining the necessary funding in
the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have two capital mechanisms in place:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 19, 2023, we entered an ATM offering. The agreement expires on April 19, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2024, we entered into an agreement with Atlas Sciences, LLC. Under the terms of the Agreement Atlas may purchase up to
$15.0 million of our common stock puts at 95% of the then share market value at our sole discretion with no restrictions on our use
of the proceeds. Limitations of the agreement include volume based on average daily trading volume limited to 4.99% of total shares
outstanding for each put. There is no assurance as to the amount of funds that will be realized pursuant to the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">No assurance can be given as to the amount of funding that will be received
from either of these capital mechanisms.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to providing working capital, if fully realized, we believe that the capital mechanisms could  possibly provide the equity
necessary to correct the deficiency as required by the NYSE American.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are committed to a focused business plan oriented toward finding senior co-development partners with the capital and expertise needed
to commercialize the many potential therapeutic aspects of our experimental drugs and our FDA approved drug Alferon N Injection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of our products requires the commitment of substantial resources to conduct the time-consuming research, preclinical development,
and clinical trials that are necessary to bring pharmaceutical products to market. We believe, based on our current financial condition,
that we have adequate funds to meet our anticipated operational cash needs and fund current clinical trials over approximately the next
fifteen months. At present we do not generate any material revenues from operations, and we do not anticipate doing so in the near future.
We may need to obtain additional funding in the future for new studies and/or if current studies do not yield positive results, require
unanticipated changes and/or additional studies. In this regard, in February 2022, the SEC declared our S-3 shelf Registration Statement
effective which will allow us to raise additional capital in the future. On April 19, 2023, we entered into an Equity Distribution Agreement
(the &#8220;EDA&#8221;), with Maxim Group LLC (&#8220;Maxim&#8221;), pursuant to which we may sell from time to time, shares of our common
stock having an aggregate offering price of up to $8.5 million through Maxim, as agent. Sales under the EDA were registered under the
S-3 Shelf Registration Statement. Under the terms of the Distribution Agreement, Maxim is entitled to a transaction fee at a fixed rate
of 3.0% of the gross sales price of Shares sold under the EDA. For the nine months ended September 30, 2024, we sold 1,305,653 shares
under the EDA for total gross proceeds of approximately $630,204, which includes a 3.0% fee to Maxim of $18,906. During the year ended
December 31, 2023, we sold 598,114 shares under the EDA for total gross proceeds of approximately $344,000, which includes a 3.0% fee
to Maxim of $10,326. We hope to raise additional funds through the EDA. No assurance can be given as to the amount of any additional sales pursuant
to the EDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we raised $2,500,000 in net proceeds from the sale of an unsecured Note and entered into an equity line of credit to raise
up to 15,000,000 (see <i>Overview; The Atlas Equity Line of Credit</i> above). Under the terms of the Atlas Equity Line of Credit, we,
at our sole discretion, shall have the right to issue Put shares to the Investor at 95% of the Market Price of the shares on the day
of trade. Sales under the agreement are limited to a daily maximum of the lessor of: $500,000, the Median Daily Trading volume, and a
beneficial ownership limitation of 4.99% and a maximum of 19.99% of the outstanding shares at the time of the agreement. In April 2024,
we filed a registration statement with the SEC on Form S-1 registering a total of 9,975,000 shares for resale pursuant to the Atlas Agreements,
consisting of 9,636,400 shares that can be sold by us to Atlas and 338,600 shares that were issued to Atlas as Commitment Shares. The
registration statement was declared effective and the final prospectus was filed on May 1, 2024. As of September 30, 2024, a total of
759,685 shares have been issued pursuant to this agreement for a total of approximately $128,000. No assurance can be given as to the amount of funds that will be raised pursuant to the Atlas Equity Line of Credit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Securities
Purchase Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2024, we entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) to complete an offering (the
&#8220;Transactions&#8221;) with a single accredited investor (the &#8220;Purchaser&#8221;), pursuant to which we issued to the
Purchaser, (i) in a registered direct offering, 5,640,958 shares of our common stock (the &#8220;Shares&#8221;), par value $0.001
per share (&#8220;Common Stock&#8221;) and (ii) in a concurrent private placement, we issued to the Purchaser Class A common
warrants to purchase an aggregate of up to 5,640,958 shares of its common stock (the &#8220;A Warrants&#8221;) at an exercise price
of $0.363 per share and Class B common warrants to purchase an aggregate of up to 5,640,958 shares of our common stock (the &#8220;B
&#8220;Warrants&#8221; and, along with the A Warrants, the &#8220;Common Warrants&#8221;) at an exercise price of $0.363 per share.
The A Warrants and B Warrants are  not  exercisable for six months after the issuance date and will expire, respectively, 24
months and five years and six months after the issuance date. The Common Warrants and the shares of common stock issuable upon the
exercise of such warrants are offered pursuant to an exemption from the registration requirements of the Securities Act provided in
Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
received aggregate gross proceeds from the Transactions of approximately $2,047,688, before deducting fees to the Placement Agent and
other estimated offering expenses payable by us. The Shares are being offered by us pursuant to a shelf registration statement on Form
S-3 (File No. 333-262280), which was declared effective on February 4, 2022 (as amended from time to time, the &#8220;Registration Statement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Purchase Agreement, subject to certain exceptions, we could not issue any equity securities for 60 days
following the issuance date, provided that we were able to utilize our at-the-market offering program with the Placement Agent after
30 days. Additionally, we could not enter into a variable rate transaction (other than the ATM program with the Placement Agent) for
120 days after the issuance date. In addition, our executive officers and each of our directors have entered into lock-up agreements
with us pursuant to which each of them has agreed not to, for a period of 90 days from the closing of the Transactions, offer, sell,
transfer or otherwise dispose of our securities, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of the Common Warrants, and the number of Common Warrant Shares, are subject to adjustment in the event of any stock
dividend or split, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Common
Warrants. If a Fundamental Transaction (as defined in the Common Warrants) occurs, then the successor entity will succeed to, and be
substituted for us, and may exercise every right and power that we may exercise and will assume all of its obligations under the
Common Warrants with the same effect as if such successor entity had been named in the warrant itself. Common Warrant Holders will
have additional rights defined in the Common Warrants. The Common Warrants will be exercisable on a &#8220;cashless&#8221; basis
only if there is not a current registration statement permitting public resale. In this regard, the Company filed a registration
statement to register the resale of the Common Warrant Shares. That registration statement was
declared effective by the SEC on July 11, 2024. The Company has agreed to use commercially reasonable efforts to cause such
registration statement to become effective within 181 days following the issuance date and to keep such registration statement
effective at all times until no Purchaser owns any Warrants or Warrant Shares issuable upon exercise thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maxim
Group LLC acted as the placement agent (the &#8220;Placement Agent&#8221;) on a &#8220;commercially reasonable best efforts&#8221; basis,
in connection with the Transactions pursuant to the Placement Agency Agreement, dated May 31, 2024 (the &#8220;Placement Agency Agreement&#8221;),
by and between us and the Placement Agent. Pursuant to the Placement Agency Agreement, the Placement Agent received a cash
fee of 8% of the aggregate gross proceeds paid to the Company for the securities sold in the Transactions and reimbursement of certain
out-of-pocket expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
assurance can be given as to the amount of funds that could be raised or the potential dilution to current stockholders. If we are unable
to commercialize and sell Ampligen and/or recommence material sales of Alferon N Injection, our operations, financial position and liquidity
may be adversely impacted, and additional financing may be required. There can be no assurances that, if needed, we will be able to raise
adequate funds from the EDA or otherwise, or enter into licensing, partnering or other arrangements to advance our business goals. We
may seek to access the public equity market whenever conditions are favorable, even if we do not have an immediate need for additional
capital at that time. We are unable to estimate the amount, timing or nature of future sales of outstanding common stock or instruments
convertible into or exercisable for our common stock. Any additional funding may result in significant dilution and could involve the
issuance of securities with rights, which are senior to those of existing stockholders. See Part I, Item 1A - &#8220;Risk Factors; <i>We
may require additional financing which may not be available</i>&#8221; in our Annual Report on Form 10-K for the year ended December
31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, the Company entered into a Securities Purchase Agreement to complete an offering with a single accredited investor.
For more information see Note 15: Subsequent Events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">NYSE
American Continued Listing Requirements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
maintain our listing on the NYSE American (the &#8220;NYSE American&#8221;), among other things, we are required to maintain Stockholders
Equity of $6,000,000 or we may receive a warning or a delisting notice. In either event, we would be provided a period in which to
submit a plan to meet listing standards. Taking into account funds received after September 30, 2024, our
Stockholders&#8217; Equity is $4,291,888.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the common stock ultimately were to be delisted for any reason, it could negatively impact us by (i) reducing the liquidity and market
price of our common stock; (ii) reducing the number of investors willing to hold or acquire the common stock, which could negatively
impact our ability to raise equity financing; (iii) limiting our ability to use a registration statement to offer and sell freely tradable
securities, thereby preventing us from accessing the public capital markets; and (iv) impairing our ability to provide equity incentives
to our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
3: Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required
under this item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
4: Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Chief Executive Officer (&#8220;CEO&#8221;) and the Chief Financial Officer (&#8220;CFO&#8221;) performed an evaluation of the effectiveness
of our disclosure controls and procedures, which have been designed to permit us to effectively identify and timely disclose important
information. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures,
no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management
is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation,
our CEO and CFO concluded that the controls and procedures were effective as of September 30, 2023, to ensure that material information
was accumulated and communicated to our management, including our CEO and CFO, is appropriate to allow timely decisions regarding required
disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2024, we made no change in our internal controls over financial reporting that has materially affected,
or is reasonably likely to materially affect, our internal controls over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part
II &#8211; OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
1: Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the filing of the June 30, 2024 Form 10-Q:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
ImmunoTech, Inc. v. Tudor, et al., in the United States District Court for the Middle District of Florida, Ocala Division, Case No. 5:2022cv00323.
On April 22, 2024, the District Court issued an order granting-in-part Lautz and Jorgl&#8217;s Rule 59(e) and Rule 11 motions, respectively.
The court entered an order finding Jorgl and Lautz were entitled to recover attorney&#8217;s fees and costs and entered judgment on behalf
of Jorgl for $216,936, and on behalf of Lautz for $76,473. <span style="text-transform: uppercase">AIM </span>has appealed these judgments
to the United States Court of Appeals for the Eleventh Circuit, and secured a stay of the enforcement of the judgments pending the 11th
Circuit Appeal. AIM&#8217;s appeal does not seek damages. AIM filed its initial brief on September 4, 2024. The parties attended mediation
on November 5, 2024. The parties did not reach an agreement, and mediation impassed. The Appellees&#8217; brief is due on December 5,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 18, 2024, The Carlyle Appellate Law firm was engaged for the above referenced appeal. It is anticipated that a Notice of appearance
by Carlyle has been filed in that matter. AIM is exposed in this matter for the amount of those Judgments (which have been bonded by
AIM), interest on those judgements, as well as potentially paying attorney&#8217;s fees in the event the appeal is unsuccessful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kellner
v. AIM ImmunoTech Inc. et al., in the Supreme Court of the State of Delaware, Case No. 3, 2024. On January 16, 2024, the Delaware Supreme
Court granted-in-part Kellner&#8217;s motion to expedite and scheduled oral argument before the en banc Delaware Supreme Court for April
10, 2024. On April 10, 2024, the en banc Delaware Supreme Court heard oral argument from AIM and Kellner in this matter and took the
matter under consideration. On July 11, 2024, the Delaware Supreme Court issued a decision affirming in part and reversing in part the
Court of Chancery&#8217;s December 28, 2023 opinion, and not remanding the matter to the Court of Chancery. The Supreme Court held that
certain of the bylaws adopted by the board were legally invalid and inequitable. The board has subsequently revised the bylaws to address
and correct said deficiencies. The Delaware Supreme Court also held that no further action was required with respect to Kellner&#8217;s
rejected nominations because Kellner and his nominees engaged in deceptive conduct during the nomination process, including by submitting
false and misleading information in connection with their nominations. Prior to this appeal, the Vice Chancellor noted in her December
28, 2023 post-trial decision, that &#8220;&#8216;[t]he context in which the Board received&#8217; the Kellner Notice &#8216;cannot be
ignored.&#8217; The Kellner Notice followed a proxy contest where Jorgl became an AIM stockholder solely to front a nomination and shield
undisclosed persons behind the scenes. Those persons included two white collar criminals&#8212;one of whom had become increasingly hostile
to AIM and had misrepresented himself as an AIM representative to third parties. It would have been obvious to the Board that the new
nomination behind Kellner carried over from the prior year. Chioini was a constant, Deutsch remained involved (now as a nominee), and
Baker Hostetler continued to advise the effort. The threat to return &#8216;guns blazing&#8217; in 2023 came to fruition.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2024, Kellner filed a Motion for Reargument, requesting the Supreme Court of the State of Delaware to reconsider certain aspects
of its ruling and requesting clarification that the trial court retains jurisdiction for any fee applications. By order dated July 29,
2024, the Supreme Court denied Kellner&#8217;s Motion for Reargument, directed that the case be closed, and specifically ruled that &#8220;The
case is not remanded for an award of attorneys&#8217; fees and costs&#8221; and deemed that the &#8220;this Case is Closed.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 27, 2024, counsel to Kellner delivered to us a demand for certain books and records under Section 220 of the DGCL, and a letter
requesting that we reimburse him for his fees and expenses incurred in the Kellner litigation. In the request for fee reimbursement letter,
Kellner stated that he was prepared to file an action in the Delaware Court of Chancery to require AIM to pay his fees and expenses if
the matter could not be resolved without court intervention. By letter dated, November 8, 2024, AIM, through its counsel, denied the
request, noting, among other things, that the Delaware Supreme Court issued an order on July 29, 2024, denying Kellner&#8217;s Motion
for Reargument of the appeal in the Kellner litigation, directing that the case be closed, and specifically ruling that &#8220;[t]he
case is not remanded for an award of attorneys&#8217; fees and costs.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioLife</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2024, the parties filed a Stipulation with the Court dismissing the counterclaims, without prejudice, in order to allow
the Superior Court (appellate) to consider the Appeal issues without the need for duplicate trials. The Stipulation was accepted by the
Court on October 17, 2024 dismissing the counterclaims. On October 7 we perfected our Appeal in the Superior Court. On November 7, 2024,
we served our Concise Statement of Matters Complained of on Appeal. The Superior Court has not yet issued a briefing or argument schedule
on the matters to be considered on appeal. No estimate can be made at this time regarding the scheduling or ultimate determination of
the matters set forth in the Petition and the underlying issues presented in the appeal. No judgement can be made at this time of the
likelihood of the Company prevailing on its claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1A:</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk Factors</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
carefully consider the factors discussed in Part I, &#8220;Item 1A. Risk Factors&#8221; in our Annual Report on Form 10-K for the year
ended December 31, 2023 filed with the SEC on March 29, 2023, which could materially affect our business, financial condition, or future
results. The risks described in the above reports are not the only risks we face. Additional risks and uncertainties not currently known
to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition and operating
results. Please also see &#8220;Special Note Regarding Forward-Looking Statements&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as described below, there have been no material changes in or additions to the risk factors included in our Quarterly Report on Form
10-Q for the period ended September 30, 2024 or our Annual Report on Form 10-K for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared assuming we will continue as a going concern. Our
management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about our
ability to continue as a going concern for one year from the date these financial statements are issued. This evaluation does not take
into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented or are not within
our control as of the date the financial statements are issued. When substantial doubt about our ability to continue as a going concern
exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt. If we are unable
to implement sufficient mitigation efforts, we may be forced to limit our business activities or be unable to continue as a going concern,
which would have a material adverse effect on our results of operations and financial condition.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
see Item 2: &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations; Liquidity and Capital
Resources&#8221; with regard to issues related to our common stock continuing to be listed on the NYSE American.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
2: Unregistered Sales of Equity Securities and Use of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
3: Defaults upon Senior Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
4: Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
5: Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
6: Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
                                            - See exhibit index below.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 0.75in">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">Exhibit No.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p></td>
    <td style="padding-bottom: 1pt; text-align: left; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">Description</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1(i)(1)</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><a href="ex3-1i1.htm">Certificate of Incorporation as Amended and Restated.</a></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">3.1(i)(2)</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223016763/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Increase of Series A Junior Participating Preferred Stock (incorporated by reference to exhibit 3.1 to the Company&#8217;s Quarterly report on Form 10-Q (No. 001-27072) for the period ended March 31, 2023).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">3.1 (i)(3)</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315219008701/ex3i-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Certificate of Incorporation (incorporated by reference to exhibit 3(i).1 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed June 3, 2019).</a></p>
</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1(ii)</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224029822/ex3-1_ii.htm" style="-sec-extract: exhibit">Amended and Restated By-Laws of Registrant (incorporated by reference to exhibit 3.1(ii) to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed August 1, 2024).</a> </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">4.1</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex4-1.htm">Common Stock Certificate.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315223016750/ex4-6.htm" style="-sec-extract: exhibit">Third Amended and Restated Rights Agreement, dated May 12, 2023 between AIM ImmunoTech Inc. (formerly, Hemispherx Biopharma, Inc.) and American Stock Transfer &amp; Trust Company, LLC. (incorporated by reference to exhibit 4.6 to Amendment No. 3 to the Company&#8217;s Registration Statement on Form 8-A12B (No. 001-27072) filed May 15, 2023).</a> </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224007230/ex10-1.htm" style="-sec-extract: exhibit">February 16, 2024 Note Purchase Agreement with Streeterville Capital LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed February 20, 2024).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224007230/ex10-2.htm" style="-sec-extract: exhibit">February 16, 2024 Promissory Note with Streeterville Capital LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed February 20, 2024).</a> </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224012058/ex10-104.htm" style="-sec-extract: exhibit">March 28, 2024 Atlas Equity Purchase Agreement (incorporated by reference to Exhibit 10.104 to the Company&#8217;s annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2023) filed April 1, 2024).</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="text-align: justify; width: 0.1in">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224012058/ex10-105.htm" style="-sec-extract: exhibit">March 28, 2024 Atlas Registration Rights Agreement (incorporated by reference to Exhibit 10.105 to the Company&#8217;s annual report on Form 10-K (No. 001-27072) for the year ended December 31, 2023) filed April 1, 2024).</a> </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224015368/ex10-107.htm" style="-sec-extract: exhibit">March 15, 2024 Addendum 1 to Lease for Ocala office (incorporated by reference to Exhibit 10.107 to the Company&#8217;s Registration Statement on Form S-1 (No. 333-278839) filed April 19, 2024).</a> </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224022329/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated as of May 31, 2024, by and among the Company and a Purchaser (incorporated by reference to exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed June 3, 2024).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224032355/ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 12, 2024 Amendment to Employment Agreement for Thomas K Equels (incorporated by reference to exhibit 10.4 to the Company&#8217;s Quarterly report on form 10-Q (No. 001-27072) for period ended June 30, 2024). </span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224032355/ex10-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 12, 2024 Amendment to Employment Agreement for Peter W Rodino III (incorporated by reference to exhibit 10.5 to the Company&#8217;s Quarterly report on form 10-Q (No. 001-27072) for period ended June 30, 2024). </span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224036060/ex10-1.htm" style="-sec-extract: exhibit">September 11, 2024 Amendment to Employment Agreement for Thomas K Equels (incorporated by reference to exhibit 10.1 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed September 12, 2024).</a> </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224036060/ex10-2.htm" style="-sec-extract: exhibit">September 11, 2024 Amendment to Employment Agreement for Peter W. Rodino III (incorporated by reference to exhibit 10.2 to the Company&#8217;s Current report on Form 8-K (No. 001-27072) filed September 12, 2024).</a> </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224039011/ex10-1.htm" style="-sec-extract: exhibit">September 30, 2024 Securities Purchase Agreement (incorporated by reference to exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed October 1, 2024).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224039011/ex1-1.htm" style="-sec-extract: exhibit">September 30, 2024 Placement Agency Agreement with Maxim Group LLC (incorporated by reference to exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed October 1, 2024).</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224039011/ex4-1.htm" style="-sec-extract: exhibit">October 1, 2024 Class C Common Stock Purchase Warrant with Armistice Capital Master Fund Ltd (incorporated by reference to exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed October 1, 2024).</a> </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/946644/000149315224039011/ex4-2.htm" style="-sec-extract: exhibit">October 1, 2024 Class D Common Stock Purchase Warrant with Armistice Capital Master Fund Ltd (incorporated by reference to exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K (No. 001-27072) filed October 1, 2024).</a> </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ex10-15.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 19, 2024 Lease extension for Riverton office*</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company&#8217;s Chief Executive Officer. *</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company&#8217;s Chief Financial Officer. *</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company&#8217;s Chief Executive Officer. *</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company&#8217;s Chief Financial Officer. *</a></span></td></tr>
  </table>
<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Schema</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Calculation Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Definition Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Label Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Presentation Linkbase</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.25in">&#160;</td>
  <td style="width: 0.25in">*</td>
  <td>Filed herewith.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
    IMMUNOTECH INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Thomas K. Equels</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    K. Equels, Esq.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer &amp; President</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert Dickey IV</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Dickey IV</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 14, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex3-1i1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 3.1(i)(1)</B></P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;<IMG SRC="ex-a_001.jpg" ></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex-a_002.jpg" ></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex-a_003.jpg"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-a_004.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-a_005.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-a_006.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-a_007.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex-a_008.jpg"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex-a_009.jpg"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-a_010.jpg" ></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="ex-a_048.jpg"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-a_049.jpg" >&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-a_050.jpg">&nbsp;&nbsp;</P>



<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-a_055.jpg" ></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="border-bottom: Black 1pt solid; text-align: center; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="text-align: center; break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex-a_056.jpg" ></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex4-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>4
<FILENAME>ex10-15.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.15</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
ImmunoTech Inc</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">604
Main Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Riverton,
NJ 08077</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
19, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">604
Associates LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">701
Bank Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Riverton,
NJ 08077</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Lawrence R Antonucci</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
Lease Renewal</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Larry,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter is in response to your email dated September 19, 2024. We are happy to renew the lease on the property at the above address for
another one-year (12 month) term as defined in Section 1(b) of the current lease. Our current lease extension expires on April 30, 2025,
and this extension will expire April 30, 2026, at the monthly rate of $3,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you agree, please sign below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Peter W Rodino</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
W. Rodino, III</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COO
&amp; General Counsel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Lawrence R. Anotnucci</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
R. Antonucci</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
  Headquarters</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2117 SW Highway 484, Ocala
  FL 34473</FONT></TD>
  <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">t: 352-448-7797</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">f: 352-480-4620</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Human Resources
  and Administration</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">604 Main Street, Riverton NJ 08077</FONT></TD>
  <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">t: 352-448-7797</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">f: 352-480-4620</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operations,
  Research and Development</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">671A US-1 South, North Brunswick,
  NJ 08902</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>www.aimimmuno.com</U></FONT></TD>
  <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">t: 732-249-3250</FONT></TD>
    <TD STYLE="text-align: right; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">f: 732-249-6895</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Thomas K. Equels, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this quarterly report on Form 10-Q of AIM ImmunoTech Inc. (the &ldquo;Registrant&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s
    most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant&rsquo;s internal
    control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
    financial reporting, to the Registrant&rsquo;s auditors and the audit committee of the Registrant&rsquo;s board of directors (or
    persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 53%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 14, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Thomas K. Equels</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    K. Equels, Esq.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer &amp; President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert Dickey IV, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this quarterly report on Form 10-Q of AIM ImmunoTech Inc. (the &ldquo;Registrant&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the Registrant&rsquo;s internal control over financial reporting that occurred during the Registrant&rsquo;s
    most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant&rsquo;s internal
    control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
    financial reporting, to the Registrant&rsquo;s auditors and the audit committee of the Registrant&rsquo;s board of directors (or
    persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 14, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert Dickey IV</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Dickey IV</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SARBANES-OXLEY
ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Quarterly Report of AIM ImmunoTech Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the fiscal quarter ended September
30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Thomas K. Equels, Chief
Executive Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley
Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
    the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 14, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Thomas K. Equels</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    K. Equels, Esq.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer &amp; President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SARBANES-OXLEY
ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Quarterly Report of AIM ImmunoTech Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the fiscal quarter ended September
30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Robert Dickey IV, Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act
of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-right: 0.8pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
    the Company.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 53%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 14, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert Dickey IV</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Dickey IV</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !R +\# 2(  A$! Q$!_\0
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MC\+-:-7G5GN:5<'X^LT\0Z]X7\-/ LL4MXU_<DG[L4*X*D>C[]N?6N\JC!8
M:I/J,RH;AT$,9'.R('. <<$DY/T4<[0:Y*4^27-V-9*ZL7J^4OB;KC:]X^U.
M;S-\-O)]E@Y! 1#CC'8MN;_@5?4M]]K^P7'V 0&\\MO(\\D1[\<;L<XSUQ7@
M#_ CQ7)(TCZCI#.Q)9FGE))/<_NZ[\NG2IR<ZC2[&&(4I)**.%TGPAX@UVT-
MWI>E7%U;AS&9(P,;@ 2/U%3WW@3Q1IME+>7FBW4-M"NZ21@,*/4\U]/>#]";
MPSX2T[1W='DMX\2-&25+L2S8SSC)/I]!TJ]K6G+J^A7^FL0!=V\D.3VW*1G\
M,UM+-)<]DE:_X$+#+EWU/D?PSJQT/Q/IFIABJVUPCOCNF?F'0]5R/QKZG\92
M)+X UV2-U='TV=E93D$&,X(->*_\*%\4_P#/_H__ '^E_P#C=>NV?AS5%^%[
M>&[N:U;4/[/DLUD1V,7*E4Y*YQC;GBC'5*-24)PDG9_A<*,9Q331\H5]FZ-_
MR M/_P"O:/\ ]!%>"?\ "A?%/_/_ */_ -_I?_C=?0&GV[VFFVMM(5+Q0I&Q
M7H2 !Q4YE7IU%'D=]QX>$HM\R/B^3_6-]37U)IF@P>)OA!IND3OY:W.F0JLF
MW=L8(I5L=\$ XXKRQO@-XI9R1?Z/R<_ZZ7_XW7NGAS3IM'\,Z9IMPR--:VL<
M+M&25+*H!QD XX]*O'XF$XQ=.5VF*A3DF^9'R?+X7UN+4WT\:9=/.DQ@^2%B
M&8-MX..F:^CY] B\,?!_4M*B"EH=)N/-=1C?(8F+-^?Z8KM:SO$%A+JOAO5-
M.@9%FN[26"-G)"AF0J"< \9-<M;&RKN*:LDU^AI"BH)V/C6OMNOG;_A0OBG_
M )_]'_[_ $O_ ,;KZ)K7,JU.KR\CO:Y&'A*-^9!1117DG6%%%% !1110!\[?
M&/P,NA:I_;U@@6POI,2QJ.(9<9_)L$^QS[5TVBZGJOAW]G8:G97/DW4;%K=C
M&IV*UR%/# @YRQZ?Q5Z-XQ\/)XI\*7^DL0LDJ;H7./ED4Y4_3(P?8FN8^(NE
MP:)\%;S3+8L8;6&VB4MU;$T8R?<]?QKU88GVL*=*>KYE]QRNGRRE)=@\-?$:
MQL_ 6B:GXMU79>7_ )^V3[.Q\SRY2O2-<# *]A_.M2/XI^"I7G1=>A!A4LQ:
M*100.NTE?F/H!DGMFO"_$_\ R2[P)_W$/_1PKLO$?A[1[7XX^']-@TNTCL9;
M>-I+=85\MSF3DKC!^Z/KBM)86BVV[Z\STMT9*JSV7E^)Z?IWCOPSJNEWVI66
MJ)+:V*[[EO+<-&N,YVD;B/<#M6>/BOX(/E8UV/\ >G"_N)>.<?-\OR_CCUZ5
MX[I]O#:>*OB/;6\:Q0Q:??QQQH,!5$Z  #T J671=-3X"0ZHMC!_:#WQW7.P
M>9C>5QNZXP!QT[TOJ5%/5O5JVW57'[:=OO\ P/:K+XA>%-1UD:3::U!+>%MB
MJ%;:[>BN1M;VP3GM5JT\8Z#?7FIVEM?[Y]+#F\7R7'E;"0W)7!P0>F:\6U#3
MK*Q\0_"Z2TM(('N(;&29HHPID<O&2S8ZGD\FF-K;^#_&_CB"^TV\>75?M*6J
MQI][>[,K'/\ "0V<C/TJ/J4)?!?;R_FL_P#,?MI+?^M+GL:>/_##^'Y->74\
MZ9'-Y#3^1)P_!QMV[NXYQBHM/^)/A#5-1AT^TUN%[F; C5HW0,2,@;F4#/.,
M9SGCKQ7BUI_R;[??]AD?^@I4_B;2-/T_2?AO=6EG#!/=Q*UQ)&@!E.83EO4Y
M9N?>J^I4KN+;W:6W17%[:5K^2/:==\>>&?#=V+35=5C@N< F)4>1E!Z9"@X_
M&L3Q)KNJ^(/#T>H_#_6[,K 6>Z<A20@7(!5U)!]B!7GNISZ?X0^*6O7WBW09
M-2L[LLUJ[0*Z?,05P&^4\#;GJ,'WK0^%6D:A;Z;XJU9[.6STV[MF6W23*[\;
MR,#N%!QGWX[U/U:%."J+RWM9WZ6\A^TE)\O_  Y<^&_B3QMKTZZYJ^MVI\.V
MLDL=YYR11$$1Y!R$& "R'.1T-=M:_$_P9>7Z64.NP^<[;%WQ2(A/^^RA?UYK
MR[PCIM[J_P !/$5G81O+<-J&\1(I9G"B!B !R3@?CTKEK6"#4/#5IH]WK.H"
M\AN6":-;Z*)95)/+*^Y2<CJ"0<C&, &MYX:G5G)O2SMI^;_I>I"J2BEY]SZ,
M\0>,= \+&-=8U*.V>492/:SN1Z[5!./?I6!XF\9V6H_#G6-6\,ZLKRVZ+B2+
M*O&2R]58 C(SU'K7G'B;3$\(?$FSU?Q%I\FKZ(;6)=_D9#%81%\RM\N[<N[:
M3W'>M2:YTC4/AIXPOM%\,3:-9R+"$FD8@70WYR%Z+MSVR/FZUA'#0BH25W>V
MNEM]NYHZDG=?\.=-X+^)FA/H&D66L:ZK:Q,F)/,1C\Q8@!G V@XQU(KTBOF;
MQ1I5A:_";PE>P6<$=W.\OFSJ@#R<G[S=3[9Z5],UABZ4(VG#JW^#*I2;T?D%
M%%%<)N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex-a_001.jpg
<TEXT>
begin 644 ex-a_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BP?M
M..-O6I::.HIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 -'44ZFCJ*=0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% #1U%.IHZBG4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5";F#[3]F\^/S]F
M_P K>-VW.,XZXSQFIJK-9PF]^U^2OG[/+\SOMSG'YT 6 01D'(I:1?NCC%+0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -'44ZF]*/,
M7U_2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !129HS0 M%)FC- "T4F:,T +1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (*6D%+0 4444
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M'- "GVIB(%)([]:<2!U_E1D&@!:*0D#U_*C(H 6BBD) &2: %HI,@CCFES0
M44F]<XR,^E&Y<XSSZ4 +11FB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *3O2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% ""EIHZBG4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'64LH([>VAE$(6$8&5')Q]>*[?X5^ I/%.GVU_KI<Z):2L;*S_AE?^*0^QH
M9K/QPUBZN\Z):0VMG@LHG >0@'J><?@":[/X=?%F/Q5>+I6J6Z6NILI:(HWR
M3X_NYZ-[?K75:IX!\.:IIDEC)I5G$K(5CDAB"-'GN".]?+][;:AX5\031 ^7
MJ&F7 "2+]XX.5/\ P)<C\* /L=<XYI<UF>']5AUOP_8ZI;DF*ZA64$C'7KQ]
M<UHAN?QQ0!YKXQ^*@\+^+K'05L!(LKPF>=WP(T<G) [D '@X[5Z1&V_8?;.1
MT-?(WCC5QX@\7:U?)*&AEG>.!E.?D3"J1]<'\Z^F/ >K#6_!6CWX.3);(KG.
M?F48/ZB@#I&ZCZUXYK'QMGT77;[2YO#Y>2UN6A.+C&Y1T;I[BO8)MVP[<9((
M'/?M7RG\394U'XEZTVG@2.9X[=0G5Y J@@?B* /I+P=XB'BKPO::P+9K;SPW
M[IFW$8)'7\*W"P!_KZ5S_@[1E\,>$+#2F(W6L/[TYZ.?F;\.37FOB?Q[J'C/
MQ'%X1\'RA(9WVW%_&WSE <.5] .Q[^U 'H/B'XA^'?#;F"[NFFN]I9;:U7S)
M"/PX'XD5PUY\>K.WV>5X?U!@6/,TJQY_.O0/#?@C1?"]KY=C;AKAQ^^NI1NE
MF/JS&KNI>'=(U.W:*^TZUN$88(>(9Y]#VH \I7]H.UW8?PW=$=#MN4.#^6*[
MKP-X_M?&T&H30:;<6263A':5E*L<$GD>E?.OCBRL-.\9ZWI^F1"*RM9%B2,/
MP#CDY^N*[7X<^%]7\6^'AITTT]CX9\UKB=H&Q)=RY *9_N\4 =YXI^,NB:+/
M):Z?%)J<\9P[Q$"%&]"Y/\LUG>#_ (UP:[K=OI6I::MC)<MMBDCE+H&[ DX.
M3VXKHO$GA3P_I/PXU73XK"VALH+1Y%W)N(<#*MGKG.*^<O"BM=>+?#Z_>D:_
M@!P/<D_EB@#[')PI/H*PO$GBW2/"^GR76I7(0J,K$I&]SV4#U-9?Q \?VG@C
M3%=HEN+^XRMO;;\9Z_,W7Y17FOA[X7ZQXW,OB'Q9J4]M-> O'$%_>A3]TX/"
M #H.: +\W[0$+W2?9?#L[0' <R7"^823P%4<'\Z]@T^\-WIT-U);R6QDC#F&
M7 9,^N"1^M>::'\&M,\.^)4U>XU%KRRM(R\,-RH^208^=B.HQGM7*^)O&.K_
M !(\4P^&O"\\T&G;\/)&=C38^](6ZJ@X ]: ._\ $7Q@\.:)>&SMOM.J72DA
MH[, A"/4DBN6C_: @%X?M&@S+9]!LG!F!]U( Q^->@>$_ .B^%M+2W@MHY[G
MDS74T8+RL>I/I7D'QOTC3],\3Z7)96Z6[744CS>4-N=I S^M 'O6C:Q9Z]I5
MOJ5A()+>=0RD=CW!]Q6C7CWP"ED/A?5XG<E(=0PBYX4; >/Q->PT %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -'44ZFCJ*=0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5SGCG49=)\$ZU>QLBM'9R;"P_C(P/YUT=>5_'/6XK'P:FEAU,^HSA=N
M>1&IW,?T _&@#YQ8B&-% W&,#@]6_BKZV^'&B'0/ VDV+IME^SB67_??D_TK
MY\^''@N;Q?XN03JHTVQ82WC_ -XCE4'XXS[9KZK10#D#% $E%%% !3'8*A9F
M55 )8GH!3Z\T^+?C*+0O#\FCV[$ZGJ$;!%'_ "SB_B9O3C(% 'B?C_7AXB\<
MZGJ"J3"'%O"0?X8QCC_>-=I\#/#B2:A?>*KP 060,-O(_ #8_>-^"G&?<UYY
MX<\*ZAXLUN'2=/7#C#33$_)%'_>/O7O_ (]@M/!_P;U.RTY##%':BSCV\9+L
M$+'W.3S0!X?XEU^^\;^-RZR/Y<]Q]CLU4\11E@/E]"0,Y]Z^I-(TRVT72+32
M[.-8H+:,(JJ/S/XG)KY&\-O?1^*-+_L^,7%^)U>"%NC.HV@'VX_2O;=1M?C#
MK%ND DTO3D;[[6\N&&2>_- ':>-/&FG^$-&FGGECDO"O^CV@<"25OIUQW)KP
MOP)X2O/'OBN;6;Z,KI2W+7-S+@E9Y2<B),_>QZ]J]!T3X)P&_74?%.IRZO<C
M&4R=O!S@DG)'TQ7J\-I;V\"0P0QQ1(,*B+M4?0#I0!X)\>]3<:SHFEH!Y5O;
MM<D ?Q,2@!'T%;/[/NEK!I&K:H54M-<>0C#J47G!_$UYS\5]26_^).L3*Y\N
M I;<]A&N&'_?1S7L_P )K2+0?A/87-P-N^.6^E.><$DY_("@#E_C7XXD3_BE
M+&8)E1)J$JMC]W_SS'U[_2M;X%>'$LO"T^MS1J+C4)2JE>@A3A0!V!;<?RKP
M/4;R7Q#K4UX['SK^[\SYNJ[WPOY BOL?1-/BTK1;33H0-EM$L7 [@8/ZT 7A
MTZYK+U_68?#^A7VJ73J(K:)Y/<X' QW-:+L(QDG"@$D]@/6O!OB)K)\:Q:Y>
M64SGP_X?@P'1L+=73LH&/50"10!Y&TLNJ:ENE=C/>7.)&/J[YS^M?9>DV$&F
M:9:6-LBI#;Q"-0HP!CVKY2^'^D?VQ\1M)LV *"X\Z52/O+& :^N%QD8'!YS0
M K].N*^8_C#8R6?Q+O)<%$O(8)D(/7 *D_F*^G'P%R>W-?.WQVA*^.-/9,@R
MV0"G/H[&@#TOX,7;W7PNTG<V?*,L(^BR, /RJ[\1?$LGASPG<O:MC4KK]Q91
MJ,M)(WH!SQ7.? 6<O\/IHLY\G49D4?W1A6_J?SHT]6\=_%9]64&31/#F8+9N
MTMSGYF'J >A]J /*/'_A%?!MYH]A"NYWTX/,P/!E#_,1[5Z_\"[M)_A[' K9
M:UN9HV7TRV1^E<Q^T#$J7/AZZ4$2-Y\1QW&%Q^IJU^SY,/[+\06PSNCO8Y/P
M9<?TH ]+\:>(4\+>%+[5VVF2!"84;^.0\*OYFO'O@QX.?4=4?Q9J2>;#;NX@
M+KN\Z5OO/^&<5>\8W%Q\3_B!!X3TN\=-*TPF6\G X+CJ1ZD D#W->OV=K8^'
MM#CM[9%M["S@.U<_=15R2?>@#S3XR>/)='A7P]IMPT=S<1EKN5.L,1[>S&H_
M@1X=C@T2Z\03P*L]Y(8H,K]R)?3V->*:[JDOB77;W46_U^H7 \L9R$7.U1^J
MU]>:%I<>CZ#8:;&BJMM;I%A>F0N#0!H]!5#5M4BT;2+K4;MT6&VB,C,S8!(Z
M#\>E7CG!Q7B'Q.US_A)H=9L(;EAHFAVXDO)(DR+B\+A4B!] 2"?I0!XOJ%S)
MJ^IW-Q\QFOYWD^8<'>>!GVK[$\/:;'I'AZPT^)0@M[>.,JHP-P49/XFOD_P3
MI9UGQWHMBRB0&[#NI^Z57YB!],8K[!10H.#G)ZT >>_&J_%E\--2B!)>Z:*V
M7G!!+@D^_ ->*_#;[/!X[M]1N#MM=,AN+R;(^ZJ)\N#ZDFN__:#OQG0M.&<A
MI+IO3 &W^9KS3P'X=N_%?B5-+1Y$M&3_ $YT.#Y P3^9 % 'J7@C1'^(OB.;
MQSXAB9[..7RM,LY%^0*O.X@]L\_6O9M@7!Y..U,MK:"UMHK>WC6.&-0J(HP
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MM:)\(-)@N%O_ !%<7.O:J&R;F[E9@1V7!/('O7H,,"01B**-$C7&%50JC\J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@"&>SM[I=MQ;PS#_ *:H&_G3XH5@0)&JH@X"*  /P%/+\\#/THW^V/J: %'
MY.:C:(."I52ISD,,Y-/W_3\Z-WT_.@"I;:79V39M+." D ,T2!2?J<<U;52"
M3Z]:7</4?G2;AVQ^= "LNX8-5I+"UFN1<RVT+S!=@D9 6"YSC/UJQN]<#\:7
M</4?G0  8&*6F%\'H31O_P!D_E0!7GTZTN9899[:&62%BT;2+DH3U(JPB!
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M\:/,_P!G]10!BZ3X1T3023I>DVENQ(.Y5^;\SFMH*0,'!H\S_9_44>9[?J*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;M@_^)KV3%&!0!XV%^-@.#>:>?\ @,'_ ,32-_PNX'Y9[!OHL'^%>R@ #O\
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MT2F9< 8<J"1Q[U<I%55^Z ,^E+0 4444 %%%% !1BBB@!,48I:* $Q1BEHH
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M]B#WH TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH :.HIU-%.H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** (IX(KF%H;B))8FX9)%#*?J#7&?%?4DTKX::K''\LUW&MC;Q*!F
M1I#MVJ._R[C@=@<5VYZ5YUKOPDM]=UPZK-XI\0),)O/B47"E8'SD&,;?D X
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MN*=2$98&EQ0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** #%)BEHH *,444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 1DL'  &*?FFG.TX.#3-
MLO\ ?_04 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% #1U%.IHZBG4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 T=:=2 TM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 -'44ZFCJ*=0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(BDP ""%]P* /J$L!2YKQ;XU3W5KJ_AQ]-\3W6EW%ZYMB$NVAA6(LN9G9<8
M++DD]!QT-/\ !-Y?VGQ2DT+3/%U]XDT=M,$UU=3W N%BFY *-D@<D<#/WL'.
MW- 'LV:3/UKY<MM1UC^Q]9UQ_BC>PW.FW;QVUB]T\C79!RC!?,V[6]-K+@'/
M%>J>(HM:\4?".RU2^UN30YH[;^T+TV<1;S4"%@HVN",C!QD\_3@ ]/S2YKQG
MX/\ @_5WM=.\7ZCXCU1Q-'(4TZ1V*,IW*"Q9CN!&&' YP>:Y.;4)+SQMXFM-
M3^(VO:3'#J?V:S2&:5O,9WD! C5OE1"H''&".F10!])9HS7A=IX<^) \%V>F
MWFH:U!JE]KB+-<K?M,]K:"/!;<'Z;LG&[G ]:Y;3H/'&J>&K[5=%\6:]>%=8
M738(OM,AWJ<8E+,WRC+(/3DYXH ^G<T5'$"L:AF+L!@L1@D^M9GBC66\/^&-
M2UA;<W#6<#3"(-C=@=SV'J?2@#7S1FO +,^-?%+Z-J6D>.AJ#W5S#+J&GVDB
MP?V>IPQ!&_+JH)!&.<=ZOZ]\1-6T+X[?8)M1_P")&'@MY+>1U2*-)(U)<G'!
M5FW9/88R!T /<,T9KY_\/^,/%/Q%^)US%I&OW&D:9$C3PQ&%9%6)"J@,G&2Q
M8$Y)QDCG JQ9ZE\2]0^(-WX1M_&T32VD/FW%TNFP[(_N_+@ID_?4?_J- 'O&
M:,UY-X\U[Q7IVLV6BZ1KGV,V.B2ZGJ.H26T;B<)\OW"I"G*GA?\ GH..!6)X
M,\0?$;5M;\)R7FO&>QU83W$T+6,2;(86VMEE0'YLK@@C[PH ]TS1FO!_#?C'
MQ=JU_P"+/M/C:PMXM*2>.W$\$(1W^<(X.U3M79G)SU&0>E=E\']6\2>(?#$N
MM:_JRWJ7$NVVC\A(VB"%E;<54 Y..,<8Z\\ 'HV:,TTC->!^$?B=XEE^R76O
M>(+81:A/):6-L-/#L\O #OLV[8E9T[[FP0!WH ]^S1FO(/!GBSXA>,$UUH)M
M!5M/;[+;R>3)Y$T_F*6;.2Q41JV.!S(OIQ)X2\3_ !#\4:G>QQ7?A9K/3;\6
MMW(D<V7 (W&(\@\9P3C)]N: /6\T9KQ[6OB;K?AKXL0^'M3ETM]&EG3]Y%&R
MR11R9"[RSX!4D%CW'(QG BD\9?$=]9\3V-J_AHC0(O/N"8IOF4J7"H<\M@8.
M<#/?O0![-FC->(V?C;XHWW@6;Q=##X?-A$KR>4891*R(V&<#=C:,,>2#A3QT
MSMZS\2=4?_A%].T:'3K74==L4OC<:E*1!;J4W;>.23@@'/IP<\ 'J>:,UY3I
M/C[Q!I<WBJ3Q@VGF#1;6WDC?3T?RIFFSLPQR3N.U<XP.<]*KS^+/B>?#4OBN
M/2M$M]+5/M0T^4R-<B 8));(7[N6['';/% 'KV:,UXUXQ^(?BQ9/"0\."QMX
MO$=K$\(F0R2),Q&5)/&P"1.=N>&]JVO!WB;Q;#XZNO"'B];*>Y^R?;;>[M&
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M9PW5HVI>%]=T[3+N14BO[J#8A#<AO0C'/RD\<C- 'J6:*\T\4?%^#PSXIGT
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M<^%[6SM+RXUZPCMKP.;>5IAME"G#;3WP>*O6OB#2;[2'U:TU"WFT^-79KE)
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M7+W)C,:O<3;]@)YVC &3@<_XG/:T >1>)I+36?CKHVC:W,8M-M+/[1:V\_\
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M110 4444 1%F$B@ $$<FI::.HIU !1110 4444 %%%% !1110 4444 %%%%
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M:.H[Y/',6'@7Q]I_C_\ X2*T\,:):M9K*8(;:1(;:4B-D7:@<L"V0><<]2M
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M?XF)\P@$#^$G&T5L7GQ#TIO@);>'XKU6UAD6SDA4$&.-9,[CQ@@HH'7^+U%
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M<A>!_ /I5#QAX<\-6VK:1::1<A-+\5:JOV^XMY4,*I#T@0K@*&=R<<_,H/\
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MQSW.3S6O/X3T&XT#^PI-*M?[* ^6U6,!%.2<C'0Y).1SDUM8HQ0!S/AWX?\
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M29IW>X<,[.0!V '15' [5T5)BEH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 8?OK3Z:WWA3J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHI#0!GZSKFF>'K$WVKWT-G:[@GF2M@%CT [D
M]>G8$]JRM,^('A36=1AT_3M<MKF[F)$<29RV 6/;T!/X5SO]DV'BKXSZA=7T
M:SQ>'K""WCMI1N0S3;Y/,QTX0A<$')P>-HKE?B?X=T7PA!?>)M#BM;>]>)=,
M2VM56)+1I5;?-A?XS'E1TQG/- 'IFI_$'PGHU_+8:AKMI!=0X$D3$DJ<9P<#
MKCM5G4_&7AS1[.TO-0UFSAMKP$VTOF!EF  )*[<Y'(YZ<CUKDK3P'X%\,^ 3
M/JFGZ7=PK:B6ZU"50YE9D +1R'E0QQM"$<D8Y->0ZC;S+\%/"NGW5I(]_?ZG
M+)8[8MTRP'@B,<$[W9" .&ROM0!]$:-XV\->(;MK32-9MKNX5"YBC8[MHZD
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M#/ ZG&?QYO3/"'Q8_P"$YM/$-_?:>+C:EM/-NC(^S;PS(%"?7D8/O7N.*,4
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M7?"VK>%KKPM-HFF^(KV2V1-3\BYMC+%;2%PWEXC7A\Q_,.N-OI7U!@48QTH
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M0JR%QC.226&U\\$CIC'.ZKX@\+Z-X<\6^#/!EC-)#IQO9=6NWN)$.XK]W+'
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M.U&W2XM)T*21.."/Y@CJ".00".:X33/@EX1L+X7-PEYJ*1N&M[>\G+10@$'
M48W#C&&R"."* /*O%T;#X:?#W2/[.-QK$T;3HJ1[Y3$2=L8 &XAMX.!_<Z<<
M;_@14\7?%J#4K3P_I_AF'0HF$^GQ($ED=PZ<@*A)!/)(^7 '\5=MXE^#VF>*
M?$LFM7VLZJ'=EQ"CKMC48^5"1E1G)X[DFM>3X<Z.WC^'QA')<P7J+AXH9-J2
MO@KO;N>, C.#@9SSD [$UR'Q&\4V/A7PA=75W'#//+^ZM;:9=RRR]1D8Z+C<
M?IZXKKSTK@/%GPITKQAK\>K:AJFJ!DV@6ZRJ8E48RJ@KE<XR2#U- 'D'P3U*
MWT_XE6T$=P;@:E8O$YV^6(I>)",=&QY9&1C[W%?3PK@I_A7I<OCF'Q8FI:E'
M>QSK/Y0=/+X  4#;D+@$8SWKO!0!YE\;F%UX3T[188(9K[5=4@MK7S" 8WR3
MN!(X[*3QPY^E>(ZSK&OZCX-T_P /O9F+3M$NOL<F" );MC)MSD9!"[P1G'<X
MR!7O/C?X93^,]>M=1/BB^LHK8+Y-O'&"(G!SO0@C:QXY.3D=<8 I>+/@^?$^
MI"=?$EU:6J[72T6 ,BRXPT@PR_,W4D@G)//0  \P\9V-EX2\1:!86VB6>HW&
MD:2LVI((%*2RMD!IPJG(!*$DGD,!D9S75^$=#T-;'Q!XSU.+3_M3Z09)] LH
MQ!#:PO'D C).94C5ATQO;@Y!&E_PI#4?[2?4AX]U07\B[7NEC82L.."_F9QP
M.,]AZ597X+W T;4;(^,-0:XU&>.2[N6BW-,B*P$;9?+#+YY..,8] #QC3)M/
MB\$R:+)X6GGUO5IXUM=2F.Q?O+M6,D>YSC@[N3@#'JNM:9=Z_P"*O"_@;6VG
MGT[2]%2_U-8G)DGE5#'G<#N;YL# Y.X]>HW3\'H9O P\.W6O75Q+#="XLKV2
M/)M  HV(N[A< \ @9.<<5)JOPC74X=/N?^$IUB+7;2V%L=3#_/,NYF.X#!_B
M('S=,9W8H Y7PQ/\,?$/CG1I='TC4-.OK,23B$P!(F*KN#2D,>5P<'(R2 2>
ME>>>'9-*O+B]T4:%:2'5[F86>IW652RMPK9D7CG8/G.2 -O)]/8X_@Y)::=?
M/:>+=4&N7P6.?4Y!O9HAUCZ[@&(3)W9P@&<9!RD^"6O0:5-I%KX\GCTN0%3:
MFS.W:3DC'F<9/7&,]\T <=\1-#T3PQ\-/#>EZ;=V^JW$U[<7":I B;9% PZ@
MJ3QDQCJ?]7U' K6\!P>']6^*NCW/@O2;JUTW2K:5[^>ZF)>5GB9%.TL><D=.
MN3P !GH=1^"VJ75UIDUGXN-FNEVT,%FJ69'DLB#>X(<?,[AG)QG+8R<5T3_#
M>6#Q];>*=+UR:T=DC34(_(4M>[2I8DC"KOV+NPO4$C&: /0!7CW[0:6)T+0I
M+AAYZZAA5'WVB*'S,?DGXD5["*X?XB_#T>/GTE'U$V<-E([2A8M[2*VW(!R-
MIPIYYZ]* /GBZUV'7K2YT"RTF.&V>[#:';0*=\,CR*I#,6RY=.I;=\V-NU>!
MZC\5?!6A:!\/+ VNF1S:O&(--M)D:12S$LQ*QAMI9CO/.2=QY-=&/A':1?$>
MS\46]X(K*U\KR].$'0QQ"- 'W=!M4].WXTWQ)\/?%_B>\\RX\;)#:6]^;ZQM
MUTU";=E9O*.\%2Q53W[^O6@"76?AA;Q_#R[\,>&X[>SEO9K=[J65G8/L9"S<
MDG/RYP,=_6O-=$^&>G^)[CQY9Z7^[ET^Y2STR2XF;".KMYA;&<A@F 3GACQZ
M>UG1?$B^$(M,A\3;=:0C?JSV:N6^<G_5D[>F%_6L'P%\/=8\#"^@7Q)'=V5P
MKNMN+ )MN#M DW;B2 %QMSCF@#SGQ=%H&G?&&RAN](U'5+'2-.@BFMK.(NQ=
M4_=\9!"@,A/S<G@YY!U/A-I/A[Q#\1O$OB&WL+F-+.6*2RANR"T3R^9O9@,_
M-N0XY.,]R 1JZ?\ #7X@VGB#4->'C2SBU6\@V23I9J_FD!0JE67:JX4<@9&.
MAR:Z+X:>!-5\%R:S)J>HV]X^HRI+^Y0J%8;RS'('7<.!P,4 >@CI7D'Q\_LV
MX\/Z79S.3JDMX%LXS.$10>'D<'@J!QGC!;.>M>NGI7C9^%GB;6_B NM^+;S2
M=3TX>9'Y.7W"+#>6@0(H&&8$\YZ\DT -^ +-:)XHT;[3%.MG>H?,@(:)R0Z%
MT;^('RACVQZFO:#7C_PU^&WBSP;XJDU"]OM(-A<1%+F&TW$N1G9M!C4+@G/!
M_#T]@/2@#P3X^PZ:->\/RSSW*3R@QSA"=B6X?E@,??RQ]<X%'PTATY?BHW_"
M$7=_/X>33O\ B827:MAI"S;0,@8.=I'&<!\<9KH?$?PW\4:_X^3Q%)JNBF*#
M,-M#-9M*J09;AD/#MAR>3UZ8XQ*WP_\ $_A[Q5J^H^![W2=.L-15'>WNT9\2
MKDX "G:N68\$XSTP!@ \@N_^$5M_&?B2'6HM8G5=5>&VCM+@!@OF.)&9F!SR
M%P/<^F:[RZ\%>(? /PLUNWCE-W<W]]&MS_9Y:1A:%=A4;EX8Y() Z'\I--^&
M7Q%TNT,$-SX2E(N7NXYKB)GEBF< %T;R?E;Y5((Z8'H -33/AOXUT+3/#UOH
M_B*QM&TR.8S18D:*661V))&!O 4H!D<$$C&: //O#&D>&O$/Q#T"+PG<ZG;1
MPR?:KJ/574.1$RL!$4)W,PSQV"DU<^)/A'5?[4U37-7E,=YJ>N1V6F1I(NQX
M"K .V,D?*L8[8(;(Y&/4/#W@?6W\8KXK\8ZA:7NIVL1M[%+%"D:(0P+-D EL
M.PQR!D\GC&)XQ\&?$;Q%KL%ZEUX?DL].O6N-.@<N& W#89,QX)  )&<=>O%
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M&]W87#O)]EB;:Q969R<@&0@X7.PY!XQG^-]8\?PZIJ-T=7U+3K:ZU9]/TVR
M:)YD&1O3 SM^YR.27R.E=%H_@C4O OQ T/4=!T&::SU*T$-_!)*'_L]B4\PB
M7H<=1ZX8#KQ1\?:EXMUSQII4]MX(U)[/0-0>2'Y'9;P*ZX;.S"@^7QUX;VH
MV_!^C^/HM5\3Z?>Z]J+P6]JUGIU[?0G9)*<8E5223M ZY8<]3TKE?"^E>-_$
MGC36=-M_'NH^5I<@CN+Q99&C<DE2%C+8!^5NW\.>XKV'Q'XBUC1?#%OJ%KX:
MN=1U*4QJ]A;ON\IBN6RR@Y"X(R <G':N"^#[>(+#7=8@U7PK?69U6XDOI;V5
M&CCCYR(P&'/+-CG/- $GQ5UKQ+9>+M%TG1?%$>G6^IQL)8G$48MPC9,K2-R
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M[>)?/FW'Y$S&VU0,?,Y &Y<GDD>P_#&Y\57GA/[3XN,OV^6X=HEFA6*18L
M,JJ,'(8\C."*\'L-#UO2GBUR[\&Z_/KMO=27&_[*WV>1V&8V90,C;)\VU1@]
M,BOH[P<-7_X1+3#KTC/JC6ZM<%EVG<><$8&" 0#QU!^M &X:\&\8_%?QGX2\
M5WNF2?V/<P6[AW\B"4F.-CN5&8D?/L*GH1S]:]8\:>(+KPYH$MU9:7?ZC=R
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M,C,D,:2?+N8@?,Q487&1GG&1GD-2'ANP\7>'CI>C^(H[&QN4DU&+4X&?@%"
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MHS0 449HS0 449HS0 449HS0 449HS0 449HH ***,T %%%% !1110 4444
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M1%6"J6!;!9\!<GCI72_"C4+"R\.>(_B!K6I0I+?W;?:P@PL6T[@H7&2S&3(
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M=NGE!2K[@24P.#@$$CL2.] '8WOCGPUIVFV6HWFL6L-I? M;2,Q_>@=2HQG
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M!HZBG4T=13J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML? O_"(VEW?P6&QHQ-',%G 9R[?,%QR21TZ'%<BGP"\+QHT::IKJ(WWE6YC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :.HIU-'4
M4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HQ110 4444 %&*** #%&*** #%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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METMMRAE4R*I!;##(P,=#R"*N:;\5!JGAO5[^#P]>KJFDMBZTMW"NJ\_-DX(
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MW ? ,# <+SW5V?C'7C)-=5X\\-:7H%[8Z*E_&9?$OB 7UY+=JI$,08_*1G@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%9B%)R>0!U([UE-\&/ +,6.@X).<+>7 'X 28%=[10!P/_"E_ '_ $ F_P#
MZX_^.59O?A-X)U 6XN=$#?9X%MX@MU,F(UR0#M<9Y)Y.2<\FNUHH YV#P/X>
MMO$:>((=.5-42,1K.)9,!0@0#;NV_= &<5DW?P@\#7]]<WESHF^XN9&EE<7D
MZ[F8DDX#X&2>U=Q10!RVL_#GPKX@%FNIZ4LJ64(M[=8YI8ECC'10$8# Q5GP
MWX(\.^$?/_L/34M#/CS&\QY&;'0;G)./8<5T%%  *YSQ)X%\.>+KBWGUS3S=
M26ZE(B+B6/:"<G[C#T%='10!YR_P.\!M<"1=,N(UR"8UO)=K?7+$\_6KFD_"
M/P?HDUS-96,ZR3P26Y9KER41P58+SP2#C/6NZQ1B@#D?"OPW\.>#;^:]T>VF
M2YEB\DO+,SX3() !XY('Y"KNA^"]%\.ZOJ6JZ=;LEYJ+F2X=Y"_)8L0N?N@D
MYP/0>E=#BC% 'F>H_ KP;J$TLQ&H02RRF5WBN!R223PRD=3Z5L^#/AIH?@6Z
MNKG2Y+R66X18V:YD5MJ@YP JJ.3USGIVKL\48H !TKSWQ)\'O#_BCQ'=:Y>W
MNJ1W=P4W""9%5=JJHVY0D<*#UZYKT*C% 'G6G?!GPUIJW1CNM5EN)X'MQ<RW
M(,D*N,-L(4 '&1G!X)'0U0'P$\,J&"ZKKP#$E@+J/DGKG]WS7JF*,4 >9W?P
M.\,7=I8VQO-6BBLXO+18YT 8EW<NV4.7)<C/'  [57LO@5H%IJT-]+JVKW(A
M8M'').!M/\)W* V0<'@CD<UZIBC% 'F>D?!/0-)L=5MC?ZC<_P!HVK6LAE=<
M("58, %'S!D!!.?I77>$?"MEX-\/Q:18RS2Q([NTDQ!=V8Y)., =AP.WK6]B
MDQ0 IZ&O,?%'P?BU?7I=;T+7+G0KZYS]J, 8K+DY)^5E()(!/."1G&<FO3J,
M4 >5W7P<D_X1,Z'IWBB\MWNKDW.I7$T7F&]8J!A@&4A<Y."3G/.3@UA2? /5
MI+,6;^.)&MA&(A$;-BH0-N"X\W[H;G'3/->XT4 >17?P5N[OQ3;:K_PE]Y%!
M:>7%;)'#B:"",86-)-^ <9YV\DDD$DYZ5?AQ!!\0W\5V.J7-DLV&N;&W79'.
M^#RQ!&03AB".3DYYKN,48H \FTKX/ZOI_BJUUZ;QU?W%PI3[4QB99+A%96,9
M?S#\AV@8(/%=!X]\#:OXPDA6Q\4W.DV@@:&XMHT9DG#'G< Z@\<8(/!KN<44
M <'X/\!ZQX4\/ZGIH\67%S)/$([*1H/DL2 V&5&9@>6!(X!VBN6TOX&WEKK4
M%[?^+YKR$7D=[<1?9F!N)$)*LS-(V3DGD@G!/K7LN** .8\:^'-8\2Z=!::1
MXCFT0K)OEEAC+-(,<+D,I [GGFN<\ _#O6O W]HVZ>(H[FSEC;[+!]F*HLS!
M?WKKN)XV 8#<C/2O2J3% 'A%[\&/&FIR:A+>^*K*9]2,9O"8F'G%/N9  Z8X
MQBM*/X0:]%X.N],A\1PKJ-]J(O+RYV.?-"@%!NSNR'R^>Y/MS[-28H \OT3X
M8ZO<Z];ZKXV\1/K9LFWVEJ,B)'X^9@<#C X YQSGI75>*M(\1ZI?Z.VB:Z-,
MM8)BU\@CW-.N5P!QZ!QU'WJZ;%+B@!!2T44 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% #<9&*39[TX4M !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )17FOQF\3>(O"F@
M6%_H5Y;VD;7!BN':-7E)*DJ$# KCA]W&>%QQFL7P_P"+O'6A>-=&T'Q=+;:B
MNMQ+)']G11):\-UV*H/(^8<@ 9!X.0#V2BO"/%/B_P ?1^,?$5OIWB'3--T[
M3)XH@+GR47YXRZ*K2(2S$*Q(SUZ<4[3/B-XNL?AX-2U2=9]6U:_^QZ6;J&.W
M2%0 &D8X52-V0,]QR<9% 'NM&?>O%O"OBGXBOXWT?0]6N].OK2YC:YEN;94=
M6A!<<2)A<AEQ@#/3WK#U'XH_$".Y>>V;3DL;C59M/M-\(+%E8 =^@#*-Q[YH
M ^A:45XWX?\ &?CR_P##'C&YO#I:7FCRBWBED79'&Z,?/W8/(5,$<<GUY%-^
M$OQ.U[Q=XENM+UEK9T%H;B%HH2A!5E4CKT^;]* /9J*\)UOXN>-;2]U2;3M-
MT:72;;5WTJ"9HY&:63YBHXE&3M7). .15Z+XD>/(+'Q:VI:9HL5UH,,+%$CD
M*[W=>"?,(($>XX!!SCWH ]HHKP*Z^+/Q$MM)L]1&F^'9XKL*4CMTDDE3<,IO
MC$NY=P!QQCCZ9VO$OQ#\?6/C^Z\,Z'H>FW3QQ+-$K(\CNA4%F)$BC&XD8P#]
M>X!['17 ?#SQUJOB:^U72-?TA=.U;3!&950L P?=_"<[< *?O'(;(KOQTH *
M*\_\9_$*[TCQ!:>&O#>E+K&O3KYCP>9M6!.VX],D9/)&!@GJ,Y.D>/\ QS)X
MVM_#FL^$[>VFEMY+@B*?<=BJVT[@S* 7"KGMF@#U:BO%=(^,GBC4-*O+V/P;
M;7$5EYC7#IJ2Q;0B[FPC LVT$9VYZCUJ_=?&#5+;P-IGBI?#$4MK>W$L#*+_
M !Y14[4_@R2Q63H,#:.><4 >MT5YOH_Q+U"3Q?'X=\3>'#H=Q-9M=Q,+L3[E
M4$\A5X^5'/7.5QCFN7A^,_BG4/[/33?"4$C:I<S1:?+)<D+<*C<@*<8(#*"Q
M8#(/T ![A17E_A[Q]XL\3^!KO5M+\.6MSJL5^;1;87(C38%4LQ+$<@G&,U6\
M"_$3QEXPU2'_ (INT325G:&[NXY3^Z*KDC!;D\KT!X/UH ]9HKR7Q3\2O%FE
M>/'\,Z3X;M;R4QB6WS,6:5,$ESC 7H1@^G4Y%5M!^*_BF^\7R>'=0\,6R7J6
MTLHMX9R'+"+S$!8DJ WRC/\ M"@#V.BO(+3XM>++_7+C1+;P 7U*V ,]O_:0
M!C!Q@DE,8^9>_>NF\6_$(>']3M-$TK39-:\07 W?8()-OEIC.YVP<<=!CIR<
M#&0#N:*\P\/?%#6M7\47V@WW@^>RN[*U>>5([GS74A0RJ1M ^;( Y[BL[0/C
M;/J/C&R\/ZOX=_LIYYA;N[W3,\4A'R*4\L');:O/3//0T >P45Y]X^^(UUX/
MU>TT^PT0ZK/+:R7<JB9H_*C3JQ^0C& WTQ[BN?T+XU:CJ^O:+I\_A-[:'590
MD-P+LME=Q4NH* $ @YY[?2@#V&BO&A\:==NKO44TSP#?74%E,\<K&9P\6">)
M%$9"-P<C)QZGK79?#GQU)X]T6ZU&33!8B&Y-N%6?S0^$5LYVC'WAVH [.B@=
M** "BN=\:>)I?"/AN;6(]+EU%(&7S8XY FQ"<%R3G@''0'KGH"1YT_QWNX]/
M&H2>!M12Q."+IIF$1R<#Y_+QR>.M 'L]%>4Z_P#&A]#ALICX3U&2WN;6&8W#
MOLB#R('$:OM(<@'MW!XXK9A^(MZ_@:\\12^$=6BGMIC%]@9"'90 ?,R5!V '
MD[>,&@#O:*X'P=\3X_&FH+;V/AW5HK?:QDO953R$('3=GDY(&!D\YQ@'$GC#
MXFV?A#7;72)=&U.^N;F$31_9$5MWS,-H!.2WRDD ="* .ZHKSGPQ\7],\3ZO
M+IT>CZI:M%;/<N\R*0J( 22 21U&..I'K6,/CW8/9)?Q^%]::P$JI-=%5\N,
M<9^89!89'RDC.>HH ]?HID4B31)+$X>-U#*RG((/((IEW<QV=I/=3'$4,;2.
M<XPH&3U^E $U%>/+^T/X>$)>71M7C)7=&-L>&Y(Z[^!D5K_\+HT(>%(-?DT_
M44@FNI+18]BEMZ1[^H;&#P/J3V&: /2J*\VU#XT:%I2Z6+W2=:2;4;1+N*)8
M$+!7=E4$%P<DH2,#D$>N*AU;XZ^%M'U>]TVXL]6::TN'MY&CBCVED8J<9D!Q
MD'M0!Z?17+>"O'FE^.K>[GTRWO85M76-_M4:KDD9&"K$'\\]/45U!H 6BN-T
MGXG^%];UF[TNQNIGGM8Y99&,#!-L9 8@]^N?>J%A\9?!VH0WLT5W<K'96INI
MFD@*_(&5,#U)9U 'O0!Z#17FT7QS\$SSQPQW%\SR,$0"S<DDG P!R?PK>_X6
M'X>/C,>%%N96U7?Y9586*!MN_&[&.E '5T5PUU\8/ =G=S6LVO8EAD:-PMI.
MXW*<'#*A!Z=02*A_X73\/O\ H/-Z?\>-Q_\ &Z ._HKC;GXI^"[33;+4)];5
M;:]#M;D6\I9PK%6.P)N W*1D@=*+KXI^#+.^BLI=9_TB5(GC2.UF?<)%5H^5
M0CD,IQUY% '9445CZ]XIT7PRD#ZUJ$5FDY*Q&3/S$<GH#ZB@#8HKGM$\<>&O
M$=VUII&LVMW<*NXQ(Q#8]0"!D?3I4%[\0_".G:G)IMYKUG#>1.(WC+'Y6/8D
M# Z\\\=Z .HHK'UWQ/HWAJ"*;6=0ALXYG*1F0GYB!DX ![50N_B#X3L+2SNK
MK7;2."]C,ENVXGS%!P2 !D#/'/<'TH Z>BJUA?VNJ6$-[93+-:SH)(I4/#J>
MA%2S31V\,DTTBQQ1J7=W8!54<DDGH!0!)17-:?X_\*:IJ0T^QU^PGNV;:D:R
M_?/HIZ-^&:GO?&?AG3=1FT_4->TZTNX0IDAGN51EW#(ZD<XYQZ$>HH WJ*P;
M+QIX9U'48-/L->TZ[N[@L(XK>X61FPI8\*3C@$\UO4 %%4M2U73]'M?M6I7M
MO9V^X*9;B41KD]!D]ZIV/BOP]JC3+I^N:==F&,RRB"Z1]B#JS8/ 'J: -FBN
M;'C_ ,'$?\C5HW_@='_C4\_C+PS;003S^(-+BBG7?$[W:*)%R1E<GD9!&?8T
M ;M%9EIX@T>_TZ?4;/5;*>R@#&6XBG5HXP!DEF!P,#DUG#Q_X.(_Y&K1O_ Z
M/_&@#I**R_\ A)-$%C!?'6-/%G/D0W!ND$<F.NULX..^*2#Q+H=W<);VNLZ=
M//(<)%%=1LS'T !R: -6BJ5CJNGZI&\FGWMM>(APS6\RR 'T.TG%5&\5^'48
MJVO:6I!P0;R,8/\ WU0!L450LM9TS4VD&GZA:79C +BWG63;GIG!..E13^)=
M"M)WM[G6=.@GC.'BENHU93Z$$Y% &I166?$>B"T%W_;&G_9C)Y0F^U)L+XSM
MW9QG'./2IK'6-,U-G&GZA:79CQO^SSK)MSG&<$XZ&@"]1110 444A[D]* %H
MIJLKJ&1@RD9!!R"*=0 44E% "T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% ""EI!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !2&EHH ^?_C7XFM]2\5:;X9N4OFTVQE6:^2V
MB422.RC;Y9;.2$8^Q+=^U>TEL_A'\0I+W5[;5=4L[S3U?3YY45[F$$C*L&(P
M0,J<8[#&#Q]#XQT_G2!<=* /DN?7_#^L:[-X@UV#5IM2>]DN'MXH(S!-& !#
M&3O!0#: Q 8D=\G-=AJOCK^U]$T#3_'6BW-]IDMK]JN[ZVB:,B9]WDF/&T9"
M'#<X.\\?+S]"\T8^OYT >,_!RP US5K_ $2'5K?PL\"PP1:E*,O/D%F5%XQC
MO[]>H'-^,OB!HOB+XD^&[DQ7[Z/HLS.PBML2R3!P0%5CRI,<7! ."W0]/HG:
M#V_6EQ_G- 'AGQI\?&6TD\(:6EXMV[QF^_=;=R,@=8AW).Y<XQTQSDBN1TW5
MI_!7Q9TF&^N1>6^CQC3)/L,+1J4*L"-N,N1)(6)YR1D=L?4.,48XQ_6@#YV^
M)GC;0M7\3:3IT$5Q'I^F:D\VHR16P5WD5@"4YPW1N2/2NP^,7B:QL/ LVFQV
MTT&I:Y$DJ+Y ! #QEO-(Z';E>_3Z5ZSS2;<?_KH ^9_ASK]IX<\56FF^')7N
MY=9OXHIY+^T\HPVRDY5=K'+G<<GH"@XYXNZ!\2] TKXF>*?$FJI?NUR!;V0B
M7>5A#<A@6&,[(\=AS7T48U+ARH+#HW<4PVT#9S#&<KMY4=/3Z>U 'G7PJL[[
M4;G7_&NI6<EG+KMPC6\#GE;=%^0]!USC) R%!'!R?2Q2 8I: /%)_$EGX ^,
MGB34/$EM>16FJ1PK9WZQ,Z *BEE!ZGD ?+G! SQS6_#\7M$N-)U;76MWM-.M
M9OL=A?3QLWVV4QL^T*HRH^4=3R".0>!Z1)#'*,21JXSG##(I&MX714:&-D7H
MI4$#Z"@#Y#\,7_A[2;G3_$%YJS3ZA:>;<MIC0/\ O;D$^5M<#:%/RLQ/(VXP
M0>.I^)GC>P\1Z1X4TQ9ET[]VMSJ%O%$X2V#K&8R%X#@([,,9]B,U](?8K4];
M6#_OV*4V=L3DVT)/3[@H \&^'OD:5\4M0M?%MU+J&L7%D6L[VX<NCP%/,8D,
M-R90=#C W+CGE$\6^"I?BWX672)(#H5C:-%:K#;R*([J5WX"D#U4YQC)Y/''
MOC01,X=HD+@8#$<X^OXTU;.V5@RV\0(Y!" $4 <+XT\;>'_AYI%QIL,L=IJ<
MUM-<6-O'"67S6+$,W8 R$GGT-<]\"]?T*'PN/#]O>!]219;ZY0PE%1-RKRYX
M; *<^GTKUU[:&0@R0QN0, LH-0VNF6-DTS6EC;6[3',IAB5#(>>6P.>IZ^IH
M ^8/%VO6OB_XA:U<Z5KTUF+B..QLP1)LO5^5&C)4_*C'+888/&0,YKW9D\+_
M  O\,6%SJ+11"VACL!>^1F:7OMR,M@D%MN<#'M741Z5I\,TDT5A:I+(07=85
M#,1P,G'.*?>6%IJ$'D7MI!<Q9W>7/&'7/K@]Z /#_A!XGTJ^\>^(9[J[;^U]
M;N6-I#Y3$>4N^0_-CCY<#!Q]P>M7[#Q7H_A+XQ^,Y_$[?8I[P6_V*=K=G!B5
M<$ J"<,!&>."4YP0!7K5IH>DZ?-YUEI=E;2D;?,@@5&QZ9 SC@4Z_P!'TW58
MQ'J&G6EV@! 6XA60 'KU% 'FVM?%OPW8^'K_ %W2;=Q?WA-O:RR6XC:[* @2
M9/S-&A)Y8=<J!G->&K)J&@V>@ZI/#:2B:]_M2"X28-<R[64$,<DJNY#U'WMW
M7%?6MQX;T.\6U6YT73IEM%V6ZR6R,(5]$!'RC@<#TJ.]\*>'=2,)OM!TRZ,,
M8BB\ZT1_+0=%7(X ]!0!YQ\2O%_A4>&)]3L;B"77-4TOR;%S&Y<VTC[7QD83
M@R=<$E<<XQ5[PB_@K3OA_H7B>YDMI5T:V%JU_P"5(QAD=@' 7&<EVQG' 8XP
M#7=7WA7P_J9A-_H6FW7D1B*+S[5'\M!T5<C@>U/;PYHK:*^C'2;(:6XP;-8%
M6+[V[[H&/O<_7F@#Y9T^[L9M2CUC4O$:Q02:E)J-WIL:3&8D,2NUMA1F8%AR
MP !Y/)Q]%^"-4L%^'%EJXTJ'0K+R9+AK9!A(T#-\XX&0P&_..C#K3W^&7@E[
M9+<^&-."*<@K%ASUZL/F/7N?Y4_Q7X.3Q#X6A\.V=W_9=@'B65((@=T"?\LE
MY&W.%YYZ=#F@#0\-^)=/\5:;_:.E^>UF6*)++ T0<CKMW 9 /&1QG(Z@ULU3
MTW3+/2-.M[#3[9+>UMT"1Q)T4?S)[DGDDDFKE 'EGQT\0V^F^")-)6Z"W^HL
MBK"I&XQ!LN3W"\8SW)QZXR?A5X:GUBQU)]=U&VUK0VM[:RM8 ^^(",!MNP<(
M5^08QDG)/J?4-9\)^'_$+A]7T:RO)0@02RP@R*H.0 _W@,D\ ]SZFI]&T'2_
M#UC]BTBRBL[;>9#'%D L>I/J>!^5 'F'Q*\1^'-9UOP?I UC3)K)=4%Q>NMX
MICA2,8VR;20N=Q R1T/N1U?Q"\6:=IOP]U"[MM4LC)>VCK8D2J_GEL+F, _/
MC<"2,@=3Q4VH?"OP/J?E^?X;LX_+SC[+NM\YQ][RRN[IWSCG'4U?U+P-X9UB
M&RAO]%M9X[*+R;92I'E(,848/3@4 >;>&O'6B^ /A/H<-O/::OJDK+NL+.Y3
MS4:5FD(<9++M!"<C[P4<9R,OXK:NU[\1[./0M8TV"]T_39E:YEO(XQ'(S.C1
MAV.$F Z9((W9XQ7J$'PP\%6\\<\7ARR62)PZ'!.&!R#R>:@N?A+X&NP?.T"(
ML7+EUGE5R3G.6# GKZT <'H.O:7:^"?$MQ)-]LUW3M):"YUY\3+/++NV0K+U
M<*VQ<\@X'8 U6L=>TK0?V=8M+CN(9M4U.WGMX;2(;I9))9&'*C)RJL.3UP!W
M KTN/X7^#HM#GT9-%46,\RSRI]HE+,ZC ._=NX&>,XY/J:71?ACX.\/:I'J>
MF:*D5Y&#LE>>67;GN [$ ^_6@#=T"TEL/#NF6<QD:6WM(HG,K;F+*@!W'N<C
MDT_6-.MM6T:]TZ]S]ENH'AE*MM(5@02#VXJZ!BJVHZ?;:KIUSI][%YMK<Q-%
M-'N*[D88(R""./2@#Q7P[;:3<_'H6<%Y&=/T+2EM=.43+\_[M5V@_P#+3_72
MGUS[#%5_B=HUA;6?A3X:Z%+'$LEV\H$\H81EB0N\@%N3*V..GKV]%LOA%X&T
MZ^MKRUT+;/;2++$6NYW"LIR#M9R#R.XJUJOPT\(:WKDFLZEHZW-_*R-)(]Q+
MM<J JY0-M(PH&,8/>@#S>Q?5=6^.>F1^)M0T>>?2;*2?S-,DVQIC=\K[SG<,
MY(Z@8/3-<G_I]WXE\0WVA:E:VNE:CKDL-W>)<H)5MPS,[[CQY)$A;@')"]=M
M>Q_\*7\ #IH)'7@7UP.O7_EI2?\ "E?A_G/]@'/K]NN/_CE %SX81>&U\()<
M>%;*ZM=-N)G?;=$[W<80MR3Q\N.#C@UV1JAHNBZ?X>TF#2]+M_L]E!N\N/>S
MXW,6/+$D\DGD]ZLWMI%?V-Q9S@M#<1-%( <$JP(//T- 'R^HGM==UOXC:;OG
MM+'Q&ZF-1Q+#(SEB2.@(95YX^?\  ^H?!738KG0-;UZXLXXEUW4)62+Y3&T
M) 4+V =I5P>P';!.WI/PB\*Z-::K;6]K-(FI1>1*TTNYDCR#L0XX&0#GDY Y
MX&)M8^%OAW6/"NF^''%W;:?I\ADA6"4;BQW9W%@V<EB?K0!@_"&UL-3@\0^(
MA!"7O-9F:W4Q+^YC7&P+P,?>_0=\UP?CZSFU;XB^)M?T:4K-X:AM;ACY&]7E
M1ER"0>-H!/(.=A'09'JGA3X2^'_!VL_VKI\VH270C:)3/.-JJ>O"JN?QR._4
M"J^@?!KPUX?U)KZ*74;J1HI(F2ZG5D8.I5B0JKN.&8<Y'S$XS@@ \^\.Z-;?
M%?6/&UW!#)IL%W!:103M I\AP59P%! ))CZYSAN>N*U-'\$Z7KGQ"\:Z7;B*
M"PT_2X-*A MP61I(Q^]YQ\RF-^1][=U'?N],^&.BZ/X/O_#5E/J$=M?ONGN%
MG G/W>-X4#&%QC&,%L]35/P]\'M!\-:_;ZQ9WNK2W$!+!9[A61B5*_, @)X8
M]Z //?'VER0>+? G@_1[6WU6YTJU!%M. JS\AF$F?EP5A)(]SUXK6\//?^)/
MCU)-KVF6FG:AHVG%G@A(E#L=NUB_J%F'/^R!727WP2\-:EK5SJMW>:O)/<3/
M,Z_:5"@L2<#"9 &>.>U:'A7X5:)X1ULZO87FJ371B,)%S<!E(..H55W=!UR.
M^,@$ '==J\H^+<<&J^*? >AR6T<XNM3\V7,F/W2E ZX]&#$Y_P!C ZUZOVK@
M_%/PHT/Q=KG]KZA=ZI%=>6L8^SW("JHZ !E;;U)XQR2>IH Y;Q;8VG_"ZO"D
M.DPVUM-90M=Z@\(6,)"K9^?'L&X/]X=C7E?CSQ%H_B[Q)KNI1!;=%B1--6*
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MFX4 .HI <TM !129I: "BDS2T %%)FEH **3-+0 44F:,T +129I: "DI:*
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MCCU"YSUQK?#_ ,)>+O"_Q(N+Z30[HZ3=QM;RW%YJ4,TBKD$2%EP6.5X&T<,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!IY84ZF]",TZ@ HHHH **** "BBB@ HHHH
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M/FVDXYX(Z'IA?!3PC:ZS:Q^*KN^U,S6M_(MM ;H&)T"+@N,9)#,W<#Y1QCJ
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M)[BYTNSGNX?(NI(4>:+_ )YN5!9?P.10!;I,U%=R316<TEM#Y\ZHQCBW!=[
M'"Y/3)P,UY1_PM#QM<:U>Z':> 8VU6S"-/"-25Q$& (R0 IR".C<9]L4 >N9
MHS7FWC#XFZEX<\0OI%AX>CU*6WTS^T;LB\\OR%!;?U7D  '/4[AQ5+0/BWJN
MI:[I5GJ?A;^SK/4;>2[CN_M1DS"B,Q<*$&?N].O(XZ4 >K9I<UX_??&+7X=&
MD\06W@:4^'\YBOKB\";D+[%8J%)&3CCGKUQS7J6C7[ZIHEAJ$ENUL]U;1SM
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MM?#2-K.HP2P7$,%^B"R# J&#,1O8 C@'KGGCGO< =J,#T% 'SE:>!_&.E:3
M-+\ FSUZ*%X?[8CUB/=AMP9EC$@"OM;;NR<=0 <8]^T&WN;3P_IEM>S23W<-
MI%'-+(V6=P@#,3DY)()ZGZFM#%&,4 <QX_\ "G_"9^$;K2%E6&<D2V\KYVK(
MIR-V.QY!ZXSG!Q7GZ6/Q3UCPO8>$&TFST*UCM1:W.I-=)(SQJ H"JC$J2HP>
MN>>5Z5[/28 Z 4 >+^-/#/B:5]#\.:%X/2[\,Z'<PSKOOX1]MV@95@Y!3[TB
MG(.<Y]J[;X>>&K;0M*N+A?#?]@WEY)F>U-]]JX7(7YN@')X'3-=G@>E)@>E
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M*"/^PQ&(?NM'<RAB,Y(8[LMGID\@< C HD^#7@.:=YI-#&6"@*ES+&JA5"C
M5AZ9).2222>: ///">OZ98:A8ZOXSDO+_P 3K;7%Y;RRRYCLH5#8C8!N&;#8
M!4D%U&,XKS^+0]3_ +&.I1ZAML=1TV6YU"X*A4\U7=EMB1_&[1QD#C.\8!Q@
M^^_\*3\!?O NCRJ'4 !;V?Y/<?/UZ=<C@5+)\'O!TFC0:4;.Y%I#.]R +I\F
M1U522<_W44?A[F@!GP8TU-.^&6G,KH[7;273LA/5F( /N H!]Q^)]!K+\/\
MA_3_  QH\.E:7"8K2'<55F+$EB6))/)))-:E !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% #6^^M.IK?>%.H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKF;CX
MA>#[6ZEMI_$>G13Q.8Y(WF *L#@@_0UI7'B/1+31UU>?5;---;&V[\Y3$V3@
M88'!Y]* -3-&:YY_'7A6/38M1;7[ 6<LK11S&889QR5'N./S'K2WGCCPOI\-
MK+=Z]80I=Q^= 7F \Q/[P]O?V/I0!T&:,UGQ:YI,^C#6(]2M&TPKO^U^<HB
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M "BC-&: "BC-&: "BC-&: "BC-&: "BC-% !1110 449HS0 449HS0 4444
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M2G.,@=!G '&<,QR6S7:_#+P5XB\'6US::QK,5W9;56UM(-S)#R69@6 QDL>
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M@M[J/8QC(#+SD$9[@@'\*\SC\&_%6S@AT.U\862Z/&$A2Z6';/'$N ,+LSD
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M8)7U(KG;VWU3_A#9M=N]11[;7+[$R/$V^::,LQ?>5V[07;HW)R,?*< 'T/\
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M110 4444 %%%% !1110 4444 %%%% !1110 UOO"G4UOOK3J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,4444 %&***
M"C%%% !BC%%% !28I:* #%%%% !1BBB@ HHHH ,48HHH ,48HHH ,48HHH ,
M48HHH *,444 &*,444 &*,4&D% "T8HHH **** "BBB@ Q1BBB@ Q1110 44
M44 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 )BC%+10
M'D4F*6B@!,?6@C/K2T4 )CZT8XI:* $Q]:;Y:%@V!N' ..13Z* (A;0A-@B3
M83DKM&,_2E-O$R!&C0J.BE1@?A4E% $7V:#(/E)D8P=HR,=*D"@4M% "8^M&
M/K2T4 )M&,<_G7.:7X1M].\7:OXBDNI[JZU!8XXQ-@BVC7JB>Q//X?4GI**
M 4444 1&UMV8LT$9)Y)*#FAK>%E56B1@O0%00/I4M% $?V>([,QJ=GW<J/E^
MGI4=U8VE]"8;NVAN(CU29 ZGG/0_058HH 9'#'#$L4:*D:C"JHP /8#I45O8
MVEHTK6UM#"TSEY3&@4NQZLV.I]S5BB@ I".*6B@#F?"G@^'PS+J5T]W)?:CJ
M=PT]U>2J%9^?E4 <!0">/<]L =-1BB@"*XMX;JWEM[B))8)4,<D<BAE=2,$$
M'J".U9VG>&- T>Y:YTS1-.LIV4H9;:U2-BI.2,J <<#\JUJ,4 9>H^'-#UB4
M2ZGHVGWTBC >YM4D('IE@:CB\*^'H+">PAT+3([*X(::W2TC$<I!R"RXPV#C
M&:V,48H PD\%^%8XGB3PUHZQO]Y5L8@&^HVU*?"OAUK>&W.@Z688!B*,VD>V
M,;MWRC''S$GCN<UL8HQ0!D6OA;P]8R+)::%IENZOYBM%:1J0_P#>! X/ Y]J
MK-X%\(.Q9O"VB%B<DG3XLD_]\UT&*,4 1Q0QPQK'$BQQJH5408"@= !VJ2BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!O4@FG4T\,*
M=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(
M: .%NOC%X%M&=9-;W.C%&6.UF)!'!_A]JG'Q4\(GP\==_M&3^SQ=_8_,^S2;
MC+LW[=NW/W><XQ7"#P/867Q3\.^'((+>XCMH+G5[Z>:W!>=9)&55?)P0,(H'
M0=>]97Q(\-0>#O 6A^#=.#WMYJ.J/<K*T>'D<#: !T!_>1KU[=.> #TVX^+/
M@VUTJRU*74Y!;7K2K 1;2DDQD!LC;D8+#KUIE_\ %WP7ILD,=SJKAY8([A0E
MM(^$D4.N<+P2I!P>>17DU^M[K?B/P/X)U+P@NE_87C.QY1.\UMD;RVT 8/EN
M6]3SQWL?$&.YN?BMJ$F@>&(=5.G6,-O/!]A$J)(X^5F3'SD!E /H!V6@#V+P
MS\0_#/B[4);'1K]Y[F.(S-&]O)&=@(!.64 \L/SKJ:\G^$6B:3:ZQKM_;3XU
M1=EMJ%G%$$M[:8_,ZQ$=5#94 <#8<9!4UZQ0!S_B+QKX>\*36\6MZDEI)<*6
MB4QNY8 @$_*#CJ.M9$/Q;\#7$\<,6OQF21PB@P2@$DX')3 KDOC;<+=ZQX3T
MB'1_[4NC<M>-!&A,LD28W1+@$X<;B?\ KF#BHO!'@;_A)7LO$FMZ'%X?NM/U
M%I;6TL[);;S8QL9?,4KDA6! /!//M0!WS_$OP9%=7%M+XBL(YK=S'(KN5 8=
M0"1AOJ,U?U'Q?X>T>.UDU'6+.UCND\R!I90OF+QR/;D5YAH?A?0_$7QI\3F7
M2;!M-TJ*.%;9+;$<DK$$N_8L"''(Y_"K/QM6TN?^$5T*+2IKR:2\,PBLXP9O
ML\:XDCC &1N5L\<?NQZ"@#M_^%E^"O\ H9],_P"_XH_X67X*_P"AGTS_ +_B
MO,='^&4'COPY+?7>C'PM=07-PEI;PP&/S(B$*&7>-S8;>,X&1G  Q533_AQH
M:?%'2_"DD(O([#2WN=2F.]/M$K$[0<'Y0-Z8P1QP2: /8I/'/A>/3(=2DUZP
M2RFD:**<S *[#J!ZXJ.;X@^$K=86F\1::BSQB6(F<8="2,C\5(_ UXO\1/#*
M^%?"/@OPK%&=1OFNIIG,2G?,Q*[D0=<$N!Q_=!QFKFGQV7C[XP:=:ZAX2_L5
M-,LM]Q92';Y@3'E!EVK\HW)@8Y''08H ^@5(90P(((R"#D55U#5-/TBV^TZE
M?VME;[@OFW,RQKD]!EB!G@U:'05Y9\?07^']M!' 9KB;48HX0N2P?:^-H'4G
M[N/]J@#O]/\ $N@ZQ<-;Z9K>FWLZKO,=M=I(P4$ G"DG'(Y]ZGGU?3+:9H9]
M1M(I4QN22=589&1D$^E>3:YX1T+PO\2O K>'K8V5Y-<NDL$+L=T2I\S'))Z%
M@3GD9ZXKS/XF7VA:]XVU.72$LK>W@1G:X4'-[-D;L<X)R3CIT8]Z /JJ>^M+
M6%9KBZ@AB8X5Y) H)QG@D^E0SZSI5K L]QJ=G#"ZEUDDG55*CJ02<8'K7G4.
MCV_Q!^!6GPS,;J\2QWV\I/S+=1*5_'D%3Z@GV-<'X#\,W7Q171WU>VB@\-Z!
M;BT1(24:YDX)&>3S\I8@C'\."20 ?1D$\5S;Q7%O*DL,J!XY(V#*ZD9!!'!!
M'>GDCUJ&SM(+"QM[.VC$=O;QK%$@).U5& .>>@KCOBAK6J:3X<L[;194@U+5
MK^'38)WZ1-)N^;/;IUP<9Z4 =1)KFD0ZHFERZK8IJ+XV6C7""5L\C"9R?RIV
MHZOIFD1++J>HVEE&W >YG6,'IW8CU'YUY%XR^%?@CPU\.]2O)TE_M&&W8QWT
MUW('FN.H^7.TECQC;TS]:YSXFQ(_A?X<SZS#/+?S6H6Y,)Q(\06(LHR,!_G'
M4'GVH ]XL_$V@:@0++7--N27"#R;N-\L>@X/7D<5JBO O W@73_%NI:)XMTC
M1AH6FV5\[/#)=2W#70C*M&Z%_P#;#*W;Y>,GI[Z#0!#-=VUM)%'/<PQ/,VV-
M7<*7/' !ZGD?G27-[:6:![JZA@5C@&60*"?3FO /CU^_\;:8+ 9O[/3VN9&W
M#Y$5V93@GJ,,>G((Z]L75M4O_BMX_P##8N+&>/2;B1;>!#_&BD-</P<;L9R5
MZ!5'4&@#Z2?6=+C8*^I6:E@& :=1D$9!Z]P15F>X@M86FN)HX8EQEY'"J,].
M37R)XXL?#'_"3ZC%X3%M!IMC$IWM<O)]IDW*K"(MDG!;UP0CMG&!7N/BG08_
M'/P6L;M_.EU"'38[^W8L69I1$&8$9PQ89'.>3F@#T674[""&.:6^MHXI1F-W
MF4*X]B3S5E&5T#HP96&00<@BOG/PMHM]\7H=#M+VTCL/#WAVV%LTT62]RQ"Y
M4$\ D(I./NY[[ACZ$TZQM]*TVUTZT0I;VL*01*220BJ%49/7@"@"U1VHZTA-
M !0.M>%?'>TL=8\0^'=*MHHVUJX)3SY+C:D4)) #*> "Q+;N#A#U[='\!M12
MX\"RZ>)-YT^[DC!5,*58[P5/4@EF////TH ]3I#UI<UY#\;[&'6K[P=HK3O'
M)>ZB8P"04VG:I8CN1N&/JWK0!Z[2]J\2N?#]M\.OBEX1M_#]]=1VNJF2WN;2
M:7S%" KC&>F2?P*?6O;,B@!:0TM!H 3BBO"?&_A:ZA^+'AJ:;6-0U&35=4$L
M=MY?R6T$4@<@?,>%#9^Z!@,37I'Q.U75-&^'VK7NCJWVM(@-Z@[HD) :08/!
M523GMU[4 =*-1L6NS:+>6YN02#")5W\#/W<YZ5.\B1QM([JJ*"S,QP !U)-?
M+=POA33Y?!DGA":>[\3?:H9;V4&20LY()4@_+G<2,*.@.?4^A?$&[T[5OB5:
M>'_%>H+8>&+.Q_M H7,8NY<[0I;.3@9P%YX..3P >OVUW;7MLES:W$4\$@RD
ML3AE8>H(X-2Y Y)Q7CWP*G1G\56NG-.WA^*]1M/,PY^;?NYQUVK$2.V?4G/F
MWAV#1M5UB#4O&&@^(&N-2U8&*Z@&RW)D;Y8R6 _CW?=.<#V((!]5T4@]Z6@
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MK4$U"X$'^BVARAZMNST4*"=W;!H ]@HKYV\2?%OQ=I/BW7=,CU+3X8;*XE6
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M68;HYHF#*PS@X/U!% %NBD-8\_BOP[:WGV.YU_2X;K=M\B6\C5\YQC:6SG-
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MI86<?E0VBLKH@)RQ4D9!8Y))SS[  .UKX,6^K>+X]=BUZ]LE21&6"WB16B"
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M>(U&$ZA\'X;1Y9M1$'B1M/T.Y?,8DA*C# '@@X8#=]W.,C;BNYM_A=XW9/[
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M\8GQ0F\<>*OM6@6OA"Z_LJ&\5UN(Y?\ CZ1,C##(&TDAO; [C-=_IFO^*9_
M]WJE[X:%MK,0D\C3A+N\W&-I]1DYX]O<4 >(M'X_;6];TF#Q3KEQ=:3I\=W(
MD,TCEY"(BT/#\,/,89&<^6>.>.M\4Z_K]G+X7\&:EXD.@2RZ7%=7VKN29/.
M<&-F5@,97EL\G'/8V_AO'XSMO'^KWNJ^&);6VUJ4SW5S-)_J @?8B\_-RP'3
M./I4.N7GC*[\0:Q!K'P[A\1:4EPXTT2(B^0H. RMAB0P56(X.>X'% &W\*4\
M2?VOK2ZCX@EUO180B65ZT@D2X8Y+,C MTQ@@L<$UZE7G?PB\(:CX4T34'U.
M6<U_=&9+!)O,6V0# &<G+>^3P%R<YKT,T >3?&GQ'XG\,'1[S0M6-K%*[Q-
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M9=#=-#. V'51G"EOG7(X*\X+"M_0]3\2_#.]UG0X/!E_J1O]0>YL98V^1E8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,'G&\D_=(X!YXK@?&UW;WVA_#WPQ8:KI9DMXD>:Y>[C=()(HE 5R#@#[W?G
MQ5KP+J^DZ?J\+^*R=6\100W&H-J7VM;B.QAZ"(N'*DD@L!T4S #!8T =/'\>
M]!E,HCT#Q$[0@F4):QDQXZ[L2<8P>M;VH?%+0[+P=9^*(H;V]TZYD$1^RQ*6
M@;!R)-S +@C'7J1C((KY]T/5?%&C^%=?UO1[F$6=](MO?_,&N(\[MKXZJ"9&
M ?U/M7I=SJG@[PO\%!H%KJ%EK$U_;E8X58%I)Y?F#LO6,(<$9P1L ^]0!UFH
M_&3PSILFGQ2IJ$D]_:07<44$ =E6491& ;[^,<#/4>M>@HV]5;GD9Y&/T->
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MSGT?Z4 >U#Q)H9U-=,&M:<;]L!;7[4GFG(W#"9SR#GITJE_PG?A#_H:]#_\
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M6=5?45NKLM:S-=BX#Q@8WJP9@-QS\O;'->C#I0 A..II-W.,UY/J5WXC\?\
MC[5] TC7+C1-'T4*);JS&7FG(^Z6# C'SC:#CY>><8Q[J?QA\+;W5M4U37;G
M6=,-N+?3EO)BQN;E\%<1[B5"8?<<C(QCKP >XYYQ2BO&]:T#XDZ1H-_XIE\=
MD7D%M]JFT];4>2FP;F13DKP,C.WYL#)[C,\:^*/$[W?@>XL/$S::GB*S@\V!
M$39;,WEYD)/)!\T^F-AY] #W:C/O7CW@O5?$MWXT\1>&1XN_MFWATYBFIK:#
M;:W1(51CH<98XR0=G;!%>?6OB+Q+/X=U/Q3)\1KF&6QNA!;6C'/VLX!4^7D
M*1D\J1\K9Z&@#ZC'(HK-\.WMQJ7AC2;Z[0QW-S9PS3(1C:[("PQVY)K1/0T
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M.CW,,C)(A7N%+DGD8QCOUJG<?$/Q[/XUU#PQIOAK2S>6UNTJQ2W1)"\;7+Y
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!!2T@I: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:* "D-+2&
M@#R[4M0\4>.?&&JZ#X>U<Z#I>C[8KJ]$'F2S3G)VKR/E '8@^N<@"EI6G>/?
M#NH^*FU?Q%>7.F6>DR-:7\D2L&EVAPZQDGE0K@@G'3UJKITGC'X::UK-G#X6
MFU_2[^\DO+>XLSM8%B,[R%8],#!'4'!(JUXFU_Q[=^!KJSNO"4OV[6!-%''8
M!G^QP8 _>D9W.V6X&!CG@Y% '&6WC7QQ?Z-:2:?XY:]UV["M'HMOI<;R;2S
MDR!-JX W<]CDXXSTFL:IX_\ ^%D:1X4M/%1M'O-/AGE9[2%A"PC82]%.\DQL
MW4#+8X S7)^%-,\4^'M9CET[PEK>GFY-K!<715I/+B5D,Y52H^^5SC/ R!UX
MLIX6U3XA?$J]O_$'A?5[#3]40B*;RS']D*1J(W;<,-PF"I[OQT% &]!\0?%%
MAX6\:VMUJ2:GJ&C/$EOJEG"A4F1MO*[0IVD>AY)ZXS6 ?$OQ/>]U?37\3_Z7
MINF?VA/#':1%@,(3'Q'D.!)SZ$'ZUU/PX;6/AYX7\36>H^&=3N);2[\VW:V@
M9OMA8",*F ?E&P-NYP'Z>M7X87VN?\++UN^U'PGJ=L-;<R"XFA>-+1%WL%)9
M0&SE%SP<C..30!8UZ?Q[!\'-'UJ+Q L$L-J;C4&(Q-*KNIA ;;U"L >F>Y-;
MWPGL?&+6@UKQ%KIOK#4+5)+6V=BSH2<ACE1CY3V)!S["L#XS^--1^SZAX/M-
M!O=DZ1%M0*L4=<AR$ 7D<!2<]=PQP#73V/CJ=/A1=:^OAV_LY+)!;V]G(,M+
M]U(W! 7*989( ^ZV,X&0#R?2_$7C?6K61G\>P:9#+J'V>$7D^QY)#GA=B,P0
M C.<+DBNDL?$7Q.7X:7^O7%^;66PNB7_ +0LE222$(H(4;.SYZCGGGC!YKX3
M^$K;7?%-@;S2]2B;30US<7$@!AG8./+4JRC;WZ$[MO0<D>D?&'QE#;:)J7A6
M/2M3GOKRU4I-'!^X4,W=LYR IZ CMGK@ M^"]2\91Z#)XK\6:Q:3Z*=,-[';
MP6X$H&T/N8A0.%!X!.<^U8%IJWQ@\3Z9_;^EG3-/L)U,EM:.@WL@'!&Y6)W=
MB2,]0 "*VYW?Q]\%K_3O#^GW]DZ0+:6\5[&L+2^5L.%P2,$ J"<#.1P*R++X
MMW<'AZVT>P\#ZJGB"&)8([,6I%NI4 >S@;1G&T8Z9Q\U !/XI^(%K\(_^$@N
M[FUL+]+AVE:^M_+E,60J(D>W&YFS]X#CZYK2^#?CC6O&$.L0:W()9[-H7258
MUC^20-Q@ ?W,Y_VJXWQYK6J>/_$ND>$9K>]T^V21(KUH[-I5%X?E8CYEW1(3
M@-D<%F^;Y:9\.-5OM-^+UV62_P!3MM13[,]XNF?9\D;=LA0<(@*E?H02!T !
M5_X67\1;R.QO[74;6&SU;4'L[%9+9 <AE )RI^4;PN<DY5O3G=T_XA^/+7P;
MXJU&^:QFN](O8;;=/#L"Y8K( J@;CDQXR1PQ/8 Y>M>/K'5/'GA?5;3P[JUO
MH^C^;)Y26*B9Y),DX4-MQD(>H/+'TST?QUU]SHT7AFRLKUI[F2.ZN'2UW1F(
M;L+NZ[]ZH>.PZ]B 8U]\3?B+8Z+:ZEYGARX^TB(BTM4:2YB$J%XS)&&RH91Q
M]1ZU[Q8O/)86SW*[+AHE,JXQAB!D?G7S5X2U&3P_X@AMO!=EJSW6IW45O+/J
M]@%\B -]T;&(.<Y9CMP$&!R<?3B]!0!S?CCQE9>"= ?4KI3-,Q\NVM5.&GD/
M0#T ZDX. .YP#P.I>+/BMX<T@>(=9TG1'TZ)E:YLX-WG(A.#R&8#MSEL9&01
MFMOXNQ7EO:^']=MM/>_BTC4ENKBWC4EB@4\\ X QR3TKG=4\67_Q@LX_#WA;
M2]0LM*N9 -1U2[0*J1J5+(I4D%CE>,Y.1Q@D@ T_B3XX\5^'/%.BZ9H*Z=(F
MJHJ0QW$3%_-+A<$[@ #N3]:P-.^)/Q!;Q;H^D7,.BW*WMUY3?8E\WY4;$OS+
M(0"JY)ST&#T(KCOBEXMTCQ-XZDBG%]'IVF6\MDA3;O:9=V'V,0 N_:"."57L
M< >[?#7PM;>%O!EE;1>8TLX%W,TT>QP\BKD;>=N %7&?X: .QKD_B-K6M>'O
M!\^JZ(;$2VS!YS>!B/*P>% (RY;8!GCDUU9X%?/7Q.\:S^./$T'@30YA#;&[
M%M/),2BSS[L ' +!%8>G)YQP#0!V_P )OB-JGCIM4@U6WMHI;-8F5[92JL&W
M Y!)YROTY_.IH'Q>N[C7/$EEK]A:V46BVTTKFW9G+/%((W&X]<EE P*\V\)>
M/5\%^/-:O-6FAN_,M3;,UFC1Q^9&%$8"%5( VE.5&.3SWPM,T32KGPM'XCNK
M\)%:7,D6HVS"13<.1OACC901A\%68E=O7GC(!Z=#\;?$EWH>H:[!X5LQIEE(
MD<LCWARK.0%4# +'D9P/>K,_Q1\=:6VGKJ7AO27?4IXX;9+>Z)=6< JKJ&8@
MD,.N*\RC\1:%%\*]-\+I>N+J\U/[5JKF(MY"!MH*= QV*C8!/4C@UT?@/Q)H
M'A3Q0T6G:G)KJ7SM)?7ES:O#]GMX(W<NJEF+MC+9QD!, 9:@#NKSXMZAI/Q%
M/AG5=)L[>W,Y1+C[5SM8'RBW!"[ODSGINK*D^,/BQI->AB\-:;')HJ,UVSW3
M2+$0VW;E1ACGL",X/3%<)*VG>.E\=:G;C9JT,PU:S9%.?LT9*N">2/E96QP=
MP![5/;:E]B^#7B/5+ZZ5M3\3ZD(XW4 -)L</(6Z +S)TXRP'?@ ["/XK>/[?
MPW;>*KWPYI4F@/)M>2%F60C>4XRY*_,, E3V]<UK:O\ %K4;'XA:+I5M86DN
MA:HMK)!<DL9I8YCMWC! 7#9&T@GY3ZC'':MXNTKQ)\-M,\">&%GDFV0K=7-T
MNR*UCCP[R._90023C 4-["N<NQIOC+Q)K*:1=/\ :8+:W71M^Z-!%;Q@2%G9
MOW8"H6!;C/<$T >H>(OBQK8^('_"+>$-+L]2FC8PO]H.TR2J"SJC;U4!0",G
MN#[9PQ\9/'-Y9:GJ=CX?T?\ L[365;J0RF3RB3@?,)!O!.<%01_.N.\'>(_#
M/A3QA/J0\R>.#2S%;S&-G\Z[95#R8(#(I)<#H=O7J:YG3!IEA9V^I27]O<7%
MIB9M)N[21TGD#X"Y'R%2GS$L0?X0#G( /7]9^,WBG2-&\.:A)HEBL>IVS3R2
M.&Q(5?!$:[\J I0Y;.XOQP*N>(_BSXHTSQ?)8:=HVFW.F_9_M]N[2DM<6@0N
MT@<-M&51R!M)Z<'OSOBM]!\5_%6QT6\GCMK>WTP:;%#"'\N.^)=%C 0?*%=E
M_P!G]V 3CBH/A.&U_P 5W,OB2.)[31-">P9IP$6*,,4VOT'$9E4DCH.>>2 7
MX/C1X]O)[1+3P[ISF^226T00RDRHA;<0?,&<;6R>.AKT_P"&/B^]\;>$CJU_
M!;PSBY>';;A@A  (/))[^M>9Z+XD\(7GQFL'L9X8-#L=,%CIP-NX225VQM 8
M9!/FN-Q SM/8Y/LL-MHG@GPW+]G@@T_2[-#(P0;0,#DDGJQ]2<DXH VLT5B>
M&/%%EXMTK^T].ANDM"Y1'N(3'YF.I7/49R,^H([5M]J ,;Q-XETWPEH4^KZI
M*4MXL *F"\C$X"J"1D_T!/0&O/)_BYXFLH;2XO?AU>V]M=2QQ12O>GYF?[HQ
MY6<GT_"I/C9=6MN/"']HL/[,&LQRW:,I8&-?O94#)^4MP.N:W[WXB^!I[W3[
M&;5+&\,THEC=2LD=NR$%7=ND>"1@GO0!0C^)NHW'Q#O?"EOX4N)?L;,9K@70
MW", '?LVX^;*[1NYW#IV@\,_%+6?$O\ ;0B\%W22:7"^42\#E[@, (>44!NI
M)&<!>AR,^9>']>N+W7_%OB:R\<0^'9[B9Y(H+R".62YCR[1H YP"H"K\N<?E
MFSI7CV/PK\&RMEJ ?Q%K%[<2.4FW2V^2 TKYSAB%&!WW;AT. #N_ _QI7QAX
MIMM%DT,61N$=HY1>>;DJI;&WRU[ ]^U7O$?Q93PUX]A\.WNCO'9R/$&U*>?R
MT"OC+A2AW*N<$[ARK=,5XCH\T_@CQUX7N;ZQ726MUB:Y=Y1-YD4C.'E(7.S,
M;$!>VT'O75>.[:S^(?Q%UR&PO8)7T_2$%@(;A7%[,I$A1 ,[CM>1<+SN4=LB
M@#TEOBD1XZF\++X<U R02D2W+NL:)"OWICNZ1@<@D\\8Y(%95W\<[+[1,=*\
M-ZOJ5C&2!>1Q[4?'4C@X&.><'V%>6)KNL:_X<\6>)KCRI+F+3;329)$W[FCD
MD&7/)R3L&3T)/3J*[+Q'XXU#0/"&C-X4UGP^^C0Z=%!-:LZR7)D^ZV8SSC&,
M_1B>U '9S?%^PM_"VD:\VBZK+!J/G,R6\8<VZQ,R$LV0.6 QR.,GM@FB?%RV
MUN'4[N/P[K<6GV-FUV+EH PE"D J #C<3G')&%))&#5/QSK T[X$;)9+:TU"
MXT^VB%M;$089]FY408( 7?\ +CH".E:TNIV?ACX+^;:W:RK9Z2L4,L<HR93$
M N#G@DL#QSCIVH K6'QDT'4O#VJ:O;V.J%=.,8EMO*0RL')PP 8C:,,221C%
M3V_QA\+2Z!-K4_V^ULTD$49GM\-<.0<K& 3NQCGL,CGFO!KBUN/!6AZ3JVFS
MEX?$>C36TP>0Y1L@2!=N.F8R,YYSGM7;>&X[*R\9^"-/U2:"ULM-T,7]B)VV
MQW%U/\S?,W ^9MPQT* "@#T*V^,&A7&IV%@^F:Y;2WUPEO"US9>6I=V"CDMT
MR17H->)V/C?Q)JWQ'TGPQKVBZ#=7$-RMRLMJS,(!Y;-O4EB"P4G^@R*]LH S
MM=UB'0-&GU.>WNKB*';F*UB\R1MS!1A>_)_+-</IGQN\*ZMK%II=K!JAN;J9
M((PUNN S'&3\W '4UW][?VVGV[3W4\4**I;,KA1P,GK7F_P/'G>"I+ZZ:![N
M^OKB[7YPT@5B$)/<?,K?F/7% &AKOQE\+>'==NM'NQ?27-LX20PPJRYP"0"6
M'3.*L>&?BSX8\4SWD5I+<VXM+9KJ:6[C$:+&I )W9(XR.M<3\2O"UCIC0Z9:
M2RR7OBW7XI9C(BL%0'!4'@@ R*>N3SSZ[OQ%\&>'UL-9O;C4DT^^UTVUA;23
M+^Y1T8,D?RJ2JN8P6)SC:#VY )H/CSX'F,@>XOH0G1GM20W7IMS^N.M>F YK
MYZFM]6_X3/P3X<\6Z?I=U;P2+]BETF7YI%4J-T@.=R?("057.#@\$5]"]* *
M>K:K8Z'I<^I:E<"WL[==TLI!.T9QT )/)'2L(?$?PC_PCS:]_;,8TQ;C[*9C
M%(/WN,[-NW=G!STZ<TOQ(U&'3/ASK]Q,<*UE) O7EI!Y:CCW8?\ UJ^=TO=1
M\">'[W0KI1/;^)='ANX-@^:)Y,@=3C[N]3@9/RXQ0![S<?%SP3;:=%?G6"]O
M+.]NA2VE)+HJLPQMSP'3G_:^M:VA>-M \1Z->:OIUZ6LK-F%Q))&R%-JAB2"
M,XP<YKQ;XB:]!H/@CP[X" ,<R6EO)JCHH8Q# )0 X^8MEN=O1?[W%KX1>(;7
M2?#OCDV;$VMFC7UHEV%W,FUPH?:>3A4# <9/7F@#UWP]X[\.>*(+^?2M0\R*
MQP;AY(VB"*0Q#?,!QA6Y]JP!\;? 9C=SJTPVXX-G+EL^GRUX1IL6K:1I-SH=
MG=6WV/7]*BU&[N-C9@AB\QBN0<=0R-P<DA>#Q6_IND26OPL\+76F6'V_5M1\
M0_;5MRF1(+=95\L_[/RDX_VFH ]?T[XP^"]5U*UT^TU"=[FZF6&)3:2*"['
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MM.$'EY)P3@''W3ST)]'^)7BRX\'^$9-0LTB-S+,EM$\V=D3-GYR "2  3@4
M=C17A-IJGQ1_X2+18K+Q'IOB"PN)@DLNG+'+;H$(+B9UC!3*G/7)[<\5[JM
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MJZ2)-(LI_<AVW-Y6<[>0.N>GT-9T?P,U^+PO+&;#2Y=7DN1LE:]D!@A 'W0
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MXV^:59F+;<XY8GU- 'DGPE\=>#O#'@&X.HZ@UOJOG/->+(K-).Q)"%,9W?*
M#Z'). 03S?B'4KFY\%>(_$<P@L#XMU"#[/8[<.]M!N^?!ZY)3)'4Y/\ %7OU
MWX+\-W^L#5KK0[":_'_+9X023QR1T)&!@D$CM4FM>$]"\120R:QI=K>O#CRV
MF3)7G.,^F1R.A[T >>Z-X-U3Q%:>&HKWQ/HMWHOAV6)HAI*%S+)$J[0\A8@$
M #. .&Z=".,34I=>^,6O>(-)\2:1HQM'\F&?4)$,<Z!?*)0YPP.W=D=F%>]:
M/X<TG0-+?3=+L(;:S=F9XD'#%NI)/)XP.>P Z 5F#X;^"_\ H5])_P# 5: /
M(?!OQ MO#?ACQ+XKU.XM[S7-2U (EK$55G*IE6*CE8^6Y]O4\\E#_:?AGQ'H
M'B/7+1XKN?41?3W9O(G-S"Y4Y6-22%P)/FZ'=CL*^B_^%<>"_P#H5]*_\!5H
MF^'7A"XFAEF\.Z>YAB$,8,/RJF<XV]/7G&>30!Y9XXUY?%/QB\.6>@7VE3'3
M LD,MW/_ *-).S!MH9,Y)VH!CG=QVJMI?C*XC;QWXGUR>UM/$*VRZ?!IF/+V
MXR 0K'<^&P3R3PW0%<>LQ?#7P=;ZG;ZC;Z!9PW5LZR1-$&0*RG(.T$#(/M2Z
MM\./"6NZE)J.I:);SW<@ >7<ZEL<9.U@"<=^O H ^=K?P]J>E^$Y\ZQ96^@:
MM817DTID1GGDBR1;(N[)<.V"!CIR1]VKT]S,WPWT;P5X=22ZU#4PVJZ@L;C+
M==L2KGD@(K%0,_*#CDX]ZN?AOX2N]-L=.GT6%[2P\S[-%YC@1^80S]&R<D#K
MFHM"^%_A'PWJJ:II>E"*\C!"223R2[<C!(#,0#CC/7!- 'G/P'UB"SUKQ!X>
M>/[,7E\^WAED#2#:2K(3P&8*%Z =&./3UB^\8Z#IWB.S\/W-]MU6[ ,-NL3L
M3G.,D A>AZD=,UGZ#\,_"7AG4UU+2M*$-VB,B2/-)+L!X.T.Q ..,]<$CN:B
M\+^"_P"S/$FN>(M3>.[U:_O)&AFY/D6V<1QC/0[0,X]ASB@#LQ2$@4M-= ZE
M3T(P: /)/B'?6NM?$KP9X>#VK16URVH73R2+M54)^0G/^P^01SD#UJ?XUW<+
M^&=(T*WGAA.K:A#'NV@JL0.2_L Q3D8XSV)K4_X4CX V[?[$DQZ?;9__ (NM
M#5OA9X/URXAFU#23(T$"6T02YEC5(D&%0!6 P!0!XO:07LNJZ!\+;]?,_L_6
MVN))8P&22$KY@VAAG!#2'TP>C5W'PGN])U!?$_BK5KNV6]U"_<217CJ&MHD&
MY5);' #8..,*!V('H?\ PA>@CQ'::^M@JZE:0B""178*B!2H 7.W@,1G&:QM
M;^$?@W7M1:_NM+\NY>3S)7MY6C$IR2=P!QR3DD 'WH L^ -!\,Z5I5UJ/AAS
M-9ZK<M<B7   !*B-!M!"*=P /3)Y-=7%-',@>)U=#G#*<@_B*JPZ196VC_V3
M;VZP60A,*Q1?*%0C&!CI]>O>JOAKPSIWA/1(=)TM'2UB+,/,;<Q).22: ,K5
M/!YU3XAZ-XEEEB,&FV\B+"0=QD8G##'& ">O_P!<2^ O"G_"&^%(-+DE26Y\
MQYKB2/.UI&/;/8# _"NGQ5/5GOXM'O9-+ACGOU@<VT4C;5>3!V@GZX_Q% #+
M?6M,N]5N-+M[^WEO[8;IK99 7C'')'4=1^=:%<7\.O!0\*:.UQ>L9]=U$_:-
M1N7(9C(W)0$?P@D_4DGN .TH KWMY;Z?97%Y=R".VMXFEE<@D*BC+'CV%?.G
MP[T"[UJWMM/NO!=G_9FK"ZGFUF6V$C0*T96-86X\L*Z="2?FR-O6O=O%OA:T
M\8Z&^D7US=P6[NKLUJX5FVG(!R"",X.,=A6?X+^'VE^!5N5TV\U"X6X"@B[F
M5@@!)^4*J@9)R>* .$^(7A?2/!WP42Q>WAO[NT(M[:[N(<2!I)=[E2OW>K'&
M<< '=T/?>%_!^E:!X4ATV;3;$2R6<<.H2"W4"Y(7#&3^\.6ZYZGUK(\3_"+1
MO%>M7.IWVK:U&UP5+6\%P@A4JH4$*R'' ]>I-3R?"W2Y/"/_  C9U?7!;&Z-
MU)<"[!FE;;MVL2N-F,?* .@/KD XSX<Z7X?M=#U[XAWFEQ):K?75WIP,:[X+
M="<*B@[0V<J!Z@8/(I?BKJT/B_PQX.&D6$E\VIW1NH+<QD3,B(=Z9Z#[V#U!
MQD9QFM0_ 'PV;;[,=;\0_9\Y\K[3%LS]/*Q5S5?@AX<UB^6ZN]1UE@J1QK )
MX_+5$55"@>7D#"CH: ./\#Z!I][XWTF\U73HO#6J1/+<66CP6TBM/"N0))=Y
M.S!#@9V[MO  P3/\/_#GAWQ)?^./$^LP6UUIKZC<)&9\%8H]QE:0'L<,N&4Y
M SZY/9:'\'/#WAV\OKG3;S58I+NSELR?.3,*N!ED.S(<8X))K(C^ /AZ*9$&
ML:RUAD-+:-*@$I![E5&!T' SQU] "W\"K?RO =S/$DJ65UJ4\UFDK;F6'Y4
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MNI)GEM"63H$QD]2-G/H<CM7<FN:\ ^&&\(>#;#1I9$DGA#/,Z$E2[,6.W('
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MIXNX=D<$%R"L*1@],*1T X%<-\+?"/C/PKK&IG6AI[6.H$W$SQR%I#-GM@
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MC*MI*4NW.%@.PX<^PZ_A6F:\F^,6H^*[NR?PWH'A_49K:XC5[F^MU+!ER<Q
M+ZX&[/4'&,'- ')_";QAXJN_&VGV^LWU[=Z?J=O.MN;ESL+1_,63U(*%2/\
M:_/Z$%?,2Z#XU\%^--#E@T[5]:73E1H%-N_DKYB#S(D8%E4?,5W<<C.,#GW'
MQ5XMU+P[)I4=KX7U#57O6Q+]E!*VP!4'<0K<_-QG .#S0!T.J//'I5X]LZI<
M+"[1,Q  8*<$YXQGUXKP72=?^*\_@D^-EUVVGTZ#?(;6>&/=,B-M8X5!\H(;
M^)3A2?2O6/B-J>H:=X(U#^S-,N]0N[I&M8UM83(8]ZD&1@,G &>QYP#@$D>3
M63>(M:^'FE?#NP\+:OIK2.J7>H7=L\<*)YAD9N1ZX.._([T >Y^'-777_#FG
M:NL31+>VZ3^6QR4W#.,]ZU*YO4=0M? OAFRBM='U2^M8-EK%;:;;^?*JA3AB
M,CCY>3ZD>M;]O(9K>.5HGB+H&,<@ 9,C.#@D9'L: ):Y7QU?>)M.T<WGALZ4
MHMT>:[DU L L:C=\N.,\'K74FO.?B/XKN$TG6O#=EX;\0WEU<V;0K=6NGF6W
M_>)@C>#GH>< X- %WX3ZQK?B#P1%JVN78N9[JXF:(B-4V1JVS;A0/XE?WP17
M*:GK'BCQMXB\21:1KZ^']$\/>9$\P8!I9ESDOCD)E6Y]!P"<XZGX57X?P=:Z
M0=)U73YM+ACBG_M"W\KS)&&YBG.2N2>2!P17EGC'1(_&FL2S>'?!_BW3]3OY
M$^T"]M1;V;,#S*_WOFY[$#OR<[@#L;#XEW^G? RW\3702ZU16-G$TA)65PY4
M._3^%<GGDCMGAMA_PE?A?Q]X6@UWQ>^HMK F6\L-HQ&VQF!0 8"AM@S\IX.!
M@D#1U/0M(\)?#*P\,:GH6JZY;R K+_95H97$IRQEY;Y/F/!S[8QD5QOPX^'.
MM/XQ7Q5J2:A;V5BQ:W74%_TRZPFU 5)^4 'N>P ]0 ;GC[QAJD'Q&30]/\90
M^'[2+3UDGDN+='3SBQ.W++G)1E/!QQZYKT#P'%=Q>$;0WFOKKKR%I$OEZ.I8
MD#/4XZ<_3M7E&L^+-'\0P:U!_P *XUA?%>I6\EJ&DLQ*4;:55MS<J5 #<+QM
MZ]Z])^'FAW'@KX>VUGK$Z)+ )+B<EOD@#$N1GIA1G)'&<_6@#LZ*Y3P)XNNO
M&NC/J[:/_9]B\A2T9[@2/,JDAF*A1MY&.IY![ $]7VH ANVN$LYVM(TDN1&Q
MB1VVJSXX!/89QS7CWA7XNZ]KWQ&M/#EW8:7%:RR2Q2/;2-*0R1LV5D#;6&5]
M.A_&N@^*WQ(C\$Z8+&T^;6;V(F L,+"O0R$]"0>@]>O'7PW[5?>";GP9+>7%
MH8[<KK"161<3F*8QEEE9@ 69(]F 3P"#P1D ]C\??$7Q-X?U^^L] TJTN;/3
M;*.YOKBZ1R(R[$* 0ZCIC ZGYNP-'P_^(GB;Q'XLATK6[+3+>"?2_P"T86M5
M?<REE"YRY X)XQFN9^-'C'0)]'NM%L8I(M;N_LLUT3;F)O+"ET60GDD!E^7G
M!;U!QZMX+DT'5O#^G:QHUM'Y0M19Q7!MQ'(8XV*[/4+N!. <4 =,.E<3\1O%
M'B'PMI,=WH.C)J  DDN99=Q2VC0 EB 03D9[\8[UVU>2?&3XA:7IFA:KX5AN
M'.L7,"*0@RB([#<KG/!*9X]&7L: .T^'VOWGBCP/IVLWXA%U<^87$*E4&V1E
M& 23T4=ZU+[Q%I&FZI:Z9>:C;07UW_Q[P22 /)S@8'N>!ZFN>^%NIZ3?^ M-
M@TF\^U)8PI;3OY3H!,$#.!N R,M3+L^"=;^)=I!<2)<>)M,B+11YDVQC[W/\
M!8;LXZC.>PP =C<W4%G:R7-S-'!!$I>265PBHHZDD\ 5Y=X9^*MWXK^)TFB:
M9#:MH*H[K<21NL[JJCYA\V,%R, @';UP>*/C79^*;_0X[?2%C315C>74IFN$
MBX7&U3N(^7J<#.3C\>4^!/V6^\;Z]J4%K%9H+18X;6-R0B,XXY'S?<7+'J23
MWX /1?%WCN[L=9C\,>%[ :KXCF3>T9;$5HF,AY3QZC"Y'!'/*AM7P?\ \)CY
M-T?%[:7YAV?9TL V5&#NWD\=QC'H?:O$=1&GI\4_%MUXF\2ZIHRQ2/Y:6GF)
M/=)CY%5@,;0H3 /7C'&37J7P8FURX^'\,NMM,^Z9VM)9R3)) <$,Q/)^8MC/
M;';!H ]$/0UY]KGQ.%OJ\ND>&="O?$6HVTC1W2VY,<4!7J#)M(W X&,>O.>*
M]!KQ'X;^-/#G@OPMJ%EXCNYK+7X+R634DN$9Y9Y"V RD9+\8S[Y)X.X@'H/@
M?QQ'XRMKQ)=-N=+U.Q=4N[*X^]&6R5() )! [@<@^Q,UMXUM+KQY>>$8K&^-
MW9PB::XVIY*J55ASNSGYP.G7/;FL3X;Q7VJ:OXD\9W5G)9V^O2P&R@E&',$2
M%$D89.-P(./;(R"#7367A?3[#Q1JGB&(2MJ&I)''*SD$(J*% 7C(!P">3D@4
M 9?B_P >0>&;RUTJTT^YU?7+Q2]O86I 8J.K.>=J\-S@_=/8$CEM+^+^L7GB
M2#0[WP)?V-U-%)*L;W#>:55&8$(T2Y!*;<YQGZ57AUO2-!^/OB*?Q!-%8&2P
MACL+BX!1&3:A?#'CD@C/JI'7(/50>// ]YJ5[J7VRR5M.V6QU.1%"MO!;RXY
M.K?=8E1Z=Z .>\._%W6?$/BB+1$\$SQ.+DP74HO2PMMI.\M^Z RH!XR,XP.2
M*ZSQKX\T[P9;1+-%->ZC<\6UA;\R2>Y]%SQG!]@:\W^'_CW1O#W@77M<U"_L
M)-;U"^N=0:P1Q'*6. J 'D@D%AUP&[G-6=$\46C_ !<.M^)9!I0NM!@ETY;J
M78D:, SJ2< G<'(]AV88 !UO@SXHV'BK4CI-WI]UI&K"+S5MKO@2COL) )(Z
MX('&2.AQD:C\;K&*[F32/#VJZM9PLR->P)B(LI.=I .1C!SQUKFM:N8_'7B7
M6_&NB>=_96AZ!<VJ7,D903W!BG^X",D!9<G."...:Z7P9XQ\$Z!\*;$/J=D(
MX;,?;+7<#,\Q'[Q?+/S,2Q(SC!&#G'- $$OQVLHO#=GK'_"/WY2YN9;<+YBA
M08U0D[^ASOX'^RWI0/CUI3&UMTT#5)=0G8*;:(HY1BY7;P<[^ =N.X'%<Y\7
M(].N7\*>!] ^Q6T6\N(\[8H?,P$+$9(SN=CD9.<\U>^##:?H/B7Q%HNKRZ?_
M &_'<!$N_/R]R&^^B%@"P#*&Z9)?VH ]QKF/&GC>Q\#:?;WFH6=]<13R>6#:
MQA@AQGYBQ &>W.3VZ&NGKR+X]7ZMX=TK1(Y8UGU"^0D22!4"*",N>R[F7GCH
M3VH W="^+NB:[KMII(T_5;&2]R;2:]A6..;C(VG=W&,<<Y'K7?BO)_#WAG6_
M%OB'1_$6N7VD+INC*5TVVT:<RH7! .YCD8^7!P<\ <8Y].;4;&._CT][VW6]
MD0O';M*HD=1G+!<Y(X//M0!B>-?&^F^!=,@OM2@NYDGE$,:VT88EL$\DD*.
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MBB@ HHHH **** "BBB@ HHHH *2EHH **** "@T44 )12T4 )12T4 )12T4
M)12T4 %)2T4 )12T4 )2T44 %)2T4 )12T4 %)2T4 )12T4 )12T4 )12T4
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M(TFSL3-CS#;PA"^.F<>F3^=:M% &1J/A?0M7OH;W4='LKNZA4+'--"K,H!R
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M?QD\0W$/B'4DTS3WEOTN4E*Q*SG*@_,5V ,2 >&5#D8R*POA]K>LV?C[3_\
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M4XSP2,9'K0!MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% ""EI!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !2&EHH \DN/@S?VMU<CPWXWU/1K"=RYLT
M#LJ9[ K(O'..1G'4FGZO\';RZTS3=%TSQ5/9:-IZB2."6#SF>?<S&0G<N, J
M O08/&<D^L44 >51?"KQ"^NVFK:EXZDOKFR28VI?3POE2NA57QOP<-M8@CYM
M@!XI/#OP:?2EUB#4_$1U*SU2!TFA-F%S*>5FRS-\ZG)!&#G!SQ7JU% 'FUGX
M#\6Z'X$7P_HWC&/SUG)6>>S4". J<QJ#N/WCG)/'08QS)\,_ >O>!UN+6]UR
MWN=,8%HK.& #$I(RY<C=P% QG'/MSZ+10!Y'XJ^'/C?Q-K\.H2>*=/$5C=M<
M:=&;0#[/\P*]!\Q^5?O$]*V_$7A#Q9K_ ,/K?09O$EN^H229O[LVX19X\L0@
M51Q@[!D8R%YZD'T&B@#@?A]X)UCPOE=9U.PU!((%M[(16:(\* DD>9@,1ST)
M-4O&O@KQGXIU%1;^(-.M]-MKN.\LHGMB7CD0<%FQS@DG'2O2Z* .(U;P/>^*
M/A\F@>(]9^TZF&\W^T(H0@$@8E3L& 0%.TCC/)X/3#A\!^/KVUL=+UGQQG3(
M)%:9[-62ZE49(4R]3V&3]3DBO4Z* /((_A)JNH^.YM=\4:K8:S9OO!A>!EW*
M4.Q0N2$"N> ">!URQJ#X??#/Q?X/\1W6H-J>CQ07%O(C6]N99(W<\QY0JN K
M'.<YQE1]XFO9J* /&M,^'WQ$MOB%!XEO?$6D7,GRQ7$S1G>T&1N18_+"J< C
M*D'D\\FM'X@^#/'/BGQ!97.E:EH\%CITT=S9";>LL<RX.YOD8-\PR.V,#'7/
MJE% 'BWACX6^+K/Q9H]_KM_H\FG:?/-<B&P+0D2.I^8*D2 DL$SD_=&.G%>S
MC@8IU% '!_$#P;J.MWNEZ]X>NX+37M*+F%I4!696_@)[=\9X^9O7-9^D^ ?$
M.I:_:^(/'&M6^H7.GOOL;&S#);QN,$2$X!)R.FWL.2.*],HH \.N_AKX_O\
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MU^2,'< =Y9\X)X&#]XBH+_X4^*M#3P[>:'I,USJ4&VZN@;V*2**X#*54*0I
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M(&W,H)(!<$+QGU&0>G2W_P 3/#]M\,9]9T][J"##Z?8%[?:SS"/Y=HZ;1Z\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)H QCI.CZ?\ 'C1(_#$4=O+'97']LVUDHCABCV?NBRJ  2S+D>R' ZGI=?\
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M1110 8HHHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH
M,48HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 8>&6GTT=13J $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@!K?>%.IK?>%.H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!N,D&G4T\$"G4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 WJ13J@DGA
MBEB226-&<X168 L?0>M39'J* %HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C-%,9PI P>: 'TF
M130XYX(QZ]Z\Q\>?%:/PAXHLM-AM%O$\LO=A7PR<\ =B>^.* /4,C&<\4TRH
M.IQVY&*\^7XR>$Y/#[ZDETZS*O\ QYLH$A/IUQ^M>(V?Q/\ $-KXQE\1_:&D
M2X?,MFS$Q!,\+CL0.A^M 'U@6 QUY]J Z^M>'>)/CO;S:*(?#D$J:C*/WCSJ
M"L/KCGD^G':N9^&OQ.N= U9K+7;J6XTV[DW/-*Q9HI#T8>B^H_&@#Z8+ =30
M&!Q@YSZ5Y7XI^->A:7"\&C,=4OG0[#& (HV_VB2#^0KI_ 7C"W\8^&H-01D6
MZ4>5=0KP$E_P/4>U '79HIF\<<$_04[- "T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>E%% $+PQRM&SQJQ0Y
M4D<J?:I=HI!U%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "D)QCWI:8^>,>O]#0 H?/\ ":X'XO\
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M52T>_:KIGD$*,'KGI7U?:W275K!=0DM%,@D4XZ@C(KXDSG@@$>E7UUW6!%Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:QV\DSFW<@H#MR 1T.6].37,?$_Q_J/C.]GT2VBGT_3+<(Z6<\;I/?.2H3Y
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M0MVU&W"F6V$@WKN!(X[\#/'3C/45S?BGQY>Z+XCCT#2/#D^LZBUG]N9$N4A
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MFMVVW.,A6_PK?O[RRTRREN[Z:"WM8ANDEF8*BCIR3QWJPJ(5P$4#L,4 <_\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!!2T@I: "BBB@ HHHH
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M]X?N([?5M8L[.:1=ZQRR@,1ZX]*U+:Z@O;2&ZMI4FMYD62*1#E74C((/H0:
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MR7X99"Z9!VMDLQ8GY1^ KL\"H?L5K]M%[]FA^UB/RA/L'F;,YV[NNW/..F:
M/*?B@\4FL2/;:3KT&OV5FLNF:OI<#R+(Q+9ADVC&W('7/#'Z-YU\0;;6KWQ:
MUWKGF6MS-IEI+:D022M$^Q2Z1;.$;S5D'S8Z]LYKZA  &!1@#_\ 70!X1:Q>
M'X_B9?R^-K'4[C69=0MGTF?9*$$;;?*QL( ^8@$'(!XZYJ:Q\$:>W@'Q1XGA
ML)Y/$4K:FJ3^8^=I:2-@JYVG*[NQ.2<<XQ[CM'^31@4 ?)>B:*UYX.\6&WMK
ME5CL8)2JVTBIYJ2J0>6.YBOF?0$D 4SQ-+X6)#^#O#>IZ?/&B2+=732F02JX
M^X Y5>.2S$], +U/UN0#2T >+V7P_P!&\>^,O%-[K!U%X2UI+;MYA0?O+9&;
MC&,C(&.P %.^#UGJ^HZM<:GJ-^MY8:+"^C6,R.66?;(6,@R2#\I50PZJ0.QK
MUV^M/MUA<VGFO$)XGB,D>-R;@1D9!&1GN"/8U2\->';+PKX?M=&TY6%O;J0&
M?&YR3DLQ &22?2@#R/QY;Z1!\1=6NO&]CK%W826D3:(;,OL1E7]X 588DW\C
M/'.3U%3_  \\./\ \)WI&IZM#=)J4?AN&=C*Q'[PL\ W#U\E4&#WR2-W->U8
MHP* /(?BO>V%GK5O<1V^M67B6UMO-TK4K*#?'.V3^Y?KN&>H(Z-WS@\G<OI6
MC^,]?U/QIH5_/JESI]K-:0PM*H,LEMMN$WQG"@L2N3G&#CI7T7B@#'2@#Y0\
MM;WP5XMM=/T^YBA26ROK6TC$[1VPRR.H+_>8&4 Y^]@L!@<-\=#3GET5=)CN
M+3PW#8F&SDU".94\X.YD8;027R0>1CIQC%?6.,TA /49H YOX>7+7?P[\/3.
M96<V$09I<[F(4 GGKDC.>XYKIJ3@4N: "BC-)F@!:*3-+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 @I:04M !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% &+XK&B'PU?+XC>)-(:/%R979 5R,#*D')., <D]*\N-M??%5=)TW3-)GT/
MP18LDWVB>,++<; 518AS@8R,\@<DDX"GT'QKX"TOQW;V<.IW-[ MH[/&;615
MR6 !R&5@>GIGKZFLOPQ\)](\*ZQ:ZE9ZOK<[6P81V]Q<H8?F4J<JJ#^\?QH
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M%MI QW/(S@X''%3^#OASI/@V>>\@N+R^U"X18Y+N\<.X4?PK@# )Y[G@<\4
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MX8?A@X( .@R*3(KQ+P5(\7Q9AL_#OBS4O$.F?8Y6U2:[E,D:-DA=C'@G?LY
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M HHHH **** "BBB@ HHHH **** *NH:=::I92V5];0W-K*,20S(&5AG/(/N
M?PJ+2]%TS1+4VVEV%K90%MYCMX@@+>IQU/'6K]% '/7'@/PG=WLEY<>'-+EN
M9'\QY'M4)9NI)XY)[^M;(L;7["+'[-#]D\KR?(\L>7Y>,;=O3;CC'3%6** ,
M?2?"VA:#-)+I&DV5D\BA7:"$(6 [$CM5#6OAYX4\0Z@U_JFBV\]TZA7E!9&?
M'3.TC)]SSP!VKIZ* (+:TM[*UCMK6"*"")=J1Q(%51Z #@5@0_#[PM;Z_P#V
M['H\(U/SVN3.7<GS&));!.,Y)/3CM7344 <[XD\#>'?%QB;6]-CN'BX216:.
M0#GY=RD';R3C.,\UH:+H.F>'=.33])LX;6U3G9&OWC@#<QZLQ &2<DUI44 <
MKIOPX\)Z1KKZS9:+;Q7S,75\LRQL>I1"=J'Z 8[8J7Q+X"\-^+Y8IM:TU)YH
M5V),CM&X7D[2RD$C))P>,D^M=+10!SWAKP3H'A.REM=)T^.-9U"SNY+O-@8^
M8GKU/ P.3Q7/VOP5\#VNI/>_V6TVXEE@GE9HDYS@+Z#I@Y&*]!HH 9%$L,:1
MQJJH@"JJC  '0 4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *\[^+&@^)/$VF6.F:'96MS;_:!/
M=^?*JYV8V( >Q))/T'J:]$I,4 >47WA[QUXNU*WOO$,%E9V6E?Z5:Z7:W6?M
M=TO*;WZ*N<#/89P.<CF+GX6>*=>'B'6-?L8Y-=N2&LC%J 4#=A=I &-B)V)!
M.,>]>_8HQ0!Y1X.TSQ]X+\ 3V T>ROKV"Z!L[;[6 3&YW2%F)"C!)Q@\Y/'K
M/\+=.\9:/=ZI;^(-"BL[:^N9=0DNOM22,T[E?E"JS<8!.3Z5ZABC% 'SIXIT
M;QIK_C"_U+5? 3WD4EK]CBA6Y!$0#!ED1U;ANO3CYFR.2*]'^%MEXFACU&XU
M^"XT^V_=6^GZ8[AH[>*-<#;U/H,DY.,G/6O1,48H YO0]5\07^O:Q!J.B+8:
M7:S>797#39>YP2"VW^Z>#GCJ!SR1TM)BEH R_$FG2:QX7U;3(75);VSFMT=N
MBET*@G';FO*](\/^*O%T/A[0O$VB_P!EZ1X>9#.[2 M>RQKMC";3]W81EAQD
ML >,5[128H \N^)GA[4+KQ7X?U^W\.)XAL[))(IK#S I+-RK$$$$ \X((R.>
MN:E\!^#;W^U_$GB#7=-AL1KBB---63<8H3G<'(XR?EX'3GIGCTS%+0!P_P#P
MJ#P'C'_".P?]_I?_ (JG>(_%5SX)N;*SM_".HWVBK; +<:8H?R6!VB/RP.%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% ""EI!2T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 @I:04M !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (*6HS(%<+S
MDT_- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% "8!-+BD%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AI1THHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** $%+2"EH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBCM0 @I:8752H9@">@-.S0 M%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 THK
-$$@$CI[4N*7%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex-a_002.jpg
<TEXT>
begin 644 ex-a_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M#1U%.IHZBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!'--%;Q-+-*D<:#+.[!0!ZDFG(RN@96#*>00<@TV:%)XVC
MD4,C#!4]Z=&NU ,8'8>E #J*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@!HZBG4T=13J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBDS0 M%(3Q32Q'I^= #Z*9
MYGL/^^J3S/I_WU0!)12!LC/%&: %HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 @%+2"EH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD4;U]?:@!:*,TFX>M "T4FX9QGFC(H 6BFEU!QGFCS%.,'(/&1S0 ZBCK10
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MO:'X>U?XO>(?^$AUPRPZ'')B"/&T&,'A(Q[]WKTZY^%_@^723IQT:W2 X&]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5\P?&?45OOB3<PALI9VT<!*]LY9A]<XKZ9FF$$<DTC;8
MD!9CZ*!S7QSX@U!M>\1ZEJ"1-(;^]9HHQ]]@WW1^G'UH ]*^ &D-+X@U/5FC
M.RV@%L'/0R,<MC\OUKZ"Q7'?#?PNWA'PE::?,P:[D)GN6'3S&Y_0<?A78T %
M%%% !7A_QZUU2-+\/K(K$R&ZN%7J%'" _K^5>O:YK5GX?TFXU/4)A#:P*2Q)
MY)[ >I-?)?B'6+KQ+K]UJTPD>XO)@$AC3+*@X0#WYH A\.Z%+XI\2V&BV^XB
MX?\ ?2 <1IU)/X UZG\<-?BMK>P\'6("P(HFF1#@;0-L:<>_)'L*ZWX5_#]_
M"^ERZAJ0C&KWP&]5Z0)V4>_<^]>&^.-0;4?'_B"[D+;5O6B3'7"':/\ T$T
M>M? '1HTT+4M;F3=<W5QY*NPYV(.Q]"6/3T%>JW^IV6CV;7.H7<-K;I_'*P4
M >@]:\,\$_\ "S9/!^EVOAI+"'2]C%;B7&3ECUSSQ[#O6Q!\(]:UZ^^U^,/$
MANXUR!#:L6P3Z$@ ?D: .-\8Z]JGQ3\7K9:):2W%E"GEV\:YPNXX,K]@?3VQ
M7JXT2U^'7PJU2)),2):RO/..KRL,<>V3@5UV@>'-)\-V"VFEVB0H!AF'+/\
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MRW/Q"^)L/AW29VD2T'D9'W(W_P"6DGIPIQ^%>P2MI7P^\$221HL5CIML&.P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MID58\U?6CS5]: &I"(U"H%5!_"!@4IB&00 "!BE\Q>W-'F>QH  F%(&.>M.
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MI2Y/I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R09'/3
MBO*O$&B_$^;7KV32M8:.P:0F!$=%"KZ8()KUC%)M'I0!XS%X?^,#'YO$,*CT
M,J9_'Y*4^'_C#@XUZ/\ [_+_ /$5[+@>E+B@#Q8>'_C(#D:]%_W^3_XBG?\
M"/\ QCDX;Q!&![2QC_VG7L]% 'BY\-?&+MXC0?69?_B*0>%_C"W)\3H/;S5_
M^(KVG%)@&@#Q8^%OC'GCQ0G_ ']7_P"(IW_"+_&'_H9X_P#OZO\ \17M&!2;
M10!XNWA;XPLI5O$L14]0)5'_ +)21^%/BY&VY?$:9QCF8'_V2O:L44 >+/X6
M^+TF-WB-./291_[)2#PE\6\?\C''^,X_^(KVJC% 'BS>$_BYYD9'B- !UQ.,
M?^@4T^$?BTS$'Q*0I/.+L\#_ +YKVNB@#Q4> _B=D[O%TN.W^FO_ (4I\"?$
MS''C"4?6]?\ PKVC HQ0!XH? 7Q-/7QG)^%X]'_" _$W_H=)/_ QZ]LHH \7
M7X>_$ME!/C>4'T^TRG^E)_PKOXGYX\</C_KXE_PKV@HI.2H/X4GEI_<7\J /
M(/\ A _BAM*_\)UD'OYCY_E3#\/_ (F]_'+D?]=Y!_2O8O+C_N+^5'EH/X%_
M*@#QMOA_\2^WC5S];B7_  II^'7Q)DY;QFV>G_'S,*]FV)_=7\J/+3^XOY4
M>,?\*X^(P_YG)_\ P*FIJ_#/XC*Q8>,@<G/,\A_I7M.Q/[J_E1Y:?W%_*@#Q
MD?#OXDAV;_A-'RW_ $\R_P"%#?#KXCN,-XS9AZ&XE/\ 2O9MB?W5_*C8G]U?
MRH \87X??$FVYA\8*"W!S*Q_]"6D?X?_ !,G.Y_%VXCCBY=?_00!7M(51T '
MTH**W50?J* /%T\"?$^ X3QEM [&8M^K*33SX,^*>?\ D<T_[['_ ,17LH
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M=G 8?=#Q*H..JL03QCN];^%NA:_XFDUV\N-12>:-8IX;><113Q@ %'PNX@@
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MGVUM'9ZCKNNZMI\:"-+"\O#]F"@ *#&H&<8X&<=..!7? 8[T +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #1U%.IHZBG4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !BC%%%
M !BC%%% !BDQ2T4 5=3%Z=*O!IIB%^87^S&;.P2[3MW8YQG&:\_T?5_BFEB+
M#4?"FGRW:J0-2EU&..)CV+1H"Q]\;<X[5Z51@4 <QX-\(0^%[*Y>24W.JW\G
MVC4+P\&:4Y)P.R@L<#W]ZZ>BB@ Q1BBB@ Q1BBB@ Q1110 V2-)8VCD4,C##
M*PR"#U!%58]*T^*19([&V1U.5985!!]CBKE% !BC%%% !BC%%% !BC%%% !B
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!HZBG4@%+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% ""EI :7- !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -%+3/,4
M2*F>6SC\*DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!FT%E8]13Z:.HIU !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,L;Y.>C+UY&.F:R_AWHDV@^%#\2]4U6^NY4TZX<64S%OD#': Y)/.T'ICYJ
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M=V/G'TKG]"\=^.]=TA[B/QS%%J#&9;73/[.B>:Y,<2R87;'@%MVT9ZD8&>E
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MI<TU@2N VT^OI3-DG_/<_P#?(H FHHHH **** "BBB@ HHHH **** "BBB@
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M>?VAI>DP2RQR3(%:]=48Q[NACY8#W'7&,^_> O#\OA;P/I6CW!4SV\1,NTY
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MG('!^4-U[CUKJ7M?%A\?+<#4K5/"RV^#:B,&5I<8Y.,CDYR#C QCG-<Y\6/
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MDP '<JJ@X[ Y.?3G/;^*U\1OID:>%Y;*&^:=!))> E5B.0Q  Y8<''H#WP*
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M!@]^I!P<#$E_X4\4^%_&FJ^)/"-MIVH0:A!'$UA<R&-HMBJ!L)."OR\#(QN
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** $!I::.HIU !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4
MM% "8I:** #%)BEHH 3%+110 8HHHH **** "DQ2T4 )BC%+10 F*,4M% "8
MHQ2T4 %)BEHH 3%&*6B@ HHHH 3%&*6B@!,48I:* $Q1BEHH *,444 %&***
M $Q2T44 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 8HQ110 F*,4M% "8HQ2T4
M )BEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD=<]Z'A3X=>,M&\:G7M2\3V]RMS@7X2,EKE57:@.5 &,#D8/%>K8HQ0!Y_\
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MQ1B@#Q_6/AEXZUS5],U:]\86+WEC,TEN18*!;?."-N!\_ !PP[8YR376^)O
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M>*]PI"H/:@#YF?0_%'A7Q?9-HWA"^N;?0YIUMYFMB_VMF+#SG9%&<@I@#H%
MSU-9TO@3QI+X:O\ 5KO3]8DOM2OD5[5 2TJC>[2S1XS]\*%Z<DGIC/U5M'M1
MMH ^8=?M/&>MZ;X5LK[P3JDEOHML(VC5'Q=+E1ABHRA*Q@'G(R3QFNST#P3K
MG@SXA)<:)H"G2=5LTBF/VK)TTM@R 2'YFVE<CCYACD'FO:]OTHVT >*^'O\
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M T=13J:.HIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<X#&)VRP!Z9 Z?C0!T-%9I\0:0-$76FU.T72V0.+MI0(\$X'S'CKQCKGCK6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;P>%-/M?!W_"+V[W$5A]E:UW+)^\"L""V[^]R3TQSTQQ7 1_L]>%DOXIGO\
M4YK=&4M!(T?S@=5+*H(!]L'T/>@"S\$K0_V=XAU>,D6.HZK*]HNPJ#&I(W#V
M.<=/X/R]3!SFLY]%LQX?DT2U3['9M;M;(+;Y#$K*5^7'0C.<^M4O!WA6T\&Z
M FDV<\TZ"1Y6EF(W.S'))QQZ?E0!OTU@&!!&0>"#WIU8WBCPW:^*]$DTJ\N;
MNWA=T<R6DOEN"IR.<$8_"@#SGX4:3;#Q]XYU.TL88;*&]-E:E(555VNV]4(Z
M# 0X'4%:T_'=CXAT[QQIGBW1]"36XK2PDMC;^<$:!RV1(,Y/0X^49P#G%7O"
MWPFT3PCK4>J:?J&K22HK#RYYT,;;A@DA4&3^-3^)OA?HWBW5FOM4U#6&C8+N
MLDN\6Y(&-P0@[3@#H1TSZY .0^#;ZAXAU/QAXGNE$2ZG,L2%6W ,H8D*>I"A
MD&>]<+K5WXI\$^#A\/)-&@B:ZF<->0-YCWX9E($:X![A,D$D #@BOHD^&],7
MPT_A^V@-GIS0M"J6C&(HISG!'.2223W).<Y-<YX:^$_ACPQJ0U*&.YOKY?N7
M%_()6CZ8*@  'C@XR.QH T=*M;/PYX$TG^VD@!T>QC9Y)57]RZ1;6*D\ X)7
MKSGWKC_A#HDNH7FK>/=1MHHY]9F9K./:"8HMQW$'/&XX'T3/?CT#Q1X<M/%G
MAZYT6^DFCMK@H7:$@/\ *ZOP2#CE<?C6G;V\-G:Q6UO$L4$*"..-!@(H&  /
M0"@"O<ZQIME>6]G=:A:P75R<002SJKRG./E4G+?A5ZO./"_@[4KSQUJ?C/Q5
M;+%?B0PZ9;K,'6WA *AN.,E3Z]2QP"1CT>@!KL$0LS *!DDG  KY7\>^(].\
M:>*-9O(+><V5E;%+%K6 ?O) RAII6'\! ;D]@O0YKZ5\1:'%XDT.YTF>[O+6
M&X 622TD"2%<\KD@\$<$8Y!(KD;?X/Z):^&;G0(-7UV.RN;E;B79=J"Q"E=A
M 3;M.02,9)5<GY10!3TGPQ9>.OA]X(N;NZ=+73(899+= &2X,:JI5\]OD(/U
M(KCO!/@*R^(OA+4M3N9);/[;KS7:YC#9B4',8/!P?-<$@]5''&*[P_![1!X;
MCT%-7UV.R2X>X(2Z0%RRJI4_)@J-N0,=23WK4\&?#K2O T]S)IEYJ4PN$",E
MU,K(N"3D!57GGK0!V Z5G:]8S:IX=U/3[>8PSW5I+#'*/X&9"H;CT)S6C63X
MBT*'Q)H=QI-S<W=M#. 'DM)-D@ 8' .",'&#D=": /G+6=9\01>"-+^&C^'I
M-.NI91#,TJ_-<,)<J4 'W=VWYQD-M(' -?40KC/#/PO\,^%KLWMM;RW=_P ;
M;N^<2R)UY4X 4X.,@9P!79B@#SOXUZG=:?X!\FVE:!+^[CL[FX SY4+!BQ/L
M=NWM]ZH?%NC>#O!_PKN[6ZL;/R$M#;P.T2>;/*5^5@>I8M\V1TP3T%=WK>BV
M'B'2I]+U.#S[.< 21[BN<$$$$'(((!R/2N+TCX,>%-'UR#5(Q>W+6W,%O=3"
M2*,CH0-N3CJ 21GG&<4 6]$T&^D^"MOH3*D=_<:*UNH=B CO$0 QQQC<,XSW
MZU$]F/AQ\')X(Y#Y]CI[DR1<[KA\Y89[>8W&>V..U=Z!Q5:_L;;4["XL;R(2
MVUQ&T4L9SAE88(XY'7M0!Y_\/?!WAN#X5V'VBVLKE;VS^T7=S(JGEU^8;CG;
MM&%XQC;GKFN7^(_A33_#GPLT7P[HT0NKJZU&*&WE;:9)I'#$L#Z,0HXXY6NG
MC^"?AZ.$VBZMX@&FM('?3Q?XMW&02I4+G!QUSGWSS5K7_A%HGB+5!?7.IZS!
ML"""WMKA5AMPBJH\M2AV_=!^M %C5?$F@_#ZUBT&RM\W@TZ>ZM[:( ;Q!"6S
M(P&06$9 8@Y*GTKGO!&@^&H_AI-XJUZWM;ZXU&">[U.]DB!=@S,748/RD8QA
M<<CL:Z#1OA9H^D^((]:EU'5]4NXX7@3^T[A9U","".5!Z,PQG'S'UK,/P0\-
M_:P5U#6$TXR^:VF+=#[.3G.W&W.W&X=<X8\B@#@/#&DKKL'@7PQ?)BPEFN]9
M,4S9\R$,1''WY.&)&<8;/6O7-=\!^&M:U+2'GM+:"6RG-RD,4:(9P,95AW7=
ML)^@'>K'BKP'HOBZ*S%^+B">Q;=:W%G)Y4D/3[O4=AC(XQQBLG1_A5I>EO=7
M4NK:Q>ZK/;O;)J5Q<YGMXV&#Y1QA3UP<$C)]30!X;XEBUB_\9>-=:T6WV6EI
M--%=3J%*HC-Y;8)&06P2=O.TMDX)S[W\-O#?AK2?#-EJ6@6C*+^V21[B<[IW
MR <,>@P?X5P,BLO0_@QH>BQ:FIU/5;EM1M9+28O*JC8^,G 7EN.K9'M6[X&\
M V'@2UNH;*\O+IKEE+M<N#M"YP%   'S,??- '5GBO#?C;XKTR\U+3?"<EX8
MK=+E)=5E2$.T*\;0I_O89FP/4>I%>Y&O.M*^#'AS2KV[O!>:I=W-U!+"\MW,
MDA'F AG'R#Y^3R<]30!@_L]:L+GPYJNE&,A[.Y6;?G.Y95X'U!C;\Q7L?:N!
M\$_"G3/ ^LRZG9ZE?W$LD!@V2E FTD$Y"J,GY1C\:W-*\+2:=XMU?7I=9O;P
MZ@J(EM,1Y<"*2=J@=AGCCN<Y))H \7^,<UWJ7Q#E^P+$LGA[38[N1_NO_K%/
M!/!QYB'Z;N_%9NBVNI^,/B[X?U#Q)M9]27^T5@P0$@CWF) I&-I\H$#G<IR3
MDDUZAH'P@71/%TVOOXFU*[>59E=9  \@D4CYWS\V,YZ#E5/;%'A/X1+X;\6Q
M^(;KQ%>:G<QQLJ^='AB2NS+,6)("Y&..W.!@@'I@Z4HKF[?PGY?C:Y\2SZM?
M7#/ (+:S9]L-NIQNP!PV2 >??.3@CHQ0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 T=13J:.HIU !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%&: "BC-&: "BC-&: "DI<T9H 2EHS1F@ HHS1F@ HHS1F@ HHS1
MF@ HHS10 4444 %%&:,T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4449H **,T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 9HI.]+VH :.HIU-'44Z@ HHHH **** "BBB@ HHHH **** "BBB@
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M&JB\GCE&<I$!D$'C:5:3@CD@#UH W?#OQ3\*^)]4BTW3KR;[9,I:&.:W=/-
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M<\#: OZ_6N!G-Q-XXUR6Q\-6&I0:AK$EI:3W%JS6R;78G;LP,E-K$YZ!CSU
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MQ)JNL6\R"VO8PEM;;"6MT)#%2YY/( _ 9R: /1**!10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 F*7M110 T=13J:.HIU !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4AI:* ..\2?#'PGXIO5O-1TM!<;BTDENQB:7./OE?O=.IY'K4FH_#7PAJMC
M8V5UH<'V:Q#_ &>.&22$)NQN/R,-Q.T9)R>*ZVB@#@[7X/>"+'4K6_M=':.:
MVD$J#[7,RE@05+!F.<$=.A[YJUIOPK\&Z/JL&IV.BK'>0/YD;O<S2!6YYVLY
M&>>..#S7944 <K_PKKPJ9M6F_LE/-U8,MZXGD!D#-N8#YOD!;D[<9P*AT;X8
M>$/#VK0:II>D>3>P9\N5KJ9]N5*G 9R.A(Z5V%% ''Z_\,O"OB;6!JNK:>\U
MWM".RW,B!P!@ A6'3VQ[YJ6W^'?ANU\'W?A>&S=-,NY#+*@G?<7RI!W9SQM7
M'LHSGG/5T4 <1X=^%/A;POK46K:;;3B\B5E1I9V<+N&#P>^"1^-6?%7PX\.^
M,KZ"\UF">2>"/RD:.X9!MR3C&<=2>>OKT&.NHH YSPIX(T/P7#<Q:-;-']I8
M-,\DA=G(^Z,GL,GCW-8]Q\'O MQ>?:CH,<<GF"0B*:14.#G&P-M /< 5W=%
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M+\O3"@57M/@_IVF)JG]E:UJ>GR:C*&>2U9%:.(,S>4AQPI)7W^0#."0?2**
M/+H/@S';:2=*@\9^(XM.960VJ3J(BK9W#;C&#DY'?)K3U/X7VVH^$]-\-KKN
MJ6NG649C:.!D'VCD',@V\X(R!TY_&N^HH X[2? LFC^$[GP_;^)M9*2[1#=&
M5?-ME&T;8SMPJX7&/<XQUKG;/X+0Z=8S6-EXQ\16UI.6,L$,ZHCEA@D@#!R
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!HZBG4T=13J
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M">"?B7:>*8-2CU"T;1]0TX&2ZMIV.(XQ_'E@IX[Y QQZUR]W\?\ 3X[YULM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M39:S;_$_Q)X1T2+RAXGF@<L)&XC/SNYVGA23+N!'3/&#S](K&J*%484#  Z
M>U0FPM#?"^-M";L)Y8G,8\P+UV[L9QGM0!XG\5=2T/PUX#M? &FW:>?');I/
M'(C.Z0@F3S"0 "Q=5) Y^;I7+>%=<\->"?$PNQJ=IKS7EVD(NI(9 ;*T4C]X
M2Z@^8?E^500/+Z\@5]&WF@Z1J$_GWNEV-S-@+YD]NCM@=!DC.*@_X13P[_T
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M"TQ64Y#"SC!!]>E9OC+P;#XTM;&QO;R:&P@NA<3PQ ?Z0 " I;JHY/(_F 0
M7O"GB2'Q9H,6KVUE>6D$Q(C6[0*S ?Q#!(VGL<UMU%;V\-I;QP6\:Q0QH$2-
M!@*H&  /0"I<4 >)?&OQ8NH26O@?2;E&NKJX07I$@55R1LB9CP,L0Q]-HSUK
M!^&&JOH/Q=O=*U2S@TZ>[A%B;>TP(5FC5=O0GDA&).?O.<]>/=7\+Z!)JO\
M:KZ+I[:CO$GVLVR&7<.C;L9S[TB^&- 353JJ:+IZZB7+F[%LGF[CU.[&<^]
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M+;/Q=XNU+3YY;.%DT^WTPDQ+N!5F)(YR">F<YZ\ 5W\VJ6$&H0:?->VT5Y<
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M ,48HHH ,48HHH *,444 &*,444 %&*** #%&*** #%&*** #%%%% !1110
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M5=Z?8-J2Z9J,=Y/IZ@DW"*"",#)/7& "<,3VP<+5O&5[\4/#USH'A;0+\"[
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M0V]RDDT-N4FR))$R55L],@=:H6?Q<U^?3]<O7\+VP714(N<7OW7W ;>G/?\
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M5W;0AQG%<;H/C&S7XJ6NI^*O&!U6TTVVE^RWB6SQQB5OD*B-5[@L=P&#A>>
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M)R2;2,DG\J4>&=!$31#1--$;L&9/LD>"1D D8ZC<<?4^M:M% &1_PBOA[_H
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M.,GO2,C';ZT8H YWP9XJ7QCH9U:/3;NPA,[Q1K=* TBKCYQCMDD?4$=JZ.D
MI: .4\?>++OPAH:7EEH]QJEQ-+Y,<<0)5"5)W-@$XXZ <],CK7D7@O6I=2\=
M1:QXL\.Z_J&MRSK%8NEN?LMHIP 0CXV;3N.<D#.< \U]#D<YH(SUH \@\0ZC
M?^!OBMJ'B*7P_<ZG9:GIZPVSVB^9(LD87*GNBDXSQSP1D@BK.@>$=?'PR\5M
MJ%L#K_B(7$[6PVKL9TVJA/ !SD\G W>QKU7;C_\ 72XXH \"M_[5\?\ A_PW
MX%AT#4--MM-\HZM=W,6V/;$I7"?WBQR<<'/J 2.]\9_$S3_!NJKI6J:#J<UI
M-;Y2X@C4QR'H4&X@' ///&1QSFO0,48YH \9^%>AK=>.=3\7Z5HDFC>'IK4V
M]I;SY#RLQ1BZKT"_)V)&3@$X..TD\<M-\2;?PEIMC]K6.-I-1NE)Q:_+E!Z=
M< Y_O"NQV]?>LG1_#ECHM[JMY;J6N=3N3<W$K@;B<8"@@?='. >['UH V!TK
M*\0ZY#X<T>74I[6[NHXR!Y5I%YDC9.!@9%:M!H ^4S8^,=2M?$?BUS-!)?;K
M&Z@>SD,L\<FT[$780  BC.1@#KS7JG@#QF^D?"VV;5](U@R:9*+,I#9,S..2
MA4<<!< DXY ]17J^.<_UI,<Y[T >/?!2]G>\\0#4;#4H-3U"Z>_F>6T,< !(
MX5C_ !%G;CT''3GV,4A&>HI10!E^(?$.G^&-);4]3>5+5'5&:*%Y""3@9"@X
M&>YXZ#N*\=\)>-[#7?CA?ZH_VXI>6XT[3(Q;[@L8PS,Q!R@RA;H?]8<X"FO=
MB,TA'^<T >._%WQM%=:3JW@[3+/49]6;RUF,5LQ18\JYY'/(P.G\5=[X&UBV
MU;PU;I:VE];Q62):?Z;:^0SE$7YE7)X_'^5=)C'K^=*!SF@#EHM3T75/'4NG
MMHTK:IIL1=-0GL1L4';E8Y3SGY\8'O4'B[X@6?@[4((-0TK4Y;26 RM>6T.^
M-#N"A"<CGG)Z8RO7/'8$48YS_6@#Q+P3IUMKGQ5C\4>%=%N=&\.16CK.\D9A
MCNI&#+M1 =N =I(' ,>3@D9P/B#%IOC#Q7<0^'=-\1#7KAUMKJW:#RH)=IVK
M(^[H %[X!QG@@Y^BRH/44;<__KH Y7X<>%6\'^#+/39B3=O^_NLD$"5@,J,<
M87 7/?&>]=/<Q>=;21 XWJ5SC.,C%24M 'A?@SQLGPX\,3>$]7T74&U^RG=;
M>V@A+"^+L2I1@.!VS@\8(R?E'=_#GP]J6GV>I:WK:M'J^N7/VNXM]P(@7G8G
M3J >?P':NWQ]?SI0,4 9^G:)I^E7-_<V5N(I;^?[1<L"3O? &?;IT]2?6O)M
M-\31?#GQ_P"+/^$JMKZ,:Q>?:+2]CB,L;PJ7VKD'/RAE& #CIQU/M5)B@#S"
M7XOV$?AV^U6XTV\M8I))H=)=@Q^W[%.&'RYCYP#N&!G@G# ><^'/B59>#OA(
MVF:9<2)XE>=W&^ LBY<?/\PVGY ./4_6OI7&/_UTUHD9E9D4LOW21DCZ>E '
MA^F>(H_ GQ UW6/%-C?JNMV]O/:W0B\XI\A9H=P Z'"8'_/-<\8-1ZY;>(_B
M#_:GB_3M)NK6UL]->WT:-OEFN=Y*RR  YSY;2;1T)*X)YKW8#'2DV]>.M 'C
M6@?&KPUI_AG3M)M=,U26^MK*.%;6" -F1$&5!SG&0><>^*Y[XO\ B;1-4UG0
M-"NA=6-MIZ^;J4<"*SVY=$(B49VEU P2,J-PQGD5[]_9UE]M^V_8X/M>W9]H
M\L>9M]-W7%13:)I5S=B[GTNREN001-) K.".GS$9XH \3^'6LV7@#Q]J_A"<
M7<L-_=6_V!_*S)AQE3)C&/D=<G'!!X'('O9Z55.FV+7ZWYLK<WBC:+@Q+Y@'
MINQG')_.K5 'C?QN\?P6&E7'A.PDW:A<A1=D+D1PL"2N<\,V%&,'Y6]2*\\T
MC7]0\$_$G0X?$-M'$=&@6PECM^2(I07W';G>1YH; ZXP!FOI6X\/:-=ZG%J=
MSI-C-?Q;3'=26ZM(FTY&&(R,'I3+OPSH-_?+?7FB:=<7BL&%Q+:H\@(Q@[B,
M\8'Y4 0ZQXJTC0+_ $^RU.[$%QJ,GE6J>6[F1]RKCY0<<NO)XKA/C-XFT:WT
M_3O#.HR[?[0N[>6Y(#?N;5907DXY/W2 !SU]*]+N-+L+RZMKJYLK>>XM6+6\
MLL89XB>I4GD?A4=YHFE:A*LM[IEG=2*NT// KD#TR1TY/YT ?(VM:;INC[[*
M[NO/N&N4,1C9BMO9'+AA_M.) 0N/E )/+5]4:[XJT/PA'80ZE<?9Q=2"WM88
MXFD9R,# 503@94=.X]15^?0='NKHW5QI-A-<L03-);HSDCH=Q&>,#\JL7&GV
M=V\+W-I!.\+;XFE0,8V]5)Z'W% %@'(I:0"EH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!!2TT=:=0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ""EI!2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 @I:04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ,R%&3P!R35?^U;#_G\A_P"^Q5G&1C&:A^RP_P#/NGY4 6**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!HZBG4@%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #1UIU1L6#+M&5SR:?0 M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 @I:0&EH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H%.I!2T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T=:
M=31U%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!!2TT=:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% ""EI!2T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 @I:04M !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 (*6D%+0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% " TM- I
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 (*6D%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% "9 QDTM12>8&3RP"-WS9]/:I,4 +1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (*6D%+0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #2<#-
M)O/M3NM&U?2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *,TT\ G&?:FQL7169"I/\)[4 24444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 (*6DS@@4M !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "44M% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 TC+ TZD%+0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% ""EI!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 @I:04M !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 (*6D%+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% ""EI!2T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 @I:04M !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (*6D%
M+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% ""EI!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 @I:04M !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 (*6D%+0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% ""EI!2T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 @I:2B@!:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K#+
M BEHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH 2C%%% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% "4444 +1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&:*AN;F&TA>:XE2
M*)!EW=@ H]230!-D4A8 <G%10W$<Z*\3!T;D,IR#^(XKQ'Q[\6-3T7QNMOH<
MT<EE8IY=U'( 5D<\]1GC% 'N1( R>!ZU E]:274MK'<1M<1 &2)6RR ]"1V!
MKR.;X\Z8WATR)83QZR5PL#@;%;^]G/W?YUXM!XCU>RUTZY;ZA.-2>3S9)MW#
MMGG<.A7L%Z"@#[,+*"!D9/:J]MJ%G>K(UK=0SB-S&YC<,%8=CCH>1Q7SCXA^
M-&M:WHD=C:0C3YGXNIXFR9!@?=_N]ZP_ /CN[\$ZH9?];IUS)_I<1Y)_VQ_M
M4 ?6088ZTNX5X+XI^.KS0RVOAFU:'?\ \OL^-PR.JIR,_6NT^%'CEO%>B26>
MH3,^K6)Q,2 /-0]'P#^= 'H^11FJ%UK.FV,\4%U>P0RRMMC1Y "Q] *N@Y_P
MH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ2R@%7QR#^5?'Y((^89%/VHZ]=I)'/7OZ4 ?;.GZK8ZK$\MA=P7,:-L9X7#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 )1110 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %,)!&,G)XZ4^O'OC5JO
MB32;:Q.GW4EOI4X,4YB'S>9GNW88H \Y^*=M;6_Q U)K-HFBF43.(R#L<_>!
MQWS@UP;D?*/0<U-,V7W<Y)+,<\L3W)[U7;KF@ !%-;D\4$XHW"@!*2E)YI,T
M %%&<\48Q0 4>]%&?EQ0 @(/ HR*:HVMDT['- "T @'FDS01D4 24Y>E-4Y
M'I2@XH ]7^!<VDVWB+4'U"YAAO'A$=KYK;<J3\X!/?@5]%JZLH.>HS7P[E"#
MO(*@YQCE3ZY[5]*?!2'66\'F^U2^FFBNG_T2&8YV(O&>?6@#U&BBB@ HHHH
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M %%&:,T %%%&: "BBHDN89)Y8$E1I8L>8@.2F>F1VS0!+1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 )1110 M%%% !1110 4444 %%%% !1110
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M%#E20>" 1R*X?0OA/;?\)->^)?%4L6K:E<7$DL<.W,$(+?)PW+$*% !X'3G
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MU/X%WUY?:?=IXJNY[Q'+7=]=LS2G# IY0R=NT9ZMUYXZ5UG_  J'PS#X0O\
M1+2V"W%W&ZG4;A%EN Q(8$M@< JIVC X]230!WR2+(BNC*RL 593D$>HK@=7
M^,O@S1[R.V;4&O"WWI+%1,D?..6!P?PS^HSC67P^\<ZM91Z3XK\61)HL<(B:
MVTA0KRA<!0SF-2!ZCG..G)-<?X:^$'BT&?3;VVLM+M9&*7.H;DFGN(20#'%]
M[RP5W'/RD[@&R.  >C^"_$;^*O'OB34["Y>?0(H+:UMI,%4:0!G;"GG(+GG
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MLU]/;01622R,^Q\!=NW<6 9<D#'(]<4 :_\ :OBKOX:MOPU-?_B*/[5\5?\
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MEU\5YM&*J/#QDDTZ"<IC=>Q*'==QP1U*XY!(!'6@#H/[5\:=O#-G_P"#$?\
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MI9Z*QR.//D'_ ++1YWC$_P#+EHH^MQ)_\371XHP/2@#G/.\8CK9Z*?I<2?\
MQ-'G^,>UAHW_ ($R?_$UT> >U&!Z4 <Z)?&'_/IHH]O/E_\ B:7S?%W_ #ZZ
M+_W_ )?_ (FN@I: .<:7QAM.VVT4'_KK*?TVU<TAM?:XF.K+IZPX'E"V+[@?
M]K=6O1@9SCF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH
M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZHB#<S,<  =23Z5YY!\:/"MUKL.GP->M:S3"!=3,(6UWD9P68AASQG'OTYH
M]&S1FN>\0^-_#?A6:*'6M5BM9I5W)%M9W*\_-M4$@<$9(QP:T])U:SUS2+75
M-/E,MI<H)(G*E21]#R* +V:,UY[?_&+PO8>)!H[-=RKYP@DOHHU-O')W4MG)
MQD9P#C-=3XD\3:7X4T>35-7G,-LC! 0A8LYZ* ._% &SFC-<CX,^(.D>-3=Q
M62W-K=VC8EM+M%24+Q\V 2,9X]0>H&1E;?XF>#[J>^AAUE6DL8I)KD>1*-B(
M0&.2O."0,#)/:@#K<T5S_AWQMX=\62W$6B:B+M[=5:4"&1-H;('WE&>AZ5T
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MA:13#&8Y)U5AGGH30!=HIN]>YQ]: ZDX!!/UH =1110 4444 %%%% !1110
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M189>!C\: &JI!S24_P"M)MH 9B@]*?MHQB@",9'44O6G,.E(!0 FWWHV^]/
MXI* &GI2 'TIX'-.7K0!&%)/TK8\.:)=^)=?MM'LM@N9PQ!<X4  GG\JI6\,
MMS<)!!$TLTAPJ(,DUW_PST'6K/X@:%?RZ3>16Y>0/(\1"A2I7G]: /1?"?P7
MAT/5K/5KS599+JV99%CMUV*''4$Y.1C Z#I7K0SM&>N*2/[@.<TZ@ HHHH *
M*** "BBB@ H/2BHKE));65(9?*E9"$DV[MC8X.#UP><4 >&?&RXTG5_$VG:
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MT,XE,<2-S(#C!.3R .Y))/0 'F&G_"G3=2\5>--(L6GN1HUHJV7S(/,N7CR
M[8  #JPQQ[GCGIOB/X+L=*^#&D/J;O\ VAH=ND421NNQI96C$@.1E@,$C&.
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M5^9&6! Q(1!S@*"2><\=E-3^#?%^LZMH^I:GXIT(Z!;VGS*\Y9"R!278JX!
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M[&O9@,#''X4NT#IQ0!0U#1]/U2-8[ZRMKF-6W!9HPV&]:N1((T"* $ PJ@8
M'I4E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% ""EI!2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4<T44 +1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )112YH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!**** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** $HHI<4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 E%%% "T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% "49HHH 6BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BEQ1B@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex-a_003.jpg
<TEXT>
begin 644 ex-a_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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MB@".12W R,@C(_A]ZKVEC':;W7<TDFTR.W)<@8%7** $4$*,]:6BB@ HHHH
M**** &GJ:=110 4444 -;I45NLJJ_FR>82Y*G;MP/2IZ*  4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !2&EHH HM8QF_-XWF/* 0F6XC^4 X'O
MBK@Z4ZB@ HHHH **** "BBB@!J @<TZBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *K75I'>1M%,-T;8R/UJS10 E+110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% "=Z:D:(257!/6GT4 ,7_6&GTP#YR>QI] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -'44ZFCJ*=0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &CJ*=31U%.H **** "BBB@ HHHH **** "BBB@!*,4M% !1110
M E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4F:4UQ5K\0X[_ ,3_ -DVNA:K)9K>/8OJ?E8@69 <
MCUQD8SQS0!Q&FVUCHWB_349O!NL1R:S(([FT/_$R260R/ND(8@["V"#G@+W
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M"-I)93)\YMT9]I/.W<6Q[8H Z&P\(166N:?J9O[BXDLK>Y@42@$L)I1)G/\
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M4Z@ HHHH **** "BBB@ HHHH **** "BBB@")X$DD21D0NGW6(R5]<5+110
M4R0,5PN,^]/HH 1<[1GK2T44 %%%% ",,C\16>ND0C6&U/+B=H!;L-Y*E020
M<>O)K1HH 15VY]Z6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4A;Q_;7A6!I\?,8PQ8+GTRQ-6J* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!HZBG4T=13J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!&SCBD7.>:=10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A4'N:"N?
M6EHH 3'.>:-O.:6B@!I0'K1L&<_G3J* &[?<_G2[1QUI:* $Q2XHHH ,4FWG
M/-+10 FWGJ?SH"X]:6B@!NWCJ?SHVCU/YTZB@!-H'K1M&,4M% " 8I:** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH :.HIU(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!HZBG4T=1
M3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@ %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ,R-X7//6GTS:/,#]\8I] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ,SB4+VQFGTT ;@W>G4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 449
MHS0 449HS0 449I,CUH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&CJ*=31VIV: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 -%+2#M3L"@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,T9H ,4A (P0"#
MV-+FC- ";5XX''M1M7T'Y4N:,T (  , "EI-P'<4;AG&1GTH   !@#BC SG
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M(]P30!U5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLKQ7%L3%*A48 #+S@=,>E5=.^'>@Z78W]K;Q39OT9+BX:9FG<'@_O"=W3WH
M^88Y+NWTN_L(IBUB]XIG@4C$Q1FVL.^.>U>D>+O&'AN[T#P@GAR^BM9["_3
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MVGD0I<1MQ/;A<!6..#[UZ3X2TRXT7PEI&F703[1:VL<4NQLC<!S@]ZV<48H
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M^YA@$;>QJ6F]2#3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9S^#O#,S^"O#]M)=/(F;=4*@Y_B//)% ';9I:R]"O+^_T2SNM2M19WDD8,T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@")80HP#@9. !@"D>VB=UD:-&D7H[*"1]#4U% # F!C=3L>]+10 F*,4M%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!K??6G4UOOK3J "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!D
MB"2-D(!##!!&016#9^"?#FGZ@U_9:)96]VP(,R1#.#UQZ9KH:* ,73_"NB:3
M?->:?I-K:W#)Y;21)M)7.<<5IM LN#)$K>S8.WZ5/10!5%E DIE2VA$A&-X4
M _RJ4Q;A@HN,YQQ@_I4M% #0" .!^%+S2TF: #FCFEHH !12$X%+0 44F:7-
M !1129H 6BBD+8H 6BDS2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHH **** "BBB@ I H'84M% !1110 8'I1THHH ,4444 %%%% !1110 4444
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!IX84ZFM]X4Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***,T %%(6P<8-*#D4 %%,,J@D<Y':E+@=B?H* '44P2JV,<YI2
MX'7- #J*;Y@QGG\J3S!M) )Q]* 'T4F:7- !11FD+8&<$T +13#( N2"*4/D
M<*?TH =132X&.ISTQ2[A^'K0 M&144]S#;PO--(L<2#+.Q 4#W-86N>-M"T#
M08M;N[LR:?+(L:2VZ^8"3].W% '1450TK6+36-*MM3LV9K6YC66-V7;\IZ<&
MKGF C*C=]"* '$@4M>?^+_B/_P (KXMTO1FTN69;TJ/M18!0&;;A1GD@GG.*
M[X/S@ GUZ<4 .HR*R_$&O6/AK0KO5]19UM;90S;%W,Q) "@>I) ';GG KR#_
M (6-\2M5\,WOB?2M(TI-&CDD &UI)XT7JQ^<!MO<XZC.W% 'N=%<-\,O%MYX
MC\"?VSK<T"R12RK+, (T"+SN;L, \GIQ73WOB'1M-2![[5K&U2X7="T]RB"1
M>.5)/S#D<CU% &E17.S^/?"%NH:3Q/I !.!B]C;^1K5TO6-.UNS^V:7>P7EM
MN*^; X9<CJ,CO0!=HR*2N1\9_$?0O SV\6I?:)[JX&Y;:T56D"<_.VYE 7(P
M.<DYP#@X .OHS6'X4\4Z=XPT*/5M,\Y86=HVCF4*\;#J& )'3!X)X(KF?B)\
M3XO!5U:Z?:Z>^H:E/'Y[0Y*+'"-V6+ ')RC< <!23CC(!Z%D49%>4ZG\7+B;
M1=&F\-:,U]JFJ12SK9.Q9HHHV92Y"#YLE3W'0UF:E\:M3G\.6&L^']%@:*2Z
M-E=QW4A=HIBJM&%VD$AAN^;';''< ]IR*,BO [7XP^/=0U6STFW\/Z=%?7KF
M. 2Q2@9#,C$_-T4H^?3:?2K,/QGU[4-*M-*M-/LD\6SWYLGBD#")1P X!. =
MQVD%C@J3W H ]SR*,BO")_B+X]@T_P 0Z'(; :_H:>=-<1PY\RV7 DD4?=W
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M5#L,<9!W#H,5UGQ$TK0/"=OX,_L)[633I9[F^4ZB&N(&23R,%UP28]N!@ G
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M(T[6YE+B6-H'(;<0,JQ4-TQD>U>X^,_$3>%/".H:VEJ;E[95VQ9P"S.$&3Z
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M78T8H Y'PE\/=*\'W]]?VMU?WM[??ZZYOI5DD/))Y"CJ3DDY)P*Z['O1BB@
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M\ZZ"B@#,A\/Z+;H4@TFQC0]52!0.F.F/2K":;81',=E;H<@_+$HY'3H*MT4
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M=R,9KZ.L93/902F6*;?&K>9"<H^0#E3Z'J/:@"Q145Q.EK;2W$F1'$A=L#/
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M=2WL* /H>.1)(UDC=71@&5E.00>A'K5+5-<TG181-JFI6EE&V=K7,RQ[L#)
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M&<$')ZYP,=[86-OIFGVUC:H4MK:)88D+$[44!0,GD\ =:L44 (1D8H50JA5
M  P .U+10 4444 %%%% !111F@ HHS10 449HH **** "BDS2YH **** "BD
MS2YH **3-+0 449HS0 449I,T +129I: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M]X4ZF
MGDBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "
M$XQ7R_%J<>H:I\3;'2[.:_74E>XBA,63\EQS)C&05\QG QGC!YQ7U#42V\2.
M72-59N68#!/?F@#YX^%4=YIOCNT^U:7KLMCJ>F?87DO+1Q&)%"DC)&#$HC*#
MT! P!3M3^$^J7NL^++*Q2]%AI@$^C0RAD@=I2LCI'G(. I3CJ0FXBOHK%&*
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M\%?$$&NRZ59QZ>-!>[6=-2FC1[F.)3D(#][/L, D9)&<5]!T +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% " 4M(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-XWVO&W0D'W!((Z'TX%<]IGP?\,Z=X9N]#V7,D=VZM/<F0++(%;<JY  "CT
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M# YQVH 6BDS7.ZCXVT33/%5AX;N+A_[2O2-D2Q,0H(8J6;&,$KCC)R1G YH
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M3.74DD-C("E6!.T]4[M@6+7XXZ=/X7O]3ETF[2_LG5)+*-Q(H+E@C&3 PF5
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M<-I%D;O=]J,$?G;Q@[]HW9'KG- %VBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $%+2"EH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML"'4M/NFF>Q:%V^T(JJ8U1U4JK%MX)8^GOGZVATVQMY!)!9V\3CC='$JG'U
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MPY;6YMX= TJ.!GWF);.,*6QC.,=<5M44 4GTC39+R.\?3K1KJ( 1S&!2Z =
M&QD8R:N8I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $HS110 M%%% !1110 4444 %%%%
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MT@<2/(R\3%=REHU/.[C"[CSQ7HGQ"U76O!_PM,MOJ!GU*-8;:6^:/#,6^5I
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M$8."&4YY(%+_ (6!XWMM<3PC?^(54KJJ6\VHPQJTBKOVL%;;RO.[D9XQG'%
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M91E/4L"69L#&"3UK5\6^$M.\9Z,NEZGYZPK*LR/!)M=67(R,@CH2.0>OK@@
M\F\>FWO?#7ATP^(I=6U'3O$,=A)J<2+&ZLR%\*5&,K\F"">0<Y.:SY?&GB71
M[;X@Z='KE[</ILD2V=S<,KR1#[4L3?PX)96Z\8QD#GCN$^ _A%(H8_,U5A$Y
M<DW0&_Z@+@=!R,'CK6SIOPI\+:9>W-W':W$[W4;Q7"W5RTJS*Q!.X-UY .3W
M&>M 'C7PDUW4X_B7IMC%=7<=CJ*N;F&:7S?/9+=OG+$9^^F1CH/ER<$GO/B^
MGAR[\4>&M.\1K+;VURLH_M&&;:UMRN.""I4MM!)' YXKM_#/P]\-^$;RXN](
ML#%<3 J9))GD*IG.U=Q.!P/<]R:T]6\,Z'KTT,NKZ3:7SPJR1FXB#[0V,XS]
M!]* /GJYN9M$/C#2/#.O2ZSID6B1JMRJK*8X_M$:M'Y@&"JI+-R, 9)&-M9?
M@PZV+?4!X3U-;.].D237%K9Q2R/,(VQ\Y;(60JY*&//I\I8U]+Z%X6T3PU8M
M9Z/IL-K"_P#K,99I.OWV;+-C)QDG XZ5/IN@Z1HQE.EZ596)F(,OV6!8MY&<
M9V@9QD_F: /F31[;P)<:5;2PV>HR:A%H]RU]O=6M8)ECD"NV5)RS;=FT@ E!
MRV15_1_ NB^(?@[<ZSI*F?Q)9NS72F<C:JL25"=.8^0>I(Z]J^CET32EBN8U
MTRR$=R<W"B!0)CU^<8^;DGK4EGIEAIR.EC8VUJKG+"")8PQ]3@#- 'SE\&;.
MPU/QY&D<9NX?['D2_26!!%DE4VA03N!&W)/+$L<5G0V_BS7_ (40:1IWAUY=
M)TZ0-*Y@=[B:X:23<T8'W@N[8P )'.>^WZD2WABSY<2)GKM4#/Y4Y8U0;54*
MOH.E 'S'IEEXR73?%UFO@W5KW^WV0O<7T!B:,J[MO*E0&<[\Y& K 'GI7:V^
MB>&=-^#]MHWBZ*QT/5+Z%RQ=42=Y(G;RW) RQ 8=>SD=Z]IQZ5S_ (D\$>'O
M%SVSZYIYNFM@PB(GDCVAL9^XPST'7TH X7X%:))_PC]SXHOY)YM0U)_)62:0
MN1#%A0,GG[P(Z]%4#&*W?''A/7K_ ,1Z/XF\,7%HFJZ<LD)BOMWE/&X(SQT(
MR?KD<_+@]M8V5OIUA;V-I'Y5M;Q+#%&"3M10 HR>> !4] '@M]\(O'%WI6KM
M)JFDS7FMW"37T.'51L)=65\=<L1C;T[U[5H4.HP:'90ZLUNU^D2K.;9<1[A_
M=&!Q^%:%% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 E%%% "T444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %&:*\W^)GQ*E\'RVFE:;:1SZO>*&C,
M_$42%MH+<C))!&,@#!)/0$ ]'S6#XN\7:=X+T9=4U..X>!IEA @4,VX@D<$C
MC@]Z\CO?BKXR@TOQ)9SQZ9!JVC31^9<01,4*&58F558G)W,I#'^'=P#@UG^(
MK[XD7?PPN-:UC4]/72;U895C6)#,R284 87"#D-UW<GD<B@#W[2M2@UG2+/4
M[4.+>[@2>/>,-M=0PR.QP:H:GXC73?%.@Z']DDE?5OM!$RMA81$@8DCOG('X
MUXIX[^(FOV5UH,NF:O/I=O/H%O?)!%"D@:5RP*L6'3:!R<XQTYJ.QLM6\'^(
M?AYJ6HZ[>W4^L32>?&UR72))#$N-QZY#H6ZC*<= : /HK/M1FODQCJAC\57G
M_"5ZBD^C7*+!'->MON<SLA;EADJ%R<#J1Q3O&GB6\\3VOAE;O4-UQ%I;//(\
MA"&0N_9?XBJ*.G)(H ]\^(WCFZ\"6-E?)I$=_;7$WD,3=^2R/@L.-C9!"MSG
MM[UT>O:M%H'A^_U:X5GBLX'F95(!; S@9[GI7SKXC\16VJ_ SPS9R:@)]2M=
M2*312/F5519<<'DJ%>,9Z<@5[OXQTQO%W@'4;'2[B"0WML&MI5<-')R&7##C
M!QU]\T <19^./'NK^"-0\7V-GH%O80&62&UG6625XH\[SO60 D%6 &T9P>G&
M>B\(_$?3M2\(Z?J?B+4M(TN]NA(PADNUC#JLC)N57.0"4/&3TZUP'@CXEZ%X
M0^',NAZM;W7]KV#S1OISPD&9GD8[,]!C.&W8([ ]#PWBJPU?3M8TN3Q;:6^E
MV=S8,EK%;P>;':Q[2-J1EQAPS!CES@N#SC% 'TCJ7COPMI$L45_KMA"\L8E1
M?.#$H<$-QG@@Y![]JX[6OC3H%AXCTFULKV"ZTR7S&U"ZC1W,(VD1A0.I+=>#
MQ]>/%_$;00>$O D%Y \5X+2>68R(06MGN&,(!ZD;0Y ]&'K7I_C7PTO@_6_"
M]WX2\(3WD5C]LF*0V[W"F9T40ER26PKJ&Y(QC@@T ='/\1+:#Q9K$/\ PD%C
M)8:;9S22V#64T<Z21A01YC81LMD8'J  >H\<F^*?CJYM;C4%\1R1'S]IMH;1
M=L88$C#%" ." "Q8X/UKHY=3UK_A9=UK-]X/UJ><Z5]BOH;73V8&<Q["RXR#
M&6& 2?NCOBGV6@:[#\"+K0I/#6JMJ-UJ(>)%A(8 >6WF."00,*RC(/(_&@#L
M1\8-/T32M+MKY;G6M4.G1W5Z^FQ*4C!0-N;+ #@@G' Z\9 JMJ7Q[TJ"ZC_L
M_1KR]LU6-[F<R+$8MX!P%.=Q&<'D#(.#CFN8TKX=^,]$N&U"'1++4H=2T0V=
MQ937'EF/]R@VOT.=R*?E/J-R]:S[_P"#_C>\O]0>[L;*ZG>-?)NXKM8XAL48
M54P#]U1& 0H'!S@9H Z?5/B7JZ?%:Q&B6MUJ>FW>F1-%IH?89=\9F$BYX5@,
M9SG@,/I9UWX\1:)XEN]+_P"$>EE@M)C#--]L"OE3A]J;2#@Y ^89QVS6)-\-
MOB+<WFC7\']FZ?>:?I<>G)(EXVY5".F[A3M;8^"5)P1E3TQ3O/@1XH62XACN
M=(OUNBI-[/),DL+9!<A1P<DL"3N) S\I- 'L_C#Q?!X4\(S:^+<WD:^7L1'V
M;]Y !S@X'.>E>>6OQ/\ %D5R-&\1:/9V&H:G8-<:9-&7159D8H)%+,1DKC@A
M@< CG([WQCX.'B;P-+X<ANC 0D8BE==PS&01N''!Q@X]?PKSBP^%WC6>^?4=
M<U"RGO-.TQ[32<2%U$@4K&S IC R3D\EL$]* *OP-\ B;[-XTNYI5:-Y5LHU
M9<.-K1N[]3U+ #@Y7/(Q6I\0]*L!\9_!4OV2'?>3 W)V#]\490I;U(&!^ ]!
M76?"SPGKG@WP]/INLW<$ZF7S+:."1G6%2,LOS*,?,2>..<UE>+OAKKOBKQY;
M:P/$*V-A9HAM?+C+30R @L%' Y(SN)/88(H Y37O'/CPS^++VRU:TM+#PW>B
M#RTM5)N/,F\M0=V>@Y)X_P +&J>+?%OC.^T31=)U.#1KFXT4:HS0N4-Q,5/[
MI23D#CIDX&XG.*V-3^#-]?7?B!XO%\L%KK5Q]HGMA8!E)$GF*&._G:3QC;[Y
MZ5-=? [1[[1=*L[G4[XW5@AB:\CP&EBW,P3:<A=I<X/.!QR,8 .67Q1XE\9:
MY#H2>,8+"6RTM[F2YTM<K=3J1NCR&&2%/5>,JQ P1CC];\6>(M<\':5XBN=7
MN(KNRNY+!7MY6B:4>6LH?Y2/F&=I/?*=\U[5J/P5\'W^EV5G#;SV,EKP+NU<
M":4=_,)!#9ZY(R.@P.*OZE\*O"FJ6>CV,]G*MCI22I!;13,JMYA4L7(^8G*Y
MSD=3F@#QOQ9X*\1^#= T=;_Q5</:7-]Y)C@D<0VQ8$[\LPR2 QQ@8YYY-8^I
MZGJFG6GB;PUH>JSW_A6&Z1IKLC>8T,@&0P(R&<X..'*Y& 3GV3XG?#[6_%UG
MI&G:)<V%OIUBK%HKJ20$M@*N"%;("Y'/KWKL-)\&^'="TVXT_3M(M8;6Y4K<
M(5WF=3GAV;)<?,>"3C- 'S[8S6>G6'CW3=)U&XD\)P0K-:W =E9;O<HA5>GW
MFW*QQ\RH#D=:K1>'WL_@]J/BD7MU>2:PR6=Q"H^2W"7 ;S)6R=Q/E*H.!CS<
M<YKZ.L_"'AVQT3^Q8-%LO[-+!VMI(5D1V&/F;=G<W ^8Y/ J]:Z3I]C8_8;2
MQMK>SP1]FAA5(\'K\H&.<F@#Y8\ 2:9<7&M>&)K5KX:Q9D6QB4ADN(E:1#@<
MXSD9]0,\$UG?:E?P"=.D\-A)Q=J8]6%L=\C?,3$SX_NG( [+G%?7\%I!;1I'
M!#'$D:A$6- H51P  .@]JE*Y(/I0!\PZA::HLD>JIX>EU2TUW1H-*T^1F(^S
MS&%(S\I!PP:-R <#G(8<U9\1:3K7AK4/#%E=:'<ZQ+IFDRQ2RPPNZ.TOFA$#
M!6R(MPQ]. *^E<48H \H^ T-[8^$+^RO=-N[1DOC(KW$1C$@9%' ;!XV\\=Q
M[UR\W@WQGX8F\4Z!I.AQZM9^( J)?LRHL2DL22I/!'F,!DC! (STKW_%&* /
M$/#?@[QCX7\9^'I8=!M[JQL[);&YN_M48PLLAEE8 L&RAD91P<A3_>X]-\=>
M&Y?%O@W4-$AN4MY;D1E)'4LH*2*X! [';CVSGGI71T8H \9_X57XJF\/V]I<
M:WILEU:7UM<VZF.0QA8(A%&F1@CC).!DX'/-/O?A5XAU_6O$5]K>I:=&FL0*
M EH'/ERQ[/)^\!E1LP?7)Z'!'L6*,4 >4?#[X5ZCX8\1PZMJM]8N;2V,%O%8
MP[=^[.YI&*@L<=^2>.0!@['CKX<7'BK7].U[3=;;2]2L8]D;&#S0<-N4CD8(
MRWKG(]*[_%&* /(8O@:-/2PDT3Q+/I=Y%9M;74\=N'\\MG<P^8%<AB.^ JX(
M(R777P/,EMH<%IXJN[5=*C^7;;CF8R%VE7##8Q..?F("KR<5ZYBC% 'BOQ-\
M%^*/$OQ#L)]$@>..UL(P=0$@B*MYCY 8$98 YP,=3TS6[_PHOPG_ ,(Y_9>+
MG[3NW_V@67SMV,8Z8V?[./QSS7IN*,4 >=6GP8\,0:!)I<SWLSW$R3W-UYY6
M29TW[<]@!YC< <\$Y(S6S>?#CP[?>$+3PS<6TCV%H!Y#;_WL9SDD/ZG)SVP>
ME=9BEH XVR^%G@RP>[:#0H?]*A,$HDD=QL/4+N8[3P.1@^]/E^%_@R>QM[*3
M0;<V]L7:) [C!<@L20V23M'7/  Z"NOHH YUO GA:34XM2?0;!KN-0%D:('.
M.A(Z,W^T03[UL3:=97$IEGL[>60\%WB5C^9%6J* *=GI=C823R6EG;P/<,&E
M:*,*7( 4$XZX  JWBEHH 3%&*6B@!,4;?84M% "8QZ48^E+10 F* *6B@!*,
M4M% "8HQ2T4 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 E%%% "T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %<AX^^'^G^/-+@MKF9[6YMG+07*+N*9QN4J2,@@#
MTY /;!Z^B@#RN/X+6IT#4;6YUZ^EU74RC7E^RJPD*OO V')VE@K'YMQ*CD#*
MG63X764OP^LO"%YJM^UK;3&9IK9EB:4EF8*P(8;06SCU4&N^HH ^<_&OPOUF
MUU6WL]'T:^U?2[33?LUG.;E%=',DDF9.!NVF1@% 48V\G!![3P]\(K&^\&Z'
M;>)X+A-1L%E&R"YV^7OE:3&5)!(R.0:]8P/2C% '!'X,^ F8NVAN7)R2;^XS
MGU_UE:5K\-/!5G;)!'X9TUT3.&GA$SG)SR[Y8_B?:NKHH YN7P!X/FMA;MX:
MTH1*V\!+55P>.X&>PSZUO6UK;V=I%:VT*0V\*!(XHQA44<  =@*FHH S9]!T
M:YOOMUQI-A+=[E;SY+9&DROW3N(SD8&/I5R:TMKC'G012XSC>@;&?K4W%% $
M+VMO)(CO!&[I]UF4$KWX]*EVC&*6B@!-H_+WHP!2T4 &*,444 &*,444 &*,
M444 &*,444 &*,4&DH 7%&*** #%&*** #%%%% !1110 445RNO>/_#?AO4%
ML=7U-K2X9/,4- Y!7..NW% '545PWA_XH>'?$$PMQ=MI]ZS[%M+P;';^ZRYZ
M[A@BNV!R2.<CK0 ^BDR,XSS]:C:9!(8_,3>!N*EL''K0!+251EU2QBVF2_MT
MW':H,RC<:Y/QWXOFT7P=J&IZ!<VEW=VCQJX$OFB-2^"6"G@YXH [JEK@/ OQ
M!L?$>FV,-YJ-L-9DM_-FMT?@ ,06]CQTJ[%\3O",\MW%'K<)-FK/,2#]T=2,
M#G'M0!V5(:XBU^*_@R[N+>WM]:#R7#JD8:)UR6.!]X"M7QMJNJZ)X/U/4](@
MBFN[2%I<3-A551EFQWPH)QW- '1<T<UX%9^/_%>I_!F^GMQ>7.K1ZBMI]MM@
M3*D9Q*7*JO\ VSXQ]X>G+O",WC.X^*&BZ7JGB6[N#:V0N[VWCD8K$"&/E2@8
M5G^=/F.<;@!TH ]\I.:#R#7A/CP>*?#WQ,T*1_%5_+8ZKJ2F*TAF>)(HA+&#
M&RJ=K##XZ<XYZT >[9HW#W_*OF;QOKUY>?%'6[+7=:U+3;"V$HMX;:X?:I$7
M[HA1Q\YVL>/XB,]ZYZQ\6:IJ%UX>M_$6K7Z:%:3>5),LLH+(7#2;G7YF(!5?
M9=N,9R0#ZZ)I,_7\J^.;SQ5J][HY\-C4[J323>O,HED9W<$J%#$G[HQN"\#<
MQ)S@8]2\$PR^"/CA?>$;&Y>72KF(GRVEW;#Y0D5CQ]\8([9# ^E 'NU%)2T
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MN3D<$$8R&/T(!&"*S)O@M(NCZ)IVG^(VL5TV0W1E2R#/+=$C][G>,8"J%'.
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M=>O[:[N=0PMS?):S[YP)V$C L0OIS7TRGPX\+1:Z^M+H\)OG;?OR=J-_>"]
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M"?EVDDD8RR]^*?BO3=,\2:9J":?%X@T9X6$L,),4L1D2-C@GKF2,CIPW08H
M]SS2,X526( '4D]*\.L_B%\0M/\ !VH>)M:L=/?3Y+6,Z?+\B[I7D55.%8G;
MM+,00/N@9'-5],\=^)_%FC>-=*:\L)Q;:<\L%R;5H1)%G#':<D;XR2,C@D4
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M\AQ*.5P=PXQ6<ESJ_P -O$_C5EU$ZAJL%E"B7TJ$EFE>([V#$\@,>"3R!VH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB2(1A1(&'7&X_+U)Z=:]6HH \@TCX!:1;6EQ!JNK7=\& ^SF%/(^SM_$RC+
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M,Y*X!& W4@YXP>G^'/PID\&ZW=:OJ&HQWET4,%N(4*(J$C+,.[' XZ#GDYX
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MTT88K[9ZX/<=#277A3P[?0V\-WH.F7$5LGEP)+:(ZQ+_ '5!'RCCH*V,48H
M:B+&@1%"JH "@8 'I2D9.:6B@!,>YH*@^OYTM% "8I:** #%&*** #%&***
M#%&*** #%&*** "C%%% !1BBB@ Q10:2@ /6E[4E+0 444&@ HI!2T %%%%
M!16)+XMT&#Q F@RZI;IJKD!;4M\Q)&0/3)'..O(]16U0 M%!I* %HI** %HI
MK,%QDXR<#/K37E2,_,X&!DY(&!ZT 2&@5Q?Q"\;+X5\,3W>GW6F/J8VF"WNI
ME_>+N <A0ZEL YX-)X=\<VI^'VE^(/$U_9V,EQ$Q<E]H<J6'RKU+$+G:,G/
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M$<: I&^'<*=HR[[1@]-HP ,:B_'3;H327'AZ:WUJ6=8[2SDD*QRHW23S&4
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BE/2DH 6BBB@ HHHH
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M9[D5X3H'P^\;Z-KVB:M;>$@LMG-^\66]3]\V2=[?,=@VM@;0>5)P<T >FO\
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M0I #;@>0>02>1CK0!Y)JOQD\2)H4^@W4T5KK45Z]M<:C!'@+"F S ?WRP;)
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MCTI:* $Q1CUI:* $HQ2T4 )BC%&:,T &*,4M% !1110 4444 %%%% !1110
M44R6:.")Y9I$CB0%F=VP% ZDD]!4$.HV5SIXO[>\MY;,J7%Q'*K1E1U.X'&!
M@\^U %JBJFFZG9ZQIT&H:?.D]I.NZ*1<X8?C5K- "T5%/<0VMO+<7$L<,,2%
MY))&"JB@9))/  '.:PM<\<^'/#EY9VNK:I%;27@#0$JS*5)QN+ $*N3U) H
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M@@ [NYN8[2UFN9G"10H9'8\ *!DG\J\]\!_%RT\<:Y+I2:5/92K 9T9I0X8
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MEB9R681LYR.20& !QZ4 3WGQ6\6W?B^72/#GA^UOXS:Q7,,;AA*4>-)-S-N
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MR* $H%+D44 %%%% !11FB@!&&1Z57M+*UL(/(M+:&WA!+".&,(H).2<"K-%
M""EHHH **,TF10 M%&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH #TI*4]*2@!:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+10!Y!XX^%L^O?$;3]
M0MDVZ3?%?[7\N4+_ *OD$KP3N "Y&<'GCNGA7X::EX;\.^+X8(X9M3O5EL=/
MDN) JM;[<*YP& R6)VD<E1T!S7K^*,4 >"#X;>/[7PQH%M9RV$5_HM]/);LE
MSRJ3%#G)7!PWF$Y['@,>*UW^'7CVQUN'4-*U'0VD31H]*:2]>5VD4(-[%=A&
M=V<9R, 9!Y%>RTF* /.OAMX#UKPCX6U31M4O+-A=2%H&M6=_+W1A23N"^@.!
M[\^G)Z!\(O&^@:;J-C9>)=-M[>_B:">(1O(K*1C<,@;6QQD?F<5[CBC% 'BU
MS\ +>+2[!]+U<QZQ;LKRRW,0D@F8'/\ JST .,#D$#!!SFI$_9_M$T^!XO$%
MU!K$<GF_:TC^0-P1A 01@@D$,#S[#'LN*,4 >4:G\#=/O='L+&/7+_?;W<MS
M+//MD:;S=GF#M@_NP0>>2<@YJ32?@9H>D:Z;Y+^[GLS%)$;.94(8.I5@7 Z8
M)Z $''/%>IXHQ0!YOHWP4\-Z-J]M?_:-0O5M#OMK:[E5HXWR#NPJC/(SCIGM
M45U\"?"-U.THEU6%GR7V7>[>2<DDNI).?>O3<4M '.Z#X+TKP]X5F\.6QN);
M"82B032?.PD^\-R@8Z]JYN+X'>!$(WZ9/*H&-CWDN/T85Z-10!S^N>"] \2S
M6DNLZ;'>/:*RP>9(X"AL9R <-T'7/2FQ^!/"L93_ (I_3Y D(MU$L(D C!SM
MPV1C)S7144 <?XC^&OAOQ%H,>D?8(=/ABE\V%["%(FC8_>P-N,, ,\<X'H*K
MK\)_"?\ PC0T:33(';R]AU#R8UNR<YW>8%SG^G!R*[BC% &)X8\*Z7X1T==,
MTJ%DAWF1VD<NTCD %B?7 '3 XX%:S6\3-N:*,MZE034M% #/+4.7"J&/4@<F
MGD444 (5SUHVC/2EHH 3&.E&#2T4 )@T8-+29H ,&C!I:* $P:,&EHH ****
M "BDS1F@!328-+10 444F: %HI,T9H 6BFJZNNY&5AZJ<UEQ^)]$EUO^Q8]5
MLY-3^;-JDH:1=O)! Z'!Z'W]#0!K44F:Y/6?B;X.\/Z@]AJ6MQ)=)G?'%%)-
ML.<88QJP4\=#S0!UM%9VB:[IWB+28=4TJY%Q9S%@DFQDSM8J>& (Y!ZBM#=[
MB@!:,UDZAXDTG2]7T_2KR\2*^U!F6UAVL3(1C/(!"]>^,UGZ7XWTS5?&6J>%
MX$G6^TY [LZ?(X^7=M/L74<XSGC(% '344F<>E&: %I,T9KA?B#X_F\*7&E:
M7I5E#?ZSJ<PC@MWE"A06"@GGC<Q"C.!PW/!H [K-&:\,N_CGJ^COJ>GZUX<C
M@UBV*K%%'+NC5L_,)#G^Z<@KG-2'XWZIIFHW%GK^C64#?8C/ UO.T@:1HO,B
M!(SE6RJY'0L#TR: /;\TM>%P?&W78[_18[[1M-^SZGY;C[/<,[K&TACY&<!L
MJ3@_C@Y ]S' % !FES7S_J7Q:\7W!\07NFOI=K9Z3<)";=X6D=U:1HPV[H3D
M#(XXS@<&KWB/XP:D/AII%_90_8M:U-I4+!0R(L1VO(F?4E<9!Q\W)V\@'N6:
M,UXSKGC77=4\1^&_#NE:M_8\&H:6M_+J;VZR,P\EY,X;@+\A!QZ^V*N?!/QE
MK?BJWUFWUF\%Y]B:%X9S&%<B3?E3@ $#8".,\GV  /6LT9KRSQ!\<]"T/7Y-
M-CL;J^CMV:.ZGB^3RY%)!4*P&[!')R!Z9INN_&^QTK4[K2[7P_J=U>QG$0;:
MB3#&X.,%FVE?F!V],<#L >J9HW<XP:\KO?CEH\'@RTUJWL9I;ZYE>!;!GVA7
M0*7)DVD;0'0@@$G<.!AMN3\#7E.N^,A=1W<5TTEN7BOIC)<#!ER'8@%B,@9(
M':@#VK/L:,^QKY@^(GAZ;2?$GB;4_%1AN)=07_B4LDF&D8R(58#!VK'&I5@W
M7( /(8,L/&M[X:^$ T&)V2\U.>9K<X!\JR8!69><J6D$H'?[QX^4D ^DUUS2
MGTV34EU&U-A&6#W/G*(E*MM;+9P,$8J'2_%&A:W=2VNEZM9WL\*[I$MYE<J,
MXSQVS7S'+JUNOP1M])COH/M;:Z9'M!(#((A$2&V]0NX#GIFNQ^%5U)X3^*.H
M>%K_ $>U@O+A3#YMNTA"&-#)D%V)*.HW=CDC@#@ 'T!FL7Q/XJTGPCI1U'5I
M_+BW!$1<%Y&)Z*O<]SZ $UP>M>(_&FN^/]6\-^%;NRTVWTF!))[FXB$AD=E#
M <@X!W8Z<;2<]JX#Q+JVI_$./P!>SM9Q-?RS6H@DC/EK,)45F)SDJP,?R]B"
M,\YH ]ZL/%NB:AX:M_$"W\-OIDXXGNG$04Y*E6+' .01CUK.USXA:5X>\5Z7
MX>N[6^>ZU(Q"&6)$,0\Q]BY)8'KUP#Q7 _&W2X= ^&>FZ=I$4-KH\=]A[= Q
M))5V7!STSN)!!R2IR,<\OXU&HZEK?A;PS)XHBO\ 7K.]DMWNU3R/LK.+?R_F
M'4J0WS9W;@1U% 'TGFC-?.^H:SXJ^'Z>+M$E\0W&IE+:!K:YED=I(C*P4L"Q
M+*P4G@'&<$5'\(M2\1:?XYL;;4KNY^R:U;RSA+J;>9MJEED )+ G!YXW#/7'
M !Z?X]^)<'@^^M=)M--GU/6;M0T-M&=JX9BJY."220<* <X[<9RO"GQ6U'5_
M&\?AC7/#CZ3=2QL8P9&9MP7?@J5& 5#'/L/6N:UBXM?"_P"T6VKZ_!Y=A?1(
M;2Y9 RJWE)'O]L,C ]QD'H<U!JVNWMS\>]+-I+H=PP;R[:YM092L#!LJY!P9
M-H?'IYGOP >\+=0/,\*2HTJ8WH&!9<],CM3!J-DT_D"Z@,V2OE"1=V1U&,YK
MY@\+:C<IXKT+7$GCMM:U'71%J.V\'F2)+* Z&WVY1.3R2><8P0,-ET#PC:>'
M_%FJ66JO#JNFZH8M(6.;:^Q778RXY.?F^;MM!H ^E]6\1:-H)@&K:G:6)N"1
M#]HE5-Y&,XSZ9&?J*BU?Q5H.@2QQ:OJ]G8R2*61)YE4L!QD#TKY[\8ZY:ZYX
MHN;K6KBVELI] 3^S)Y_,55=E0EXPB<OYGF##8&05)&,59N++P_KL_P .K'7K
MF:SGN-'\FXG!"_N^5MEYX7Y@WS8.>,Y!R #WG4O%F@:/+91ZCJ]I:F]5GMVE
MD"HZ@9)W?= P1R2 <\5Y_P#$CQGXH\+>-/#]O8W%JNE7K@&,V^6D.Y5=78YX
M^8$%<'GGMGQCQSHMIH'B6\T;^T)V.F6T$2?:]Q,[$*6\L<B-/G9@I..&P22!
M5_6_%=O>Z'X$M;IIEO-$:5;H2QE<1B2/R]I/WODCQ^% 'UB*6D%+0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%)2$X]: '44W=]:;+-' N^5U1.[,0 /QH DHJ&>ZAM
MHC+<2I#&.K2,% _$U4FUS2;>QBOIM3LX[.;'E7#W"+')D9&UB<'@'IZ4 :-%
M9$?BG0);"ZOH]:L'L[1@MQ.MRA2(G& S9P,Y%9VN>.]#TGPE<>((=1M;NW0%
M(/)G5A/+CB-2,\GOZ#)/ H Z>EKQSQ/\7+B#P!H&K:-/8'5[^>/[1:APYC"@
MF1=IY + +D] W'.#7:ZY\2?#7AK58=,U:^,-X^W>BQLPA# 8+L!@#GK_ (4
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MVA,G.<5K:IJ/B#PA\6/&%[X6TZU\J&U2YO8IUS'&ACC=W^\IW;V8X!YR>..
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MFK2:U8P:?=@&"XN)UB63(S@;B.>#D=1@Y%?+5E?Z9<OX2;76N)="M;::QNY
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MJ!L-*MVA,<5S$C2;I&=F!.0I(*#D'[OOP >M3?%_2H_ ,/BI+&ZD22Z%FUJ
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M$,))BB2,MUVJ!GZXKG_"'@C2_!L-X+ S237LOFW$TS99SDD# X &XXQZ\YH
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M $8X4FF;C3STIN!0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR!R,=!<?#?QKJ?B#7-(6X.F>&;V\>[:X\Q&,^%VHNU3N(/&0P"\9Z@ ^[44
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M223T %<%H/QB\-^(]9M=*T^WU-KFY;:FZV&%X))8AC@  Y- 'H5%(#P.*,T
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MO#(QQP&&>H)6@#V+-&:\PNOBPNC>']$$OA_59M8U!%2&RF 1Y3M4;\C=PS,
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M,Q([#!D(+!CM Q@]2<C&#J>.O$NJ:!XIU6]76;TVNO:(C:6;.0,('+1X53T
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M2A(P<%2#@X'&<<#T%9G_  K'P>=&72?[&C^PK<&Z$0FE'[W;MW9W9/'&,XH
ML?#]X)OASX<:W>-U&FVZDH00'" ,#CN&!!]P<UXWI>I:%\/_ (IZ_!'IB2S'
M4K:*Q'E%C:PON,[)M&0 KX"CDC'7!KWO1M%T_P /Z7%INEVJ6UG%G9&N3C)R
M22223D]358>%-!&MOK7]D6?]IOG==&(%SE=IY_W>/Q/K0!\O7-]X6G\"^(XR
M8G\1W.KF6S<Q/N-ME<8;&U0=TF02">,CA<6?B#=VNH^-[W4Y+SR[#4-,AN+&
M9K?S3*HB10H!(,>9$<%NHP>#GGZ47P=X;6Q2R_L#2VM4&%B>SC91WZ$5>FT;
M3;BV@MIM/M)+>!UDAB>!62-EZ,H(P",G!'3- &1X&BN+7X>>'X98V2=-.A!C
MDX(.P<'TKY5O;J\;Q3?:G>V4RZHNI&ZFLDC.%8R,[J3R1A@ .#D$G/ S]G <
M8HQSF@#YR\>:9K6F>+/$LHT&XN[;Q);*+62)-S1LJQNW R05".#G!(&:M0>'
M_$I\.> O$L>A3W[:,LGG6!PDI19=T3J",G@#& 3PO7.1]!XHQ0!\RZUX8O--
M^$FKZQKT<=G>:MJD-W:V@4AHR?,R""?E^61SM.< #.">.KTSP3XE\4>)+KQ'
MJ=I%HI72#:V$;2B8N[V[1!V([#>Q.1GD#G&:](\8^ ]'\<1VB:LUTHM&<Q_9
MY=GWL YR"#T'Z^IK<TS3K?2=+M=.M586]K$L,09BQ"J,#)/7@4 ?/4OPW\>G
MX<6FC'3GN';43=+:F]CQ9HB,H&&;;\YD9OE/&T$\MQTVN^$_'JRZU8Z+8V7]
MG^)VCGO"9U_T&1@!,IW'+ \_,H)QT .*]JQ1B@#R.S\'^*],\9:.]K;VK:7H
M6D-9VUV[A3/(T!RVS<2/WN!@X 'KUJW\(?"7BCPBVJP:VELMK=%)D\N;>QEY
M#' XP1C\A^'J.*7% 'E'C;X:ZW?^+VU[POJ4-A)J$/V345<'E",,_.0V5"#;
M@<J#G))$&I_!:Y>UT"UT?Q$+*/1HRT3O:AG-PTF]I<@CDD)@'. @YKUW%&*
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MJ@$$$#CG'(!Q7BO6/%/B/Q5X*U%I8;66_2WGTV%F_<P3&0*6(Y)!8*V3D[6
MYP:UK76SH/Q7\::Q!:6]VYTJ6^LYF.49=D;JRD'E&!['..XYK8U3X(ZK>^&=
M"L4U^!K[3O,1G>-E18G._:I&2=K9QG&0?X<"K]E\'+RW\4/+)JMN=#;3#IK1
M(C"9XS$$(YR%.[+[LGG QC@ %'2O%OC'1[GP?>ZWK<>I6'B9/+\A+-%>V=\;
M&78H+8W)G.?XN#P:Y&Y\=?$'3X]=EN/$H>;1M1BM94^RQ[9F)E7C"C"?N2<
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M.ZBMD^5WC?:<]#C"L6/'8U!X%\:P>-]!?58K1[15N&M_+=PY)"JV01[-^AH
MZJBHS*@<(6 8]%SR::US"D@C>9%?&[:S ''KCTH FHI <C(I: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH #TI*4]*2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HQ11F@ P/2J]W9VU_9RVEW!'/;S*4DBD4,KJ>H(-6** (H
M8(H$"11)&H 4!%"@ =!Q4M%% !111F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@
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M* 25+ <9'L>>*S=+^/$&K:C:V5OX5U&6>;</+AE5WW@$@*#C(P!DG&.>#CD
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MMP 6 (!&.F S8QTW''4TE]\/_"FI302W>@V,KP1)#&?+QM1.%7 P" .![<4
M>%C2M*\3^.M".N:J5-SX?@O+\S7&UI9UC("%OX246-SG!*Y/5@:YHR07_P (
MXWN;F2;4;#6/+@0REC#;RP@D;2?E0NG7'WO3)KZBN_!_AZ_UD:O=Z1:3:@!@
MW#1_,PV[<-_>^7CG/'%)'X,\,PVL]K'X>TE+><J98ELXPLA7.TL,8.,G'IDT
M <KX>OX];^$NI#PSHUSH\"6]U;Z;%]YGP&VNI'.2Q.>^[/)ZGQK1(M%N;'P?
M::79WG_"46^KA[T);/N,0<-N+#L@"^XVL>.I^I;:T@L[6*VMH8H8(E"1Q1H%
M5%'0 #@"IL4 >$?L^W>G#4O$5I'C[3)LDB C/^I4D=<8'+KP<$^G'#/B3:7'
MA_XOV&NZ7X:?4%DLBS1I;,\<]RPECRV 02,QDCJ>.A.:]Y$:JS,JJ&;EB!R?
MK2XH ^:K.[U(>(/'#:MX6U&34]7LI[2-+.R:=4GP5;#8^YN4'(ST'7&:I:KX
M>\2ZW9Z)?CPIK44&E:5#IEW']GVS-M:1=T:.N7#*X/"G;SG& Q^HL48YSQ0!
MYE\)/"-QI7@"ZM=6LI[.?4W=I8GD^?RV3:"5Q^[;&>.3P,^@XW3/AWXQT^S;
MPF=%TR2S>ZF,>OR.K-;12QB.0HFX-N*J./4C/8CW_%&WZ4 ?/'A/X5>)M)\0
M037NAV>=.N#=I?&]RLQ1<Q1H@88RX!+,!P>V,'NO@]X7U_PKI^J6>NV%O;B6
MX2Y@DCE5V9BI5QP3@ !<?[QKTW'THQ0!X-;?"SXB0>&9=$&MV!T^*)K:&QWM
MY4J2.SN[$#APV",ANI&0,YL:;\,/'%I=>%)GFT,+H<WR!)9"QC:4N^[*X/!(
M&,=?QKW'%&* /'M5^$6MZ]<>)_[1U>P6'4KM+VT,43%EE0,JAQP OENRG&3D
MANQ#17WP=\2:]X<E77?%]Q>:P) \$3S.]FNU2H!4C(8CJX&1GHW)/LV*,4 >
M)0?L^,//\_Q9/^_A*RK#:!0SY##=\_S('56VX'W1R" 1IQ? ?2UTN!7UN_\
M[:CF$IU2,E6XX50A8[0H"X.=V1UQ@#UK%&* .9\$^";'P1I<UG:337,MQ+YT
M]Q.1ND?&.W0?GU-<YJGP2\-ZIJ]W?F[U2U6[F$T]K;SJL+-G)."I/)+'KQN.
M,5Z510!QL?PTT*#Q9;^([;[5;WENJ)%%#*%B5$C$87;C.W: ,9JYXF\#:/XO
MN[";6H6N(K))E2 2,BL9-F22I!XV<<]ZZ:B@#CKSX6^#;^\GO+C1@]Q.29'^
MU3#=]</TX''M0/A9X,.DQ:8^B(]K#.]Q&&GDW*[@!L-NW8(51C./E'I78T4
M8^H^%= U>VM+;4-&LKF"S&VVCDA4K$, 84=A@#CIP/2G7GAG0;^VMK:\T33;
MF&U39;1S6B.L*X P@(PHX' ]!6M24 >4_$3X<>)O&'B2RN[74-)_LRR"_9[6
MZC8;#D%]P .\,57N!@ 8&"3Z9:Z98V6G)I]K9P162)Y:VZ( @7TV]*M8I: ,
M^ST/2M/LI+*RTNRMK21BSP00(D;$X!)4#!/ _*I[.PM-.M4M;&T@M;:/.R&"
M,(BY.3A1P.23^-6:* &[1Z8^E&W_ #FG44 )M'I2;1Z4ZB@!NT>E+CG.*6B@
M -)2T4 )12TF: "EHHH **** "B@'-% !1110 4444 %%%% !129HS0 M%)F
MEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ /2DI3TI* %HHHH **** "BBB@ HHHH **** "BBB@
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M5L8+D8'DRW**_/3@G/-?*VL+:WU_XOO-1EE'B1=23["BD[CF9@X3J20-N!V
M&*I:YJEWJNMZSJNJRPV>KI-$[120N7\U,(54X.S;C.&XP,=J /J^^\5^'],D
M:.^UK3[>1'6-HY+E RLQ  (SD=1]!R>*UP00"""",Y%?'-]Y5WJ7B&;Q->_V
M7JKRFX^SM8&1I9CO8QYW#RA\PZY!R/[M?4_@=2GP^\.*P*L-*M00>"#Y2T 0
MZW\0O"OAW5AI>JZO';WA0/Y?ER,%!SC<RJ0O3H2#T]17$:A\5X+'XJ6EI)J\
M7_",7%A&=WEC:LL@W*^_&X#!4'G !.>0<<!\3[2SO?BEXF:Y2\B6VLHY$>U@
M,WF2B&,KO[*N#@GH-H]:ETFY\2^&=;T+5=/\+7%[?3^'DMXT6W=E4[F5)&P#
MSL1"1E>#U6@#UWQ-\6?#7A36SI-]]MEN8PIG-O"&6#(!&XDCG!!P,TWQ3\6_
M#'A6ZAMIY)[V26(3$V!CE"*0"I8EQC<""/4'->/W6D>+]"LO%6D:AX0NM5O-
M;,4QOK6V>:.-@S.Q4HIR<L<#(VD=QUU-/^&GC3P7J$L^FZ+8>(([W33;S1S-
M&(HW<JQ5D=QOVL@YZ,/0] "[X@U"S\/?&S2==-W?G3;FP?5)8YIRV<PS?*@9
MN^U0$Z!C@<8 J?$[4X_&/AC2?'6G6M[;6VGWK6P6]^7S%.UA*@!(QO!0E3G_
M +YXD^(W@/QMXFUBPFMM CD@MM/AM5\JXA3)"[GRI8!<,S* .,+Z8J_K?A_X
MH^(? L?A?4M'LIBC*?MQO(P[!3E05'' XSWQZ\T =5H?Q=LKW0M=O=9TV?2K
MO1L&XM'?+-N)"A=P7YBPVX(&#C\,C1OBA#XUO(_#'B'P^^EVFMVKI!,;EF$N
M[( &47@X8!@>H [UGW/PQ\2ZUXI\8_:DBL=-U@LT$YD$OSI,CQDH"#RJM]-W
M?'-K0?A=XBG\2^'+OQ&VEP6&@6\<<"6#NS3-&VY"^X#!+'<2.N,8YR #C/!?
MBR^\">%K^WTBWMKS4;S6Q9PK.IVMM0#. 1SDKP6'6K6EZOJG@;X@^,=6U>PL
M5U*'2_,-O9@I;EY9;<+M[XRX)[D[N<\UO6/PC\27^GWCZC>6FFZPNL_VE;SP
M+YL+%AE@%R-H#8(R/X<8(.:T[GX3Z[KNMZ_=^(-;M7_M2QC@6:UMBOENLD;K
M\A/W1Y2]\G<>1B@#DK+XV^*_)O+:;^RI[N6U:>WF0'9;[4:1@RKG<Q52 "1A
ML9.,U;MOB5\34\,W7B&;3;.72C!^[NVC5%1C(J!@ V6P21MQ[]L'K)_@_<2V
MUC;Q^(Q;16FF26 %MID:-*9%*N\AW98$'D'G@$$-DG6M/APZ?#"7P3>:P\\3
MO\EU';[&1?-$FW:6;/((SGH?:@#-^#_C?7?&?]L-K,MJZVODB)84","V_<2,
MYQPN#]:[;Q?!K-QX5OX_#]T+;5/++0/L#$L.=HR< MC&3D#-87@GX<6G@S5M
M1U&*\>YFO@ 1Y"0I&-Q8A53@ DCC'&.*[<C- 'S!IWQA\36FHZ5=76KSWEK%
M$%O8#;(H8EWXSW.T*=PV],8X)+[R#Q-KTG@K7]1\02C5-:NWMK::!53[)%N5
M<C8!R2S'KTP/6O6+CX1:/-HVOZ<+FX5-5OOMJ,BJ/LS DJJ#H0-S#GL<=LU+
MJ_PKL=8OO#TSZKJ%O'HEJMO"+?:KL4*E'W8^4_*<X'/&-N.0#RW7O&'B?P[I
MGBS2+;7[^X6SU>"U@NKB3=.D;).S .!GDPH/SQC-;7AG6M6\._%O3O#J>(;S
M6=,O[9&=KR<RX+QF3<AR<'(]3P3UX([A/A!X=:^UFZO;C4KYM74BX6XG7"DR
M+("I5000RKC)/ QTI_@KX4:#X+OI;^ S7E\2PAGN0N84.>% &,D<%NIYQ@$B
M@#O" 001D'J*^4&T*RA\%>*?$-EJ,MM<V.LBVM8+>;:C1;N,8.3PY(/I&<=Z
M^I]1LHM2TVZL)RXBN87A<QMM8*P(.#V.#UKB(/@MX%ALU@?29)F48\Z2ZEWG
MWX8#/T% 'A_Q&O8_%7CS6KY=2MA9VMM&]OYEP'##RT_=Q 9R2[$G' ^8D\&M
MS6//MO"OA7XFZ=?RRZG$5M;P7+,RO*JF/?SZA-K<X88/7.?9%^%W@I9;20^'
MK5VM8UBCWEF4J,XW*3ASR>6!)_ 5K6_A30[7PZ_A^+38AI+APUJV64[F+'J<
M]3D>G&,8H ^9-<\.#P[I/A.WGU%H+'5;+[?.]TLAACF9<9$: MN5&1<@<G!/
M' ]A^ BF/P1J*"5IH%U:98),,%= D?S*#R 3N./4G/.:]'O-*L=06);VS@N5
MA;?&)HE<(V",@$<'!(_&K$%O%;1+%!$D4:\*B*%4?0"@#@?C:<?"G53_ --+
M?OC_ );)7DEW<>$Y_B9H<?A-%BT^\TLV95(VW">:*:$%@>68;X]Q[X/.<U]-
M/$DN-ZA@"&&0#@@Y!^M.VB@#Y9T"SO=6N/!N@V.B7L6K:5?R2WUQ)"8Q&OGA
MN3_L@')(!S@#.>>K^''_  E.D>.GTE/#<MC9SZE/<WMQ);'"Q;"%C5V&-H;!
M!!).1VSGWRE% $%W +JSFMV=T66-HRR'#+D8R#V-?/6G>"?&^G6Y\+VWARUV
M_:;F(:Y/M8+;S((W*C.5!4;NYYQC-?1E)0!\YZ5\,?%5S<Z;X8U+3EM-.L-1
MFNGU1&5DD1EC&% Y)/E\%O[V"!M I][X9\9ZWI7B];KPI/"^HWL.H6JB1/DD
M$FTJ!GYLQN22< %3W(Q]$T4 ?+]U\*_'FH7D,LOAZWVO:6]MN>[CVQA(4B#$
M;PVX!,D8(SG&>*WM=^!^O1ZNLFEWMOJZ7<16XN=4<J\4I7YI#@DMD\J?F(R
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MY/O,2223^)-:4T,4Z;)HDD3.=KJ"/UJ2B@!**6B@!*7%%% "8'H*, ]A2T4
M9^H:+INJ75E<WUE#<2V,OG6S2+GRWQC</?\ J >H%: Z444 &!1BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ /2DI3TI* %HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /.OBIX5US7WT#4-!AMY[G2;HW/D32;-Y!5E
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MV%0WF#@_,W3@M[ UM_#3X<2?#X:FKZL+];WRL*+?RA'LW_[39SN]NE=YBEH
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M]DMYIUY!=VS\++;RAU)'49'?VKP_5_'_ (GUWQOJ^D6/B?3/#4.G336UN+C
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M"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !1110 4444 %%
M%% !1110 4UV"(6/0#))[4ZD=0RE6&0>H]: *FGZK8ZK$TMA=PW42L59X7#
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M<.Y! YRV,@]<;5[O4-1TGP-:WTY:Q^QM%"UTYCA5OM4L1S)C@*BP@GLH'KR
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M<L);BUFL/.GAA('VB5"5C#DG@84 X]!VS7M]CHNE:8[OI^F65H[@!FMX%C+
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M/N6)9%VN4  P67@GTKI/#'AFP\):%!H^F>=]FA+,#,^YF+'))/ _("MG%&*
M#M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 'I3<TX]*;0 ZBBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TI
M*4]*2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!*6BB@ HI,TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 'I24IZ4E "T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !4,TX@BDD8'"*6P!DG SQ4U(5!ZT 9'A_P 16?B7
M3!J%@DZP%V3]]&8V!!P>#6Q31&@  4<'(XIU !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 'I3<TX]*3% "T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E-IQZ4V@!U%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 '
MI3:<>E)0 M%%% !1110 4444 %%%% !1110 444E "T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%%  >E-S3CTIM #J*** "BBB@ HHHH **** "BBB@ HQ110 444
M4 %%%% !1110 4444 %%%% !1129'K0 M%)D>HH)'J* %HI*!0 M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %1S3QP -(P4$XYJ2D-  #D ^M+0.E% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% "-]TU'@^E2GI3: '4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110: "B@4
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M>E-IQZ4V@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 52U">[@^S_9;<3!YE64EL;$/5JNTAH %SCD8_&EI!2T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E-I3TI,CUH =
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 (W*FF;3Z5(>E)F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@!">*2E[4E #J*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@!"*,4IZ4E "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E)2GI24 +111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !
MZ4E*>E)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 'I24IZ4E "T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 !Z4E*>E)0 M%%% !1110 444E "T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %&:#TI* %HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*2E/2D
MH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *,444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex-a_004.jpg
<TEXT>
begin 644 ex-a_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "F2H9(F0,5)[J>13Z* *ME91V2,L>XECN=F/+'U-6J** "BBB@ H
MHHH *0TM% ""EHHH *1P2A"]<<4M% %:S2=(@+AU>3)RRKM'Y59HHH ****
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M% "'GBD"A>!3J*  4444 1MRXI](.HIU !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 -'44ZF]"*=0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 44E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -;[ZTZF-]
M]:?0 4444 %%%% !1110 4444 %%%% !32RCJP&3@9/6G5!+;1SD>8@;:<CG
MO0!/128]J6@ HHHH **** "BBB@ IK,%ZTZFGD@8R#UH $<.NY2"#T(IU(JA
M5V@8 Z4M !1110 4444 %%%% &?/YL$CS[)IE9T5854$)\WWJT*2EH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** &G[PIU-'44Z@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &CJ*=31U%.H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BB@T %%(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** &CJ*=2"EH **** "BBB@ HHHH **** "BBB@ HHHH **.@IH=2< T .HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHH/ S0 @I:;N&!1D4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%M-H]QIT9G.\["<OC..1V_K7/+.;CPIXQTSP[=3-:0WT=P+1),![,,0Q7O\
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MK'DD]@%"X[EP>V#].JH"A0, # %<=K?PL\(^(=:DU;4],:6ZE \TI/)&KD#
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M>HI<4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %4[W2=/U)H6OK*WNC XDB,T2OY;>HR.#5RB@"I+
MI=A/8M8RV=O)9M]ZW:)3&><\KC'7GZU:"@>M+10 4444 %%%% !BDQ2T4 )B
MEQ110 8HQ110 8HQ110 8HQ110 4444 %%%% !10:2@!:**0G% "T4@.12T
M%%%% !1110 445QOC3XE:'X'FM[?45O)KF=#(L-K$&8)DC<2Q48R",9S[8H
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MH(XSTN71=P*;225((([FO'- MY]+^*,7AF'4]0N-/U:Q\N\!GR93/:;V<$\
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M5W\Z4.ZXQ@8^4J><AB9.^..MET_0YO%OQ*_M!8OM-O#>R6"2#Y?,WME@<XW
ME<#G.[CIR ?1%_XDT33[*"YO=9L;2WNDW032W"JLHQG*DGYA@@\>HKQSX,^,
M=0EU'6Y/$/B&>>PMK1'\V^G.Q#OP&RW0G.,=\BO/Y'M3:>"M7NX//T>TQ97O
MR!AN2Y>5XB#U)BD4CL<GT." 1:X_C.'P_:N;=P+V&WC7E;9)QQM'H'4X]%/H
M* /H_0_B/X5\00WTUEJT2QV0W3-<Y@PG0/\ /CY<\9]>N,C/C?CWQGIOB'Q_
MH.H>'-9OI!'+'#*F'B1,2*0R@X/S;B#Q_"/6N/TSPROB^2.'P\]S=74&FM/>
M(UJD:)(@PL:E#\Q;;PS<DD$Y.[#KW7;>Y@\)Z=:Z')!>Z/(8Y]J?O+N4R*=N
M ,[MRL,')RW2@#ZH\2ZJVA>&=2U18)IVM8&E$<(RQ('OV'4^@!KR;X;_ !0E
MLO!NJW7BDZK=_99FG6],.Y)%8HOE*^0-^]B0O "GC@<>PZQ9_P!HZ+?V7S?Z
M3;R0_*0#\RD<9[\U\Z:;X.^(VO>#F\+QZ?'8Z7I\TSOYK"(W4X?E"V3OP2=I
M V<<L2!@ ]-\+?&"T\0^)HM(O=)N-)^U1"2QDN'S]HR3CC  W <$$@D$ YQG
M?^(/BZZ\%^&O[5MM+:^/G+$WSE4B# X=R >,[1]6'(K@-)\,>*O%/C[1=5UO
M18]#@\/P10G:0RW+QLQ'E@=%.?< #@G/'=_$W1=5\1> [S2=(@2:ZN)(LH[A
M/E616/)('\(H \[@^.NKPZ-=7VI>'EB#QC^SW5)5BG?=ALN01@#+<==I&16S
MX?\ C!=WQUNRU32K:/5+"RDO($M+D213!$W%"X+ 'H<@D=1P1@V+[X=ZMKGP
M@TSPS=M:VFJ6#*\3"0O&2H90"0.,JY'0X/K7-Q_"#Q=J&G36=W=>'M)A6V6%
M$T^Q4M<E<'$LH4. 2JECE@2,[30!;\"_%_7O$7C#3M&U*UTHPWB2-OLQ(KQ%
M4=\-N=AGY.1VR/I7G/B[Q+XI\:^'TU_5!;#1EOS;VR)&@:&4Q[M@;&\KM&3D
MX) ]!CT'0OA+XMTW6/#^KM?:/;SZ<R0O# C<P@MO9FQ\[L'8'IPW7BBX^!.L
M+8S:19>*8QHINOM45O/;$L'"E%8D'[VTX., ]<=, 'JO@WGP+X?_ .P;;?\
MHI:^?X/BMXMNO$:79UB6*!M3C1;'[.AA$+,V5+@ \  >I!)R,<_0/A;1[O0?
M"=AI%Y>_:I[6'RC.J[<@$[< ^BX'X5Y7#^S_ #%9;*X\53-IC2"811VNUFD
M*AFRQ&0"1GW[4 <S\1O'?B:+Q?K=E;ZY=VT-G=)';QV$JB)4VG.]Q\V_.WY3
MG!+#^$5[OX0OI=1\"Z)?2SF:>;3X7EE8Y+/Y8W$^^[->;7GP+U"\N=0<^-9_
M+OY%DN4>P!\Y@<@MB0 D$DC@8R:]:TC2[?1M'M-+M%9;:TA6&,,<G:HQR>Y]
M: /F*&YUA_ [?$$^)M236TU06G,WR2+L5AQ[9/R\J0.G6NL\.:7;ZA\<;:\U
M:4-+J&DC4C;38P99H0K08;.Y0K2$#KA1GH<]6WP)\-OXJ?4FDF_LQCO_ +,
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MV(H.A P>$4Y;_OD =0#Z7\-O#UWX7\"6.E7Z(EY&TK3"-]ZY:1B,'_=*UUM
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M6Z5RTB3 MN.Y6)4\\].* /!OA[9QCQ9HZ^5:6&D:II\MM>VTE^)C>1JCAW*
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MUTX?>I!!^0J.HSC&*[ZB@#B+7X3^$;6'4H%T^5X-2VBXC>[E((5]X (8$?,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M18\MH2TN\,C$Y&#W_IQ6C%IOCA]8U2ZC\+7MO%<Z6^F6]J)!LBB";5W%C\V
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MM.I:* $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQMHKO_CX2&W55E&",, ,$8)XZ<GUH ^?/A1X4T'7]'U35;L7-UJ^E%I$LXV
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M\8'Q]KEMJ5M';^&+=!%IR)&BJ,;=FP@!B-F=V<@-P.E=U24M !1110 4444
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M.&4-N Z[3T;CGC/0^AJE>_$KPAIVLG2;O7+>.]$GE,FURJ-G!#.%VKSZD8H
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M0X?<'##(;*YPF!]X_+[UXE\1M,T#4OCK:6%U*;>WNXX4OYH9EW"4@A?O9"G
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MYVCRXPO'0XSZ="O@WXC7/Q&G\5)<Z+ILLJ)"26:8+"5 (5=OS,-N>2N3TP.
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M+:)=J0Q*%51Z 4 >5_"[Q;X;TKX2VRZEJMG"UF\XN(9)!O\ FD=U 3JVY3P
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M@8 .=J+X4>*SKMAJ5SXEL)/LEM'8>4+5MKVJKM,1 (R&!;//4Y!'&/8L48H
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MZDMEFB:>, R1JV67/3(H LT4E% "T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% #2<#-)N/I2XR,4;10 ZBBB@ HHHH ****
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M.R[2QDYX!ZGT!KZ*Q1MH \?\1^"F\'_#V_\ #7A;2=3U<:K*7E9V1O(.$&>
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M<:XVF^'M$L[B)M+36(;N[NV026Q4'E N5;<=H&?<X'3K_!^OOXG\(Z;K3P+
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MJI<[5R<9/H/R-"NKE@K E3AL'.#Z&@!]%07=[:Z?:O<WMS#;6Z8WRS2!%7)
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MX5M-$DU%[_[.7VS-'LX+$A0,D@#/<G\L =#10 =J*** "BBB@ HHHH ****
M"BBB@ HHHH ****  TE#?=-1_G0!+1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 (:X*X^,/@N#74THZH68N8WN5B/D1L#C#/
MZ9_B *]R<<UTGB^TNK_P9KEG8HSW<]A-%"BM@L[(0 #]37RM'<VT_@J+PQ;V
M%Q+X@.MF?8L(9BGE;/+!'S9W ?+CL30!UOQ=\9ZCJOC631])O+M;6P=85CM7
M=3+<'[QP#DD$[1]#CKSZ9XH@\4Z5\'YY;WQ ZZY8()I;NT4)Y@#<H3CG@_>
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M59/%Z;=3\]P-R(KF/C&X)A<YW=!TQ0!-\0-!O_$_@?4=&TV:*&[NO*"O*Q5
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M2Y(A]G$<7EJ4Z?=P,=^,"OENS+:QX-\0Z;I=O]H\G5(=1CC@A8MY)$D1( [
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M8U(4MZ 98#G^AJ[VH 3&:,4M% "44M% "44M% "4M%% !1110 4444 %%%%
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M* $Q2T44 %&*** $Q1BEHH 3%&*6B@!,48I:* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
MQ2T4 ,\M-^_:N_&W=CG'IFGT44 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%%  >E)2GI3: '4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1BBB@ Q1BBB@ HHHH 0T56OY)8;*XE@B\Z:.)F2+.-[ '"Y]Z^;;'Q
M?J^LZ;JUW?\ C>[TK5X2&M+8OMMWZYB(VY#<;0<]J /ILY/3BEKPWX8_$"P\
M/^&I(/%.I7<4D]P\UL;I'D+1X!.& YP<UV=Y\8O!UG')NU"9YD&1 +9U=CZ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TI,4IZ4F1ZT
M+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4
MM3DFM]/N;BVC\R>.%G2/^\P!('YU\[>'O$&E:S'>OXR\+2ZCJ#DLM_:6!1@0
MN-C; .A&,U]*D9-11V\<"E88TC!.2$&.: /F>#0U'PGO1K%Q#9:G#<?;M,LK
MMPLPB PRA6.XHP_/&:DL/#&LZM\*]1UNWMFO;V]O84"E-TIMX<CY/<L<^X K
MU?Q-\)=(\4^(AK%Y<7"2R#9<(C#$B!2  2,KVSBNWL-.ATO3[>PLXQ';6\8C
MC4'H!TH ^>/ _A+69)?$#1:-=QJ^AW-H5N8]NZY93A!NQGG'M[TVT\%>//$O
MA>+31:/9V.E1LMO;7)\MI9BY)<^I&3STKZ0>-VQRN,\Y%/"D=\_4T >&:7\.
M_$-C!J,D?ABS@N)-)>SC?^TF=Y9F(4N<\ %,\=./>LB[^&7CJY\,:3H7]EVJ
MQZ=-+*)4O0#*7;)!XX]/PKZ+HH \!U'1_'&@>*]2^(=UI-DKK#(9(A<[@B;
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MB@ HHHH **** "BBB@ HHHH **** "BBB@!&Y4TS:?2I#TI* %HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,4M%%
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MF.2.3\OY4 ?3>:6O,O%OQ>MM$&G0Z/ITFJ7E[:K>^62R!+<H7#$@')P"<#.
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M#"^"%RUI\0=2T^V@2ULKVP%R+<3B8H 5,>6'!.V4YR >>B]*Z+XGI9:5\5O
MVKLT4#23^7<2AMIV*Z ,W8* [<^F>PKT3P[X*\.^$_-.B:8EJTW^L<NTCL/3
M<Y)Q[ XIFN^ _#'B75(M2UC2DN[N.+R5=Y' V9) *A@IY8]1WH ^=)-$\+I_
MPL&<318TYS%I4'F]=TQ7<N#EPN N>1ALGUKW#X-Z@E]\,M,07)FEM/,MY06+
M-&0[%4.>F$*8'IC%:Z?#OP8DDD@\+Z23)@D-:HP&/0$87\,5JZ1H.E:!;S6^
MDV$%E#-*9GCA7:I<@ G';@ 8' Q0!\:W4T,VF7[^; DDMT&2&2+]]@B3)W]%
M ) *YY)!_AKUF?Q1X3USX^Z/K%K=>;8M$D32>45#7!#HF05!P-R<GIMZX%>W
MP^'=%M]0GU"'2+".]GSYUPMN@DDR<G<P&3D@&KT=M!$VZ.)$.,910/Y4 ?-O
MP]M])UCPUXO\*7]Y#9W%V5GM!*X10\9.""<#(8)D>E:GP/TV[\0^)#X@U I+
M!I%FEE:AT&5;&%Q@?PIN!)Y^<5Z)\2?AK_PGSZ=*FJ"QDLQ(I+P&4.&V]MRX
MQM_6ND\*>%[#PCH$&DV <QQDL\CG+2N?O,?<^@Z=* ///CY.)_#VEZ/#:7-S
M>W%VUS%Y*%@JQ+M8D#G_ ):KCCU_'S#Q?::GXA\=ZK<V?AW48H[QO]'CMK-T
M\T$!E>0$=6^^W0Y]QFOJW:-V>]+B@#Y_N=%USQ5\&-$DM-%N;;5M!NECMP4*
MS31  %X\@%?F*D^\9YX%9>F?#'Q7_;N@SZA:7DMIJDZ7>KQF0 (5F9B)1D Y
M0@\\Y=@.17TIBC% 'D&G6_B"W^/NHZT_AN]_LV\0V/VG.$10(\2YQR"8NG'W
MNO&#S&J^!/'TVG:MX;MM#AEL+G6)=2%X;N,*P(PJA201ZG(Z^F,GZ&Q28H \
M1T[PIX]_X3CPKK5SH]O$ND64.GS22WZ2&5%#J\G R"1(V!S@@<FNR^+/AK6_
M%7A"'3]#93(+I))X7F\L31@-\I/0X8JV#_=SU KO<48H \)TKX/Z]>2:M!K#
MZ?IUAJEHDK06 ^6WNE?,85.X4;L\X/F$#GYATMC\.?$TMI?V?B#Q8VHV4^DG
M3X;=5=$1AMV2$9P6&WEB"QR<G'%>HXHH \T^&WP]UOPK?S7VMZRETXM%LK>W
MMW8Q)$&W#.X#D'(  XW-USQ#KGPLU+_A(M1UKPKXEDTB75(V2\B>+S ^\Y8J
MV<KDXQ@9&3AAG%>HXHQ0!XKJ?P2OCI>@:;H^N)!%8N\UU+(K!C,Q7,L:KQD!
M0%!(P /FY)KV2TCFBLX$N9A/.L:K)*$">8P'+;1TR><=JFQ10 4444 %%%%
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MH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*2E/2FT .HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **,T4 %%%% !1110 4449H **** "BBC- !111F@ HHS1
MF@ HHI"<=J %HI"<=B?I2;Q[_D: '45%/<PVL1EGD6.,=7=@JCZDU#<:I8V8
MA^UW<%N9CB,2R*I<^@R>3]* +=%)FC- "UF:QIUUJ#:=]FU":S6VO$N)A%UG
MC4-F(_[))&?8>N"-+-+F@!!2T9I,^QH 6BDW ]C^5!;Z_E0 N:*\XMOB/?Q?
M$ZX\*ZOIMI86L8=X[M[@_/'C*-R .1^1R.U=\VH6:6@NVNH%MB 1,9%"')P/
MFSB@"S14%K>VM]&9+2XBGC!VEHG#@'TR#UY'YUGZSXHT/P]Y/]L:I;61FSY8
MF< MCK@>@R* -?-&:PM1\9^&M(6V:_URQ@%S&)H"TP_>(>C#'53V/0TC>-/#
M*Z,NL-KEB-.:7R5N#*-ID_NCWX)QZ<]* -[-&:XB/XM^!Y-0DLQKT*L@SYKH
MRQ-T^ZY&#U_0U=B^(_A.XM-3NK?6(IX=,C66Y:)&;:K="N!\W/'&<'KB@#JL
MTFX>M>?VOQF\&WVJV>GV][<%[F3R_,>W9$C/\.XL!U/ QGGKBL/2?&ZM\7O$
MZ7NN7<>CZ;:2D6TRCRU:(J)" H).,,1_$<G\0#UVC-><Z3\:O"FKZI;V$"W\
M4D[$!YX51%P"26.[@  G--T[XS>']3UFQL8['5XH;^Y-M:WLUL%@E?(& =V[
MJRCIQN&<4 >@7=[::?;FXO;J"V@7 ,DT@11GIR>*E1TD19$961AE64Y!![BO
MFKXM^,[3QK!$VEZ;J+6.G3O$=1=B+=V.1@* 5R0%96)#8)&W'->Z_P!HRZ/\
M/$U*"U>ZEM=,69((^LA6,$#_ #D^QZ4 ='FC->-3?'"XC\':;KRZ"6$U\]I=
MXE_=QE5#_*V,[F5L@$?PMZ<W?$?Q5UFP\=_\(QH6@0:G*ZQF!O/*F4O&'STP
M  >I., DGT /5S7+V7Q"\+:EXC_L"RU:.?4B[H(DADVED!+ /MV' 4]#VKA7
M^-DI^'SZT-)1=4:_:PBMM[-'O"!]Y( ) ! V]2>_IR&FQ:KH'QHCUK7],MK"
M6.QN-7N;>S/R!/L\@8@$GYB^<C)^;=C(YH ^DLT9KP'2/CIKMSK^G_;K'3/[
M.N[CR&M[<MY\8+ !R2W;<.P#;6Z=I+GXH_$IO$T_ANTT32YM4MI=CI;6\D@(
MR &)WX5#N4[CC&1G% 'NMS<0VEM+<W$@CAB0R2.>BJ!DG\A7)>(_B9X=\-V.
MF7MQ+/<6^I+YEL]M$65DRN6SP!@-G'7CIFJ/Q>.IM\+=0>U:.)L1F[3&_,1(
M#JIXZ$@YQT!Z$UY=+ [_ +/4MO>W5G,]C);W=I;0J?-MEFG<!I#N()<.^!@8
M'J>@!]#Z=J%MJFFVU_:2B2VNHEEB<#&Y6&0<'D<&K.X>M?/7A_Q!XL\,Z]X)
M-YKB7NFZS;PJMEC"P0G:@&W'W@-I# \D,#ZGEM2^*7BW4FGU6/7[FT8S*([*
MWBVQ)'@D'=T)R,8.2>3T&* /JB[N[>QLYKNZE2&"&-I))'. B@9)/T%>3?\
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M **** "BBB@ HHHH **** "BBB@ HHHH #TI*4]*3- "T444 %%%% !1110
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M#YUY-"^!$OMP<_7M7E/AHZOK?AG7?"FBZ0;I;V^647 <;;4!SG<._08KL9O
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M* "BBB@ HHHH #TI*4]*2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHS0 9HS534=1L])T^>_O[A+>U@0R2ROT51_G
MIWK#\)>/=#\:_:AI$LQ>VV^8DT>Q@&S@@=QP: .GS1FO/_$?Q=T#PSKUSHMS
M::I<7UNZ(T=K C9W(K@@EQGAP,=<@\8Y-SPE\4/#?B^Y^R6<\UM?$L$M+Q D
MCA1DE=I*GC/&<_*>,"@#M**:3A2>?PKA?!OQ0L?&7B6^T:#3+VRDMH3,/M8"
MN=K!75D&=I#,!C)_#I0!WE%&:3<,]#^5 "T4A;![T;O8T +129]C4,]Y;6NW
M[1<10[L[?,<+GZ9H GHI%8,H93D$9!'>EH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*2
ME/2DH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8^13] #S#P;XOUR#Q9X6_P")UKMT+NX%O=K?73O ^^3R_P!V"3G:K Y/\78
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 48HHH ,48HHH ,48HHH ,48HHH *,444
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M"<$@8+8XSTKCO"WPG\3Z/XGTC6[[Q!:&6TMVMI(X(F.R-8_+B53@!QCDY /
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M5 "@8  P *6EHH 2BEHH 2BEHH 2EHHH **** "BC-% !1110 4444 %%%%
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M<<8.5(QUW#'459^*?C#7/"L&BIH-M;W%S?7?E>7(I=I,8(15'/S$X+=N/7(
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M6FI?:5+^]=HR4FA"Y) SP:HVWC[QWH_A:\\3:O;PW%E>)$=/^Z%61V(X .[
M SS0![B90%SQSP.>M*) 5)PP ]1BOGR#XJZ_ING:O975_!J<KVOFVE_#$T21
M2'[R$D#H"<>X%1?"7Q#X@U'XAVUI>:[>7,/D2O)%<2LP<8!! /3\* /HH'(I
M:8AZ\'TR>]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ****  ]*;FG'I3: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2#'MMD6O/O&:_P#" ?&^WU70]/EO)9[9[][-68[WD$RR8(!.T;3(>"!ST X
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M+--)(66"/RG2- 3TY;A1VR>@->A?'Y;R]T'1=)L].N[J2YO3*K6\9?E(W&S
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MA9#0([Y[GSHR6F ( X7U( SGIDT <=I$P\5:MXIUS7$2>2/2);B0CJLF56/
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MT2K%/!G8'0$*2.X&>1WKT+ ]*0 #H * /%KGX/>(-8TI+?6/%@FFMT6&V2.
MF)4!S\W<GT/:M[P?\-KKP]XL;6;S6C?&"V%I:KY.QBFW_EIVR.@QU'6O2]BC
M'RCCIQ1@>@H :F0,'\Z?110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 !Z4F*4]*2@!:*** "BBB@ HHHH **** "BBB@ HHHH
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M .W)YR3GC#/BSI^HP_#O3/#MAI6IZU-F)#=Q1M*\?DA?G<+DEGY'/'4YR!D
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M?6ET^$:FZ;#=>7\^,8QFM- ><@CL,FG44 %%%% $$L"3$"2-'4=-RY-2*H
MVX Z"GT9H **** "BBB@ HHHH **** "BFEP#@^F:7<",@Y% "T4F:-P]: %
MHI RGO06 ZF@!:*0,#ZT;@#CG\J %HIGF+G&><9Q[4OF+Z]!DT .HIH=3T.:
M7(H 6BDR* 0: %HI,TM !11FC- !1FC-5KZ_L],M)+R_NH+6UCQOFGD"(N2
M,D\#)('U- %G-%9^DZWIFO69N])OH;RW#E#)"VY0PP2/KR/SJ_F@!<T9KGM=
M\;^'_#>IV>FZG?\ E7MX5\F%8V=B&;:"=H. 3QD^_H:-)\;>']<UV^T73K[S
MK^QW>?'Y;*!M;:V"1AL,0.,]: .AHH%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 'I24IZ4F: %HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "DQ2T4 )BC%+10 E+110 F*,
M4M% !1@&BB@ Z4444 %%%% !1110 4444 %%%% !12$XHS0 M%(#2T %%!JK
M+J-G#?6]E+=0)=7 8PPM( \FT9;:.IP#DXH M444F: %HJM>ZA9Z9:27=_=V
M]I;1XWS3R"-%R<#+'@9) _&H].U?3M8MS<:9J%I?0*Y0RVTRRJ& !QE21G!'
M'N* +M%4-6UK3]#L&OM3O(K6U5@IED.%!)P!^=2:;J=GK&GQ7^GW,5S:39,<
MT3;E;!(//U!'X4 6Z*3/THS0 M%)FC/TH 6BDW#U%&>,T +12$X]*:\J1XWN
MBY( RV,DG 'YD4 .S2UY=XC^(6KZ3\7]&\-_9X8=+N#$K.XWM<>:=H88^Z X
MVX]02>,5Z1<W]K9P>==W,%O%G;OED"KGTR?H: +-%4=0UG2](MTN-2U*SLH)
M&VI)<SK&K'&< L0"<#-7$D61%=&5D8 JP.00>XH =29K&O?%OA_3M433+S6]
M/@OG(4027"AP2 1D9XSD8SC.>*\S^*7C;Q'9^,]+\-^&)&@O-GGO]PBX=LA8
M\.,8P#QW+#H0,@'LI( R>E-\P9 ((). *\U\4>)O$_A3X3V]_J"Q'Q!)MAF9
M%!2)G)^8[1C(&,@<9S@D<GSWX6>*O$%GJ]\K3W%[I:P2W5V\T@81L$+!P3R,
MGC'2@#Z-W8QD&E!R,U\LOXP\9/!!XZ.KR;I+MK9+8$B(83?M*]",9&>M>U>-
M/&3Z5\+I=?TZ3$]Y#$MK(!]QI, -C!&0"6QW(Q0!WF?:C/M7RGX:\4ZMX+\2
M:-J]YJ-Y=65_;>=/&[M)NB9W0C#'E@T>[.1Z=SG/^V:_]@D^(2ZQ-'J(U46:
M[2Q.YHVF/)/W!@+L((()[#! /KPL!UHS7S9\57UBZDT+Q-;:W=FSUA$GL+3>
M8S9N%C/&#@G<0=W!R._6OH;5+]=(T2^U&2-Y5M+>2=HX_O/L4L0/<XH NYHS
M7CEO^T#8/LFN/#>HQ6?F".2X1PX0D9QT )QSC.<5=\1?&F+3]7EM=!TD:W:6
MD"7-Y=PSD+&C$9QA3G&Y.<]201P2 #U>DS7BOB'X[7-C=6K:5H,<VGW4 FM[
MBXF*M*,E6&P#Y2KJZ'DYVY'!!/H7A'Q<WB+P3%X@N;*6W8I(TD*1LQ.PG[G&
M6! XQU/'6@#I+BXAM;:6XN)4A@B0O))(P544#)))X  [UD:'XO\ #_B666+1
M]5M[R2$9D2-OF4>N#@XYZ]*\IL?CK<Z]XBTG24\.6T-I?7<=K/Y]P969)&"<
M#:H!&[)!W ]..M<KH=UJG@GX@^+K_P -:']ML=,\^":+>0EO#YH*L>YQY9]3
M@,>QH ^G,T5Y3XE^+%]I&A^&-2@TBV6+6H!*\MS.WEP-\N5^0%B!G.<=.@)X
MK&3XJ>)K[X4W/B2U@L(K^QU-;>Y+1DQF)@,;5W9R&=%ZG@$T >W9HS7B4?Q,
M\;VGA.^\3:II%A'IT\:#2VR!ND9\ D!]Q 4,V"!G Y'6F_"SXJZ]XB\7G1M9
M-O<1W*R/$\400PLHW;>.JX!ZY/3DT >WYHS7EOQH\:ZOX3L-+AT:YCMIKQI#
M)-L5G54"\ ,".=W7':N3LO'GC"_^$^M:FVK&WU/1[^)6G^S)OFC<A3&P(VJ0
MSYSMZ*![T >_9KB?B3X\N/ >F6=Y#I#WZSRF-F\PQI'@9&6"GD]A[&N$T;Q3
MXQT77/"4VN^(4U*PU^R>Y-NUNB>6/+#J-R@'=DJ,].37G^JPZUXJ\$:GXWU3
M7GD/VQ+?[ #E>=N. P" 9X&WG&>^: /J:SNUO+"VN@I59X5FP>H# '!_.O(9
M/C?=RWUQ8Z;X<>\O!</%:^7*VV:-3@G YW?TKTB&\CL/ ,-[*S^5!IBR,8QE
M@!%G('>OF6UL(K3P;;>)K#4YH-6&IM;A5E"%T9=V5QR".,^N<4 ?4FJZY#HG
MAN;5]0C*1PP>;)&#SNP/D&>Y)Q7ENA?&;4[G5]*.L:+!;:1JLIAMKF)CNSNV
M@MGCC.#4?BOQ+_PEWP:&+RU?6(X8KN[M8I1O"))M=BO4#H<=:XG5)(-9\%_#
MW3-(FBEOO,FB^SJWS"0R9R1V!/>@#L=<^,>O1:WJDFCZ=;3Z-IMRMM*[@[F;
M)7DCLQ!Q5CQ+\5]6OM4T_2?!4,$ES-"LTLK*)024W%%YQ\N&S^%>=6%W::9X
M*\;:1>3F'5II;>".U? 9W2;+?4Y!S].*L>";C_A$_%J2ZI&;#[7ILRP/*FT
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M.>Y'3U J>^TB^\:7_BOQ'I<'VBP@N6GR 07##^'/4C R* .FT'QMXK\/>+M
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M12([D$XRQ#H#E21P..3FO6_BEXDUBU\$:5JGAQ9'BO+B(R@VWF%X70D(R$'
M8[01C/..]>5>(X]$\5'3;?POX0OM*\637 $]O$ACAA"@^H '.&W!5P <GC!
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M1-=BVN)P\<<JQG$8( ^7/&X\D8R:\YN_@EK2>!].L[&XM'U,3O=7:RRE5#%
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M=R2V,#*D<]^* .PHJAHNJP:YHMEJML'6"\A2>-9  P5AD @$@'UY-7R<#)H
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MEWEV\-A>HP>"3@ X!ZBG3?$CPS#X33Q+]O62P=UC41C=(9#_ ,L]G7>!R1V
MSTH ZO-&:\+^)GB[1_'OPWN+W0;ZY$FDW4,UQ T;1D+)NB7/8\L",$_3TZW0
M/BEH4FJ:5X4MHKZ]O]B6[S6R))"K*HW-OW<J,'+ $<4 >D4F:RO$?B+3_"VA
M7.KZF[+;P ?*@W.[$X55'<D_AW) !-<AI'QAT;4M7TO3;G2]6TZ74\&UENHD
M$4@;(0A@Y)W$8&!C)Q[T =U/JEA;7$=O<7EO#/)C9')*JLV3@8!.3D\5:!R.
ME?*WA[PY>_%'QSK$MQ=7-K<,[7#7L<9E2!M_R)RP(X!"_-QL[CIZ=\>]6O;#
MPA:6MNK)!>7/[ZX4L#&4&]0".Y(SS_=_( ]%O?$VB:=JUMI5YJEK#J%T0(;9
MI!O<DX'';)X&>O:M;-?._P 4X]9DTOPEXFU*SCL/$32-&8[8%B I#Q=2?F!S
MQSRWM74Z7\7]3M)/$5GXIT6&TU#2K/[4(H9"JL=R*(V.6P6,L>",CDY''(!Z
M_FC->(>$?C-K&M>,]+TR]LM-%I?Y0);%_-A;+ %BQQ_#TP.&!SVKOOB9K^K^
M&/!4^KZ.;0302QK+]I1FPCG9\H!'S!F4\\8!Z\4 =CFC->,^%/&GCD:_X8_X
M206LVD^($?[.8(U#*=NY2<=#TX]">XQ7&:+\7_%5QXWM7N]2C^P75[%%-:B$
M&..(R '9_%G:3SDD^] 'TSFC-> ZS??$K4?B;K?A?1=?.Z$FY4+LB2.':I49
M*D\"1 0,Y//O7L]_!K4OADPV-Y#!K/D+MGEC#QB4 $[@.QP1D#C.0.,4 :^:
M,U\[Z=XY\>^)KRQ\'0ZB]GKHO9H[VZ\B-=L: '' &"I60' &?E&>37(ZKXR\
M7KJL^K1^)KW4;;3KQ8XKI',4$I&XI^Z&!AEC8D8.><D]2 >X:?\ $RYOOBK/
MX.DT<V\4;2QB:20^82BE@VW&-K*,CG."#[5Z/FOGCQ?:/=_&O688/W<USHTV
M"#M^<V3 <_@ ?:N+NKN]G^$^F3-JTH2UU>YABMC*P+*T44F0!_=)<Y)X\SCK
M0!]87>J6%A+;QWEY;V[W,@B@6:54,KGHJY/S'GH*M9KY;\;G4/%GQ DLI)EG
MD@TZ#[-YEW' HS DK-ESM.2S$@8) Z\5[7\(+R_O_AMIUQJ-T]S*SS*DLC[V
M*+*RC)[XVD?3% '6OJVGQW?V22^M4NL@>2TRA^1D?+G/2O,/BQ\2M0\/:A::
M!X=D0:G*5DFEVAS&"1L0 C&6[YZ#MR"/,730M;3Q[J'BN]=->AD/V RN0QD#
M.!&J9^;[JH01A%YXZB#S87\0>!-2U>=&N[A[>6_EG=2K0+<!(GD)[^4N"3_"
MH)YR2 >^V6OZW8?#%M;\16Z6VKVUI+)/$PVC<K$(2 3@L IP.[=NE>,:)\3?
M&]QXEMKA)S?27916LEB!7R\@X7'0_-][_"O>O&=_)8^"]4O;>R34"EJSK 1N
M20<=0.HQS7R=IU]>6FI6USIDEQ#?%CY)MOE;<3]U1Z<]/;WH ]/\6>//%FI>
M)->AT#4/L=AHL>YE@3+-M*JY)(^8[]PQQP*]-\'^-(]8^'__  D6I#REM89?
MMC(G!\H9=U49.."<5X0;J]\&:EXHTS6MPU._T\1F0AF#/(5D+9 [YY]R1VKK
M_!>J#2O"VE?#[5-/NX[CQ)%<DRDB,PQ2AD1L$').UC[<=<XH Y+4?$_C75X)
M?&RZC<+86>J!(H%E)2!R ZJ4& 4 VKD]2<=2:VOBOKGB\G1M5DU)K72;^VCN
MK*&SE,9BD\M68,1ABP+<')&.P.:Y9[K6-,\-WOP\;3KA-5N-52:2-!N\T*FW
M8!W&]48,."!UKKOC<\>G:3X1\.2MF[L;',C@8C8;5CX)ZG*-QV&/6@#W_29Y
M+G1[&XF;=++;QN[8QEBH)->>WGQR\/VFK7EB=*UF06<K1SS1PH40*VUF/SY"
M@^H]/6NJ\!Z[:^(O!>F7]FDJ0^5Y.)0 VZ/Y#T)&,KD<]*\)DUZXTOXA^/;'
M3M'N]1FU87=FD,&7=&+'+X5<E?O'&.!CGO0!ZWK'Q=\.:?9V,EF+S4[C4+=I
M[6"TA)9@"5 ;/W<LK+T)&T\5FZK\:]-L/#^D:M!H]_<1:BKD'<J+&R$JZ%N<
ML#CM@@YSVKRR\^&&N^&[/2=5U'3=1NK9HY&U"WT]U$MJ 6X##<,%2&)QC[P)
M&<U<UGPWXJT[X=^&;<Z!<3*NH37D=N(S*\"L5\N*4*,DL2QS@8R <'@ 'MO@
M/QO%XYT6XU**QFLUBG,(21MVX!0=P( '4D8]JXWQ5\<(/#OBB[TJ/1Y;B&R>
M2.>3S0I=@@*[1C@;R0<YX&1GI7J=C!';6$<4-I':H%SY$2A50GD@8XZDU\[^
M*_A=XQU?Q?KES%HWGQWE\[V]R+J-$6,DD%E)R?E*CV(/6@"]J=]+X1^.=Q?>
M']!DU"2ZL_-:P@8J6,B!G(PI[KNQ@Y.:ZM_C%*WPT'BF#2XC<G438FV,Q*(<
M;P2V,GY,=AR?2J]IX8\<6WQ0F\0+IUH88-/>TAGEG4BX*0[8V*J05+2!21@
M D9Z&N-3X4^.&\#C26TN)'@U$W:PF\3,P>)4/1L#;Y8ZD'YSCIR =QX<^)^O
M^(/ /B;68M/L1J.DXDB10WE-'C<=P+9)"ASP1GCCL<31/C/XKN%DU+5-"M?[
M#@BE:2Z@@EC4R*A*1B1F*[F?8N,$_-GM3M*^&OQ#L3K4T$WANUCURV>"[L@\
MBQQA@0-JI'@%0Q Y/4YSUKIM*^&M_+\*7\&Z]=VRR1S-):W%B78)EO,!;<!N
M^9GR !\N,'/- '-^!_C/KFK>*K#2=9M+&2&_DV1R6GRM$3G&1N((RIX.#@YY
MX!]RKPO2OA[XA\,1IK&M3:5!:^&[&YN+:33X0\MPY5GR[.@)VY[^@ '4UTWP
M/N?$-[X.>YUFY-Q:23,;&21BTA7)\PDGJN_.,\]>V* *GC/XB^(/!WC\6E[%
M;1^'I[=WMIGA9B[B+IE3VEV@C&<-[@UP]M\7/&.KZ3'I=A<1OX@U#42D92)5
M\F+:FQ4W#;\S;\EB< 'U!'K7Q+\ CQWHMM;PW26M[;3>9#,\>X;2,.IQR >#
M]5%4=&^%EGH7Q A\16=P5M8+-8([78 1((Q%NR,#!09/<L2<T <.L&JK;_%/
M3+O4X9]0M+2.2;4ULHT>YC\IBT14#@,J[<YR#SS639QRV_P,U"*7Q)YS75K'
M<0:08QFWB2]*LP.<D,QZX'ISCCU"P^&]W!XF\0ZC?:_]LL=>22*[L_L80E&!
M" 2;CC:K$9 &>]<_9? E;+1]4M%\22M<WR) LQLQM2)9%<J4W\DE5Y!&,>YR
M <KX/USQAX?N_ EHVLJVBZO)MBM!$A"1^9M92=N[/S YSW[XKV[QQ?7.F^!=
M<O;.5(KB&RE>-W8KM.T]""#N]/?%<)/\&)[FP\.6Q\57$9T5)%CECM<,6:4R
M!D)?Y"/E'?[HZ5Z3KFC6WB#0[S2;QI5M[M#'(8B P!]"0?Y4 ?,7A*[\5WUS
M)HR>(M9TZ.YLI[RW#32#S656=2K?PJS!B67&<'J:Z&Z\2:J_PG\(:S!XIU!-
M2BU*:WG07K;I@9&8>9ELMM54X;(P_O7IG@WX5VOA#Q ^JC6+N^*V[6UM%.,"
M",L&QG//3T Y)QZ9H^ 7A$WT\[RZAY+R[H[=)558TX^3.TL1G/.<X('49(!P
M6NI>>)_$_CJ^N_$1TB_T:>.&R\VX:&/R!+(N/EY&?D(.#R_OD.O?#&F^,?BE
MJMK<:X;U?[#CNUO854>=,L$2@D<@@@^80,=<>IKU*^^$'A/4-;L=3FM9<VL:
M1M!YF4N-@"J9,Y+$ 8//S?Q9JZ?AIX<;Q3)XC:&X;4G<ON\XA5RFS 4<8VT
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MTTK^T6L=EPL_F>5Y@;"L-I7*\?-GKU% 'GMIXH\:^"?%.@V?BK4+?4--U2U
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M:"><#TH&I630M,MW T*$!I!*NU3Z$YP.H_.O'?CWIEG-?>%[RZ=@KW)MI<L
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M,%>9,@= WN,Y_P .3"/''A_4;>X6\2UL;B34(K:R,7V:-8G #M@"0MD?/W)
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M"ZDC^Z>#P2PX[/\ %>JV(ET+PCHVHWFH:=8R*;E_M_RS3/L&Q),;0B*-JMC
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M%?0.*,4 ?-T%GXBM-)^'1_X1'5;EM)N+F62+[.P+,UP& 8%?W?0,"W'/L:]
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MUP7@KXB>)O%7CRPL()X;C2ELXIK]EMMOER>0OF+N_P"NQ('Z<#-7_P!H0@>
M;(L,K_:<>1_VREH ]9!S1GG&:\!G\>>+/AGK\^D^(M1&MF;3DFC)'^IF*MM&
M>,KO!#'J1AA@_+67X&\>^*)/&VBP_P!NW.LC4W O;)D+"W!=E..FTA5WDK@
M'O0!])BB@44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?;(.6;(]?2@#:UKQAX>\.W4=MJ^KVMG-(GF*DKX)7.,X],@_E7"?%3QY;_\
M"NX[CPYJX<ZA="W6XM7.0J@EQN'*G@#U^;CU'/?$6;3_  _\:-.UKQ'I;7FC
M2V6U5,:R"1U5U^ZW#$%EX.,9!["O.;^VDM_AL\[V,EK;7^M>;8^=G_5+"X.T
MD?,#O0;AP=GM0![G\%;'Q%:>$Y)=9N3-979CN-/5YC(ZHRY)).< Y&%SP=W
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M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH P .PI<8Z4M% #=HSG'-*!CH*6B@!,<T 8&!2T4 )BBEHH 2BEHH 2BEHH
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M% !1110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 4444 %%%%
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MDVZUC#JB. RELD=5(; R<$>HKKY-6M%T9]5BE%Q9K ;A7A(82(%W94]#D=*
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M>JZM8Z]=>*=:BFUK4PFR2 ;DB*D$$D@9' 7:H "CJ>, &->3>/=>\%^)-/\
M%=J\EI'8+J<%\B1QJ"FV01@J '&W.>X*GDY%5_AOX^\7ZQJF@^%+-]-BL[,)
MYLC18D:VC&"I);!.T@#: <@'.-QKH[/X6^,ETG58[_Q/!/=S::NEVB;G\F.'
M<H;=\O78I48!/S$DYYKG[3X&^,=.O+:]L=<TFVN[4[H98S(K*<DY/R<]2.<Y
M'!R.* /H2B@44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@=J*6B@!**6B@!**6B@ %)2T4 %)C/:EHH 0*,CCI2TF:6@ HI,TM !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %)2T4 %%%% !1110 4444 %%%%
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MI%D>(J"2I /#<'@XKR;49]=D^+_A&QO+C3&U,:;(?MT%NCJUQY=RI.[ 8HK
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MD?,0V=W45ZS10!Y2GP?NK/7= O\ 3/$7V.+1X$BC46I=V.YFD)8OCYV=^,8
M;&*9<?!"";7[_5$\27T/GW#WEO''$!Y-P6+(Y.?FVDGL#[]<^LT4 >1VOP,M
MX_#-YHEQXBNIH9;A+J$K;JBPRJK*6VY.<JV",C[H]*U;/X/:0]A?KK^HWVMZ
MC?1B.2_N&Q)$%.5,6<E3PN<E@=N.A(KT>B@#S'3_ ('^'=.U2SU"+5=<::TE
MCDCWW$>/D(('$8..,8!'%>A:IIMKK&EW6FWL?F6MU&T4J@D94C!Y'(JY10!P
MEG\(O!UGI-WIO]F>?%<D,TL[;I4('&Q^J^O%:?A7P#X>\&^:VD6>R:7AYY6W
MR%>#MW'HN0#@=ZZBB@!DD:2QLCJK*PVL&&01Z$5E6'AC1=,T1]%M=.MUTQRY
M:V9=Z-N.6R&SD9/3MP!P!6Q10!CZ7X6T#1+AKC2]%T^RG9=IDM[=4;'ID#I4
M6F>#_#VCRWLEAH]G ]Z6^T%8L^8&ZKSG"?[(^7VK=HH R-.\,:%I#3G3M'L+
M4W"[)O(MU3S%]#@<CD\5?M+.UT^U2ULK:&VMTSMBAC"(N3DX X'))JQ10 44
M44 %%%% !1110 4444 %%%% !1110 449HS0 4444 %%%% !111F@ HHHH *
M*,T4 %%%% !1110 449HS0 449HS0 449HH ***,T %%&:,T %%&:,T %%&:
M,T %%&:3<,XS0 M%)N [TF]2>M #J*RU\0Z.VIOIHU.T^VIC=!YHWC)P.*T0
MZ =>,T /HI"RCN*-RYQD9]* %HR/6FLWRG R?2N1\2_$/0?"FIVNGZI)-]HN
M-I411;E +;02?3- '844U.^1W_.G4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !10:3\* %HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHI"< GTH 6BJLVH06VS[1+%"KL%5I) H8GH!GJ3Z"@7\'F2QLZ*
M\*JTJEQE-V<;N>.E %JBL^36]-B?9)?VBMQP9U'4X]:2ZUW3+*&.>ZO[2"&7
M/ER2S*H? R<$]>.: -&BL6\\6:#I\$LUWJUG#'$%+LTHX##*_7(YXJK#X\\+
MSS/#'KNGO)'"9I LX(5 ,DD^P_E0!TE&:YFW\?\ ABZO+VTAUBU>6QA,]SM?
M*I&!EF#8PP&1G%5]%^)7AC7]=_LC3K_SKDIO0A#LDY.=IQSC'ZT ==1358-T
M(Z9IU !29I:\Z\6?%_2?"'B";1[W2=4DEB1'$L:($D##.5+,"1U&?4$=J /1
M<T52TK48M7T>RU.!'2&\@CN(UD #!74, <9YP:N9H 6DS6#XP\6:?X-T&35=
M0#LN[RXHH_O2R$$A1Z="<GH :Q?AQ\0QX^MK]SI4EA)9N@/[[S4<.#C#;5Y&
MTY&.Z\G/ !W-&:8TJ1KEW51G&2<5A>,/%5OX0\,7>M30M<B!E00QL S,S  9
M[=<T =!FC->1_$GXA>(= FT2]T&73'T:^5?](8B0-(&!*LP. FW'(Y^]TP*]
M2L[^TOXVDL[J"YC5MI>&4. >N,@]<$?G0!:HJM+?VD$$L\ES"D,2&221I %1
M ,EB>P [UC1^//"D^I6>G6WB#3KF[NV*0QV\ZRY8#."5R%)[9(R>!DT =%1F
ML:/Q9H$NMKHL6KV4NI-Y@^S1SJS@IC<I Z,,_=/)PV!\IQD:A\3_  =ID]];
MW.MPBXLG:.6$*Q?>O55XPQSQQGGCK0!V&:,USUYXW\-V'AZ'7[G5K==+G(6&
MX3+^82<855!8D8.1C(P<XP:R;_XK^$K+P['KD=])>6DLYMT6WB;S#(!D@J^W
M;@<\XX(QG(H [>C-<]X2\9Z/XTTQKW297PC%)(90%DC/;< 3P1R""1^(($WB
MKQ3IOA#1)-5U-G\E6")'& 7E<]%4$C)X)Z] 3VH V\T9KS[2_C!X=U;0M1U*
MWM]2,FGQB6XLQ;[I1&6"[Q@[2N3S\W !)XJCI'QOT'6-?T_3(K"_B2]*Q+/*
MHPLS, $PI.1S][.!0!Z5/=06RAIYDB4G :1@H)],GZ4^.1)45XV#(PRK*<@C
MU!KP'XR>,M'\0QW.A6NF7%Y-I<H8ZA&W[J"3.UE(P<CMDX^8<=.?1/@V[/\
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M&RQR?W&(P#^!J>B@#S'X9_"Z\\#:A=7-YJ=M>)-$J)'';@;6!^]N;YAQD8&
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M[F&5W2.5':,[7"L"5.,X/H<5XYX2^(^J:[\7-2T^XM]4CTZ>-H(++RANLRA
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MZU%IW@3Q'X[\=7/B+QA8'2;$1M +.*4B21#&RA Z'.!NRS'[W*XP<#W#%&*
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M5Y!((((!!R#U%9LWCKP]'HEYK$5\;JQLIS;W$EK$TOEN#@Y"C./]KI@@YYH
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ME"B19?F! RK $<#/(XX%K5[_ .(^BZKX9TC5/%L\-YKCK'*B00M]EW2K&/F
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MGYOE;?A<<(W;D4_$_P 7_$MG?6]I90V%E=V%G'<:E%/\RRRNJYB0$Y^7S%)
M(;*L,X7YK$'P.O+>X\*S)=6*/8D-J;A6S(PE,B[1C#<'9D[> .O07O'7P=OM
M7\27&M^';RS22^#+=07Z[E4LNUG0[6P2.V,@\@C@  I:Y\5?&<<NB2Z)IVF3
M0ZS:K+;6WE22SAP ) 0&'&[=M/<#/K7IW@K4M;U;PO;7GB&Q%EJ;M()8!$T8
M #D*=K$D94 ]:\[O?A%K5GJOA630-2M?L^BHH::[RLAD,S2R,%"D$'><*2,
M8R<YKV4=* /"+[XG>-KC5/$NH:7_ &<FCZ!=+'-;3)\[QF1HQAO4["3R,9XS
M7,^+=4N?&_Q"\+73;(K?5+>U%O;SQB58 TKQN&'1_G5SGC*[>A''?ZQ\%+F\
MUG5+C2_$T^GZ=JLGF7=IY);<=Q8C(8!@&)(R.,]Z?K'P;N;GQ#IFH:-KD6FV
M^EQ01641L_,:(1L7R26PQ+EFY'?% 'H<6@II/AE](\.&+3/+A9+5]GF")SG#
M$'[QSR<YSWKQ;X0VU_J7A+5XSXCM;>UU![JW73IXDW2SM;J3*),[N%/( /"D
M^M?0(^Z*\MM/@AHMMK=_?+?WL4$K,UE!!M4V3,,,RD@@D=%.!M&.I 8 'E?A
M/7/$OA/X>R>(=)UJ.*P361;S:?):(ZRL8D8N9#\V" %VC'3((-;/CSQYXN_X
M3O6['2=4OH+:R4>5#90A@$4*6=SC*C#,Q;G& ,8Y':GX%Z>-!.CKXCU<637"
M7+08BV&0?*S8VYR8_E'. <'!QBM;7/@]X?UV_6_EO-5M;MH1%/+:3(AN,*%W
M."A&2 ,X !]* .D\$:O=Z_X+TK5;^(1W5S 'D & 3TW#V;&X?7O6_5#1M'LM
M TFWTO3H?)M+==L:;BV!DD\GDY))_&K] !1110 4444 %%%% !1110 4444
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MM9K6YB26"9&CDC<95U(P01Z$$BL3PQX)T'P>;LZ)9M ;HKYI:9Y"0N=H&XG
M&X_G70T4 )2T44 )12T4 )2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH H:UI-OKNCW.F73S)!<+M=H7*,!['M3]*TZ+
M2=,M["!Y7B@C$:M*^YR!ZGO5RB@ HHHH **** "BBB@ HHHH 3%&*6B@!,4M
M%% !1110 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8I<444 %)BEHH **** "
MDQ2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !14-RLS0N('"2%3M8C.#C@X[U0T.WU6WTN"/6+R.\O1GS
M9HX]BGTPO:@#5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HR*#TKB-0^+7@K2]3N=/N]7
M9+FVE:*51:RL%8'!&X+C@^] ';T4R-TEC62-E=' 964Y!!Z$&GT %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "T4F<TA8
M#J: '44W=[TW<0,G) _V>OTH DHJ,,W'.>O04]3E>OUH 6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#!UWQ1H&ER+IVI:U;V5S=;8HT$P$P\P[58
M 9(&?XB,#')KYH\0>'#X4\/6OA^_M[6?Q/=WPGVVN)9880FQ8RP&278[@HS]
MT=R*^C[[P!X7U+Q NNWFD1S:D'23SFD?EDP%)4':<8'4=J\?3X2?$:34M1NW
MU/2X[G4E=+JY%PY9E8@D ^7N4' 'RX^7CIQ0!Z%X*\4^'= \/:+X:OO$EG)J
MD-O'%(C7 <*Y&?+#C*D+G:O/0 5Z)7GWA3X1^&M!M=-GNM.ANM7M%5WNB[E3
M+UW!"=N 3QQV!ZUZ"* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#GKFEI#0!72[CDNI+=6/F1
MJ&8;>,'IS5@9QSUI  "2  3[4X=* "BBB@ HHHH **** "BBB@ HHHH *8YP
M"?2GTG>@#Y>T;XG>+[V#Q'++K;122V0NDE<?+;,DD8"Q@*0NX,4QCEF4DYR:
MUO%_Q0\0G1/"UO;37,$SVT%Y<WR*%%W(,$HHQ@A6'S <9X(P.?:9? GAB:#4
MX7T>WV:I(LM[MW*9F#;QD@Y W#.!@9SZU.?"6A&QTRR_LV 6VERI-91@$"%U
MZ,.>3SDYSD\G- '@^J>-?$%W<^.9;S4;W0[OR(?LUA(^QT3S%78%/1BC@EEP
M><@XJGXV\4Z];>*M*OUU>=6ETVUN(8X'.(Y'B!*D>I.3SG@BOH2^\(>'=3NK
MFYOM%L+FXNE5)Y98%9I N, G_@*_D/2GGPWHCS1.=)L_,CV&-A"/DV#"]N !
MP!0!Y)\!;N^O-9\0374UW<)LC'FRNQ4/N8LHSQGFO<HSE 3UJO96=K91.EK;
MQ0([EV6*,("W<G'>K0Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !BC%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD-  :45FW27YUFR>&11
M9+'(+A#U8G&W'XYK17.T9ZT +1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4AI:* $I1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex-a_005.jpg
<TEXT>
begin 644 ex-a_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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M#110 AH%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %(>0:6B@"E;6$=O<M<#>\S+L,CG)QG.*N"EHH **** "BBB@ I#2T4
M(*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M#R*JS6<4\T4LJ[FB;<A'8U:HH :BA1BG444 %%%% !1110 4U!C-.HH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T44 0W-O'
M=6[P3+NC;J/6GHH7H,=*?10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !2'I2T4 100QPJPC0("<D8
MZFI:** "BBB@!H/.*=3 /G)[&GT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 T=13J:.HIU !1110 4444 %%%)0 M
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T=13J:.HIU !11
M10 4444 %<YXRNI[+PS=S6SE)5:+:P&<$R"NCKDOB1(8/ &L3+]Z-$<?4.N*
M .MHIJG*J?4"G4 %%%% !1110 4444 %%%% !1110 4444 -?IQU[53TS4[?
M4Q<M;NKK!,T+%6!^9>O\ZNL"5P#@^M16]K#:^8(8EC#L7;:.K'J: )3UI1TJ
MGJ&GPZE;^1.&,>02$8J3CWJU&@CC5%& H  SGB@!U%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 T=J=312T +1110 4444 %
M<?\ $_\ Y)SK?O"O_H:UV%<C\2U,OP^U>-!EF1%'XNM '5I]Q?H*?35X11["
MG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12$T*V<\$8H
M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :*7%(.HI
MU !1110 4444 %<QX]4OX/O5'4O#^LJBNGKG/&YQX4NSW\V#_P!')0!T6*6B
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#TI::XRI'K0!E:]/
M-'HMY+!=K;- GFM-@-Y:J06R/=0:T8)1-"LR-N210RY&."*S-1T&QU*RU&U?
MS4344*7#1O@D8Q^HXK0MH([6VC@CX2)%C3)Z@#']* )PQ)Z@^H%.JC9V,=D)
M522=C(Q8F1]VW/8'TJ\.E !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 @%+2"EH **** "BBB@ KG/'/_(JW'_76#_T<E='7->.2/^$7G7OY
M\'_HU* .EHHHH **** "BBB@ HHIH=20 >O- #J*** "BBB@ HHHH **** "
MBC-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %&!Z444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 @I::.HIU !1110 4444 %<SXX4_\ "-3MV\Z#_P!'1_X5TU<SX[;9
MX6EXSFX@_P#1R4 =-1110 4444 %%%%  >AK/MQJ/]JW'GK;"P"K]GV.QDSC
MYMP(P!Z8)K0HH **** "BBB@ HHHH **** *.HW[V A*65S="658\6ZJ2F3]
MYMS#Y1WQD^U75)*\C!YH*[NOIB@ * !T% "T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% #1UIU(*6@ HHHH **** "N6^(+%
M?"QQWN[5?P,R5U-<M\0!GPJV>UW;'_R,E '4T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !14,\Z0(7D
M=8U&/F8\<G%2J<B@!:*** "BBB@ I*6L35XM9FUG2'TV[BAL89V-_&P^:1-O
MR@?C0!MT4B\J#2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% ""EI!2T %%%% !1110 5RWC_P#Y%9_^OJW_ /1R
M5U-<OX]_Y%>3_KYM_P#T<E '44444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% #)$60;7167T89%.'2EHH
M**** "BBB@ HP/2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,#TI:\S^!VC:MHG@62+5[2:UDGO7GBBF!#A"B#)4\KEE8X//?O7IE !1110
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MA1M/F84]2>.!FMCX>_#O7/#UCKVG>(+S3Y]-U56W6UD,*'<%7(&Q0H*X&T#
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $%+2"EH **** "BBB@
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M$G)).2.!\[CG(->RT4 ><>'OA9+I?BBQU[5O$MUK$^GP>3:1RP!%C&TJ.YX
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0L%4EB  ,DD]* P8
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M,C!Y;.<YX].>VTC2[31=(M=,L85BM;:,1QH/0=SZD]2>Y)- '"?&GPW>^(O
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M].L[J:*:YM8)I(3F)Y(U8H<@Y4D<<@=/2K5% "8]Z,>]+10 F*6BB@ HHHH
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M+\9-:U#Q18:#=>%#'.+S[%J$D,K2".3=L)&%PH5LDY8\ X/>@#V.BO-/B/\
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MB8!7W*0!M/#"/'0[2.1@T =]<?&_P-#=VT":E-,DI;S)H[:0+  ,@L"H8Y/
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M=:]0KB?"GPWM_"OB*ZUM=;U;4+NZA\J8WLBOOY4@D[<DC: .>F:[:@ HHHH
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M=46\FFU*ZLK@^09Y\M(&0,$+-D_>SR2<;L=!7"^$)O[9U&#Q/K7BA].U2+Q
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M7=6)N+BW%S$T336[ 2(&&"5)! /OBKM% '+^"_ NF^!;&YM-,GO98[B02/\
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M/J#Z]0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*\E\1^*_%NH^/M;\-^'+JUTZ#2+#[3-<S6XE9VV*^!D8&=ZKSGA6//2N5O\
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MM VCL>IYZ4 5/"5[<M\;[B]\5Z7;:5JD^D^:@B8[!P"78[C@[%8'/3;^)Q]
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MR\;7RPR/F!()SBO4M+^&OA/1=?76]/TMH-01G99!<RL 7!#?*6*]&/;O764
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M5;95.2V2#'G!&T*.O50?:H])^$]CIOB"76+C6]5U&:ZMW@OH[J12EV'7:P?
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M*6B@!,48I:* $Q2T44 )BC%+10 F*,4M% "8HQ2T4 &***2@!:*!10 4444
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M9K*6!%62V7:I4;P-ZG>"2,\Y!P., 'K6E:O9:UIR7]A.)K9V= ^UEY1BC<,
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MAPN1DI#EP#G(!!^NV@#W7/&>*YKQQXAU#PSHD-_IND3:I,UW%"\,()*HQY.
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M2KM[_,N3QS@>/);+6/&_B>\M-6T8PFUMWC,[EFGVP1Y$#!2-X*[<$C[Q'/.
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M\<6^K>%[K6TT^32?$,RPQ1Q0$-&-X3=D'@DL#@EN!T%=O\8DU-OAKJ3Z;=&
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M.^"GA;3]6AO1)J4T,$YG@LIKC,$;''08W'&U>IR=HSG%>CB@!:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@! *6FG@9INX^M
M $E%%% !1110 5QWQ&_Y 5G_ -A2S_\ 1PKL:XGXG?\ (M6G_84L_P#T<* .
MVHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN;\:>,;#P3HO]HW
MJ/*SR+%!;QG#2N>P)X& "23QQZD"L#1_BM:ZS::Z(]$OH]4T9&DFTYW3S)%4
ME6VG/52/F'N,9)Q0!Z'5:]O[33;22[OKJ&UMHP"\T\@1%R<#)/ Y(%>21_'V
MW:&WOG\+W\>DM<"WGO3*"L;8W87"X9L9.W(.!6IXL\82ZQK.K>#K'P@NO0PV
M:7%P[WHBC92%=2/E.>2I'()(X]: /1=/U.QU:U6ZTZ\@O+9B0LUO(LB$CK@@
MXJLWB'24UX:&VH6ZZHT?FK:EP)&7GD#OP"<=<#/2N#^ MSY_PTCBVX\B\FCW
M9^_G#YQV^]C\*YZ\U"=OVCKN)=/A.H+I\EMIKL3M$OD&19']<C>AQC@COF@#
MVV&>*=6,4B.%8HVU@=K#J#CN/2I*\ \!>*O$NB?#K7_$T\>GWEBMU-,V\NMQ
M)=R-&"3CY/+RQ)Q@]N*=\.OB;XM\4?$"RT^_O+(V4JRM) (EC! 4D;#C<6!
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MIVGV=UI[RBQ5$28RD2R(N2%=AC(Y/'';&,"M2[\ ^&+VXTV6;2(-NFJRVD*
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M=GKZ:K>6&HV<(BA>%4=1AF8$JP.>6-9R?![2AX)@\.O?W:R)>_V@]]!A'>8
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M44 (*6BB@ HHHH **** "BBDS0 M%)FEH ***3- "T444 %%%)F@!:*3-+0
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M,@9QB4&NLKFO&4:S6>FQL,C^U+;]'S0!TM%%% !1110 4444 %%%% !1110
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M(]165=?%CPG::%9:T][*]E>N\<1C@8L'3[RLO52,_P!>E '<45R=E\0=(O\
MQ;!X<@CO#>3VJW<<AA_=>6R!QDYRIP>X SQG)%=4[A$9B0 HR2: '45Y;+\<
MM$$4MY;:)KMSI<,OE/J$=LHBW$\=6&,Y! .#\PX%3ZE\8[&VU0Z7IN@ZQJ=W
M-;">R\F$!;H,F]2O.[;C.3M)&#QQ0!Z5FC-<GX&\?:=XZM+F2T@N+:YLW5+F
MVG7YD+ X((X(R&'8_*<@=^!^)_B7Q%9?$_PU8:9IY?[.WG6D;R 1WLL@,9!R
M0!M!9>3D;R>A% 'J8\4Z(?$(T :I:G5B"?L@?+C"AB#Z'!SCK@$]C6OFOG[Q
M1)K-C\;] U+2M!C_ +?N]-6X?37G3;YQ2:-P9 0IPBYSGG;^%=%;_&F0>"=7
MU/4M*6WU2SN_L,4",7CDF969<\Y &QL\]%X.30!Z_FC->._";XH:SXL\07.D
M:RELW[A[B&:"!E(^<?(W) 4!L D \<DD\[7Q@\;:OX.T2Q?1HX1+>2/&US*
MWDX7("J3R3R<D$#:<CD4 >D9HS]*\2\/_$GQ+>_#CQ=>3/'+J.CE5AN'M DA
M#,02\8^4,H[8P,#.><X^C^,O%_A]/"_B76=;GU;3M<EDAET\1+N55;8I7'&[
MG=QC.,'/8 ^A-P]17%M\18%^)D7@D:7<BX<$FZ=E5,>4905')(XQGCG/I7E%
MS#X\$WC&_C\:7F/#<[,JESB;DG[OW0 AZ8(SQC'-;6G:Z?%7Q4^'>N/$D5Q=
MZ;<K-Y8( =%N%(&><;@Q YQGJ>M 'HW@_P >V/C&]U>TM;.ZMY--F\IS, 5<
M$L 00>#\IX^G7MUF<5\KV?BC5_#O@;Q?8:9=3(PUF-&NO,Q*!()@Q!&#N/D(
M"1_>.,=:WY+'4/"'A;QG;0^+93:BTMI[!5N3)(4DD0F3"_ZO>7*=LYR>,$@'
MT0[A$9V.%49)]JY"S\=)K7PZN_%>E:?</Y<4[PVT@^>1HR0.%SP<9X]Z\?\
MA]+=0>/+S0=0%S:1:CH7E-;-=F7YV@1]_P _1F&]L8.W>1T%1>$[SPY'\)]5
MT));N76-4TRYO[G:VZ&W\@N8U8 C82%4]"3N&3@J* />_"6IWVL^%M/U+4K/
M['>7$(>6#:R[#D]FY&1@\^M:.H:A::58S7M]<1V]M"A=Y'.  !D_7@'BOFY[
MN"?3OAK9^(0O_")K#(\KL6V/,))%96VG^#$8' QO;MG%&:WL(O"/CS[$8YM
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M;&ZJX'<JP##Z5Q5E\&]$LE\,O'-(+K1;C[1+<+&JM>-NW_/Z8<*1R<*"O?(
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MG_98?.SN\SRQNSZYQF@#YLNO[9T[Q?X?\1_$/2630Y9I76V$ $=KO9FPT:C
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M10 5SGBSB+2\=]4M_P#T*NCKG/%?^KTCWU6W_P#0C0!T=%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!YU\:+?Q#=^!)8= C>13(&OEB_UA@ )X[D
M;@N0.2/;->5>'9? TOCCPZ^AK?:-+:Z@!)!J3%UGS@ @KNV2%L#!(7CKTKU;
MXN:9XEU+2M'/A>&>2]M=06X/E.J[=JMM8[B 0#CBN5\4>$/&?Q+O]-&K>'--
MT!;7B>]:[2>25"1\JA!GCYB%)P2>H[@%[P[XOU^Z^-'B*R33+B\TTSI9R,KD
M"Q6/>%?!XPYWDC@G/'3!BN_CW;VNI2Q-H@%C'?-:M,]X5G5%/,I@,>X#&>"<
MY&.#5G4?!'CN'QSKM[X=U6QL+#6I8)9KQLM-$L8(*!,$$\D^^%^9>17)7'P4
M\87UMJ%M<R:&TKW37?\ :+M(UQ<,PY0MM^5<Y8@C.X]2* -<:WXLE_:!U)-,
MM8;XVUNL)@EEV+'9L87+J2V Y)0]#U/''#]3^/%S#<:G)I>E65SI]I<K;Q2R
M73*\X;?AU4+]W]V3[!E]:U=8^&/B>;Q;=Z[HOB6&QFO[2*VN9!$R2+M6,,4Q
MG&?*4]>Y'2N9N/@-K5I?7D6DWNCRZ;<#RT>_C9IX$W Y7"8WX&,@C/3B@#V?
M1_$%KJGA.V\0MNM[6:U^U.).3&NW+ XZXP:\9'Q>\<OH+^*X[#2#H:ZC]E-O
MAS,O ?!;.,;2!NQU/W:]CT3P[;Z3X/M?#LY%Y;PVOV60R)@3+MPV5YP#D\<\
M5Y:?@AJZ0S:'!XIV^&)[G[3);M;YE##(7D\$X"@G(!QG;QB@#+:.+QQ\>;9-
M5@2ZTF[TU9+>&="/]'>VWK@@ A@[L=W4'.","O4/&]A:Z7\)]=LK*WCM[6#3
M94BBC& J[3Q6>WPWNC\1+?Q3#XAD@CM4BAAM5M03Y*KAHV<GG=S\V,_-[#'2
M^+O#S^*?#=WHZ:C-8"Y 5Y8D#97/*D'L1P<$?ED$ X/PVMC?_LWE;T#[,NGW
M.[><8:.23!X/]Y01^%>8Z%XXUOPKX)T&QLKN73[:\OYYI[I(4E?R0T:D1J^1
MP?,)&!D@8/7/IT/P7NSH\.A7?C749-"C<LUC#;I&&RQ;KD_Q'=R",]NA'1ZQ
M\+?#NK^'--T<)/:#3!_H=S;N!-$<Y/S$'.3R??GB@#RJ^\4ZQXH^$7C!=8:6
M[2SN[5[*]N($B=HWF4+E%  .T9R.SD9XJOXLU_74'@_1M)U+5(HE\,0W'D:9
M<&%S+Y+G<Q')4"-"0?X0V,$YKTV7X.:++X=O-*.J:MYM]=)=7MZ9@9;EESA7
MRN"N6+8QG=@Y.*EU+X.^&=3&G[Y=3A>RMS:+)#=G=)#R/+<L#\H5F7C!VG'0
M# !YPE_XI\3_  6_MZ#Q%J%M>Z%/-&[07,D;74&(R3(P8%G4$D$]L\9.:Y^+
MXA:S:>(V\821ZE<64D$MG ES<L8HYO)7<%[;0V&QP<<Y)%?0/ACP'H7A%=23
M2H) FH2!YDF<NH4 @( ?X1ENN2<\DX&'KX#\-+H5AHG]F*VFV%R+JWMVD<A9
M0S-DY/S#+MPV1SC% '@WBW3GM+/P=X/N;US<16$EU=+?2^3:PR3>8^]C]XNA
MW=<YP !EF!S[*6*^^ NKQ75PAET[58FLXI.642!0RJ,\ _O&_P" M^'TEK7A
M'P_XB97UC2+2]D50BR2Q#>J@YP&'(&2>,]S5)_AYX1>PEL3H%DMK+<"Y>)$*
M@R!2H/!XP&8 =!D\4 >(^./#%GX:^&=C>>&Y[B;3]9EA?49O.#JQ5&,:Y&.-
MS/US\P7)X%:'P>+VOQ5OH;&:SEL9K ^;_9WF_9D.5*#YP#N&&Y/J_O7N\&C:
M;;:,NCQV4/\ 9RQ>2+9DW)L_ND'.1]:AT7PYH_AR!X-'TZWLHW.7$*8+GG&X
M]3C)QGI0!Y3\?1817/A2XOHE, NG%P0!N:$&,LOJ>,\5PSW7AN_U[XA?9[>S
MN(YK*6XTMTM@RQ[1N9D./W9P>O'3UQ7T_+!#. )8DDQTWJ#C\Z:MG:H&V6T*
M[E*MA ,CT/M0!\Q^(M3N[KPOX"?4!=V.GVELT;:G#;G[0DB$C8O*\;%C(.>=
MQ/.TT[PS'I<_@/7_  ;XBCCTG5HY#J-A-J;"W"N8XU"C?@@D*..<JWM7U!7-
M>+/ FA^-?LG]LQ32&TW^48IF3&_;N!QU^Z/RH \K^'>I7F@?#;6_'=W;?:KF
M.*&RM$D C!MX=L:@$#D;B03SDQ]:]5\'^('\9>![35Y8%MGO$D5HU)8*0[)Q
MZCC-7/\ A%]%_P"$;7P\-/A_LA8Q']EYVE0<\G.2<\DYR3R2<UH6%A:Z9806
M-E"L-K @CBC7HJCH* /!8/!GC_3O!]_X#@\/6=Q97-WO_M5[I H&4.X(3N'W
M.N,C/ S6U9>%_%]C\1O"DRZ*DFEZ!9IIYO#<QJLRF,J\H7.X??X7!^[UYX]I
MQ1B@#R3X/>&O$F@:OXBNM;TH6<6HR+(I,ZL0ZO)D #.0?,//M[U>^)WA'Q)K
MFN^'=8\-O:BYTR1LB=\!"S*0_(P0-O(Z^@->FXHH \4'@SQOI7B?PG=V=E9:
MC)HT+1S:E=7I9K@S;O,#D@/M0N^S@G!SR25J#3?A!K6H^'/$EAKL]M:W-WJ
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MF_%W30_^PM!_[-725S?BX\:)[:M!_,T =)1110 4444 %%%% !1110 4444
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MC&7A60%TZ=5ZCJ/S%1ZEK&F:-"LVJ:C9V,3ML62ZG6)6;&< L1DX!KRSX-Z
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M&X+*Q"(79\$'  /0]<?6KGABWUFT^/ NO%-O9QZA)IKW;&UC(3!CV[@",[@
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M,4M%% !1110 444E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>:.YM7B*ANF<C@GK@\D5#\1_$%SX7\!ZGJEF2MTB+'"X .QW8(&P>#C.<>U
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M>?J9$5$"*,*!@ < "G8H \5^$&@ZK8>,=?U#['K-II$L$<<8UJ(I<S/D$$\
M';AQD=F4>N/3/&/AR/Q9X4U#1I'$9N(_W<A!PDBD,C?@P'X5O8HQ0!XIHU_\
M4-%T>+P?;^&(Y9+>-K6'5GGQ$B\[6!P!A5( [G:.,\4MK\,O$GA'Q%HVO:%-
M!K%]';-%?B_N&7=(5/S*QR=N,(!CC:">I(]IQ1B@#P&?X2>)K?X<7.G6\=K/
MJ>IWB75W#]H"BW5 P5%)&'/S$L<@#H >IV?C;=7)^&6C)J*PVNJ27D4CV\,F
M0K")]VSN0I(Y]QZU[-BL3Q#X2T+Q7';QZWIZWB6S^9$&=EVGH?ND9![@\'TH
M \\T#P3K/B_6+_Q-XLNK-;;5M(%I!#ILC,!%(JG<&;.W'7'S EB>G6K%\(-?
MU"RT_0-?\06LOAS3)7>WCM82)Y02WWB1A>#C@MC./0U[)#!%;P1P01I%#&H1
M(T4*JJ!@  = !VJ3% 'F7AWP+XKT[XB:CXHO-<LC'?3.MQ;1PL1+ ,>7W&UE
M 49YQ@\MDYIZC\%YK[5]<N(O%#V]EK-SY]U;K8J9"-S/L$A?[NYLXQSM7/2O
M6,4N* /-+WX3-J.BZ':S^([A=0TF&6V2_AMU1WA;Y1&5SC 3Y?<9SU-7(OA=
M:VNO:+J%IJ]W%;Z78I8?92JLMQ$"Q99#W#;N1C' ]!7?XHQ0!Y@GP/T 7312
M:EJTNA^89DT=KIA LA!&[@Y. >#U]21D5L0_#/3HO&=[XI_M75FO[L2JX\U
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M\2Z/H-U'=/>:JVV$PQ@HF6"@L21P2>P/0YQ0!TU%-W=^WTIU !1110 4444
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MD]<!>G(K O/B;XFMO"?B*1K72TUSP[>Q07KJ)&MY8Y&*!HQD-NW <$].>O
M/8Z*\A\/>,O&T'C;P]8^)%TV2R\06IF@CM%*F#";N<\YX&1DCYN#QBO7ATH
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MC5S')'*NUXV'.&&2.A!&"1S6\*\.^"=R(_&?BNWAM;B*RNW:XM"(ML(1)G7
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M#W@U"YVW1GB\AY/W<>% (4?[6X9]2!7JPZ 5Q/BGX:V'BW7[35KW5]7ADM%
MABMYE5(R#G<N5)5L@$D==H]!0!XJ]GKVK:KXUE;Q=JHD\,//-;M-=.=^R5AV
M("DB/@ 8SC@ 8KZ#\%ZE>ZQX,T;4=1""[N;2.639C#9'#8' R,'';..*XYO@
M=X?E6Y\_5]>E>[?S+HFZ4"=\[MS@)@G<2>>YKL?"7A2Q\&Z.=+TZ>[EMO-:5
M?M,@<H6QD#   XSC'4GUH WJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!!2TT=13J "BBB@ HHHH *Y7Q8/^)CX9_["R?\
MH$E=57+^+!_Q,?#/_867_P!%O0!U%%%% !1110 4444 %%%% !1110 4444
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M@#W)P![FO"O'.CZ]X<L= \)2^))];&I:C)FS9S$\\3-$%1W+$@;]W)XRY/\
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MH<KQA3[UE^#_ !)XB74_"CR:UK=W#K?G6EZ;S?Y*,9"%,#, -P4 Y!;!R/4
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MM !1110 4444 %<SXJ(_M/PT,\_VHO'_ &S>NFKE_% SK'AD_P#44_\ :+T
M=11110 4444 %%%% !1110 4444 %%%% !1110 4444 0W=Q':6DUS,2(H8V
MD<J"3M R< =>!7S9?>(/$_CKP%XMUB]UR2'2;6XB\O3%BC(*O*"$:0*&PH*]
M^<<U],'/:O)[CX"Z*]S<K9ZSJMCIUQ@O8PR!DR#E<EL[@.<;LD$]?4 P]2O-
M2T_3_@_/;7,PM91:120; 8]Q6-<YQG<5=Q@GMD $$UR'BWQ3XKDU;6-2@U36
MHK6'5I+5+RPOG%C&B !4$0&"^-K9+8;)X/)KV";X1:;<Z7HVGW&N:Z\6D9-J
M5N54J=VX'.W@KC"XY Z=*IR_ OPY)<2.NHZRL$UR)Y[8W0:.7!)PV5W'J1N)
M+<GG)S0!Y7X@U_Q;J$6O>([36=;DTW[9Y-I=:;J$D%M" 5&'B/S#<KH!]WYB
M?O5NRZFWQ"U'QUJKZ[=VUGI-IYFE&":2&- "Q#[,CEA& <C/S]B!CT%O@IX2
M\^0Q+J,%K,P::RBO&$$N#E0R]2%/09XK3UWX6^%/$6J+J-_II%QL6-_L\SQ"
M1% "JP4@'  '&#@#T& #RS^V+_6_#OPLO-4N'GO)/$ !DD^](JW"J"?7 P,_
M2JMXEII'CKXE:5J^I*MI=:?+(B7$^UIICLE@4'(W%0Y 'IQC&:]>UOX7>%?$
M$EB;VQD$5E +>"WAG:.)8P<XVJ1U[D<GCGBK^J^ _#&N7*76J:):W-PL8C\U
MP=Q4= 2#S^- 'SA>VFFW'PZ\$7D\A'E7MQ8WLD9)\J+SO,VD#."%<L.Y![\5
MNZK<^%K+Q-X'UWPW:?V/9_VK)!).9"HFMXYHU\XECG:RM("6[ @]*]U'@?PP
MNC+HXT.R_LY9A<?9_+^4R#^,^IQQD]N.E79O#VBW"PK/H]A*L*>7$KVR,(U_
MNJ".!P.!0!\S(/#%OX>\;Q>(82_B9KYDM$DW&<,6(W GMN)+=R!]*Z77#HZ^
M)?AT_C)0;_[$6UH7F<[<9@\T'C[^_(ZXR&&.*][FTK3[FZCNI["UEN(B#'-)
M"K.I!R"&(R,&JU[X:T/4KY;V_P!&T^ZNU78)Y[9)'"\\9()QR?SH \M^#^J:
M0OC;QCH^D3J]C+.+RR6-2J>6&*MM'0 %T /< 8'''2?&71=4UOX?W,6EF1WA
ME2>:WC&3/&N<J!W()#X[[/7%=I9Z)I6G3F:QTRRM92NTO! J,5X.,@=.!Q[5
M>QD8- 'SYX8U*S\0^//#&J:)HUQ#;Z-I;)K,RV^0?W3#&U0=QR>,#<V>G%0?
M SPQH>NWFK75]IANTLI8392SAMJ_>)!Q\K-C82#FOHC8H)(4 DY..YH2)$&$
M15&<X QS0!4U73TU31KW39))(TNX)(&D0_,H=2I(]QFOG.#P[XMD\)'X=OX2
MN8[E]5$QU/R6%N$VX),F,'O@Y^Z=N,\5]-4W:/2@#Q#1M!\1:=\;;;49=%U"
MYL(84L&OMB*)-L(C\XY( 4E=V!S@\9. ?6O$]GJ.H>&-2M-(NC:ZC+;NMO*,
M</C@9[9Z9[9R.E:XI* /EC0?AWX[L;S3;ZS\),MS87OGB2XG1!)CRRJ%2X.U
M2K'*]=Y]!7I.G:'XVE\5^,]7G\/P69U?2_*B#WJ2 3K"$0+CJ"PYW;<#OZ^O
M44 ?,NKZF/#/P^O/AKX@TF0:I#*)K.XLRKQR;GWAV.023EE VYQ@8!KVCX7>
M%7\)>"+2SN(?*OY\W%V"02)&_AX_NJ%7\*W-1\,:)J^I6NHZAI5K<7MH5,%P
M\8WIM.0,]2 23@\9-:P% '(_$?P_K7BGPL^C:-/90?:77[0]TSCY%(;"[0>2
M0,Y[9]:QK[X7#6_AIIGAS5KF+^T]-AV6UY;JP5&' &#R00 #TSC(QQCTBB@#
MRJP^#WVFRU&+Q+JYOI+JWCMHA:0+;QP"/E'"@<N#GGI\S YS4^C?"3;IES:>
M)M<O-96:S%C&@)C6")9%==G).<HAYXXP<BO3J* /.-#^%7]BW5G,?$^L74>G
MJXL+>1@(X"P(R5'WL9SC@<<Y'%6O _PS@\%MJ*#5;G4+:_0+-;W$:[&(S\Q]
M202#ZCZ"N]HH Y+PU\.M \+6&K6-E%-+:ZHQ^T17#AQY>"/+!P#M 8]<GDY)
MK.T7X1>'-#URTU2";4IS9;C:VUS<[XH6)SN48SGZG'?KS7?44 <EX5^'FB^#
M]2O;_39+YY[Q=LIN)_,!^;=GIR<]SDUUO:BB@#BX?A1X)@U=]230H?.9BVPN
MQB4Y!RJ9VKR.,# [5:_X5QX2_MXZX=&C;43<&Y\YI9&_>DYW;2VW.>>G%=51
M0 E8EKX/\.V6M-K%KHME%J+,[FY2(!]S9W'/J<G/U-;E% &5<^&M"O-2&I7.
MBZ=-?!E87,MI&TH*XVG>1GC QSQBK-YIECJ C%[9V]R(V#IY\2OM8$$$9!P<
M@'\!5RB@"&:VAN8C%/$LL;=4D4,IYR.#[U)M]S3J* &D9]:6EHH 2BEHH 2B
MEHH P/$/@OP]XJ>!];TQ+MX 1&Q=D*@]1E2"1QT-:,VCZ;<:8-,GT^UET\*J
M"UD@5H@JXVC81C P,#'&!5ZB@"CIFD:=HMK]ETRQ@L[?>S^5!&$7<>IP/\]!
MVJ]110 4444 %%%&: "BBB@ HHHS0 449HH **** "BBB@ HHS1F@ HHS10
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M,\51L_B5X/U#5AI=IKMM+>,[(J*'VL1G.&QM/0XP>>V: .LHS7GL'QL\"SE
M-6E3<VT%[.4 <X!)VX [U'??&KP=::XFEBXGN SB-[RW16MXR3@Y;<"0/501
M0!Z+FC->46=I<6/[1$]O+JVH?9KC3&OHK=KAGC=B0A0J1@*,,0.,;%Y['O?%
MNL-X>\):IJ\:>8]I;/)&OJV,+GVSC/M0!I7FH6>G1++>W4%M&S;5>>54!/7
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MYO/B+-'M";23'R-H4?@/05M>$?AOI?A#3-1TVWO+Z]LM0 $L%W(I0?*5; 4
M L" 3U(4>E 'C'A+Q%XW'B#0M?N+W6+G3]0U,6DS7%R?LLC2/MVHG(4#GHN
M1@8Q7TC97UI?Q&2SNH+F-3M+PR!P#Z$@]>1^=<-H_P (M$T:_M;E;_5KR"QD
M::RL;NYW06TA.0ZJ .0><GZG)YI/@_X,U/P7X5GM=6\M;JYN#,8HV#>6 JJ
M6'!)VYX]: /0Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML.RCRP!_P+U)KD/$7V636O$(L[RTDMO[2E:%?O/,GF.%:-PI^7#9(##/!P<
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MHBS1D^9MR!C+;25.-P/(QD#R.XBN98;^6:WO+:[>]$@T^&U98!RQ8]?EV_=
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M@7XB^#AC[WVQ?_(:FNRKC?$2;OB)X/?GY3>'\?+4"@#LJ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HI*,\XH 6BDS4<\\5M!)//(D44:EW=V"J
MJCJ23P!0!+17GO@[QIK6M^/O$>@:K:65O'I9Q$8 Q9@6P"6+$'(P>@ZUVT.J
MZ?<7DUG#?VLEU",RP),I>/I]Y0<CJ.OK0!<HK,/B/0Q>+9G6=.%RS*BP_:DW
MEFQ@!<YR<C ]ZM7M]:Z=92WE[<16]M$-TDLKA54>Y- %FBL?0?%&B>)H)9M&
MU.WO5A($GE-RA/3(/(S@X/?!]*K:QXX\-:#J<.G:IK5I:W<N,1R,?E!Z%B.$
M'NV!0!T-%<4?BUX&%DUV?$5MY2R>65"2>83ZB/;N*_[0&/>M'5/'?AS2/#=O
MK]UJ48L+I!);LH)>8''"I]XGGD8X[XH Z2BN/M?B=X6N_"T_B)-0V6$$IA?S
M$(D\S (4+U)(.1CW]#C&NOC#X?OO"NNWNBW,CWUC:F2.": ABS':C;2?F0,R
M[L=!U[4 >D9HS7B4_CRU\2_!2[.J7>K0WD20P7EU9VHW;V<A6'*JRG9\P!'7
M'!.*W(/B=HWA#PYX7M=1&JW*7=A'(+Z2#&Y GWC\S9;.T%021NR3TR >HYHS
M7 ^'/BMI.M6^KF^M+K2+K286N+JVNU^<1 GY@.I.-N1C@L ,YS7,7WQVE33;
M2>Q\)WSR7T[I9&=@$N%63:=NW)+_ '00.C'J<<@'LN:,URWBOQK#X/\ !XUS
M4K1EG=46.R#C<9F7/E[NF!@Y89X!(!Z5RMI\6M0BU&^TW7_"S:7>Q:9)J-M$
MUT'$X1&?:3M^7(4\\X*D$9&* /5*3/M7S_\ !+PW;^(M;OO%U\+U;ZSNV,4Z
M3CRY6D0[E(V[B5# _>P0X!&!SI7'B7Q7!\==5BLM#2^ECL?L\-D]\L2B ,K"
M8L<C))SC&<-CMR >K:1XLT#7[B6WTG5[2]EB7>Z02ABJYQGCM6QFOFG2[CQ'
MH?Q&\;_\(?IEI))!]H#1LH @B63(*)D9(QPH_+UZSQ-\7M37PWX6N](%E87.
MK)++</=@ND(1MG7T+;CGKP..: /:LT9KSOX3>/-1\;Z1>-J-HBSV;JANHAB.
M?=D\#L0 ,_4'C.*XZ[\<>-_%&MZMJ7A"0+8Z-<PVRZ:\:$7"NSJ9)&.,#*C(
MR-H.<C:20#W7-&:\'O\ 6_B/JOQ.U?PGHOB:UB$+&Y@:2&-46$A)$7<(F8D+
M(H]\'GUI:EXR\<ZQXGU32M*U2^BO-,@CA2WLM.#BYN%*I*S9!\M2Q=E9L#:%
M& 3@@'O>IWCV&E7EY':RW4EO \JV\(R\I520BCN3C ^M<#I/QCTG4?"NL:_+
MI=_#;Z6\22QJ4=V\PA05^8#@GG)'%<#I/CGQ)\2O&>FZ$NKW&@VQMR)_L(VN
M\J)N<Y/(RPX'8=<G-9OA9;F#X6^.?['U:2+4+*]2:2X@8KY\"Y'!)& V)#ZG
M&.<T >Z?\)QHXG\.0.9TE\01>;9H4!*C8'^?!./O <9Y]N:Z2OGO7E6Z\>?#
MS4M7U.X$,^C0W%Q)YK1LFR-I'*LF&RWMR3P.H GO=0MO%WBO4;35/$>I:=X>
ML=&BU#3(!(PE8-;(_F$Y+2NN6;!+,3WZY /?<^U&?:OE?4O$/B;4/!/A[5KW
M6=2M9Y;R:R-RMV\/G0J(RKE0P#;6:4%P.V&/ K5^(_A74_"L.CV0\8ZKJ-QJ
M4DQQ>7ODVX5 A!W/)A3ENI.#GL1\P!]'P7$-S&9()4E0.R%D8, RL589'<,"
M".Q!%*)HS,T(=?,50Q3(R <X./3@_D:\F^ !D'A/5K>60/Y6IL/E8,,F-,D,
M.H)'4'!ZCK7FFI-8/XA\<R>._,&NI PTS<&7$@)\O;MXQ@1X)XVY/K0!]'ZO
MXLT#095AU;6+*RE8!ECGG57*G/.WKC@\].*T+'4+34[&*]L;B*XM9EW1RQ,&
M5A[$5\OWUC;W.I>!4\5S>7=7L7_$QEFE*2"W,N(&D8]#LS\QYP!D\<?0 \+K
MX=\ :AH?A4203BVG^R$RY?SF!(.XG@[B.> * +'_  EVC7^I7&AZ9K5@=;"R
MJD#G?LD3@AE!&<'JH() ;'0D<O\ #+QC<WW@?4=7\4:G"!:ZC-$]S+B-%7Y"
M >V-SD#\!7F/PM.GP>*-&L!HMXWBFTU*X^T3%MJ0P>65?S!DY()('3D]3G:<
M0W\]U\*-5T:SM)9Y+?Q )[LHA;RXW1@F<#C+QD9[<#^(4 ?1VA>._#GB/3+O
M4-.U*-K>S#-<F3Y#"@W?.P/(4A20?3\JHZ1\4O"&MR7:V6IL1:6[74[RV\D:
MI$I +991W8<=:\+T2WE4>*M.TW2]3NX=4TEA:W<MD49WA"O)C P%)W #KD(#
M\QK.T_PYXHM;6[ET30M9VR:8\&J+=V>P$.<$1@X+#A",#=D'@B@#WOP]\6_#
M'B;5['2M/-[]LO#(%CE@V[-B%_F.<<@'&,].<5N>*/%^G>$H;-[^.ZF>\F\B
M"&TB\V1VP3PN<GIV]17A/PW\.:I'X^\-W<&E:W;FSBD:_EU*'RXD!5EQ$2HX
M._IURW3@M7IGQ'\/:W/XJ\+^)]'LCJ(TJ8B>S1PKE68'<N2 > 1UZ[>HS@ @
M\2?%6VN/A[KFJ>'1<Q:A92I:R)<0A9+5G8+O9#G ^\!G^(8QUK-^!GA2YTW1
M_P#A)9=3F\G48&3["Z$*@20A9"Q;YL@'!P,!C7,ZKX1\3W.C^-M:N/#=S;W&
MN7%NEK8P8E=5$XD=V"Y/\ YXR6)QC!KU;X:/>2_#^QL=1TJ\TV:SB%FT=RNU
MI JCYU!'W3GOW!H YY?CEI#:I#$NCZBVFSWALX=17;Y<K @94'!Q\RG'7!Z9
MXJGJ/Q[LM*U2ZT^[\.7R3VLS0RKY\9PRD@X['I6/X6\)?$/0+E/"UM96<6DP
M:FM[_:LZ1RXC&5RBG/S$)QA=RDC)4-FM_P"&OASQ78>,/$^I>(M)2RM]8!E;
M9<(_S[V(4;&)QAVY([#I0!G7/Q\@CUHM;Z,T^@BX$(NS,$F/'+",]NI .,C&
M2#P*7Q(\4W?BO1?%>G0:#;R:;H-TD;W<UR1,DH8IO1 ,8^^.3]T_A4"?!CQ#
MINO3V>E#2#I,MPC1ZE>6Z3W$$0R=JHX(R,XR "Q4'*@FMGQ!\+_&!U/7U\,:
M[91:3KKF6]AO,K(S,3N7*QM\OS'H1P<$'&2 ,M!;S^+_ (66EWH\4ROHR20W
MKR2!D>.'?A0K!2050G<#P_Y9OP^\5ZOHT7CS6=22*YM;6XDGN,W+ FXR56-
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MBZUQM?DLX=Q*M9VF&#S;BI&U1NW D' SP 37%647A[_A46HM-]D_X2-M1C$
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M.O05R6M?!.UU'Q!=WEGK-S8Z9J+A]1L(U!$IWA\*<X + 'D'!SC@X'K&*,4
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M,444 &*,444 &*,444 &*,444 %%%(: %HH%% !1110 4444 %%%% !1110
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M444 %<OXC(_X23PL,\_;Y#CV\AZZBN3\1.H\6^%5+ ,;J; [G]T] '64444
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MIMB98X"R6UP6$2*T,<CX .1\QP .!G' ''07_P :[]/AWI6KVVG6R:MJ%Q)
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M482JR*J%O5\D>ZOVVMCEO#>DZ^_B'PSI,^G:DKZ=JH;R7M-L<2^8C2'?C/\
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M$5+="<?+L7?W/(4<@YT/%WPAUS7[^WUJ#5M-?5S:1PWOVJU!BGD3 W@%6"Y
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M\ .H/'?TYK'N--\3:Q)XV\93>%[VT74=*.G6FG^5FXDWM&A<J!N.T)N.5Y!
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M$G(*C!Q@]P>>>.0#T>BO%-"^-.M:AKVB)J&@VUOI.LW9M[:2.4M)]\(,Y/\
M"S*#D#/) KU+Q3K9\-^%M1UD6[7#6<#2B)?XB.F?0=R>P!H V:,UXUX1^+>O
MZ]J=]!<Z;ITZQ:1+J,,%AO:5G3&(CDGYB3TQD9'7-0>#/B]KWB#Q9HFFWL>A
MO;:F9=T=FLHGM]H?&\L2N3LS@9X()QD4 >K:;XFTC5]8U/2K"\2>[TUE6Z1
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MG)"HCGN"3*^WY27)Y+9!R?7-?/>HQ:=X@?Q_J'BG59#JFFS2QZ7;376W8=[
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M) #),\<3B/*_=WY:+N0..0!FN#\4ZC;ZMXG\1Z@&ET\RR^;]BO5_?%]RJT?
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ME=D< @(AZ(,DG Y/XUP'CB"TU[XQV.A^*[R6UT%=/::R42^4DLQ^]N?Z!O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M('. .3QT/I6=HVH6OPN^+/BFSM-(O+VU6#*16S;WBCPDI)+=5 8\DY'&<]:
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M8!8JBEB "0,X'J*X#1?C=X>US6[#2XK#58);YQ'%)-%'LR20,[7)ZC'2NO\
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M^:O$WPZ\:ZWXOUZ6XT$W=S=RA[>^6YCBACC!P..-S%%5><8Y)!)##Z5I,#-
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MJ(H 'T I]+10 E%+10 E96F>&M(TC4K_ %&PLHX;O4)/,NI026D;)/<G')/
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MP5AR"0 "3T( -9WAWXD:+X(^'WABRNH=6OY9[%KA?)B1BB!GW#EQA5P0/]D
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M-LR%AN*D=<+D\=.M,UWQ9?KKWAJT\-RZ)?6NH2AKHR7B>9Y&Y07B7>N[C?R
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M 'N 21BL7X7>'=;M_!/B MHS:;KXN))--N;^U"M&[1!?EWKN !R"<8^;OS7
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M ,48HHH *,444 &*,444 )BEHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN1GY0.P% 'U6**!10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC(+'&<8QRTGP8\12^']&@FFT22^TF9PD322M!<P,YEVR'8"&#EQP,%6Z@C)
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M22ZW-=W&NR.^I3R7)V<LJ;&_W-^&SQE>P%9VMW-M87/Q0M&U"!IKR\C: 0R
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M,O)5D8=&5AR#_,$@Y!Q6=X5^'WASP8\TNCV6R>4;6FE<R/MZ[03T&1G Z]Z
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MHH *,444 &*,444 &*,444 )BC%+10 4444 %%%% !124M !1244 +124IH
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MB5(([E&=D*A@P4')!4@YZ8.>E &G10** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!**** %HHHH **** "N1N.?BO:9[:)/C_O
M_'775QUQ_P E?L3V_L.?_P!'QT =C1110 4444 %%%% !1110 4444 %%%%
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M5%5I#)L<KC!*J03P=Q'.<DUT.M?!W5=<UVUNKSQ$9()[*&VU>0(4EN=C X4
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110
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MSP,'1MBH5< $J<Q*V2.5;L>EGQ]IGBZTU?P5J.G^'XS>6=D(UAT^%I8[>8'
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M;>QTZUMH6QN2*)5#8Z9P.?QJP]I;R^5YEO$_DL&BW*#Y; $ KZ'!(R/6IZ*
M*Z6-I'<27"6L*S2$%Y%0!F(&,D]3QQ]*GQS2T4 -QQ_]>EQ_G-+10 W:/2@K
MGM3J* $ Q00#UI:* $QCI12T4 )6;KOA_2_$NEOINL6BW5H[*Y0LRD,IR"&4
M@@_0^HZ&M.B@#*T+PWI'AFP-CHUBEI;%_,**S'+;0N2222<*OY57T[P9X;TC
M41J&G:'8VMX-^)HH@K#><MC^7L.!QQ6[10 E%+10 E+110 4444 %%%% !11
M29H 6BDS2T %%&:* "BDS2T %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 )12GI24 +1110 4444 %<;>#;\7],8?Q
M:-<@_A+$?ZUV5<1J#L/C)HZ@\'1[GC_MI'_@* .WHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!,48I:* $Q1BEHH 884;[RACZL,TX# I:
M* $Q2T44 )BC%+10 F*,4M% "8HQ2T4 )BEQ110 4444 %%%% !1BBB@ HI#
M1S0 M%)S2;O\XH =1110 4444 %%%!Z4 %%9=WXBT>POX+"YU.UCO)Y%BCMS
M(#(S-]T;1SSZ]*MK?VCWK62W4)NT02- )!YBJ>A*YR!R.: +-%(#FEH ***2
M@!:*#2<T +12<T<T +17(Q^.HI?B7+X,6QDWQ6WGM=%\+G:&VA<<\,.<]<CM
M76\T +12<TTNH<)N&X@D+W(&,_S'YT /HI.:8DR2@^6ZMABI*G.#Z'% #\TM
M>6>&_BZ_B?XA#0K+22VER-(D5\'.041FW, "-K;<#GN#[5Z8]U#$RI)-&CMT
M5F )^E $]%0_:H3-Y(FC\W_GGN&[IGIUHENH("!--'&3T#L%S^= $U)FLO7M
M0:PT2_E@N+>*[2UE>#SV &\*2I.3TR.:\OL/B1K]Y\)(_$#W>GQ:L-32!?,V
M1)*@D3<I#'^ZQ!V\@<CIF@#V3-+7%7OQ'T;3O'7_  CUY?V5O%%9-//<RSA5
M2;>H6+/3=MW,0>>E7-;^(GA3PYJHTO5=82WO-JL8_*D?8&Z;BJD+Z\D<$'H1
M0!U-%<EKOQ+\)>&]0?3]3U<1WB(':&*"24@$9 )12 2,'!/0@]"*JZK\6/"&
MC6UG+<ZDS/=P1W$<,43/((W7<K,!TXQP>>10!V]%5=.OX=4TRTU"V+&WNH4G
MB+#!VLH89';@U@>+O'^A>#!;KJ<TSW-QDQ6MM'YDKCUQD8&> 21D_0X .IHK
MB;WXGZ#8^#].\4,+V33K^01)Y< +H^2"'!( P58'!.<<9IWA3XFZ#XOUF;2]
M/%['<1P^>GVF#8)4R 67D\#(Z@9SQGF@#L\YHW#U%?-WQ8\>:5XJT^VN-$GU
M^)K:9TAF\ORK2? RS#G<7&5QQP#R.:[SQ]J(U+QQX'L[6Z-O;PN=9NI7EV(E
MO'M;+C/ PKC)X&?K@ ]6HKS.R^,^BWFOV]JEG>QZ-<R_9H-8EC*PO/P=F",@
M<CDGC/( Y&+JG[0%OI6LW=A-X;N=MM</"SO<A&(5B,[2O!P,XSWZT >RT9KE
MM=\=Z7X?\&0^);P3+#<11M;P,NV21W3>J$=%.,Y],&N9\.?%FZU35SI&J^&K
MC3M0GLOM>GPB;=]K&PL%!95 + '!Z9!!P1B@#T_-+7B6G?'/5KC1'U>;PBSZ
M?;3B.]NH+GY858KMPI&2V&QC@9QR,\>M7FL)!X:N-:MD:YBCM&NXT4%3*H3>
M ,C()'MWZ4 :6:YV+QWX7FFU*)=<LMVF#-V6?:L7S;?O'@\X'!/) [BO-/!_
MQLU'5O%=K8ZO964=CJ<WE6OV5]\ENQ(55DYR06'<*?FSTZ9>F^%XG^-'C?1(
MHA<6TNG7$AA<A03+Y4@4= -KN,'C&T'J* /<-#U[3?$>F)J.DW27-H[,HD4$
M<@X(P0".?:KGVJ$RR0K-$98P&>,.-R@]"1VKSCX$'=\,+<YZW4W_ *%7+^%)
M/&UO\9]>6_72Y)76$:G*25A2$[?+\K^+=MR #U/WCGF@#T_PYX]\/>++VXM-
M%OC=2VZ[Y/W#H-N< @L #^%=+FOFL6FOZ)\0/';^#;VWTR/3HI+F9#"C9C'S
M[$5E(&"3@<8&!74^(/B9K-WX=\#S:9JUIH\FMF07E]+"#%"T95'&'!PNYCS[
M#G&30![706'J*\P^#7CS5/&6G:E;ZP\<]UI[QD72(%\U)-^ 54 9!0\@#((X
MSDGSO7OBCXIB\3ZK<0ZU-:6EOJ?V2*V2T1X/)5G#G>RGYL*IQU.\D8 Q0!]$
MIJEC+J4VG)=PM>PHLDD <;U5NA(]#_GK5K(QG(KY]BAO[;XW>++NZ\4-IL5@
MAN9[DQA@]ONB98"#T^5E7(YRHP#FFP^)/&VO^ ->\;)XIEL!;70CBT^"W0HJ
M_*"-Q&?XUP?]DYZ\ 'T)FN*F^(2VWQ0@\%2Z7*IGB$D5[YG#'87QL(^[A6&X
M$\C&/3RIO%FO_$?5=0FL]8;P]+I=@MQ:V1O?*224.AD9SM&Y=N>&Z$IV+4?$
MS5KS2+[P?XAMKJ&;6+C1"CZC"F!(Q4 R(, #_6.1P"-PX& * /6_'OC2Y\$V
M-G?+I OK.:<0SS&Y$(M\XVD_*<@_-Z 8]Q77YQUKP+4Y[6?]GG5M0_X2*[UB
M]NOLIN_M=P6,,HF0F,(2=F!_WT!NZ8HL[6]\#_%E=,M=8O;POH;S2-<2EQ-*
ML+D84D\9CR!R0.,XH ]])[UYYX1\>:QK/Q#USPQJ]A9VGV!6>(1,Q=@&4#))
M^;*LIR *\>%U':^"M+\;V.OS2^-Y-283IYY=Y%)8",Q _=P%/3!#D=P!U7BJ
M\L['XA>/IM+N(OMDGA\JQC;+B7Y!(%[@A "<=,9/2@#L?&7CO6/#OQ%\.:%;
MVM@VGZG-%'([N6E(>0(3M!&S&<@D$-SZ$#OWU2PCU&+3GOK9+Z5#)';-*HE=
M1G+!,Y(X/..QKYJM=,\(:>/AO>Z/>V[ZM+J-JVJ*MSEE)=&.]"?DVG*@@ $>
MM9_B.:?4?$'BV[O+FSAU.TU/=;WEW?&&>".)Y J0QCEN G09& >IR #ZCGU?
M3K:[^R3ZA:17.U7\F295?:SA%.TG."Y"@]R<=:S-7\;>'=!U2#3-4U>VM;R?
M!2.0GH3@%B!A03W8BO"(/"7ASQ#\5%T>_P!5N87N-/CFNI$8*]Q?LJO( 6#*
M,Y+%>QR!C&!P'B"SBM]3UV"&[WI:7K6\:W3;KB15+H#G&#@*-W(ZK@'' !]K
M45#:S-/;13/&T;2(KF-NJY&<'Z=*FH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ****  ]*2E/2DH 6BBB@ HHHH *X;4?\ DLVC?]@:
MY_\ 1B5W-<-J!!^,^C@=1HUQ_P"C$_PH [FBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***Q?%=UJ]CX;O;K0XK.2^AC,BB\9A'M49;A>2< X&0
M,]Z -JBO!6^*GQ#M?#FG^(+K2M!-CJ$_V>T7:Z22L<X;'F<+\I&3CMV(-=-H
M?C_Q'-_PE^FZM9:7)K>AQ"2&*W=H8IA@Y),ASM'RG/&0PZ<&@#U2N?\ %GC+
M1_!FGQWFKO.$E;;$L,+.7;CC/W0><_,1T/I7D_@?XLZ]JOC*UCU6[MI[&]M)
MI7M8+7RA;/&KG",W+DB/)RQ'SXXQ@8>L:KXL^(/P^\0>(YM9ABT.UO@J:48(
M]VT%&'[P -E?,3N=QSTXR ?1.EZC;ZOI=KJ-HQ:VNH4FB8C!*L 1D=C@]*MU
M\UZG\1-=T?3_  SX?\-WGV*.#1;>65H[59WFF>'?MPP; S@< 8+'/ P/6?A;
MXPN?%7@J"]U61!>I</:O*0J"=@ P*@8&2& P!U!H U/&'CK2?!%I;W&K)=LE
MP[)&+>'?R!DY)( ^A.3SCH<;]G=Q7UE!=PDF*>-94)X)5AD?H:\G_:(/_%%Z
M6>H_M$?^BI*PM*\3^)O!6OVNG7FK/K-K)X<;4$MY45%B98G=54CGCRL9SR&/
M&0* /?*XWX@^/XO =A;3R:7=WS73-'&8B$B5Q@[7?G:2"2, D[3QQ7C'AGQ[
MXT35-%N?[2UB^AU+4A%>17%K&+:1BX C@D8D E2V0-@4XZCFO1?C^BGX<PLP
M!*7\14D=/E<?R- 'J4K^5$\A5FVJ3M49)QV [FN?\'>+[3QGI$NI6EG>6D4<
M[0%+Q K$J%)(P2,?-CKU!KR/3;>_T'XCZ)X<@\1ZO>V&O:,AFE-Y(&C9UD/F
M0DXVD&(%21D D'K51;O4=;_9QU34=2U>YN[F"_!1A=NSE2\:&.7GD8=B%/&"
MIH ^B<@YYZ=:Y'XB>+-1\&>'?[6LM*%\BNJRN\VQ(06"@L.K9)QQT.,UYUX8
M\/W?@[QEX-O;779[I/$UNW]HQ3L"9F$1D##.<@;E&<Y&.N&(KSQ?L^K^ O$.
MIZ_K%U)XDM;J)+>VN+P[B"Z^8!$3S]YR<="O;!H ^@(_&6K7]GX3OM+T"6YL
M]9VM>N),FQ4[!D]-W+-SQPAXK?G\4Z!:_:!<:[ID)MI!%/YEY&OE.<X5LGY2
M=K<'T/I7B$QM[;5/@]K2>:LUQ#%92_OB5 C,40P/X?\ 6-D#K^M4+OP;X6?Q
MWXVM4G>2UTO39[N!&FQLGQDC=U8(QQR>O#9YR ?15]J=EINGR7][=16]G$N]
MYI' 4#US^(^M95IXW\-7^JV6F6>L6US>7L1E@CA)?<H!))(&%X!X8@\&OGSQ
M'JZ3?"SX>_:W-Y'%-<^=;2R,/,$4@4*6!RH"G:.X##'2ND^!6D:7J7B?5_$
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M);V^P/\ .9+8*,@_,<R$$D]^?>N@^.\NHCQ-H+6>G-OM83/%>PQEWW[_ +A
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M9F&55B>"[=,YP.!S73>$- \1:-\9M<U2]T*9--U5KA8KOS8V5%WAU)PQ(W8
MP><D>AQ[#2&@#@/BSX'N_&OAN%-.D47]E-YL,;D!901M9<GA3T(//3'?(Y6Q
M\'^-/$7CRQ\2^*K&TMY-&M8UB6*=<7TJ%V3E2=GS-ECC'  !R<>U"B@#YVC\
M&?$6P^&UUX-7PW'/#=W8N&N([^$%%&P[-I(SEESG/<\=*]5M=(U^_P#A)_8U
MX(++6Y-.:U^20[(VVE5RRYYV[<XSSG'%=I10!\U#X+^-['^S[JV71VN;6X0Q
M^3*=V=^[S'+* P4XXSG X!KMM-^'OC2T\<:AXDDUG3!=:E9S1331+(?L\C !
M-BM]X+M3&3T'3@9]?HH XCX9>$=6\%^'IM)U&]M+F);AI+;[.C JA SN)ZDG
MMCCU.1C"\0_#/5M9^)AUJ/5UM]%N#;R7D",PD=H2"J%?NL,J"&)XR>.!GU2B
M@#R-OA'X@75=?U&#QI&DNLI+#<*VF[A)&X^Z?WGRXZ @< >^*J-\$=1?PII^
MFGQ,!>Z=>27%G,L!"1(^TLH^;<#O4.#GKGCG->ST4 <CX(\&R^%K>\N+_4I=
M3UC4)!)>WDI)W[<A% /("J??KZ8 Y*X^ VE3WLY_MW4DTZ>X,[V*XV<G.,_H
M#C(%>MT4 >>ZW\'O#VO^+)?$5[<Z@;B66.62W#QF%B@4!2"A."%&1GN:@O?@
MEX7O;^XF6XU.UL[B99I--M9UCM2P&.$VY'4]#QD@8'%>DT4 <-XI^%'AKQ=J
MEOJ%]'<0311B)A:.L8E4?=##:?N]B,''!R ,)XC^$_AGQ/>6UQ>+=P?9K9+6
M&*UE"1I&A.T!<'&,]O:NZHH \\L/@KX)LH98I+&XNUD8,?M%T_!&<<(5'<]<
M]36[9> O#6G:O:ZK::6L=]:1+#!,9I&*(J>6  6(X3BNFHH YD> /"R^(#KP
MT.T_M(R>;YVTX\S.=^W.W=GG=C.><YYJU'X1\/1:O+JJ:-8C4)2Y>X,(+DN,
M,<GN02#[$CH:W** .<M/ /A&S<20^&=)5PP96-HC%2.A!(./PJY<^&/#][J!
MU"[T+3+B])5C<RVD;R$J %.XC.0 ,>F!6O10!DCPSH U/^TQH>F_VAO\S[5]
MDC\W?_>WXSGWS3I?#FA3:BFHRZ+ITE\CAUN7M4,JL#D$-C(.><UJ44 (*6BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TI*4
M]*2@!:*** "BBB@ KB;N/_B\.FR'&1HT_?\ Z:K_ (BNVKCIXO/^+=M* 1]G
MT63)['=, /\ T _G0!V-%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5FZ_97FI:!J%C87$=O=7$#Q1S2)O5"PQDC_/T/2M*DQ0!XK#\%?$$WA:QT
MB\\7Q)'8S/<6\$=GYB1.>F)"P;'?&,9)ZUIGX-W=]K&HW^L^*GO/[4A\J^2.
MQ6(R8"E"#N.TJZ1MP.=N#P37J^*,4 >2:3\$3I6I:+?_ /"47<TNESJ\2?9P
MJ>6)"YC #97)9LG)^\>/22]^!FFW-[J"6^M7]CHUT1*-,ML!$F X8EB05'S?
M+@'D88 5ZQ28H \[D^#^C2+I,L>HZI:7^FVOV1+RSF6)Y$PP^;*L,X9AD8X/
MTKE_&?PM=9?!NB^&[&<V5E-*UQ<S2;EB#-&2[9(Y.QCA0!V %>VTF* ,#Q;X
M/TOQII\%EJPG,,,PG40R;#NVE>3CIAC65I'PN\,Z-J7VV&UGN&%NUM'%>7#3
MQPQ-G,:JV?EPS#!SPQ]3GM:* .#T7X1^&-"UV#5;:.[D-L6>WM9[CS(89"?O
MJI&=PZ#)/0'J :Z/Q)X8TSQ7IL>GZO \UHDHE\M9&3) (&2N#CGL:V:* .)T
MOX4>$M)^UM;6,X>ZC\HR-=2;XX^!L1P0RC  ZY(X)QQ1_P *E\%"RN;--(9+
M:X>.26)+N8*60$*?O\8W&NVHH Y=?A[X76^TF\72PL^D1K%9$328B522.-V&
M.23DY)/6I[WP+X5U*]EO+WP]IUQ<RG=)+) I9CZDUT-% & ?!'AAH[*(Z%8F
M*Q+M;1^4-L1=E9BHZ DJO/M3+KP)X4O9WGNO#NF3322/*\DENK,[,<L2<9/-
M=%10!Y-X[^$D^JR:5<>%&T^P%@6(L)X@+<DL&+@!2"QPH8,"&"J.,<V_AU\,
M;WPQKUWXAUJ\M)-1GC,206$?E0QJ=I)P H/*@8"@#&>2>/3J3% $4UM!<*%G
MACE4'<%D4, ?7![U)M^OYTZB@" VENUR+DV\1G P)=@W@?7K4H7'2G44 -V\
MYY_.C&?_ -=.HH 3' I-O^<TZB@! ,44M% "44M% "44M% "44M% "4HHHH
M**** "BBB@ HHHH **** "BBC- !1110 4444 %%%% !111F@ HHHH ****
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M^H&I_P#([4 =71110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M** "BDS2T %%%% !1110 4444 %%%)F@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD=G&K(WJ"!D&K]C866F6JVMA:6]I;J25BMXUC09.3@  59HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TI*4]*2@!:*** "BBB
M@ KE8/\ DJ>I_P#8$M/_ $?<5U5<K!_R5+4_^P):?^C[B@#JJ*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *HMH]@^KQZJUK$;^.,Q)<%?G
M"'JN?2KU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 'I24CMM0G&<4SS?]DT 2T444 %%%% !7,6\9/Q,U.3M_8]HO_D:YKIZY
MNW_Y*/JG_8(M/_1US0!TE%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 'I24IZ4E "T444 %%%% !7-6C _$G5L'[NE6:GV/FW)_D:Z6N/TD[
MOBAXH SN6RT\#/0<SF@#L**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ /2DH)P,TW</>@!]%%% !1110 5QVC9_X6GXJXX^QZ?\ RGKL:Y71
MX6_X6'XGN,C:8+.+'?Y5<C_T,_I0!U5%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1124 +10** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH 1AE33=OO3STI,4 +1110 4444 %<OHO/CGQ23V^R ?
M3RC745R/AWGQUXR;/_+S:K_Y++_C0!UU%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %9NMZH-&T>\U%K>>X6WC+F*W7<[8[**TJ3CTH K6MS]KM8+A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX/I77#I7%?#WX=VW@&UO4BOGO;B\=3+,T>P;4!VJ%R>FYCGOGVKM: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!",@BL:\\(^&]0NWN[WP]I-S<
MR$%YIK*-W8XQRQ&3T%;5% " 8I:** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ****  ]*2E/2DH 6BBB@ HHHH *YGPN2^L>
M+2QR1K  _"TMZZ:N7\*_\A?Q=_V&?_;6WH ZBBBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***:YPN>W?Z4 .HJ"RN5O+5)T5E5L
MX##!X.*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*2E/2DH
M 6BBB@ HHHH *YCPK_R%O%WOK/\ [:V]=/7+^%N=5\5?]A@_^DUO0!U%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:*  444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E)2GI24 +1110 4
M444 )FN8\*X.K>*L'_F,-_Z3V]=/WKDO!Y)U#Q:W<Z[(/_($ _I0!UU%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%%
M "=ZX_P:3]L\6?\ 8?E'_D&&NP[UR/@W_CZ\6?\ 8>E_]$PT =?1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 QN
MH]>M<EX)4A?$,A^82ZY<L#] H_I77D9-06]E!:+(L$802.TC =V/4T 6****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^U>)_P#H#V'_ ('-_P#$TOVOQ1_T![#_ ,#F_P#B: .@W#U%&0>]<\;KQ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 )BC%+10 F#1BEHH 3%+110 F*,4M% "4,H;
MJ*6B@!NW'0"C;]*=10 W;[TN*6B@ I,4M% "8HQ2T4 )BDV\=3^=.HH :$%)
MY:^F3ZGFGT4 ,"$#J.OI1L/J/RI]% $?E^XZ8Z4X)@8!_$TZB@!GECVSZ@8-
M 3'/&?:GT4 ,*>G\Z/+&. HQTR,T^B@",(1P#@#H!2[&[-^=/HH ;L'H,^N*
M%3:2>.?:G44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E)2GI24 +1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z4E*>E)
M0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 'I24IZ4E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E)2
%T8H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex-a_006.jpg
<TEXT>
begin 644 ex-a_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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M4 %(R[D*Y(R,9!P12T4 4;*R2TD9P',LFWS9'.2Y"X'-7J** "BBB@ HHHH
M:.HIU-'44Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** &CJ*=31U%.H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!HZBG4T=13J "BBB@ HHHH *HZI.]IIM
MY<Q\O#"\@'T4_P"%7JS-;&=#U0#O:2 ?]\M0 NC7,E]I%C=S?ZR>VBE;CN5S
M_6M'<OJ/SK(\.G_BF-(/;['#_P"BUJU<?;3DPQH0K\*S8W#'7/..?Y4 7=ZY
MQN&?K0&!&00?QKBAI?C.XBU 37]I:/<7<?V=H#YGV6 ( Q7<HRY(_4UL66F:
MQ%?W$EQJ@DLY 1% 85!BZ;3D=3PQ/UH W<C.,C-&Y<XW#/3K6/?6VMRW+?8;
MNU@MC;.NV2'<WG_PMD'H.XJFVE>(9)XI&UB)5Q;B2-;<8)0L92.?XP5'MB@#
MI-RYQD9^M&X#J15&>&\,MN;61(D5LRAQDLF#A1CN"0:8(]5,<X>:#>9!Y+*#
M\J]\_J* -+('4TW>F,[EY]ZJ7MO=7%G+%#<>3*T15)0.4<\!OPJ&6PNI?LY%
M].ACC9'VA?WA*A=Q^A&?QH TMPR!D9/04M94.F7<5]-,VHS/$\<2B(@84IU;
MZMW^E:F/:@ W#U%+D>M4XK-HIFD$LI!W?*Q!')%21QSK<2M))NC8C8N/NT 6
M,CUII89 R.>G-!&17.:QX4_MJ.:"YU*^%K+OWQ1R[,;MN"".<J5X_P!XT :%
MUJ$Z:W9V4=C++;3Q2.]VI^2%E(P#[G)_*M%2H 7(!Y !XSBO/9_ACJ$UT+D>
M./$*R!-BXG4!5P!T P3QUKH?#_A*/P[Y_P!GOK^=9U421W-P7!<=9 3R&/4]
MJ .C#KMSN&/7-.JK+:F2Z@F\R4>5GY01@Y]?6K5 !1110 49%%07%L+A=C$A
M,ACM.": )Z**3!Q0 M%-"D'KFEQ0 F]3D[A@=>>E*I#+D$$>HINP+D!<@]:<
MH"J !@"@!K.J#+L%'N<4ZD90PY4-2\T !Z4Q)8Y'=$D1F0X=0V2I]_2G,"01
MZTV.)4=V" ,Y^8^M $E%%% $,]S;VJ![B>*%68(#(X4%CT'/>IJAFA$PP\:N
M <@, >?7\*FH **** "BBB@ HHHH **** "BBB@ HHHH ;)S&PYY&.*JVMT;
MB\NHC;SQBW8*'D4A9,@'*GN*N&D% "T444 5KJY-N$/DRRAI F$0MC/<X[59
MI*6@ HHHH **** "BBB@ ID@RO&?PI]!H QI+S5%BNS%I!9X9-L*&< 3K_>!
MYV_C5C2YKZXC=K^P^QN&^5/.$N1ZY%:'-** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH :.HIU-'44Z@ HHHH **** "L[6/\ D"ZC
M_P!>TG_H+5HUFZSQH>I'TM9/_06H @\-\^%-&][* _\ CBUL8K'\,?\ (IZ)
M_P!>,'_H"ULT )BC%+10 F*,4M% "8HQ2T4 )2T44 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%)FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@! :6FCJ*=0 4444 %%%% !69K?_("U3_KTD_]!:M.LO7SC0M3Q_SYR_\
MH#4 1>&/^13T3_KQ@_\ 0%K9K&\-\>%-&Q_SY6__ * M;- !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !2&EI" 1@T 9,NHWJ:Y!:K9DV3VTDLES_
M ,\W5@ N/Q/Y5JJ21R,4$"A0!G% #J*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@!&&5(]JS-%O;J^MGDN]/DL'$K(L4CABR@X#<>M:AY&*;L&X-QD#%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<$[B<>@& ./SKU/X;:[?^)?AC;7DM\MQJVV>%Y3MRLBNP3< ,9V[#R.<@]Z
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M').2&#<_W@>]>AUXY^SO>PR>$=2L% \ZVO?,9E7AE>-0,MT)RC?0 >HKV.@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &C
MJ*=31U%.H **** "BBB@ JGJ#[;"Z9N D+M^AJY67KKB/0-5=^BV<K'Z;6H
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MM"(#_H)&8P  A_>\J !Q["O4O"GA;3_"'A^+2=/5O+4[Y)&/S2N<9<^YP/H
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M%!/K@?A4U% ";?<T >YI:* $QSGFEHHH **** "BBB@ HHHH **** "BBB@
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M %%%% ""EIHZTZ@ HHHH **** "LK7O^1=U;_KSE_P#06K5K*U[_ )%W5O\
MKSE_]!:@"+PQ_P BCH9_Z<(/_0%K:K%\+C_BD=#'I80?^@+6U0 4444 %%%%
M !1110 4444 %%%% !1110 444&@ HJE9:OIVHRS165]:W+PX\U8)ED,><XW
M8/&<'&?0U<S0 M%)FC- "T4F:,T +129HS0 M%)FC- "TF:,YK@_&?Q%?P?X
MGT;2I-&DN+?4G5?M?GA F9 K!5P=Q4,#@D=1[T =[17GO@WXB7?B;QMK/A^[
MTN*P;3E; %SYCL4DV-G@#'(Z=/?->@E@HRQ '3)- "T9KB?BCXMU/P9X5BU7
M2H+6:8W21.+E690A5CD!64YR%'7N:I/X\U9];\(6-EI=M=+K5M'<786?Y[4%
M59CCLH5LC/WL8'- 'H=&:C:>)6V-*@;T+#->2:+\0M0@^+?B#1O$FMV5IH]J
MDOV99S%"@;?'Y8WG!+;&;@GU]. #U_-&:\@^+7BS7;#2=%UCPCKL;Z?=3M;X
MLUCF$TG.W:V#G[K+@=Q7<:GX_P##&A:A!IVJZQ:VM[*,M$S$F+@-B3'W,@C&
M[&>U '39I<UD:IXAT[2_#4^OO.LVGPP>>)(#O$B]MI'7.1STYK@_A?\ $F'5
M_#$[>)=;LTU&VE=Y6F=8ML)90K,>%'S/M'3L.M 'J>:,UQ>A_%3PAXAU;^S+
M#4_]))VQB:-HA*<XPI8#)/8=3Z5D?%WQ]?>#M,L(M+#QWMU,&\]H \8C3EER
M>-QX&/3)XX- 'I08'UI<UX#\4=0LYM=\$>.HGNFL#.I^S2H4D"PS!RRHV,%A
MD9Z'"<\BO2-$^*/A_7!J@1+VSETRW-U/#>Q"-_* RS*N3G QG./O+ZT =MFH
M;FZM[.VDN;J>."")2TDLKA40#J23P!7">&_B[HOB77;#2H-/U.UDOHY'@DNH
ME5'V9X4ACG(5^>@*XZ].,^,3RZ]\1_"WA&:5H["7RI7*DY+2RM&21ZA4.#VW
M&@#U.T\<^%+^[BM+3Q%IDUQ,P2.*.Y4L['H ,]:Z 'O7C7C3X26\&J^'K_PG
MI5O!%;WJG4 ;@CY-Z%7^=L87:P(')W#@]HK_ ..\ZWDU[IOAFXNO#L,@A:]9
MF0NY4$ '!53D\ DDCGC.* /:LTN:\>U3XSW]GXDCTZP\,MJ4-S:Q3V7D7#>9
M<;U#A@ AXQN&,$Y4GZ5'^+?C.Z\10Z!9^$K2TU2YCWPVU[<L67Y"_P WW,'"
MDX.#T!H ]LS1FO%HOC;>:WIVD6GA[28'\17\Y@>WN7)ACP =^002K;N,XQM;
MK@9=<_$GQA!IWB33Y[;18/$.A,)IL"4Q26I7EHQNR7#-&1N(!#],B@#V?-(3
M7A]E\2?'D'@75_$&K:;:1PF&$Z;<,@B$C2-C(4M\X"_,!U/'8UF:/X]\3^*?
M!_C33;O5[:6XM---U#=Q6^S?&IS*OW1]Y/E!V@C.>V: /7;OQYH=KX*;Q8)9
M)=,Q\I1/F8[]F,=CNXYZ5?\ "_B&U\4^&[/6K-)$@NE)"2##*0Q5@?H01GO7
MSSHR>()/@WJ5O#KVE+IWD/.FDR0(]P\*R,)9 2,J W(.&Y48*D5T=QXL\4>(
M;_P?X.T;5!I;WNDV\]S=HGS,QB\PX/4 *G0$9)(/% 'O6:7-?-M[X\\5R> ]
M5L/[5G_M#P_J<<4VI6TC9N(G,J88X'1U&#U8$<<$G:\%ZOXG\/\ Q+T71]8U
M^?4[;7=/2Z99V=Q$61V4+N/RD%""1P0>1D# ![OFC->5_&;6[RU;P[X?M]2?
M2[?6+HI=7R.5,<:E%(ZCY?WF3R/NXZ$UQ$ U6V?QOX*;Q/J3VVBZ>]W9RPSX
MPD*$>2W^R1*JLH[IP0!@@'T46]C^5<??>,KVT^)-AX6&D,UI=6K7#:AO($84
M.3QMQ@%5!.1RX]1G@?@_X6U][W3?%EYK)NM-ELY$6"2XDD=&WE N#D8 7/7C
M.,<9INLZ+%=_M SZ5-?WBV^L:3+'*1*"R*\3JR)N! 'RY P<$^PH ]'\&>/-
M,\;KJ#Z:DZ"RF$;"90-X(.UQ@D8.&[]O>NF-Q"LPA,J"4C<(RPW$>N.N*^4/
M#E_X>T'PWXDN+FXG_M^99K'3DA9PP1D*LSX(0J=P^]W3(Y%7/A-IYT[XJ^'&
MG2,BZMY9[=HI58;3#*,MC."-KJ5.""/S /IV]U&QT\)]MO+>V\PD(9I53<0,
MG&3S@ FN/\2?$*TT/Q-X>TZ*>"2WU',L\Q8%4A(^1]PXP3WKROXU!M1^)$L$
M4EJYM=&WF.XDQM(+LP3MYFTA@.^._0YEC;>'XO#7@/5M:7_0U>]M[T,IQ+&D
MKR*O^URP''T[4 ?0&K>-/#^@W-G!J6IP0R79 A!8$,IZ-G^[[U?O_$&DZ5;1
M7.H:A;VT$QVQ2RN KG!. >_ )KYW@O-%OM4\47GC*U.FRSZ6#I5G<*W[J(J=
MBIQUQM].35'3X);*?PC=^.( WA][*6*)WB9U5"'V;@1PP8Y'MB@#U+Q[XFUR
MT\2>%9_#^H0W.FZE/L6VA /GD8SN;NF&SBG^+?'^FZOX9UJ'PMX@6'5;")KA
MFA3+&-&&\*Q'0YZUYEK=QH\7@7PHFBW$UDD.I7 B:Z?YW5B ;@X PH(_#I5S
MPQJ^BQ_#OQ7H$,$?]M+:3R+=H/\ CZA4Y!5AZ* 0* /1? /Q.T6]TW1M&U#5
M99==ECV3&9?O2 $D;NG;BNFU_P"(?AWPY?K8ZA=.)C'YCB./>(UW;<L1]WFO
M%$U;PYI/A'P%?01HU[;Z@MS?&"$^:0F=V21R.?QQ4T$]QX9U[QH^M6%],FN6
M4C6K1VYD$FYCLYYQP<X/3% '4?$674KCQ?X.U/0M7N7M;Z=8HXX)OW3,&R3Z
M'(XJ#XL>/]'O-)U'1-,U._M]4L9U8M;J1&S \J7!Z5S,::EX.MOAW#J,%U)/
M:7,EY- BD^1%(RJ 3Z]3^-5KA[SP;HOB[PA?Z3<3WE_,3;WJPEE<$G#9P3DC
M'% 'HME\1[7PMX'\-K<P7^IZC=60G:.)<OY8ZNY]!ZU+??&[P_:Q6<]K9:A=
M03$"9EC"K"Q/(.>K#TK@;W2-9T^V\-ZW=6&O0V']G#3;B.U^6XB &.%&?D?K
MS[UGZ_H&LZ7\/+"Q32-4@235[BZB@=6=DB\M0N\KSG()Z#K0!Z'<_'?14T_[
M1;Z?<RW!N&B%L6"ET'\8.*Z_P'XWB\;Z1/?)9O9F&<P.CR;\L!G@UPWC[0]6
M\2Z-X4FLO#,WV)!Y][:0*D<T9('RCT[UM_!SP]K/A_0[Z/4[3[';SW)EM[=S
MNE0'KN(H \GE-KXN^)?B35/$US=Z9:V"23NT(&^(Q2)%&G(ZG('3)->AZ3\;
M+V[U/2QJ7AA[#2M3E:*VO#.2'89  RH7[VT$YP,D]!6&?AWXMUGQ/XM:^TAK
M"TUQ)!#=&YAD6)EF26/<JONPWEA20,C=TI+;P9\0-9MO"^AZQHD6GZ5HLGFF
M=+F)WEVG(& Y^8@;1T&6R<8H E;XX>*?[7DTI?#5H+R*\>&:-#),4 <)M^7J
M0=P+#@\8 [^C?$KQ5K'@WPVNL:99VES%',J7/VEB-BMPI &,_,0#SQGIUQR7
MPPT3Q5I?C?6]5U7PTUG9ZX[W!EDNXF:WR[R!-H.XYWXZ#&.16Y\8O#^M>)_"
M,&F:)IXO)3=K)(!.D910K<C>0#UQUSSW[ ''K\5/B&=4DT=O#^EKJ4ML+R!,
M.?+A"%SN <Y)48'*D' (R<"Y<?&/5Y_ .B:CIVGVO]LZC>M8E9 3 &7&2HW
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M,UW>:?!Y\UG;C=-@J64!>Y;&![UE>"/&]IXXL+R[M+.YM!:W!@9+C&XG (.
M3C@]/YUYQH$NH:=\;?%DVH:]:648N85E,T083QN<PPJQ(VL$VC.#T_$\=X:?
MQ;IWA'Q5K>B:^NG6&GWOF/;K;H[3R[E!Y9?E4*1QR#TQWH ^H:*^=?&OQ/\
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MJ2-K1.2"1G(YR 0&.0,BF:1I=EH/AGPAXML-2:SUBZU=X)GW+MBB!*DE?0*
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M 9A]DM_*)D<C.TX()/&0JM[ YL&GZ%8?##1/$"'=K/\ ;8CGQ,2XB16;:J9
M[1G.,Y8<@$"@#Z=U;Q;X?T*YAMM5UFRLYYB D<TZJW.<$C^%>#\QP.@SR*Y#
MQY\5(/!WB+0[.-8+JVN%,U_C<7B@. CH1P<_.<<Y"8XR#7B7Q&O++7/'_B#4
M(9XK>*-49/,=F:ZP$0%/J"& X 49]JM:IJVF36/PZU>ZA$L-FHM+\,@8R);R
MIF,@\,/+;H>SX/>@#ZHMKB*[MHKF"19(9D$D;J<AE(R"/8BFW=U!8V<UW<RK
M%;P1M++(QP$51DD^P )KSKP?\4$U/4- \/WVD-:ZAJ-F;A/LXQ!$F)&1<$YP
M8T4Y''S#M6]\3;_^SOAGX@G,9DWV3P8!QCS<1Y_#?G\* *<7QA\"2R.@UY4V
MYYDMY5#8&>"5P?3U)X':K5Q\3/"]KX8LO$4UY,FFWDS0PR>0Y)92P.5QD?<;
MK7SIX%T6YO?%VBQP6LTZ77F1W'F6Q$:(R.K'=G##RSNSQSQ@X&;&H:W=+\+4
M\&W_ (?N%NM,OI':\96VP#<V[D<;MSLASE<'UP0 ?0OB/XE>%O"FHI8:MJ#)
M=-&)?+BA>3"GIDJ"!G!XZUYCXHUX>'/C+HGB27Q!<3:#>VXN4Q(SI'"R%&54
M'\)(5N!UY/(S7,:O*(O$EWJ_B3P]J5U!XDTL+91LFR47($8&.ZX>/  YV,O!
M!Q5B[UV"P^(7@F*;1;IKK1]-LX+BRBCW2N[1;U1$8YROFC[Q!SGT!H ][\(>
M,-,\:Z-_:>EB=8UE,,D<Z;7C< '!P2#PRG()'/UKH*\2^!>MW'VW5M(DTJYM
MX+V1]5MY#'A%4L(RN<#NH QQ\K=,5[;0 4444 %%%% !102 ,GI29!H 6BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :.HIU-Z$9I=P]: %HHHH
M**** "L[6/\ D#:C_P!>TG_H+5HUG:P?^)+J/_7M)_Z"U %?PS_R*>B?]>,'
M_H"ULUC>&/\ D4]$_P"O&#_T!:V: "BBB@ HHHH **** "BBB@ HHHH ****
M "D-+2&@#"T'QCH'B>ZO;;1M0%U+9,%N%$3IL)) Y90#RIY&>E;N:^:]+U+Q
M'IWQ'\=7WA&&Q98&N9KD72D((TE)^4 CYLAL9]ZWM6^,GB64^&HM!LM.>?5K
M6-BLH9]UPTK1%!EE"C>G<]^M 'N^:3(KP36_BQXUTJ"RTC5+.ST369F:66ZG
MB+1K!N*H0@+D$LC@\'@*1UR(+CXPZ[>?"]9EDCMM9>_%C+<QJ-QC*%]\:9X;
MHI[#((Y(P ?0>:P_%WB./PGX7O=<EMI+E+4*3%&0"VYU0<GH,MDGT%>,Z%\4
M_$&C>!_$;:A++?:G87L=O;F]3RY(S)O'SK_LF)CM/(.1G%/TS4_$OV3Q)IGB
M/Q$M]9WGA2348PQ4R+OCR,*.1@%@1W !^@![+X3\0Q>*O#%EK<4#P)=*Q\IR
M"5*L5(R.O*FMK-?,'AUO&6@Z%X4\10:S,NB3:D+6.Q69@@!D((9. P8B3U(X
M/';Z<(XQD]: '9SZUP_Q ^)5EX!%DDUC/>3W8=E2-@BJJXR2Q[\C  ]>G%>)
M276M>*?#_BSQK<:[J-G-9W$(BL(+AU5/,D5<'G@*IP,8R1GVI-:N6\:ZOX#O
M-3NG2;4(X[*Z^<(0L=P4:96/ +Y8].&7C/8 ^A/!7BD^,/#L>KFPEL=\LD?D
MR')^5B 0<#.1CMUR.<9K?:>)'"/(JL>@) )I(D\J%$RS[0%W.<L<<9)]:^/_
M !4\>N^(/%&M6BR:A:"\$J7TC;#'&SD*H0G)!X4=P%!P.@ /L(S1APA<;ST7
M/)_"FK<0LA=94*CJP.0/QKYW\=/;:M?_  UD;4?,N;FUAM[R[@GQ( QB!);)
MVM\[\GU.<U<\.^&-);Q)X]^'MCJLD%M<PPBTW2ABTD8#-G  .&.&48.W([9
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ME">^*[+PGXJUGX<^'O"6B:OHQ@34K^8,9R4>*$NHSMZ[@T@;D?=&,<Y'NNT
M8 &/2L'4O"&FZMXITO7[L.]QIJ,MO$0ICW'HQ!&=P/(YX.#0!JZ@ES)IMREH
ML+7+0N(EG&8R^T[0^.JYQG':OE?3?!'BN+4$,?A*_?4=-NUNI\LL<31@H5C3
M^$G(;E2>"..*^LL4;?I0!Y#<:?XOM_B;J7B:/P<UW:7FE+:-$=1A3!*(S8YR
M?F4IT&<YS7 Z7\,O%MUX/N;9])GL[VQNQ?6\4Q4)<Y0*4'S9##8",\')!Q7T
MY@8QBC;]* /#_"6B^._^%MVOBK6M&CM8]3C=+OR<%8D$0505+,5),<9ZGJ?<
M#T'XC^#7\;^%'TV"5(;N.9)[=Y&(0.,J=V 3@JSCZD&NPP/2B@#P[0? GC'5
M]:T:Z\0VFGVMOX;M?LMG$YW"YD13Y;D#^'=L).1]S@<DU8T'X=>++KP3XLT+
M6TLK6;5;F.]@E63<OG%MSYV]%^1,?4]:]HQS1B@#Q.]\%^+M&TOPWKUS>6#_
M /")6DKO;+N)E1'8D)A<?-"L:Y(!R,GVY_2HK'XK?%VTU:UTH06$$$=QJ<5P
MH96=20!QPV[Y!SC(5N..?HMT$B,C ,K#!!&016?HV@:7X?M'M=)L(+.!W,C1
MPK@%B ,G\ /RH T:\O\ $?P;M_$?C6;6YM7N(K&\"&^LT&&E90  &Z!3M0X(
M/(.#R,>HTF* /'9O@9,?,TRV\5W<7AN2=;EK!X=[%Q@'+!@#P#@XXXR"1FO6
M=.L8],TVUL(-WD6T*0Q[CD[54*,GN<"K-+0!YYJ_PFT[6?'P\3W%_=!&>*6:
MS7 622, (=W4#"C(QU[C-6;'X5:!8:7JNFQ2Z@;755472/<YW$-NW#CAO>NZ
MHH X&Z^$'A6\LK&"6&]$EE#Y$-PMVXE\O+$*3T(RY[9Q@=.*Z+POX4TKPAI)
MTW2(7C@:4RL9)"[,Y &23[ <#BMRB@#G/$O@7PYXO>!]<TQ;F2 %4D$CQL >
MQ*D$CO@UBW_P<\%WMK8VRZ6UM'9A@AMYF5G#')#L<EN?4Y':N]HH X_3OAGX
M9T[6-4U-+%IIM261+A)Y"\>V1MSJ%Z $X_(59MOAYX2M-(N=*BT&T%G<DF5&
M!8DXQD,26! '&",'D8-=/10!Q>F?"OPCI6E:AIL.F%H-0&VX:29B[*&W!0V<
M@ @'CKCG-4S\%? 1&#HLA'_7]/\ _%^PKT"B@#G9_ GA>YU.TU&?0[22ZM(Q
M%$[ID;0 J[@>'(  !;)':NAI:* ,G_A&-"^TWUR-'L1/?QM%=RB!0TZ-]Y6.
M.0>_K48\(>&A:K:_\(]I7V=6+B(V<94,0 3C'7  S["MJB@#-?P_HTDL$KZ1
M8-);QB*!VMD)B0# 53C@8.,"GPZ+I=M9BT@TRSBM0V\0I JH&]=H&,^]7Z*
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MF>>GJ1TKJQ1BB@!,48I:* $Q4-W:6]]:RVMW#'/;RJ5DBE4,KJ>H(/!%3T4
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MX.W[*<E<R ')^;"X!YW Y%=AX=UM-?\ #NG:L(O(^V6ZS^26W% 1TSQGZXH
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M6MR@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAH \8\<>+/%'B'7]?\
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MC+$DC;U)SC';IGGK5FS\!>%K#2KW3+?0[-+.]P+B/83YF/NY).>#R.>#R.:
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MQ]0LY['X5:WKU_";5_%6JQ-:VR1X6*-&DE#<X^4Y8#CH%/1N/J%4" !0  ,
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M[;4K;3#J1ENX[=H1(4(#*V"#@\[@HZ?Q5T":BL&CQ7^K>5IO[I'N%FF7; Q
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MF8,"#P%QSD=*OQ_'"-?#-[/=:5Y/B&"\^QII0<EBY!PQ! ; 8,I &00!W!H
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M-S\=Q^%;&G?#'QA/J_A>77]0TB:R\/*!;):M(LC;,-&&)CP1N2,$]=H/4\D
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MN$W*BPH"H+$;V4\$#+9/0\X^C)?AOX/ETV73CH-LMK+*DSI$6CRZ@A6RI!R
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M% !1110 4444 %%%% !2&EHH \P\7_#'4[[Q4WB/PGK/]D:A<PM%>EG;$@(
M!&,XR ,CIE5(P1FL'5/@7>2>'=,TO2]7MHOLZS37+2Q$>?<L!M((Y"@#;WVC
MG#$FO;*,4 5["&>WTZU@N9S<3QPHDLQ&/,8  MCW/--U2R;4M(O;%;B6V:Y@
M>$3Q'#QEE(W*?49R/I5NB@#R[2O@KIEEX6O]!O=3O+R"ZF2X1@JQ_9Y5#*'1
M>>2IP<YR *9%\"/#L-I8"&^U2VU"T7)OK:98WDESD.1@[<'H%(P.Y/->J44
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MG\:6YMH+RVDM[J".>"0;7CE4,K#T(/!J:B@!,4M%% "4M%% !111F@ HHHH
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MD7$P;D ;6C=0<8S'N^88KWNQGGN-/MY[FV-K<21*\L!8.8F(!*Y'!P>,CTH
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M5WXW;?F/&>F,Y(!K3T[X:1:?X_E\8'6K^XO)9)&>&4+L*LI4)D#.%&W'^Z*
M.TA$JV,8NRK2B(><4Z%L?-CVZU\R>&O!=_XEL=4O? &M3VUH':":QO)C!,\9
M!*J?+W*ZD''S8&=WID_4+(&1E.>1CBO*(OV?_#4*LL6KZ^@==C!;F(;E]#^Z
MY'L: /"?^$HNSX6L= CGN+?3XII)KCRI#^_+LI!*Y .W;P">ISQ5Z]\8>*++
M1;KPM>:E=>4DP\P/<,[HBJ5\H,&(\LY!(&0<#!QU^@;GX->";C2H[)=+D@>,
M-MN8IV$V3C+%B2&Z# 8$#G &:6R^#G@VST*;2C82SK-M9[B:=C*64,%8$8"D
M!VZ  ]P: /%O%6@+I/A_4=/M_%;ZTFGW<$ZVL<TACM8'\Q=[ G9O+/$/EY!8
M\#-5=>U#09/AI8:=HL]W]HM;F"2^$K_)-+-;'>57KM0Q!>@ SWR"?H#3/A;X
M/TK2;O38M*$D%X$%R9I79I0C;E!.> " <# ..:KO\'O <D0C.@@ .SY6YF5L
MMC(R'R1QP.@YQC)R >,M/I?B?QM<P>+M4W:=I^C?Z$LDVU/,$,9"@CJQ)=O5
MBH'/2N6O))KWX;VUS?7MU/)::B;6UBFF+1I%Y.]@JGIAMG3H"!7TG+\)/ TM
MA!9-H,?E0%BC+/*K_,<G+AMS<^I.*GNOAAX-O8;""?14:"PC:.WB6:154$Y.
M0&&XD\DG)/>@#R/P?#I_A/X^G1=)O2NF%!:D^=N$SBW!(8C@MYH;CLV0,=*^
MB"RHFYF  &22:Y*P^%W@O2]1@O[/0HHKF"431-YLC!7 X."Q''4<<'GK757-
MM#>6LMK<1K)!,C1R1L,AE(P0?J#0!X3X;\3^'K/X\^(=2.K6T.FW<!2&Y\T"
M&1R(B<L?=7Y]<T_XW06EF^@>'[2UCMK/4;^2^NC"-K/*2J%_KB1OT]*]$_X5
M+X$QC_A'8,?]=)/_ (JMV^\+Z'J5QIL]WID$DFF,'LCMV^0001MQC@;5XZ<"
M@#Q7XQZ#XACU&XUR\EL#X>M(Q:V%K/-DKOC"'8@ R^[+@DG&P$_*N*VOV>+V
MYET+6+)_+-K;W*21$ []SJ=^>V,*F._7VKUG5-&TW6[>*#5+*&\ABE69(YEW
M*'&<'!Z]3^=.L-'TS2E==.T^TLUD(+BVA6,,1T)V@9H \6^,\'V7XB>%]8UB
M$R>'%\J*;(+H&64M("ONA7C^(*1SBN)ADTN[M?'^L6]NEOX?F3RK)&CVH+AI
M080JC@$*'/'W0V. >?J>:V@N%VSPI*N<[9%##/K@TP6-J(# +>(0DY,8C&TG
MZ8QV% '"?!>[TJY^'%E%INSS+=BEYLC*YG/S$DD?,<%>1GL.V*Y[XZ*;:Z\)
MZO\ 999H[*]<R>6I/RC9(1Z9(B;KV!]Z]@A@BMXQ'#&D:#HJ*% _ 4_;SGF@
M#YF\3^++G5/$'@K6O$,%OIL8F>ZC$MNSHMF9E\LL@Y8X5N@&1M/&:S=->;Q:
MGCW3M$BENI+VX75;>)< M&EP<CD\-MF!QU.TCKBOJL*!ZT%0>YH ^:/A5:MJ
MOC_P]JFG6FKW$%C$8KZ\NI%DBC;[.Z*B84;5'  )) (&.,GZ7%&T9S2XH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@! *6
MFCK3J "BBB@ HHHH *P_%7_(H:\?^G"?_P! :MRL/Q5QX0UW/_/A/_Z U %G
M0 %\/::HZ"TAQ_WP*TZS=!_Y &F_]>D/_H K2H **** "BBB@ HHHH ****
M"BBB@ HHHH *0TM(: /)_$%W?P_'[PS;:C):S:9)%*UE'Y +PL8B"2V,[BZ#
M!S@#TY-<5;>)O'M]'XNNK/Q$8;70+M[IXIDW.V9' B7CA $;Y3P.!CN/1/&O
MPQU+Q1XOM-?L_$IT^6TC1;=#:^9Y3*Q;<#O'4G/(_,5DVWP8U2*S\00W'C"6
M6368U$TBVA7<XE#[G^?YN-ZXXX<_2@#GO&-MK'BO4/AI/_:TEK=ZG8K()\;8
MX)@J2-(NW&&.1QG^%1QUJEK?BSQ%XJ\1P^&/#.M:G<Q6%LZ1W5A<"*34)D4D
MR,VY $S@8!/ )&=PQZ&GP=TR]\':5H.M:G?73Z:\KQ74#>40LAY0*VX!<!??
MC@@'%0W7P-\/M]A;3]1U+3I;:!H&FMV17F!+$LY"C+$,5)[K@=!0!YUXNO?%
M*^'? EU/K.I6^K72S6TB?:F5 T<P6.1@O5RKC<QR3@?CJZ-INHW/BKQQ\/;G
M7]2FL&L6ECN)9F=T9'C8<'C#>9AP,;@,<5U^I_ [1-0M=,M$U;4[>VTZV\B&
M)'5ADNSNYR.&9FR<8' '0 5L^'_A7H/AW6QK,%SJ=UJ'[SS)KNZWF4."&#@
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MQM?6;+PG:ZKI6M7=@+6X"S1V\K1F8/A0=RX/RGMT.3W H ]0W#UI<BOG0_\
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M5CFGDN+&5]@5582Q RXSCE70D<#*G  XKZ7TO2--T2R-IIEC;V=OO+F.WB5
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M<<LI&">!U]!Z4 ?-GBW6/"M]X<T?P_X;M[JV\J;?<222>7:S2,D:L[!B2Q!
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &CJ*=31U%.H ****
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M@$+3E(W\QD3<V -P!.<<@=>* /I7PYXV\/>+);J/1=16Y>UQYJ^6Z$ YP1N
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M;V$^F7^ESWB%[(W2?)=!?O;&'!(P?;WSQ6 ?CY:!;IAX4U?;:$"X)V@0DMM
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M^WZ7!>E9[@S,JP*C, O0EL*<D]@03QBOH/0Y[^YT&QGU:W6WU!X$:ZB3HDA
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M"2O\!J_\0O#^G>#M3\->'+>YEF$$SW;RWZ P*LLBC#*!\P C^;GH/?CWG6O
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M HHHH **** $!I::.HIU !1110 4444 %<YX\Y\ >(A_TX3?^@&NCKG/'O\
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M4@A@>A!'44XUX?XX^)?C#P?K3VEEI>GP:0(H1922V<NV7,2EE1@P7Y22,<8
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M%%% !1110 4444 %%%% !1110 4444 >1_'35]>T'2],O-)UJXLH)9C#+#
MK,P4L&WCYAP"",X/'ISZ%X4CNXO".DK?WKWMU]EC,EPZX9R1GGU/.,]3C)Y-
M>7_M&74(T#1+(N/M$MV\B)ZJJ%2?S=?SINI_%>672]"\/^!E>]UF401N[0%4
M7:!NC&_&2<8)Z!23G/( .Y/Q6\%#5QI?]NQ&[,XMP!!*4WEMN/,V[,9[YQ[U
M->?$7PU8WFL6<U\?M&D1"6[1(78@$@?+@?,064''3<,]\?+#V=W9EM1NK*]B
MGBO>87M'2,88E@9#]U@XV[<'ODC&#ZE\2+.^U34-!\3^'+&[M9O$MH]A=QM
M=[;U"A7!R!E-W/'"9!X! !Z(OQA\(-;6-PMU<E+V9H(A]E?.Y2H.?0?.O/O7
M2^*/$NG^$M!GU?4G(ABP%1.7E<]$4'J3^@!)X!KQ/X>>![NS^+5QI=^9KBQ\
M.F2X@=H_W;2/L$9.00"5P_'>/@\5V?QP\-WNM>&+*^LX);IM-G\V:UC!8R1L
M &( Y)&!^!:@"33OC3HVJZ;J\T.GWL-Y86C74=I.HW7( )PNW<<="3CA3NZ
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M0,4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC![\^AH ZBBF1R"6))%^ZZAA]#3LF@!:*3)I:  ]*0=:HC5K(ZNVD_:8Q?K
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M@@GCD T ?2PI*^8_&=QXR\,+HFB:MXBNC)!%/(S:?>RM.4,APTA+#(PN5ST
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M$H'WCTXYPMAX*\;> =;U'2_"]E::AINKF%1?W:AEMU1F_P!8N1TWMD@$$8(
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MLI^[D$?*I!)8"LZP7Q5=Z)J7P\TO1+E;V349+B^D<!0(B!M1F;A060'.?FP
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MYBO'M1>I)91@]\'DCG&*^:--N;2-]1OI8OM=N=%>V>6&PVQVUPT7EQANP.5
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M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\CY!*[5.<JS @XR#5&T^&/B/3?B'%KMEJ=@;2UL%M+=K@LTK%;40J74*!_K
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MH6]2 ,$\"IEMK=83"L,:Q'J@4!3^%344 -2-8T5$4*J@ *. !Z"EQ]?SI:*
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M;_Z-*J@J"Q&0RGGYC7:00K;V\4*9*QH$!/7 &*EHH 2BEHH 2BEHH 2@4M%
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MB"<9( X(P1P.M=-F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+W3;J*ZM7)"S0MN4D'!P?8UY)X ^&/AG6_A?9W-Y81-J-[%,?M9W;HV+,JD
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M@?C6-XJ\>Z%X/TVTO]2G:2*[<+ +;$C.N,EP,\H 021ZCJ2*\7\0>*]>\8?
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M1FC- !11FDH 7-%86L>,/#V@7D%GJNK6]K=3[?+A<DNP9MH. "0,@C/3@UN
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M4 %%%% '.>,O&FF>"-*CU#5$N9$EE$4<=M&&=FP3W( X!/)%9.F?%OPAJO\
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M:* $P/2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*ZG(8'H0>XH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%X5L]:DGMK;SD!FC:=2(GR1M)SZ@XS@^U97Q@A$_PLUH>67*+$X &<8E0Y_
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MWSD\'H.2W 3L/AWX2UWP]_:U[XCU*.]U+49D=O(D)B543:I *KANW QA5]*
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MM% "8HQ2T4 %%%% !1110 4444 %%%% !1110 4F*,T9H *6BDS0 M%)FEH
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MID=]JGVAQ+)Y<45N@9W;J<9( P.>2*?X0\7Z;XVT0ZII8N$B65H9([A KHX
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M%Z*-4U4S&)I!#''"FYY'()"CH!PI.20.*P;+XN>&[[PYJFN1)?BVTQH5N$:
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M3_":"^C0QZY=B62&Z>0A4=79%0@<;/E&>">2?05[!XQ\/+XJ\)ZCHI<(US$
MCGHKJP92?;<HKS30X/BGX<\$?\(U8^%;-I8'>."_^WQ_<<L2P3<.02<$D=1\
MIP: (]!\7:MX"\+Z!X3;21JOB2Y:1H+**Y0+';[WVDR*"I)P2!SP"21@ V;O
MXYH?"LFI6FA2IJ$%TMM<6L\HVPDY(R>"<A) ..&4Y'3.3_PJ+Q!X/U+0=<\,
MQ6FIWUE%_I<$LQ02S'<&=2Q V[7 ZJ?D!P2345[\)?%E[X6U.ZN?LDVOZIJ*
M75Q$)@BHBB3H0-I8M(3V  '.: -.7XUZR=+U75(/!LHTZW,?EW4\I18Q(%V;
MQCYB2ZMA3]UE[<FQ8?&'6-*U:VM_&_ATZ59WD8>&YA5C@'N1DY'(R!R..#FH
M/'[W&A_ '3]#UP10ZHZ6]HD4)WC$3*<Y_P!Q 2>F3@=JKZ9X/\3_ !&_X1C4
M_$=[I$WAVVMU98;-W#S#;SN&WAR556P0!@X /4 M3_%W7X8$\3?V%;_\(;)>
M&V23=_I; $@L!OQS@X!'4=>Y36?B=XT/C"XT'P]H.G7;[1<6C,6<SVY4%7^^
MHY!!]NF#59OA-XQ?15\'OJFEMX:6_P#M*7)#_:47G@+C;W)QGKWQQ71^'_!O
MBG1_B5)K9?3AHYB.GK"K$RBUCC_<MR/O;E7=SW/&,8 .;\8?&+Q+X>\2RZ9%
M8:3:>5:PRO%>++,XE:-7:/=&P!(+;0<8XSGFL_XJ>)M2URR\#ZM90)%9W9%U
M;PECYJW*LHPS<+MY&TC!^\>*V-6^#>N7'BC7[VPU/3$LM89][W43231*[B1M
MHQ@$," <_=]#5R\^$^N7GP[T/0CK-LNI:3=O-%+AC&$+$@ XW94$$<=L=,&@
M!OBZ^N(/B5\/FU?3M+FEE8Q22P9D*S[E!"[B,*C-&P)YY;Z''U#QUX^UB[\2
M:UH-Y96&B:!)LDM;A%=IPI;/.PDD[>?F4 $ '()K7U'X/ZQ]KT--(U^.*+2V
MDO!>747F3M=O(KLVW[I4[%P">,'.[.1;U;X/WDU[JJZ+XEFTW2]9D\R_LQ &
M!YW$(<C )+?@<'(XH Q_%_Q#\37]EX/O_"MZFGP:YO@\J2)'87 D6,ABZL-H
M8X!&,\G'2MGX6>,M>U3Q-XA\-^([V*]O-.D;9.D2IG8YC<850",A2,C/)_!/
M$/PCU"_N-%BT77H].T[1HU^Q0/;^8T<H;<TA;(W$D*>>..GK-X1^%NK>&?'%
MQX@E\2+=I<F8W,8M0C7!D.[YOF(7YL-\H[8Z&@#%^,.CZYJ?C#PO'#J<2V%S
M=+#;121JP@N,@[V7'S@@#ALC@C&#SF:@WB.SUGQAIGA?5H]#T?PQ:_:1;VUL
MG[\E-YR<?>.&YZ#   KMO&/PVUGQ1XJM]7MO%<VG16JJUM"(/-\B4=64;P.<
M#-+XB^$5AKVO76JQZSJ=A)>Q"&^2V=0+A1C.>.,A5R,;>.G6@#R_5OB-XOU'
M1_#M_I^KW%K=7C2V$T49CV32Q>5B494!2_G<CH,<5[+X'TKQ!X7\+7D7B74D
MU*]6:6X619WD 3:#MW.H/W@QZ<;JP-9^"6CZGIFE:=;ZC>V=MIR2*OW9&E:1
M@S.Q..20.@'0#H *](LK7['I]M:&:6;R(EC\V5LN^T ;F/<G&2: /F^UU#Q;
MX@\'ZO\ $(^+[NUFTZ^ BL5<B'GRS@#=MQ\X 4J<[><YI^M6>L>/?%OAL1ZK
M-:W&NZ:+PPR3.8+=U5@PC4'*JPBSCDY)Y->KS?!KP9-J<E\;"93+<_:)(%G8
M0N>NTITVYR<?[1'3BK5_\,M&O_&MMXJ:XOXKVV,1CAAD1(OW8PHP$W8]1NYZ
M=* "_P#!5SJ?POM_"T^IRI>0VL48NH7(#2Q@;<YY*Y R.N/2OG(^(M:D@TAQ
M-J#?\(['F</<, N;C@=<CAHT]> ,8%?8('%<^W@?PV[:P7TJ)SK!!OMS,?-Q
MR._R\\\8YYH ^?\ 7_M&J?"K5?$U]<SJ=:\0B2VMMS,B*JRC&3VY8<<?NU^@
MG\5IH3?$'PYJ]]<7/]GW>B0ZE<-'/LD=HXI-J(V1M+&)$P"#EC@@FO>KSP1X
M<O\ P_::%<Z7&^F6C!X+?>X", P!R#D\,W4]ZH:C\,?".J)IZ7.DJ5T^-(8
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M*6B@!**6B@!*#R*6B@#@-3^#_A?4M0O+P-J-H][+YETEI=%$GYW%67D;2W)
M[],5T(\(:/'X4?PS;02VNE/&T9B@F=6VL=Q^?.[DDYR>02#Q6]10!S'A/P'H
M?@IKLZ-'.GVL()1+*7SLW;<9Z?>-=-2T4 )2T44 &**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 04M(*6@ HHHH **
M** "N3^(_P#R3KQ)_P!>,O\ Z"*ZRN5^(RY^'/B,YZV,O_H- &WI?_(+LO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@Q#11MQG.!R0#G Y.#C.*I>%_&_B#4?C/K-K>6&J_8 OV86" ,EF0Z!97YP
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M3>';%]=MXX-5\L"YC1PRAQQD%>.<9P,XSB@#RC4_C'XE&JZS/HV@V-YH.CW
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MML0QY> 0RQDD'L>N<'!M?@QXH/@5O#-SK.FPPMJ2W9$6^0%-@1N2JG(QD*
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MAC9V1%!?=@?[2J.?6@#@;?1H_#_Q%TGPUIVOZI=Z;X@L&GU /<[B"ZNPE5E
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M!TN[UFSU>>RBDU"R1DMYVSF,-U]C]3TR<8R: /G>ZT[2?!?Q U_1DOI((/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXNMGFAYWDSMSC[Q./O'I704M% !@>E(12T4 ( /2EHHH ,"C ]*,T4 %%%%
M!11FB@ HHS10 4449H **** "BBB@ HHS1F@ HHHH **** "BC-&: "BBB@
MHHHS0 449HS0 449HH ***,T %%)N7UI<T %%%% !11FC- !11FC- !11FB@
M HHS1F@ HHS1F@ HHS10 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% ""EI!2T %%%% !1110 5S7Q 8+\/O$.?^?";_ - -
M=+7-^/H_-\ >(%SC-A-V_P!DF@#3T8%=&T\'_GVB'_CM:-9^D_\ ((T__KWB
M_P#0:T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ,TW>#V;\J:[,JN43<PZ#.,UY;H?Q:DNO&\WAO
MQ!IL&ER))Y"LMP9!YH. "<#ANQH ]4WC'0_E1O'H:\UMO'?B.3XFCPE<:#:1
M+M:<3+.Q)A'1QQWZ8[5%X;\>^)O$'B/5])70]/A.F"1)<W#$^8"P1 <<Y(Z^
M] 'IWF+CC)^@S2[^,X/\J\F\ _%^3Q9J;Z3J-C;66H/&QM2LC%'< Y5@>AXS
M5#_A8OC'2V\27&M6^E^1HL2PF.'/[RZD(\O83R1@DGB@#VG<#WI XV@X/->$
MCQU\2AXAT_0&.CKJ-[:K=)&UN0%5@2 QW<-QTQ5+4/BKXM?P+9ZQ!-:V[_:I
M;.Y+6Y!>0?.K1Y/( &"/6@#Z",BC&>,TX-D\5XKXW\8>+-&\)>&]:MM2LTEG
M4)>)"H;?(RD@X],#\ZZ[PQXNMM,\):)<>+->M8K_ %*'SE:=EC# GH/ID<G
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M;YD!RV X3G;E@.AVD YQFEX;^.EKX@U>QTW_ (1V[BDN7*EXYA(J  DMT!(
M&3P,#- 'KF::LBN6"D$J<, >AQG^6*\@T+XZ6VL^*[#3WT=[:POY%@@F^T*\
MHE9@J[T'W5)('Z\BL?X<>*_$EYX]\6O'H7VQ[EFEG57\L6\L89(D+L<8;&WN
M<C(& : /;[34K*_\S['=P7'EMLD\F57V-Z'!X/M5G-?/'@KQS9^!_AKK6H1:
M.!?R:P8?L^_;&C-'D+DDMM0*PP<GWYR.FM_BWKEOJEWHFM>'[>RU@6)FM(UN
M"5EFV;U1O[NX9[]1@D9S0![#FES7S_8?&WQ7'HT&MW^A64VD1W/V2XN(6*,\
MA4. JEB00F3T(.1R*]^SN% "DU@:%XW\.^)+^[L=)U$7%U:#,T1B>,J,X)&]
M1D9XXSU'J*\4'QN\3-XB;R_[/-G+?B%+)X'WQQ9 SO& 2><DDG(. !6?&/%&
MD?$GQE=>#+:.-;-YVN3Y2>7'%OW8^;C)*D@#G@XZ4 ?36:PO%_BJR\'>'Y=8
MOHKB6!'5-ENJEB6.!U(&*\SU[XKZU%\.O#.K6D5M97FL221SWL@+Q6YC?8S!
M<$_-@MC!P 1\QP:YJ7Q=J?C'X,>*HM;E6[N=-NK1HKK:$+AYE7!4*!P W..C
M#@$9(!ZT/B;HH\6:?X;DM[]+V^BCDC<Q#RAO3>H)W9]L@$9[]<===W<-A97%
MY<L4@MXVED8*6(51DG !)X'0<UX5=#S/%_PAN7&ZXETVW\R5N6?"*>3U/+'K
MZGUKV/Q7!?7/A75(],NUM+PVS^5,T8<*0,]#ZC(SSC.<'% $7A+Q9I_C/1%U
M;38[B. R-%LN%"N&7KT)'<=ZW<U\WZ3KOB/0_@19ZMH6II8I9ZE+%.!;QLSH
MY&.64\AF_(]> *UXO'/CCPGXCO-+\0:G;:K(=&DO515C7[/((C( 2BC)!4C!
MR""#QG% 'I_C#QO;^$[[1+.2RGN9M6NA;QE"%2/YE4EF/?YP0 .<'I74CCK7
MS5+=>)=:T;P=XG\0>)_M=O/KL4,5EY2QK'MD(,C%<+GY6ZC(#=>2*G\??$#Q
M,_CC7+"QUJ[T^WT[<MM;VD6[>5V[R[ 9 QO?)R!MQWS0!]'YI<U\_P"LZIXY
MO[OP9<CQ-=:>GB1(XQ!%"JK;,!&K/@$%]Y8R8.,9QD]:P%\2>.7\*ZWJDGBN
M_6/1KQ+5 H7,[N^&);KA0H(!S][ZY /I_-9^N:G_ &-H5_JAA>86=O)<&)."
MX12V!]<5X9XLU?Q#KWBSP-%;:Y=:<^MZ3;-*+5V1(VF)\PA0>>.F3Q@<CK2:
M1-K:>$OB5X7N-:O)AHJ^9;W)E;> C.64$DD!Q$.,X&3ZDT >DZ_\3+#P]X)T
MGQ!<VDKS:K;I+;6<;C.YHP^&8]%&0"V.XX-7_A]XV3QUX>;4A8R6<D4S0RQD
M[TR,$%7P-PP1V&#D>Y\7\66:ZSI'PEM[F9HK:\M8[)PI_P!6 T",X)XR01V[
M#K6=XJL]3^&7BZ\M#JVH7%E=V5S);NMPX8^<DB R#.-ZN0Q(ZX#<$X !]2YH
MS7+?#[P_?^&_!UG9:I>7-S?OF:X\^8R>4[8)C4Y/RCIP<$Y/>OGKQIKNJ:CX
MS\4;]2O$E@O'@M5BU!;>*-(W*<H2"Y*K_"1R23G.* /JW/L::\J1(7D8(HZE
MC@"OD?Q/J,OB?67O(;V34DBTN&:X\V8Q+!(L*)(1N(#'> < ?,3@ ]:UGU.+
M7-&^'WAO6+]HM%VRO=SM<A0#YTB*&9L@;$48ST#CMB@#U[QQXW\0>%?$^AP0
MVFG'1-1N8H6NYM[,N6 <<, N <@G(Z^AKT4'GH:^6M?33[7X=Z1HL7B-=6C@
MUV5#/&C)'"HC4,$+9!4%]VX<'?QZUWWPR71-!^+?BG0],N4-NT,(LQYWF>9L
M4&3#9.2&8\>Q]#@ ]CNKNVLH#-=W$4$0(!>5PJY)P!D^IXJ4MCL?RKRS]H".
M.3X<Q,^-Z7\31@GJVUQ^/!->>_9])M?&FFQ> ;F>:>3P]=&Y^RRO(3.;:4KD
M]=Q?9E>S!1@&@#Z'CUO2IKF:VBU*S>X@#&6)9T+Q[3AMP!R,'KGI5&W\9^&+
MR:**V\0Z5-++((HTCO(V9W/10 >37RSX+B2;Q/X9W26$<2ZB!(0P$K1@JS^9
MZIM!4$]06'(''0^&_"_A36]-\;:O))=21Z0\L]G;VK^6#!\YC.Y@<YVX]1CG
M.: /HFU\5^';[41IUIKFG7%\691;Q72-(2H)8;0<\ '\JI'X@^$QK']D_P!N
MVGV_SOL_DACGS,[=N<8SGCKUKY@\':IJ&G^)=%?1;>WU#446<6T$$863S)8V
MCP[;<G;]_!)4#/*Y;&K$_AO_ (5C-X?.GW3^-GU0*(FMSYV\,%(!QD#;E=IY
MWDG&.0 ?0U_\1_!^F7\]C>Z]:PW4#E)8VW$JPZ@X%;.BZ[I?B&Q^W:1>Q7=M
MO,?F1G@,.H^O(_.O!;K6/#^D_%K38O%T<$_V#1H[+4))+?=&UV(R=^Q0=XVL
MJ9(_# !KLOV?[N"7P5?6D9/FPW[NZE2,*ZKMY[_=- '>:IXPT#1M=L=%U#4%
MAU&^*BW@\MV+[FVKD@$+E@0,D=#6+'\6_ \UM>7$6M[TLX_-E/V:5>-P48RH
MW$E@,#Z] 37/?'30#/X?M?$]F9(]0TB56\V$?,(RPYR.1M;:P(Z<^I(\8B\#
M>(KC7=#L]2MY;4^() \<KD$E2079E!R" P;!P>>QZ 'I4_CJ+PS\:+V\U+6K
MX^';RR2>&+=)(B[XD9?W?\))5L8'&X9P,UZ+'\3?"TGA-_$HOG&GI/\ 9CF(
M^9YO78%ZDX(;Z<UY?KVJ^'O#_P ?)9M8LU.F6MC' J"V\Q8V\E2F%QTP=HQT
M)^N.'M+&_P!?\&:H^F64]Q#9ZR+VYM8X\MY<B,%8 ?W=K @=-P/T /HGPK\2
MO#GC'4I[#29YS<11>;B:$IO7.&VYZX)&?J,9YP[XE7]SI7@+4M0M-4FTVXMP
MK1SQ1A\L6"JI!!X8L!D=,Y[8/GGA=)_$/QP_X2'2=&OM-TB&S6.<S1M!N_<[
M%4KT."%7:,C]V#79_&&5U^&FH6T5E/=S7;10QQQ0F3!WAMQ !P %.#ZX]: &
M3?$K0?"FC:)!KFK37UW=:?%<BYAMR?.4C_68 &T,<XR.U=3X=\2:7XJTE-3T
MB<S6S,4)*E65AU4@\@]/P(KYF\3P7NNII$HTO6C;Z=H=M8>8FGO@7**25.<9
M4G(W#D=0#C!]V^$>GZAI?PXTRUU*T>UG5IF\J5"DBJTK,-P/0\Y^F* $UGXM
M>%]%U2YT^1KZZELVVW;VMJSI;'./G;@=<#C/) ZYQ6UOXR>&=%FL2RWUU9WM
MJ;F&\MH@8VP67;\Q!W94@C'RDC..W!:CIOBC1+CQYHEOX1NM07Q#<R26][%&
M6149V;YCTX5R1DC#9ZCI4?P5XC\/ZSX-CFT*[U.STJ+SKQ;5!(A>29W=1GAB
M%*#T)% 'MWA#Q39^,?#T.L6,4T44C,A28 ,K*<'IP?PKE)_C+HUOKFLZ3+IV
MHI/I:SEB53$OE=0OS9&0,@GM7H=O;P6L"PV\$<,2YVQQJ%4<YX ]^:\>^,7P
M^OO$.NZ1JFE6AD,KBTO3"A+JN?ED(Z$ %@>A^Z.>P!O6?QBTJ^TO3KR#3-0:
M2_U$Z?!;9CWE@$);[WW<R*/QJK)\<] 343;KI^HO:"[^RB^0(8F.<;QALD8^
M;IG&*YWPA\--9T'XGW[1+)%IEC%.VFWEP/,3?(H5#M! 8J"0P^7.WMQCA+WX
M>>,+:X:"3PM<W-]%>O+)?PMN2=3MPJ@8 7<&;/7Y\$#;0!ZCX@^.]IHNMZEI
M\.@W%TEA.T#S&X6,%U)5L#:>-P('/.*]8MI3<6L4V-OF(K8],C-?,NJ?#OQM
MKFMZU-=^$F-]>S"X2=+N-(K<LQ)7KMD&#@]P5!SU#?2&F6EQ9Z!:64EPS7,-
MJD33L-Q+A "QR3GD9ZT >13?M$VBW>R+P[<F 2;2\ETJOM]=NT@'VS^->VJ0
M0"#D8Z^M?*TWPE\=R6MS;R>'1-<F9I&OC>QEI!@@J,OSN)W9(S].E?3>B&];
M0M..I0)!?FVC^TPH<K')M&Y1R> <CJ?K0!?HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** $%+2"EH **** "BBB@ K \:#?X(
MUY3T-A,./]PUOU@>->/ ^O$=?L$W_H!H O:*=^BZ>3U^S1'_ ,<%:-9^D +H
M]@!P/L\0_P#':T* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 0C/>OG9O"EKXW^(/CNUMY42\MG26Q
ME#_*),_/TY.<$<=*^@+LSM;3I:R+'<%66)G&0&V\$^V:\'\-?"3QOH=W#JT&
MI:=9:C;.=BO(TBR@YRS8ZGYCP?6@"3X7:IJFH?$;R=:)2ZTW1I+&02$;_ED4
MX8]S@DYXXK7^&NH6B^/O'S&\B#/>23*2XPR;G)8>P]>U76\"^-&\3R^(XM5T
M!=0GL_L=PHMF,<B9!)(SU.!R*S(/A-XKLWM'M-4T*">T2:.-XK,@S++DN)#S
MG[Q 'I0!QV@^$O\ A)OAMJ&H:8H_MG3-0DF@6&3#R0GDJ#U[DJ>^,5U/PGN[
M;QKJ7B7_ (2"S2XNY9X+MDDA*HK(-HXSP01_.KOA[X0>)?#K2RZ7XPCLY9E5
M9C#;!\A3E0-V>!5_2?A1KNC7-[=V'C2:*[OGW7,BVB?/SG@'(')/3% &!K>M
M:=-^T5HUVEW UK#$ML9@W D.\;?KEA5WX[-IUGX7L+"W\F*\:[:=+<)M+##;
MGX''S8)]:;%\ A#<K<1>(Y5E602JWV0$AP00?S JU??!*;6+Z2]U3QA?WLY5
M@DA1<J22>F>!D]!0!RWCK0O EA\-K&_T:,QZK=Q1RVA$TK&500LAVL2. 6/0
M=*U;[6?!&G^&_ LOB30[K49?L:&WGAX2,*1G=\XW_,!\I!&,^N#<F^ TDT4$
M<OBJZ=+<8A5X<K&.X SP/I7<>%? &GZ%X:AT2^(U:"&<7$?VN(,L;C[NP'.,
M<_F: .R%,EC1U^=58#!^;D#'>GB@T > >&/%.F:G^T)J&L6$DUS87\:VT,L<
M#8WF.)06!Y49C;D^E;7Q,UW2!\1O#,6HZ9?7UKI322WBK;N\?[Q5\O'9RI"L
M<<=LDY ]?AM;>W+F""*(R'<YC4+N/J<=:F  Z4 ?*CVM_P")8/'']FZ;?.]U
MJ,>J0Q-;/O>$2S @  Y8>>AV^BMZ<ZOPFTC5KGXDZ=J;65^UI:V[13W$\'EJ
MA%OY:IGN -@'<XR0*^EL9H*@]: .$^+'A"Y\7^#O)T^)'U&TE%Q K8!? (9
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M 8I,4M% "8I<444 &*,444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **,T4 %%&:,T %%)D9ZTM !1250U?6M,T&P:^U6]AM+56"F24X&3T ]3]*
M-"BJ>F:I8ZQIT.H:==17-I,-T<L1RK8)!_(@@CL15EI$&2648&3D]!ZT /HK
MGO#OC?P[XJN;FWT74TNY;4 RJ(G3 )(!!8#<..HR.GJ*Z'- !129JGJFJ66C
M:=/J&H7,5M:P+NDED. HS@?4DD  <DD"@"[17DS?M!^$06 LM88+W$$?Y_ZS
M->JQ2"6-74_*P##C'44 2449HS0 449HS0 44FX>M(6'8T .HK,L=;L=2O\
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M<)<6DZAXI8SD,/\ /&.H(P:\-^-TJ2?$7P_:W:6UQ:"TSY%[</# "SL"S,C
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M1$58 [L<'A2#G )^4G@&N$^(6NWWQ U/P7';6TR:9J**T<2OUN#)LF7)P"4
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MM*T6TM;H*465%)(!ZXR>/PI^@>"/#GABYDN=&TF"TGDB6%I$W%BB@<98G&<
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MD4YP"XYZ;J[GPSX;LO#6AV>GVT%NLL4$<<\\,"QFX=5"EVQR2<9Y)K;P*,4
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M@!,48I:* #%)M]S2T4 &*,444 &*,444 &*,444 &*,444 &*,444 &****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BBB@ HI*,\XYH 6BBB@ H
MHHH **#P*@GN[>U3S+B>.%"<!I6"C/IDT 3T5'!/%<Q++!*DL;='1@P/;@BI
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** $%+2"EH **** "BBB@ K"\9_\ (E:Y_P!>,W_H!K=K \9LJ^"==+$
M?89N?^ &@#5L!BRMP/\ GDO\JM56L@19V_\ UR7^56: "BBB@ HHHH ****
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MJJN"<%@OI59_'OQ!/AMO'IN[6/0TOS''IKQ+NEC+%<;@N< _+G(.0Q[#(!]
MT5\_^(?%GQ%U+QG=Z%X<O#<)<VB7,$=M;I$T4+*'R68G:WS!22V#D8P2!7LW
MA-=7C\+Z;'X@E5]7$ -T05)#>AV\9 P"1QD=Z -JD-!KP34M9\7>+?'GB>+1
M_$$FD1>'DD:"W1_W<WEL5.\\#+8)RP(&0.V: /5O&7CC2? VGP7>J+<2">7R
MHX[=59R<$DX9AP,<G/<>M<I=?'KP=;Q6SHFI7!FCWLD4"YA.<;'W.!NX[$CW
MKS+Q%J.J^-M2\ :N\BVMWJ %JDHAW11S)=%#(%/!)RK%?H.E:"^%)KGXW^(/
M#^D7=EIL;P;N=-BN(?+*Q2;/*?Y0,D<CT]Z /:/!GC?2_'-A<WFEQ7426\OD
MNMRBJV=H.1M8C'/K72U\P>&O%VLZ=\*A:6>JFR:?6XK.*X;_ )=HFCWN0>H&
M<$GG@M71^)_$?C/P/X6U;2KWQ%9:E=O>);PWD,P-U:Q.CL3(O5"P52O7&7^;
MA* /?**^:]/\1>+HHO$FC7&M>(+18M+?4;*74H6CNR(F!QR20K R D$\H,'@
MJ>C^%2^)[6#_ (3'Q+XHF'AQK=P$O;YY=QWA0Q#DA "#R#D\#H: /<ATI*2-
MTEC62-E=& 964Y!!Z$&N:^(6I76D> -:O[*4PW45L?+D'5"2%R/?GCWH Z:B
MOE3X>?VM9^(M."W%Y;:?K[/8SR07P61R0V)!CYE9&((8CDAAG#$5FK:W$/A.
MTUF+7K\7\&M/8V8\\B. % [29SE2S,"2.#@YSF@#Z[#JS,JL"RG# 'D=^:8E
MS!*Q6*>-V R0K@FO -.T>V\,^/O&OA==3U&2&YT9YA,\Y6668(LFYF7&6^9_
MJ"0<Y.?/TTVPTCP'IWB>QUF2#7Y=0:(6\$RHT,2JQ+X'SYR$YR!AQQT- 'T-
MIOQ#N;KXHW?@RYT=8/)#LERMUOWJ%#J=NWC*D'&>*[P.A=D# LN-R@\C/3-?
M/EAJMXOC/Q?J=Q.8->/A-)4Q\KB?[+"[X7 ^8$9QCC!]*YJW&AV%OX)U/P_J
MD_\ PD=U=>5J2QW#&3YF"G(ZKD.5!_B!)Y()H ^JJK7-_9V3QI<W4$#2G;&)
M950N?09/)XKY>U3PSJ>C^+]5^'NGQ><FJW=LT%Q*CEA&NYU;(Z@!VWM@C]VW
M2HO&6CVECXYU?0F>UCM-/L(X+274I9 44(CY4J#N=BSX7&T[C@=!0!]1WNJZ
M?IBHU_?6UHLG"&>98PQ]LD9JQ;W$5U D\$B2PR*&21&#*P/0@CJ*^0+R]UG6
M[^PB\32QQ^3IA2T?5EEB7R=K;'4J-S,?X6P=Q4 [N_OGP,%Q_P *QM3-YFQK
MB8P[R<;-W\/H,[NG'6@#T661(8GED=41 69F. H'4D]A619>+/#NIK.UCKNF
MW MX_-F,5TC"-/[S8/ ]S61\5;:[N_AEKL5DDCS>0&*QG!**ZL_U&T-D=QD<
M]*\<LKOPS?>(/!0\/P0PBTT\R:_*(@(C $'FB;@[L@."3D'>HSTP >ZP>-O"
MMU=QVEOXDTF6XE<1I$EY&S,Q.   >236_7SA\'/#?ACQ+XAU"]N5E>XL;E;F
MSMCQ&(B3M+#'.#CC/8=J^CS0!B>(/%VA>%Q;_P!M:E%9_:&*Q!P26P.3A02
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MR25^0;@"=RL0,'A>=N<C*O/!_CM/ _@S2K/P\IN=)NY;R8_:X@Z.)2T8W;N
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M9))]N;>55*JZ;0.>><]1QTSF>R^#?A2VT*;3)X+BX:X:.2XN6G99)'0'!X.
M/F;@>O? QZ%28H X*#X/>$K>VO8$MKHB\58YI&NF9RBD':&/(!(7/KM Z5F>
M(?A[+I'PBUGPUH)N]0>>X2>WAE==R#SHV**>!@;6;UR37J-(1F@#F_A_H$_A
MCP+I6D73 W$$;-+@Y"N[,Y4'T!8C\*W+^PM=3L9[&]@2>UG0QRQ.,AE/459
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M_P#^1 U[_KQE_E72US?C[_D0->_Z\9?Y4 ;EI_QZP?\ 7-?Y58J"T_X\X/\
MKFO\JGH **** "BBB@ HHHH **** "BBB@ HHHH **** #%)BEHH 3%&*6B@
M!,48I:* $Q1BEHH 3%+110 4444 %%%% !1110 4444 %%(:44 %%%% "8I<
M44R65(4+R.J(.K,< ?C0 ^BHXY4F0/&ZNAZ,IR#^-+YL?F^5O7S,;MF><>N/
M2@!]%%% !156\U&TT\0F[N8X?/F2"+><;Y&.%4>I-6<^] "T53GU2PM;VVLK
MB]MXKJZ+"WADD"O+M&3M!Y./:K@H **C>9$=49U#-G:I(R<=<>M24 %%%!H
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M,"Y0@X&3D@X'XXSVI-3\;^&-&O)[/4=<L[>Y@B$LD3R?,JDX' [\CY>O.<4
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M^%OB^?0?#?B32=3CO[D^'D:Y163:ZP ?ZO:V"I!4G!R #QP!G'^*?B.+Q?\
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M5GY0+D?,'/)R>YY)H ;XO\3ZMXG\;^ KOPY'#')-;&ZLEO/NB5F99%DQV C
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MM*LRSA"I.!PN"HX5<G&3@<]JNR_!;PQ_PB]UHT1O/-GF%P+V:7?*LH5@I(&
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M3-+0 4444 %%)FES0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/EW,$XQU^]47CGXE:W>^*;H:9JU[I%O;6D+6]O -_P!HD;8YW=E.V1N3D8C
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MS\X/4'H>3>^WZ=<_%#0?$&A7=PYOM%N%@2Z<O,7B22-"0Q))?8, Y+$$]2:
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M*W M NV%@<;2S$ G/'&<'@\\5'\$-"NM&\"/-=P20-?W;W,44FX.L6%1=RD
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MV8*[05()7.<9(KVCPGH9\->%].T8S^>;2$1F4+MW'J3CL,F@#:HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH 6BBB@
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MJ]M\,6U]I?@?1;._A$=[:V44,L2NI&Y$VA=V2.PY!KH*6@#P>XT7XA-\2O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110 M%%%
M!1110 5QWQ.D,7@/4".K/$@_&1178UQ?Q3Y\"W0]9[<?^1DH [->%'TI:0=!
M2T %%%% !1110 4444 %%(3C'&:16#$CTH =1110 4444 %%%% "4M%% !11
M10 44F:,T +129HS0 M%)FC- "T49HH **8)4,GEY&\#<5SSCUQZ4QKF%"X:
M5 8P"^7 V@],^E $U%1Q31S('C=70]&4@@T_- "T4A.!G%5K/4['4)+B.SNX
M+A[:0Q3B*0,8G'56QT/L: +5%%9FL^(=)\/6RW.KZA;V4+':K3/C<<9P!U)Q
MZ4 :=%4M+U:QUK3X=0TVYCN;28$QS1G*M@X/X@@@BKF: %HI,T9H 6C-(:Q-
M(\6:-KE_JMC878>?2Y3%=*P*[2,C()ZC(89]5/M0!MYI:X*?XR^ H)6C.N&1
ME?83%:3,O7&0P3!'N"<]LUWF: %HI,UGZCKNEZ5=65K?WL-O/?2^3:I(V#*_
MH/S ^I [B@#1HKEM3^(&@:/XKM/#=W-,-1NS&(U2(LN9&*J"1TR1^M=1F@!:
M*3-&: %HI,^U&?:@!:*3/M1GVH 6C-<YXW\4_P#"'>&9M8_L^XOO+8)Y<)P%
MS_$[?PKVS@\D>M/CU^YN_ L/B&RTYY[F;3UO(K)&Y=FC#! <>IQT_"@#H**X
MWX<>.O\ A/-#N=0>R2SE@N3 85G\W(V*P;.!C.XC_@)KL<T +1FO.[_XA:E8
M?%>P\(3:/'':70W)=-/N>1"IPP4<* R.,'DC!X[[GCSQA;^"?#<FJ2QB>8NL
M5O;EROFN>V0#@  DG':@#J**\W^'?Q'U'Q6MZ=8T9=/BM8!<&]#,L+(>GWA@
M< G.XCBO05O+=[9+I9HS;NH=9@XV,IZ$-T(.1CZT 3T9JA;ZM9:C'<+IE]9W
M,L7RL(YE<(W. VTG'0_D:\V\%_$Z_N_%NN:+XMDTO3VM&;8_GA%5E*H8U+'Y
MAG+9)SS^0!ZQ16=>Z]I&G:?%J%[J=G;V<P!BGEG54?(R-K$X.1SQ4%UXJ\/V
M5M%<W6MZ=#!,"T<CW2!7 ."5.>1GCB@#8HK'B\6>'I['[=%KFFO9F3R?/%VF
MSS,9V;LXW8YQZ5C>-O&:Z)X(GUO1;S2KB?<JVQGN%,4QW?.H(8;F"AS@'.1^
M% '89I<URX\<Z!8?9[36M<TJSU-HD:>#[4"L;% WWCV.[()QD=*T]"\1Z1XF
ML!?:-?1W=ON*EDR"K#LRG!4]\$#@YH U<T9KFM<\?^%O#>H+8:OK$-M=%=WE
M;7<J.Q;:#M_'%<+?>-M5\._%J"#Q%KEHGAV6RFNK<PQD(8F+% V,EI!Y8 QG
M.>/O8H ]?S1FL*R\8>']1\/OKUMJMN=+CR)+ER8PA!P0P;!4\C@C)R,=161>
M>-M+UWPUKC>%=>@;4+.R>X#K'N,> 2#M88/3'?&: .TS1FOG>Y\?>-9/A)!X
MF3Q$8[F/4Y+:4"SBS*I563G;@!2&Z#G=R>.?;]3\1Z;X?T%=6UJ[6UMMJ;GV
MLWS-C "J"QY/8&@#9S1FN0TWXG>#=8U6VTRPUI)KRZ_U,?D2J&.,XW%0 <#H
M2#GCK3-6^*G@O0]5GTS4-:$=Y =LL:6TTFTXSC<J$9YYYXZ&@#LLTF17EWB;
MXL:=HGC[1;$:BJZ/]GDEU.40&1</&&@*, 6)]=N1A^>>FE\4-2-Y\'[_ %32
MKV2.&XA@ECECW(9(I'3CL1N5N?8X- 'H&:,UY1\./BEIE]9:)X>U*YOGUF6#
M:;FY3Y)GRV%WDY+8'4C!/&<\5KO\8O"<?B;^Q&ENB?.^SB\6(&W,F0"H;.3@
MD9.,=\XH ] S2;A6#XJ\7:5X.T<ZEJTCB,MLCBB :25O11D9XY["O'_!FNQW
M_P :]1U:SDU>'2Y;2:ZNDU ;3", G<%)&P$#;^7;) /?\T9KS30_C;X=UWQ!
M;:5'9ZC;B[E$-O<SQJ$=ST!PQ(R< =?O#.*=I?QI\.:IXBBTM+>]AM[B9K>V
MU"5 (9G&, <Y&<C&1W7.,T >DYHS7D3_ +0&A*TR#0M;WPOAU:.,%1G!+?/\
MIW$#'J:V/#WQBT+Q%XAM=(CL=1LC>(6MIKR-464\X PQZE6 /3(QUXH ]%S4
M<LT<$;2RR+'&HRSN< #U)->5GXYZ3_;Y@&FW/]ABZ^S?VQO_ '>['7;MZ9YZ
MYV\X[5@?$SXA1>*M#UOP_H6DW=_96C1M=:I&<PQ[9-V< '*'80&R <$C(&2
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MKK=]GA>0!Y=HRVT=3@<G%>->+?C3K6BSZ*MAIU@5O-+M[^<7 =B&E!)5"&&
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M@%=V77\ 3U-7[GX:^+9O$7A[Q -<TMM2TJQBMR9H)&5V7?G.""P^<C/RD]<
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MR*1[:24<&3;C#'WP1GW&:IS?"2PGUC6M4?7-6-QJ\,L%Q\Z8$<A&5'R] %
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M[L7,FL1L)'*+_P L1&YQ@D \H<$\D@;:^B\48H ^=-?\#?$G7=4E\1W.F?\
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M*** #%&*** #%&*** #%&*** #%&**,CUH ,48I,@]"*6@ Q1BBB@ Q1110
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M&*]UN\-K;RRB%'$3R9<@G&$!/13^57-*U6RUK2[?4M/F\ZTN$WQ2;&7</7#
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M.<$]N_):M\1_$NNP:9++JU];PKI<AN8]%FVRK*K.BRS8 V;G$1(S]TY&-V*
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M5E())V[=AQN!.[@BJ_P_^)'B_7_%=OH6K:9:1+$)OMLK(8I00"RX0L,8)48
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ML0<<<#GK6CJOPENKCQ-;:[H_BJXTRXM(UAM$-HDRVT2IL6-!E1@ MUSG/XT
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MZ\U%M7M9;>[_ '8C#,[AO-'+?.",@G/)/TH S?@@%L=*1;GQ%),UW;B:'2I
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MU0Y.\;7(]  .F,'U[%)B@#Y[FT_Q5X>E\<^+]4T$65OJ-E-$D<DL<Y1I940
MJ#R,$DD\8'0]#Y_X8U:?P]KWA_69D@U&&&4I#:M,)I(EWX8+&&S&Q+,R[L L
M=W/6OK^YM8+VVEMKJ&.:WE4I)%(H974\$$'@BL2T\#>%+"[BN[3PYI<%Q"P>
M.5+5 R,.A!QP: //K30_'T'CSQ9KRZ+:_P#$QM)H+1Y+M% " "'Y06)8A5R#
MM')Y'2L33?AQXLN/@Y?:#<V,5I=Q7XOK6%Y0TDP"X93C*J3CY3GD\':.:]\"
M@# HQ0!X-=_"CQK?7&G:K<WFG7NI274UW?6VHRM):*Q*[0$"G(*KM./10,
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MOAWQ'<QW.KZ3;7D\:>6LDJ\A<DXX/3)/YFMF&"*W@CAAC2.*-0B(BA551P
M.@ [5)10 TH">IJM>Z=;ZC9S6=Y%'/;2KM>*0$JP]QGFK=% %#2]%T[1+1;7
M3+2&TMUR1%"NU<GO^E72N>O3TQ3J* &>6<YWG\0*7;U^8_ETIU% ";<C!-&T
M8QCBEHH C$6"#G)^GO3P/I^5+10 F/>JMII=C8R226EG;6[R\R-#"J%_J0.>
MI_.K=% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BEQ110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #2,D&EHHH 6BBB@
MHHHH *Y#XG/Y?P[UF0#)6-3^3K77UQ7Q2_Y)QK__ %[I_P"C!0!V:'Y%^@IU
M,C_U:?04^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** #%&*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**** %
MHHHH **** "N*^*7/PWUP=_*7_T8*[6N2^(L#3^"-1A49,OEI@>\@_QH ZJ/
M_5I]!3Z:O"@>U.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HH
MHH 6BBB@ HHHH *Y?Q[,T'A&]D'5#$P/_;0?X5U%<E\1AN\'W48./,E@0D]@
M95']: .L'(!I: , "B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M 2BBB@!:*** "BBB@ KDOB. ?!LX/3[1;_\ HY*ZVN3^(I'_  B4G_7S;_\
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M(&!R:]W\%:I\0KW5IHO%WAZQL+(0EHI[:523)D?*0)7/().>,;?>@#NJ***
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M!4%D;7^R=X/'F/,Q?&2>O;K77Z/H]GH6GQ:?I\"6]I$H5(UR<>^: -"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!**6B@#G+?P%X5M-575(-"M%O
MEE,RS[,L')SNY[Y.?K714M% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% "4444 +1110 4444 %<QXX/_ !((U''_ !,+49_[
M;(:Z>N6\=';HD..^H6I_\BK_ (4 =31110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !399%BB>1L[44L<>@IU% %/
M3]1@U2RAO+4EH)EW(3P<=#Q]:N4Q(EC "C  P !@4^@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@!**** %HHHH **** "N4\?\>&XF'4:A:<_P#;=?\ &NKKE/B!
M_P BS'_V$+3_ -'I0!U=%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%5)[V"'4(+1W(GG5C&N."!UJTOW10 M%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% "4444 +1110 4444 %<KXZ0/HL"'H
M;^U_]'"NJKE_&Y_XE-J/74;4?^15_P : .HHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@"-X4>59"H+J"%;'(S3UX4"EHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH *Y
M;QQ_R"[/_L)6O_HU*ZFN7\<#_B5V/OJEJ/\ R*O^% '44444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% "4444 +1110 4444 %<KX\)72]-P>N
MJVG_ *,%=57*>.^=,TW_ +"]I_Z,% '5T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% "4444 +1110 4444 %<SXV_P"0=IW_ &%+3_T8*Z:L
M?7])EU:VM(HI-GDWD-P3[(VZ@#8S124M !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "4444 +1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 )1110 M%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 E%%% "T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4444 +1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )12G
MI24 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 !Z4E*>E)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
7110 4444 %%%% !1110 E%+BC% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex-a_007.jpg
<TEXT>
begin 644 ex-a_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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M,4ZBB@ HHHH **** $I*=10 4444 %,(?S,@_+Z4^B@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"C=Z<E[-F=G:';@PY^5CG()J[SCI2
MT4 %%%% !1110 4444 -IU%% !1110!'()"5V' SS4E%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %5[F SQE \B9/+(<''IFK%% %:WM([6
M)8H5*H <#ZG)JS110 4444 %%%% !31U%.HH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_=JK;V<<#R2(A$DA^=V&2_U
MJY10 4444 %%%% !1110 T4M(.HIU !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 - IU-!IU !1110 4444 %%%% !1
M24M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T=13J:.HIU !11
M10 4444 %%%% ',6&HWEQX]UC3W9396MM;R1@=G8MN_E73UR>ELP^)/B",H
M&L[-LY'7,E=90 4444 %%%% !1110 4444 %%%% !1110 4AZTM(RAA@C(-
M$;SPQE!)-&I=@JAF W$] /4\'\J598V)"R*2 "0&['H:Q&\(Z2]Y;736K^;;
MR-(A\UN&((R>?0\>F:FTWPUIFD3RW%G:A+B=(XY96.YG"*%7.3Z 4 ;-% Z"
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :.HI
MU-'44Z@ HHHH **** "BBB@#D-(4?\+,\2R<Y%K9I_Z&?ZUU]<EHOS_$/Q0W
M3$-D/S5S76T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #1U%.IH
MZBG4 %%%% !1110 4444 <EH7_)0?%7_ %SLA_Y#:NMKE-"7_BO?%;]C]C4?
MA&U=70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )BBBB@!:***
M"BBB@ HHHH YC0_^1U\4_P#72U'_ )!KIZY;0/\ D<_%G_7Q:_\ I.E=30 4
M444 %%%% !1129 [T +12!@>AS02!0 M%4K+5++49+M+2<2M:3&"? /R2  E
M>1SPPZ>M7!TH 6BBB@ HHHH **0L <4M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 -'6G4@-+0 4444 %%%% !1110!RN
M@'_BM/%H]+BU_P#2=:ZJN4\.,K^,?%S@_P#+U;J1[B!*ZN@ HHHH **** "J
MFI0W<^G3Q6-RMM=,F(Y63<%/N*MT4 10)(D:"5@T@0!V'&YNYQ3V7=_+-.Q1
M0!!#:Q6YD:**-#*V]]BXW'ID^IX%3CI110 4444 %%%% #7W8.S&[WHCW^6/
M,V[^^WI3L44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@! *6FCK3J
M"BBB@ HHHH **** .0\&?\A7Q5_V&'_] 2NOKCO!Q_XG?BV(#E=6+$_6-#78
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% "$#/2F)%'$"(XU3<=QVKC)]:DHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"*:18EWMG:O7 S2Y'K4&H)/)IUS':[?M#Q,L>XX&XCBL/\ LS7O^>T/
M_?9H Z>BBB@ HHHH **** ./\(C9XF\8KW_M)&_.%#785QW@\%O$?B]SWU4#
M\H4%=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -/+ TZF9P13
MLT +1110 4444 %%%% ')^$,?VQXK(Z_VN0?^_4?^)KK*Y#P8K#5?%A9<?\
M$Z?!]1Y4==?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -QD@T[
M%,)P,TFX^M $E%%% !1110 4444 <CX-D\S4O%##I_;$B_B$05UU<9X%/^F>
M*!V_MVX_DE=G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 449HH **** "BC-&: "BBB@ HHHH **** "BD#J3@$'G%+0 449HS0
M 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 44UY$C1G=@JJ"2Q.
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M[/%-)Y?[C(*$LV 3R1GC.WI0!Z?17EWP^\=3)\,AXD\9:S:[&N6C6;RSYG7
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MBH?]1Z?^25VM<5X!^>7Q1)TW:_=#_ODJ/Z5VM !1110 4444 %%%% !1110
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M THR&_ND] W'0D'IZBI-7\7:!H%S%;:OJ]G93R@,D<TH5BIS\Q'89!&3QD4
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M=BME"_F;7&3]X!.,YP&(Z\BMHOQH\3:EXTL;7-B+#4-3C@%LT)+P1-(JXWC
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M444 %%%% !1110 4444 %%%% !7FOQCF\3:7H5KKOAW4I[5;%V%VD0!#1OM
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M@$]SG)S[XK4\8^&+?QAX8N]%N)6A$VUHYE4,8W4@JV#U&1@C(R"1D=:W\"C
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M5,YPA_AY]/2K7A_X<>&O#<ES)8VDCRW$9BDDN)3(Q0YRH)Z#!QQZ5UN!1@4
M<KI_PZ\+:;H=SH\.E1O9W+%IED.YGYXYZC'08]*M6/@KPWINFS:=::1:QVDY
MW2Q% X<^IW9R:Z# HP* .;M_ 7A2UU&._@T&QCN8QA'6$#'?./7WKH1& 3C(
MR<T_%% &,WA+PV_F[_#^E-YS;I<V49WG).6^7DY)Z^M6ET72U4*NFV8 & !
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MT.,M&I)'1^>N:T?#+^%-+T;Q%)8:M=M=7/A5A/:BW*013&-8W5G)R[&5AMP
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MY8J3WQG% 'M(HH%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI2;1Z4ZB@!**6B@!**6B@!**6B@ %%%% !1110 4444 %%%% !1110 4444
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M #%%%% !28I:* $Q1BEHH *3%+10 F*,4M% "8HQ2T4 %%%% !1110 4444
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MT]K*T,NRU<J'4D,,GK@@CTXXK1U'XD^'-/\ "4'B07;W-E<.L<*6Z;I9'/5
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M;6-U>0B2(6P(66+RI-K\NW/;J. .!W /H^B@44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% #>K TZFCJ*=0 4444 %%%% !1110
M!QW@!M\?B)O37[T?^/@5V-<QX.1!9ZC-&I"3ZK=2G/J9,?S%=/0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%<SX\U_4?#/A*\U?2[*"[FMMKNDTF
MU4CS\S=L\=@1U[XP0#IJ*Q=.UZ%M.TDZO-:6.I7UJ)_LS3+R0@:0+S\P7/)&
M>*N0:QIEUITFH6^HV<UE&&9[F.=6C4*,L2P.!@=?2@"Z:!7C=Q\1+N[^-.EZ
M18ZW:SZ#)*$*VJYRYC9=COCYOG&1MXP1SP:]$'C?PV?$#:#_ &S9C4U?RC 7
MP=_&$!Z%N<8!SGCL: .AHKCF^*7@N+5)M.EUZWCN()#')O1P@8<$;\;>#WS4
MUM\2/"%]KD.CVFNVT]Y.=L2QABC-C(428V9/IG.>.M '5TE<)JOQ>\(Z-JFH
M:=>7<ZW%B=L@6!B&;C*J>Y&?8<'FLWXA>,K.\^%7]K:-KC60OYHHK:\C,B,C
M!MSJVP%E.U'!&/:@#TVBO!OB7J&HW>I>$/!EQK4D$5U:0->7<>XB>5VV*S#(
M++N3/;&[/:D^%HOM)\;Z^=5\1RW%OH]@T5^)'D,:F-RH +<E4",0<#ACCJ:
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M\ZYAN"<2A/D8AC_K2RDA?^FG&!Q0!]/IX@TB74DTV+4[22]<,RP),K.0OWN
M>W^>E8GQ"\;P^!- 74&A%U<2RK%#;&389.[$'!Z#/;J1ZU\_?!V58OBAH:I;
MJ"5G1BA.3F)SN.2>@P.,< =\D^E_M$6C2>%=*NTCR\-X8]X_AWHW'XE!^0H
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M+N4@@NR/ST!()[DUS[?$SXA:=HND^*+S4;6XTRYN9(EMO(C5I1&1NW87C."
M0<CTH ]YB\4Z?-XNG\,J9/[1@M5NW!3";"P7AO497_OH>X&R6XR,5XS/?ZQH
MWQ6\5:FBVMQ(WAA]0L5= 2(U9 B.1@CD/D \\<G QQ&E?$'QCJ(ATNU\6[?M
MD%Q-(\]M\\+@2,8U<@D\#Y2",9 XQB@#Z0TK6;#6[$7NFW4=S;%W02(>"RL5
M;]0?KU'!J]N^E?.O@JZU;0OA5<:E9>*UL99FNKFRTYK:.4R^4H+X+C(X7/'
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M<$<'!!'X5\]2W7A&]^-/B.Z\6/:K9-:*T<=P256;RH05('.Y1O'J"#W'':_
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M ')YX[?CH>,?A;XQUGQ%_;-OH\,LFI1)-<Q+=(!9SD .N68;AQG(!')'. 2
M>W^%]?@\7^%;'5XH3%'=QG?$S!MC E67(Z\@\^G8=*\#\,:YJ/@GQGXR?PQI
M*:II-JTK31K*42&&.1MK;CUV@L.A)Y(XSGW3P%X=G\*>"M-T6YE66>!&:5E^
M[O=V=@/4 MC/?&:\VUKX>^/(]>\47FAG0TL]?W6\D2$HRPL?O8*X#$9W$$Y+
ML0,X( $U;XZ2SZ7I*^'[6S34[I&DNA?R_NK;:6&S.Y<D[<@DCC'!+<1ZE\;M
M6'@S2=9T[3[-+F2ZDM+Y+@.R^8B(^8P&!VD/GDY!XYZU)=_ 9[2/2;C1=1MG
MO[8AKL:A$7@N&!R"% .!_#M/48YR"3;U+X*7NI>&;#2_[=MHI8[JXO+EULMJ
M/)*$&$56 51M(_$< #% %G0/BCKW_"1VUCXMTFTTVUN=.DU"&6 L[-&J%\\,
MW\*OQP>/SX?3OC;XDD\26E_>WEBNG7%PL$NF+$W[F+*YD#8SGYCSN.2I^4#%
M=C=?"[Q;JGBO3]3U7Q!IEU!:P?92!:&/,!5E=-BX'S!F&0P(W<8P!4^E?!:X
MTF:..V\4S+IJW\=ZUM]A4.^Q@0IDW9Q@ >F0#B@#C-/T*_\ %GQ@\9)<V=A>
M20BZ"KJ((52#LMB N"<;8P3_ '<]R*Q[X7+_  "M+R#RX[6XUJ22\C2+&X[<
M(1CA5&T# ')(YSG/J5O\)M8T_P 5ZCXBTOQD]G>7TDS.1IJN LC[ROS.> <?
MD*;:?!N6#P5>^%Y_$T\UG--'/;XLU40.N<\;B6#?+D9'3CJ: .N\"PWNG^&+
M?3M4U:/4M1M%6.?9MS;G:"(FQR2H(Y;D]:\RUW6?%/C7XC:WH6E:]+H^GZ-!
M+(/LSE&D:, $L00S9=L?W0!T)P3Z3X#\"V7@729;2VN);J>XD\RXN)!M\QN@
MPO\ "/S/O6)XC^#^FZ]XBNM;@U74-.N+N,I<+;D%7W+M;KR R\$=* /%?$?B
MK6?&/@O0CJETS&WO9+8G:,2ML0B1O]H!ROXYXS7TKH'AJV\/:$FGVGE)<&,"
M>\BMXXWFEVX\U@!@MGGG/OFN,U+X):'>:-IFEVM_>V<-B\LI="K//(X0%V)[
MXC &,8%>AZ;:2V.EVUI+=2W<L,2QM<2_?E(&-S>Y[T ?/W@"P@L_$_B*[U/Q
M%?)-:ZB]G$GF$+J,[^<O[P<[B=I/MSS7*:/9ZC9?#2;Q/IOB6YM9K34$A%A'
M.T:@D AR,X))(/3&%;).,#WFV^#_ (7@\3W6O.+Z>XN'ED$4D^(XGD))9-H#
M C)P2QQG(Y (;_PI/P!Q_P 223(&,_;9_P#XN@#Q[XGZK=^)O'VH:??1S3II
MT!6PAM47 ;:CLS9R2I7<3CGA<=Z]F^$.IZCJ_P .=/NM3N/M$NZ6..5CEFC1
MRHW>XP1GN *EUKX4>$==AL8[K3W0V4,=O$\,S*QB085&.3N '<\\=:ZW3M/M
M-)T^"PL+=+>U@0)%$@P%'^>_>@#YZ\7:+HOB'XD?$*[OKQ!_9VG>?:HLBCS)
MUMT7!SR=K+@@=SCV/+:WKMW<^'/ ]OJ<1O=,M;21Q SM&LVVXECV%E](TC (
MY ;WKW+4/@EX.U'4;B]D@O8WGD,K)'<D*&)R2 0<9.3^-;\'P^\+0>'X=#.C
M6T]C$'V"=?,<%_O,'/S!C@<@CH,8P* /FVU'V;PEX7U2\G1H;;6GCB*@[H(E
M*2."._S$L,9//7L.G_X1/PCXN^,U]H^EWD5OI+6SS*UE,,23\%EC+ @\L6PO
M&$..!7M>J_#[POK.E6.EWFE)]AL<FVAAD>%8\]?N$9S[^I]:O6'A70M,O5O;
M'2;2WNUA$ G2("38   6ZGA0.>>* /D/7]+M-,U?6K*VNU\G3[M[6-+AL2RA
M69<@*,<;>>G4<5]3^"O%>BZO:0Z+87@FOM.LX5N8UC8",A0I&XC!P<C@]0:W
MH]%TR&>6XBTVS2>5_->1;= SOUW$@9)]ZY_PWX(;0?&&O^(9M3>[EU9\B(P!
M!"H8D+G)W8&T \?=YSG@ \N^/;7J>+= EGVQ:5'#^ZG>%9$64R9DRI'SX58S
MM(P1D<Y-<-)<>$M/\&Z]I0NQJ6IB_B;3KM(/+ 7D,X)8G:47!4]V7@XW#ZVF
M@CN(S%-&DD9ZHZA@>_0U$UA:N(@UO"1#_JP8QA.GW>..@Z4 ?+7A6:SU+X9^
M+-#L-.EN->?R+H/!&9&DMUFBRHQR-IRQ'?.>W$.B:1J/C& MI0U"6XMM*DMI
M'BLUC@/EJI6$NI;S"Z9'S!3NV'D U]9\T4 ?//PT6TU6_;3[#PD\>H6NE3V6
MIWLDQ1-YW!5,>,;V( .[!X;KMS7'M/K&H^&=#\.1>'M5EO?#US-)<+':NS*)
M7#J&4 E3G=U [8SS7UM10!X#K6B>*M$^)7B+4/#OAJ[8ZO;B*VN%7*0-,(S*
MY(;;N#!^IP"<\CKGC1/%L'@*X^'R>$)Y)7U/(U,*1!M#CYPQ /)7&XX^0].U
M?1U% 'C']E>(+'XM>'X6T*?4-'TJQATV*[$0";3$ \K,>"02>..F!R3GBO'7
M@+79O'.MO8>%[Q[65T-F]C$$@ VKU 7'3.>1\W))YS].44 8'A/3=3TKP5IN
MFZC<(^HV]J(6D3!52!A0..<# Z<XKY[MOAQX]AF%ZOAP_P!IVMW]M%V]TNZ9
M@R$*%#X^]E\\'!// %?4E% 'B,'A;QG>?$7Q/J=_I,%LNJ:1-9&:&</ SF&-
M%VDX8 M&#RO'3FL<_!OQ;-X1L[*673TO-/O)9;>+S25DCE$>[+8X(,8(R.03
MSP*^AJ* /'?"?@7QG8?%!_%6KC1U2[63[4+:5SC<H^5%(Z@JO4D8SR>*Z7XJ
M>#M6\:^';33])N[>!X[H2RBXD=$==C#^%6R02#R*[VB@#PC2O@QKHUJ\?4FT
M*VTR_M6MIX=.DG)B&%*-&'7J)(T8[F.?F]>$_P"%4>/IK30K:XUO0_*T28/9
M!0[; 6#%C^[&X@JN%/7N1W]XHH \=UGP)X^?QAXBUS2M0T15U6%K5?/>3>L'
MR@ #R]H;"XR21R?K6(WPA\8Q>%M'M8+_ $]=1TR_ENK8I.P6)76-AR8_O"2/
M(XQ\W7'3WVB@#QC2_!7Q!?6/%-[?S:/:OKUA)%*8F9T$FW;'@=5 !(SD]<D,
M<5BI\'/&%_H.G:!J.IZ;!IUK=SR QAI&C5U7##A=V2&PO&-Q))X ^@:* /*M
M5^&?B'4/%.KZF-=M&M+[2Y=,2%X2&2%H\(IZ]) K$CDX/3.*;H7PBO+;7=/G
MU[75U+3=)MWM["W2'RCM8$?/CL Q]2<#G P?5Z* /&M+^!3:>-50^("5GA>U
MLV:WWF&)V&]B"0-Y3<F1@?,3[#J--^&4%K\/+OP;>ZM<7=E/*9(Y1&(VA&Y7
M"J.1]]2W/]XUWM% 'F&A?!?3M$UZPUC^W=4N;FQDS LA0*$&0J'C.,''! //
M Z5J:3\)_#FE>*[WQ JS3S7)E*V\I7R8O,R'"J ,@AF7!R ":[NB@#S?1O@G
MX1T;66U(17%T5E66WAN)<I 0V1C&"^.!\Y;IWZUKZ+\,_#?A_P 0_P!N6$-T
MM]ESODNI'!WYW9!//4]<^O7FNQHH \TD^!O@^?5Y]0N!?R^=,\S6YG"1?,Q8
MJ J@A><8!Z5Z/'%'%"D,<:)&BA411@* ,  >E244 <A:?#+P;8ZS_:UOH-JE
MV'$B'YBD;#!!5,[5Y&>!UJ(_"WPJ?%'_  D7V*0:A]J^UY\]]GFYW;MN<?>^
M;TS[<5VE% %'4],L=7TZ2PU"V2YM9^'C=<J<'//XUF:'X.\/>&I)CH^DV]JT
MZ[)2H)+#T).>/:NAHH YZR\#^&-/BEBM="L(HY94F=1$""Z'*'!Z8).,>M;9
MMX2X<Q1EQ@[BHSQ[U-10! UK;NQ9H(F8\DE 2:?'%%%GRXT3/7:H%244 )TZ
M44M% 'GOBGX3Z?XK\3?V[<ZWJUO<A8UB6"1 (=G382I*\Y;KU)->@8%.HH ;
M@>@HP*=10 F!Z48!["EHH ,#TI,#T%+10 4444 %%%% !1110 4444 %%%%
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M/"Z1Q+%I\ =[QK@#?+E04"^V[!.>"I&*YSPU\0+ZP\=>)M&\;:UIMK':NIM
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M ]Z />J*04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQP*XA1]C,47@ !MN.#C-;^M?%K51\._#%[9-;6>L:Q)(KSNH,4212&-G^8$
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MRPKABI"[22Y09ST (X)->M>*=7U;P=\++G4);E;O5[2VC1KAD&&E9E0OMX&
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #6^\*=36^\*=0
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MRXQG!&<9!'X5ZG1D>M 'D'QT\*W.L66E:EIUB]U<V\K0R1PC+LC]#CT#@?\
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M"\C,5PL:;3(A&""1S^M3Z?X.\-:5<0W-AH.FV]Q""(YH[90ZYZX;&<^];E%
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M4 %%%% !1110 4444 %%%% !1110 4444 -;[PIU12.$>/Y&8L<9 SCZU+0
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M2VK316C3,T, ,BA0B\#A>,XR>2>IH ]QHI,TM !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** $ I:04M !1110 4444 %)2TWHW/O0!ROPV3R_AWH>>IM\GZEB3^IKK*
MYCX?@IX!T-2#_P >J_SKIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M I" <@]*6B@"I;Z9I]H[O;6-M"T@PYCB52P]#@<U6TWPYH6C3M/I>BZ=8S.N
MQI+6U2)F7.<$J!QD#CVK4HH :RJ>J@_44%5;J ?K3J* &;%R3M'/7BE"J 0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 T=13J:.HIU !1110 4444 %1OTSV -25#(P6-\Y^7.?RS0!A^!O^1'T3
M_KRB_E715SO@8_\ %"Z"?[UC$P_%0?ZUT5 !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %(>E+01D8H \B\51Q:S\>/#.GR
MQ!H[*S:Y8OP&.6(QZXP*]:08XQ@X''I6/'X7TU/%,OB,PYU"2W%L7+9 0=,#
M^$^N*VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"3VKW$ #@# % "T444 %)FEKCOB-XW'@3PZFH);QW-S-,L,,#R;=W!9CP"<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#0-#U.ZU+3=+AM[VZW>=.I)9LMN(R2< GDX]!Z"M6.U@BN)KB."))YMHED5
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M,6T$L^?F"CW=B,]>.N*^I"">E>0Z)\-+^+XTZKXAO5VZ9#.UW:.6&9Y)1G
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ML90@STR=M=<;&V;&^")POW0T:_+].*D\B/G@D'L22/RZ4 <B/BGX0.?^)D^
M,Y^S2X_ [>:CTKXH:'KGB.#1M,AO[AYE+>?]G*QKCUW8(Z>E=E]GB( **<>J
MBE6&-&+*BACU(4"@!RG*@CN*6@<#%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ""EI!2T %
M%%% !1110 5@^+B1X*UXCK]AG_\ 0&K>KG_&_'@?7CT_XEUQ_P"@&@"3PG_R
M)F@?]@^W_P#1:UN5B>%>/"&A#_IPM_\ T6M;= !1110 4444 %%%% !1110
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M+>:[FW[P\YB+<!SP3\O&.M>P>$M?\.^']1M/AY:W\MS?64) =DPK'[Q7(XR
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M[5YO\3_B_<6R6-IX3O8Q'<VOVF6]$66"L<*J!A\I^5MV5R,CH0:\IUVYFO\
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MIDMF2=0L4N<!CD@] "1CGUK-?X;^)[+P?J<TFE?:]?UR;RYE253]EAW;V(Y
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M:)\.O%ME\1(?$MU=:9,@(C=E9P[1+'Y8(&,!MH7/TKV!00N* '4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^S%CPN"2<Y.?NEACD$T >HT4@I: "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1<8QZ XYZ4 6/%M_JU[\;;S3?#TQCN[JU@T^>5#RBD;W/L0,#VK0^(GA#0/
MG@[3KG0XA!K%M?Q-:W+-F61L\Y/<?RJAX8 \%_$[^T?%6J6K7=_I3WDUP>D4
MC-DI]0JX]^U97C[4KKQ'IUQXAOY'LU6X1-!TV08<Q#&^9EZX(YR: /;?AYKM
MUXD\$V&JWP07,P82;!P2"1_2NIKA?A'=Z?+\-M)BLIE?R4*2@=5DR2<_SKN"
MX&>Y'.!UH 7<,XR,UYW\8-&_M/X>W5Y&N;G3)$O8LKG[APW'^[FM'Q+XUBTZ
M<Z5HD)U+79'\M;:'E82W\<IZ*![UT5Q=1:=I+W6K7$*1QQ9N)#@(>.3SV]J
M/.M%\6^-O$'A6UGTS0+.W62-1_:EQ=QF%0#@MY0.1@9/X5Q?PPL!?_%R\NXK
MQ]02T:>4WBQE%G+8&['\(ST'<4FMQ1ZO?S:;\,AJ;6EU)YFHB#(MLGH%W8Q_
M*H/A7X8N-0\2ZYIHU:^TS['&L<XLG4.Y5BI4L01C(/3TH ^DLX!)XI:\L\5^
M&O$_AW1Y=:T+Q5JEQ/9(998+S;()4'.T8 KM/!OB&/Q/X2T[5P1NN(@9  0
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MMML=K%EG&[&=P ^7'O7%>#[N&\TKPCX7TEVFO)-0_M75G0_ZH*Y(4_@!Q[4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 E%%% "T444 %%%% !7+^-_^0-!_P!?]K_Z.%=1
M7,>./^01;?\ 80M/_1HH Z>BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *;N&[&1D]LTZJ.K6MQ>Z5>6EK<&WGFB9$FQGRR1C- 'S'\1[^Z\5^/=
M8EM;6>YM+$BT0P1%PBKRQ)4'&6SUKH[SQWJ:?!_0UT:^EM[^&Y&GW4D9 ?Y%
MRN#Z'(&>YXKM_"?PHO?#FEZO:OXCF9]3A\MI+>((8FSRP)SDGO\ 6L]/V?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@!:*** "
MBBB@ KE?'<@32;('^/4K1!]?-%=57$_$>0K9Z$G9];M ?^^R?Z4 =M1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %)BEHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *3%+10 F*6BB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**** %HHHH ****
M "N(^(PS!X>S_P!!RU_1C7;UQ'Q&_P!1X>_[#EM_Z$: .WHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH *X?XC_ZOPY_
MV'+7^;5W%<1\1O\ 4>'O^PY;?^A&@#MZ*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ J-Q)O7:1M[U)10 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% "4444 +1110 4444 %<1\1>8?#H_ZC=M_
M,UV]<5\04,G_  C<:\LVMV_'TW'^5 ':T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% ",P7&<\T YJK<V2W%W:W!FE1K<
MDA4;"OD8^8=ZM*,#W[T +1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )
M1110 M%%% !1110 5R7B] -7\+GDYU=6]O\ 5.*ZVN1\9DKJ?A4 X!U=,_\
M?#T ==1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110 M%
M%% !1110 5R7BYL:OX7R/^8PO_HIZZVN2\9<ZEX5([:PG_H#T =;1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 )1110 M%%% !1110 5R/C)
M,ZGX58DY75T/'^X]==7)^,<?VGX57UU9?_0'H ZRBBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 8[;$+8)P,X'4UE_P!O+_T#K_\ []K_ /%5
MK=128H =1110 4444 %<IXPXO_#)[_VNF#Z91ZZNN5\8_P#']X9_["\?_H#T
M =51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110 M%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH 6BB
MB@ HHHH *XGQH<>*_! ]=3D_]$O7;5P_C(Y\9>"0>G]I2_\ HAJ .XHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH *X_
MQ-;_ &GQEX2!X\JZGES](FKL*YK6R/\ A,/#([[[HX_[9&@#I:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!**** %HHHH **** "N7UHC_A
M-_#(R,G[5Q_VSKJ*Y36PI^('A;(.\+=D'_MG0!U=%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 E%%% "T444 %%%% !7)ZU_R4+PO_N7?_HN
MNLKDM9/_ !<7PN/]B\_2-/\ $T =;1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 )1110 M%%% !1110 5R>L?\E#\,_[EY_Z+CKK*Y?5N/'W
MAU>Q@O3_ ..Q4 =11110 4444 %%%% !1110 444AH AN;B&VC,L\JQ1KU=F
MP!]:E1@Z*RD,",@CO7/>*(_[1BCT:'[$]W<%95BO86DB=$8%LXZ'TKH8\",
M<#MQ0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 2BE/2DH 6BBB@ HHHH *YC5AGQ]X=]K>\_E'_A7
M3URVJ./^%A>'H^_V6[;_ - % '4T444 %%%% !1110 9HI,4M !1110!&T8:
M4/M4L!PV.13QP*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS3:?M1T::V'3+'@N.X%==0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 )1110 M%%% !1110 5QHX^,DQP<?\(_&,X_Z>'KLJY*-S_PM>\7&<:)"
M0?\ MM)Q0!L7>AVM]J>G:A.A^T6$K2P.#C!9"C ^Q!SBM6DI: "BBB@ HHHH
M ***1CA2<9QVH 6BF"0$XQ]:<IR* %HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHS0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4444 +111
M0 4444 %<M$@;XFZD<X*Z/:D'ZS3_P#Q'ZUU-<Q;'/Q.U4?]0:S_ /1US0!T
M]%%% !1110 4444 %(PRI%+10!AZUX:AUK4M*O9+RZ@?3I3*B0OM63(QAAW%
M;2K@GWIV** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "JU_/+;6<TT%NUQ*B$K$O5SZ59I",^OX4 ,MW>6VBDDC,<C("R$YVDCD5
M)0!@44 %%%% !1110 4444 %%%% !1110 44E+0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 )11BB@!:*** "BBB@ KFK4#_A96JGO_ &19
M_P#HZYKI:YJU_P"2DZK_ -@BS_\ 1US0!TM%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4AI:* $I>U%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 E%%% "T444 %%%% !7-V@_XN1K![?V59#_R+
M<UTF:Y".X*_%K4+<9_>:%;/[?+/./_9Z .OHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ I,BE/2L>;73!XDM=&:PNF-Q"THND0&),?PDYS
MG\* -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_L%C_P"A3T =;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )
M1110 M%%% !1110 F*Y32T+?$OQ+)_=LK!?KS.:ZRN6TEC_PGWB8\<162?AL
MD/\ 4T =31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1129H ,T9KC
MOBAK%SH?P[U:^L;A[>Y")''+']Y"[JN1Z'!//;K7EOPGO;K5O$UA/>?$2_EN
M$5V?1[F:9O-."H7+L4?CYN 3QP!C( /H044W(4#M3A0 4444 %%%% !1110
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M HHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH 2N6T3_D>O%GUL_\
MT4:ZJN5T4?\ %=>*SZFS_P#11H ZKM1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% "$<]Z*6B@! ,>M!I:*  4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 E%%% "T444 %%%% !7)Z'('\;>+F'\$UK'C
MW$ ;_P!FKK*XGP>Q?Q;XW<]?[3C7\!;H!0!VU%)FEH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH *X?P5SXH\<Y_P"@JO\
MZ)2NXKB_!EN4USQC,3Q-K! _X#$E '9TM%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 444Q\8ZXX- #Z*AM;B*ZMQ/!('C8G# Y!Q
MQ_2IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**** %HHHH *
M*** "N6\)_Z[7O;6;C_T%*ZFN6\),&E\0X[:W,/_ !U* .IHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FNNX8[=Z=10!5T^Q@T
MVR2TMEVQ(25'U))_4U:HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** $HHHH 6BBB@ HHHH 3-<GX,.9?$G_8=N/_04KK#TS7)>"_\ 6>)/^P[<
M_P#H*4 ==1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -)P,T
MF[VI2,C%)M'O0 ^BBB@ HHHH 3KQ7,^$(T4:VP&"^LW1;W.0/Y 5TC=1]:Y[
MPC_Q[:D?75;O)_[:&@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2DI3TI* %HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ S139"P7Y "U*N=HR,'O0 M%%% !1110 444
M4 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E)2GI24 +1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z
M4E+28H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
/BBB@ HHHH *2EHQ0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex-a_008.jpg
<TEXT>
begin 644 ex-a_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,#?,!ZYI]1;,
MR(^?NYX^M29H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!&98[<;&W%U]FV@@X()QP:V-#\9WNK>.K?2+'4],UO3/LCS7=U8V[)]G8'"
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M=K<7%];6[F:YLF"30J,,&9 ZCG .01SG'OP:\@\$?$FR\)^"M*T*_P##FO\
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M-CF/,C#9G:R G=@L<#!(6K^J>)--TF,>?.'G>86\5O#\\DDQ&X1A1T)&#S@
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MYB[ESD=17%^&=<\6>*;'5;G3?$^E7KQ6'EQ1P:?) L5VV"IS*OS+@,,]#D9
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M ;+*.H/ SZ9'4<>J=J\O\2^./%>G:UKEWI=IIDF@^'WB2]CG9EGFW(K,5(X
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M[N>F,Y[YK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -'44ZD%+0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$<LB11-([;549)]*K_;(/^>]6'_U;< \=#TK-WWW_/*"@#6HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG>ZK
MI^FQB2_O;:T1C@-<2K&">>Y/L:N5X_(L-Y^TDPUQ8ECM-.7^R!-\@D?Y#E<_
M?;+S]/[O^S0!Z._BWPY':/=OKVF"W1E5Y?M<>U2V=H)S@9P<>N#4$'CGPG=7
M$=O!XETB6:5@B1I>QEF8G  &>237%^,M!\.V&@^/[[3I(WU2ZM(WOX%D4B$]
M5.P?=+<MD\D\US.A6IOM"T(>+]'T_3/#,=I:M::C;,AFN+H.@BW%<LNY"=PQ
MQ@DL.@ /8]3\4Z!HMPMOJFM6%E.Z"18[FX2-BI)&X!B.,@_D:5_$^A1Z5'JL
MFL6*:=(VU+IKA!$Q] V<9X/'M7G?C+4)])^+]I?Z;HL6L7\/A^5Y+=YQ$4B$
MK8="P/S??7 &2&/:L+X:>%K+QOHVM:C>31VEO>:M%=)8:>5"P-%N(!4@@!MX
MXQR%!H ]7A\=>$[F>."#Q+I$LTK!(XTO(RS,3@  'DD]JFOO&'AK2[R2SU#7
M],M+J/&^&>[1'7(R,@G(X(/XUX]X)\+KXI\2>+$>Z-M]@\3Q7^5CW;_+DN,)
MU&,[NO/TK:^-]O;&^\(R2PPGS-2"2LR#YDRO#$]5Y/!XH ]*N?%/A^RLK:]N
MM:T^"UNAFWGEN45)1_LDG!_"H+;QMX5O+J*VM?$FDSSRL$CBCO(V9V/0  \D
M^E<Q\9+.VB^%&I+';PJ(7@\L*@'EYGC!QCIU(X]:XOX9>&+CQ6MI+XBT@V]G
MI M;C2KF*$0^<-G0N/\ 6*=J.>X;C(&5H ];N/&_A2TN9;:Y\2:1#/"Y22.2
M]C#(P."",\$'M6K<:C96EL+JYNX(+<@$32R!4YZ<DXYS7DGBFQM#^T)X4B:U
M@,4UI(\J&-=KL1.<L,8)SW-3_$2"PU7XM>"]%U@0G2/+ED,4C;4>0@[5/KED
M1<=\X[T >CVGB?0-0O\ [#9:UI]S=X+>1#=([XQG. <T6_BC0;S4CIMMK6GS
M7ZLRFVCN4:0%<[AM!SD8.?3%9#>$?#5EXRL]>C6&QU*.WE411LD:2H  SE.^
MT,!D8^\,YXKYSU_Q!;ZGXTOO%UM=O#,-5B:WABC(8P("!*#TSB-,@XY?ZT ?
M4U[XBT73;Q+._P!6L;2Z=-ZPSW"([+SR 3G'!Y]C2+XET)X99DUG3FBBV^9(
MMU&53<<#)SQD\#UKS;XC^%]+U+0M=\<0W2W,=QHJQ01^6"F-Z.DJMUSQ^M5M
M2\ Z5I7@?7O%%N7$]]X>6-K?:OEH=B,S#C.244^QSZ\ 'J]KKFDWH<VNIV4X
M3&XQ7"-M^N#QT-7@<C-?,OANRTW6O#EII^M^&;?2/#GV-GG\2"!3,THFQD3E
M<)EP4V')P>N,8^EK>1)85DC971P&5E((8$<$$=10 ]Y$B0N[!5'4L< 51AUW
M2;F[^R6^IV4UUDCR8[A&?(Z_*#GBO.?V@+J>W^'T$44C*ESJ$<4J@_?41R/M
M/MN13^%8'Q#\*>&]*^$-AJ6D06UI<6\L$L5Q!@O([ *XWYSGC=GGE/QH ]DN
MM?T:QG:"\U:QMYE +1S7*(P!Z9!.:LVE_9ZA")K*ZAN8CTDAD#J>W4'V-?/O
MQ,GU![OX?ZG_ &:ESK4U@D\L#VI<S3XC.UD'+<Y^6O2_AUX+AT2>]\2&-K>Z
MUN&&:2Q:W\LV;$;Y$&23C>QXXP  <XS0!W]1?:H!+Y1FC$F<;"PS^52&OEKX
ME:E9:M\2=<OH)_[-NM,B6.VD"A))[F&55R".=V"Y4]<1KTH ^H7N88V"O(JL
MW168 GZ4&XB$RPEU$K*SJA(W%00"0/0;ER?<5\\_$V\3QUHO@;4;& _VGJ$5
MRBJ-N[>FP,H/4D.#M'OT!.*Q](\2ZGXM^+/AG7KY&C$EQ#:Q%"=G[M5$@4^A
M9BQ'.-^,G&: /H]O$FA).T#:SIPF5_+,9ND#!LXVXSUSQBK4FHV<,UO#+=0)
M+<Y\A&D4-+C&=HS\W4=/6OF+5[.VD\9^+(3X7.IF765@2X5I%6V\R1P0-A W
ML<;2V1D<@YP>E^(7A6(^#O VA:%=KJS&>>&SN=ZCS0WS<-G:!P!Z<"@#W7^U
M]._M#^S_ +?:_;?^?;SE\WIN^[G/3GZ4RUUS2KZY-M::E9W$X!)BAN$=@!UX
M!SQ7AO@O7;3Q;\6=(U:_L4MM5M-.F_M!MFP-/'E YYZB,@'/0C'855\$>"O#
MNJ?!C5]>OK!3J5M#=M%=>9(#'LCRIVAL'!YZ<T ?0WVN#[1]G\Y//VAO*W#=
MM.<''7'RGGV/I2R7$42.\CJBQKO=F8 *OJ3V'!Y]J^5O$%SJDMYH'B"UD=M4
MM-"M[^ZO7E^=L3&(,>1G^ 'NP))[UM?#G6)O&GQ=NKO5MLR:E:W"3P9_=F+:
M (\=U XY^O6@#Z&L]:TO49&CL-1M+N11N9;>=9"!ZD ]*LM<PI.D#R(LTBLR
M1EAN8+C) ZG&1GZBOE#PGI>G:KJ)L&T)VM+^\FACU*1I!]BB$9;@A@NY 4<[
ML@@>^:[CX@:1JKZUX2TKPY=M<WFCZ*US;7*/^\G"%1E<9!)"#C.#DCZ@'N\]
MS#;6[SW$BQ0QJ7>21@JHHY))/ 'O3/M]GC/VJ#'7/F#_ !KYNT73HOBEXRUX
MVLD%I)?:-'+(XB;;'=;H"Y"YS@LKC.>C9YJSX<\!Z-JOQ4\4^%[BVB^S0:=)
M'!(J8,4@,($JC/WLDGTY([F@#Z/!R,BEJII=BNF:39Z>DCRK:P)")'^\P50N
M3[G%6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@!O6EVKZ4@ZBG4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9NIZ!I&M>5_:FF6=[
MY1S&;F!9"GTR.*TJ,4 8@\(>&Q:2V@T#3!;3.))8A:IM=AG!88Y(R>OJ:BC\
M#>$XBIC\-:0FU@XVV<8PPZ'IU]ZZ#%&* ,TZ!I!UD:P=,LSJ@X%YY"^</EV_
M?QG[O'TID/AO1+9;U8-)LHEOCF["0*OG\D_/@?-]X]?4UJXHQ0!@Z+X,\/>'
M;V2\TC2XK6XDC,;R(S$LI()SDG/('/6H-4\ >%=;OY;[4M&@N;F7[\DC-D\
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MG^5=KBC% '+ZY\/?#'B35%U/5K":XO$"A)!>SILQTVA7 7UX'7FNG'%+BC%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %9?B2UO+WPQJUII[E+V>RFBMV#["LC(0IW=N2.>U:E(1F
M@#Q;X=^.?#?@WP.VBZ^[:;JNG2R?:K22!A)*7=BI  ^;Y2J^P4=L&O/-0TN_
MT;X$Z:;Z,PB_UO[5$I;[T1MMJL1[E21[8/>OJ.\TVQU *+VRMKD*0R^=$KX(
MS@C(]S^=236EO<F,SP12F)MT9= VPX(R,]#@D?0F@#RSX1^&;7R]0UN34[/6
MXKB2V>WDQO>WECB(;.1A7'F;>.P'K@>L 8IL<4<2[8T1%SG"C I] !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ""EIN<$"G4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 444E "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E+0 44&
MDH 6BDHH 6BBDH 6BBDH 6BDHH 6BDHH 6BBB@ HHHH **** "BBB@ HI**
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ME8M<0/\ \LV&/X2"-RY&2I[$5T&KZ=XXO?A3)I$D%A<:]-']EG:*?8K0G(+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ,(W;<]13L>U)TI<^U "T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!O6EQ2#J*=0 4444
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M'+X2.?\ O=2I,192>O!&#SQ5WQ3\)O$^HVOAG[#J%C=7.EV0MYGO6)#,&W#
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M'#X?O+EUU"4IM18V9?FY7+'@'BO((/#CZG\$];O;J'[)Y5]-J.F))\K(H(R
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M<$'D=Q5S6O'N@:!H5EK-Y/+]CO&C6)HXBS?.A=2R]5^49P>?:O%?AQI<NO\
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M!K:H ,48HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M #-@R3M'/6EVCN*=10 4$9HHH ;M^OYT;<=/YTZB@! ,4M%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% #6^\*=3>I&:=0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !116-XG\26'A/1)=7U(3&VC=4;R4W-EB .,C
MN: -FBO-]/\ C?X.O]0AM/.NK7S6V^==1".)..K-NX'O[UH>)_BMX:\)ZP^E
M:@]U)=HBO(MO#N";AD DD<XP<>XH [BBN&N?BOX7M_#%OX@6XGGLYIUMF2&/
M,D4I0OM=21@X4^OMGK6+_P +\\'[\&'550#)D-NN!_X]G]* /4Z*X'Q9\6_#
MOA#5SI=W%>W=TBAI5LT1A%GD!BS+R0<X&>.M;'@SQMIWCG3;B^TVWNX(X)S
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M:2TLD#*P\^YD=6([LI;:>><8Q[4 >'_%.>U;XGZU<6$HE*E!.+B),"155&5
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MXC5B?F)R3DDG]: /(_ FF>'X_C-K5S8:[<W%\)+MC:-8-&JYD^<&3)!"DX'
MSQ]*]N%8^F>%]%T?5+_4K#3X;>\OVW7,B9_>')/0G Y))QC)K8% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -
M'6G4@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HQ10: "B@44 %%%)0 M%%!H **2B@!:*** "BB
M@T %%)2B@ HHHH **** "BDI10 4444 %%)10 M%!I* %HHI,C.* %HHHH *
M*** "BBDH 6BBB@ HHHH **** "BBB@ HI*6@ HHHH **** "BDHH 6B@44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% ""EI!2T %%%% !1110 4444 %%%% !1110
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M.4K$9AN9V/)W  Y49XSBK&L0>+[3XFMX:C\92QI?VZW)NG(4(@!&,8P&RC'
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M\2A<RZ;+9:6B"SCNE97X4,PD*Y4X)<C&>U=0?BO;QP6U]<:!K-KH\^%_M*>
M+&A)VKD9Z$_SI]S\3!:^*+G13X<U:>XCC22W:T02F>(G_6  \)GO0!:\/_"[
M1]&\&7GAV=Y+L7ZG[9<D;'D;L5Y.W& 0.>1WKB]*^ $-IXC2;4=42]TB,[A
M(BDDISPK\XVXQDCD],"NI_X6]I(TG6[QK&]BGT=E2>TF4+(6+A .O'S$5DW'
MQODL["/4+OP1KD%C(%*7,B;8V##(PY4 Y'3GF@#-\2?!/6-8\3RW]KXB"V;.
M#%]J+O+;+DG8F.-JD_* 1@?3)[/3_AU$OP[?PEJ^I3WX<NS7/*D$L6 7)) '
MIGGGUK(\3_&O3_#/B.[T=M(N;IK?9F:.5 K;D5QC\&%;G@7X@V_CRWU"2VT^
M>U-HZ*4E=6W[@2,$?[IH \[/P',]K/;S>)(GU7<I 1,*(LX^9,YR?7I7:?$+
MX8KXQTC3HK:\$%_I\?E0O*"8W0[=P8#)!^4$$?3Z8WA378M5^+U]->Z+?:7J
MEUIR@0W"J5*(<ENF>1BK/B'XMZUH7BVX\/IX'N+RX4EK<17A9[B+G$BHD3'!
M )ZG&#GH: (=#^"B:3X:U2V.MW":IJ%LL+3VXVQQ%7#C:/O$$JH.3R,],\<O
M9? ;Q);:A;RMKUI%$9!Y\EL\BRA,Y.W@9/ Z\=^U=5#\<K-_!<VO2Z)-'<)>
M"SCM%N RNY3?GS-HP-H.?EZXZ]JNK?&S5].:TC_X02\C:^C#6?VFX*F8G &U
M1&=W5> <\C@9% &AX]^#MKXDU"35M*N$M=2GD#7'GY:&0=,[1_$*;=_!V#_A
M X] LM3DBO!/]IFN2GRW3\_+(H/*@' Y[5Z;:22W-G!-/ UO,\:L\)?)C8C)
M4D<$@\9JGK.H/H^EW5\EI/=B%-WDP<NWTR<9H \\U+X)6>H:'I&GQ:]>1?V>
MCA7=/,!WD,VT;AM&0<#GK63XW^&6LZQ/X>T+28U?0].MO*,UPZ[TRPRW'4[1
MQ]*V[+XR0W?BNWT!]"O+:6>X2WWRLI,18<;E4G^+@BK&K_$R:P\67_AZS\,7
M^J75FJL1:[6R& .XCJ!S0!WVGV4.G6%M:0+MAMHUB09_A5<"I'NH3.+=9XO.
MZ^7O&X#UQ7F<7QKTIM"N[YM,O([N"Y6V%@Q7S'9LX('H,'->9:K>:BGQ/TOQ
M#>:)J6DSW=["1#.S#<0RJP7IP0>E 'H_B7X,V_B+Q9<ZQ;ZF+&&Z4/)&L.X^
M9W(.X<'N/6I-(^"%E8:?K%I=:U=72ZC (>(PBI@Y#;=QW$$<<CC(KU./&#CH
M"?YFN?\ &7BNS\&:!+JMX"RJXCBB7K*YY 'X T >82? ."20P2>+&:4H3M:T
M4L!Z@;\XK?\ $GP5T_7$LY(=4N;>ZBM8[:XG:,2?:@B@!F&1AN <Y/TKSOQ=
MJ>MS>,-+\2II6LZ-J-XR0P%W5A)RN%3Z@GY37H7C#XR0^'->FT:TTY[RXMB/
MM#,VQ5RH(4'NV30!D>*/AO?Z1X)_X1GPSI]WJ,EU=)=7-Y)*B LF/E*]=O'
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M#QIX/@\:Z7#I]U>W-K'%<+.#"1\Q (P01R.:X=_@'IDZ/O\ $6JOYF,[PC9
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MEXAM=;M8[>:.X@FMX1Y<SM@[-V>".E=AXS\:VW@73[2:YL;RZBF80J]O@[2
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MQL\"K)L_M*X9<XW_ &.4*?S45J>)_B'X9\*W1M=4OR+C 8PQ(78#W Z<<^M
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M\Q4."H]2#VH ^?QX)\8_V)?^&W\+VC16PDD;47A7?+@Y&R3J2>>,5HZEX?\
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M#2;NYBN)TEED9X5VI\SEL ?CZ"NGQ10 =J*** "BBB@ HHHH **** "BBB@
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M>#TD$H\.:>'!W9\O.36CKGA71/$L,,6LZ;#=I Q:+?D%,C!P00<'C(Z<#T%
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MHWB!&C(=8\-E1@CD'/'.:^B=-\+Z-HT\EQI>F6MI<2_?DCC&2,Y/-4KCX?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!**** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHI* %HI** %HI** %HI** #%+244 +1244 +124M !1110 44&DH 6B
MBB@ HHI* %HHI"<'% "T4F?>C- "T444 %%%)0 M%)2T %%%(3@4 +12 YH)
MYH 6BDS2;AZT .HI,XI: "BBB@ HHHH **** "BBB@ HHI* %HHI* %HI*6@
M HHHH **** "BBB@ HHHH **** "BBDR#0 M%(3SCO2T %%%)0 M%%% !112
M$XH 6BD)P.32T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 )1110 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSYLB*Z7RG:0@[C'S*0"#\PZ @GT;PIX@UK77O3JWAFXT1(2GD&><2&?.[=P
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MGL*]3->*_$+P_P",M$\?CQOX72>]5XT26&%"[(H"J8VC'+QM@-QD@Y/RX!H
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MB4)!)8\G:I))/\ZXCXQW_B75E3PAIWAFYGM+YXMM\N7$K#YM@QPF".2QZ G
M'-96N6/C;QW\*9(-2T-X=3TS4D9(/(:)[B%8BA*JQY(+DY'!QQ0!UD?QN\.R
M7D=I_9FO"=Y$B"&R&[<_W!C=G)Z@8R>U6O$'QA\/>&M=NM'U"TU07-LP#E(4
M*G*A@0=XR,$5Q.GZE\5-:N-*TFX\.VMG:0SPN;BXL#MC$9!#L68\C:",8)(
MS7&^,/"WBZ?Q?K=]<^%KZZ^U74ACDAMY)%"Y^1E,9_NXZY&>HSF@#VG7OB7;
MQ_"Z3Q9I%K>,+C?!;EXES#)N9 \@R0%#+Z\Y4=ZQO ?Q>.NC2-$N=)U2YU:1
M1'/=11IY1QP92<C Q@GCJ< 'C)\.=,U8_!W5=$OM!FM)S'=1P)/'Y;7.]202
MK8(.3MRW8#FN9\&^(OB9X>L++PQ9^"GECMW=5DN;66,'+%FS*2(^I.#T/&,]
MP#M]7^-/AO2-5N].>+4)IK21HY6BA&W<IP<9//6NG\)>,M-\9V#WNEB<11OY
M;B:/:0<?6OGSQQX&U^'QKJK0Z->7EM<7$EU%+;Q9#1N02/8C%>F?!#3M8TS2
M]0AU'2GLX6G#++-'MEF?'S9&<!1P!0!ZM-*D$3RR,%1 69CV Y)KS.3XX: W
MF2V6DZ]>V<+$37<-F/+0#G<26! QSS@UZ3=0I<VLL$F=DJ%&QUP1@U\Z6=O\
M0? OA?4O!MOX7GN3J#L_VZVC:X0*ZK&P&T%1D)QN((W9(Z4 >B>)_BO!;_#]
M->T*SOG>]$D=O-);9CMY%<*?-.< \G;U!*UD?#'Q!\1?$7B)7UN25-'CM_-D
M^T6 B\[</DV,%&>?FR#C ]ZS/$^CZYX0^!MKX8;2GOI+QF^USVQ++9DRB15*
M@$MGE=W !'N,^C?#_P 5W7BK26DGT*\TU;9$B\RX/$SX^;8, X'')'?V- '8
M]JXSX@7WB[2]._M/PW_9_P!FLX)I[Q+K)9P$.-H [<MU&< =*[.O,_B]XFU'
M2]&FT6W\/7=[;:I:20F]B9ML+D$8("')QS@D9_ T 2>$?&'BN_\ !5WXHU?3
M+>[B>-7L+/2E(ED 9E8L&8XR0IX)XSQGBJ5A\=M#NM+:\DTC6L0HANC;P++%
M S< &3<."<@$@9]*SOAMXEUT_#V\TJU\*3SW&D0JD:R7'DFZ\QW)QO3@JO/4
MY]LURFBZ)XJL/@IKNF?\(U?.UYJ$6(VA=9PF%W.(\;F ,:#H/O$]J /5M1^+
M/AVQFTN"&'4M0FU.V6ZMX[&V\QBC$@ C(.[*L-HR1M.:+/XIZ9=>(+;0Y-$\
M0VE_<*TB175AL.P DMMW;B/E;H#DC KS$^#?&FBZ=X/\5V>F&XO-*LQ'/8*N
M95432LOR\DEDEP0!N4CIZ=?X:U+XH>(_$46HW=G%HFB%9 (+FV4LN%PORMB7
M);!SP,9XQB@"R?CCHLED;RTT'Q%<0(3YDB6:[$QURV_ QQGZU+=?&C2+/2]-
MU-]'UE["_0LEPD495&#LC(WS?>!0\=QR*X*QE^*WA+0W\)VF@RDW,SB*_@B,
MA0NWS,)%.Q 3DAG (SGC'#O%VA^*M%^&>A>";70[B]BDB:XO);2WDG,4AE+B
M,% 0,;NISG'% 'H&G_%N#5;2[NK'PIXDEM[>$SF46R;70,%.T[L$\DX'.%/I
M5"/XZ:9-9M>1>&?$4EJH):=+=#& .N6W8X[UM^&O%%[?^!KO4O&FG)HJ(SP-
M%,'@#Q[0!\LA!!))4<\D<=:\5\'ZSXXU?P//X+T.PBO+&4-$\I #6Z299E+;
M@ &._E@>I Z   ];NOC/HL*Z:+73-8OYK^U%TL-K KLB[F4AANZ@HW3([YYH
ML?B]!J=_)IEIX;UE-5\AI[>SNT2!KC:1E5))_AWMSP=A'7 KFM4\*^)/AZ_A
M[7/#=@-4N++33I]]%&KR%V9R^X(N&*[F/3IA> !5;3+;X@ZOXCNOB#>>'56]
ML[(PZ?82@PEFR%(V,0^ KS-\QR20!QC !L:?\<I=4NVM;+P7J]U+'S+';-YK
MH <$E0N1@\<XYK7\1_%=_#PTK?X6U9VU&W,R1R@1.A!.4((/S #)'8$>M>??
M"Z;QQH?BEK4>%[Q;+5KE'O)+JQEA6%02697; & S8!SG  Y/.]\2_ ?B74?'
M-MXCT[3H-=LU2-?L$\F A3^%E9@"A/S<'DD@C'4 ZSPY\3?^$I\,:EJNEZ'=
M37EC*D9T])D+R;B,,#Z8)/(_A-<CX2^*WB*:QNI3X2US6?/OI9(Y8,O% K-D
M0A@G1<XY/Y# %[X->&_$_AK4-936=%%C9W8259/.0D.I.$55)XPQYXQM'7/%
M+2;;XG^$M0UC3](\-V-U9WFIS74=S+(H1?,(P0HD&U< '&,CF@#JOB?JMS#X
M!/FZ7JI6Z5?M+:?*!)9;1YA+, 1M!7:3TQW&16IH>NZ?HWPJTW6IFNOL-OIL
M4K&3]Y*1M'7U)/\ D5B>*XO'U]X171(=%T[4+B^L##?745V(UCD.0=JMC.1@
MY]<]NM70-#\6:M\/+CPAKND0:5;KIHMK>Z%RLKNXQMW(N0 ,<\_3V )9_C#Y
M-O;7LOA#Q';:8SH9[ZZM-L4<3#AP1G/)7CC()P<X!BU[XKZGINKV]IIWA:?4
MK;4+7[1I5Q!*6-X"H;<$"Y4+DY7[V,'@5RW_  COQ9U72(_!M_#;PZ,#'"]Z
MQB?$*$ 8.[<PX#= QV@9'-=;'X,\1VOC_P ,SV_V$^'?#\'V:V9W/GLC0!'9
MQT+;NF,# % &I\//B!/XQEU"PU+2WTW5=/8>= 0<;6SC[P!5@0001Z$=P.\-
M>9?#[PIXIT?QOKVN:]%IZ)JJ;V%K,S;7#Y  (Z8+?I7IAH \AU3XQ:M<ZM=V
M7A'PK=ZM'92-%<3&-W!8,0"HC!PIVD@M@GT&.=*\^)%_J'P\N-6T?0M1.H!)
MX)ML2,+&X11DNK') +9& ?N\@'BLJQ^'GCGPMK>O3>%=2T1+'5)"P^V&7S$&
M6*XVJ<,N]@#D@]2.PLV7@7QOI/@"XT"PU#1VOM1N+B6_N9I)>%D '[M@F=QP
M221QGB@#E_AE9>*M=U/1M3NM8\5&P226>>:>[8VLJI@1QJ&8ELMNW$C&. ."
MU?0->?> M!\:^&[>STC5I= DT6UA9$-H9OM&[.0<LH4C)/I7H- !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% "4444 +1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7!3?%?P_%K6H:08]1DNK .
M9A%:EON?>P!SQZ]*[VO!=9@M]0^.6OV_]J2:3 FD?Z9<PE59%V*SY/T89/L?
M2@#KH_C-H,GA^;5UL-2,,4HA"K%G<3SG(X''/)IB?'+PB70.U_$&&<O#\H]>
M]<CX$U3PSI?PU\4Z;>:O:?9VN+B"/<ZJTRF/:I ]6&:YWPQ!X3T+1+3Q+JFK
MV6K3&WP^CL4+^<S@+D'H% SF@#V#3OBYX5U>^FLK>YGW1V\EP6>(JK*@);!S
MUP#Q6AX3^(6B^,KBXBTE;O\ T= SM+%M !Z<UX&=*TOQ9X]\0K::U!8VWVEK
MB.5G6-! 2/-P1W"D\=*[_P"!5_I,,NOZ9:7Z22&\,ENK8$DD"C ;Z=* /:AR
M!UKSF]^-'A:QN9[2X:_AN(I&B9&MOF#CMC.3_6O1DSL&:^9O%VONWQJNI_#M
MUI_VJ<Q6:2SJCQ>9M"L3D''.!D4 >IZS\6]"T==%NHXYKFQU,Y%RH"I"H.#N
MSR2">17;V.MZ7J4S166I6ES(J[F6"97(7.,D UX!\0M*M_"/@KPYX=N=1C>^
M%Y)=W 0A65'SN*^@Y./7%7-,&@^%?CEIEMX>?=9W-M]GF5ILC?*I8'KST7([
M&@#W%_$6BQ3-"^KV*RHVUD-PN0?0C-37>K:=8!#>7]M;B3[AFE5-WTR>:^1]
M?U"VU^^U>[^RZ992"Y+1VD<1\R5CE3@YX^Z">G7C.37=:YKOAS5O@19+>7L%
MUK=BJ10B<IYZR!N<*3N*8X]#CVH ]V/B70E^]K6G#ZW2?XUFK=^#H];?6!J&
MD#4FC\II_M*;M@[=:\X\-^$?A1<^&UUGS+>Y-K;>;?%KECY61ABT8.5&0=HQ
M7F=E;>#KLZ5'<3QQ,VJW NBSX_T;;F(^PZ#UH ^JY]:TJU$1N-3LX1*NZ,R3
MJN\>JY/(YZBI[6\MKV$36L\<\9R \;;@<<'D5\J^)==M-1\(^%-&WVDBP6WF
M/?/&&E7,C+Y0XX"@9([X!K9^'M];6:>.=+T^[DF>;2ISIRE6'F[58_*O3/(X
MH ^BY=8TR"[-I-J-G'<A2QA>=0^!SG:3G'!_*I(=1L;BT2[AO;>2VD)"3)*I
M1B"0<,#@\@_E7R_X:U3X7Q^$/L/B+2KR35)&?S+R ;F7DA"C%@!A<'!!!(Y!
MIGB:_P!/'@OP!/#I'^C6Z7J_9;URRSL'0LVY2I*LQ)XP.HZ"@#ZF%Y:LC.MS
M"57&XAQ@9Z9K.U'Q1H6DV,5[?:M:0VLLODQRF0%6?)!4$=Q@Y],<U\R^$;72
M-7\:ZS%<#3V@>RNWCM[2%A;RD1D@(&PRA<;@6&<J.AP16M/$VB?\*HN/#MW;
M33ZK'??:K*3.(X%(0,0<^@?Y<8^;/T /H+QC\3-*\(7VC6TJ"[&HD.TD4RXA
MAR!YIZD@Y)'8[6YXKI-$\1:1XBMGN-(U&WO(T;:YB;)4^A'4?C7SKXXL-*M?
M"OP[UFWLX[F*:S6.^E3Y?/\ +$6(V8?Q "10>O'MQW_P^\=>!+:;5+70M$N=
M'LX+5K^\N;@;F(1E4 X9V/WR0,\<X')H W/"WQ ?Q%\2O$&BP2VTNE6D0-JZ
M+AV92JR'.?F&YC^ 'KSW5UJ%E8QF2\O+>W11DM-($ &<9Y/K7@/ACQ/X'T;X
MO:[K:3I9Z.UMY=DWV=R"Y\O>P4*6&2K\\<,?7%5]?OO#B?'>]O?%5H;K1KB&
M(P-)&2JAH8]DA7J5^^/8G.,B@#Z)2[MI5+1W$3A1N)5P<#UI%O;5V"K<PEB<
M "0$FOGW3M4\(IX>\;W7@[PU=6LD6FF%[FXE>53%*^TC;N.WC+<G^')Z&O)P
MEM:"RN8+F.6;'F/&B%6A97( R>I(4-D=-V.HH ^IOB1X\U+P-:V\]GH#7\,R
ML'NFD*QP-D!0V%/4GU&<8KJM(U>+4_#MAK#E(8[JUCN#N;A-R@XR?3->8?%+
MX@^';_X=_8[:Z::?6K9)K944':HD!.\Y^4Y1EQURI':J^F>./#FO?!R\TF[D
MO'ETS2H4O44!'8 *NY#G!&[C^G- 'K:ZSI;D!=2LV)..)U/]:N*RN,J01C.1
M7Q+?064=Y)#978N<$""1(2#*>"I"CH>@QZYK[*T"6YGT&PEO+<6]R]NAEB_N
MMM&10!+JNJ6>BZ7<:EJ$X@M+=-\LA4G:/H,D_05YJW[0/A%7*"TUAL' (@C&
M?<9DS^==!\6]*N]8^&VJP62EY8PEP8QU=8V#,/<X!..^*\HT3XA^"(/AHNE:
MSX>BGO8%6W:V@0*;E>OF^9U4YR3SG/3@\ 'O%KXCTJYT:VU4WT,%G<PI/&]P
MXB^5OND[CQGI4\VM:5;VD=W/J=G%;2D+',\ZJCDC( 8G!XYKP+Q)'X<T_P"*
M4,OBW39T\/3:1"MG;RI*IM0$0"-0ASE6# @' +G/-8>FFPA\$^,[VYM&MM O
MKC9HL,ZE@MSERNSKAEC^4N#VP2>E 'TK-XAT6V6-I]8T^)95W1E[E%#CU&3R
M.13?^$ET$V_VC^V]-\G=L\S[7'MW8SC.<9QVKP+X4Z/\.=>M%TK7+<SZ_/+(
MR)*98E* <*C(P!X!/.#DD<@ U#K(\&:-\8O$B>)-':;3,+Y,-JI79*4C8GY6
M7@Y;\Z /I&UO+6^A6>TN(KB)ONR1.'4_B.*FKQ;X"Q.$\5:A:6TD>E3W2"S3
M(S\OF$KR>H5XQDG\>*Z7P+\5[3QUK,VG6VE75KY=L;CS9'5E(#*N#CH?F_0T
M >B5S?C;QE;>"-%35+NSN;J)YU@VVX&5)#')R0 /EQ]2/6NE[5Y9\>KJ&+X?
M+;NX$T][$L:_WB S'\ !_+UH [O2_$^B:S';&RU6SEEN(Q(D*SH9,$9P5SD$
M#J.U6+S6]*TV01WVJ65JY&0L]PB$CZ$U\P7]UX+NO#&DVWAW3M2M?%RO; W,
M6[YYN Q'SGJW(V@'.W&.16/XON&_X3[Q%)-$)':_G7%PIW*-YVG&01@ 8]J
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M 44"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOH$5Q#<1:'ID<T#;XI$M$#1MZJ0.#5Q=,L4OWOTLK9;QQAK@1*)&& ,%L9/
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M'52"1MS@<?CB>&O@M)X<UZVOH_%=Z]G!,LQLX8C")67IO(<@CCD;>1QQ6O\
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M;LHR[B2#N'?ID<AN(?\ A0:;"O\ PENH[3"("/*&#$&#!/O?=W ''3(!J_\
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MUAI,;VCVHCCC"W$S!U9"Q.3@#(SD9P..!CT\# P!10!X)?Z]XE_X6K:^*O\
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M]DT2^33'"7[6\@MF8X"R[3L)_P"!8KY*U+P_XGOC>+J>C>(;G5X3^_NKAGE
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M];G'OMZ<]*/BQK?B#Q#X9\,R6-HL>CZTL$BJC-YPN75L0LP(4H0XQQR5).,
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MGCEN^2-P[@'!]!WG:@#QSXD7C6/Q,\)?;M)L;B-[J,6-TLTL<T?[Q X<*0&
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MZ2S/,\T8&4ZJ,L& ^8G(YH YOX4^#W\2+XM35KO4K6[N[6&.21'V.ZS,92[
MCG=L7KP5=AWJAHGPJTNZ^+VI>%;BZDDL-,B6Y9M@#SKB(["1C;_K.2/3C&<C
MU/2O!GC+3+WQ!J(\3:?]OU98L2"P.V%D8!< M]T1[EP<]CG@YQ],^'_C[3?$
M]WXG7Q%H\NL7D BG,MLY1OF48PH7&$C0@XZY&/XB 97Q\O-1M]3T2.2>]M]#
M*L9)+?H9<].H!8*. 2.K>]9_PW\/Z;XH'BC18O$-]>:?/;6S)*5>&6-PS')4
MEEX(QU.0?KCL_$7@OQS-XZ?Q)H'B2RMV>U2V$=PC81 !N3;M8$%@7R>03CM4
MWAOP'XC\/PZ]J_\ ;>GR^)=552'^QA+9'4EB6"A22V3EL#DY(8]0#P2*S\-V
M7AB2Z75]1BU[S)81:6T0V'##8[-D84C<" 2<L"!A2#N7GE>%?B'H>K>);C5F
MO/LD&H:@\1'G^<0VU 6VX7 C5@?]H#C%>G^ ?A/>Z#JHN_$!T2]2#]Y;F*VW
M2B;<&#F1E!&W' YZ]L"K5UX%\1W'Q@MO%3W6E/8Q\#="2R1J<!-I_C(9L.#P
M1T[$ Q?"5O'XKTGQUX@L-=UZ"UNIIEMH6N-A@.U)BP"L0#N.T8_@&._'GGA>
M^UOQ7JVD:1:>+-=BU.:.=I)9;R3R82B,\2X!)(.W+,?[X 'R\^MZ?X'\:Z9I
M/B:VMM>TE)]7O9+P,+9B-S_?!SG:&X'\6T#(SFN8TWX8>/6\)KHLTF@VT(CF
M@C,I=YXHI&5G =!MPQ7/.3@XR!P "EXNGU'P?XSLM+U/QKXD33Y-.6XEEM[E
MGD\WYE(4'C!9,^V:V/AIK7BW4AXGO-*N;[5K*)433QK4N-\H.2I89 .TG.#C
ME<UK7OPTUK5O'UEJ&M7>G:GI<&G16LANK<EI,#;( H8$.27</D[2P'.*S8_A
MEXY\+66IZ?X3\30FPN8S)L=3%*9,XVHWS;#LQ\X()( P/O  (OC/X@OY+/1M
M-\+F;Q*9I(KNVD!6.,JQ "G=G@#YBV ,'MR/9XO,$2><5,F!N*# SWQ[5X$O
MP@\6>'[/1]8\.7L?_"0(LC7>95&QG  "ELJP + YZ]1[>]6JRI;1)/*)IE10
M\@7:';')QVR><4 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 E%%% "T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5XEKGQ/\6:7XCU_2XM.TJ:+2RT
MK,7*GR?X3]>1FO;:^1?&E[%JGCG7KU[6ZC$ERRQJ\)!^10H8^QP3CM0![9;>
M-O%WB'PEINM^%_#MK<RS/*ES#<3[-FW&"N67.>?TJI\-_B+XF\53ZA?:MIME
M#H5K%(SW=O&P,<BA6V<N2WRMG@=O>L+PIXLOOAM\-M/EOM"O;K[=>3- BG8$
MCP""QP<$Y.!CL?2JGP=\1QG3I? MQIMU$^HFX87J+E03%_$"!C 4X//.!0!T
M]E\8M7UBTN]0T;P%?WNG6[E3.+H*<=LKL/.,$A2V,]>]4]3^+^KWG@N#Q1X?
MTB-8;6Z>#4X;AO,$0POED%2K;3O'S8Z@CIUX_P .>,]:^&.DZQX3O/#AN+SS
MF:(N#LW,H7Y@ =ZD $8(SDC/>G7%KJ'P]^%$^B:C92R:CXE8N(E&1:QH$!WD
M=7.1\HX&3D\8(!VR?$/QKHOBK1['Q9X?T^PT_4IA LL4A;#$XSO#,!R5X('&
M3D=FZ+\3?%VK>$/$>M+H^DF32&4;%E8 [<M,2-Q/"@8Z9YQG&*Q_ O@*?Q!!
MI7B_7_$&I:C:6P,ZV-RDC.)(V^[EF;<H8'& -WMDBN T[P[I&J^%_$^N:@-8
MCU"RD#6T<=NOEDR9V;\@M]X'=@C P<DG@ ]FU7XF:[I'@#1?%,N@63Q7L8,Z
M->^649C\FU2I+!E^; )(SSP":WO"OC._\5^ I=>LM*B:_P RK%9+<<.ZG !<
M@8S[^M>*ZCXOB\8V/@CPC9QR6T5HMLLD\UKYQ:=4\L;8P?GCZY]<].,'1\+^
M/;/X;^-?$^GZR9;N"XNV>2>W@"-]H5CN 1GP$.YL'.>%/?@ Z"V^-7B2\TB]
MU6#P7$UC9-MN93?[?*;C@@J#GD=!2S?'>ZM_[,NYO#:QZ7?8*R_:MS@(P6;"
MA>=K9QG&1@\9P/+-/\/ZAXF\.Z[K.E37$HMKM);K3HD9MZN7VNI!P[)EN-HP
M"3GG%:=YK'AOQ;=>%M&AL+W2[.VMWL\1 3E9Y2-KKR"XW\G."<F@#T_1OC+=
M^(?'4?A_2M$@FMY;F2.*[-RR[HER?,V[.,JN<9[@57T+XWW.H>+;/1-0T&&U
M6>[^R--'=%]LF=HP"@S\Q Z]Z\WL=7T[X;_$&^DT]KFX>QM)K-7NH@!+=A=I
M8J&!6(N.F20/7BN:NK34I_"2ZK-.&L;K4I8]I7DSB-69\XQR&(Z]5/% 'VAD
M4 @]#7FNJ?$XZ-\,]*\4#3)7DO B?9Y<IM.TY.3U7Y20>X(/>NT\-:LVN>'M
M/U1X1;O=P+*8<YVDT :QKS;XH^+?&'@[RM1TBSTR71O+5)9;E6:1)BQ&,!U^
M4C;C /?..*])->)?'/QE8BPE\(F"X^VDPW/G?*(]N2<=<YX]* -:7Q;\0[?X
M;OXHDLM +D174859,?9&3<25W_?R4XSTSU.*Y>3XK^,M8\/:=>Z3)I<-XVH+
MID]LD)+/+("T+C>2%4@,N,\%<Y.<+'<?$>&_^!UQID&G3(]I!::5+-(X\LED
M(WJ1UP(NAQC<*P?"N@?O/"7BW2[6[^S_ -K6UC>0%2RK*"H,RMR=C9[CY6++
MG&!0!Z!XN\?>+8-7_P"$;\*Z>]_J>GQQG4[N*T+J790<(F3M!SG)/L.ASI?"
MCQAXG\2:AK=EXBMT5]/**7\GRFC<E@49>_W<^WXBL+Q5J^J?"[XDZEX@.GK?
MZ5KRQ;WY0Q&,;2@;D;N_/7/'0UV?PW\3ZWXKT^ZU+5-$BTNW=D-JZ!@;C*_,
MWS=1C8 W0\^E '</C&3T%>*^-?B]J_AKQ??Z-86%D]M:A%$DVXDL5![?6N@^
M&WC3Q9XOU+4TUO1[>QLK0&(/'"Z,LV[F,EV.2!G.!QQTR >MO/".CWVL76IS
MV*/=75G]CED/_//GC'J=QY]A0!B?#'Q#JGBOPW)JVK_9A,]R\<<<$90(J_+@
MYZ\@UW(^Z,=,5F:#H-CX;T6UTK38REK;+M0$Y)R<DD]SDFM,#  ':@!:***
M"BBB@!**6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M >K[VYSM '4@]/TIRG(SG(]:^8OB-KEWJ"Z=XABT?5-$FOQO6<W;&.<!1M
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M0!I2VU>0NT9^7OC)[5OZK\1_!^BWAM+[7K5;A25>.+=*48'!5M@.T@@C!P:
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MZ'%;ZTUG:Z7*5M(X9(<Q'(X38 1MP/3  K<ABCMK>."&-(HHU"(B*%55 P
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MW^M<5\4M$36_ >JI]E$]Q!#YUN0,LCJ<Y7\!S7:@^F*:0ISG&#U!H ^4S?\
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M]!N/&&C7?C+4/B!#I^J)*TDB3MM97&-AW"1=@/ &%XQ@ XQ5#4O$6MZAX?\
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M>'FWD:QJN>/++>4=OKGY.?PQ^- 'GEWXI\?6MJ\[>+9BJZ;!J!"LN=LTB(J
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M.1@\#/2M[Q1\4M!\,W=G#,+F>6YMUN5%N@_U;?=))QUYXKRB\TGQ9>_!;2-
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M4[B4/W0 %Y&!R0.G'D_ACQ5XG@\2>(M*\$-IUQ:ZAJDTMND^W<@=GQ-&"P)
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M **** "BBB@ HHHH 2BBB@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *#THHH P/$'@OP[XI^;6=*@N90H03<I*J@Y"AU(8#)/&>Y]:O
MZ5HFEZ'9"STJQ@L[<<^7"@4$^I]3[GFM#%% &;<Z!H]YJD&IW6EV<]_  (KF
M6%6DC .1AB,C!R1Z4W5O#VC:\L2ZOI=I?"$DQ_:8A)LSC.,],X&?H/2M2C%
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M< HZAEX]CQ3X;>&VC6.")(HU&%1%"@#V J3%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%$>6!&!NR<+QP#5WPMK_ ,0/$?AVZU9-,T>-9K?S--9<?O7W8.X;N!C/7'-
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M':;\4O!6K7J6=GKL37$G"))#)%O/8 NH!)[ <GM50?&7P RY&O\ !_Z<Y_\
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M%*[0N".&Z'O6)X)UT>$-&2PN_AQ>7M_%(V;L6P^;GCDKVKZ*9,]<$>N*:S,
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M50S'+$#D\=Z /F+49_#/CRTL](\$^#IK/7W=9)9$91%$@'S'<&Y4$KRRK^9
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M90E0.PSQ0!QGQ_\ #8MX[7Q-'=W#B686TEM+*61&\LE3&O1>(SN'<D'UKN?
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M*)&;:.3TQ^@H ^<-&T&?XE6NN^*-<\5Q:<MK+O=9P90BOE@!ND78F<*HYSC
MZ5/J^DW_ (F^$VF^-+B]N9;W2\V-PLXQYT0F(1E;N5+A23G.#GE3GURZ^"O@
MR\NY[E[2Z1YY&D=8[IE3).3@=AGM72P>#M$M_")\+K9AM*,;1M$[$E@3N)+=
M=V><]<T >*6::?\ %+XW?;[%;V#3H(DNI7+[78Q!5!']P%BJX'. 3P2<:?CO
MP^/#?Q<\*:S97VH376KZGNE66?[F)(E*(W!"%9"NTYXXZ<5ZEX0\#Z-X)M)[
M?24F)N&#S2SR;W<C..P  R>@'6N3U;X'Z%J=S<7::KK$%U*[21L;A9%C<\Y
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M0+S3Y;@E8GG<,0V"0"!^-9/BGQ]JFC?%*"(:#J$B0VCP_9XI#_I08@B50 0
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M5W:]\@5X5X/^$^O:)\1+.[U!(I-/LD^T"XB8;99=N  F<@C)[8KW5!@$>_%
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MP.:O?$:S\2VNF>#_  U9:!?7\6C6MO/-=6MK)*LDR+L"!E4[0 I)YYW+QQR
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M-+-ERKL<*"H92J]R_('?&.>Y'2@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH ****  ]*2E/2DH 6BBB@ HHHH **** "BBB@
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MYY;Y1G.<$B'X;?%/6/%VN:CI6J6-EYMO:M<Q-8[@&V,%*_,S Y+K@@XX/7-
M'K-+7S:W[0?BIV9X].T9(R255HI6*CL"?,&3CO@?2O??#5]>ZGX8TR_U&**&
M\N;:.::.'.U690<#/(Z],GZGK0!JT444 %%%% !1110 4444 %%%% !1110
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MXC*>7MZYYH \6MOAS\3(-+;2X_LUM;2%][">-B-_WR&4;@#QQGG%=?KGP_\
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M0JY)G88:48+#.U3D^U2:5\7+P> =2U_6K6V25;@V=@;=#BXEVDC.3P!CVZ4
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M J>2<H6Y[=*^@O!7AZ7PKX3LM&FOFO7M]V92NT?,Q;:!DD 9P,GMVZ#?I10
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MHL7AZT\,&28:BCSR>48CMVERPY^A%=WXEU+PE\NE>)+K3=A43?9[P@#:#@,
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M7@\?.N<\9]NU+2['6;"2QU&TANK63&^*9 RG'2IXH(X(ECA1(T7HJ* !^ H
M^)5>&QOK>Y26.Y2)HYF\H,H!X8I\P'(Z9Y'H2.:]+^)&H^%-6^+=B]RI73(X
M8UU.6*%TE+_,=K#&[<%\M3QN'*GE<#Z!MO#VDV=C'8V^FVD=I%,)XX1"-JR!
MMP<#^\#R#VK,U'X>^$]7OY;Z_P!"LY[J4YDE*D%SZG!&3[T <;-X=\(ZO\(]
M:E\'Z0D\-Q')+"K1NS^?&"H*B0DAA\P&/4^M<1X!\=^%=%L=&@'A%+GQ#YWD
M-<V\*F0@G"R*6R=Q#$$ CD=@0!]":=IMGI&GP6&GVT5M:0+MCBC7"J/\\D]S
MS5:P\.Z1IFIWFI66GV\%Y>MNN)D3#2'.>3]3DXZGF@#YNU:VN/"GQ'U@ZO96
M"BZ>1HY]0M&GBD1R3N3_ &L<?A5G3O[,TOX7>*U<K<Q37T*:=));L@,NQ3D
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MVUVA)6>&T1'!((.& R,@D?C5N?1=+N;N"[GTVSEN8"QBE>!2\9;[Q4D9&>]
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M4 %%%% !1110 'I24IZ4E "T444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !1110
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M_4/^_O\ ]A0!Z]FC->0?\+ON&X7P=J.?^NO_ -A0?CC*J\^#M0S_ -=?_L*
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M::#=MJ"O&]Q]IU2-H9 !\X"JHQGW/2O?]/C:'3[6,PK;E(T4PIR$.T#;GT%
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MY]TKTX/;BI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=@JI(+9(Q^6?'/!NO6WAK5DUB*2635;5'6Q@6 2122.C)\YWJP W'A02?;N
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-"8).1[8%.HH
M88P1CJ,Y((IVWWI:* $Q2&,$8IU% #=@)SDTU80H(R>>3[FI** &-$K@@]",
M$$ @T>4,8/(XXQZ4^B@"/R@"".,=.!Q]*!"HZ>N>O>I** &!,#&?:G!<#&:6
MB@!C1AB">H]J#'GJS>O7%/HH 8$Q_$?TI]%% ",H8<TTQY7&XCZ=J?10 PQ
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MP_"+:@?"FF/J\IEOWMD>=V&TEB,\BML,&S@@X.#@]* %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*2E/2DH
M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@G YHIKG"T
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M **** "BBB@ HHHH **** "BBB@ /2FTX]*;0 ZBBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I3:<>E-H =1110
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M9\+VUI-L\U+>9XM^T@@''4'ZT <_:^)-3L?$-GXPA93+XDO19Q:>\>7^PQD
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M0\&>/[GQ)+XAT[1K71;EMP1()U79D<G!!Y/>@#IOBWJ%OIW@ZP\+VP66XO\
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M-QXG2V6"#2!>BQ@/SPR-*$CC9N[,,UO:'K?CK65L;R31--LM/GEW.DMPQF6
MC@],;J\]U'P/\1-3U35+ZXLK!GOY(78>8I4")MRJ 1G&:V]2@^,>HO&$2QL(
MU??BT=,]. 2P- $T/C;QIXSN]:L/"]A86<5E*\ O+B1B25R/EXQG('YUMWWB
M+Q!IFJ^#=#G>T:]O5=]3ESP$C3+[?3N<^U<EI.B_%70M"ATK3;;3+6%2TCSR
M-&SLS,68OD8[UR A\:?$;7+AXVBOKK35-L]Q$RQ18+\JKKPV0* .@E\1ZI\2
MM>U+?J4NG>$M*W/<FW8H98OX06[[P#]/QKEK=M1\=^()=-\,VT.D69T\VXMB
M %CM@^26;^(L3DGZ#M703_#?QX=)_L:WT^TMM.^T-<2K!=C,S$ #<2#P,' _
MVC3;'X6>)X-(>TD\.VC708E;TZBRR$'HN%&,#D_C0!ZYX&\$VW@O2FM8KJ>Y
MFF.^:9SA2>P5>BC''X5U2L#D!@?8=J\(MO ?Q2M[7[,FM2+;!<&+[63D>F<9
MJ[X;T[XF^%;62VL=#L[A7E\R1[FYW&3MC.>* /;<4$9KS+^V?BM_T*^C_P#?
M\_XTJZQ\5R?E\,:*I]6N#C]&H ]+(!HVBO-3K'Q8'WO#6B'TV7#?U8TG]L_%
M7_H6-(_\"#_C0!Z7M%)M'H/RKS1]8^*YC(3P[I",>_GYV_K6?-<?&21@T5K8
M0*!AE7RVW'UYYH ];VCT'Y4[%>/O-\:$^81V!Q_#MB-=SX*;Q3)IDTOBL1+>
M-.WE1Q* $CP,9(ZGK0!T]%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKQWX0Z1K<'BS7-2U;09K4WNYS<21[-C%\LB@\D8QR!7M:9*Y(P3VH 6BEHH
M2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 9(@DC9" 0PP0>XJKINE66D6R
MVNGVL5M .=D:@ GU/O5VB@!**6B@!**6B@!,>U%+10 F*,>U+10 F**6B@!*
M*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!&^Z:CJ1_NFHZ ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@!K)EL\?E3?+/.UL'MUQ^6:DHH 8J%3U&/84I3.>>O6G44 -
M"8';VXH"X.?6G44 )BC%+10 F*6BB@!,48I:* $Q1BEHH **** "FLN['.,4
MZB@!GE\@DDD=,]J<!C/-+10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEL\@52T/PSXFM?%N@VY\.7$%[H=W+=:AJ2*3]L@,H;AB/WC8\Q5Y+$/T !P
M?14FHV<5]#8R7,27<ZL\4#. [JOWB!U(&:MUXSK.JVFL_%+X?:O;:/J4$\XF
M$GGV^V3RP75 RY.-IWL3V5L^P]FH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ****  ]*3%*>E)0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %!HHH 2BEHH 3'UHI:* &X^M.HHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*2E/2DH 6BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1C@9
MIN[VIS#(--VB@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 'I28I3TI* %HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ****  ]*2@G S3=P]Z 'T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",,C%-V^]//2D
MH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH #TI*4]*2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ /2DI3TI* %HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ****  ]*2E/2DH 6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TI*4]*2@!:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2DI
M3TI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ****  ]*2E/2DH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH #TI*4]*2@!:*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ /2DI3TI* %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*2E/2DH 6BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #
(TI*6C% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex-a_009.jpg
<TEXT>
begin 644 ex-a_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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MDZO)Y[H^6RNU,8'N>]6J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *#R*** *4M@DUVLTK,WED-&F.%([U;1=H]Z=10 4444 %%%% !2&EHH
M 04M%% !2'[II:* *VRX^VHXD46X0ADV\ENQS]*LT44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 A&152[LA>!%>218Q]Z-3@/[&KE% $<4:Q
MJ%50H4!0 .@]*DHHH *2EHH **** $-)3J* $'2EHHH *@NTG>$"WD5'WJ26
M7<-N>1CZ5/10 U1SR*=110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% $5Q&TL)19&C)_B7J*CL[.*RB,4*E5SDY.<GN?K5FB@ HHHH **** "B
MBB@!#UH'2EHH **** &3!VB81D*Y'RDC.#4=JLBP()F#2!?F95V@GZ5/10 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37&5XS^!IU% %.VL$@
ME>0L[ROC<[G)('0?AFKE%% !1110 4444 %(>M+10 @Z4M%% ""EIHZBG4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 T=13JC)82* ,@]33\GTH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH :.HIU-'44Z@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0L!U- "T44
M4 %%%% !12;AC.:19$8\-U&1[T .HI"Z@X)YHW#..] "T4FX8SGCK2;UR!GK
M0 ZBBB@ HHHH **,T9H **3(HW#..?RH 6BBDR!0 M%)N'/7CVHW#.* %HI,
MBES0 44A8#'7GVI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**,T4 %%&:,T %%&:* "BBB@ HHHH ***,T %%&:,T %%&:,T %%%% !1110
M 449HS0 449HS0 4444 %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%%%
M!1110 4444 %%%% !1110 4444 %%%&: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH :.HIU-'44Z@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 9AO,SD;?2H;N*XE2,6\XB(<
M%B5SN7N*LXHH 1<XYZTM%% !2'H:6B@"A8_;F27[<D2R>:3'Y9R"G;.>]58K
M368O$$TQO()=)E08@8$20L!CY2!@@GGFM<*!2XH JS17;7=L\4Z+"A/G(5R7
MXXP?K65K=GKS7UO>Z/>0[(4=)+&XR(YRP&UBP!(*^F.:W\4;: *LJW?V B!H
MOM6WY3)G;N]\=J=9FX>TB:Z2-+@J/,5"2H;O@GFK&* #G.: %HHHH **** *
M6K2WD&D7DNG0K/>I [6\3'AY "5!Y'4X[BN&TKQ9XVUL7@3PL=/>&U#1_;%D
M02S%U& 6"\;=YP,X(&3R!7HN*,4 5KR2:*T9[>W^T2;E CW;<@L 3GV&3^%1
MW\UQ;Z?)+:6WVFX5<I#OQN/IDU=*Y&*39E<,<^M %:SFEFM(Y)H#!/(@9XBV
M=A],]*BM5N))C>M/((G0 6S*/E/KGWJ\$P,<8'3 I<4 96G:A?7=]>P76ERV
ML<# 0SLZE9P>Z@'(_&H["^U47OV2_L0,)O:\B8&%N>%&3NS^%;!0'.>]&SWH
M A$TGVDQ&%MH&?,XVGVJ*[U%;029M[B4HF[$:9W<C@>_-6]@_+I2>7SG<WTW
M4 9FKZE)9:,]_#97=RZ*&%O H\Q\G[H!('ZUI02&6%7*,A8 E&ZKD=*7RP!Q
M\OTIP&.Y- "T444 %%%% !1110 4444 %%%% !1110 4444 %!Z444 8NO:C
M=0VEQ::-):2:Z+<W%M:7#8$RJPR.HZ_=SG + FHO!OBB#QAX9MM9MX)(!*62
M2%SDQNIPP!_B&1P>X[#H'Z_X1T;Q*86U2U,DL(98IHY&BD16QN 92#@@8/L2
M.]6WT2Q;2X]-CA%M9QE"D5J3"%"L& &W&!D<CN,B@"^<UD:#K;ZMIDEU=VC6
M$T,LD,\$DJ/Y91B#EEXQ@9I#X;MV:T)O=0S;7DMVN+I@':0L2C@<,@+_ "CM
MM'/7.'J_PSTO6?+,^K:W$_V%+&=X;W:;N-<X\[(.\G<Q)[Y- &U:>*=.O;W2
M+> R,-5LY+RUD9=H9$V=0>02) 1QT!K0O]2@T]8?-9=TTT<**9%0L6<+QN(S
MC<.!SZ G%<UJ/P^MKW_A'WM]8U*RN-"MWM[6>$QERK(J$ME,$X7L!UK1C\+I
M_P )>OB*[O[B[FAM!;6L$H7R[<G_ %CJ /O/@9/7J.F  #?!R,UC>(O$/_"/
MPV\G]CZMJ7G/LVZ=;><4Z<L,\#W]JJZWX>U?4M+:QL_$L]CYK3^=,+=)'9)&
M)55)QMVJ=H(YQCG(S5*#PGK]EX:L-)LO&5Q ]H-GVG[!"[-& %1,$8 4#KR3
MW- &UXE\06WA?P[>:U=PS2P6H!=(0"YRP7C) [^M6M(U)-8T:RU.**2*.[@2
M=$EQN56 (!P2,X-8$W@6"X^'!\'RZE=2(T(C:\E.^0MOW[CD]-W;/3C-;>AZ
M:^CZ'8Z;)<?:&M(%@$NS9O"C )&3S@"@#1KS2_\ BD;SPQKVI:!8,SZ>4M0+
MN01R+<R2+&N8\'Y!NSDL,E2N!UKTL]#7)W_@#2+Z77S()!#KD*+=PC!7S4SM
ME7N&''3C*@XSF@"Y<ZQ=Z=JOAS3;A(I7U%I(9Y0V"LB0F3*CC()1ATXR/6JM
MAXO0^,[_ ,+ZI$+2]4B;3R<A+N J#E2>K@[P5]!QG!QBZ5X'\1QZ_;ZQKGB2
M'4KC3;62#3"+/8$=UVF210>3@ $ Y/KZ]/JWAZ+5-6T'5'V+=Z5<-*KA,[E>
M-D=,]@25;_@- &;'XV2\\ ZQXFLK; L5NC'%,X)<P[A\VW[N2O3K@CUI_B#Q
MQ9^'++1M2O()1I6HR+&]UG_CVW)N0LHSD'!!(Z8[U1UOP->WUK-HVG:A8V'A
MV[=6N;-+',@&XO)L?=C+M@'(^4=.F#T/B'P]::_X6O-!E1([>X@,*80$1$#Y
M& _V2 0/:@#85@RAE(((R"#P:6J&C::NCZ+8Z:DTDRVEO' ))?O.%4#)]^*O
MT %(:6DZCU% 'F?AKQOJFN^+?LDFLZ' @O+B%]'>-ENECCWJ"&+?,Q*JQ&!P
M3Z4[P[K/C;4/'FKZ'>:EHYAT=[<W'EV3@S)*N_"G?\I ]<\^M;%EX5\1G6]/
MO]8\36M_#9SM.(DTE879C&Z#YPYP '/;M5V3PW<1ZSXAU:TU 17&JV<5O"1#
M_P >[QJX5\Y^;EP<8'2@#"\'?$*?Q-XLU/37BMULFC:YTJ9&YEA24PL6&3_&
MI(Z<?A7/0^./&L'AOQ;K%[=:3(="N)+$016K#?,K(-X;=]T;CQCG%=!HWPLL
M?#.H^'[[1KA;>XL8WBOY=A+7ZLO.020OS 'V'TIUQ\.II?#/C#24U%0VOW\E
M[%(8B/)W%&VD9YY4C([<^U %KX=Z[K/B"&[NM1UK0M1@3:J#3$<-&Y&2'W=.
M".,'OSQ5SQ_XDU#PYI6G_P!DQ6\FI:EJ,.GVWVD'RE>0GE]I!Q@'IZ]#4O@[
M0M2\/V7V2[;1DA"_+!IE@UNN_H6)+G<2 ,_*.:/&WAF;Q1IEE'9W:VE_I]]%
M?VDKIO02QDXW+W&"?\\4 >>ZM\1?%^B_:=(OY]!AU.VU*"VDOV606ZQRP-+R
MIYR,8SWSC'<][X"U35=8TB:]U/5]'U)6E*PRZ4K!  .0V[G.?TQZUA6WPZU*
M[\1'6M>O=-N9IM0BN[B"&U;R62.W>%0 ['D[@3GTS[5Z#:VEM90K!:0100KG
M;'$@51DY. ..M '*>/M>U[13H,.@K9>=J.H+9L]XC-&"RL5!VD$=#T]*Y/5?
MB3XDM/[)T]F\/:??7-W?65U>7CR"UC:WV8=22"H;=@;L\X]:[GQGH%]KUOI+
M:;<V\%UIVHQWZ&X1F1]BNNT[2#_'^E<E<_#?79Y]*U'[?H\VI6MY?74T=S:N
M]LYN-HP%SG"A>,GKCKCD ZC1==U.?Q2VAW_V.0P:1;7<L]N&P\SLROM)/W/E
MR.,^]9_B[Q^WAGQ/I.EK:QR6\H$^H7$DH46T#2"%6&2/^6CKDGH >.<J^7P_
MXKB\3#7K&^T<W,^FPVEW'<02[#(A9BR;6!"DL>#DU2USX90>+KN]U#Q"T$]_
M)IT=K:-#YB):R!7+.,,-P+OD!L\#KS0!MWOB2]@L?&-Q%# PT1&^S,22'<6R
MS%7&>Q8<@C(..""34USQNVD?$+1O#QBC-G>*%N)WX,4LF_R%!S@[C$XQCTY[
M'F];^%WB#4[VZFLO$\5I;SVHB:W-J75W:W6"4DYXW(@YZ^W&3>U;X6KJVO7^
MNW%\IU+S;6339PK*;7R<$JP!PV[;U.2/PH H1_%/5%^(4VARPZ7):C5AIB6\
M;2+=@$X\[NK(,'/ _3-'AKXC>(/$'C)M,^T>&;>U6_FM_LLCS"\:*,GE1G:3
MM'7CD'@5NGX=$ZB;U-3:*4>(O[:#+!RR; K0D[NAPW/3!Z&K'AGP=JOAFXN%
MMM8L);&XOY;UXY--;S@)#DJ)!+@<#&=OX4 =KFBD%+0 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ HQ110 48HHH ,4F*6B@ Q1BBB@
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MSSRW>V0 $;F"GKQDX%=)XE\3Q:!<:-:*AFNM5OHK2&+)^Z6'F/\ 15)/U(H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M-'44ZFCJ*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 -5=IXQCM3J** "BBB@
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M.8XM[)N)8#'!&>!F@#3TKP/XJMY=#TVY?0XM"TC5'OX6MWF:X()E*H05"_\
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MBDLT<C<=P)+M\JC<2#@'')!'HN*,4 <5H?@G4=,BU>>^\1W&HZOJ5JMK]N>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 9O4.JEE#'H,\FGU"88VFCE*Y=,A3]:FH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!O0@4ZH)9XXI8E=U4R':F3R3Z5/SZ4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !110: "BDHH 6BBDH 6BDHH 6BD%!H 6BDHH 6BDH% "T
M4AI10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $90,RE@#CH"!P?6I
M,>],+*K =S3\T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)N4C((-
M  W3\:\G\3^(?$&K?$Q/!>BZHFEVT%N)KF[1=TF"I)'/L17JY.1QS7F'C?P#
MKE]XI'BGPQJ2V6IBV6%XV.WSL>C=N..: ,C2KCQO#K'BW0-3UF]$=K9M<6NI
MB)6V@'<A'8Y4$$?6N$C^*/C"?3K5[?7;B747F(-H+10ICQA2&_B);J!TKTC2
M_!WCEO"VM3WWB-WU;4+4PP6[R[HXOF)Y;'7!(R!WK@H/A)XY6UCM$TW2T3S1
M+YXD7SHV]I!\WX4 ='K'CWQEH7B+3-*U36]/LQ>6,=U-/+I__'LS;@5*[N<;
M/UJF?B?XROO!<%_#+#%=RZL+2*6.W^65&3*@ \9S@>V:CNOAGXSUOQS"-:)N
M;&-8X)=0,BJ9(%X.T=0QKL_"_@+Q)X9\.ZOIT6IV+N)C-I,LEN)/*D/5R"."
MW3';K0!PL'Q$\?VFI?Z7>QRPP:C'83Q"%"2[_3GIG'OBNF\?^,?&GA/Q?;6M
MO>V#6>HD_9%>W/[OYP,.>YY[51^&6@>-;?Q9=W&KV/D:?=R-<7YNHT;S9QG8
M8P/N_.V?^ U7^*6D^-=8\96C1:>;BRMIR=-:!0=IPA)?GU7]* .G\7ZOXX\)
M^"8M6GU/3;B[CGVWB1VQ*[7("A<D?=_7-<GX9^*_BS5?%^D:3=RVGD7%XD4Y
MCM]I"\@KU.,XZUL>,]*^(GB3P%IEC=Z=!/<O<22:A%;E%;"MF/&3CI5_X2>
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M3+Y>Y0,@L,CWP*V/AE]ITKP[JMU+X0E.J:7;2>7<2(R/=AV+>6 1U (&1UH
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH ;@$@D4ZFCJ*=0 4444 %%%%
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M)6TDW97/4%1^I%?)D-N5TZUNC>6R[;A$,)8^>I!!W$8QC\: /I#_ (7;X+7
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M3"\BFDDF.%"KD,?R- &E%XL\+:B?L<6OZ1<.^5$8NHFW8&3\N?2J\/B?P7-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ;G! IU-(RP-.H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M54MKJXGU/=]EL0H\QMK%23V'(H XCPYI'Q5EOGU2ZDN5:R0O':W\Q"W+D8"
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MZD I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH :V,X(!R*X/QG\.(/$&I1ZMIE[-I&L9"27MLIW21XP0<$<X[UWU%
M 'E47P>L]/\ "&KZ;I]\ZZKJ,026^E!^8!L[2.RL>O<TWX<_"J[\(>('U34[
MJRN)%MQ#;K;HPV9/S$YKLO&GBJ#P?X=N=6F@:?RV5$A5MOF.QP/F[#K7GNA?
M%G73J6D+K_AV.TTO5W$4%U ''S,<#[QY'/- 'LV!V S7*^.O!UKXRT,V;OY%
MW&V^UN%!S$^".<?PD$@CH>/:O+=8^-?B?2=4O--NM T^.6WG:,B0R#"]5) /
M<"N[^%OCRZ\;VE^+ZTC@N[&0*[0$F-PW(QGG(Q0!S.@?"[Q='J&GW&O>*)I+
M2PNEE6WAGF;>%Z8R0%!_EFLWQ+\&O%6N^*-3U7^U-.=;F?>GF%U/EYPJX .,
M*!WKW:7<$)5-[ '"YQFO%Y_C9J]NFLPR>%0ESIQ*N3=92,[L9<8S^1H R)?@
MQXT;2HM*_MG3);&&8W44.9%592,9SM["M;1?A9XG\,>*M*O]'U=/LQC4:BTD
MF"S$DNH&,%>F*FN?C!K5OX T_P 0#0(#)=7C6S.TA\D8!.0/O<X(Y]#61IOQ
M]O8YV74M MFA9/D^R3,K9[ [Z *T_@7XG7'C-?$#QQ2W0?:MP;J,J8<D;"O<
M;2<BNO\ BIX8\7^(+6*QT P3Z2ZA)K%ML15E.0V6Q\O P!TP*@@^..GGPK_:
M=SIK_;5N?):R28#CD[E8]0 .?>K.L_&,:/9Z7?2>&[Z2WU"S6Y60RA A)QM/
M&/3\Q0!6\,:-\1].\#:M83FU@O(HXTTJ)FC=E +;P2O&#E<9]ZY[X7?#OQ%8
M>-8M7US37M(+<2E"SC+2G@=/X<$_E7?^#_B9#XLL=6O&TBZL;?3HDE:21A)Y
M@(8_+P.@7]:YK_A?VFEQC0+Y8&? G:5>FX#/(]\T +\6M"\::]JMI!I5@UYH
MD*I(BQ.BN)>1DY8$C%5K3P'XG\3_  O&A:TJZ?=Z=="73VF88D4 _+(!G Y.
M#6SX@^,VG:%K<NE+H6HW4D<GE^9N5%?."-A)YZBHD^-VEGPY)J<6E732Q7*V
M\UFTJ[HU;.)-V.1GCV- '/V?AKXM3:I8/J4T)32CYT#231LDK <+@#))'&3Z
MURR?#?QMKVHZGJ&H:3/:NZRSMYC*6E<GY8EYZ8(&3VXKTO1?C98ZYK^GZ1;Z
M)>*U[((_,,JG8Q&>G<8!JE<?'RR@NKF$^';MC TBLPG50=K$>GH,T 9NBZ'X
MSLOAO#&/"UNVM:;(T>GO<,OGQ1.C[V7D#(/1>^?:K?PF\.Z]H[7::OX6@A\@
M&6TN[A$$X=AC8I&3@[>>1MS6I9?'CPPUNKWUKJ-K.>#"(A*!C_:'6NC\/?$[
MPYXJEN8=/DN1+!"9C'-$8V=!U*^O:@#P7Q)X5\8WFNZG<W_A:\EN-0F:=C;Q
MF18\]%##J ,#\*]O^$-AJ^E^ +6RU>U^S2+([0Q-PXC)R"P['.>*HK\=/!BI
MR^HKC/6U/8_6NS\->)+#Q5I(U/3?.-LTC1CS4VG*G!_"@#*^(_ANX\7>";[2
MK1D6X<I)'YGW693G;[9QU]Z\IN-.^(?BO0=+\'7FA-IFGPB,27LR9P$'+$@X
M'?  YKV[7O$&G^&M*;4=6F:"S1PA<*6P2<#IS7/V'Q3\':M?0V-GJP:YG($2
MR1NH8YP.2/6@#QWX@:+XFU/Q/%9P>'KT6.EA;"RECMBXDA&%5V8G!SUKWGPC
MX7T_PIH4&GVD$0D1%6>=8P'F<#DL>IZU@ZO\7/"FB:K=:7>7%T+JVF\F58[=
MB <=O;FMJQ\;^'KWPV^OIJ,<6FQMLDDD&WRVZ;3[T =*.E?._P 6M3UK6?$Z
M1KX?O(K'1;@@77DNPFR5Y&!@@U['IOCKPQJMZEK9ZS;2W#X"H'Y;G&![^U9-
MQ\6/!5MJ-W97&KJ);:7RG/E,R,V<'! (.#Q0!Y[\3?%=SXE^'^G,V@WUB]W?
M!F\]"0@C7((QS\V_ _&N=\ Z'X@B\1:7;RZ=>I87]G/'#-L;; DB$%P3]TYQ
MGH3@5[OJ'C?PK:V]G+=:Q9F&[?9"X<,I(ZD^@'K5J'Q;X=N)%B@UO3Y'PQ"I
M<KT498]>PYH \$T3Q!<^!M"U/P5K'A1[NZNI-B)NR)C\H^8CG!X(QTS6CXBT
MW5-%C\%Z[+X76*UTV%A<:=&Q=(3YA;YLY/\ M#KS7M$/B;PU?WL,5OJ^GW%R
MQ"Q*D@=R2,C'/I5B_P#$>A:=<-:W^JV5O.8]YCFF"G:>^#0!\_3>(;K6OB(/
M'%MHEY!H]HR/<26\/S>4%96+GC)Y /L/:N#C_M&[TG4!9F[_ +-C<2W/ED^4
MI;.PL.Q]:^N[?7="GTV:XM]2L'LH ?-=)5V1C_:YJE9:GX4&@F]M;G2UTN5M
MCR1A$C<GC:P[GVH \0\>^.-'UOP-X;T_2X;BVN[41SHKK\L*HNT ,?O$G&/P
MJ2V\*:AJ_P )=<\3+YM[J6JR1R21!0"L4<N3@?09_"O7KN;X?7,%H+R;09HH
MHA';AS&=D8Z*OH!Z5T>EMIS:;;_V4T!LPNV'[/C9CT'M0!\W:IXHTSQ'\/M,
M\)Z;HLZZUYL=ON6!<-MXSNZY.1FL7Q#?SWWC"%-/CF^W0VL&G^4RAF\Y$$3*
M >V1G/KS7U4NC:;%=&\BTVU2ZSN\Q8E#Y_WA5/\ X1716UK^V/[)M3J&0WVC
MR\'(/7Z^] 'S]H'C/2/#_P +-=T50[ZY=R%3;W"?("<(6^J@%C[@5S'A/79/
M"_B73=7C-Q% DBB1L8$D&=C?4=\5]0ZIX.\,ZBADU/2;)AYGFL[($RV>I(Z_
MC3+C0/"FJS62SV>F7#68(ME^7Y!Z;1U''Z4 ?/OC]/"MOK-M_9%\+YYKN6]U
M":(\K&[J1$H[$*#7?2V?@70OAWJ\G]JV=[;:FT\UAY\8)27R\!5XX((7GCI7
M?ZKX)\)>(LO?:99S/$-IEC;8RX]TQT]ZDN?!OAC6=,M;&;3;2>SM#^XC0C$7
M&" 5]>^: /*/AXNG7'PMUJUTM8/^$OBM+G=L0?:-N>,'KM/ _$5R=H_@V/X0
MSQ7$<)\3F1ECCVMYOW@%R!QC:!UKZ)T3P;X?\,7DMUI.FQVMQ-'Y;NC,<KP<
M<_057?X?>%IM=.KG1K=KHC#9'R$\'<5Z;O>@#Y_\1QM=Z7X.$MS%#KD=F[S2
ML^&2-23;M(1WV@<]<FK_ ,&L7_Q1BN;@++(UI-+N=1D.2/F'H>O->V^(/AQX
M<\3ZI;:CJ-F_VB#',3[1(!T5AW%7-,\&Z+HVMWFK6%BL%W=*$D*] H'&T?PY
M[T =$.@I:!THH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH 8?O"GTT=J=F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,^QI
M:\?USXXQZ/KFH:6N@R2-9SM 9!< !RIQG&WB@#UYG"]0<>M =2< C/I7EU]\
M6[J'P18>);;PY,T=W.\>UW)$:K_&Q X!/ IW@[XKWGB==0,GAZ95M;9YHWMV
M9UF91G9DC@GC\Z /4 P/0T9YKR[PA\81XLUZ'34\.W\"2,4:8'>L) )^? &T
M'&,UJ^.OB,/!-S91R:+-=QW:G;.D@1%<<[,X/..: .\R*,UY1X=^-UEK5W-!
M-HES;I%;27&Y)!(6"#<0%P.<<]:K67[0&D2WD,>H:/=V,#KEIC()-O\ P$#D
M8YS0![#FBH+2ZBO;>.X@8-#*BR(P_B4C(-9OB?Q':^%-$DU:^@N9;6)E$GV=
M S("<;B"1Q0!LYHS7F4'QT\)3W%O"L>HAIV558P+M!+8&3NK2/Q:\,1:_/HU
MX]S974$TD+M<183<@).&!.<@<>N0* )OB;X=NO$_@N]LK4%YXG6XBB SYQ3D
M)^)KS.34O''C'4]*T*^\*P6MO97L-P6$3QK$(\$KN).,XQ^->D^'/B?X>\6:
MN-+TZ._^TF)I@)8-@"@X/.>*[&>2*VMY+B9]D42F1V]@,DG'7@4 ?)_BJ77_
M !5XYN9[G2+BUO99DMS"(6 12=JY..N.<^U?27@OPAIW@S1DT^QAP[ -/,3E
MI7[D_2N<C^,W@(+DZO(QX!;[)+EB,]?EYZ5<7XO>"1&CMK! 97.#;R;EVD9#
M +D=>/I0!VMS*(HGDV.Y1"VQ!DMCL/>OD'Q!?7&M>)-:U*6PNK=[NX+B$1-\
MN"!AL#G@9_&OI*P^*7@W59[:WL];B>>X8)%$T<BDL>@Y7BG+\3O!(DDB;Q%9
MK(C,'#!E((X/4<]* /#M2U&6X^"ND:1]BN5==6D9I6B;;A0[#MWW@?@:X:TO
MK:*\\RYC2Y784,1.W+$8S[8-?8&A>(]'\1QRW&C7\5Y#&^QVB)PIQGD'O5][
M2TQDV\3;L\>6O/Z4 ?&#V%PVE/J0B=[%G^S+=8.P.5SM'O7K'COX@Z5=_#>Q
MT![.=)M0T^"5'? 6$HZC&.X.P]/6O5W\5>#1&+9M8T5AYA40M+'@..P4=P:L
M:AKOA6SOVL]0U#28+F%0&CG= 4'4#GIZT >6^&_'EI_PI#5(+2U>2[TN!+6=
M#RK>:2H8$=OO?E7CUM)<726.DP"2]=+@F*T)&UB2%P!_M!%#>P%?6</B+PL+
M6YN+;5=)-M$%^T/%*FU-W W8XYP<9]#67_;/P\TZ9]22XT".527\^'RBX).,
M_+WZ^] 'E'Q3\:+%XMT&"&&*WU/0Q'-<(0#$)2J,4'J #C\*JZ_H46@_#BYU
M_4[Q9=4\22PE$A3;'&N_S648Z<=_PKVG5]2\$I>10:S+HIN+@JZ+<*FYBW*L
M3C@'U-:6GZCH.NZ<YL);"]L8#L(7:4C('/!'& : /F+P+=VMM\0_#DD=P9 T
M\>\,G$9VD$#U'/6H/&6K6>L^--6OM-WI;74C>6KCDG!0X Z9(S^-?4.GCPU<
M7!_LI=*>XMGV?Z.D>^,CM[5G-X*\$S2R2RZ/I):0[V(QR0>O7UH ^;[N\TQO
M NEVB21IJ2:C-+<;U(8Q%1CD]L@CBMCX8ZWI6B>.4U'6;H6L*VK(A\HD$L!P
M<#IC!KW_ /X0'PC=001#0[!X+<,(@%!";B2V"#Z^M6;KP7X;N+M;NYT:SFF2
M,1*S1 X0# &/2@#Y:\4W6EZCXGU*?0[:2WTV24O!&P).< .R^@8@GVS7TW\/
M=0T34O!MD^@6S6MG$OE&!NL;@#<">YSW[U2;X6>!W66 ^'K(%SN)&0W_  'G
M('M6_IEAI'A?3%L;&*WL;1"652X49/<Y/K0!B_$R738O 6K?VH8Q$8,0F7O-
MR4 ]\XKYFAE1=*L426U:<ZBLP"1$7"Y !8OC_5[NB_C7UCJ=EH7BVPDTR]6T
MO[=L,T8D#$>A&#D'WKF=.^$/AK2-<AU>(W;M;RF6*&27*(>P ]!V% '!_'B+
M0X+K3/)%K'JT\NZ\*8#M$0HRW]*L_%RSTFS^'^AP:'Y<6FC4%+FS.Y.5Y+8Z
MGZUVGB;X5^'_ !9K4VJWL]U'=NBQR&WD ^Z.">#@XK8TOP1HFE>&9?#D-KOT
MN;/FI*[,TA/))/KG'2@#P;7H?"5EJ7AEO!5W)-?K=(UTP9BJOE3NP>C=<XI?
M&6E:7IWQ5O\ 3;#2;:6":-4^S+.8E6:5,$YSP<G(%>U>'?AGX<\,W:W=M:M-
M<HY>*:Y<N8<YP$!X'!QZUDZG\%_#>I^)+C69WN]MQ<">6T!_=NY.6R<9^8\G
MGB@#R7Q#X,7PA\-;<ZW'&FN7MZK0*C9\N%4PX/..0<GCK6AX T> ?%22QU1;
M25$L)7*P$")0T:YQQUVMS^->P>-/AOIOC9+,7-Q-:-: K$85 X)7/Z#'XU@?
M\*%\,+<R.ES?I"8PB1K-C8W\3 ^XQQ0!X(NH1:3XF_M#0PL*6]V\MH"P8JJN
M0!EAW48KO_BO>^'M?'A?Q';1^9)J,8^V(D@!,2%24/\ =8'*YKTBR^"_ANRT
MJ^T_S+R47@C#REP'4)R IQQS5&+X$>&4>WDCO-1\Z%]SR&0'>00<$8P!Q0!Y
M_P##33].UK6?$]E<E+;3+VUW'3I2!(V')0ACCE#S[YYKB#JEPGAO^P-R26"W
MKW:C"[FDV;0"?3'/UKW[Q)\$]!U[5+B_BO+NQDN)/-DCCPR%LY)"D<?A5=/@
M;X?_ +%6PDO[EI!<&9KD!%=UQC8?]F@#R/QG8:3IUMX9&G(L<TNC12W8RC!F
M/0_[^?O>HKUCX$^(5O/#=QH;'=)IC@H5 YC?)!/N""#^%/MO@3X<L[VWG6_O
MV\J8,L3LI# '.SITXK8TOX:V_AA];O\ 1+ZY_M*_MI(8FN''EQ%F+# '/!Q^
M5 &[IWCSP]J_B2?0;"]\^^@1GD"H=HVX!&[U&:Z13D9%>1?"SX9ZGX9U6YU?
M7GB6Z\MHH(HY=X^8Y=R?4D#Z5ZTAVYRR^WTH R_$^B6_B3P_>Z1=.R0W,85F
M4X*X((/Z5X+\&O"L>K^*M1U*:\N5DT2>(0F(8$G,@(;UX7]:]M\;^')_%GAJ
M?2K;49;"61E99XSTP<X(!!(KS_PS\%+SP]XEL=6_X2(2);2"62)(F4RXR0#\
MW/6@#SNYU2]\'^._$T=A]HN+$7$\$ZM(=CB08!?U()XQ67X<U35/LL/A6PU"
M6R.IW<:RW7FLNW&0!ZJ,D$XZXKT)O@?KEWXFNKB]UJ%M/N9'>:=-XFER<A64
MC'![YI\WP+O1X:$45U:R:NE[Y@D9F16AZ8R,D$=0?:@"]X5\*>+O"GQ*L;:;
M6;B]TN:W=II))BRR8!^78QR&R <CMWYKUV/4[#[8;-;N$W8!8P!P7 '7BO+_
M  )\,M=T?Q<OB'Q-JZWEU%"T,*K(\N01C)9@. .U26_PYU:W^,\GBN.Y@73'
M<S,P.';<N#'C\CF@#U@-NSUX.*6D!XXHS0 M%)FES0 444F: %HI,T9H 6BD
MS1F@!:*3-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1[8H \NTCX<VFE>*?"TNF>(--F,VVXGB,X1W'I&H&74\C).<@UP/C&TMM/\
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M]Z?F8R\@\!B=PX')-:?Q'O=#T7PC#H&@:/-:VVK%-3FE=68%-W0[LG/3Z 4
M>J>%OB3I/BG2]2O889[8Z<"T\$H&_:!G(YKEU_:"\-NNY-*UAAD#_51C@]_O
MUYMX1,WA/QW:V&I*6@U2W%K<)"2=\5PN4(./X?S&:@UO5/#^E>/M)BT[3)X-
M+T:3R'BF),EP=Y#MSG(Z8[<4 >NWOQQ\-6;6P%KJ4Z3P+.'C@4 *W;ENN1@^
MGK6SX,^)FE^-;JYL[.UNK6Z@3S&CN%'*9P""":\B^+QT6QO=!T33H9K>*SA.
M0ZL%$4A!'S,<MCDD9P,8K0^!4]N_BG68[:!)(TL0JW"E@6 ?'S#) +=> .E
M'T$IR#]:6FIW^M.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $ I::.M.H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIV*R[?N(><$$#)/7%8?A?X:^-;3Q+H]_)I5CI0L& >8S*WG  \E49L^G4=:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U
MOOK3J:WWA3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA!/'RWER/%L^F2VH3]T+91OW?AVKN'SL;;@''&: (((H;6W2WMT6..(!%1.
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M_+C12<,WH&QCMQSS6-JMY\+Y?%LDVKSZ&=:MOEE:Y( !'&&S\I89[Y(Q_L\
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MUN21SSP* /4E/6N9\<>"+#QSHZ6%[*\#Q2B6*>-5+(<8(Y'0CJ/8'M7G]_\
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M+B@#YX^'?PM\7Z5XYTS5-3TV.RM+20R.TL\4A;*,,!59N>1SQCKVKZ'-&**
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MNI:5!<QW"JRC?<NZX(P>"<4 >7:UH/V_XUZSH0\3W.C6-XJWD@6=D$TA13M
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M;:'?+=^9]UL X(_$5V[ D<?E6-I_AG2],US4-9M;79?:@5^T/G.<>E &T#D
MCH:6D'3FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ Q1BBB@ Q1BBB@ Q1BBB@ HHHH ,48HHH **** #%&*** "C%%%
M !BC%%% !BC%%% !BC%%% !BBBB@ HQ110 8HQ110 8HHHH *,444 &*,444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+:2Q3,84M6+[Q'DJ%3<0"!DJ1CIGUGQ%\/O#/B@V[:KIOF/;1>3"8IGBV)Z
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MN2<;&5AO^4#@IT(R>YO_ (/6TO@^P\.:9K=W806\[7,S[ _VF4@?.PR,8QP
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MBBB@ HQ110 8HQ2 @]#2T &*,444 &**** #%%%% !BC%%% !BBBB@ HHHH
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M;C9#*%SQRO3/'/Z&NIZS\&-5TK2X)[AK'5X;NZ6!BQDB>(KC:.6"NBM^O\-
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &GEABG4WH13J "BBB@
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M>%(;I;J/PYI:7"2"191:H&#@Y#9QUSS4>L> /"_B#46U#5M(@NKMD"&5BP)
MZ="*Z6B@#)T'PUH_AFUDMM&L(K2*1][JF3N;&,DDDFM:BB@#)U[PWI'B>Q%E
MK-E'=VZOO56)!5L$9!!!!P3T-8,_PK\'RZ!<:-%I$=O!.58S1DF97485ED;)
MR.?4<G(.37:8HQ0!Y[J/P9\):C<6$NR^MELH5A2."Y.&122N2P+9!)Y4@U-X
MH^$?A;Q3>M?3PSV-Y(VZ6>Q<(93_ +2L&4GG).,GN:[S%&* ,3PKX4TOP?I
MTW2HW6(MOD>1MSRO@ LQ]< = !QP!6T1FEHH \[UCX+>$=:UJ;4YH[R"2=FD
MFBMYMJ2.Q)+G()!R<\$#VK2U#X7>$M0\-QZ$=,6"UA=I(9(&*RQNPPS;SDDG
MC.[(.%R.!CLL48H X'2_A%X:TC0=3TJW>^)U%/+FO&E47 0$$*K*H 7(R1CG
MOD8%5=!^#&A>'=8M=2LM6UWS+>02B)KE%1R.@8(BDCVSST/!->D8HQ0!X/\
M%7PMXL\4^+'EA\*RW-A:VCPVLL-Y$OF'&[>P/(PQ^Y@%L<&O1/"WPS\/^&=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ,48HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH :WWA3J:?O"G4 %%%% !1110 4444 %%%% !1110
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M#"@R\DC!54>Y/ J*RU2PU)7:PO;:Z5#AC!*L@4^^#Q0!;HI,TN: "BDS2YH
M**;N''7FG9H ***,T %%&:,T %%%)F@!:*3-&: %HI,T9H 6BC-)N&<4 +11
MFC- !129YI<T %%&:,T %%)FES0 4444 %%%% !1110 4444 %%%% !1110
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M)8C@ \9],UW%GJ%EJ-LMS8W<%U;L2%E@D#J2.N".*LT +129R,]J,X__ %4
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MF@1@,SA5P=@&/\:YKX:^(O!7AWQQXHM=.U%+?2[^2T33/-#X<A7WC<PX =\
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M?P^?PW;^((C)<7<<\X,/EP*BACL55Y)+E26/7:.F!5B]^%FLWL/@I)-6L_\
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MRKZJP((_(UX_#\*O'.GZ#=>';#Q?9+HLWF*8)+0$NK]<DJ6!/?#?2@"QX_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8OA 248+\OJ!R1R*Z[XN:!I'AW7?"UK;W5Q GV$6=W.'W2BW3;$&*C')0N.
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M^[>XLKV.(H(%?;E -QXRI;MRY^IF\-?"OQ!H'C*'Q#)XFCO)R0ERT\;,\L/
MV9)ZX48- 'K#GY#SCW]*\#^,NN^*+/7K2S=6LM,242V,UNQ)N)!U+X[C.-O3
MG->^D9%<-\2? DWC;2[1+6Y6"\M)_,A:4DH0>&!'TY'T% '+V]UXO\2_#CQ2
MGBNT:SN;>$R6C)&UN244N3G/L/;FN1\-?$KQ9H&B:/<SZ>LGANWD6VFN2A9I
M2PSE6)SQGKTKKM)^&/C"R\/Z[9S^(HII]1B2&,2R22HJALL3N[E>, =ZAN/A
M9XKN?AY'X8EU2P98+X2P ;PJPX;*$XR>2* .E\=_$&Y\(1V<]MI*7]K<PF1I
M7NEC:,DC: N,G/\ DUA2?%:[UKX;:SK%CHUQ'>6\GV5ECEW>6''$P(&>!_*J
M'BGX4>*M9N].U%+_ $V:]@LHX)A)E4W*2/D&#@8.?K5CX<> /$NC6/B#2]8$
M=K8:A;"$;) [;RI4LOH.>G>@#&\ _$SQ7]BTS2UT&?6(VE,7VYY)-SDG).2,
M8 SU]*]\B.>2/FQR1TS7A.D?#SXIZ+;P:58>((+2P1F ,<N0H)^]C;UQVS7N
M5G#+!;0QS2F618U5Y#U9@.3^- ',?$3Q/>^%- %[9Z9+>AV,<K1MCR%(^^>#
MT.*X+X:?$W4K]M&\.7&CW-Y.04FU(REEP"S;C\N,;>.M>QW\!N;.>'"'S(FC
MPW0Y&/RKQ7P9HOQ0T$1^'+9+.RL+=W_TVXC\Q6!).%YR<\#'&,F@"I)X^UCP
M#X^\0:=<O=ZYI_FAXH7D^:+=AN#@XP.,=.*]';XEZ"? C>+%:0VN3&L)P)#+
M_P \\>O?Z<UYOH^@^/H?%OBK7+GP_MN[VPFB4!E,;N=H79DGL#6?8_#WQ9J7
MPYN-)N-)DL[G3+L7EHDQ&;K>I$B\$_,,#!]\4 >B>"_B_I?BG5AI<]C)IUV_
M^JWRB19#Z;ACFO2=P]:^;? 'PX\5P>-=+O;W17L;2TF\Z62X9>1@C  )SUKZ
M/*$^G3!Q^- '-^+O&GA[PJMLFMS<SDE(A%YAPN,MCV)%9OA/XFZ%XMU"6PL$
MO!+'&TP,\> Z@X)'/Z5R'QMT3Q#J>I:8VEZ6U[9M$R.;>U,LJ.&S\Q X4@C'
MT-8'PV\#^*X[O5KT6ESI+R:=+;Q-=1F-C(WW< C@9 YH [JW^.7A2:^6W"WZ
MHTFSSGA 0<XW=<XJ[\7O$,6D>![JT26ZCNM0B:.WEMT8@8*EMS+]W*D]>O->
M#2>"O$PT^XLCX0O3/;RLYNUM9&:7C;M7'!!(SFO7O'GB'7-/^'%AID?AFZE?
M5=/-K<.NX_96V*,%0I))!;J1C'>@#K/#FN6>C?"G2-7U6]'V:#38&EGVGYOE
M51@8R23@#C))KR;7?BMK<WQ"M9=!UF;^Q9Y;<):36@0!20KJ=RY()#'<#_%P
M1BM&VL-?\9_ >XT9]&NH;S2Y(HK103$;I$(SE6QG"$\9(+*,<C%<OXKUKQ=X
MQNM(UBX\(WD,&F.$406DAWON4D$E<C.% !X&3U.: /J <5A^+?%>G>#M%;5-
M2+F+<(TCC&7E<YPJ]N@)YZ &MRN"^+G@^X\7^#FCL8C+?V<@G@C#X\SLZX/!
M)4G'3D#GKD XE?C3XKM[S3!JGA2.TM;^9%C=TE4R*64'86P&.&_45Z7JOQ$\
M)Z)JITW4-;MH;L ED"LX3DC#,H(4\="0?:O/-%^)7C>YFT?1[?P9<RRQ>5#?
M3744JEB#M9LD 1\<Y;/.>*X+QWX8U5?B+K;3Z1JLD5U/)+:O:6QE$I;&S!'!
M&3R!SVXH ^A[WQUX9T^#3+B[UJUAM]30O:3.2$D4;<G=C QO7KCOZ'%;_A97
M@PS20KXDT]GC5G;$N5PHR<,.#QZ9KP?6TNM"^">F:1JFCW=E>76JRS1O.I7:
MBJ,DAN49BP 7 R%9OKZS\/V\%>*_M.JZ1X.BT^2$>4TDUE&J/O4AA&5RI&,@
M\ X;D?-0!5\*_&G2-3O]8AUN[LK"WANR-.GPR"X@+,%+ YPP"@D\#YQP,<]1
M\0O$T'ASP;?W U!+2^FMY$L6ZEIMI*A>",_6O$K"XN?A_P"-?$.D_P#"&#6+
MVYNA+IL3V^=L4<DC+)&H0D@@J<KC!3K\N!V?Q1\=:?'X331M:T"X75M1T]9H
MO/@1HK69EPV'8YW)D\J,@XZ4 >G>%[R:]\(:-?7<N^>>P@FFD( W,T:ECQP.
M2:\OU_X_6^F:Y=V6FZ(-0M;>0Q_:?M>SS2#@E $8%<C@YYZUJ>"OB/H]WX'^
MS)IVJ3C1M+B6X"VH99BB*K*G."<GH<<'/2N*^&WBGP3)XGU&#4]#MQ/J.K>?
MI,TMHDIB$C@)$, ^7M.""..3R,#(!Z9\1OB$O@WPTES:_9CJ]P$:WM+H'.W(
MW$J"#P..HY^F*["PN)CI%K/J36T=R8$:X,+?N@Y4;MI/\.<X]L5Y5\?-3T=/
M#T&E3@'6'=9[4F(DJF[#X?'&?3//%<GXMUZ+Q5\']*MO#YN'M=$CMH]6@*D&
M/]WM0EL8<!E.2.F02!V /;;/QSX4U"^%E:>(M,FN6942-+E29&(X"\_,?IGG
MCK5J\\4^']/U :?>:WIUO>DJ/L\MRBR9;I\I.><BO"(]<^&OB*]TC3]-\&:I
M#J)NHM@M#%'O;."&;?DJ.3T'3JO-<[XON]+UGX@^*9_$5_>6DD5U);VR6EJL
MNX1DQKNRZX&$7Z[CR,<@'OWQ#7PHWAA[WQ/;07=K!E[>-IMCR.5/RQG<"6(S
M@ ]L]J@^'=YX&CTN*W\*RVEO)=QBZEL1=^;.AP,[P68Y&0#7!Z+:Z;XF_9UE
MBDM_MU_I$-R$7:S/!*&9U"^OR,G3C'!Z$5G?"_7/A[9WF@1R:;=_\)0S^2+L
M;C&9)-R?W\8*MC[O>@#WF[U?3+"2..\U"TMI)#A%FF5"W3H">>H_.K:L'4,I
M!4C((Z&OBSQ(;]_%&K?VQ)YFI"ZD2Y8GJX8@X_V?3MC&.*^BO@5=+<?#6&,2
MM(;>[FBP23LY#!1GMA@>..: /26944LY"J!DDG@5!]OM/^?N#_OX/\:J>(UT
ME_#U]'KKPII4D12Y:9]BA#QU['D8QSG&.<5\S>"?#?@G7/%>IZ=K6H26T+W(
MATE(6($^YW ^<J1T" 9(SO[F@#ZI\Z/;N+J%X.XGC\Z%EC9=RNK#U4YKYT^,
M5H_AZ30O#FG?:HM)MK%O)CWOB20/ELD'DXR?QZ"L#PIK6J6OA[Q>FG:E<HJ:
M:DB1QLQ*YF16=<\K\A;)ZC.>V: /JVD(]R/I7QSKVF:+8^$= O\ 3=2\[4KJ
M.;[?;>>K&!E(V?(.5R,]>N,BO4Y-)\)^$/B!KNA74_V+1;G0$+Q27KH9Y ^<
M!BP)8A3QGG)'0D4 >X>1%L:/8NQLY7'!R<GCWS^-<OX/\6:%XN-\FEVDD+:9
M/Y;I-"B%2<C<NTG@[2.QXKSSX(VEC?\ PYUF#5G*VK:BID;[0T.,1Q$?.K C
MD>OM5[X,W&GVWB/QGIFG7:26:W@ELT,@9FC#.I8$_,P'R#//4>O(!ZY-;07(
M GB20#D!U!Q^=.DC21&20;D8896&01Z'VKYUN?##ZY\7M6\,:-XIO[*T@C:?
M>9WG$;@(6C WKP"Y'4D8P:T/'I\0_#/PGHNDV7B>\N)+FZGGDNBNQ\!4 0$E
MCMRQ/)/)]J /;[#2=,TI733K&TLU<@N+:%8PQ'3.T#-7MP]:^<_A[XM\=/\
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MLX;7S%*?:0#EP<C:N"21UX''6J6C_$#PGKFH1:;I6L6]Q=.I,<*JRE@!DXR
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M[5]%8HQ0!ROP\\+W/@_PC!I%W>+=3([R,4!"1ECDJN>2 <G.!G).!TKJJ**
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MEX]N_",-O="ZM]X\]E C=D W <YXYYQ@X/MD [' HVC.:6B@!-H_R:4#%%%
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M>$/#^I7C75]HMG/<./FD>($M]:F/AO1_[)72?[-MCIR@_P"C>4"F3W K7HH
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M9_FQDX)#*,@]B.#VH ]HS1FO-]-^+D-QX)N/$]_X>U*W@@N%@:.W439#*")
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MC.U0"QQD9P.,U1\/_$#PQXHO?L>D:FL]UY1E,)BD1@H(!^\H]10!TU%)FC-
M"T51UC58-$T>[U2Z#FWM(FFD$:Y;:!DX'K4EA?PZCIUM?VY)@N8DFC)4@E6
M(R.W!H M9HKF/$'C;3_#WB30]%N89Y)]7D,<;QKE8SD*-WKEF XZ<DUT;S)#
M$TDKHB(I9V8X"@<DD^E $E%<?I/Q/\(ZYJPTRQUB-[IF*H)(WC60YQA68 ,3
MV //:M2[\5Z?9^+]/\,R"8W]] \\15/D55S]XYZG:V.#TYQD4 ;E%)NHW#VH
M 6BDS4$U[;6\]O!-/''+<,4A1FP9&"EB!ZX )^@H L44F:-V>F* %HI,T9H
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MGGH:]&0Y0&@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8''/4G!'4RZ9XG\6_#+4-+\06]II^M7<<D86)MT0PV4)P6P#@9P3CK[5W%%
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MNY.<9Y)Y-=?10!7U%;IM-NELF"W9A<0L<</@[3SQUQUKY3UCP=XWU*2:74]
MUZZU9I6$UR_[U"H& % '.#G!#;<8P.]?6M% '@OQ.TKQ=XAE\-:A%H%X9TL6
M-Q' ?,:"4GH2HQGH>G\JN?!GPYXGT?Q%J5YJ6GS6=E/$J2+<Y5W<<J5!Z@#@
MU[;CV%&,= * %-?.7QNU.;6_%%K80Z'?(VE&1))FBW"X#[&4C;GY?E..?XCP
M.:^C:3% 'D,DD7Q"^$VOV^A^&WT:_P!RAK181&)FC99%"L%7=E1C! P3CI@G
MRNZO8-6\.Z?X1L_ MO::Z\ZV_P!N*E)9I%.&4[E# _,N[+$ 'H!C'UEC_.:3
M'U_.@#QCXO>,(=%\(#P5??:;O5+FR@+WQ18XGVN-S=?O$QD[0,#=UK4\&_%3
M23\-VO[BROD31(8;6Y\J(2!SMVJ4(.,< G=C&<>A/J8&.E&.?_KT ?.7PO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!129I&8*I9B H&23P!0 ZBF1RI*@>-U=3T93D&G9.10 M%)DY-+0 44F>:,T
M +134D61 Z,K*>A4Y!I<T +129HSB@!:*3-&: %HI <TM !12$XHW<XXH 6B
MDS0#F@!:*** "BBB@ HHHH ***3- "T44E "T4F:,T +1110 444E "T444
M%%%% !1110 4444 %%%% !1129H 6BBB@ HHHH **** "BBB@!,4M%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,CKR: +FD?&N)M'UN;Q!IR:=J>F[?+L#+MDN2V1M57 8$$?-P< @UF?\+?\
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M.223T%>3>(_#>E:1\<?!^JQ(5EU::Z>Y$C90R)$ C 'H26'?J!CFJ7Q9FO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX!L?&1\4WX<7?V5+7S3\J@_,02W/*\UVFHW/B#Q?X[\1Z1#XMATFTL45?(9
MZ3)M!8XR#W)H ]>\/ZCHFI:2C:!<6<EC&2B"TVA$P>@ Z5,FCZ7!=&[CL+..
MXP 9E@0/@'/WL9]37S[X<N+G0OA;XQN=+U.2*>RU-"EU:$+YN %YR#P>O7O2
M:CK?C+2=/M]1?QE=S(MM8W3Q!1_RW)RA^;MM/8?AF@#Z'ET[3YG:26TMG=N6
M9HE)/U)%<Q\0/ L?CK2;2P&I/8?9IO-4I'O5OE*X*;AZ\'/'/K7F'Q2\?^(+
M'QM>Z?I>I7%C:6:1JZH%)=R-V1GH,5!>?$+Q5)\*8=1:_:&[@U9;,7J #[1'
MY98D\'G(% 'L/@SP;8>#=$6PMI?M#B1W:XDC57);&02/H!4MQ9^%=;UVYLKN
MQTJ^U2VB0SI-;)))&C9*Y)4X'H/>O-X-0\7>%?$/A@:YXJ^WQ:Q)Y#VVU=T.
M\<-TYP2.3Q7,Q^&O&?\ PM76-)TOQ6IUF*T1Y;^X8Q-/%A"%PH8Y&5_*@#WW
M4_#^D:W;PV^IZ;:7D$)W1I-$&5#C' /3BC1_#NBZ!YW]D:7:6/G[?-^SQ!-^
M,XSCKC)_.I=&M[RRT>SM=1O/ME[%$JS7&S;YK <M@=*O4 <]=>!?"=]<RW-S
MX=TN6>5BTDC6J99CU)XY)JQ)X9\/MHR:1)I-@=,C;>MJ85\M6R3D+T!R3S[F
MO'K+Q)\3_&&EZOXET;5['2]+M2X%HZQL1LC#,%+1L??YB!D]A4/C?Q3K^O?"
MG0]:CNDM[+4G^R7=LI^>299& <.%X#&+.W'?'O0!Z[IOA;P? ;C^S-(T<&6(
MQ3>1#&2T;#!4X_A(ZCO68WPB\"O?"[.@1!]P;RUFD6+CMY8;;CU&,'OUKG?A
M'\.=3\'ZC?:AJ;6X:YMDBAC@D+ +D%MV0.<@5ZP: ,G4_#6AZS%!%J>E6=XE
MN,1+/"K^6.G&>G053M_ OABUT>]TFWT:VCL+U@UQ"H.)"#D9.<\$<#/':O.M
M0U7Q5XL^,E]X7L->FTK2]/022_9\!S&%CW$'&2Q:0 9.%'.#CFZ!XK^'4_B'
M6-5UF;5= M;3;IL=Y=%I)97==BM\I.X8*D]]P]]H!U\WPV\(3Z;;:?+HD+6E
MJ\CPQ&1\(SXW'[V><#\JZ2SM8+&S@L[9-D$$:Q1)DG:JC &3ST%?/UA\9_$V
MFM::KJ]YI.HV%T6$EA;,JSVXSG<0!D< X!)SGG!KI_%/CKQKX:^(EWH6GV%M
MJHU".&72[<KS"N"K9"@$@LKD[CA0 <@9% 'I.O\ A;1/%$$4.M:?%>1PN7C#
MD@J2,'!!!Z=O8>E9FE?#?PCHFK6VJ:9HZ6UY;;O*DCFDP-RE3P6P>"1R.]>7
M>+==^(UW\,=1BUW2K>UAAO!:WES\T<LB;E(95'RE"V%+J2"&X'!-=I\+]<\:
MZM96QU[3;>/2C8H]M?;P9;EOE"EAN/5<DY YQ0 NI?!?P;J>KW=[=?;/M5]/
M)<2!;G&YF8L<#'3)-:.H_"OPCJ6AZ?I-S9R>781F*WE68K*JDY(+?Q G)P00
M,G&*XWQ2VNVGQ^\,W=\L1TZ28P:;C;]PQ*LN<<YW2=_;'>NO^)>OZ]X<\-S7
M^CVL#Q*"+JXD;YH%. &5?XN30 SP_P#"7PMX:URUU?3_ +8+JVW&/S)]R_,I
M0\8]&-=SYT0G$'F)YQ7>(]PW;<XSCTSWKR+X<#XAZAK$%YX@O;N/25A$@6;R
M_P#22PX"@#.,<U%92ZQ=?M'1R:OI_P!G\JRGBLVA;Y9+<,^R1OF.<[B"/7'
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M8]%!YP!@?A^%=3110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$\,Z[:6]MJ&DV[I;QB* QIL:)!T52OW1["K&A>$]"\.*W]CZ;!:%P%9T3YF
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $%+249H 6BBB@ HHHH
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MM?#%RWA^VMY9C#+YSRR;3%&$.64=V'85S'PNUWQ+?^&=+M)M&>;33OB75C=
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M!>)LN8XH%59EP1AACD8)X/J?6JD'@+PC;3Q3P>&M+CEB<.CK:H"K Y!''J*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$HHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIPIR3A1GKZF@*<],>X- 'CNI0C0/@=_8[Z?J[O<VTD<8DM&)1L[MS@?ZM>>
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M&^,]/\:Z,^I:?%-&B2^4Z2@9!P#V]F% '244@.1VIOF+S\R\=>>E #Z*C,R
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M6T5RIC@P0<D9_B523[GVKZ4(!Z\UF:UX?TOQ#:BUU:QCNX%;<$DY .,9_4T
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ML<5U%"]P;D2"<EA+M(!/J!Z5=\&_#32?!\RW<$UU<7QB,<LLDGR-GDD)T&:
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MA\&KZ[\(Z78_VQ;MJNGETAE="(?)8Y\KCYC@\AJ31O@KJ>DZ3J7EZ_']OO\
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MB7&G7Y9)9&+AU5QM8_-[>GIQ6CXH\#>*G\,>'-"T;['=6VCJDLC2RE&GE4\
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MGW6G76FBY_X]KB<YCE/0#..#46J_&S2-$U76=.U"PNDGTZ<01)'\QN>3ELD
M(  #R>=W&<5YKIGPZ\=7?B'24U;3+IK2SNHW+S72LBH&!.T?0&M_4M0UH?%6
MXUF[^&NHZA%'"+")#$\B##G$ROY94Y4D8[9^]0!H^)?CB3X5TR]T"S:.\O9'
M$GG@,L#1,A=/]K<&'S#H&['@=1X!^*]GXZU6ZTV/3Y+*XAA\] T@D$B@@-R
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M  YX6O8[36-2%O,Z&38(7D(7U(0$BFV?Q#\-W^BWVKVVHM+86)VW$HMI5VG
M/1E!/X5Y?XIDM]!^(FLZWXG\+SZEI-W;PB&0H"(3CH<YP<\&IH99[SX:^);O
MPIX8N=/&H7"[H)R&5D*X=HE '  'XF@#TSP_\0?#7BF_>RT;4Q<W"1^88_*=
M3MXYRP [BN6UWXR:;HOC1=)!ANM.C0B[NH=S-#*#@K@#!_"O)/A]<7>D>-=$
MNX;>[,$DXM9"\#*/FX(..N-H/XUV/Q.T.QT7Q_I6MW>E23:#<X-^EM%GS'4G
ME@.I.1GZ4 >M:'XQT;Q#HDVL6-TPL(-PDEFC,80*,LQSV J+0/B#X6\3WGV/
M2-7CGN2&80M$\;D#&2 Z@GK_ #]#7FWBF_N/%'P<U!-&\.WNDVUE<1[K9AMW
MP+\S/M&,@<$CGIGM7F'A'5I8_'WAVYT_2H(IH[J./RK0R9F#':V3(YY*D]P/
M6@#Z]JKJ&J6&E6C7>HWMO9VRD*9;B01J">@R>*LCIUS[UX7\<8Y8?%.@7^L1
MW-QX50+'+#!,$/G;F+CV8IMP>,A6 *]: /8M'\1Z/K\,TNDZE;WB0N4D,39V
MD$CGV.#@]".02.:\Q\4_'FST77+BQTK2X]4MH  UV+S8C/C)"85L@=,YZ@\8
M )Q?AO/I^K_%FZU3PEI]QI_A]+#;>PRA0N\@@#"EAR0"!G/#'V/.^']2^'"_
M$'7+K58(#X?E4#3U:UD,:Y*Y.P#*]#R1W/K0!](Z7>2W^EVEW-;/:R3PK(T#
ML&,9(SM)'!Q5VJFG0V=OIMK%IZQK9)$JP",Y01X^7;[8QBK= !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% "444N* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ JM?V%KJ=G)9WMO%<6TJ[9(I5#*X]"#5FLGQ+H4/B70KC2;BYN[
M:*?;NEM) D@ 8' )!&#C!&.AH \M^'_@WPO/X_\ %ZI817$.E7T(LM[%A WS
M%@/7#KCG/W:R-3C\7:Y\7M=\+Z-XLN[**-S=IF=PBY2,E1M.>-^,=.#P":Z;
M0?@=8Z!KUAJ]MKVH&:SF615$:KO ZJ2.=I&01Z$UMZ7\,8-+\?W'BY-8O9+B
M:::1[?"JC"3/R$CDJ,C ]5'I0!Y=I_Q%\1VGP[N;3^TWGU635Q80WDS[GAC9
M=V23R1D/@GW[ 8Z&\T3QKH6I:++=_$2*:*XN(ALGN#%YIW#*@ '>"/7UKH[3
MX,Z+;Z+K&E7%S<W<&HSK.K.J!H&7=@J1_O$5'HGP8TG3KF"ZU+4-0U.2U='M
MQ/*0D6WD84$]Q0!R\NJ^-_''C'6!X;UA=-MM*N!;_9'E*+M5B"YX.<D'([<"
MJZ^/?$^H_#O6+B+5/L^J^'9E$MU#$DB7J,2AR&!P1DGMTKL/$WP=TO7-4N]2
ML]1O=-N;J3S+CR"2CD]>![Y/XU->_"337\(1^'-.U"^L;7S3/,R-N^T'C(<'
MJ../2@# T2S^*FNZ?INLCQ):V\3!9$MW@"AT[;P ,Y'X\52TRX^)>N^*-<T:
MS\5V\9TN39)(UK$%.[@!5*$X&/6NV\#?#X^"[FZ$>M7=W;S*%-LP"QKVW 9/
M../PKQFS\->*?%/C&]DDL=6LY;RZ+M=F!XX@H8_,[<9PN  /0>] '3-\2_%V
MH6,/AG]W:ZO)J3:;+K*J!%N!P=HQ@-Q_ABM/2=7\7>%/'%KX5\1ZR=2_MB$B
MVF!W&W?G!R0*ZJZ^%NCS>!;;PV7E4V\@N$O!@2M-U+GZYQ53P;\)[3PM?3ZG
M-JDUYJ4D30QS[=HB#<?*"3S0!R.EQ?%+4]0\0Z!;^)XG>PDC26ZE&UMQ&0(R
M!\O'7/6M#QIK/C/POX'TK29]9\_Q'>W;(C6<#--+"N#\I ZY* \9(;CO5J#X
M1>)[?5WO8_'5ZIEG665AN#.5X!8;MI.WU%=/XW\!W'B>XTW4M/U>;2M9T\E8
M+I 2"C## @$$'W![D$'/ !R?P[\>>+O&$VO:5<O9PZC;VX>VEDMRHADW%2'0
M<G^F.]<3X1TCQ[J'B[Q1;:#X@M[74X;EAJ,\KE5G<22+N $;?Q;NPX/X5Z-X
M3^$5_P"&O%<>OMXLFGF)<W4:6@0W&X[F5F+MP6P3QGCL>1'KWP4.I^(;_5],
M\2W.EF]E::6)(-PW'D\JZ]\GG/6@#IOB5HNLZYX'N;32M12VF"%KA'0;;F+:
M=Z$X.W/4$#MCC.1%9Z^_A_X-6&MM:[Y+;1H)%A+=3Y:A<GTY!-1:SX#UJ[\&
M6'A[2O%5Q9+;Q-%<3/"':[4XX9@P9>_0\YP:B\*_#O4-*\,:CX=U[7#JFE7,
M/DP0)%L^S@[MQ4G)SDJ1V&.E '&CQA\2?^$<7X@&XT9M$*J&TQ P;:)?+)Y4
MD,3GG>>.W&*T[[QIXIU+QAHVG:%/8VMGKFE1WEH;J#S'MB5R<XX)_,5!)\%-
M<>T_L<^,Y_\ A'EF++9&,L0FXL/X@N[OTQGG%;J_#?58?B!8>((M906&G)'!
M:VK1;F6!4"E-WJ?6@ ^'WC+6M3\4:WX8\1?9I-0TYMR36\>Q74'&<?E7I8''
MO7F?@#X=:MX8\4ZMK.J:E'=O<AHT969FD4MNR^1P1TP,UZ4N$7)XR<T >+?'
M#^W;F^T?1Q=VR:1J=U'%'&%8.)@0-SGNO[P''^R.,UU/P]\#:GX'\,ZO9)?V
MDVI74K202#<84;RPJ[EX/WASCDC'I6;\1_AQXF\8^(;:^T[6[:"TMT4P0S,Z
M&&0')=2H/)XYZ\#TK<M=%\8VWP\_LD:[ _B)<HM^^YQMW<9+#);;@9(_$T <
MA\"I#;GQ/I<P3SK6]&Z<+@R$Y4CZ97('O6=\7_!6FZ=?V/B.Q29+F]U2..[7
M=E2>H('8Y%:W@[X=^._#6NFY?7; V5S<BXOD&]FG//J!@_C_ (5#\1?"/Q%\
M1ZF\%I+!<Z)]I6:VA66-'A(  )W#G!R>": .N^(_CC_A!]!BG@MQ<7MR6C@1
MC\JD MN8=2..@ZUP_A?XN:Q-XOM=,U:33[RSNQM1M/C*M&Q7<.#SCUK7NO G
MB_QCX)CM/$M[!;ZQ!=F:V;<&5$QMVOLX/&3GGK63X7^%GC"RU#2IKJYTO3H=
M.G#*;6,>=*@SD.R@ DCCDGK0!G^*O$7B#XA>%M7N[32[>'P_92_>DE_?NR'E
MD(XX'4>AKT+X//<R_#+26N>2#*(F)^]'YC;2:X;4?A;XTL[R]T30]3C;P[JL
MDD]P97$:QDXR&4#)]MO!QS7=_"[1/$OA_P -_P!G:[Y"PPR$6<2.&:-,GAB"
M0?4<T =XXW+CC\:\(^&FO>(M%7Q!I6F:%)J]K9WLA#M="/RQN(V\YS]W.*]T
MN/,-M((-OF[3LW' W=LUX'IGA/XI^$9+FXTV*S:35I6%PL15Q$Y)(D/ Q@9Y
M&>O3F@#7NOC-JOD:5JZZ!'!I,]Z]G.))P9/,&!MZ +U)Y]*ZW3?&-_JOQ.U'
MP[:V=K+I.G1JUQ=@DN)"H('IP<C\*X+Q;I^C^$?A9)X7U+44N_$4LJWRA<L_
MG,W,AX^Z #U_K75_!3P]'8>#3K#2&2XU5O-+,<L(U.U%)]<#/XT >G* %&*\
ME^+FN>(M,O=$ATZT=+)KZ%A<0W6UII><0D=E([UZT#QSQ7$_$WPY?^(?"P&E
MKNO[&X2^MT.!O=,X3D]\F@""[;Q%XH\*ZW:ZQILGA^41$V\UO=^8Y(&[J.G(
MKE?#WQ,\0:;X4T&[UOP]-_9LYCMGU1Y]S,3P'*8S@]C4?VKXQ7>G:C=S:9;^
M7)$88K5BGF;6/+J >H'&#5'Q+HWC!_A3X2TBTT.X9[9E:ZA3!E1X_N9&?NG)
M_(4 =5XE^+ T;Q<?#FFZ.=1N8P!,?/$0!QG:N1VK7^'_ (_A\;VU\9+3[#>V
M4VR2U,F\A>,-^>1^%>:^(? ?B:X\3Q^(E\,QZK#J*":YL)YE7R)2H4AAN&[I
MD8]374?!SPGK_APZK+J^DQ6$=P1Y($BM(O).T8)P@[ ]R: /6ATKQ_X@^,/$
M-MXVM?#MC?PZ#9R*KKJ5U%E9'STR1C KV!0 , 5XYXPM_&=]XHU&%O"=KKVA
M[D^R1W9C4(<<LIW!ASGK0!9T?QYJ'ACP#_:/B>4ZK>2ZB]M9FVD0FY7C!4CC
M'6M?0?B<FI^*X?#^I:%J&D7LR%XA='AP!GIU'&3GVKSZ[^&/BB;X:6J162QZ
MC;ZE-=C3XY5)6.3:NU6SC@+GKW]:J>%/ GC.#QI8W-]HUY':A7C:>:Z4F,-&
MR[MVXGC/04 =C>?&ZU=[L:/X?U+4H8"56X3(C8 \L6 .T?TQ3[CXRRQ^'-/U
MV/PU>2Z?<LZ33*XVPLK 8SC!!!&"<9.1VK#\/R>/OAUHEUHL7A!M4LHY9-DZ
M,&WY/!VCDC'M3?$D7B^\^&5MH4OA-DGOYEED^Q0A4MP9"0A0'.[Y22<8^89Y
MH ZKP[\7[/Q#XIMM(M])NTM[D.\=U(PQA1DM@?PCIGU%4)/C]H*73)'I>H36
MZ,4^T+M(.#C(&>G>NB\ SW6I^!8(KK0Y=,N8+7R$\Y F\;<;E[J">N<<\]*^
M?YO WB_3;P:2VB7[S'A3#&'C8#N''&/J10![)XY^*J>'[O0GTV,RV%SBYFG*
MX2:#^XC'^+/7TQ6]X;^(UOXB\+ZMK]MI-XMOIP<B,X9I]J;B(\<'IBN3\1Z)
MJ^E_#KP?/9Z$[SZ/=1W%Q9&3S64!2".,Y&<<#-6/^$J\6>(/!6O_ &/PI=Z)
MY5F[V\L1*2,^X;@B$ YVY.0,^G.* -+P[\:='U[Q%;:+)IE_83W#>7&UP%QO
MQPI .1GI]<5-KGQBTGPYXBN-)U;1M8MC$K%9FA3;,!G!0;N5;!PWKUQSCP--
M/U!-0TN[B\,ZRL\$J2W4DB22?:'#ABP!0;<X/&6Z]:[OQMXBBU?XN6-S/X8U
M&]T[2 T$]L]IYAN 'D&\*>"F2",]<=J .RB^/?AI]-^V-INL96012)' C!&8
M,5RV\+R%; SG@\<5KZ[\7?#^@)I336FJ7!U.TCO+=;:!2?+?[H.YA\Q]!G'?
MJ,Z$&FZ'XI^'SVYT=M*T_4("#;2VZV[PX.%;:!@$$!@>>QKR3X0:;=^+?$=C
M?:GY=Q8>&K006^6+ RF1FC."?X020>,!(^.,T ?0T4AEB5RC)N4':PP1GL?>
MLGQ-XGTOPEI+:EJ\QB@W>6@5"S2.02$4#N<'K@>I YK9KRSXS:8\J^&];;3Y
M+ZRTK4!+>Q(F_P#<$H7RG0CY,'/3/H30!M^%?BOX9\7736EF]S;7>UG2"[B"
MM(JC)*E2RGC/&<\'C%<1XG^/J6^IK'X7M[74+$1 O<7"2)F0DY !P< 8Y(ZY
M].<I=7L/&GQ1\.2^$?#TVE&TN3->7OV54,B9RV]4! &T$!F.29,<=32UKQ7X
M4C^-.KZMKVG27^F+"+<02VH+).BH,E)".FQQ^- 'OGAC4Y];\+:7JMS D$M[
M:QW!CC;<J[U##!/L16ID#J0*K:9);2Z7:26:".U>%&A14VA4*C: O;C'':GS
MS&W@EDVERJL^ .3CM0!YS-\7[4V.JZC8:%?WVF:9*(IKJ-T"Y]0N<X]Z35?B
M[I&GZEH-M!&)(K]$FN'ERAM8&QM8^IYSCTKRO4]<T<Z7J-[H]YJFB:[=38N=
M!VLT$C,<,=FWH03P:VO&+/)HWP\U;7])$85@FHM);\>4NP*&';(W$ ^E 'LU
MAXN\/ZA;7EQ;:O:2V]@!]JF24B.(')'S>_\ 2DL/&WAG5;J*WL]:L)IY?]5'
MYHW-] ?7M7FDWC'P:WA'Q+'X/\/#=';B:7=9[(90&"@\=<;LUY=IT%AHWBCP
MW=)K5I<M+=13W M6.8,D<'CKZ@9QB@#Z!UWXL:!X?\8V^@7)WJZC[1>1RH4M
M7+;0KC/&,$M_=!7@Y..NL-:TO4[!K^QU&TN+-20T\4RL@QURPX&*\2^+6AZ+
MIWQ*T35=4MRFBWRE;[[,"K.Z$EF.WYB2'3..<+QDU9US7/"<_P ']:T[P;;7
M?V.!XD=1;RC#NVXEG(RW"\Y/ P.F!0!ZQI/BG0-=G>#3-7M+N:,G=''-EN.X
M&>1[UN<=*^+-)NYK36=-N+"3[/=13QJLT8;IN'4 9(_"OLV'+!&)YVY)QC)(
M'/M0 EY>6VGVDMW=W$4%O"NZ265PJH/4D]*JZ7KNE:Y!)-I6HVM]%&VUWMY0
MX5L9P2.^*\E^,LEG<>-O"VGZ_+=6_AUA))/+$QP7Z= #ROR\X) <]*SO",.@
MZ-\7]/LO!FJW-]I-U9RG4?WC,D>$8@[@%[A.3G!?@\B@#N==^+VA:)XDGT1K
M#4;R>T;-Q+:Q*\<2A-SM][)V@_-QQAN>*[73;R'6]$L[[[.ZPWD$<XAG3YE#
M , P]1FOFJR\.^ ;KX@ZQ97OB62#0X C6=R)U/VAR%+9D*D8#%ATR>N>#GZC
M'2@"M>7,.F:;<7;H1!;0M*RH!G:H)( X'05Y[8_%_P #:GJUI:(DD<EU)M\^
MXME1$)&068GN<#/J>>.:ZOQV/^+>^)3_ -0JZ_\ 135\\.GA=_@:K/+IJ^(X
M[PE$79]I=#+@A@/FV["3SQP/6@#ZD;9*NU@K G!4X//I5+5=032=+GO#!-.E
MO&7,%O'O=A[**^5_&^K:E>WMA8ZCJ4\J6.G6H"W#8P[0 L2 P)8YP2>?:O4/
M@/J=W)H^NV=Q=2&SLI8S )7R(0RMN&X]OE'MS0!V?@SX@:+XTNKBUL()X);=
M1*4G15)!."0!Z$8KLBJ2+AU5@#T(S7AWPSOM.N/C1XKN+.>'[+<*YMBAPKKY
M@SM'US7(_%+Q&+_XAW9TO6+]XX"L#[)3&D,B<,J $ @'.2>ISC(Q0!]0C';'
M'I2YKYQUZ]U76O@OH&MSZI=H]A>-:SFWE(,L;':&.#RXV@#/'S'UK/D\9:UX
M^\5Z)8V5Q?:5(DSP*UG>R K;<,69B<M(%60LQ^]A>!S0!]/<4V2..5-LB*ZG
MJ& (KY)N/'7C%(C>V?B'7C8-.Z03W' ;'*@D94OM()7)QGN*]-^)FJ:W;>$-
M'\7V/BFYT\7-I;QFP@X661E+LX;/4 ^G\(H ]HCCCA79$B1KUPH %<W)\/?"
M4NN?VS)H=FU]G.XJ=A/J8\["WOMSWKC- T?QSX9MY_$GB+Q1]MLK339KB:P,
MC28D"%MI/3C .X'KD#(YKQ^7XB^.KQI+MM?U$!<%S" D:<\<*,#G Y]>] 'U
MT.@I:Y[P1KDWB3P7I6K7**L]Q!F4*, NI*L0.P)4G'O5CQ9J\N@^$=6U:"-)
M)K2U>5%<_*6 XS[9H V,CU%+D>M?/EQK?Q+T;PW;>/;K78)M,N9(II+#8.(F
M.% 0@8!&!A6SSDG@FCQ1=^/;OXMWOAC1O$MSND/F0+O$$<493S-IVCG:#C."
M3@?@ ?0>1ZTE><?"+QGJ/BO1+RWU8*][ITJPM,O_ "U4@X)_VLJV3T->C' '
M- "U'%<03EA#-'(5.&V.#CZXKY3\3ZE+X2^(OBD>'+MHX)WDM))8RPVF0!G4
M'/#*X< ]MIQ[;/PXU74_"/A?Q'?6CZ78S)>V\#G6%E5&*I,6C4)R9 =OR_7-
M 'TQ1D#O7C'P_P#BWX@\5>)_[%U&QT^!I[:1[=XH9%VR*,C=N<Y7 ;ISTJH_
MQ8\0Q>&O%7]K76C:;KVG2Q06MHL;!R=^V1E5R=_'(QP,9/!% 'N6<T5R_P /
MI_$=SX0M9O%*!-2?)VE K^7_  EU'1SU(XQGD Y ZB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 2EI** %HHHH **** "BBB@
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M>A:9K]LX+/\ :T96\H#.5Z-D$=.*T_AEXJA\5^#;>YCM$M9+=C;R0PJ%C4@
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M6)!^]L;)Z !1@Y)H T-0^"R7=IX>MX?$>H1_V2&!ED =SEMX,?\ <(8 #J,
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M,#TH \L^"WA+7/"^GZM_;FGK:274L;QY='=@ P.2I/<YP?4^IKU0=*3 %+0
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MFN_$,<VH&_NA('8W&0 XP<#'_P"K%5K'X4Z#8Z%J>CP76HK:W\J2.1<$.A4
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MVIP6.M:S917\GFO;+(C6X8,67*; 2%/0;LX YKU&DH \VU_X4RZWX>T?3_\
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M<K<R-)-'GYMA)^[@]@!G R,BN?\ #/B#XC7'Q/O+'4])D&A--(#)+:F..&)
MP1HY,X8L2F1ELY., ''J]% "T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN*U73)[AY#"L*V^9'8#)P-WL:]O\):AJ&K>%=/OM5@^S7\\>98PNW:<GMVH
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M9ED52WR[B3@@X)'3(W8YGPU<VE]\+/&L-VJVVD_;%GTU'?:?/(),8P><*L7
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M4AB=V1EN>?EZXR#QFE3P:W\7?#TM_:M%K=LDL.JQLH;-W;12;9@WW2244X'
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MR,0T<BJV&'8\$C!R.:\1^'VG_#:RT_2O$>NZZ1JD;EGL96!2.16.UMBKN(P
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M9MQ 24KU[]#C/-=AIW@SQ+IOA5-,MO&=REY&T;0W#6D;)$J CRMAZJ<CDG/
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MFR_A\L3-Y17*%AT![XXR/6N%^'VK:EX3MXM&E\!W-SJ2S&*34(DQN&[J6(Y
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MT=XY_LUO+)-$_G'>K/C=S[XJ_HGPY\+^']4AU+3=.\BZBB\I&#L0!W//<^M
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MR^C'(IX4@]_Q-.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 2BBC% "T444 %%%% !1110 4444 %%%% !1110
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M)/M]SX9DTYK<RRPZ?<*\T7 V_*'+#D@'=ZGIQ6;??&S^SO'MW87-G_Q([5C
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M7$HP[QKR1G./_K5MX %+@4 <1\/_  -)X4EU>^OIH[C5-3NY)9)H\A?+W$J
M,#!.XDCU..<"NWHQ10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% "49-%% "T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 &,TF!Z"EHH 0JI.2HSZXHP/04M
M% ";5QC _*@  8  %+10 $ ]128'I2T4 ( !T HP ,8%+10 FU<@X&1TXH"J
M.B@?A2T4 -V+_='Y4NU=NW:,=,8I:* $P,YP,TO2BB@!-J@YVC\J H'0#UI:
M* $(!Z@&D"(IR%4'IP*=10 8HP*** "DVK_='Y4M% "8'H* J@8"@=NE+10
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M0>CJ#4M% $26\$<K2I#&LCXW,J $X&!D_0 5$VG6+CYK.W/.>8EZ]<]*M44
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MV,X_NC':NRHH X6U^&6F6WCV3Q8;N>2Z>5Y?)8#8&8 '^5=ROW12T4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4444 +1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %&:0UXC\2-9
M;P]\5M$-SXDU:VTF4)=7EO'<2+%&@;;P$Y(;RSE>>^,9H ]OS1FO"_AU!J'C
M'Q1XFN8O%NMMHD+2P6VV]DW,LN\(X#?=*J-PX!! ]Q7'Z+=ZKK!GT./QAXE/
MBA[J:&T3^U)$MF6-0PWYR<MME48;@[,C!)H ^I,T9KYLU+7/$GPR\1K;7VN:
MMJ-S<:(',<]XTB6UU(",@,65@C(2..0?SW_A1;:[XQT'Q!<WGB_6X[ABMK R
MW!80M\K^9@GKP%P,?*6Y^;( /=,TF:\:^'6C^*-7UK4+K4?&VIR6VBZO+926
MP)(NC%CDDD[5)(R,$XSR.#61XJ\;Z];>/?$.GS^,I- M;4#[!$=/,RS-L4A2
M0C%0<Y+'/7@=J /?<TF:\&\1:OXMF^"F@^)GUZ\AODN&:<V\JQ^=&[L(RQ3'
M*C:-ON<C(XIZ=XJ\5Z7XB\.:4GC4:S'J\2I(D2)(UHTPPK,Q!+%"X?!/(0@@
M"@#Z&S1FOE?3?'NOV]EXALM0\7W\=R+?;9R.7??*DH)4$ E-RAAG('(R:ZC5
M/$GB^U^#_ACQ+!XDG6<7,L<^44M+EW"%B0<[0A&".<@]0* /?\T9KYLT#7OB
M3XAUH:=HWBB:ZC\TP/>K;[H$"IE79FCRH8*<9&20<]>:EGX^\>2>%[CQ#_PF
MMJH@G$"V,Z1>?,2%^94\OD /G.?X6].0#Z?S29KP'QKXA\?6FF:-XTTW69DT
MJ\M83Y$<("VTC1C=YBE<,K-N(8^H [9ZCX<>)_$GB_QGKFI/=22>%83)#:*\
M:H-^]2F, ,2$R3GIN&>: /5Z3-!^Z?I7A?Q#\7^.=!^(EUINEZS:6]G-;17%
MM'<R6T:*F-K?/-M&XNKG&<XQVZ 'NF:,UY#X8\<>-?&G@*^N]'BT[^WK*\5"
MC1E4FA\L'@,V Y)[D+QVK*^'7BCXC^*_$TD,^K6@L]-FC&HQ3V\:L5)8%5V+
MG=\C=P <=>E 'NF:3->*7_Q-\9^(=:U./P'I,%WIFF_ZR<H)&E'/S#++D':=
MJJ"Q SWP)=8^+&K7W@&#Q'X;%C!+:S"'5K:Y_>20EL*A09&4)SR>3^#4 >SY
MIH<'UKP_PM\6_$@UO2;/Q38VQL]:5?L4\"[2-S%%8@,<J6X(.".OL7V?Q4\5
M#P]XBO[O3]/^U:1.EN\0)4KRRN^,Y;!"\#MF@#V[<,9I-X]_3I7DFL_$;Q3H
MW@30/$4NEZ?(=0;;.#*W[LL,QD#W 8GTQ6U#XXU34OA>/%.F65M+J"*3/;&0
M[4VMA_R'- 'H.X>]+N'O^5>(VOQ@\4+I]OKE]X8B'A]Y CW44A! )QN Z\<G
M%:TWQ?-GXR32+S2TBL)2C1W8G)W1.FY),8[XQB@#UC<#Z_E1N&<9YKRSPG\5
M+WQ?K=S867A[$,$,DQ87.6ROW5Z?Q'%7?"'Q8M_%'B1]#GT>73[I5;!DG5PS
MJ<,O ZT >CT4@.>U+0 9HS2$XYKS/Q/\77\*:G-9ZAX6OU0NZ6<YD"K=;&4$
MC(R!@Y[]NQS0!Z;FC->6ZU\8CHFE:#J%WX7U"&'43)YXF8QFV".5(Y7YF(!8
M*=O&/7B:X^+ M_B%:>&CH-S]FN9$2*^>0H75NDBQE>8\Y^;=T4GMB@#TS-%>
M3WO[0'A.WO3!;VVI7D60!/'&BJWN [!OS KTC1-8L]?TBVU33V9[2Y7=&SJ5
M)&2.AZ=* -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@!:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#7DGC3P?XOU/XJ:3X@TNTL
M);*S6%(WEEQM4,2WF*>3RS8VYXQWKURC% 'EUIX=\;V'BKQUJ-I]D@@U*W8Z
M>5D4EIU4+"P!&%PNX'=QNQU'-><67PW^)NFV,%K9:?';_9YY;B*:.[B$J/)&
ML;$-NX^51@]0>0<XQ],8HQ0!X/9?#7Q?K/B9[OQC8V>HK!IGV>UEENSY;2HH
M\K?L(D/S%MQ[Y;VJUX-\/_$CPKI?BF2#3;%;F:19K6 F/9+-Y@WL@4@!-F[
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M]DV*4FP=P!SVSU&.1QQ79"@ 8X&:\*^*WBS1)OB!X/\ +O@QT346;4%6-\P
M2P-TQ\W"-]W/2O=3S6/J'A3P]JLADU#0].NY"YD+SVR.2Q"J3DCKA5'T4>E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%(2!U- 8$X!S0 M%)N ZD4;E]1Z4 +11D4A8 9)P* %I#6?K6K
MV>AZ3/JE_,L=K;H7<GJ?0#W->#>//BQ+XGT]-*\/PWEI#,ZB:3/[V4DG;$HZ
MC)P<^QH ^B1TI:RO#45[;^&=,BU-]]\ML@G;.<OCGGN:T7DCC5F=U55&26.
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M,S2/8HP$<@4YRW^S@5S/P_T^Q\4?$+4/$\\4%KHNF.TZ@_+'NY$0&?0*6_\
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M1>'[4O+):PH]]=%1^\D<9VI_LX.*I^)O#>O:)9:;<:V$V3Q+#;A)Q(43&0H
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MEH **** "BDS1F@!:*3-&: %HI,T9H 6BDS2YH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!**** %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *:[;=ON<4ZD8!A@]* *NF:E;:OI\-]9R>9;
MS#*/C&1G']*MU%;P0VT(A@B2*->B(, 5+0 4444 %%%% !1110 4444 %%%%
M !1124 +1110 4444 %%%% !1110 4444 %-* MG)SC'%.HH SM1T+3=7@6W
MU&TBNH%8.$F4,-P& ?KBJ6D>#/#V@7#7&E:3:VD[ @R1QC=@G)&?3CI6]10
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M HHHH **** "BBB@ HHHH **** "BBB@!**** %HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ*5RD+LJ[F"DA0>I
M]*Q_#6NGQ!I2WLMC<V$HE:*2WN%*O&R]0?4'M0!NT4FX'H11D>M "T4A91U(
MH#*<88<\CF@!:*0,",@BC(SC(H 6BDR!WHR/6@!:*** "BBB@ HHHH ****
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MIVEV>N)XBNFN[B:11;"Y)=2JX#N!U4^E 'T2/AMX374;R]&DQ>;=1-%(JG"
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M.TECY0V1[3_K&(&=V.1WJ;X/:?>1^$SIVJ:$UK%#*)H9YTP]P6Y#D'D,.@H
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M0!Y[:?"'PW9C4U6&61;^U6V8,1\@ Y8<_>)YK*_X45HATF*U^WW:W0EW37@
MW3(?^69&< 5ZOBC% %/3-.M])TVWT^SB\NVMT$<:9S@"N<\=?#W3/'5K$+MY
M+:\MU86]U%@E<]F4_>7(!QD=\$9KL** /+=%^!OAZPT.]L=3=M3NKM=OVPQB
M-H .08AEMISU.3GH>.*Y&R_9ZOUUNW6_U:TGT@-F<Q!DF=1G@*00,\ G=QD^
M@KW_ !1B@ 7I67KNAVWB#1+W2;Q3]GND*.5/(SSGZ@@5JT4 >(VW[/5NH;[1
MX@D+"0F-H;95(7WYZ_2JS_L_WWE.!XAC;]]D(;?"LGO@_>QW]:]VQ1B@#Q[Q
M!\"+&]M[5=&OWM)XP%GDN5\[S\?QGG[W],UU7@#X<P>!1?M'J$M[)>B,,7C"
M! N[H!_O?I7;XI: *]Q"T\4D>XJ'0ID=1D8R*\,@^ >M021PKXFC2U<XE*1-
MNQ_WT 2>E>]48H \E\0_!#3;O3+--"E%C?6L?EF1\E+@=?G Y!SW%1:;\#X!
MH5]!J^HM/JMYL(NX1\L!7I@'DYZ&O7\48H \0T'X'ZMI?B#3M0N-=MVCMKA9
MI!;QE7D"\XR?7H?K523X+>,SJLMTGBQ0;B1A)<B:59=@Y0D \\\;=V%XP3V]
MZQ1B@#R_QY\,=7\2#1[W2M<\G5=.M1;--.SIYPXR^],LK'YL]<[L<=Z'@;X2
MZSX.\<+JAUFVN+%8&CDQ$1)/O!RI!)VX8(V[.3CMDUZ_BC% "CI1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0!+1110 4444 %%%% "9'K2TS:!S3@<T +1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 TM@@4ZD(!.:6@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 2BBB@!:*** "BBB@ HHHH **** "BBB@ HHHH
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M$=S-&Z[3L8$C [=?UKV7/RY'I7BGB<:KX-^,">+'CD30;XPVEQ*&^3!&#O\
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M2$ C!H 6BH'O+>.XCMGGB6:4$QQEP&<#K@=3^%2KC&0<@]Q0 ZBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BF2' W<X'7 SFH[2X%U;),(Y(PW\,B%6'U
M!H GHHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@!:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KM:Q,[,8(
MRS=6P,_RK@OB1\-Y_&[Z?/:WD-M/:*Z%9E+1R!NG3H1ZX[UZ+28H Y/X>^%+
MCP;X6&E7-Q'<2FXDF+QC ^8^];5YH6EWUP)[O3+.XEZ;Y858X^I'%:5(YQ^1
MH ^9/B)X*U/1M;O-6NHK1+&\OG%NGF#[IY  XQWXKD-/T>\U9;\V")_HT/VA
M@9=H5.AQDC\A7LWBCQGIUUXE\3>&?$T5N;"V@#V#%<NLNS]#R*\;LK2]N/#]
MSJ%C;-%!I\ 2]F63 D#-PON<,,CM0 WPW;ZI=ZY;GP_:&XN[?_2(DC&0F.[;
MN@],UZAI<OQ.LKJ6Z;PI;W-Q<2 W-P]O%&\J%<%=^ZO.O#]]=^&#9ZSI6I!=
M3$YMA9JIP4]6.,,*@O=>UN\O+BZDU&Y6:1G>0+.P&2<, F>,4 ;!^&/C>9I%
M3P[.F^0G:9$"X)SC.[@5EW5A<WZW"6NBPVJ:5$?MOD;F52.I8^O%;_B'QCK2
M>"_"FG6^JWC+)9RSW,R.5D?]\RKEN3QMKEEU74(-)O\ 2T=C!?.MQ<IRS2D'
MJ3UQZT 7]!\+ZS<7VG7R>'+C4=/D<2)$JD),N1W],]>P[UT?B+Q3J_CZ2TTO
M1_#Z6\&ER_:%M[<;F+*<=1QP17-Z=>ZWH6GVWB2SUA8I(+K[-%:B4Y.03CR\
MX"'')S^M;6J:5+K_ (_U:7PK+;62I8I=3_9W\M%/EJTBJ0>3N)H FDT'Q7KO
MBJXUW7O"%WJ).UIH,&,.%C&T8ZFLY-,U/Q;J4VOZ?X926S%RBRVMHQ\J38N#
M&!PW/7.,5Z9\/;[4O&GPEU+2I]5>"]MW-M#>%L-&N R%F!R1VSUI/A K:A\+
M-8TVUNDM[UI+B/S4; B+*0KY';/- &!XCD\5^)9=&LT\"75K;:+,TWV52=DO
M"[ ,@=!]>M5-=TK5M=U6^U:_^&=WYL\(7$%P0%(& V%X)K.\WQMI7A9]:CUS
M=9:%?/"G[XR"23*@G<?OJ>>.V:N?%#QEKFH:CIMK'>2VD9TV&YEMX9"F9)%S
MRP]J ,!]&\91Z7-I*:/K,>FF8S&V\MR"2,9.!GWQ76>$O$FO^"M!^RV_@:9H
MQ&9;B\N-\;2 'J3C@#L#S[5O_!+Q?K&KS7F@:E<M=1VL"RPSO_K%&[&TG/->
MN7MO%>VEQ;3H7AF0QR#=QM/!H \3G^+VN^)]!U*WTSPX1(MN4N)XIBWD!EQN
M''KZU#\/?B/+H/A:UTJ#PI>WD%JYCDN+!C)O?.2Q&/TKA=1FD\'>(=>T[1;V
M3[*2;1F5N6C)QC ZD5[9\)DTOP_\+;+4)9Q;Q7.;BXFE<!0Y;;U].G% '-^&
M/'<'@[0YK5/"'B)5::6>2>2'[S,W!)_2JW@SQ=/X?T[53?\ A+6[G4-1N7N;
MB2.$[64@[!D^V:]QBEAO;=)(V2>"0;E8$,K#UI\@*+GD@<G'7B@#QK3_ (N>
M'_#.FIH]OX:U>TAM%95@=TW)GY^[9_B_"N UG6-7\1^.)_%.E6&I2R0SPRV9
M6(MY*(,E&*Y'.3773^"=/\:_&#QC:7%Y/:K"() 4P2Q*KNZ]N,?C5'2]<U[P
MAX.UW2]/U&-[BWUZ/3H)0JN$1P<E0<<G Y- '0ZS\8-!OM)?2=<\-ZPOVF()
M-$\2+C(^\H9@>O0UYCIGB:Z\-7=X/"=[?PV5PNP)<(KRKZL!D@'^5=MHVO\
MBKPWX[L])\8P"^AU-DC5;G8Y')VR(X!XSU'O5O4;32=#_:&TR*SM_P#C\CS-
M&5!2.1U;!4#_ '<GZT >1.R3VUZUX]W+?R'>,<CDX8MWS@GKQ77^"_%EOHVM
M+K&OV>HZC+9VZVMA'&@VPJ?KWP#^M;/BJ/6=/^-6H1^$K=%OY[9':-(UDX*@
ML2IX!YS6WIWQ*O3\+=:U&^M8DUC3IEM%E6)2))6Z';CJ!G- '+Z]X]DN?&R^
M*?#4%_;7C0BTFM[F ,) O.< G K$\3>,?%7BZV>#4)IDM7.SR(8"J;L<;AZU
MV'P[^)&NZAXPLM*U66WNX;Q&C5FA6,I* 3Q@=#@56E\<_$4W&K6"6UL\^E3L
M]W*EHCB-<\ ].,#KUZT 4AXXFTKQ1HFIZ+I,T$%GI:Z<]O<1%0W.6VXZ\CK6
M.WC/5QXRN?$LMFKZC+;E55U9DM0PV@J,<&N]U3XJ:A?^#-!;1[2*+7=4F>,,
M8@RJ$.&*@^N1C\:H6'C/Q=!KZZ)KUK%'>36<^TR6*+)(VW,9;!QP5/3- '!:
M ^A6M_'>>)HM2E@C8RA;:$+YLF<_,V>F1TKK?$7C3PKXJ\=:;>7ZWIT&WL&B
M^SQH5=9#GH 1P..<XZ4EKX^\>^(-.@.G:-:SQ0?+++'8!Q*XZ[L\ ^PK1T#Q
MQ>0>)M0TKQG9Z5:E+=W7S+2-/*E"AD&0/FSS^5 '"GQ'J,FF?V%>ZK=)X?3<
MBQB-3\@.5) '/4=ZGL_B!XET^"&QM-?FBLX$$:+Y:'"<XR,9''O5_6[;5O$'
MP_3Q?K3Q03"Y%M9QQ0)$LT3$EL!0,\C SZ&NQ^'VN:GXKUZRMFT#3%T6V1X;
MN:.T7#$(I4,S#(//(% '*Z=>>#KBVU2X\0:Y>:EK%[;RPV\EW;L5@=D(#=^^
M ,=A65_;]UJ4=OX;U7Q.Z:/;*(E,46%*#N54;B/PKZ:;PUH.T;]&LE"C@^2N
M!^E>4Z_JL'BW6+OPGX*T&S,B[H;O4VMU"Q("-Q0@\\\<T <%?3Z3=>&UM[SQ
M1<W:Z9(XTRS2U*AMW\1<X[^M1Z1X]UC1/#JZ3IUW%:Q(S32NB[I99&.".,X!
MS]:ZGP[X TJY^+/]DV%Q)<6.C0K)>SNH(FF_N8Z ?X&O<5\+:&LOF#1[$/D'
M(A';I0!\Y>'8QX#\<6FI>*K"ZC@CA:XBVH)-\CXVG=GC@D^U>V:G\4?"6DV(
MN'U:.<R$%8K<9<@^H[5T^IZ'IVLPK#J5E;W<0.0LR;L?3TK*M?A[X4M)C-!H
M%C'*>,B//\Z /.+73K[XP>*!J]^LECX<TUPMM;$8:X<<Y(/;_P#57M@&  !@
M=AZ4R*!(8PD:(JC[JJN *D P * %HHHH **** "BBB@ HHHH **** "BBB@
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MAOXN^)+CQ#86NJ36CV<EW^^D"8VKZ#FJ4GQL\5SW1=/L4,>&7RO+;('8Y]:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !124M !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% "4444 +1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 AKR[XB7Z:]XK\/>!/,=(;Z47-XV.3&
M@9U /;E#7J$A 7<>@YKQK5?$MAHOQAU[4]1@0PZ5HJQPG/S.Y9.![G<?H :
M.2^*_A2'2?%-J;6ZEN)=:=RD+K\L&"@101R1U]N*Z_\ X4+:-%)M\0WR&7DK
MY*[20<\\\\Y-+\-]'U7Q-XID\?:X2(7#Q:?$ZG.W.-V.@&. >_6O8D4*H '
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MJ^ZXF0_PG^Z<<&O1-"T+3_#FCVVF:9"(K:$8 [GW/J36K2]J "BBB@ HHHH
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MOPJU10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% "4444 +1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !17"ZS\7/"&B7=_9W&H2/=V199((K=R6<
M<%%8C:6SQR0/>J1^./@<3B/[?=%2N[S/L<F![8QG/X8]Z /1Z*\]C^-?@61U
M7^U9E!.-S64P _\ ':V/!GCO3O&NG7U]9PW$$5G,T3^<!\P'(88/<<X['(YZ
MT =55.]OQ9O$IMYY3(X4>4F<>YK+\.^-?#WBQYDT34TNWA4-(HC=" >APP'%
M;^,T +12 !0 .@XI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!****
M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BD+!1DG%+0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 )1110 M%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 -=%D&&&13@,#%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BB@T %% HH J>1<"]:4SDP%558=@^4@\G-6Z**
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *.E%(>5-  &!Z'-+56%;L7TQD,7V8@>6%&&SWS5J@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **2EH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!,4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110 M%%
M% !1110 4444 %%%% !1110 444E "T4E% "T4E% "T4E% "T4E% "T4E% "
MT4E% "T4E*: "BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDI1T
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **0TWS(]VW>N?3- #Z*B6XB?[LB'//# U(* %H
MHI#0 $\T9H%+0 4444 &**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM(:  4M(*6@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M#7 (P5R#6;)H>G/=?:&L(&F#!@Y3G(^Z>O:M2B@#'M?#FDV(06NFV\05<+MC
MP0/3K6L  0<8XQBG44 %(:6B@!!TI:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!**** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** $HHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 2BBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!**** %HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@!:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!****
M%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** (95D9 (V ]<TNV3^^*DHQ0 M%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
>4 %%%% !1110 4444 %%%% !1110 E%+BC% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex-a_010.jpg
<TEXT>
begin 644 ex-a_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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M:=10 4444 %5[E9FA(AE\I^S;-WZ58HH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ;(I>)U5BI*D CM56TL8[-G*;F>0AI'8\LP&,U<H
MH **** "BBB@ HHHH :XR./6G#H*** "BBB@ /2HXD91AG+^Y&*DHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&SM.!DXXI:* **6*B_P#M
M<A=Y1N5"3PBG&15T4M% !1110 4444 %(:6B@!!2T44 %%%% #1U%.IHZBG4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 T=13J:.HIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 -'44ZFCJ*=0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 449HS0 449HH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BC-&: "BC-&: "BC-&: "BC-% !
M111F@ HHS1F@ HHS1F@ HHS1F@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!H[4ZFBEH 6BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ6W:7MM?VT=S9W$5Q;R#<DL+AT8>H8<&O)?B7X5TC0M/LKG2]&6XFO\ 5K"
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MX$\MH]L:C8Q!*\="1P<5/0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1124 +1129H 6BDS2T %%%% !1110 4444 -%+BD'44Z@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[YJU)K7A]/','A.Y\/NEY)*;ZVN'LX_(DEV%VE1LYWCD%L9S^= &_P")L_\
M"*:QMSG[#/C'^XU>.7MAI-AX"\/W&EVEC!=W7AJ[^VR6\2"23_0"Q\P@9/S
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <1XP\'OXG\6>
M')I!-%8V271GGMI_*E!94"H""& //(],'K57QS8:Q:)X570=$N-772KL3N#=
MJK;4C**&9SDEM^<\_=.>M>@TAH \O\1#Q+H_Q5C\1:3X7GUBWFT46.U+E(@C
M^:9#N)SC  ZC!SP:R/$4&L67Q!E\01>$=<NYI[.SD2+3[LQ1B92=ZS,@(?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=J]FQ1B@"CHU@=*T2PTXR>:;2VC@\S;MW[%"YQDXSCUJ]1BB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** &]QS3J:.HIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 -'44ZFCJ*=0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !29H->1ZK\3
M/$^H^-]1T+P7I%E?+IL4AF-PY)D*%0Q7#*.&.T#))//% 'K>X9Q@_D:/,7=M
MR,^E>+Z+\6?$FH^#]<UM]'L#-I4\0E :2-?+8-NX8D[E('&1][MCG/M?CQK$
ML\,<OANVD6486."X<.Q/"XR.>>* />-XSCG\J=FO#;;X]W,%S-%J7AE0L)PX
M@N3OCQUR"O\ 6N@\0?&S3M#;2C'I%S=1ZA8+?!A(J%%8D*,$<GY6STQ@=<G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% #1U%.IHZBG4 %%%% !1110
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MMM&H,3@*TC+G:RL<J6P0N& & .:Q](\!^.H[R_\ '&HS6TOBLV[+:6;[/E?
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M>^ : /;:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH 0"EIHI: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH'2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :.HIU-'4
M4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH HZMHVGZ[ITMAJEI'=6DHP\4@R/8CN".Q'(KAM*^"?A'2=8@U%1?7#0,
MKQP7$X:,.#D,0%!/(Z$D>U>CT8% 'C^L? >SU;Q3>ZK_ &[<0VUY=-<RVZVZ
MEP7;<X63=@<DXRIQQUQSZII6FV^D:39Z;:AA;VD*01;CD[54 9/<X%7,"B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &CJ*=2 4M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M21@Y/7Z>E5/!OPD@\+V^LVMUJLFH6NIQ+"T2H855!GD@,<MR.>,<^M>E4F*
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M6WA%63#9WG^*)A@@']#4,UIXLL_@VEO+X6:\UAX9--\XJ)+F"T<X^ZH+'CC
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M1Q(H5$4*H X  QB@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(9)'0)-C<-K8[''/6@#H**2B@!:*2EH **** "BBB@ HHHH ***2@!:*2EH
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M)+G1[>SBCCFY@F1>0Q/W>!TKGT\$^.M0_P"$H:71VL/[519?L\<B+&[!\E0
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M., #'>@#T.\^+.DR>#]0U2VAU"QNXXY$MXKVQ?\ UVPE-VW*[20.2<>I%0^
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MK-&)8PR.K#(.&'H:^=?!/P_\->*O%'B#2[W7YF6VG(L6M;E!)=)E]S?.AWX
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MKZ?HOQX34+_3TU"RMXX5EM0JMP8L#"GC<-P8 X[=.M?0J7MK(^Q+J%GQG:)
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M&ZR(KHP9&&593D$'N* %HKSOXR^))?#W@Q19WUU9ZA=7"I;O;X!PIW/EL<#
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M:L,5N07.",$EN.OH:]G'04F*6@#S_P"*'A?6-;MM(U;0&B.I:)<F[CAESB7
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MXVM6.I:?;&[18U0'@+B,[,CG>I#9(P3Z5S7QGUN[?XH:?;Z?/>V=S901QPR
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M&=JD8.&X/H:ZT5XY\98=!F\2>$DN_L?VJ348H[O<P#_9"PR'.00G)Y/J<=Z
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M+,:S-+'K<1AC9H1NMURQ&26/F'D9/RYP>F>*6I?!>XN-'T:&S\47,.I:7!)
MMVT;?O$9B508?,:C<5ZMP<=A7KE% 'EW@;X6:EX/\7RZQ)X@%[!+;F.56B(D
ME8[22Q)/&X$]<\#WKU$=*3%+0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 -Z$9IV::>2*7% "T444 %%%% !1110 4444 %%%%
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M444 %%%% #1CUIU1L@,BGGCWJ3% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $HYI:* $YHYI:* "FXIU% $,EO%,
M5,L22%?NEU!Q]*R-8\&^'/$$QFU71;.ZG( ,SQCS,#H-PYQ^-;M% '(I\+_!
M,<<D8\-6)$F,EE+$8]"3E?PQ6I%X2\/0Z0=)CT.P&G,XD:V,"E'<8^9@1RW
MY//%;5% '#77P?\  =W</-)X>C5G.2L-Q-$@^B(X4?@*BG^#_A*30)M&BMKF
M&UDN?M2,EPQ>&3;MRI;/&WC#9_/!'?44 >>^'O@UX2\/7_VU8+F_F5E>(WLB
MN(F!SE0JJ,YQUSTXQSG(\9_!E_$WBBZURUUV6V>:/(AE0OMD"D+M?=E4S@D8
M.,MCJ,>LTF* ,[P_I9T30+#2S.UQ]D@2'SG&#(5&"Q&3C/UJ_(@D1D90RL,,
MK#(([BGT4 >%2_!WQ=H.IF+PCXE:VT^Z8F9O.>W:/&<!@F=_!P#QSV'6M#Q1
MX+^(1TC0= TS48]5LK4FXN;JZDVO).LA=!(&))0#:% )Y!W=%KV3%&* /#;;
M0/BNGB&6^;2]'#"REM.)$C@=92&8A4.=VX DD#.WOUK-L?A%XD_X1*WEATZW
MTSQ-IM]N@G6Z7-Q#P0S%2P#*W0\< Y&>OT)BC% 'E?Q!L_'?B'P5;Z);^'X9
M)[F.-[Z>WO4"HZG+(JN0<$A2#D]P??HO#>HZ[9_#Q'N?#%S%J6GP+;Q6!N$+
M7&Q%4,&Z*"<\'D8/7BNRQ1B@#Q;P2GBO3?B=JVHWOA"]@MM=D#.[3*5M5!SD
ML,ANO3@U5^(NG:EXW^)6EZ-<:#JMMIEN)(%OXX=P8O\ \M<X*A%95."02 >A
M(Q[EM'H*7% '(2^';/P]\+;C06@N]1M8+"2)T@C#32[@2Q5<@9R20,^F,UYG
M\"=(ETS7KYM4T'58+^2#$-U-:M'#&F1O&6 ^9CMZ \ ].<^^'D4F* /&_BK!
MX<O?'6@6>M:9KMW//&L<"V+1K#*#+@H=PR6]<$8##D9R/9  .E&VE% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 -;[ZTZFGDBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E '/ZQXV\/Z
M!??8]5U**UG*;PL@;D9QU Y/M3M/\:^'-6ANIM/UFSN8[5#+.8Y,[$'5C[>]
M<5\6-4MTOO#=A#?6<.HIJT-PIG;/D*.COZ+NK4\&^#?L"W.MZ]/#?:MJ$/E7
M$J!?):/I@  #G]: -_3?''AO5;:&>TUFR=9G$:*9@&+'@#:><YJV_B;18GDC
MEU?3TDC;9(K7*@JWH1GK7GW@C0= _P"%A>+IA9V4K6EU;FSE"KB'?&QVIV![
M<5S?Q%T;3+?XHP7$&@#4VDTV2XN[: A3N!P9&]2!VH ]OLM3M-0A$UI<0SQ$
MX$D4@921UY%._M"WV>89H1%D*)/-7!)X'YFO O!FFZA;_"G6[FSURSTZ+5'C
M2U7S>(<MM(<_P%AQ65'HUGX>UOP]I>N:%>:/*)D/VE+CS4N")!C"#/))S[4
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MJ\\#6LD6EV=L5U&6(%(B,, I4]^GO0!V?B_XJZ9X2U2#3VMIM1E*EIC;2+F
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MWP7*?,R'OQW![USWA/X;:[IGB6TUG6]9MIVL8Y(;>.VBQE&4KECM7D<>OUH
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M@RGUY%2D[.#CGH<T .3Y5P?4G]:\"^*=K#IWQ-.K:_I5W>Z)<6BPPM YC D
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M&G Y% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ/>MGP=\1KOQ5\0]:T2*SMUTJPCD,5PA8NS+(J D],-EB!CH.IH ]'HH[44
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M$7,*,,KP.F17KL-S:7BEH9H)@O!*.& S]*CN;2RO;0V\\$,T!/\ JV *Y'%
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M&I6L.KZ)]@LIMH:Y68OY9;H<$=,]30![3134/'7/O3J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!O4BG4T=13J "BBB@ HHHH
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MD7S99+E60#C.T YQCVKZ=HH ;$NU>F/\:?0** "BBB@ HHHH **** "BBB@
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MM@@[>*^:8H[;3/!=OKUCXFNO^$K9P$L8I"Q5?-9>G.>!0!] W'@W0=1\&_\
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M** "BBD- "T4E*.E !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 @I:04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% $$\<5Q')%( 592C ]P>U<>?AAX-.F2Z:FD1BU>7S&03-_K NT'
MKUP:["=)9(G6)E1\'8S#.T]CBO!/ E]X^U34M<ATC4;)FCU R7;W2$J[EBK%
M/[JG:?EH [O5_@_X<U:"S22;4(7LK9+6WECGY 4Y#'(P2,D?2L;_ (458LLC
M_P#"0ZD]T2!',P7Y%[CU.?K6-XEU;Q;IGQGNAHBW=_MM5E:P5V>(J5VD[,X
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MA&E>(/ DPN3&TIU&[MG"/R2%^88!'2@#U&;Q]X7MKFZ@N-;MXY;1MLJL<8.
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MY1U/Q]XKU'5IKH:WJ-N!,<V]M*4$8W$;,#TQZ5[S\(-9U'7? D=YJ=TUU/\
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M*_.G6C7L&?+G$ ++ZX(Z&@#Y_P#B'-#'=^![&[N);?4K.S1+^9"?.A5@ISN
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M_#OPOX;U W^D::D%R4V!]Q;'N,]ZP/BMX\U3P;%ID6EQ6_FW9<M+."X4+CC
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M-XD\V[M-3L8HBJ17#( '= Z$*??K4%M\.O'2:7#I$WC9?[-4+$\20,6\H$'
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M4_.F7/+"O2'X0\9]O6@#D6\=Z2GC8>%)DO(]08_NW9#L?C.0?3M75*BD[S&
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M** "BBB@ HHHH **** "BBB@ HHHH **** $%+2=J* %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ S15>]O;73K.6[O;B*WMHANDF
ME<*J#U)/2B&^M;G:(+B*4L@D41N&RI (88['(Y]Z +%%)NYZ'\J-WL?RH 6B
MDS2YH ***3- "T49HH **** "DI:*  T@I:* $-%+10 "DI:* $YIH4 $!<
M]?>GT4 1;/E "X'H ,4P0(LGF+ @?&,X )'UJQ10!S=WX&\-7[2O/HEF9)F#
M/((@&)%3ZKX6T?6XX(]0TZ*9+=62($8\L$8^7\*W:* .?T'P;H7AF6672--B
MM99@%D=26+ =,DUOLNY<4M% '%ZO\,?"^LWUYJ%W8RF\NV#O*DI5@0,9';MW
MI^F?#CP[I?AZ[T6&Q>2UO0/M;32;I)<="6'I[5V)H% 'EMO\#?#<<Z227.HR
MF-MP4R[0?FR!^' _"O3XT$<2(,X50!DY-/HH Y;QGX0C\8:7!;M<-:SVTRW$
M$WEA]K@YY4]1[5CZ%\/M2TGQ9<>))_$?VR\GM6MV1[%8UY.X<AN@8 UZ#24
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M.^%@\*P7MTVIS7&MW=LT!O>,09R<ID$CG'Y5REI\-/B1;>(!J?\ PD<'VFX
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M&*R&^//AT7&$T_4I+7?M%P(N&'/('4_2J#>#=;U+XM>+KB_LGM](U337M!>
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M=J6@ HI"<56L]1LM121[&\M[I(I#%(T$H<(XZJ2#P1D<=: +5%%% !1129H
M6BDS1F@!:*** $Q1BEHH 3!SG/X4N*** &[?>FM$&7'![U)10!&8R<?,?SZ4
MNQMV<\4^B@")H%=U=@I*Y()'/(Q^%2*H10HZ"EHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** $HHHQ0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >;_ !=\5>(O"&DV&I:++:) T[07 FB+ON*Y3:.F,*^?PJO\._B#K_B?
M6M2TG6;?2XIX+5;B":P/FQ8)Q\Q61U/WE. P/!_#)^.FDZ_K']D)I^BW-]86
MS,\CVI,CEVXVF-1N  'WN?O8X[Q_"[1+_3M>UCQ##X6O-"TQ; P1Z=<32O+/
M,"'W*'4,>!C)&,G S\V "A!\5/B9-XDFT"/PYI,^J6Y/G6L,4F5 QD[_ #2H
M'(^;IR.YQ7<^)_BQI7AKQ$-!73]1U/40JEHK*,-M)&0O)R6Q@X Z$>^/-M(\
M8WND_%N\\3ZYX3UJR.L6HM+>R2V9I&<>0OR[PF_[G89!8#'>MGQ#?ZEX#^,6
MI>+M1T*XO-$N+981=01[A"NV-<[NBMN7;AB,AN#0!TFE_%VTU6UUADT+4H]0
MTM/,>P<*)7CW;2PSC!&1N!'&1C/:K9_&[19XA<7&EZM;::'V->M$'C5L<*2I
M/.:YS3-?.J>)O$WQ'DTW4;718])-O )$'^E9(7KT."O(7(!QD]CR/P\T'4?&
M.FWGA6/7(K+2TD6XNK;RP9),';N!^N,CZ4 >TGXIZ!!KS:/(EYYQ1&A:.W)$
MX9=V4'H!WI= ^*&D^()M6-O!>16^FVYN9))(Q\T8+9P!SGCH:\PU@?:_C'IV
ME^'=0ATV73;5;)+IX^4:-26^7OQQ^-5?!_BZWT+P_P".;^ZN8+O4+N98XR5
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M6DD[0JA,CL P&".@!PQ]E-=1\-/$%YXG\$VNJ:@(_M+R2(SQKM5]K$;@/?%
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MAXF^W^0DDBH0@X!C"QX#MNSSGC->[Z VJOH%D^MK"NIM$&N5A'R*YYP/ITH
MTJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** $HYHHH 6BBB@ HHHH **** "BBB@ HHHH
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M@R,!R??ZGD]3S6E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110 M%%% !1110
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M6Q@L-<E>"UN(9#(RN =K%?[NX9/L#4WAKXR:6MD;;Q1=QVVIPW+V\ACB8QN
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MTOP9:3P:;YS"XD,DKNV23Z_T_"@#IE.5!]17FOQ6L[3;X<OO)B-XFNVT:RX
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M$T=O>SV%Q/\ 9R(TR\3#.=WY5'I'Q8\/:SX@BT:W:Z$DWRQ3R1[4=O[H]_\
M&@#OJ6O+?B'\3(-,MKO3] UF*+6[:11(CVYD'7!7/0&NB^'7B'4/$W@NSU'4
ME*W;[U9MH7S,-C< . .U '845%+*EO"\TKA8T4LS,<!0!DDFLR;Q%I$.ER:F
MVJ6WV*)/,:99E8;: -BBLJS\0:9J.D0ZI;7T364WW)BP52<XQDU>60-\ROO
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M%*3@9/%9^CM+)I%B]QN$Q@C,FX<[MHSFL+XGR21_#;76A$ID^SG;Y6=W4>E
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MC;/RY8 %=N/QKF?#&I>.K#P#+XAT^^BDTNPN9IY+>Z8O)+&IPRASR1@$CWH
M]9U7P%X?U;P[#H<UBJ6ML,0&+(:'W4G)JAX8^%^A>%[_ /M&(SW=^"VRYN7W
M%,]A5#Q%\0=4BNM!T[P]I$=WJ&M6@N8C/*52(<=14GA7QSK%[XKG\,^)M&33
MM26'SX3;ON291U/KB@"76/AX=1\1WNI0ZW=V-OJ,*PWMO"/]=M]#_"#SD=^:
M@U'X:W!\,V6A:1XAN[*RMK9X)(S@BX5FW$MZ'M]*R5GUK3OC?9Z)'K=]<:;+
M UY+%<.I &&^4<=B16_XB\>"+5[CP]I>GZI=W<0'VN>QBWFU4C.X \,<=J *
M&D^ ?$FC^%[O1(?%0\EHQ'9D09: 9&1GW&1^-53\,M6C^&LOA&UU]%$D[22.
M]N2H0\^6/;/.:R_ WQ&OX[;Q/>>)[J:>RTCRD#?9PLA)+#YAD?-P*W(/C;X7
MFNK> VVIP).RHDTMN JDG&>I[F@#G_B#:7'@K5K'7].UY=/O]0A2SN4\K>LF
MQ<[@.H&1C/:K/P$MIW@\0ZE,'87,\>V8J=LA ;<0>_)_6M;Q3XX\'-JTFB^*
M='NRT!8I)<VBLC8_B0Y[^O2MCPMX_P#"NKZ/<W.GRK8V-@RI)YZ")4W@[<'I
MS@\=J .V;[IQC.*\4^('A;Q!=>+M1NT\/MXBM[RS,5CO<*MB^.N"1SGFN[7X
MI>#VCA==8C82R")=J,3N)VC(QQS77EUQGMUH ^?H]"\81_"+4/#0\.ZA)+<7
MX$(?;F.$89CC<3]Y2!]:W]426PN?AO##X=O(/(DW2!("?(W+L.<#KE@Q]A7K
MMS>6UG"TUS/'#$OWGD; 'XU0LO$&C:O<-#I^IVMW+&NYHX9%8@=,_I0!\\7'
MEZ-HVN>#[_PZUSK0NI3:Z@+?<Q!;ASD9 ..*]9^#=\]W\/[6WDAEC:T>2 EQ
MMWG.<@>G)'X5?\2?$3PWX3OX8;QFEN)D9C]EC$C(!ZG-;GA[7;#Q'H<&JZ6C
M_99\E!+'L.<G.1^% &M(BS1.DB@HRD,I&00>HKYP\4>&I_#_ (DU+PGI]G;"
M+7Y89+"53C[.BR%MI^AR?RKZ1+?)D>G%8VGZUHNLW]U#:317%U82^5*ACPT3
M_B/Y4 >-^*M!TW2O$?AWPCK%[)8^%X;1G%QN"B2YSDL20><_SJYX/T[1Y/%V
MJ^%-"U6ZOO#E[IKO?E^=DY..&VC!(R<>WM7I>I-X7\2ZA/X9U#[/>WD,?G/;
M2@[E4]\_X5<T#P[HOABQ:VT>S2UA9C(0,G)XYR><=* /"O!&C>'K<:Q=ZMXF
MN=+_ +.U$01A+KR7ECCQLW#^+C/Y5I_$'Q[<IXZM(K/6[N'1/LL<V=/EVF8-
MSNSM/;%>FZE\-/"6JZ@]_>:-')<.VZ0J2 QZ<C\:C\2_#+P_XGM+."X@:V^Q
MH(X7M\*WE@8"GV&* .1^#OBG4M8U+6=-N[V6YLK;][;/=-NFVD_WNXKV)N5Z
MD?2N2\)?#S0O!Q\[3H':[:/RY+F9\NRYSCTKJV<=!G.<<"@#R%=>\>^,]:U9
MO#5S:Z?I^GW369$\?,C+U.3WK4\+>*/$/B/P/J7E_9$\0:;,]L\C\QNR=7 '
M?'ZBG:O\,KI-5NK_ ,+>(+S16O9M]W @RDA)^9AZ'FM-/ =QIW@3_A'-#UFX
MLI]Q=KYD#-(S$EMP]\T >3_#CP!>^*=7M_$]TXBTU+IIRY;=+/*K8Q[ $9S[
MU]'1_=_/M[UPG@3P1K/@Z-;*77$O-+3<R6X@VL&;J=Q/K7=I\J@4 .HHI,T
M+11FB@ HHHS0 4449H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH 2BBB@!:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *:YPA/\SBG5'<1K-;R1.I99%*, <9!X- '+:5XQTK5_
M$VL:-"%632]AFF=UVR9[@]P.!SZU4UWQYI_AOQ)IVC7ME=%+W:@N4 \I68G
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M(RFH:@T.WR_]H$]CWKVVUGANH5GMY(Y(G&4DC8,K#L013C&JDG R>&..H]Z
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M]00Y*F'9G<?3FO>)[>&\@>"XA62)P0Z.,@CW%4-.\.Z/HS'^S-,MK0MU:&(
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M;,7D9%_'/@.3G]V5'S#IWZUWGBSQEIW@S2ENK]F9Y$(MX8QN:5P.%'Z5Q7Q
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MIJEEHL;A[+3;:#Y[N02%068] ,_K7;_$'XE)X,E@L;#2UFO# LGF3#;'$AR
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M-)+]H=]JYR#M)P>1W[9'0G/?XHQ0!@>#?"\/@[PU!HT%S-<I$S,9)>"68DG
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M* "BBB@ HHHH **** "BBB@ HHHH 3%&*6B@!,4R6%95VNJL/1AD5)10!%%
MD0PB(O<[5 S^5/4$#%.HH 3'%-,?(QC@YZ4^B@!A0Y]><\GI1L]\'J2*?10
MS9G/;)SP:JS:597!+36=O(Q_O1*?Z5=HH @-I$8?*\M/*(VE-HVD>F.E1P:;
M:6T;I;VMO"LGW@D8 ;ZBK=% &)<^$]#O+1[6XTBQ>W:4S&(PC:9#QN^N*T=/
MT^VTRTCM+.&.&WC&$CC7 %6J* ,[6]%L_$&ESZ;?QF2UG7;(H;!.#D<UQ/\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFLP12S'  R3Z4
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M0XZ5=KQ/X*VWA@ZKJ]SHMQK$DJ1HK"^1$ 5NG^K)4MQU->V4 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "4444 +1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !VK+U^QU#4=(FMM*U4Z7?,4,5V(1+
MY>&!/R$X.0"/QK4[5S7B[0-;UZW@AT?Q-/H87<)FAMUD,H.,<[E*D8/(/<T
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MY**L**2RA<C;CD8KYZT7XFZQ80ZK8Z[K-\VI[)H(',"#[,R*2KE2,[F8;<'
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M '>NIQ7"?$_QAJ'A'3-..F"V%U?70MU>Y4E(QC)8\B@#MW)8Y R..,5X3??
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M_$%OY.K:?#=1CD;UY'T/6@#Q;7]3\)7WA_QGK7A))OM<EM#!>@H88_+>3!=
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M* "BBB@ HHHH **** "BBB@ HHJ"\NX;"SFN[ABL$*&21E0L0H&2< $GCTH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% "4444 +1110 4444 %%%%
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MP'T,:@>V:]W/2N:\*>!=%\&2ZBVCI+&E\ZLT;ON$84'"J<9Q\Q/)/6NE/(H
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M9VWVBT<V4;@$G8/E*#&,C(Q]: +_ ,//$VH>+O!MIJ^I62VUS(S@>6#LD .
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M (2?24U2WUZ'3;F*[",)"$.T 9=><[L\>^:W_BCXVU^U\6_V7INJ7-E9V,:
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M,G;R IY+=\8)I=8\7?%?POH9U[6[?1K>&.80?9'C#L^X</F-R, C'WAWR.E
M'M]+7BVF>./B+I^L^&Y/$^GVD6CZO<1P*T:*KYDR%S\Y*D<-@CIQUR![30 4
MA.**KW\#7-A<0+*\1DB=!(APR$@C(]QUH L YI:^=_AU\9+/PUX6BTS6K34K
MCRI"PNXW$HVN<\[B",9Z#.:],\7?%32/!]S9P75EJ-R;JW6X1[>)=H5B0,EF
M'/!XH [RBN5\)>/M'\7Z-=:G:M+:PVC%;A;O:AB 7=N)#$;<9YSV/I7+S_'K
MPA#=RQ(FISQ(0!/%;C8_J0&8-CZB@#U*BHK>>.ZMXKB%MT4J!T;&,J1D&I:
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MDX+ L?E< X&<$9P0,^OT";RU#E#<PA@<$&09SZ5/0!\O^%)+[3O _P 0+?\
MLF^%M/9QM''*K QC>RECE1G:K@L0!PG0=O/(@]V4LX(_.DF<*D<<8:1V/ 5<
M#<<YZ#KZ9K[C(SZU MG;+/YZV\0FR3Y@C&[GKSC- %70!J2^'].&L%#J7V=/
MM10 #S-HW<#CKZ<>E:5)2T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 E%%% "T444 %%%% !1110 4444 %%%% !1110
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MLXY=BQD;R64!N=K*H;CJW..E>W?\*>\*1^';[1[>WEA6\8.]R'S,&4Y7!/&
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M2))=1-'L=9 &78S$CAQ7GVJS^*H=5OWO+[7K#3UNI0]R=Y1%+D ]1G@],]J
M/=-/^%6B6W@^\\.2S7D\%Y.)YYR^V1G#!@1QCL.WK6_X3\(Z=X,TJ33M+,Y@
M>9IV,\F]BQ"CK@<845HZ.0-%L LS7 ^SQXF88,@VCYB.>O6KN: %/2N0\;>
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MHE19 IZC(SBN8@^&/@NVN(YXO#MD)(V#H2I;!'(X)P:ZP# H 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*
M*** %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQ110 8HHHH ***
M* "DVC.>]+10!&8(RNUAN'HW/\Z(((K:)8H46.->%55  _ 5)10 4A&32T4
M-*Y[FD\M>G8=!Z4^B@!NSD')'.<>M*1D$9(]Q2T4 -* CDD_C44]G;W2;+B%
M)4SNVNH89]>:GHH HOHVG2+<J]E 1=+MG'EJ/,7T; Y'UJ";PUHUQIB:;-IM
ML]C'_J[=HP43KT';J:U:* .>U3P/X;UHVYU#28)C;H(XNJ[%'  QC@#BGR>&
MK6S\,W>CZ&D>G+)"Z1F->$9AC=[FM[ HQ0!Q'PT\!_\ "#:1<Q37*7-[=.K3
M21KM7"C"@ _4_G7;T@4 Y Q2T 9'B+0[?Q)I$^E74MQ%!/@M);R['4@@C!_"
MN%\/?"'^P-46[A\3:GY"3B86T6%5R/[_ />]^!7J&!G..:"H/49H \I\2_"&
MY\3^*Y=1OO$,[:9(^_[)L.Z,?Q*AS@ _0UTOB?PIJ5WH5EIGAG51HB6K878#
M@QA<!!@YZXYKL2BGJ ?K2;%SDC/&.: . ^'GP_N?!K:E=ZAJ2WVHWVW?,$.
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MH 6BFJP;!4@@C-.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX7U.3UR.3@"NPHQ0 F.GM31&!U)/UI]% !1110 4444 %%%% !1110 4444
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M92,@CVJ6H+:UCM88X845(HT"(BC 50  ![#%3T %%%% !1110 4444 %%%%
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M1=F#R,YS@]_6L^?X(^#96#1Q7B8&/EN,K^1JB?@)X=\UGAU#48E;^%63'\J
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MM4M-+!3SCFE!S0 M%%% !1110 4444 %%%% !1110 &@444 %)2T4 )12T4
M)12T4  I,4M% "8HQSFEHH *K7=E!>!1<00S*O\ #*@8?J#5FB@#('AK1E@\
MA=(L?*!SL\A,9_*J[^#O#\EQ!<-HE@);=MT16$#:?Y?I6_10!QM[\+_".H33
MSW&B6QFN#NE==RY/M@\&NDT_2[72;"*QL($@MX5VQQH, <=_>KU&: ./\>>
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M;[*R)EBP7)W'.0,YZ5';Z)H=_P""M<U*RO)_[6TUS.+648#6QD 5O3.#S[T
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M+MS(9[FYGN'\VY=S,9>[,>]=/J'AJXM_!T#2>)=/O;6'R[F'3()B9<.?GX/
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M%% !2;ANQWI3TK-TE-3$<AU4VYF$LFPVY8J8BV4SD#Y@.O:@#2HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BDS2T %%%% !1110 4444 %%%% !1110 4444 )2T44 %%%% !1110
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M+:OI=O>-"I6,R@_*#UQS6Y28H K65A!IUG;V=H@BMX$"1QJ. H& *M8HQ10
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M'-&24D7<I88.*GI  ,8%+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !24M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 48HHH 3 SFEIDAVJ2 3["HX)6F1)-K*'7.UA@B@">BBD!!S@]*
M%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ****  ]*3%*:2@!:*** "BBB@ HHHH PO&+$>"M?*%@PTVX(*G
M!'[INGO3?!T)M?!VA6YX*6$((QZ(,_K47CJY%KX$\03$'":?-T]=A']:U],B
M,6G6:G'R0(@Q_NC_  H NT444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !28I:* $%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% "44M% #7.%X!)ST%9^FWM
MU=7NH17%B]O%;RB.&1F!$ZX^\,'CGCG%:)&12 $$Y.: '4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "
M44IZ4E "T444 %%%% !1110!Q_Q+8K\-/$1')-JW'UP*ZJ!=B+'_ ' %SZX&
M*Y/XG.R_#[4H(XS(]TT5LH']Z214!_,BNN4_/_/]: )**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** &OG'!Q4=NTS*WG*JG/ !SQZU-C-(
M!B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2DI3TI*
M%HHHH **** "BBB@#E?' ']CZ<.S:M8 CU'VA*Z=0 >E<;X\FD"^&[>-B@EU
MZRW<9R ^\C_QVNT[T +12&@4 +1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 )2T44 %%%% !1110 4444 %-
M=@N,MBG55O;*&]$(F#'RY1(NUB,,.GX4 6J*9'G!)&,\X]^]/H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*2E/2DH 6BBB@
MHHHH **** .0\7<ZUX35AE3JPR/<0R$'\ZZ^N0\3.)_%'A&!0?,%]),5/4*L
M#Y/YL!77T !I!2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,=U0C<
M<9Z4^FL@<C/:@!W:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ [4G>EI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ /2DI3TI* %HHHH **** "BBB@#D-7CD_X6'X8EC@>1!#=*
M\H'" JIY^IKKZ8(@#G)SG.?R_P *?0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)WHZ=:
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M% !1110 'I24IZ4E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!5N[=KF-HQ)/$#_ !1, :S[303:7S7/
M]J:E-N_Y8S3AD_+%;5% &/?6.KSF/[#JRV8 ^8-9K+N/_?7%%M8ZQ#;[;C5H
M[F;85#FS"#?V; ;]*UZ6@"AI,&H062+JES#<W8SNEBC,:D9XXR:OT44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 E%+10 E%+10 4E+10 &DI:*  4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%%  >E)2GI24 +1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M'I24IZ4E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E)2GI24
M+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 !Z4E*>E)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
54444 %%%% !1110 'I24M&* /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex-a_048.jpg
<TEXT>
begin 644 ex-a_048.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^FX/F9IU
M% !1110 56N$F:*00L$D*D([+N53VRO>K-% $<2R")1(P+]R*DHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "D[TM)0 C#*D9(R.HJE96*VLC2#>\
MTFT2RN>7V@@5>I: "BBB@ HHHH **** &O\ =I1T%+10 4444 %5;9+A%;SW
M5R7)7:N,+V'UJU10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M36SM.WKCBG4E %);!?[0%Y(7:1<B/)X12!D?F*NBEHH **** "BBB@ I#TI:
M* $%+110 4'I110!41)Q>LQ=?)V@;-GS9]=W>K=%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %4;NQ2]6..<L81RT8'#8((S^(%7J* &(H X
M&!]*?110 4444 %%%% !35!RW%.HH ****  ]*K3)<,\)A=442 R!ESN7T'I
M5FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&ZC::W9
M$D:-CC#+U'-1V=K':)Y<2%(^2 3W)))_6K5% !1110 4444 %%%% #6!W+3J
M** "BBB@".<2-!((F"R%3M8C(![4VW618D$I#2!0'8# +=SBIJ* "BBB@ HH
MHH 04M-'44Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** &CJ*=31U%.H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!HZBG4T=13J "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MD) ZT +129H!!H 6BC-)D4 +11FB@ HHS2$\4 +1444\,^?)ECDVG!V,#@^A
MQ4A(% "T4F12YH **CCN(97=(YHW:,X<*P)4^_IT-29H **,T9H **,T9H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &CJ*=31U
M%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 T=13J0"EH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M110 4444 %%%% !1110 4444 (*6D!I: "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[3L"9Y'?!R>F #M/$O@G5]7U^^O=*UZ/3K;4]/6QOD>U$SE5+'*9(P2&*\]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>NB\(>"/^$6O=0OI];U'5KN]"*TMZ^XHJEB /3EV/IZ 5UM% !1110 4444
M%%%% !1110 4444 %%%% !1110 @I::.HIU !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8F!Z,N>,]1_B"* -_-&:X>3XH:0EUK=NNFZS*=&9EO'BL]RI@D9X.<$*S D
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MWKCUR,5TWAOQ3:>)EO\ [-;7EM)8W!MIXKN((ZN #C )]>M &[1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 WH0*=3>K TZ@
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M1M6%O::BVZ_TZ2#>LC<DLKY^4[CGIQN;G!P #,\2V,%K\8OAVL"I'"L5[#'
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M&@('S')QR?6N-USP3J6M^-M*UV3Q!LL=-E26'339ATW ?,2Q?[Q[-MRO;UH
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M!;4!FDD!RK,S<Y!YZ]<>@QJ7_@NPO?% \3)--;ZQ'9/:03H%*QE@0)=I'S.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% #&^^M/IH[4Z@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *,TAZ5R_BCQI#X>U'2]*M[-]0U?4Y@D%G%(%(0'YI&)^ZH&?K@^A( .IS1
MFN*UCQ/XB\-W$4NH:):7FG7.HBV6XL[EE:VB=U2-I%=?F8ECG;P" ,\TV/QE
MJNI^)?$GAG3=*LXM3TI(WAFNKIC#*'P06"IN7Y3G SSQGO0!VV:7->:>(O'?
MBCPKX/N-6U+1---Q:W9M9/*NI/+E!52DD>4R1EF4@D<H>?2:R\=ZYI^L:!IG
MB31[/_B>Y-K=Z;<,R+P#M='4$'Y@20>_ .#0!Z)FES7G'BSQ9XQT'3M<UFWT
MO2UTK395CC6Z:7SKA?E!D7&%V[FP/H?;-I=2^)$.H"TNM)T%Q+:RRQW%O+.8
MHY$VX60E<\[N  2<$]C0!WF:,UXV_P 4_%"?#&+QB=,TLA[XP&$"7Y8QE<GG
M@[P1UQR.]=#I>O>/[Z.PDDT[P^8M3LWEMY(9IB;=S$7C:92,E"VU3MZ%AST!
M /1,T9KQ_P &_%'7-0B\4WOB&WT\66@0YE%A$XD>3<P 7<Q!'[MNN.H]ZV-/
MU7XGZQ;VNK6VG^&+;3[E%G2RN9IS<>60#@N%VAB.1QQD9'!H ](HS6+X>UBY
MU+PM:ZMJMB=*GEC:6:WF?_4@$_>) QP 3D#&:Y[P-\1[?QKK>LV4%F\,5FRO
M;2EL^?$25W$=CD9'LP]* .[HS7F_C+Q;XP\-:9K6MQV&D_V787"11)<"433(
MQ1=XP=N-SX^@/XR7FJ_$VP3S9]+\-M L$LTDL,TS"+8NX*P.#EN@V@]#GW /
M1,US_BGP?IOBVVMTO&N;>YM9/-M;VTE,<]NW&2C=LX .0?S (XK1?&7CK6_!
MO_"3Q6OAJ*SDCD,,4DDWFR.KF,)@X4%F&!\W4CUKTC^T%M]&&H7^+=4M_.GW
M':(\+N;.>F.>M '->'_AUIV@ZV=:FU'5=9U(1>3#<ZM<^>\"<Y$9P,9R?UQC
M)S'8_#33].\7-XE@UC6S>2,3-')>;HYAT"OQN91Q@9P-HK(T/Q=XW\:Z8VL>
M'M,T73]/,FR :I)*[SA20YS&,*.W0\@_6IK#X@W^L^%_$8MK2VL?$F@!A=6]
MP6EA)0G<RD$$@A' YX.,Y') /1AP.:Y;Q=X"TKQG<V$^HSWT4E@6,!M9_+VL
M2IW=#S\HP17+Z=X@^)5QI6E:K+'X3FBU%89;:RC>:*>=74.RAG;:K"/<W\6-
MIX/?K?'.IZQHOA6\U7138^=9(T\HO$=E:-58D*%(^;(7&3CK0!#K?@+3O$'A
MJTT'4;W4YK6V<2>8UT6EE(SCS&(.[KG\!22^ M.G\%CPK+>ZF^GCC>;K]Z5S
MG86QRO;!&,8]*X:]^(/CW3_!FE>+9[+1)["\DB#VL,,PE"MG!W;R!NP,<'&X
M<&NQD\;KJGPVN_%/AUK:62VMGG>*XW$(T:[I(VQ@[@ 0#T.0>AH I77PCT6]
ML--L;C5-<>WTT8M$-Z/W1SD$';U' 'H  ,5;T?X8Z+H_B*#7?M>JWU] '\M[
MZ\,P4N"&/(ZD$_G5?5_'-_9:AX=\/6-I:W7B/5X5F96D98+=,99SW9<+)@9!
M^4]\ PW6K_$31=;T6/4+31=0TR]NTMKA]/BE22#<<!CN8C Y.<=L<9!H ]#Z
M4N:\XM/&OB#Q9XAUG3/"EMIUM!H\WD3W>IAY!,^2N$1"-N"C\DG(V].E3Z;X
MSUG_ (2^;P7K%G:V^KM9M<6NH0!WMICC@^6<, #NS\W)0C(R* /0,TF:\=L?
M'OCN3PIK'B*>/PX8-)N);>>W\N:-F:,J&VL7([\9'-:OC7Q_KNC_  \TCQ?H
MMM9K#=I&T]M>1M(4$B[E(977H>.G.0>,4 >FYI<UP5EXJUW2?&-MH'BEM*D^
MVVCW-O<:>KQB+R\EQ(')X(Z$'@CD<Y%72O%/BOQLMQJ?A=='L]%CF:"WDU&.
M622Y*DYD 1EV+R  <G@_2@#T?-)FO.].\7:]K-]KOA(PVFF>*M.@$D5P09;:
M<9'SA>JJ0R\$L1N[[2*XJ/XF>.;+P@GC&\FT2XL9[M[5-/$3HP()Y5@><;3W
M/')R: />LT5G:-J0U30+#5"@B6[MH[G86W! ZAL9XSC/6N,\#_$V/Q5XCU/2
MKJT6R<;;C30[$-<VQ'#8('.,/Q_"_3Y22 >AYHS7G/C+5/''AO3];\0V]]I+
MV%I(OV>PFM&?=$=@WF0.I#;BWRD8X]QB&VU;QY%X2F\33:CHT]I_8/\ :$,7
MV)U<38$NU@'Y&S<FX,.<';P<@'IF:7->0W'Q-\0:=X%T759;;3[_ %G7I-EC
M9V\3QK'U'S9=F?DKTVCG&>AK2\2WOCCP?ILGB:YUFTU2UMVC-UI4.GB) A(5
MC')N+C&<Y.[GG '% 'IF:3->1^*?B)K^DKH_B/1?L>J^'[^&646:P-'.H1"S
M%WRWW<$D@#&T@CO6WKNNZSJ</AC4?"NN6]M8:U,EN!-9B8KNCDD+YW=0(]I7
MU[T >A44=J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM*??J+QLD,K#S0VTL!D 2/R/^>9]J]B:-&&&16'N,T>6FW;M&W&,8XH ^5M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!HZBG4F*,^] "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
ME+2"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"I[G(![%FES7E>M7VLW'BK0_ &DZO>6D4EB;Z]U,N)+K;\VU0S?[0&2.<$=
M#FX?"GB#PWXFT"ZT[Q1K^IZ:]T8;ZVOY?/VHR,=Y( PH( Y'!(YH ](HH%%
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M3SR16!HOA[4]-\3ZAX*U281>$M(N?[=DG"MAH1\T<9?@;2>2,9S$V/6O:Y-
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M HHHH **** "BBB@ HHHH **** "BBB@!HZBG4T=13J "BBB@ HHHH ****
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MSY<H8Q@9R6'X&N-OOB?%J^@75YX6O;!9K6\CAF^WOL58L\N!W!Z#Z&@#?L_
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MS\/?V?/J(UFT^Q6T@BFFW_+&Y_A/H:L'Q%I?GV,"ZA;;[\%K1=XS.N,Y3UH
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MM8?GL\@E K@98G'.>*GU75O&DOQ'D\/:9J>FV]G):?;(GFM"[HOW2I^8=^:
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M#JJ*R-!\0Z=XETY=0TJ[CN+<G!V\%3Z$'H:UZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** &GA@*=36^\*=0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444$X!-
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MQ(V@RZ;LDNRH$4URJG<4QV(/)]:U7^$$TD>Q_&OB-T8Y8/.3\W;BIH?A-)$
MI\8^)#$.BI<!,'\.: )_@U/:7'PWTR.!H7FMPT=QY9!*/NR ??!!K)U?6M)L
M_CS8&[OEB,.G& L<A1(22%8CU&:U!\*L32N/%WB7#XR!=D'/N>](/A0TD02Y
M\8>)I=K;@!>$ >E %*[U6#XD>*M%M=",TNG:/<G4+B]:,B/SE!$2#/7DY^@-
M<5X<L/#USJ]OI&O)XB_X2"/4W9[:&0FW:?=N\T \+QU]C7;W7P6M[@[D\4^(
M$8G+;[DOG]:;;_!*SC;,OB;7']-L^V@#E;+4M/GL/BNYM_[0CFF-Q' -R"6/
M<R[ACL",Y]J/ NMQW/Q0LI9VO[TW^DK:*SV1B12""RJO01J!][')^M=M:?!S
M188%$^I:W--SND^W,A/X+Q4T7PETF*Z\^+6O$28&%5=0==I]0?I0!YU/X1\2
M2+KWAN"95L_#DIU73U6(;I9)"S1J<_PX$G'KBM:XU"\_X5\GBS4=.B^TZSJ,
M%S--Y'FK:0IA8Y"@^]@*6 /&6R:[>?X:QO$JQ>*/%41!SD:J[?H34 ^&$F[=
M_P )EXK#>IOR30!Y+)K^GV6F>.X[AM0NFU>WBDMKFXLRAF)7/F, ,*"W0C K
MI?%=CIMGX6\#:K)87":%$FZ_^Q$QR*S1 +(2.<YSR>?SKO8?ALJ1.LOBKQ/(
MS'ECJ+@_I4I^'<1QCQ+XF&.XU-Z ,[X4VNC0:?J#>';&]CTJ2<,EU=N2URP&
M"R@_PCIGVKT:L#P]X;B\/02PQ:AJEVLS[O\ 3KAI=G^[G[N?UK?H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;C-&T_WC0.HIU !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 1DNK@ 9!ZGTJ3FFGDBG4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 44E+0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% #1U%.IHZBG4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!Z4 %%(2!U.*3<I
M[C\Z '44W(SC(S]:S!XDT)M,?4QK6G'3T?RVNA=IY2MQ\I?. >1QGO0!JT50
M?6=*2]MK)]3LUN[I-]O 9U$DR\\HN<L.#R/2BSU>PO[R[L[2[AFN+-PES&C9
M:)CG 8=LX/Y4 7Z*** "BBC('4T %%0Q7,$[S)#-'(T+^7*$<$HV =K8Z'#
MX/8CUJ:@ HIDDL<43R2.J(@+,S' 4#J2>PK#3QQX2=PB>*=$9F. !J$1)/\
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M$N)K.]M=-UI +2^F4>6)MS+Y,FTG8W (/0Y//!KM\T &**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH :.HIU-'44Z@ HHHH **** "BBB@
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M,\63:!J&H0:@=>']HQ3VUQYPBG92SQOQPV <^A4?WN/>*\C^(OP]N[B;1Y_
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MN[>;AR05D/9=G' /+ Y."*M#PI\1/$/AN6T\2:C8*R6$UO;6\3G,LS#8))V
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MP$'PO\7Q^"X_"0\66,.DY/F"*Q/F,C.79=Q;IDGTSTZ<4 17VI6NLP?"F]M
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M'0/[4D>?0A%<PZJL*EVA=TQ%(=NW>5D!! !_=MUZUH&3Q]%XPT;0O^$S$_\
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M;HZ-(6/<L/E"=\GL#67HOA*?3?C'J6L65G+::.=/BM\&0".1PL:J(D4#"HJ
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MAGQVR<G'O7,>.?%'CG4O&FLZ9X6;4$CT40D1V,"-O+)N9I,DD]2%4 YQTSU
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MSU^G'4AVL?$G5O#_ (VLM%U?PY#::=>W?D6^HM>Y5TR!OQMX/S#()&,]<<T
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M <9YJ!O@_P"'9-'LM*EN]8DL[28S+$U\<.Q  W<=% P-N,;F]:]"HH X:_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH :.HIU-'6G4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 )BC%+10 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1FBEQ0 4444
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M0K%:D@!LD'<>?NCTK,O?C(]O#H<L'A2_N$UF)6M2LRC?(6VF,8!R0<=<=>E
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M,D;F!Y8#!/!->@^*_'MWH?C2R\.6-G8SSSV9NA]LNS )FW,JPQMM(#L4;&[
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MR<8Y^H]: /-[_P"'OCW28O$.E>&[[3)-$UR::62.<E9(1(2&4$@\E,*3STX
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M'M3;:98V]G;ER_E6\81=QZG XK!\5>-8O"E]ID%SI=]/#J$RVZ74(7RXY&;
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M7DL5T@[X8&LA-ERV78MO7[P"#&.-N1UKM]W.,&C.?6@#RZ'X5:Q#%XIC'BY
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MG"J,+VR=HZ'FO1** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYE[*2X))/.<Y)/4Y/7U.:MO\'_"ELMDL::CMLKC[3"K7TA59,@YVD[0<J.0
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M#D@[E0G&1@8SG& >H! !R6NZK-HNK_$K5-.9(-072[ N4?<8I2KIV_B"XQ]
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M **** $HHHH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M35BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 2BBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BD)QUHS0 M%)GUI: "BDS1GI
M[T +10:0'F@!:**0GF@!:*3FDW8[T .HI,T9H 6BDS1DT +12 YZ49- "T4F
M>,T9H 6BF"12S*'4LN,@'D9]:>* "BD)Q5:#4;*ZN)K>WO+>:>$XECCE5FC.
M<?, <CD8YH M44F<5#:WEM>P^=:7$-Q%DC?$X=<CJ,B@">BDR:,T +15>:]M
MK>:&&:YACEG)$2.X#2$=0H/7\*DBGBG5FAE2159D)1@0&4X(X[@@@CMB@"2B
MBD)QUQ0 M%,\Q=Q7<,CJ/2LK4O%6@:/<FVU+6;&TG""0QS3JK!20 2">!EA0
M!L44U'61%=&5E89# Y!'K2Y- "T4F31DT +129-&30 M%9NL^(-)\.V8N]8U
M"WLH&;8K3/C<WH!U)^E2S:OIUO:PW4^H6D5O, 8I7F54DR,C:2<'(YXH NT5
M7M+VVOX!/9W,-Q"20)(9 ZY'49%3Y- "T4F31DT +129-&30 M%)DT9- "T4
MF31G% "T56M;^TOA(;2Z@N!&Y1S#('VL.QQT/M5C)H 6BDS2T %%)DT9H 6D
MS5%];TQ-8CTAK^W&I2(9%M?,'F%1SG;U ^M&J:SIFB6Z7&J7]O9PR2K"KSN%
M!=NBY/?J?H">@H OT4F35*+5[&?6)]*BN8WO;>))IH5R3&K9VD]AG'3KC!Z$
M4 7J*3)HR: %HI,FC- "T4F35/5-7T_1+![[4[R"TM4^]+,X49[#W/M0!=HK
M-T;Q!I/B&T-UH^H6]["K;6:%\[3Z$=0?K6CDT +132P4$D@ <DGM533=7TW6
M;=KC2]0M+Z!7V-):S+*H; ."5)&<$<>XH NT4F361K_BC1_#%F+G5K^&W#G$
M<9.9)3D#")U;&1G'2@#8HI,FC)H 6BDR:,F@!:*3)H).#C% "T5G:)KFG^(M
M'@U;2KC[18S[O+EV,F[:Q4\, 1R".16AF@!:*PY_%NC6_BJV\,M=@ZO<1F58
M%C8X4*S99L8'"GC.>G'-/T?Q1I&O7^I6.FW@GN--E\F[01.OEOEAC) #<HW3
M/2@#9HI,FC.* %HK(\0^)-.\+Z++J^J2LEG$RJ[(A<@L<#@>YK0M+N*^LH+N
MW??!/&LL;8(RK#(.#R.#0!/129-+0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 )1110 M%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %!Z444 <9\1AXN_LBPD\(1B:YCO
MXI;B$2!#)$N6VEB1\I8*& .2#CIG,/A2R\60^./%5WK2QG2[B2,6+"?(V)D*
M$3G:-I&[./FZ9ZCN:Y[QKJ.LZ9X;GE\/:7+J&J2?NX$3;A"?XVR1P!Z9YP.F
M2 #RZ\\9^(K7XM6&L72S1>&)]0FT6!!(/+<(WEM(>,?ZSY\GG",!TY[SQI\1
M['P3>V-I=Z=J-W+> LGV6($8'! )(RV=ORCLV?0'B/$/P?W> %-K?^(;O4H8
M$DCT][M9(C<,<N=C< Y=\D-QR>><E[<>-=5A\&_VAX.U0SZ->)<WLJ21MYVS
MY05!?)8C).2.?7.0 7])^*FO:]X\T:P@\.7-GI=TLF])BOFR8'+\XPJ'L.2.
M>>!5CP1X@\/Z)X3\5>*F34[6U_M69IA>R>9*6^7"A  $)9\;3DYZMZ:7B.QU
MUOB9X6UW3=':ZMX[:6"XWS"/[/OQDMUY )X&<D8KC(_"GBW6O!/B;3ET=]+N
MCK/]L6 F*@R[B28QR0&&T8R<9(!/4T =!JGCW_A*/"OC#1Y]+U+1-3LM(DNC
M%.VURNPGJ.@^Z"#U#?6F^'/'UEX:^'OA"Q-K<7>JW]L%@M%*QEE4D%V=R%5>
M."3S],D6;_4O&/B+PIK\5SX+.G^=IDEJ(Q<))/<3R85=G0"-0SEBW/(QT-<A
M;^&/%-I'X9U=_!T6HII]A_95YI=YY;.P#LWFIG*X((P>H.1C'- 'J_@?QK:>
M.-(GOK6WFMFMYVMY892"58 '((X(((_7ZG)N[?QB?C!:7!C27PI]C>(E7 $6
MY,DLN02Y=%&<$!3V.36MX)ANET^ZN+GP_::"D\V8K"!4W( H4ER@ ))!(]L5
MTQQ0!\XSZ7X)\*_$+Q+I'B1[@Z-;Q1SZ=;/=3G]XR*Q4;#G/)4;N< 9)ZG9N
M+F>QL?!7@WPQJFJV-EK[?;99Y)AY\,,A#F-' ^4CYSD=3CD@FMCP=8:_-\2/
M$=]KWA2XBT[6L;9+CRY1%Y8(0-ST*DC@'G:.G-;?CSP->7TN@:OX9CM8M1T!
MPT%LQ\I)HEVD1 @<?=P,X&&.2.M '-^./!]I\.=$_P"$N\+3W5KJ=G.@?SYV
MG29)#L965LYR6!_^O@C)DMM-U_XX^$+Y;22"'6--BU::'SV/[[9*ZG.>QCCX
M& =O3DUUOB>Q\6_$'3+;P_=^'9=!LIIUDO;N2^AGVHAR%14))).#D@ $4>*O
M">JZ;XX\->)_#&C+?QZ9:M8R6*7*0;8@KJA4M@<"1OR7CO0 OC;PQH=]\4?!
M[7-HKS:C)<"Y0NVV=88"R;ES@@$+GU'!R*\TU?2O!'AZ#Q?%=WU\FN6>H.FE
MP6\[JT2E0T1&3@JI)#,23A1T)&?5[*T\1>)/%FE^)-:T :1!HL,YM+07233W
M+S(%))!"H !C#=SSZCG;;P/JWB/3?&.EZ[X>^P/J=[)J.GZA+/!(R/GY(W*,
MS  <<9&UG''&0#6\->#KKQ?X&T,>/!>37-J[R1PM,T3M&1M03;<,6P >H;ID
MYW \YX5^&GAS6_$_C.SNHKI;>QNA:VB1W4@\@%2=P.<E@?[V1[&O0? -WXN;
M1VM/%VD_9[NU152[^U1R_:^O)5"=I "Y)ZYSQ6+X'L?%6F>./$EQJGA_[-IV
MKW'VA)UO(G\HJ",$ [CN!'88(_&@#D'L_"WA3X],M\AM;""R2>UB2-Y%^U'
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M\Q\R3H<-D;CC)?CIBJWA:P^(7P\LIM!M/#5IK]@LS2V]Y'J"6Q 8\AE?G/?
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MP* &:I\1O%^J:)X/U;0X+&SM]6O5MI%=]YDF\QE\H[E^5,)RPYR>,8Y?XO\
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M0K]F&-L:KN^4#&3UR3G@]?60N!@4N* /)I_A-K3^$-!\/1^+$BBTNZ>Y#K8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BD-** "BBB@ HI#0* %HHI* %HH
MHH **** "BD-*.E !1110 44E% "T4E% "T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 )1110 M%%% !1110
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MYBM\@'WN.>/ZURNJ63^%_B!\+TU:2*".UTY;668O\@D12K#/IEUY..M '?\
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M8&*0V_D?9P!O 4^85V\$;_O'J3S0!Z1J>MZ;H=HESK%_:V,3,$$D\H16;&<
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M[FUCM6S:Q[UPS28+2E@#QD[0,#&: /I:;QYX7@\0+H+ZU;?VHTHA%N"2?,/
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M(D('WASMQD?>SGY:\RU#5[RY^%L&JZW91-&?%4=P]TD/EK?H$8-(5''.TKD
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M"JD8;J"<5YYK'B3PI>^)/B;?O>VTDEUIL5MI[.I!D<1JCA PZB1(SGK\NX<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4TC-*3BN2OOB#HEGXTMO"LDSB_G!4XAD/ER'88UX7!#!F.<X4
M(<D9H 73?AGX2TC68M8L=*,6H1NTBS&ZF<[F!!)#.0<Y/45TM[96VHV4UG>0
M1SVTRE)(I%W*P/8BO)/ /Q/MK"UUBS\;>)HFU"WU&6*-I(]NZ-0 2 J]-P;
MKT/6/&_AO0;J*VU/5X()I8?/1#N;,?/S_*#QP>?:@"KI/PX\(Z'JHU/3]#MX
M;M22C[F<1DXR55B54\#D 'M6IK_AS2/$^FG3]8L8KJW)W /P4;&-RD<@X)Y%
M6K+5++4=+BU.TNHI;*6/S4G5OE*^N>WOGI7G%AX@\2_$F]U0^&M3CT+1+&7[
M/'>BV6XENY!DDC) 5<;3CKANO.  =AX;\#^'O"1E?1=/2WEF $LS.TCO]68D
MXR,X&!3],\$>&]&U$:AINCVMK>#/[V($'D8/?GK6/X;U[7-,LM?D\=2VUM%I
MUSB*^$?E12Q%00R^O)' R<G;U%:2_$#PN]K>W/\ ;$"Q62H]SO5D:-7("DJ0
M#@EASCN/6@"WH?A'0_#EW?76DZ?':S7S^9<,K,=YR3T)( R3P,#GI5;3_ /A
M;2=1BU#3]#L[:\B)*31H0RD@@]^X)K+D^+W@2,$GQ% <8^Y#*V<YZ87GISZ<
M9ZBK^A?$7PKXEU1M,TC6(KF\ 9O+\MTW!>NTLH#>O!/'/2@!L_PW\)W.O+KD
MFC1?VDLXN!,LDBYD#;@Q4-M)SSR*9<_#'P?>:P^K3Z)"U\\IG>02R*&D)W%B
MH;:3DYZ4EM\3_"%Y>6EI!JV9+R4PVSM:S+',X.TA9"@0\D#(/<>M07GQ:\$6
M&I3Z==:V(KJ"=K>56M9L(ZMM(+;-O!'7.* .BTSP]I.C7VH7FGV$-O<:A();
MIXQCS&'<]AU)XQR2>I)K3KE(?B5X0N=;CTB'6X)+R2801[(W,;R$<*)=NPGD
M#[W4XZUS%[\6=#US1/$UG:7=WIDMO!)#;WTL$JKO*,%<E%)C^9> V&/89XH
MZ34?AGX6U;Q.?$-[I[S:@TB2,3<.$9D "DJ#C@*..AQS4NI_#WP]K'B>W\17
MMI(^I0-&R2"=U7,9RI*@X.#4.E>*K#2/ .B:GKFN1W)N8HXQ=I$Y-S*1T5 N
MXG@_P@G'0'BD7XI>#6TF;5!K<7V2&589#Y,N]';=M4IMW#.QL<=C0!-X=^'7
MAOPLMZNF6)"7T8BN$GE:59$Y^4ALC!W'-7/#G@KP]X3\_P#L33(K4SX\Q@S.
MS8Z#+$D#V'%4=#^)OA#Q'JT6F:5JXGO)@QCB:VECW!02<%U Z ]^QK=UK6K#
MP_I,^J:I<K;6< !DE92V,D < $DY(& * (M?\.:3XGT[^S]9LH[NVWB0(Y(*
ML.A!!!!ZC@]"1T)%4M8\"^&?$%S;7&JZ+:7,MLNR)F4KA>RG!&Y1DX!R!VQ7
M&>._'T6I> =4U/PAKTT%WI,]NUQBU>-BLC[ A$JC .[=D _<]ZV_ OQ$T'Q!
M8:?I<>MQW>M1V2-=!XGC+R*@\P@LJ@G.3QVYZ4 =!J/A71=5GTR:]T^*232Y
M!)9$$H(6&,8"D#'RKP<C@<53O? 'A34;FYN+K0+&2:Y8/._E[3(0P?)QW)4$
M^O.<@G*:;X\\-Z]J8TO2]4\Z\>-Y(L6\@1U5BI9'*A7 8$9!(.#BO(#K_BU?
MAOXY:[\1W9U'1M42 7$>%8@.(V56 RJDX/&.GN<@'L]OX,\.VNN'6H-'M(]3
M,CRFY5/GW-G<<^^3^=3:WX6T3Q(T!UG3+:]\C=Y7G+G9NQG'UP/RJUIMQ_:&
MAVMS&SI]HMDD5B!N&Y00>XSS[UY!\.OBCI>AZ%J%GXP\332WT&HR1Q-<)+-(
MT05<'*ACC<'[\?E0!ZI'X3T*+5KG5$TFS6^ND:.>81#,BG (/;D 9]:K0^ ?
M",-N(%\,Z.T88N%DLT?!.,GY@?0?D*CU7X@^&M#OKBSU"^E2>VB6:<16<\JQ
M(WW69D0@ ^YJ>'QKH%QJ^FZ3%J*O?:E:B\LXUB?$L)#$,&QM'"-P2#Q0!&G@
M#PHD#0+X=TSR'G%PT7V==C2 $ E>AP&8 =!DX'-7H?"^@6]_'?PZ'ID=Y'@)
M<):1K(N!M&& R../IQ6;_P +"\,>==P_VF/-M+U-/F0PR BX9BH1<K\YRISM
MS@#/2KOA[Q;HGBE;HZ-?I<FU<1SKL=&0G.,JP!P<'!Q@X/H: );;POX?LM0&
MH6FA:7;WH+-]HBM(TDRP(8[@,\@G/KFI+WP_HVI7L5[?:1875W" (IY[9'=
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MIUI>Q*<A+F!95!]<,#7$^-)=/OO'?A/2YO$=[I][%/\ :H[&W@8K<\\%G^Z
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MR*UM"26?RY$^58LXWDL1[_+Z"@#W0@'J ?K33#&95E,:&15*JY7D D$@'T)
M_(>E<]X0\::;XSM;R2PBNK>6SF,%Q;7<826-L=U!.!U'U4CM72T 1^1%_P \
MD_[Y%'DQ_P#/-/\ OD5)10 WRUW!MJ[AWQS4<MK;SHR3012(XPRN@(/US4U%
M #515&%55^@Q3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSU//^/OAWKGB;4[R_P!.CT^VU".YMVT_44F>&9(O+(D5RO4AP"IY.&(!&,4
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M=.$<P SF,M/NS] ,_@*O^-9)9?C3X!M9;=3:I]HECD9<[I"AR.>/EV(?Q^E
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M# \$GG([=*PM1&K^./BAKGAZ#Q1?Z)9Z/;Q&*.PD,;S,P!9F(;) W8]/N_B
M>EZ]KMCX;T6ZU;4I/+M;9-S$8RWHJY(RQ/ %9/A3QI%XJO-0M1H^IZ;-9+$[
M)?1!"R2 E#P3@X'([?GCP_Q!J&J>,/@L-7OM0GEGT._^QSH&(2X0[ LD@/WG
M&X#(]37OFE^&SIGAV;1SK6K7AE61?MEW<^9<)N&,J^!C'4>E %+Q;X]TKPAH
M0U>X2:]@^U?9&%GM<I(-VX-D@#&T@C.<\5TT4BS1)*GW74,/H:^9FT2*T^"/
MB:XDO;J<QZRL"I*^8T*2JID5>SL&(8YY&*[JQL]1\!?$G3DDUV\UNVUVQN6E
M%TY 5H4\P,H!( P-H  P"?:@#V*BOG/1!\1]1FT[Q=;7DZH UU<W-_JZ-8>4
M['*B+ \M0%^9<L1A3\I KU+XOO?6_P .-1O+#4KFQEM2DA:W;:TBD["A/4 [
M@>.?E% '=45XU:V/BWPCXE\.ZI?^+Y-3LM5S;SVUPC)%"/)+@A-Q7C9RPVG@
M\')KA_#'B#4M,\8>$+Z"_P!5O?[4N#;7MU>/)]GNV>4(WE!L$A R\G^(#C'%
M 'T3:>&]#L-3DU*ST>QM[Z7<9+F*W59&W'+98#/)ZUJ5XC\)=/\ $>N7,'B"
M\\57L\&FWMS9RVDS%A,I4-GKU+N#SG&T8QBM7XFW-YX4\8>'O$PU344TB>X6
MUU&VCN6$84?,I5!Z@.3Z[<=Z /6:S?$&MVWAO0KS5[R.:2WM4\QUA +D9 X!
M('?UKQ[6M1U*X\-:EK]KXPOK32=1UGR+,+*[3/;(Y!%J%.[>SJP ./E7DJ,Y
MS;+6]0N/#WQ-TW5I-2DM;*T$<-I?WGVF2"0EUYDSS\P!.#CC'..0#W70]8MO
M$&AV6KV:R+;W<2RQK* & /8@$C/XUH5X)I&M:IIU]\*[.SU&YBL[VT"7%LK_
M +N0!L<KZ_,1^ ]*?XK\5>(/#6D:_IVGZM>2W$NO+8VUU<R!I((S"KD*2,#D
MXSV!]>: />**\U^&VG>+=)U;68?$EQ,T$J1RVL%SJ7VR2+E@<$G(4_3L/0YB
MUF6\\5?&!O"_]L:KINGV&DFZ8:=<F!I96=1DL.2H5Q@'N/<Y /0]6U6RT/2K
MG4]1G2"TMTWR2.0 /0<]R< #N2!7/^&O'4?B+6+C2I-!UG2[J& 7 %_;A%:,
MD '()P3GI['T./(=>N-3U?X0>)HM7U&\N9_#.IFQBN/,95O%\Z-<S+T=EZ@G
MD9'?D^[>'M%@\/:';Z9;3W4T$(.QKJ7S' )SC..@Z#T% '!W_P ;]#L]=U&S
M@T[4]0L]/C+37=E&K@%6"L<%A\@) W^O8@@UT_B;Q[I?AC4K33);74-0U*Z5
MI([/3X1++L )+$$CCY6]^#QP:\>U@R^ _'&H>)/"#6NLZ)?63WEY%YBR0^4T
MVQU#*<'Y^F,XRP((!STVC7%M<_M%3W5U#,LEUI,4MCN!P"8D)]L8$@],Y[T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+N33-6M+I+,_Z0\<@Q&/4GTX//3BHY?&?AJ&>&!]>TT23$B,"Y0@X&3D@X'
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MB?FXZ@#*CD?,<#WH 2X^%_@J[UHZO/H%O)>F4S,S.^QG)+$LF[:<DGJ*UO\
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ML@@'V:*0RH$;<#@2X) 7&<$CL15GQ_X:TGPSX=\-/H*36>@ZQ-'/J,YS<J2
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M+/5/#<QN/(=0&D<AGYZ%BB[SCL<^IKU'_A"_"_V-;/\ X1W2_LJRF98?LB;
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MX8 8;J>OK2?\(QH'D- -#TSR6<.8_LD>TL 0&QCK@D9]S0!Y=96WAKPS\;=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH #TI*4]*2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&>TM[K N(8Y0.
M0)$# ?3-344 <9XU\/>*=9:P3PUK\6D0Q"1+A&CSO5@%!Z'.T;L#CD@YX&-[
MPYH5IX9\/66C6*D6]I&$4GJQZLQ]R22?<UJXHQ0!!-9VUS)%)/!%*\+;XF=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ /2DI3TI* %HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HI,UER^)=!@NGM9=;TV.X0$M$]W&'4 X.03D<\4
M:M%8U[XK\-Z;=O:7_B#2K2Y3&Z&XO(XW7(R,J2",@@_C4VF^(=$UF1X]+UC3
M[YXQN=;6Y24J/4A2<4 :=%9E_P"(-$TJ>.#4=8T^SFD&4CN;E(V8>P8@FK=M
M>6UY"LUK<13Q,2!)$X=3C@\B@"Q1698^(-%U2YEMM/U?3[R>($R16]RDCH <
M<A22.:?;:YI%YJ,VG6NJ64]] "9;:*X1I8\$ [D!R,$@<CO0!H45GWVMZ3I=
MQ!;ZAJEE:37!Q#'<7"1M(<@?*"03R1T]:SO^$Z\'_P#0UZ%_X,8?_BJ .AHJ
M&VNK>[MXY[:>.:&0;HY(G#*X]01P14V10 4444 %%%(: %HK ?QOX2CD:.3Q
M1HB.I(96U"($$=C\U13?$#P=!'O;Q3H[#(&([V-VY]E)- '244F:,B@!:*0,
MIZ$4R:>&"&2::5(XHU+.[G"J ,DDGH * )**R]!\0Z5XET[^T-'O%NK7S&C\
MQ59?F7J,, :U,B@ HHR*3(H 6BN9\0_$#PMX6O$L]9U9+:X==XC$4DA"]BVQ
M3MSVSC-=(CJZJZ,&5AD,#D$>M #J*,BC(H **,BDS0 M%9VGZYIFJWE_:V%W
M'<36$H@N@F2(Y,9VYZ$COC.#D'!%5]1\5:'I.L6.D7NHQ1:C?,$M[8 L[$G
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MM1 !E0N1\^1G)' Z<G('4AATSS0 ZBBB@ HHHH **** "BBB@ HHHH ****
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M"X4#A<@\GOM&:Z;XB>$M;\4SZ$^DW5A -,NQ>DW0<EI%QL V@C;US^%2>/\
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MW;@2O QTX SGK6C/\-=7&N^']5M/%$<4VBZ>+*$OIP?)V%"^-XZACQVP.O-
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M&\0Z/>I)%KBW DGCE)WE5^4Y![JY.3_MB@#T+PKXV_X234;_ $V?1=1TJ_L
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M ^JM0!O:U\0-0TSXD6'@^W\/I=27R)+'<F^$>(SNWL5V'[HC<XSDXXZUW><
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M=4E"E0VUBIZ^X/UKPKP1HVDR?$6;0=6L-'AM;_0$$ME87$DL32>9'(@=F/\
MK-H!^4D=""237++#;+X"\#6_G6=K%J%]>2W\MR"8GDC=5C,P') 5B,>^>Y-
M'U<"#T.:-P]17F7PCT"+PQ<Z_I@UZVU"??#/);66?(MMV_&,G 9MO(]%3VKE
M);*Q\7_&'QA8^+(86CL=.=;0,VWR(E*D.&S@'#[SGNQ],  ]2\=^,8?!/AJ7
M57B2XGWK'!:M+Y9F8D @'!Z#+'CM5/POXD\2ZI!K<>H:/9FZL7Q:2VLY%K>
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MA;")7+"678!N,A)<CY@!A.R\<[ING:+X@;X:65[-%>-*UW9WF)RK^0DS&%6
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M\I8%0; F,;<=,8JW10!PVF?"3P9I&NKK%II6+B-@\2/(SQQ.#G<JD]1VSD#
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M*9VX;=D 9/'3FK&J_##P;K45K'>Z)"1:Q)#&T;O&WEHNU5+*06   Y)KL**
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MY0NT18@D@L2<Y'![=L9-1W'P]\*7>IWNHSZ);/=WR-'<2'=\X8 ,<9P"<?>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**9OSGCO1YG3(QZT /HII?T&:;YOS8V_AW- $E%1^9U&WI[TOF DX&<>GK0
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MM #J*3--25)%+(RL 2I*G/(."/J""* 'T4F:,T +129I: "BFN^Q2W''.2<
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MID-S%<1>9#)'(I/!1\@_C0!-12 Y .,>QHS0 M%)FC- "T4F:,T +129HS0
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M-<226DL*0P+N9BXVC ^IKRFPFOK/X/6&@/X9UN6X2_CCFC-JR@!91*6SC[I
MQ]: -G5/%MOXP^$FMM,&M]9TR)OM%LKLCQS(0 PP02M=WX;T*SM?!=E8Q>>(
M)[-3*6F<LY=!N;).0>3TZ5Q/Q7^'9U>PN->T&-H=66(_:8HL@W2<?*<'&1C\
M:]1L 19Q*5*D(GR'JORCB@#P>+1+:PM_'?AV^O=1BN-.4:C9W!NG.(5&4YSU
M).#_ $K0TS4+?4/V>XHH)Y_MLTHM#_I#&07+S 9SG.,'./2NG\<^![G6/%VD
MW=EYB6UXAM=8=2-K6RX8*P/J1CBJ6E?#R;3_ (H7D^S9X>7&H6T2#Y3<%3&
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MCB9AD'<">JC&,UF0>#/&6B:?8:I'H]G<W>F7-TS6AE21;B";YB!CK@Y&#]:
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MJ%O;:+-J%OI2(=3N(W"B!G^XH!^]GUKEIO#?C&3X<6/AU?#1%W:ZBLY?[9"
MT:N7SUZDG%9WB"QUW6_''B230K)KC3FBMH]8M([R-&ED"[F3<V>0,CY<8[4
M>IP>+[B\\ -XG@T6Y+&!IDLF8!W4'@Y[#'/TKR+Q#KFH^*/@PVJZM;2))%JJ
M26]R&^5U:1A\H&#@!B,'->J>#=0LO%/@&W>RL)-.LS;-:16\A),:*"BX8]1C
MO7F-WX<\<CX80^$3X=65;6]"I+#<C<X4L^[!P-N>,T >@:!\2%GU'^R]7TJ?
M2F_L_P"W6TL[96:!1RQ_NG@\&JVE_&"PO_$5EITMC)!;:D<6%P9$)E^8@%ES
ME >,9ZU@:SHWB+7O'&G2W7AK4(+#^SCI]U()XW">8N"XVM\P'!(]JC\)>$-=
MMM3LK"]\+:18II5QNDUMX%:2Y13\OE]<,?7H* .D^,ZP#P?;7%TS*D6HP!W4
MLNQ"V&Y!]*Y#1-2T[3?B<!\/X[BZT);,OJ<$#/(@8;L$;SPW Z&NX^+%GJ>I
M>&;6PTK2)M3D:_BD>.,C"I&=YR2>^,?C70+-,GA::_@T&2WNI+;<=/7:LA;!
MPF1QQDT <E9?&2UN-(N]5N=!U&TL(83)%<2@!)V#8V*>F34A^,ND10:LMU;B
M&\L(T=84N$E$V\@*%8'&06&1G@9K!C\,>(M>^$]CID^CFSU+2+E9H+6\V,ET
M%)(&!QC!Q@]:O6.D>*%\&:I9S>#-$@>4QHNFQ,H$ZDCS&+9P#C.!V.* #Q7X
MTMM8\+:I:Z_X2U-;2***=Q#<1G*,Q"NKJ2, J,_[PXK7O/%-D-+T_0++1+O4
M9;W3!<BR$@4QV^,9D<D=\]*X*X\&^+;'PYXATVPT.6'2+^-5MM*FO8II(7W!
MFF!' 48(VCG+CT-:O]@>,-,UW1O%&EZ*D]U=::EA>6$\J@VI"X#9Z;2 #['Z
MT 5OAWXR@\)?#>VS:O/=7NJSP6UJ)0!D8X+L<* ,<G-;EW\:X[/P[)J)T3SK
MJVO!:WELEVN(<J65]X# J<$<=^]<I9_#WQ<G@JWNVT^U&IZ?>SWD%C-ME$ZR
M8#J4(*Y^7CZU8\5>'_%6I_#PVL'A:"UFO;M/^)=80HAM8XP3N;:!DL>V<"@#
M=U+XL:S)H&OQ#PQ<:3K%E:).D5S,=PA<E6FP57[AV\=\^QKM_!=Q?:[X%LFU
MW3C;O<6RHT<L_FM/&4 WL<#!?DX.3SR<]///$/AWQ5XE\;Z_(-$>T@O/#XL5
ME>X!B,N$DQNP,X;<G3MNXKO_  *_B)/!]LFO:;!:7EO$L4,$<N6=50 %^H5B
M1T!.* /+?!'CF]\'^"-16R\*WE_INF7T_P!HNA<K''$I<!57<"7(SSCIP3UK
MIO%/QMM-$U&6UT[2UOQ;PQ37,DMVL&T/M(1%()=L.,@=.?0XP[#0_&<?PB\0
M:/+X;8RW]T9+:'[0@E6.1LON7U4J.XSO[8JHG@KQQX-U6#4M(TFPUMM2LX(K
MN*]59?(G"+OR=R_+N#88'&#@] : .SE^+\4XT]M'\.ZEJ*ZA9O=0*@4/E)'C
M=6 )Q@IU!/6J.N?&I-"O%M9])3S[>*)]0A>Z5'A9P#L0?QL <G%3:;X<\5Z9
MXM\/:A+INF2106$EK=M9NL$<'F2N^V./'W478/?J>>:RKWPCXM\/>*M6/AK2
MM.U'3=3F\Y)KYD<VLC<L?FYP"21B@#8BUW0KSXK$0Z$\VKG3!<VM\L[8FC*;
M@NS.!G@9ID'Q>N6M[._N/#-U!ICW?V&YG,J[HI\X"A>XY&34)T+Q3;?$VV\1
M0:-!?6UM8+8-*+Q(S,=O,@'89R,5CW?@KQ5+\/H-(30[4WXUI[]R+Q,%,[P<
M^ISM^@H DL?%U]X1UCQA#I?ARXU""UU4W%U(LAQ%"PR<9).[.3QQCM6YJ?QE
MLHX-,?2+:&[:\MWNG%Q.(%B1<@KN/5R0<"H7TSQI87/BB/3=%LIXM>D66.9[
MM<V[.@1PZ_Q;02>/3O63/\)[WPS-9WOARPTW5R+86UW8ZFJLKMU,R;N!SC@4
M -\3>-=2\7IX-NM"L$:TN[T-Y4ESL,DZ!MT+8'"C@Y[YK8TC5#X>FUJS\'>%
M?MD%E,9-29K[ \\C+QQ9!SMY].E4]4\*^,9)?"OD:/I>S2Y_MMTUM(L"&5CR
MBJ,'A<<]ZT#HGC+PYK&O_P!AZ;8ZEI^M3M<[I;H1M;2.,-NS]X#G&* $D^+E
M]=WFGQ>'O"UQJ,-];M- SS")G"<. "#]T\>]5-;^-YTJYDA&A[6M_+2YBN+D
M),LC<E50 [MHZG(IN@^#M?\ #GBSP\EI80W.CZ5;/:M=M=H'D\T[I)0IZ!6)
M '4XJ34?"/B^Q\8ZM<:!::3-:ZM/'/\ ;[R-&:S.-K@*>6R/2@#NM3\5"T\$
MS>)+6U>>-;7[4D3?(2N,X.>]<UH_Q,U&_P!2T&.^\-M8V&N BTNOM(?+;=W*
MX!Q_C70>)M+U'4/ .HZ5:!;F_FM# I<K&LA/&1C@#K7!S>&/&,%AX$BM=%M9
M)-!1GFW70'SCY  >^1\U &Y:_$Z].OZ;8ZAH'V2#4Y7CM-UR#/QG:7BQE W8
MDUE+\8=:_L_4]2?P<XL=,F\B[E^UKE'!P0!CG&16#;?#GQS%>6&J+9Z.^IZ;
M>--]HFN':6\YR-S= HS@ 8Z59;PIXY;P%XETQM'MOMVL:D9FB%R@5(R 68$G
MDY '/I0!UUC\2;T^)4T[6-";3K.XM9;VVN&E#,T*(&R5'0_>X^@K#@^.,7VN
MSN;RRM(M(O)71#%=;[J)1TDDCQPI^M.N/"GBG6O&?AJ]O]/2"TM=,-K?NDZ$
MAI$97"]<XR*/#_A7QUI]POAZ>731X?MV"C43;H\\T&?]6!S@D9!)'% '.?%'
M7]0\2>!GU=M!M8]'^TA;&[EG<7 &<;P@XPV#WZ5[GIL>-*LE!.WR$7!]-HKQ
MW5/!?Q$O_##^#F72VT>VD1+>X=L231JV5Z'Y< <Y%=7X2UOQ4WCB^T'5TL9+
M.TL(V#V6YDB?@8+$#+'DXH H>*KJZTSXKZ7/HVEB_P!6N-)F4Q&4QJ1N7#.>
M@  (^M3#XHWEUX*M]4L]-MHM0DU,:;*+J8BWMF^8M*[C_EF IY_'V-V_T;7I
MOB[::S!:0+I,%@UO+-++@N&YP![,!^%<?)\,O&">'(M.C?2I?+UL:@UO(Y\B
MX1CDB10!N52 2O<9QR!D MVWQLN;CP/+J+6NGQ:LNIII_P [O]FC#JS+,V!G
M;A'! )/RY[@5W7P_\0ZMXCT>]FUB.P%Q;7KVRS:>6,$Z!5(="Q.1\Q&<]J\H
M@^&7CO31J4:6&@WMG>7RS3V?RK%,H#G*Y ,2C>0 N&'&.!SZ;\+O#&H>%/"\
M]GJ(6*2:]EN([5)3(MM&V L8?^+[N<_[7KF@#MZ*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH #TI*4]*2@!:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK@O'/Q#E\-ZO::)I5C%?ZI<
M023LLCL$@102"VU23N(('3&.2 <T =[17D$OQ@U6WT+P]KL_AY4TJ[D,.HS[
MG)MW#[2 N,XV_,,YSG;U'-X?%J2W\/:SXBO-*1=)2Z-MHLB2$-J!RP!PPX7Y
M=Q;L,@ D4 >HT5X;I/Q^EATR]D\1:$Z748W6QM59(Y>?N-NSM(ZYY!P> <9Z
M.3QYXVT>#5FUSP6@:UM3?02V]P?(,8*EHGDP0'5=Y)_B*8"\@D ].-)D>M>4
MZM\8+JPC\,-!H$,PUZVCD3S+TIY3LP4J<1G*@D8/4\\"L;PK\1=;TWPOXAUO
M7(8KTRZJ\%K#'(^\W!"#R54@XB P1SG.>#G- 'M^%'.!68=9TJ/68M*>]@&H
MR)O6V+#>5ZY_K7G,7Q<NM+DNX_$V@R0/&JF"6TCD,<SL/N98#D9_0UD0W6K/
M\<_#%SX@TJRTZZFM95C%M(7WKL;;N/J.5H ]PX ]*0@=0!_C33+&\>Y'# G@
MJ<YKR_6_B7JUEXSFT2RTJQ<17L%F$GE87$OF8/F*HXVC/6@#T&TUO3M0U&[T
M^WO89KNTP+B%3RF>F:TE"[0?QR:\FT?Q=;Z=XN\<7-SX?AL(].C$]Q-%DS7&
MTG;G/&".>*BD^(GC6VOM$$OA_2;A=;!>R@AG<2*H&<.QRN<8]J /7\*.0!Q2
M84\<>N*\5_X6EXV&DZMJG_"+Z>MKI5TT-V7N"60 C*XXR1D9/OTK0UKXIZK_
M &G+%H%C92V]M8PW<JW0DWR&0!O+7:",X(Z^M 'J\\D-O \TKI'&BDL[' 4#
MUK/T+6]+\1:;]NTNZ2ZM2[)O Q\P//7WKAM1\9ZUK$>G:1HVB6XU&\T]K^\M
M=3!6.*WSLVY'5BQJ+X%N/^$!E!54==0GWHG1<E>OTQQ0!ZGQ285NP/:O&/$7
MQ?U31/$FJ6@T[3OLNFSK&T$LC_:9H_XG4CY1QSS5B[^)7BV76-<LM&\-V=P-
M."3EWN,[8F7=EN1R0#TZ4 >MNT<2%CM"KG\/6LS0_$6D^(K5[S2+R.Z@20Q/
M(F0 P^M<0?'&M>(K70[;PWIUFFI:I8->S-=EFCMXPVW& .=S @51^"9N'LO$
M[75N+6X_M5O,MXQA8GVX*J/K0!ZX H' &/:FR8P"<\'H*\>\9_$_7M!\1ZC9
MV=I8QPZ:L<HBN [S7JM@?*5X0 $GGTJS#\1]6\77PT_P;:69FM[/[7=-?[L9
MR 8H\8SR0-QH ]%EU[2X=:BT::]@&HS(72W/WBOK6FI7YNG7FO%=5\9QVOB#
MP=XJ\0:;+I<GV6]6XA=,OP  %[D$CC/K6CJ_CKQUIF@0ZVVB:.MK=SHMM')*
M_FQK(<(74'!)SV/% 'K152.0,?2ER/:O+;+XE:OIE_XBM/%6FV<,FCVD=U_H
M+LP;=_#S]13+?QUXITO4=*7Q+IU@MEK9V6%Q:LQ^SR,!L20=P<C)'3F@#U7C
MVJMJ%[;:=92WMW+'%;PKNDD<X"KZFO)+KXG>*;'1-<NKG2=)BO=(OH[:>W9W
MRZOPI49[DCOT-7QXSG\6V6CZ;;V>GS0:OIMS/J(W'_1U0!1CG^\0.: /1])U
M.PUFP2_TZXBN;60?)+&<J<?6KORG!X(->(^'O%\_A7X1>%[?3+=;K4+^6:*W
M$BL5"B1RS$+R< @X[YK3LOB3XACTB6TU+1D36Y[M++36$;Q0W3..'PW(51R<
M4 >AVGB/2-0UZ_T:UNXY;ZS0-<1J/N ]!GO6S@8P<&O$-$EUKPUX^\8:QKL$
M#3II*7,L5C&=LYZ#;GD=#FKVF?$7Q/#?Z0^O6^DG3-3M9;\26P??%%&NXKUY
M;D>W- 'L#8"\#\!7-7MWX?\  .DRW4[1:?:/,TC8!8RR,>?<FO-[#XJ^)I;^
MQU9M*\_0[QG+6MO9R>9;Q*V/,+]&..<#C%5?&NO^(O&/P_UG6[-+*U\,1N$C
MCFBW3W*B11Y@)^[STQVH ]S@E2>%)4/R.H9<]<'D50U7Q#I&BW-E;:E?06\]
M[((K:-V^:5B0, ?5ASTYJM/'JDOA..+0Y+>#46M8Q!+= E(\@<G Y(&<#IG&
M:\6TXZ]J'PDT;6+V2TU&9M:@DTSS@?-60W3B02.>S-CIVH ][U+4K/2-+N=2
MOY5AM;:,R32$$[5'7@<GZ#DTMA?6FJZ?!?64J36MQ&)(I%Z,I&0?_P!=>2OX
MQ\6+9^*]$\4Z'I%S?V.G?VC'  ?)F@W_ +P-\QR O3H<KSGK52\^*6OV>C>&
M62WTBU34;+SI;R\BD\A7!*A5"M\O % 'MVU#V4XXZ=*7"YW8&?6N;\'ZQ?ZU
MX.L-4U"&-;NXC9V6$X5OF(4@^X _.N T'XJ:OJ6O6B7D.BK9W.H-8FVB\S[3
M"<D(Q;.S!([>M 'L8"YX S1A<YP,UXHGQ$\;36'B.[CTS10FA3D7*M(Q^51\
MR)CD\#.XUJV_CSQ9;:YX=&L:3IZ:3KK!+<6S,98B5!&[)P>M 'JN5!Z@'I2
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MT#K;1>8X+K$,9QCO78_#K4]6U;P^]QJ]_9:DRW#QPW=H>)(QT+#L3^= &O\
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M6$#S&4LL);:<LA( [' X^8"O4?!T>L+X7L)-?NY+G4YH5EG+PI$8V89\O:H
M&W..><@_0 &]1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z4E*>
ME)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5YGXX\*^*4\:V7C'P?);27L=M]EN+6Y<!9$W9 &< @Y.?F!& 17IE(: /
M)KO0/'VN6MCINNBVGL-2O!<ZT(YPBP0 KMMHN=V %W$CDDXW=2V)'\-/%=QH
MFH>&)?\ 1M/L;V2_T*_^U@LCAB%C8 E@K*Q8$8*MDG=G ]QDDCAC>65T2- 6
M9V( 4#DDGM7,>'OB!X>\4:M-IVERSO*D N(VE@:-9X\[2T>X L WRDX'/3/-
M 'G6N>#?B;X]T1K7Q'<Z79+9CS+>WBY-U)C'SE6*J,9P?4],<C9T7P]\0]=L
MI;'Q==V]M90V$UO%%#(&:ZE>(QAIR,[E 9CC(RV#@XKI=1^*/@S2-2GT^]UE
M8KB!]DP$$KJC8)VEE4C/!XSVKJ-.O8=3TRTO[<-Y%U"DT>Y<':RAAD=C@T >
M%R?#OX@ZK:^'+:XLM%MH- VI!ON26EPP)<LJGY3M''MTK1?X:>*[W2]>L)Y=
M/A_XG#:KI]Q$S!Y)&(R>IV+@# .3G/.!S[9Q3'*HK.S*JJ,DG@ >] 'B=UX'
M^(?CC0GLO$M]96RV39M$,>6GD7C<[=<'KGOGI3IO!GQ!UOQ)H.N:DNDVUQI*
M+&)3*YW!=Q+L !SR.,U[7M'/KZTA0$$'!!&.: .#^%VO:_KVAWLFOE)GM[QX
M8;H1A/."]2  !@=,XK"\5>!O$7B/7_(N+>Q>W-ZL]MJZN5N+:WSEHN!\W/ R
M>*]6AMXK>,)&B(B\*J+@#\*Q(/%FGW7C>\\*QQW/V^TM1=2.57RMI*X .<[O
MG';'O0!PNL:3KFAS>/?$FH_8DM;S3MD B_>-B,$*"& '.[GK7G>@RS^$&TG5
M<^'=7:*-8[>WCU7?.C/SE$S\AR>0!ZU],7%K#=6[V\\4<L4@VO&Z[E8=P0:S
MH?"VA6\\4\6CZ='/"VZ.1+5%93]0* /,QX+\:3^$O%VG7-KIWVC7+W[2FR<E
M4#MF09([ *!ZXI]GX0^(.A7EKJ.AS:=')<6D,%];3ME \:&-6!VY(QM/;I7K
MX0#'.2!C)-+MQSQF@#R6Y\">,M&UF'Q#H^K6^JZM-:-;7W]HLP7ELYBQ]U0?
MX>G&>]:GPG\'^(/"%GJ,&LO9^7<S><D<#,Y#'[Q+''Y5VB>(=+F\1S>'H[H-
MJD-N+F2 (WR1D@ EL;<\CC.><XJY=7"65I-=2JYCAC9V$<;.V ,G"C))]@,T
M >.:M\./&%Y?>+;>RGTR*PU>=I?.F3?-(IY$>['R+D>]3Z5X.\?Z=JFM73IH
MTSZO9+;RGSGC6,JNT$ +SU-:$7QY\,,\F_3->2*,D23/:H5CQ_>PY(_*O0-%
MUS3O$>EQ:CI5W'<VTJ@[D8$H2 =K#^%@",@\C- 'FNF^!/'&AVNAW&G7FD_V
MIIMM+82&1G\N6W+!H\C'526_2MWX<^#_ !!X9?6)=;O+*XDU"Y^U?N <^8?O
M$DCOZ5W%[>V^FV4U[=RK#;0(TDLC'A% R2?PKB=!^,/A;7]:BTN,WEG-<8^R
MO>PB-+G)P-AR>IX&0,G@<\4 <_>_#;Q4VJ>)EL[_ $E;+6V9S/-&S3QC^%!Z
M#&0369H/PG\:>#[Z#4?#^JZ4+N6W,-T)U?8HXP%X^8<9YQR!7?ZM\3O#^C^(
M/['F^U2O$4%Y<P1!H+'<P5?.?/R<D>N,\U-XK^(>B>$8+-[KS[R:]YM[:P59
M99$QG>!N V^^?IGF@#B[_P"&GB;5-2T5M9N;#6K6U9Y+IKN1U=S+@.J@#A5
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M3!(99!PQW89!DJQK4O?&^IW,7AGP]X$-U<6LVC^<758TNL1DQC!?Y P:)@P
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MV].:]X\+6EQ8>$M&LKL$7-O8P13 G.'6-0W/?D&@#5P/04M%%  :S]8UK3=
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M&(P.?EW,5SC (^D+6VAL[6*VMXTB@A01QQH,*B@8  ] * )AP**** "BBB@
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M&,>U.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>L:Y-K]MK4%C%<Z;?FV46C;E*[0PR=S#///3'0@$$4 <?\1].\-0?%7PQ?\
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M'I1@>E%% !@48'I110 8%&!Z444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E
M"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 E*:**
M $Q0!@8I:* $HI:* $I3110 E!&>HI:* #M24M% "44M% "44M% "56L].L]
M.65;*UAMQ-*TTGEH%WNQRS'U))ZU:HH 2BEHH 2BEHH 2BEHH 2BEHH 2BEH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2D
MI3TI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ****  ]*2E/2DH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH #TI*4]*2@!:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ /2DS2GI3: '4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E-IQZ4F* %
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M*  ]*;^-./2DH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH #TI*4]*2@!:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ /2DI3TI* %HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*2E/2DH 6BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0D 9)
MP*C^T0_\]5_.I'4,A5AD'@BJ?]FV_P#SR7_OHT 7:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2DI3TIM #J*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2DQ
M2GI24 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%&:* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *0TM% "#I2T44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E)2GI24
M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 !Z4E*>E)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 'I24IZ4E "T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444UG
M53R<4 .HI 00".E% "T56N+VWM5+SW,42CJ9'"@?4FH%UC3I(?M":E:-#G&\
M7"[<^F?P- &A16<=9T[RWE&H6OEJ,LXG4A:)=:TRW?9-J5JC8! >=02#WH T
M:*RTU_1Y'*IJUDS#^$7*<?K36\1:*K%&UBR#CD@W*<4 :U%8?_"7^'>G]O:9
MQU_TM/\ &C_A,/#O_0>TO_P+3_&@#<HK!?QEX;49;7], _Z^UJS%XATB>,21
M:M8.AZ%;E#_6@#5HK-_MS2_^@E9?^!*?XTO]N:7_ -!*R_\  E/\: -&BLW^
MV]+_ .@I9?\ @2G^-(=>TD#+:K8J/4W*_P"- &G167_;^CG_ )C-@?I<I_C2
M?V_H_P#T&K ?6Y3_ !H U:*QY/$NAQ#,FMV !Z?Z2G^-0OXP\-1CYO$FE ^A
MO(\_SH WJ*Y\^-?#/_0PZ7_X%+_C0/&GAER%_P"$ATO)/'^EH/ZT =!160OB
M31&D"+K6G.YZ*MTA/Z&ICK6F@_-J-F.N?])7C'- &C16+_PE.@FV6Y&MV'D.
M=JO]I7!.<8'-3KKNE$E1J=D6'!'VE>M &G16-<>)M"M)(XKC6K&-Y!E ]RH)
M%2)XAT9URFL6+#_KY3_&@#5HK)E\1Z+$ 9-8L$R<#_24Y_6A_$6BB/S6UBQ5
M!P6-T@'\Z -:BLF/Q!H\YQ#K%C*P&?DNDZ?@:(M>TF>6%(=5M9'F4M$BSJ=X
M'4CZ4 :U%46U&S0C?>P*6. #,O)HFU*QAA>66\@1%&69I@ !]2: +U%8=MXI
MT"[$IMM>TV=8AF0QW:'8/?!JRFNZ48UE&J61B?E7-RN#].: -.BJ<>HV4J[T
MO+=U/1DF!'Z&G?;+7_GYB_[^B@"U155+RU?>$N(VVG#X?H::FHVDCNB7<#,G
MW@).GUH N452EU&TA3?)=P1C.,M(,9IEQK%A:2>7<7UK%)L,@5Y@N5&.>?K0
M!H45F2:WI<4)GDU.S6%/F:3[2N />GKJNGM*D8OH"SIYJ@2@[D_O#VH T**S
M6UC3D)W:E:A@I8@SKP/6FQ:YID]M'<QZE:M;N=J2I.I5CZ9H U**SFUG34)#
MZE:#!P<SJ,&E.M:8 "=2L\'H?M*_XT :%%9C:]I*G!U>P7V-RG^- UW2B,C5
M;$^XN4_QH TZ*RO^$@T8==:T\'_KY3_&C_A(-&_Z#>G_ /@2G^- &K164?$.
MC#_F-Z?_ .!*?XTUO$>AC[VN:</^WM!_[-0!KT5CCQ'H9!*ZYIV!_P!/:'_V
M:I!KVDD(?[6L2&^Z1<IS^M &I16=_;>ECKJ5EG_KY3_&D_MW2O\ H)V/_@2G
M^- &E16;_;FE?]!.Q_\  E/\:/[=TH_\Q2R'_;RG^- &E16;_;NE?]!2R/\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CEC65621
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MHH P&\%^&G.6T+3B?^O<4P^!?"S')\/:83ZFW6NBHH YW_A!_"W_ $+>G?\
M@.E!\#>%2,?\(WI?_@*G^%=%10!S@\"^%0<GPYIA_P"W93_2G?\ "#^%?^A;
MTO\ \!4_PKH:* .>_P"$'\*?]"WI?_@*G^%+_P (3X7' \.:;CVMD']*Z"B@
M#G_^$(\,?] #3OI]G%,_X0;PJ>/^$:TT?]NZ5T=% '.#P)X5'/\ PCFF'Z6Z
MT?\ "#>%B,#PWIH^MNM='10!S!^'OA%CEO#6ED_]>ZT?\*\\(?\ 0LZ7_P"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E)2GI24 +111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M)BEI,T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
11110 4444 !Z4E*>E)0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex-a_049.jpg
<TEXT>
begin 644 ex-a_049.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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M HHHH **** "BBB@ HHHH 9D*,GH*/-3^\*" PP>AH\F/^Z* 'T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #,_O%'8B
MGTT#D'O3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH :.HIU-'44Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** &CJ*=31U%.H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,[6-9M-$T>ZU.]<QV]O'O=L<^@ ]R>/QKPO2M4U+XQ>.5LKYY8?#\ ^U&T
MV@QYP%8C[Q)]>F*ZWXZZJUMX1M-/B;$E[<J0 ?O*G)S[9Q6?\ -*"V6L:WF0
MBXE$$1;H57DX_P"!$T >FP^$]"ACC2/1]/41C:F( <+Z9K2L;"VTZTCM;2".
M""/A(XQA5'H*LT4  Z4444 %%%% !1110 4444 %%%% !12,=HS2!CG!4CW[
M4 .HI%.X?I2T %%%)F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 04M(*6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&?V@K
MTII>B6&"4FN7E('<HO'\Z\_^$0W?%?2"W3;<@?A&U=W\?X9Y6\.^1!+(=\PS
M'&7.2HXP.YK#^&_P[\6V?BS3==EMEL+6!V?]^X+NC @C:.G% 'T,OW12,"R$
M X)& ?2E7I7.^-M7;0O!FJZBKE7CMW",.S-PI_,B@#YH\<:XNN^,]7OXQOCD
MN1%;N>@1!M'ZY->N_ +1C:^%[[5G0JU_<80GNB9 /YDU\]^6T400%6<=0/[Q
M/'ZG]:^P?!>DG0_"6E:8V 8+1%('][JW\Z -\4M%% "=Z^:?C6P/Q+E*D;DL
M8@?KDU]+=Z^1_B-JJZS\0=9O(VW11RFWC/J$'7\\T =#\#;9IOB/YZ?<ALI"
MWT; 7^5?3!KPW]GW27CAUC6&Y1REI"YZD*-S?J17K'B3Q+8>%M$GU349,0Q@
M;47EY"> %'<Y/Y9/:@#5FE$*%W=54=68X _&N4O/BAX.L+B2"?6X/,C +; 6
M'4CJ/H:\\T<^(?C-=O<:E*VF^&[64JT%O)\TKCG:".N.,GWK"^+/@?3/"/\
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M7ZYXKBO$_P (?#NB^'=0U."^O;865K+( 6R"0/E_7 _&O(?#&@R^*?$UAI
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW145MH_D?SKZSL81:V4-OD8AC5..G  H ;>W,-C:W%W,P5((S*Y8X& #WKY
MTR.\\6>,[-;AE>?5[Y6D#]!N8L>G89KZ&^,VKMIOP[OXXI DEXZ6P/J&/S#\
MJ\D^#6E/=?$R"8J'CL(9)'XR%XVJ1[YH ^F2L<5MA 56-> .,8KR3X7:/_;O
MB36_'&HAS)/>2PVF_'W5.-WX#Y:]A.""/6JR6T-I $@CC@B4EMJ*%5?4T 8/
MC7Q=9>$/#TM]<8>=P8[: ?>ED(X'T]37F?PH\-WOBG7Y_'GB+S)Y0VVU$BXW
M,, N!_= X'TS7#?$/7F\<>/C%:-,]NDRV%FA(Y.[:S =.3DY]*^G](TZ'2-*
MMM.MU"PVT2Q( .P% %M<;>F!7A/QWU\3:C9Z#$1LME^UW!S_ !$80'WQSBO:
MM5U2VT?3+J_NY!'!;1F1V(. /_UU\B:SJ-[XM\2S7LOS7&K7"JB YVAFV(/P
M7 H ^@/@GI,FF^ H9YL^9?RM<C(P=GW5S_WSG\:](<X7.>!U^E5K&SCT^S@L
MX$V001K&B^B@8I]Y=06MI-//*L<,2%Y'8X"J.I- 'AGQ[UW=J6E:*&4K!&;R
M4 ]).B UZ#\-=#3PEX M5OE6&XD5KRZ9N,$C<<_05Y=X8T>7XG_%*_U^:-_[
M'M[E97$H^^%QY<7Z9(]*]/\ BOJKZ/\ #G4V7'G76VT7W,APV/PS^5 '@FMZ
MC<^//'Q82E_M=X+>U./N0YQT^G-?5UC:16&GV]I @2*&-8T4#   Q7SE\$M&
M^U^/GNMRM'IEJ7)(ZNQV#'X U]*!UQ@'I0!YG\;M4:Q\!-91/MEU&80=.J_>
M;]!BN&^ NG)>>+K_ %1HB5M+,)&_H\AR?QP#2_'C53/XCTO24=R+:%KAU]&<
MY7] 1^-=5\ -/%MX3OKXJ0UU=LH..JIP/YT >M\5B^*]1ATCPQJ>H3,%2"UD
M."<9., ?F:VF( R:\M^.^I?9O T>GJZA[^X6,@]=B_,Q_ "@#QOX=Z.=<\>Z
M)8ON-O&YN91C^%!OP1[G KZSC " @ 9&>!BO!_@'IZ3:UK>J>4Q$<26\<C#^
M\=Q_0 U[VIRN: ,W6=5MM$T>\U*Y \BUB:5P#C<1V'OGBOF[P=:W/Q%^)UK<
MZMYDZNS7MSD\)&N?+3'IG;7J7QTU-K#P"+9&"_;;I(F]U'SG^5>7?#7Q%>Z#
M<ZE%I&B/J.L7:QPP,.8X0.2&8< #K0!]"^)/$NE>%-*>\U*XBB5$)2+/S/QP
M%7OSQ^-> Z5X1UOXG>*[K6+FTEL;"[G$EU,V1M3 PB>O3K7I/AOX52R:F-;\
M:7C:QJ0;?'"7)AA).>![=/2O3XHUB0(BJJC@*HP /I0 RRM8;&SAM+= D,*!
M$4=@!4](*6@ HHHH **** "BBB@ HHHS0 449HS0 449HS0 449HS0 4444
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M%W.(@^/96!/\J /GKX;QH?B3X=C8!@EQ_%C^$''XYR:^LGGCAB,DKA$')=N
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MFSG4QAG"#@ID_,0,#-<#X-OFDB\;^+4L++5_$L6ILB07-Q'&;>W3&&#N?W:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$%+2"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLNX?W6P,XZ$=B/I0!UV:*RM,\1:5K-[>VFFWD=U+8LJ7/EY*HQS\N[H3\IR
M>.^,BM3- "T9I,UF7/B'2K37++1)[R-=3O0S06PR7955F+''085N3C."!S0!
MJ44F<4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 @I:04M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7%?%:QU+4?AQJUMI2-).R*SQH,L\:L"X [G:#QU/2NUI" 10!R
M_P .["ZTWX=Z'97L#V]S'; 212##(22<$=CSTZBN!^&$,OB3XH^*_&3HR6ZN
MUG!D [CE1U]52-,_[XKN_''C+3O"GAZ]E-];1ZD86^R6[O\ /)*1\ORCG&2,
MGH.Y%8?PM/A[PSX*MM+CUO2YK]8GO;];>]CE96P-Q(5CPJA5R./ESWH YGQ-
MK45S^T#8(-/O=0_L>V6-+>W0,7G<;E/+!5 \Q268@#;]*TM'\8^,M1^,R^';
MV.TL[&U@,UU9VX\X*IA#+NE*Y)#21@XVCL,]39^#(GU5/$WBNX"C^VM0)CQP
M?+3=M&.G&\CUX.:YSP;XTT6#QEXQUJ5IYM5U"[\FRL8+1I)3%&#AOES@' W9
M('RY^@!T_B#QKJ.KWFNZ=H.H6^C:=HB$:AKMS%Y@64-CR8T[G@\\G/  )&=/
MX2:EXCU?P2NH^))FFFN9FDMGD0(YAP ,@*!@D,0>X(->9?#2T\$R>')-;\6^
M(H;BY:X:ZET^\O"%65"3YABW9F9@0>0V<D8)S7N6@:W9^(+!KW3DE-B6VP3O
M'L690/O(#\VW.1D@9P<9&"0#6/3FO*?A?9ZCHNI>.=4UNR:SM9K]YQ=S)M,J
MJ\Q<]?NKU! _B/7MZN>E<%\8-632?AGJQ\SRY;I5M8_]K>?F'_? >@#A/@_X
MNT/^UO$.I:O?VUIJNM:@IAMW/S88DA0<=-SX_P" BNDN_%?BZ?XNZ-X;:.WL
M+&0-=310$3OY*^8!YCXPN[:#@#C<O)/%=-\.-!.A?#[1;&YC'VA8?-<,F&5I
M&,A!R 1C?C\*\W\/^+M.;XX^(]4NIVG9@NFZ?;P0M+)*0RJ2F!@*/+9B21PW
M>@#5^)OB[QUI.H:/8Z5:VMD;^Y9+=89//GN"A "L"H5%;>#@$GU8=#J?VEXQ
M\&:5XB\4^,KRVO[:-4^QZ=IY^169PH&XH"!ED&3N.-QY/6I/Y?BK]H-+:11-
M:>';#S "WRK<$J<\=_F7@Y'R'N,5O:QXE\*Z_KFI> M7;YO)4RB8F-&;A]JM
MQRHV-G\LX(H I>&=-\;7E]HVNW/C*"ZTF[B^U7%E'9HJ+O4%8XVY)7YC\Q((
MVC@YXX[Q#?>)/%'Q?TFT/AJRDN-!A-Y]A:^4A@Q7+-)C ^;RR!MSW[\;/P>T
MW^SM=\4P:/J<E[X8AN5BM9&8%7FQERN.N 0"XP&X./3"\+>,-)TCXI>-M7U>
M6:2ZENA964,41DFFQ(R;$1>N D8_+N: /:M$NM5N[#S=8TR+3KG>0(([KSQM
M[$MM7D\\8]*T3UJ*UG^U6<-QY4L/FQJ_E3+M=,C.&'8CH16?I_B#3]4U?5=+
MMI&:YTR2..Y!' +KN&#W[CZ@T >2?#[Q?'X'U;5?"GC("QOI;UKD:A(,)<-)
MU9VZ '&0W3!()!'/I7B_6[_PUX8N]6TG3K6\6")YY/,G\M5&,[@ IW\G)&5S
MSSFN6^.&DZ/<>!)]2OD"7MFR"SE1<L69@-GNI&?IC-9?Q(FNO#_P&TC2)T,=
MU+;V=E, I8*40%AN' Y3'OVH =\%[+Q%I/A&":+3;"ZL]4NS<O=/?,DR)@(<
MIY9#$;&(^;G=VYJS>>)?$7C;3M7U3PSJ\6A:5H\TT?VHQK,;[RUW%@6X1<8]
M>O7C B@\;Z7:?"66RT-+II;/0\27-M;8@MYS&HVES@%B[$G&>C9YZ\1!XS@L
M?@,N@:7;7<]TZR17\ZQL(;17F.0SD8+,I4!1_>)]B >C?"#6O%&N^$=1UC5[
MLZA(\I2RCE"1YV+SEE' +''(XVYYS7#Z%J?B?5_BWK?B>Q\)B_N['-G+:1:G
M'$D#8\OEW'S_ .K?[H YS]>U^#^NV9^'L-G865V?[.MGEGN'BVP23,SLR*Y^
M\PXS@8 (YKF_@KXLTJRT::RD\^YUW5-3:5K:WARVTJGS]E5!\Q))'?KQD [C
M5_&>HW/B:/PEH:6<.KQVPN]2NKEB\%BF%) 'RF0_,OH &![G%#X0Z[K^M)K_
M /:VI'5;.UNA#97XA"),!N#%< 9'"'VSUK@O!T7A[5_&OBRY\6ZY#%F^(-K<
MW*P17065BN[)&\*4 V=.1GM7M/AC7-&U6.XM= AQIUCMC2:& 1VSDYRL1& V
MW R0,?,,$]@#H:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5]'-E -.>$P&V1-J;",%0!T'TJF_A'09/#D7AYM,@.DQ;"MK@A?D8,,\Y;D
MG).[G.<FMRB@")(8D@$*QH(@NW8% 7'ICTK.T3PYH_ARUDMM'TZWLXI&WN(D
MQN/N>I]O2M:B@#EKOX<>$+_4Y=2N] LYKN63S)'=3AV[DKG:<]3QR>372Q11
MP1+%%&L<:C"JBX 'L!4E% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 @I:04M !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 (*6D%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% #0>E.IHZBG4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 T=13J:WWA3J "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :WWA3J:WWA3J "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MDW4M>4?%N#5--CLM5TKQ#K<&HWEW#86ME;W*I;Y;.3L"_,QP>2>I'8 4 >K
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MHX!/([$@\'X(MO"\_C:*YT_4O$^F/IT,E[<Z=JI8-/QPX*GH <L#RWRXR-U
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M@U+#X@T:XM9[J#5K"6W@QYTJ7*,D>>FX@X'XUXIXB\"6=GXGT?3]1AMKN_\
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M% '$>*?#GBK7_!<.BQ:S81W4\9CU&=[<[901R$'.T9[]?I7*ZY\+/%FK^&-
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MN8C/;2PK*\1D0J)$QN3(QD9[BI:* /(])^"U]HL*VUCX^UJUM=VYX;3,(8X
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M?XLAL[675-1L=/M(4ACL;1U$'RY"ML8$9 .,^@KNJ* ,CP[HKZ!I0L9-5O\
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M,Y!R5S@] ,'@CJ*]"HH YSQ3X*T;QB+5=76X9;;?L$,[1YWXSG!Y^Z*S]/\
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MN[&0-O!48? 7)Z=Z /+);7P_9/X8@TO2M9TW5#=0&XU?43)"F_<"P11GN>"
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M4)S_ +1Z8KT37?AG_:VMZ+KEGK,VG:O8JJ75[%$#)>* !EL$ -@,,X/#8((
M%4O%OPPUWQ5JOVEO&TT-I'<"YMK-K(.MNX^Z5(=<X'<C/7UH =X1^%MOX4\9
MZA?VRQC2[C3$LUC\TE]YV>86X'4H#D'N>!VY72OAUX1U+XP:[I*Z.ATC3;&+
M,(N&V^>^TYSNW=,C&<9!SVKU*[\/ZM<>%K?2H/$EW;W\83S-3$2-)*1RW!X
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MVTFW:2F !R.H((.!GH* +6M?##P!)I<5E/I]GI?GRQPPSPLL4K/G(16;.YF
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MV;W4ZBW#&Z:XC!^9NOR$\<'T&*\E6\O+'P7JNO1>#-%N--U6]F\B_DMUD^Q
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MS&1+$X89@9)25R.<'8J\<<,.U<WXAM+O0HM7^&H267SM7MYM+ROF.(G#;F!
M SQ$,<<E_<UZV?@;X'V[?LEYMSG'VR3&?7K723>!M!N-3T749K622YT>)8K1
MGE8A0H^4D9^8CKD\YH XO5;2RO\ XX^&]&M;.U6TT73)IY8O+39L=3&JX]!\
MF >F>!UIOA^+2[SX]WUUX>6W2QL]($=X]HBK%).\F[&5X8D8.>>4]16[J'P>
M\(:IJEWJ-Q;7GVF[E:64I>2*"S')XSP,GI73:!X9T;PO8_8M&L(K2$XW[!EI
M"!C+,>6/UH U^U>37,VDZA\=;N+Q%<VQ@TS38SIT%T0(E=\%W&X[2W/?MC^[
MQZSVKF_$7@/PSXLFBGUO2H[J:)0BRB1XWV\G:60@D<G@^M ',^*-0\+VUOJF
MHZ"EA/XCT?2I[FW:U _<(XVE\CY"1C.,[L9P/FYI^$Y/!/AWX56&JZE)83QS
MP>=>37")++-.P!D4C&68,=N/0#/K7;^'O!OA_P *V;VVD:;% LJA9F/S/+C^
M\QY/4\=.363#\)? EOJ0OX_#MOYX?> TDC1@YS_JRVS'MC% 'E>HVEW8?!/P
M_P"%I8X+:^\1ZHODQ2MDQ0O)O5LCI@F+/4X8\9R!K1)JVO?&;2-*\9M86#:/
M']IT^.PMV6*Z9<.-DC\X&W)'3]V1@')KT36?ACX/\0ZO/JNJ:/\ :+V?;YLG
MVF9-^U0HRJN!T '3M5WQ%X&\-^*XK6+6M+2Y2T!$ 61XM@.,@;"./E''3B@#
MS+4+SQ/JOQ"\6^(/"/\ 9L[Z/"FFJD\+-,^T%I%C'3=O#CT.!C/=FAZC::9^
MS_X@\0)<^?J&J"=KUB5&V>1O* "*,*,,K 8YW \ C'I7A[X>>%?"M^U]HNE"
MVNFC,7F&>20A202!O8XZ#I6;<_![P'>7DUW-H(,\SM([+=SJ"S')P X Y/0<
M4 >=VVB76B016'CY%?PY+;6NEV5GI\NU7F9A)O*A@VX,K%V/4L<<5U.C3:!:
M?&WQ,VI7MO;W]K!:VNG1SNJ*L1A5G$>>^?QP3V)K=L?A#X$TV_M[VTT$)<6\
MBRQL;J9@&4Y!P7(/([BM+Q!\/_"OBF<7&L:-!<3CK,K-%(W& &9""P ' )..
MU &+=IX.\=#Q-':7,#W L8[.\U6 AD6-MSJ%DSM.TC+8] ">!CG?#L6B7WQ6
MU#2K6XMOL&EZ%'I5B8F0E]P#.RMD[G&6!(]\]\^CKX1\/Q^'I]!BTFVATNX7
M;-;PKL$G &25P2V%'S9SQUK,T7X8^#O#VJPZGI>C"&\A!\N1KB639D8. S$9
MP3SB@#9\/:%:^&M L]'LI)I+:UCV1M,P+D9)Y( '?TK5I .*6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@! *6D%+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 8HQ110 8HQ110 8HQ110 8HQ1
M10 8HQ110 8HQ110 8IN 2"0,CI3J* # %%%% !1BBB@ Q1BBB@ HQ110 8H
MQ110 8HQ110 8HQ110 8HQ110 8HHHH ,48HHH ,48HHH ,48HHH ,48HHH
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MRQ &,IT[<8]*?0/$7C+X)Z;)-J.I1:[%&]S&#(8VN3N;8KXP3E,8.1R03WH
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MO2G0W$%P"T,T<H!P2C!@#^%>(^/M$\/^!?A):>')4&HWD\[M9O,S(!,V0TV
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M(]E5B.V0,UQOBSX6>$/#/P\U/493(NJV\!F34Y+AQ))<CE<#.T;FXP!W]>:
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M/*D46O:7)+(P5$2\C+,Q.   >237S7!H5B/@_->_V?%>ZUJFN+8V-VK$R*
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ME52UDF59&+?= 4\G/:O%I/!7AFQ^ 2:MJFGPQ:J;)IH[F;,<C2N247J-W&
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MR<#G@]L<^8Z;?:_:>#_$_BJQU+08M-UJYN9)K:[!^T299@45>@.'R%R>H]:
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M;3+@07^KV%I,5#^7/<I&VT]#@G..#^5 &E14=O<0W5O'<6\T<T,BADDC8,K
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MW7_^)H [6BN/N?B?X,M(+*>?78%BO4>2W<)(0RJQ4DX7CYE8<XS@XJW!X_\
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M&[30/ .GS6\;K/J,$=W<LY/+LN1QT  (''IFN\/2JFFV$6EZ59Z= SM#:P)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP6D!B!:10R@E5P/O!2%&.<GCD"@#T^X\4:#::I'I=QK%C%J$C*J6SSJ)&+'
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M* @YY/?&*U37C.L>'=(C^/\ X?ATO31'/LFU74I=YVR%BVUN6ZAQG '\0]\
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M[<*Z7&1M'F?*"^!TSTKO** .4\%^!K3P0EY#8:AJ$]M<N'6"YD4QP8W'Y%4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@!**4]*;0 ZBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 1@2I .#46R3^_4M% "T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "44IZ4
ME "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E)2GI24 +1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z4E
M*>E)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 'I24IZ4E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
MAH 6B@44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %(0#UI:* $  Z4M%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z4E
M*>E)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 'I24IZ4E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M>E)2GI24 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 !Z4E*>E)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "'I4'FM[58/2F>6G]T4 /HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ]*2E/2DH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH #TI*4]*2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ /2DI3TIOXT .HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*2E/2DH 6BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TI*4]*
M2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ /2DI3TI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ****  ]*2E/2DH 6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH #TI*4]*2@!:*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2DI3TI* %HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TI
M*4]*2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ /2DI3TI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ****  ]*2E/2DH 6BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH #TI*4]*2@!:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2DI3TI* %HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ]*2EHQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4449'K0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 !I*4TE "T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5&_F979CKSGTJ2DQ0 M%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1129H 6BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3%+10 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG\[CH&,?4>^* /1Z*Q-"\3:/XCA,NEWT%PP^\BM\Z#W4\C\JVAT'- "T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,T4 %%%% !1110 4444 %%&:* "BBB@ HHHH **** "BDS2T %%%% !1110
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MYJGX8TRUO=12UT^-D\,:3N@MX2N/M=UGYY6!^\%/1NG)K5.KVFJ:G;-<_:#
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M?5)I+V215QN\QBR_^.[:Y/7Y2/&GC:[D+L-.\-!(XPV 0ZN6_'@5VMG,FA>
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MTVQ?3);EB)C"B2&)(EBC9V+$>N ![F@#G_%&O7&L_#'6C_9@C*V#+-,O";@
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M^-+_ ,*;U7_H>=6_[Z/^-)'XW\23:UI6L7^FI#82:%=ZG;V-G=M(9QA&42#
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MFXC-6K6ZM[VVCN;6>*>"50\<L3AE=3T((X(H FHHHH **8\BQJ6=E50"22<
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M'@OI&VF) %LV#F-0?[W!_6K?C>TN(+N2]+:B;?\ LU[2!=/0M(L[OG<%SV
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MR1G.Y3)L3:#D\88'/2@"#P]XOO/"_P"SK;ZI)-(]]^]M+)I#NVL9&1#R"-J
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MN2",L%0$_>)Z]:N^+/A9X=\7ZK%JET;RSU!-N;BQD",^W[N<JPR.Q !Z<\#
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M'@G^;;N9CG>&&2S,<X[^@%;/A[X?Z/X9\+WN@6+W1MKWS//EED!D8NNTG(
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M/3--VW1^X\LC2^3_ +FXG!]^3R1G!-'B?X8^%O%VH)?ZI8M]K P\L#F-I0,
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MS1-)&2HSC.QAGJ>M:%AX6T/3-!ET.STVWCTV4,)+?:6$FX8;<3RQ/J3G@>E
M'B?B3PEX/AT#6_&">-9+B_NY9;VP-O<+'EV8LD>WERP)P3D$8Z+@UV/C;3T\
M2_!S2X-;U>WT[5)+6WN0]](D FN1%DHVX@ DENG0\XXQ70Z9\*O!.D:@E]9Z
M#"+E#E&FEDF"D'((5V(!&!@XXK6\2>$-"\7000ZWIZ72V[%HCO9&0D8.&0@X
M/&1G!P/04 >*Z%J7B?XA_$W1([U].-OH#"XD:R;?$@!4'YP6W,Q4  ''!(Z&
MF?%'6+^]\3W[Z[H>L'1-/CD@TY?)9;5[@@JL[N0 PR<@ \X S@D'WC1M!TOP
M]9?8])L(+.#.2L28W'U)ZD^YK-\2>!?#GBZXMY]<TXW4ENI2)A/+'M!Y/W&&
M: ,7X-1M'\+='5X7B;$K?,N-X,KD,/4$$<UWU4M+TRTT;3;?3K"$0VEM&(XH
MP2VU1VR22?QJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[/ID.DQ_:(5W%%D_=E>3_$02<G.<OW)JEXVT?PII%SJD-W:S^)O&.NRR_9H
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MB;0KR[O=-\;0Q7UUN\ZZ?3%DF;)R?G=BPR>3@\U[+Q2<9QQ0 V-2L2*QW,%
M)]33ZBEGCA,:R2*K2-L0,P!9L$X'J< G'L:;=7EO90^==3Q019P7E<(H/U-
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M'0/AUX3\,:B=0T?1TM[LJ4\UII)"H/7&]CC\*ZFB@!  *6BB@ HHHH ****
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MY<_*"1@GC% &'#\4_$G]AWEN]OH\_B-KE(K&&'*Q,@B265G#R#:JJV VX9)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex-a_050.jpg
<TEXT>
begin 644 ex-a_050.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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MB7+QD6TB1R97#.NX8SS^E6$!"C/6G44 %%%% !1110 4444 %%%% !2&EHH
M!1110 4444 %%%% !4%Q&TL;HCF-B.)%'(J>B@"I;64=JCJ@.'=G;/.2W6K8
MHHH **** "BBB@ IO>G44 %%%% !3)0Q1@A ;'!(S3Z* (K99D@19W5Y0/F9
M1@&I:** "BBB@ HHHH **** $%+31U%.H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!F[YPOJ,T^F;?G#>@Q3Z "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M:.HIU-'44Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** &CJ*=31U%.H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!M+FDHQ0 ZBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** &CJ*=31U%.H **** "BBB@ HHHH ****
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M 4444 %%%% !1110 T=13J:.HIU !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4456EO[2%BLMU#&P&2KR!3^M %
MDUYS\2=,LO$OB'P;X?N5C<3:@]U*"-Q,,4;,RD9'RMPI/;CKTKT0'(!!R#7'
M^*?!W@W4;Q=:\2QJLJ@1)<3:C+ JCH%7$BJN<G@=<F@#@&MHO#_CSQ>W@66W
MLX+/0!+=%$$D$-TD@.W'0,8U; [,6)Z$5T.@'Q*WP6MK[1A86NL2QO>!8+%
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M@I6V599$9 3DC<K!CDDGDGGFN?O?A]\+[[6+70S#I\.HVJ8%C;77ERR+@/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMEV1.+Z8L$)+%<ECQN)./4FE\ ^"_"_AK[5J'AO49KZ.[ C>7[4LT?RD\#8
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MZ06AG)^1Y75"R^X'/X5T;7^@>#]*MK2ZO[+3+2&,1P1W$ZK\JCH-QR:R]7\
M^%?%M['K%] ]V9E1T=;E_+==ORD ''(/4=: ,_QM>^%['1-+M=81[Z2&2-[/
M3[8@M<,O"_+T*^YXJIX5TN?1;OQ!XT\026>F_:XP6M+=@8[:-!D%R.K_ $[_
M %II\'?#C4]5N]->P1I-'MX8II#<R!( VX(F_=]\8Z>X^E36G@[PCK.A6]MX
M?O(E\/1WQN+V*UG,D=RR@$([L20 =K$=,4 6O!VE/J-]/XTU:(Q7%XABL89#
MQ:6@^Z![M]XGWQ5/P7!IEO\ $+QA?6R65I:1>1:Q>4RJK%5:25L?\"'/3@^E
M;4.L^#O'UG>^&[74H+Z-4'FP6[LAV*PY4C&5!V\@XY'K6/>>&O 'PWM&UA],
M\@R 6:HLCRM.7&-H5C@DC.?;- 'GGBFSUFW3_A 4L+ MX@UB6Z6^AF626>,R
MA@[)U7 /4GD*0.ASZ'XL;_A.O$R^"K5\Z99M'=:Y(C'D9REOP0<MC)(/&/:K
M>C:=\/?!^JRZ1HLVE:?K-P=@C:X\V<.1\H^=BP[';D9S[T6U]X4^&%G;Z=JF
MMJ+_ %";SI[BX):6YE;AI7 SL7(QD_*,=3R: ,;Q-XKT&R\:-;Z%;66H>*I+
M8V+3W,X2UT^-2V=['@8+'<B\G&."0#FVFDVNA>,? ?A:[U*";3=.L[C4P[[5
MCGN&9V# 9  4EF7K@#\:L^)/AQ\+?#>G'5-:$\%M(X"DW<KEV;LH!);UXSQS
M76ZMHO@?Q'X5T^_U."SN=%LH1-:SM(R+'&% ^\"#MP!E3U(&1D4 >433Q:C;
M_:+J06N@>*?%;3?:93M5[:'[N[.,!V!ZX(V9Y%;'C+4[LZGXW\7Z3(6@L=,B
MT**:+.&DDE4RLK@\&/=CCN1SQ7<V%[X(^)^B3Z5:JFH:=9-&&A$,ENL1 .S8
M<*1P"/E/3@\&NAM_#.C6OA]M!M].ACTIHFB:V4?*RM][)ZDG/7.>] 'E/PT_
MM+PMXTM/"$&NZ=J^ERV#WLRV,2E;=]W4NO).<#+'H5&!\M>VBL'PYX-T#PE%
M-'H>FI:"=@TK!V=FQT!9B3@=AG')]36\* "BBB@ HHHH **** "BBB@!K??6
MG4T\L*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%)F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %
MHI,T9H 6BDS2T %%%)F@!:*3-&: %HI,T9H 6BDS1F@!:*3-+0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 444F: %KRCXXV\5[8>&[4
MZ=/J$CZF'-M$Q!EA5&:10<\$@#!QQ@_CZM7)>)_A[IOBO5;?4;[4-6AFMXC'
M"+6Z\M8P?O$#'!/0GN /2@#A_"/PH\.ZQIFD^(;C26TE9H+C[1I\5Q./,CD+
M+'EVDW+^Z/(& VXYP.*/ACX"\(WGAV3Q0VFR1"[FO/(,MQ(AM[1B\6S(;!_=
M[OG//S$YX%>AZUX.L]>T&ST>YO\ 4HK>UVX>WN-DDFU"@WMC+<$Y]36%;_"/
M0[71I]*@U378[29D9D2^(&%W_* !@*2Y)&.2!^(!S7P@TSPUH'A^W\3R*EI=
MZQ>RV-I(\K-O1I=L<2CH23'G) /![5Y_%HVF:KJ^JP7VG1V^G:A?7MRGB*Y,
MDAA@$ACCVC<,DS84[\EM^/>O3/\ A5'@B.]AT;_A(-26ZB(GAL?[40.AR2'6
M/&1R2<@=S4EQ\*_ _AZVA_M#7+ZTL!*KB&[U-8H)&# X(( /('O0!4B\!^'M
M>^)>K17UA%-I6B:5:6(1W8 R%<AL@C!6-0",_P 0/>MWX-F5?!]Y )I9].MM
M4N8-,EDP=]JK#:0P W#=OY_#H !0N?A-X,N(I]3N=:U(VVHN)I96U(>5<9.Y
M<MCYASD'/?BO1;.SL-"TM+:VCAL[&V3"J,(D:C_)))^M &=XQT[2]2\*ZC'K
M5M]IT^*$W$L)F:(-Y8WC+*00,K6!\-M"MA\)M-L9K>1;?4+5Y)HS(02LQ).&
M&"!M88(YZ=^:T?&'@NQ\>6MF+C5]1MK:-7(6PG54G#A>6R"&&!Q]3ZUS&F>"
M_"=]HUSX1TOQCJLLD$ZW$P@U-3,BJNP)M VB/YAT7KMR> * +GPCT&STFS\0
MW-C;+#9W&KSQ6>V3S UO$?+4AN21N$G4G]<GK(/^$@;Q7=^>;-=!%N@MPH)F
M>4D[B3G  ],'.1[UROPZ\,>$/"VJ:K;^'O$#:A=LJQW$$EU%(T00GHJ*".6P
M3Z\=0:U=!_X1C1O$&KV]IXC@N=6U.^:>>VFOXY)4D''EJ@(("@8Q@D 8["@#
MSC6K.+5?!?CC6M2C@N]5O-6?3M.W1>9)$$D$<<2'&1GD\8ZY-:%E_9NH:]XJ
MUGQ-'!=VOA>PCL(K2?$@5A'F1PK<;F9=JGJ>G:NQM_ 'A32/%;:VS,MY=7#3
MPP3W \H3MU>.,_Q\]><;N,<8AUWP#X+N?%/]N:M(D-S,%,UO)<K'#=;3P9$/
MWAD+D="5&1UR 6?A-I]SI?PNT&VO,><86FQG.%D=I%!]]KC([5F?&2\TP>#W
MTJYT^34M2OMPTZTB#%_,53F7"Y)"!BW3!X'N/0K>:&>!);>2.2)A\KQL"I'L
M17+7_P /=)U#QK#XJGNM2_M"%HS&JW.(U"#A0,9VDY)7."2?4T >#:?;R1Z+
MJW@"T:6.35KO3Y+*/4K9K=F8C,SE<$A0R*._ XR<TU;W5O&\7@KPY=03_P!G
MVMRNGS([@"22-OGZ#/RP%1GJ"3]3[L?AKHCW-Y<S3W\]S>7<5W)/-,&D!C;<
MB*Q7*H#V&. !FK=SX&TJ\\9V_BFYFO9;ZV&(8FG)AC^7;E4[>O!QGF@#HHHX
M[>!(HT5(XU"HBC 51P !]*\VU_1-+D^-?AF:#3XOM\B3WM[<"3+E8XQ''E2<
M8W;<$#/R_4UZ&^HV270M&O;=;DD 0F5=Y)Y'RYS7GT?PK\":'JJ:A>W4QNO.
M%Q&;V_V_,K;LXXR,]<Y_4T 4_&,VCW7B;4+32])?Q-XNFM?(CM9T22VT]0 2
M6+85,YSU)) &1FKKS7'PY^'6A^%K6Y%SXBO!]CL<DLOG.V6?IGRX]_7'0+Q3
M[SX/^ +>&XO+VWEBC&99YIM0D51W+,2V!]35BRTG2-$UF;QIJFN6CZ=';1VN
MDN9L0V]OL7HQ)#.Q!Y'4#WP ".^\$:%HGPPO+#4XO[2CM(YM0GFN)"C3W.QB
M9&88.<D@9SQCJ1FJ5OX6U.Y_9]CT"Q62#49=-WA"W+,S>8R9S@;\E>O&[FN@
MU;PYX2^)5C9WMU(FHVD ?R9+:[8(,XW9V$<\#@\BL'3_  [\,-6T6?PWI][:
M75I;S'494AU!F9&"A#(7#9VA< \X&10!S?@6^DU3XLH8] CT6ST'26M)H5<.
ML9W#[S@ !CD\?[+'/6NHTB9?&GC&7Q9=8C\.Z+OBTF1Y,17$GS"6X(/&!T!Z
M<9ZCBO9IX-\3>&[WP7X(UFUL5?'VO[/$_F/%PKD%L;RP 4MEN#SG(SM:S=^!
M[6RM? &H7D,"W2Q6L5A"[JY!8; 2@^7<<=<9SSP: .$?1= \?WT^@^&;4#3F
MU!K[4O$,X_>R2L2QCMR<%CR1DC: ,X.06AU#4;&?P_\ $[7[Z*.>_O-0.C6U
ML K,I11'$5SSD[BW S^[.*[G2_@WX1T;7[76;*&[2:U<211M<%D# <$YY/KU
MQ6G#X)\(-XRN/$$=M!)K2/OD/G%O+<C ;R\X5N.N.O/6@#B]!BM-+\5Z@?$3
MQL/!_AVSM$0D/&VZ+,TJ*<<G:$]2& /4"N0N-/\ $6H:-X%\$V:6MK]JBDU7
MRK@C9S-)(JNIX<*A!V;3WR../9M<^'_A?Q'KD&L:M8)<WD*H@W2,$8*Q8!D!
MPPR>A'/0U'XN\-^#O%(M&\026[&U:2.%OMGDD'@.O##/(7([4 9GP@UZ]U[P
MK=O?M:R36FH2VHFM8EC6555"&PN%_BQD < 5Z%6'IT_AWP_X8@:SNM/L]%MA
MY:3"=1"OS;3\Y."2V<DG);.>:L:;XDT/6)FATS6-.O9%&62VNHY2![A2: -2
MBBB@ HHHH **** "BBB@ HHHH :.HIU-S@@4Z@ HHHH **** "BBB@ HHHH
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M-!;"X65+H31RJ9&3*$ ''R@_,%(STZ$^:?LZ^5#9^(+5XFCOHYH?-5Q@A0&
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M^F,"1P<'L:9ME_OT 34444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#Y@#@\ =N>]3'P9I1TO4;%FO&&I?\?EPUR[3S+_<,A.0F"0%&  S8')KHJ*
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T=13J:.HIU
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7<K&"S ;N0<8;OQG@;3GC;NSU'5/V@O$?]@Z@EAJ5O8,\#O$KK)((8EV$-P
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MZ$$'J*[/QEX[MO!6EVTM[:M<ZG=_);6%LQ8RR8&0&Q]T$@9QGD87/%>4_M%
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M3@;OLS<#VV"(_7- '6VOQ=TR^U"\TZUT'Q!-?62,]Q;1VB&1 K*C?+YF3AF
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MUP:W=Z7$^J!D87(=U<%0 IX(Z8%97Q0\1:MX4\)_VSI,MNLD4R(\<\'F!PQ
M[,,8Z]\]/>LO2/$WB75/A#/XK-[81Z@L5Q=JHLB8Q'%O'EX\S))*$[NV<8/4
M@'5:WX(\.^)+I+C6=-6]D1=J>;*^U!WPH; S@9P.<5HG1[$Z(=&,"_V<;;[+
MY&3CRMNS;G.?N\>M>>6?COQ//\()O&;+I"3HSO' MM(4:-7,94_O!ABPSGD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 (*6D%+0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1B
MBB@!,48I:* $Q2XHHH *3%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ
M2T4 )BC%+10 F*,4M% "8HQ2T4 &**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 04M(*6@ HHHH **** "BBB@ HHHH **** "BBB@
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M7PI\)['3YM4_M6>QU<QPS,N&MHWB9O*QDX'RHV/]H=L5J>)%\0:MIMMI-_\
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MM(L/ 7B VEJI2(RAB^,D\D*.>:IV?B&V'BN\\37FA^,[/4KF,Q;(K?S(]C#
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M<]I +2+2T\N.0;@65& )SUX'>N<T:36+7P?\23IOFPV23L(UB^Z )&60*?\
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MOOB3X<\-ZE^^T^6TB>>VCG:.*XE8$$E@<X#"@#V_*^7O4@\9!!R#7%MXWO\
M4?$M]I/A_3;6_33@%NWDO!"WFG^!!@YQT+=,FK'P^M-0TWPNNFZIJ5K>SV4C
MPB2!RVQ<\*Y[L*X+Q!X*O-5UF_\ %7@+4GM;Z*5H;FT(,;-*GWMISWZX/!H
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M&W_LTR6Z%HE=@Q8@#IY9!.>ASZ5O^.]?\0:=K^H6:7\D%F^FR2Z?#8.AG,R
M$L^X<)C.<_A0!ZN7QVR?3%(7((X'/7)Z"O#]3\=>(%^"&D^((M0*:B;GR99=
MBMO&2.1C'0"M#4=6\7>#_"MUXJU#75U#[?;1);6I@V+#._W6'8 #\S0!["K[
MFP,8I]>9^!KKQ6=6L&G:^O-&N].26>XO"GR7) )\O'.T\\=*]*4D_3% #J**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*5P@WGH*//7WIS %
M@#TIVT>@H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *R/$46L3:5/'H-Q:V^H-M\N2Z4N@^89X^F:UZ* /+KWPSX_
MU%<7U[X7O2A#H+G2RV''0Y(Q^-2II7Q3BM0L6I>&@1SY8M2%^G%>F44 >66'
MA;Q[874E];/X1M+V<?O9(=/(+<="PP3^=9S^'?B%HVJOJ&DZ9X4DO;A3YU[!
M;F-^2,@ECSD@'\*]DHH \#O/"7Q)O_%9\07VB:)>7?D"#RYCNCP >0NX<\GF
MM6QM/BKINF?V;9>'/#,%D0P-ND8V$-]X$;\'/>O9Z* /&--T7XD:-.+O3O#G
MA&UN)_W<ACA96C7.>,/@#/.!WK1TW2?B%H]Q-<6^@>#_ +5.3YMS&&BD<$Y.
M2O)YYZUZM10!Y+/X>\87.H7-Y/X2\'27%TGESW&]P74]<GU]^M$WA[QA)HL.
MC2>$O"$FF0MF*V,L@"$=&W=CUYZUZU10!XKJ/A/Q7+=V=\_@GPS<SV<:16XA
MO)D6)%.Y0%W!< \TW5-+\<:W?I?ZIX$\/3W,8V>8UTR;UZ@-A_G7/0-W%>V4
M4 >+W^G^.M3N;2XOO 'ANYEM ! [S,/* Z!1NP ,4VWT[XB:9J-QJNF>"O#5
MK?7))FG65Y'DR=QR=_/.#7M5% 'B6K:?\2M<9!K?A+0-012#L:4JN/3&_@]>
M:1O#FMN4A?X6Z5)9P@>3"^IGY#U..2.O;%>W44 >-W^E>(-6U,:IJ'PPTVZO
M!%Y ,VIY79T'RGC."><9YJ32K7Q7H6GW.GZ;\-]+@LI_];"NH[FD)X.YN_';
MM7L%% 'CD]UXI2QL].;X5Q26FG.KVD::@&\IAT*DCC%7I_&'Q18AX? ,"H!R
MLETI.?;FO5.]% 'A>L1^+]=O?M6H?#6)KMK<V\\J7[Q^<C?PDQN,CV-0ZE8^
M)M8M;"PU3X61/864>V&W3471%.#R%1P"?<@FO>J* /*M!\3>/-/TR*TG\ W$
MOE +&8[S@+C@$RN6)'N:HV]O?V>M76L6_P *;N+4+D,L\PU-<G=UV@-@$^HY
M]Z]CHH \'?P]&=)_LL_"34OL8N//,2ZN2#)C;D_/UQ3O$)DUBUM+.]^&.O33
M:>BI!=?:CYH"],R#)89YZ]>:]VHH \9TWQEKNA::;#2_AAJT-NK$JK!W+YY9
MG)&2Q]3FLI-4UF*2^>R^'?B6P?4',ER;:_F!=CU(&,*3ZU[Y0: /!+C5;R7P
MM%X;E^$^J-I49SY?GN"3G))8 $MD\U:W:3?V>F1ZC\-O%22Z8"EL(VE)C7/W
M=^X$BO<** /&='N=(T$:C#IWP]\6Q6^H(5G@,3/&<C!PK,<?6J&EC1K#0;W2
M3X \7_8[U6C=)$:78F21LS]TY.>!UKW6B@#P3PSK<'@B-9T\(>+[C:ICMY;X
M%A%&QSMC4#"!B!T%6_$7Q(TCQ%#;0WGA#Q 6@D6X@N(X]DD#J1@H2,'TY[9K
MW"B@#Y_L/&>DZ;'K!A\-^)?M>K-_I5\X1YI<@\ A=JC!/ _I4O@_Q]I/@NPN
M++3?#OB>2SED\Q8IXE<1MC!(8#G/'7IBO>Z* / /%/BKPUXVN+6YUK2/%D)M
MCMAA@@4*I/.<E223@<>U6+;Q)X8F\21ZW=Z)XKU?58=JV\EY#D6^T9RJ@*HY
MYYSSS7N]% '@NN:IH6H>(8?%:Z)XQTFX48GNK2U,8GC(V@EC]WCCCDUGZSXL
M\(2Z[HMY<+XAT]](2)X+3[-'C"MOW'=\WS;1D_C7T5S32N2,CD=* /EZ?4_A
M[+;:I:O?>)_)U"87)143;%("23CHY^8#)Z"NHU+QQX'\0>']+TRZM-;N+73I
M8Y(V2V5O,*@C#$>H/(KW@H.XR/I2JH&2HQ^% 'B$'Q"\$3>.7\2QZ7K#:@;4
M6T@2UW!.<9('.[!Q]!5+7=0\#:WXFO\ 6I-3\1P?:K9K6:."SD56S@<GJ1Q]
MT\5[Z!CUYYYIPH ^=)KCP+-X#B\)G6]=6V%V;D2MIS%F;&-@7& ._%=1>>-_
M >K>$U\.ZHVJ7=MY"QF4V$BN=F,,"1P?>O8Z* /(_AOJ&AIJMOI=OKVMZA+%
M R6<5[:&".&+@[>@#'@8/IFO64P23Z@4\T@H 6BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH :WWUIU-/+BG4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M)F@!:*3/M1F@!:*3-&: %HI,T9H 6BBB@ HHHS0 44F:6@ HHI,T +1110 4
M444 %%%% !111F@ HI,TM !1110 44F:6@ HHS29H 6BBDS0 M%)FC- "T4F
M:6@ HHHH ***,T %%)FEH **** "BBDS0 M%)FC- "T4F:6@ HHHH **** "
MBDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-+0
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M+]T_-L'^\^-J_B17D?@O5[-/@)XPTR5_)N+4MY@D^49E 5%!]=R,,?2N9?\
MLI?#GPX>Y%NMJU[=?;RX&UE^TQ[M_K^[V_A0!]*Z!XT\/^*)[F#1=3BO)+;'
MFA%88![C(&1QU&16Z3@9KQ?PH\,7[27B:"U,*P?8RI2(+@$"#(XZ8.<^^:[K
MXA^*++P_X?-K)J5M9WVI,MG;-,P_=^8P1IB/[L:DL2>. ">10!S?A;XG?VW\
M5-4T5Y<Z9/'MTHA.)&B!+L"!R' <@DXQ'CJ:]4KYX^(VD7_@2^\,>)EU2PDF
MLC'9P0V5L;4O%&">29'W J2A[88#G->DS_%;1TO_  M#;07%U;^(3B&:/;^Z
M8NJ ,I/9B0WIM/6@#LM6U.UT72+O4[U]EK:Q-+*P&3M SP.Y]J\U\#ZOXI^)
M$E]K4^KS:'HT<A@M;2PCB:1F&"6=Y$;. 0. ,G/ QSV7C[P_)XI\#ZIH\,HC
MFGC5HF89!='5U!QV)4#\:\X^"WBO2=$\/7GA[6KE=+U*VN9)FBO?W)*E<D_-
MT(VMD'I^- '<:.?$]AXOU.#6;X76A0V,4EM=-"L0W;FW;R  7 4EL87&TX7.
M*UM,\8^'=9U%M/TW6;*ZNU#$Q12@D@'!(]1[BN9\9>)/#NO_  [\12":YO=+
MMXT26:Q(42,64A8Y&!4D';NQG&<=>*\D\&Z_!/\ %?P;?7EW:I''8K:C8<"+
M$,L2(Q).6)V\\<L.* /H)O&7AR.]O;2;7+"&>Q&;E)9PGE#(7+%L <LH^I'K
M6!JGQ7\.6'B33=&BOK*?[4=T]Y]J5;>VCVD@LXR"QP,+QU!)&1GSK0-%T3Q/
M\=_%UCJ]K!>VQCGVH[='#QJ2I!R&'S#(Y'/2M?6E\.^&_CMH45W'9V>F1Z&D
M40D0>6CB24)R1P?E&"?0<T >J7OB;0=-N4MK_6]-M9W4.L4]VB,RDX! )R03
MWIUSXCT2SU :?=:SIT%Z<8MI;I%D.>1\I.:^?]1:&X^*'CO3/$VJ66DQ7T15
MKB6W$I,2%'C"<C:QC5#WR1TW 8U?&.GZ9=>*?A?H_G?;(1;0Q2F6,I)+#F,*
M9$/(#!7X/JU 'N>GZG8:M:_:M-OK:]M]Q7S;:59$R.HRI(S3[Z^M=-LY;R^N
M8;:VB&9)IG"HH]R:XS4-=\*_"D:9I M+BUMM4N99$\A-\<3;EW%LMD+\ZX"@
MX Z5N>-D:7P%XC14+LVF7("@9)/E-@ 4 <?<_%.'5_ WB/6=!>&&ZTJ;$$<Y
M#M-$"@$K1\,JMN8#W7KG(&O\/_','B/0M+34+ZR_MVY@>>2UB.T[1(R@A>W
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MN(^\G][(\IT^&WU_5O&<.O\ B2QT6\-X+@W-Y;&2<>5(^5A?>NTKA1M&20%
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M_/..]&><=Z\ \<PS^"O"_@[PPJQV\5_/]HU;$\B+/(OEAT9U)/E_.0<9.%7
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M>A%.IK?>%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ)MH0X6+Y#&I!( X&=_S'CU/2O2]4UO2]$LUNM5U&ULH&. ]Q*J!CC.!GJ<
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M;)YK9\,>)++Q9X?MM:T\2K:W!<()E"O\K%3D D=5/>M=W1$9F9551DDG  H
M=17/ZWXST#P]:V-UJ.H)';WS*MK)&K2K+D @@J#Q@@YK?R.Y&: %HI,C&<C%
M+D>M !1110 4444 %%8=EXNT74/$-SH%O=L=4ME9YK9X)(V500"<LH!'S+@@
M\@@C(K<H **,CUHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>3QDM%Y4K(<%EZ?*N<YZ,#Q5'0[0_"7XH&$V;7.@:FJI!?\ EAFCB8@AMP/
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M)(J2.%5UR%4^6"=O.'(SQS#\())(/B1\0+-I#,3>,7FD #NR3S#)V@#)W$G
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M6$HP I;'.TN-N">?-QUZ^J>&=(;0] MK*5_,N?FEN9<Y\R9R7D;/?+LWX8H
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MF&ZG6R15!B1W=_N=L ^6V!TX..>0#W5-5T]U@9;ZU(GA,\1$RGS(Q@EUYY4
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M(]?GF734DCCCEF54+B38<@ !C\O&>G;K5GP%K6L:M\5==T:Y\1W][IFFB4P
MNGS[9%0;BJ\\$^G- 'LV**^=-$UR]A\9>,-.U?Q)KTFDZ/!=S1HNHNLKF&4*
MBA\YR5)'N<9Z5Z<WA[5-$\#>*+6\\0:I=E6FNK&]:Z<7$<:PH54L.F'5N!P0
M<XY(H [VBOGS1+N_OO@QJ?B:]\6:W:ZI9W$GDW OY660JJ[(C&3M(9CC(&03
MDG (KHFU3Q%XC^!+>(;F_O++5K1)+F.XM)3;^>B$C+!>""N3@ <@$8S0!U\?
M@B^/C2?6;KQ1J-SI33+<1:/(3Y4<BCY3G/W5.6"A1R%))V\]E7@&C17^L^']
M%@A\9^*#XEU:RN;F&-=1!AC,3$+O4X8!\8!SC(;TK0^+5_K6C3^$W36=1T^Z
MU &/4?LUZZ1Y41 E5SL7&]^0!GOG% 'MQ4'J :1E5@ 5! [$5XC_ ,)'?Z'\
M7-'T;PYK][XATF\B1KF&6\6[VDEPY#]5VJBOC/KV(%2^(M2U[P!\4-.GU#7]
M0F\*:G=-)MFFWB+CYD.5^559@P ZJ,=030![1Y:'^!?RIQ53P0"/>N0+7^M?
M$ K9:I>V^E:1&J7D487RKFX;Y@@)7/RJ07Y_B4<'-7/'/BN'P;X5NM6E3S)5
MQ';Q_P#/25ON@\CCN?8&@#H]H/4#UI,#.<<^M><>#].\4>)O"_\ ;FJ>*[ZU
MO-23S[6*TC18;5#]SY&4E^!W/(/4GYCD>+Y_&GA[X:7>H7NMW@U6SU(HMS D
M2+-;LX1&9%4A1C! X()[YH ]=$4:RM($42, &8#D@=,GVR?SI]>+Z.WBC5/#
M5I=V/B[5;K76T]-4-@ZPK%(F\CRLA=P+!2 >F?3MH_%'4O$&D>)O#5OIGB*]
MM;76+Q;:2&.*']T-T:Y1MF[^,G#$\^W% 'I]GI]EIT)ALK2WMHBQ<I!$J+N)
MR3@#J3WJM8^']%TR]EO;#1]/M+N4$23P6R1NX)!(+ 9.2 ?J*\MU;Q!XF\$?
M$?0-!_X2!M8L=5FA$D=["GFQAI/+8@H!@=Q[J??-CQ:GCK2_#GB77[OQ-<VD
M=K=.VG6=O#  (?-VJ7<*2<J00,Y&.>>  >I7VG6.J6CVFH6=O=VSD%H;B)9$
M;!R,J01UIDNDZ=.\3RZ?:R-$H6-GA4E .@&1P!7G7A"#Q=>Z9X6UR#Q3<ZC:
MWI#ZG;SQP;8T*,3L;;N&UP%('))[ &LWP1XV\4ZU\4=1\-:C?Q2V>G/<AGBM
M%1I/*D$8SUV@YSQ],T >KP:3IMK/Y]OI]I#-@CS(X55N>O(&:=%IMA!<O<PV
M5M'</G?*D2AFR<G) R<GFO)+7Q7XHO\ XNZCX5;7OL]A9"6194LXBS*%5@'R
MISC=VQG%:>GR>/M?\/7U_IOB#:+BUMKO296L(8]^1+YD4BG>%)Q'SD@?+_M"
M@#U*LO4/#6@ZM.)]2T33;R8=)+FU21NPZL">P_*O//A5X\N=8\,ZY>^)M9D>
MYTYM\XD@CC$$.TG< B DY# @Y.5]^>F\.ZG>Z/X,EU[Q?K#>5(QN4-S"D;VL
M#D".-]BKN?!&?E'S,0!Q0!U=O:VUI"(;:"*"($D)$@503UX%4['P]HFF3S3V
M&CZ?:33 K+)!;)&T@)R0Q !(SZU=M;FWO;:.YM9HIX)!N26)PRL/4$<&IJ ,
M4^$/#)BFB/AW2#'.XDE0V4>)'&<,PV\D;FP3_>/K5IM$TE]-337TNR:PC&$M
M3;H8E&".$Q@<$]NYK0HH S/^$>T4Z/'H[:38OIL8 2T>!6B&.1\I&,YYSZU8
M73-/73#IJV-L+#RS%]E$2^5L/5=F,8]L5;HH S$\/Z)%##!'H^GI# ,11K;(
M%C!).%&..23QW-/M]$TFTU*;4;;2[*&^G!$MU';HLL@)!.YP,G) /)[5H44
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M+A&,*H)XQC'YUTU% '+:3X T+1O$MSXALX[E=2NI)GFD-RY5_,8LP*YVXSC
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M93Z/IES!#!<:=9RPP#;%') K+&,8PH(P!@#IZ5/]CMML2_9X<1#;&-@P@QC
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M-;[PIU-;[PIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 -;[PIU-;[PIU !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %)2U'-$L\+Q.6"NI5BC%3@C'!&"#[CF@
M!]&<\5\W>";W3=9&J1^+=;U*^N8[Z"UT^VEUF99#YDFQBB[\MC*D\'A>:V/B
M9::IX,^'&@+%J5Y'?6.I7$$-U'=.'>%O-*ER" 6*A,^G(&,F@#WFBO'/BD=0
M\%_#7P^-&UG489H+A+4S"8AI5:)V)?'4Y08].:R?&.K7N@>'/"&N:3XDU&;6
MY1;O+I;WTDJW1>,.2T8;."P"XZ'?@8H ]YHKR;XJ>*Y= \3^%[>]N+^#0Y/,
MGO!82O#+*5& NY2"5!8$J#R/4XJSIUG?:[IVOKX8\4W%YIEY!;K87<E\YDLW
M\US-'N)+@A2"&8;L,JY(48 /4**^=?%JZGHOQ;TCPU:>)_$G]GW4EHLF_59B
M^))-K8.>.*]+M?/^&FEZ[J6NZSJ.J:,L\+VAN)FN+B,-A&!+8XW$8P>@SUZ@
M'H%%5=.O[;5=.MM0LI1+:W,:RQ2 $;E89!P>1QV-6J "BBB@ HHHH *#16+X
MCL=6U"/3X-+U*73E^UAKN>%4,GDB-_E7>K#)?R^W')]J -FBO#_#FK^*M8^*
M>M^%+CQ=J2VEDD[0S1P6XD.UU"[LQD'AN< 9QVI?&7B#Q+X5U;P-:ZIX@FC2
M24'4W78B2*DZ@N=HS@HQR,XP!QD4 >X45@^'_&.@^*1='1]1CN#:L1,.5*C)
M ;!Q\IP<'I4-GXZ\,ZAJ$%C:ZO;R3W&?('S!9\$@^6Y 5\$$?*3^M '245YS
M?_%.TMOBA9>$XHT$&]HKRZER-LI3*(@]VV@D\?-@>M=OJVK66AZ3<ZIJ,ZP6
M=LF^60\X'MZDG  '4F@"\:45XR?BQ<Z[\/O$^IZ=.EAJFGS![:,0[F6W+H%+
M[LJ6.7!QTXXZ$]'\._B%INM:)HVGZEK<$_B*XA=I(L ,Q5V&#M&T-@ [>"1S
MC'- 'H=%<_K?C7PYX<O[:QU?5[:TN;G'EQR$\ G 9B 0BY_B; X//!K>#!E#
M @@C((/6@!:!7BFES>--2^)6O^$_^$WO(X].@,L,_P!D@);.PJ&^7L).2.N.
M,5T/PF\<:OXN75[35Q:2/I9BB6\M0P6XSN!8YX)^3=D8X;H* /2Z*RM/\2:'
MJUR;?3=9TZ]G";S';722,%SC=A23C)'-)?\ BC0-)N3;:CKFF6<X 8QW-Y'&
MP!Z'#'/- &M15&]UC3M.FMX;Z_M+66Y?9 D\ZH96X&%!/S')' ]13;;6=+O4
MNFM=2LYUM6*7!BN$<0L.H?!^4\=Z -"BO+KCQ]J"_%W1O#^GZAI]]HNHPB?S
M(5#E<K+\H=6(/^K!S[UZ=+(D432.RJB@LS,<  =230 ^BLW3=>TC6?,&EZI8
MWWE_?^RW*2[?KM)Q7F-U\1M>U_Q?J6B>$+C2!)9,J6T=T"QO^3YK*^X !0.
M 21DC(Z 'L%%<?\ $C7M1\+^#9]:TR:U2>VECS'<Q%UE5G"E1AEP?FSGVQQG
M(XZ\\?>,],\%Z/XVDATJ^TNX %W90V\D+P[B0K"0N^<GY<X')7@Y. #V&BN(
MUCQ7<WVF>'[WPQ>::4U"XB>5;R9%8VYX;:"P^<'C SR"*ZMM4TZ.XFMWO[59
MX4,DL9F4-&H&26&<@8(.3ZT 7**H3ZSIEMIPU&?4;.*Q/2YDG58NN/O$XZU8
M:Z@2U-R\T:P!/,,K. NW&=V>F,=Z )Z*S+S7])L-#?6KG4+==-2,2&Y60,A4
M]-I&=V<C &2<C'6JOA/Q-;>+/#5MK5NGDQS;]T;2!FC*L1AB.AP <>] &[14
M8EC92RR*5'4AN!1YL9VXD3YN!\W6@"2BH_-CR!YBY+;0-W?&<?7 -/H 6BH+
M>[MKQ&>VN(IT5BC-$X8!AU!QW]J\QN_B%XIOO%U]9^&=#MK_ $K3K^.PNRX;
MS]Y)#.,, $4J>2.V>AR #U6BD[T4 +14%W-);V<\T-NUQ+'&SI"K &1@,A03
MP"3QSZUD^$M5U/6O#=K?ZOI,FE7L@.^UD/(P>#@\C(YP1D?K0!NT5PUYX_N+
M#XG6'@V?1X]M['YL=XEV20FUR-R&,<YC(P&/4<UW% "T4E% "T4E% "T4E'2
M@!:*2B@!:*SM;UBST#1;S5KY]MK:1-+(01D@=ADC+$X '<D"J&O^(Y=$U71+
M*/2;N^74[GR'E@!(MAQ\[8!XY'IP">V* .@HI 1ZT<'O0 M%)2F@ HIN1ZU1
MUG6;'0-)N-4U*?R;.W4-+)M+8R0!P 2<D@4 :%%(#U^M&1GK0 M%%8?BGQ/:
M^$M%?5KZVNIK2)E$K6P0F,,0H)#,,C<5'&3STQD@ W**I:5J4&KZ19:G;AU@
MO+=+B,2 !@KJ&&1ZX-2WMS]DLIKD0R3>5&S^7&5W-@9P-Q S]2* +%%<]X0\
M8Z7XVT>34]*%PL$<Q@99T"L&"JW0$]F'>N@!H 6BC-)D>M "T49'K1F@ HHR
M/6HY98X8WEED5(T!9G9L!0.I)[4 245B:MXHTS1-6TG3+V5TNM5E>&U4(2&9
M0,Y(Z#+*/JP[9(U#=0"[6T\Z/[04,@BWC>4!P6V]<9(&?>@">BC-17%S#:0F
M:>6.*)<;GD<*!DX')]R* ):*,CUI,\4 +17.^'_'&@>)[ZZL=,NY'O+4'S[>
M6WDB>/#;2"'4<@\$=1WKHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** &M]X4ZFCJ*=0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !4<TJPQ-*^[:HR=JEC^0Y-24AP>#0!\\_"30],
MU/4-7M]4L7CU W<%Y83RV;!U6*0R':[+\N2%!&02#75?'NSOM8\.Z=INF:;J
M%[=+=>>RVMG+*%38ZY+*I .2.,YKUSK0: /'/C"UUXE\ :/!I&DZO<71NTG-
MN-.G#QJL<J'>-GRG<0,'KG(R.:P=<\&W?A>]\,^,_!VD7MRT2QQW5D+)EDWJ
M@0L8MFY=X#ACMX8AAR<U] TFT'M0!YQKNI:?K/ER^)M+OCX6O--65TN+"8-8
MW,;L6+E5WQDJV-W PG!PW.5\)_#MO9>+?$.LZ TK>%;E$AL996?,S#!<J& )
M56+J&/X$\FO7,#.>]&!G..: /G[XAWEA8_M":)=:E*D5I"MK)([$@+AF()QV
M#;3_ #XS7K7Q U6UT?P7?:A=Z-#K5M$8R]E+@I(#(HR<JPXSNZ=NU=1BDP,Y
M[T 9^@2I/X?TZ6/3GTU&MT(LGC$9MQC[A4 8QTQ@=*TJ08' I: "BC-&: "B
MDS2YH *#1FDH \!\!ZE8R?M$:_*EY;M'<BY2!UD!$K;T.%/?A6/'H:T?B[=6
M;_%'P);R3P$Q749GC9A\B-/%RP/0$ ]?0U[;10!\^^$M;TZV\1_%6XG@6XB9
M)Y/LUJ>9HEDE5BO7C#*2W0;LUR-MK$4VI> ;V5H[6QM;]56&.%U@MD6XC9L2
M.,R,<EV(9@-P^[TKZPQ_G-&/\YH \#U&==*_:B@N[Y98H;ED6!C$W[S?:B)=
MH R1O^7/8@YQ@U[3XA4OX9U15!9C9S  #))V'M6GCC%&* /F[PM<1-^SAXKA
M60>;%=@NN?N@F$#/Y'\JQ-):'3_%'PTN(KA(FDBA,G8X:\F!)/3!#$>P'TKZ
MLQ_G-5S8VC,&-K 65BP)C&02=Q(]\G/UH ^<KZVAM_B[XIL?&&JWFE6NJI,B
M7 C1_.A:13$N75L+L0 %<$% ,C&*]Y\(6L5CX1TRUMX=0BABMU6.+4L"X1>R
MOC@$# QV&!6G/IUE=7-O<W%G;S3VQ)@EDC#-$3C)4D97.!T]*L  =!0!\^6E
MSX6UCXX^+)M=OEMK#RVA1Y+UK7?)'Y<;#<C*6'R/QGD<XK%\*MJLGP^\?6&E
M"ZN-#2+=;2"(AG_>X." "<Q@EACC';//T(?!_AALY\.:0<]<V,7_ ,36O'%'
M#&D<2*D: *BJ,!0.@ ["@#P.6X2_U3X0P^'IXI+Z"U!E"/EE0+%O5R.@PLPQ
M]1QFN6\9:KI<U[X[CTVZ%M#<7EN9;?4$W7%S.DLFXQ9P8D7+9# G  ^7=@?4
M,%C:6S%K>U@A+#!,<84G\J5K.U;S-UO"?,^_E!\_U]: / ?BA=Z9=?##P%/]
MIAE!$:;XY-QV+$%E QW#  ]P1BMCXN>%]#\+^#K(:=IWV;3I]:@EOHX,X*"-
MEQ@G Z<=LG->RM8VCQHC6L+(GW%,8(7Z#M3KBVAN[=[>YA2:&1=KQR#*L/0@
MT >%ZGJ.BW?[2>@S:7<6KQ+$D<TD+#8TOER #/0G:8AQ[#J,5W?QF2\E^%^I
MK9)*^3&TPB7)\H.&<G_9 &3[9[5UUIH.D6!0V>E6-N8U5$,5NBE0,X (';)_
M,U>9%D0HZAE(P5(R"/>@#P'24N6^(WPX.B@>>OAVT:^,(&?*V$-YGX8'//W<
M<XK2^$UMIDWQ2\;2FTM$N+:Z?[(FU=T*^;*KE!V&-H)'J!WKU^QT/2=+\[^S
M]+LK3S\"7[/;I'YF,XW;0,]3U]34=CX;T/3)UGL-%TZTF52JR6]JD; 'J 0
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M,.=NPN1[$XK8\8:G:7OQ6TO3CJ=E;:!)I36]C.T8DM81(KH73#*H.1M# X&
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MR<\<#&,UC_#R[\87MYHFM)/<O;2:HT5_?7FK*8YE<J#"(&888<D8!)+#'
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M,5E5-^QN2,YXST.,]ZT[CQCKG@GXEZGH^IWD^KZ4^G27]OYI421^7"\A&54
M F.1<8X&WG@Y /8\T9KYUN_B%XJM/!.E^,!J\IN;G59HI[,HAMS$HW"-5*Y4
M#;C.=W)YSBM3XA^-->T/QWJ.GSZIJ&G63P1G2Y;7R_*#8&XRAE)*[B0Q4Y4
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M1CDN[L2S,?4FM-6#*&4@@C(([TM '-P^!/#D'A]M!CTQ!IC7 N3;[V*^8&#
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M\*/+J]R8/#:H+:)8D'F,I4DLW7DHO [#CKFJ6I?"AY;_ ,0-I.M/IUAKEO\
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MXJTJ&/\ :0\/*)KDBZCCN7)F;*L#-\JG^%?W8^4<<GUKV#Q%QX8U;_KRF_\
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M1110 4444 (*6D%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-[$9;4ZA:B-9UP2-I#'.0&(/0X/.< \]\?D0?#RU=$">9J4;-E<$_NI!S[X
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M9HS0 44F:7- !111F@ HHHH **** "BDS1F@!:*3-+0 4444 %%%% !1110
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MF:6LSP\NHIX;TQ-7_P"0DMK&MU\P;]Z%&[D<'G/2M.@ HHHH **** "BBB@
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M@D[B,D>PW7M8^+N@:5)?^5:ZC?P:=.MM>SVL2A8)69U"D.RD\QGD KR!DDT
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M>F!UKR;PIJNM_$KQ7JLUOXFU?29[>[BNK:W5W\E;4,0T;*I";^4^\#G!Z\D
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M%[XI\"Z=K.H^4+JX,P<1+M7Y9708&3V44 :6J>%= URY6YU71;"^G5!&LEQ
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ML-M;QK%%&O1548 Y]JLT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 )1110 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZN9+TPW5U%=W%DL^+>62, *63'.=HR/XB!G.!CJQP* %HHHH **** "BBB@
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MLA1<G<Q:0(,@9 W$G(XSQ1=_%+0K'P/9^++JWU"*QN[@VT<+1+YP<,ZD,N[
MQY;'KV]>*Q_B5X/@\33:=8/HUY]G@MG\B_T]%9K9P0%C>,D!HR!GCD%1@C)J
M&QD\>:#\)=,5=%35?$/VAEDM[OYS%%ND8,YWC<>% .1]X9R0<@'J%M.MS;QS
MJK*LB!P&&" 1GD=C4M16SR26\;S1>5*R O'NW;&QR,]\'O4M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %)2T4 )BEHHH **** $Q2T44 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )2T44 %%%% !111
M0 4444 %%%% !1110 4444 %)BEHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH 2BBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&: "BBB@ HHHH **** "BBC- !1110 4444 %%%&: "BBC- !1110 449HH
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M($^1P?N_=(QQACUSBLK7+:*^\,_#&:[W32W;W$%P\DA+21BY0 $Y]';\_84
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MN:6N ^$$.F_\(%97EC=375Q.@^VRS3M(XG'WD(/W0,\# X(/.<GOZ "BBB@
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MFACN(7AFC62)U*NCC*L#P01W!':LR?Q3H%K<75O<ZWIT,]H@>XCEND5H5)4
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M(KVR?:$W3JP)4H,Y8$ X(]*72]=TC6UE;2M4LKX1$"0VLZR[,],[2<9P?RH
MJ6OA#P[9:L^J6NC64-ZW/G)$ 0>.0.BG@<@ FDN/!OANZUJ+69M&LVU&)Q(E
MQY8#!P<AN.I!YR>>GI5^TUC3;^\N;.TO[6XNK5MMQ#%,K/">F&4'*\@]:@\2
M3:E;>'-0ET986U)82;99B A?L"20/S.,T 07G@_P]J&H2W]WI-M-<RLK2NZG
M]Z5"A=XZ,!L7 .0,?6MK: ,"LFVU4:?HNGR^(;RQL[V6%!/NF5(S+M&\(6/(
MS6G%-'<0+-#(KQ.H9'1@58'D$$=10!BP^"_#5OJL>IPZ-:1W<<AEC=4P$<@
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M10V",@$'GD\^] 'SAXGL;]]#LM8T>\B9[;PQ9VNH6<J1D_96C!\Q-V05W<'
M#*PXZYJYXSLGEEMM<\-7MLPM?#=N+O3;R16,-FT9V@%\%QC@@@,&9"/O#;[M
M-X7T"X\OS]"TR7RD$:;[2-MBCHHR. /2GW7AS0[Z;SKS1M/N9< ;YK5'; X
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M2B,"#URZXYYKT[PYX&L-(L=9M;JULI+?5+DS/9Q0A8(X]H58PO0XQDG R3G
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M **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH ****
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M8LG<2S'[V%)"]^.1G-<%\!?+?5O&4T,0M8Y+F(I:!0IA&Z8@8' QG;_P'VH
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MPS[K\)W23X7: 4=6'D,,J<\AV!_7BNIN--L;LL;FSMYRP4,98E;(#!@#D=B
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M **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH ****
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M(/IZBNGKYQ\#:=-I_P 1= D\."XGLY/,FO-,NH7#:7N7RY S.H!(X =<,P4
MC!Y]<^'_ (ZE\:V^H_:=(DTNZL9Q#) \A<\C(SE5(/!X(H N:QX_\,^'];32
M-7U(6=V\8E7S8G"%3G!WXV_PD=>HQ7+^)/'.C:DGA2_M/%%YI-C<W\KK(D)5
M;I(3M96XR!N(P&&#DY&0".;\>Q6-W^T#X>348DDL$MH8[CS5)CW;IBJMVZLG
M7CGFJWQXTJUTUO"T6FV$5M;JUT[):P!5!S!DX4>WZ4 >E^)/B;X:\+:B=/O[
MF:6\10\T5K"93 IP07QT&"/?D<<UQGQ;\7?;_A]9:SX5UVZBB&IFV::SDDA,
MA"29&1@D94'T/%<IXIO+'1?BGXVCBU&WM%U#3#;2/>QR.H,R1,VP1ABQVXQG
M'4]0O,?C7^Q+#X%:%8Z)J,>HP?VFQEN@AC+3;)"P9" 5^\  1G;MZYH ]A\'
M?$#0/$PCTVRU/[3J,-I')-E"NX[1N()'.#U^HK(\'?%K3_%WC"\T>&-X82BF
MPW1,7FP&,C,5)55X7&<9SZG%<1I^J6I^/WAY8+I8#'IT-K=<[?-D-NQV''4\
MQCGNH'4"M;X2ZM'9_$;QGH5Q#<+>75[+=(2GRJBR-G=W&?,4@XP?7ID ]9U+
M7-,T?R?[0O(H&G?RX$8Y>5_[J*.6;V )Y'K6=9^./#=_I^I7UMJ:/!I@)O28
MW5H.OWD(##H>W8^E<3\;-6M=$M?#^H26(N+V"^,EI*\C+'"Z@'<P4C=R%(7O
MM/T/GO@R<_V'\4=.EDGEO[BQ,RA[=DDE53+N<ICY3^\0X_VO8T >S0_%CP-/
M/' GB&#S)&"J&CD49)P.2N!^-;&M>*M$T.5;;4=3CM[F1&D6%09)=@!)<(H)
MV@*Q)Q@;3GI7S!J(L1\%=,:(6_VR369PY7'F,!%T/? #+^8]:](U'7;'0_CY
M:Z[JTH72+K3%^QWA):,J8@0T94$-R6&!_?SW&0#K_A-XEU/Q+8:Y)J&J'4H[
M;47@M;@PI&7A !4X15'.<\C/-=/JWC'PYH6HBPU;6+6RNFB68)</LRA)4$$\
M'E3^5>9_L_ZC UIX@L0CI)]L%RH9< HPVX'N"O([9%1_%NZLK/XI^"KC4UC:
MQC.9A(?D5?-7+-[#@GZ4 >G:?XU\-:K87=]8ZU9S6UF";AQ)CR@/XF!Y X.#
MT/:HK;Q]X1O;N&UMO$>FS7$SB.*-+A2SL3@ #U)KQZ[\J^U[XIZIHXA?0CI)
M@\^%<1M.(X\A2!@\B0G'7(/((-:_P>\*:9J?P]DU2*TM6UI;N9[6\E0,8957
M;&<X/ )SC!&><=* /45\9>&FU+^S1KNGF]\[[/Y'VA=WFYQLZ_>SQCKGBO*M
M?\>Z]XE^)%QX8\,>(+;3HH2$LIO++)<W";2ZNVUB%QY@& 02B]<UQ/A"TL=5
ML#X6U+4-7BU6RU-KBWTS3X4)EE "%A+CY"NTY+, !R,UV7AR]MS^T-XN1+V!
M)I[2:W@)F"EI081L4Y^\-K<#GY3Z4 >FV'CK0I-2BT6YU:U.M!Q;310J_E"X
M"Y9%<C&<@X!.>W7BGW/Q \*V=[J%G<ZS!%<:<N^ZC=6!C&0/3GEE'&>M?/7@
MBWL=0MV\+:UK6J6-]#JR3VVFVMH'=[D (S%BORE=O.6  !/K7;:;HN@^)_C]
MXMMM6MH)(UMRL5JY(W/LC1W&",,!N.>HW9'*YH ]3O\ QSX9TN&REO=7@A6^
MB$UN""6>,C<'V@9"X!.X@ 8.>E.U#QMX:TJ^L[._UFUMY;R(36[2-B-T.<-Y
MGW<''<^GJ*\/\7?8=$^,<FG:Q/-IFARZ:FG1SV\2LRVK1;!@R!SUW*7 W8SC
M'-2:W8:&VN_#33HYKR?1"TBQMJ9 >2(SC;G@#RVP-O RA6@#W/0?%6A^)H)9
M=%U&&]6)@L@C)#(3TRIP0#@X.,'!J&U\;^%[[4$L+37]/FO'<HL,<ZEF8=@,
M]>#7BOAAYKKQO\3X=#FS=S6=Y]C%LXRQ\P@%,=\L,$>M6_AAJ7@R^T7PO8W\
MTH\0:5?R_9((U8,QE?.<#@IC:23@C8>W4 ]DN_%OA[3]532[O6;*'4'*JML\
MRB0EONC';.1CZTFH>,?#FE7SV-_K5E;72!2\,DH#+NZ9';.1^8KYU\BQ.O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD@!>V0,X2^"?&^E_#W6? ]OX::]BN+\30:DE]!&&160Y\MFR,^6.">-WMS]
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M:^EO)3##:,-]X8'/UI&AC?&Z-6(XY4&@#R'XK:+!H,_A34]/T\6VDVFLB[U
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M/5;AU6XN!:MO$6R,* [#A>68D'D;1TR,RZG'!X?^-/P^TB:X4+I^EPVOG.V
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MH/NKP<$87)P* /4Z*Y31_B/X4U_6H])TS5DGNY8O-C78RAAC)4$@?, ,E>N
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M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5SWBC1=0U=])ETS4(;"YT^]%T)9;?SE8>6Z%"NY>"'P3D$#..<5T-(2!0!PF
MK^"KWQ+XGT#5=8_LZ*+22)66V1VDGE!! WG&V,, VWGD=3GB@G@/71\49/&C
M7.FL)$\MK++_ '?+"??V]>,_=QVQWKL]8\4:)H!M!JFHQ6QO&*V^[)\P\<#
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M!93.F)6)W;CSA5P, Y(8].PKZ:JO<WUG9+&UW=06XD<1H9I FYCT49ZDX/%
M#=1-Y_9ET=.$/V[R7^S"?/E^;M.W=CG;G&<=J^<AX.\=R77A[6;CP[=37UKJ
M1+A[E I"R*R*(Q\L$0*OR!CG/0KGZ7HH \?FT+6D_:#N=7&E73Z7/:F-;M4S
M&#]FQR?]Y=OU-<-:^$O$L/P<N=&?P[J1OKC6EF6(0'(C6%06/MGCZYKZ9HH
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MQVGC_P 0:4OQ#TNYL2;6:XT@LVJE))1)$\3%!'$< Y'R[N1F0\96O>_LEO\
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M  \UX:GA369/%7C'P+9",Z1EM2=(HPK9V%[=(RP(&6:-3ZB,@$=_H^DVCU-
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MS<K-H\%E>_:HY[?35G$DHC4$'>_"[CDL ,8 QDDX'+>./"7C;Q%X(\,6O]@
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MHW" XE0+TW9)PW(.<8'6.U\>ZSJGQBNO#\.D3/I]E;O!+ )D5AF2(-<-DX(
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M6\4:9%K%G-=:PJQQ2O&P"K\P=GR"=Q5SQS@]ZZ[PCX5N=&\ Q>&-3FB<I%+
M9;4GE'+'/S#AOF/J./PKKJ* /*_!OP_\7^&9K?39O%4/_".VT[2BUMH )9OG
MW*&<KE0W!8!CW7D'-=-X(T3Q1I U%O$OB :J]Q.)(0JX6(8YQD @'CY1P,<=
M3GKJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ /2DI3TI* %HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*2E/2DH 6BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N8\7>.-.\%0P7&JVUZ;69@BSP1*Z[R"=I^8$'"D],>]=/7D7[
M1/\ R3^P_P"PHG_HF:@#I=;^*6D>';:QN-5TW6;6.]B\V(O9].2-K?-PV &V
M]0",XZ#0U'QYI6G>%K/Q&(;R[TRZ5&62TA\PINQC<,_+R=OL>#S63XPL]/\
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M\(TLW1_:<=KRQALK@PL'2"7S%;_1^&W;5)S[@5[M0!&]Q#'(D;RQJ\A(168
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M'X(.=W'!!QD8SK/X\TN#3]=O[N.ZMK/1IVMIIY50+-*O58@&)8\J.0,EA[X
M.JHKF_#OC.Q\0WD]DEM>6-[#!%<_9[U$5WBD&5D7:S!EZ X/!X.#724 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/H.>A&0#T6BD!'K1N'K0 M<EXZ\"6OCS3H;*]U*\M88&,B) $VF3! 9MRDG
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M8W.5^8EPPP1SP>O>@!VO^&M5U7Q'HVJV>MP6<>F,[K"]D93*7&UPS>8OR[>
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MOP%J%GXQM_%%U_9C7T%D\4GV821F\G( \R0G(48SG SDYYX%>?Z_X+U+X?\
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M*V%TS?9F)F!".#D$!5&01]T8K@GOM97X16OBR7Q%K$^IQZN(H&FO798E"%N
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MR;6X('"R@ E<]\9P??([4W7=?TWPWIWV_5;I;>WWK&"027=C@*JCDGV'8$]
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MN 3TW?2N\^&D7BV34[/5+R6[?0;_ $J)W^V:A]I+7. ?,0$EHPV6)7H,D'H
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M$,22@<AE;RP 2>#[8K)^(7C76=/^(OASPIIMU]BM[Y[=KBXCC5I2LDS1[5+
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MAC!+32$A4C7 /+,54<=37D'PLUC6M'^)7B#POX@G,EW>LUVQVD*;@ %BHP
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M0 4444 %%%% !1110 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<WXK\#Z'XR%J-9@DD-HS-"
MT4S1LN[&X9![[5_(5TE% '(V'PX\.:6=8-A;RV[:M"T$Y29ODC90I5 >!SEL
MD$Y8\XXK.@^$/AN+PS_PCTTNHW.G"[^UJDUS@J^S;QM XQDX]37?T4 <M:>
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M"KGD=.*]/HH \I\2?"_7M8\!Z+X5B\0V\L5@S--/<6Y4R 9$04 G 568=3G
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MLTIC3GCE@K$<$GH?ZU?HH \9\)^"?'O@KPWJ6C:<FAR7%^^X7[7;E;?Y0O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TI*4]*2@
M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***2@!:*** "BBB@ HHI* %HHI* %HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110
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MO^>AY^<=. N.2<I/@9J%A/=+H?C>ZL+2?CRQ&V\IQP[+(H;IUP*[/[9\2?\
MH%:!^-TY_H*/M7Q((_Y!WAQ/<S2-G]: +7@;P!I/@:RD6U9Y[ZXVFYNY2-TA
M Z#^ZN<G')YY)KS;XB?#_P 0>-?BQMM[$P:;]EB'V^0_NM@SN.<'Y\D@+C/
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MV'38YBD4$FS"EQR%Y X7ZDG.!Z$+WQB3@Z/H^/\ L(R?_&Z?]K\8?] C1_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0'B@#T;P!XAUKQ+H\]UKFCQ:;/'.8T$;9#K@'.#DC&<>]=1!/;W49DM[J.9
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M@ HHHH ****  ]*2E/2DH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E)D4IZ4W!H =11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M!Z4E*>E)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !124M !1110 4444 %%%% !11
M10 4444 %%%%  :2AONFH_SH EHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2EHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH #24IZ4E "T444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E)2GI24 +1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z4E*>E
M)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 'I24IZ4E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E)
M2GI24 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 !Z4E*>E)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%%  >E)2GI24 +1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M'I24IZ4E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 )2T8HH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ /2DI3TI* /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex-a_055.jpg
<TEXT>
begin 644 ex-a_055.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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M1110 4444 %%%% !1110 4444 %%%% !28I:* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!HZBG4T=13J "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H[444 0!I3<( 4\O!SSSFIZ
M:  1@4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** &CJ*=3%(8\=J?0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% $:*5)SW.:DIHZBG4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MURBHX',MO'(0064-@]LU)0 4444 %%%% !1110 4444 %%%% !1110 4444
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M>* )*:_0'&<&D61&&58$>H[T[()Q0!BZIX9T?6+J.XU+3H;J9$\M6FR0%/7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T +12 GN*6@ HHHH
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M03>*KV];5]<OY&L7AFAM8[EUSQU//*D\8]:]8\;^'D\4>%;[2CL$LB;H'?\
M@E7E6_"OGWX>ZW)X3^(%KYH6*VN'^P7)8_*.<!L^SYH ^A_$?A:V\1P1I<7-
MY T(;RVM9S&06&,G'7'H:^=?%J>)/"7B271I]:OI2BB:"X%T^60G !Z=*^I6
M;CD?6O"_C[]@%QHA7G4PLA;:.?(QQG_@5 '0?##PM::GX;TKQ#=:K?WUX^9&
M#7;B-6#$8*9(R.AKTZYA$\,D4C,$D4AMC$''L>QKQWX#:\?+U3PZ[@K"PN+<
M'CAOO8]<DYKV661$0R,1L522?;O0!X5XI\-7/_"RM.\,>']3OT6:U$URK7CD
M6ZA_F.>3R/YBO7_#7ARV\-:6MG9RW$B$[W>XD+N['J23T^@KB/A>LGB#Q'XC
M\:S(0EY-]ELF//[E&Y_4"O4ESM&3DT >#_%#XB:DFLR^']#G,,5NXCN)D/S2
M3'@J#_"HS@_6NJTOX,:%'9I_;,EWJ-^ZJ99I+EL;L$8'M6)KGP<O=1\<W&IV
M][#'IMW>B]E!4EU.0S@#ODC->QN\<:%F=453\Q)X'U/:@#YQ^('A"?X>:K9W
MFBWEY#I]T"L<BS$-#*.=N?0@&O5_A5XPN?%OAZ9K]4^W6<@AE=. X(W*V.W!
M_/-<?\;?$>C:GI5II%E>PW6H0WB2O%&^0J[6')Z=Q3OV?/EM?$/.2)+?<?4[
M&_Q_2@#TOQ%_PDDJI#X?%C$9 =UQ=.P,?T 4Y_&OF'Q=J&N7FKWMOK^H27%Y
M:RO&8RQ"A@5X0< >O0U]>,@;J.^:^4OBDQ7XC>(&P,B4 8'_ $S'ZT >H>*7
M\1>.I&T3PQ.D.G:=;J+VYWD+<3D#]RK#J ",GUKRO1M'\0Z7XWL;"&RN[;4H
MKM"T<:MRN[YR6SM(V[N]?2_A;1;31?"VG6%HBK%' #G'+%ADD_7-;)15._:,
MCOCF@#*\0^(+'PWHTVIW\BK%%G:H;YI&P<*N>I/I7FOA_1-9^*<7]O>);RXL
M]'9L6FFVSF-9%'\9/7KD?@?QPOCKK+W.LV6AJR>5;0F>1<8^=P57!/\ L[A[
M$UUVD>-?$%CI%I;6W@#4Y(8H(T1O.4;@%'/3Z?KZT 0>(O@GI%Q82-H<D]I?
M(NY-\Q:.0^C=_P 17FGA7QYK?@K43!<2336,4GE7=E.Q.SGDJ2201UQT]Z]<
M/C_Q,QR?AUJ@P<_\?"_X5Y3XD\)>*M?\27^KV_AB]M$NY!)Y+ -M. #D\9SC
M]: /I6RO8+ZR@NK=@\,R*Z,"#D$9[59KA_A99:KIW@>VLM7M#;7%O*Z(C#!,
M><CO[UW% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M #1U%.IHZBG4 %%%% !1110 4444 %%%% !1110 4444 %%1AAYFS?\ -UV^
MU24 %(Q(Q@4M(0,B@!BR!W(4@@'!]C3^]-"*I)  ).33J *\$<L;2&1]P)^2
MK-&** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKL=5N-<CGM[60R^4-^7)&,<G&*]>I,4M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% $;G;&2 3CTJ+>W]UJG%+@^M "T444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHS0 T=13J:#R!3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *2EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "D/0TM)B@!H'S ^V*?31U%.H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH-
M!12"EH **** "BBB@ HHHH **** "BBB@ HHHH **** &CJ*=2 4M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %-?M3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M04M(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &CM3LTT4N* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ***.M # 3GIQ3ZA,:^<DG.X# ^8XQ]*FH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BC-% !111F@ HHS10 4449H **,T9H **,T9H **,
MT4 %%%% !11FC- !11FC- !11FC- !11FC- !11FC- !1110 4449H **,T9
MH **,T9H **,T9% !11FC- !11FC- !11D49H **,T4 %%&:,T %%&:* "BC
M-&: "BC-&: "BC-&: "BC-&: "BBB@ HHS1F@ HHS10 449HS0 449HS0 44
M9HH **,T9% !11D49H **,T9H **,T4 %%%&: "BC-&: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &G[PIU-/+"G
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7&^*OB-I7A&^%KJ%IJ+EER)(K8F,L>BAS@%CSQVQS79&O*O'
MWCCPY)K/A_3&U>(QVNKK<7_E9<1"'=A7P#_'M&,$\=J /0/#^N1Z_IK7L5I>
MVJ"9XPEY 8G8*<;@#V/4?EU%:N:IV.I6>I:;#J5I.DEG/&)8YN@92,YYZ?CT
MJIX?\1Z;XHT\W^E22RVOF-&)'A>,,1UV[@-P[9'&01VH UZ0GCBE[5Q_C'QA
M_P (OK'AVUD>V@M-0N)!=75R3LBC1<D#!&&)(P3QP>.: ,V[^+FDV-^UG-HO
MB$R&1HX2+# GV]2@9@2._3.*9#\8M(N9YH(-!\22S0$"6./3PS1DYQN ;*YP
M>OH:J0^(]-\2_$P:S:WD9T+PYITOFWSKB+SI" 0K$#HH'.>V .<GSZRU_2+O
MQ3-K3^,!I]K/X@6\GLC#(OF0Q$F)N >6Z%21UR1E0  >IQ?%C1)/#MWK@LM6
M^RVMTMK(GV8&0.5W9(#8"@=22.>/2JLWQFT2WM1=SZ+XBBMF 8326(5"#T(8
MMC!['O7*>)?%^A7'PIN/(AATN]\174LZ09+O(OVG#RR$CC(4\<] %X'&]\/?
M#EG=)J%_+K4/B+1&AM[2T,\)^58/FP4884*YX'/K]0#3D^+FD)>_8UT3Q%+<
M>4LHCCT_+%#C# ;L[<G&>F>A-5I?C9H,27!?2=>7[.!YV^T5?*W?=WY?Y<\8
MSUS7 :AJ$/CGQ[KLVA^*Q8W=XD-AIB8=1<PE5\T%@N5&06'<GBNE^+&J^'[#
M0[?0[:XMK2[U"[@%Y*(<R"&%MOF2@ %]I0  ]=IQTR #J-$^*6GZOJ=II]SI
M.KZ9+>-LMI+RVVQRMM!P&]>N.W .1G%4U^,.GS3W$-OX<\2320,JR(EC\R9Z
M[AG*G'(!Z^U<M%=-H7CK3-5\>>(KB_TPVOVK1[[RREN[D8RT0!VOM;/Y<\"L
M33O$.@S^*;CQ)?\ BHP1MK;W;Z=Y<@$T,:L(&&%P7S@8) QUY&* /2(_B]I'
M_".G6IM+U=+=+M[24) K&)U"G+'( !WJ.>^16B_Q&L%U71=-33=4DN=5BCG1
M$A5C#$[%0\@#' !P2>@!SGM63=Z_X>?X23ZAJ5I#I-OKT=PRP,2YDFEWL&W!
M>6;&[....>!5+X(2:1=Z%<W<=TUUK\FW^T6DW%HT!984!(QMV)D ?CT  !ZJ
M.@KE/&'CF/PG<6%L-)U#4)[TL(TM8\@D#A<]V/H.< GTSUF*\P^*\NH?V]X,
MM=%C1]6>]EEMED'R951N+>P#9^@- &KJGQ*BT^[T^"'0=6O!?!0C01J=LIR6
MA(SQ(H!++GC'UKN@>*\1^%/AZ6V\::MITT[S6/AV[E,&[Y=]Q(/+\QE[GRT.
M/3<?6O5G\3:7'XI3PV9F_M-[<W*Q!"1LR1R>@/!ZT ;-(QP,T"LW7=<L?#VD
M7&IZE(T=K !O94+GDX   )ZG_(H X:#XPP77VH6_A+Q)*;1BMSY=JK&$C.0^
M&^4\'@^AJWJ'Q5LK;3=&U&QT?5-2L]4DECB:WB&[<C,NT+W8LO XXR?:O(].
MU;0I_#=[<7WCK7M/UN^>XN)[2U$BVQE=FQO")@Y&,X/? QC%=O=R0>%[?X;7
MVM64]CIVG6<CW+06YQ!</&@ D '&26SQDL?K0!VD_CT6_C&V\,-H&K?;+@(R
M2;8_+"%06;.[!"9(;&>00,\9S[#XG2W_ (K;0E\*:TCQ3)#<R&,-]G+'AG"Y
M 0CG=GD<BJ&E^);36O%.J>.B\\7AK2=.^QP3M 1Y[,^Z5U ^8@;5'3\N:YS1
M_B9X=TW6?&FNR7C-?:A*OV*(VT@66.&+;%G&=N3P<X/? S@ 'IGC/Q?_ ,(A
MIZ79TB_OT9'9GMD&R';CF1C]T$L/7OZ5+X5\42>*+66Z_L74=.MQM\EKV,(9
M@1G<H'5>G.><UYE\0_'D=S\/+30]1#Q:WJ,%K->Q>2\2QQG$C%21@\J%P"<9
M(/((K>'C^/Q/K=MH/@IHYK?[!=-,SPO#L*Q[85!8#:NXKD@9Z>^0#4U'XH6R
M2W4>A:#K.O"VD:*6>RMB8%D7[R;\=0.> 1R.N:T[CX@Z##X7L_$"3336MXXA
MMHH8B\TLI)'EA?[P(.>>QKAO!WQ'T+0O!]EH%MI=_P#\)!:H8!I*P-YDTXX.
M6VX7)R3GE0#P<<U?*;X=WW@^]\2V[R6<4=V)I;5"T-M<S2;^@]%+#CD@'&=M
M '7V/Q(N)=;L=+U+PIJVFRZ@&-HTX7$FU68@@D8. ..N3S@5!8_%>WD@U>[U
M+1;S3;+32\3RS.F9+A6_U"KD9D*E3@$CKD@ $RCXG^&KQ9M0BL[JXTW3H3.^
MHO;;420G8L<8;#%SR.  !U/7'F6AZ*LWA.;QCIS7\^IZ?>F\;2KFVWVK+))M
M.T%0'8QX.Y23\H'!VD 'MWA#Q)/XHT==1FT>[TU7P46Y(_> C.Y<<E?0D#-=
M!7/IXNTN3P=)XIB:0Z<MN\X+KL=@F1C#8Y)&!ZY&.M6?#.M/XB\/VNJOI\]B
M+E=Z13$%BG\+<=B,$9P: ->L/Q+XFM?#-M:R3075U-=3K!!:VL>^65CR<#V4
M$\D=/>MRO*/B=KVB+K%MI?B&PUB*UMD2\MM5T_*M%<;B %)X/ !SU![=P :F
MG?$;5KW79]&E\&WMM?Q63WGD2W*!I$&  N0 <L0,YP,-W&#1L_BQJFH:<-0M
M?!%_):%G42B[C 8J"6 R!G !Z>A]*R_!WBN[TO3=:U2:[\1:MX=4QQZ=+=VP
MDN&E;=O 8$EE&%^8D+GC /7C/"][%X9_L_5C'X@N]0L;.X*V+V3F W4F1E>?
ME3!&XCDE<^U 'K8^)MK_ ,(KI&K?V9=/?:NSK9:7"0\LI5B,YP %P <]@15>
M/XD:R=;MM(N/!%_;WEU#-+!&]U'F3RT+8SC R0%R3_$*I7FKP^$/&D&LZ_IC
M)I<VCV]M;7]K:LT5FZEB\6U02@8L,#G@*.<';;E^*,%WHNJ:EINAZG+:0Q".
MSNFMSBYG;?\ (% )VC:N6_,#C(!7M_BOJ=SHC:W'X)U"32T+^;<174;[ APY
M*]>.>N!QUQS6EJWQ!O+75-#L]*\.7&I+K5J;FT8W,<._";ROS< A2"=Q'4 9
MKS&R\+21?#73M:LX]7O8M/G/]IZ'>!X8[@$KO**O.T?*<_-G!)&05-KQAK6D
M>+-:L"MGXBT_3K/39883;Z>P,4SA0 %!QMVY5@",[< X(- '>:?\1]0EU466
MJZ"NG#^RWU,3?;HYD>-0<E63*X)Q@D],Y'(K(L/BSXGU"[AMK?P*LLUS9C4(
M8QJ:J?LWW=Y)3&-P/7!Y''0F]X#U2UN]*O\ 3?[(E?1](TR& &?3W$]YN$AD
M4(2<J=N/+&[);KT%4?#6L6M[\5;H#PQJ]I ^FQ:=8B2Q,*6T*Y=PZ\!%)*@<
M'H.F<4 :%U\3-=@\,:1KL/@\W-OJ"*?EU!!M=Y"L4:KM+NS#!X4?>^N-VR\8
MWFJ?#Q/$^F:/]JNG1G_L_P"T;.5D*.-[*/N[6/W><8'45Y_-_:7C'QHL>BRZ
MCH&C^'X"U@[Z.TT1D7*LPC.!NP?D4AFP,@*21571=9U31OA_X@\+CP_XAN;R
M7SQ9N-'E0LDP(WR+SM^;><<\#UH Z$?%K7D\/1>([GP-(FAO\QNXM21V"Y*Y
M\O8&ZC&3@>]=%XE\9ZQH>O:3IUIX<%W;ZFR10WLMWY4:RL3\C (Q&!@\]><
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M'- B02&3:N\C;NQSCTSZ4^B@ HHHH ,>],DB65"CJ&4\%6&0:?10 U$6- B
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!C#YEIU-;[PIU
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MX@ANVWH.0,_>,&B?#*_U'P7=6.M:39Z9K43F6SU%7629Y3(7+2%"1MX1 .<
M$]\  E\2^+/%R>#O">MIJ\.A2:E*EO=1M:(43?N(F+/N*KM4';COUXJQX?O?
M&=]K>@W5KXLN-:T&ZNIX[F7^RH+=56'(SGDE7((!&#Q^46HZ;\0_$%_HE[?>
M&M+!TE)08+J]62.ZE>/9YK*N0 #A@O7J,C.:UO 5AXJL-9CM]0T*'1/#]I92
MQVUK!>><K2O*KY/SL20 ^"<8W'UH ])I:XJR\0:SKGQ#N;+3!"GAW2@8;V=H
MSNFN2I_=J3TVY4G ^I^85V@H #S7D^F-XZ\1>*_$=I;>-5LK32[M8DVZ3%(K
MELDJ Q##;@#DG.<@UZAJ#W<>G7+V$4<MXL3&".5RJ,^/E!(Z#->7:)I?Q1TV
M+48([;P_%+J-U)=2WKR,3&[@Y( SG&%"@@],'.<@ ELO'OB6[TN#0HK*!_%4
ME]<:>UP!_H\:P;1)<,,=MXPHX)].%J;[=XS\'>)M!CU[6[?6=,U:X%D^+9(6
M@F8G85V@$CIR<_Q# X-/F\"ZWX?72-4\.7D%]J]LTYOA?#:MZ9RK2/D?=(*K
M@>@')P0VEI'A_P 1:QXAL]>\8-I\;Z=O%A86.61&;AI)&;JV,8 X& >#0!W.
M:\V^+>JZCI%IH\MEXC_L>*>\\B9A%N(!!/F\<E5Q@K@YWCH0*])Q7!>)M!U[
M6?B'X>O8K:S_ +&TMV=WEERTA<8;Y<=@ ![]: .<L-=U#QA\2!:^'?&<YTV+
M31.TD=JOEB4$(5,;@9SNW9[9 '2N;\&:GKWBC4(+&?X@:K#>2W$L1MH+42,J
M(H;S';=A%).!\IYXSZ=A;Z+X]TOQ9KVL6.F:#+]MVQ0EIFBQ$A(7"J/O$$,=
MQ[8!Z"N?L/!7Q!TS0XM/M],TD306D]K%?"\=9T65F9B"#C=N*X.,@+CN: 'Z
MS<>+=&T+PE!K?C&31KR[DFCO-VV5TR[.)&8'YE53&F,X7(YK7\&7VOW7B.]T
MNR\7/XATTV;^9J?V0(ME<'_5["=PD..=N<>O0@OO/"'B[4/&6BRWL.D7FC:.
M@@C:\<R--&459'=3G,C;<CL#CKUK4/A#Q)X;\2WM]X,ETI-+OU\R;3K^218X
MY^[H$4XSZ @<XQ@+@ X'P]JNK:YXH.BCXA:NLK7T]M#%%;*[-%&I996?< H.
M#P 3QZ'(N>);[Q5X;T7P>NK^)[VPNKV:1-0PRN\:EUR^1G.Q".!GD]>>;VE?
M#WQ_HVD6]C:R>%Q);6]Q;0WAFN!,B3$E\,$'S;MI#8R-H X+9U-0\(>/O^$@
MTF^T^_T&X31K4VUE+?O.9&W1A'DD !!<X/(/USTH A\#:W?7_BZYT_3/%=SX
M@TK[ 99KNXM@IM9MV$"YP3D9)&,<#\,>#5?%VFSZ_P"$DUF]U+Q1+<Q063M_
MJXK8C>UP3C"?*<'DD$KC/?NO"_A35[7Q%>^(M>.D+J<MJ+2)=-B98U3>6)<D
M N>(P#Q@)CW.-X>\-^/[3QE/XBU!?#0;4!#%?!&F:18XP%/E<8!. >21TZ8H
M [W0-/O=+T6VL]0U.34[J(,)+N1 C2DL2.,G& 0.O:I=9U./1=$O]3F4M'9V
M\D[+TR%4G&?PJZ <"L_7M*77?#^HZ4\QA6]MI(#(HR4W*1G'?&: .%M?#OC;
MQ!ID>L7OC*72[FZ@66.QL8 (;?*G"DDDL<E"3VPP&>".1U:[\2^';S0(/$OC
MC4-/^UVDTMWL5',13[JKM!W%B>I]/6NMTW2_BK]@ATV?5=!MK:,B+[7'&S7)
MC'&5&W9R.F1GUJKJ_@WQW?>+=1U='\,W-O<V3Z8D%V\^#:E]V&"*#OXY.<<G
M@<8 (M(T;Q9+;K?WGC'4_P"Q+C0_M+WC*H=)9-QPJ*25*1[3G)YZ'TXJSUZX
MOO#,5R?B-K1\2*Q>UTZW2619""0D3!5^9V*CDD@!NA!R>\E\)_$&XTW71/?Z
M";W58X[,1)),L%O:A) RQC;PV7&,@\;N>14UK\-;Z;P39V=]-I]MXATHYTR^
MT]2HBVX*!R5!8%MQ;(Y+$]>H!!XMB\5WNBZ?<7=Y?Z1#I^ARWVI7-A<>5YET
M$&V+Y3G@@D\8P>#FJ'@O1/%<.K^#=8FUW6]0L+^VFN=0BN+IS%!F/]V""QW9
M+KCOE2?8=#XOT'QWXD\.P:5;W6A0BXMRFIAGE&Z3(/[L[#A>.XSZYKHM!M?$
M-GX5%MJ/]DOJL$1C@6U,BP8"XC#$@MV&2!]!0!YWJ'A?6[KXF2Z'%XYUV**X
ML)M2/EW;KY.9=BHJ!L;06'IPI Q5OXJSW?AO3O#,EOXEU:U$<ZVLS+/\TL>W
MYYG &9'P!UR,MTR:FTKPM\2+7QD=>O-1\/,;GR8;P1F4DP(P)" H &QD=>_X
MUH>*]!\=:EXHL]1TBX\/);Z<[261N?.64%T"N' #*>-P&,<'UP0 8OABU\3:
M[>V.J:3XMU.ZT5+R6WNS>E%:1%7_ %D0"D%220,\@@'UQEV<?B:SU?6_!4.O
M:Q>:Y=3H(+N>XD:.ULP%<W&>S'.S"GKQQW];T#2'T/PW;:?&MH+B*+YS!%Y<
M32GEFVCH"Q)_PZ5PNB>%?B%;>-1KVHZEX?/VB)+>[:%9&+1*VX;5VJ W&W.>
M <X)H ]!T33'T?1K;3WO[N_:$$&YO)-\LA))^9N_7 ]@*9XADO(_#NI-I\+3
M7OV67R(E/+R;3M'4=\5ICI4-VMPUI,+4QBYV-Y1DSM#X^7=CMG% 'AFG^'?$
MD_BB_P!!/BOQ%)-I^CI<S"+4I!B[8*1$"3C:03CG/?/!I^IW.J^'=5\%0:KJ
MWB229+(SZM:6EW),W#%E+!3ELNQ4DDC"@#@5U'AWP3XVTOQF^N:AXDL9EO"O
M]H+' -TR(I"*,KA>W0C\:U;;PGXB7XCW7B6XU6P$#V[VL210-O$.2R*P)QD,
M5)/4[<# )H X6VEN/%<WC?Q!!XF\366F6$9DM(OM;P[)=A=@5!P%4KMVXSAA
MDYYK'T'29_&6E7,&DZWKK^(H+**XF>ZU!T@:21@<8(+8"9Y[DCM77)\-_&O]
M@ZWI[^(M-WZS=>?=NL# ON!#C/\ ""=O '3/([OC^'7C:X:UMM1\2Z<UBD\#
MS+!:B-Y$B(VH2JKN  XR>P]!0!Z9H=@^EZ#86$DK2R6]ND3R,<EV  +$GJ2<
MG/O3=<,(T.^^T7S6$)MY ]VC[&@!4C>&[$=0?45H 8%<;\1O"VM>+]#CTG3+
M^TM;:23?=>>K%I I!0 CH 1D\9X'(YR >7> -0$'Q!T>XM_$5U=6&I7%[!'9
M7%TTDL<2+^Z:8$\%SR!C^$<G.!TGQ7TO5I)=4UU[Z^LK&PL[>&QCM;G9]IN'
MEPVX#G #@=NF1T-:.L_#"[D&@SZ VAZ9?6#1S7,\6GA#-,H'S97G9G=\G .>
M3TQ8\6^#/&&NBRM;7Q%9?8K=+=V\^W(>2>+)\PXR.3@XX' &.,D PY? 'BK2
M$UN+2-5OKDW&E06T3W-V2&G>51,RY/R!44GU^?@DBLE? >IZCJ/B^VTW7-:/
M]E"**P!U @37!B#R(^[' )&",#![XKUUM.UP^%19)K$2:R80K:@UMN4.3\S!
M,@=,XSP.,@]*Y;PG\/\ Q#X8N;V0>+4FCNVDGE7[ !OG92 [$L> <$@8S@<B
M@#C_ !ZEC#KWA_0;CQ/?:=/#IZB^N6O6:**-(R0, +NDD(/)QGY>.0*Z&#QC
M>V_P;\-SZ:"-6U'R-(M))CN"7',9D8GM^[8C(/.,Y&:N>&_AG?:->:I?:AK%
MCJMY>9E22YTM6\NX)SYA);=@?W05'TXJK;?"2]7PI/HUSXGD9TODO["6"V$0
MM)@&!(4-T.X\ J%(R,&@!NO?"6\U#3)Y[?Q1JTOB"5"K7%S=%()-Y D4HBY5
M"N0%''"@Y K&NKY=+^,VN73VGBC6!:)&L4>EHTHMVEB&X,N0 N,%?=>Y%=?I
M?A'QC)K,%UXB\:2W=I;2K(EK9P+ )BI)7>5 X]5Y!Z9I^D>"?$.G+XAN)_%8
MFU/5XU N4L$C\IU7:KX!Y(  QP.,]2: /+HK%9?A3J_B<ZIKANI;\QZ6&OGW
M%-X1590<,22Q;']WC'?3\/>&U\6^=+I&HZ_8I9:LEO(-3U*3=+$HW2KL51ME
M']W/'?%=(_PM\2-X?TS11XQM_L6GOYD43:4I4D,&3=ESN YX/KSFM?3O FOP
MZS9ZGJ?C![U[:2281+I\<2&5XGBW\'J _?KC% &%!X5C\2?$KQ;#/J^L?8K8
M0;?)OY$,<TBARJXXP ,8[;L=N.A^&\]XB>(-)N+^74+?2M3>TM;F8EGV!5;8
MS$#<5+8/IVXQ6+9?#'Q787M]<6_C^2%K^9IKJ2+3U#R,<\_>P.O08 [8KOO#
MOAW3_#&DIIVG1LL0)=Y';=),Y^\[M_$Q]?H!@"@#6/0UX_\ $7P19:GXQT$+
M<WS7NKWA28?:.([:-,OY8(PH4<X]6/!KV ]*\PU/X<>+-3\11ZR_CE8[FW:3
M[*T>G ?9T?@JHW^F!SDT :'B#1M3\+_#9M+\)F^E:!L,RGS;H0LY,ABZ?.,\
M<=.G.#7(^%-.L-0\=Z:NE:QXDL)[ -<7VE:T\JS.O&S:.F,N 03R,<<DUW7B
MCP;JNOOHUW:>))=-U+38Y%^T16^1*[A S%=P 'R'CG[WM3_#_@R]LM>_M_7]
M<?6-66W^RPR"W6W2*/<20%7@DD]30!V KS?XU7NF6G@=TO1)+=32;;.&.X:/
M,F#\[ 'YE0'=@Y&=H[UZ17GNJ_#>]UKQM_;U]XB,MK&RB"RDL8Y%CB_C3YLK
MR?XMN?<X% &-\&+FRM+CQ#H-E?\ V^*":*XBN<X$@= &PIY&UEP>O4>Q/K9Z
M5P>D_#ZZTKQU/X@AUJ.&T<&-;"UL(X5,620CE>&P3PV-W YKO#TH \_^)/AJ
M37SI\]VT8T33H[JYO/WI1PPB.PC ^Z"#GGO7(>%/AA')IGA+6Y#-$7BEN=3D
M6[=9-K1L8O+QT(R,XP:] \=^%-7\6V$5A8>(6TNT8.MU$(-_G@XP"<@@#!XS
M@YYJE'X&UX^"G\/S>+G$COM^U0680K;@?ZE5WX R?O#G&%Z 4 >,:=:^'/\
MA'(3#:>(CX@N+AUTJY5S!%(Q9E@^<D+P0&.,'<I&<<5Z'XE\-MXC\7^"M'UV
MZ::_&G/)JB1SLJ.%"Y*A0-I9]W(VY"^PKHK;X9H?AY-X3U+5YKY2Y>WN&C ^
MS8QL"+D\#'(SSEAP#3M9\ :GJ#:3J-IXGFM?$%C$T3ZB;5#]H1CDAD&, $G
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M =H(S\PP,DXR=W!Z5V=O\+H=,LO$5OHVLW-@=9D4[TC4F",;B8UY''SN,C!
M(';)@L_A.7LK73M<\3:CJ>E6FP0:>JK!#A>BN!DN.!CD8]: .J\%W&H7?@K1
M;G5"QOI;.-YBX 8DC.2!WQBF>.-9G\/^#M1U&U&;E$6* X!"R2.L:$Y[!G!/
ML*WHXUBC6-%544!551@ #H .U9WB+0K3Q-H-WHU_O^S72A7*$!A@A@1D$9!
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M4 %%%% !1110 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )B@C(I:*
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M4M% "8HQ2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[BM"@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"6 R<$C/%8NL:?+H-O!X5T^Y\[0_%S67V:>$[EB(*+/@9(^;*-D?3MFO:O\
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M:=I\&EZ;:Z?:H$MK6)88DSG:BC &?H* +=%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 )1110 M%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F*
M6BB@ HHHH **** "BBB@ HHHH **** "BBB@!,4M%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E%%% "T444
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M[>><#&#3\'?$O5=>\0ZSH5]8Z>FH0F7[ D;ND4C1L0\;2'))Y4@A.@8D#@4
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M36MK\0[CQC=Z ?'B&.TM8KB6Y728 ?WC$! A'7"L<Y(Z?2MG6-7\1Z[XIO-
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M'SU/ QST['('KVVEQ0!@:;KFHR^&+C6-4T:>QFC665;%2))3&N2H[#>P'3W
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ****  ]*;3CTIM #J*** "BBB@ HHHH
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M:2%YP$&"Q&<\#'8_#*#PZ_A:/5?#^CQZ8E\29X@Y=@Z,RX+'D@<XZ?>/ R:
M.UHI!2T (S!%)8X Y-)GGO7,?$.]TBR\$ZD^M/\ Z*T940B=HFN'ZK&&7GYB
M.<=LD\ UY1\%)]-T_P 7FQL]66Z:]TA99E ,:K<+)DQ@-C<53G(!_CP<9H ]
M_I%=6+ $$J<,,]#U_D17AWCSP3]KUT7VJ*);[6O$%O9VA23/E680AB5]>.>N
M,+W)KN/ '@8>#]:\1RQ01165W.GV("3S'$04D@G (&6P!R?EY)^\0#NZJ7NI
MV&FH7OKVWM4 !+3RJ@QG'<CO5HUY[X_TBVLIIO$T/A&T\0726S+<&\N@$MXD
M!;>(W!5N,YQ@\#'4T =]%-'/$LL3J\;#*NK @CV(J6N,^%D%M;_#;1$M9GEC
M:%G+.NTAF=BRX] Q('L*V/#I\0O#>/XA6QCD-RXMXK3<0D0.%W,3\Q(YZ#Z=
M@ 7=1U?3M'MVN-2O[>TA4 L\\@0 $X'7W(%/N=2LK/3FU"YNX8K)4#M.[@(%
M/0Y/&.17G/Q7\*Z=J<VCSQZ<LVK:CJ5O8F?<S,D.&9B%W;2 JG/'0D^]>@:I
MHNGZSI!TN]MU>R9HR81PI".K*N!VRHX].* *-KXV\+7MU%:VOB'3)[B5@D<4
M=TC,S'H  >36^*\G\.Z%I?B#XH7&N:9I5C;:+H0-I UM&@6ZNNK. HQA V,^
MNT@]0/6!0 A.*8DJ2+N1MPR5)!SR#@C\""*X/QW/>:IXFT+P?;7\EE::JD\E
M_)"!YK1(H/EJ?X=WS G'I[@Y.K>$]*\)^._!LGA:W2QO+BYD@F@20XFM@I>0
MMN/.T9_$K_=% 'H;:]IZ>(ET&2<1ZB]O]IBB;CS$R0=OJ1CD=<<^N-(G'K5>
M:PM+B\MKN:WBDN+4L8)70%HBPVMM/49!P<5Q7C.2?7O%>E^"TNY+6QO+>2[U
M%HLB26%3M$2MV#'.[O@>_(!V\5W!.SK%-'(T?#A'!*\D<XZ<J1^!]*AEU;3X
M)'CFO[:)T^^KS*I7A3R">/OK_P!]#U%<3-\(_#":UH^HZ9"-/>PG$SQ1LS"X
M"\J,EL@A@#N';@@\8QU\)^&];^->IJVFPE+"S2XN(C]R:ZD;=O89QPK<@]2<
M_4 ]8WC8&SP>]5K75+"^EFBM+VWN)("!*L,JN8R>FX \=#U]#7 >)-<@\6WG
MAKP]IE]+'I.N37:W5Q;G#216X8-&K=E9@1D=5]CSE^*]"T#P9XH\'W7A^"+3
MK\WGERQP'B6S"DREE.2QV\9ZG/<@$ 'JMYJ-GIZ![R[@MU.<&:54!QUZD47&
MH6EF%-U=0P!F"J99%7<3@ #)Z\C\Q7G7A3PII?CC3T\7^)8TU2\U$LT$<C'R
MK6$,0L2J#CCOG^+/?)/*^,/ FDZ!X8TK2M*']K7-]KIGLH0X61H60!XU?GY<
M1Q@N>,X)H ]L?5M/CM$NI+ZV2W>/S4E:90C)C.X-G!&.<U<4Y%>/>#?"VF>(
MO$5X_B#3$@O-!"6MOHQ@Q;VT)9S&V\Y\_=\QW''.3CD5["* (IKF&WP9IDB!
MX!=@H/YU';ZA9WC.MK=P3M&VUQ%(K;#Z'!XZBO-OC';Z?+_PCAN-'FU*Y?4D
M C@C+R/ OS2QJ,\EAV[XY/ IGA3PU)<^/;?Q%8>&&\,:39VK1"%U$<UXSC^.
M-3\JKG//<#KT4 ]6-4Y=4L(-0AL);R!+R<$Q6[2J))  22JYR1A6_(U;KQ?X
MMQ3-XUTF\TJ"#^T=)L7U5V,9W2I%*FU21C<!ACC/3/J* /6]2UC3M&MOM.IW
M]O9P9QYEQ*$7/IDU=!S7B1L[WQ?\4O#>HZU:O%'+%)>V]@_ M[6,@Q%QS^\=
MSEAP "@SQBO:PZERFX;P 2N>0#G!_0_E0 ^B@=** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF2/*W5V/<]/RJ7PSI5]HOA^UT_4=5EU6ZA#!KR9=K2 DD9Y)X! R22<5KT4
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M5GD\P#@#G@'/ ZD4 5;CXC^(_P"W?[+L/ S7+O;"[A9]6BC,D!.!(?E(4%N
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M#QEXWU?7I["7PS81P6-TEO?3+=']WG!;83PQ"G.!ZCUJWJWCC6)]7N]*\':
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MDQN('J< J".[ 8R,F%?%7Q$TWPM:^+[Y=&O-(:%+F>UB1HYUA;!R">,X/O\
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M]?T&SN=.\/Z;8WD_VBZMK6**:8DGS'50&;)Y.2">>: -&BBB@ HHHH ****
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M12T4 (*#2T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4  HHHH *2EHH
M2@4M% !1110 E+110 E I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH #TI*4]*2@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BDSSCC-** "BBDH 6BDR:6@ HI,FC)H 6
MBDR:,F@!:*** "BDR:44 %%%% !129H)Q0 M%)FDW#U% #J*0&D+#UH =13=
MW&:7- "T4F1B@,">M "T44F10 M%)N'K1F@!:*;N'K2,Y XVGZG% #Z*C9V
M' #'L3Q^=+N.W)X_ T /HJ,2%N@&/?-!D(/.!['O0!)13-S8R< =?6@.<]!T
MSQR: 'T4PLV,=#ZXXIP.10 M%(3BDW4 .IKYV';C=VS2YHZ\&@"&U681 W!0
MR]R@P#^%3TG2C.: %HI,T9- "T4F31DT +129HSGI0 M%)DTM !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ+#X3\/3:I+!)<.&6*&WCZS2,<*N>PSU/IGJ<"N,O_#GQ,N=%DOSXN U:/\
M>1Z?;01QPD8!,>_ .<YY.1],DCH_B)X4NO%OA^"UL;F*"]M+M+RW:;/ELZAA
MAL D##'H#R!63;1?$S5;NRM=1DTS2+.-P]U>6)$LTP7^%5?*KN/7C_XD@%>&
M\\4^*VCT'3M2ETV/2HXX=7U<Q*99[L(I:*-.@&3EFZ<C''WL75M6\4:'X>\6
MZ3/XB>:\T;[/<V^H(BB66.9B!"P(X.0,$<G( ]*V7\.^./#7B+5Y_"TNE76G
M:K=-=-'J#N&@E?[S?+CY0?3)( &.*2]^&5W_ ,(CK<<>J->>(]4FBNIKR7Y$
MD>)PZ)MY 3KCT)'8   R_%'_  DVB^'?"13Q5J+7][=16LNV-<R-*2Y)'7Y1
M\H&/K56/Q!X@T+XBW5E?Z_=W^A0R1:;<W3I&!#/-$#&P53P0P +?[V>>O2:/
MX;\6:SKFGZQXTEL1_9(<V=I9CB24@#S9#DC/7@8Y ( '!IZ3\/M?N%\5P^))
M]-:VUTB<"UDD=X9@Q9""P7"J<8Z_=':@#"M[CQK>Z?XJ?3]<U:_O+;5%TNW
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M2H=QT9L8Y/(Y'O0!':)K7Q'U'4+U->O-'\.VT\EK9?V7,%DNRC8:8R8^X<<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ /2DI3TIM #J*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ /2FTX]*;0 ZBBB@ HHHH ,T48HH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2FTX]*;B@!U%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 'I24IZ4E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 !Z4E*>E)0 M%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@I:* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BB@T %%)^%** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TI*
M4]*2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ /2DI:3% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !124M !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444'I0 F
M1G&>?2EJO;727*EU5@0Q0[E*_P QS5B@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** &A2#DD&G444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444AH
M6B@44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !2&EHH !THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **2EH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HS124 +1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !12$$]#0,@<T +1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(>E - "T444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E(.
MM+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%':@!,TM)WI: "BDI: "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** *[/+]J505\K8203\V<U8I*6@ Q111
M0 A&>Y% &!2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M(V0.*8CN964H0!_%V- $E%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 $9&*3'-+10 4444 %%%% !1110 4444 %%%%
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MRKO<Y^@IEO\ $.P&I1:?JEE>Z3<S[?)^V185R3@#(X'/K0!V5%,#Y/R\BG4
M+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.['\-Q%^/7N,T >Q#H#1FF+*CJK*V58;@1W%17MU#9V<MQ.^R.-=S?X?CTH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I,TM&* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRN.I /Y&@#FHM<\?1VR2)8>'M55U5DDM[]H0X/<!EJT_CO4--8)K7A75K;8
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M/6ES7&^#?$EYJ$EWHWB"%+?7]/Q]H1,^7*G\,B>H/Z5V(.2* %HHHH ****
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M5DA\EL.<E.V<?Q <;NI[YH XOQ#I.JI?!K.]9=<TE3<:;(6P;^ \R0..^W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ/?6_A_3+:'2H)8Q"521Y]A;;UR*FU+59=7\F"_T.SVPSC:[71PK%@O;U.*
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MI%9UV_+R%P!E3FNIU80QVL5P\8D,$JM&#_>)P#^M8>B7=J=?DQIXM1+$1:R
MY$B*<'CM6WK9']F.#QN= #VSN&* .=\(*L'C/QG;JP.;R*<KMQRT?//?I7:"
MN)\,@K\2O&//!^RM_P".,/Z5VPH 6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ H/2BB@"K?65OJ-H]K=P1SV\@P\<B;@PK.TKPIH
M>B2;]-TNWMG P&1<L!]36W10 U00,$?KFG"BB@ HHHH **** "BBB@ HHHH
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M1?$2Y\26$")HUII[:7!=8Q]K?S5=F3UC7;M!Z$YQFO/+RSU&;PEJ=U91O-X
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MS2+TRK;72;',388<@@@D$9R!VH XRY6^N[[PUXM\-68UBRM;.6T-G(1%,H;
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M!:M<.UO#(<_,D1.U2"21@<'IC% '7"EI ,4N: "BBB@ HHHH **** "BBB@
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M;&VCA@MRT@4C  E<GK[D]<>U #(7BUS3!#>V_P!FF(#2P,=S1MST/X5SVO\
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M75S,VYIY/[QS72T (*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^4C*H%P@QP#C)Z\UB>(/ EMX@\0VNN'6-7L+VUA,,)LI8U"@[LD;D;DAB#[
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M3MC<"L;%?Q;'6@#E-/\ #FIVVE7Z7&J_\?%S]HMK>&3+0R*^<AQR<C@UT/\
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M<RRS)MVA2_!P!D#ZU%IOP^T/3-2M;V,WL[6FXV\=W=/.D3D ;U#DX;"@#T%
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MSNA^"/#WAS4)+_2[*2*ZDB\EI9+J68[,AL#>QQR >*Z(4<44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%)WH[4 ! (P:;L4#&!CTIU
M+Q0!D:IX8T/6HV34=+MKK<,%I$RQ_P"!=?UKGKOX9:(\@>SN=0TUPP8&TO&4
M9'3Y6)'8?E7<4<4 <%-X+UU92MIXZU*.W*X\N:%)NWJ?Z 5#'X%UB) B>/M3
MC'<0PQ(">_ KT/BCB@#@;CX:6NH0)%J7B+7;T*P8B2[X8X]% Q^%:FF?#[PM
MIC*\6DQ2S+C][<$RMQT.6)YKJN*3 ]J &K&B_=4*/0<4HC0'(4 ]:=1D9Q0
M@  P*6BB@ HI*6@ HHHH ***2@!:*** "BFNZQH79@% R23@ 41NLB!U8,I&
M00<@B@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %&.<T44 )@48%+10 8HQ110 8HQ110 8H
MQ110 48HHH ,48HHH ,48HHH ,4444 %%%% !1110 4444 %%%% !1110 44
M44 ,C^[3ZCB.Z)2*DH **** "BBB@ HHHH **** "BBB@ HHHH **** ,W6-
M:L]$@AGOG,<,L\<'F8^5&<X4L?X5S@9/J*=:ZQ9WFK7VF02A[JQ6(W"@<(9
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M"MMIBYD_Y>$$P(_W?W@Y^F.];/B#PO<ZUJMX4DBAM;K0KG3/,ZE'D9<';QD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4E+10 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!#!]VIJAAYW8[.:FH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&WZ/
M_P!=&_G4U0P\;AZN:FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@""#D.3V<U/4,/'X\FIJ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex-a_056.jpg
<TEXT>
begin 644 ex-a_056.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6+!$D# 2(  A$! Q$!_\0
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M;O2J,UA]INDEF=C&@#"(#@.#G=5X( Y;N:=0 U!A>>M.HHH **** #-%)2T
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MH **** "BBB@ HHHH **** "BBB@!@/S8]*?3%_UAI] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1K_K&J2F@<YIU
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 -'44ZFCJ*=0 4444 %%%% !1110 4444 %%%% !1110 44F:,T +1110
M 444F: %HI,T9H 6BDS1F@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH :.HIU-'44Z@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO)DA@C +.YP!DX ]R20 .I) %0:;J]CJ\+RV,ZRK&QCD&TJT;CJCJ0"K#NI
M([BLGQU86^K^%IM)N+QK/[=+%##,JYVS>8K1Y]BR@?CVKSN7^V;C08++6Y3;
MZK'XIL[*[N+60+)."L>QV9>X5D((QT&0"#0![1P,9Q2\5Y@-9U*7QQJ-@-0N
MGL;FVOT25)!&(WB*#$:=59/NEC]XDL,=^>\+:GKRQ>%=+T6]\P_V6MTBSR;(
MF8S[)4?.2RHBD*%Y!.1Q@  ]P'6EIJG-.H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***:^>HZ^E #LBBH4,I+;T"@] #S4H^Z/I0  @]"#2U7MTN%!
M\]PS;B05' 'I4DXD:%A$P63'RD],T /-(2!U.*CMXVC3#G<Y&6;U-+-$)5VG
M(]Q0!(.E+3(T*(%R3CN:?0 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+\YE++ NP 9V[2<Y)&1M[\;=2Q\!75K+(9+^-X[=+Y;)4#(6^U$,WG<X(4C
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M", AA&H9LDD <$8^M/\ [9C35[;3)X)H+BYBDEB\P+M8(P##(8_-A@V/0^Q
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MZGX;NM?LH+R>PMG96V1#>P7!+*N>5 .?7@\5#!X^M+FP2^@T37I;5X_-65+
ME67&<CGD8H ZZBN93QII_P!OTV">*>W@U1(VL+F11LN&==VP $E2 5Y8 $G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_;?)\CRS-F+R\?=VD<#(#<'[PS52Q\!Z-87,LR&ZEW9")+.66%3*)61/16<
MD'.<8[F@##_X1.WT_P ?^'[RR#O?I'))JEWNX=/*$2[ESA=[\J !]U\=.,;P
M/9VYUVUM&C7;J>C7LEW(.))6-YC)88).'(SUZ5VC>!-+?Q8_B-KB_-X\B2-'
M]H(B8HN%RHZ@=0"<9K0T[PUIVE7T]W:*Z22*412V5A0L7*QC^$%B6QSZ#
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M@/G01J%(+(I8,ASZ;FS_ !5W"^&X(M2TFYMIVBM],A:&&S"*8P"NW<.-P;
MSG&,C'S$U5\8^$(_%UI91_;Y[">SN5N(KB ?,I'7'0@]P0>" ><8H L>->?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML,21J69R$4 %F)9CQW)))]230!E^)FUQ=$G7P]';MJ#*0CW#X6/@G(&,,>
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MGAX:I,MW=:YIUK:7S3&./R'#[K=23&"XZX+-V'4\<UN"@ Q1BBB@ Q1BBB@
MQ1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1^6I=6.<CIS4F
M*:*7\: %HHHH **** # HQ110 F.*, GI2T4 &!1@>E%% !@>E&!Z444 &!Z
M48'I110 48'I110 4444 %(0/2EHH 2@ >E+10 8'I28'I2T4 )12T4 )@9Z
M4M%% "&CBEHH ;@>E+@8Z4M% #<#TI0!Z4M% !BBBB@ HHHH **** "BBB@
MHHHH **SM5UFTTE(Q.SO<3!OL]M"A>6<J-Q5%'4X_ =20.:IKXIL([BVAO$N
M;'[6ZQVK7<)C69F)VJ/1B,':V#\P&,A@ #=HKFY/&>GC6[S1[>WOKN]LE#7$
M=O;$^6",CKC.01TSU'OB:/Q7ISC4MXNHFTQ%>[1[63<@9=W  .[ Z[<X_*@#
M>HKECX_T"*SM;VXN)K:RNGVP74]NZQ2?*&!W8P,@\9P<JPP"I U;[7K"PO\
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M;KT96&01^!H YZ\T35]9LI-,U'4D2Q9T65[>/$MY#M;S$?M'NRH.WGY6P1O
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M<7<9DAD\O]VP4,6&[U&%R.OSKC/. #4HI!UI: "BBB@ HHHH **** "BBB@
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M%IMQ#LA^52 .G+'/JJ^IQK:A9W>I:#<V<CQ13W-LT,A7+(C,N&(Z$CDXZ=J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!IY8&G4T=13J
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Q1
M110 4444 )BEHHH 3%+BBB@!,4N*** #%&*** #%)BEHH 3%+110 8HQ110
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M*,444 &*,444 )BEQ110 8HQ110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!&7"N%P<FGY-)U(IV!0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(: %H
MK-L=<L-2EO([283/9SFWG"J1LD'5>1SU[4^VU6SO+^\L8)E>ZLR@N(\$&/>N
MY>HYR/2@"_1619>(=,U&"6XL[CSHHI)(I'5&&QT^\N",Y'Z]JHR^.O#L.AVF
MM-?YTR[++%<B&3:2N<@_+\IRI !QD\#- '2T5'%*DT*RHP9' 96'0@\@U1CU
MS3Y];GT>&X$E_;HKS1(C$1!AE=S ;5)'(!.?:@#2HJCIVK:?JT<TFGW4=PL$
MS02E#]R1<94^XR/SK-N?&?A^SMKRYGU.%8+.86\\H5BJRD9V @89N.0N2.,X
MS0!T%%8^I^)=+T:\MK2_N&BN+H'[/&L+R-*00"%"@DD;AQUQST!PVU\5:+?0
M32VM_'*T">9+;JC&X1?>''F GC VY.1C.10!M45D:;XDTO6-*FU+3KAKFVA+
MARD+[LJ,L A&XGV Y[9J"Q\8:#J6DW&J6FHQRV=M"9YI C#8@!))&,\ 'CK0
M!O45@R>,- ALTO)-2A%JX9EGPQC*JQ4MNQC;E3@]#Q@G(JS?>)-&TR>W@O-0
MBBEN5WP(<DR#U4#K0!JT5EZ7XBT?6WG33-1M[IX"!*D;99,],CJ.A_*HK?Q5
MH-WJW]E0:I;OJ&2/LX/S\#)X^@S]* -FD-9EUX@TRRUNRT>XN@E_>JS6\6QC
MO SGD# Z=S5ZYN8;.VEN;B01PQ*7=ST4#J: ,7Q3X5M_$UM;MY[VNH64GG65
MVG)@DR#DKG##Y1D'\,=:BU#3/$&JV4FF75_906\\>RXN+6)Q*ZDX9$5F(3*@
MC=DGYN "H)M-XN\/QVMO=RZM;16MQGRIY6V1OCT=L#]>:L:OKVFZ'IIU'4+I
M8K,8S*%9QST/R@G'O0!A^)O"5W?:)IFG>'[JSTZ+3IX[B*&6W+HS1G,:Y!!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJWRLWS/P/G) .\G:-OS &5XRU GQKX&O+*6:9'>:1%@C#"1'0?=)P"2I(Z\
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M&W&XE00.@W=]OS2ZAX:U2;7?#.IV\]K--I>\74MTT@DF#KM;;CY1]YSR.#M
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MN86 \M'5U4X))(VCDYR./>@#/\+:['X0T;6]$U6"5'\/EY8@L:AKFV=V,;(
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MBLK J6'4<C('3MIV%IK[V$TNIW]JNJM$\<7V1'^S1$_=?8QRQR%SD]L#;DY
M-_-%9FA1ZE!HEE#J\L<^H1PJMQ+&<J[CJPX'7KT%:= !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% " TM-Z$4Z
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M",T44 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 %%%% "8H
MQ2T4 )BC%+10 F*6BB@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%
M&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K?>%.IK?>%
M.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]I&)95:%E4*2!P2.>HZ<'MG!H VJ*2ES0 4444 %%%% !1110 4444 %%%%
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MS6']]AMXY"C(R<T =11110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 WH1FG4UOO"G4
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MSG:CN#M*QR Y(?D%>5;IELC-O2)/$$7Q)\3+)>PWEK##!(MOM92L;+*45!R
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M'S.SC*XP<!1W.3T%=&*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** &M]X4M(*6@!:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!F<<TNX5'+$9"AWLNUMW'?
MV-/VGVH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M* "BBB@ HHHH **** "BBB@ HHHH **** $HIDG:DH EHHHH **** "BBB@
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MH^90!@$DX(%0:A8^(K.;1?$MEHMM->P02P7.D02K&J1R'< 'P060@;BH&3G
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M<);Q3R; VV=MQ+8( 4$$G\JTA#KVB_$35+ZWT4:CIVKK 3-#<*C6XA0K\P;
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M:X'XP1C_ (0=IERLT=Q&L<JDAH]YV,01ZJS+Z88^Q !WG>@=*X;QQJ6CZ?\
M#S5]+BU2&.:WLS;I&MR!(&4*%4X.<G*Y'<-SP:U=%U./3_"6AI(US=WD]E'(
ML9D\R:8[%9V+.W;<"2Q &0.X% '2XHQ7)3_$+2[32=1O[F"]B_LV[^R7<(AW
MO$Q; 8X.-I&#G/?'7BI!XXM4U=+"ZT_4;3ST9K266#BZ97*LJ 9.< ,,XRIS
MTY(!U).!2*RNN58$>H.:YK3O%\&J6VKB73-0M+G2UW7-G-$#*5*%E*A"0VX
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MKR*B6"))WE6-!+( '8#!8#ID]\9/YUS.F>.K6^\00Z)>:9J6EWUQ&);6.]A
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M$8SC.:;)+%#&9)9$1!U9B !^- '!Z/:>(+SXFCQ!>:"VG6;Z4;-Q-=QNRL)
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MD1M,4$A*Y*$ C=PF['^QZ9R 5/AY:W=OX,L9-1GAN;RX7SGN8R&\Y2!Y;,V
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MUDF1'. S*I(4GW( KD/!GAS2O$GA:SUS7["VU/4[[,TUS<Q!R?WA*JH.0J@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z4W-./2FT
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M "BBB@ HHHH #TIM./2DH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEQ-+$]S&@+*UL6' )(.>QP<K]"8-.T?5]:^"=OHPMI-/U2*WCB6*Z1H]S12
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MI7FOAEKR+Q-8-I&D:YI^FW<4DFJ6=^K"WMG.YAY)?D-O8Y"#:0P.!@X]*ZT
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M-)_M>^@V&XA^TK L*.&*DNP.6.W[H'3DXR,TE\<VZZ!9ZM/I]U&D]_\ V?-
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MICND2-)(ZHB LS,<  =237&V$FE>#WN=+T;3=2GO[E$OSI4;;_)0@1\.Q\M
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M=:9:W4)D,MQ?IIWV5@/,CG9L%6P2!A0S'G&%X)R*<?&=JFDZK?3Z?J%N^F7
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M$;JXBA$TJPQ^8X7>[?=49ZD]A4XP0#BN%O?$IO=!M=1O=%M[JQN=;@@LBTA
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MI]+O%FN8HK591?M8/; R;V5HR&)!( 4Y7CFNJH **** "BBB@ HHHH ****
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M=$(P=QX^Z0<9QZ'E_P#A#]6OM6UTMHEKI-EK&D"W3[+<*1#*,8$HQU/0E 0
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MA$K!7#_:-^P@DY;:"W3IVX-==/JT&B^.=/U+4G>+2;[1H[6WNSS$DX<N4)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M!Z4E*>E)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !12&@4 +112=Z %HHH/2@ HI** %HI :7- !1124 +12<44 +1244 +12
M44 +1110 44AH'2@!:*2EH ***0T +1244 +1110 44E'% "T4E H 6BBB@
MHHHH ***0]: %HI** %HHHH **** "BBB@ HHHH ***0T +124M !1110 44
M44 %%)2]J "BFY (!(!)P,GK3C0 44G&<9YH% "T444 %%%% !12&D9E12S$
M*H&22< "@!U%,5E=0R,&4]"#D4\4 %%)1Z4 +112&@!:*2E% !1110 4444
M%%(:A2Z@EN9;>.:-IH=OF1JX+)D9&1VSV^E $]%)37=8XV=V"JH)))P * 'T
M50;6=-336U%K^U%@@+-=><OE  X)W9QUXJ[&ZR(KHP96 ((.01[4 .HHI* %
MHJO<7=M:"(W$\<7FR+%'O<+O=NBC/4GTJ>@!:*** "BBB@ HK'UKQ+H_AY4;
M5;Y+8.?ERK,<9QG"@X [D\#N:U(9H[B))H762)U#(Z,&5E/(((ZB@"2BBB@
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M(KGS<SVP&6).55U<#/96ROM@#TKI/',,MQX%UR&&*265[*0*D:EF8[>P')H
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M%'N?/DOF(MH[2-IVE Y+ ("=H[MT'>@#7*(Q4E5)4Y4D=#@C(_ G\Z=BN*\
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MT,(2 QE8,1A "">_8 GBK'A_7;;Q'I,>I6D-S%!(S*JW,7EN=IP3@]LY'X4
M:>*7''%<I?\ CNTLCJ,JV%W<66F3""]N8E4")R"2 &(+8^3./^>BXSSB:_\
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MD#YMK8;;R0*K:9XZ.JWNF"WTB4Z=J<LD=K>BXC8-M5F+% 2RCY#UZ$@'!XH
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MD37MC&T?VNUV%)9@."6RSC>N,9)!&"U>UE592I4%2,$$<&DV)LV;1MQC&.*
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MJZ5KEG;JEKJUJC,MXK  J0GWN3M.02  W\( ]&@@BMHA%#$D:+T5%  _ 4_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ****  ]*;3CTIM #J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "HKBWANH3#<0QS1-C*2*&4X.1P?<"I:* (XX(X8EBBC1
M(U&U450 !Z >E"01QLS)&BE^6*J!N^OK4E% $?DQA2!&F#U&T4OEJ1MVKM],
M<4^C% #0BJ %4 #L!2@8I:* $Q35C5!\JJ/H,4^B@!H4+G  SSP*=110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z4VG'I3<4
M .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BB@T %%)0
M* %HHHH **2B@!:*** "BBDH 6BF[Q3J "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)VA_>JHZC]XP&.G''>@#M+^6\>S\,.WB>#3I7EA,Z3)&#J!(7,:YQ@MSPO\
M>^E6(_&NBR>)IM"%THNH57>3P YD""/'7=DJ?3# US7BZZL3H_@25IH"YU:Q
M>)RPY3'S$'TY&3TZ5?2XM+;XS7B3-'')/HD&QVP-Q\]EQGN3E0!WQ[4 =R*6
MJ.EZK8:O:BZTVZBN;?<4\R,Y&X=1]:O4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH #TIN:<>E-H =1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !110: "BDH% "T444 %%)2T %%%(: %HH%)0 M
M%%% !1110 444E "T444 %%%% !1110 4444 %%)0* %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BDHH 6BDI10 44E% "T4E*: "BDHH 6B@
M4E "T4E+0 444AH 6BDHH 6BDHH 6BD%+0 444AH 6BBB@ HH-)0 M%)10 M
M%%% !10:2@!:*!10 4444 %%%(: %HID<BRHKQL&1@"K*<@@]"#3Q0 444E
M"T4&F22+&A=V"JHR23@ >IH ?15>SO;74+87%G<17$!)421.'4D'! (XX((_
M"K% !124M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >
ME-IQZ4V@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!Z
M44AZ<4 <MXR\6#PP=+;8KQ37:+=Y&?*MSE6D// #,@R>,D#J172PS13P1S0R
MI+$ZAT=&!5E(R"".H(KST6]_XLEUN\GT**ZTN_@>RM7DNQ'*D2;API5@"TH+
M!B<CY3_"!5SP)JEW>^$[W3-7GBM]0TN1M/F=7&4 4!6., =\=,X'>@#N(Y8Y
M!E)$8$ C:P/!Z']#^5/KS3PLITC7]'TW6]*TQKJ6!QI>L:;]RZ 3<^\=0Y4!
MLG(.3@\\['Q)U._TKPU!-9R&&%[Z".[G!(,4!;YB"/NY.%)R.&/.<4 =;#=6
M]QO\F>*38VQ]CAMK>AQT/M7):MJOB+4;_5;'PY<:;;W&G^5&@NU+?:)'42$9
M!^0!#Z$DY^Z!DPW]C;:%XW\-MHD,-H-0::VNK:W14CEA6,N'*C RK8PW^WCO
M2^%;.T/C'Q>#;PDQ:G%-'E!E':W7+CT)W-R/4T =<6NUT_<L437GEY\O>1&9
M,=-V,A<]\9QV[5@>!]=U37]+OI]6M8+:YM]0FM0D#$KA"!USSABPSQG;G'-=
M1G%<EX A,-CK888<ZW>D\Y_Y:G'Z4 2W7B*_LO'6GZ/=6D$>GWT4IMI8R\LL
MCH(R=P"XC4;V'.>F<BND>:*.2.-Y45Y"5168 L0"2 ._ )_"N(UZ1C\8?"<8
M<;5M+MMI[97DCZX'Y5T6IZ98WFLZ/>W-U)%<64TCVL:S!1*S1D,"O5L+D\=.
M>V: ,CQ1KVL?VK%HGA=M,;55C%Q,E\Y ,9) "@$$G@D^@'N*EUK6]6TJST6S
MCAM)]:U*Y2W;8KB", %I7'4D # SSSGH"*=XA\->&?$"74]Y#;&]M8\-=QR!
M)K8A=RDL#E2N=PSTZUAV>@W_ (P\)>#M:DO'L=;TZ-)TEGC,JR$A0V]25)WA
M >HZGKUH Z+2]9O5\47F@:HD1F2 7=K<PKL2:$D*P*EB0RL<=3D8/&>4\:ZA
MJ6C^%]0U6PEA66SA:8+-&75P,9! (/3..>M<WX9>]\1?$:YU:XEL;RSTFT:P
MBO+.)HXY)V*LX 9FSM&1P2.1SSQT7Q#D@A^'FOM./D-E(H&<98C"_P#CQ% &
M+=>)?$'AN_T :M]FO;#5)X[5Y(82C0R&., @YVX:3S&QC(7N<8'8ZRUTFB7T
MEBY2[2!VA(CW_. 2/E[Y(QCK]*YK1_!MK<_V3J>J:M=ZW)9@2VC3E/+C)102
M H^;[JG))Y&>I.>E?4K"1KRU6\@:>VCWSQB0;H@02"P[=,\T 8'P[\47GBKP
M\]UJ,$4%Y#-Y<BQ9"L"BNK8.<95QQD].W04]:\:7*?$'2/"NF1C<\P-].T9;
M:NSS/+7/&2@R3S@$=^G+07EQX+TOPYXKM[!Y+&]T:"TU"WM8U/[]4'DO@8ZL
M2N<],#KBK<VE3Z+XC\#B\N/,U.]U.[O+N16(+.\8XP>RIL3@ 84<#.* /6*R
M?$>MIX?T:2^,#7$I=(8+=3@S2NP5$SVR2.>PR:OI>6LEW):I<PM<Q@,\*N"Z
M ]"5Z@&N+^(,UPFN>"X]D;6CZRGF!U#9?&$_(%S]0#VH E\4:YKVB:!IES)]
MDAO[J^AM9(XE,L:>82#@M@D@#(/'/;%7Y+#Q):SZ8T6M"["W(6\CDMXXUDC*
MX;;CD8P6 !)R><@5C_%J!;GP]I4$F[9+K%M&VTD'!W X/8\UJWFBZ;HNI)XF
MO-5U,+9*X*SSM-'L<!=BI@G).S&WYF('4F@#=GU73[2X%K<7UM%<E%<0O*JN
M59P@(7.<%V"CU) ZFI+K4+*Q:!;N\M[=KB00PB654,CGHJY/+'T'->/Z])!+
M;>.XK26SM+&2=UN9-0VRW%Q=( P2%,@+& "0QW,"20!CC;NK/4K^YT*_T>XT
M:\U.VT5%ETV]&2\3X\QHWQU8IY?(P 3DC/(!UNJ>,M)TV?28Q=6\XU)MT;K.
MH18 C.TQ;IL 7KTYJ]>>(M$T^Z6UOM8T^UN6 80SW2(Y!X!P3GFO,)[G2)[K
MX;745BFGZ>\]P!!<LC!.  -V3D;SQGGD< U=M9K+7O$'BS3-3U2"&*98I8V$
M43+)8^6&3:S*0-N[<,Y(+9H ]-FOK2WB\V:Z@CCV&3>\@ V 9+9)Z <DU6&O
MZ,8VD&KV!185G9OM*8$;?=<G/W3V/0UYK)8>&K_4?AQI]NJ7NC".[$*7BAC(
M @VEE([L.XZ^E:%QH&B+\7]-LWL89+==!98[7R2Z1[9"%9AR "I906XX '.*
M /1H+F"ZB\VWGCFCW,N^-PPRI*L,CN""#Z$5SNJKX@@EU>^&L6-EI\4"M:K)
M &VE0&=Y&)&,_,N.@'/!K,^&8BAA\36D 1(+?7KN..) ?W:@C Y^F?QKI/$T
M[VGA?5KB/ >.SF9=R;QD(<9'<4 <[X5E\4ZGX<TO5Y=5M9S=F":2&6V"!8BH
M$@!7^/[S#MG'09%;NB2W$4.I/?ZI:7<4=[-Y4\9 $4>0?+?L&1BR]>BC/.<9
M?PP"K\-=$ ,9'DMS&,#[[=??U]\UR^H6EG/X,^(]N]NDBV^HW-PA?YL2F%&W
M#T(8G'I0!Z):^(M&O;\V%MJMG-=[%D$,<ZEF4J&# 9Y!4@Y'8BIM-U;3]7@>
M;3[R&YCCE:%VB<,%=3@J??\ I@]#7FVM:5H<^G> KMK"VLDN[B)99(\0MY;P
M.Y0NN#@L>1W)/K5FZLWL_&OBO3_#UJENTOAQ65;4^7MN!YBQX ( 8@C!QQM'
M3/(!W-MXAT:^U6?2[;5+2:^@W>;!'*"Z[3ALCV)P?2L_3-?F'BB[\.:BCFZ2
M(7-M<B(I'<187=CJ 59L8STQWS7">']/\-:EHOA63_A*;Q;FR:/[/91F%9XY
MF #Q@)'YN,_>R2-H)/'-=-XDD$7Q4\#E-H,R7\<AQR5$2L!^8_G0!VES<P6E
MO)<7$R10QKN=Y&VJH]2:K+K&GL;@?;(%-L-TX=PIB&64%@<8!*M@GKBN4^*9
M8>%(!(A;3CJ%M_:6"!BVW_-W]=@_&HY[=7^+UC>Z:8Y8;S3'BU(I"'38I)C)
M<=&8\<YRJ8^@!U$'B71+G[&(-6L9#>$BV5;A292.NT9YP>#Z'CK6K7B.EVVG
MP?!W3+^**(7MMK,4L<S1@&.3[4@.TD<_(%SU'&.W'MA(P3GI0!R/Q!\677A;
M2H9;"W6XNI'+E&S@0H-TK<=,# SZL.#T/46M]:WEA%?6\\;VLD8E64."I4C.
M<^E<1'!J7B77;[7-*FTV?3)83ID1G>7F)6/FLFQL'<W&[@X1<<<F7X>S?8%U
M3P;=;FFT6;;&7(826TA+1GC_ &2 <^HH ZAM?TA8+.X_M2S-O>R"*VE$RE)G
M.<*K X)X/Y4:GK^DZ,4&I:C;6N]@J^;* <D$]/3@\^U>1:EJEG%\%&L[>XA\
M\:@T30.ZOM_TACC'.Q< $<#'&.HST][KHTKQ[=ZA]HTZ_CO-(B:*)KN.)HA\
M[((Y)&"M'(P;<1D@F,D8YH [:/Q!HLBVK)K&GLMVYCMR+I#YS@X*IS\Q!(&!
M4O\ :MC_ &K_ &7]JB%_Y7G_ &<M\YCSC=CTSQ7F4%LGASX4^'S)=V=S]BU6
MWGNKJ&421*3<98LX_NA@"?:MFYU#3U^,.E7$=S"[2Z3- S+,I _? )WYRVY<
M#))XQP< '6GQ%I NOLQU&V$QF: (7P3(J[F7W(')].,]15+PIXOL/%T%_-8*
MZQVETUON8@B0  JZX_A8'COQ7%6$LFDZCX9@_M"UUS0KF\5]+!+0WEJSK)AF
M4??14<AMP!&X<#'.G\,KBVAN_%NFB2&.==>NI4M@P#B/Y5#!.H3C /3M0!T6
MNVGB&_U"UM],U!-,T]49Y[N-5DF+X(5 KJ5VY()/!XP".:H>%=:OX_[<T[Q#
M>137&BS8DOBGE"2%D#J[# 4$#.<>GXFUXQ\7VOA>TME,MN+V]E$%NL\@5$SU
MEDY!\M>IQ[#C.1SEU%H.M>'_ !%H'A758K_5]0BDOIW64RB0E^%,GW%Z! N>
M!@X(!R :6@ZK<^*)H;R[U5+"WN94O=,TZ&55N)+=00?.Y.Y6.&(7IC!8]!V]
M>)>(4TF_\!>$1H<MO%K:W-I:0.'5+F-]A4JY7D$'!/YUZRGB/1WU^30EU"'^
MU(U#FV)PV""W&>IP,D#D @G&10!7\00:[=FVM=&O(K".1S]IO#"LLD2C! 16
M.TEN5)(.,]*P_#6HZWIOBG6M$\0ZI%?6]M;)>P7LD:0L(F)!W!<  %3R?0GH
M>-SQ5XFLO"FBS7]W(@DVL+:)R1YTH4E4R <9QU/ K!TBZT&]O-6M=/\ $4&J
M:UJD4KOY<Q>.-%!"J!'PBKO]=Q+$Y)- &8FL^(8?!,7C6[U-W1)Q>&P6-%BD
MLV;:%^Z&#;&WC+'D#/ML_$'5M4LO!#ZSH5^MH8S%*SM '9XW(  W<*?F!.0>
M,CCK7/PZJL7P9.CM(IU?R7T-;42+YAN"QA5<<'&,/Z[!GGOI_$A(]*^$5Y9-
M<AVBA@AC>4@&0JZ'\\*3^% '6>(-;M_#FB7.IW*LZ0@!(USND=CM1!@'DL0/
M;K61X1O+B]N+IM4UV"ZU9>)]-MV01V/).T <L03M+DD97 Z'.=\2[;[=X6TK
M4)8B]KI^I6U]>(JEB(1D.0!R<!\GV!J*^EMK_P")OAB_T"4R-/:S&]N+<!X6
MM<;E#D="7Z'U^E '6>)M83P_X9U'5GVG[+ TB!@2&?HJG'."Q _&L:XUR^\(
MZ'IYUUKC5]2O+I(':T@"1H[L!@'@!1G +'+'_P =@^*GF#P)/)Y:/;17-O+<
MJRY/E+*I.!WY _#-)\52T?@OS_*\R."^MI9 0<!%D!.['0>I]Z *EQX@M]#^
M(EQ<ZCK-Q%IMWI<,\-I-YF5<LP.V';D':A+< CN/3K8?$FD7&DVNJ17\3V=W
M(L5O(N3YCLVT*!UW9!&,9&#GH:XRV\0:/=_&?S8]4LIHFT+9"R2 C/F>8?FZ
M'Y,MQVSVKG;/4+.WT"RO_MDHTFP\1WBW+6+.?*A=G"G,8(5/G5NHX/RY.* /
M6-(UVPUM9OL<C>9 0L\$J-'+"Q&0KHP!!P?H><5A:_KNIV'C30].%C<2:5>?
M*]Q I^67=P&/8#"Y'&0QZXQ57P5#X;&K7EQX:::]#0B.\U"6XDD+NK':N6'S
M-@G)SP F,Y..X(S0!YSJ&L:Y>^%_&,5XM]IEUI#236U[;+Y:2J@WJJL1DCY<
M-ZANO) O_P!BW5UX-M[F'Q!J=GJTT23P2W-[\L<\BJ%C8<JR[L+MPWWCC)-:
M_CF6&'P)KHGN(H%DL98U>9L+N92JCZDD #J2:X_1E\ 2^%?#NKZO<Z<M]:VM
MK<>:]ULE$L*! =H8%MK(1C!!(Z&@#:USQ+'!KFCZ(;^59 \DNHF"W<%XXX&D
M(4@'JP7*J2W:LE9_^$8\4V/A1M5UJ2QN$N)GGF$DA3S-L<,<<G)"H,Y)R 6!
M)STLZGXIL+OQ5X%=[FVMEG\ZYDAFF7S(2]N1&K8.!GS,>YQBDUC5].@^,>C*
MVK6T!@L)XIT,JC+,05C?GY2>&&>N!ZT :\7BG2O#$,&BZKJUQ=W5I'%'<7K6
M[LB[B0AFD&51CCG<1Z]ZZ"_U:VTZ)9)1+*6QB.WB::0@]PJ@D@ $\#MQDX%>
M30:AX?TO5?$'AWQE=74=U=:I)-LC:YVW<,H&P*(2.?N@Y&#C:,XXNVNNIX&\
M502^([#^RK._T>UA4QN\\=O)$6'E;@#N(4\G)Q@=0<T =7>_$'3(VT@V*3WL
M.HW$<2RQ02%-K&120=OW@8S\G7'MDBS87>G3>-]0,.KS2WYL(?,TQB0(5!)#
M[3T8[UR.HR,_>%<9XMNM,TJU\"ZS#I]S::7:7995:$ETC*Y7(!)R^ <$[B3\
MV#G&_!=6EQ\9T$#1^<GA^03H,;T8SQL%?'0X8''N/6@#HM.\3:;JFF7NH6\D
MHALG>.Y$L+QO&Z*&8%6 .0"*K3>,](ACM')NY&N[4WD<,5I(\HA&/G9 -RCY
MAU'/X5R6NZ5J]OX_FL+1W;3?$PB>;D;83 T?G9R"#NB! &/FW8(PN:3Q'<:=
MH'C93XA6XM=#O+2*VLKBVNY8(H#&)"R.(R.3OXZX X[X /0M)U:PUS38=0TV
MY6XM902DB@C/;H>1^-<KXSM)M*\!^*+M]3NC<SI),DGGM'Y0SB.-!N^48P"!
M]XDGC.!K^#+71K7PY;_V!9S6NFRL\D*S%MS@L</\Q+;6 ##/8C@=*S_BC,D7
MP[U9&C\QYHQ%$F,DN6&"!@\C[W_ : )UTNZ>?3]4LM3N'M9;41WD#3LRS(4X
ME1@"1(..1C=Z@\FEHGBO0=+\#VVK-J6I3Z899$6YOP\LP)9CM=L$X'W03U^4
M9R:Z31I[8^';"XBVQ6OV2-TS\H5-@(^@ KR -%)\ YK,-/,UG?F+ C;<<3[U
MR #@%&4\X'.,C(H ]#M_B/H%QK5UI>^XCGMU9MSPG;-@J (L9,A;>I4*"6!R
M*T-+\7:3JFA3ZNDLL%O;R-%.EQ$4DBD&/D9.N[YEP!DG< .3BN;U#4+6?XJ^
M%A;(X'V&<_/:. @D52G7&PD(1W(QM(YXY#4['4KK3?'-O8I/)?P:T+YK40./
MM$08;=N&RP&"Q&.P(P<4 >FP^(K/6[^Z\/R0:GIUV]LSCSD\AVC/REXF!SD9
M'(Y!]#6%;^%-8E\/>'R^K:B^J:>_F*[RF&.5/,#JMPG))V!5P,D'/.,FG>$;
MOPYJ6OBXT?0+V&\AMA#<75S&Z>0H"JL7S$Y^[C Z;3ZUWW- '(V2S^&_&<.E
MM>S3:7JL+R6RW,AD>.Y3!=0Q.=K)EL'/*D\9.>O'2N)\6))=^.?!D%JW[Z*Y
MGGD )&V,1X)..F?N^^<>M:_A7Q5:>*[*XN;6"X@-O.;>6.= K*X )''UQ^!H
M EU7Q);Z;>_8H[6YOKP0-<O;6FPR)$.-Q#,.K?*!U)SV!(HOX[TE[+3)]/$N
MIS:DVVVMK(H\A8*&<,2P52H(SEABN4\2,GAWX@7NLZUI-]J.D7EI%'%/;0AS
M;R*2"IVE<#!)R<DY&"<<0WMW!INF:$EOH5SI7AVZO+B.6.UA9KF7<"D6.-\9
ME!/((;& #0!V=GXXTNZ\.ZEK4L=Q:0:=,]O<QW"J'61,90;6(8DL%&#R3@40
M^([36M0?P_=Z9?6EQ=6+7"Q7B*HEA)V'[K$J>>5."*\_L-#U.ZT3QOX=M-+N
MX+I]26^MFNW)CE421R*GF'.7(7J3SN&2,$UU^@^-V\0W(8>&]4LT@AE^UW,\
M)Q&ZX#11;06D;<,8P#\G3/  .;\#^,(_#'PYTE;VPOI[2WFDM[R\B3,=N6FD
MVG)^\H&,D<#*CD\5ZE<7#QZ?+<6T0N9%C+Q1K(%$AQD ,>!GUKQVSLM1@^".
MH:&+/5HM1:Z> 1FUD#R;F#C/R_=9>">F3MSS7K6BRFXT'3Y3#-"S6\9,<R;7
M0[1PP[$4 <?H?C37+CPUJ^N3:.]];PWDQMUBEC1_LZLP(QW9-HSW;=QDC%:5
MYXX\B#PO=P:>);/79HX?,><1M S@$?*1EOXO3H.>16;\/X]4T634M U'2=2/
M^GW$Z7SA3 T;'@[LCECDX5>^3CG&59^ ]231M:TR4EH-*D9O#S&-&D0Y$R.L
MA&2=Q"$<#@@Y&, '3ZCXV?2M1U-+G3/-LK(PQB>VG#,\TC*!#L8+^\VL'(!.
M!C/WA3++QI!?ZY=>'=7M;*WN&@,L(CNUN8;B/;\X8X!!'S94CD D9%9=WX5U
M/4OA_'-Y<8UU[J/67MI4"QFX&"T1 &<8R,$YSQNQTNZ&U_$TE_!X&MM)\FU8
M20(L*SW,I*D)&RD (,')?&?EP.#0!FZ3XBE\*?!6PU>STV.\%LNUHHYBJ%?.
M*EE8@G!/(X.,^@KK;CQ#*NO:-I]G9Q7=OJ$,D\EREQQ!&H!#8P0RL6 !!%8W
MP_TFZ'PYBT'7M+DMVB26TFAE(Q-&V3D%2>"'QV.0?8TO@OPO?Z?8WUMX@C@N
ME"_V;:AXT):QCR$5L'!#!B<$9]<\  %9_B5!Y-MJ<!TZ?1[FXCA3%RRW4:LP
M5W>)E  4D=^A![BN_KRG1=*\8:9I_P#PB\^CV<CPD+8ZV1$R)$I'WU()W;<@
M<9.>>A:O5J %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?F=2 "&_O< #)R<<5K'I7%_\)'J>J>+]5TC3Y;2Q_LV%4$=]'N:YF?YE90K
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M4 %%%% !1110 4444 %%%%  >E)2GI24 +1110 4444 %%%% !1110 4444
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MF:-9'$9)[_(%_P#K5A>/M+EO/$L5T]D^KZ>FG^5=65O+MGM0TG$\:]6?^[P
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MZU;49K0RV.M:9?11RWT8RSE45NQQT. 1@AD!Z<'T.*&."%(HHUCC10JH@P%
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M4+N)IYI ()9@P>,.<!63>&VY')&1ZUZ5?^%]%U6TMK74=-@NX;5=L G!<H,
M=3ST ^N*EN_#VCWVFQ:==:79S64)#1V[PJ40C."!C X)''8GUH XW2Q9Q_'7
M5_LLB%IM'22<*^=TF]!DCUVA?\FMGXDRZ?#\/=9;5(Y)+3R-I2)MK,Y8! #@
MX^8KR01Z@BMG3O#^D:1Y'V#3K:V:"$P1M'& 0AQD9ZG[HZ\\5=GMX+J%HKB&
M.6-L9210P.#D<'WH \TLK2UF^*6GM<7NGW,-UHCQA+4_NYAD8C?YCYPV.2,C
MD*#CC-<O::?:+\ [W4#:VHN8;EY()UBQ(C"95W;LGYL<9&/E '.,UZ];>$=
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MD!8L<''&2S'_ ($?6@#S>RTN;2;KPI;.]CJ_A]]09M,FB1DNH6=9'PY;=NC
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M/FR ,^K%@#USK574M1M-(TVXU"_G6"UMT,DLC= !^I/8 <D\"O.(]4N+O0?
M2337M]>W5O)-]B# +?,D/'FR$@KM9E;/S9P3@D UB&"&3X?>.WU:UL?M=K>/
M((K=0T4$[PQC* #CYB><9SDDDY) /3M7O]4$>EW&BPQ7-O+>(+LLP4K P(RN
M2/FW;1C^7)&ZSJB%V8*JC)8G %>:>+K&SAT7P-*I<6<6J62B!/FC8,"2Q R6
M/'7GJ?4U+;6%AXC^('C*PUL+)(;:"SAM78#_ $8KO+J.YWG=NZJ<=.X!Z.2
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MD(Z\@D<=\5Q$NIBW\56_Q&M=/ TAQ#:7]U&[ 3"1%WSA=I.R,[4(ZEDQU!H
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M "ZIXAEB6*;6KCSU06_DLL(R(PPR26(RQ)/\5 '79%5++5=.U(R"PO[6Z,1
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M?=MV@YY.[C'K5Q""@(((/0BO(-/\(:#-H?CZ9M+LS+!=WD-LRQ(P@00AE\O
MPN-_0=#Z=!Z)X,F-QX'T"5I/,=M.MRS9SEO+7/XYS0!J7=[:V,/G7=Q#!$"
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M3[F['ED@\*68?+GDD9&<4 >AZ7XGTJ_O8M,2^B?43;+.T2@X(*HV0<;3PZG
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MU=QQ$NL[2E7C=EVMY?\ =4\_)R.3G-;?A[PQ8^'(IQ;-//<7#!IKJZ?S)I,
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M>HH FT_1[#2GNFL;6*W^US&>81C >0@ M^G;OD]2:MR1)+&T<J*Z.I5E89#
M]01W%84/CCPU<Z;=ZC!K-K):V@+3NK$E!P,XQDC) X'7BK#>*-%328-5;4K4
M:?.X2*Y,@V.Q., ^N0>.V#GH: +.G:-I>D1F/3--L[)&;<5MH%C!.,9PH'.
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M:T(K*U\2^.] CUB"9KB;PNES=8D>(LQ=1CY6!&"7R/?G->@_\(WI(N;F862
MW4J3SIN;9)(ARKE,[=V<'..2 3G I)O#FF3^(HM?>W8ZG%%Y,<WG2#:G/&T-
MM[GMWH \O?P[;MX0\;V<KSW4&B3W"Z; \K;;8>6),@9Y8;L9).!G&-S9NZY8
M6_B>7X<0ZHCW:WD<OG-%NB9QY 8D;L$#*@GH2!P.0*[NV\':':VNI6L=I(8-
M3D,MY')<RR"5R<EB&8X)[XQGC.<4?\(=H0T[3;!;(K!IC^99[)Y%>%N>0X;<
M>IZDYH \[_L33_#FM^+-%MC=OH=OHPU$VJ7DBK%*H/RD!P26 W=1P #QBDU,
M)>_#GX;O#?20G[=9VS2PN49249'PPY!!5AG^E>F6?AK2++3;O3X;3_1KW=]J
M$DKR--N7:Q9F)8DJ,9)JA=^ /#=Y96-F^GM'!8,[6BP7,L7DLS;BPVL.=W.3
MTH Y2VT&W\(>/[VWT2"=5NM FFB#2-,S3I+UPQ)/5,#W/J:R_#OAV\U?P]H6
MKVNMVEM-;2&\O+U%8WLI<Y=)&!YX&W!SD*OI7IZ^'M/3Q$^O&)GU%XA")7D9
M@B#LBDX7/? &<?7-/3_ _AW3=<DUFVTN!+]V+B7G]V2N#L&<+GGH.YH Y'3[
M72_$4OCHZRUK_:%O=7-NLN[FUM?)"*R[CA0?G+'@%AST&.F^&TJS?#G0F5@?
M]%53CL02"/P((JU=^"/#=[K8UBXTBW>] (9_F"R9ZET!VN?=@3P/05H:1H>F
MZ#:M;:7:K;0,V\QH21GVR>* .1\7JEYX]\/6MM +G4[>&6Z@AN#_ *,/F4;V
MXR7 #;<=#@]L'AWBFA^%/C*S21FBM]>9 S';&(5EC^YN^7&X'A>>?<5[#JWA
MS2=;N[&[U"S6>>PD\VVDWLI1O^ D9' R#D''(K&7X9>#OWV[0+)_-D,ARF-F
M1C:F/NKCHHXSSUH RKZPL= ^*&@3:9 D<^HVUZMX%&Y[@*JN"Q.3G<HY^OX\
MM$VF:U\(/$VH7202ZX9I9;U[G:95D5R(@"P7D1L%7: ,D@ $D5ZM<^&M+N]7
ML]5FMRUW9IL@?S&'EC.> #U]?4<'-5+KP+X5O;R2[N- L'N)-_F/Y0!<OG<6
MQU)R3D\YYH O>'W63PUI3HRNC6<)5E.004'(-<<8;36/B9KFC^)(+6:.33HD
MTR"3J\#%C*5[[MRC/<;!CIFN]L[.WT^RAL[6,1V\"".) 20JC@ 9["L_6O#&
MA^(54:OI5I>%!A6FC!91G. W4#CMU_&@#@XS9MXA\%^'OM<^HZ,L5R$EN"Q6
MZGB48;GAU7G:/N\\$X%6)--@A\9>*-$M[=VT2[TG[==1JS>7%=EB,#'W"RC=
M@$9VYZ5W.HZ!I.KVD-K?V$$T,+*\*E<>45Z%2.5Q[5"GA70X[?48%T]!'J3;
MKP;F_?'_ &CG/<T >86FD6-O\//!6N17<_V^.^M"MTTF]E$D@62(9_@'/RC
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M_9@H@81#=&%"@8;J.(T'T4>E6+K3;&_>"2[LX+A[=M\+2QAC&WJ,]/\ ZPH
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M8.<^H):V\<TLR01K-* ))%4!GQTR>IQDU'::?9:?%Y5E:06T>2=D,809.,G
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MW*H!+*J; []R%[#/0<X'K3X+BWNXR]O+',@8J6C8,-P.",CN#P:GQ0 4444
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MJ3@]/0UR6FWEKIWQ3\36^J-' ^H0VLME)/( )HDCVNBY]&W$CW)QW/&N5L_
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M%DDT5<6<F2NUB &; ."3C/.>>:Z"DS5/5KN2PT>^O(8EEEM[>25(V;:'*J2
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M!CI719I-P]1^= &6/#NE"YU2<6@$NJA1>N)&S*%7:HZ\8&>F*S!\/?"ZP:?
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MHP/;7"EX9%;(=58(S#V#,H)Z#//%3MK.G#2EU0WD'V%U5TN X*,&("X(ZY)
M '4G% $ZV=LMLMJ+>(6Z*$6$(-@4= %Z8&*<EO#&Y>.&-'( +*H!(' &:PKS
MQIHT/AS4-:AN1/;6+-'*$5MPE!P$(QE<DKR1C!!Z54GURVU#PUH.I/KT6F"[
MN;9A*ARD[9R\ )P<-M89]L\\@@'4QPQ1%C'&B%VW-M4#<?4^IHF@AN(9(9XD
MEBD4JZ.H96!Z@@\$56O]6LM-CF>ZG2,0P/<NO)81)]Y@H!) R,X!ZCUJI<^*
M=$M-!76Y-1MVTYL[)HVWAR,\+C.3P<CM@YZ&@#7P,8[4N*SK'7=,U*^N[&RO
MK>XNK,XN(HI S1'<RX;T.5/'T]1FC;^-/#]UJD.FQ:BK7,Y(B!C<+(1GA7*[
M2?E/?M0!OU')!#+)%))$CO"Q:-F4$HQ!!(/8X)'T)KD]*O\ 4&^*?B"PEGD-
MBME;2Q12!L*>1N3G !.[/!R0.1CGJ[BXBM8'GGE2*&-2\DDC!511R22>@H D
MQ3!%&,?NU&UBPXZ$YR?KR?S-<D_C'3/$NE:G8:'?W<.IBQ>:$?9GCEV[?E=
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MSCRB%.0>>>2<"H=?G'B6U^'FHW\5Q!<WE]$[1P/(L05T+ AQT?Y5(Y#8+>G
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M&!0!Z12=<5X8[:_IOA;PMXK3Q+JEU<WEU#&]F]RS0L'W$CY@.NP Y! R<$@
MGW/@<=J .,7QIJ5SI$NM6GAN9M*B6:7S9;I$>2*/^-4P<[ADC)'W3Z@G<@\1
MV4FD:1?RDQ#5!#]GB)RS-(NX+[X&2?8$UP-KI&K>%K1]=\"WMOJ7AJ<->R:7
M+P2I'/E-MSTZ X(V@$,:?K%KHOB3Q'\/[Q+.6*RO8KA$C=?*"1B$LB;>G7&
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M"&&#TR/<'BNIWJ"JE@&;H,\FO/?"]O+;^/-1'BJ83^(9$)TZ4_ZIK/C(B&
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MAM[(1OY;2;<0N0Q0'+8)Z#&>E &YX"OKW5/!6G:AJ%[)>7-RAD:5TC3N1@!
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M?E]"">M\"VEU8>!]'L[VWDM[F"W$4D4F-RE21V)^M '14444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 'I24IZ4E "T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4AS@XZTM!H XR#X=V5I;75A:ZMJL6D
M74C-+I:R1^05;[T8)3>J'N%8=3ZUI:QX3M-8;2\W%U9KIDJS6L=HR(B,N O!
M4\ ?+CI@FN@K'U_Q%;Z%';1E1/?7LGDV5J'"M-)CID]%Z9;MD>H% &N1FN=O
M/!]M-KDNM6-_?:9J,T0BEFM'0B10<\I(K+GWQZU8T#6[[53>1:AHESI=Q:R^
M6PD</'*",AHW&-PQC/'&<=:V\T 86F^%K&Q^WR7#2:A=:@NR[NKL(9)DQM"'
M:JJ% XV@ =3U.:S[3P%:01"TN=2U"^TJ*82V^FW4@DABP,*I)!=U4\A2VT8'
M'&3UM&: .?A\*PV_B2_UR/4+\7%[:K;21"11& N K@8SO&#@DG&YO6LN/X<6
M,/@ZY\,0:IJ*65Q@N^8RY;<6)R4_B^4$<#"C&"6)Z#Q%K']@>'K[5OLK7/V2
M(RF)7"E@.O)Z =>_3@'I5C2K[^T](LK_ ,OROM5O'-Y9.=NY0V,]\9H RD\*
M1IK>EZJNHW:SV%F+,1H$\N1."<@J2"<#H1T'OFE!X#CM=*UVQAUO4S_;#-)+
M)*8R8Y&^\R[4'48!'H.W6NM)P*Y:]\7W*7^J6^F:+/J*:2$^V%'*NS,-VR%=
MI$C!>2"5ZC&<T +<>!-,N= TK26GO8_[+ %I=PS>7/&0,9# 8R1UXJQ:^$H;
M>#43)J5_<ZA?QF&749S&TR)SA4&S8J@DD +C)K<BE:1%9XFC) .UB,CV..,U
M(2!UH XV[^&^GWGA/3_#LNIZH;6PE\V&8RH9,@G:"2A&%#$ 8X&!781JRQJK
M,78* 6.,L?7CBGYXJ 7D!O#9^:GV@1^:8\_,$)P&QZ$@C\#Z4 <I:?#71[/1
M1HZ7FK'3B'$EN;YPD@8DX(&  ,_PXSWSDYMZOX%TC5K'3+,++90Z:Y>V^QR>
M6R9!! /8YP<]<CKGFM#1[_4KJ?4H=0TTV@MKIHK>7>"MQ%U5P.W! /OGIR!K
MT <Y<>#K.6^O[VVO-0L+G4(TCNY+6XP9@B[4Y8,5('1EP>3S3;WP-H=[X>M=
M$%H;>UM"&MGMVV2PL#G<K]0QYR>^>:Z6B@#BHOAEH\6B7>E_;-49;UU:[N#=
M?OIPHQM9L<J>XQ^E:C>#[!M<T_6(Y;N&]L8!;AXYO]=&/X9<@EQ]?KUQB;Q9
MKEQX=\.W>J6NGM?26Z[S&)5C 7NS$\X ] 23CCN-+3;Q=0TRTOD5E2YA295;
MJ R@X/YT 0ZSHUGKVE3:9J,1EM)]N] Y4G#!AR.1R!7,P?#'1H+RRN_M>JRS
MV4HDADEO&9E & @.,A>3TP3GK@"NUSFN<O\ Q+-9>.=+\/?8-T5_!),+KS/N
M[ Q8;<>R<Y_B]J *=O\ #W3;8V<2WNI-I]I</<QZ>]QF#S"^]21C)"G&%SCC
M)!)8GH]2TRSUC3I[#4+=9[6==LD;$X89SVY'.#D5;S1F@#E[?X>>';>\LKQ;
M6=[JR&(9I+N5WQC !);) '0=!VK<U72K;6=+GTV\#M:W"[)%20H67TR.<'O[
M5=S1F@#&D\+:3-X;7P_<6[3Z<D8C5)I6=@!TPQ.X$=CGC Q6?HWP_P##V@?;
MAI]HZK>P"WF$DS/\G.0"3D9SS@]A73R,51BH!;!P&. 3[GM6=H=WJ5[8&?5+
M%+&X\Z1! DID 56*AMQ SN W#@<$4 4](\(:;I#VS1M=7'V-2MFMW.THME(Q
MB,'@84;0>N"1G!-9J_#30-VIB87=Q#J+O)-!-.3&KNX=F0#&ULJHR.< "NQJ
MG::I9WUU>6UM,));.013@ _(Y4,!GH>".E %(>%]+^UZ7=F*8W&EQ>3;2FXD
MW!" "&.?GZ?Q9ING>%-)TK7KW6;*"2*\O=QG/GN4<LP8G83M!R.N.Y]:VR>*
M,T 9^LZ-::YI[65['NC+!T93AXW4Y5T/\+ \@TRTT.SLS=21B4W%T-LMP\S-
M*PYP-Y.0!N. .!GBM.D) 4L2  ,DF@#(\/\ AK3?#-O/!IJ3*EQ*9I?-G>4L
MY !;+$G)P,^M/UWP[IOB*VCAU&W+^4^^*1)&CDC;U5U((_ U9BU.UFU:YTR.
M3==6T4<LJ@<*KE@N3TS\A..N,'O5R@#!@\':+;:A#?Q6L@NH+3['%+]HDW+'
MEB<'=G<2S$MUYZUGM\-?"TFEC39--,ELKM(@>XD9D9LY*MNR,YY]<+G.T8ZZ
MB@#-T70--\/VLMOIEMY*32F:7+L[.Y !8LQ))X'>J.N^"]%\1W45SJ4-Q)+$
M5:-DNY4"$="H5@ ?< &N@Z4&@#$UCPII&O)9_P!H6[O):',$RRLLB9&"-X.2
M".H).>^:H:O\.O#&N:DFH7VF@SHBI^ZE:)2J],JI /IGK@ =A7544 4Y-)T^
M32CI;6-O_9YC\K[*(P(PG]T*. /I1-I5C<:4=*FM(GL#$(?LY7Y=@& ,=L<8
M],5<S5#6=6MM#TBYU*[WF*!"VR, O(>R*"1EB< #N2* ,;1?A[X9\/WMQ=Z;
MIY@N)HVC,GGR%E4]=I)RI]QS[UH6/AC2=/\ #;^'[>UQIDD<D3PM*S;E?.\%
MB<\Y/?O5*XU^_M_'&GZ))9PI9WMM-+'/YN9"Z;<C;C@ -[YS[<]+G!Q0!@:9
MX.TK2;Z"[@%W(]NC1VZW-Y+.D (P?+5V(3@;>,<<56A^'OABWU\ZS%I,"W>X
M2  ?(L@;<'5>BMG'(_J:ZC/M45P\L=O(T,8DE"DHC-M#'' )P<?7!^E "7=K
M!>V<]I<QB2">-HI4/1E88(_(US5O\._#%FT/V;3Y(XXI!((?M<QC9AS\R%BK
M#.#@CM5+1?$'BKQ-X>BUG3;+2+5)P_E074TKME6=2&*J!R0/I@]<\:>H^);B
MQ\)V&IOI[PWMZ]O"EK,?]3+,P4!^A(4GG')QVH N:MX7T?7+VSO-3L(KF>S)
M,#/GY<D'D9PPR!P<_J:+GPMI%UJ4VH26I6ZF:%YI(Y7C\QHCF-FVD9*YZ^F!
MV&.8O/$/B7P[=6NCZE+IM[?ZA.D.G7:QM$A4 &1IDW$@CL%X.1R.:Z'1;[6#
M=WL6N)80P^>%T^:"7'VF/'4J6.#G'YX[9(!;U3P[I&LZ6NFZAIT$]DNW9$5V
MA,# VXP5P..,<<56F\':!/H=KHLFF1-IMK()(K8EMH89.3S\W+,3G.<\UM22
MI$C/(ZHBC+,QP />J.M:W9:!HMSJU](!;01ESM(R_HJY(!8G@#/4T ,'AW1E
MO+*[73+9;FR3R[:41@/$O/ /7')X]SZU>N;6WO8#!=01SPDJQCD4,I(((X/H
M0#^%9NJG6!J^C#3Y;5;(SN+Y)3\[IL.T)]#R>_ [9K5:6-#AG4':6P2!P.I^
ME &5:^%="L;Q+JUTNWBFCQL*CA,*J_*.@X5>@[5SZZ+?:E\3+_4+W281I2Z>
MEDKRR9,WS>9O "XQDE2"<C:#WKM([B&6)98Y8VC;@.K @\XZ_7BG(Z.H9&5E
M/0J<B@#-'AS1AH?]B#3;<:7C M=GR?>W=/\ >Y^M \.:,M_:7R:9;)=6<8BM
MY40*T2 $!01VP2,>A-0ZS+KAOK*VT=8(HW+-<W5Q#YJ(H'"A0ZG<3^&*Y#3]
M;^(FJQZT;)O#;OIEU+:!&MI@9Y$4'C]YA0=R@9/KZ<@'>1Z5IT6I/J4=A:I?
MR+L>Z6%1*R\<%\9(X'&>PIUUIEC>SPW%S9P2W$&X0S/&"\6X8.QNJY]B*J6D
M>M+K5W)=SVCZ6Z)]ECC1EE1AG=N)X.?;TZ"KJ:C9R30PI=P-).ADB02J6D0=
M649Y'(Y'K0!6'A_2A:V-J=/MVM[ J;6)TW+$5&%8 ]QV/44DWAS1KC4QJ4VF
M6K7NUE:?RP&D4KL*N?XQMXPV1T]*T$GB>62)9$,D>-ZA@2N>F1VS4*ZC:-?/
M8BYA^UHH=H/,&\*<X.WK@[3^1H R[;P7X9LT1+?0=/18YA.N(%.) ,!N>X%6
M_P#A'=$^T2W']CZ?YTT7D2R?9DW/'M"[&.,E=H P>, "M+-(SJB%W(55&22<
M "@"GIND:=HUN8-,L+:SB)R4@C" GU..M%]HVEZH\3ZAIMG=O$<QM<0+(4^F
M0<58@NH;E28)8Y0.I1PW\OH:AEU.Q@?9+>6T;^:L&UYE!\QAE4P3]X@Y ZD4
M *NF6"6<MFMC;+:RAA) (E".&^]E<8.>_K5;1_#VE:#;^1I=A!;)SDH/F.3G
MECR?Q/  ':K=W?VNGVQN;VYAMH 0#)/($4$].3Q4D,\=Q"DT+I)%(H='1@59
M2,@@CJ#ZT 1WMC:ZE9RV=[;QW%M,NV2*1<JP]Q47]CZ:-/?3QI]I]BD7:]OY
M*^6PP!@KC!X _*G/JEC'J":>UY;+>NNY;8S*)&'/(7.2.#^1I8=2LKEYT@N[
M>5[=MLZQRJQB//#8^Z>#U]#0!7_X1[1OM4=U_9=F;B*-8HY3"I9%4$* << !
MF'XU-+I=A.\SS6-M(\X19F>)6,@0Y0,2.=I)(ST[5SK:Y<_\+!M+9-01M&N-
M&DO H5/+W"10'$G4@JWTZ'G/'2VE_:7]J+FSN8+F D@20R!U..O(R* ('T/2
MI-+_ +,;3;7[!N#?91$HCR&WCY0,?>&?K4PTZR$T,PLK<2P)LB<1+NC7T4XX
M'L*99:I8ZH)/L-Y!<>6<.8G# 'MT_P FL#P/J6J7EKK46M7:7%W8ZI-;EEC$
M:*@"LH&.V&SR20#@G(H W9M%TNXU"/4)],LY;V, )<R0*TJXSC#$9'4]^YJP
M]G;RS1S26\3RQ_<=T!9?H3TJ"VUG3KO4)K"WO;>6\@&98$D!=!G&2.N,\?6K
M<LT=O"\LSK'&BEG=V "@<DDGH * $BAB@4K%$D8)+$(H&2>I^M)-:V]P\;S0
M12/$=T;.@)0^HST-8U_KUK>:?JUMHVIVLFJVUF\JI'*K-&Q3*,1SQRIR01R/
M6LOP7XPL[_PUH*ZIJEL-7O8 1%)*HDF.YEW!>.I0]!V([4 =5+86<\PEFM()
M)!C#O&&88# <GT#N/^!-ZFIS67J/B;1M*N8[>^U&W@EDE6$*S='894$]%)'3
M.*??^(-)TJ0QZAJ-K:R"(S%9I0IV X+8/;/'UH O+!&LC2+&@=L;F P3C.,G
M\3^9I1#&)?-\M?-V[=^/FQZ9]*R;CQ7HEMI\-^^H1-;31&>)H\R%XP0"X502
M0"PR<<9YQ5^QU&SU.V6YL+J"ZMVSME@D#J2.HR* +&P=A2[1Z50U+7-.TA0;
MZZ2$E"X3EG900"0HR2,LHX'5AZUD>(?%UI9>#;[6-,NK>Y9;266VD5M\;,I"
MC+#C[SJ,9!//H< '2E5ST&<=:7 -<7X,T_SV@UZR\2ZA>6=W;C[1;3@E7G"J
MID&_YD^[G;TYXXXIWB?7;R3Q-I7A31[Z.TO+S=-=7. SP0ISA5(*[GPP!.<8
MSCD4 =G30BJ20H!)R2.YQC^5<GK>A:W%I\+:'K=^]W%<0.\5S*I2=%D7>&.T
M%>,D[2,\CH:UM4\3Z3HMS%:WEP_VF5'E2&*%YI-BC+,50$A1ZGB@#7(!ZTFT
M>E8<WC#1X],TS4([AKBVU*XBM[5X4)#L[!1G.-H&3G.",$8SQ6?'\2O#LE_<
M6!:_6^@D*&T_L^9IGP,[E15)(QSVXY.!0!UN!2XS7,W/CS1+3PO_ ,) [W#6
M88QLJ0,9$E&?W;KCY&R-OS$#)'/(JK#\2-&FU7[ +7549X&FMI7LG5+L*NXB
M$?><XY'RX/;J,@'7[1Z4M<_I?C+2]3T6]U.03Z?'8.Z7D-\@CDMRO/S $CD8
M(P3G/KQ4-MXVL9KG3HKFRO[!-2139S7<:JDSL ?+^5B589_B !P<$C!(!TV*
M7-<5-\2]-COM4LH])UJXN-,#-<)%:KPH&2V2P & 2,X)QQFNJTS4(-6TRUU&
MVW?9[J)9HRZ[2589&1]#0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT0 7>._&>A'6@#ISWKS;POIGVKQOXU5+V^MVBN8EC:*<\$Q$;B#D,1P?F!Y
MZUZ0>0<5@:)X8_L77-7U3^T)IWU.1'>)D157:H / R6SN[@<XQQF@#B_!O\
M;VK^$+'Q+/XLN872*],JW)0P%RS!';@85.6P<XP,8 VEVDZMJ-IXK\-64>I:
MA<:?JUBPFGU%"$GD0%O-A#-N0MZ$8P5X/6NCT[P#:6G@>;PE<WL]SI\@(#@"
M.1<D,<$<'Y\D9'0X.X=8[?P+<I)H<UUX@NKJXT:<M:R&"-/W114,3 #G(7[W
MWN3[8 ,?1]/U;Q=I9\01>(KRSU+^TW,$<4SFWBACDV>3)"&VOE59LX4DN,G
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M*8X.F?+>,1AA@!E'S$+CJI.*YK6('L/#?B2WTAHH[ >(P+Z&.3"QVNU#)QG
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M>1+<K!_8AMW*VDFW=YF\*SE=H!# Y!X*8.,X/=[%W!L#< 0#W&>O\A2X&,4
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MG(W8.7P0O4C[HSFNZQ@<"C-4-<U0:+H=[JC023I:1-,\<9 8JO+8SQP,G\*
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MZ=>Z9:S640 B@:,;(\# VC^' .!C&*TZ* *]M9V]E'Y=K!'"G'RH,#@ #CZ
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M=CCBNAU[3[S2O"_BV*356O+*XTNYEMHKF0M-"1$P<;CRZ9*D9^Z3CH1BU<^
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M^%HK.[UB[@U&_6ZU62.26;>FZ(H,+L^3H!@8;<,#W.0#A8-6U+Q'I7@BPFU
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M@>E%% !@>E%%% !1110 4444 %%%% !1BBB@ Q1110 4444 %&*** #%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 8HQ110 4444 %%%% !1BBB
M@ HHHH *2EHH 3 ]!2XHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\L=C8/\ :$U!EP?((#VZ#.<D2]3T(C89!J[X0CO=?MM0UOQ&KPO9:<^C$M<
MY9"QN9&QP"6"C//W#]:]/VBF>1%L9/+78V=RXX.>N1[T >#I+#??L_60M?*N
MY=+NUGO("2^P>:_# =!M8$_[))^O8:EJVE7'Q.\$:E;-8S6=Y;745M=))@[L
M8 ]."=@&3R[< XKT:"UM[9-EO!'$F<[8U"C/T%2[1Z4 <!\.C WB+QHUO@Q2
M:H9%89PP;/S ]P3NY'%>@FD YI30!P=_>II7Q=AN+N.58KW1DM8'6,LKRBX8
ME<CH0&!YZYP,D@5CV5U;W^@_$8PO-<>?<S-%!$&#2@PJJE0HWD,PVYZ$#TSG
MU/%)CZT >.#R=+3PSXFU739-2TAM#CTNXV6^9(9@X;<T;8^7(89 ]>ORY[[P
M8;26UO[BR\.-HL#W6V,20>2]RH53YK+@$9+,!GT]\5TN/K0,#GF@!U%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 444UNG )XZ"@!V*2O)KGX@ZY:W>GSS&VB>^O
M_*CT-X/](2W#F,LSAC\^[' '7=P0"1M6FM>+=2\7:]H4#Z1 =-$#K*T<C@AP
M6QC(.67&3GY2.-V<@ [^D/3IFO+V^(.MOX8T?4[:TL9KS^T_[-U&S$C9:7)5
M0A&=H) ;H<9'7FMK2-7\267C==%\22Z<T5[;23V+6:D#*,-R'/.0ISTP?S
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MYF&<\*"#NKG#XWUR+P=XB$TMM_;NA7*VC2Q1%DN"S!58J?NDG.>W!X% 'J=
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MXRK$*0Q4(3@8Z<G% ';SZQ?:IX8M=6\+16UV]QY<L:73M$&B)&X9 .&QD#/
M//.,'=0DJ"1@D<C.<5Y%=:3IL7P3T&[@5A+ML97:.=UW/+)&LN=K#.067V'
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MX<O=&FF>!+I-AE3!*'((.#[BJ?B'PS>ZPUG_ &?KUYHZVP($=HB[6XP,_09
M[<]*Z3%&* .>\->'+W1)+N6^\0:AJTD^T 73 )&%S]U1T)R<D=>/2NAI:* .
M9G\(I'XLD\2:9?365]/&L=U&5$D-PHX&Y3@AL!>01T]SFO>>!Q/X,F\.V^JW
M4 N69[JZ(#R3ESF3.>FX\G'N.E=;BEH H:5:7EC:)!=7:7.P!49(?+PH  !&
M3D\=?TJ\>E+10!R0\#01:EK]Q;WT\-KK<+)=6P1& D;(,BLP)'!;Y3D98GT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "D;I2TAH X;P#"D>I^,G6)8W;79<D(5)&Q
M6&<\]6)],L2, U@30:?X&^+JS6<9@L=2TN:6:U@C 53&I<D $#I&<>Y/KQI:
M#!XOT*YUAU\+V\PU/4Y+Q<:@B")6X(?@G/R@Y4'.X\#&*T;+P?=ZAX@O]?\
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MK0%<S!8>)[-=.MUU*VNB]T\VH74L1&V/.X11)N. ?N@DG &>373"@!:,444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 8%&*** # HQ110 8%&!110 8%&***
M $I<"BB@ P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **,CUHS0 44F1ZBC</44 +12$CU%(&7^\/SH =12;E/\0_.EH **,C
MUHH **** "BBB@ HHR/6C- !129![TM !1110 4444 %%%% !11D>M% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC(XX/% %C-&:IC5+ W?V07ML;K)7R!,N_(&2-N<]*KGQ%H@QG6-/&>>;I/\
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M--=PB,Y!PHR<#)_(4 /S167HNOZ?XAM9;G396EABF:!G*,GSKC/! /<5IYH
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MGNKFXLVG!D?YA$!O3^  DC/WL<&I2?&]S%#;26^B63$J)KV"ZDF*C'S,D31
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M0&&&XD(XZ*,]1G.U?QAK.D;[V[N;6*--9^QO9"W,@2VW !S(I^5BIW?-UX
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M8M_PD21W:W.+_0[R!+<>65;F F,R-M..IY*MDJ,5Z+J5X+#2;N]9"XMX'F*
MX+;5)Q^E<K:^%=:N->T74-<O-/N9=)#;+N")TFN,HR892=JCYLG&<D<8SBNN
MO+6*]LI[2==T,\;12+DC*L,$9'3@T </II\9ZCIGAK5[?5H)5O;A+J_MS!&D
M<=K(@;RU."Q*#(!SDEN>.E37];U^QLM=OH]9$%Y87@:*P2VCDB^SAD55D8\A
MG617/S*WS< "M'0_!6L:1;1:4_B2270H)2\4"0!)V0-N$;RY/R=B% R,C@'%
M9\GPYUM[/7[!/$-NMGJ]Q)<ONLRT@=G1AEB^, )C@?Q'VP ;EIJFJ'XDSZ5<
MS+]A.CQW:0!0=DAD*,=V QZ'KQTX%8$.M^*/^$5\030W5QJ-S9:W+:K)!!%Y
M\5M&RAB$VA'?&<#!^][8KH7\,:FNNZ?K=MJENE['8I87JR6NZ.9 V\M&%92C
M;BV.2.1QQS0MO!6M:=97$-AK\8EDUAM2$L]N6W@C)23:ZYRV"<8!QTH P?\
MA,+U="U&YTKQ+%?0WE]:V>FW%VB>;;-+]]G4(N>[*"", =0"*U8]7\3:/K-U
M<:C!J4V@6U@\DUQ??95/FJ V5$*@@=5/WNN>@R;[>!I=3L=:77;R&>[U/R@)
M;.#R5@$6?+*@ECN!)R23D8'KF?0/#.MVMK<VGB/7SK5K+;FW6(P",;6SO+GD
ML<8 YZ9ZT <?XCEU.Y\ :-X@O-2DF>\OK.]:S:)/(3<RE8U&-VU1C/S?,<GC
M.*]:<_,!GK7GL'PVU)] _L._\3S3:=#/$]FBVR;X$1]V-Y)+''RC/ QT(^6O
M08U?RU65@T@ RP&,G&"<=J . \-V-S#XJ\8337URZ0S*(PVW#@Q;L$XR0,X'
M-<U'>ZGX7^&_A36[/4WC@CECBFL50>5.LDAR6)Y!&[MZ5Z%%X;OK7Q-J.HVV
MJLME?)NELVCS^]V[0P;L,#I6/-\.OM/@FV\-SZS<F.VNA<><L0R0&W! /0&@
M!;R^\01_$&^TRUU$20SZ/)<VD31@"*8':OKD9P>:R?!7B.[NM=TO2[[5=3AU
M18Y3?Z;J,2AI#MR)%(7[N>P/:M35[73;7Q))K&H^(X;*<:6UF(RP5F4J6+XZ
MJP/( ]*QK1M;U'Q!IFIZ=IU[?K96[I:7.H0"S3#*5WL3\[D]-N!US0!W7B[6
M9=!\*ZCJD(B::VB+1A\[=W09_$UAPP7MAJ>BW#>)%6.0$ZC!+.I$\K(" BGI
MSG@=JL2^'M8U^-UUW5@MM+&8Y;&Q7;&V1@_,W)K!T'X?^'_!^LOJ5UK/VN[0
MMY(N,,8MP !(&>0!U[<T <_%XL\4>*K*:Z\.6^M_VB]P7LYFVBS\G=]T_P .
M=OKSFM,OXRUWQKJFCKKTVBH;""Z\E-LK19.&"D<#.#WJ$BQ&LS1>";[6+Z*9
MFFDT[3RD=FC9^8/(^ @)[#)KH(O!6JZCJMQJFHZDVF_:[2.VDLM._A5#D#S#
MT//44 9?A[P>M_XI\86VJ:QJ=T1-#;LR3^66C:(,-P'<9ZUF:1X?L;GX-Z[=
MMYAO'^U&6\)S-*%;H7;)P0HX''%=[8>#4TSQ3=ZY9ZC=1B[6,3VW!5V1-@)/
M<XJ.R\"06?@B\\,?;YVM[MY2TH #@.<D#\* ,OQ'=7F@^!O#UQIMY*LPN[*,
MDD 2JV RMVP0?TJU=+<>)/%>L:-/>7-I:6EC"8OLKX=WD+DR%E_N[5 'U]:T
MM8\(1ZQX<L]&:^N(([1HWCF7:6#1XVD]CTJOX@\%-K%Q#?V>KWNEZM'&L+WM
MNPW2Q@Y(91Q^/:@#.OKK5-)3P_I&I:RFH7-QYL$\4$>R:\8#Y2&'";1RQ.,U
MRM[>2ZI\+-?.I7-V#I^K>2D3S[9-HE155SWZ_CBN[U#P(DUQHUU9:G<6=WIK
M/FXP'>97&'#$]S527P3I-AX?UG2Y]4GM[+5+@3$RR*&C8,&.&;KDC/Z4 +J%
MW=)XNT7PU;R%;7[ ]U<&24HTB[@@"<<L"<X[5M>';36-/L9[?5[B.XV3,+:1
M2=ZQ'D!SW(Z5R'B"+PO>V5A/+XDO9]2L)&-I>V),UP&<X((12,9QP>!1;^)9
M]"G&AZ5I5_>:E.Q_?7\J[RV!\\B@DJN,\D"@#2\?VT=WX@\'QR?/$VI.C1A]
MA;,+X//I26)M_%7B'Q%I\]]<16^G>7I\=M%*T;KE26D)[D_+CTVGUJ>7POKV
MKPVG]N:Q;"XMIS/'+90'<&VE3@GIPQJY<^!["?4X]32YNDO?+6.64-S-MX!8
M?WAZ^YH R_"OBR>UT:]M=1-SJ5S87[V<4D$9EDN$ 7#''4C."?:D\8R7U[=:
M%Y=H+&X75HTBFN)5Z,A#%,?Q8/3UKM-,TNTTFS6TLH_*@7)"KW).23[DFJVM
MZ);ZS:1PR220R13+/#+%C=&Z\@CB@#RO5;6\\'2:IHT.L:AJ5E_8$][ +R4L
MT#JZC/&#@Y//:MO0-!OM N]%N[.:RTZPEC47B0W32+>2,HRP0\;]W\6>G:NM
ML?"EE:W-[>W4DM_>WD0MYI[HYS%WC QPIZXJKI/@'2](O;>6&ZU":&T.;:UG
MN6>*$XQE5- '0:@DTEC/%;2I%.R%4D?)"DC@G!!->>:!)%IGBS3-.U&#4=)U
M!+>6)%>X:2VU$G'(8DY8?>QP1FO1=1L8-2TZXL;E2T-Q&8I ."5(P>1TK$L/
M!MAI]S93^=>7$]C:FUMGGDW^4A/)''WN -W7% '$:1/?P?"+7Y89;F6]BO+H
M29F+.BK+\P4XX^7L*U[&.*7QMI%S8V]TEB-&\V5Y4D6-]Q 3/;/4MGIQ4^J^
M#$T_P-?Z'I2W%Y#<S>:]M)+\Q1G#2*AXQG)/7J:XV\TV#5KK2M'TYO%%D-1G
MVW%M?R.B"U3 =5&>GR@9H Q;?3X]1^'WB3QCY]Q));7LAT9IG<&U3S@=PYX8
M[OPQ7?3"XUOXC7&FZBT<EJNBQO'9R2_NW:1CO<#^(Y&,]JZ.U^'_ (=M_#<^
M@QVLW]F7#;W@:=R.W YX^Z*GU;P3H.M1V:7=F0UGM$$D3E'15Z+N'./:@#@H
MHG%_X6\,7VO-J%A+>733.S8\UXF'EP-GJO)X[XJW+=V/@[QGK][!:PVT?]EV
MY5"2!).[LJ(%ZJ,XR *["_\ !GAVY\/P:1/8*+&V8/%M8AXFS]X,.0?4U@>&
M_#>@W_BMM>TZ*.2VTY9+&-Y'>1C,K?.V6)R > ?RH T;_1K:V\ ZE!J$4<S2
M6DL]V9$W!I2-Q8_0]/3%<A?:78R?"WPS%8VUD5DN+%Y2< N2>"<$9)SW->MF
MWBEC9'0,C@AU(R&!Z@BL.+P+X:@L$L(]+A%HD_GB'G;O!R#^';TH YO3=%T[
M1?BO=6MC#%#!=Z2K/:Q1@KE9.2WN?UKF])LK74?AAJ6F2ZA:Z?.NO2I;F5OD
M$XF!2-NY!]1R!ST!KU:3PYI$NK'57LD-^=H,^3N(7H.O2H5\): FGW-A_9-J
MUG<S>?- Z!D>3^\0>] &+X)U&\N=8URTUG3+:SURW>)KJ2U.8KA6#&,CGJJC
M:<\XVY]!V3-MP3T[GTJE8Z5IVD1N-/LX+57(9_*0+NP, D^P&/85R-_XQN_$
M-[<:/X0M;:_DMI EY>W7%O!SR!D?.?I0 WX2NH^'\+#!"7-R2VX8QYK=ZCUK
M6+75/B1X?T9;^V6""-]0E5)AF60#;&OY$FM_1O"=I96,$5V4N986;:Z1"%/F
M)SA%X[^]7;C2;"'R#!I\*R1NOE.D(!CP,#!QVH TA&&53@#O@\X^GI4A3)!S
MR.E &% %.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#0 A ':@ =<5P'C
MS7[2^\,>(=/CL[VXBMXC!<7=O&'B@E(!PWS M@-EMH( SGTK0TK7XM)\/^&-
M-BT^]OKR[TY'B@M%7A$C3<S,[*JC+*.3R6'K0!V  ]*6N,NOB1I-OX7MO$<-
MK>W>G2MY<IMU0O;/P-L@+  Y..IYQZBMTZU&-7T[3C;R>=>V\EQC*GR539G=
M@GJ7 R,C(ZT :N!Z48'I5#6-6MM%TY[VZ\QD5E18XE+O([$*JJHZDD@8K*M/
M%:/K\&AZC9/IU]<6WVB!)9D;S!G!4%3]X8)QZ GM0!N7-W:V@4W,\4.XX4R.
M%W'T&>]6  1TKS1FF\0_$;Q)H6I:4U]IOV>WM7_?)MM8V1I/, ;!W,VS[H)!
M4'/RJ*]$L[6'3[&WL[6/9!;QK%$F2=JJ, 9/)X'>@"3< <<T_ ':O*WU>XC\
M;P>,Y+R/_A&YIWT5"&X"#I+]//5U)/0*#R.:[KQ/XCM_"VCG4[F&6:)98XBD
M1&[YFVYY('>@#:P#VI"H]*R)==$/BN#09+20/<6SW,-P&!0A" RD=0?F';%<
M\_Q+LETF^UI-*OI=&LI1;S7"&,.)25!&QF&5!=1N!ZYXP,T =S1BN:L_&$%W
MK&EZ>=/O8#J=C]M@>95X'&4<*25(!!YXYQG-58OB!IS:)JVIW%E>VXTNZ^QW
M$+A"YE+*H"D-C!+ 9) [].: .OVCTHKC-0\8:G8:=J_G>'WBU'3K 7OE?:5>
M)T+."0_!(4)DC /8 \$Z_A'4[W6/#&GW]_;&":>"*3.5Q+N127 4G:"2< \X
MQG!.  ;IJNUW;K<BV,\8G(R(BXW$>N.N*;J%O-=Z=<V]O=/:S2Q,D=PBAC$Q
M& P!X)'6O,?%?@C3/#L/A^Z\/QSP:S_:<%K'=?:7\V7?G=O8JX/ )/RX SP1
M\I /4+B[M[.,274\4"$X#2N%&?3)^E2!E=0Z_,",@CG(K@Q<1>(?BUJ>DWT0
MGT_3-.0+:7"J\32N5<R[2/O!6"@GI\W]ZI_ WEZGX=US0YXA]AT_4[O28D5B
M"UN#P"0<Y"OMR.>!WH [<$&JM]J=AI</G:A>VUI%S\]Q*L:\>[$5R'PJFC7X
M?Q2&4) EQ<D*QPL">:QV[CR1WW$D\]>*YC2==TU4E\?^(+#5K^&XN98K2Y>W
M1H=/MP^U,)NR"<#+ 9R".^7 /8!@@$=*=@4U&#J&4@@\@CO3J $P/2EP***
M# HP*** $  '2@@4M% #<"E %+10 8%&!110 8%&!110 8%&!110 8%9NJ:#
MI6M/;OJ5A!<O;,6@>1?FC)QDJ>HZ#\AZ5I44 - ]>:=@444 &!1@444 &!1B
MBB@ P*,"BB@ P*,"BB@ P*3%'>N+\2ZO?/XITWPY:W4=C%?Q2.]X&_>X7JD?
M8-]: .KN;N"S57N)XH58X!D?;D^U3(VXCW&?45S=OX)T:,!KM)M1F+AC/J$K
M2OGMC/3\JZ1%"8 X &,#H* ),"C HHH ,"C HI-P.>1QU]J %Q28II8!<YXQ
MG.:Q=7\3:1H]Q':7EVBW4O*6\>7E?Z*O)H W*@N[F&T@:XN)4BAC&7DD;:JC
MUS7*R:CXGUE5.E6,.EV8;FYU 9E8>JQCI_P*E/AFTB@>^\3:G)JGDYD=KPJM
MO'WSY?"B@"6X\8Q2;TT/3[W69$Q\UMM$63ZR,<?EFJ3Z/XLU_#ZOJ\6C6F,B
MUTHEI?HTK\9'^R,5I1>)+)[9%T"TDU%&&4^QKB'_ +Z.%Q]*!8>(-7MU%_>_
MV2A8YAL3N<K[R'D'Z4 5H="\)^%"ES/'!'=9!6XNV\V9B.F"><^F*MG7[R]F
M$6EZ1<2QMD"[F(BC4XR#@_,P^E9%R?#7A>_$-O9OJ.O,H984S<7##LS9^X,X
M^8X JQ'I6KZI/]K\0Z@;6S,03^SK=@B[B<MO<_>[=* *+WMZ\T=O<:A<ZSJ*
M3%)(-)C$,"9!($K$G XZCGIQ5NP\%++=&]U)Q$'P?L5I\L:C!#*[]9,^O&*T
MO[>\,Z$B6"7]E;\[4BB?)S[XY-5O^$XT^65(=/T[4[T[]A\NT=0GN2P% '1V
M=C:6-NMO:6T4$2<!(T"BK.T$<C(]*Y)M;\47=Q)'9>%_)4-A9KVY 4CUVK4E
MK8>*[K=_:>J6UF"I4)8P;C_O;VY!H Z=@BIAL*/ITK(U'Q-HNEPF6\U.TB#G
MY0TG)Q[#)_2J+^!M(N /M9U"Z/<S7DF#^ -:]MHFF67E^18P(4&$.S)'XF@#
M&N?%ZK:S3:?HVJ:FR ;5AMMH?/NY''X57CO_ !IJ*D0Z3I^CQR(&22ZN#-(I
M)Z%% &?QKL<#TI>!0!R<?A_7;@Q#4?$\Y #B5+:W6)6SVSDD8J[!X1T. @FQ
M$[*V_=<,9,MTS\W>ML[0V<CIG/85P&I^(M9\2W,NE>%+:6*W9O+DUUR#'&/X
M_+'\1QT;IF@"[K.O26%P-&\*6=G?:N6*M$CA$LTQ]^3'Z#O5_P )>$;?PU!+
M))*U[J=TYDN[V3[TCGJ!Z*.PJ_H7AW3- LT@T^!8V"A9)<?/*>I9CW)//XUL
MT -  /'I2X&0>XI:* #%)M!SQUI:* $P,8Q2XHHH ,4F!2T4 1OU!(^F/6N)
MTJ4:U\1]<OP0]GI<$>GQD-E3(P$DI^H# ?A78WDZVL,MRV"L$3.P[\<_TKD_
MAI:-;^#[2XDBF2747DOY/,[>:Y8#\B/RH [-0=HW=<<TIP :!]T?2L'Q-XC@
M\.Z4T[QM<74I\JSM8SF6XE/15'7J1D]J ,OQ+K6H3ZE%X9T,!]2F4/=3L,1V
M\!ZD_P"T1D"NETW3K33+&*RLX5BMH%5(U'0 "LGPAH;Z1IOFW4DT^I7I,][-
M-RQD/\/L%'RC'IFNC%   *7%%% !BHII4@MY)97"1HI9F8X"@#))-/) SD@8
MKSO5C-X^UJ\\-(6CT*T(%[<P-_K7'/E _P \4 -LO$-U\2+F^T[2X9K/P]&2
MDNHLQ#W74%8ACY1GJ?2NXTO3++2[&.SLK6."W085%4#\3ZDU+IUA;Z98P6=K
M$L5O"H1$'0 5-,RA02V.>Q_SQ0 VYF6WA>5MVU!D[5+'\N]4-'N9[Y9KV:.:
M!)&VQ12GG:O&[';=UQ5"&[N-<U K:F:#3+9\&=1C[4XSE5]$'KW/2NC0?+G
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M;Q!8WFI?8;:2660$[G2)C&".HWXV_D:V*@BM4MXA'"B1IR=JC S4] !1110
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M-+-@L6]>G'X8J\$% &+IWANVM;>,74\^I7*DDW-Z0[DY[#H,=!QT ZUL%/D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8SR: -N+P3IB6@MI;F_N8P,?OKQ^!^%78/"6@0P1QIID&$Z$KS^?6N7M-/\
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MB5[C6I5N6*-(L:#R@<_,J@\X^M '0 # I:1?NCC'%+0 4444 %%%% !1110
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MU[&6+=SP:UUTVR5-@LK8+Z"%<?RH_LRR[65I_P!^5H \EM]$\/Z9X=LXM/\
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M(0 MF"08S]5J0^/_  NIP=5Z?],9/_B:Z/:V?O'BE\MC_P M&_.@#G?^$ZT
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MH[^+5!IFGL8K>PM[.1C<N>&DDV]NP6O81D=S^=0I;B,ML5%!()VK@D\YSZT
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M0H!R.5QGG ))S@UBZ7#+)\2]8L-8^RMJ%_H<3N]K'M$8W%'1&)RPZ')&3@=
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MJ,4 1K'M4#=D]^/Y>E2444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "C-%&* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<Y!!(^A(J_:VL%I;I#;0QP0H,+'$H55'L!P* )^U%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %&*** #%(5#=12T4 (% Z<4*H4848
M%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex4-1_001.jpg
<TEXT>
begin 644 ex4-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *C X0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\P_MH?M9_"O]A;]EOXU_M:?&FXOHOAU\$O!L_B?5[/28
MXIM;\1:K=W]CX?\ !_@S0([F2"R/B+QUXTUGP]X,\/MJ5U8Z3'K6O6,FK:AI
M^FI=7L'R3X/_ &QOVNO#/P-^$7[5G[3?[/WP6^&_[/\ XR^&/C?X[_M")X*^
M+GC3Q-\0OV+_ (2>'/@#\0OCIHUUXMLM7^&&CZ3\?=3E_P"$7\.^ ?B!<>"V
M^&\W@;QMXBBM?"_AOXJ>%UO/&6D?3/[>G[''P[_X* _LA_'+]C[XIZCJVB^#
M?C7X5M=&GU_0A&^K>&?$/A[Q!HWC7P/XKL;::2&WU";PKXY\,^'/$)TFZEBL
M]8CTV32KR6*VO)9%\4^%7[,W[2OBS]F$?L<?MD>)O@OXX^%$7P!\5_LR?$/Q
MO\,1XWB\>_M.^!?$'@+4/A3#XSU_0M:TSP]H7[-OB*Y\&R-J_C'PKX5UOX\6
MGB'QGKDDOAKQCX!\/>&AH_BX ^$+/_@MCXW\(?L\_L6?M[?'?X">%/AQ^Q'^
MV_\ '_3/@EHJ6?CV]U;X]?L]>%?B(_BVT^!/QY^*-O\ V,/AMXV\&>.V\#WO
MB+XI>$O#&M^&?$7P2\+>*O#C>']0^.GB#3M:T4>PVG_!8_3O!7_!0W]H/]A;
M]H[X'6_P@\.?"WX _$W]H;X2?M":/\4AXYTCX_>&O@YIFE^)/B;X0T;X=/X
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M-\>_!K6;;5X ?CE\,_&'@.SBT;Q%I6I7_@+POXK\0V^GZQXC\!W>@VMSX2U
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M3RNTLT\SO++(S22.SL2?HO%_P0K^$V7Y'CZW$E#/5G6/QF!C2HY77R]X=X/
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MEX4L_$6F6&OPW%GX>@\1O?V[6]UKMQI%YJ&F78!_-WXE_;U_; _9N_X)K_\
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M>#QU9_ 8S7\?P@\2?$:Q\7^,/&VO)::7\7->\;VOF%_Z7?C)^PQ\!_CGX?\
M@!9>-;/Q5#XY_94\3Z+XU_9P^-N@>))]*^-'PC\4Z'IL&BKJ&B^-#;W*>(=*
M\0:):VNC_$#P1X]TKQ=\._BCIUG90?$KPCXM:QLI+?A]'_X)C?L8P?!W]I?X
M)^,OA'8_%SPW^V=XBU;QE^UCK_Q6OKSQ1XZ^/'C+5GAGA\3^*?%<$FEWGAJ]
M\(WMM::I\*=.^&4?@/P[\$M8LK+6/@SHO@+4[2WNHP#RSXT? ;XU_L\?L[?$
MSXD>"_VS/VA_$FM?#?\ 9@_: \0>/KCXA:UX9\4W'Q!^,6F_"W6->\&?'+14
MO_"]Q8_"_7?"'BO2//L_@_\ #RT\/?LXZEHNKW%MK'PEO[S2-,N9/R\_X([_
M /!1[QS^WUI_[,W[/GQH^-_QX^%_[1OP_P#V??A[^UI\2M;\9^&?!G@C6/V^
MM$^)6H>)[*]7X-FTT.X\#C]F3X5366C^'_'>L?#[PSX2^*&L?$;3Y?#GA[7_
M  -I'@/XM77Q8_<#PU^PW\/M&^&6N?"3Q)\5/VB?B=X.U;X,:W^SK8P_$/XO
MZOJ&H^'?@EXDL=+TO6_!FG:CX?M/#<VLZ]J&EZ3:Z=)\9_&X\6_M PVC3):_
M%B!G5T\*L_\ @CG^PMI5O^R&F@^"?B)X9U/]@R'Q39_LF^*?#'QI^*?A_P :
M_";2O&.I6>J:]X?_ .$STKQ3:^)?B!X6NI;66Q'A3XIZGXX\-KX?U77_  LV
ME/X8U_6-(O #]1P !@<#THI "  3D^O3/^?; ] !Q2T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%'2ORX^&?\
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M0"/V)/V(2" 01^S;\!R"#R""/!A!!]1Q2_\ #OS_ ()O?]&1_L1?^(V? ?\
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M5Q;V>L_$+P^?"6H_V)D ]0#]0#1@8Q@8],<>O\Z /X8/V@/V._V^OC[\??\
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M\<6'A7Q-/HMSJ%UX2UG5-<T72]=BET'5=8L39WFJ^&]=L(P;L7"W&EW2R0H
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M?VV62JX*;;OS4^6=;#R77^%4<'=+6FK73N?XGVF?\@VP_P"O.V_]$I7]G?\
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ME1_P5<\,?$/]ICX.1?\ !.+X*>-7^'GQ2_;B\ _'71]?^($7FD_#3]G[X8^
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M/&5T]I::U->>*M7N](\5:]9:NBW9UZ%)[N*.\AD6O?O@7\3/V8/^"4W_  1
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M'_YDJ^T:* /B[_AW!_P3X_Z,:_9"_P#$</A#_P#,E1_P[@_X)\?]&-?LA?\
MB.'PA_\ F2K[1HH ^+O^'<'_  3X_P"C&OV0O_$</A#_ /,E1_P[@_X)\?\
M1C7[(7_B.'PA_P#F2K[1HH ^+O\ AW!_P3X_Z,:_9"_\1P^$/_S)4?\ #N#_
M ()\?]&-?LA?^(X?"'_YDJ^T:* /B[_AW!_P3X_Z,:_9"_\ $</A#_\ ,E1_
MP[@_X)\?]&-?LA?^(X?"'_YDJ^T:* /EGP-^PW^Q=\,?%VA>/_AO^R5^S5X
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M>_:'T#XA?LQ>)?@GX?\ C5^SSJ'A_P"%EM\8O"^G_M%^,;3P1\&?'6DZA/\
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MB)I=W+\,_P!H+X1>.=(\*Z+\8?A)K6M^'XKW2O$%OX4\8>%_U<HH _!'X$?
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M9_M ?LD?M>?LW_%?X=^)_CU^T?\ #SXF?LZ:Q^SE^V'=?%3Q!^RYX+E\%?\
M"*^+KGXS?!#XSGP]\,O"_P ,G\>_$/2OB]\3?VD4^)30M\0=>\2V?[0'C;QO
M+X]UO6_"6A>&_'?N/A#X7?&K31_P5FFO_@[XJM3^TI\9+SQ_\$(6\3?"6:?Q
MUHA_8._9>_9<CCA^S_$F:W\-ZC-X_P#@1XHUF.W\:3>&X!X,UOPO?SW46N76
MN>'= _3>B@#\7O\ @FK^SY\2?V>/!_[(O@+Q'^R%\6_AIX_^%?[(WP\_9_\
MCW\9?B1^T)\//&WPUO9?AW\-_!6E7=E\%_!?A'X]?&37K@^(_B9X6L+O19;_
M ,!_!S2K+X?1:K<:TT>M6GAGP?7HWP_^'?Q]_8H^-/[;.H_#3]G;Q?\ M.?#
MC]K[X]0?M6> =0\"?$7X.>$=9^'/Q6\1_"'X2_![XF_#SXSGXS_$CX<S6'P_
MEU3X5>&O'_P]\:_"?1_BSKD?AO7OB!X9\0>!-/UGP)X&'Q:_5NB@#^:#]DW_
M ((Z>+_A?\1/A-\)_P!H3PIK?Q!^#^E?\$[_ (F_!7XL?%;X;_%6\\!>$]2_
M:%^/W[5WCG]J/XP>'?"ND^'_ (B>%/BWJWPKM=1^)/B7PMX3O?%_@UEU/3+'
M2D\0Z-$+O4G/Z<?\%&?A9\8_B3<_L1Z]\(/A/XC^+3? 7]N#X9?M#^/]%\,>
M)/AAX<U:+P%X!^'WQ8\/ZC!H[?%+X@?#W1M3\0ZGJGCG1X=(T[^V+>U>*#49
M]2U+34@MOMGZ3T4 ?SH?ML?L&?M1_M8Z)^V%^T9J7P@BT[XL?'7X:_L<?LN?
M!']F[0/B%X''BOPI^SQ^SW^UE_PT[XZ\>?&_XD7WC;0?AS9?%WQUJOB7Q5I-
MCX'^%'B[Q/X:\!:/X4\("P^)WCO6/&6N7G@+T/\ :)^ /QR^(7[/WQL^&GP!
M_87^-'P]7QE^T7^PK^T/J-O\9/VC/@IXO\=?$OQK\$_VE?@-X\^(IT667]I/
MXL:!X-\->%_@=^R_X8T#35U/XB6+>+/B#XVT.'3?!6AZ?IWCKQO>_O910!^9
MGQZG_:F_:E^%/Q3^"3_LU_$KX%_#+XR)\-_@QK_B+6?&/[,7B/XSZ9\-?'VI
M^,;7]J7Q;%X7T[XK?$KX2V/A^#X2P^'O 'PUU-O$_C+QT/'WC_Q#XLU+X0W?
MAWX>:7:>.?/?@5^QMX]\ _%O]O\ _9S^*NC>.OCG^Q%^V;X:M?B/J_C_ .(E
M[\"] N[_ .+_ ,5? =[\)/VK_A]<^%_@PGPYU.S\(_$WP;I'PY\7Z9K>C_"S
MPF)/B3??&W4]7_XF&MZ3XL\7?KK10!_.G\"?^":?[7OAGQY^P3\1OB[XA\#>
M(/&5EX=N_@C_ ,%&/$ND^(-<.I?$[X<_LJZ_\*/'O[ _Q%\&M=^(IXYM=D\;
M?LN>#KOXM>'M7A\36LZ?M:?M+Q:78>'[76;)O#/TK^VY^Q!\7OVWK[]J2;5?
M&GQT^",?@KX1:'\-_P!DZ#X?)^S!KUKXO\8Z)JOAS]HBU^,^D:SXRM=8^(_@
M_P 0#]I+P'\$[27PB?'?P#0_\,W_  \\6#QV_P#PDUV_@C]4/BS\6_A]\#?
M6M_$[XI>(!X7\#^'6TQ-7UK^S-9UI[>76=7L-"TN&'2/#NG:OK>H3WFJZG96
ML<.G:;=2+YIFE5+>*:6/XT_X>O?L#_\ 1<KSH3_R1_XZ=!U/_),^@[^G>@#\
MZOC/^P]^U;^W%XU^,?Q'^+'PAUCX!_$?XB?\$_?V+OA]IN@:O\>[R_\ V7?$
M_P"TK^SS\:?VG/C'\6_@/^T+X ^!OQN?5?C?^R#\83\8O#7PLUA_&'@/7/$M
M]\)M9^)T^AV'PX\:3:<^M=C\3/@%\9?C?^UMX7_:$^-?_!/_ ./-Y\,O$/\
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M@?HE17YV_P##U[]@;_HN=YTW?\D@^.GW?[W_ "3/I[]*/^'KW[ _/_%\[S@
MG_BS_P =. >A/_%L^A['O1==U]Z_S _1*BOSM_X>O?L#\_\ %\KSC&?^+/\
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MOP)DMGL/&NGVMYJJ^%8GO9GD^)/AM\6_BY^VE\5?VHAX(^)OCWX/?!/]G_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^*OBC\-_"]_XJ\.>!K71=3EN=3T*^M-"L/$'D'@7]E_QE%_P45\'_M6?#/\
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M(I5TS0ULHY[6&!%TI9@1IWA<>'O#46@F348AXK\.^!M+\3,\W_"O/'RB._\
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MW>VNT\.^"?%_B&^NKOQ3H.HV^CZ"OA#5K72O%^LZWX.G^'OA?4?#WC3]EO\
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MFCFZ\17_ ('FT>\TX:/XETG6_&.FZSX6\-V%K=^,;BW_ &B/!WACP3XN\?\
M[&[_ .(?9G>RQN!=VU&\,;%R<9N$TTZ%HN+34;RM5>E-RBU-K_73 6;>%Q:L
MKR][#-).//'556W=--V3<%K-1:<5^W-%?B/+^T#\;-)>YTZ'XN:SK-S<:/HJ
M:E>I:7$-VFH74-IK-]8-8>*O!7@O7O#WBG0]>TGQKX>\1P?\*R^&9?6&^(6@
M:/X2F\.?#OQ1X+_8,35?V@?C39C4]&T[XM:QK.Z_LDM=;T"WEO+J^NXMUGX>
MNM!M]3\+ZQXP@MY+K7_"TUEHL_PY>]\;WNE^"[*V^'?[1VI?$#P!\/\ ]O,7
MA]F;:2QV7M2LXR<<;%.%[2F^;#KE2>JC)QG*/O))7:?^N> 2;>#QBM=-<V%;
MYMU%6K/F;6CE%2C&5XMMJS_;FBOQ0/Q_^+*:C?:!9_&<7&AMXA@MAXMM9KJ[
M\/S:=92/;6_B'3]5E.N>-(?!]WX;UWPYJ4]N;V#6KO0-/\'>*]1MOM7C3P7\
M;_VSX(/V@/C%?W>E:'?_ !?OM*L#X@>/4/$5^9X;*Q6Y>.+Q#K/B6ZT738O&
M%GX>M-&\/>,=0U;15TGPEJ_A#3-1\>ZS_P (-\"KCX;^/_B-_P $[U_J!F=K
MO'8%1Y>=_N\=S*GR.7,X?5N;GTY?8V]M?>FG:#/]<L#M]4Q5^;D^/"6=3F4;
M*7MN7DUO[5M4K7]^R<E^VU%?B1IW[0GQMU!+33I/BWK&B^7+JUR-2O[&6YND
MU9[9K=[:[3P[X)\7^(;ZZN_%.@ZC;Z/H*^$-6M=*\7ZSK?@Z?X>^%]1\/>-/
MV6_V:X[?]H+XR:O-I]LOQ:U30[>QTC69]-ND)U2VE-K!=:QI>E37GA&R^+5Q
MXCU;6M;UKP+X?\,:E=:C\0-)N-83X;:%JGC*^\/?$[P9X2_X*,C\/\S3E?'8
M!*";F^7&RY8V?*_=H/FYFM8P<I17O-/1,7&> =K83&/F:45S85-R^TGS5ERJ
M*O[T^6,FN5:WY?V[HK\1X?VA_B_J%D))/BQ>:;8:5HC7%C;2W5NB:SI[7@U5
M-(37M&U'5[&[NW\+ZQL@\9>)/BO#X<?P/I%OXS_X:)N_#-SX8_; \>QR_M"_
M&"\.J7VJ_%G4K)=&T"RDDL;F0:%!X@BM+FQT.72[:[T]? ^A:5K9TO3?B'XB
MUC7?%_C?X/Z;_9UO\4+VY^(.E^+/A3XG7_@FT_\ B'V:7:>-P*:=I)0QLFFY
M1C3BDJ'O.?-&_*W&G*\9M6<HK_73+[)K"XMW2<;RPR37+*4FVZONJ*B[<UG-
M*\(NZ3_;RBOQ,F_: ^-MY!>7=[\7=6@OK3^R-*&FBSFT?4-3GCB.BRZE;V=K
MX(\+Z5I]]I^OZ?I^H>(+#7=.\#^(K[Q9J5IX0M_AC=^,M3U+]DC6ZT_[0?QD
MU$:MK)^+>JV=[<ZSI=M9Z'8PR1R3SZW'=WL.K>&++1]#UOPK/IOAR2[^&NGO
MH%K=^+];UY[WX7'P5\)_CYHWQ>T#6_\ @I<EX?YF]\=EZ2:3:CC9)2;5DO\
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M\<_B7HWC;X3:3X>^';:)X1T?QOXR\ ^&]=^)7Q'\->(/#_A[QIJ6B:+HFK?
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MCO\ @J[^P%X5^*GQ2\4Z'H?C*[_:%^%]_P##G1= O&U6;2;*'PAKOPA^-?\
MP@N@^/O&/P=\+?9/ ?BKQEJNI^+->TW77U[P[=:/^N>M? _X*:SK7Q;\6>*_
M@[\/+_XE?%>Y?3?BKJNK?![P'>:S\4M"UB+QFWC27XG>+=7L=!\1ZM<6&I+%
M;6FB>+M.\.Z/J4.DQ7GB#XH_L_WOP3UGP_\ \$S'7GP"^!VH6?@;1+SX%_";
M4]0^&GBN:Y^'O@;4O@'\/[_PQ\,M0M]9TC4K"]^&^D3?#C69O!?B*+Q@'T]=
M$\._!CP7+HL3)916FBZ_XFA_9C^,6$<AG&ECXNKA)+%I.E#V4E1P\8YA]=]D
MI*'OX26'E+#2Q/+"K3:=.E5^JSE0IZ/.(.IA)*&)B\.FJD_:+VM=O!/">TE'
MF]S$PKQ5>-#G=*::J5*3Q,8UI_E)X+^$OP_^&7_!:W]FKX5>#O#VEWOPYM_^
M">_C?Q?;> ]?T32O%_A2ROO$7[4_B"XT-&T&[TQ/">H:3%X>U/1/ W@6RN]$
MOI%^&<'@WP?\+[GP)X-N/@SHOPR\#_X(F_"VU^(/[(W[/7Q ^*OP=^&NH>'O
M^%3?&QH?C(UJ-8\;?&&3QQ\4_P!KW]G_ .)_PV^/NO\ B+PI8V<GAOPY\(]:
MLHO!'AWQ)=_%'PJEC;:5XX\,ZMHE_P##?XE^ C^\#_"#X3:OXSTSXIR?"SP7
MXA^.$EWJ6CS>.]8^%7@O7_'BZ!=V?A<:9%;_ !--M\1?&>N?\)K=:CJL7C#P
MM->-I>J0^)=1U33=<_:SD^.MAJ?_  4QV?AEX#\!_!;1--T?X ^$]#^$EI%:
M>(KR\TCX1>!?#'PKTS0I]6L=7T_6M0\.W7@+6-'LI+C7_"-H+[Q/XFO/&/PG
M:6XT>P%S\1]>T?P#<?&K]ESIADT88Z6(G]5E05?'U8T/8N*E]9J8"=&G6O2<
M(8>A4P=6I2G2495*M91IR495Z5?!YJWA%0C[=570P=-UG5UBZ,<;&K4I6J1E
M.M6IXJ$)QJ<RIPIMU$YJE*C^)O\ P3M^'_C+PS\5/VH_V"/B-=:/X_\ AG_P
M3V_:JT_XM^'O'/C6UBUSXA^-KG]HCPOXV^(_[->C>*I[VPFL+;QO\.;6X^-'
MQ%^*&KZW>WOQ#TWQY;>#/#6@76G?"[P;\<?"/Q'[_P#X+J> /"GAO]@C]IC]
MH#P\(;[XM:9X$_9D\*>'_'QT.1/$'PK&E_M.?#OQ%JT/PVUZ_A.M^ /%5[<^
M-(]$\:^,O">HV.I^+?#,'A?1=3OK[P;>>#M&\/?K+X/^%_PS^'7B36?'7PJ^
M&WA'P%\1/'7AS7M/^*OBOP-\,/"_P]\4ZM;S7WC"#5?"6L^+O#'AWPOXB\:>
M$(/#2B]G@\76_P ,I_#]WHT7AJ\^ GP>M/@UJ]M_P3EL>//AO\.OB7H=QX9\
M8?#WPK\7/"T]CHMUK'AKXE_"_P .>*]"?4K6^T'5#ILF@ZOX-^*EA?Z)8^+'
MT]=)N#H>NZQK%QKNH7,/[/7BO6?'^E_#K]M>Y93S97B\N<J+G6ABJ.'JU5.4
M:=.]6EEZQ$IQ]I%X"A.-+"2I32JQCSQDXR4G,<RY<PP^-2JJ-.="I6ITW3C*
M<[4JF-=)1ER2^NUH2J8B,XVA)N+BI)Q/QI_X*1_ SX?_  ,_:5_X)I>&OV=?
MAUX!.E>/OV]I=1N? SMJ'P\^%^MRW'PH^#$>J^"(+?P[X-\4:3X7^'NAR>!_
M".OR:#\.?AG9?"]O%(_X6E;> )_!?CWX?^&/ -/]A_QWXF^%>K_\%D)=.\.^
M%]0\8V7[?&M_#?X>^!/#3:7JGAVV\7>*H/%'A[P'X+\,ZK\4/"W@37-&^&5M
MXJ^)/B;Q=XUCUW3M#\&+X.T_QQ\0/$G@#4/AWX2^)W@/X@_L+X@^"OP6\1OX
M3N[GX2?#WQM#\/- \,_\(7KGC3X3> =2U/P-+##X3U2Z@\)ZI->?$R'P]9:/
MXT%F^A>*O#'Q:\9?\)$^L2^-I/&=OJ/Q4TGQ7_P4 R+W]G/]G;3;C7=0\+_
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M^?0W$6A:FFH_V[8Z/;7X&B:EYJZQ/?\ @O6W\-V:S7%OJ1U>RUW0O"-M#?\
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M]<O::4-;CA?6H]!TGQ+XCM_"EU<QZ%XH\7:YX;N[+3-;L?[>\8IXZL/&>O\
MA&Y\=_'FU^*VD?#G_@I-%:WMY<:;I.GZ_JWB33_#5A+XCU'2C9*=5CT[6]0T
MVPU+4=3T2'4/%W@O2HM0UW4X/#NN^)/$</CC2;F/4M<U#XER?$'Q.FM:/^U?
M^U*W&SZ)\TI)PBI2C-N:=:FN1\V,D]:E)IJ,7=*]G)*5]]4U&+4VXQE%*#5*
MH[KEPL;>Y47O2EITERR27[ZT$T_Q#JD6EV^A:5XDCMS-I$AN(KU[+XDZ\FBZ
M@;H:EK#W.LZEK?C:S34_&%WX@N=!LH]<O-9O+GP+X+^/OAWXQSB^GUF<KJ^J
M)97OAVQFMM%M$T/4FN[O6(O'%]K,?AN=-/N4\2#5Y?$^O:^S7_B+7KWQI%J%
MHWA>[\87'Q1MCX_NJS7-Y<1Z/8^(;W7=,T31M#\2V_AB+3=/9[#0VW>(=<L=
M#\.Z/JDGP:M= T'4O'FFQ7NK7EIIW@67PE=^#M"\=P>"[/5?@GJ'B?\ X)HK
M)/<7UM96OB*?5TATGPX-)\':-)HLFJZ1!81^(;J"#P;;Z5J&@Z+)H'@6&6]\
M3:&-+TKX27LMK96J_#5?V;[2^?4_V,/AN<L5:RC&S;BJ:4E!2E44O8-Q:G*J
MM,5S)JE"4Y1M:+9S/5MMWLFYNSDXJ-E5M/W8PWH--N;C%2OJD^*^DUES>W&I
MQ#4]%TG0;#PW9V6CW4LNM2Z1=?#+0;/1H!X-?P_=I>V.BZ?X0U*?4[:^TG6M
M7N%T"U.KCQ+XW_9RO_@G#)=0Z[:7FIWVL6KW\%AX?TG3+*STRSCBU;1['PA-
MX<-S;W7A6PT;PY9IH_A#3+2XGNH-.L=-UJSN)_$,>EOX!A\0^!]3+R>XU=KD
M^*;C7=5O8/"V@Z;X;M-5TUO%-GK=I92>'M*T?PSJT5];>-+BT\*V?@G6M8?2
M)-)^'_QI%V?&FO>%+7X>:QI'Q]MKK_@IN_4[R[U?[=J'BG6/$6J>(7MO#T5K
M+KL7]NRZIHUMH2"WO=8\1WWBWQ-?17.EZ/I_AW6_#]S;7WC^QU/4(+7QJ/BS
M;:5X>LOVR-(:BE*%K1M9+V:OR)N,I0H7B^>C4:OB)RUIS;49)I<HY-J5];W;
M4W;F<>9*51*7NU(*RHPC=3BKM-/5^I:DVM_\)!XHU35[0Z_?ZG+/>V46C165
MO=Z=J:_$R]\1:ZQ@MQX:T?3M&U&?Q59W.GZQ9:CH7/B5]=T+Q%'X'_:>?XZ7
MAKMZNJ#QY%J\#>-'\8WNOW-@GAVX,,-ZNN:)XD&NO90R0:8UI-XN^R:=)X7F
M-PMK/%9Z9JD=WXAU7P7XE\-4-4O=0U"]U_6_$6I>)IO'+^(;'4'FO+9Y+R6;
M;K<VN>*+GQ%J&I^'M;\.>*O#.J>&_"]MX?:;2O!">1X&\,W>I_%W]GB\_9VD
M\/?\$P;AO]9.O1>(%U'Q!)\21XTN-5F$NDW4EY;ZY%J5C<6FLVNJ+X?U7Q+_
M ,):/$M[J&BMILGPI\/W>D6%_=:2EOH^L^,6_9@^,T<D?9I*-*WL>3E7\+V?
MLU_LZER6^H6TE6?O:6[Q5<[YF^:=W/GN[\_/SR_?.-_]]6ZI7Y7>[W4G5TO4
MFT$:)XGT75[9M;M=6MKS[(VC1WUIID>CP?#.Y\)ZK,1!;^%-6M-?>'PNECID
M>F-9O&GAR;PG9>#])\;_ +,MA\"ZT%W!X?L++4-*UBT>2ZT/5]/UB&YTVTEM
M-$L-0TWQ9X;$-W=:[87_ (0O8]3\+:GX@U"UU2\T/5=&TQ3?75EI5G;^'_B#
MIOC&;2+W4;&\T37/#^I>)QX[M_$=[=P7,%L\VH6$DB:'=Z)KNE^*=.U3QYK6
MH^(/%VJ^(_%$GBBR0)]M;QSXEUG2/$_[6-Q^T,NJ_P#!3ANFWEUI+Z=J7A/6
M/$5IKR:5K:W^H:7$-)U'1;>]LM:L-0?P]XIT_P 6BYFBU;PE ]_K^MWOCWX4
M0K<Z79^9\0];T?P)=?&O]EVI15Y7Y9-WBW-)*:4I.-.K:#<<-"34J,X^_4FE
M%N5[N8RLH[JUI+E?PMI)SIWE%2Q$DFJL'[L(-O1KE4LE]+HNVYL=3CDNM8T[
MQ':>(8;S1KN/^Q]2U^\^)>AZ[X>E_P"$HFUB*757TR_\5WSZB[ZAXMT6YDUV
MTUGQ5JWBWP1^T-K'QED2_GT-Q%H6IIJ/]NV.CVU^!HFI>:NL3W_@O6W\-V:S
M7%OJ1U>RUW0O"-M#?^$[W1?&FI&2PMO"OB_1W\2?#2]\ 5+">YTE;23PS<:W
MIVH7'AC7])\20Z?IC^'TT:QN'\0Z1J_@S3KJPM-$N-1\%Q^"M'T=+JSU72?A
M+)H,?@[0_!U]\ O@_I7P&N+'_@FZY9[FSAU.'PW/K%Y9ZOX;M-)\4VDFC2:?
M!JUC>7.AW>K^#=6LM+T+Q\FO^!;CQ'+8V@TR^TGQ))XJ&OZD9_V</&>I_$+3
M/AO^VP.$6VFHR3=I>T48JHHS:C[=J-H*DK?5'&259)2FW&5V*326K32;7*[N
M/-&[]DG*\G4;?MTU>F^91]Y<I&]XFC6,VDZ%JUKJFAZQX?\ #]J;I=-L8HKR
MW73_ (=^()K#3;JXT^&PA31]2T?PI8-K7@S3/#6@:U8C2;ZQTQ/ /C'X(^'/
MA3-J]W#I]MKGANRUFTU/PSJ$]S--J4^D0Z8NIVNF6/C>"[U&-_%%IJLNCV5C
M8^)?',FLPRVAT.*"RU.Z^)VC^.M#\,?%K2?B<S[9>6EMJT/AO5O$MWI.M:#X
M</BB]O%.GRZ_,I\/:[?0>);C3/%OC^Q\1V6E>/;^6\T3Q5=_%7XF?\))=^*-
M4\>S>,[?5OC!9^+O^"@JZA>7MC8Z_I_AS5/$3>%;C4M-O9[CR3X.EU"YT :S
M)X7UK78++Q!I&C:5KGA..'5=0\*7;_%2/_A!Y_">A:C;_$;]FZ#X<ZS\1O\
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M'CS2_"/AUK[Q;;^*)YM4M]$T+Q)-\7)+_P"&]E^TW!XDCLHM0:QT+_A)8O&
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M4KFY5I/2,+\ZDTHOE4?;63OAV[*@E\,^5ZZ)V97F6PLKSQ5)X@CL)_!O]J>
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MO1!'XLT/5]=^"A.G6_BJW_8LTKQNQ]-DTB**PN[#1=7N=:T;^S[>SBNC-?\
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MD\(Z'ID/Q'_X7Q?>&O"LW[2%QHE^X@CDU>[\32:)/#HEMXPM[5O#%_XFU?\
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M+H)TN?5;69]/AM+;QL--N+SQE>:PEM+KU_X7DUJ\M_'Z_#./5,V_LVT2;7=
MGC\-W=UINLVMVGBBQU*ZOK?2;+PLGBO3M573-2TC4=#\,7/AZ\G\#7U[JOB"
M#3_!NOZ9-\'$_P"$(^*?P'TCPEX7T+_@FW;_ +$:758_ HM?#1U.W\5W.AOX
MB35H7TYR-2T[P4MK-JL^B:GX#B\(:9J=^JQ:[8_#;0]I\2212V^D>![VY_9Q
M^+D<RY.;VB:=-5W.S46E3B_K+@Y)K#QO_N;?,[-V?Q.K>\TJ;7O>R4+KF7OM
M>QYK.]9Z?[2O=5U=VLBOI=G%K2Z)X=T.RLDU6ZU>&R.J#Q+I]CH&H17\'PUM
M_!.GM>V]U#X(T2PTLIX!N?"^N'7$TC4].\2? EOAA<7N@I^PU=>/88+>RURP
MLK#3M/TZT6WT35KS7=1U?Q#HNG>'-3TRRL?%6OQ76I2^*+C2?AUHVFVOA.P\
M5V>GV.O:PGAO7[:R\81Z)-=Z1<_%^/2)-,LWU^71]"@3PW!=7.O3F3Q7>ZC=
M6=M=VGC"+PI%H]IJ^JZWJ'C+PY8:#$_CBQU;1M8@9=1UE_C')=?$'Q%^T];>
M+O$VK?\ !1V*S$>L)8^2F@:&=*TK5M5O/$.H:KJ>F0W:6]MKGB[[?K.I:KXI
M2*POCI_A2ZT_0T\,^.OAE=ZJ/#<(F\=:UXQL_#WQ>_9MN3:;]]Q<&YW;E)P<
MI-*K))IU(S;4:>'^*G-0E:+44I7O)>ZI<R4;)1BI))-PBW&U-QLY3K-\E2#D
MKR5[6'M_[96.WM+'[%<:;IGB*]\12ZYK]S:)JVN:->?$G6/$&H7 \;'1EMO%
MT%A#X_T?4O"NHR2?$_5/$&@?&=/%.CCQW<_MDZ-X*D%K+JK&XT#3I=,_L.PT
M>[N5&OZE]LN_$=M>>#=(74?#L86UUG4/&6J:]JW@2XT/PGX"MM;^+%M-<^ Y
M?!&B:I?6GP'DU>M#82WJVUHMEH.@3>'-"UZRU.[N[F72'UB_\-7/BS5;BWO?
M[0L]%T^V\4V-KX%O_!FE>%O!^F?#+PY-'\+K>PT7X&?"GQ#X<\+6'_!/9?[-
M?7A=_8;'1-)>QT>PT\VGVKYM?OI+CP_X?:VT^V\3:+XV;6_%?B2\\=Z;?W/A
M:QTGQ%X7N$\22^1^S]XP\.7_ (T^'G[84W2?QI*&J<GSPIJI)J\VGRU8UH/]
MU9/ZO"2YTHKE&DVMFY23TBE"4^2*TA>-Z;I27[R[3K23Y6^9-QO;6FK6<NI:
M!9:9I>@Z1X?T"Y@MAX@T*:RDM)--^'V@S:GX40W=IH>N:;J]YJ'@'6DTKX8'
M7?"^B^$]7^%DUI<R_"RQ_9;U_P 43:W!9WMOK?B"WT^PT7PM9S7%N^G:YXDT
MV<6.GZK9>-6UB!5\97&EQ:YHT.FZ)\2F^(.K&TD\(Z'ID/Q'_P"%\7WAKPK-
M^TA<:)$8TURVO->LO^$?TFSAT+P_>JD&J:CN\0L+7PQIMSKVCMXG\4>-_$7B
M'5M?G\?:;X[UVW/Q+^)$=C_PGUWJNE>+(-$UGQ?XL_;L-4@^U6FM^)K1- \*
MVEK>17"Z;;:E?1&Q@MHM?U2>?08-6UW1_%U]I7A&W^'&K76L:M/\28]1\+#P
MU]JT_P"('[/6HZ5\._B#^PC2TG%<\H\LX4_><IN$IS5Z<[-NI7F_>59*7LFW
M!WE="=G&3Y5).,I^ZE%348RM..D?9TH+W72;7M/=G%*#BUJ7$$<FKW?B:31)
MX=$MO&%O:MX8O_$VK_\ "4P6VHZWXRU*V\/(==BM?B;>>7=:1X]T>Z\6Q>&W
MNK/QS;^/(]3%I\;+KX]>&](KV-O!:76A>(KO24U#0+C7["RL]!L_$AL]9U*Q
ML;[P%J.F:3IB:.USXJL-+O9=9^&5CX(\4>&-$NM U'Q1=_"JW^#%WX@^)</[
M*^B^(736T:WU]K_]@>&-.TZ/Q;;PQ_#I+[4H(HK74+S784\-V6G-9Z)XRN_"
M5B/ .J>"+O5WM9=:LSX>BT2_G=]/\#_!?]C:O9VP@?1?$3V'AS6]/NO$D!E\
M(7M]?2?V]:32^&\6&HV.DS?\)?#X4\8?\++T?PO::ZFL>*];UU_&3Z1/XT^-
M\NN?$3X>?\%"8WA;F=N1T5%3L_X+D\.JBGR^VVOC;\CT?/9.9>TKV3]_VCER
M:?Q+>V=/ENZ3Z86W/?:&T2"RMK+3[33]<UNRTS6-"O[76+)K5?$6AV+S0Z;X
M1T+9=ZC;)<W,NB^'+/P[K?@K5=*NM;M++X?^(?A_'X=@\/:O>_ &+X;>(KB:
M2U723'>^)[&&_36])\2R+;7VOK!JMOJ$=A\1-"_M+Q+9ZU(WB+2+[1KS3?B1
MK-YH7Q'L="U?6_">D?&"?6X;;X77'[7VO^$8;55TBQT[7[T^']9M[H:Y_H-[
MJFHQ7$'D:)IWB*#7]8M/#?BKPEXATV VWC;3?&WA_51XPTN/6Y)?[5N_'?B3
M5[GQM^T]^TF_[&WAP6-W>VV@W\-SH_B& Z1=WMS'<Z%=);^*=+MKK6;7PD_P
MFN]!USP[=?#G5?'.BZ2^F^"-&NC\.H-6U/P?9:#X?\#^*/\ @G;<G>4O?<G*
M4X+E;@ZCIRD_9T[N/LJE-KWZS256T8JSM:%I%/E245&3<E&2ASJ*<Y^Z_:QG
MKR4U=T[N3TNBT+632YFDU73IM1U77["6ZT=[;7]3D\0:;XDF\<7FFKJ.JV>G
M+?>.[?QG!XUT;Q!I]SX3\3Z?H_Q9_P"$]NGO]0T2#X]RW6B3116YTAWLWL!>
MZOJ>DZ%J7A>?PUK\]]>:/>:K=_#;6K._L8?AP=<U:[UNYTFX^'>CR>&]$$?B
MS0]7UWX*$Z=;^*K?]BS2O&['TV32(HK"[L-%U>YUK1O[/M[.*Z,U_P"';YO$
MESX)^RS:5HFB:1I>G>++>^\.W?A(>%O$/PON?"\-IJ263_L^67A1_#7[(OP^
M9)8M;O/IC6N@^)9O$V@:,NE-9W<VLS:5=:O<^$M922RCL[?QEHMYXE-IX_TS
MPAJ_A[QGX&^+NDZ?#\5;BVNO .K>)?$OC"Y_X*-RFG=N:DI:MI\D:D:4H).-
MW:E3I1O[5-*.(C&3BG&:4FTULFG%I;*4H2FI:2M&]6=5ZTW%MT925^5Q;3FM
M[+1;*]TV:PTZZNYK#0=2TC5/#WB#1-5T:PT"[\)3ZZ\=D/ EUK7A'4[#4O >
MHV\DL>DZF?#_ (=\&V6LVDC)\&XO%VIZ:[4;*+2/^$@\-ZG96+:Y8ZD]KJ.J
MV_B:PU/1K'2+)?B5:>*M-U"ZM[F[\)ZGH&HZB_Q!N]<\1^(=:A\%6/\ PCGQ
MVB\;W\!;]NF7P"R\$=C'>6CKH&O2W]OHGB"V\0Z7JNHZRUM:7.A/X[>/3;VU
M\4>)=)O!>Z=>Q:SX@.MZAXX\0:;-H#W=G\3K;QM9W_[6>DK?V;:)-KN@3Q^&
M[NZTW6;6[3Q18ZE=7UOI-EX63Q7IVJKIFI:1J.A^&+GP]>3^!KZ]U7Q!!I_@
MW7],F^#B?\(1\4_@/I'A+POH7_!-MQ?-+6<FY-5-Y1E-QG&/M4FVZ=.#TEAI
M>]4J7E9MV::23M%)*\%HI*"<92]FVDE.<EK&O%<L8.,;JRM=ET>\-Y-X+BTU
M?^$S3Q7J&AW6J1^*96L7GDUG1]!.F7.JV\S:;#9VWC8:;<7OC*_UF.REUV_\
M,2:]>VWCQ?AHFJ?N]X/01^$O"T8\K$?AS1$'V>6UF@PFF6JCR9K&26REBP/W
M<MG+):R)M>WD>(HQ_!N?1#)?-X&^S>&O[1M_$][HDGB1-5BDTYMM_8>"A;3:
MI+HNH>!(_"&EZE?@1:[8_#G0 I\2/%+'HO@>]N?V=/BU^\OA 8\)^%QYD<N/
M#NBCS8I#-%)C3;;]Y%,;F\,L;_>20W=T74AC<SY\UOSKQ E>AE/OJ7-4Q571
M/WU.CA>6M%N34*4U_#H.TJ2=MKW^XX-5JV8^ZU:&'A>ZM'EJU[TW9+GJ0?QU
ME=5&KW=M.BHHHK\S/O HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /RR_;5BBOOC7X8LY;[3-%>U^&5K?VNL7T.OO/Y\6N>,
M=1AT^R'AS1O$/BJYOK[4=$TO3]#B\#^&/%&H1>+-1\-+J\.F^(+SX8Z1XV^.
MK=K+54TVV#^&?#T>C>%KV&TNH[01'6HM++ZUI=H[^%9/%BW>I:H(/"_AKPK?
M:0DGPPDT[2O@[!X<\<:OX4F_96\6_M%_87[:L-I??&C1]/U"^MM,LY/A1:3&
M:31SJ<NHW$>H?$IK72O[,L]$UF3Q4=4NTM_"MEI^O>%/BIHNDZAXO@TJ7PQ9
M>&?B!X_^&_[1'Q_!-'JJV]KJ>MZ9:0:-HNOBSNHK!;V?7KPW/B[Q-:/J=]I-
MYXAU/Q?JOBK5_%-Y8Z9\2?&=]X^\0:EI'Q&\(Q>)OC/\2_#?Q6\=ZU^WY^[\
M.?\ (@REWE'EP-)IJ,I>S4Y8M<\$H259U7[LZ;YE27OVB[M_D&>:YQF6D7S8
MNHK.27/RQP_NR=XNE&$?>4TU*K\#<K)!<_8M8AO)KEO"FA)I/A:"V^RR6UO;
MQ^)([-DTFYMF6YNYM,DOM5M-8U[5_$&H^,M2\'_"B33K7XAS>*?'WA73K;XT
MR_"Y]T\>M2ZQJ<\^BZ%>6FG:*3IB6?B"SU/7;VV:/0[AX8+K2Y==A\6W,U_X
ME\7>*6^(VG^!->N-5F^+$S:+:?$"#]HWX?\ P/$GCU07<][KFE:#/I6DV/\
M9;VMK+HBWMWI-SX>TZTF>Y\*ZUX6BTO4[73[.7Q#J?Q0U/5_"WB: ^ -8UN;
MX[^#?%GP\^'GC7]DZ(&#4[6\GOK[3])N-)T'P_I>F>'[/PS8Z";D:1;^%?"B
M:4N@^$O#7A?PQX7UNUT318[O7F?X??#>/7M7^'/B6#4?")U[X8> ?!/[$?MK
M3^>/(XQ^&<_9J?LWRQO!^VC5;;G4;E]7NTG34%R^4[NVTN9-W<HQYW'VB<G:
M2]DZ:2Y81Y?;:-J7,V[%]+!J4FJ^(HW\/:'=C4]%:V\-:#9:U#=3M<,DEI<>
M&[+PW8>*-0@M]!N] \-?8H))%\6SZC>_#@?!;P]\5O$M[\ -#^+RBXL9+J\\
M4)%X)MPGBFVN5\"VEE"-"ELKQ/[0EAL;+1]0U7P6/ 6F66C>'O#EU93>/XY1
MX;NOAVMA/?\ PHNO@E\4/BA7U(PZ_9:WJ=[J.G1ZG=7D:Q>'=&T&UABU:WUN
M'Q$NK)I.@:5HOB#P/I-M<?:(-+A\,#P-+I_CY_B7I&B:AX%_:"TSXM?%3P+^
MVQ>EU,W=Y?\ C.;6O#DVOOXMMM932;?1+.;P_,MW>:_XCOM6M+%+_7/!%EX6
ML-4FAO/^$6&MIISZ3\0=*\1::K)\2OB/\:OVMY2M'EM)-)4N7WWRWC"V'4W!
MN=.6O-C+N=-WM.+T3;NT[IIOVE_<3=G*];E<K1J17PX9)1G?6#NVX;::UL;B
MQ\2RCPKJ4Y\2WLEWX.U2RNKBVDC@MWOKN;Q-:7PTS1CX9UJWUSQ3HFJV>O\
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MN6\*:$FD^%H+;[+);6]O'XDCLV32;FV9;F[FTR2^U6TUC7M7\0:CXRU+P?\
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MI)_"'B6]@T[6[^Y\$:]X*U?0]7\*66F:CXT\#^,?AGJ-QI7PT\6V&E^.-/\
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M1;._UN^\.:3H%I?V'A6T\-> V\:>'-(N[KPQX<@\+:7X/NH+5= ^%'P_U;X
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MT7F339)K?1YKOQ,WPIM_&-VUE;RZ#8W"PV!^Q:!<W]GX-FTB^\$V?C23X>7
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MMX=\4:=K!T.W_P"$3MK71[ZSU:WUBQT5/#$?@R?3_"VH>"O"_A&W\26D^C>
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M-5?67A&B7$GA.^U*PMAKT5GIEU=Z'XYF\+> ?B?^[_@_RO\ A$O"_DLSP_\
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MSH_Q!\1_\$^I[N/4#::W+HNF>+-*\.VTOARQ\1V^K7%UJ=OIWBMXI=*MM/\
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M/J>@R_V4M[XQU]_&#P>$]/\ A_X[U2V^(O[,MC\./'?C_P#8>TI]):RU"_\
M LNE:,-=B\76^B+J\FM6:+9RV6H^)_"ESHMMJ\%KX>^'%WX=U'4M,5)?$_\
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MY7=_N.#&O:YCK%WIX>:2BDY*56O^\5DN2$_LT+_NOY5TZ&BBBOS,^\"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _*[]M:Z
MET[XTZ%/;#2[JZO_ (666FPV6I:#:>(HL7NK?$+P^TY\.:OX:\0Z=XJN3)XI
MA_L6"Q\%_&75M%UJ&TL+/PEI6N>-O"_PN_:B_,WQO^S_ /!CXA_$KX,_'#Q9
MI)\6_%#X7:)\0+[X6Z[!X\^*=K<_#&+XKV^H^$/&5C_96F>/9?!VNZGXY\+Z
MSX)UC5?$^E#XQ>&?B%I>J?#;7+WXY?&KQA\4O"FN?\%#/Z3]=^'/@'Q1JRZY
MXD\&>&M?U8:5/H37VL:-8:E+-HUS;ZK9RZ9<B[@FCNK+['K^OVD=O<I+'!:^
M(->MH5CAUK5$N^=M?@9\'K-Y9(/AMX0\RX@U&"Y>?1;2[:Z76+;4+359;HW2
M3&ZO-2AUGQ";Z_N/,O;J;Q3XNNIKA[GQ=XEFU7]#RWC'+L)EF"P&(R[$XB6%
MHT(3DI83V=6I0J5JE)I5'S05&I.%6E)6J>T@G+2,7'XG'<,8[$X_%8RACJ%&
M.(JU913CB.>G"M"G"HKP7+)U81E3J1;<.27NZN2?\[?P^^!?PB^!B:"G@&R>
M?3O"'PYL_"/@BUUWX@?$7QQI7PB\"MI7@$ZIX1^&-M\9/B)8P?">[T_3O@[I
M.AZO\0O FI^ [+1M/T#6CI/[3'@3P;X!\7>-_P!CFM\6/V=/@W\4_%_PK\3?
M$70W\;>+_@7?Z;XP^%VM:3XL^+W@(?#SQSJ>G:!<:M>:7X2TBX^$":5XST:Y
M\%ZQX$\16FN_!SP3:1Q:-XP\!>'_  2/ OPP\2_#[]@S^B^W^!WP?M$NDM?A
MOX0MA>0);SM;Z+:0R@17NFZC#/!-'&LUI?V]_HNA7=KJ5H\.H6MQX?\ #TEO
M=1MH&CFR9;? KX,V=M<V5K\+_ \%E=VD.GS62>'-,%FMC;76FW=O:6]K]G-O
M:6\$NA^'HXH;2.!([/PSX5T]5%AX7\/VVF]<>-LEC3=%9-B'2E.$Y4K8",*D
MH*@J<YQ5TIT50IJERNS5*BI<O)%1YGPGFDIJH\SH^T49QC/_ &MSA&;K.<8R
M:3E&LZU1U.;6]2I;F<Y.7\XGC;]F3X'Z_P#&F]^.5QHFH:Y\;(/A[J'P1TSX
ML>#/B+\<=)U5_ACXAOM=G_X0WPKX:T[Q(9-+\/:WKWQ&AUL:2GP93Q!XX\2W
M>@7UCX+_ &B?%7Q,\!^#?V\_/;3_ ()__L:Z9X2^$WP/T/P7;6GPD_9V^+:?
M$3X$7.@?&_\ :<L?"_PO\6VGBGQ#XKL_B5\/_$>F_&:^^)6EZ#!>_$>Y\<Z3
M;3:Z=0T2'6+'QGING:5/\3/#/QJ_;5_I^/P+^#36-UIC_#'P1)I][+!+=V<O
MA[3I;>X,,.IV[1RQR0,KVUY;Z[XAM]5M#_HNLV_B3Q-!JT-[%XDUQ+]X^!_P
M@%K-9GX<>$9(+B[M;^;SM&M)YGO;--26WNOM4R/=+/'+K>NWIE696DU3Q!X@
MU>4OJFNZO=WDSXSR2:?/DU>I)SJ3<IQRYN52M*C.KB)+X55G4H4YRA']W4G2
MI2FVZ=/DJ/"V;0LH9I2A%*"48RQJ484U6A"BGO[-0K5(*3]^$:M6,5:I/F_
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MY(331I6@IID!C,&G1>%O!T-E'!%X-\+)I"6GP+^#5BY>U^%W@6(-:WEB\/\
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MA1WJP7^AZG!J&AVEU?72Q()-)MS)I'B"^M[&]\5:MX-N/"OB'1I?!]]I]_\
M$GP]K/@ZPT."SUVZTS]I3P1X7^'/B/Q]^QBUYFT6.^T2WNM%U?[9HF@6^H3)
MX=EAGT^[>'1-7N]*TS3_ !5X,\%^(/ GB+0]8\(:UX2\36.D?#/X30S3Z%XF
M\&Z7X.G\&_"'5O 7[ 7[?V_P.^#]HETEK\-_"%L+R!+>=K?1;2&4"*]TW489
MX)HXUFM+^WO]%T*[M=2M'AU"UN/#_AZ2WNHVT#1S9,MO@5\&;.VN;*U^%_@>
M"RN[2'3YK)/#FF"S6QMKK3;NWM+>U^SFWM+>"70_#T<4-I' D=GX9\*Z>JBP
M\+^'[;33_7_+M;Y=CI-N+=ZF"7M'%4^64K/W72Y/<4&HSM%U%>]S_4S':6QN
M$246E:&)?(FYMJ-U[RJ.7O.?O1N^2UD?B)J=P;*WUCPYI]UHVOP7-]:QQ:MI
M>@MK=SJ$VW5-/TH^'H/$/AKQ!XSLM,UB3QW8QWOAK_A72R?%(W.BZ/??#;]I
MNZ^*W@_X=_M]VWN;3[;?^';?7_"MYHC^*[>0>-HH+Z_T^6TT^?4EM_$.G>*K
MF?7OB/!X)N](\96GB6ZT[^V8-2OK>?1?B#JUD^M_$;PQ\>/VU?VQ/P+^#36-
MUIC_  Q\$2:?>RP2W=G+X>TZ6WN###J=NT<L<D#*]M>6^N^(;?5;0_Z+K-OX
MD\30:M#>Q>)-<2_>/@?\(!:S69^''A&2"XN[6_F\[1K2>9[VS34EM[K[5,CW
M2SQRZWKMZ95F5I-4\0>(-7E+ZIKNKW=XO]?\NM;^S\<W=-R<\%[T[12KM)\J
MJ1L[4HVHO1235D/_ %-QUT_KN$M:UN7%NT;R;HI[N$KKFF_WJUL]V?B):7,5
MS)HWARZU+P]HVF1>)$%SXEO=.FACTM,Z1#JNIZ_K&C6$?C[3O">AZ;X#U/76
M\,067A"\^'8L->\6Z;X ^ &L?!SQ7\3_ /@G+%9S-JUGI^AW-UHVCP6AUQX]
M0OO#CRWWVZXTRUT>33-5D\,^#/%GBC7!+JWA Z!X=\+W?A37M-\/:O<W_P .
M$^'/A$^%?&'[*7[-/[?/\#/@Z]G;V'_"M?!R6EI=R7UI##H=E +6Y==*$;VS
MP1QR6Z6;>'_#<^EP1.D&D7?A;PI>:7%9W?A?0)M.'^!?P:DM+>PE^%_@:6RM
M9KR:"UD\-:7)!&;^VT^QNH?+>V96LY-,TG2-'6P<-8PZ)I.E:)!;QZ3IMC9P
M-\?Y=NLNQJ?,Y*U3!^[-N3=97;YJDKJ+A*]-*[BK[+_4W&ZWQN$:LDUR8I*4
M5R_NG9:05FU.-JC>[L?B$EXNOMI]C+>Z)I5K9Z-XAFL;TZ;_ &M_:#^5K>L6
M5AJFM>$;;XM:MXTU_7-6\:Z%X3\,:UK&M?$FPEG\0>&/!^I>-;SP=\;M$\$_
M\%)W+J$6K6T-Y<7^A:=!HFB"ZT]@B65QKML-;E\51V\WBCPWK&H0:OX@FTWQ
M#-J@^)?B_P"+9L+KP[IMO\19_P!I:_T:?PI^V-X[_;JY^!GP<O8[**\^&G@V
M[CL(9H+=;K0K&XS'<W.J7=S]J::)VOY+J77_ !(ES-?&YFN+;Q5XMLIG>S\5
M^(H-3=/\#_A!<BS^T?#CPC+)80&WM+E]&M&OH@VI7FM-<&_*?;9;]M=U&^\0
M-J<MQ)J)\07=QKQNCJ\K7I/]?\M]VV78V-F[6J8-J%W/FE'F=Y.LI6FIMJ%W
M[*TDFC_4W'.]\;A'=*]X8E<]E'EC+E5HJFU[CBO?LO:73=_P_FOH[PWNH:A?
MZ-HY\.>'=(,-K!9?\(A_:ZZ1<:%H26=CJ6@-\/\ 2=)\4?V;X2\2^)]<\5^,
M?'?PAANK7PCXIU74_B18^,_@)=O_ ,$RI;MSJ,5[?7MWH=A>VD6BZ&NC:=X?
MF\)RWZV^E-X.>[L-&T/P=X,\/://875C9IXDTO5M'\!Z_JFNZNO@5/AA?^*]
M<UK]D3Q!^W-Q\"_@[<S0W$GPU\'I/;6EG96LUKHEG92V=OIUKIME8_8WLXX&
MM)K2WT/PX+>ZMC%=12^%/!UPDPN/!_AF72BZ^!?P9O)!+<?"[P*S+:6=@@C\
M,Z5!&ECI^FP:)9V<<4%M%%':P:%;QZ"MNB+"= :;0V1M*N;BSE%Q_ERY;9=C
MHV6G+4P3Y%IS0C=^]&HUS2E)N<'I3:20/@W'/FOC<)*[;UABESMWM*5E[K@K
M*,8^[)7<TV?B'?7PUF76O$,]YH5IJ%_KEA!!X?TW0$M(+Y_$B:YJ$MUX>T30
M-$U;P/?>'=)E\3>%[+4/!\;^,KWQ5+XW\.2>$O@_\?\ 1_VB7UO_ (*@7#K0
MCU&/QL;KPHVH3^*+C6CX?%CI]OI,!%W8^+X;J33Y-2TOX:7G@R^-K>V%IH-K
MX_UW3[W3]*U#Q-=1ZWX,\(Q?M(_!K]L;SX&?!W4+Z]U&]^&G@VYO-1FGGOYI
M="L3]K>ZFO)[M+B/RA%+;WLVJZ\]]:-&;6^/BKQD+N&8>,O%(U>T/@S\)QK!
MU\?#OP@NM'5#K3:DNAV"W3ZJVH)JSWSR+"/,FDU>*VU>4N&675K'3=3E5[[3
M+"XMI_U^RWE45EF,M[/DY?:81Q4.2,?8)WYG2;6M1OVR6B:6]?ZG8[F;^OX6
M_/S<WL\3=RYW+V[7PJHDU:FOW3[7/PYT^^_L.32-?CO="N=2@UZ_SX?U704,
M5L/"J:%.+W7/#GB'1/"'@JZ\-ZG=>&O%.G:?HHTZ6?P+)X(\2Z;XR\*?LKZ=
M^SU'HO\ P3&+5_['%A)9W6B:G?:AIVJZ:VE7WA^77GTR:YBU;PJ;;4O"GB7P
M;?Z5X@UB6+Q#8:MHMAH'PY^*MSH5U?Z'81> _#GC3QOIGPC_ &G/V\L?@;\'
M=,O+>_T_X:>#;2ZM+JUO;:2#0K%%AN+$V9T]DA$7DA--&E:"FF0&,P:=%X6\
M'0V4<$7@WPLFD):? OX-6+E[7X7>!8@UK>6+P_\ "-:6]M+97]A>Z7=6<UI)
M;/:S6LFF:GJVGK;RPO%%9:SK5K"D<.L:FEW4N/\ +FY/^SL;*ZL[U,&N=<S<
M:4N67NP@W>,XVG)_&VG92N#<<DO]MPBL]+0Q3Y79*52*::<I+1QE>"6L5>Q^
M(-M?1V,=A>6.H:-J\OB'P_K%Q<6MU9_\)')H\'B"XUW1D@OSXAG\3Z9?>)9M
M+\5>'/%&@_$'P?J?Q-M-1M?%GA7Q!HG[0?Q3\8?':UUO_@I ^34(M"CO5@O]
M#U.#4-#M+J^NEB02:3;F32/$%];V-[XJU;P;<>%?$.C2^#[[3[_XD^'M9\'6
M&AP6>NW6F?M*>"/"_P .?$?C[]C']N[7X&?!ZS>62#X;>$/,N(-1@N7GT6TN
MVNEUBVU"TU66Z-TDQNKS4H=9\0F^O[CS+VZF\4^+KJ:X>Y\7>)9M5=;_  .^
M#]HETEK\-_"%L+R!+>=K?1;2&4"*]TW489X)HXUFM+^WO]%T*[M=2M'AU"UN
M/#_AZ2WNHVT#1S9#X_RUMWR['23<>:]3!+G2GS14N5^[[&-E3<5>?*O:\S;2
M%P;CDE;'81-*25H8I\C<;2:YE:7M'\?-\%W[.R2/Q >9M%COM$M[K1=7^V:)
MH%OJ$R>'989]/NWAT35[O2M,T_Q5X,\%^(/ GB+0]8\(:UX2\36.D?#/X30S
M3Z%XF\&Z7X.G\&_"'5O 7[ 2ZG<&RM]8\.:?=:-K\%S?6L<6K:7H+:W<ZA-M
MU33]*/AZ#Q#X:\0>,[+3-8D\=V,=[X:_X5TLGQ2-SHNCWWPV_:;NOBMX/^'?
M[??[=VWP*^#-G;7-E:_"_P #P65W:0Z?-9)X<TP6:V-M=:;=V]I;VOV<V]I;
MP2Z'X>CBAM(X$CL_#/A73U46'A?P_;::I^!?P::QNM,?X8^")-/O98);NSE\
M/:=+;W!AAU.W:.6.2!E>VO+?7?$-OJMH?]%UFW\2>)H-6AO8O$FN)?G_ !$#
M+N92>78Z5IPD[U,%'GE%IJI+E:<9PMRPA#]VTKRO+4/]3,=9I8["1O&45:&*
M?*FFN177O1GO*4O?BVU%\NA^)SW-I]MO_#MOK_A6\T1_%=O(/&T4%]?Z?+::
M?/J2V_B'3O%5S/KWQ'@\$W>D>,K3Q+=:=_;,&I7UO/HOQ!U:R?6_B-X8^/'[
M:L%I<Q7,FC>'+K4O#VC:9%XD07/B6]TZ:&/2TSI$.JZGK^L:-81^/M.\)Z'I
MO@/4]=;PQ!9>$+SX=BPU[Q;IO@#X :Q\'/%?Q/\ ^"<O[=CX'_" 6LUF?AQX
M1D@N+NUOYO.T:TGF>]LTU);>Z^U3(]TL\<NMZ[>F59E:35/$'B#5Y2^J:[J]
MW>-?X&?!U[.WL/\ A6O@Y+2TNY+ZTAAT.R@%K<NNE"-[9X(XY+=+-O#_ (;G
MTN")T@TB[\+>%+S2XK.[\+Z!-IR_U^RZUO[/QW^/FP+ES^S</K'+=0]IL_96
M]C;1))MC_P!3L;O]=PG^'EQ=N3G4O8<WQ>SM?]Y_%UWN?B#9S-JUGI^AW-UH
MVCP6AUQX]0OO#CRWWVZXTRUT>33-5D\,^#/%GBC7!+JWA Z!X=\+W?A37M-\
M/:O<W_PX3X<^$3X5\8?LI?LTJEXNOMI]C+>Z)I5K9Z-XAFL;TZ;_ &M_:#^5
MK>L65AJFM>$;;XM:MXTU_7-6\:Z%X3\,:UK&M?$FPEG\0>&/!^I>-;SP=\;M
M$\$_\%)_V]?X%_!J2TM["7X7^!I;*UFO)H+63PUI<D$9O[;3[&ZA\M[9E:SD
MTS2=(T=;!PUC#HFDZ5HD%O'I.FV-G ES\#/@Y>QV45Y\-/!MW'80S06ZW6A6
M-QF.YN=4N[G[4TT3M?R74NO^)$N9KXW,UQ;>*O%ME,[V?BOQ%!J;_P"(@9==
MM9=CH^].4;5,&W3E*]ZD>9OFE.]IQJ7A&]XV8O\ 4S'6L\;A):03O#%+G4;)
M0DTKQC#5QE"TI-)2=C\15U"+5K:&\N+_ $+3H-$T076GL$2RN-=MAK<OBJ.W
MF\4>&]8U"#5_$$VF^(9M4'Q+\7_%LV%UX=TVW^(L_P"TM?Z-/X4_;&\=QS7T
M=X;W4-0O]&T<^'/#ND&&U@LO^$0_M==(N-"T)+.QU+0&^'^DZ3XH_LWPEXE\
M3ZYXK\8^._A##=6OA'Q3JNI_$BQ\9_ 2[?\ X)E?N!/\#_A!<BS^T?#CPC+)
M80&WM+E]&M&OH@VI7FM-<&_*?;9;]M=U&^\0-J<MQ)J)\07=QKQNCJ\K7I;<
M? OX.W,T-Q)\-?!Z3VUI9V5K-:Z)9V4MG;Z=:Z;96/V-[..!K2:TM]#\."WN
MK8Q744OA3P=<),+CP?X9ETH7'^6IK_A.QL4N;EM4P;Y%*47)1O?F]JE+G<US
M4W+]U:T4#X-QUO\ ?L(V^5RO#$KG<8M1;LO=]FVN50TFHKGW9^(UVYU&*]OK
MV[T.PO;2+1=#71M.\/S>$Y;];?2F\'/=V&C:'X.\&>'M'GL+JQLT\2:7JVC^
M ]?U37=77P*GPPO_ !7KFM?LB>(&7U\-9EUKQ#/>:%::A?ZY800>']-T!+2"
M^?Q(FN:A+=>'M$T#1-6\#WWAW29?$WA>RU#P?&_C*]\52^-_#DGA+X/_ !_T
M?]HE];_X*@?MY=? OX,WD@EN/A=X%9EM+.P01^&=*@C2QT_38-$L[..*"VBB
MCM8-"MX]!6W1%A.@--H;(VE7-Q9RK>? SX.ZA?7NHWOPT\&W-YJ,T\]_-+H5
MB?M;W4UY/=I<1^4(I;>]FU77GOK1HS:WQ\5>,A=PS#QEXI&KD>/\N33_ +.Q
MR:22M4P3Y(\T9.E&[?-";3;G+]XF[1=D@?!N.::^NX1J]]88I<SY7%5'9:3C
M=)0C^[:U:NV?B<=:$>HQ^-C=>%&U"?Q1<:T?#XL=/M])@(N['Q?#=2:?)J6E
M_#2\\&7QM;VPM-!M?'^NZ?>Z?I6H>)KJ/6_!GA&+]I'X-5-/OO[#DTC7X[W0
MKG4H->O\^']5T%#%;#PJFA3B]USPYXAT3PAX*NO#>IW7AKQ3IVGZ*-.EG\"R
M>"/$NF^,O"G[*^G?L]1Z+_P3&_<8?!GX3C6#KX^'?A!=:.J'6FU)=#L%NGU5
MM035GOGD6$>9-)J\5MJ\I<,LNK6.FZG*KWVF6%Q;5;'X&_!W3+RWO]/^&G@V
MTNK2ZM;VVD@T*Q18;BQ-F=/9(1%Y(331I6@IID!C,&G1>%O!T-E'!%X-\+)I
M$_Z_9;RN+RS&6]FH<OM,)RN"C**P[ES<RI*Z2J+]ZTO>;NVJ_P!3L=S)_7\+
MI/FYN3$I\_-%NO:UG4=FW3?[I-Z+8_$.U?\ L<6$EG=:)J=]J&G:KIK:5?>'
MY=>?3)KF+5O"IMM2\*>)?!M_I7B#6)8O$-AJVBV&@?#GXJW.A75_H=A%X#\.
M>-/&^F?"/]IQEM?1V,=A>6.H:-J\OB'P_K%Q<6MU9_\ "1R:/!X@N-=T9(+\
M^(9_$^F7WB6;2_%7ASQ1H/Q!\'ZG\3;34;7Q9X5\0:)^T'\4_&'QVM=;_P""
MD'[?6GP+^#5BY>U^%W@6(-:WEB\/_"-:6]M+97]A>Z7=6<UI);/:S6LFF:GJ
MVGK;RPO%%9:SK5K"D<.L:FEV6OP,^#UF\LD'PV\(>9<0:C!<O/HMI=M=+K%M
MJ%IJLMT;I)C=7FI0ZSXA-]?W'F7MU-XI\774UP]SXN\2S:K3X_RY\U\NQTN:
MU[U,$O:+WN6$[/W53<DXRA:4VDINW->5P9CERI8W"1MM:&*?(_=O.-U>4JEF
MI*=XQ3O!7L?B))J$6A1WJP7^AZG!J&AVEU?72Q()-)MS)I'B"^M[&]\5:MX-
MN/"OB'1I?!]]I]_\2?#VL^#K#0X+/7;K3/VE/!'A?X<^(_'W[&+7F;18[[1+
M>ZT75_MFB:!;ZA,GAV6&?3[MX=$U>[TK3-/\5>#/!?B#P)XBT/6/"&M>$O$U
MCI'PS^$T,T^A>)O!NE^#I_!OPAU;P%^P%^W]O\#O@_:)=):_#?PA;"\@2WG:
MWT6TAE BO=-U&&>":.-9K2_M[_1="N[74K1X=0M;CP_X>DM[J-M T<V3+;X%
M?!FSMKFRM?A?X'@LKNTAT^:R3PYI@LUL;:ZTV[M[2WM?LYM[2W@ET/P]'%#:
M1P)'9^&?"NGJHL/"_A^VTT_U_P NUOEV.DVXMWJ8)>T<53Y92L_==+D]Q0:C
M.T745[W/]3,=I;&X1)1:5H8E\B;FVHW7O*HY>\Y^]&[Y+61^(FIW!LK?6/#F
MGW6C:_!<WUK'%JVEZ"VMW.H3;=4T_2CX>@\0^&O$'C.RTS6)/'=C'>^&O^%=
M+)\4C<Z+H]]\-OVF[KXK>#_AW^WW;>YM/MM_X=M]?\*WFB/XKMY!XVB@OK_3
MY;33Y]26W\0Z=XJN9]>^(\'@F[TCQE:>);K3O[9@U*^MY]%^(.K63ZW\1O#'
MQX_;5_;$_ OX--8W6F/\,?!$FGWLL$MW9R^'M.EM[@PPZG;M'+') RO;7EOK
MOB&WU6T/^BZS;^)/$T&K0WL7B37$OWCX'_" 6LUF?AQX1D@N+NUOYO.T:TGF
M>]LTU);>Z^U3(]TL\<NMZ[>F59E:35/$'B#5Y2^J:[J]W>+_ %_RZUO[/QS=
MTW)SP7O3M%*NTGRJI&SM2C:B]%)-60_]3<==/Z[A+6M;EQ;M&\FZ*>[A*ZYI
MO]ZM;/=GXB6ES%<R:-X<NM2\/:-ID7B1!<^);W3IH8]+3.D0ZKJ>OZQHUA'X
M^T[PGH>F^ ]3UUO#$%EX0O/AV+#7O%NF^ /@!K'P<\5_$_\ X)RQ6<S:M9Z?
MH=S=:-H\%H=<>/4+[PX\M]]NN-,M='DTS59/#/@SQ9XHUP2ZMX0.@>'?"]WX
M4U[3?#VKW-_\.$^'/A$^%?&'[*7[-/[?/\#/@Z]G;V'_  K7P<EI:7<E]:0P
MZ'90"UN772A&]L\$<<ENEFWA_P -SZ7!$Z0:1=^%O"EYI<5G=^%] FTX?X%_
M!J2TM["7X7^!I;*UFO)H+63PUI<D$9O[;3[&ZA\M[9E:SDTS2=(T=;!PUC#H
MFDZ5HD%O'I.FV-G WQ_EVZR[&I\SDK5,'[LVY-UE=OFJ2NHN$KTTKN*OLO\
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M?%WB6;576_P.^#]HETEK\-_"%L+R!+>=K?1;2&4"*]TW489X)HXUFM+^WO\
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M_:7^'.CZ'\<;OXY_"OX ^&_BGJ?Q<\8>%M*T#PSJ%AX$^%WCWXBZ-\/-(O\
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MNT\ ^ OB=X^TOP)IUW\9O@YX(3P1J/@/PKXRU2'XL:1F^./^"=WQ@^-_CO\
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M:Z=%</8>*O O@C2?$NMDZZ->?Q/J]_JFD:OI7AEK'PY:?IE_P4K_ &S/B?\
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MA)866B>#M2DEN[SX+R)\4-5UBZ\(:EXI3X@7K:/I=O%\4],$]Z7K?!3]H?\
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M,ZI#H/QW\&:K\&M2\&7>K>!Y==\)>/;635/&^B?#7PSJ'CGPQ\)?A/[%HO\
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M^OVUCID,D?AF?PT >T?LU?M"_&/X@_\ !2W_ (*1_LU^,/%\.J?"3]EWP/\
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M6\#>$+C6KWQKXATRVU3PW?>)])\-S>$M/\3^%M4UZRUW3O'?"'["/[6'PO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX#75O%H!B_\ !,+_ (*/_M(?MN_MF?\ !2#X,_%+P7\)_ /P?_99B_95\5_
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M3P[I7Q.^ NL67A[5M,\5WSI]*_LL_MD?M'?'+_@I3_P58_8Z\4R_!33/A?\
ML+VO[)"_"?6_#_PW\>6_CWQ)>_M4?!G6_BNEQ\0]6U'XU:GX>U2U\!SZ.-#>
MS\-^%/"DWBJ*Y-^M]X:>(6LGQ/H7_!"GQ=\(?@[_ ,$MO@Y\'_C-X9\40_\
M!/;]JS3/VK_'?C_XL6_B*V\7_'W7M*N?[)TOP,(]!MM:M/!FD^&OAM;>'/AI
MX.\02W'B(>'_  CX$\&:,GA.XM-,D$WVYX8_8G_:)^ /_!0S]M+]LOX >)/@
MOXT\*_\ !0/P;^SWIOQ7\)_&.\\<>%?$/P0^(/[,/P\F^%7PZ\9?#R3P3X?\
M4Z;\7O!OB#POK6MZIXU^&WB2]^$FMMK]CI4>A?%;3].OKM+  ^*_VEO^"J_[
M;O[*_P %?^"=G[66J_"/X-?'O]G;XH?L[:-^T5_P4-T7X7> OB%X0^+WP;^%
MFNP?!*QU'XO_  %LM7^-/CK3M<\*?#/6OCKHEYXV\$^(-)\5:_<:'X>;4'\4
M>&/"FL>+/'WPG])_:I_X*[>-?V??@3\7/BO\.++X._M$:O\ %W]L[]FW]C7_
M ()SQ:#8>)?!GPY\7:]^U7^R_P#!7]H?X;_$+XX?$(^/O&K>)? NGZ1\3O$>
MORZMX \/> QXKTGPKH7A>UC\,W'C&;QMX8_0GP1^R3=>!O$'[//@@V_@WQU^
MSU\$?V+O%?[(6JZ=X_E;5_&7Q TGQ#%\$--2\\2^%T\(KX#U#1;C0/@M_97B
M?1YKA;7Q WC*\FCLM,L=#_LC7_R]L/\ @WN^%WA/]C?XL_L>?#'XP:]\/M"\
M._\ !0F#_@H-^PCXQ>QU3QQ??LN^-]"\%^ M,\"^#/$>D>*/$3-\4_"7@_6]
M.^(F@BTU;7+?4-=\">)=)O=5U>7X@V5[XFN0#W;XK?MR_M._L:?MN_L<?L@_
MM"^(?@C\;]&_;Z^'7QLT?X)?$KP/\,O%OP2U3P3^T[\"?"?ASQ!J'AKQQX9U
M'XK?%K3]2^#OQ6N_%WAC1? TFF:O#XR\$>(-1N+#Q5K_ (IT95\1V7C"?MB_
M\%7-0_X*'?$W_@G/H/CC_@GYJ'Q)\!?\$\=$_;%TKQQ>_LM_M%:7X1\3?$Z_
M^)^F?#MOA+<6R_MNW^J^'_!6HW-TZP?$@IK&LZ*ES'JL_@'6A8RZ)J'U9K7[
M!?Q?_:A_;A_9"_;0_;*O?@[X:M?V#_"/Q4B^ WP0^"&J^*?B)I7BGXT_&>P\
M.Z+XQ^-GQ#^(_P 0_ _PYO-+T#1- \+:'%\/?@MH7@+5=1\,^,]+M/'>H?''
M7[<R>#*Z'PS^PQ\5=%_X*]^._P#@I#=^+/A]+\/_ !I^QMI_[(*?#6VD\1GQ
MGIMOHOQ(TKXI6'Q)?6)=)30[N>]U33IO#5[X)6.VCLM/O(O$,'C&^N=/?P]J
M8!^?GA7_ (*B?MD_%O\ ;@_;X_88\#?&K_@G_P##7XT?!+XS:?\ "?\ 8V^'
MGQ.^ OQF\3>*OV@KZ]^!WC_X]ZD?&H\-_MG>%M8T+PWX,\.^!)]%\:_$SPMX
M&U31M$?4M/UE_"SZCJ&C^"=4^RI/VZ_CC\>_^"C7Q"_X)U?LZP_#SX97'[+O
MP&^&OQA_:Z^-WC_POJ?Q,O=)\<?%JVT;6/ GP#^%GP]TWQW\/[&UU.^\(ZW9
M>.]8^+^L^(?'_ARRTU+KP7%X&BURYL?%$?E?PR_X)P_M9?!/]I[]O3]J'P+K
M/[(OB[QE^UG\:_ ?QX^#L'Q4T_XNZG9?LU?$'X>_"CXC?!BQUR2+PO'X>U#X
MF-XA\#?$;6-+UJVTC6_A-=0Z3J?B;PZ-8U'3_$"W&F][H'_!.GX^?L^?MIC]
MO_\ 9]^(_P /_BG\7/C)^S/\+?V?/VV/A=\;]5\1_#3PG^T!XR^%'ASPWH7A
M#]I7PM\4/ 7@GXEWWPV^).CVOA6RT&_\&GX0>)/ WB?PKJ.J06X\'^(&BU\
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M_8YNO@_XU^'?[>,W@+Q3^T)^SK\:?%7C?X4#P3\:/AW9>(+*/XP?!WXK>!_
M'QDANK'XC1>*=<O?B5\,_%OPIBOKWQ==KXJT?XL6&C6MCX#M?N?PQX>_:ZLO
MC1X)OO%_Q*^!7B'X!6OP7\3V?Q"T30OA?XQ\+?$_5OVA;SQSI5]X<U_PIJEY
M\1/%7A[2OA#IWP_?5M"_X1S5(M1\7VVNV4.HW_B#Q/'XB1_!@!]-T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P $_@M\._C7XO@U+X _\('X*\)_$'Q'K.AZL^@>%?#OBS7/%]U\,G\-I?\
MASXB>*=7\6:[J#@']$U'3K7XL_M"?\%5?B_^RIX1^)E_\<_V.]%T?QUH/[+I
M_:X^%?A/PA^T@/%GA_XA_#SPS\4OA5\*/B[X&\5^-[CX(>'E^''QC^&&N_&_
MX57<N@:=X=^(GPY\66'BV&7P_P#%>3^RM=;3/?O WCC6_P!M?QS\<_@Y\3O"
M=W\#O'_[ _[97PR2XO?A'\?/BYKGA_QW;7'P*^'OQ[^&FOQ^(O!\7[-M_J?]
MH^%_C5I-A\0_@U\6O WQ3^"BZ[HM]I6L:'\7=*.D:YIP!^D^1G&1GTSSTST^
MA!^E+7X^?M >)]7_ ."?'C__ ()Z7VB>./'GBWP3^T!^W)JO['GQ#\&^(/%_
MQ \=6%]X;_:ETKXW_$[X8^([/4?BW\0?B+XSB\7?"/XN^%?"5I!KEYXVOM._
MX5QXO^*GA3P]X8T'PL/A7X+^&W[! Y /J ?SH 6BBB@ HHHH **** "BBB@
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M%OV;O'WPSTGX=^)_"FFZ#\;/".B_%30/C!<7<G[0'C+6_!OPEUOXG>/-6O\
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MGXSU2+1_#7AO1[6-9+G4-4U*\E:3R+6&7['IUKJ.LZ@UIH^EZE?6H!V-%%%
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M,CI\/[-OACQ;X;^/?P"OVT_X?^"?"?P76;5?C;^RW^V-X2N%N_V?-0^%FO\
MBK4?#GQ2_9$^,O\ :?A;X[^)(/&MY\.?#.A>)?%FM^-[[]]?$'BS0?#4VA6.
MJ:GI]OK/BW4[[0?!F@W&J:7IVK^-/$EAX9\0^,Y_#/A:#5K[3X-6UX>%O"?B
M7Q ;".X0P:-H.L:O=R6VF:9?WEOY'^RU^TAX#_:Z_9^^&7[2/PRT_P 4Z3X#
M^*^A3^(/#FG>-M-T_2/%5G9VVK:EHTL.MZ;I6KZ]I]I=K>:7<GRK75[^/R3$
MYF#,R( ?!O[;OP@^+7A?]NO_ ()^_M\> ? /C/XP_#K]GW1_VEO@A^T1\/\
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M7>^$?#UQ!K<_B.7Q5X)@\%V&L^,8=5\-:3HEOI/C_P "OX?USQ%?7/B6P\,
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M_P"!GQB\3)\6;:XU[PG8ZO8V7B>U\2ZO=>/?"47B[JM5^&_@*]^#;:A\/O\
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MAWXD_L\_$?Q1\3OV8/"_Q"TC0/VF])^&\?ACQF^O?"WXGZ)J7BC^DFDR/?\
M(_X4 ?R2_L[_ +$?C _M$_"CP9\;OV&_B;>?LH_!W]HS_@L6NI^%/B/\+OAO
MXB^%FG? S]HYOAYX[^!/@OP]\,O ^K:MX3UKP!XHNHO%>I:%X*^'7@J]^'OA
MWQUJDL2Z?I'C*VU%M.]&\&?LL_&9+[_@E9KOCGX'?$?X@_&?X4?LD_\ !,;X
M+_&_X;?'OX$WOQ%^&ECKOP'^,4>J?&KXI_![]J+PIK-AXE_9>_:4_9NFT?QU
M\3OBA<>//%>J?!G]O#X7S_!_X2^"_"_Q>\4&RATK^AW]H_\ :'\$_LO?#2'X
MK_$/3?$^H^%)/B+\'OAE/_PB=CIFI:I9Z_\ '+XL^"_@IX&NKBQU36-$632&
M\>?$#PS9:Q<6<]U>:=8WDNI#3[BVM+IHO=PP/Z@X!QD<$9P <'CZ\=>* /Y>
M+/\ 9AUKX"_!+X?:QX3_ &$O&NJ?".W_ &^/V^?%/[6'P)^!/[-WP,D^+/C7
M]GSXU?&_]L+7/V)_B3#\-OB=X6C\,?'CP#\(?A[\5_!'AZY^"5E)KGBWX6^%
M_B.][:>!+37?A+)X=T_5D_81O=)^->@>*IOV ?'WQ4\*? '_ ()$^)_"7[-O
M@+XM?%+3O$/CK0_VE/ /QD\0?$7]GKX2VW[35GJ]]>?"3]IS0/A[;^%]#\.?
M'?X:Z[K>B_LV^(;W4?#'P9^/_B*WT"S\1>)?Z<LC..^,XP<X_*O%OB7\=/"_
MPK^(G[._PW\1:+XJO-3_ &F/B7XJ^$W@36M&L=*NO#ND>,O"GP4^*?Q\N+7Q
MA<W>M6&IZ;::KX!^#?CQ]'N]*TG7%FU?3;>PODT^.\ANB ?REZ-^R3\63KGC
M^'P/^P[\:/AQ^RO=?$G_ ((@_M0W/PRD^ OAOX<>"?\ A&OV=/C9XTTW]K*T
MT/\ 9I\+>/\ XF^-M9^*-K\*M,\&P^.O 5^OQ1^.?Q%\*?#:QT_Q)JOC6TU'
MX*Z9XQ^_O@Y^R5\1_A=\4?V7[GX7?!;Q7\(OV;],_P""J?[57[1WP9^&.G^'
M+T:+^RW^S5\0_P#@G7\9/V;]"O[CX<!WM?A%X;^+?[6_Q$UKXX>%O@CIMCIE
MU\./"7QU=_''@OX777A+XF^&/ ']$%("#Z_D>WX=?;K0!^$'_!)GX3?$/PWX
MG\/>)?C%^R_^TA\&/VC/A_\ LN>'/V?_ -K/XO?%'5_A9X8^&O[0'QG\,Z_X
M5UE_&'@G2OA(UZW[5#Z[XF'Q<^).G?M+_%C4)_&G@2R^).L^%M/U?Q'XA^,'
MQ6M_"GGG[4/[,OQM^(?Q8_;.TF/X1>+-4_:S^(7[2_[,/Q/_ .";?[9\'@BT
M\3Z!^S]\'/"7A;]FO0O&?AO1_B[<2ZXO[//A_P""/C+P+^T+\2?B]\'?$NH>
M =-_::\,_&;QCHWPO\,?&CQ5\7?B#X"M_P"B+/U_(_X4!@20,Y'7@\<9P>.N
M.<>A'J* /YI/V;?V3?&OPI_:%^!_QHF_9I\9^#?$?AW_ (*T?\%0?B/XT^(^
MF_#R\?Q#%^PY\=/A[^U?>?!K27N- BOO$<_PI\8_%3XB_L^^(]*^#MI8M+H/
MC73IO&OB#P-X>U/P9XHUO3F_L^_L<?M#_ []G'_@CG\9_!?PKM_#_P"UI\#/
M@/HO_!/K]I'X9^.U\"V>K/\ !SXL>'/[#UKQ;:7&LZ=X@C\2ZS^RK\8O"_A[
MXXZ9#X/UH+XE_9^N_P!I#1=(?6?^$XAMQ_2Z"",C.,9Z'I^5>6W/P0^#EY\8
M;#]H2[^%W@.Z^.FE^!C\,M,^+USX5T>?XC:=\/?[6U+73X+L?%TMFVN6?AO^
MV-9UC41I-O>1V9NM6U.019O[KS@#Y4_;.^!WC"/]AJ_^"/[+G@"768?!=Y^S
MG86?P3\,>+;+X?W7Q+_9]^%OQJ^%.O?&[]GW0O%6KZGH^CZ7>?&/]G;PM\0_
MA#9'Q)KVB:%JUQXO73?$OB/1-*U+4-;LOQT^(O[&/B'Q3\7/#GC/X!_LP>,?
M#O[%'BS_ (*(?\$^?BUX8_9_N/A#<?"S3?!=G\*?!7Q7T;]LS]H.W_9_\6:7
MX/UGX1_#/XA)XD^"_@#Q3X U/PGX7\7_ !9\9_";XC_$>U^%/BCP;X\L/B-\
M2OZ;8?$WARY\1:GX0MM>T>X\5Z)HNA>)-:\,P:C:3:_I'A[Q1?\ B+2O#&NZ
MIH\<K:AI^D>(]3\(>+=.T#4;NWAM-9O?"WB2UTV:YGT+5$M8M9\6^%_#NH>%
M-(U_Q%H>B:MX\U^Y\*>!]+U?5;+3=0\8^*;/PKXE\<W?ASPO9WDT-QKVNVW@
MKP9XO\77&E:5'=W\/AKPMXBUR2!=-T74;FW /SX_X)T_!"+P%^RK\4/@/X[^
M#T/@_P"'B?M2?MUVW@KX0>*/!-AI7@1?V;OBC^U5\9/B!\$?#?ASP%>V:^']
M,^&-W\#O'/@RPTKP$ND:=I_A*P:Z\":MX=T/4M!U70[+\/\ P9^PMKGC3]C[
M]F'X.>*?V"_%^BV?P^_X(;?M<_LS?$OX<>)_A!X8TS3?%'[='B"#]A:X\(:K
M)I.D7UQI6I^,?%OQ/_9F^)'C'PI\7/%+:3Y/BCP1X)^)UQXFT:Y\2_"?Q/KW
M]7?@SQ/>>+=*O]3OO!WBOP/+9>*_''AF+2/&46A0:KJ-GX-\::_X1L/&-A'X
M>U[Q%9'PEX_LM$@\<>!9KN^M->NO!?B'0;GQ)H'AC7IM1\/:;UA('7/ ST)X
M_ 4 ?S4?"[X:?M*:C\9?@]HW[5?[*?[3GQC\<:Y/^PE\7/V?_P!HG2KGX-QV
M7P'U+X._!'X >&/VA_AK\=_C;XFTF\^./P9U#PA\9_!W[0'Q1\0Z9X/\4^(?
M"_[5W@GX^_$+X6Z(?$Z>-O%VA>(?J_\ X+(_!+Q9\:/"GPG@\&>"/$_C[Q'X
M6T#XY:EX=\*>)/V;IOVL_P!ECQYXJU?0/!WA[0/A-^T%\*?#>HZ3\4O .M_$
MJ34KO3?A7^U/\*]<\':_^SO;Z?\ $;4=<\=:-X/\7:_HOB?]J:"0.30!_+AX
M<_9(^(_@[Q[^TWJ-S^P?<Z=X!U?_ (*<_!W]I;]IGX>^$O"_A74-&^.O[%NK
M?L)?"CP9JOPV\%:]I&E6U]^U%:?![]L%=4_:$\7_  9LM*:[^)1^$7CB.Z\.
MZK\4OBCX8^&WQ)T]3_9G\?\ P[OM$\0>,/V'OB%^TI_P2\\0?'_]L'4/!_["
M6G>&-"\1^,O@?\/_ ([_  ^_95\-_ 3XGV'[*7CG4/#=AIG@RS^*_@_]LS6_
M#WP:^U:?XL_9O^&/[7VA:UK_ ,.?AOK_ (,\8>#/A3_3WN''7GID$=B>X] :
M,CW_ "/^'_Z^U '\T'CGX&_M/^#_ -I5/B=X1_8[\4>/?V7O#G[,_P#P2O\
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M0YO#7P>^#^H>%?#FJ?#CQ%X5T*X^'6MZC_9P&4\ Y_ \<XYXXYR.<=#Z&G4
M?S7>&?@-\6]1_;#_ &:/BSXU^!OQ ^*NL?\ ")? KPY^T!H/[4GP U/QG<^%
M_#^D_L=/X6^)7QG_ &<?VR/"D^K:IX,DT3Q9XIU;X=?&#]C/XSR>.]"_:$\;
MZE\4/'/PR\*:/K'C36?B9K'S9\)_V2/&?P$_9[_9O\/>./\ @GU\5?&OP3UO
MQ-_P4P\%_M6_ 'X'? ;]GC7_ !^WBOX_?M46'B[]B[XK^(?AY\4=+/@CX@>&
MO#O[,MQ\2?A+%XP\*ZQ=:]\"_"_QEO/"%]J7A;2?^$[T72_ZY <^OX@C^>*3
M/..?R./SQB@#\8?V4/V1-/T;]MWQI\4OBY^SG<6^H^$OV)?^";GA/X:?$;XI
MO!\;/$^E_'_X'Z'^UUX9^,U];?'_ %O1X]8^(/Q2\)_#_P"-_P ,/!&M_'#5
M(=%\0_$RRU#7X=%N+V#0?&6FZ#\U_P#!33]DO6/BY^US^T/XN\0?LA>*_P!I
M.P^+O_!+'2O@3^R7K>B^&=.\1Z-X2_;4\$?%C]HSQ-X?N+GQC+J"VO[,GC;0
M=.^+G@GQ/X"_:5\:_P#"#Z)X5M;?QI9^#OB78>*UNO"_B'^C+/3KS[']>./Q
MQ1D9QSW'0]O?&/IZCD4 ?S4>(OV7?VH+[Q)\2_!7Q)^'_B[XA?MZVO[6_P"Q
M+\1/V4?^"AEE\.-)U?P_X?\ V;/A[9?LJZ7\;?[!^+TL6H6_P'T'PQI?@G]J
MJW^*O[+WB74/ T'Q]F^,?CF7P+X8^)$O[0/C^Z7>^"'P"^.>C?%3]FOQ5XK^
M!GCOP%^V9\!?VR?VKOB/^V[^U5IW@ ZW8?M)_L?^*O#W[4$_@S0?#GQ=TY)6
M^._A#XQ7GB3]F"V^&?[-D.H:OXS_ &:G^&/AC2KKX<_#NV^"/P[MM4_;NV_:
M/\!W7[4>L?LCKI_BJ/XGZ+\!]"_:*N-1ETRP'@R?P!XB\?:]\-]/@M-835I-
M1D\1KXD\-ZK]ITJ7188H-/BANS?-]JMXI/?L_7\C_A0!_*+^SM^S7^T[X3_8
M@A_9E_:K_9[^-M_XS;]BG]A+P-\._P!J#]G[X9> O$7Q'^$?A+X5:W\*O OQ
M$_8T^)/P@^)%UXP\,_$/1O@1X]\&>+/C#X\T;0-+\;_!_P#;H_9NU[QAX0UK
MPLWB_4?"_AKXH_JY^R)\*OVBM+_X)H_$SX2>"/#?PL_9M^.VJV/[8&F?L_>*
MO"'PO\>? KX>'Q!\0?&WQ2UOX,?M#:K^SGXVNO&WCC]G:3QEKGB?1OBAXQ^!
M]W>:_/X$U"]U33M*T30K.2R\">'_ -7R<?YS_*O#?CC\>O#GP-L_ =O>^&_%
M_P 0/'GQ;\:WWPV^#OPJ\ Q>&$\9_%'Q]I?PW^('QAU3POH.J^/_ !3X"^&O
MAZXT_P"%WPI^(OC.?5_B-\0/!'AF2T\+3:+:ZY<>*]9\,^']; /YW->_8WU?
MQ[\ _B=9?#+]B3QU\'M0O/\ @DU^T-^SE^UE\%O%O@F&]'[1O[?&N0?!6;]F
M01W6J7USX0_:=^(GP;\<>%OC-XDN/VY9Y];\+2M\6O#>M6WQQUZ2;XD'X6?=
M7QS_ &48O%G_  0D^,/[+OPP_9NTBQ\>ZQ^P=XU\,:!\"+7X9^&O"MV?VAK;
MX47T9:Q\)W.GZ;H:>//^%NV3ZWH_BZP\PZQXG6P\9^&-?U+[;I&N77ZH^#?C
M/X1\6^!?@]XUO[;Q#\.+SXYZ;I,_@'X<?%[1I_AA\6+GQ'J?@+6_B7<?#C4O
MA_XO?3-;T[XF>'_!WA?Q;K'B;P9)$^I:)9^$?%-_=#^R]"O[^'C_ -E_]ICP
M3^UK\!?"G[0GPTT'QGI7A3Q?>>/-.TWP]XUT_1-'\8VVI?#KQ]XL^&WB&PU&
MRTSQ#KF@P7#>)O!NKII[P^(KBTN+)[*ZFNK7SI8[< _GA_:Q_9$\8_%'7OVN
MOB9\%OV*?'_AMH_A_P#\$;O$7[#^AV'PL\/> O%GPV^('[,'[5GQO^)7Q7U[
MX6V%AJ.GZ=\%_%_P\^$WQ6TR_N97U/P;XANM&\5^,OAMIUOJ&O\ _"?>"(?L
MK]FSX=?%&;]NBZNOC=^RS\?7^+WPZ_:/_:[^)7A?]L2,_"#PU\#O%G[)WQOU
M?XNW/P2\,ZS\2=$T/3?CC\3M8\*?#KQ!\$?@EJ/[*OQ%FO=.\$^(?@UX"^*P
M,6E_"/X?W$'[;>"?$ESXP\&^$_%M]X5\3^!+WQ/X9T'Q%>>"/&L&D6_C+P;=
M:WI5IJ<_A7Q;;^'M9\1Z!!XG\/2W3:1K\&A^(=>T>'5;.[CTS6=4LE@OI_*/
MVC_VE/AG^RYX%TKQM\1Y]8OKKQ=XV\,_"WX8^ /"%A%KOQ(^,/Q;\;3SVW@W
MX6?##PQ)=V \0^,=?^QZCJ+I<7^F:%X9\+:)XF\=^-=<\,^ _"?BGQ-HP!\
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MX^CHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#QC]H^._E_9[^.D6DQ^+I=6E^$'Q(CTJ+P GBZ3QS+JC^#]873H_!\?
M@ -XX?Q,]X8%T1/""GQ(VHFW&C WY@%?S?> _@[XR^&7P$_8@\-_&[X9?\%
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M^%7QW^(WA1/V6O#?@?7/COH_AGPKJ'A^W^/GPV\"Z[8ZA\5OVB/"GQ$_6/\
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MU_X-?#WQ+\4_!7QEUNRUZZ\>_#W0/$7AKPG,GCOQW9>%+/3?%,^G7.K7%_\
M#>Q\2VWPW\0ZZ)=+M!I'BKQ%X2U;Q/X=B%U;^'=8TJ"_OX[D ^)?V^/A5JWA
M?_@D?^V9\#/ >B>/?B?XMO\ ]A/]H3X1^#=$\)^&?&WQ)^(7Q%^('C7X+^+/
M!>A0Z;X;T.+QCXQU?6/%_C/7K:6X"G4X]*74+F_U._MM&TZ\O[;\KOCMX3^-
MOA'Q%_P43T;X(^"_VW$^&?B/]H'_ ((O_&7X26^E>"OVQ_$DWB*[U'XY?#R_
M_;,USPW/K&CZOXIUZ#_A2GA:T/[0/A2WFO;"PGTV>W\;>'K7QY>ZG'>_T_;E
M_O+^8JA%J^E3:K>:%#J>GS:WIVGZ9JVH:/%>VTFJV&E:U<ZM9Z-J=YIZ2F[M
M=/U:[T#7;73+V>%+:_N=%U:"UDEETV\6$ _$W]CZP^*FC_\ !1CXTW&H^$/B
MKXX^'/B+_AL>2V^,'Q0^"OQ^^ WQ(^'&IC]IOPJUO\+OB/XE\6077[/_ .V)
M\%=1TO2=(D_X)_\ Q<\$:SIOC_X2_L[Z+KGP^LO"6H>%];\9>(['XQ_X+%^!
MOC#\28_^"FOP^\<? ?\ :8^-$_CG]DGX'Z9_P3D'P0^$/[0GQ:\&Z7XBTE?B
M;>_M!V#ZG\&M!USPI\*?BQK?B*]TRR\?CX@:CX4O/CK\%I/ WPOTVV^(^AV6
MN>"9OZCRRCJRCZD#U_P/Y&O*OCE\:_AY^SE\'OB5\>?BUJFJ:)\,/A%X.USQ
M_P#$'7=%\*^*_&U]H'@_PS92ZGX@UX^&?!&B^(O$]_8:+IL$^IZM-INCW::7
MI5K>:MJ+6NEV-[>6X!^$7QLUSX[6_P >?&/A+P/X1_;3\FX_X+0?L&_M >#M
M0\*_"W]JA? >G_L9^-_V;?V3M ^-<Q\;:?X;C\$6OPNN?C1IOQY/QD^"4^MR
M3>%]?NO$7B_XB?#?0M&NF\2)R_@;X;_M&_#KX7:;^U3\,?AS\>+GXA_LZ_\
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M((?'E_\ &+Q1^R[I/Q5\/>!]>T3Q=9?%V_\ &^I:9?>!?%=A\39] UR#\?\
MXQ>!?BOJC_$#_AG[P5^UYX5_8H\3_MY?\$D==^#OPM\&?#G]I[X3:_X,33/C
M19:M_P % =7\$?"CPWX5\'?%_P"$7[+MS\&/^$$U/6M$US1/"WPOL_C%I7QB
M\3^$]"TSQUJ[ZSKW]..Y?[R_F*\;^-7Q]^&'[/FE^ =9^*>L:MHNF_$WXR?"
MCX">$;O3/"7BWQ5#<?$[XV>,M-\ ?#?2-9F\*Z)K,/A32M>\6:QINC-XL\5R
M:)X3T^^OK&SU#6[:\U'3K:[ /S^_X*4_""/PA_P3Q\&_!'X(?#OXC^*=&^'G
MQS_X)T:3X-\#^ _#7Q0^-GB_3/AO\#_VV/V9O&FN7D\6DVGCSX@:UIO@GX7?
M#S7M=UGQ#K4VJ7LEEHLCWVHWFJ7=NEW\F:-;?%/6OCM\=;KXIV/[=WPH_:G^
M"_QN_;;\0>&OCMX*^'^EV/[+VO\ ['GC'X??%V\_9Q\37OQ1\2^!=-^"/Q<\
M#_#GX<>+O@1H&F_LMW?Q/D^)>E?MC?"JV^*FN>"M#\*6OQV^*$O]#!('4@9Z
M9.,UR?CSP-X)^*/@KQ9\./B/X7\/^./ 'COP]J_A+QGX.\4Z99ZWX;\4^&-?
ML9]+UK0==TB_BGLM2TO5-/N9[2]L[F*2&>"5T=2#0!_*7\'_ !%K.D_!+XG7
M'COP?^W/J?Q7\7_L3_L5_#[QO^RM\/?!?_!6SX07_CGQ+\./B]\/O _[;G[7
MFA:A\7?V=_A3-\2OB?XBT+XG_"J;XX^'_@OX7^)_Q_\ &'PP^$?B5(?B7K-]
M\8?%-_'[7^RM9?%S1OC3\%?"OB+X5?M-V_P^^'O_  6U^,?Q5^%XU/\ 99_:
M@\%?"_X<?LN?%?\ X)+?'7P/X7UOP5H?C30?%=I\$/@=<_M)_&74-(TSP!JG
MBNQTSX1ZOXUN] UO2O!$.C:UHOAS]MO _P"SY^SU^Q_I^J?$;PKX8^,OBO68
MK+3?!R^)O%7CG]IO]LWXP:1X5\3^)_#MFW@[P1J'Q+\6?&_XK^'?AN=>CT'Q
M!XF\(>!IM.\#Z=!H$?C+7])M[3PPVJZ?]?AE/0@]>X[4 ?EW_P %(/AU<?%O
MQS_P3U^'EYH/QV\0_#7Q3^U_XDT;X_67P>G_ &@=+\.?\*1\1?L=_M4^%+J/
MXQ>(O@5=::GA_P  :C\7O$7P;TBYO?'&KZ9H+3WY6\N!X87Q@R?G!X2T/XDV
M_ASX]0>/O#W[=?PM_:=^!_@#_@H[X0^*7B;1M(\0^ ?V7/B!\#]4L_B-K?[/
M7Q"TG]IJ_P#A;H%U\>=(T318/@XG[,WAWPA\:+[]H?\ 9F=O&?A2ZD\,^ M$
M^(]EXP_I5TS5=+UO3=.UG1M2L-7T?5[&TU32=5TR\M[_ $W5-,O[>.[L=1TZ
M^M9);6]L;VUFBN;2[MI9;>YMY8YH9'C=6//^/O!'ACXG>!_&'PY\9VMWJ/@_
MQYX8UWP?XIT_3]<UOPW>W_AWQ)IMSH^LV5MK_AG4M'\1:-+=Z==W-NNI:)JV
MFZI:>89K*]MYU250#^./6/!_QW\=?L8V'CK]EC2OV\;G3/'?_!*+]C*S_:0F
MT33/VT+/Q;\7?VLM5^+7[+\_PX\4?".[N[&/XC>-/$'A7X ^&_VC])^,'C'X
M+ZG+X1C^%_B7X0:1XKU#6- 7P-%H?Z=Z-\'I/ O[9'BKX'7_ ,-?V\-"T?PC
M^TA^S7\<_P!@GQ_\(=(\6ZY\('^!.N:5X"\1?M$?#CXF_M.^*/"OCJT^&^CV
M'QIM?VMO$_[1?P:^//Q.\#>)OBY\&?B;X)^'_P '-&\7>,/^%#^'/#7[5:)H
MOPK_ &4?@#IN@:#8ZUX;^"W[._PI@T[2-+M!X_\ BAKOA[X:?"[PLL-GIUA!
MGQO\2_&]YHOAG1H[6QLH!XG\6:P;:"SM8M2U":**7S;4?VV?V=M*^#7[,_Q]
MO/%>OCX6_M>^)?V>?"/P'\0VGP\^(6IMXDUW]J9]#3X*0>(-/TOPQ>WWP[L?
M%#^(](AN=:^(D'A;1-!O;VWTK6]1L=7NK/3[@ _GINK+]K+P5XT\<>)O#OPT
M_:<^.7P7N?B?-\2?CM\0=!^ ?[2/P3_:XN_@WXE_:YM=6\8?LZ_%/X&^/?"G
MC+X._MC^/OA[H7B7P=>>!/BA^SCI>H:=\7OV-_V>?B/^SSXK\ V/P]\??!I?
MB+[_ *A\&&\8?&;]AOP=/X<_X*(>)/V*=:\/_P#!3F[\8:'\0M _:,\##1_A
M9XY\.?#[7OAEX!\6_#_X(>!OA9K/PF\!Q7LOQ0\%?LO?!+XL^'[#XK>&_A;#
MHOPL\.Z+HVD3^'/AKHW](NY?[R_F*KW5Y:6-M<WM[=6UG9V=O-=W=W=3Q6]M
M:VMO&TUQ<W,\S)%!;P0H\LTTKK'%&C.[*JD@ _DK^'VA^,O"GPRUKXJ?%_\
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MO+7/"7P470O!7Q;^$_P=7]F"?X,:Y\8KR]\!^%?A#K7QC3QEKMG/<?M"Z?\
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M_;N\&>$O'/[8OCWX>_M4_P#!!OXO^(?"/PW^/NK_ +1?QP\77W[6<5Y^T/\
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MT\4V/Q0EU*TL_C#X6\;ZVXOK3[ _:V^*%_\ $OXY^)-+^,&N?M P_%_X:?\
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M^(_$%YIGA/PG%X?\+P:MKVOZ\VCR:_KVM:I?_0/^?SZT ?@!_P $]K^YUO\
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M7XHDNM7T:]LM4L?"5UKNH>&9'TYO%%KHT6LZ/)? 'T#1110 45R?AWQMX?\
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M\(O!.N_$#Q+\&_BG>?LC?&+X>>$KC1-*UGXI? _]N6_\,?"KP)H5]>WYCO\
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MQR(X#(Z,"K(Z-E65@Q#*P(()!!% 'X\?M&?M+_!5?CO^S_X=_P"%T6/P1_9
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M_P#V>_\ @C1X6^!OQJU?XL^/?BK\&OV_]2^,_P #?%7QJT[QE=?%3]JWX6?
M2#Q=X=^&WCW7O'NLZWXR^'OBC2OB1J%M'KG@.R\3>$-#T#7_ !1>^(/%7A4>
M(+O^UT_K!\:>.?!'PWT5/$_C_P 4^'O!7A^;7O!WA)->\3ZK9:)I;^(_'OB_
M1/ 7@703J.H306_]I^*O''BG0/"OAVR:43:EX@UW3M,LDDN[Z&)ZOA+XC?#K
MQWJ7C?1/ OCCPAXOU;X:>*I/!'Q&TSPKXCTG7;SP)XW_ +)TOQ%/X1\8VVE7
M=U)X<\51Z)KNBZW<Z!K"VFKPZ9K6F:A-:);:E:RS '\M?Q&_;2^-VB_LEZ]\
M9/@A^V;XV\9Z]J__  1Q_:S^/'[7VKWOBKX::JW[+'[>?PR\*_!^Z^"<<GAG
M6O"^M7'[-'Q4^*7Q<\2_&7X 2?LI73^&=%U-OA5XAC^'OPX\/?%3X3?$SQ5K
M'ZS?L.?&'Q+KG[<?_!1;X$7'[1>N_'[X;_#O1/V-?BY\+YO%?B'X>^)M3\./
M\??A=XTU7QLGAK5/ ?ASPU;1_#_7F\)>$/%?A_0DM;C0]$N?$6H7GADV&B>(
M;/3X/UB6*-6=E15:1Q)(R@*TD@C2(22$8+N(HXXP[9;RT1,[54# \6^+?"G@
M+P]JOB_QOXDT3PCX5T&U:^UKQ'XEU6TT70])M \</VC4-3U&>WL;2)II8H(V
MGF023RQ0Q[I941@#^9;XL_%R7X3?MV?\%%?BMX6_::O_ (0:AX)_X*/?\$1O
M!7B'PKIWBGX6Z?X.^(/@[XUV7[/'P,^,/AKXG6/BSPSK&NZEHUK\$?&7Q@U:
M.TTWQ!X?B\+ZCX6;XD1"VUOX=6^LZ5B>$?\ @HS_ &WXY^(NI?#?_@H#/X-T
MSXM?L7_\%9_$%IXG_:)U;POKVJ?!C]I3]EWXK? 9_@SKOCO]F:S\!:I:_ #Q
M'^S?\+?BA\6-4\4? KP;/K6J_$;]G'X<^%_C]^T?\-;#Q\OB.YM?Z.O#W[2'
M[/\ XM^'GA+XM>'/C-\-]7^&OCWQCI7PY\'>-+3QCHW]@>(?B+K7C9OAII_P
M]TZ]>\C23Q[)\1HY_ ,_@Q@GB:Q\:6E]X7O],MM;L;RQ@]K !&1T('/()Z<Y
M//0#GJ<#- 'YE_\ !+GXTZU\:/A7\<[W7[GQ5)JG@+]I'6_AX]E>_'C0?VJ_
MA3IUAIWPD^#/B'2YOV;/VH+"VLO%OQR^!OBG3/$]MX_L/$?Q>LM.^+WA+XB^
M,/B/\*_&.E:4/A_INGV_YE>"?^"A-C;_ +/7[17[07Q*_; ^.O@7]JOX8? ;
M]M5/VO/V1_AOX/\ AS\:?%O[)OCKP!X[UJ+X7_%/1O@AXYLK#1_A]X<^ ^CV
MMEX%^$NM>(K?PKX"_:I\-^+/"OQ/^.][XIN]!\8>/-$_IGBAB@01PQ1PQC.(
MXD6-!N9G;"( H+.[,Q !9F).2<T_ X]LD<GC/X_@/0<#CB@#^5_P!_P43U_P
M?\<)O"EM^V!X#N_V<OAA_P %1/V=_A_XD\7W'[0_ASXZ>"?#O[&O[37_  2U
MUSX[Z&WC#]I#XA6&G:[KWPM\<_M<KI5M\(/C#XXN;#6[SQ1<R?!WP'XZU70H
M+?PT. UO_@H#\>)/V;/@Y\1M3_:;NO'=QX7\1_\ !2S0/'GPW\#_ !:\#_!#
M]M?Q#I_PP_;_ -?^#GP+^,_P+\%>)O!NF?"G]K[QA\ _@#X4UGPUKO['7BNY
M\":U\3YOB/X.\6);^,_B_J'PJCA_K>V)M5=J[5*E5P-JE"&3"]!L95*<?*5!
M7! ICP0R,C21)(T;B2-G4.8Y%5D62,MG8ZJ\BAUPP$C@'#MD _F=\4_MJ_'R
M]NOVJ?$/P9_:1OM;_;J_9TO?^"HGA[7_ /@FK;_!WQC\0?&'B7PW\+-+^,/B
M']B_QYK'PWD\:P:OX*^'L7A?0?V;/$OPT^/WPW^&FF>#OVEKWXS6/P?UR^\2
M?$SXP^#M1\!?0W_!/CXJ_L_?$K_@H[^T3K_P'_:U3]K'PGX]_P"";7[!_BWP
M[X^UKXH>#_B!XFUDZ5^T7_P4!L?B));CP[IGA^?2X],\6^(-/USQOX+30=,T
MOX/^,/B*GPYT7PU\-?!-MX!^&7A?]W]B^G. ,Y.<*25!.<_*22O/!)(P2:;Y
M<: D(JC)<[1@%BS2,Q ZDNS.20279F^\Q) /Y#?^"G'B/P7X<^*7_!<O3?&7
MQ4U72?&>H_L^?\$MI_AMX-\9_%_7_L@^''_"[]5NO&&M> OAEXJ\27'A-O"G
MASQ_?1@ZYIOA6YTCPCXO\7^(-.MKC3=0^(OB6Q\1_2WQ%_:[^*GPN\4?&KX:
M:)^V7XA\3VWPN_X+N_\ !/+X&Z?K7B;Q)\'=1\9:E\ ?VDO!/[(_Q(^,_P (
M?$5YI7@_284^'@\:^/OC[;:/'H.E>'M8\)Z)X8USP19:_%X2\ WN@:;_ $O8
M4Y(SSU()4\9&.,$8)/'8DG&232[1[]<_>;V]^G'3H.<=30!^(O[%G[27C?QQ
M_P %"/CA\'?%OQ=N/B[86.F?MB^(/#OBCX3?%[0/'7P:.F_#S]K;PE\.M*^$
MOQV^!>M>'_#OQ"_9!_:7_99\)ZAX7^#?A;3?"5IJ/PI_:F\+3?$_XT^(O%/B
M'XJ:+JLEKS^M^*/!O[,7_!<GXK?&;]J7Q-X6^'W@']I']@CX,_"G]E/XX?$?
M4?#_ (.\ :1JWPE^+/Q#\2_&W]FFT\?^(KW2K&S^('B34/%7A/XT6'@^2>2?
MQ=X>M;_4=,FNG\%:E9Z=^ZZ0PQO)*D4:22A!+(J*))1&"L8D<#<XC4E4W$[
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ML="^'5I\)OCYI7Q1@T7XC6WB_P :^-=!UOX<_P! @ 4       <  #  '0
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M!OBCP)%:OXOT'4]%M?LS:N -HPN-JX^4;<%<#I\I *\?*0",$"@#^6[]K/\
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M= \/_!^\N_"1^$GACQ)IDWC*&X^*6B6-OX/MO'B?$77/#OCG6?!NN7&H>/\
M4?"5YX;@TA8O"%MK&EVVL* >C>'M)ET'0-$T.;6-7\0S:-I&FZ5+K_B":TN=
M>UR33K.&T?6-<N+"RTZQGUC4VA-[J<UEI]A:2WL\\EO96L+) FQ110 4444
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MEX_D_:<_9&_9A\,?&CQ%^SGX1_:+\$_M.^)&^,?@;PK\.?$7C?7OBC\&-/\
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MP6\/_L^_$^\TCX*_$C]D?XC_ !J_X5W;>/M>^ VF_ SQ_P#$_P !^.="M9?
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ME8?$>R\.W/[-_B'Q=967QBT+P'J'[-M];>%)OBG]K'Q9^T/XM@^-'[.'B_\
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M?&KXJ>&OAE\)KD>/])UWP%\*[OXX,3'>:AHNB"7YTN/VH/B]XE'Q7^%GA_\
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MOA+Q$G@[XGQ>%?#6F?!;XK^*;!_'7P?^&O@'PSKVA6-?T=7'PG^%MWX3\0>
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M.JZGJ<%U?:A=SS 'KE%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<6]W;P7=K/#<VMU#%<6US;RI-!<6\R+)#/!-$S1RPRQLLD<L;,DB,KHQ4@D
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M0#_:<_\ F"H _;^BOQ _X?\ O[%?_1)/V_\ _P 0#_:<_P#F"H_X?^_L5_\
M1)/V_P#_ ,0#_:<_^8*@#]OZ*_$#_A_Y^Q9_T23]O_\ \0#_ &G/_F"H_P"'
M_O[%?_1)/V__ /Q /]IS_P"8*@#]OZ*_$#_A_P"_L5_]$D_;_P#_ ! /]IS_
M .8*C_A_[^Q7_P!$D_;_ /\ Q /]IS_Y@J /V_HK\0/^'_O[%?\ T23]O_\
M\0#_ &G/_F"H_P"'_O[%?_1)/V__ /Q /]IS_P"8*@#]OZ*_$#_A_P"_L5_]
M$D_;_P#_ ! /]IS_ .8*C_A_[^Q7_P!$D_;_ /\ Q /]IS_Y@J /V_HK\0/^
M'_O[%?\ T23]O_\ \0#_ &G/_F"H_P"'_O[%?_1)/V__ /Q /]IS_P"8*@#]
MOZ*_$#_A_P"_L5_]$D_;_P#_ ! /]IS_ .8*C_A_[^Q7_P!$D_;_ /\ Q /]
MIS_Y@J /V_HK\0/^'_O[%?\ T23]O_\ \0#_ &G/_F"H_P"'_O[%?_1)/V__
M /Q /]IS_P"8*@#]OZ*_$#_A_P"_L5_]$D_;_P#_ ! /]IS_ .8*C_A_[^Q7
M_P!$D_;_ /\ Q /]IS_Y@J /V_HK\0/^'_O[%?\ T23]O_\ \0#_ &G/_F"H
M_P"'_O[%?_1)/V__ /Q /]IS_P"8*@#]OZ*_$#_A_P"_L5_]$D_;_P#_ ! /
M]IS_ .8*C_A_[^Q7_P!$D_;_ /\ Q /]IS_Y@J /V_HK\0/^'_O[%?\ T23]
MO_\ \0#_ &G/_F"H_P"'_O[%?_1)/V__ /Q /]IS_P"8*@#]OZ*_$#_A_P"_
ML5_]$D_;_P#_ ! /]IS_ .8*C_A_[^Q7_P!$D_;_ /\ Q /]IS_Y@J /V_HK
M\0/^'_O[%?\ T23]O_\ \0#_ &G/_F"K]/?V8?VE/ /[6GP?T/XV_#31?B3X
M?\):_J7B#2K+3/BS\-_%GPH\;0W/AK6;S0[]]0\%^-=.TO7["VFN[*673[FY
MLTBO[-HKJ!F1^ #Z"HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OPR_X*,_$K5/!/\ P47_ .";?PXU;XJ_M">"/@7\;/A%
M_P %!=:^./AKX(^+_CG:ZAXDN_@?X%^!.J?"O6+/0O@O->^+[/4/"&L>._$5
M\K>$--MO^$BFOK>Q\70^(=/M;#3X_P!S:^)?C'^Q[<_%O]L/]DS]KMOB8/#V
MJ_LBZ)\<_#GA#P/%X,34]-\6:1^T;HO@?P]\3$\5ZU+XHM+M+VTTWX?:!-X#
MNM#LM*C\/ZH^I7/B&V\:6-U#I=J ?FG^S;_P4I^.OP4_9;^"'A?]M73!XF_;
M"^)&A_M3?%OP7X<^-^O?"[]D#X@^,OV8O@E\5['PY\/?%GQ5T/Q38>%?"/P[
M^/?Q/\-^._AIH/@GX5'PMX4C\0^*=3N[GQE/\-=#\+_$OQ3X1]BTK_@KMI%E
MXA_:7^*/Q"^%7BGP3^Q_\%_V#OV-OVR_#GC#5K;0-+^,%ZO[2\G[2QN/"7BS
MP+JWC6TDTCQ;J^N_"CPK\)_!7@)K.TN-+^(6F>+M2\5^,1X6\4^$+NQ^L/VJ
MOV,_&/QJ^+7P<_:0^ O[0^M_LN?M'?!SPSX]^&5MX_L?AOX/^+7A;QY\%/BG
MJO@GQ!XZ^%_Q!\ ^+)M*_M:T_P"$F^'/@[Q7X+UW2O$^B7_A'Q'IEQ=&'6M/
MU34-+G\@^(__  2U\,_%S5?CEI7Q'^/OQ4\8?#+]I/\ 8Y^$/[*WQEL-;L?"
M\_QB\2>)/@9XG^.?BWX=?'O2OB];Z?:Z+X5\;Z7XF^/_ (K\;OX?T'X56OA>
MS\=^&_A_/X8M?#7P\\/7OPRUH X:?_@L%X*TN'6]*N?@3XT\=^,=#_:5_9'_
M &=2OP'^)GP8^*7POUJ7]L[Q!?\ AKX6^-/#7QDUCQE\//"VMP>'?$FBZWX!
M^*'@RWM$\;>"?B':Z<LVCWWPGU_1_C#<^T_MU?$;XLV/_!*G]K;XXW>B^,/V
M<OCS\/\ ]BG]H#XT:1H7AOXDQ7_B+X3?%KX?_!3QIXP\/0+XW^'NI6^@>,8/
M#?B?2K*Z>+-]X5\20VZ0ZOH]U9RSV X?4/\ @GA\=OB1X(^'FC?M'?MW^-_C
MMXW^''[0_P"S#\>-'\5W?P5^'WP_\+2_\,G?$.[^)_@/1#\-/!6IV.BV7B'Q
M_P"*KFW/QL\=Z?J5M=^,-(TC0]&\(:)\.;+2+%(?MC]J[X$O^U#^S;\</V;9
MO%G_  A&A?'WX5?$'X,>,?$MOH*^(-7TWP3\4/!^M>"/%<WAJUFU?2;&S\3I
MHVNW4FA:KJ:ZQIFG:A'#<7V@:O K6K 'Y&_\$ZOCO\4/BK^V[XQ\&_";XN_%
MGXB_LJ?#;]C;X1R_M.^#?VB[_P 50_%'X4_MV>/_ /A#_%_@T>$?#'QZATC]
MJ32? GQ.^!5[K'CBYU'5_#Y_9RUVZ-C)\&M>N/$&G^.M"T3Z]\.?\%./ %W;
M?LY_$OQS\/->^&'[+7[85_XHTS]F[]HOQCXK\(:9IVMSZ!\.?'?QA\+:I\4/
M NHWNFZ[\,O"_P >?A+\-O%_Q-_9\UNPOO'EQX@\*Z=9Z=\7M)^!_P 0?$7A
M?P)K6U_P[Y_LKXS?LX_M+>!/C9K7P[^/OP4^$5M^SI\2=?\ #?@?0)OA]^U!
M^S]I]Y9:EH'P^^,OP_UN_P!4U&+5?!FL:>FO^!?''@GQQX9UWPWK.N^,X@M]
MX8\21^&=*\\\!?\ !*OPEH7@?X,_L[_$+XIWGQ2_8X_9A\2^,=<_9V^ ^K>#
MFL?%&EZ-XK^&7Q7^$>B^ /C/\7[OQAK]Y\6?!?P?\$?&;Q7I/P5;PYX.^$_C
M3PW+H7PZU_QOXS^(_C+P:OBC5 #Y8\0_M<^.?C%\<OAY\7_%'PJ_:K^%'[-O
MQ<_X(X_\% _C_H7@7P3^T'8^%/'?Q.\"Z+\1_P!AR[^'_B;3/!.A_%/P)HOP
M&_:Y\(?#WXC>,-5T+Q)=^*-*O_ VB?&?P5I]A\<[3QEI7Q%\(?"WW^+_ (*3
M'P3X!_9P\'?"#]ESX\?&G6?B-_P31F_;O\%/XE^,OPOCN)OAO\.+/X+:9K/@
MCQU\4?BI\1[CQQXB^+%O8_%CPS+K?C+Q%HE]8>*?$FL:/=2^*-674/B!K_P^
M9X!_X)7_ !(\,Z+\.?#/B_\ ;?\ B#\1M!^"7['_ .T_^PS\)%UCX/?#/3]=
M_P"%#?M!#X(6GA^7XM^(K4SWOQ(^)GPWTGX%>#;.\\<:!'\-;?X@7GA[PIJN
MJ>'=&N5^):?%?TOPY_P3;/A=O@?)IWQNO)YO@7_P3G\<?\$Y]!FO_AY82OK'
M@KQRGPF-]\3M66U\4V4"^-;6X^!OPYFATRTAA\-.A\8P_P!GQCQ!H[^%0#5L
MO^"D7A[XD^&K'Q1^S1\&/'WQ\@L?V2O@;^V]XZT2TUWP7X%\3:!\#?VA]&\:
M^(/A3X2\/:5X@U:Y3Q1^TAXVT;X?^+M8T#X5:I=^#O ]KI'A^YN?&WQF\$7?
MB'X=:?X\^X?@Q\7? /[0'PA^%_QU^%>M'Q'\,_C)\/O!_P 4/A_KSV-]I<NK
M^#?'>@:?XF\.7]QI6J6]IJFDW=QI.IVKWFDZI9VFIZ9=&:PU&TMKRWFA3\Z/
MA;_P3/\ %G[/"_#>Y_9P_:?OOAEK>D_L9_!#]ASXPZSJOP;\+^,Y?BA\._V:
M]/UK0_@/\8O#EO)XDT&/X??M+_#70/%WCK2]-\8ZL_Q(^#^N)XK8>+O@+XBL
M_#GA*PT/Z1_98^"'Q%_9QUK6/@=H-_I<?[&7PC^"O[.GPN_9:\)76A:?#XT\
M'CX=^"[_ ,'>-=/U?QI:>*-6U7X@:??66C>#M8;Q!XN\/>%];'B/4->L;6WU
M33[-=<U, ^T:*** "BBB@ HHHH **** "OYO_CK^TAXJ^%'[=_QI^#O[<'Q-
M_:7_ &48/C1\5?A78_\ !,K]K3P-XX\=Z;^Q)XH\'R>&/AO'+^RO\0_#/AJ_
MU?X6>'OC3XP^(NE?&,>/O%?Q[\'_ /"P-;\'>+=:O/A7\2_A?8^$/@!=1?T@
M5^:7Q\_8 \6?M%?#SXT?LZ?$;]H4>*/V4OVBO'&K>*_BG\,?&/P@T+Q3\1-$
M\/:UXUT?QGJ?PO\ @G\6)/%6FZ/\//!-_=Z*TJ:QXN^%OQ5^*G@_7?$WBKQ+
M\)?B5\--0L_A@GPO /S0U_\ :,T_PC_P4+_X+$>$_CIXR_;U\=?"O]FSX>_L
MD?$SX'_##]F_4OVT?$D'A&[\;_L^_$7XB?%W2(-0_9V^T:#X;D\=>(-!T*X\
M.V7Q?U_3O#.DW5M<0^$'T+P]#XAB7Z2\'WGQ0_:&_P""@?C;]@?Q!^T#\;5_
M9S_X)U_LA?LP:A\4M0\.^._%'PC^/G[6'[2OQQ@\2MX6^)'Q1^/'P7U[P5XT
MM/!'@[P#\+KG6M7\ _#RY^%UCX[^*OQ \07_ (Y@\7>!M%\.^&+'ZG\*?L,_
M$[X;_M7?M9?M:?#7]I'2M$\6_M?R? ^W\?>$O$7P/L_%'A/P_H_[/'A'7_ _
MP[L?"C0_$C0->AO;W0O$=_-XWU+5]8U6/6M9$-YX>T_PAIZ'2&R)/^">'BKP
MI\7OA?\ M5?"+]IOQ3I'[7_AOX)S?L__ !P^*_Q<\%0?%+X;_M8?#Z\\4W7Q
M!2?XR? _PEXO^#>E^'_&'@?XB:IXA\1?!OQ)\%?%OPK7X<:#XDU3X63Z;XJ^
M$EIX<\#Z  ?(7_!0C0_BQ^Q[\&?@Y>VW[4'[3'B[PSX__P""K_[(/@_3IM/\
M:?%#5/BKX<_95^.GCWX3_#[XF?LY2:G\.;QO'WQ;6"#2_&T'P[\40:7J7QUC
MTSQ!HT47BCQ5\7AXB^(WC;EOV:OCO\=?B]^R/_P5E^+/AGXP?$OQ3^QUX6;X
MPS_\$Z?B9X_\1:QX:_:T\,S?"+X3Z_%\;M(^($\47AKXJ^'?"GP^_:6\+:QI
M?P<TC]H:PL_VA;KPC9:K9_%VUU?PI?>$&U#]'?VA?V(?$G[17A#X.:%XK^/6
MK1Z]\+_VJ?@W^V+J>O7/@Q=5TS7?BE\"/%GAGQK\/?!?ACPLWB^QL_AY\#[#
M5O#-MI]_X)TR]U;QEK&C8O\ 5OB=>_$/4_&/Q"\7\)XI_P"";%K'\0OVM?&O
MP9^-^O\ P:\-_MU?"S6_"'[3WP8LO!FD^*O@YXC^+FO>$3X U']J;X>>&+_6
M--U;X7_';5?!?D>'O%UWI'B+4? 7Q)&FZ-XC^)O@;QCXXTJU\5J ?(__  3<
M\>Z;^T!\)O\ @GCXE_X6M^W[:?M#>,_V./"O[07QA\;?$6#]K*#]G/XG>,=4
M_9S\%^$/&^DZBOQ[TZS^!WBVUUCXE_'FP^-GP^T_]GVXM8IK[X6QZEX8UK3_
M (9Z?J>D:SSA^$7Q#U#_ (*>?$#]@[3?VNOVR=*^'ND?\$B_AK\8/#OCF3]H
M_P")>J?$#3/VDO$O[1/Q<^#]_P#M"W<MWKB^&M8\33:!X1\/ZA-\-KOPZGP&
M_M:UN9+/X56%O?7$+?H;\!_V,OC%\#_A?^R]\ [']K77;CX&_LOZ!\(?!NE>
M'?#/PJ\/^#?'GQ)\"_ WP3;^$O O@KXA?$?_ (27Q!(NA:C>:/X4\0?$(>#/
M#?A'4/' \/3>$[B^T[P-XG\5^&]9ZM?V.]3M_P!O/Q)^WC8_%*UB\5>(/V6]
M(_9,7X>W/@)KGPQ:^ O#'Q$\8?%OPSXBFU./QI::S=>,[7Q[XSU)=8NXI+'0
M-6\'10:!;>'M(UQ1XO4 _/3]HO\ X**:C\+O^"HO[,OAS3OC;\-IOV;6^+U_
M_P $Y_C1\%+?Q);S?$Z#]I7]HWX?>"/C5\)/CA_PC&G:U<+J_@;PMXET3X8_
ML\6NM:EI5C+X,\3_ !6^+MI=2S.\4*_//_!2W]J[2_V<_P#@I!\1]!^,/[17
M[6WPD_9NL/\ @DOXF^/=M:?L\Z]\4-1E\(?M)0_M0:'\)O /Q*M=/T>'5OAQ
MX79]*U:#PE&/CLVC_LN3ZWJ6EWWQ9AA2:76H_P!4/B?_ ,$Z] ^,7[ OC+]A
MCQW\1$O#\0XM7O\ QE\;](\!V7AWQMJ7Q$\0_%FX^.VO?&_3]$T7Q%::#X?^
M,>I?&FZNOC -:T,67@O3/B7<2:SHO@'3=!CM?"MM6A_X)Z7'B;]JZV_:J^-O
MQ:T3XTZGJG[$>M_L%?$KX;>(?@QH&G_#WXI_"#Q3XZMOB'XNUWQ1HR>)]1MA
MXT\7:W:#3/$%K;VQ^&MSX5OM5T2U^'-E)=P:A9 'R#\8_"'_  4V@_X)V_L>
M?M0>+?&'B[4_VY_V6_"GPT^+_P"US^S;\$O&5QI7A#]L+P+H<.FZG\=O@R\7
MPOU&T\)67QSOO!UK<>)?!WB3X4VFJ>!K[XP:3J?P_P#!^D:]\+/&NEK9?:W[
M(_C"U_; \9R_M\>!?B+\5D_9L^(/P]\/^%/V:_AQ?>(?''A[P7X\\/VKZA?>
M)_VF/$WPQUY-%ET+7/&VHZDO@'P'X.UG0!#I?@SX>6_Q9FN;_7?BY:Z5\/N]
M_9)_9,\5_L<_ JZ_9U\!_'CQ#X^^&_@R232?V;H_C#X9B\7>(?@5\-86DA\-
M_!^Y\2:1XB\+ZI\3O /P\TB.PT#X=/XDFL?&.A:'9QZ/JWBWQ%I%KH>GZ'U7
M[$?[+\'[%W[+GP>_98TOQO=?$+PO\#_"6G^ O!?B?5-!M_#_ (@N_">CQ+'I
M4?B:*QU._P!,U'7H2UP+K5M+M="LKN VJ+HEO/!/=7H!]64444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^&7Q1^$WC#
MP3^WQ^P5^S?>?M,_M7:_X5^/OP$_X*">/?C5J4?[17Q8\,7?BWX@_"K4_P!F
M"X^''B'0-/\ #?BNPTKX=:7X&D^,/C6U\/>#?!-KI7AB[TM]#LO&EAXRFT6*
M]G\:L?VOOB9^PA^U5^WS:_$V\_:(_:G^#GP/\ _\$K-$^(7CGQ%\2-"_LSX8
M6/C_ ,+^,_A5X^^,6A_#WQ#XBL-*D\:?$/Q0N@_$#QWX"^#/A#2;7Q*^D^(=
M8OKRS\0#P9H'BO\ 6_XE?LL:K\0_VN_V=OVKQ\2K;1;K]F_P5\:?A]X8\!KX
M'.H67B#PY^T')\*I/B5)XA\0/XMM;O\ MJ$_!_PJW@B_TK3]/LO#[S:P=<TK
MQ?'=P16GS7^T'_P3!M/C]J?[=%]??'76_"UO^W+H_P"RUH7B.VTWP#HFH2_#
MFP_95UR[UWPL_A:ZOM9"ZK>>+9[^[@\4S:_:W4$<)MCH5KI,D,KW(!TWQ=_X
M*6^"OA)!\=_B+=_"[QAXB_9G_9/^,OASX&?M-_'G2-9\/,G@+Q-KFD_#G5?$
MOC3PAX"66?6/B-\*?@:/B=H=E^T-XDL]5T+Q5X(U'3/%FF^!? 7Q4U+P9XLL
MM%\OU7_@K7:Z?X^U'PY!^R+\>[SP=HG[=&N_\$]]2\9IXK^ 0U&_^/2^#;#Q
M)X!'ACP=!\5[NYO_  GX_P!4O+?2CK_B+6/"4/@S2M>\*>)/%:62MX_TKX<=
MEXF_X)EP:WJ7[6'@K3/C=?\ AW]ES]NWQUI7Q4_:H^ UA\/-+_MW6?']YX8\
M&>"_C);_  D^+4/B2TOOAW\./VFO"GP\\,^'_CIX-\8^$/BWKTMCJOQ"O?A+
MX\^$OB/QE;Z_X>I3?\$OXYM1U'46^/.K!M1_X*9:1_P4T>(?#O1ML7CS1O#V
MC^&;?X3HQ\0%C\/I=/T.QEFU)@?&!O7NY8];CMY8+6U -;1_^"E2:W\ 9?BN
MOP,U;PQXR\._M-?%_P#92^+?A[QY\1O"_AKX.? 'Q[\#;7XD:MXZ\=?&W]HZ
MUT[6_"O@SX(W.G?#==#\(?$F+PQJBZ[\3_B3\)?AEJ.A^'];\6W]SX?X[0O^
M"O?PG^(&@_L?ZM\+OAQXEU[6OVR/@%J'[1GPS^'?C3Q;X+^&OQ"\3^#]%U#0
M=*\2^"/A3IVL7VH^&OC7\;O!_P#;S>,/%/PJ\%>*UU.W^&'AWQ%XOT*_\1:M
M/X+\(^,T'_!*R[LM;\%^*-$_:0UBTUWP7_P45^+W_!0>R@UCX6>&_$OA";7O
MCQHOC#PSX\\$OX*U/7_['FUGP;H_CK7]0^ /Q2U7^U]<^%'C)=-\3:MHGQ"M
MX=1T35?+(?\ @C)>WW[(WPH_8@\<?M/1?$;X!_#SX?Z7\.)+#Q7^S]X1;QIX
M8'A;Q9KFK>!?C)^SQXVTOQCIVJ_ C]I?PCX;U:+1[/XLW2?$S0KG7UU'Q&_P
MXATF;0?!WA@ ]R_X+ >._%'PN_9O^%GCGPAXW^*O@6_?]LG]BWX=>(;_ .$6
MN?$BT\4ZM\-?B_\ M._"SX<?%/PU8^'/AD]SXF\5ZGXC\!Z]K>C:)8Z#H>L^
M,[34[V*X\ Q6WBJ2RF;)\)_M#?!7X&7OQL^+'AK4OV\]?\*>%+']G;X36WP8
M^.VE_M 6^M?$WXT_'_XM2_#[X*V?P+T/]MR7P+XNL=?\>>./%OA_X4:MXTU/
MQ?X=^ 4E]/82>(/$W@UOAK\2_$B?5/[:O[*6I_M?_#SP1\.[;XJ7'PHL_!GQ
MJ^#OQVCUK3?!>F>,-7O/%_P&^(WAGXK_  ZLHTUO5;72+30E\:^%-*N/%-I/
MIFH7>NZ1')I5E?:'YT]W-Y!\=_V%_B_^TQX7U[0/BO\ ME^-](N;+3_ ^M?"
M&7X0?"OP%X(T+X9?&SX7?&_X9?M!?#+X[:EX=\83?% ?$3Q9X(\??"#P?IVE
M:!KVIV?A!_ ^I>/O#]SHTFI>,6\0Z6 <GJ?_  4_T;P/\0O%_P *?BA\#/&.
MC>-_AU^U7^QM^R-XX;P/XO\ "/C;PC;>.?VW8M*NOA=XQ\-:WK;_  _US7OA
MYX=M_%?@VU\>76H^$O#GC/3]8OO$,'A_P3XDT70+#Q!XEZOQ]_P4O^$_@%_B
MCX?UW1/^$7\?>!?VQS^Q%X;TOXB^-O!W@/P+XR^*$O[-GA']K:+QE?\ Q,NK
M[5-*\#_";2/@-XLE\9^+=?US2I_&5G=^%M>\$>#? 'CWXBZK\/\ PAXW^"O"
M?[$?QA^/GQ]_X*-^'?B=XQ\6^"_B/:?M#_\ !,[]HOX,_M+R_L\>)/#?P<\8
M_&?]E3X0?#+7O^$D\&_#[Q#KD.D>-OA99_$SP7?>&/%'P_TWXRZYXCL-'N[F
MP_X6=%JR:7XGC^H/$W_!*SQ%KFG?%;Q7IO[97Q<\._M&^*_VP?#/[<?PG^.^
MF> /A7;CX+?'#0_V7O"7[)VKZ?!\/M/T+3=(^(?PK\;?"G0]:\&>,/A]XOU>
M2+5_ ^LV.D2ZO_PF6F:M\1O% !R/P4_;#?\ :G_;<_8G\;^#7^+7PY\*>+/V
M7O\ @IYX7^*OP;UWQEJ-]X&OOB;^S=^T+^PGX&T3Q7I^G^$_$FK_  ?^*NC6
ML7CKQYJ_P>^.'@U-5C\9?#/XAV-_::G8?VA=>&]&^NOV%?VZ/#7[>'@F7XI_
M#KPE;VWPJU;P9\-_'7@GQ[H?Q$\&?$+2-17XD0^*[Z\^$GCJ'PO.;SX:?M*?
M!;3]!T*+]H?X.ZG%JUE\.==\<^'-%T7QUXY3[=J-M#X+_8T\;Z3\;/@/\?\
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MW_Z3? #]B/XR_ +X,_LV_LXZ#^V#XA;X*_LV6/P>\-Z-:Z#\(?"/ACXF>./
M/P3.D_\ ".^ ?&7Q .N:WI8T'Q3:Z!I.@_$:Y\.>!M!UOQ1X6&K:-::IH<VM
MW^I-#J_[!?C/QS#\&/ 'Q<_:&C^*7P*^!7QZ^''[2_@OP_K_ ,'/#Z?&\?$S
MX1>/)?B?\,= F^.3>*;S1]*^%7@'QA_9>G>'=*\)?"'PU\6[WX:^&M'^&OC?
MXW>,]#UCXCS?$  _)/X]_$[XS>'/@W_P5@USP[\??V@M$UWX&?\ !5C]BO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3 '( !ZYP
M.OK2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>26
<FILENAME>aim-20240930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa+GybP9z5Z8mekhvWB5bRmqDyAgDfrYvy7ePrj2ESkL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:AIM="http://aimimmuno.com/20240930" elementFormDefault="qualified" targetNamespace="http://aimimmuno.com/20240930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://aimimmuno.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/BusinessAndBasisOfPresentation" id="BusinessAndBasisOfPresentation">
          <link:definition>00000007 - Disclosure - Business and Basis of Presentation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
          <link:definition>00000008 - Disclosure - Cash and Cash Equivalents</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/MarketableSecurities" id="MarketableSecurities">
          <link:definition>00000009 - Disclosure - Marketable Securities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
          <link:definition>00000010 - Disclosure - Property and Equipment, net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" id="PatentsAndTrademarkRightsNet">
          <link:definition>00000011 - Disclosure - Patents, and Trademark Rights, Net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/AccruedExpenses" id="AccruedExpenses">
          <link:definition>00000012 - Disclosure - Accrued Expenses</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/UnsecuredPromissoryNote" id="UnsecuredPromissoryNote">
          <link:definition>00000013 - Disclosure - Unsecured Promissory Note</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/Equity-basedCompensation" id="Equity-basedCompensation">
          <link:definition>00000014 - Disclosure - Equity-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>00000015 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/NetLossPerShare" id="NetLossPerShare">
          <link:definition>00000016 - Disclosure - Net Loss Per Share</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
          <link:definition>00000017 - Disclosure - Recent Accounting Pronouncements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/FairValue" id="FairValue">
          <link:definition>00000018 - Disclosure - Fair Value</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/Leases" id="Leases">
          <link:definition>00000019 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" id="ResearchConsultingAndSupplyAgreements">
          <link:definition>00000020 - Disclosure - Research, Consulting and Supply Agreements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000021 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
          <link:definition>00000022 - Disclosure - Property and Equipment, net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" id="PatentsAndTrademarkRightsNetTables">
          <link:definition>00000023 - Disclosure - Patents, and Trademark Rights, Net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
          <link:definition>00000024 - Disclosure - Accrued Expenses (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/UnsecuredPromissoryNoteTables" id="UnsecuredPromissoryNoteTables">
          <link:definition>00000025 - Disclosure - Unsecured Promissory Note (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/Equity-basedCompensationTables" id="Equity-basedCompensationTables">
          <link:definition>00000026 - Disclosure - Equity-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/FairValueTables" id="FairValueTables">
          <link:definition>00000027 - Disclosure - Fair Value (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/LeasesTables" id="LeasesTables">
          <link:definition>00000028 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/CashAndCashEquivalentsDetailsNarrative" id="CashAndCashEquivalentsDetailsNarrative">
          <link:definition>00000029 - Disclosure - Cash and Cash Equivalents (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/MarketableSecuritiesDetailsNarrative" id="MarketableSecuritiesDetailsNarrative">
          <link:definition>00000030 - Disclosure - Marketable Securities (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>00000031 - Disclosure - Schedule of Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative" id="PropertyAndEquipmentNetDetailsNarrative">
          <link:definition>00000032 - Disclosure - Property and Equipment, net (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" id="ScheduleOfPatentAndTrademarkRightsDetails">
          <link:definition>00000033 - Disclosure - Schedule of Patent and Trademark Rights (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" id="ScheduleOfChangesInPatentsTrademarkRightsDetails">
          <link:definition>00000034 - Disclosure - Schedule of Changes in Patents, Trademark Rights (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" id="ScheduleOfAmortizationOfPatentsAndTrademarksDetails">
          <link:definition>00000035 - Disclosure - Schedule of Amortization of Patents and Trademarks (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" id="PatentsAndTrademarkRightsNetDetailsNarrative">
          <link:definition>00000036 - Disclosure - Patents, and Trademark Rights, Net (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" id="ScheduleOfAccruedExpensesDetails">
          <link:definition>00000037 - Disclosure - Schedule of Accrued Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails" id="ScheduleOfLongTermDebtDetails">
          <link:definition>00000038 - Disclosure - Schedule of Long Term Debt (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative" id="UnsecuredPromissoryNoteDetailsNarrative">
          <link:definition>00000039 - Disclosure - Unsecured Promissory Note (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>00000040 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" id="ScheduleOfUnvestedStockOptionActivityDetails">
          <link:definition>00000041 - Disclosure - Schedule of Unvested Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative" id="Equity-basedCompensationDetailsNarrative">
          <link:definition>00000042 - Disclosure - Equity-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>00000043 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/NetLossPerShareDetailsNarrative" id="NetLossPerShareDetailsNarrative">
          <link:definition>00000044 - Disclosure - Net Loss Per Share (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails" id="ScheduleOfAssumptionsToEstimateFairValueDetails">
          <link:definition>00000045 - Disclosure - Schedule of Assumptions to Estimate the Fair Value (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfPotentialLiabilityDetails" id="ScheduleOfPotentialLiabilityDetails">
          <link:definition>00000046 - Disclosure - Schedule of Potential Liability (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:definition>00000047 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/FairValueDetailsNarrative" id="FairValueDetailsNarrative">
          <link:definition>00000048 - Disclosure - Fair Value (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" id="ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails">
          <link:definition>00000049 - Disclosure - Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" id="ScheduleOfOperatingLeaseFuturePaymentsDetails">
          <link:definition>00000050 - Disclosure - Schedule of Operating Lease Future Payments (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>00000051 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" id="ResearchConsultingAndSupplyAgreementsDetailsNarrative">
          <link:definition>00000052 - Disclosure - Research, Consulting and Supply Agreements (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000053 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="aim-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aim-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aim-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aim-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="AIM_SeriesAJuniorParticipatingPreferredStockMember" name="SeriesAJuniorParticipatingPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_NotePurchaseAgreementMember" name="NotePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_StreetervilleCapitalLlcMember" name="StreetervilleCapitalLlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_TwoThousandEighteenEquityIncentivePlanMember" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember" name="RestatedTwoThousandEighteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_DirectorsOfficersAndEmployeesMember" name="DirectorsOfficersAndEmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AllianceGlobalPartnersLLCMember" name="AllianceGlobalPartnersLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_RepresentativeWarrantsMember" name="RepresentativeWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_MaximGroupLLCMember" name="MaximGroupLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_EquityDistributionAgreementMember" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AtlasSciencesLlcMember" name="AtlasSciencesLlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PurchaseAndRegistrationRightsAgreementMember" name="PurchaseAndRegistrationRightsAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ClassBCommonWarrantMember" name="ClassBCommonWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PlacementAgentMember" name="PlacementAgentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ClassAWarrantMember" name="ClassAWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ClassBWarrantMember" name="ClassBWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ClinicalStudiesMember" name="ClinicalStudiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ManufacturingAndEngineeringMember" name="ManufacturingAndEngineeringMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_QualityControlMember" name="QualityControlMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_RegulatoryMember" name="RegulatoryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AmarexClinicalResearchLLCMember" name="AmarexClinicalResearchLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AdvancedPancreaticCancerStudyAgreementMember" name="AdvancedPancreaticCancerStudyAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PostCOVIDStudyAgreementMember" name="PostCOVIDStudyAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_JubilantHollisterStierMember" name="JubilantHollisterStierMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AmpligenManufacturingAgreementMember" name="AmpligenManufacturingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SterlingPharmaSolutionsMember" name="SterlingPharmaSolutionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_MasterServiceAgreementAndQualityAgreementMember" name="MasterServiceAgreementAndQualityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ErasmusUniversityMedicalCenterMember" name="ErasmusUniversityMedicalCenterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_JointClinicalStudyAgreementMember" name="JointClinicalStudyAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AzenovaLLCMember" name="AzenovaLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AlcamiCorporationMember" name="AlcamiCorporationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ClassCCommonWarrantMember" name="ClassCCommonWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ClassDCommonWarrantMember" name="ClassDCommonWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PreferredStockStatedValuePerShare" name="PreferredStockStatedValuePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_GainLossOnWarrantIssuance" name="GainLossOnWarrantIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_GainFromSaleOfIncomeTaxOperatingLoss" name="GainFromSaleOfIncomeTaxOperatingLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" name="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants" name="StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_StockIssuedDuringPeriodValueCommittedShares" name="StockIssuedDuringPeriodValueCommittedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_StockIssuedDuringPeriodSharesCommittedShares" name="StockIssuedDuringPeriodSharesCommittedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_StockIssuedDuringPeriodValuePreferredSharesExpired" name="StockIssuedDuringPeriodValuePreferredSharesExpired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AbandonmentOfPatentAndTrademarkRights" name="AbandonmentOfPatentAndTrademarkRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ChangesInRouAssets" name="ChangesInRouAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ProceedsFromIssuanceOfEquityWarrants" name="ProceedsFromIssuanceOfEquityWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_OperatingLeaserightOfUseAssets" name="OperatingLeaserightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_UnrealizedGainLossOnMarketableInvestments" name="UnrealizedGainLossOnMarketableInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ConversionOfSeriesBPreferred" name="ConversionOfSeriesBPreferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ConversionOfNotePayableInterestIntoShares" name="ConversionOfNotePayableInterestIntoShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract" name="DisclosureResearchConsultingAndSupplyAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ResearchConsultingAndSupplyAgreementsTextBlock" name="ResearchConsultingAndSupplyAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock" name="ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock" name="ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_FinitelivedIntangibleAssetsAbandonments" name="FinitelivedIntangibleAssetsAbandonments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" name="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_AccruedClinicalTrialExpensesCurrent" name="AccruedClinicalTrialExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ConvertiblePreferredStockFaceValue" name="ConvertiblePreferredStockFaceValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" name="CommonStockSharesWithLimitationsAndRestrictionsOnUsage" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_PercentageOfOutstandingStock" name="PercentageOfOutstandingStock" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_WarrantModifications" name="WarrantModifications" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_MarketPricePercentage" name="MarketPricePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_TradingDailyMaximumLessorAmount" name="TradingDailyMaximumLessorAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_BeneficialOwnershipPercentage" name="BeneficialOwnershipPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_StockIssuedDuringPeriodValueCommitmentShares" name="StockIssuedDuringPeriodValueCommitmentShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_LowRangeOfProbability" name="LowRangeOfProbability" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_MediumRangeOfProbability" name="MediumRangeOfProbability" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_HighRangeOfProbability" name="HighRangeOfProbability" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" name="OperationLeaseRightOfUseAssetAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" name="ResearchAndDevelopmentExpenseCostEstimatedLives" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_UnitsManufactured" name="UnitsManufactured" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_NumberOfVials" name="NumberOfVials" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_MonthlyRetainerFee" name="MonthlyRetainerFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ProceedsFromRepaymentOfSaleOfPropertyPlantAndEquipment" name="ProceedsFromRepaymentOfSaleOfPropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_MutualFundsMember" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ScheduleOfLongTermDebtInterestCostsExpenseAndCapitalTableTextBlock" name="ScheduleOfLongTermDebtInterestCostsExpenseAndCapitalTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="AIM_ScheduleOfLongTermDebtAmortizationExpensesTableTextBlock" name="ScheduleOfLongTermDebtAmortizationExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>27
<FILENAME>aim-20240930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aimimmuno.com/role/Cover" xlink:href="aim-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BalanceSheets" xlink:href="aim-20240930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BalanceSheetsParenthetical" xlink:href="aim-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfComprehensiveLoss" xlink:href="aim-20240930.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="aim-20240930.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfCashFlows" xlink:href="aim-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BusinessAndBasisOfPresentation" xlink:href="aim-20240930.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/CashAndCashEquivalents" xlink:href="aim-20240930.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableSecurities" xlink:href="aim-20240930.xsd#MarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PropertyAndEquipmentNet" xlink:href="aim-20240930.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" xlink:href="aim-20240930.xsd#PatentsAndTrademarkRightsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/AccruedExpenses" xlink:href="aim-20240930.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/UnsecuredPromissoryNote" xlink:href="aim-20240930.xsd#UnsecuredPromissoryNote" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Equity-basedCompensation" xlink:href="aim-20240930.xsd#Equity-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquity" xlink:href="aim-20240930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/NetLossPerShare" xlink:href="aim-20240930.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/RecentAccountingPronouncements" xlink:href="aim-20240930.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValue" xlink:href="aim-20240930.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Leases" xlink:href="aim-20240930.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" xlink:href="aim-20240930.xsd#ResearchConsultingAndSupplyAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SubsequentEvents" xlink:href="aim-20240930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PropertyAndEquipmentNetTables" xlink:href="aim-20240930.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" xlink:href="aim-20240930.xsd#PatentsAndTrademarkRightsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/AccruedExpensesTables" xlink:href="aim-20240930.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/UnsecuredPromissoryNoteTables" xlink:href="aim-20240930.xsd#UnsecuredPromissoryNoteTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Equity-basedCompensationTables" xlink:href="aim-20240930.xsd#Equity-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValueTables" xlink:href="aim-20240930.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/LeasesTables" xlink:href="aim-20240930.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/CashAndCashEquivalentsDetailsNarrative" xlink:href="aim-20240930.xsd#CashAndCashEquivalentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableSecuritiesDetailsNarrative" xlink:href="aim-20240930.xsd#MarketableSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="aim-20240930.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="aim-20240930.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" xlink:href="aim-20240930.xsd#ScheduleOfPatentAndTrademarkRightsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:href="aim-20240930.xsd#ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:href="aim-20240930.xsd#ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" xlink:href="aim-20240930.xsd#PatentsAndTrademarkRightsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="aim-20240930.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails" xlink:href="aim-20240930.xsd#ScheduleOfLongTermDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative" xlink:href="aim-20240930.xsd#UnsecuredPromissoryNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="aim-20240930.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" xlink:href="aim-20240930.xsd#ScheduleOfUnvestedStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative" xlink:href="aim-20240930.xsd#Equity-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" xlink:href="aim-20240930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/NetLossPerShareDetailsNarrative" xlink:href="aim-20240930.xsd#NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails" xlink:href="aim-20240930.xsd#ScheduleOfAssumptionsToEstimateFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPotentialLiabilityDetails" xlink:href="aim-20240930.xsd#ScheduleOfPotentialLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="aim-20240930.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValueDetailsNarrative" xlink:href="aim-20240930.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:href="aim-20240930.xsd#ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:href="aim-20240930.xsd#ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/LeasesDetailsNarrative" xlink:href="aim-20240930.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:href="aim-20240930.xsd#ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" xlink:href="aim-20240930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRevenues" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingCosts" xlink:label="loc_us-gaapManufacturingCosts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapManufacturingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_GainLossOnWarrantIssuance" xlink:label="loc_AIMGainLossOnWarrantIssuance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_AIMGainLossOnWarrantIssuance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:label="loc_AIMGainFromSaleOfIncomeTaxOperatingLoss" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_AIMGainFromSaleOfIncomeTaxOperatingLoss" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AbandonmentOfPatentAndTrademarkRights" xlink:label="loc_AIMAbandonmentOfPatentAndTrademarkRights" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AIMAbandonmentOfPatentAndTrademarkRights" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ChangesInRouAssets" xlink:label="loc_AIMChangesInRouAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AIMChangesInRouAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:label="loc_AIMGainFromSaleOfIncomeTaxOperatingLoss" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AIMGainFromSaleOfIncomeTaxOperatingLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaapGainLossOnSaleOfDerivatives" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfDerivatives" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="loc_us-gaapProceedsFromSaleOfInvestmentProjects" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfInvestmentProjects" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ProceedsFromIssuanceOfEquityWarrants" xlink:label="loc_AIMProceedsFromIssuanceOfEquityWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_AIMProceedsFromIssuanceOfEquityWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/CashAndCashEquivalents" xlink:title="00000008 - Disclosure - Cash and Cash Equivalents" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableSecurities" xlink:title="00000009 - Disclosure - Marketable Securities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PropertyAndEquipmentNet" xlink:title="00000010 - Disclosure - Property and Equipment, net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" xlink:title="00000011 - Disclosure - Patents, and Trademark Rights, Net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/AccruedExpenses" xlink:title="00000012 - Disclosure - Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/UnsecuredPromissoryNote" xlink:title="00000013 - Disclosure - Unsecured Promissory Note" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Equity-basedCompensation" xlink:title="00000014 - Disclosure - Equity-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/NetLossPerShare" xlink:title="00000016 - Disclosure - Net Loss Per Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/RecentAccountingPronouncements" xlink:title="00000017 - Disclosure - Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValue" xlink:title="00000018 - Disclosure - Fair Value" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Leases" xlink:title="00000019 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" xlink:title="00000020 - Disclosure - Research, Consulting and Supply Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PropertyAndEquipmentNetTables" xlink:title="00000022 - Disclosure - Property and Equipment, net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" xlink:title="00000023 - Disclosure - Patents, and Trademark Rights, Net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/AccruedExpensesTables" xlink:title="00000024 - Disclosure - Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/UnsecuredPromissoryNoteTables" xlink:title="00000025 - Disclosure - Unsecured Promissory Note (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Equity-basedCompensationTables" xlink:title="00000026 - Disclosure - Equity-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValueTables" xlink:title="00000027 - Disclosure - Fair Value (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/LeasesTables" xlink:title="00000028 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/CashAndCashEquivalentsDetailsNarrative" xlink:title="00000029 - Disclosure - Cash and Cash Equivalents (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableSecuritiesDetailsNarrative" xlink:title="00000030 - Disclosure - Marketable Securities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000031 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000032 - Disclosure - Property and Equipment, net (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" xlink:title="00000033 - Disclosure - Schedule of Patent and Trademark Rights (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:title="00000034 - Disclosure - Schedule of Changes in Patents, Trademark Rights (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:title="00000035 - Disclosure - Schedule of Amortization of Patents and Trademarks (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="loc_AIMFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_AIMFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" xlink:title="00000036 - Disclosure - Patents, and Trademark Rights, Net (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000037 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AccruedClinicalTrialExpensesCurrent" xlink:label="loc_AIMAccruedClinicalTrialExpensesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_AIMAccruedClinicalTrialExpensesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails" xlink:title="00000038 - Disclosure - Schedule of Long Term Debt (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative" xlink:title="00000039 - Disclosure - Unsecured Promissory Note (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000040 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" xlink:title="00000041 - Disclosure - Schedule of Unvested Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative" xlink:title="00000042 - Disclosure - Equity-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000043 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/NetLossPerShareDetailsNarrative" xlink:title="00000044 - Disclosure - Net Loss Per Share (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails" xlink:title="00000045 - Disclosure - Schedule of Assumptions to Estimate the Fair Value (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPotentialLiabilityDetails" xlink:title="00000046 - Disclosure - Schedule of Potential Liability (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000047 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValueDetailsNarrative" xlink:title="00000048 - Disclosure - Fair Value (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:title="00000049 - Disclosure - Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:title="00000050 - Disclosure - Schedule of Operating Lease Future Payments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/LeasesDetailsNarrative" xlink:title="00000051 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:title="00000052 - Disclosure - Research, Consulting and Supply Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000053 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>28
<FILENAME>aim-20240930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aimimmuno.com/role/Cover" xlink:href="aim-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BalanceSheets" xlink:href="aim-20240930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BalanceSheetsParenthetical" xlink:href="aim-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfComprehensiveLoss" xlink:href="aim-20240930.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="aim-20240930.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfCashFlows" xlink:href="aim-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BusinessAndBasisOfPresentation" xlink:href="aim-20240930.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/CashAndCashEquivalents" xlink:href="aim-20240930.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableSecurities" xlink:href="aim-20240930.xsd#MarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PropertyAndEquipmentNet" xlink:href="aim-20240930.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" xlink:href="aim-20240930.xsd#PatentsAndTrademarkRightsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/AccruedExpenses" xlink:href="aim-20240930.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/UnsecuredPromissoryNote" xlink:href="aim-20240930.xsd#UnsecuredPromissoryNote" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Equity-basedCompensation" xlink:href="aim-20240930.xsd#Equity-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquity" xlink:href="aim-20240930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/NetLossPerShare" xlink:href="aim-20240930.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/RecentAccountingPronouncements" xlink:href="aim-20240930.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValue" xlink:href="aim-20240930.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Leases" xlink:href="aim-20240930.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" xlink:href="aim-20240930.xsd#ResearchConsultingAndSupplyAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SubsequentEvents" xlink:href="aim-20240930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PropertyAndEquipmentNetTables" xlink:href="aim-20240930.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" xlink:href="aim-20240930.xsd#PatentsAndTrademarkRightsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/AccruedExpensesTables" xlink:href="aim-20240930.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/UnsecuredPromissoryNoteTables" xlink:href="aim-20240930.xsd#UnsecuredPromissoryNoteTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Equity-basedCompensationTables" xlink:href="aim-20240930.xsd#Equity-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValueTables" xlink:href="aim-20240930.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/LeasesTables" xlink:href="aim-20240930.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/CashAndCashEquivalentsDetailsNarrative" xlink:href="aim-20240930.xsd#CashAndCashEquivalentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableSecuritiesDetailsNarrative" xlink:href="aim-20240930.xsd#MarketableSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="aim-20240930.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="aim-20240930.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" xlink:href="aim-20240930.xsd#ScheduleOfPatentAndTrademarkRightsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:href="aim-20240930.xsd#ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:href="aim-20240930.xsd#ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" xlink:href="aim-20240930.xsd#PatentsAndTrademarkRightsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="aim-20240930.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails" xlink:href="aim-20240930.xsd#ScheduleOfLongTermDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative" xlink:href="aim-20240930.xsd#UnsecuredPromissoryNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="aim-20240930.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" xlink:href="aim-20240930.xsd#ScheduleOfUnvestedStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative" xlink:href="aim-20240930.xsd#Equity-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" xlink:href="aim-20240930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/NetLossPerShareDetailsNarrative" xlink:href="aim-20240930.xsd#NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails" xlink:href="aim-20240930.xsd#ScheduleOfAssumptionsToEstimateFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPotentialLiabilityDetails" xlink:href="aim-20240930.xsd#ScheduleOfPotentialLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="aim-20240930.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValueDetailsNarrative" xlink:href="aim-20240930.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:href="aim-20240930.xsd#ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:href="aim-20240930.xsd#ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/LeasesDetailsNarrative" xlink:href="aim-20240930.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:href="aim-20240930.xsd#ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" xlink:href="aim-20240930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="loc_AIMSeriesAJuniorParticipatingPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesAJuniorParticipatingPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AIMSeriesBConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesBConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOtherAssetsNoncurrent_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapNotesPayableCurrent_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapLongTermNotesPayable_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockValue_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="loc_AIMSeriesAJuniorParticipatingPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesAJuniorParticipatingPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AIMSeriesBConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesBConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PreferredStockStatedValuePerShare" xlink:label="loc_AIMPreferredStockStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMPreferredStockStatedValuePerShare_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:label="loc_AIMStockIssuedDuringPeriodValueCashlessExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMStockIssuedDuringPeriodValueCashlessExerciseOfWarrants_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants" xlink:label="loc_AIMStockIssuedDuringPeriodShareCsashlessExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMStockIssuedDuringPeriodShareCsashlessExerciseOfWarrants_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodValueCommittedShares" xlink:label="loc_AIMStockIssuedDuringPeriodValueCommittedShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMStockIssuedDuringPeriodValueCommittedShares_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodSharesCommittedShares" xlink:label="loc_AIMStockIssuedDuringPeriodSharesCommittedShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMStockIssuedDuringPeriodSharesCommittedShares_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodValuePreferredSharesExpired" xlink:label="loc_AIMStockIssuedDuringPeriodValuePreferredSharesExpired_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMStockIssuedDuringPeriodValuePreferredSharesExpired_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/CashAndCashEquivalents" xlink:title="00000008 - Disclosure - Cash and Cash Equivalents" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableSecurities" xlink:title="00000009 - Disclosure - Marketable Securities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PropertyAndEquipmentNet" xlink:title="00000010 - Disclosure - Property and Equipment, net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" xlink:title="00000011 - Disclosure - Patents, and Trademark Rights, Net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/AccruedExpenses" xlink:title="00000012 - Disclosure - Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/UnsecuredPromissoryNote" xlink:title="00000013 - Disclosure - Unsecured Promissory Note" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Equity-basedCompensation" xlink:title="00000014 - Disclosure - Equity-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/NetLossPerShare" xlink:title="00000016 - Disclosure - Net Loss Per Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/RecentAccountingPronouncements" xlink:title="00000017 - Disclosure - Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValue" xlink:title="00000018 - Disclosure - Fair Value" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Leases" xlink:title="00000019 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" xlink:title="00000020 - Disclosure - Research, Consulting and Supply Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PropertyAndEquipmentNetTables" xlink:title="00000022 - Disclosure - Property and Equipment, net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" xlink:title="00000023 - Disclosure - Patents, and Trademark Rights, Net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/AccruedExpensesTables" xlink:title="00000024 - Disclosure - Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/UnsecuredPromissoryNoteTables" xlink:title="00000025 - Disclosure - Unsecured Promissory Note (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Equity-basedCompensationTables" xlink:title="00000026 - Disclosure - Equity-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedShareActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfNonvestedShareActivityTableTextBlock_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValueTables" xlink:title="00000027 - Disclosure - Fair Value (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/LeasesTables" xlink:title="00000028 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/CashAndCashEquivalentsDetailsNarrative" xlink:title="00000029 - Disclosure - Cash and Cash Equivalents (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableSecuritiesDetailsNarrative" xlink:title="00000030 - Disclosure - Marketable Securities (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000031 - Disclosure - Schedule of Property and Equipment (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000032 - Disclosure - Property and Equipment, net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" xlink:title="00000033 - Disclosure - Schedule of Patent and Trademark Rights (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:title="00000034 - Disclosure - Schedule of Changes in Patents, Trademark Rights (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:title="00000035 - Disclosure - Schedule of Amortization of Patents and Trademarks (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" xlink:title="00000036 - Disclosure - Patents, and Trademark Rights, Net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000037 - Disclosure - Schedule of Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails" xlink:title="00000038 - Disclosure - Schedule of Long Term Debt (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative" xlink:title="00000039 - Disclosure - Unsecured Promissory Note (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_NotePurchaseAgreementMember" xlink:label="loc_AIMNotePurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMNotePurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StreetervilleCapitalLlcMember" xlink:label="loc_AIMStreetervilleCapitalLlcMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_AIMStreetervilleCapitalLlcMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLongTermDebt_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaapUnsecuredDebt_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapUnsecuredDebt_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaapInterestExpenseDebtExcludingAmortization_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapInterestExpenseDebtExcludingAmortization_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanProcessingFee" xlink:label="loc_us-gaapLoanProcessingFee_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLoanProcessingFee_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentGross_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:label="loc_us-gaapDeferredFinanceCostsNoncurrentGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNoncurrentGross_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountNoncurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountNoncurrent_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsNoncurrentNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNoncurrentNet_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaapDebtInstrumentRedemptionDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentRedemptionDescription_60" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000040 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_110" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_110" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_110" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_110" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_110" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_110" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" xlink:title="00000041 - Disclosure - Schedule of Unvested Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative" xlink:title="00000042 - Disclosure - Equity-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_AIMTwoThousandEighteenEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMTwoThousandEighteenEquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_AIMRestatedTwoThousandEighteenEquityIncentivePlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMRestatedTwoThousandEighteenEquityIncentivePlanMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtOfficerMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_320" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_320" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_320" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_320" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000043 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="loc_AIMSeriesAJuniorParticipatingPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesAJuniorParticipatingPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AIMSeriesBConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesBConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapWarrantMember_480" xlink:type="arc" order="482" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassBCommonWarrantMember" xlink:label="loc_AIMClassBCommonWarrantMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMClassBCommonWarrantMember_500" xlink:type="arc" order="502" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightsMember" xlink:label="loc_us-gaapRightsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRightsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_WarrantsMember" xlink:label="loc_AIMWarrantsMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMWarrantsMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_RepresentativeWarrantsMember" xlink:label="loc_AIMRepresentativeWarrantsMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMRepresentativeWarrantsMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PreFundedWarrantsMember" xlink:label="loc_AIMPreFundedWarrantsMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMPreFundedWarrantsMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_DirectorsOfficersAndEmployeesMember" xlink:label="loc_AIMDirectorsOfficersAndEmployeesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AIMDirectorsOfficersAndEmployeesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AllianceGlobalPartnersLLCMember" xlink:label="loc_AIMAllianceGlobalPartnersLLCMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAllianceGlobalPartnersLLCMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MaximGroupLLCMember" xlink:label="loc_AIMMaximGroupLLCMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMMaximGroupLLCMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AtlasSciencesLlcMember" xlink:label="loc_AIMAtlasSciencesLlcMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAtlasSciencesLlcMember_390" xlink:type="arc" order="392" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_EquityDistributionAgreementMember" xlink:label="loc_AIMEquityDistributionAgreementMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMEquityDistributionAgreementMember_350" xlink:type="arc" order="352" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PurchaseAndRegistrationRightsAgreementMember" xlink:label="loc_AIMPurchaseAndRegistrationRightsAgreementMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMPurchaseAndRegistrationRightsAgreementMember_390" xlink:type="arc" order="393" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PurchaseAgreementMember" xlink:label="loc_AIMPurchaseAgreementMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMPurchaseAgreementMember_400" xlink:type="arc" order="402" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SecuritiesPurchaseAgreementMember" xlink:label="loc_AIMSecuritiesPurchaseAgreementMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMSecuritiesPurchaseAgreementMember_460" xlink:type="arc" order="461" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AtlasSciencesLlcMember" xlink:label="loc_AIMAtlasSciencesLlcMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AIMAtlasSciencesLlcMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PlacementAgentMember" xlink:label="loc_AIMPlacementAgentMember_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_AIMPlacementAgentMember_520" xlink:type="arc" order="521" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_540" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_540" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PreferredStockStatedValuePerShare" xlink:label="loc_AIMPreferredStockStatedValuePerShare_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMPreferredStockStatedValuePerShare_540" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_540" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaapCommonStockSharesSubscriptions_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesSubscriptions_540" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ConvertiblePreferredStockFaceValue" xlink:label="loc_AIMConvertiblePreferredStockFaceValue_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMConvertiblePreferredStockFaceValue_540" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_540" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_540" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_540" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_540" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_540" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" xlink:label="loc_AIMCommonStockSharesWithLimitationsAndRestrictionsOnUsage_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMCommonStockSharesWithLimitationsAndRestrictionsOnUsage_540" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_540" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_540" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_540" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_540" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_540" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_540" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_540" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_540" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PercentageOfOutstandingStock" xlink:label="loc_AIMPercentageOfOutstandingStock_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMPercentageOfOutstandingStock_540" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_540" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_540" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_540" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_WarrantModifications" xlink:label="loc_AIMWarrantModifications_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMWarrantModifications_540" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_540" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_540" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_540" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_540" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_540" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MarketPricePercentage" xlink:label="loc_AIMMarketPricePercentage_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMMarketPricePercentage_540" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_TradingDailyMaximumLessorAmount" xlink:label="loc_AIMTradingDailyMaximumLessorAmount_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMTradingDailyMaximumLessorAmount_540" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_BeneficialOwnershipPercentage" xlink:label="loc_AIMBeneficialOwnershipPercentage_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMBeneficialOwnershipPercentage_540" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_540" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodValueCommitmentShares" xlink:label="loc_AIMStockIssuedDuringPeriodValueCommitmentShares_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMStockIssuedDuringPeriodValueCommitmentShares_540" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_540" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_540" xlink:type="arc" order="36" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/NetLossPerShareDetailsNarrative" xlink:title="00000044 - Disclosure - Net Loss Per Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails" xlink:title="00000045 - Disclosure - Schedule of Assumptions to Estimate the Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassAWarrantMember" xlink:label="loc_AIMClassAWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMClassAWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassBWarrantMember" xlink:label="loc_AIMClassBWarrantMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMClassBWarrantMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_230" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPotentialLiabilityDetails" xlink:title="00000046 - Disclosure - Schedule of Potential Liability (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000047 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaapInvestmentsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapInvestmentsFairValueDisclosure_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValueDetailsNarrative" xlink:title="00000048 - Disclosure - Fair Value (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:title="00000049 - Disclosure - Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaapLeaseCostAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCostAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseCost_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeaseCost_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCost_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:title="00000050 - Disclosure - Schedule of Operating Lease Future Payments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/LeasesDetailsNarrative" xlink:title="00000051 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="loc_AIMOperationLeaseRightOfUseAssetAccumulatedAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMOperationLeaseRightOfUseAssetAccumulatedAmortization_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaapDebtWeightedAverageInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtWeightedAverageInterestRate_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:title="00000052 - Disclosure - Research, Consulting and Supply Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClinicalStudiesMember" xlink:label="loc_AIMClinicalStudiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMClinicalStudiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ManufacturingAndEngineeringMember" xlink:label="loc_AIMManufacturingAndEngineeringMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMManufacturingAndEngineeringMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_QualityControlMember" xlink:label="loc_AIMQualityControlMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMQualityControlMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_RegulatoryMember" xlink:label="loc_AIMRegulatoryMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMRegulatoryMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AmarexClinicalResearchLLCMember" xlink:label="loc_AIMAmarexClinicalResearchLLCMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAmarexClinicalResearchLLCMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_JubilantHollisterStierMember" xlink:label="loc_AIMJubilantHollisterStierMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMJubilantHollisterStierMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SterlingPharmaSolutionsMember" xlink:label="loc_AIMSterlingPharmaSolutionsMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMSterlingPharmaSolutionsMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ErasmusUniversityMedicalCenterMember" xlink:label="loc_AIMErasmusUniversityMedicalCenterMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMErasmusUniversityMedicalCenterMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AzenovaLLCMember" xlink:label="loc_AIMAzenovaLLCMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAzenovaLLCMember_460" xlink:type="arc" order="461" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AlcamiCorporationMember" xlink:label="loc_AIMAlcamiCorporationMember_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAlcamiCorporationMember_520" xlink:type="arc" order="521" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AdvancedPancreaticCancerStudyAgreementMember" xlink:label="loc_AIMAdvancedPancreaticCancerStudyAgreementMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMAdvancedPancreaticCancerStudyAgreementMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PostCOVIDStudyAgreementMember" xlink:label="loc_AIMPostCOVIDStudyAgreementMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMPostCOVIDStudyAgreementMember_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AmpligenManufacturingAgreementMember" xlink:label="loc_AIMAmpligenManufacturingAgreementMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMAmpligenManufacturingAgreementMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MasterServiceAgreementAndQualityAgreementMember" xlink:label="loc_AIMMasterServiceAgreementAndQualityAgreementMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMMasterServiceAgreementAndQualityAgreementMember_370" xlink:type="arc" order="372" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_JointClinicalStudyAgreementMember" xlink:label="loc_AIMJointClinicalStudyAgreementMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMJointClinicalStudyAgreementMember_410" xlink:type="arc" order="412" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ConsultingAgreementMember" xlink:label="loc_AIMConsultingAgreementMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMConsultingAgreementMember_460" xlink:type="arc" order="462" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_580" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_580" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopmentCosts" xlink:label="loc_us-gaapDevelopmentCosts_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDevelopmentCosts_580" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" xlink:label="loc_AIMResearchAndDevelopmentExpenseCostEstimatedLives_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMResearchAndDevelopmentExpenseCostEstimatedLives_580" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostMaintenance_580" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_UnitsManufactured" xlink:label="loc_AIMUnitsManufactured_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMUnitsManufactured_580" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_NumberOfVials" xlink:label="loc_AIMNumberOfVials_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMNumberOfVials_580" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SuppliesExpense" xlink:label="loc_us-gaapSuppliesExpense_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSuppliesExpense_580" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_580" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_580" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MonthlyRetainerFee" xlink:label="loc_AIMMonthlyRetainerFee_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMMonthlyRetainerFee_580" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductionCosts" xlink:label="loc_us-gaapProductionCosts_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProductionCosts_580" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000053 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SecuritiesPurchaseAgreementMember" xlink:label="loc_AIMSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassCCommonWarrantMember" xlink:label="loc_AIMClassCCommonWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMClassCCommonWarrantMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassDCommonWarrantMember" xlink:label="loc_AIMClassDCommonWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMClassDCommonWarrantMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_80" xlink:type="arc" order="3" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>29
<FILENAME>aim-20240930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="AIM_SeriesAJuniorParticipatingPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:to="AIM_SeriesAJuniorParticipatingPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SeriesAJuniorParticipatingPreferredStockMember_lbl" xml:lang="en-US">Series A Junior Participating Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="AIM_SeriesBConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SeriesBConvertiblePreferredStockMember" xlink:to="AIM_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksMember_lbl" xml:lang="en-US">Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_NotePurchaseAgreementMember" xlink:label="AIM_NotePurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_NotePurchaseAgreementMember" xlink:to="AIM_NotePurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_NotePurchaseAgreementMember_lbl" xml:lang="en-US">Note Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StreetervilleCapitalLlcMember" xlink:label="AIM_StreetervilleCapitalLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StreetervilleCapitalLlcMember" xlink:to="AIM_StreetervilleCapitalLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_StreetervilleCapitalLlcMember_lbl" xml:lang="en-US">Streeterville Capital LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="AIM_TwoThousandEighteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="AIM_TwoThousandEighteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2018 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember" xlink:label="AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember" xlink:to="AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">Restated 2018 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightsMember" xlink:label="us-gaap_RightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightsMember" xlink:to="us-gaap_RightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightsMember_lbl" xml:lang="en-US">Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_DirectorsOfficersAndEmployeesMember" xlink:label="AIM_DirectorsOfficersAndEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DirectorsOfficersAndEmployeesMember" xlink:to="AIM_DirectorsOfficersAndEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_DirectorsOfficersAndEmployeesMember_lbl" xml:lang="en-US">Directors, Officers and Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AllianceGlobalPartnersLLCMember" xlink:label="AIM_AllianceGlobalPartnersLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AllianceGlobalPartnersLLCMember" xlink:to="AIM_AllianceGlobalPartnersLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AllianceGlobalPartnersLLCMember_lbl" xml:lang="en-US">Alliance Global Partners, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_WarrantsMember" xlink:label="AIM_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WarrantsMember" xlink:to="AIM_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_RepresentativeWarrantsMember" xlink:label="AIM_RepresentativeWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_RepresentativeWarrantsMember" xlink:to="AIM_RepresentativeWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_RepresentativeWarrantsMember_lbl" xml:lang="en-US">Representative Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PreFundedWarrantsMember" xlink:label="AIM_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PreFundedWarrantsMember" xlink:to="AIM_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MaximGroupLLCMember" xlink:label="AIM_MaximGroupLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MaximGroupLLCMember" xlink:to="AIM_MaximGroupLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_MaximGroupLLCMember_lbl" xml:lang="en-US">Maxim Group LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_EquityDistributionAgreementMember" xlink:label="AIM_EquityDistributionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquityDistributionAgreementMember" xlink:to="AIM_EquityDistributionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_EquityDistributionAgreementMember_lbl" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AtlasSciencesLlcMember" xlink:label="AIM_AtlasSciencesLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AtlasSciencesLlcMember" xlink:to="AIM_AtlasSciencesLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AtlasSciencesLlcMember_lbl" xml:lang="en-US">Atlas Sciences LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PurchaseAndRegistrationRightsAgreementMember" xlink:label="AIM_PurchaseAndRegistrationRightsAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PurchaseAndRegistrationRightsAgreementMember" xlink:to="AIM_PurchaseAndRegistrationRightsAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PurchaseAndRegistrationRightsAgreementMember_lbl" xml:lang="en-US">Purchase And Registration Rights Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PurchaseAgreementMember" xlink:label="AIM_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PurchaseAgreementMember" xlink:to="AIM_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SecuritiesPurchaseAgreementMember" xlink:label="AIM_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SecuritiesPurchaseAgreementMember" xlink:to="AIM_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassBCommonWarrantMember" xlink:label="AIM_ClassBCommonWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClassBCommonWarrantMember" xlink:to="AIM_ClassBCommonWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ClassBCommonWarrantMember_lbl" xml:lang="en-US">Class B Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PlacementAgentMember" xlink:label="AIM_PlacementAgentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PlacementAgentMember" xlink:to="AIM_PlacementAgentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PlacementAgentMember_lbl" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassAWarrantMember" xlink:label="AIM_ClassAWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClassAWarrantMember" xlink:to="AIM_ClassAWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ClassAWarrantMember_lbl" xml:lang="en-US">Class A Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassBWarrantMember" xlink:label="AIM_ClassBWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClassBWarrantMember" xlink:to="AIM_ClassBWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ClassBWarrantMember_lbl" xml:lang="en-US">Class B Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClinicalStudiesMember" xlink:label="AIM_ClinicalStudiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClinicalStudiesMember" xlink:to="AIM_ClinicalStudiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ClinicalStudiesMember_lbl" xml:lang="en-US">Clinical Studies [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ManufacturingAndEngineeringMember" xlink:label="AIM_ManufacturingAndEngineeringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ManufacturingAndEngineeringMember" xlink:to="AIM_ManufacturingAndEngineeringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ManufacturingAndEngineeringMember_lbl" xml:lang="en-US">Manufacturing and Engineering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_QualityControlMember" xlink:label="AIM_QualityControlMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_QualityControlMember" xlink:to="AIM_QualityControlMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_QualityControlMember_lbl" xml:lang="en-US">Quality Control [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_RegulatoryMember" xlink:label="AIM_RegulatoryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_RegulatoryMember" xlink:to="AIM_RegulatoryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_RegulatoryMember_lbl" xml:lang="en-US">Regulatory [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AmarexClinicalResearchLLCMember" xlink:label="AIM_AmarexClinicalResearchLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AmarexClinicalResearchLLCMember" xlink:to="AIM_AmarexClinicalResearchLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AmarexClinicalResearchLLCMember_lbl" xml:lang="en-US">Amarex Clinical Research LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AdvancedPancreaticCancerStudyAgreementMember" xlink:label="AIM_AdvancedPancreaticCancerStudyAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AdvancedPancreaticCancerStudyAgreementMember" xlink:to="AIM_AdvancedPancreaticCancerStudyAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AdvancedPancreaticCancerStudyAgreementMember_lbl" xml:lang="en-US">Advanced Pancreatic Cancer Study Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PostCOVIDStudyAgreementMember" xlink:label="AIM_PostCOVIDStudyAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PostCOVIDStudyAgreementMember" xlink:to="AIM_PostCOVIDStudyAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PostCOVIDStudyAgreementMember_lbl" xml:lang="en-US">Post COVID Study Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_JubilantHollisterStierMember" xlink:label="AIM_JubilantHollisterStierMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_JubilantHollisterStierMember" xlink:to="AIM_JubilantHollisterStierMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_JubilantHollisterStierMember_lbl" xml:lang="en-US">Jubilant HollisterStier [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AmpligenManufacturingAgreementMember" xlink:label="AIM_AmpligenManufacturingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AmpligenManufacturingAgreementMember" xlink:to="AIM_AmpligenManufacturingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AmpligenManufacturingAgreementMember_lbl" xml:lang="en-US">Ampligen Manufacturing Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SterlingPharmaSolutionsMember" xlink:label="AIM_SterlingPharmaSolutionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SterlingPharmaSolutionsMember" xlink:to="AIM_SterlingPharmaSolutionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SterlingPharmaSolutionsMember_lbl" xml:lang="en-US">Sterling Pharma Solutions [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MasterServiceAgreementAndQualityAgreementMember" xlink:label="AIM_MasterServiceAgreementAndQualityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MasterServiceAgreementAndQualityAgreementMember" xlink:to="AIM_MasterServiceAgreementAndQualityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_MasterServiceAgreementAndQualityAgreementMember_lbl" xml:lang="en-US">Master Service Agreement and Quality Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ErasmusUniversityMedicalCenterMember" xlink:label="AIM_ErasmusUniversityMedicalCenterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ErasmusUniversityMedicalCenterMember" xlink:to="AIM_ErasmusUniversityMedicalCenterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ErasmusUniversityMedicalCenterMember_lbl" xml:lang="en-US">Erasmus University Medical Center [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_JointClinicalStudyAgreementMember" xlink:label="AIM_JointClinicalStudyAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_JointClinicalStudyAgreementMember" xlink:to="AIM_JointClinicalStudyAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_JointClinicalStudyAgreementMember_lbl" xml:lang="en-US">Joint Clinical Study Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AzenovaLLCMember" xlink:label="AIM_AzenovaLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AzenovaLLCMember" xlink:to="AIM_AzenovaLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AzenovaLLCMember_lbl" xml:lang="en-US">Azenova LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ConsultingAgreementMember" xlink:label="AIM_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ConsultingAgreementMember" xlink:to="AIM_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AlcamiCorporationMember" xlink:label="AIM_AlcamiCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AlcamiCorporationMember" xlink:to="AIM_AlcamiCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AlcamiCorporationMember_lbl" xml:lang="en-US">Alcami Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassCCommonWarrantMember" xlink:label="AIM_ClassCCommonWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClassCCommonWarrantMember" xlink:to="AIM_ClassCCommonWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ClassCCommonWarrantMember_lbl" xml:lang="en-US">Class C Common Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassDCommonWarrantMember" xlink:label="AIM_ClassDCommonWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClassDCommonWarrantMember" xlink:to="AIM_ClassDCommonWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ClassDCommonWarrantMember_lbl" xml:lang="en-US">Class D Common Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Funds receivable from New Jersey net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patent and trademark rights, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Current portion of note payable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long-term liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Notes 13 and 14)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible preferred stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 58,668,647 and 49,102,484 as of September 30, 2024 and December 31, 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PreferredStockStatedValuePerShare" xlink:label="AIM_PreferredStockStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PreferredStockStatedValuePerShare" xlink:to="AIM_PreferredStockStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PreferredStockStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, stated value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Clinical treatment programs - US</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingCosts" xlink:label="us-gaap_ManufacturingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingCosts" xlink:to="us-gaap_ManufacturingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManufacturingCosts_lbl" xml:lang="en-US">Production costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Total Costs and Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Gain (loss) on investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Interest and other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense and other finance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_GainLossOnWarrantIssuance" xlink:label="AIM_GainLossOnWarrantIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_GainLossOnWarrantIssuance" xlink:to="AIM_GainLossOnWarrantIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_GainLossOnWarrantIssuance_lbl" xml:lang="en-US">(Loss) on warrant issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:label="AIM_GainFromSaleOfIncomeTaxOperatingLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:to="AIM_GainFromSaleOfIncomeTaxOperatingLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AIM_GainFromSaleOfIncomeTaxOperatingLoss_lbl" xml:lang="en-US">Gain from sale of income tax operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares outstanding diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issuance, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issuance, net of costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:label="AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:to="AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants" xlink:label="AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants" xlink:to="AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants_lbl" xml:lang="en-US">Cashless Exercise of Warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Equity-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodValueCommittedShares" xlink:label="AIM_StockIssuedDuringPeriodValueCommittedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockIssuedDuringPeriodValueCommittedShares" xlink:to="AIM_StockIssuedDuringPeriodValueCommittedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_StockIssuedDuringPeriodValueCommittedShares_lbl" xml:lang="en-US">Committed shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodSharesCommittedShares" xlink:label="AIM_StockIssuedDuringPeriodSharesCommittedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockIssuedDuringPeriodSharesCommittedShares" xlink:to="AIM_StockIssuedDuringPeriodSharesCommittedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_StockIssuedDuringPeriodSharesCommittedShares_lbl" xml:lang="en-US">Committed Shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Net Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Issuance of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodValuePreferredSharesExpired" xlink:label="AIM_StockIssuedDuringPeriodValuePreferredSharesExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockIssuedDuringPeriodValuePreferredSharesExpired" xlink:to="AIM_StockIssuedDuringPeriodValuePreferredSharesExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_StockIssuedDuringPeriodValuePreferredSharesExpired_lbl" xml:lang="en-US">Series B preferred shares expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Equity-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Equity-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Series B preferred shares converted to common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Series B preferred shares converted to common shares, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AbandonmentOfPatentAndTrademarkRights" xlink:label="AIM_AbandonmentOfPatentAndTrademarkRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AbandonmentOfPatentAndTrademarkRights" xlink:to="AIM_AbandonmentOfPatentAndTrademarkRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AbandonmentOfPatentAndTrademarkRights_lbl" xml:lang="en-US">Abandonment of patent and trademark rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of patent, trademark rights</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ChangesInRouAssets" xlink:label="AIM_ChangesInRouAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ChangesInRouAssets" xlink:to="AIM_ChangesInRouAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ChangesInRouAssets_lbl" xml:lang="en-US">Changes in right of use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:to="AIM_GainFromSaleOfIncomeTaxOperatingLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_GainFromSaleOfIncomeTaxOperatingLoss_2_lbl" xml:lang="en-US">Gain from sale of income tax operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Equity-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US">(Gain) loss on sale of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl" xml:lang="en-US">Loss on issuance of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of financial obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Funds receivable from New Jersey net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets and other non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects_lbl" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Purchase of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">(Purchase of) property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Purchase of patent and trademark rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from sale of stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from note payable, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ProceedsFromIssuanceOfEquityWarrants" xlink:label="AIM_ProceedsFromIssuanceOfEquityWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ProceedsFromIssuanceOfEquityWarrants" xlink:to="AIM_ProceedsFromIssuanceOfEquityWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ProceedsFromIssuanceOfEquityWarrants_lbl" xml:lang="en-US">Proceeds from issuance of equity warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_OperatingLeaserightOfUseAssets" xlink:label="AIM_OperatingLeaserightOfUseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_OperatingLeaserightOfUseAssets" xlink:to="AIM_OperatingLeaserightOfUseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_OperatingLeaserightOfUseAssets_lbl" xml:lang="en-US">Operating lease-Right of Use Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_UnrealizedGainLossOnMarketableInvestments" xlink:label="AIM_UnrealizedGainLossOnMarketableInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_UnrealizedGainLossOnMarketableInvestments" xlink:to="AIM_UnrealizedGainLossOnMarketableInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_UnrealizedGainLossOnMarketableInvestments_lbl" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ConversionOfSeriesBPreferred" xlink:label="AIM_ConversionOfSeriesBPreferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ConversionOfSeriesBPreferred" xlink:to="AIM_ConversionOfSeriesBPreferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ConversionOfSeriesBPreferred_lbl" xml:lang="en-US">Conversion of Series B preferred</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ConversionOfNotePayableInterestIntoShares" xlink:label="AIM_ConversionOfNotePayableInterestIntoShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ConversionOfNotePayableInterestIntoShares" xlink:to="AIM_ConversionOfNotePayableInterestIntoShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ConversionOfNotePayableInterestIntoShares_lbl" xml:lang="en-US">Conversion of note payable interest into shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Business and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Patents, and Trademark Rights, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Unsecured Promissory Note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Equity-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract" xlink:label="AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract" xlink:to="AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract_lbl" xml:lang="en-US">Research Consulting And Supply Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ResearchConsultingAndSupplyAgreementsTextBlock" xlink:label="AIM_ResearchConsultingAndSupplyAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ResearchConsultingAndSupplyAgreementsTextBlock" xlink:to="AIM_ResearchConsultingAndSupplyAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ResearchConsultingAndSupplyAgreementsTextBlock_lbl" xml:lang="en-US">Research, Consulting and Supply Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of Patent and Trademark Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Patents, Trademark Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Amortization of Patents and Trademarks</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Long Term Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Unvested Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock" xlink:label="AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock" xlink:to="AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions to Estimate the Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock" xlink:label="AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock" xlink:to="AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Potential Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of AIM Recognized Rent Expense Associated with Operating Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Lease Future Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federlly insured limit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xml:lang="en-US">Held value of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity" xlink:label="us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity" xlink:to="us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity_lbl" xml:lang="en-US">Equity securities description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Furniture, fixtures, and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross carrying value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Net carrying value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_FinitelivedIntangibleAssetsAbandonments" xlink:label="AIM_FinitelivedIntangibleAssetsAbandonments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FinitelivedIntangibleAssetsAbandonments" xlink:to="AIM_FinitelivedIntangibleAssetsAbandonments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="AIM_FinitelivedIntangibleAssetsAbandonments_lbl" xml:lang="en-US">Abandonments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_4_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:to="AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_5_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite lived intangible assets, estimated useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:label="us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:to="us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_lbl" xml:lang="en-US">Finite lived intangible assets, weighted average amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AccruedClinicalTrialExpensesCurrent" xlink:label="AIM_AccruedClinicalTrialExpensesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AccruedClinicalTrialExpensesCurrent" xlink:to="AIM_AccruedClinicalTrialExpensesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_AccruedClinicalTrialExpensesCurrent_lbl" xml:lang="en-US">Clinical trial expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Unamortized Original issue discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Unamortized Financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Unamortized discount and debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Less current portion of long-term debt, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Exchange of unsecured promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Unsecured debt original issue discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US">Debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument stated interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebt_lbl" xml:lang="en-US">Unsecured debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US">Interest expense debt excluding amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization expenses of long term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Original issue discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanProcessingFee" xlink:label="us-gaap_LoanProcessingFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanProcessingFee" xlink:to="us-gaap_LoanProcessingFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoanProcessingFee_lbl" xml:lang="en-US">Loan fee amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US">Future maturities of long term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">Future maturities of long term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentGross" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross_lbl" xml:lang="en-US">Long-term debt, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xml:lang="en-US">Debt discount, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Debt origination costs, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentGross_lbl" xml:lang="en-US">Long-term debt, non current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent_lbl" xml:lang="en-US">Debt discount, non current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US">Debt origination costs, non current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="us-gaap_DebtInstrumentRedemptionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionDescription" xlink:to="us-gaap_DebtInstrumentRedemptionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionDescription_lbl" xml:lang="en-US">Redemption description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding, Beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contracted Term (years) Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options Outstanding, Ending of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contracted Term (years) Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Vested and Expected to Vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and Expected to Vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and Expected to Vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options Exercisable, End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable, Ending of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contracted Term (years), Exercisable at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of Options Unvested, Beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Unvested, Beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Average Remaining Contractual Term (years) Unvested, Beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Unvested, Beginning of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Number of Options, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of Options, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Average Remaining Contractual Term Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Number of Options Unvested, End of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Unvested, Ending of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contracted Term (years), Exercisable at End of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value Unvested, End of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xml:lang="en-US">Number of Options, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders equity reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Number of stock is reserved for potential issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Option vested years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise price range</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock issued as payroll, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Preferred stock conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscriptions" xlink:to="us-gaap_CommonStockSharesSubscriptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xml:lang="en-US">Subscription price</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ConvertiblePreferredStockFaceValue" xlink:label="AIM_ConvertiblePreferredStockFaceValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ConvertiblePreferredStockFaceValue" xlink:to="AIM_ConvertiblePreferredStockFaceValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ConvertiblePreferredStockFaceValue_lbl" xml:lang="en-US">Convertible preferred stock face value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Net proceeds from warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" xlink:label="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" xlink:to="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage_lbl" xml:lang="en-US">Common stock specific limitations and restrictions on usage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued upon transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Shares issued price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants exercised aggregate</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PercentageOfOutstandingStock" xlink:label="AIM_PercentageOfOutstandingStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PercentageOfOutstandingStock" xlink:to="AIM_PercentageOfOutstandingStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_PercentageOfOutstandingStock_lbl" xml:lang="en-US">Percentage of outstanding stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xml:lang="en-US">Proceeds from issuance or sale of equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Pre-funded warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Warrant gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_WarrantModifications" xlink:label="AIM_WarrantModifications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WarrantModifications" xlink:to="AIM_WarrantModifications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_WarrantModifications_lbl" xml:lang="en-US">Warrant modification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US">Aggregate gross proceeds, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Amount of stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MarketPricePercentage" xlink:label="AIM_MarketPricePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MarketPricePercentage" xlink:to="AIM_MarketPricePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_MarketPricePercentage_lbl" xml:lang="en-US">Market price, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_TradingDailyMaximumLessorAmount" xlink:label="AIM_TradingDailyMaximumLessorAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_TradingDailyMaximumLessorAmount" xlink:to="AIM_TradingDailyMaximumLessorAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_TradingDailyMaximumLessorAmount_lbl" xml:lang="en-US">Trading maximum lessor amount</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_BeneficialOwnershipPercentage" xlink:label="AIM_BeneficialOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_BeneficialOwnershipPercentage" xlink:to="AIM_BeneficialOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_BeneficialOwnershipPercentage_lbl" xml:lang="en-US">Beneficial ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity investment ownership percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodValueCommitmentShares" xlink:label="AIM_StockIssuedDuringPeriodValueCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockIssuedDuringPeriodValueCommitmentShares" xlink:to="AIM_StockIssuedDuringPeriodValueCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_StockIssuedDuringPeriodValueCommitmentShares_lbl" xml:lang="en-US">Commitment shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Proceeds from warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Net loss per share, antidilutive</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expected holding period</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_LowRangeOfProbability" xlink:label="AIM_LowRangeOfProbability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_LowRangeOfProbability" xlink:to="AIM_LowRangeOfProbability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_LowRangeOfProbability_lbl" xml:lang="en-US">Low range, rate</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MediumRangeOfProbability" xlink:label="AIM_MediumRangeOfProbability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MediumRangeOfProbability" xlink:to="AIM_MediumRangeOfProbability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_MediumRangeOfProbability_lbl" xml:lang="en-US">Medium range, rate</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_HighRangeOfProbability" xlink:label="AIM_HighRangeOfProbability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_HighRangeOfProbability" xlink:to="AIM_HighRangeOfProbability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_HighRangeOfProbability_lbl" xml:lang="en-US">High range, rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash equivalents-Marketable investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xml:lang="en-US">Conversion of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired" xlink:label="AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired" xlink:to="AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired_lbl" xml:lang="en-US">Cashless basis, expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_HighRangeOfProbability" xlink:to="AIM_HighRangeOfProbability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_HighRangeOfProbability_2_lbl" xml:lang="en-US">Probability, rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease costs:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term and variable lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:to="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease Payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lessee, operating lease, remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="us-gaap_DebtWeightedAverageInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtWeightedAverageInterestRate" xlink:to="us-gaap_DebtWeightedAverageInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtWeightedAverageInterestRate_lbl" xml:lang="en-US">Debt, weighted average interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expense excluding acquired in process cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopmentCosts" xlink:label="us-gaap_DevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentCosts" xlink:to="us-gaap_DevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentCosts_lbl" xml:lang="en-US">Development cost</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" xlink:label="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" xlink:to="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives_lbl" xml:lang="en-US">Estimated lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance" xlink:label="us-gaap_CostMaintenance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Invigilators cost</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_UnitsManufactured" xlink:label="AIM_UnitsManufactured" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_UnitsManufactured" xlink:to="AIM_UnitsManufactured_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_UnitsManufactured_lbl" xml:lang="en-US">Number of units manufactured</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_NumberOfVials" xlink:label="AIM_NumberOfVials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_NumberOfVials" xlink:to="AIM_NumberOfVials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_NumberOfVials_lbl" xml:lang="en-US">Additional number of vials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SuppliesExpense" xlink:label="us-gaap_SuppliesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SuppliesExpense" xlink:to="us-gaap_SuppliesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SuppliesExpense_lbl" xml:lang="en-US">Unrestricted grants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Stock options, aggregate intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Stock options, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MonthlyRetainerFee" xlink:label="AIM_MonthlyRetainerFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MonthlyRetainerFee" xlink:to="AIM_MonthlyRetainerFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_MonthlyRetainerFee_lbl" xml:lang="en-US">Monthly retainer fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductionCosts" xlink:label="us-gaap_ProductionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductionCosts" xlink:to="us-gaap_ProductionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductionCosts_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Grosss proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:to="AIM_SeriesAJuniorParticipatingPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SeriesAJuniorParticipatingPreferredStockMember_doc" xml:lang="en-US">Series A Junior Participating Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SeriesBConvertiblePreferredStockMember" xlink:to="AIM_SeriesBConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SeriesBConvertiblePreferredStockMember_doc" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PreferredStockStatedValuePerShare" xlink:to="AIM_PreferredStockStatedValuePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PreferredStockStatedValuePerShare_doc" xml:lang="en-US">Preferred stock stated value per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_GainLossOnWarrantIssuance" xlink:to="AIM_GainLossOnWarrantIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_GainLossOnWarrantIssuance_doc" xml:lang="en-US">Gain loss on warrant issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:to="AIM_GainFromSaleOfIncomeTaxOperatingLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_GainFromSaleOfIncomeTaxOperatingLoss_doc" xml:lang="en-US">Gain from sale of income tax operating loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:to="AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_doc" xml:lang="en-US">Stock issued during period value cashless exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockIssuedDuringPeriodValueCommittedShares" xlink:to="AIM_StockIssuedDuringPeriodValueCommittedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_StockIssuedDuringPeriodValueCommittedShares_doc" xml:lang="en-US">Stock issued during period value committed shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockIssuedDuringPeriodValuePreferredSharesExpired" xlink:to="AIM_StockIssuedDuringPeriodValuePreferredSharesExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_StockIssuedDuringPeriodValuePreferredSharesExpired_doc" xml:lang="en-US">Stock issued during period value preferred shares expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants" xlink:to="AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants_doc" xml:lang="en-US">Stock issued during period shares cashless exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockIssuedDuringPeriodSharesCommittedShares" xlink:to="AIM_StockIssuedDuringPeriodSharesCommittedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_StockIssuedDuringPeriodSharesCommittedShares_doc" xml:lang="en-US">Stock issued during period shares committed shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ChangesInRouAssets" xlink:to="AIM_ChangesInRouAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ChangesInRouAssets_doc" xml:lang="en-US">Changes in Rou assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ProceedsFromIssuanceOfEquityWarrants" xlink:to="AIM_ProceedsFromIssuanceOfEquityWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ProceedsFromIssuanceOfEquityWarrants_doc" xml:lang="en-US">Proceeds from issuance of equity warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_OperatingLeaserightOfUseAssets" xlink:to="AIM_OperatingLeaserightOfUseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_OperatingLeaserightOfUseAssets_doc" xml:lang="en-US">Operating leaseright of use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_UnrealizedGainLossOnMarketableInvestments" xlink:to="AIM_UnrealizedGainLossOnMarketableInvestments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_UnrealizedGainLossOnMarketableInvestments_doc" xml:lang="en-US">Unrealized gain loss on marketable investments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ConversionOfSeriesBPreferred" xlink:to="AIM_ConversionOfSeriesBPreferred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ConversionOfSeriesBPreferred_doc" xml:lang="en-US">Conversion Of Series B preferred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AbandonmentOfPatentAndTrademarkRights" xlink:to="AIM_AbandonmentOfPatentAndTrademarkRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AbandonmentOfPatentAndTrademarkRights_doc" xml:lang="en-US">Abandonment of patent and trademark rights.</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ProceedsFromRepaymentOfSaleOfPropertyPlantAndEquipment" xlink:label="AIM_ProceedsFromRepaymentOfSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ProceedsFromRepaymentOfSaleOfPropertyPlantAndEquipment" xlink:to="AIM_ProceedsFromRepaymentOfSaleOfPropertyPlantAndEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ProceedsFromRepaymentOfSaleOfPropertyPlantAndEquipment_doc" xml:lang="en-US">Proceeds from repayment of sale of property plant and equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ConversionOfNotePayableInterestIntoShares" xlink:to="AIM_ConversionOfNotePayableInterestIntoShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ConversionOfNotePayableInterestIntoShares_doc" xml:lang="en-US">Conversion of note payable interest into shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MutualFundsMember" xlink:label="AIM_MutualFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MutualFundsMember" xlink:to="AIM_MutualFundsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_MutualFundsMember_doc" xml:lang="en-US">Mutual Funds [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FinitelivedIntangibleAssetsAbandonments" xlink:to="AIM_FinitelivedIntangibleAssetsAbandonments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_FinitelivedIntangibleAssetsAbandonments_doc" xml:lang="en-US">Finite lived intangible assets abandonments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AccruedClinicalTrialExpensesCurrent" xlink:to="AIM_AccruedClinicalTrialExpensesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AccruedClinicalTrialExpensesCurrent_doc" xml:lang="en-US">Accrued clinical trial expenses current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_NotePurchaseAgreementMember" xlink:to="AIM_NotePurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_NotePurchaseAgreementMember_doc" xml:lang="en-US">Note Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StreetervilleCapitalLlcMember" xlink:to="AIM_StreetervilleCapitalLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_StreetervilleCapitalLlcMember_doc" xml:lang="en-US">Streeterville Capital LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ScheduleOfLongTermDebtInterestCostsExpenseAndCapitalTableTextBlock" xlink:label="AIM_ScheduleOfLongTermDebtInterestCostsExpenseAndCapitalTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ScheduleOfLongTermDebtInterestCostsExpenseAndCapitalTableTextBlock" xlink:to="AIM_ScheduleOfLongTermDebtInterestCostsExpenseAndCapitalTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ScheduleOfLongTermDebtInterestCostsExpenseAndCapitalTableTextBlock_doc" xml:lang="en-US">Schedule of long term debt interest costs expense and capital table text block.</link:label>
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ScheduleOfLongTermDebtAmortizationExpensesTableTextBlock" xlink:label="AIM_ScheduleOfLongTermDebtAmortizationExpensesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ScheduleOfLongTermDebtAmortizationExpensesTableTextBlock" xlink:to="AIM_ScheduleOfLongTermDebtAmortizationExpensesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ScheduleOfLongTermDebtAmortizationExpensesTableTextBlock_doc" xml:lang="en-US">Schedule of long term debt amortization expenses table text block.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="AIM_TwoThousandEighteenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_TwoThousandEighteenEquityIncentivePlanMember_doc" xml:lang="en-US">2018 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember" xlink:to="AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember_doc" xml:lang="en-US">Restated 2018 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Share-based compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_doc" xml:lang="en-US">Aggregate intrinsic value, granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_doc" xml:lang="en-US">Aggregate intrinsic value, forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_doc" xml:lang="en-US">Aggregate intrinsic value, expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for non vested option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award options vested weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award options nonvested weighted average remaining contractual term2.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_doc" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest options outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_doc" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest granted options outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_doc" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Options Expired Aggregate Intrinsic Value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_doc" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_doc" xml:lang="en-US">ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Total Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ConvertiblePreferredStockFaceValue" xlink:to="AIM_ConvertiblePreferredStockFaceValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ConvertiblePreferredStockFaceValue_doc" xml:lang="en-US">Convertible preferred stock face value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" xlink:to="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage_doc" xml:lang="en-US">Common stock shares with limitations and restrictions on usage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_DirectorsOfficersAndEmployeesMember" xlink:to="AIM_DirectorsOfficersAndEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_DirectorsOfficersAndEmployeesMember_doc" xml:lang="en-US">Directors, Officers and Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AllianceGlobalPartnersLLCMember" xlink:to="AIM_AllianceGlobalPartnersLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AllianceGlobalPartnersLLCMember_doc" xml:lang="en-US">Alliance Global Partners, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WarrantsMember" xlink:to="AIM_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_WarrantsMember_doc" xml:lang="en-US">Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_RepresentativeWarrantsMember" xlink:to="AIM_RepresentativeWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_RepresentativeWarrantsMember_doc" xml:lang="en-US">Representative Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PreFundedWarrantsMember" xlink:to="AIM_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PreFundedWarrantsMember_doc" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PercentageOfOutstandingStock" xlink:to="AIM_PercentageOfOutstandingStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PercentageOfOutstandingStock_doc" xml:lang="en-US">Percentage of outstanding stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_WarrantModifications" xlink:to="AIM_WarrantModifications_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_WarrantModifications_doc" xml:lang="en-US">Warrant modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MaximGroupLLCMember" xlink:to="AIM_MaximGroupLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_MaximGroupLLCMember_doc" xml:lang="en-US">Maxim Group LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_EquityDistributionAgreementMember" xlink:to="AIM_EquityDistributionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_EquityDistributionAgreementMember_doc" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AtlasSciencesLlcMember" xlink:to="AIM_AtlasSciencesLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AtlasSciencesLlcMember_doc" xml:lang="en-US">Atlas Sciences LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PurchaseAndRegistrationRightsAgreementMember" xlink:to="AIM_PurchaseAndRegistrationRightsAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PurchaseAndRegistrationRightsAgreementMember_doc" xml:lang="en-US">Purchase And Registration Rights Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MarketPricePercentage" xlink:to="AIM_MarketPricePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_MarketPricePercentage_doc" xml:lang="en-US">Market price, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PurchaseAgreementMember" xlink:to="AIM_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_TradingDailyMaximumLessorAmount" xlink:to="AIM_TradingDailyMaximumLessorAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_TradingDailyMaximumLessorAmount_doc" xml:lang="en-US">Trading daily maximum lessor amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_BeneficialOwnershipPercentage" xlink:to="AIM_BeneficialOwnershipPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_BeneficialOwnershipPercentage_doc" xml:lang="en-US">Beneficial ownership percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_StockIssuedDuringPeriodValueCommitmentShares" xlink:to="AIM_StockIssuedDuringPeriodValueCommitmentShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_StockIssuedDuringPeriodValueCommitmentShares_doc" xml:lang="en-US">Stock issued during period value commitment shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SecuritiesPurchaseAgreementMember" xlink:to="AIM_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClassBCommonWarrantMember" xlink:to="AIM_ClassBCommonWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ClassBCommonWarrantMember_doc" xml:lang="en-US">Class B Common Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PlacementAgentMember" xlink:to="AIM_PlacementAgentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PlacementAgentMember_doc" xml:lang="en-US">Placement Agent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization_doc" xml:lang="en-US">Operation lease right of use asset accumulated amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:to="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_doc" xml:lang="en-US">Lessee operating lease liability payments due after year three.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ResearchConsultingAndSupplyAgreementsTextBlock" xlink:to="AIM_ResearchConsultingAndSupplyAgreementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ResearchConsultingAndSupplyAgreementsTextBlock_doc" xml:lang="en-US">Research Consulting And Supply Agreements [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClinicalStudiesMember" xlink:to="AIM_ClinicalStudiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ClinicalStudiesMember_doc" xml:lang="en-US">Clinical Studies [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ManufacturingAndEngineeringMember" xlink:to="AIM_ManufacturingAndEngineeringMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ManufacturingAndEngineeringMember_doc" xml:lang="en-US">Manufacturing and Engineering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_QualityControlMember" xlink:to="AIM_QualityControlMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_QualityControlMember_doc" xml:lang="en-US">Quality Control [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_RegulatoryMember" xlink:to="AIM_RegulatoryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_RegulatoryMember_doc" xml:lang="en-US">Regulatory [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired" xlink:to="AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired_doc" xml:lang="en-US">Class of warrant or right number of securities called by each warrant expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock" xlink:to="AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock_doc" xml:lang="en-US">Schedule Of Assumptions To Estimate The Fair Value [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClassAWarrantMember" xlink:to="AIM_ClassAWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ClassAWarrantMember_doc" xml:lang="en-US">Class A Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClassBWarrantMember" xlink:to="AIM_ClassBWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ClassBWarrantMember_doc" xml:lang="en-US">Class B Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AmarexClinicalResearchLLCMember" xlink:to="AIM_AmarexClinicalResearchLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AmarexClinicalResearchLLCMember_doc" xml:lang="en-US">Amarex Clinical Research LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock" xlink:to="AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule Of Potential Liability Estimated The Range Of Probabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_LowRangeOfProbability" xlink:to="AIM_LowRangeOfProbability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_LowRangeOfProbability_doc" xml:lang="en-US">Low range of probability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MediumRangeOfProbability" xlink:to="AIM_MediumRangeOfProbability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_MediumRangeOfProbability_doc" xml:lang="en-US">Medium range of probability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" xlink:to="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ResearchAndDevelopmentExpenseCostEstimatedLives_doc" xml:lang="en-US">Research and development expense cost estimated lives.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_HighRangeOfProbability" xlink:to="AIM_HighRangeOfProbability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_HighRangeOfProbability_doc" xml:lang="en-US">High range of probability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AdvancedPancreaticCancerStudyAgreementMember" xlink:to="AIM_AdvancedPancreaticCancerStudyAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AdvancedPancreaticCancerStudyAgreementMember_doc" xml:lang="en-US">Advanced Pancreatic Cancer Study Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_PostCOVIDStudyAgreementMember" xlink:to="AIM_PostCOVIDStudyAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_PostCOVIDStudyAgreementMember_doc" xml:lang="en-US">Post COVID Study Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_UnitsManufactured" xlink:to="AIM_UnitsManufactured_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_UnitsManufactured_doc" xml:lang="en-US">Units manufactured.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_JubilantHollisterStierMember" xlink:to="AIM_JubilantHollisterStierMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_JubilantHollisterStierMember_doc" xml:lang="en-US">Jubilant HollisterStier [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_NumberOfVials" xlink:to="AIM_NumberOfVials_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_NumberOfVials_doc" xml:lang="en-US">Number of vials.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AmpligenManufacturingAgreementMember" xlink:to="AIM_AmpligenManufacturingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AmpligenManufacturingAgreementMember_doc" xml:lang="en-US">Ampligen Manufacturing Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SterlingPharmaSolutionsMember" xlink:to="AIM_SterlingPharmaSolutionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_SterlingPharmaSolutionsMember_doc" xml:lang="en-US">Sterling Pharma Solutions [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MasterServiceAgreementAndQualityAgreementMember" xlink:to="AIM_MasterServiceAgreementAndQualityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_MasterServiceAgreementAndQualityAgreementMember_doc" xml:lang="en-US">Master Service Agreement And Quality Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ErasmusUniversityMedicalCenterMember" xlink:to="AIM_ErasmusUniversityMedicalCenterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ErasmusUniversityMedicalCenterMember_doc" xml:lang="en-US">Erasmus University Medical Center [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_JointClinicalStudyAgreementMember" xlink:to="AIM_JointClinicalStudyAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_JointClinicalStudyAgreementMember_doc" xml:lang="en-US">Joint Clinical Study Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AzenovaLLCMember" xlink:to="AIM_AzenovaLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AzenovaLLCMember_doc" xml:lang="en-US">Azenova LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ConsultingAgreementMember" xlink:to="AIM_ConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ConsultingAgreementMember_doc" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_AlcamiCorporationMember" xlink:to="AIM_AlcamiCorporationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_AlcamiCorporationMember_doc" xml:lang="en-US">Alcami Corporation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClassCCommonWarrantMember" xlink:to="AIM_ClassCCommonWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ClassCCommonWarrantMember_doc" xml:lang="en-US">Class C Common Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ClassDCommonWarrantMember" xlink:to="AIM_ClassDCommonWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_ClassDCommonWarrantMember_doc" xml:lang="en-US">Class D Common Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:to="AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_doc" xml:lang="en-US">Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_MonthlyRetainerFee" xlink:to="AIM_MonthlyRetainerFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="AIM_MonthlyRetainerFee_doc" xml:lang="en-US">Monthly retainer fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_2_lbl" xml:lang="en-US">Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_2_lbl" xml:lang="en-US">Marketable Security, Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_2_lbl" xml:lang="en-US">Gain (Loss) on Sale of Derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_FinitelivedIntangibleAssetsAbandonments" xlink:to="AIM_FinitelivedIntangibleAssetsAbandonments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_FinitelivedIntangibleAssetsAbandonments_3_lbl" xml:lang="en-US">FinitelivedIntangibleAssetsAbandonments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_2_lbl" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_2_lbl" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:to="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_3_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Forfeited [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_4_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2" xlink:to="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_3_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_2_lbl" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_2_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:to="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_3_lbl" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_3_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization_3_lbl" xml:lang="en-US">OperationLeaseRightOfUseAssetAccumulatedAmortization</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>30
<FILENAME>aim-20240930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aimimmuno.com/role/Cover" xlink:href="aim-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BalanceSheets" xlink:href="aim-20240930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BalanceSheetsParenthetical" xlink:href="aim-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfComprehensiveLoss" xlink:href="aim-20240930.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="aim-20240930.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StatementsOfCashFlows" xlink:href="aim-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/BusinessAndBasisOfPresentation" xlink:href="aim-20240930.xsd#BusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/CashAndCashEquivalents" xlink:href="aim-20240930.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableSecurities" xlink:href="aim-20240930.xsd#MarketableSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PropertyAndEquipmentNet" xlink:href="aim-20240930.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" xlink:href="aim-20240930.xsd#PatentsAndTrademarkRightsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/AccruedExpenses" xlink:href="aim-20240930.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/UnsecuredPromissoryNote" xlink:href="aim-20240930.xsd#UnsecuredPromissoryNote" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Equity-basedCompensation" xlink:href="aim-20240930.xsd#Equity-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquity" xlink:href="aim-20240930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/NetLossPerShare" xlink:href="aim-20240930.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/RecentAccountingPronouncements" xlink:href="aim-20240930.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValue" xlink:href="aim-20240930.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Leases" xlink:href="aim-20240930.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" xlink:href="aim-20240930.xsd#ResearchConsultingAndSupplyAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SubsequentEvents" xlink:href="aim-20240930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PropertyAndEquipmentNetTables" xlink:href="aim-20240930.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" xlink:href="aim-20240930.xsd#PatentsAndTrademarkRightsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/AccruedExpensesTables" xlink:href="aim-20240930.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/UnsecuredPromissoryNoteTables" xlink:href="aim-20240930.xsd#UnsecuredPromissoryNoteTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Equity-basedCompensationTables" xlink:href="aim-20240930.xsd#Equity-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValueTables" xlink:href="aim-20240930.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/LeasesTables" xlink:href="aim-20240930.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/CashAndCashEquivalentsDetailsNarrative" xlink:href="aim-20240930.xsd#CashAndCashEquivalentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/MarketableSecuritiesDetailsNarrative" xlink:href="aim-20240930.xsd#MarketableSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="aim-20240930.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="aim-20240930.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" xlink:href="aim-20240930.xsd#ScheduleOfPatentAndTrademarkRightsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:href="aim-20240930.xsd#ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:href="aim-20240930.xsd#ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" xlink:href="aim-20240930.xsd#PatentsAndTrademarkRightsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="aim-20240930.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails" xlink:href="aim-20240930.xsd#ScheduleOfLongTermDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative" xlink:href="aim-20240930.xsd#UnsecuredPromissoryNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="aim-20240930.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" xlink:href="aim-20240930.xsd#ScheduleOfUnvestedStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative" xlink:href="aim-20240930.xsd#Equity-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" xlink:href="aim-20240930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/NetLossPerShareDetailsNarrative" xlink:href="aim-20240930.xsd#NetLossPerShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails" xlink:href="aim-20240930.xsd#ScheduleOfAssumptionsToEstimateFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfPotentialLiabilityDetails" xlink:href="aim-20240930.xsd#ScheduleOfPotentialLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="aim-20240930.xsd#ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/FairValueDetailsNarrative" xlink:href="aim-20240930.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:href="aim-20240930.xsd#ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:href="aim-20240930.xsd#ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/LeasesDetailsNarrative" xlink:href="aim-20240930.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:href="aim-20240930.xsd#ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" xlink:href="aim-20240930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="loc_AIMSeriesAJuniorParticipatingPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesAJuniorParticipatingPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AIMSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="loc_AIMSeriesAJuniorParticipatingPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesAJuniorParticipatingPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AIMSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PreferredStockStatedValuePerShare" xlink:label="loc_AIMPreferredStockStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMPreferredStockStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaapCostsAndExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingCosts" xlink:label="loc_us-gaapManufacturingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapManufacturingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostsAndExpensesAbstract" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_GainLossOnWarrantIssuance" xlink:label="loc_AIMGainLossOnWarrantIssuance" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_AIMGainLossOnWarrantIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:label="loc_AIMGainFromSaleOfIncomeTaxOperatingLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_AIMGainFromSaleOfIncomeTaxOperatingLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:label="loc_AIMStockIssuedDuringPeriodValueCashlessExerciseOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMStockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants" xlink:label="loc_AIMStockIssuedDuringPeriodShareCsashlessExerciseOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMStockIssuedDuringPeriodShareCsashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodValueCommittedShares" xlink:label="loc_AIMStockIssuedDuringPeriodValueCommittedShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMStockIssuedDuringPeriodValueCommittedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodSharesCommittedShares" xlink:label="loc_AIMStockIssuedDuringPeriodSharesCommittedShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMStockIssuedDuringPeriodSharesCommittedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodValuePreferredSharesExpired" xlink:label="loc_AIMStockIssuedDuringPeriodValuePreferredSharesExpired" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMStockIssuedDuringPeriodValuePreferredSharesExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AbandonmentOfPatentAndTrademarkRights" xlink:label="loc_AIMAbandonmentOfPatentAndTrademarkRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AIMAbandonmentOfPatentAndTrademarkRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ChangesInRouAssets" xlink:label="loc_AIMChangesInRouAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AIMChangesInRouAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_GainFromSaleOfIncomeTaxOperatingLoss" xlink:label="loc_AIMGainFromSaleOfIncomeTaxOperatingLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AIMGainFromSaleOfIncomeTaxOperatingLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaapGainLossOnSaleOfDerivatives" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:label="loc_us-gaapProceedsFromSaleOfInvestmentProjects" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfInvestmentProjects" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ProceedsFromIssuanceOfEquityWarrants" xlink:label="loc_AIMProceedsFromIssuanceOfEquityWarrants" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_AIMProceedsFromIssuanceOfEquityWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_OperatingLeaserightOfUseAssets" xlink:label="loc_AIMOperatingLeaserightOfUseAssets" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AIMOperatingLeaserightOfUseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_UnrealizedGainLossOnMarketableInvestments" xlink:label="loc_AIMUnrealizedGainLossOnMarketableInvestments" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AIMUnrealizedGainLossOnMarketableInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ConversionOfSeriesBPreferred" xlink:label="loc_AIMConversionOfSeriesBPreferred" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AIMConversionOfSeriesBPreferred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ConversionOfNotePayableInterestIntoShares" xlink:label="loc_AIMConversionOfNotePayableInterestIntoShares" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_AIMConversionOfNotePayableInterestIntoShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/BusinessAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/CashAndCashEquivalents" xlink:title="00000008 - Disclosure - Cash and Cash Equivalents">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableSecurities" xlink:title="00000009 - Disclosure - Marketable Securities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PropertyAndEquipmentNet" xlink:title="00000010 - Disclosure - Property and Equipment, net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNet" xlink:title="00000011 - Disclosure - Patents, and Trademark Rights, Net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/AccruedExpenses" xlink:title="00000012 - Disclosure - Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/UnsecuredPromissoryNote" xlink:title="00000013 - Disclosure - Unsecured Promissory Note">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Equity-basedCompensation" xlink:title="00000014 - Disclosure - Equity-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/NetLossPerShare" xlink:title="00000016 - Disclosure - Net Loss Per Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/RecentAccountingPronouncements" xlink:title="00000017 - Disclosure - Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValue" xlink:title="00000018 - Disclosure - Fair Value">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Leases" xlink:title="00000019 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements" xlink:title="00000020 - Disclosure - Research, Consulting and Supply Agreements">
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract" xlink:label="loc_AIMDisclosureResearchConsultingAndSupplyAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ResearchConsultingAndSupplyAgreementsTextBlock" xlink:label="loc_AIMResearchConsultingAndSupplyAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureResearchConsultingAndSupplyAgreementsAbstract" xlink:to="loc_AIMResearchConsultingAndSupplyAgreementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PropertyAndEquipmentNetTables" xlink:title="00000022 - Disclosure - Property and Equipment, net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables" xlink:title="00000023 - Disclosure - Patents, and Trademark Rights, Net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/AccruedExpensesTables" xlink:title="00000024 - Disclosure - Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/UnsecuredPromissoryNoteTables" xlink:title="00000025 - Disclosure - Unsecured Promissory Note (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Equity-basedCompensationTables" xlink:title="00000026 - Disclosure - Equity-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedShareActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValueTables" xlink:title="00000027 - Disclosure - Fair Value (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock" xlink:label="loc_AIMScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_AIMScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock" xlink:label="loc_AIMScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_AIMScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/LeasesTables" xlink:title="00000028 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/CashAndCashEquivalentsDetailsNarrative" xlink:title="00000029 - Disclosure - Cash and Cash Equivalents (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/MarketableSecuritiesDetailsNarrative" xlink:title="00000030 - Disclosure - Marketable Securities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaapHeldToMaturitySecuritiesFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapHeldToMaturitySecuritiesFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity" xlink:label="loc_us-gaapDebtInstrumentConvertibleTypeOfEquitySecurity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapDebtInstrumentConvertibleTypeOfEquitySecurity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000031 - Disclosure - Schedule of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000032 - Disclosure - Property and Equipment, net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails" xlink:title="00000033 - Disclosure - Schedule of Patent and Trademark Rights (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails" xlink:title="00000034 - Disclosure - Schedule of Changes in Patents, Trademark Rights (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_FinitelivedIntangibleAssetsAbandonments" xlink:label="loc_AIMFinitelivedIntangibleAssetsAbandonments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_AIMFinitelivedIntangibleAssetsAbandonments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails" xlink:title="00000035 - Disclosure - Schedule of Amortization of Patents and Trademarks (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="loc_AIMFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_AIMFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative" xlink:title="00000036 - Disclosure - Patents, and Trademark Rights, Net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000037 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AccruedClinicalTrialExpensesCurrent" xlink:label="loc_AIMAccruedClinicalTrialExpensesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_AIMAccruedClinicalTrialExpensesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails" xlink:title="00000038 - Disclosure - Schedule of Long Term Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaapLongTermDebtCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative" xlink:title="00000039 - Disclosure - Unsecured Promissory Note (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_NotePurchaseAgreementMember" xlink:label="loc_AIMNotePurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMNotePurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StreetervilleCapitalLlcMember" xlink:label="loc_AIMStreetervilleCapitalLlcMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_AIMStreetervilleCapitalLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaapDeferredFinanceCostsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaapUnsecuredDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapUnsecuredDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaapInterestExpenseDebtExcludingAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapInterestExpenseDebtExcludingAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoanProcessingFee" xlink:label="loc_us-gaapLoanProcessingFee" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLoanProcessingFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentGross" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:label="loc_us-gaapDeferredFinanceCostsNoncurrentGross" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNoncurrentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountNoncurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsNoncurrentNet" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNoncurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionDescription" xlink:label="loc_us-gaapDebtInstrumentRedemptionDescription" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentRedemptionDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000040 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:label="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails" xlink:title="00000041 - Disclosure - Schedule of Unvested Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="loc_us-gaapGranteeStatusAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapGranteeStatusAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="loc_us-gaapGranteeStatusDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusAxis" xlink:to="loc_us-gaapGranteeStatusDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGranteeStatusDomain" xlink:to="loc_us-gaapShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue" xlink:label="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_AIMSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative" xlink:title="00000042 - Disclosure - Equity-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_AIMTwoThousandEighteenEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMTwoThousandEighteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_AIMRestatedTwoThousandEighteenEquityIncentivePlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_AIMRestatedTwoThousandEighteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember" xlink:label="loc_srtOfficerMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000043 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesAJuniorParticipatingPreferredStockMember" xlink:label="loc_AIMSeriesAJuniorParticipatingPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesAJuniorParticipatingPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SeriesBConvertiblePreferredStockMember" xlink:label="loc_AIMSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassBCommonWarrantMember" xlink:label="loc_AIMClassBCommonWarrantMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMClassBCommonWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightsMember" xlink:label="loc_us-gaapRightsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_WarrantsMember" xlink:label="loc_AIMWarrantsMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_RepresentativeWarrantsMember" xlink:label="loc_AIMRepresentativeWarrantsMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMRepresentativeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PreFundedWarrantsMember" xlink:label="loc_AIMPreFundedWarrantsMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_AIMPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_DirectorsOfficersAndEmployeesMember" xlink:label="loc_AIMDirectorsOfficersAndEmployeesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_AIMDirectorsOfficersAndEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AllianceGlobalPartnersLLCMember" xlink:label="loc_AIMAllianceGlobalPartnersLLCMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAllianceGlobalPartnersLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MaximGroupLLCMember" xlink:label="loc_AIMMaximGroupLLCMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMMaximGroupLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AtlasSciencesLlcMember" xlink:label="loc_AIMAtlasSciencesLlcMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAtlasSciencesLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_EquityDistributionAgreementMember" xlink:label="loc_AIMEquityDistributionAgreementMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMEquityDistributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PurchaseAndRegistrationRightsAgreementMember" xlink:label="loc_AIMPurchaseAndRegistrationRightsAgreementMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMPurchaseAndRegistrationRightsAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PurchaseAgreementMember" xlink:label="loc_AIMPurchaseAgreementMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SecuritiesPurchaseAgreementMember" xlink:label="loc_AIMSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AtlasSciencesLlcMember" xlink:label="loc_AIMAtlasSciencesLlcMember_2" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_AIMAtlasSciencesLlcMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PlacementAgentMember" xlink:label="loc_AIMPlacementAgentMember" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_AIMPlacementAgentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PreferredStockStatedValuePerShare" xlink:label="loc_AIMPreferredStockStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMPreferredStockStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaapCommonStockSharesSubscriptions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesSubscriptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ConvertiblePreferredStockFaceValue" xlink:label="loc_AIMConvertiblePreferredStockFaceValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMConvertiblePreferredStockFaceValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage" xlink:label="loc_AIMCommonStockSharesWithLimitationsAndRestrictionsOnUsage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMCommonStockSharesWithLimitationsAndRestrictionsOnUsage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PercentageOfOutstandingStock" xlink:label="loc_AIMPercentageOfOutstandingStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMPercentageOfOutstandingStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_WarrantModifications" xlink:label="loc_AIMWarrantModifications" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMWarrantModifications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MarketPricePercentage" xlink:label="loc_AIMMarketPricePercentage" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMMarketPricePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_TradingDailyMaximumLessorAmount" xlink:label="loc_AIMTradingDailyMaximumLessorAmount" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMTradingDailyMaximumLessorAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_BeneficialOwnershipPercentage" xlink:label="loc_AIMBeneficialOwnershipPercentage" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMBeneficialOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_StockIssuedDuringPeriodValueCommitmentShares" xlink:label="loc_AIMStockIssuedDuringPeriodValueCommitmentShares" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_AIMStockIssuedDuringPeriodValueCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/NetLossPerShareDetailsNarrative" xlink:title="00000044 - Disclosure - Net Loss Per Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails" xlink:title="00000045 - Disclosure - Schedule of Assumptions to Estimate the Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassAWarrantMember" xlink:label="loc_AIMClassAWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMClassAWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassBWarrantMember" xlink:label="loc_AIMClassBWarrantMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMClassBWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfPotentialLiabilityDetails" xlink:title="00000046 - Disclosure - Schedule of Potential Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_LowRangeOfProbability" xlink:label="loc_AIMLowRangeOfProbability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_AIMLowRangeOfProbability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MediumRangeOfProbability" xlink:label="loc_AIMMediumRangeOfProbability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_AIMMediumRangeOfProbability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_HighRangeOfProbability" xlink:label="loc_AIMHighRangeOfProbability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_AIMHighRangeOfProbability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="00000047 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaapInvestmentsFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapInvestmentsFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/FairValueDetailsNarrative" xlink:title="00000048 - Disclosure - Fair Value (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired" xlink:label="loc_AIMClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_AIMClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_HighRangeOfProbability" xlink:label="loc_AIMHighRangeOfProbability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_AIMHighRangeOfProbability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails" xlink:title="00000049 - Disclosure - Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaapLeaseCostAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCostAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails" xlink:title="00000050 - Disclosure - Schedule of Operating Lease Future Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:label="loc_AIMLesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_AIMLesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/LeasesDetailsNarrative" xlink:title="00000051 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRenewalTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="loc_AIMOperationLeaseRightOfUseAssetAccumulatedAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMOperationLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaapDebtWeightedAverageInterestRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtWeightedAverageInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative" xlink:title="00000052 - Disclosure - Research, Consulting and Supply Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract" xlink:label="loc_AIMDisclosureResearchConsultingAndSupplyAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AIMDisclosureResearchConsultingAndSupplyAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClinicalStudiesMember" xlink:label="loc_AIMClinicalStudiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMClinicalStudiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ManufacturingAndEngineeringMember" xlink:label="loc_AIMManufacturingAndEngineeringMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMManufacturingAndEngineeringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_QualityControlMember" xlink:label="loc_AIMQualityControlMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMQualityControlMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_RegulatoryMember" xlink:label="loc_AIMRegulatoryMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_AIMRegulatoryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AmarexClinicalResearchLLCMember" xlink:label="loc_AIMAmarexClinicalResearchLLCMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAmarexClinicalResearchLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_JubilantHollisterStierMember" xlink:label="loc_AIMJubilantHollisterStierMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMJubilantHollisterStierMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SterlingPharmaSolutionsMember" xlink:label="loc_AIMSterlingPharmaSolutionsMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMSterlingPharmaSolutionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ErasmusUniversityMedicalCenterMember" xlink:label="loc_AIMErasmusUniversityMedicalCenterMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMErasmusUniversityMedicalCenterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AzenovaLLCMember" xlink:label="loc_AIMAzenovaLLCMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAzenovaLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AlcamiCorporationMember" xlink:label="loc_AIMAlcamiCorporationMember" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_AIMAlcamiCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AdvancedPancreaticCancerStudyAgreementMember" xlink:label="loc_AIMAdvancedPancreaticCancerStudyAgreementMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMAdvancedPancreaticCancerStudyAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_PostCOVIDStudyAgreementMember" xlink:label="loc_AIMPostCOVIDStudyAgreementMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMPostCOVIDStudyAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_AmpligenManufacturingAgreementMember" xlink:label="loc_AIMAmpligenManufacturingAgreementMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMAmpligenManufacturingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MasterServiceAgreementAndQualityAgreementMember" xlink:label="loc_AIMMasterServiceAgreementAndQualityAgreementMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMMasterServiceAgreementAndQualityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_JointClinicalStudyAgreementMember" xlink:label="loc_AIMJointClinicalStudyAgreementMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMJointClinicalStudyAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ConsultingAgreementMember" xlink:label="loc_AIMConsultingAgreementMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopmentCosts" xlink:label="loc_us-gaapDevelopmentCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDevelopmentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ResearchAndDevelopmentExpenseCostEstimatedLives" xlink:label="loc_AIMResearchAndDevelopmentExpenseCostEstimatedLives" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMResearchAndDevelopmentExpenseCostEstimatedLives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance" xlink:label="loc_us-gaapCostMaintenance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostMaintenance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_UnitsManufactured" xlink:label="loc_AIMUnitsManufactured" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMUnitsManufactured" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_NumberOfVials" xlink:label="loc_AIMNumberOfVials" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMNumberOfVials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SuppliesExpense" xlink:label="loc_us-gaapSuppliesExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSuppliesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_MonthlyRetainerFee" xlink:label="loc_AIMMonthlyRetainerFee" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_AIMMonthlyRetainerFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductionCosts" xlink:label="loc_us-gaapProductionCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProductionCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000053 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_SecuritiesPurchaseAgreementMember" xlink:label="loc_AIMSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_AIMSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassCCommonWarrantMember" xlink:label="loc_AIMClassCCommonWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMClassCCommonWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aim-20240930.xsd#AIM_ClassDCommonWarrantMember" xlink:label="loc_AIMClassDCommonWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_AIMClassDCommonWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562529564160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 11, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-27072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AIM
IMMUNOTECH INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000946644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-0845822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2117
SW Highway 484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ocala<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">448-7797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AIM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,706,446<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562528917888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 915,000<span></span>
</td>
<td class="nump">$ 5,439,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">6,287,000<span></span>
</td>
<td class="nump">7,631,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Funds receivable from New Jersey net operating loss</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,184,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">368,000<span></span>
</td>
<td class="nump">302,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,570,000<span></span>
</td>
<td class="nump">14,556,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">117,000<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">653,000<span></span>
</td>
<td class="nump">697,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent and trademark rights, net</a></td>
<td class="nump">2,532,000<span></span>
</td>
<td class="nump">2,313,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,716,000<span></span>
</td>
<td class="nump">1,688,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">13,588,000<span></span>
</td>
<td class="nump">19,381,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,264,000<span></span>
</td>
<td class="nump">6,443,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,011,000<span></span>
</td>
<td class="nump">1,986,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">232,000<span></span>
</td>
<td class="nump">223,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of note payable, net</a></td>
<td class="nump">2,593,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,100,000<span></span>
</td>
<td class="nump">8,652,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">437,000<span></span>
</td>
<td class="nump">495,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, net</a></td>
<td class="nump">139,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,676,000<span></span>
</td>
<td class="nump">9,147,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 13 and 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 58,668,647 and 49,102,484 as of September 30, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">59,000<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">423,714,000<span></span>
</td>
<td class="nump">419,004,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(420,861,000)<span></span>
</td>
<td class="num">(409,508,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,912,000<span></span>
</td>
<td class="nump">10,234,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">13,588,000<span></span>
</td>
<td class="nump">19,381,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember', window );">Series A Junior Participating Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 689,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562533167792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">58,668,647<span></span>
</td>
<td class="nump">49,102,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">58,668,647<span></span>
</td>
<td class="nump">49,102,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember', window );">Series A Junior Participating Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_PreferredStockStatedValuePerShare', window );">Preferred stock, stated value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_PreferredStockStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock stated value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_PreferredStockStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562532751952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Clinical treatment programs - US</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManufacturingCosts', window );">Production costs</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">4,533<span></span>
</td>
<td class="nump">7,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,079<span></span>
</td>
<td class="nump">5,439<span></span>
</td>
<td class="nump">9,485<span></span>
</td>
<td class="nump">10,280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total Costs and Expenses</a></td>
<td class="nump">4,524<span></span>
</td>
<td class="nump">8,203<span></span>
</td>
<td class="nump">14,042<span></span>
</td>
<td class="nump">18,049<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(4,489)<span></span>
</td>
<td class="num">(8,157)<span></span>
</td>
<td class="num">(13,917)<span></span>
</td>
<td class="num">(17,912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on investments</a></td>
<td class="nump">273<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">3,379<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense and other finance costs</a></td>
<td class="num">(202)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(453)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_GainLossOnWarrantIssuance', window );">(Loss) on warrant issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(458)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_GainFromSaleOfIncomeTaxOperatingLoss', window );">Gain from sale of income tax operating losses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (3,700)<span></span>
</td>
<td class="num">$ (7,816)<span></span>
</td>
<td class="num">$ (11,353)<span></span>
</td>
<td class="num">$ (16,386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding basic</a></td>
<td class="nump">57,677,016<span></span>
</td>
<td class="nump">48,635,165<span></span>
</td>
<td class="nump">53,351,467<span></span>
</td>
<td class="nump">48,483,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding diluted</a></td>
<td class="nump">57,677,016<span></span>
</td>
<td class="nump">48,635,165<span></span>
</td>
<td class="nump">53,351,467<span></span>
</td>
<td class="nump">48,483,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_GainFromSaleOfIncomeTaxOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain from sale of income tax operating loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_GainFromSaleOfIncomeTaxOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_GainLossOnWarrantIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on warrant issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_GainLossOnWarrantIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred in the production of goods for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562530347056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series B Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 418,270<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (380,546)<span></span>
</td>
<td class="nump">$ 38,468<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,084,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net Comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,661)<span></span>
</td>
<td class="num">(3,661)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Equity-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Series B preferred shares converted to common shares</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Series B preferred shares converted to common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">418,456<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(384,207)<span></span>
</td>
<td class="nump">34,989<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,407,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">418,270<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(380,546)<span></span>
</td>
<td class="nump">38,468<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,084,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">418,796<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(396,932)<span></span>
</td>
<td class="nump">22,602<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,797,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">418,456<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(384,207)<span></span>
</td>
<td class="nump">34,989<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,407,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net Comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,909)<span></span>
</td>
<td class="num">(4,909)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Equity-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Series B preferred shares converted to common shares</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Series B preferred shares converted to common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">418,513<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(389,116)<span></span>
</td>
<td class="nump">30,135<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,419,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net Comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,816)<span></span>
</td>
<td class="num">(7,816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Equity-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Series B preferred shares converted to common shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">418,796<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(396,932)<span></span>
</td>
<td class="nump">22,602<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,797,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">419,004<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(409,508)<span></span>
</td>
<td class="nump">10,234<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,102,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants', window );">Cashless Exercise of Warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_StockIssuedDuringPeriodValueCommittedShares', window );">Committed shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_StockIssuedDuringPeriodSharesCommittedShares', window );">Committed Shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net Comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,817)<span></span>
</td>
<td class="num">(5,817)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">419,412<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(415,325)<span></span>
</td>
<td class="nump">4,826<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,251,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">419,004<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(409,508)<span></span>
</td>
<td class="nump">10,234<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,102,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">423,714<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(420,861)<span></span>
</td>
<td class="nump">2,912<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,668,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">419,412<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(415,325)<span></span>
</td>
<td class="nump">4,826<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,251,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,884,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Equity-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net Comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,836)<span></span>
</td>
<td class="num">(1,836)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_StockIssuedDuringPeriodValuePreferredSharesExpired', window );">Series B preferred shares expired</a></td>
<td class="num">(689)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">423,206<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(417,161)<span></span>
</td>
<td class="nump">6,102<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,136,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">653,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net Comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,700)<span></span>
</td>
<td class="num">(3,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_StockIssuedDuringPeriodValuePreferredSharesExpired', window );">Series B preferred shares expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Equity-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Equity-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 423,714<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (420,861)<span></span>
</td>
<td class="nump">$ 2,912<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,668,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_StockIssuedDuringPeriodSharesCommittedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares committed shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_StockIssuedDuringPeriodSharesCommittedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_StockIssuedDuringPeriodValueCommittedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value committed shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_StockIssuedDuringPeriodValueCommittedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_StockIssuedDuringPeriodValuePreferredSharesExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value preferred shares expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_StockIssuedDuringPeriodValuePreferredSharesExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562529947152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,353,000)<span></span>
</td>
<td class="num">$ (16,386,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_AbandonmentOfPatentAndTrademarkRights', window );">Abandonment of patent and trademark rights</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of patent, trademark rights</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ChangesInRouAssets', window );">Changes in right of use assets</a></td>
<td class="nump">226,000<span></span>
</td>
<td class="nump">151,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_GainFromSaleOfIncomeTaxOperatingLoss', window );">Gain from sale of income tax operating losses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(900,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">490,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">(Gain) loss on sale of marketable securities</a></td>
<td class="num">(95,000)<span></span>
</td>
<td class="nump">201,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Loss on issuance of warrants</a></td>
<td class="nump">458,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of financial obligation</a></td>
<td class="nump">232,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Funds receivable from New Jersey net operating loss</a></td>
<td class="nump">1,181,000<span></span>
</td>
<td class="nump">1,676,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets and other non-current assets</a></td>
<td class="num">(63,000)<span></span>
</td>
<td class="nump">192,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="num">(231,000)<span></span>
</td>
<td class="num">(136,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(1,028,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(179,000)<span></span>
</td>
<td class="nump">2,411,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(799,000)<span></span>
</td>
<td class="nump">915,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,933,000)<span></span>
</td>
<td class="num">(11,509,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfInvestmentProjects', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">1,597,000<span></span>
</td>
<td class="nump">924,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of marketable securities</a></td>
<td class="num">(158,000)<span></span>
</td>
<td class="num">(1,155,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">(Purchase of) property and equipment</a></td>
<td class="num">(18,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of patent and trademark rights</a></td>
<td class="num">(419,000)<span></span>
</td>
<td class="num">(377,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">1,002,000<span></span>
</td>
<td class="num">(618,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of stock, net of issuance costs</a></td>
<td class="nump">860,000<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from note payable, net of issuance costs</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ProceedsFromIssuanceOfEquityWarrants', window );">Proceeds from issuance of equity warrants</a></td>
<td class="nump">2,047,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,407,000<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(4,524,000)<span></span>
</td>
<td class="num">(11,789,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">5,439,000<span></span>
</td>
<td class="nump">27,053,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">915,000<span></span>
</td>
<td class="nump">15,264,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_OperatingLeaserightOfUseAssets', window );">Operating lease-Right of Use Assets</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_UnrealizedGainLossOnMarketableInvestments', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">373,000<span></span>
</td>
<td class="num">(71,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ConversionOfSeriesBPreferred', window );">Conversion of Series B preferred</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ConversionOfNotePayableInterestIntoShares', window );">Conversion of note payable interest into shares</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_AbandonmentOfPatentAndTrademarkRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Abandonment of patent and trademark rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_AbandonmentOfPatentAndTrademarkRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ChangesInRouAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in Rou assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ChangesInRouAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ConversionOfNotePayableInterestIntoShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of note payable interest into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ConversionOfNotePayableInterestIntoShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ConversionOfSeriesBPreferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Series B preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ConversionOfSeriesBPreferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_GainFromSaleOfIncomeTaxOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain from sale of income tax operating loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_GainFromSaleOfIncomeTaxOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_OperatingLeaserightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leaseright of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_OperatingLeaserightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ProceedsFromIssuanceOfEquityWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of equity warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ProceedsFromIssuanceOfEquityWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_UnrealizedGainLossOnMarketableInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized gain loss on marketable investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_UnrealizedGainLossOnMarketableInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfInvestmentProjects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of investment projects held by an entity in hopes of getting a future return or interest from it.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfInvestmentProjects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534487824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business and Basis of Presentation</a></td>
<td class="text"><p id="xdx_808_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zvXrSbojjZ67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1: <span id="xdx_825_znFavMe4BT99">Business and Basis of Presentation</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
ImmunoTech Inc. and its subsidiaries (collectively, &#8220;AIM&#8221;, &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;) are
an immuno-pharma company headquartered in Ocala, Florida,  focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical
and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system
of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM&#8217;s
flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (&#8220;dsRNA&#8221;)
molecule being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has not been approved
by the FDA or marketed in the United States but is approved for commercial sale in the Argentine Republic for the treatment of severe
Chronic Fatigue Syndrome (&#8220;CFS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently proceeding primarily in four areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
                                            clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic
                                            cancer.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating
                                            Ampligen across multiple cancers as a potential therapy that modifies the tumor microenvironment
                                            with the goal of increasing anti-tumor responses to checkpoint inhibitors.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exploring
                                            Ampligen&#8217;s antiviral activities and potential use as a prophylactic or treatment for
                                            existing viruses, new viruses and mutated viruses thereof.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluating
                                            Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (&#8220;ME/CFS&#8221;)
                                            and fatigue and/or the Post-COVID condition of fatigue.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic
cancer, ME/CFS and Post-COVID conditions having priority over antiviral experimentation. The Company intends that priority clinical work
be conducted in trials authorized by the FDA or European Medicines Agency (&#8220;EMA&#8221;), which trials support a potential future
NDA. However, AIM&#8217;s antiviral experimentation is designed to accumulate additional preliminary data supporting their hypothesis
that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection.
Accordingly, AIM will conduct antiviral programs in those venues most readily available and able to generate valid proof-of-concept data,
including foreign venues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM&#8217;s
business plan requires one or more Contract Manufacturing Organizations (&#8220;CMO&#8221;) to produce Ampligen and its Active Pharmaceutical
Ingredients (APIs). This includes utilizing Jubilant HollisterStier and Sterling for the manufacture of Ampligen and our Poly I and Poly
C12U polynucleotides, respectively. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, all adjustments necessary for a fair presentation of its consolidated financial statements have been included.
Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (&#8220;SEC&#8221;),
and do not contain certain information which will be included in the Company&#8217;s annual consolidated financial statements and notes
thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements should be read in conjunction with the Company&#8217;s consolidated financial statements for the years
ended December 31, 2023, and 2022, contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023,
filed on April 1, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (&#8220;GAAP&#8221;)
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the
reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use
of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent
and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern.
The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements
are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Financial Accounting Standards Board&#8217;s (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 205-40, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern, management must evaluate whether
there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue
as a going concern for one year from the date these financial statements are issued. This evaluation does not take into consideration
the potential mitigating effect of management&#8217;s plans that have not been fully implemented or are not within control of the Company
as of the date the financial statements are issued. When substantial doubt about the Company&#8217;s ability to continue as a going concern
exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt. The mitigating
effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented
within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will
mitigate the relevant conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern
within one year after the date that the financial statements are issued. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s principal source of liquidity is its cash and cash equivalents, marketable securities, and proceeds from financing
activities to provide the necessary funding to meet our obligations as they become due. The Company has suffered losses from
operations and net cash used on operating activities for the nine-month period ended September 30, 2024, and has a working capital
deficit as of September 30, 2024. Additionally, the Company&#8217;s stockholders&#8217; equity was below the minimum requirements
for continued listing on the New York Stock Exchange American (&#8220;NYSE American&#8221;). These conditions raise substantial
doubt regarding the Company&#8217;s ability to continue as a going concern for a period of at least one year from the date of
issuance of these unaudited condensed consolidated financial statements. Management evaluated the conditions, and the significance
of these conditions related to the Company&#8217;s ability to meet its obligations and determined that the primary cause of the
deficit was related to certain accounts payable which the Company is currently in negotiations with the vendor. These negotiations
are ongoing and could result in significant amounts which could partially alleviate the negative working capital. There is no assurance as to the timing or outcome of these efforts. If the Company is unable to implement
sufficient mitigation efforts, the Company may be forced to limit its business activities or be unable to continue as a going
concern, which would have a material adverse effect on its results of operations and financial condition.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562527935376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zSSHZ6DUZhN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2</b>: <b><span id="xdx_829_z2nryRywse58">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
includes bank deposits maintained at several financial institutions. The Company considers highly liquid instruments with an original
maturity of three months or less to be cash equivalents. At various times throughout the nine months ended September 30, 2024, some accounts
held at financial institutions were in excess of the federally insured limit of $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20240930_ze3nab0wDKN1" title="Federlly insured limit">250,000</span>. The Company has not experienced any losses
on these accounts and believes credit risk to be minimal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534723280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zFfeajKKv4L6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3: <span id="xdx_829_zM8Uaj60oD13">Marketable Securities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable
securities consist of mutual funds. At September 30, 2024 and December
31, 2023, it was determined that none of the marketable securities had an other-than-temporary impairment. At September 30, 2024 and December
31, 2023, all securities were measured as Level 1 instruments of the fair value measurements standard (See Note 12: Fair Value). At September
30, 2024, and December 31, 2023 the Company held $<span id="xdx_902_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_c20240930_zGPiXdFoGmFd" title="Held value of marketable securities">6,287,000</span>
and $<span id="xdx_906_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_c20231231_zSQimBV7QZEd" title="Held value of marketable securities">7,631,000</span> respectively, in mutual funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutual Funds classified as available for sale consisted of $<span id="xdx_902_eus-gaap--MarketableSecuritiesCurrent_iI_c20240930_zBmGron1f3Si" title="Marketable securities">6,287,000</span> at September 30, 2024. <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleTypeOfEquitySecurity_c20240101__20240930_zFGH0MtdGcjg" title="Equity securities description">The net gain recognized for the three-month
period ended September 30, 2024 on equity securities was $273,000. The net losses recognized for the three-month period ended September
30, 2024 on equity securities sold during the period were ($59,000). The unrealized gains recognized for the three-month period
ended September 30, 2024 on equity securities still held was $332,000. The net gain recognized for the nine-month period ended September
30, 2024 on equity securities was $96,000. The net losses recognized for the nine-month period ended September 30, 2024 on equity
securities sold during the period were ($277,000). The unrealized gains recognized for the nine-month period ended September 30,
2024 on equity securities still held was $373,000.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutual Funds classified as available for sale consisted of $<span id="xdx_900_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_z6a3a5ZWvIY2" title="Marketable securities">7,631,000</span> at December 31, 2023. <span id="xdx_908_eus-gaap--DebtInstrumentConvertibleTypeOfEquitySecurity_c20230101__20231231_z6EMBUekZ2D3" title="Equity securities description">The net loss recognized for the three-month
period ended September 30, 2023 on equity securities was ($309,000).&#160; The net losses recognized for the three-month period ended
September 30, 2023 on equity securities sold during the period were ($42,000). The unrealized losses recognized during the three-month
period ended September 30, 2023 on equity securities still held was ($267,000). The net losses recognized for the nine-month
period ended September 30, 2023 on equity securities was ($201,000). The net losses recognized for the nine-month period ended
September 30, 2023 on equity securities sold during the period were ($130,000). The unrealized losses recognized during the nine-month
period ended September 30, 2023 on equity securities still held was ($71,000).</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534592272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zCggWfUlxyhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4: <span id="xdx_826_zuXooo4pXdGc">Property and Equipment, net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zRGGwIRYWFyb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8B1_zCYYYn4y7eL1">Schedule
of Property and Equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_494_20240930_z5hFwuCCDQ9f" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49B_20231231_zBpvQnD47La7" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENztUG_zMy3sLzXGS6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Furniture, fixtures, and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,466</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENztUG_zQo49N7TPXn1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,349</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,321</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENztUG_zFFesyhVHXMa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">127</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_z4fpO1sgVRZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful
lives of the respective assets, ranging from <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20240930__srt--RangeAxis__srt--MinimumMember_z7CckCeoYvx8" title="Estimated useful life::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0753">three</span></span> to <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20240930__srt--RangeAxis__srt--MaximumMember_zZJtA53jY7E3" title="Estimated useful life">ten years</span>. Depreciation expense for the nine months ending September 30, 2024 and
September 30, 2023 was $<span id="xdx_902_eus-gaap--Depreciation_c20240101__20240930_zfY7dvT8xSP6" title="Depreciation expense">28,000</span> and $<span id="xdx_909_eus-gaap--Depreciation_c20230101__20230930_zOpQXeIXQdDb" title="Depreciation expense">30,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562528888608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patents, and Trademark Rights, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Patents, and Trademark Rights, Net</a></td>
<td class="text"><p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_z4UG7EhRAl92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5: <span id="xdx_826_zXFFyQk49l5d">Patents, and Trademark Rights, Net</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zBCDvBpBjFmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
and trademark rights consist of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt"><span id="xdx_8BB_zAa7JNWy89tb">Schedule
of Patent and Trademark Rights</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Gross Carrying Value</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated Amortization</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net Carrying Value</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Gross Carrying Value</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated Amortization</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net Carrying Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zbUICxw1Xj8c" style="width: 8%; text-align: right" title="Gross carrying value">3,315</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zpwzsHMhXvG4" style="width: 8%; text-align: right" title="Accumulated amortization">(887</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zEPpi2tMxpDa" style="width: 8%; text-align: right" title="Net carrying value">2,428</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzxSZR35aLli" style="width: 8%; text-align: right" title="Gross carrying value">2,947</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8J54CytraFk" style="width: 8%; text-align: right" title="Accumulated amortization">(750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAGxijkjvRf" style="width: 8%; text-align: right" title="Net carrying value">2,197</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Trademarks</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zvfvEdCm6oY3" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">232</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z33LHiL2D1bg" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(128</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zQvo28Jaoe61" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zjJM7f8pmrPd" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zoBAV3VSrXfk" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(113</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSX6Kv6qQrbl" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">116</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net amortizable patents and trademarks rights</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930_zwH2Yy8CWW62" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,547</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930_zxHNsNce0g53" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(1,015</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930_zUBZJdMlSL8b" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zXvptjERIbih" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,176</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zheFoTKFHNB6" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(863</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zL8AbrNZtT67" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,313</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zhTQpzAtb0vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zGqBFECNpEW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
and trademark rights acquisitions, abandonments and amortization:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8B7_zkcpxAOiTA8">Schedule of Changes in
Patents, Trademark Rights</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20240101__20240930_zYazcw4FAWm1" style="width: 20%; text-align: right" title="Balance">2,313</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Acquisitions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20240930_zQkkLOeVr6Pl" style="text-align: right" title="Acquisitions">419</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Abandonments and expirations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20240101__20240930_z1PWeAKfCbvg" style="text-align: right" title="Abandonments">(46</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20240101__20240930_zbcdeHtCc1fd" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Amortization">(154</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20240101__20240930_zCEi51a2i4Qc" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">2,532</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zp0yeFhg8wCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over an estimated useful life
of <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zqy5tcBpRkbc" title="Finite lived intangible assets, estimated useful life">17 years</span> for patents and <span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zbUxrGLdmBZa" title="Finite lived intangible assets, estimated useful life">10 years</span> for trademarks. The weighted remaining average amortization period is approximately <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_c20240101__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvpKWnMvDxb4" title="Finite lived intangible assets, weighted average amortization">12 years</span> for
patents and <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_c20240101__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVS9hQqXWWUe" title="Finite lived intangible assets, weighted average amortization">6 years</span> for trademarks, respectively. The company expenses annuity costs related to its trademarks and patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zFn3Ia1SZmGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of patents and trademarks for each of the next five years and thereafter is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8BF_zgAqJXpNuYmj">Schedule
of Amortization of Patents and Trademarks</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Year Ending December 31,</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20240930_z1tIYpVuM4Xe" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzzOp_zwjhISSXC6c7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: justify">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 24%; text-align: right">72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zTsNY3ua6BM7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zoOVx8HtnVqi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">265</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zd5hADRcvfP4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zrSd1XdSTIfk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzzOp_zJfUCy3CpjH1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,469</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zWhqaolA3oN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,532</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z68D5vV7JGv" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562635351872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zDu3gHvXqICe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6: <span id="xdx_82F_zcgvTu96dolf">Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zQi5554CwUCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8B1_zCZ86rKhvOt7">Schedule
of Accrued Expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_493_20240930_zpvTaGPeAyEl" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_492_20231231_zyfNm3w9hjBi" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zxZUuEaIXWSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">414</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zErRAiIuwHzd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">790</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,352</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_z8kZCQ7m4g52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Clinical trial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzYmu_zxpeMg9SgGIi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ziLMURobsHek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">37</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">36</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zFlkF5q6M6L8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,011</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,986</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zs0RdJN0aHGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534728800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unsecured Promissory Note<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Unsecured Promissory Note</a></td>
<td class="text"><p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_zYKkX7jA2XU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7: <span id="xdx_820_z1itmEsEwwC5">Unsecured Promissory Note</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2024, the Company (&#8220;Borrower&#8221;) entered into a Note Purchase Agreement with Streeterville Capital LLC
(&#8220;Streeterville&#8221; or the &#8220;Lender&#8221;). Under the terms of the agreement, Streeterville paid the Company $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zWAjx8pvr3e9" title="Exchange of unsecured promissory notes">2,500,000</span>
in exchange for an unsecured promissory Note with an Original Issue Discount of $<span id="xdx_900_eus-gaap--DebtConversionOriginalDebtAmount1_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zSDdVIlvnB4a" title="Unsecured debt original issue discount">781,250</span>.
The Company will pay $<span id="xdx_90C_eus-gaap--LongTermDebt_iI_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zJpVZkQMLegi" title="Long term debt">3,301,250</span>
consisting of the principal amount of the Note, together with the original issue discount and $<span id="xdx_901_eus-gaap--DeferredFinanceCostsGross_iI_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zqKMVPANOnc3" title="Debt issuance costs">20,000</span>
of lender transaction fees, no later than February 16, 2026. The stated interest rate of the note is <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_z7D8T6ZrVfm3" title="Debt instrument stated interest rate">10</span>%.</span>
There was <span id="xdx_905_eus-gaap--UnsecuredDebt_iI_do_c20231231_zZMrBphQAdud" title="Unsecured debt">no</span> debt at December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"></p>

<p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_z8qR51yTaila" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span><span id="xdx_8B3_zzL1KXT6vYW6">Schedule of Long Term Debt</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240930_znIPEbSifguf" style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Debt schedule at September 30, 2024 (in thousands)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: right"></td><td style="padding-bottom: 1pt">&#160;</td>
    </tr>
  <tr id="xdx_40F_eus-gaap--LongTermDebt_iI_pn3n3_z5Qzrbi8hhlh" style="vertical-align: bottom; background-color: White">
    <td style="width: 77%; text-align: left">Long-term debt</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">3,301</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_zme2jc2Cl9lc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unamortized Original issue discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(555</td><td style="text-align: left">)</td>
    </tr>
  <tr id="xdx_40C_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_zEzzylzYJd6g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Unamortized Financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(14</td><td style="padding-bottom: 1pt; text-align: left">)</td>
    </tr>
  <tr id="xdx_400_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn3n3_z1sjpi9zFbp3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Unamortized discount and debt issuance costs</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,732</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_z3tDTtSH1sf1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less current portion of long-term debt, net <span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,593</td><td style="padding-bottom: 1pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zfrhvPyY2899" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt, net <span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    </tr>
</table>

<p id="xdx_8A0_zNlZ4r61hy0a" style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Interest expense related to long-term debt was $<span id="xdx_906_eus-gaap--InterestExpenseDebtExcludingAmortization_c20240101__20240930_zPBg5i4epKn" title="Interest expense debt excluding amortization">226,000</span> at
September 30, 2024. Amortization expenses related to long-term debt was $<span id="xdx_905_eus-gaap--AdjustmentForAmortization_c20240101__20240930_zYRX6B9Jm1b6" title="Amortization expenses of long term debt">232,000</span> at September 30, 2024. This consisted of $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20240101__20240930_zL3PbyesAp83" title="Original issue discount">226,000</span> in
original issue discount and $<span id="xdx_900_eus-gaap--LoanProcessingFee_c20240101__20240930_z2VnrXySTJX" title="Loan fee amortization">6,000</span> for loan fee amortization. Future maturities of long-term debt at September 30, 2024 were $<span id="xdx_90C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_c20240930_zZweHYSlJ3j5" title="Future maturities of long term debt">750,000</span>
for fiscal years ending December 31, 2024 and $<span id="xdx_90E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20240930_zPHus6N6Alqd" title="Future maturities of long term debt">2,551,000</span> for fiscal years ending December 31, 2025.</p>

<p style="display: none; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
                                            portion of long-term debt of approximately $3,000,000 is net of the current portion of debt
                                            discount of approximately $397,000 and the current portion of debt origination costs of approximately
                                            $10,000 as of September 30, 2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
                                            portion of debt of approximately $301,000 is net of the long-term portion of debt discount
                                            of approximately $159,000 and the unamortized debt origination costs of approximately $3,000
                                            as of September 30, 2024.</span></td></tr></table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current portion of long-term debt of approximately $<span id="xdx_90F_eus-gaap--DeferredFinanceCostsCurrentGross_iI_c20240930_zNYv0YVPyoB9" title="Long-term debt, current">3,000,000</span> is net of the current portion of debt discount of approximately $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20240930_zBDxCiJYsPK2" title="Debt discount, current">397,000</span> and the current portion of debt origination costs of approximately $<span id="xdx_904_eus-gaap--DeferredFinanceCostsCurrentNet_iI_c20240930_zNKvXoyp7qsg" title="Debt origination costs, current">10,000</span> as of September 30, 2024.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term portion of debt of approximately $<span id="xdx_904_eus-gaap--DeferredFinanceCostsNoncurrentGross_iI_c20240930_zEs4B5YzXbf9" title="Long-term debt, non current">301,000</span> is net of the long-term portion of debt discount of approximately $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20240930_zC0vbMLiyli1" title="Debt discount, non current">159,000</span> and the unamortized debt origination costs of approximately $<span id="xdx_909_eus-gaap--DeferredFinanceCostsNoncurrentNet_iI_c20240930_zaA5Ts4qZz5c" title="Debt origination costs, non current">3,000</span> as of September 30, 2024.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentRedemptionDescription_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zdzkBdvHSll3" title="Redemption description">The
agreement allows the Lender to redeem up to $250,000 per calendar month beginning in August 2024, upon providing written notice to Borrower.</span>
The Note further contains triggering events which can be remedied by the Lender requiring the Borrower to correct the triggering event,
increasing the outstanding balance by applying the triggering effect, or making the Note immediately due and payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534555104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Based Compensation</a></td>
<td class="text"><p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zh3Get3u1WJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8: <span id="xdx_826_zl4NLBGUAcmb">Equity-Based Compensation </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2018 Equity Incentive Plan, effective September 12, 2018, as amended and restated on August 19, 2019 (the &#8220;2018 Equity
Incentive Plan&#8221;) authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock
Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii)
Performance Cash Awards, and (viii) Other Stock Awards. After taking into account the <span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20180912__20180912__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z5Ns7upVg8jl" title="Stockholders equity reverse stock split">44:1 reverse stock split</span> which was effected in
June 2019, initially, a maximum of <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20180912__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zM5eWYs3gOz9" title="Number of stock is reserved for potential issuance">230,390</span>
shares of common stock were reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan. When the plan
was amended and restated, an additional <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20180912__us-gaap--PlanNameAxis__custom--RestatedTwoThousandEighteenEquityIncentivePlanMember_zepBZ2X2JJ91" title="Number of stock is reserved for potential issuance">250,000</span>
shares were reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan. The number of shares of the
Company&#8217;s common stock available for grant and issuance under the 2018 Equity Incentive Plan is subject to an annual increase
on July 1 of each calendar year, by an amount equal to two percent (2%) of the then outstanding shares of the Company&#8217;s common
stock (the &#8220;2018 Plan Evergreen Provision&#8221;). On August 3, 2020, and July 1, 2021, 2022, 2023 and 2024, the number of
shares of the Company&#8217;s common stock available for grant and issuance under the 2018 Equity Incentive Plan increased by <span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20200803__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zSpUj2Db4E4b" title="Number of stock is reserved for potential issuance">685,012</span>
shares, <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zf33XvYiGk97" title="Number of stock is reserved for potential issuance">956,660</span>
shares, <span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zBbAwwsEjpd5" title="Number of stock is reserved for potential issuance">960,976</span>
shares, <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKsli0FMfluf" title="Number of stock is reserved for potential issuance">968,389</span>
and <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zBPGcH9fZNL5" title="Number of stock is reserved for potential issuance">1,142,733</span>
shares, respectively. As a result of the 2018 Plan Evergreen Provisions, a maximum of <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zVScmBNLTND9" title="Number of stock is reserved for potential issuance">5,167,160</span>
shares of common stock is reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan as of September
30, 2024. Unless sooner terminated, the 2018 Equity Incentive Plan will continue in effect for a period of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20180912__20180912__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_znPFYVH4i0Sa" title="Option vested years">10</span>
years from its effective date. During the fiscal year ended December 31, 2018, the Board of Directors issued <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20180101__20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zWJLKt2DDjY2" title="Number of options issued">1,189,284</span>
options to each employee, the officers and directors at the exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20180101__20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zCcvL9Kb4Xnb" title="Exercise price">9.68</span>
expiring in <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20180101__20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zGI9O7TGMhKe" title="Expiration period">10</span>
years <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20180101__20181231_znVg4dNtEGU5" title="Stockholders equity reverse stock split">(27,028 options post reverse split)</span>. During the fiscal year ending December 31, 2019, <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zeW3j5Ztk5Cj" title="Number of options issued">1,727,756</span>
options were issued to each of these officers with an exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zcUoNv9gWtJ8" title="Exercise price">9.68</span>
for a period of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20190101__20191231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zPXJcKkMOhde" title="Expiration period">ten
years</span> with a vesting period of <span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20190101__20191231_z2xit69fxrcb" title="Stockholders equity reverse stock split">one year (39,266 options post reverse split).</span> During the fiscal year ending December 31, 2020, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zmeg4dVDRNm3" title="Number of options issued">1,025,000</span>
options were issued to each of these officers and directors with an exercise price range of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zTVwL4ez8rTl" title="Exercise price range">2.77</span>
to $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z713DIxSEuT3" title="Option exercise price per share">3.07</span>
for a period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200101__20201231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z5uk8Bere3nb" title="Expiration period">ten
years</span> with a vesting period of one year. During the fiscal year ending December 31, 2021, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zsCDxuA8GMLg" title="Number of options granted">613,512</span>
options were issued to officers, directors and consultants with an exercise price range of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_z4RfXftsVTMi" title="Exercise price range">1.11</span>
to $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zxTnbndBT9Gj" title="Option exercise price per share">1.71</span>
for a period of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKybHGnE7cKh" title="Expiration period">ten
years</span> with a vesting period of one year. During the fiscal year ending December 31, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zzlmhdaSrfYh" title="Number of options granted">850,000</span>
options were issued to officers, directors and consultants with an exercise price range of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKAhZBMvT4m4" title="Option exercise price per share">0.31</span>
to $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zSdfv7msygx6" title="Option exercise price per share">0.71</span>
for a period of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zA0GtgA6Paga" title="Expiration period">ten
years</span> with a vesting period of one year. During the fiscal year ending December 31, 2023, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zbza9FnqKFl9" title="Number of options granted">400,000</span>
options were issued to officers with an exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zTLR2sRmaCzc" title="Exercise price range">0.47</span>
for a period of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zIvzsvbAwMue" title="Expiration period">ten
years</span> with a vesting period of one year. During the nine months ended September 30, 2024 there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20240101__20240930__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zY288SslhGRk" title="Number of options granted">no</span>
options issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation
model. Expected volatility is based on the historical volatility of the price of the Company&#8217;s stock. The risk-free interest rate
is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical
data to estimate expected dividend yield, expected life and forfeiture rates. During the nine months ended September 30, 2024, and 2023,
there were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20240101__20240930__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zJZRsp0gA9hk" title="Number of options granted"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20230101__20230930__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zxe4UkvTeVB1" title="Number of options granted">no</span></span> options granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options activity during the three months ended September 30, 2024, was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SOSBCSOASA-KMP_zh7fODkBMfI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zELmZh9E6l79" style="display: none">Schedule
of Stock Option Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/> Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding June 30, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjyD49yckon5" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year">2,407,775</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUDZ6B9tPuhk" title="Weighted Average Exercise Price Outstanding, Beginning of Period">2.50</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zA6WtLyZASid" title="Weighted Average Remaining Contracted Term (years) Outstanding">8.70</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsI90ptM0jv6" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl0997">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlJOUT20gvv" style="text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHLE9He70K7f" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1001">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUqxUDPKGHFg" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1003">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9AaJcEwgYJh" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1005">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7JJEhxpI8t1" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1007">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zH3aSRizWyMk" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1009">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIJ6I7oTvk64" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7AT3mlVDgFa" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1013">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zaxovopTHiic" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1015">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSb3FI5Sl4P9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period">2,407,680</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziURHvTtM7Wk" title="Weighted Average Exercise Price Outstanding, End of Period">2.44</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7nelISYhCrd" title="Weighted Average Remaining Contracted Term (years)">8.70</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zqhlUrLQeYt5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"><span style="-sec-ix-hidden: xdx2ixbrl1023">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoXN9PEJ5iLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">2,407,680</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCF6ICTITSrg" title="Weighted Average Exercise Price, Vested and Expected to Vest">2.44</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjEemedfkDJ3" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">8.70</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNwglLCnLnB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1031">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbhf65Q8YFt7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">2,341,014</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl7Tc0AMcUah" title="Weighted Average Exercise Price Exercisable, Ending of Period">1.66</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSKGKa98BCnd" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">7.17</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zb7jfHMAqa5e" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1039">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zrU2qa2FTRGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SONSATTB-QOTKSOK_zQj05qtEmQE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
stock option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z9DxytPfegse" style="display: none">Schedule
of Unvested Stock Option Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/>Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/> Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Unvested June 30, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z84haaRrIaI6" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period">166,666</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOPx0OQtrqJb" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">4.11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhcjV7bPlK7e" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">18.87</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbJjxQA7vjk4" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1052">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMg0PpIF6h3c" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1054">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOG76PIF5jX9" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1056">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zytehApLdBq6" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl4AwqJtOUXg" style="text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVvGzMWc26n8" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1062">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z702F2nVWw5l" style="text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1064">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRGMkXjIjQIh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested">(99,905</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z5W5LUTZBwu2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested">0.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zGhlSXfeXe6d" title="Weighted Average Remaining Contracted Term (years) Vested">7.17</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTPUpqtwN4og" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjiOohm1j9rd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">66,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbnRsZ3Zcdk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">9.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV3ToK6T3u89" title="Average Remaining Contractual Term (years) Unvested, End of Period">36.22</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUafxgzWlok5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1080">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zuH4ZGrHpM0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SOSBCSOASA-DNQVA_zuXh3tppq76j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zx8D0sBXYWv9" style="display: none">Schedule
of Stock Option Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding June 30, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaF5yDYcOZA7" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning of Period">885,055</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z7kZUofcgBYe" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period">2.02</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zftq24OTTlz7" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.23</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcJElAxfvgD6" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1092">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdySOjgFrc5a" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1094">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCvgHS82Mkwi" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1096">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z2s1Nfh7zpJe" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1098">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMpaDHJEvhw2" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1100">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeKE3oa92K1f" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhjdzz3wNJak" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1104">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z710pkk0K0uh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabMb2JSrqdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1108">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztqKFXx2XeCd" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1110">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeAutH3C3k71" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period">884,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z30GS8sFl1ak" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period">1.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9ABWbeWmxz3" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.23</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfXx2BNnCGS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zz9QdZSHTZuj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">884,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhLvrb2naeBe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest">1.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXLoaRrf9Nvi" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">9.23</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAnWbQZRLmYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1126">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRESdE1Et5lh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">729,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zl9srwqwk9kc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period">1.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zu2ni2MpRR0a" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">10.06</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFkhX2aFesW2" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1134">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zNrthgPuYDXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_893_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SONSATTB-BWM_z7TXuu6oUU0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
stock option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zXrhTt3hW8sd" style="display: none">Schedule
of Unvested Stock Option Activity</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/>Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Unvested June 30, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjsXfy3G7EIc" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period">155,001</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zng86shSyV5i" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">3.42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zyzkdqaqA9La" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">11.30</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUSMNti8XCE7" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1147">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZW30cPwV71a" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1149">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFNQl2tfVz83" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1151">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zo7fYGT9D579" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0n4X6iePLti" style="text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zr8ObjoHO3b4" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1157">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRzwbedcMbrf" style="text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1159">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYIPol713VB9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested">95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcCNSfs1wMbi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested">0.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwaIDvMMIrt5" title="Average Remaining Contractual Term Vested">10.18</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMTvchDc45Of" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1167">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zE2w3bbv2uFl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">155,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zyZlk7DeOZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">3.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUOg3jQg6uz8" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">11.31</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBQ8EF5Zv8ui" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1175">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zQqB44N6O36d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense was approximately $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20240701__20240930_zlWx30wz2pFi" title="Share based compensation expense">80,000</span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20230701__20230930_zBP7qd56yUj8" title="Share based compensation expense">50,000</span> for the three months ended September 30, 2024, and 2023, resulting in an increase
in general and administrative expenses, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
stock option activity during the nine months ended September 30, 2024, was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div id="xdx_C06_gL3SOSBCSOASA-KMP_zFYpVLRmIcz5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_134_zbpFI8KrQIwe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/> Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWsKzf9ySWcd" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year">2,408,438</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrvicYzwmdP5" title="Weighted Average Exercise Price Outstanding, Beginning of Period">2.50</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zN11clVZ5eVd" title="Weighted Average Remaining Contracted Term (years) Outstanding">8.70</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zS9HesshdjB8" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1187">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zy6V6T5rRRN" style="text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl1189">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWJ8tezMnSG9" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1191">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhNtAfhE9CKc" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1193">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUJy01uAGkja" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1195">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z4k29IU5MeS8" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1197">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZ3INBtll8s8" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3RLPP1Z58l5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(758</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z5a9p87y7Nvl" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1203">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7rBX5pcldNj" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1205">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9PiyYO55108" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period">2,407,680</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zgiaI51Yf8Ud" title="Weighted Average Exercise Price Outstanding, End of Period">2.44</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV7PHskuC1te" title="Weighted Average Remaining Contracted Term (years)">8.70</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziTI4BvTbXZd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"><span style="-sec-ix-hidden: xdx2ixbrl1213">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9jbdJ1UeeN2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">2,407,680</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrwk3sPKL9r7" title="Weighted Average Exercise Price, Vested and Expected to Vest">2.44</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zISzyz1ExvRd" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">8.70</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8k63vScsNze" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1221">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8jCkn80oLDd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">2,341,014</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zm7FjiaJ5nX1" title="Weighted Average Exercise Price Exercisable, Ending of Period">1.66</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlpZTqTiXH5" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">7.17</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNuy0VHkTDIi" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1229">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0E_gL3SOSBCSOASA-KMP_zZkor6JBlWQd">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
stock option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_C0A_gL3SONSATTB-QOTKSOK_zBTuXomo6wV6"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></span></p>

<div id="xdx_C06_gL3SONSATTB-QOTKSOK_zZpy4ve80s04"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_134_zAZ64rbchUKi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/>Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/> Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Unvested January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrsbidNc06B2" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period">366,666</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zStSkwQd2cG2" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">2.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zheVkcZA5wN6" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">12.44</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0qY0UsmBYE8" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1237">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zudH9uJhIe6a" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSLDdwvQEmd1" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1241">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z27QE6z6S5j5" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1243">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zorokXUxmwrj" style="text-align: right" title="Number of Options, Expired">(758</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zKpUHgKinFYd" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRFXpXaqQykh" style="text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1249">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zu3UHcuxfiG2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested">(299,242</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXQeItkxToq4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested">0.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zh9JpIprSBu" title="Weighted Average Remaining Contracted Term (years) Vested">7.17</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zucRbwQeqIJg" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1257">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zouqYb3AJvB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">66,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziPvgbO0hBaa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">9.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJpG8ywn1Zi" title="Average Remaining Contractual Term (years) Unvested, End of Period">36.22</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRctqqO8TGzl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1265">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0C_gL3SONSATTB-QOTKSOK_zgDqFqbCeDhd">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<div id="xdx_C04_gL3SOSBCSOASA-DNQVA_z9pVz8jZzuFk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_134_z5EIUSL00SQj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAx9aZk5OJy1" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning of Period">885,055</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8Yy6kGEQ4gb" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period">2.02</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zveAC0DMk4z8" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.23</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWf50mYIhqz3" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1273">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWvZ5bQsiAw5" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1275">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfVgCh1XgInb" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1277">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGBxQLenuel9" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1279">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zLhHJxFeAAWb" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1281">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIBK4GHzRX4" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1283">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPHXTzz1QA24" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1285">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMBcS49SknKb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUTYNo2XeF6b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1289">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwxBMmTX69k8" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1291">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zg8oTRGTPnQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period">884,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMuWMj8NH6ef" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period">1.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzu1hl5CNjUc" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.23</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztMrm84L0PBa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1299">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpinr46l4aYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">884,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zM7xY4RRunc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest">1.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsq7ABwkucle" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">9.23</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUPo1PxB47Df" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1307">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpXb0qGCGuW6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">729,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHk8CF75wanf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period">1.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuXm6S64XwJj" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">10.06</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZvKwcanEdFa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1315">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C08_gL3SOSBCSOASA-DNQVA_zzy3q39sC92l">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
stock option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_C0B_gL3SONSATTB-BWM_zfB4RMT3VGs">&#160;</span></span></p>

<div id="xdx_C01_gL3SONSATTB-BWM_zOhQk7WcFAvi"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_134_zi3j29Bqb4l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/>Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Exercise <br/> Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/> Intrinsic <br/>Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Unvested January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztMKYaa2HcQ7" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period">335,001</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwWwzRJl4Fs4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">1.83</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvt3P0Xidfej" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">10.70</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoypW4H5aJF" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1323">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKQZKbADmTGg" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1325">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIn40faYM6ml" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1327">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zedKPVdPJhJb" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1329">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z1CmUEv6YRF2" style="text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zItSoXu7NGHb" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zN47RSNjmyNe" style="text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1335">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTJT17NtE8M4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested">(179,905</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zbPwr0p8XMQ" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested">0.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhOprlOO2tMk" title="Average Remaining Contractual Term Vested">10.18</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcKVg4IKRwBk" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqPrUzeBm0jc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">155,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVCsCim7RUvc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">3.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeugZ61eatxh" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">11.31</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzEf8hRTmQY7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1351">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_C09_gL3SONSATTB-BWM_z5foyejtwwn7"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense was approximately $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240930_zl13KkQhH6r1" title="Share based compensation expense">490,000</span> and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930_z40MJp1EWLu5" title="Share based compensation expense">182,000</span> for the nine months ended September 30, 2024, and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Company&#8217;s cash conservation strategy, the Company issued common stock as a substitute for cash salaries to certain
executives. For the three and nine months ended September 30, 2024, stock issued as payroll totaled $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20240701__20240930_z2yi3uNrBDij" title="Stock issued as payroll, value"><span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20240101__20240930_zaXVnXiACW1l" title="Stock issued as payroll, value">250,000</span></span>, which is included in the
overall equity-based compensation expense. There was no stock issued as payroll for the three and nine months ended September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, and 2023, respectively, there was approximately $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20240930_zKS25oHb6946">53,400
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230930_zgb2CZZ4zs42">35,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of unrecognized equity-based compensation cost
related to options granted under the Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534687872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgmcER7ZoG6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9: <span id="xdx_825_zvWLU1z6KInl">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930_zOqRZT6lrsj3" title="Preferred stock, shares authorized">5,000,000</span> shares of $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240930_zyGSvb1nsSxi" title="Preferred stock stated value">0.01</span> par value preferred stock with such designations, rights and preferences as
may be determined by the Board. Of our authorized preferred stock, <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zRTeQtHLu6kk" title="Preferred stock, shares authorized">4,000,000</span> shares have been designated as Series A Junior Participating
Preferred Stock and <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zhMAyH0nNXuk" title="Preferred stock, shares authorized">10,000</span> shares have been designated as Series B Convertible Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
A Junior Participating Preferred Stock</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series
A Junior Participating Preferred Stock to <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230509__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zfxXoYbt2Aqj" title="Preferred stock, shares authorized">4,000,000</span> from <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zKWhsVN7Y272" title="Preferred stock, shares authorized">250,000</span> shares. As of September 30, 2024, there were no Series A Junior Participating
Preferred Stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series
B Convertible Preferred Stock </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has designated <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zI3n7ruFUJ8d">10,000</span> shares of its preferred stock as Series B Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;).
Each share of Preferred Stock has a par value of $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zs73uTZx61vb" title="Preferred stock, par value">0.01</span> per share and a stated value equal to $<span id="xdx_90C_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zA0Fuo8Eh4c" title="Preferred stock, stated value">1,000</span> (the &#8220;Stated Value&#8221;).
The shares of Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository
Trust Company or its nominee (&#8220;DTC&#8221;) shall initially be the sole registered holder of the shares of Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option
of the Holder thereof or at any time and from time to time on or after the second anniversary of the Original Issue Date at the option
of the Corporation, into that number of shares of common stock (subject in each case to the limitations determined by dividing the Stated
Value of such share of Preferred Stock by the Conversion Price). The conversion price for the Preferred Stock shall be equal to $<span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20240930_zR3DqConzAKj" title="Preferred stock conversion price">0.20</span>,
subject to adjustment herein (the &#8220;Conversion Price&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a registration statement relating to a rights offering (the &#8220;Rights Offering&#8221;) declared effective by the SEC on February
14, 2019, AIM distributed to its holders of common stock and to holders of certain options and redeemable warrants as of February 14,
2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each
right entitled the holder to purchase one unit, at a subscription price of $<span id="xdx_906_eus-gaap--CommonStockSharesSubscriptions_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zKFSenSQuSh3" title="Subscription price">1,000</span> per unit, consisting of one share of Series B Convertible
Preferred Stock with a face value of $<span id="xdx_909_ecustom--ConvertiblePreferredStockFaceValue_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zqxI7z5v5fZ6" title="Convertible preferred stock face value">1,000 </span>(and immediately convertible into common stock at an assumed conversion price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN3mPLUCoTSa" title="Conversion price">8.80</span>) and
<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240930_zmqXhS7lPcxe" title="Number of warrants">114</span> warrants with an assumed exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930_zCFqUw37Tfm9" title="Subscription/exercise price">8.80</span>. The redeemable warrants are exercisable for five years after the date of issuance.
The net proceeds realized from the rights offering were approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zJ5uCOPkTQP4" title="Net proceeds from warrants">4,700,000</span>. As of September 30, 2024, <span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_pid_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zAzKca2mMK04" title="Conversion of shares issued">689</span> shares of Series B Convertible
Preferred Stock had expired, and none were converted prior to expiration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Common Stock and Equity Finances</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has authorized shares of <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_zKV0ggF1L197" title="Common stock, shares authorized">350,000,000</span> with specific limitations and restrictions on the usage of <span id="xdx_90D_ecustom--CommonStockSharesWithLimitationsAndRestrictionsOnUsage_iI_pid_c20240930_zHeSxRoLoD11" title="Common stock specific limitations and restrictions on usage">8,000,000</span> of the <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_zOLECR8Uf3c8" title="Common stock, shares authorized">350,000,000</span>
authorized shares. <span style="background-color: white">As of September 30, 2024, and December 31, 2023, there were <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20240930_z5s2RDcpK1Ng" title="Common stock, shares issued"><span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240930_z3VuKo6Z0eh3" title="Common stock, shares outstanding">58,668,647</span></span> and <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zLy7uy3idNR7" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zGzCzttgT758" title="Common stock, shares outstanding">49,102,484</span></span>
shares of common stock issued and outstanding, respectively.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Employee
Stock Purchase Plan (Not equity compensation)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to
an aggregate of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200707__20200707__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsOfficersAndEmployeesMember_zpDOzkNs9kNe" title="Common stock shares issued, value">500,000</span> worth of shares at the market price (including subsequent plans, the &#8220;Employee Stock Purchase Plan&#8221;).
Pursuant to NYSE American rules, this plan was effective for a sixty-day period commencing upon the date that the NYSE American approved
the Company&#8217;s Supplemental Listing Application. The Company created successive new plans following the expiration of the July 7,
2020 plan. The latest plan was approved by the Board on October 21, 2024 and expires in December 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2024, the Company did <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_do_c20240701__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zJNGUQY8NQi3" title="Number of shares issued upon transaction">no</span>t issue any shares of its common stock as part of the employee stock purchase
plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2024, the Company issued a total of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_za44fl9EQlw8" title="Number of shares issued upon transaction">335,603</span> shares of its common stock at a price ranging from $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zixXXzTxGMTa" title="Shares issued price per share">0.33</span>
to $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zd2pavd939oa" title="Shares issued price per share">0.41</span> for total proceeds of approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zPotQyhb5qZ7" title="Proceeds from issuance of common stock">120,000</span> as part of the employee stock purchase plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023, the Company issued a total of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zBJQFnmATZ73" title="Number of shares issued upon transaction">62,841</span> shares of its common stock at a price ranging from $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zEP0jVJQ2aF5" title="Shares issued price per share">0.44</span>
to $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zQ6VeuTyZU68" title="Shares issued price per share">0.67</span> for total proceeds of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zeyu7mvaf40i" title="Proceeds from issuance of common stock">35,500</span> as part of the employee stock purchase plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the nine months ended September
30, 2023, the Company issued a total of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zzN3cXNuqCf" title="Number of shares issued upon transaction">385,424</span> shares of its common stock at a price ranging from $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zy0tzmCUB1i6" title="Shares issued price per share">0.31</span> to $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_z6XHYrdt27K3" title="Shares issued price per share">0.67</span> for total proceeds of
approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zgJMA0cJubDi" title="Proceeds from issuance of common stock">135,000</span> as part of the employee stock purchase plan.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Rights
Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer &amp; Trust Company as
Rights Agent (the &#8220;Rights Plan&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants
(Rights offering)</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the &#8220;Offering&#8221;)
of (i) <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20190926__20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zBg7vwwbMv06" title="Number of shares issued upon transaction">1,740,550</span> shares of common stock; (ii) pre-funded warrants exercisable for <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zzFUxZG6TFE9" title="Warrants issued">7,148,310</span> shares of common stock (the &#8220;Pre-funded
Warrants&#8221;), and (iii) warrants to purchase up to an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zk06vIxeMAvj" title="Number of warrant to purchase shares of common stock">8,888,860</span> shares of common stock (the &#8220;Warrants&#8221;).
In conjunction with the Offering, we issued </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Representative&#8217;s
Warrant to purchase up to an aggregate of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zpn7ey1dppSj" title="Number of warrant to purchase shares of common stock">266,665</span> shares of common stock (the &#8220;Representative&#8217;s Warrant&#8221;)<span style="background-color: white">.
The shares of common stock and Warrants were sold at a combined Offering price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zxpcFYlkmU31" title="Shares issued price per share">0.90</span>, less underwriting discounts and commissions.
Each Warrant sold with the shares of common stock represents the right to purchase one share of common stock at an exercise price of
$<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Ahw2qUTV0f" title="Warrant exercise price">0.99</span> per share. The Pre-Funded Warrants and Warrants were sold at a combined Offering price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zr7VaKtovb9i" title="Shares issued price per share">0.899</span>, less underwriting discounts and
commissions. The Pre-Funded Warrants were sold to purchasers whose purchase of shares of common stock in the Offering would otherwise
result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than <span id="xdx_90B_ecustom--PercentageOfOutstandingStock_iI_pid_dp_uPure_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zedz8pMBZfjc" title="Percentage of outstanding stock">4.99</span>% of the Company&#8217;s
outstanding common stock immediately following the consummation of the Offering, in lieu of shares of common stock. Each Pre-Funded Warrant
represents the right to purchase one share of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zz4bJv3T8bt8" title="Exercise price">0.001</span> per share. The Pre-Funded Warrants are exercisable
immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full. A registration statement on Form S-1,
relating to the Offering was filed with the SEC and was declared effective on September 25, 2019, the net proceeds were approximately
$<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190925__20190925__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_z0ASZUL2lSYa" title="Proceeds from issuance or sale of equity">7,200,000</span>. During the year ended </span>December 31<span style="background-color: white">, 2020, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zYmSzHIwGVuj" title="Stock issued during period shares other">1,870,000</span> of the Pre-funded Warrants
were exercised and <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zctQaPregbB1" title="Pre-funded warrants exercised">8,873,960</span> Warrants were exercised. </span>In addition, on March 25, 2020, the Representative&#8217;s Warrant was amended
to permit exercise of such warrant to commence on March 30, 2020. These warrants were exercised on March 31, 2020, and an aggregate of
<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200331__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zLqkg4B09CUi" title="Warrants exercised aggregate">266,665</span> shares were issued upon exercise of this warrant for gross proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200330__20200331_zh9jjVbDpWwg" title="Warrant gross proceeds">264,000</span> and a $<span id="xdx_907_ecustom--WarrantModifications_pp0p0_c20200330__20200331_zhlfJIMnyV66" title="Warrant modification">46,000</span> expense for the warrant
modification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2024, there were <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_do_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMLHdojv32bi">no</span> warrants exercised and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240701__20240930__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember_zHNu2Pq7YRr7" title="Warrants expired">15,000</span> warrants expired unexercised. During the nine
months ended September 30, 2024, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh9Mlm1aHhB">205,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants were exercised, and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20240930__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember_zoUWDRKMyD7l" title="Warrants expired">5,830,028
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants expired unexercised. As of September
30, 2024 there were <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_do_c20240930_z89reMuARwi6">no</span> warrants outstanding and December 31, 2023 there were <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_zX4TJjnw8aLe">152,160</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-split
warrants outstanding, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity
Distribution Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 19, 2023, the Company entered into an Equity Distribution Agreement (the &#8220;EDA&#8221;) with Maxim Group LLC (&#8220;Maxim&#8221;),
pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate offering price of up to $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230419__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zMEtwbeO6O05" title="Issuance of common stoc, value">8,500,000</span> through Maxim, as agent (the &#8220;Offering&#8221;). Sales under the EDA were registered under the S-3 Shelf Registration Statement.
Under the terms of the EDA, Maxim will be entitled to a transaction fee at a fixed rate of <span id="xdx_908_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230419__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zGKFVuUhU4M1">3.0</span>% of the gross sales price of shares sold
under the EDA. During the year ended December 31, 2023, the Company sold <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zOJlSDZcgXu4" title="Sale of stock, number of shares issued in transaction">598,114</span> shares under the EDA for total gross proceeds of approximately
$<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z3ggv6RmBjze">344,000</span>, which includes a <span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zhWfTBAG9ojb">3.0</span>% fee to Maxim of $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zMIXKv7gdpsi">10,326</span>. For the three months ended September 30, 2024, the Company sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zCHh2hYi6Ji5" title="Sale of stock, number of shares issued in transaction">10,975</span> shares
under the EDA for total gross proceeds of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zr2xUwumO2Yd">4,110</span>, which includes a <span id="xdx_901_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zhodRipzm8lg">3.0</span>% fee to Maxim of $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zFuh0L88Yfz9">123</span>. For the nine months ended
September 30, 2024, the Company sold <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z8NOpmnjpGOa" title="Sale of stock, number of shares issued in transaction">1,305,653</span> shares under the EDA for total gross proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z90Up4udVZB9">630,204 </span>which includes
a <span id="xdx_90D_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z61pkh309uQi">3.0</span>% fee to Maxim of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zy8xvhzKMFqd">18,906</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Equity
Purchase Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2024, the Company entered into a purchase agreement and a registration rights agreement with Atlas Sciences, LLC (&#8220;Atlas&#8221;),
pursuant to which Atlas committed to purchase up to $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240328__20240328__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAndRegistrationRightsAgreementMember_z6Qmmo76xiK6" title="Issuance of common stock">15,000,000 </span>of common stock of the Company for a period of 24 months from the date
of the purchase agreement. No assurance can be given as to the actual amount that will be raised pursuant to the purchase agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the purchase agreement, the Company, at its sole discretion, shall have the right to issue Put shares to the Investor
at <span id="xdx_90B_ecustom--MarketPricePercentage_iI_pid_dp_uPure_c20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zd08R2QALC9e" title="Market price, percentage">95</span>%
of the Market Price of the shares on the day of trade. Sales under the purchase agreement are limited to a daily maximum of the
lessor of: $<span id="xdx_902_ecustom--TradingDailyMaximumLessorAmount_c20240328__20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z3GK5yc5iheb" title="Trading maximum lessor amount">500,000</span>,
the Median Daily Trading volume, and a beneficial ownership limitation of <span id="xdx_90C_ecustom--BeneficialOwnershipPercentage_iI_dp_uPure_c20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zc2r96719jHl" title="Beneficial ownership percentage">4.99</span>%
and a maximum of <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240328__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z8iLdsFcRGO7" title="Equity investment ownership percentage">19.99</span>%
of the outstanding shares at the time of the purchase agreement. In April 2024, the Company filed a registration statement with the
SEC on Form S-1 registering a total of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z0e2Ittf2D41" title="Number of stock sold">9,975,000</span>
shares for resale pursuant to the Atlas Agreements, consisting of <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240401__20240430__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zpx0vsEx6u2j" title="Stock sold by the company">9,636,400</span>
shares that can be sold by the Company to Atlas and <span id="xdx_906_ecustom--StockIssuedDuringPeriodValueCommitmentShares_pid_c20240401__20240430__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ze5ADbNSqO0c" title="Commitment shares issued">338,600</span>
shares that were issued to Atlas as Commitment Shares. The registration statement was declared effective on May 1, 2024. There were
no shares issued for the three months ended September 30, 2024. As of September 30, 2024, a total of <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_znhEJEEFbAF4" title="Number of stock sold">759,685</span>
shares have been issued pursuant to the purchase agreement for a total of approximately $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pid_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z0YJkGyaGQYf" title="Amount of stock sold">128,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Securities
Purchase Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) to complete an offering
(the &#8220;Transactions&#8221;) with a single accredited investor (the &#8220;Purchaser&#8221;), pursuant to which, on June 3, 2024, the Company
issued to the Purchaser, (i) in a registered direct offering, <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zvsNQakMz1Dk" title="Number of shares issued upon transaction">5,640,958</span> shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;),
par value $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zjHrPc0hk8Df" title="Common stock, par value">0.001</span> per share (&#8220;common stock&#8221;) and (ii) in a concurrent private placement, the Company  issued to the Purchaser
Class A common warrants to purchase an aggregate of up to <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_z0WsGfhJuftl" title="Number of shares issued upon transaction">5,640,958</span> shares of its common stock (the &#8220;A Warrants&#8221;) at an exercise
price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zvOT7C0I7JFf" title="Exercise price">0.363</span> per share and Class B common warrants to purchase an aggregate of up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonWarrantMember_zEJtUG87iYxd" title="Number of shares issued upon transaction">5,640,958</span> shares of its common stock (the &#8220;B
&#8220;Warrants&#8221; and, along with the A Warrants, the &#8220;Common Warrants&#8221;) at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonWarrantMember_zwuJnVqAau9e" title="Exercise price">0.363</span> per share. The
A Warrants and B Warrants are  not  exercisable for six months after the issuance date and  expire, respectively, 24 months and
five years and six months after the issuance date. The Common Warrants and the shares of common stock issuable upon the exercise of such
warrants are offered pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of
the Securities Act and Rule 506(b) promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares were  offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared
effective on February 4, 2022 (as amended from time to time, the &#8220;Registration Statement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Purchase Agreement, subject to certain exceptions, the Company could not issue any equity securities for 60 days following
the issuance date, provided that the Company was able to utilize its at-the-market offering program with the Placement Agent after
30 days. Additionally, the Company cannot enter into a variable rate transaction (other than the ATM program with the Placement Agent)
for 120 days after the issuance date. In addition, the Company&#8217;s executive officers and each of the Company&#8217;s directors have
entered into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 90 days from the closing
of the Transactions, offer, sell, transfer or otherwise dispose of the Company&#8217;s securities, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The exercise price of the Common Warrants, and the number of Common Warrant
Shares, are subject to adjustment in the event of any stock dividend or split, reverse stock split, recapitalization, reorganization or
similar transaction, as described in the Common Warrants. If a Fundamental Transaction (as defined in the Common Warrants) occurs, then
the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the Company may
exercise and will assume all of its obligations under the Common Warrants with the same effect as if such successor entity had been named
in the warrant itself. Common Warrant Holders will have additional rights defined in the Common Warrants. The Common Warrants are exercisable
on a &#8220;cashless&#8221; basis only if there is not a current registration statement permitting public resale. In this regard, the Company
filed a registration statement to register the resale of the Common Warrant Shares providing for the resale of the Shares issued and issuable
upon exercise of the Common Warrants. That registration statement was declared effective by the SEC on July 11, 2024. The Company has
agreed to use commercially reasonable efforts to cause such registration statement to keep such registration statement effective at all
times until no Purchaser owns any Warrants or Warrant Shares issuable upon exercise thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maxim
Group LLC acted as the placement agent (the &#8220;Placement Agent&#8221;) on a &#8220;commercially reasonable best efforts&#8221; basis,
in connection with the Transactions pursuant to the Placement Agency Agreement, dated May 31, 2024 (the &#8220;Placement Agency Agreement&#8221;),
by and between the Company and the Placement Agent. Pursuant to the Placement Agency Agreement, the Placement Agent was paid a cash fee of <span id="xdx_900_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240501__20240531__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_znAyC7lznWWi" title="Aggregate gross proceeds, percentage">8</span>% of the aggregate gross proceeds paid to the Company for the securities sold in the Transactions and reimbursement
of certain out-of-pocket expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the Common Warrants under the guidance of ASC 480 &#8211; Distinguishing Liabilities from Equity and determined that
they were in scope under the guidance as freestanding financial instruments but did not meet the criteria for liability classification
and are classified as equity within the condensed consolidated financial statements. Proceeds allocated to such warrants totaled approximately
$<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20240930_zRbP2wp9At8k" title="Proceeds from warrants">2.5</span> million. For the nine months ended September 30,2024, no Common Warrants were exercised, and all remain outstanding on September
30, 2024 related to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, the Company entered into a Securities Purchase Agreement to complete an offering with a single accredited investor.
For more information see Note 15: Subsequent Events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534592272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zQ16CfIusnze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10: <span id="xdx_822_zMey225KA1Dd">Net Loss Per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period.
Equivalent common shares, consisting of stock options and warrants which amounted to <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z0jmiCxJTYMe" title="Net loss per share, antidilutive">14,574,557</span> and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z7URUNwRkmuh" title="Net loss per share, antidilutive">2,763,020</span> shares for the nine months
ended September 30, 2024 and 2023, respectively, are excluded from the calculation of diluted net loss per share since their effect is
anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562527607520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zqKxGYvluOn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
11: <span id="xdx_82F_zzidmEODBJMb">Recent Accounting Pronouncements </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on
the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements
that have been issued that might have a material impact on its financial position or results of operations. Accounting pronouncements
issued by the FASB since filing the <span style="text-decoration: underline">Annual Report on Form 10-K for the year ended December 31, 2023</span> did not or are not believed
by management to have a material impact on the Company&#8217;s present or future financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562527671632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_zWqt4sq0Z5s5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12: <span id="xdx_828_zF9MURIPxiUh">Fair Value</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the provisions of FASB ASC 820 &#8220;Fair Value Measurements&#8221; for its financial and non-financial assets
and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset
and liability category measured at fair value on either a recurring or nonrecurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to
the short-term maturities of these items and are considered a Level 1 instrument of the fair value measurements standard. The Company
also has certain warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair value of the warrants
(&#8220;June 2024 Warrants&#8221;) related to the Company&#8217;s June 2024 common stock and warrant issuance, are calculated using a
Monte Carlo Simulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also had certain redeemable warrants in the Rights Offering with a cash settlement feature in the occurrence of a Fundamental
Transaction. No Fundamental Transaction occurred. In March 2024, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240331_zpLyvAzh0wVj" title="Conversion of warrants">205,000</span> of these warrants converted on a cashless basis and <span id="xdx_902_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired_iI_pid_c20240331_zEh3F7bf07v7" title="Cashless basis, expired">5,830,028</span>
expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimated the fair value of the June 2024 Warrants using the Black-Scholes Model, which uses multiple inputs including the Company&#8217;s
stock price, the exercise price of the warrant, volatility of the Company&#8217;s stock price, the risk-free interest rate and the expected
term of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_ecustom--ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock_zDgvahFw0swl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilized the following assumptions to estimate the fair value of the Class A Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zsQidJVgfr37" style="display: none">Schedule of Assumptions to
Estimate the Fair Value</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Underlying price per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zD97ws5Uj1Gf" title="Underlying price per share">0.350</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zehpniDao4D1" title="Underlying price per share"><span style="-sec-ix-hidden: xdx2ixbrl1550">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zjz2yccjPuc7" title="Exercise price per share">0.363</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zsLb2u8NbOT4" title="Exercise price per share"><span style="-sec-ix-hidden: xdx2ixbrl1554">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z7chJrnIJQE7" title="Risk-free interest rate">4.42</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zPjaVxg5CK5d" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1558">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expected holding period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zKeOpE0BWuQ6" title="Expected holding period">5.5</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zNudCoGdbWBf" title="Expected volatility">110</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zGaYNRsqxF3i" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1564">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z1vSOtTunSqa" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1566">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zsbSz68ay1yc" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1568">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilized the following assumptions to estimate the fair value of the Class B Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Underlying price per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zY6l4IrI6hpg" title="Underlying price per share">0.350</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zGWPwsoNbCb3" title="Underlying price per share"><span style="-sec-ix-hidden: xdx2ixbrl1572">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zHle8bqMekBg" title="Exercise price per share">0.363</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zvs0Pb7XXGH6" title="Exercise price per share"><span style="-sec-ix-hidden: xdx2ixbrl1576">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zO3kY87vtQM1" title="Risk-free interest rate">4.82</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zZS7CsO8Cih7" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1580">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expected holding period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zRFXnPoLRT89" title="Expected holding period">2</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zhSJz61mkdKd" title="Expected volatility">89</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zczDmWDxJonc" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1586">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_z4dFcP95gwc" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1588">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zBmcWKIhTX0l" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1590">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zcMvkDWRsSjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free
                                            Interest Rate</i>. The risk-free interest rates for the Warrants are based on U.S. Treasury
                                            constant maturities for periods commensurate with the remaining expected holding periods
                                            of the warrants.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Holding Period</i>. The expected holding period represents the period of time that the Warrants
                                            are expected to be outstanding until they are exercised. The Company utilizes the remaining
                                            contractual term of the Warrants at each valuation date as the expected holding period.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Volatility</i>. Expected stock volatility is based on daily observations of the Company&#8217;s
                                            historical stock values for a period commensurate with the remaining expected holding period
                                            on the last day of the period for which the computation is made.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Dividend Yield</i>. The expected dividend yield is based on the Company&#8217;s anticipated
                                            dividend payments over the remaining expected holding period. As the Company has never issued
                                            dividends, the expected dividend yield is 0% and this assumption will be continued in future
                                            calculations unless the Company changes its dividend policy.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Probability of a Fundamental Transaction.</i> Put rights arise if a Fundamental Transaction
                                            1) is an all cash transaction; (2) results in the Company going private; or (3) is a transaction
                                            involving a person or entity not traded on a national securities exchange. The Company believes
                                            such an occurrence is unlikely because:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company only has one product that is FDA approved but is currently not available for commercial
                                            sales.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company will have to perform additional clinical trials for FDA approval of its flagship
                                            product.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry
                                            and market conditions continue to include uncertainty, adding risk to any transaction.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            nature of a life sciences company is heavily dependent on future funding and high fixed costs,
                                            including Research &amp; Development.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has minimal revenues streams which are insufficient to meet the funding needs for
                                            the cost of operations or construction at their manufacturing facility; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company&#8217;s Rights Agreement and Executive Agreements make it less attractive to a potential
                                            buyer.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_z1oSiJHN4Lh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the above factors utilized in analysis of the likelihood of the Put&#8217;s potential Liability, the Company estimated the range of probabilities
related to a Put right being triggered as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zh1FKqV7mGub" style="display: none">Schedule of Potential
Liability</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Probability</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: center; padding-left: 3pt">Low</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--LowRangeOfProbability_pid_dp_uPure_c20240101__20240930_zkvLgwu2uHej" title="Low range, rate">0.5</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 3pt">Medium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--MediumRangeOfProbability_pid_dp_uPure_c20240101__20240930_zATLeRfk5Hnf" title="Medium range, rate">1.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 3pt">High</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--HighRangeOfProbability_pid_dp_uPure_c20240101__20240930_zVtQC9DS1mZj" title="High range, rate">5.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AC_zyFa61NFGg14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Monte Carlo Simulation has incorporated a <span id="xdx_903_ecustom--HighRangeOfProbability_pid_dp_uPure_c20240101__20240930_zK5LHEzjENPa" title="Probability, rate">5.0</span>% probability of a Fundamental Transaction to date for the life of the securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Timing of Announcement of a Fundamental Transaction.</i> As the Company has no specific expectation
                                            of a Fundamental Transaction, for reasons elucidated above, the Company utilized a discrete
                                            uniform probability distribution over the Expected Holding Period to model in the potential
                                            announcement of a Fundamental Transaction occurring during the Expected Holding Period.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            100 Day Volatility at Announcement of a Fundamental Transaction</i>. An estimate of future
                                            volatility is necessary as there is no mechanism for directly measuring future stock price
                                            movements. Daily observations of the Company&#8217;s historical stock values for the 100
                                            days immediately prior to the Warrants&#8217; grant dates, with a floor of 100%, were utilized
                                            as a proxy for future volatility estimates.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Risk-Free Interest Rate at Announcement of a Fundamental Transaction</i>. The Company utilized
                                            a risk-free interest rate corresponding to the forward U.S. Treasury rate for the period
                                            equal to the time between the date forecast for the public announcement of a Fundamental
                                            Transaction and the Warrant expiration date for each simulation.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ix)</i></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
                                            Time Between Announcement and Consummation of a Fundamental Transaction.</i> The expected
                                            time between the announcement and the consummation of a Fundamental Transaction is based
                                            on the Company&#8217;s experience with the due diligence process performed by acquirers and
                                            is estimated to be six months. The Monte Carlo Simulation approach incorporates this additional
                                            period to reflect the delay Warrant Holders would experience in receiving the proceeds of
                                            the Put.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the actual historical prices input
for the relevant period input change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the
extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements
in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These
levels are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1 &#8211; Quoted prices are available in active markets for identical assets or liabilities
                                            at the reporting date. Generally, this includes debt and equity securities that are traded
                                            in an active market.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2 &#8211; Observable inputs other than Level 1 prices such as quote prices for similar assets
                                            or liabilities; quoted prices in markets that are not active; or other inputs that are observable
                                            or can be corroborated by observable market data for substantially the full term of the assets
                                            or liabilities. Generally, this includes debt and equity securities that are not traded in
                                            an active market.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3 &#8211; Unobservable inputs that are supported by little or no market activity and that
                                            are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities
                                            include financial instruments whose value is determined using pricing models, discounted
                                            cash flow methodologies, or other valuation techniques, as well as instruments for which
                                            the determination of fair value requires significant management judgment or estimation. As
                                            of September 30, 2024, the Company has classified the warrants with cash settlement features as
                                            Level 3. Management evaluates a variety of inputs and then estimates fair value based on
                                            those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in
                                            valuing the warrants.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3JfoMmGwGK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy
as (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_z9N8VFqklMWa" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxI1fwhW7vZh" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">67</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zo0YJhRvvtb9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">67</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYjPFy5GJxAk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1608">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2eiI3hcGQT3" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1610">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQt1FjptGw6" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">6,287</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziVXcJcvj0gl" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">6,287</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zBULbOALFRw8" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1616">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8u55ydix3j5" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1618">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left; padding-bottom: 1pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zP7N3paE1grj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">4,805</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zW1g7juGpFkb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">4,805</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeQ27myYYqe5" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1624">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVkicbnuFTJj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1626">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCfaO7iLt9a6" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">7,631</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zf9yCE8hz1x2" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">7,631</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zOKyfcRFHeS7" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1632">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zN7gLJdiHbEa" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1634">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_z6H1m7PmFMPk" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534594960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zgKnSyBHpoMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13: <span id="xdx_821_zOwjbGkph6b8">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging
from <span id="xdx_906_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20240930__srt--RangeAxis__srt--MinimumMember_zqwBK1mnUDV8" title="Operating lease term">1</span> to <span id="xdx_908_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20240930__srt--RangeAxis__srt--MaximumMember_zDUrzhch49s4" title="Operating lease term">5</span> years, expiring at various dates during 2024 through 2027, and requiring monthly payments ranging from less than $<span id="xdx_90B_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_z0n4pZ8k0RBi" title="Operating lease Payment">1,000</span> to
$<span id="xdx_904_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zn6gAKjYwXZa" title="Operating lease Payment">17,000</span>. Certain leases include additional renewal options ranging from <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20240930__srt--RangeAxis__srt--MinimumMember_zLNbeWAp0ADe" title="Operating lease term">1</span> to <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20240930__srt--RangeAxis__srt--MaximumMember_z7z7Q1pL5c9f" title="Operating lease term">5</span> years. AIM has classified all of its leases as operating
leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
September 30, 2024 and December 31, 2023, the balance of the right of use assets was $<span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20240930_zRALP3AZf36j" title="Right of use asset">653,000</span> and $<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_zFPuPCMI2857" title="Right of use asset">697,000</span>, respectively, and the corresponding
operating lease liability balance was $<span id="xdx_906_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20240930_zEzgo2kCuqyb" title="Lease liability">669,000</span> and $<span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20231231_zXwnqwpVXCwc" title="Lease liability">718,000</span>, respectively. Right of use assets are recorded net of accumulated amortization
of $<span id="xdx_90D_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_pp0p0_c20240930_zWZmwuKDzSwh" title="Accumulated amortization">404,000</span> and $<span id="xdx_907_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_pp0p0_c20231231_z8FNm7i71c9i" title="Accumulated amortization">363,000 </span>as of September 30, 2024 and December 31, 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zjz1PFbiezc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
recognized rent expense associated with these leases are follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zun1HQhN8Be1" style="display: none">Schedule of AIM Recognized Rent Expense Associated with Operating Lease</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930_zTI3OTTC3hs3" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930_zDEerU0nJsUd" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2023</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2023</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_z4nmxel6skb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseCost_pn3n3_maLCzBan_zsdk9W45uZG6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">226</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">214</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzBan_zvageJeGouK4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Short-term and variable lease costs</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">253</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_mtLCzBan_zZ6TvucId2ae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total lease costs</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Classification of lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3pRw35uNfzi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research &amp; development</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">358</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0Zk0RR1SeEd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">General and administrative</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_zpv8JbELhHWh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total lease costs</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zP1336Ol7TIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s leases have remaining lease terms between <span id="xdx_908_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20240930__srt--RangeAxis__srt--MinimumMember_zHehfpZopOj9" title="Lessee, operating lease, remaining lease term">6</span> and <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20240930__srt--RangeAxis__srt--MaximumMember_zXMllmtef8j9" title="Lessee, operating lease, remaining lease term">35</span> months. At September 30, 2024, the weighted-average remaining term
was <span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240930_zduiQC1TIYp4" title="Operating lease, weighted average remaining lease term">32</span> months. At December 31, 2023, the weighted-average remaining term was <span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231_ze6WAzQMLW97" title="Lessee, operating lease, remaining lease term">41</span> months. The Company&#8217;s weighted average incremental
borrowing rate for its leases was <span id="xdx_90B_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20240930_zvandRUOlQn7" title="Debt, weighted average interest rate">10.2</span>% at September 30, 2024 and <span id="xdx_90B_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20231231_zaCkvHD1PB38" title="Debt, weighted average interest rate">10</span>% at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zK8RbzJr9QNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments as of September 30, 2024, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zttuDYqICJa1" style="display: none">Schedule of Operating Lease Future Payments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Year Ending December 31, <br/>
(in thousands)</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20240930_zfOCBbh5b624" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_zo2ACskIj2Qi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">78</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zS98VF0BHrU2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zdqBlEQ5CUp8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">244</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_zNiQ2sSMMXGg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pn3n3_zCshRWIxwxm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1707">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_di_z50YeeiL5h9e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(88</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zCm8nqEVfErg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">669</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8AB_zAxPU8YUGbll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534747808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research, Consulting and Supply Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract', window );"><strong>Research Consulting And Supply Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ResearchConsultingAndSupplyAgreementsTextBlock', window );">Research, Consulting and Supply Agreements</a></td>
<td class="text"><p id="xdx_80F_ecustom--ResearchConsultingAndSupplyAgreementsTextBlock_z4IcQw1sEmy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14: <span id="xdx_829_zWLDangXpff6">Research, Consulting and Supply Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into research, consulting and supply agreements with third party service providers to perform research and development
activities on therapeutics, including clinical trials. The identification of research and development costs involves reviewing open contracts
and purchase orders, communicating with applicable company and third-party personnel to identify services that have been performed, and
corroborating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced
or otherwise notified of actual expenses. The Company expenses these research and development costs when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2024, research and development expenses were comprised of: clinical studies ($<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zTk3z4c27k03" title="Research and development expense">582,000</span>), manufacturing
and engineering ($<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zACVIeWesRCb" title="Research and development expense">306,000</span>), quality control ($<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__srt--ProductOrServiceAxis__custom--QualityControlMember_zivZgJJgb9ob" title="Research and development expense">398,000</span>) and regulatory ($<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__srt--ProductOrServiceAxis__custom--RegulatoryMember_zkQFYesVWaq6" title="Research and development expense">151,000</span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2023, research and development expenses were comprised of: clinical studies ($<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zQNh5kq4Z2e7" title="Research and development expense">1,916,000</span>), manufacturing
and engineering ($<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zupUCNY2Trl5" title="Research and development expense">396,000</span>), quality control ($<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__srt--ProductOrServiceAxis__custom--QualityControlMember_z8P3FwA2w4Gh" title="Research and development expense">251,000</span>) and regulatory ($<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__srt--ProductOrServiceAxis__custom--RegulatoryMember_zpuXm6pGKq38" title="Research and development expense">170,000</span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2024, research and development expenses were comprised of: clinical studies ($<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_z2D4Vsoc5GVb" title="Research and development expense">1,880,000</span>), manufacturing
and engineering ($<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zQpvr0yAVnCl" title="Research and development expense">882,000</span>), quality control ($<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__srt--ProductOrServiceAxis__custom--QualityControlMember_zR24LXVpVcKd" title="Research and development expense">1,232,000</span>) and regulatory ($<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__srt--ProductOrServiceAxis__custom--RegulatoryMember_znM5pgBoWe8g" title="Research and development expense">540,000</span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2023, research and development expenses were comprised of: clinical studies ($<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zFVEJM3kuco8" title="Research and development expense">3,845,000</span>), manufacturing
and engineering ($<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zMC20vz8K0Hb" title="Research and development expense">2,783,000</span>), quality control ($<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__srt--ProductOrServiceAxis__custom--QualityControlMember_zaikd6VzLOz3" title="Research and development expense">752,000</span>) and regulatory ($<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__srt--ProductOrServiceAxis__custom--RegulatoryMember_zXXJOCSDxS4a" title="Research and development expense">359,000</span>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the most substantial of our contracts relating to research, consulting, and supply costs for AIM as they related
to research and development costs for the nine months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amarex
Clinical Research LLC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amarex
is the principal administrator of several of AIM&#8217;s largest clinical studies. AIM has multiple contracts with Amarex Clinical Research
LLC (&#8220;Amarex&#8221;). During the three months ended September 30, 2024 and 2023, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zJTgqcLWvxHc" title="Research and development expense">275,400</span> and
$<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zNE78m7aQYr6" title="Research and development expense">516,284</span>, respectively, related to these ongoing agreements. During the nine months ended September 30, 2024 and 2023, the Company
incurred approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zXqFOIS9xQR3" title="Research and development expense">881,987</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zj1X3YFg2Lyg" title="Research and development expense">1,294,265</span>, respectively, related to these ongoing agreements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic
                                            Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is
                                            managing a Phase 2 clinical trial in locally advanced pancreatic cancer patients designated
                                            AMP-270. Per the work order, AIM anticipates that Amarex&#8217;s management of the study
                                            will cost approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pp0p0_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z5DzZbNvoecl" title="Research and development expense excluding acquired in process cost">8,400,000</span>. This estimate includes pass-through costs of approximately
                                            $<span id="xdx_902_eus-gaap--DevelopmentCosts_pp0p0_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zLIDOqZK9X77" title="Development cost">1,000,000</span> and excludes certain third-party and investigator costs and escalations necessary
                                            for study completion. AIM anticipates that the study will take approximately <span id="xdx_904_ecustom--ResearchAndDevelopmentExpenseCostEstimatedLives_dtY_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zzyuOSUiuroh" title="Estimated lives">4.6</span> years to
                                            complete.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_zPMxjNbFMZJh" title="Research and development expense">129,000</span> related
                                            to this agreement. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2023, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_zfeeqhHOLYG5" title="Research and development expense">82,600</span> related
                                            to this agreement.</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_zG31AwmZq5P3" title="Research and development expense">141,100</span> related
                                            to this agreement. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_z1q1nkd6jsp5" title="Research and development expense">350,600</span> related
                                            to this agreement.</span></span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-COVID
                                            Conditions - In September 2022, AIM executed a work order with Amarex, pursuant to which
                                            Amarex is managing a Phase 2 trial in patients with Post-COVID Conditions. AIM is sponsoring
                                            the study. AIM anticipates that the study will cost approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pp0p0_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zfZAe3tyMpIh">6,400,000</span>, which includes
                                            pass through costs of approximately $<span id="xdx_900_eus-gaap--DevelopmentCosts_pp0p0_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zEBQi3GwnBJ7" title="Development cost">125,000</span>, investigator costs estimated at about $<span id="xdx_902_eus-gaap--CostMaintenance_pp0p0_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zxvPX41gZc06" title="Invigilators cost">4,400,000</span>
                                            and excludes certain other third-party costs and escalations. During 2023, the original work
                                            order increased to approximately $<span id="xdx_90C_eus-gaap--DevelopmentCosts_pp0p0_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zqNQf0sVXvN7" title="Development cost">6,600,000</span> for the addition of patient reported outcome
                                            (PRO) electronic questionnaires (devices/tablets for patients to complete); services associated
                                            with the ePRO system and additional safety monitoring services as well as changes to study
                                            documentation (such as protocol amendments) which resulted in additional IND submissions
                                            to FDA. This study was completed in 2023, although certain activities are still ongoing.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2024, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zzwC0omYI5Fk" title="Research and development expense">27,500</span> related
                                            to this agreement. During
                                            the three months ended September 30, 2023, the Company incurred approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zKfmtSA1QyB7" title="Research and development expense">447,600</span> related
                                            to this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zUAvqKyWhV9d" title="Research and development expense">195,800</span> related
                                            to this agreement. During
                                            the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zkZx6pQrBXF9" title="Research and development expense">783,400</span> related
                                            to this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Jubilant HollisterStier</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Jubilant HollisterStier (&#8220;Jubilant&#8221;)
is AIM&#8217;s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company entered into an agreement with Jubilant
pursuant to which Jubilant will manufacture batches of Ampligen&#174; for the Company. Since the 2017 engagement of Jubilant, two lots
of Ampligen consisting of more than <span id="xdx_906_ecustom--UnitsManufactured_uInteger_c20170101__20171231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zUcdr5GVZmk8" title="Number of units manufactured">16,000</span> units were manufactured and released in the year 2018. The first lot was designated for human
use in the United States in the cost recovery CFS program and for expanded oncology clinical trials. The second lot has been designated
for these programs in addition to commercial distribution in Argentina for the treatment of CFS. Jubilant manufactured additional two
lots of Ampligen in December 2019 and January 2020. In December 2023, Jubilant completed manufacturing of <span id="xdx_901_ecustom--NumberOfVials_uInteger_c20230101__20231231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_z4T5Sy2GSRu4" title="Additional number of vials">9,042</span> vials of Ampligen for
clinical use.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2024, the Company did <span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20240701__20240930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zd7Xy1vOyrR6" title="Research and development expense">no</span>t incur any expense related
                                            to this agreement. During
                                            the three months ended September 30, 2023, the Company did <span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zT4YJsfc8UBf" title="Research and development expense">no</span>t incur any expense related
                                            to this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zr5aN8UyKlA2" title="Research and development expense">1,200</span> related
                                            to this agreement.</span> During
                                            the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zA9ohgAhx0ck" title="Research and development expense">1,432,000</span> related
                                            to this agreement.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sterling
Pharma Solutions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (&#8220;Sterling&#8221;)
for the manufacture of the Company&#8217;s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling&#8217;s
Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_z7DbKXwdCOX4" title="Research and development expense">133,000</span> related
                                            to this agreement. During
                                            the three months ended September 30, 2023, the Company did <span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zE56Y1J9FBpf" title="Research and development expense">no</span>t incur any expense related
                                            to this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_z5JuugVYuFfk" title="Research and development expense">261,600</span> related
                                            to this agreement. During
                                            the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zuA6kpr77eg2" title="Research and development expense">357,000</span> related
                                            to this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Erasmus</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2022, the Company entered into a joint clinical study agreement with Erasmus University Medical Center Rotterdam to conduct
a Phase II study: Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic
pancreatic ductal adenocarcinoma for therapy efficacy. This is a study in collaboration with AstraZeneca. AIM&#8217;s limited responsibilities
are limited to providing Ampligen. Additionally, in April 2023 AIM agreed to provide to Erasmus MC an unrestricted grant of $<span id="xdx_903_eus-gaap--SuppliesExpense_pp0p0_c20230401__20230430__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_z7O3hYhkXxHk" title="Unrestricted grants">200,000</span>
for immune monitoring in pancreatic cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2024, the Company did <span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20240701__20240930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_ziXn8oDJb23l" title="Research and development expense">no</span>t incur any expense related
                                            to this agreement. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2023, the Company did <span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zaxmqBcY8vRl" title="Research and development expense">no</span>t incur any expense related
                                            to this agreement.</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zk7nDOkwB5Zg" title="Research and development expense">79,000</span> related
                                            to this agreement. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zajwWSFsXS9g" title="Research and development expense">100,000</span> related
                                            to this agreement.</span></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Azenova
Sales International</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, the Company entered into a consulting agreement with Azenova, LLC whereas Azenova will provide business development
services for AIM&#8217;s Ampligen product for solid tumors for a 12-month term that is extendable upon the agreement of the parties.
In exchange for its services, Azenova will receive a fixed monthly retainer of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pp0p0_c20231031__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zERemEyApHXh" title="Stock options, aggregate intrinsic value">30,000</span>
per month in addition to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pp0p0_c20231031__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z5z9qgncyonk" title="Stock options, vested">360,000</span>
stock options that vest monthly. In August 2024, an agreement was made to reduce the fixed monthly retainer fee to $<span id="xdx_906_ecustom--MonthlyRetainerFee_pp0p0_c20240801__20240831__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zIfgDHoAayy7" title="Monthly retainer fee">10,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zw3TeYRvVbif" title="Research and development expense">50,000</span> related
                                            to this agreement. During
                                            the three months ended September 30, 2023, the Company did <span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zHDu2ilh8y6l" title="Research and development expense">no</span>t incur any expense related
                                            to this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zyLJ2J5JZ1sg" title="Research and development expense">230,000</span> related
                                            to this agreement. During
                                            the nine months ended September 30, 2023, the Company did <span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230101__20230930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zPsV8praX1a3" title="Research and development expense">no</span>t incur any expense related to
                                            this agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alcami</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2023, the Company entered into an agreement with Alcami Corporation to perform an extractables study for a primary packaging
component. The agreement called for fixed costs of approximately $<span id="xdx_903_eus-gaap--ProductionCosts_pp0p0_c20230901__20230930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_zWWl9oaMHjB7" title="Research and development expense">30,000</span> upon completion of the study and issue of the final report,
along with solvent costs, and pass through items to be billed on a per activity basis. The final bill for the initial study was received
in December 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9675;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During
the three months ended September 30, 2024, the Company did <span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_zJ6NGjhJCKs6">no</span>t
incur any expense for lab services from Alcami. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the three months ended September 30, 2023, the Company incurred approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_zjdPb2zWY2n7" title="Research and development expense">8,800</span> of lab
                                            services from Alcami.</span></td></tr>
                                                                                  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                            the nine months ended September 30, 2024, the Company incurred approximately $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_ztSYpQQ3uOOc" title="Research and development expense">14,000</span> of lab
                                            services from Alcami. During
                                            the nine months ended September 30, 2023, the Company incurred approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_zo2yiiwwdb8g" title="Research and development expense">25,000</span> of lab
                                            services from Alcami.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ResearchConsultingAndSupplyAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Consulting And Supply Agreements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ResearchConsultingAndSupplyAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534759872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zaJ6SoNeqCx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
15: <span id="xdx_82B_zbBx8nigwpTe">Subsequent Events</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 30, 2024, the Company entered into a Securities Purchase Agreement (the &#8220;<span style="text-decoration: underline">Purchase Agreement</span>&#8221;) to complete
an offering (the &#8220;<span style="text-decoration: underline">Transactions</span>&#8221;) with a single accredited investor (the &#8220;<span style="text-decoration: underline">Purchaser</span>&#8221;). The Transactions
closed on October 1, 2024. Pursuant to the Purchase Agreement, at closing, the Company issued to the Purchaser, (i) in a registered
direct offering, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx00GvBaYtf8" title="Number of shares issued upon transaction">4,653,036</span> shares of the Company&#8217;s common stock (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;), par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoVgIkZB8Qn1" title="Common stock, par value">0.001</span> per share (&#8220;<span style="text-decoration: underline">Common
Stock</span>&#8221;); and (ii) in a concurrent private placement, the Company issued to the Purchaser Class C common warrants to purchase
an aggregate of up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2scs6y8z3O1" title="Number of shares issued upon transaction">4,653,036</span> shares of its Common Stock (the &#8220;<span style="text-decoration: underline">C Warrants</span>&#8221;) at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGzc24PkOgwj" title="Exercise price">0.28</span> per share
and Class D common warrants to purchase an aggregate of up to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassDCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOmoY0HHQ79h" title="Number of shares issued upon transaction">4,653,036</span> shares of its Common Stock (the &#8220;<span style="text-decoration: underline">D Warrants</span>&#8221;
and, along with the C Warrants, the &#8220;<span style="text-decoration: underline">Common Warrants</span>&#8221;) at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassDCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpvPwH27tzRc" title="Exercise price">0.28</span> per share. The C Warrants and
D Warrants will not be exercisable for six months after the issuance date and will expire, respectively, 24 months and five years and
six months after the issuance date. The Common Warrants and the shares of Common Stock issuable upon the exercise of such warrants were
offered pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities
Act</span>&#8221;), provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received aggregate gross proceeds from the Transactions of approximately $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_pn4n6_c20241001__20241001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhwL3YQEkmcf" title="Grosss proceeds">1.26</span> million, before deducting fees to the Placement
Agent and other estimated offering expenses payable by the Company. The shares underlying the Common Warrants are being offered by the
Company pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared effective on February 4, 2022
(as amended from time to time, the &#8220;<span style="text-decoration: underline">Registration Statement</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Purchase Agreement, subject to certain exceptions, the Company cannot issue any equity securities for 60 days following
the closing of the Transactions (the &#8220;<span style="text-decoration: underline">Closing Date</span>&#8221;), provided that the Company will be able to utilize it&#8217;s
at-the-market offering (the &#8220;<span style="text-decoration: underline">ATM</span>&#8221;) program with the Placement Agent after 30 days. Additionally, the Company cannot
enter into a variable rate transaction (other than the ATM program with the Placement Agent) for 120 days after the Closing Date. In
addition, the Company&#8217;s executive officers and each of the Company&#8217;s directors have entered into lock-up agreements with
the Company pursuant to which each of them has agreed not to, for a period of 90 days from the Closing Date, offer, sell, transfer or
otherwise dispose of the Company&#8217;s securities, subject to certain exceptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price of the Common Warrants, and the number of shares of Common Stock underling the Common Warrant (the &#8220;<span style="text-decoration: underline">Common Warrant
Shares</span>&#8221;) will be subject to adjustment in the event of any stock dividend or split, reverse stock split, recapitalization,
reorganization or similar transaction, as described in the Common Warrants. If a Fundamental Transaction (as defined in the Common Warrants)
occurs, then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the
Company may exercise and will assume all of its obligations under the Common Warrants with the same effect as if such successor entity
had been named in the warrant itself. Common Warrant Holders will have additional rights defined in the Common Warrants. The Common Warrants
will be exercisable on a &#8220;cashless&#8221; basis only if there is not a current registration statement permitting public resale.
In this regard, the Company has agreed to file a registration statement to register the resale of the Common Warrant Shares as soon as
practicable (and in any event within 45 calendar days of the date of the Purchase Agreement) providing for the resale of the Shares issued
and issuable upon exercise of the Common Warrants. The Company has agreed to use commercially reasonable efforts to cause such registration statement to become effective within 181 days
following the Closing Date and to keep such registration statement effective at all times
until no Purchaser owns any Common Warrants or Common Warrant Shares issuable upon exercise thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently evaluating the Common Warrants under the guidance of ASC 480 &#8211; Distinguishing Liabilities from Equity</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534689392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zRGGwIRYWFyb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8B1_zCYYYn4y7eL1">Schedule
of Property and Equipment</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_494_20240930_z5hFwuCCDQ9f" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49B_20231231_zBpvQnD47La7" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENztUG_zMy3sLzXGS6g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Furniture, fixtures, and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,466</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">1,448</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENztUG_zQo49N7TPXn1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,349</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,321</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENztUG_zFFesyhVHXMa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">127</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534672464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patents, and Trademark Rights, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Patent and Trademark Rights</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zBCDvBpBjFmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
and trademark rights consist of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt"><span id="xdx_8BB_zAa7JNWy89tb">Schedule
of Patent and Trademark Rights</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Gross Carrying Value</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated Amortization</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net Carrying Value</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Gross Carrying Value</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated Amortization</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Net Carrying Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zbUICxw1Xj8c" style="width: 8%; text-align: right" title="Gross carrying value">3,315</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zpwzsHMhXvG4" style="width: 8%; text-align: right" title="Accumulated amortization">(887</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zEPpi2tMxpDa" style="width: 8%; text-align: right" title="Net carrying value">2,428</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzxSZR35aLli" style="width: 8%; text-align: right" title="Gross carrying value">2,947</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8J54CytraFk" style="width: 8%; text-align: right" title="Accumulated amortization">(750</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAGxijkjvRf" style="width: 8%; text-align: right" title="Net carrying value">2,197</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Trademarks</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zvfvEdCm6oY3" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">232</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z33LHiL2D1bg" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(128</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zQvo28Jaoe61" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zjJM7f8pmrPd" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value">229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zoBAV3VSrXfk" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization">(113</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSX6Kv6qQrbl" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value">116</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net amortizable patents and trademarks rights</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930_zwH2Yy8CWW62" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,547</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930_zxHNsNce0g53" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(1,015</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930_zUBZJdMlSL8b" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zXvptjERIbih" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value">3,176</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zheFoTKFHNB6" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(863</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zL8AbrNZtT67" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value">2,313</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Changes in Patents, Trademark Rights</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zGqBFECNpEW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
and trademark rights acquisitions, abandonments and amortization:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8B7_zkcpxAOiTA8">Schedule of Changes in
Patents, Trademark Rights</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20240101__20240930_zYazcw4FAWm1" style="width: 20%; text-align: right" title="Balance">2,313</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Acquisitions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20240930_zQkkLOeVr6Pl" style="text-align: right" title="Acquisitions">419</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Abandonments and expirations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20240101__20240930_z1PWeAKfCbvg" style="text-align: right" title="Abandonments">(46</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20240101__20240930_zbcdeHtCc1fd" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Amortization">(154</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20240101__20240930_zCEi51a2i4Qc" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">2,532</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Amortization of Patents and Trademarks</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zFn3Ia1SZmGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of patents and trademarks for each of the next five years and thereafter is as follows (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8BF_zgAqJXpNuYmj">Schedule
of Amortization of Patents and Trademarks</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Year Ending December 31,</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20240930_z1tIYpVuM4Xe" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzzOp_zwjhISSXC6c7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: justify">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 24%; text-align: right">72</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zTsNY3ua6BM7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zoOVx8HtnVqi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">265</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zd5hADRcvfP4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zrSd1XdSTIfk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">219</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzzOp_zJfUCy3CpjH1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,469</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zWhqaolA3oN5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,532</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562638583072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zQi5554CwUCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"><span id="xdx_8B1_zCZ86rKhvOt7">Schedule
of Accrued Expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_493_20240930_zpvTaGPeAyEl" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_492_20231231_zyfNm3w9hjBi" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zxZUuEaIXWSc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify">Compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">414</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zErRAiIuwHzd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">790</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,352</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_z8kZCQ7m4g52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Clinical trial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132</td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzYmu_zxpeMg9SgGIi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ziLMURobsHek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">37</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">36</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zFlkF5q6M6L8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,011</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,986</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534407792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unsecured Promissory Note (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Long Term Debt</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_z8qR51yTaila" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span><span id="xdx_8B3_zzL1KXT6vYW6">Schedule of Long Term Debt</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240930_znIPEbSifguf" style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Debt schedule at September 30, 2024 (in thousands)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: right"></td><td style="padding-bottom: 1pt">&#160;</td>
    </tr>
  <tr id="xdx_40F_eus-gaap--LongTermDebt_iI_pn3n3_z5Qzrbi8hhlh" style="vertical-align: bottom; background-color: White">
    <td style="width: 77%; text-align: left">Long-term debt</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">3,301</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_zme2jc2Cl9lc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unamortized Original issue discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(555</td><td style="text-align: left">)</td>
    </tr>
  <tr id="xdx_40C_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_zEzzylzYJd6g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Unamortized Financing fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(14</td><td style="padding-bottom: 1pt; text-align: left">)</td>
    </tr>
  <tr id="xdx_400_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn3n3_z1sjpi9zFbp3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Unamortized discount and debt issuance costs</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,732</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr id="xdx_40B_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_z3tDTtSH1sf1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less current portion of long-term debt, net <span></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,593</td><td style="padding-bottom: 1pt; text-align: left">)</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zfrhvPyY2899" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt, net <span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">139</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    </tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562528333424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SOSBCSOASA-KMP_zh7fODkBMfI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zELmZh9E6l79" style="display: none">Schedule
of Stock Option Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/> Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding June 30, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjyD49yckon5" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year">2,407,775</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUDZ6B9tPuhk" title="Weighted Average Exercise Price Outstanding, Beginning of Period">2.50</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zA6WtLyZASid" title="Weighted Average Remaining Contracted Term (years) Outstanding">8.70</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsI90ptM0jv6" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl0997">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlJOUT20gvv" style="text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHLE9He70K7f" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1001">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUqxUDPKGHFg" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1003">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9AaJcEwgYJh" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1005">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7JJEhxpI8t1" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1007">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zH3aSRizWyMk" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1009">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIJ6I7oTvk64" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7AT3mlVDgFa" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1013">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zaxovopTHiic" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1015">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSb3FI5Sl4P9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period">2,407,680</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziURHvTtM7Wk" title="Weighted Average Exercise Price Outstanding, End of Period">2.44</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7nelISYhCrd" title="Weighted Average Remaining Contracted Term (years)">8.70</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zqhlUrLQeYt5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"><span style="-sec-ix-hidden: xdx2ixbrl1023">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoXN9PEJ5iLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">2,407,680</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCF6ICTITSrg" title="Weighted Average Exercise Price, Vested and Expected to Vest">2.44</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjEemedfkDJ3" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">8.70</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNwglLCnLnB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1031">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbhf65Q8YFt7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">2,341,014</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl7Tc0AMcUah" title="Weighted Average Exercise Price Exercisable, Ending of Period">1.66</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSKGKa98BCnd" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">7.17</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zb7jfHMAqa5e" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1039">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_134_zbpFI8KrQIwe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average <br/>Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/> Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/> Intrinsic <br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWsKzf9ySWcd" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year">2,408,438</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrvicYzwmdP5" title="Weighted Average Exercise Price Outstanding, Beginning of Period">2.50</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zN11clVZ5eVd" title="Weighted Average Remaining Contracted Term (years) Outstanding">8.70</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zS9HesshdjB8" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1187">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zy6V6T5rRRN" style="text-align: right" title="Number of options, granted"><span style="-sec-ix-hidden: xdx2ixbrl1189">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWJ8tezMnSG9" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1191">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhNtAfhE9CKc" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1193">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUJy01uAGkja" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1195">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z4k29IU5MeS8" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1197">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZ3INBtll8s8" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3RLPP1Z58l5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(758</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z5a9p87y7Nvl" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1203">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7rBX5pcldNj" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1205">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9PiyYO55108" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period">2,407,680</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zgiaI51Yf8Ud" title="Weighted Average Exercise Price Outstanding, End of Period">2.44</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV7PHskuC1te" title="Weighted Average Remaining Contracted Term (years)">8.70</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziTI4BvTbXZd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"><span style="-sec-ix-hidden: xdx2ixbrl1213">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9jbdJ1UeeN2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">2,407,680</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrwk3sPKL9r7" title="Weighted Average Exercise Price, Vested and Expected to Vest">2.44</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zISzyz1ExvRd" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">8.70</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8k63vScsNze" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1221">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8jCkn80oLDd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">2,341,014</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zm7FjiaJ5nX1" title="Weighted Average Exercise Price Exercisable, Ending of Period">1.66</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlpZTqTiXH5" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">7.17</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNuy0VHkTDIi" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1229">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Unvested Stock Option Activity</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SONSATTB-QOTKSOK_zQj05qtEmQE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
stock option activity for employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z9DxytPfegse" style="display: none">Schedule
of Unvested Stock Option Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/>Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/> Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Unvested June 30, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z84haaRrIaI6" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period">166,666</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOPx0OQtrqJb" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">4.11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhcjV7bPlK7e" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">18.87</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbJjxQA7vjk4" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1052">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMg0PpIF6h3c" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1054">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOG76PIF5jX9" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1056">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zytehApLdBq6" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl4AwqJtOUXg" style="text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVvGzMWc26n8" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1062">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z702F2nVWw5l" style="text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1064">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRGMkXjIjQIh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested">(99,905</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z5W5LUTZBwu2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested">0.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zGhlSXfeXe6d" title="Weighted Average Remaining Contracted Term (years) Vested">7.17</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTPUpqtwN4og" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjiOohm1j9rd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">66,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbnRsZ3Zcdk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">9.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV3ToK6T3u89" title="Average Remaining Contractual Term (years) Unvested, End of Period">36.22</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUafxgzWlok5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1080">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_134_zAZ64rbchUKi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/>Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/> Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Unvested January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrsbidNc06B2" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period">366,666</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zStSkwQd2cG2" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">2.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zheVkcZA5wN6" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">12.44</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0qY0UsmBYE8" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1237">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zudH9uJhIe6a" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSLDdwvQEmd1" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1241">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z27QE6z6S5j5" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1243">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zorokXUxmwrj" style="text-align: right" title="Number of Options, Expired">(758</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zKpUHgKinFYd" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRFXpXaqQykh" style="text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1249">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zu3UHcuxfiG2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested">(299,242</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXQeItkxToq4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested">0.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zh9JpIprSBu" title="Weighted Average Remaining Contracted Term (years) Vested">7.17</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zucRbwQeqIJg" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1257">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zouqYb3AJvB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">66,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziPvgbO0hBaa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">9.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJpG8ywn1Zi" title="Average Remaining Contractual Term (years) Unvested, End of Period">36.22</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRctqqO8TGzl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1265">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Share-Based Payment Arrangement, Nonemployee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SOSBCSOASA-DNQVA_zuXh3tppq76j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zx8D0sBXYWv9" style="display: none">Schedule
of Stock Option Activity</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding June 30, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaF5yDYcOZA7" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning of Period">885,055</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z7kZUofcgBYe" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period">2.02</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zftq24OTTlz7" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.23</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcJElAxfvgD6" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1092">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdySOjgFrc5a" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1094">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCvgHS82Mkwi" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1096">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z2s1Nfh7zpJe" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1098">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMpaDHJEvhw2" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1100">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeKE3oa92K1f" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhjdzz3wNJak" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1104">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z710pkk0K0uh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabMb2JSrqdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1108">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztqKFXx2XeCd" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1110">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeAutH3C3k71" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period">884,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z30GS8sFl1ak" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period">1.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9ABWbeWmxz3" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.23</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfXx2BNnCGS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zz9QdZSHTZuj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">884,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhLvrb2naeBe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest">1.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXLoaRrf9Nvi" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">9.23</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAnWbQZRLmYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1126">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRESdE1Et5lh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">729,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zl9srwqwk9kc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period">1.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zu2ni2MpRR0a" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">10.06</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFkhX2aFesW2" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1134">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_134_z5EIUSL00SQj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of<br/> Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAx9aZk5OJy1" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning of Period">885,055</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8Yy6kGEQ4gb" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period">2.02</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zveAC0DMk4z8" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.23</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWf50mYIhqz3" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1273">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWvZ5bQsiAw5" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1275">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfVgCh1XgInb" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1277">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGBxQLenuel9" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1279">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zLhHJxFeAAWb" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1281">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIBK4GHzRX4" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1283">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPHXTzz1QA24" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1285">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMBcS49SknKb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUTYNo2XeF6b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1289">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwxBMmTX69k8" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1291">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zg8oTRGTPnQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period">884,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMuWMj8NH6ef" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period">1.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzu1hl5CNjUc" title="Weighted Average Remaining Contracted Term (years) Outstanding">9.23</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztMrm84L0PBa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1299">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Vested and expected to vest September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpinr46l4aYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest">884,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zM7xY4RRunc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest">1.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsq7ABwkucle" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest">9.23</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUPo1PxB47Df" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1307">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpXb0qGCGuW6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period">729,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHk8CF75wanf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period">1.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuXm6S64XwJj" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">10.06</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZvKwcanEdFa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"><span style="-sec-ix-hidden: xdx2ixbrl1315">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Unvested Stock Option Activity</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SONSATTB-BWM_z7TXuu6oUU0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
stock option activity for non-employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zXrhTt3hW8sd" style="display: none">Schedule
of Unvested Stock Option Activity</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/>Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Exercise <br/>Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/>Intrinsic <br/>Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Unvested June 30, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjsXfy3G7EIc" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period">155,001</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zng86shSyV5i" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">3.42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zyzkdqaqA9La" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">11.30</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUSMNti8XCE7" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1147">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZW30cPwV71a" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1149">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFNQl2tfVz83" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1151">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zo7fYGT9D579" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0n4X6iePLti" style="text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zr8ObjoHO3b4" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1157">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRzwbedcMbrf" style="text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1159">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYIPol713VB9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested">95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcCNSfs1wMbi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested">0.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwaIDvMMIrt5" title="Average Remaining Contractual Term Vested">10.18</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMTvchDc45Of" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1167">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zE2w3bbv2uFl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">155,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zyZlk7DeOZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">3.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUOg3jQg6uz8" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">11.31</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBQ8EF5Zv8ui" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1175">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

&#160;<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_134_zi3j29Bqb4l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of <br/>Options</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Exercise <br/> Price</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Term <br/>(Years)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate <br/> Intrinsic <br/>Value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Unvested January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztMKYaa2HcQ7" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period">335,001</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwWwzRJl4Fs4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period">1.83</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvt3P0Xidfej" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period">10.70</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoypW4H5aJF" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"><span style="-sec-ix-hidden: xdx2ixbrl1323">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKQZKbADmTGg" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1325">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIn40faYM6ml" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1327">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zedKPVdPJhJb" style="text-align: right" title="Aggregate Intrinsic Value, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1329">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z1CmUEv6YRF2" style="text-align: right" title="Number of Options, Expired">(95</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zItSoXu7NGHb" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1333">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zN47RSNjmyNe" style="text-align: right" title="Aggregate Intrinsic Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1335">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTJT17NtE8M4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested">(179,905</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zbPwr0p8XMQ" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested">0.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhOprlOO2tMk" title="Average Remaining Contractual Term Vested">10.18</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcKVg4IKRwBk" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Unvested September 30, 2024</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqPrUzeBm0jc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period">155,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVCsCim7RUvc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period">3.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeugZ61eatxh" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period">11.31</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzEf8hRTmQY7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"><span style="-sec-ix-hidden: xdx2ixbrl1351">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562529500208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock', window );">Schedule of Assumptions to Estimate the Fair Value</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock_zDgvahFw0swl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilized the following assumptions to estimate the fair value of the Class A Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zsQidJVgfr37" style="display: none">Schedule of Assumptions to
Estimate the Fair Value</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Underlying price per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zD97ws5Uj1Gf" title="Underlying price per share">0.350</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zehpniDao4D1" title="Underlying price per share"><span style="-sec-ix-hidden: xdx2ixbrl1550">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zjz2yccjPuc7" title="Exercise price per share">0.363</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zsLb2u8NbOT4" title="Exercise price per share"><span style="-sec-ix-hidden: xdx2ixbrl1554">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z7chJrnIJQE7" title="Risk-free interest rate">4.42</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zPjaVxg5CK5d" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1558">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expected holding period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zKeOpE0BWuQ6" title="Expected holding period">5.5</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zNudCoGdbWBf" title="Expected volatility">110</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zGaYNRsqxF3i" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1564">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z1vSOtTunSqa" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1566">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zsbSz68ay1yc" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1568">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilized the following assumptions to estimate the fair value of the Class B Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">September 30,</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Underlying price per share</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zY6l4IrI6hpg" title="Underlying price per share">0.350</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zGWPwsoNbCb3" title="Underlying price per share"><span style="-sec-ix-hidden: xdx2ixbrl1572">&#8212;</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zHle8bqMekBg" title="Exercise price per share">0.363</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zvs0Pb7XXGH6" title="Exercise price per share"><span style="-sec-ix-hidden: xdx2ixbrl1576">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zO3kY87vtQM1" title="Risk-free interest rate">4.82</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zZS7CsO8Cih7" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1580">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expected holding period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zRFXnPoLRT89" title="Expected holding period">2</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zhSJz61mkdKd" title="Expected volatility">89</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zczDmWDxJonc" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1586">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_z4dFcP95gwc" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1588">&#8212;</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zBmcWKIhTX0l" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1590">&#8212;</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock', window );">Schedule of Potential Liability</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_z1oSiJHN4Lh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the above factors utilized in analysis of the likelihood of the Put&#8217;s potential Liability, the Company estimated the range of probabilities
related to a Put right being triggered as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zh1FKqV7mGub" style="display: none">Schedule of Potential
Liability</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Range of Probability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Probability</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; text-align: center; padding-left: 3pt">Low</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--LowRangeOfProbability_pid_dp_uPure_c20240101__20240930_zkvLgwu2uHej" title="Low range, rate">0.5</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 3pt">Medium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--MediumRangeOfProbability_pid_dp_uPure_c20240101__20240930_zATLeRfk5Hnf" title="Medium range, rate">1.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 3pt">High</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--HighRangeOfProbability_pid_dp_uPure_c20240101__20240930_zVtQC9DS1mZj" title="High range, rate">5.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3JfoMmGwGK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy
as (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_z9N8VFqklMWa" style="display: none">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxI1fwhW7vZh" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">67</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zo0YJhRvvtb9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">67</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYjPFy5GJxAk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1608">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2eiI3hcGQT3" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1610">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQt1FjptGw6" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">6,287</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziVXcJcvj0gl" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">6,287</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zBULbOALFRw8" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1616">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8u55ydix3j5" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1618">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">As of December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 1</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 2</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Level 3</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left; padding-bottom: 1pt">Cash equivalents</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zP7N3paE1grj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">4,805</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zW1g7juGpFkb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments">4,805</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeQ27myYYqe5" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1624">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVkicbnuFTJj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"><span style="-sec-ix-hidden: xdx2ixbrl1626">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Marketable securities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCfaO7iLt9a6" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">7,631</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zf9yCE8hz1x2" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities">7,631</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zOKyfcRFHeS7" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1632">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zN7gLJdiHbEa" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"><span style="-sec-ix-hidden: xdx2ixbrl1634">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Assumptions To Estimate The Fair Value [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Potential Liability Estimated The Range Of Probabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562527618160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of AIM Recognized Rent Expense Associated with Operating Lease</a></td>
<td class="text"><p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zjz1PFbiezc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
recognized rent expense associated with these leases are follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zun1HQhN8Be1" style="display: none">Schedule of AIM Recognized Rent Expense Associated with Operating Lease</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20240930_zTI3OTTC3hs3" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930_zDEerU0nJsUd" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2023</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2023</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_z4nmxel6skb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease costs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseCost_pn3n3_maLCzBan_zsdk9W45uZG6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Operating lease costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">226</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">214</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzBan_zvageJeGouK4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Short-term and variable lease costs</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">253</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_mtLCzBan_zZ6TvucId2ae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total lease costs</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Classification of lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3pRw35uNfzi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Research &amp; development</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">358</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0Zk0RR1SeEd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">General and administrative</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_zpv8JbELhHWh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total lease costs</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">467</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Future Payments</a></td>
<td class="text"><p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zK8RbzJr9QNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum payments as of September 30, 2024, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zttuDYqICJa1" style="display: none">Schedule of Operating Lease Future Payments</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Year Ending December 31, <br/>
(in thousands)</td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20240930_zfOCBbh5b624" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_zo2ACskIj2Qi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">78</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zS98VF0BHrU2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zdqBlEQ5CUp8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">244</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_zNiQ2sSMMXGg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pn3n3_zCshRWIxwxm3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Thereafter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1707">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_di_z50YeeiL5h9e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Less imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(88</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zCm8nqEVfErg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">669</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534752448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federlly insured limit</a></td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562527987264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held value of marketable securities</a></td>
<td class="nump">$ 6,287,000<span></span>
</td>
<td class="nump">$ 7,631,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 6,287,000<span></span>
</td>
<td class="nump">$ 7,631,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity', window );">Equity securities description</a></td>
<td class="text">The net gain recognized for the three-month
period ended September 30, 2024 on equity securities was $273,000. The net losses recognized for the three-month period ended September
30, 2024 on equity securities sold during the period were ($59,000). The unrealized gains recognized for the three-month period
ended September 30, 2024 on equity securities still held was $332,000. The net gain recognized for the nine-month period ended September
30, 2024 on equity securities was $96,000. The net losses recognized for the nine-month period ended September 30, 2024 on equity
securities sold during the period were ($277,000). The unrealized gains recognized for the nine-month period ended September 30,
2024 on equity securities still held was $373,000.<span></span>
</td>
<td class="text">The net loss recognized for the three-month
period ended September 30, 2023 on equity securities was ($309,000).&#160; The net losses recognized for the three-month period ended
September 30, 2023 on equity securities sold during the period were ($42,000). The unrealized losses recognized during the three-month
period ended September 30, 2023 on equity securities still held was ($267,000). The net losses recognized for the nine-month
period ended September 30, 2023 on equity securities was ($201,000). The net losses recognized for the nine-month period ended
September 30, 2023 on equity securities sold during the period were ($130,000). The unrealized losses recognized during the nine-month
period ended September 30, 2023 on equity securities still held was ($71,000).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the type of equity security or securities into which conversion will be made (for example, common stock or preferred shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562534587968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture, fixtures, and equipment</a></td>
<td class="nump">$ 1,466<span></span>
</td>
<td class="nump">$ 1,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,349)<span></span>
</td>
<td class="num">(1,321)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562533130336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562533024608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Patent and Trademark Rights (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">$ 3,547<span></span>
</td>
<td class="nump">$ 3,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,015)<span></span>
</td>
<td class="num">(863)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying value</a></td>
<td class="nump">2,532<span></span>
</td>
<td class="nump">2,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">3,315<span></span>
</td>
<td class="nump">2,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(887)<span></span>
</td>
<td class="num">(750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying value</a></td>
<td class="nump">2,428<span></span>
</td>
<td class="nump">2,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying value</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562529677872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Patents, Trademark Rights (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Balance</a></td>
<td class="nump">$ 2,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Acquisitions</a></td>
<td class="nump">419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_FinitelivedIntangibleAssetsAbandonments', window );">Abandonments</a></td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Accumulated Amortization</a></td>
<td class="num">(154)<span></span>
</td>
<td class="num">$ (150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Balance</a></td>
<td class="nump">$ 2,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_FinitelivedIntangibleAssetsAbandonments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets abandonments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_FinitelivedIntangibleAssetsAbandonments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562533114768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Amortization of Patents and Trademarks (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour', window );">Thereafter</a></td>
<td class="nump">1,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 2,532<span></span>
</td>
<td class="nump">$ 2,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562634424528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Patents, and Trademark Rights, Net (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets, estimated useful life</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension', window );">Finite lived intangible assets, weighted average amortization</a></td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets, estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension', window );">Finite lived intangible assets, weighted average amortization</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562532781440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_AccruedClinicalTrialExpensesCurrent', window );">Clinical trial expenses</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">51<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,011<span></span>
</td>
<td class="nump">$ 1,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562528033712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Long Term Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 3,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Unamortized Original issue discount</a></td>
<td class="num">(555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized Financing fees</a></td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized discount and debt issuance costs</a></td>
<td class="nump">2,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion of long-term debt, net</a></td>
<td class="num">(2,593)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">$ 139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562529947280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unsecured Promissory Note (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,301,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense debt excluding amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expenses of long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoanProcessingFee', window );">Loan fee amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Future maturities of long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">Future maturities of long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentGross', window );">Long-term debt, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Debt discount, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt origination costs, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentGross', window );">Long-term debt, non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent', window );">Debt discount, non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Debt origination costs, non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AIM_NotePurchaseAgreementMember', window );">Note Purchase Agreement [Member] | Streeterville Capital LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Exchange of unsecured promissory notes</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Unsecured debt original issue discount</a></td>
<td class="nump">781,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="nump">3,301,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument stated interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionDescription', window );">Redemption description</a></td>
<td class="text">The
agreement allows the Lender to redeem up to $250,000 per calendar month beginning in August 2024, upon providing written notice to Borrower.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of debt redemption features under terms of the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanProcessingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses paid for obtaining loans which includes expenses such as application and origination fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanProcessingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=AIM_StreetervilleCapitalLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=AIM_StreetervilleCapitalLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562529455360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning of Period</a></td>
<td class="nump">2,407,775<span></span>
</td>
<td class="nump">2,408,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning of Period</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contracted Term (years) Outstanding</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Beginning of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options, Expired</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending of Period</a></td>
<td class="nump">2,407,680<span></span>
</td>
<td class="nump">2,407,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, End of Period</a></td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contracted Term (years) Outstanding</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and Expected to Vest</a></td>
<td class="nump">2,407,680<span></span>
</td>
<td class="nump">2,407,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and Expected to Vest</a></td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and Expected to Vest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable, End of Period</a></td>
<td class="nump">2,341,014<span></span>
</td>
<td class="nump">2,341,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable, Ending of Period</a></td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="nump">$ 1.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contracted Term (years), Exercisable at End of Period</a></td>
<td class="text">7 years 2 months 1 day<span></span>
</td>
<td class="text">7 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at End of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Share-Based Payment Arrangement, Nonemployee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning of Period</a></td>
<td class="nump">885,055<span></span>
</td>
<td class="nump">885,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning of Period</a></td>
<td class="nump">$ 2.02<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contracted Term (years) Outstanding</a></td>
<td class="text">9 years 2 months 23 days<span></span>
</td>
<td class="text">9 years 2 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Beginning of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options, Expired</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending of Period</a></td>
<td class="nump">884,960<span></span>
</td>
<td class="nump">884,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, End of Period</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contracted Term (years) Outstanding</a></td>
<td class="text">9 years 2 months 23 days<span></span>
</td>
<td class="text">9 years 2 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding, Ending of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and Expected to Vest</a></td>
<td class="nump">884,960<span></span>
</td>
<td class="nump">884,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and Expected to Vest</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest</a></td>
<td class="text">9 years 2 months 23 days<span></span>
</td>
<td class="text">9 years 2 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and Expected to Vest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable, End of Period</a></td>
<td class="nump">729,960<span></span>
</td>
<td class="nump">729,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable, Ending of Period</a></td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contracted Term (years), Exercisable at End of Period</a></td>
<td class="text">10 years 21 days<span></span>
</td>
<td class="text">10 years 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Total Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate intrinsic value, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate intrinsic value, forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate intrinsic value, granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562532919280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Unvested Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-Based Payment Arrangement, Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Unvested, Beginning of Period</a></td>
<td class="nump">166,666<span></span>
</td>
<td class="nump">366,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Unvested, Beginning of Period</a></td>
<td class="nump">$ 4.11<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm', window );">Average Remaining Contractual Term (years) Unvested, Beginning of Period</a></td>
<td class="text">18 years 10 months 13 days<span></span>
</td>
<td class="text">12 years 5 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Unvested, Beginning of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Options, Expired</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="num">(99,905)<span></span>
</td>
<td class="num">(299,242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Vested</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm', window );">Average Remaining Contractual Term Vested</a></td>
<td class="text">7 years 2 months 1 day<span></span>
</td>
<td class="text">7 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Unvested, End of Period</a></td>
<td class="nump">66,666<span></span>
</td>
<td class="nump">66,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Unvested, Ending of Period</a></td>
<td class="nump">$ 9.61<span></span>
</td>
<td class="nump">$ 9.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contracted Term (years), Exercisable at End of Period</a></td>
<td class="text">36 years 2 months 19 days<span></span>
</td>
<td class="text">36 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Unvested, End of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="nump">99,905<span></span>
</td>
<td class="nump">299,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Share-Based Payment Arrangement, Nonemployee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Unvested, Beginning of Period</a></td>
<td class="nump">155,001<span></span>
</td>
<td class="nump">335,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Unvested, Beginning of Period</a></td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm', window );">Average Remaining Contractual Term (years) Unvested, Beginning of Period</a></td>
<td class="text">11 years 3 months 18 days<span></span>
</td>
<td class="text">10 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Unvested, Beginning of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Options, Expired</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(179,905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Vested</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm', window );">Average Remaining Contractual Term Vested</a></td>
<td class="text">10 years 2 months 4 days<span></span>
</td>
<td class="text">10 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options Unvested, End of Period</a></td>
<td class="nump">155,001<span></span>
</td>
<td class="nump">155,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Unvested, Ending of Period</a></td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contracted Term (years), Exercisable at End of Period</a></td>
<td class="text">11 years 3 months 21 days<span></span>
</td>
<td class="text">11 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Unvested, End of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">179,905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement by Share based Payment Award Options Expired Aggregate Intrinsic Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest granted options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for non vested option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award options nonvested weighted average remaining contractual term2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award options vested weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562533743008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 12, 2018</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Jul. 01, 2023</div></th>
<th class="th"><div>Jul. 01, 2022</div></th>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Aug. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders equity reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one year (39,266 options post reverse split).<span></span>
</td>
<td class="text">(27,028 options post reverse split)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 490,000<span></span>
</td>
<td class="nump">$ 182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock issued as payroll, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,400<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 53,400<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders equity reverse stock split</a></td>
<td class="text">44:1 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of stock is reserved for potential issuance</a></td>
<td class="nump">230,390<span></span>
</td>
<td class="nump">5,167,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,167,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,733<span></span>
</td>
<td class="nump">968,389<span></span>
</td>
<td class="nump">960,976<span></span>
</td>
<td class="nump">956,660<span></span>
</td>
<td class="nump">685,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vested years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member] | Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="nump">613,512<span></span>
</td>
<td class="nump">1,025,000<span></span>
</td>
<td class="nump">1,727,756<span></span>
</td>
<td class="nump">1,189,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.68<span></span>
</td>
<td class="nump">$ 9.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member] | Officer [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member] | Officer [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 1.71<span></span>
</td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember', window );">Restated 2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of stock is reserved for potential issuance</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=AIM_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=AIM_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562514493312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 03, 2024</div></th>
<th class="th"><div>Mar. 28, 2024</div></th>
<th class="th"><div>Apr. 19, 2023</div></th>
<th class="th"><div>Jul. 07, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 25, 2019</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 10, 2023</div></th>
<th class="th"><div>May 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage', window );">Common stock specific limitations and restrictions on usage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,668,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,668,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,102,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,668,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,668,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,102,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="nump">$ 532,000<span></span>
</td>
<td class="nump">$ 329,000<span></span>
</td>
<td class="nump">$ 233,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 860,000<span></span>
</td>
<td class="nump">$ 338,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrant gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_WarrantModifications', window );">Warrant modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=AIM_PlacementAgentMember', window );">Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Aggregate gross proceeds, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AIM_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">759,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Amount of stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AIM_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Atlas Sciences LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AllianceGlobalPartnersLLCMember', window );">Alliance Global Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,148,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued upon transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,740,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_MaximGroupLLCMember', window );">Maxim Group LLC [Member] | Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 630,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Aggregate gross proceeds, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,305,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Amount of stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AtlasSciencesLlcMember', window );">Atlas Sciences LLC [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,636,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_MarketPricePercentage', window );">Market price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_TradingDailyMaximumLessorAmount', window );">Trading maximum lessor amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_BeneficialOwnershipPercentage', window );">Beneficial ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_StockIssuedDuringPeriodValueCommitmentShares', window );">Commitment shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 338,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AIM_DirectorsOfficersAndEmployeesMember', window );">Directors, Officers and Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued upon transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">653,430<span></span>
</td>
<td class="nump">6,884,747<span></span>
</td>
<td class="nump">807,577<span></span>
</td>
<td class="nump">377,959<span></span>
</td>
<td class="nump">11,937<span></span>
</td>
<td class="nump">322,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Pre-funded warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Atlas Sciences LLC [Member] | Purchase And Registration Rights Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=AIM_WarrantsMember', window );">Warrants [Member] | Alliance Global Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,888,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=AIM_RepresentativeWarrantsMember', window );">Representative Warrants [Member] | Alliance Global Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrants expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,830,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=AIM_RepresentativeWarrantsMember', window );">Representative Warrants [Member] | Maximum [Member] | Alliance Global Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,665<span></span>
</td>
<td class="nump">266,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=AIM_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_PercentageOfOutstandingStock', window );">Percentage of outstanding stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Pre-funded warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=AIM_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member] | Alliance Global Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Pre-funded warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,873,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RightsMember', window );">Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Subscription price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ConvertiblePreferredStockFaceValue', window );">Convertible preferred stock face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember', window );">Series A Junior Participating Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_PreferredStockStatedValuePerShare', window );">Preferred stock, stated value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued upon transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,603<span></span>
</td>
<td class="nump">385,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued upon transaction</a></td>
<td class="nump">5,640,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued upon transaction</a></td>
<td class="nump">5,640,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=AIM_ClassBCommonWarrantMember', window );">Class B Common Warrants [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued upon transaction</a></td>
<td class="nump">5,640,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_BeneficialOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Beneficial ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_BeneficialOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares with limitations and restrictions on usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ConvertiblePreferredStockFaceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock face value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ConvertiblePreferredStockFaceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_MarketPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market price, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_MarketPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_PercentageOfOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_PercentageOfOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_PreferredStockStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock stated value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_PreferredStockStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_StockIssuedDuringPeriodValueCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value commitment shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_StockIssuedDuringPeriodValueCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_TradingDailyMaximumLessorAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading daily maximum lessor amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_TradingDailyMaximumLessorAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_WarrantModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_WarrantModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=AIM_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=AIM_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AIM_AtlasSciencesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=AIM_AtlasSciencesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_AllianceGlobalPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_AllianceGlobalPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_MaximGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_MaximGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_AtlasSciencesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_AtlasSciencesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AIM_DirectorsOfficersAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=AIM_DirectorsOfficersAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_PurchaseAndRegistrationRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_PurchaseAndRegistrationRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=AIM_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=AIM_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=AIM_RepresentativeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=AIM_RepresentativeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=AIM_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=AIM_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_SeriesAJuniorParticipatingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_ClassBCommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_ClassBCommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562514553008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Net loss per share, antidilutive</a></td>
<td class="nump">14,574,557<span></span>
</td>
<td class="nump">2,763,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562528083824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Assumptions to Estimate the Fair Value (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Class A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Expected dividend yield</a></td>
<td class="nump">0.350<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | Class B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Expected dividend yield</a></td>
<td class="nump">0.350<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member] | Class A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Expected dividend yield</a></td>
<td class="nump">0.363<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member] | Class B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Expected dividend yield</a></td>
<td class="nump">0.363<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Class A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Expected dividend yield</a></td>
<td class="nump">4.42<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Class B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Expected dividend yield</a></td>
<td class="nump">4.82<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Class A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected holding period</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Class B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected holding period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Class A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Expected dividend yield</a></td>
<td class="nump">1.10<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Class B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Expected dividend yield</a></td>
<td class="nump">0.89<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | Class A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | Class B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_ClassAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_ClassAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_ClassBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_ClassBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562529055872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Potential Liability (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_LowRangeOfProbability', window );">Low range, rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_MediumRangeOfProbability', window );">Medium range, rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_HighRangeOfProbability', window );">High range, rate</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_HighRangeOfProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>High range of probability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_HighRangeOfProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_LowRangeOfProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Low range of probability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_LowRangeOfProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_MediumRangeOfProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medium range of probability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_MediumRangeOfProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562532923120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents-Marketable investments</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 4,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">6,287<span></span>
</td>
<td class="nump">7,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents-Marketable investments</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">4,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="nump">6,287<span></span>
</td>
<td class="nump">7,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents-Marketable investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents-Marketable investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562532779344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Conversion of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired', window );">Cashless basis, expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,830,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_HighRangeOfProbability', window );">Probability, rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of securities called by each warrant expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_HighRangeOfProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>High range of probability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_HighRangeOfProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562638617872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">General and administrative</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term and variable lease costs</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">General and administrative</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">General and administrative</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562528405600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Operating Lease Future Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 669,000<span></span>
</td>
<td class="nump">$ 718,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562532736688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 653,000<span></span>
</td>
<td class="nump">$ 697,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">669,000<span></span>
</td>
<td class="nump">718,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">$ 404,000<span></span>
</td>
<td class="nump">$ 363,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">41 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">32 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt, weighted average interest rate</a></td>
<td class="nump">10.20%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease Payment</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease Payment</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">35 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operation lease right of use asset accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562531251392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research, Consulting and Supply Agreements (Details Narrative)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>Integer</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,437,000<span></span>
</td>
<td class="nump">$ 2,734,000<span></span>
</td>
<td class="nump">$ 4,533,000<span></span>
</td>
<td class="nump">$ 7,739,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember', window );">Amarex Clinical Research LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,400<span></span>
</td>
<td class="nump">516,284<span></span>
</td>
<td class="nump">881,987<span></span>
</td>
<td class="nump">1,294,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense excluding acquired in process cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_ResearchAndDevelopmentExpenseCostEstimatedLives', window );">Estimated lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Invigilators cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember', window );">Amarex Clinical Research LLC [Member] | Advanced Pancreatic Cancer Study Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,000<span></span>
</td>
<td class="nump">82,600<span></span>
</td>
<td class="nump">141,100<span></span>
</td>
<td class="nump">350,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember', window );">Amarex Clinical Research LLC [Member] | Post COVID Study Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
<td class="nump">447,600<span></span>
</td>
<td class="nump">195,800<span></span>
</td>
<td class="nump">783,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_JubilantHollisterStierMember', window );">Jubilant HollisterStier [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_UnitsManufactured', window );">Number of units manufactured | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_NumberOfVials', window );">Additional number of vials | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_JubilantHollisterStierMember', window );">Jubilant HollisterStier [Member] | Ampligen Manufacturing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_SterlingPharmaSolutionsMember', window );">Sterling Pharma Solutions [Member] | Master Service Agreement and Quality Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">261,600<span></span>
</td>
<td class="nump">357,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_ErasmusUniversityMedicalCenterMember', window );">Erasmus University Medical Center [Member] | Joint Clinical Study Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Unrestricted grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AzenovaLLCMember', window );">Azenova LLC [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Stock options, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock options, vested | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_AIM_MonthlyRetainerFee', window );">Monthly retainer fee</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=AIM_AlcamiCorporationMember', window );">Alcami Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionCosts', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AIM_ClinicalStudiesMember', window );">Clinical Studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,000<span></span>
</td>
<td class="nump">1,916,000<span></span>
</td>
<td class="nump">1,880,000<span></span>
</td>
<td class="nump">3,845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AIM_ManufacturingAndEngineeringMember', window );">Manufacturing and Engineering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,000<span></span>
</td>
<td class="nump">396,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">2,783,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AIM_QualityControlMember', window );">Quality Control [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,000<span></span>
</td>
<td class="nump">251,000<span></span>
</td>
<td class="nump">1,232,000<span></span>
</td>
<td class="nump">752,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=AIM_RegulatoryMember', window );">Regulatory [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,000<span></span>
</td>
<td class="nump">$ 170,000<span></span>
</td>
<td class="nump">$ 540,000<span></span>
</td>
<td class="nump">$ 359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_MonthlyRetainerFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly retainer fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_MonthlyRetainerFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_NumberOfVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vials.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_NumberOfVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_ResearchAndDevelopmentExpenseCostEstimatedLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense cost estimated lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_ResearchAndDevelopmentExpenseCostEstimatedLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_AIM_UnitsManufactured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Units manufactured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">AIM_UnitsManufactured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>AIM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized development cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes acquisition and exploration costs and capitalized interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477385/932-360-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized production cost incurred during period for oil- and gas-producing activities. Includes cost incurred to operate and maintain well and related equipment and facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(a)(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_AdvancedPancreaticCancerStudyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_AdvancedPancreaticCancerStudyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_PostCOVIDStudyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_PostCOVIDStudyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_JubilantHollisterStierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_JubilantHollisterStierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_AmpligenManufacturingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_AmpligenManufacturingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_SterlingPharmaSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_SterlingPharmaSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_MasterServiceAgreementAndQualityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_MasterServiceAgreementAndQualityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_ErasmusUniversityMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_ErasmusUniversityMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_JointClinicalStudyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_JointClinicalStudyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_AzenovaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_AzenovaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=AIM_AlcamiCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=AIM_AlcamiCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AIM_ClinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AIM_ClinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AIM_ManufacturingAndEngineeringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AIM_ManufacturingAndEngineeringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AIM_QualityControlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AIM_QualityControlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=AIM_RegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=AIM_RegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46562533097072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2024</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Grosss proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Grosss proceeds</a></td>
<td class="nump">$ 1,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued upon transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">653,430<span></span>
</td>
<td class="nump">6,884,747<span></span>
</td>
<td class="nump">807,577<span></span>
</td>
<td class="nump">377,959<span></span>
</td>
<td class="nump">11,937<span></span>
</td>
<td class="nump">322,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AIM_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Subsequent Event [Member] | Class C Common Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued upon transaction</a></td>
<td class="nump">4,653,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AIM_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Subsequent Event [Member] | Class D Common Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued upon transaction</a></td>
<td class="nump">4,653,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=AIM_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued upon transaction</a></td>
<td class="nump">4,653,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=AIM_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=AIM_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_ClassCCommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_ClassCCommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=AIM_ClassDCommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=AIM_ClassDCommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>85
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MF _2!.#]M1#Z96(.DO4/![/_ 5!+ P04    "  *A6Y9,Y7.?],%  #]&@
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M"P"<FE'>W.RFOAGKN=F<_*8JNS;DYZH017O]"(#OT;-7]#<LJO!.;#^2-/E
M6,(R!,_R^.5I!$ZZ=V;J]:5]SG0>6WF/K;3:$$@VS:VL'NO=*JT4Y@)S6ZTV
MP]6Z3+XP6YZ+JP&DJA'Z20P6?_\;G23_P&Q^)V4M#V1[#V0Q[8LO4'A*90QF
M9+URXE>ZZO*T&%*:CM,D22Y'3X<68)*3=#8YE&S!&^_AC:,!NB[^!RE5[W"K
MH SEJLIE*4C5X';?NNO<17)G("=D=7P8Q^\9QG=2UO+39.^G232,GP0HS27W
ME19*P58[']@7PJN"B#]V<NM\B+F@UCL^"!V;=0/<E7*[H">XTSWH:13T]0.@
M4Y5#YC%#+8,KA]AJ7@#[Z6]$NZJ.[LYI!U(VZ0+O2M&L%_AL#WP6![Y1VLH_
M@[<]\@]'P9YU 8VS+FY,K-_C\SWP>13X<LVK1V%<CGB$#CPD#>'&"!SNO+L]
M&.+FKA@=TUZX- EDET0!_Q/ZFKHT&PY9#W!EE:N-()9_/TAS5PD$BC^N'\]*
M@F5WH^C0Q.$\Z0\)/2!T&K7Q9TA/^S)TO4U!P#AH^(S?6J@]M+OMYTDW((@<
MG;%^M"R@95&T9RXDYW7MA=W_&A:WZX7E#_#)B'RG?<U%#6"('\>( 5TYED2V
M5*!\&N73Q:\-<FG,CE>Y1__,M>85G@&-NI;'QTB)C-_VJ)W6MBA0.(US^-MR
MM)(5&"9Y2=1#*1_[]U+6=7'*$,NBM_\!RP+[TSC]U_7*E:NZ0GER*"5_D&4_
MJ=-W9?7WTM;V0.!U&B?VW^U::-?W"/GDL@O?HE$=IQ2Y+L_[(M>3<X'H:9SI
M/^^JPAQ849?T+W!F_$5H(UY\"]<NYZB=")O3&45V+"(XF?:WHS0P/XU3_ZT6
M6RZAI_KNRK2H=Z3R08*JIWT#$[9J_4.EJF'[1]2X+N4/)TBOC<C1>:2RA]Z
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M])D5'WCH&CVBV^-TE;;5%EF\R@5T_Q&H6C#<#A9L1ARY1*"'I"?"N#OG"^I
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M]8U37OSS9.:#@S_\ZR&=(\F]ATE2C!SZI<S5FQT$@5=NI7:.O_]F_')T](3
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MJUPZMR89$L\"0@>;D7U]:5UX$92K $  :(0\"85%KV Y5?G(!ECE< -=*$9
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M-T;%DEL\(G\I?*6FU&*<&U!/W6V$"S5KXR!7EMVALCAS*%(8F028J2@I.XF
M8 C"#8$P ^$JD0]QBP :466DEE<_)268]SMI<>;4QG;9>:GA=$#VV0W@QC+/
M3(*8B8%7K,B60C?D$CXOO[%C!XB[3&GX0?8?[2%E+#"&,3_^P,:S*.SW^Q ]
M\;^',_<[& _<[Q\T;?@-31N$AX/:*/\;548-IOV'QN7@B>\8MD$XFWD;9E4
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MO4876-<V9]O6@V".&H,,YKQ+"(SZ@^E]A^YM8'B^WZ-XU-3F!(^IMO'$P0!
M+%?4UJ*K6'(;;VA+LFILPX9P.CIN+*RT=]D- BK<(S(-UJQ;O%AK@,4[!:[&
M%J,ETG4(B*#;B*R01DV"X$+5Z8&X1M$WPE@B$_3O^'MK%(618_A1U?_=(#DI
MZ<'BUAEG-RHM/:%<Y($GD>>3R2XYX0O6^(U+LXUUE9VS?V(+(FUK>^M37NMD
MCW36&*U'-!BMT]H&0577*M,:_%XI.'KA+'"7BT'TF16XRLLX%=@BH<SZ/9GF
MN5D)UT"U]F:6.J9,8!$D&&=9VQ92$)R722KN0O;Y[ZZZN\TM;:6U2LH*:J0N
MH]*NP;W89_K-=MMX&I7H<MV K?OFA7;H>^LWAU@T&1 =HFY-G<*?-#=9Z0!U
M+N)V>7H!6?]1,G_0N-X]I(Y:\.=<HOTUA+1+D;CQ"R>.72N+GX1G%'ZL9B3(
M!G4AN[CP8H_(AB44N;,4*P^NS@\^#IBD4P4TQAL1?RF<-3+?R*6DECLI-=BO
MS/C26_++Q^N#(<Q3U)4S!-6B,T]EII+'91+0PJIQO6FK%R3+7&<O<F!*QS)7
M6!D5[#4O$* 5':7$=[25!V7CCU=AD<14:<K]@030Z(L[[0_^+7(1\^[]78',
M) $=^QBJR7 I=0<\ 4I^\](#>BO=\4Z#439/?%VGGC9T[%^WU$-?RRE#K=F"
M+NL\72Z(_\L<BM%"Q*1FK;EG8L#FF];LBD__7%?IA;SQ<ID^ZG^_8>\XJ%JB
M^6_ U98'-SP5M!*Q*G+N$TGK\E-L5;4LAR\NR_:QX_W%6&D(W<9U!\P*;"^K
MA[Z UXA8E@8.&G/OG+$Y>*LVW@U:FV+L^=6Z 0:+"R@K,V)6>L#1!AZXD(&_
M=>;[2"P1<6L107<06!;^ +-E>%5!Z$"0=L4!^A=Q&Z/"KX63*K%F:\/"^\Z
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M$[R3GG=R"CU=XE#F#0<B"W*\=<<8G\0\SGB7:/!NHL$9$\24LM%HUL,!MLA
MM0+5]XG<0=99(F<9#1X:)9AI%/BD8%LK:-_!0O_XD9^,Q_9,K@;?0.L)3F[6
M5 VG!G(<..28,>I&^BSR1\DU&3HACLAP<$ 5#G_GCR2*+NT97Y)CK0CVIJ@"
MM7:[0I-,-L*T ]5;^W5TTT[A/_=VESU2M69"$PX%AH;GEQ<>4>U^:!4C:S>3
M*VEPPIU8XDH%91WPOI#2[!2;H%_2Z5]02P,$%     @ "H5N64'VM2[/ P
M/ H  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULI5;?;^,V#'[W7T'X
MAB$!@OJWDW1)@+3=;O=PA^+:W3 ,>U!L)A9J6SY)OK3[ZT?9CIO<$J/#7FR)
M(OF1_DB9B[V03RI#U/!<Y*5:VIG6U;7CJ"3#@JDK46%))ULA"Z9I*W>.JB2R
MM#$J<L=WW=@I&"_MU:*1W<O50M0ZYR7>2U!U43#Y<H.YV"]MSSX(/O-=IHW
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MM/)ZE*RLD:M2<)"83]U9,)[')M\F_"AQJ_;F8)2LA'@VB[MLZOJ&$%:8:H/
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MO^+Z4WXI<=:I4:(XY9F*10:23P;6"3T^I<0HE!*?8SY7:V,PIHR$N#:3M]'
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M<,99Q*41P.\3(?1R8A:H[U6'?P%02P,$%     @ "H5N63:B"?)M!   K P
M !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULS5=9;]M&$'[GKQ@H!Q)
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MF%J9*F?C\F!D[N;14!J:;MTVH;\3J"P!O:\D]8/J8!74?U#F?P%02P,$%
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M3NT>E36@_4Q*\S2Q!W1_()9? %!+ P04    "  *A6Y91LPM?_\!   F!
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M'[KMAWX'@(L1UV'[^[#O_4[$)>17)/ NB>_YHS9"W>8+B-!\:,V##CI!G87
MX@5'\#[R+2B-FT.K2[* E2:4Q^3=UR+5WYMY^?UNI;3$TO^C+0FECU&[#],.
M;E5.(Y@YN-\5R"TX\Y_>#$/OYS8!_B.P%W*,:CE&7>CS#\!BLJ6L "+66.UU
MB:I:BK;X2]#0@IKNM9V'_O7$\[RINVV&=KAN$@;#YKH7K,<UZW$GZ\>^/,<]
M>1ZNZ^09UCS#3IY56?W@B&U/13+-35]MX]L-]TL"A.-QL\$C _MZ)#8\_1-B
M@B<,T?A.)Q+@;6;V[R 'F8J8@-G%6->YAFP%LMZ(!/LZ'+#;447._$EPB9%?
MD;T[)I3"E]T.2;O#0;=#);#\8ASQC06L0'8@ ?O?^,80N2B9%!R/3F;=F_A[
M\AF\3@"E4\9(8C:%U2((_)=:').>8ZI.$<)ZNPG["O^/[EKB'/36W9],7BE\
M+SZ#5^A>U6!;N^RW1XQVI^V1X'BFSL\"KZK-LA.?L%<&?1UWYVSDMZ?LD% #
MXF0Q_I8W+)VP63I]B_B43/C>\%]X_#]2,$3CU^?@5!4.4C"I]&B[';B-ZVL&
M<F-O]8I$HN"ZO,G6L_6'PYV]+[L_EI=?'7@&;TPW8+!&4^]J@F>H+&_RY4"+
MW%Z&5T+CU=H^)OCQ ](LP/=K(?1^8!S4GU/SOP!02P,$%     @ "H5N67#'
M.&F' @  >08  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULK55=;YLP
M%/TK%JNF5DK+9Y(N(TAMLFJ3-BEJUNUAVH,#EV#58&J;I/WWNS8)2CH:[6$O
M8)M[CL\YX$N\%?)1%0":/)>\4E.GT+J>N*Y*"RBINA(U5/@D%[*D&J=R[:I:
M LTLJ.1NX'DCMZ2L<I+8KBUD$HM&<U;!0A+5E"65+[? Q7;J^,Y^X9ZM"VT6
MW"2NZ1J6H!_JA<29V[%DK(1*,5$1"?G4N?$GLZ&IMP4_&&S5P9@8)RLA'LWD
M2S9U/",(.*3:,%"\;6 &G!LBE/&TXW2Z+0WP<+QGO[/>T<N**I@)_I-ENI@Z
MUP[)(*<-U_=B^QEV?JS 5'!EKV3;UHX]AZ2-TJ+<@5%!R:KV3I]W.1P _.@-
M0+ #!/\*"'> T!IME5E;<ZII$DNQ)=)4(YL9V&PL&MVPRKS%I9;XE"%.)TO\
M++*& Q$Y64C\.*1^(;3*R*>GAM7XNC0YGX.FC*L+<DD>EG-R?G9!S@BKR/="
M- IK5>QJE&((W72W[6V[;?#6ME!?D= ;D, +HA[X[#1\#BG"?0L/C^$N!M"E
M$'0I!)8O?(-O[WQ %IRBY>, ?MVLE);XP?WN,]HR1_W,YA!.5$U3F#IXRA3(
M#3C)^W?^R/O89_L_D1V%$'8AA*?8D[M&5DPW$@8D9\]FH 8V"=@GT6>_Y1Q9
M3M,R-HD?C4:QNSFTU5<477=%1W*C3FYT4NY74&J";2!MRH93#1F>7DPE9=3T
MASZI+=_P0,6E'T8?7FGMK0K\?K'#3NSPI-BCH]7E.2 5](8Z_#LO?_Q*9T]-
M,'ZETCUH#*8I?Z-RS2I%..2(\J[&2"+;1M=.M*AMKU@)C9W'#@O\-X T!?@\
M%T+O)Z;]='^;Y ]02P,$%     @ "H5N68+3I*WK @  7@L  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&ULM5;1;MHP%/T5*YNF5NH:DP"%#B(5VFF5
MQH2*NCU4>S#)!:PF=FH[0/]^M@,IZ=)TG=(7L)U[CN\YOG'N8,/%O5P!*+1-
M8B:'SDJI]-QU9;B"A,A3G@+33Q9<)$3IJ5BZ,A5 (@M*8M?#N.LFA#(G&-BU
MJ0@&/%,Q93 52&9)0L3C"&*^&3HM9[]P0Y<K91;<8)"2)<Q W:93H6=NP1+1
M!)BDG"$!BZ%ST3H?M[ !V(B?%#;R8(R,E#GG]V9R'0T=;#*"&$)E*(C^6\,8
MXM@PZ3P>=J1.L:<!'H[W[%^M>"UF3B2,>?R+1FHU='H.BF!!LEC=\,TWV GJ
M&+Z0Q]+^HDT>V]'!82853W9@G4%"6?Y/MCLC#@":IQK@[0#><T#[!8"_ _A6
M:)Z9E75)% D&@F^0,-&:S0RL-Q:MU5!FCG&FA'Y*-4X%4Z$K0JA'1%B$KAXR
MFNHS4B>(Z0HZN@1%:"S1#R($,78?H\_H=G:)CCX>#UREMS<D;KC;:I1OY;VP
M51]-.%,KB:Y8!%$9[^JTB]R]?>XCKY9P!NDI\O$)\K#7KLAG_.]POR8=O[#2
MMWS^*U:>H&E,F"H[BNZ^ZW!TK2"1OZN\R[G;U=SF93Z7*0EAZ.BW58)8@Q-\
M^M#JXB]5PALB*]G0+FQHU[$'EZ!)0TKL6PI;?=](J!*<LW0MB[ELUH'7PQ@/
MW/6ADK^C?'P854JQ4Z38J4UQ0AE-L@3=32"9@Z@\CUJ&MYY'0V0EL=U";/<=
MR[+;I T-D95L."ML.*L]\RNIJ+[U(4*9A$46HY@N*NNRGL9'CT"$K%)7"_Q/
M=;U"7:^^HLGVU8JN97CK439$5A+;+\3VW[&B^TW:T!!9R886?OIVXV9J^A6>
M%GZYJNNA;Y7H'G0J"8BE;> D"GG&5/[A+U:+)O'"MD;/UD>F>;0=T!--WGE.
MB%A2)E$,"TV)3\_TY2OR9BZ?*)[:?FC.E>ZN['"E&V 0)D _7W"N]A.S0=%2
M!W\ 4$L#!!0    (  J%;EEO+,[G7P,  #$.   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;+57;6^;,!#^*Q:;IE9:"X:0ERY!ZHNZ56JG:-W+AVD?
M'+@D5@%GMDG:_?K90 DD#ELE^B78<,_CYRYW/GN\8?Q!+ $D>DSB5$RLI92K
M,]L6X1(2(D[9"E+U9<YX0J2:\H4M5AQ(E(.2V'8=IV\GA*96,,[?37DP9IF,
M:0I3CD26)(0_74#,-A,+6\\OOM#%4NH7=C!>D07<@_RVFG(ULRN6B":0"LI2
MQ&$^L<[QV27V-2"W^$YA(VICI%V9,?:@)S?1Q'*T(H@AE)J"J,<:+B&.-9/2
M\;LDM:HU-; ^?F:_SIU7SLR(@$L6_Z"17$ZLH84BF),LEE_8YA.4#N4"0Q:+
M_!=M"MN!;Z$P$Y(E)5@I2&A:/,EC&8@: /<. -P2X/XOP"L!7NYHH2QWZXI(
M$HPYVR"NK16;'N2QR='*&YKJO_%><O65*IP,[E5>1%D,B,W1E$A()2)IA+YR
M$JE\X0\H_V,%.KH"26@LCM$)^G9_A8[>'J.WB*;HZY)E0D'$V)9*CV:UPW+M
MBV)M]]#:L#I%GO,>N8[;,\ OV^%7$"HXSN%>$VZK*%2A<*M0N#F?=X#OFJ94
MPLFM2JL(W:22I LZ4Y$Y%P)4!'[>*GMT(R$1OTR^%N0],[FNQC.Q(B%,+%5N
M O@:K.#=&]QW/I@\[XBL$0>OBH/7QAY\Y$P(%!+.GVBZ0&L29V!RN&#IYRQZ
MMU@'GM\;C.UUW1&#$1[T*Z.&P%XEL-<J\#P,LR2+5;9&B"2,2_J'Z#W!)+)@
M\FOKGV '^SLJ#5;#OF=6Z5<J_5:5G]4>_.\@^GLKN[[G[L@S&'GX@+Q^):_?
M*J\H=I76=Y#,@!M3NI7AI2G=$5G#V4'E[. U2WO091PZ(FO$85C%8=A):0_W
M$L[S]HIFW\@=U>J_(7!4"1QU5MHC0]$.=_<?@]' =\PBL;-MFDX'M5V2-"+4
M<X<["DU6>'0@CKC6UW&KQ*J#MY=X.\M+<[LKMJ;/VP:.7[6#XTY;>%=LS5AL
MFSCNIHN7-,WFLMN 3$;NZ$"*;MLX[JZ/8U,CWZ\ED]6A3HFWG1QWT<I+DOI9
M!SN]784&([Q['K)KYWE]F;HC?$%3@6*8*Y1SJF\?O+B?%!/)5OD1?\:DNC#D
MPZ6ZTP'7!NK[G#'Y/-&WANJ6&/P%4$L#!!0    (  J%;EGCWB3?\ (  -((
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;*U676^;,!3]*Q:KIDYJ
M"P'RT2Y!2M)]]*%2U+3;P[0'!VZ"56-3VR3=?OUL0UB:4+9%>TEL<\_Q.=<7
M7X8;+AYE"J#0<T:9'#FI4OF5Z\HXA0S+"YX#TT^67&18Z:E8N3(7@!,+RJCK
M>U[/S3!A3C2T:S,1#7FA*&$P$T@668;%CPE0OADY'6>[<$=6J3(+;C3,\0KF
MH![RF= SMV9)2 9,$LZ0@.7(&7>NI@,3;P.^$-C(G3$R3A:</YK)33)R/",(
M*,3*,&#]MX8I4&J(M(RGBM.IMS3 W?&6_:/UKKTLL(0IIU])HM*1,W!0 DM<
M4'7'-Y^A\M,U?#&GTOZB317K.2@NI.)9!=8*,L+*?_Q<Y6$'H'F: 7X%\/<!
MX2N H ($UFBIS-JZQ@I'0\$W2)AHS68&-C<6K=T09DYQKH1^2C1.17-=%DE!
M ?$EFJ:8K4 BPM ,*V!*GJ%[@1-=-^(1V0.6Z/0:%"94OD/GZ&%^C4Y/WJ$3
M [E/>2$Q2^3055J8H7?C2L2D%.&_(N(2W7*F4HD^L 22EWA7&ZI=^5M7$[^5
M< [Y!0J\,^1[?MB@9_KW\*!%3E G.;!\P2M\GSA/-H12I-.#;IC2:28+G?.Q
ME*!3>DUD3+DL!*!OXX540M?V]Z8LEKN$S;N8]_U*YCB&D:-?: EB#4[T]DVG
MY[UO2L%_(GN1D+!.2-C&'DTPQ2R&)H\EL&>!Y@I:1W[0T8>PWM7>RGZD]FZM
MO=NJ?1P_%402<PDUEGJ)[NX8"#N7>_I;=SA2?Z_6WVO7O]!5R%EFWN\F_;T#
M_>=A;T]_ZPY'ZN_7^OM_R']<9 75%U2"QAD7BOS$YC":O/0/O72ZX9Z9_D'%
MZ2"O#GHA<E"+'!Q;X(/# N\&_IZF5O9_3;"[TQXR$"O;-26*><%4>:?6JW5C
M'MM^M+<^T0V[[*^_:<IN?XO%BC")*"PUI7?1USD790<M)XKGM@DMN-(MS0Y3
M_=$!P@3HYTO.U79B-J@_8Z)?4$L#!!0    (  J%;EFTKW^7S0(  'L)   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;*V676^;,!2&_XK%JJF5MO(5
M2-(E2&FB=;V8%#7M=C'MPH&38-5@9INDVZ^?;2A*$T*F:#?@C_.^?L[!8$9;
MQI]%"B#12T9S,;92*8L;VQ9Q"AD6UZR 7,VL&,^P5%V^MD7! 2=&E%';<YS0
MSC#)K6ADQN8\&K%24I+#G"-19AGFOV^!LNW8<JW7@0>R3J4>L*-1@=>P /E4
MS+GJV8U+0C+(!6$YXK :6Q/W9CK4\2;@&X&MV&DCG<F2L6?=N4_&EJ.!@$(L
MM0-6MPU,@5)MI#!^U9Y6LZ06[K9?W3^;W%4N2RQ@RNAWDLAT; TLE, *EU0^
ML.T7J/,)M%_,J#!7M*UC'0O%I9 LJ\6*("-Y=<<O=1UV!&[OB,"K!=Z_"OQ:
MX)M$*S*3U@Q+'(TXVR*NHY6;;IC:&+7*AN3Z*2XD5[-$Z62T4-LB*2D@MD*3
MC'%)_F!37]6?8PFY% CG"7KD.%'[1^TM=#D#B0D55^@C>EK,T.7%%;I )$>/
M*2N%"A8C6RHTO8 =UQBW%89W# .*:^0['Y#G>+T6^;1;/H-8R5TC]]_*;560
MIBI>4Q7/^/E'_.X82[:$4I/Z?2YQOB9+5:2)$* *,B,BIDR4'-"/R5)(KC;C
MS[:DJU5Z[:OH%_1&%#B&L:7>0 %\ U;T_IT;.I_:2O"?S-X4Q&\*XG>Y1T<>
MRVVE"HU*?S V4=\;V9M=[$[C,[%[#7;O%';0AEVI@AUL+QSL<7<ZG\D=--S!
M*>ZPC3MHX0[VN#N=S^0.&^[P%'>_C3L\Y/:'>]R=SF=R]QON_BGN01MW_Y#;
MW>?N=#Z3>]!P#SJY'U-01_=* F^C'QS0N[UP'[]S@3/QAPW^L!N?24S;R(<'
MGQ4O\/<_+"U!ONLW0161O7,TZM^2KYBO22X0A962.==]51Y>'?551[+"G)9+
M)M79:YJI^CL"K@/4_(HQ^=K1!W#SOQ7]!5!+ P04    "  *A6Y93T^?4;$"
M   3"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R]EFU/VS 0Q[^*
ME4G3)C'RT-(6UD:B,#0D0!7LX<6T%VYR:2P<.[,= OOT.SNMZ:02I$WP)O'3
M_>]WSMF7:2O5K2X!#+FON-"SH#2F/@I#G9504;TO:Q X4TA548-=M0IUK8#F
MSJCB81)%H["B3 3IU(TM5#J5C>%,P$(1W50550]SX+*=!7&P&;AFJ]+8@3"=
MUG0%-V"^U@N%O="KY*P"H9D41$$Q"X[CHWD<60.WXAN#5F^UB0UE*>6M[9SG
MLR"R1, A,U:"XNL.3H!SJX0<O]:B@?=I#;?;&_4S%SP&LZ0:3B3_SG)3SH))
M0'(H:,/-M6P_PSJ@ ZN72:[=D[3=VE$2D*S11E9K8R2HF.C>]'Z]$5L&J+/;
M(%D;)(Z[<^0H3ZFAZ53)EBB[&M5LPX7JK!&."?M5;HS"689V)EU0 \+H/4)%
M3KXHFN-'5[?$?1T<O<*\>'<*AC*NR155BMI-?#\-#?JV"F&V]C/O_"1/^#DD
MEU*84I-/(H?\;_L0F3UXL@&?)[V"-U#ODT&T1Y(H&?;H#?Q&#)S>L'\CR(]+
MJ):@?NX*L5?!GI\C7=,,9@$>$ WJ#H+T[9MX%'WLX1MZOJ%3'SS!=\8$,_#A
M K<_)^?"4+%B2P[D6&NPV!>XGIP;J/1.].$+H!]X](/>K>W0"7?H[!&=.O0]
M MHP/%\XV6@H&HXK"]@51+^;>$P>@"K=0SSRQ*/_(F[=8<<Y>@<*+R]"*ZD,
M^TWM3;.+O-]=G#Q+/O;DXUXI?X3[,[E7Y!_38>(1)R^9R9,70#_TZ(>OD\G]
M;N+HV7R(H\<+/GK=7'[&W^AI]G"K3E6@5JX::Y+)1IBN9/E17_&/NSKWN+S[
M7;BD:L6$)AP*-(WVQW@WJ*X"=QTC:U?UEM)@#77-$O]:0-D%.%](:38=Z\#_
M!Z5_ %!+ P04    "  *A6Y9*1A=U;\"   <"   &0   'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6RM5EUOVC 4_2M65DVMM#5?$&@'D5K8M#Y,0Z7='J8]
MF.2&6'7BS#;0_OM=)VE$P41[V NQG7O./>?FVF:R$_))Y0":/!>\5%,GU[JZ
M=EV5Y%!0=2DJ*/%-)F1!-4[EVE65!)K6H(*[@>=%;D%9Z<23>FTAXXG8:,Y*
M6$BB-D5!Y<LM<+&;.K[SNG#/UKDV"VX\J>@:EJ ?JX7$F=NQI*R 4C%1$@G9
MU+GQKV=C$U\'_&"P4WMC8IRLA'@RD[MTZGA&$'!(M&&@^-C"##@W1"CC3\OI
M="D-<'_\ROZE]HY>5E3!3/"?+-7YU!D[)(6,;KB^%[NOT/H9&KY$<%7_DET3
M&PT<DFR4%D4+1@4%*YLG?6[KL ?P3P&"%A#\*R!L 6%MM%%6VYI33>.)%#LB
M332RF4%=FQJ-;EAION)22WS+$*?C);9%NN% 1$9NDD1N("6?G[%'%"AR/@=-
M&5<7Y"-Y7,[)^=D%.2.L) ^YV"A:IFKB:A1AJ-RD37C;) Q.)83JDH3>!Q)X
MP< "G_7#YY @W*_AX5NXB]8[_T'G/ZCYPA-\"_I"5QR]HINF )0K\NMFI;3$
M%OMM,]@P#NR,9MM=JXHF,'5P7RF06W#B]^_\R/MDL_N?R-Z8#SOS81][/!.%
M^=+4;"B;T08=U6AS'&QC?^)N]]4?1PS\01?S1M2@$S7H%;60(@-E3@G*209@
M[;&&8KB7=W3E'6@[CO'#86 7-^S$#?LKA@LL06%:,OR%=J?8) XMZ8,#B9:8
M\8GR19W"J%?A7:D!.T7;)$5'Z8:''[27W-Z.I*<31YWJ4:_J[SH'V5O.T9'V
M<'2@W1(2V8LY[F2->V4]"$VY3<WX>&=X_F$M+4%7XT-%[M[9;>[-;U2N6:D(
MAPQAWN4(_<CF+FHF6E3U<;X2&B^'>ICC]0W2!.#[3 C].C$W1/>'(/X+4$L#
M!!0    (  J%;EF]'DRKHP(  ,8&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;)6546^;,!#'OXK%JJF5VD(@)&E'D-I&U29M6M2TV\.T!P>.Q*JQ
MF6V2;I]^9Y.@="%1]P*V\?WO=^?SD:RE>M9+ $->2B[TV%L:4UW[OLZ64%)]
M*2L0^*60JJ0&IVKAZTH!S9U1R?TP" 9^29GPTL2M356:R-IP)F"JB*[+DJK?
MM\#E>NSUO.W" ULLC5WPTZ2B"YB!>:JF"F=^JY*S$H1F4A %Q=B[Z5W?CNQ^
MM^$;@[7>&1,;R5S*9SOYE(^]P (!A\Q8!8JO%=P!YU8(,7YM-+W6I37<'6_5
M[UWL&,N<:KB3_#O+S7+LC3R20T%K;A[D^B-LXHFM7B:Y=D^R;O;&H4>R6AM9
M;HR1H&2B>=.731YV#,)#!N'&('3<C2-'.:&&IHF2:Z+L;E2S Q>JLT8X)NRA
MS(S"KPSM3#K#4\YK#D06Y+,4"_((JB03F!MR.@%#&==GY(0P01Z7LM94Y#KQ
M#3JVYGZV<7+;. D/.8'JDD3!.0F#L$^>9A-R>G+V6L9'[A8^;.%#IQL=T'68
M$Z8S+G6M@/RXF6NC\*!_=C$V6OUN+5O\U[JB&8P]K&X-:@5>^OY=;Q!\.$(:
MM:31,?74IO;"V-3FR-Q%U]@/G+V]2:LTBH)>XJ\ZO/9;K_VC7I\$+:4R[ _D
MY*MB"R8H)TSK&DB.69.UZ$1I1.,=E(LXCKM1XA8E?C/*/7*(C&&Q%0"=Y13O
M$_3ZW0"#%F#P9H!M\ 3+V1V(2PHR <FD-IU(@SVD<!B%W4S#EFEXO"I :[SD
M2@&R5)8.^Q1>1/ZJ6LZ)@,YS&NYG*8ROHFZF4<LT^H]*/>A[M%>NO>CJ'\_^
M3ENR'?X+55B"FG HT"JX'"*Z:KIF,S&R<IUJ+@WV/3=<XH\&E-V WPLIS79B
MFU_[ZTK_ E!+ P04    "  *A6Y9".2>HZD%  #*'P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6RUF5UOVS84AN_W*PBO&%H@C3[\%7>.@<1JL ))
M%R3K=E'T@I:/;:*2J))4G [[\3NB9,FR93H&F!M;E'A>DH_X\8H<K[GX+E<
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M0929\PS-'+B?#X.9$+:\;^8IZ^=ULGXP?5N[9Q: =/K**WHM2Y@P<5NURC9
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M?':Y..2!/@8,45'?CS4AD$%EWHU/GEW:P=*3I>0,AN7,:\XO]=D ?5C,ZA:
M]#PHL81AL62U:>98Y>EIVC,-9M"6B96TP;"TJ:VL?8PC]IKB&NS'MF34%IJ>
M%:5[</]_+K!A4'A9IZLE-#U=2G=A6'>U4&3+/6A5MG[?<8XK4P8[0C0[G8/2
M8!B6-ZT7VG)_Y?V)=$L3-N=3M7*[HQ.E-JP4%:Y15/]BL:W&M>OFFPPI-AE3
MB2RG7X/EY%BC @O7;EA*?F%8?K58<(,]V6Q;+5>AB!)T!!9T=D4W&,R"< M
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MCL1AM]S0A@Z# ]5<J.9!-1^EE6/@.)>#UD_FD)]9/ T31C9Q=MA*=GM;W 2
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M6.B<7&@O!JJIJ*:AFEYJM:N!Y>%T(%]<=66@8TU4LU#-1C4'U5Q4\U#-1[4
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M0S4?U0)4"U$M0K48U1)42U$MH[1Z?E6U%H<OR4.$0S3%2$U!-175-%334<U
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M?6P,**'7.:!(34$U%=4T5--+K1Y0T]GL,J#(H2:J6:AFHYJ#:BZJ>:CFHUJ
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M*Z&O,AVGIO=Z7D3+&!"?HU.I!S/+V95(<70I%=,\ 5(+0%>4"?1 XR6@WRY
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M*0X70",0^0WZ^IQS]7Z2O_)6O>(X_0]02P,$%     @ "H5N625C]_). @
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M"(T&7[!QY=/O%T96+G%;:3"_;EK@@PG*%N#Y3F+2VH45Z)[@]"]02P,$%
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M=Y05!XCG[](T>[I3#'"\$-GZ?U!+ P04    "  *A6Y9)#N<KCD#  #0$P
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M?L)!><E5>6%9^.@WH(I96$5>=TI]@[)S?6IXM?U/R/;_+%_^ E!+ P04
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MS5!DS5!DS5!DS?Y3UG=CEG_]N[B]I[4NFT,^Z_[)3SX!4$L! A0#%     @
M"H5N60=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    "  *A6Y9X,-81^X    K @  $0
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M965T-"YX;6Q02P$"% ,4    "  *A6Y9F$NEM*L,  "[?P  &
M    @(&X'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M"H5N6;0 8L&Z!P  5R0  !@              ("!F2L  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    (  J%;EEM)9W7@PX  "TE   8
M          " @8DS  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    "  *A6Y9!GIS<<X"  !,!@  &               @(%"0@  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ "H5N66YA#V?O P  & T
M !@              ("!1D4  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    (  J%;EFE@V$1]@(  * &   9              " @6M)  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ "H5N62BI\E\
M!   F0D  !D              ("!F$P  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    "  *A6Y9."M7F:4"  #*!0  &0
M@('/4   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (  J%
M;EF(Y%7+3P0  '\*   9              " @:M3  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ "H5N6>@%/F9@!P  S!D  !D
M         ("!,5@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    "  *A6Y9)WR7?HX-  #D(P  &0              @('(7P  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  J%;EG'>O9RE (  +8%
M   9              " @8UM  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ "H5N64W>;JD) P   @<  !D              ("!6'
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  *A6Y94X'2
M[#\+   #'@  &0              @(&8<P  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    (  J%;EDW?DA%"00  -\(   9
M  " @0Y_  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M"H5N6<0QN=1G"0  I!T  !D              ("!3H,  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    "  *A6Y9A>@AN8@#   #"   &0
M            @('LC   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    (  J%;EEE][//@P(  + %   9              " @:N0  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ "H5N64'VM2[/ P
M/ H  !D              ("!99,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    "  *A6Y9#]#-O*8"  #&!0  &0              @(%K
MEP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  J%;EFU
M]>5ML@(  .P%   9              " @4B:  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ "H5N65'R[YID!   8Q4  !D
M     ("!,9T  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  J%;EEPQSAIAP(  'D&   9              "
M@1*P  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ "H5N
M68+3I*WK @  7@L  !D              ("!T+(  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    "  *A6Y9;RS.YU\#   Q#@  &0
M        @('RM0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   (  J%;EGCWB3?\ (  -((   9              " @8BY  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ "H5N6;2O?Y?- @  >PD
M !D              ("!K[P  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    "  *A6Y93T^?4;$"   3"0  &0              @(&SOP
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  J%;EDI&%W5
MOP(  !P(   9              " @9O"  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ "H5N6;T>3*NC @  Q@8  !D
M ("!D<4  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  *
MA6Y9".2>HZD%  #*'P  &0              @(%KR   >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  J%;EF71SQG" <  (0V   9
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M970T-"YX;6Q02P$"% ,4    "  *A6Y9G_#ON1H%  #N*   &0
M    @($V$0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M  J%;EDE8_?R3@(  (X%   9              " @8<6 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ "H5N6<679.B( P  +Q(  !D
M             ("!#!D! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    "  *A6Y9F4J<(Y8"  ! !P  &0              @('+' $ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (  J%;EE"1R[@2P,
M $@,   9              " @9@? 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ "H5N60ZM[*JU @  B D  !D              ("!
M&B,! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  *A6Y9
M1&77-*(#  "L#P  &0              @($&)@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    (  J%;ED;-0I* @P  +*6   9
M      " @=\I 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ "H5N67V'"IJS!@  E$P  !D              ("!&#8! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  *A6Y9)#N<KCD#  #0$P
M#0              @ $"/0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  J%
M;EF7BKL<P    !,"   +              "  69  0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    (  J%;EGY1C8_O 0  %,C   /              "  4]! 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  *A6Y9?'[I&]0!  #&'P  &@
M            @ $X1@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  *A6Y9*F32ILH!  ";'P  $P              @ %$2 $ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     /0 ] *(0   _2@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>286</ContextCount>
  <ElementCount>307</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/BusinessAndBasisOfPresentation</Role>
      <ShortName>Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Patents, and Trademark Rights, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/PatentsAndTrademarkRightsNet</Role>
      <ShortName>Patents, and Trademark Rights, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Unsecured Promissory Note</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/UnsecuredPromissoryNote</Role>
      <ShortName>Unsecured Promissory Note</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Equity-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/Equity-basedCompensation</Role>
      <ShortName>Equity-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Research, Consulting and Supply Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements</Role>
      <ShortName>Research, Consulting and Supply Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Patents, and Trademark Rights, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables</Role>
      <ShortName>Patents, and Trademark Rights, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/PatentsAndTrademarkRightsNet</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/AccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Unsecured Promissory Note (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/UnsecuredPromissoryNoteTables</Role>
      <ShortName>Unsecured Promissory Note (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/UnsecuredPromissoryNote</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Equity-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/Equity-basedCompensationTables</Role>
      <ShortName>Equity-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/Equity-basedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/FairValue</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Cash and Cash Equivalents (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/CashAndCashEquivalentsDetailsNarrative</Role>
      <ShortName>Cash and Cash Equivalents (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/CashAndCashEquivalents</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Marketable Securities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/MarketableSecuritiesDetailsNarrative</Role>
      <ShortName>Marketable Securities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/MarketableSecurities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Property and Equipment, net (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative</Role>
      <ShortName>Property and Equipment, net (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Schedule of Patent and Trademark Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails</Role>
      <ShortName>Schedule of Patent and Trademark Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Schedule of Changes in Patents, Trademark Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails</Role>
      <ShortName>Schedule of Changes in Patents, Trademark Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Schedule of Amortization of Patents and Trademarks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails</Role>
      <ShortName>Schedule of Amortization of Patents and Trademarks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Patents, and Trademark Rights, Net (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative</Role>
      <ShortName>Patents, and Trademark Rights, Net (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails</Role>
      <ShortName>Schedule of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Unsecured Promissory Note (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative</Role>
      <ShortName>Unsecured Promissory Note (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/UnsecuredPromissoryNoteTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Schedule of Unvested Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails</Role>
      <ShortName>Schedule of Unvested Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Equity-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative</Role>
      <ShortName>Equity-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/Equity-basedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/StockholdersEquity</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Net Loss Per Share (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/NetLossPerShareDetailsNarrative</Role>
      <ShortName>Net Loss Per Share (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/NetLossPerShare</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule of Assumptions to Estimate the Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails</Role>
      <ShortName>Schedule of Assumptions to Estimate the Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Schedule of Potential Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfPotentialLiabilityDetails</Role>
      <ShortName>Schedule of Potential Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Fair Value (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/FairValueDetailsNarrative</Role>
      <ShortName>Fair Value (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/FairValueTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails</Role>
      <ShortName>Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Schedule of Operating Lease Future Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails</Role>
      <ShortName>Schedule of Operating Lease Future Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/LeasesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Research, Consulting and Supply Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative</Role>
      <ShortName>Research, Consulting and Supply Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimimmuno.com/role/SubsequentEvents</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aim-20240930.xsd</File>
    <File>aim-20240930_cal.xml</File>
    <File>aim-20240930_def.xml</File>
    <File>aim-20240930_lab.xml</File>
    <File>aim-20240930_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10-q.htm">form10-q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="908">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-q.htm": {
   "nsprefix": "AIM",
   "nsuri": "http://aimimmuno.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "aim-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "aim-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "aim-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "aim-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aim-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    }
   },
   "keyStandard": 256,
   "keyCustom": 51,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 39,
   "hidden": {
    "total": 259,
    "http://fasb.org/us-gaap/2024": 191,
    "http://aimimmuno.com/20240930": 64,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 286,
   "entityCount": 1,
   "segmentCount": 71,
   "elementCount": 501,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 908,
    "http://xbrl.sec.gov/dei/2024": 29
   },
   "report": {
    "R1": {
     "role": "http://aimimmuno.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://aimimmuno.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://aimimmuno.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://aimimmuno.com/role/StatementsOfComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)",
     "shortName": "Consolidated Statements of Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://aimimmuno.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "AIM:AbandonmentOfPatentAndTrademarkRights",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://aimimmuno.com/role/BusinessAndBasisOfPresentation",
     "longName": "00000007 - Disclosure - Business and Basis of Presentation",
     "shortName": "Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://aimimmuno.com/role/CashAndCashEquivalents",
     "longName": "00000008 - Disclosure - Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://aimimmuno.com/role/MarketableSecurities",
     "longName": "00000009 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://aimimmuno.com/role/PropertyAndEquipmentNet",
     "longName": "00000010 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://aimimmuno.com/role/PatentsAndTrademarkRightsNet",
     "longName": "00000011 - Disclosure - Patents, and Trademark Rights, Net",
     "shortName": "Patents, and Trademark Rights, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://aimimmuno.com/role/AccruedExpenses",
     "longName": "00000012 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://aimimmuno.com/role/UnsecuredPromissoryNote",
     "longName": "00000013 - Disclosure - Unsecured Promissory Note",
     "shortName": "Unsecured Promissory Note",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://aimimmuno.com/role/Equity-basedCompensation",
     "longName": "00000014 - Disclosure - Equity-Based Compensation",
     "shortName": "Equity-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://aimimmuno.com/role/StockholdersEquity",
     "longName": "00000015 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://aimimmuno.com/role/NetLossPerShare",
     "longName": "00000016 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://aimimmuno.com/role/RecentAccountingPronouncements",
     "longName": "00000017 - Disclosure - Recent Accounting Pronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://aimimmuno.com/role/FairValue",
     "longName": "00000018 - Disclosure - Fair Value",
     "shortName": "Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://aimimmuno.com/role/Leases",
     "longName": "00000019 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements",
     "longName": "00000020 - Disclosure - Research, Consulting and Supply Agreements",
     "shortName": "Research, Consulting and Supply Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "AIM:ResearchConsultingAndSupplyAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "AIM:ResearchConsultingAndSupplyAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://aimimmuno.com/role/SubsequentEvents",
     "longName": "00000021 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://aimimmuno.com/role/PropertyAndEquipmentNetTables",
     "longName": "00000022 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables",
     "longName": "00000023 - Disclosure - Patents, and Trademark Rights, Net (Tables)",
     "shortName": "Patents, and Trademark Rights, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://aimimmuno.com/role/AccruedExpensesTables",
     "longName": "00000024 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://aimimmuno.com/role/UnsecuredPromissoryNoteTables",
     "longName": "00000025 - Disclosure - Unsecured Promissory Note (Tables)",
     "shortName": "Unsecured Promissory Note (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://aimimmuno.com/role/Equity-basedCompensationTables",
     "longName": "00000026 - Disclosure - Equity-Based Compensation (Tables)",
     "shortName": "Equity-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://aimimmuno.com/role/FairValueTables",
     "longName": "00000027 - Disclosure - Fair Value (Tables)",
     "shortName": "Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "AIM:ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "AIM:ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://aimimmuno.com/role/LeasesTables",
     "longName": "00000028 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://aimimmuno.com/role/CashAndCashEquivalentsDetailsNarrative",
     "longName": "00000029 - Disclosure - Cash and Cash Equivalents (Details Narrative)",
     "shortName": "Cash and Cash Equivalents (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://aimimmuno.com/role/MarketableSecuritiesDetailsNarrative",
     "longName": "00000030 - Disclosure - Marketable Securities (Details Narrative)",
     "shortName": "Marketable Securities (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:HeldToMaturitySecuritiesFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:HeldToMaturitySecuritiesFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "00000031 - Disclosure - Schedule of Property and Equipment (Details)",
     "shortName": "Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative",
     "longName": "00000032 - Disclosure - Property and Equipment, net (Details Narrative)",
     "shortName": "Property and Equipment, net (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_srt_MaximumMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails",
     "longName": "00000033 - Disclosure - Schedule of Patent and Trademark Rights (Details)",
     "shortName": "Schedule of Patent and Trademark Rights (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails",
     "longName": "00000034 - Disclosure - Schedule of Changes in Patents, Trademark Rights (Details)",
     "shortName": "Schedule of Changes in Patents, Trademark Rights (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails",
     "longName": "00000035 - Disclosure - Schedule of Amortization of Patents and Trademarks (Details)",
     "shortName": "Schedule of Amortization of Patents and Trademarks (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
     "longName": "00000036 - Disclosure - Patents, and Trademark Rights, Net (Details Narrative)",
     "shortName": "Patents, and Trademark Rights, Net (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30_us-gaap_PatentsMember",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_us-gaap_PatentsMember",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails",
     "longName": "00000037 - Disclosure - Schedule of Accrued Expenses (Details)",
     "shortName": "Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails",
     "longName": "00000038 - Disclosure - Schedule of Long Term Debt (Details)",
     "shortName": "Schedule of Long Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative",
     "longName": "00000039 - Disclosure - Unsecured Promissory Note (Details Narrative)",
     "shortName": "Unsecured Promissory Note (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:LongTermDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:UnsecuredDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "00000040 - Disclosure - Schedule of Stock Option Activity (Details)",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails",
     "longName": "00000041 - Disclosure - Schedule of Unvested Stock Option Activity (Details)",
     "shortName": "Schedule of Unvested Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative",
     "longName": "00000042 - Disclosure - Equity-Based Compensation (Details Narrative)",
     "shortName": "Equity-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2019-01-012019-12-31",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2019-01-012019-12-31",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
     "longName": "00000043 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2020-03-302020-03-31",
      "name": "AIM:WarrantModifications",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://aimimmuno.com/role/NetLossPerShareDetailsNarrative",
     "longName": "00000044 - Disclosure - Net Loss Per Share (Details Narrative)",
     "shortName": "Net Loss Per Share (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-09-30_us-gaap_StockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails",
     "longName": "00000045 - Disclosure - Schedule of Assumptions to Estimate the Fair Value (Details)",
     "shortName": "Schedule of Assumptions to Estimate the Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30_us-gaap_MeasurementInputSharePriceMember_custom_ClassAWarrantMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "AIM:ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_us-gaap_MeasurementInputSharePriceMember_custom_ClassAWarrantMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "AIM:ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://aimimmuno.com/role/ScheduleOfPotentialLiabilityDetails",
     "longName": "00000046 - Disclosure - Schedule of Potential Liability (Details)",
     "shortName": "Schedule of Potential Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "AIM:LowRangeOfProbability",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "AIM:ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "AIM:LowRangeOfProbability",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "AIM:ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "00000047 - Disclosure - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://aimimmuno.com/role/FairValueDetailsNarrative",
     "longName": "00000048 - Disclosure - Fair Value (Details Narrative)",
     "shortName": "Fair Value (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "AIM:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails",
     "longName": "00000049 - Disclosure - Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)",
     "shortName": "Schedule of AIM Recognized Rent Expense Associated with Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails",
     "longName": "00000050 - Disclosure - Schedule of Operating Lease Future Payments (Details)",
     "shortName": "Schedule of Operating Lease Future Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://aimimmuno.com/role/LeasesDetailsNarrative",
     "longName": "00000051 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
     "longName": "00000052 - Disclosure - Research, Consulting and Supply Agreements (Details Narrative)",
     "shortName": "Research, Consulting and Supply Agreements (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "AIM:ResearchConsultingAndSupplyAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000053 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012024-10-01_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "AIM_AbandonmentOfPatentAndTrademarkRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "AbandonmentOfPatentAndTrademarkRights",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Abandonment of patent and trademark rights",
        "documentation": "Abandonment of patent and trademark rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r37",
      "r43",
      "r706"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r583"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funds receivable from New Jersey net operating loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "AIM_AccruedClinicalTrialExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical trial expenses",
        "documentation": "Accrued clinical trial expenses current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "totalLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r110",
      "r439"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r10",
      "r344",
      "r347",
      "r403",
      "r457",
      "r458",
      "r630",
      "r631",
      "r632",
      "r641",
      "r642",
      "r643",
      "r644"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r583",
      "r777"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r641",
      "r642",
      "r643",
      "r644",
      "r712",
      "r778"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expenses of long term debt",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r290"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r76"
     ]
    },
    "AIM_AdvancedPancreaticCancerStudyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "AdvancedPancreaticCancerStudyAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Pancreatic Cancer Study Agreement [Member]",
        "documentation": "Advanced Pancreatic Cancer Study Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_AlcamiCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "AlcamiCorporationMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcami Corporation [Member]",
        "documentation": "Alcami Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_AllianceGlobalPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "AllianceGlobalPartnersLLCMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alliance Global Partners, LLC [Member]",
        "documentation": "Alliance Global Partners, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r323"
     ]
    },
    "AIM_AmarexClinicalResearchLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "AmarexClinicalResearchLLCMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amarex Clinical Research LLC [Member]",
        "documentation": "Amarex Clinical Research LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original issue discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r57",
      "r252",
      "r723"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of financial obligation",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r252",
      "r636",
      "r723"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails",
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of patent, trademark rights",
        "negatedLabel": "Accumulated Amortization",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r200",
      "r206",
      "r562"
     ]
    },
    "AIM_AmpligenManufacturingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "AmpligenManufacturingAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ampligen Manufacturing Agreement [Member]",
        "documentation": "Ampligen Manufacturing Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://aimimmuno.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, antidilutive",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://aimimmuno.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://aimimmuno.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://aimimmuno.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative",
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r95",
      "r113",
      "r134",
      "r169",
      "r173",
      "r179",
      "r180",
      "r192",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r339",
      "r341",
      "r376",
      "r430",
      "r506",
      "r559",
      "r560",
      "r583",
      "r599",
      "r673",
      "r674",
      "r731"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r119",
      "r134",
      "r192",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r339",
      "r341",
      "r376",
      "r583",
      "r673",
      "r674",
      "r731"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_AtlasSciencesLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "AtlasSciencesLlcMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Atlas Sciences LLC [Member]",
        "documentation": "Atlas Sciences LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "AIM_AzenovaLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "AzenovaLLCMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Azenova LLC [Member]",
        "documentation": "Azenova LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_BeneficialOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "BeneficialOwnershipPercentage",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beneficial ownership percentage",
        "documentation": "Beneficial ownership percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/BusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business and Basis of Presentation",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r66",
      "r67"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r108",
      "r555"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/CashAndCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r433"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents-Marketable investments",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r63",
      "r131"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r63"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/CashAndCashEquivalentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federlly insured limit",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ChangesInRouAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ChangesInRouAssets",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in right of use assets",
        "documentation": "Changes in Rou assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ClassAWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ClassAWarrantMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Warrant [Member]",
        "documentation": "Class A Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ClassBCommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ClassBCommonWarrantMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B Common Warrants [Member]",
        "documentation": "Class B Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ClassBWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ClassBWarrantMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B Warrant [Member]",
        "documentation": "Class B Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ClassCCommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ClassCCommonWarrantMember",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class C Common Warrant [Member]",
        "documentation": "Class C Common Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ClassDCommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ClassDCommonWarrantMember",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class D Common Warrant [Member]",
        "documentation": "Class D Common Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails",
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r116",
      "r117",
      "r118",
      "r134",
      "r159",
      "r160",
      "r162",
      "r164",
      "r171",
      "r172",
      "r192",
      "r228",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r259",
      "r260",
      "r264",
      "r267",
      "r274",
      "r376",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r494",
      "r515",
      "r533",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r621",
      "r637",
      "r645"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r171",
      "r259",
      "r260",
      "r262",
      "r264",
      "r267",
      "r272",
      "r274",
      "r467",
      "r468",
      "r469",
      "r470",
      "r567",
      "r621",
      "r637"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "AIM_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless basis, expired",
        "documentation": "Class of warrant or right number of securities called by each warrant expired."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised aggregate",
        "verboseLabel": "Conversion of warrants",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ClinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ClinicalStudiesMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Studies [Member]",
        "documentation": "Clinical Studies [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Notes 13 and 14)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r85",
      "r432",
      "r493"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock is reserved for potential issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r590",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r641",
      "r642",
      "r644",
      "r712",
      "r775",
      "r778"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r494"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r494",
      "r512",
      "r778",
      "r779"
     ]
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesSubscriptions",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription price",
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r47"
     ]
    },
    "AIM_CommonStockSharesWithLimitationsAndRestrictionsOnUsage": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "CommonStockSharesWithLimitationsAndRestrictionsOnUsage",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock specific limitations and restrictions on usage",
        "documentation": "Common stock shares with limitations and restrictions on usage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 58,668,647 and 49,102,484 as of September 30, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r435",
      "r583"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r121",
      "r123",
      "r128",
      "r425",
      "r443",
      "r444"
     ]
    },
    "AIM_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement [Member]",
        "documentation": "Consulting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ConversionOfNotePayableInterestIntoShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ConversionOfNotePayableInterestIntoShares",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of note payable interest into shares",
        "documentation": "Conversion of note payable interest into shares."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ConversionOfSeriesBPreferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ConversionOfSeriesBPreferred",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series B preferred",
        "documentation": "Conversion Of Series B preferred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of shares issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r17"
     ]
    },
    "AIM_ConvertiblePreferredStockFaceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ConvertiblePreferredStockFaceValue",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible preferred stock face value",
        "documentation": "Convertible preferred stock face value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Invigilators cost",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Costs and Expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r671"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r671",
      "r672"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange of unsecured promissory notes",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r17"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured debt original issue discount",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r17"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNote"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Promissory Note",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r132",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r226",
      "r227",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r248",
      "r253",
      "r254",
      "r255",
      "r386"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleTypeOfEquitySecurity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleTypeOfEquitySecurity",
     "presentation": [
      "http://aimimmuno.com/role/MarketableSecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity securities description",
        "documentation": "Description of the type of equity security or securities into which conversion will be made (for example, common stock or preferred shares)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r26",
      "r40",
      "r75"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument stated interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r238"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionDescription",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption description",
        "documentation": "Description of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount, current",
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722",
      "r724"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount, non current",
        "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722",
      "r724"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized discount and debt issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r256",
      "r385",
      "r386",
      "r387",
      "r563",
      "r564",
      "r581"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Original issue discount",
        "documentation": "Amount, after accumulated amortization, of debt discount (premium)."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r721",
      "r722",
      "r724"
     ]
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtWeightedAverageInterestRate",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, weighted average interest rate",
        "documentation": "Weighted average interest rate of debt outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsCurrentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsCurrentGross",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt, current",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r724"
     ]
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt origination costs, current",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722",
      "r724"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt issuance costs",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r724"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unamortized Financing fees",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r721",
      "r722",
      "r724"
     ]
    },
    "us-gaap_DeferredFinanceCostsNoncurrentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNoncurrentGross",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt, non current",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r724"
     ]
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt origination costs, non current",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722",
      "r724"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation of property and equipment",
        "verboseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r19"
     ]
    },
    "us-gaap_DevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development cost",
        "documentation": "Amount of capitalized development cost incurred during period and excluded from amortization for oil- and gas-producing activities accounted for under full cost method. Excludes acquisition and exploration costs and capitalized interest."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r742"
     ]
    },
    "AIM_DirectorsOfficersAndEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "DirectorsOfficersAndEmployeesMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors, Officers and Employees [Member]",
        "documentation": "Directors, Officers and Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r292",
      "r320",
      "r321",
      "r322",
      "r573"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_DisclosureResearchConsultingAndSupplyAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "DisclosureResearchConsultingAndSupplyAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Consulting And Supply Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r613",
      "r614"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r157",
      "r159",
      "r162",
      "r163",
      "r164",
      "r168",
      "r334",
      "r337",
      "r353",
      "r354",
      "r426",
      "r445",
      "r556"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r159",
      "r162",
      "r163",
      "r164",
      "r168",
      "r334",
      "r337",
      "r353",
      "r354",
      "r426",
      "r445",
      "r556"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r165",
      "r166",
      "r167"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r103",
      "r124",
      "r125",
      "r126",
      "r136",
      "r137",
      "r138",
      "r142",
      "r149",
      "r151",
      "r153",
      "r170",
      "r193",
      "r196",
      "r213",
      "r276",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r335",
      "r336",
      "r337",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r352",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r388",
      "r390",
      "r403",
      "r442",
      "r457",
      "r458",
      "r459",
      "r472",
      "r533"
     ]
    },
    "AIM_EquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "EquityDistributionAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Distribution Agreement [Member]",
        "documentation": "Equity Distribution Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r328",
      "r622",
      "r623",
      "r624",
      "r708",
      "r709",
      "r710",
      "r711"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity investment ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "AIM_ErasmusUniversityMedicalCenterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ErasmusUniversityMedicalCenterMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erasmus University Medical Center [Member]",
        "documentation": "Erasmus University Medical Center [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r367",
      "r575"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r367",
      "r575"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r577"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r577"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r366",
      "r367",
      "r369",
      "r411",
      "r412",
      "r413",
      "r563",
      "r564",
      "r569",
      "r570",
      "r571",
      "r575",
      "r577"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r360",
      "r575",
      "r716",
      "r719"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r423",
      "r575",
      "r578"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r280",
      "r285",
      "r357",
      "r367",
      "r411",
      "r569",
      "r570",
      "r571",
      "r575"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r280",
      "r285",
      "r357",
      "r358",
      "r367",
      "r412",
      "r563",
      "r564",
      "r569",
      "r570",
      "r571",
      "r575"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r357",
      "r358",
      "r359",
      "r360",
      "r367",
      "r413",
      "r563",
      "r564",
      "r569",
      "r570",
      "r571",
      "r575",
      "r577"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r360",
      "r575",
      "r716",
      "r719"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r366",
      "r367",
      "r369",
      "r411",
      "r412",
      "r413",
      "r563",
      "r564",
      "r569",
      "r570",
      "r571",
      "r575",
      "r577"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r575",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite lived intangible assets, estimated useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite lived intangible assets, weighted average amortization",
        "documentation": "Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r553"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r197",
      "r205",
      "r562"
     ]
    },
    "AIM_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r553",
      "r562"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r553",
      "r562"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r553",
      "r562"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r553",
      "r562"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r418",
      "r422",
      "r553"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross carrying value",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r205",
      "r422",
      "r562"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r205",
      "r208",
      "r209",
      "r211",
      "r418",
      "r553",
      "r562"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r553"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/ScheduleOfAmortizationOfPatentsAndTrademarksDetails",
      "http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent and trademark rights, net",
        "verboseLabel": "Net carrying value",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "totalLabel": "Total",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r663"
     ]
    },
    "AIM_FinitelivedIntangibleAssetsAbandonments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "FinitelivedIntangibleAssetsAbandonments",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Abandonments",
        "documentation": "Finite lived intangible assets abandonments.",
        "label": "FinitelivedIntangibleAssetsAbandonments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfChangesInPatentsTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "AIM_GainFromSaleOfIncomeTaxOperatingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "GainFromSaleOfIncomeTaxOperatingLoss",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows",
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain from sale of income tax operating losses",
        "label": "Gain from sale of income tax operating losses",
        "documentation": "Gain from sale of income tax operating loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) on investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r620"
     ]
    },
    "us-gaap_GainLossOnSaleOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on issuance of warrants",
        "label": "Gain (Loss) on Sale of Derivatives",
        "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r87",
      "r521",
      "r522",
      "r523",
      "r524"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on sale of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "AIM_GainLossOnWarrantIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "GainLossOnWarrantIssuance",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Loss) on warrant issuance",
        "documentation": "Gain loss on warrant issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r517"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationTables",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationTables",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesFairValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/MarketableSecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Held value of marketable securities",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r188",
      "r357",
      "r366",
      "r424",
      "r429"
     ]
    },
    "AIM_HighRangeOfProbability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "HighRangeOfProbability",
     "presentation": [
      "http://aimimmuno.com/role/FairValueDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPotentialLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "High range, rate",
        "verboseLabel": "Probability, rate",
        "documentation": "High range of probability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r220",
      "r221",
      "r361",
      "r363",
      "r368",
      "r454",
      "r456",
      "r518",
      "r553",
      "r576",
      "r746"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221",
      "r361",
      "r363",
      "r368",
      "r454",
      "r456",
      "r518",
      "r553",
      "r576",
      "r746"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Funds receivable from New Jersey net operating loss",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r635"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets and other non-current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents, and Trademark Rights, Net",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r210",
      "r212",
      "r552",
      "r553"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense and other finance costs",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r173",
      "r176",
      "r177",
      "r180",
      "r384",
      "r559",
      "r560"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense debt excluding amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r251",
      "r565",
      "r566"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714",
      "r718"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r102",
      "r186",
      "r187",
      "r374",
      "r375",
      "r743"
     ]
    },
    "AIM_JointClinicalStudyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "JointClinicalStudyAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Joint Clinical Study Agreement [Member]",
        "documentation": "Joint Clinical Study Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_JubilantHollisterStierMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "JubilantHollisterStierMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jubilant HollisterStier [Member]",
        "documentation": "Jubilant HollisterStier [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r582"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease costs:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of AIM Recognized Rent Expense Associated with Operating Lease",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Lease Future Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "AIM_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "documentation": "Lessee operating lease liability payments due after year three.",
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, operating lease, remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r725"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r36",
      "r37",
      "r38",
      "r42",
      "r43",
      "r44",
      "r45",
      "r134",
      "r192",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r340",
      "r341",
      "r342",
      "r376",
      "r492",
      "r557",
      "r599",
      "r673",
      "r731",
      "r732"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r86",
      "r437",
      "r583",
      "r639",
      "r653",
      "r720"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r107",
      "r134",
      "r192",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r340",
      "r341",
      "r342",
      "r376",
      "r583",
      "r673",
      "r731",
      "r732"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r638",
      "r671"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r41",
      "r227",
      "r638",
      "r671"
     ]
    },
    "us-gaap_LoanProcessingFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoanProcessingFee",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan fee amortization",
        "documentation": "Expenses paid for obtaining loans which includes expenses such as application and origination fees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails",
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt",
        "verboseLabel": "Long term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r84",
      "r246",
      "r257",
      "r563",
      "r564",
      "r581",
      "r744"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less current portion of long-term debt, net",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Future maturities of long term debt",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r135",
      "r250"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future maturities of long term debt",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt, net",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable, net",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "AIM_LowRangeOfProbability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "LowRangeOfProbability",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfPotentialLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Low range, rate",
        "documentation": "Low range of probability."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ManufacturingAndEngineeringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ManufacturingAndEngineeringMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing and Engineering [Member]",
        "documentation": "Manufacturing and Engineering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManufacturingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManufacturingCosts",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Production costs",
        "documentation": "The aggregate costs incurred in the production of goods for sale."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "AIM_MarketPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "MarketPricePercentage",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market price, percentage",
        "documentation": "Market price, percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/MarketableSecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain) loss on sale of marketable securities",
        "label": "Marketable Security, Gain (Loss)",
        "documentation": "Amount of realized and unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_MasterServiceAgreementAndQualityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "MasterServiceAgreementAndQualityAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Service Agreement and Quality Agreement [Member]",
        "documentation": "Master Service Agreement And Quality Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_MaximGroupLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "MaximGroupLLCMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maxim Group LLC [Member]",
        "documentation": "Maxim Group LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative",
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r287",
      "r324",
      "r360",
      "r416",
      "r453",
      "r455",
      "r465",
      "r484",
      "r485",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r550",
      "r551",
      "r561",
      "r567",
      "r572",
      "r577",
      "r578",
      "r579",
      "r580",
      "r585",
      "r675",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r577"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r577"
     ]
    },
    "AIM_MediumRangeOfProbability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "MediumRangeOfProbability",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfPotentialLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Medium range, rate",
        "documentation": "Medium range of probability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative",
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r287",
      "r324",
      "r360",
      "r416",
      "r453",
      "r455",
      "r465",
      "r484",
      "r485",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r550",
      "r551",
      "r561",
      "r567",
      "r572",
      "r577",
      "r578",
      "r579",
      "r585",
      "r675",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738"
     ]
    },
    "AIM_MonthlyRetainerFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "MonthlyRetainerFee",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly retainer fee",
        "documentation": "Monthly retainer fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows",
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r65",
      "r89",
      "r105",
      "r120",
      "r122",
      "r126",
      "r134",
      "r141",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r161",
      "r192",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r334",
      "r337",
      "r354",
      "r376",
      "r441",
      "r514",
      "r531",
      "r532",
      "r597",
      "r673"
     ]
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/RecentAccountingPronouncements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r104",
      "r139",
      "r140",
      "r143",
      "r144",
      "r154",
      "r155",
      "r184",
      "r194",
      "r195",
      "r332",
      "r333",
      "r335",
      "r337",
      "r348",
      "r351",
      "r402",
      "r404",
      "r405",
      "r419",
      "r420",
      "r421",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of non-cash investing and financing cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_NotePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "NotePurchaseAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Purchase Agreement [Member]",
        "documentation": "Note Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of note payable, net",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "AIM_NumberOfVials": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "NumberOfVials",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional number of vials",
        "documentation": "Number of vials."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OfficerMember",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r776"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r558",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r582"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfOperatingLeaseFuturePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "verboseLabel": "Lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease Payment",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r397"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use asset, net",
        "verboseLabel": "Right of use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r582"
     ]
    },
    "AIM_OperatingLeaserightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "OperatingLeaserightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease-Right of Use Assets",
        "documentation": "Operating leaseright of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_OperationLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "OperationLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated amortization",
        "documentation": "Operation lease right of use asset accumulated amortization.",
        "label": "OperationLeaseRightOfUseAssetAccumulatedAmortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r656",
      "r657",
      "r658",
      "r659",
      "r661",
      "r663",
      "r666",
      "r667"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of patent and trademark rights",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Purchase of) property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "AIM_PercentageOfOutstandingStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "PercentageOfOutstandingStock",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of outstanding stock",
        "documentation": "Percentage of outstanding stock."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_PlacementAgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "PlacementAgentMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent [Member]",
        "documentation": "Placement Agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704"
     ]
    },
    "AIM_PostCOVIDStudyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "PostCOVIDStudyAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post COVID Study Agreement [Member]",
        "documentation": "Post COVID Study Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "AIM_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock conversion price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r590",
      "r593",
      "r594",
      "r595",
      "r596",
      "r775",
      "r778"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r259"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r494"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r259"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r494",
      "r512",
      "r778",
      "r779"
     ]
    },
    "AIM_PreferredStockStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "PreferredStockStatedValuePerShare",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, stated value",
        "documentation": "Preferred stock stated value per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible preferred stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r434",
      "r583"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "AIM_ProceedsFromIssuanceOfEquityWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ProceedsFromIssuanceOfEquityWarrants",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of equity warrants",
        "documentation": "Proceeds from issuance of equity warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance or sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r467"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from note payable, net of issuance costs",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ProceedsFromSaleOfInvestmentProjects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfInvestmentProjects",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of marketable securities",
        "documentation": "The cash inflow from the sale of investment projects held by an entity in hopes of getting a future return or interest from it."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant gross proceeds",
        "verboseLabel": "Grosss proceeds",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r417",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r554",
      "r568",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r669",
      "r670",
      "r678",
      "r745",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774"
     ]
    },
    "us-gaap_ProductionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductionCosts",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "documentation": "Amount of capitalized production cost incurred during period for oil- and gas-producing activities. Includes cost incurred to operate and maintain well and related equipment and facility."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "auth_ref": [
      "r181",
      "r417",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r554",
      "r568",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r669",
      "r670",
      "r678",
      "r745",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r97",
      "r98",
      "r99"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture, fixtures, and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r109",
      "r440"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r400",
      "r428",
      "r440",
      "r583"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_PurchaseAndRegistrationRightsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "PurchaseAndRegistrationRightsAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase And Registration Rights Agreement [Member]",
        "documentation": "Purchase And Registration Rights Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_QualityControlMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "QualityControlMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quality Control [Member]",
        "documentation": "Quality Control [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative",
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r279",
      "r287",
      "r315",
      "r316",
      "r317",
      "r324",
      "r360",
      "r414",
      "r415",
      "r416",
      "r453",
      "r455",
      "r465",
      "r484",
      "r485",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r550",
      "r551",
      "r561",
      "r567",
      "r572",
      "r577",
      "r578",
      "r579",
      "r580",
      "r585",
      "r591",
      "r668",
      "r675",
      "r716",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative",
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r279",
      "r287",
      "r315",
      "r316",
      "r317",
      "r324",
      "r360",
      "r414",
      "r415",
      "r416",
      "r453",
      "r455",
      "r465",
      "r484",
      "r485",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r550",
      "r551",
      "r561",
      "r567",
      "r572",
      "r577",
      "r578",
      "r579",
      "r580",
      "r585",
      "r591",
      "r668",
      "r675",
      "r716",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738"
     ]
    },
    "AIM_RegulatoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "RegulatoryMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory [Member]",
        "documentation": "Regulatory [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r286",
      "r406",
      "r407",
      "r431",
      "r438",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r511",
      "r513",
      "r538"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r286",
      "r406",
      "r407",
      "r431",
      "r438",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r511",
      "r513",
      "r538",
      "r730"
     ]
    },
    "AIM_RepresentativeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "RepresentativeWarrantsMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Representative Warrants [Member]",
        "documentation": "Representative Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r553",
      "r559",
      "r739"
     ]
    },
    "AIM_ResearchAndDevelopmentExpenseCostEstimatedLives": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ResearchAndDevelopmentExpenseCostEstimatedLives",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated lives",
        "documentation": "Research and development expense cost estimated lives."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense excluding acquired in process cost",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ResearchConsultingAndSupplyAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ResearchConsultingAndSupplyAgreementsTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research, Consulting and Supply Agreements",
        "documentation": "Research Consulting And Supply Agreements [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_RestatedTwoThousandEighteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "RestatedTwoThousandEighteenEquityIncentivePlanMember",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restated 2018 Equity Incentive Plan [Member]",
        "documentation": "Restated 2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r76",
      "r436",
      "r460",
      "r464",
      "r471",
      "r495",
      "r583"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r136",
      "r137",
      "r138",
      "r142",
      "r149",
      "r151",
      "r153",
      "r193",
      "r196",
      "r213",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r335",
      "r336",
      "r337",
      "r343",
      "r345",
      "r346",
      "r349",
      "r352",
      "r388",
      "r390",
      "r457",
      "r459",
      "r472",
      "r778"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical treatment programs - US",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r169",
      "r174",
      "r175",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r277",
      "r278",
      "r417"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r127",
      "r134",
      "r169",
      "r174",
      "r175",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r192",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r376",
      "r427",
      "r559",
      "r673"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightsMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rights [Member]",
        "documentation": "A security giving shareholders entitlement to acquire new shares issued by the entity at an established price in proportion to the number of shares already owned. Generally, rights expire within in a short time after issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of stock sold",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock sold",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate gross proceeds, percentage",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://aimimmuno.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "AIM_ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions to Estimate the Fair Value",
        "documentation": "Schedule Of Assumptions To Estimate The Fair Value [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long Term Debt",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r328",
      "r622",
      "r623",
      "r624",
      "r708",
      "r709",
      "r710",
      "r711"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r205",
      "r208",
      "r209",
      "r211",
      "r418",
      "r553",
      "r562"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Patents, Trademark Rights",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r662"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Patent and Trademark Rights",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r655"
     ]
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unvested Stock Option Activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "AIM_ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Potential Liability",
        "documentation": "Schedule Of Potential Liability Estimated The Range Of Probabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://aimimmuno.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r400"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative",
      "http://aimimmuno.com/role/Equity-basedCompensationTables",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r27",
      "r72",
      "r74",
      "r75",
      "r76",
      "r116",
      "r117",
      "r118",
      "r171",
      "r259",
      "r260",
      "r262",
      "r264",
      "r267",
      "r272",
      "r274",
      "r467",
      "r468",
      "r469",
      "r470",
      "r567",
      "r621",
      "r637"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Amortization of Patents and Trademarks",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r664"
     ]
    },
    "AIM_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "AIM_SeriesAJuniorParticipatingPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "SeriesAJuniorParticipatingPreferredStockMember",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Junior Participating Preferred Stock [Member]",
        "documentation": "Series A Junior Participating Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r627",
      "r628",
      "r677"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative",
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity-based compensation",
        "label": "Share based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option vested years",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative",
      "http://aimimmuno.com/role/Equity-basedCompensationTables",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants expired",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options Exercisable, End of Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Exercisable, Ending of Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate Intrinsic Value, Expired",
        "documentation": "ShareBased Compensation Arrangement By ShareBased Payment Award Options Expired In Period Total Intrinsic Value",
        "label": "Aggregate Intrinsic Value, Forfeited [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value, Expired",
        "documentation": "Aggregate intrinsic value, expired."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value, Forfeited",
        "documentation": "Aggregate intrinsic value, forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "AIM_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value, Granted",
        "documentation": "Aggregate intrinsic value, granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Options, Granted",
        "label": "Number of options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value Outstanding, Beginning of Period",
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending of Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options Outstanding, Beginning of Period",
        "periodEndLabel": "Number of Options Outstanding, Ending of Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning of Period",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, End of Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Vested and Expected to Vest",
        "label": "Stock options, aggregate intrinsic value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Vested and Expected to Vest",
        "label": "Stock options, vested",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Vested and Expected to Vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "verboseLabel": "Exercise price range",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationTables",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationTables",
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails",
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued price per share",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Exercisable at End of Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contracted Term (years), Exercisable at End of Period",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate Intrinsic Value, Expired",
        "documentation": "Share based Compensation Arrangement by Share based Payment Award Options Expired Aggregate Intrinsic Value.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value Unvested, Beginning of Period",
        "periodEndLabel": "Aggregate Intrinsic Value Unvested, End of Period",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest options outstanding.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate Intrinsic Value, Granted",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to non vest granted options outstanding.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options Unvested, Beginning of Period",
        "periodEndLabel": "Number of Options Unvested, End of Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Unvested, Beginning of Period",
        "periodEndLabel": "Weighted Average Exercise Price Unvested, Ending of Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Remaining Contractual Term (years) Unvested, Beginning of Period",
        "documentation": "Weighted average remaining contractual term for non vested option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contracted Term (years), Exercisable at End of Period",
        "documentation": "Sharebased compensation arrangement by sharebased payment award options nonvested weighted average remaining contractual term2.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contracted Term (years) Outstanding",
        "documentation": "Share-based compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term1.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contracted Term (years) Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value, Vested",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Vested",
        "label": "Number of Options, Vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Vested",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfUnvestedStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Remaining Contractual Term Vested",
        "documentation": "Sharebased compensation arrangement by sharebased payment award options vested weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term and variable lease costs",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r582"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails",
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r116",
      "r117",
      "r118",
      "r134",
      "r159",
      "r160",
      "r162",
      "r164",
      "r171",
      "r172",
      "r192",
      "r228",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r259",
      "r260",
      "r264",
      "r267",
      "r274",
      "r376",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r494",
      "r515",
      "r533",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r621",
      "r637",
      "r645"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r50",
      "r51",
      "r103",
      "r124",
      "r125",
      "r126",
      "r136",
      "r137",
      "r138",
      "r142",
      "r149",
      "r151",
      "r153",
      "r170",
      "r193",
      "r196",
      "r213",
      "r276",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r335",
      "r336",
      "r337",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r352",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r388",
      "r390",
      "r403",
      "r442",
      "r457",
      "r458",
      "r459",
      "r472",
      "r533"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails",
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r170",
      "r390",
      "r417",
      "r466",
      "r483",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r533",
      "r592"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/BalanceSheetsParenthetical",
      "http://aimimmuno.com/role/LeasesDetailsNarrative",
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfAimRecognizedRentExpenseAssociatedWithOperatingLeaseDetails",
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r170",
      "r185",
      "r390",
      "r417",
      "r466",
      "r483",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r516",
      "r517",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r533",
      "r592"
     ]
    },
    "AIM_SterlingPharmaSolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "SterlingPharmaSolutionsMember",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sterling Pharma Solutions [Member]",
        "documentation": "Sterling Pharma Solutions [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "AIM_StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless Exercise of Warrants, shares",
        "documentation": "Stock issued during period shares cashless exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_StockIssuedDuringPeriodSharesCommittedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesCommittedShares",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Committed Shares, shares",
        "documentation": "Stock issued during period shares committed shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B preferred shares converted to common shares, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r23",
      "r47",
      "r50",
      "r76",
      "r249"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issuance, net of costs, shares",
        "verboseLabel": "Number of shares issued upon transaction",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r46",
      "r47",
      "r76",
      "r467",
      "r533",
      "r545"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-based compensation, shares",
        "verboseLabel": "Pre-funded warrants exercised",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "StockIssuedDuringPeriodValueCashlessExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless exercise of warrants",
        "documentation": "Stock issued during period value cashless exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_StockIssuedDuringPeriodValueCommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "StockIssuedDuringPeriodValueCommitmentShares",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares issued",
        "documentation": "Stock issued during period value commitment shares."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_StockIssuedDuringPeriodValueCommittedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "StockIssuedDuringPeriodValueCommittedShares",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Committed shares",
        "documentation": "Stock issued during period value committed shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B preferred shares converted to common shares",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r50",
      "r51",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issuance, net of costs",
        "verboseLabel": "Issuance of common stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r46",
      "r47",
      "r76",
      "r472",
      "r533",
      "r545",
      "r598"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity-based compensation",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_StockIssuedDuringPeriodValuePreferredSharesExpired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "StockIssuedDuringPeriodValuePreferredSharesExpired",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B preferred shares expired",
        "documentation": "Stock issued during period value preferred shares expired."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued as payroll, value",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r46",
      "r47",
      "r76"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://aimimmuno.com/role/NetLossPerShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://aimimmuno.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets",
      "http://aimimmuno.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r68",
      "r496",
      "r512",
      "r534",
      "r535",
      "r583",
      "r599",
      "r639",
      "r653",
      "r720",
      "r778"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://aimimmuno.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r133",
      "r258",
      "r260",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r276",
      "r350",
      "r536",
      "r537",
      "r549"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders equity reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "AIM_StreetervilleCapitalLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "StreetervilleCapitalLlcMember",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Streeterville Capital LLC [Member]",
        "documentation": "Streeterville Capital LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r409"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r409"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r409"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r409"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r409"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r410"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SuppliesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SuppliesExpense",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrestricted grants",
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r651",
      "r729"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "auth_ref": []
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TrademarksMember",
     "presentation": [
      "http://aimimmuno.com/role/PatentsAndTrademarkRightsNetDetailsNarrative",
      "http://aimimmuno.com/role/ScheduleOfPatentAndTrademarkRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademarks [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r562",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r663",
      "r665",
      "r666",
      "r667"
     ]
    },
    "AIM_TradingDailyMaximumLessorAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "TradingDailyMaximumLessorAmount",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading maximum lessor amount",
        "documentation": "Trading daily maximum lessor amount."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_TwoThousandEighteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "presentation": [
      "http://aimimmuno.com/role/Equity-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2018 Equity Incentive Plan [Member]",
        "documentation": "2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative",
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative",
      "http://aimimmuno.com/role/SubsequentEventsDetailsNarrative",
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "AIM_UnitsManufactured": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "UnitsManufactured",
     "presentation": [
      "http://aimimmuno.com/role/ResearchConsultingAndSupplyAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of units manufactured",
        "documentation": "Units manufactured."
       }
      }
     },
     "auth_ref": []
    },
    "AIM_UnrealizedGainLossOnMarketableInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "UnrealizedGainLossOnMarketableInvestments",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain (loss) on marketable securities",
        "documentation": "Unrealized gain loss on marketable investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnsecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/UnsecuredPromissoryNoteDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured debt",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r84",
      "r744"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r590",
      "r593",
      "r594",
      "r595",
      "r596"
     ]
    },
    "AIM_WarrantModifications": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "WarrantModifications",
     "crdr": "debit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant modification",
        "documentation": "Warrant modification."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrants",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://aimimmuno.com/role/ScheduleOfAssumptionsToEstimateFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected holding period",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r717"
     ]
    },
    "AIM_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aimimmuno.com/20240930",
     "localname": "WarrantsMember",
     "presentation": [
      "http://aimimmuno.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "documentation": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r164"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://aimimmuno.com/role/StatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r164"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(a)(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001493152-24-045971-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-045971-xbrl.zip
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M$GQ)A5K#K, 1O,25X@-5,2IMA2; [+ZL I-*TW,FD_>]$U(UPM,&#RS>8%$
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M4:FH9PZH 8<1L!M]2VDE(\(#$6Y[L]AL?(VIC9"M>9DVO)$<K>\C[@(T@VE
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M5[,J#>%(G:%MO?F_> >\W8D3[\+/_P!02P,$%     @ "X5N6>8.58O\$0
MB]X  !0   !A:6TM,C R-# Y,S!?8V%L+GAM;.U=ZV_<-A+_?L#]#SP7.+1
M-WXD:9LTN8/C1V' L0T_VKM/A2S17EZTY%:4_.A??Z0>NY(H4L.U)#*X*XK6
M<3C#F?F1G!ER2'WXY],B1@\XX831CUN[KW:V$*8ABPB]_[AU<S7;OSHX.=E"
M/ UH%,2,XH];E&W]\Q]__0L2_WSXVVR&C@F.H_?HD(6S$WK'?D9GP0*_1[]@
MBI,@9<G/Z-<@SN1OV#&)<8(.V&(9XQ2+OR@Z?H_>OMI[<XMF,P#?7S&-6')S
M>;+B.T_3)7^_O?WX^/B*LH?@D25?^*N0+6 ,K](@S?B*V\[33OE/0?XA)O3+
M>_F?VX!C).Q%^?LG3CYNR7[+;A]?OV+)_?;>SL[N]K\^GUZ%<[P(9H1*NX5X
MJZ*27+KH=M^]>[>=_VW55&GY=)O$51^OMRMQ5IS%WQ)#^YHDG+SGN7BG+ S2
M'/;>;I"VA?S3K&HVD[^:[>[-7N^^>N+15F7\W(()B_$EOD/R_P*]5:\!69#%
M(J-,(K8M_W;[@(D1*43-Z>8)OONX)5H)[GMO=MZ]WI&\OVFT29^78F!R(L?5
M%MK>M-]/02R-=#7'..4]_7>V'4..BR#!-)WCE(1!;"-4)^% $LHY@Q>"/3^_
MD],YP7-,.7G IXSW60Y$.X:<\X#>8WY"KU(6?IFS.!*KS]$?&4F?;23NYS*&
M[ &?'\?LT<JV;9JA1F?&"<6<[]/H4\")Z.DBP5STF:\F?2,41#R0I-("HB/Y
M/XG00Q!+R_0M+$:B@23['"1?<!K<QO@*AUE"4H+[Y#*1#"351<*6.$F?A?I2
M]:4<2&<X[1&LAVHHV<3 %CB(3JZ3(!+N*_ER2>[G*0<("" =2,K],$PR'!T]
M+<62U@NIIO5 LMP(GF*@X$@ M""<L^3YC*6X1Z8>JH%D*Q;,F0P:(ND#A/Z0
MU:./;+"5U]I!C.P+Q$B5WO$")U=SX=9[Q-&T'DB62QR*Z23&+LMH*O($,5"H
M^#$L_$Z/:##B@20]#DB21_4]0BGM!NK_% ?]BT"ST6 8<1PDX?R 49[%TM!B
M];O*ELOX>?\^P4"H+'@,-?.R6X[_R 3GHP> B+KFX_K#:^F$^T0#T4[@&V'"
M@AF,XR=!0AIIQO69(/E M"/[3Y"@,.*AUV"0:)K6@Z['($&ZFHZ:E1R*V)[$
M_"Q($@'&0Y_+LF,R8M9B*;<-BZ%\2CC'419CF6JJ:W+9>9^CL>$QKO>Q-+@E
ME^%MGKL6U;-8VQW&9W#Y5_L]I8]\H1IV[ ;79G_!DI3\F2_WE4T;;M]:(6N.
M$\0\ME-D U;#(].,;JQA,)(/+NTIH_?7.%D<XEOK%=1 .VX49SDL++D,;N-\
M4^%\*2?6?BAZ$C&;K:G[60PN]0U]P#S%T0#2PUF-'%5;#AQ;-J/M6EG*#6<P
MSJZ6I;A ZN%7:LZS13X:^34[XBE9"/^Q2ERL%VX;;L-'9TRZ/A+$IR2X)?$&
MD[27PQCVQ[FWKGH4*<1GD:[)I7H_79GNG%[*Y3LA]#X_:=H F &Z&3J+MIPC
MO73#HT,6PB#LGI(_<70I=^:*D$28DX5$C.WH-Y+.SY>R-D38+,^SK:%Y>1^#
MZ]WL[3A+Q3BY")X7M;0<K)\%KT%W1BP'EYEHRIUL2\%?Q'.DG6Y;7PTD-TD;
M!G&8Q7EH<BK^W*# 3V)9CW!4\9$R@TMV4I+*UF49U2Z:R9JK3%I5_%BV'$^4
M[LJ<ADA[0HY5J40ND^A +""1_(FSF$1R$4$E)U2R*B6N9(Y9V) SEO54K%6W
M5-6FY553=P&_S4NG,CZ[#X+EMH1T&\<IKWZ3@YP#7/[B]\(-'0@/(T2M>,?!
M+8[S'G\OV[6:;3N1M7M3<C\]$*/R6<RRQAF;J@.0O*U;;>SL)R%BB8A?/V[M
M5OV(B=X8,6H-6]EB6P1BBYS-C(B14='?B>S/9.K2K&P35>J0""FVT".6&P^Y
M]&X@[-J?[1U\1B(87'M.X0)H[1-(Y?$YEX?I8FP)L44NU+]$&*E@,+UV"A-$
M;Y]PNDCP,B#5IIQ8#\[3.4Z *SJ(&(;:&Z>H65C!)_ * ?L\KB_N2#=C?+=R
M=3QU(2*M5%-!V#4W3%1^>!SM;.A7V"> FKEH?BYR?G>3Y]HFA'K(_/ V&HA
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M015;"Q]44@591E$CGU8>X%'MP?G@FY8@()+60@@5]I6#<S"-+;3:@ #"J!7
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MID$8[)V:S,\6EF$B)+.UFZF#CUP ]_8R*QG!^9%-M<7:94S74DB*FVH78]Y
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M+6CS'KD)7)55K173NV#Z0U=T^3FYC%,Z)K(JF1$A*"4*ZS\U:MLK0 &7RFM
M>1_.K )U( 77@:HZ<SZE12#(R>L7_]\XR4^Z%">[:'7BP.I2&3W<7LQ^/$TS
M2*]YO_;G2):6H=V1G<R9-F@IXRW2F$OY-K9 =W(-;LLP',WN*3/GI5?05)M9
M.FVY[9N(Q9(X-T:OW%\I*ILM;679F$&&*PTXFKHXA?Z25.Z]U!H^<TI;IPEL
MX0PKB>1<+$' =>4>E]$<)VGXAR3BH-_7;L$L$M*YH54@1Z5&70MD2K=;@"X%
M D=>Z\&GU9V\Y5RN$X-J%-Y58U"5"WE7%86"8%0?62/5=VH9=JL53(K%;1:I
M5\2M]KT.P9%Z#*X?@465H&J))8VZ/I6:4%?R2_81QGV$<1]AW$<8]Q'&?81Q
M'V'<1QCW$4;7%E3["*/5\LR.(HQN)BW!PJID+:E0VTJ-Z21BX7KF$LSY;X@M
M1M%D](P2?UK>T'*"GG""KNE4<X=B]-V/;I)SMIHF+<.0V@_9*>-H)[W"B&TI
M]K5QQI0P^-.HG:L%?QH'3O4:U[K"\?0!)?,S]"BN@FK4UU6%8+UXK!N/]=.+
M","A66I!JD;5G>#X+%=B4^S=NWDZI3R&Z84?A%&8OBH$I21D=H9B'E.2X).
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MBC$ML#88/K:T#V,0%YY$$ 3'K>N0@#K4($NHHA#1 D-*-CZVE(*W/2R*LH$
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M:/* DKG^F[E).[9T4YR!%Y,K"H2?X7OAML O'TE^Q1%UMJ,\:4T/0B[Y^.-
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M"S=7$4<E<EMUJFV05!<(PM)>E6KND)]BDHX>&=N!(*VZT=16]:*R(\GGV+D
M0WU)QOB%06BV=1X%@&7G/,3[&4Y2EO:L $.SK?,P "P[MU6MH/WA*%U-U^\M
M!;W6L:/Z.WJ1I5F"RILRA0GF']Z)8D2;<9^B7V_9<2_Y]?F3B5)4[\/AIC %
ML3MW#^PC5_O(E2I )$DKX-"_UL#0/\9W[')<(#9%?Z_\[&@4JLYD/]Z$BD[!
MY<^2X66#GF-'7'UA/FL]Q8,,JM/)V(ZZRON,UTBT_H6J;)[!1Q31-K4F?:?O
M K:*8>Z<&!O*"R*%:JTVZ3W-2J[7!GN@8BV&,PA!J.[-WJ$8??<C<6FPA'
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M9I&OOWY%A%7 Q1,F9D _/F#V5>72^M&4KK^F5&F7<9J$,0F#_$H& =*V6!J
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ME *<'H&?;-C@1+RU-A@>3H8LK C0 MZQ$E!=1'^Y^@0UI<#Q<#J;/V<IWI7
MDC*@<%AIGBV-A0*.@LDJU)/)W"L(#I\7+T$>T<TFS6@]DG%ZC%H&;W!4NB\
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M6.:BB,G"<2*+M"3L32JZ/=8-B1>O85)%.+HD#47S\E8EFUV2P*W.CWJ+<WX
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M98-0F!<3'<24W#+FK]5C3("4?\F2)"Y*ROI8\9:Q6=P57VQ -W31R8)@BP7
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M?_$:/A%06'$A02[FVO7+0([=?U\&! 4TP(1)22V*&ED?%Q*Z(6ME#@)6WH*
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ME@ <!<8]"1 <4<)2A<7]MP+\Y,ZK'I,XO$RR0+W*,I!QG#%/A#=*EM<) &*
MB$J5(H\)(B;II?U/@_37O-J4X?8VST*,Z2FKHO56IO4W2VVWG)EDTI!-5JJ
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MC19J8$AICU62P(1J(LQ5"S:X9FQ+.!Q$>]X9:<,]CRPS\LD?<\JL#))KVSF
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M?>\AXO<'NEPIC?#O_W#R;_]&_N]W_\XD?O?'D_???SCYW1]^AX*"+F[>DR;
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M:P&-@O^W N[P,TXK;'HM0!1SNPTN!SG<]![*@.&* IB04*T6\W_\L$9R29J
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M!$#=:>;;^E5C@= )/\D*^W@@Y*60?R@SVDO8GC#H[M$L=.RU?U@7"J"#3*P
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MC\:,.Q!])YZN)?4N_0W*]]Y;+H,X_RE(JEYP;7+S>A67[+8!WV>M3AX,&RU
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MIX/MRQ3=S655;S)T)OH)Q+X!H$<9'!&[V'6SX6?7TXC]=;'9Y#B,^3U7M@K
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M9G2>2_[])2Z?4/?://L> ,Z)5Y':H>E34-*G=>SFJ;-*\GV=S-)4TQTS0S&
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MY<?Z]L$^ZFF<!=?MWI7IZT>Y_&U7I0=9^]9_&F266&=F'UOFV$-4C/<MKQF
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MV-=I5_D3"[.-N.")0"13WSV4Z>SAA7V9W[[!L&N!W@?4?5HA&V3I53OT2,/
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M%0VDK[-T17.VT8183:S%+B/4O9_$UC4J=FS\ ;^6I^0[O\KLWT.AKB*A_55
MR].=2X1%YGV9(S"^+IA&Z0DIFN7X0Q$IO(O3V4.6;6(C.A,+ZY[!E_)*\@WT
M2#]RF#!>;GP_D6PS-L[L%#9%^>T*]L;J.X"YG".@O;41$\C>SS/<14N3^'T@
M0CR\9 ]/6560?G?!\B/BE.]Y71&UE+Y+35==Y*/U%%U0#3\#N/B>V/L_(*Z$
M6BU$U7P&6W>8'UW>I57GE &J=7<P0'(;DQ\%A]G<;(WLT7QG_5%Q9[UW.5V5
MY_<L2\N<YN[A#ZN\%P8"]Q! D<V?_>);\>0S[]AWZ$&=%@L*.C#H<<N71+E8
MLS >4$!-Z@&4=9!T29O##A8;Z=Y[.>NU8]:&'^FY#):3DQUT8D]/J?.YN/DB
M/'Z[,%=8:E*E8SGAB84\G3/=L3HNLWR)8[>,L_GFF^+<!(,GL&[9E'J,O*N/
M>KLCG?&#;XIQMM9.H)O/P_0[QC2?LY1G+[*,:/8=4T[]/CPJNC=^S,R?[0,_
MZAE12@)-_MTZCN1!9=$,UB?T&/._WJ9_2S^EYP_I7\A_[O^5:JZ#DOE60OA@
MO4D(\__U]OW??O_I_<?S?Z5G-T@=TZU 5#Y1#)LLIY^@V43I,DN68K3%04Y*
MH/.Q-<VJ1%.YT9-*3W%.IWPH"K9^KB'LV) _^>Q"DS[^IOK/',NE4[$]S,3J
M#C5A$G:,1)_JL3[X'B\^O"G"S[7^4*1/&SQ3>/_AJ(EOD4K6Q??>)JWUQ@H1
M.7O@GA+UY2D.GUC849]J(5%'G-=W7TGL07^IT@CGR98RDF<.P:_\Y"G]L;T/
MN<EC?AUH627)MO'J[,QIG2L4E5D;0<G6X8Z:W6P)J&CFXJZY;O7UM\G\*:8#
M[ ?US.&M](=ZC< 1__5?>U-\MS)5&JT@'H?T/XL6PW"E+U=_&[&/H_KKJ/X\
MZM9R6@"((3A&LO[D,B[1?NQ-4=7&4CB>&%PTLOL*K<-M%_,7X5';A;E23WRJ
M=\2GM2,^M?##5RGB$!##,/;&WBYW27))7@8AEG+/K &*.]9PY?>X>)K,S2@)
MXY+H<M_FYT+>>IVE/(\DNT/V<UP^7<?KF%="L4BCN_JI&W:,(_U2!"M).\XI
M!5C;[F""V-ZTL";+)D\J\T+*0TE7(!N&\EZ1]&I_10OUP8-SXE-"^EC=S7))
MQLR<VGNQWB39%F/%O3H+%5 M;(]7>%FTT3Q!C2YKO5;;Y^&X19+$- _+CTGV
M&"0TL7)*\%U?G\E;S2 .JL7LL J!9*V%N!IJ]$ZLKZ <J*6:]#KRAAG^"JH=
MI-"$G=1:R.^YX'H?-:#G5O7UK9,%5?L60,7SO'T5!*%I2,!$[R[C2-\J"C%0
M#:+'*$FZ_8Z+PV@',C6FMJWPS;)W*)<%/D)C:&1AM8@9J- LK0H[8-$["\RB
M-A\Q6$V/3UD4DR"#1XF*46(@ ZHI-  5(P9:]V1]U/NGX#5>_YAGU489-4E$
M0-6Z&I^01X)*(B;J.Q[B]TS.8SH%>JS8,HS^0KM1 52;V*(5GI/GUV_ZBC"N
MN"_*)"CNPQ@3J4)YMUTN!:IEM!"%Z0051HVT[S[3YDF@RQ$K2A%F)$]S9N@^
M4W1!M=<,X,)PWR:+(//V?B&(EP*CA_'LD+=TUZ*+3\2Q2"($JKUT",7QB,KR
MG9H3FH>Y%O>2 -@NK\HQY%29ED\%5BH5FKR1!.+G09QL6;A2K:]Q460YWR(<
M-X=!'%2SV&$=-T^MA2*JAM9<#R5,D=ZYK_RD(CK%*29Q>QPD-R]T@>TIWJB]
MEE885!O9(!VW4*>#LD;)LS,S/X1"*V'NXR^=+JBVFP%\YO,OS$EZ?/\%AP1:
M&>/"<M R*L!J1TNTXL.$C1ZP]&!G9!)!7UND^X+-$HFTG92"H-K'A%+8$*7R
MB+X7R39&02R$)D'(:+%8J2,]B0RH=M  %&*\1A0Q69]57[].D*7L28.[X9,&
MBY"87"4T'4D_1=&X:>:4 :KI=C! \=H#Z5CLM0<D/O> @J[ 098F'V,7C7@Q
M'KYK<1T'CW$2E]OZT%-Q7N'%LL3YWW"0/SP1#SXFP+Q20%%@)Q/&)."%]1^?
M9%Q(FO*::T@%"6H(*VB1[$XI*FFA/GAPAPOR_?#I+$N+*J&8%VET7VTVR;8=
MLPME:K9IVJ#:?19T2<XF5@CJ2F&+6[R<+NHA@RPM"K&R_(0^/(GN?5E%L>HP
MD50(5*/I$(KA3ITWN!;VNZ:85O0>.9O)T"-/Z2I.,:9_4^UU&11 -8LM6G'=
ML:?'3W-UFC[;Z[^J@+IK=ALU2^1-)),!U2H:@..&J$51+>OW^-"*ADA9OE4=
M&1K^#JK*%>#$8:,1\SX=;A_EO,E9^/NYHG#HHTO-)/XL2!(<G6XO@O"IEE6\
M9KMS@:#:<E_6R*?AW;NE*,OKR4+*"F=/QW1+*"$KGU[)P>0+K9+/E#UM*ELR
M3:K6_$K$0W91E/&:S&T>GO!E$.=LN<\VL>_$@D#Q9%<KE*E];Y:H5R)ZR%!3
M)B*%(EHJOV9"@DN6W==WB$EXO3"OJRV KZA)\<D[\:)91//NQD\MUC.!U[L4
MGVH-$T"]+]9!CE^;648S$U2?^=>+@VH/.ZSBY5&JA=IY5SLY]GQ<IW/0MQE]
M7# .DG:!I_&H$?&H=_0*('L![I'_&MMGIM^U9%#-OW>S=$-<^PG4?J,=YR(V
MT+'/,-'^AV ,>M?9BU +6V&55"8$JL5U"(4USNP%L=NR]=N&C;B74\,XBJNU
MN054<J :P0!26#QAXF":HO'VBS0ZQ\\XR=C[EO6C%O19E[937\?/XFF'B>J@
M&FX>=N5:,ET'B[IRVN=JZ.,U"+>ND3YJY^78PU_(9-7<Y>12H-I-"W'</%08
M3&=;1,_T=F5T2_XWQ\2^\(S^/:=+W5O#(90INJ"::P9P(42MBT!=&8@7PG8)
MMC#.J=R2CGYV\]/5N4US:H5!M9\-4N' !/5Y3 E2 WU)X[+H-B_$E5!! %1#
MJ-"-*Y_)H75/T(>O^VM%_"R9Z_\E2Y*X*&E_CW$N[PPZ65!-8 %TW!J-"AKJ
M^.P'S6KX3V3Z)D1T@Q]!5;X,F?"Z:;L6_TREO SRZTT2KW ZW%TU#.X6.J#:
M8@)@<;V)JZ+A-C*($>*>=,^$'GU^"O)U<)\E[ JAXMR%5AA4:]D@%<]R<QW$
ME5"KY?= !G.@]'W<L#O63"9P]4ZXH9M-5 ?5AO.PBT<W:"FH+J;7Z>CQI^8X
M 8BN>)$'Q;HJ2##SC/."P*(+)V&0G&'Z*JSBDK.%#JA&G0!8N.K,55&GBVIE
MQ+5]-MY?LS@M^Z>^3#W3J "JV6S1"K$@U4.#$VY >MOB'SC-G@/U-MCH=U#-
MH0 G!!Y<S/>^5N_DJKY/* 5!5;X)I22?8WOD%@3SDS!8QV=9OLGX10!5[C>I
M&*BFT&,4<[U1:=03]WX<XLSVDI=,$%13F%#*#TB<C2YY>6^0<]L&D0G":Q -
M2GF#G -JD$L2-928;D5%5\3.=$53XK(;3X7D/?KVWLLEJ<IQD^U0%*A&W=T.
M12;U;#FXZ<4>GV.7P>BCBV%2L90"RS@-4G9OO;XG1J90JRR+7N(D.4%)$/[*
M[C\_;0L6[175(\V31F9=+)WMDF%'2;S$@XSJC_0-HS!;I?$_Z'TS=M=H20 S
ME8(6Q&X>+;,DR5[8.T=-HO?NUV_1!4.)"_IH),[C-0,7I"E]#(G?R"[0RQ-.
MV]^;?Z1/&71OZ!'RM>6S9\[9:$V3PK>V;S(R]Z!U%-$3CE_G=)63W@K8;/(L
M")^^\7*^@#[REVSO<!G$*<XOQ1MPH@0H8BOA"?-Y+DB:C$NBI?O[:%7Q;A4$
MFU]XQSOC=.E7N%3@EP^_)(^)LQH?X*YK6H]+< U,Z@35<EXK65V[X*K54)^>
MJK$YM$9O J@)*TH!JEX-..'L5R?JF[\]*(8:AUG5-G7LJ6I9]I6G+(EP7O!$
MB+(:%J5^^1V8BM: DZ=Z/$&+DJ=Z9*=*2?QT&\!@-[V6;-4@)AV8_4 /5=,Y
M^'U1)NZID>[P,TXKN?]I?@-4Z0(D\00B%_!4G?2D)'L/@L^RI-4ZE@%4O4IH
MXL(E$>3LK44]57B;].(J#;,UOLX*:9U+Q !5NPZ=(D<+F55R8?0U%?_&4_5?
MT1DS+IJ#PK*J'XD JG85LG&5-W(-UT]0UPBT"WS.TC9;BJ]PAR60ZZ6LET8[
M8Z%?/H)I"S4VZ?MG] 6=3M9GC*E($GA3/@U7AZV5 '40>ZSRY(=<%7'=^I6Y
M$W[?E[0?+<!3R_%DP31*[B[!_QC$*76E%\V:)@/X\!2D#WA-=X7R[=5Z$\0Y
M2X8C:]K=2P74]GLT1IZJF<U1ZK+)U(66[7<L:ZR[2>\#>G'PG/#UF3U\(VUM
MC3B@9K1!.6Z?7E/0M^2H(EWF[JEZBS;HA8<"GV/^WZN4$? .AY@@(WR2-I19
M"U![30 KABE<!7W=*'^#2$,R?=0K $SC+<*0;C 5'3:[YA/U0#>@!JYE$S8E
M]%H13"/>YIAX_.B\?HRTV5Y,(\8[]0K]O)) -_0D RR;OBZSF7JP^0;OT5ZW
M#!1NJIT736EWF2;H=M8"GN25NWDDL-9L/,YML)WNEVLET&VHPCK5(]?ZD!HN
MK^@E;>W.DHT>].93P;5O05H"\K]5]1F79T'Q=)MGSW%$T[!]*>@1GL[!A"3F
M5C:EO3:@!IT!6KC<ADM$RT!-(32]W->T'-*ZW_0]:UN6I_9M$C _9(OPMRK.
M"7W)%*I4+B/HY &UH15,X2YTDSNZS%"MAGIZ4%J(<(KPI]S>TLNJ=#^$_"M+
M9&'57DIMR*UG!FW3EDTI)XB5<])N<+*BH#3O^'RD92\<*D%N3"56N_[8*/N-
M2A6#!'<7<\=%B3:@AIP!>N*XV!;E?UQ4&'O)3]/.;%^)-OSVU8&>V+YM4?[;
MEZ*D_T?=_W.08+8$1M^BI:>[Z0_L&<[^/_0D^6:1&/C7&P\7K^$3S6-T%Y3X
M8KG$H71D=HL $,\\&2Z<$B$%GW"V]LH_0=VG$1<)V&.J@W\<:G!,2#*7.T$M
M,M1 0Q0;XN".D?RM1>=QL<F*(&'/;-/4;'%!ODW<-YFYMH_UR \9.?P^H&,$
M7LP^'.T[:C>0ZA?7J68?%>I@^3J+WST,=8XW.0YC!H?\.<'LS?)T\ +5I!G6
MOLH&Y*'W;I)PHZ#W4%?_"R>H_09C4?\K)[#F;]VMMD1ZJ^V1@,M281UE@AH
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MO3+D1SQPP.9E/\[X#W+8%46A@..$2.K$VS;4141S$E5=.J-)D(3\2+7.P:Y
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M3LQ4<1_3\"Q. ^V^O%4,BB_B*50B%@J\1T'R*RL6>?AZS=*0$'%]DJU&&^!
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MF@A4E<=V'AS"EEYV=&H.F8R4F8P^'C(9^9+)"&]_76>2L=MF:RMYL]L&T@)
MP(-9;"NY8?$SK3C($+K@_*:<U8#EJ)>\%O<7PV\H\'.Q0&X?=I1 H9M5%/E)
M&<]R77:L3,AP29[+OVBW%:#JWIR\0$,5"H<?,VB_MY6V#F>O5]^; ]= ^A2
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MN&35<:NZYZF7&-,&RL4']SHMK#N&]B,3VQCX=&S8Y<@_X4>JLX RB'/%EOJ
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M<ZIV)\N&#^8=N]YF&2%MHE9QHTM(;XC8!D7"@GS&60GB?_+MJTZRX6TB;S1
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ML#N8TH"OG@WS5"40P\F0H,%SWG\J^+;3J20573NC*O&?HY3/(FY7G$=:)'L
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MK *RY#,PZ8B$<$]>H.V-+/<L/G$&'1+0OL +\J*MI!PC8R9:#AVX%>@2EY%
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M7/)0:=5@=/*!6AK>&HZO'\,7>+[/*UD7?ULU?"V=?T\=OL[N/U!+ P04
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MZ"))@ULJD$>K9>R$^ED92(S&/HXN0$VHDP@F&49(N OFHS,C?$H!)PY8'*L
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M9(VDH.[FZ3%!SHVA>7[LGBSYY($REW2)I"*'FV]/SSJ22%>SAB_39^F' V^
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M,Z\58=@;"(H!8C[I2A.GUH-D0Q24!Z#+FG0-OS-ZW[@(CV36'EF?ZOKRB;^
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MJ*D2<BM@# !C 1D848:#H:M)*7G0P0# 49 ZIB8^?1>4J;<L%A3TH"Z:T,U
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M6][7(NUD7$U!;0 ]SU] T+LCZ(?NLC]N LNA%@O183XC68(^ OP3D:NC<Y:
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MB)^?!.$Q#[5+=SG0'^'$SR=@"0T6XN=GT<_/&XB(GY\C/S]GX")^?C;\_'S
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M1C3!67]&B2, 70KX]B<X-P-K%1:%7VNE4F^8?ZF18% #68&!FZ H\$=4PF_
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M"=S=Z9J$&LR^+<+!E[0IM,*AUJ@C/B5"PB""SF)9$> *Q<2H.4*)>ZLICMB
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MM=+O*9:ZN%AHLB0_A]5#FXWE[R6+&PN)E @498'F_\ZA1J&_(5FB\_?F&V!
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MSP5M!Y:-_MB\>Y#;%\.2B,_9\+BG=P'8B-:ROH$)XO=YV3P #G\@"+SF[#&
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M5(0\Q'69J&K70R0)%'W$4"Y)P%&U!5P>)@K_'T9,D>U3I3U.M41BB11+>3+
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MFT&_ (,V#+8*RZ VIW$#50'QOA5#K1QZZ)--%0@Z";T3(S* W@X,N!1>',+
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M2.*E"3E_=M/&BB[QD(-AW($P"17Y59>-T@D[/>YF9_\'6SX0M!!:3D"%%2?
MM$SZP%MBJ#P!>]",JB"(K92W9&V["%4-$;H54$0*5M<$L@BV>W2Q]C)BV[MR
M0U$RBKVJ(+*6"./WA<.7KP/L?#FLQ?;_W %A AY0 SQ[ DMJ4BGO/-S"U(-B
ME30\'>"I3#G5]O0]-::A>Z&#@=#9H>J%S6&Z/#/3B> ;4PF\VL@!P4HS\'=A
MNK7L"X6<L.*=LT/LW"I(@8'RA'M#%:<&4QN))DW3)U,CO$:), YA?YH%LE#U
M0G=K I>%WL A;!#T54GD0'"\\KA6:$>VHW5:K7;LA#\LYE30[M!\P2T/,EX-
M+8U5*+?5;]JV1E4P$VPHZ_<Y%=!5KFDT<L8W$(T1--PQ3!/H*&0RXIT!,I&\
M.(3)0(2F;V3M;,*9Q:WHE\;'X&V(AG*(?9@&@&XN)\$'#XQ%&>=A9C3AU1\D
M!DR,BK Z U!C=2BF9TGPP@QZN++-1# %JAZ!,Y*/ !' 'F!X*0*;*:I&W8;L
M0 +)$^;5C_%=WFP2)V;<)_RC,>,QMS[CT?X&^ ":@'/4YV"Y-"RP!B0T'C;@
MI %,X1H?0W$M_!XZ+&O"@$$?^ZP'B'%50.(])20/T/BFZZ.+G[^%3\1V?W;U
M;K+?O9OX>C?9[]Y-O+V;J-O?8N/$_)R#E?C]*BX<[X/%K\F[S9<B,-4\<,F0
M=3Q5H-&NP]LV5<;M2Z>P(?RGOF71:7C5:]@)NLSI/')_X8TK=/'X4-ETPT47
M3 _8<LVLBWGK*A<!J1IU,"/$"@.#%8YS/51%Z/@5T;>Z&-<2_>CQ@NE<;W\%
M\.@5"ZX578RAW 8W!,9FY1##2W!O?S@'\Z-PZ!/<$.!;*T]IW2.;$%[HSL'A
M>4.7?0S.UOB#VZ&'/2/BS(Y64">8<;L W%K5F!9N7>UA]>SVQ&-?1E@ZX'1T
MX(GGS)H8,QPT3M*,JIHV%U5742>()&6>4WF-J"G@?^Q<W$_X#3.F:U:[-?OV
MU?.[=52U.S!XV0H%JUT[YY[K*5-Q0-!D\:A YHF35=P(H4YE,_MNL&%?T6$M
M!=$ /\\<R4'$J O(VO4U*5U3V'G')1TQ ;1?U<9_C 483QE9=W2[X"CI 9$B
M#"%A)(-NUGBKI122@1N-5&$$GI$W9%KE1-@(J?<UV ,&"0H;S&;FTCTO!U:+
MM^0_MZEB4,!J:P(S#O55!,1*$9BWVL(J$N05P>@MF\%$ (*BLO:'/H"N.%>5
M/T#X1;!1N";!R JL77O:^X&W^J:"0_K5[EZ#=X8H1C40D6$V5K4O'F'&P\B!
MS%1%LMC2I!6DA_D;:\/^VWT8@W?&/ @/79]#=;7:&C-9?*19C&04 '@1#&I6
M@T*:/C1:@6$K%2=)PESDS#NNS64;A6*K)^;\CR!/C*WZ+&B(9&FQQKY#B'LV
M)GY2O\":C.HZI6\8",LV&>NTC(?Q1E2(X#S$G'ERVZV4^32? S/2!#]IG^7
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M QX?Z7]\*Y$WQD)_"%!>P6Y5\%OP%B#(')!7:$_6\*G-6= B./CI5%4^$8V
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MHT+,/A28"X'O(G[2__ME74;,H&@ZTP-K.R:\=YPS=KSAH:$=-( 5@YD:&4Y
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M%TF<%?QASQ38F?)Q.6@*.5.V!KL8;*U3Z::51CY__;RIEN:O;X4 1?QXS$K
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MTZD* A+T]UMH,S7D3 2"+ZAZPA<D]&X,B <;I#= #[JU>O>ZVJT>G;1O[JO
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M1GAOG8^"-^6G 6M<C!DC)I1A6]5H9J#S?F-N3!*57FFV""OZ^U.?J9[/:Z5
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M=Y)Z+-!VYS8:28U?&'[P_GM(C=78WHOQ8Q9Z2)V3T_;81HJS<MECAD&2[7+
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MPP$O7MM7VH\LDJ7G.Q!TNC%F$-KU2#9[C&&)/?P2 W.88'<TDEH6@T37Z%?
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MO*J^7X]E_F^@;PI)8>S(G;M M&X4HH6M<"0=C,.'$%'3VW__T[NO*3?B!XH
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M"WJF5QJ<'EOQ?^N_SM?@3__[KRG!_]/A_\'QX/_B8XXX<!T);WMMA-D5/WM
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M:$<N$-,Y9$MN/[-M_0:BI$7N,>[J%_^42W<:=A.@1VB=VH-V9+,-9B4WDOT
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MJFJ0_R=Y@]GULE%UYQICX"5 &[==.RYDKD]->G&12#=HKX2$&5(L49:HMH'
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M0SII8O#@2R0+_Q\68UWR:^P,@6_J='1!1R'V4L5W"_NB.G1Y9UL'7KROF(Z
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M*2XHIC%WQOTP4?=37HBS[%8D5/W=G-Q>7OQNU);'-6Y[4;K+:+#S\D@Y%NS
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M>0D^ \<G/7OHOHL7OX<?O\1-K,6=L?Z0BYHAHV WID^'A&J58O0$*A=-O;!
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M;)VE)*,0$2^Y>7TD$.!$<GRWIL:YH)(3"1(\MQ4LC:BZW,D<U$P(X5"2 :^
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M4RA4TB0R6B@#C/;?INF01W><E6/_<#BENUC>0G/BWA[;&!8TRYL2^'5:P0\
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MM>"6_LWDK.B5"U*[BKIHVNSG) +54"0HN#/RK?-^F8TGDA(#M2K;\))P+CE
M0E<&]'5&_LH8W,DMKW92A'Y(HR!]P_J;A2$3">:V.5+E6@,&XBZ,&373':?@
MK1)$N-V(FL>T+ZG%U(15H,(SSPBY-Z,T9S*1"9I E#).G+%6>3K@O2BWO&13
M7V]FTV*#>9'&<\A[6@(!TT-*<'P*AY8.AH&Z(]%EGI1[EG7!>:0YKDO!6T[@
MBS:N2>GRT"K.O@8FRQ)%B^2H3,(1<_VE(T_K@5(-O,I#T+@J'-9XZ90;KR[=
MF@J0(R&.X' @:DNQD]+-F<XQ5L.1?L+V)NI?*/>4YABTIV(?FH!-1>T/)PR-
M&'/9>M4^=D."J1%.W5UF/NZNU?*3"*$OYKW^'"TF#:*_?/?TU_<(+'W73B^/
M*R]D52N+EC,K>0X-0,"NQW-8EF?"^O)KZ(GE6B\3=>LO-=NAT&7-O* ,JPY"
MJ7 @S)R*#HGSILLE]JP:S.DL%!93:W4(&V]4L%HN&HU^'8[FRQ1<YM D]=8"
MAOC]&K30G.&8I3/ <!BBDR@%H_+Y,E84>BO@:K+KR1S783$\FA-I+C?I1(M#
M.@UQ&KJ398[<D"".<*YR9(<5V<7A^47[*/VEW=NL#+= VZS"WV6>3!D/QTJ$
M)T;HA&EM)NB\BSB&)\&-1)O+(BX"SX3A,D[.BQFB43 G2OVF]\+K4C,UA<ZJ
MJN]#UU\.*+G6!"MU!@8A\L%0'LYDI72^QA/ERS4--A6N0\9_+FVCZ/MKGD]A
M&AC+[ .)T=BU;-O74[VRCG\&&IRTS&,NM,7>\2QE*VY7V<$\'V9%YENHK6WX
MJDIZIJ#NW$638N<$+3I! F[1Q08^]VN(K%S"7)FT[&\4&@I4J/>+,!:_Z:>H
MO?Z%27ZCP.>/_0W[UHV'AK6AUUS"[>+>/B/ADYZEGPU#L+@@=N]T*Z^RFF4%
M.X,MY54;C7-ZM?E- A<R9FG$$JW=S$)KEHGMQL ]WZQNX]Q6HS(N:0, YP%5
M9DC/3*L: R&SS+SHE!R 6MHY(FO^KT<R#=H$'E*IV#@(IV+S&S<PM!3I#IR1
M'54AJR,%P5L\$-@EF(;KC7<K/Z1JD],GEW\428./*@D.,*1[2(-\/IT5Z93C
M=(SUCT@D5N2]I(YH8"5K%0O6I"D,I>&('#^. 0_#(HAB,3<Y]YY)! )>;6!I
M!-239P_<<SF")]%XTK()9PDO =,X=U&L-677*&*3"C0W3F!O;R/& 6M>&^%4
MU"X]B9Y TE:])Q-EK0I8\Q(ZBV0?QQ.J6%08BU!%U(5+0"J&Z@W-)4!"8S"3
M$$^9^U=I7**34I9O@K4YCX;ADAIL&\4VBU )J4 &Z"T"0NI=/43!<VB(=A>W
MFS>EXXCP)$'.! QQQ-@11R*M1<8CF<8)Z/8XVH]&=BW_Z-WQ.8(X#J\'\@P:
M>'T?(HJS%"<DY)G8.A))[/K@+DBG.%,M0VC0I],TU,TO(7VW*M2KMA. 2G&8
MJ0TJ%!W]"'ZG"Y2?2^N,6<CC"^I(\[K^,[LQGG?\0[IY(8=Y9\L>&F.]>39C
MHS >>Q<#4!F$_;2*]49LEIGJ/?MC;3A22 %ZB*2@R-)AFG.G'"TZ' G_^02&
M&L.S EK*S]&TG'HQZ@6XV5"KM[LE$2I&9[N9&D1@;)*JZEV%CDRQ?R%G4WE]
M+=%]DO)^@,5$<[I@X@3_4)C.N0-$P;U$8-/*:&4HZT/[2*;![H4GYC@3#1D:
M#1N7K77U6/ :6FZ'#^NIW>@,:F^!2+/.S;MYXNVU)'VMV=] X()\LJ4^0)*6
M-@\L(70Q'=SJ0+>MDU,L4,V%6P+QP4A"V]J!KC#*2DH_.J3LT)Q1"A>T\D9-
MF8HN2:/;10'(#R[6+B95"XLT^Y17J7)(CV:P'TE*B"/5J;IH7HT[!4;#Y#J8
MZWA'Z-' #"K8,! J : G)2QN'@&WA>2UT&5J,6.*YJW4-K?5DSDC&]>G\P<P
MYR\-E-8#]$NC:-\]=/H'?T_WC(!>U@I,G6H[V^8P_UX1T2?X K^#[?JWDGP?
MM-1D'1<F&7C^I/IP*/V&;$[+>(61,*W7 <:.K]MH.[.4 T)J\3AK'*9@V6/[
M;[:T&M. >PX_G+5WN_N6>XI[*#JY>K]"#FW;GDHZO$F OEX*1E>$M$S6Y/;V
MMRH#ELW+[CZ,R;TM;D3J )HXHUF9YG[WIZZTA&2CUR^NHT'8O@[#3TR?1&8S
MF8/27T^RZO7 4II9@QBKT04"(?RD:6$OT!:J[7*&3EB2OBRN4_F1].6V[G0#
M;N5FSMFXIG6&R\DA"[=ET]NPGY4 TM'"[6C/1OI?VYS4,_>T.Z!.1.C>ZV]!
M8F^UUJ<_0D[?&=6]MT9U/R"J>V^-ZGX*J.XG5=+Y6 =;_=_W[U^ G]V8V19G
MPG><B;HG<0=KM.E5//!R/6;=5/W?DP-:U'ELEO-[?%./XS&LW0_8$3^N@)>-
MW1BP![;'G5I>VSU=LE05;Y>I!S#0OB8:L*+^OBL/DO<%'J0ZRMBQL[O;]=*&
MP#\R-O:Y8B%)K19 JUK6W?/WMK3!(F.U[-.#/V;G8>#^,I:65+B:(F%Z:C[A
M&*/E+BE\B$WDQ6NIS7KBKF4]"]\TK$_2I-F[VA, ;(:.>C7 N#;XAD_QP$PE
MCW6/_H%.(P?3G0BQ\/1GX421ZP;>ZQ8KLYO)KKC6+6MUB[1PMR5)]O>TJ5N:
M@P=+,7N;PY#SO9S\=9O;8A>V:@&![E[CO#FU0:9 !F?J\..'P\NE7-H-,,A=
M>;4]RZOMTUED>7 1SHIP*J7CFEJPXQK0290VN+4C3NO&G.FNJ*I:^9J'.D..
M@S)1%%M56.1A(GG'/R4W'9'U[A9#BK?J0Q D5',DLC#T6/VZB@IA8):_OQK!
M.$-GXRLN7&HD$E//CEU+ZFC?TDX,9Q;NO3B5^CVXKZ8.:F#)=9%UC:0Z@I,P
M3@F#LLWSBF2AQ)Q![0#D._PMP6 SJ1+?P6X0AIR-I;[$W1"<0D2UE?)#\'XV
M%_$FS7/ $TA#I9RT+'G[\Y"M2N+ZDD2:3PO>'6\':UX?1'^N<\4-^]+@K.7_
M]0PQ.!*TIJY1SYEMR3A$+C?JE[6H7.VDK"7QLYJI@2\Y8)R &W,G[3@@C\:Q
MDVT=9#VZVJW*)Q%W=&H7P>?&_3C3!L&TO27#?03V(FW$)3DHXH]$]#!D, )#
M#6"?UP.7.*4I,X8P"YMB/=-DB7W&> O.CN::A'<:A7@V<BS"A2T/[5Z#/@E&
MKNI\JX4H)@SF%%64@Y*NG/IX83,6;=;2B9"F-% PQ>XX/80] 8(8"W1IS64-
M_P2U<+EL0)7T:!*.-$3VR?GKFG7K284H[2JWBFMQPJF5I'9(,PLV)>D1C!-.
M ? X'9REQ*09FV6UA#Y$T[\D<SP$S 7GZJ";_88%W>84L\+;JNPX-TL6Y-MR
MBD84TN*9E3+=%FVVTU*4+;"QWLMJ9C:U8>IOJF/1DL6"46$V^9)S4J72$8"O
MO\2E;N8F0-J>D 7)F*K\0<@); ;9.M?:F_+S*]0L'RJ:\LD']P79N+N%^KKD
MB@K[]?J!^D7UFCI1WHR=63;XF];-CL4>+8!N%1/1GW->PN_V6BYM$ \!7KM]
M-4BXF_R,6T[)-<X VV7L$YDSUR0_"BM>'K.-3'G9E+XHL[6+\<QF2@X_NPII
MLN!<B#"RTMOBR* ';Q?%-T:.*M0YQ%O">W&,WY&3PQK ],IRPPODGTO5",8)
MR35D: I3IBK% S/.HS@@$5F(8 4J!&A?FYB5D80=&P<P!?WV 8$G;%KA<)G/
MQ(6F7!\+Y(V<_(36A\XFAG+^7\%T]NJ8WF,P%:U)SR Y$3QTQ?]CW4G/,VRZ
M%$7S0<-8;Q;"6#>W>))MN/EM\36/8<6>YSZX>_B\B(/<0U$/6:_O$<,@R7B$
MVI5B'1W_=B+N0;OI)9[R5NP;RY<1/*8G)B.A9R7] K920 J,26JD8$^EQ)GY
M^M!\7?E_'* #X80%A&<P6O/&K3R]U;G[RW/YY>)=63WSYO,ON%$F9OC^_1$0
M\S\7P<2'_0I#+HY,^:3I^6D=55Q=D532#/,2=(W@IV2'4VX_$5BW4BQRQWF=
M*SET].=_=G=11A.KAR0@\ND4.ID,_D\=_R-7]93BW@S0ZS(TF'2KDU')!J4[
MI:U;J/=B@C%!!!5MAF>N6%SQ'ZUVUX?LE@G]#)')_C0J=G(34?W-Z;GJ(-74
M"5Y\QRU35LO?\SD20#(@S!SYZ,=*_LDE##F8.Q!IP5:6F@21V!P Y)_>9U/7
MSOX1'PX^QX>\?ZNLU07\4HYRPFZ$0Q\A3LY(LCCV^J&[!J9I*Y]<GH*.&.60
MZ6! 8Q"ODU::UXS^VT+6":/+4V'_(H].)L^M%C#*WDZ;Q@U0(&(\0T.TI3QC
M$#Q#H<\!?+TNIY#P$@$UP.V,_4]NH4;R\PF9R1IMJ'QR,^8^2G3SDA98PE@W
M'%N&'^(O9JP=:7WO32.Q?LG%FZ,%H7"K[*37P6]"*@.P80SG&(VOB.*%IWK.
M4U$$& YB]L0MRY A&L%01,Q+O)G\"HZ;,U@1^SK1(#J[[3R#*.>9#FV9C"#J
MG3. ?@LHFIZ8<H+%I6,G):>QYJ,H'$HLX:9E6SX!\_2%<>/W,D!F3IE[W=;#
M8Q'70O9A)R2B37KBBG 40*W0&4J)&TM$Y@C0LVN%(\2HJ/RF<)P&GT(K(;7,
M@X1-%B(AOT2".>%%[]+6!M&8RAD)(1%PN>DH/LLB.H'XG$<DPD3&,2T9+2T5
M>CI>S8Y5YL6AF XB91V9I/,222L93@E[*/60]$ :<+1,^1!J/)&T7$O$K0U>
MUL@BN.J021.JJ;<T@1F83K #2]594R722%V>+%)?G^Y81XA[T!T@IRUUQ(BY
MM[1]B:^Q>Z@"E$C)C=:']1%/Z!E-!>FR)"P,IB"_5=^+85\=2%8_F>!\Y\H7
M$V&',V4<$[F&(K4:)YL-!U!'#-1C(*GFV2'8I(X<)N--,+@)!P91/:F*GT6%
M<H=*QP#0\&>SE".+)/00(5R?I&\PH2\CZU^ND?4/B*Q_N4;6/S)D_5H0/#C_
MV "%;$5-7W#<G=7,AR@!G8%_QB;G!KM$(\L+#AZ)?UV\(2<^1#>69/-V-29!
M*B4,GX'P+!%X*ESJ8#Q&S@P9:Z:+88KP[D'GX.!/)K@!.A00!#.5K]JVH@TK
M?_PF#4HC#S^'@[* U_=:@%?7H7JVS&86%"T/S?5JG%\">1*[<Y+&F)R!.ZP5
MW".>D.75XRB)&_LU. \V;[#QA9E7@M;DY&F(BFOW(91AU)A\%(A(\F @+H?P
MV"4X!E$V9!J N6F$PW$CSQR5&Z,1G5K ^"I,A(R5(W.I,-JA2C-,QI"?3. W
M!UE+P@BGH,A3Y5L"V0<[E_@Y.)GP;R\',0D?; Y=9?XD'([YGQ*?DS/4P<!J
M,:'%R+W0O!]>?I!9?P#)B?]7!BA%.8]WB!\:FCSQ&+%\'MN$SKJM3\TCGM!A
M[AD4C$3#L)UMTD-PHUD67J4#L5>J,*X;#U;17,Y4.$OXFN'.M0BVA.&"&EBV
M"@9X-IIW\_EIR4-$L#MWN2$*KL* &W3,]>@QJ[HT]7"F,PJE]1;/Q".[3^"X
MW<Z6548+,6P))MYPLVMN!QP-[SQ@BRIAH%*.\RG1D.WM_=;>UM9-P9UGM!N?
MW?&"T[\L)*T1Y5M#\=SHCB.%--9T*C [M:%,YN,ZR!A*CC$X87'<'W.:"HR-
MX_15TL>FCIC')G2Z*=A\$>L%C;:%-P;6A7/*IE@2 (YR5D@S4FQQ,5_OS4<\
MH>.2J1_Q"C7K)0R-_2#YE)6S8L",_'D:7R'HU*+-ESJM!?&6X^A_RTAIYS2F
M!#I@?"69&N?#EM(<8ANSQ6+_;#&*&&#2<*3>!,94#<./@VMF<TODGZ8$12_A
M5NU]#E&3A)0(5J3=>Z2]($[(()H%2GN/3Y055;B;<&,QD#P4L$3#"-%O32R:
M(A'EPQ"J6F=F"H!S)N2;BAZF"JD>Y3258/LIRJ=1;B#/])B]+?)JYCG[)$@-
MXD>FY0>/T>K;*H+?5ZVV/FF/>$+0 K>(;H5&BC.0&[$O7H1L-R-RE81YBFJG
M-(G%^3#AUVIW5C_GA*M\H]A/3F3C\;@1$N)QU7Y"^6$;ZH$-MR7WU>RU8]XY
M27EC>;'QHX$#;MP:</&49U4/+"BXYEJX%.:#+)K5M-2A\U@:,RRS"*E</9D1
MO*6"W!_RQ?IS ?-SS$Y=FU$)= .*OFQ3D>J.I@L:%D-3S8@:<-N9G-Y>I[LE
M)#7\SUV.#Y1<%;'M'R9)R:W!N$:-IOD6=:C=K?;?UX?Q*R;T0Q"*%^@?%&%'
M+C'7OC]&\4F_P(4=V?L66,2YO]V]&8E8O<]EANL=08D,H-<R=)0#@%420LJ]
M_-*)#YD+/>UW(*VY4.7#4%<>'<I/2-HN&T&V"#/T+<R0IFAP0@UL7];R-Z)-
MJ8<37 OWM3;!(1UTR]]M[>ULM0YV]QT_\E;(U@7_S!D42"R1:?+_<ZNSM=5U
MX @;#LJ+[G6!>]G5@/C<B,P049)@6G5E3,,IE&369;]IFOX1F3GD'ID!J_[,
M:X$(<(F9J#(FR$ U;]G4HR*_>>J'_J]Z]PJARLT-R8W/!E%N !ET'UJ+[;UM
M9RTP71GJZ^90O2\.=>E;NG6HK\T_&B/VN2P]8-**BN[8SJOE-<!Y=/-[SUE+
M"NT-> U>5W_:P&L_-'<+M&S8RZ///D/O<NV@[D8_),J/N_$MPL^S"*U LU J
MKJ]"M*GH[=@;H&4&$%M"HL?!IR_>G@?O-9; >NC+8RYR!TS!AKSL*ADKS.[/
M@+M/C%@\N0=;EG8ZD[ ;R.\7$'V*2A+C1\TA1[0=#@I3&\K6T(4BZ'8V@LV-
MWN8-5V!JYR6-?7=K;Z._B3M,RUAQ3/  62_^4!OFH37&\].!OX85\7DE1L;,
M46[A';;^TM52')9%0NMS-*5KR/S_SUYK:^=E:V]_OV4("FA#*<O!**R*PLZ,
MH"9EJ6$L3QQ]%%5.>0=9+2D-@%&]',SYJ##&1$2%J!:G?,R<#\&AU$X)'<$P
M'MT$V52SV[MH;_L;;P&+_9AV_.WM[79OK]?;W]HT3O<-V,[48<K987NBQSG/
M8,K-'9:AVQS!68O?79A!66CS<]IPS^\(G3FU'+6DQ4WYA"4@SO SFB^I0V]R
MRQRW@1'#09M0RI[R2@C#W=98CU/=CHQX33&U*MEN,IAL7P@_NW98DN!L4+3I
M/VV%5]HC.),&!)7^7SC K!*W92P=[]#R,4&O7G,A2C-?ZM?2I&Z>S]\P/<$"
MI:RY_/#%(6PJ$:TN!P_(6Z*C3Q++%B6924VH7+%N);M$]7T8"'T+?B(F,.*"
M'-RNN0CHT0N>6S>T@B$ZTJ>J\3$WI7%-I0^-!#<D:]NJI8#QNP/S<HW\'<1I
MKEG8ICANR>MJ<=*V)>L).@(30[T&5_XPRA'BL5E<NY>^L"G7$NA1SPB&YZ)U
M;5*-CCE:-0JI2,[J/U&5VI)JAVI/2&&X84QA0_4J-*VNYV+->MS0B9&FM+=F
M<53 Q);V(F+NV@\5"*HY@&4Y =/NP!$,TAV*(WO]"ALAX_?,%.F(H^7M6_2Q
MX29GL7M,:CBDV@WL&FU*^8] RI4]0AK[IA(A+.;B1?"G[&!JHYJ0H_XF7R!
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M7 >F)1()K4)L<C)_RFD9VRS")SJ/6#9%LI!5UZ(CQ28;^ZZ2NJ#EK2ULRXO
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M1J6<).[!D:>78U1GV<>[(-5:Z6ZQXJ&5LVG!Y1PZ0I>G!*P)&C#BWU2Q3P<
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M>7OUY-=9EB)]%"ZK/3.$/I%E5'8ZACG-1+E=DO#:@_LGGT79BAQTS*Y>ZY1
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M./ W=O?^M.FZ/*MY=$4AS8MP9T8*<H,F"\VVW\]GE]-H0%M'P-?TRWZ<ID/
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M;#">G/B3*"]2SE@4D; IK<W"I^6;@OL"=!XVW&+@IV#78^383Q8Z=B_<&&]
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MW46-(MC=4MQT9$2[E;T#[H3Q6QHE!GHQCLE COU)&,2TVP&XYWHE;ZGEYU#
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MIV!:#&T?8F"T^%)&,R-* *8>SO(WN)5@8BA,#Z@$!%-11"_06^QCH(MP 43
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M/&BHYF =2,^RJ_-;>LME@ZB;<H2?\6RYT1XLYU587EE)QJ=+*3:&\)&HO6E
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M-*JM/SK].KP.$S@VDDOM'O9W OJ2T]SA.LS]41G/_&%8YF Z@#6>Z\H\>/M
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M_P]02P$"% ,4    "  +A6Y97>K"D7T1  !JOP  $               @ $
M    86EM+3(P,C0P.3,P+GAS9%!+ 0(4 Q0    (  N%;EGF#E6+_!$  (O>
M   4              "  :L1  !A:6TM,C R-# Y,S!?8V%L+GAM;%!+ 0(4
M Q0    (  N%;ED8YFH>S3(   1B P 4              "  =DC  !A:6TM
M,C R-# Y,S!?9&5F+GAM;%!+ 0(4 Q0    (  N%;EE:@3=_&VP  (90!@ 4
M              "  =A6  !A:6TM,C R-# Y,S!?;&%B+GAM;%!+ 0(4 Q0
M   (  N%;EG?=[_^.T8  -/!!  4              "  27#  !A:6TM,C R
M-# Y,S!?<')E+GAM;%!+ 0(4 Q0    (  N%;EF9DLXN1@4  "8L   +
M          "  9() 0!E>#$P+3$U+FAT;5!+ 0(4 Q0    (  N%;EG-.:HU
MN0(  )HY   +              "  0$/ 0!E>#,M,6DQ+FAT;5!+ 0(4 Q0
M   (  N%;ED-[)S7: @  -5.   *              "  >,1 0!E>#,Q+3$N
M:'1M4$L! A0#%     @ "X5N62=+WS94"   7$\   H              ( !
M<QH! &5X,S$M,BYH=&U02P$"% ,4    "  +A6Y9XP3;_8$$   B'0  "@
M            @ 'O(@$ 97@S,BTQ+FAT;5!+ 0(4 Q0    (  N%;EG8Q6UI
M?P0  .@<   *              "  9@G 0!E>#,R+3(N:'1M4$L! A0#%
M  @ "X5N6>+K!BB, 0  D0,   D              ( !/RP! &5X-"TQ+FAT
M;5!+ 0(4 Q0    (  N%;EE4R[1G%Q8" "80%0 ,              "  ?(M
D 0!F;W)M,3 M<2YH=&U02P4&      T #0 ) P  ,T0#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:AIM="http://aimimmuno.com/20240930"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="aim-20240930.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2024-11-11</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-02-162024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">AIM:StreetervilleCapitalLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-16</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">AIM:StreetervilleCapitalLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-16</instant>
        </period>
    </context>
    <context id="From2018-09-122018-09-12_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-12</startDate>
            <endDate>2018-09-12</endDate>
        </period>
    </context>
    <context id="AsOf2018-09-12_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-12</instant>
        </period>
    </context>
    <context id="AsOf2018-09-12_custom_RestatedTwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:RestatedTwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-12</instant>
        </period>
    </context>
    <context id="AsOf2020-08-03_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="AsOf2021-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="AsOf2022-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="AsOf2023-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-01</instant>
        </period>
    </context>
    <context id="AsOf2024-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_srt_OfficerMember_srt_MaximumMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_srt_OfficerMember_srt_MaximumMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_OfficerMember_srt_MinimumMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_OfficerMember_srt_MaximumMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">AIM:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-09_custom_SeriesAJuniorParticipatingPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="AsOf2023-05-10_custom_SeriesAJuniorParticipatingPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesAJuniorParticipatingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_RightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-072020-07-07_custom_DirectorsOfficersAndEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AIM:DirectorsOfficersAndEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-07</startDate>
            <endDate>2020-07-07</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CommonStockMember62774140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_CommonStockMember62774171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-26</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:RepresentativeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="AsOf2019-09-27_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="AsOf2019-09-27_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="From2019-09-252019-09-25_custom_AllianceGlobalPartnersLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-25</startDate>
            <endDate>2019-09-25</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:RepresentativeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-03-302020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:RepresentativeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AIM:RepresentativeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AllianceGlobalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-192023-04-19_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EquityDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-19</startDate>
            <endDate>2023-04-19</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EquityDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EquityDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:EquityDistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:MaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-03-282024-03-28_us-gaap_CommonStockMember_custom_AtlasSciencesLlcMember_custom_PurchaseAndRegistrationRightsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAndRegistrationRightsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AtlasSciencesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AtlasSciencesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="From2024-03-282024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AtlasSciencesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-28</startDate>
            <endDate>2024-03-28</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember62774609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">AIM:AtlasSciencesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-28</instant>
        </period>
    </context>
    <context id="From2024-04-012024-04-30_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-04-30_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AtlasSciencesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-06-032024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="From2024-06-032024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="From2024-06-032024-06-03_custom_SecuritiesPurchaseAgreementMember_custom_ClassBCommonWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBCommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-03_custom_SecuritiesPurchaseAgreementMember_custom_ClassBCommonWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBCommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-03</instant>
        </period>
    </context>
    <context id="From2024-05-012024-05-31_custom_PlacementAgentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">AIM:PlacementAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_MeasurementInputSharePriceMember_custom_ClassAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_ClassAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_MeasurementInputExercisePriceMember_custom_ClassAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_ClassAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_ClassAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_MeasurementInputSharePriceMember_custom_ClassBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_ClassBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_MeasurementInputExercisePriceMember_custom_ClassBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_ClassBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_ClassBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassBWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_ClinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_ManufacturingAndEngineeringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ManufacturingAndEngineeringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_QualityControlMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:QualityControlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_RegulatoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:RegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_ClinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_ManufacturingAndEngineeringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ManufacturingAndEngineeringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_QualityControlMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:QualityControlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_RegulatoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:RegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_ClinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_ManufacturingAndEngineeringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ManufacturingAndEngineeringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_QualityControlMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:QualityControlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_RegulatoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:RegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ClinicalStudiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ClinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ManufacturingAndEngineeringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:ManufacturingAndEngineeringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_QualityControlMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:QualityControlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_RegulatoryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">AIM:RegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_AmarexClinicalResearchLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_AmarexClinicalResearchLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_AmarexClinicalResearchLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AdvancedPancreaticCancerStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AdvancedPancreaticCancerStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AdvancedPancreaticCancerStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AdvancedPancreaticCancerStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PostCOVIDStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PostCOVIDStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PostCOVIDStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:PostCOVIDStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AmarexClinicalResearchLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_custom_JubilantHollisterStierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_JubilantHollisterStierMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AmpligenManufacturingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AmpligenManufacturingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AmpligenManufacturingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:AmpligenManufacturingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:JubilantHollisterStierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:MasterServiceAgreementAndQualityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:SterlingPharmaSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:MasterServiceAgreementAndQualityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:SterlingPharmaSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:MasterServiceAgreementAndQualityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:SterlingPharmaSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:MasterServiceAgreementAndQualityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:SterlingPharmaSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-04-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JointClinicalStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusUniversityMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JointClinicalStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusUniversityMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JointClinicalStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusUniversityMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JointClinicalStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusUniversityMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:JointClinicalStudyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:ErasmusUniversityMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-31_custom_AzenovaLLCMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="From2024-08-012024-08-31_custom_AzenovaLLCMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AzenovaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-09-012023-09-30_custom_AlcamiCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_AlcamiCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_AlcamiCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_AlcamiCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AIM:AlcamiCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-10-01_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-01_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-01</instant>
        </period>
    </context>
    <context id="From2024-10-012024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassCCommonWarrantMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassCCommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassCCommonWarrantMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassCCommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-01</instant>
        </period>
    </context>
    <context id="From2024-10-012024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassDCommonWarrantMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassDCommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassDCommonWarrantMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AIM:ClassDCommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AIM:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-01</instant>
        </period>
    </context>
    <context id="From2024-10-012024-10-01_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>AIM:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-09-30" id="Fact000004">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-09-30" id="Fact000005">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-09-30" id="Fact000006">0000946644</dei:EntityCentralIndexKey>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0052"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember"
      id="xdx2ixbrl0115"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      id="xdx2ixbrl0116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0134"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:GainLossOnWarrantIssuance
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:GainLossOnWarrantIssuance
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:GainLossOnWarrantIssuance
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:GainFromSaleOfIncomeTaxOperatingLoss
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:GainFromSaleOfIncomeTaxOperatingLoss
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValueCommittedShares
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValueCommittedShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValueCommittedShares
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValueCommittedShares
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValueCommittedShares
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValueCommittedShares
      contextRef="From2024-01-012024-03-31"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValuePreferredSharesExpired
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValuePreferredSharesExpired
      contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValuePreferredSharesExpired
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValuePreferredSharesExpired
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValuePreferredSharesExpired
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValuePreferredSharesExpired
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValuePreferredSharesExpired
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValuePreferredSharesExpired
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValuePreferredSharesExpired
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:StockIssuedDuringPeriodValuePreferredSharesExpired
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-03-31"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0522"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0528"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0594"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:GainFromSaleOfIncomeTaxOperatingLoss
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl0621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0631"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0634"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl0639"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0652"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0688"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:ProceedsFromIssuanceOfEquityWarrants
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0691"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:ConversionOfSeriesBPreferred
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl0714"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:ConversionOfNotePayableInterestIntoShares
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl0718"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-09-30_srt_MinimumMember"
      id="xdx2ixbrl0753">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0851"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl0997"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl0999"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1001"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1003"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1005"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1007"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1009"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1013"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1015"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1023"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1031"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1039"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1052"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1054"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1056"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1058"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1062"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1064"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1072"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1094"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1096"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1098"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1100"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1102"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1108"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1110"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1134"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1147"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1149"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1151"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1157"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1159"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1167"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1175"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1189"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1191"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1193"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1195"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1197"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1203"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1205"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1229"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1239"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1241"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1247"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1249"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1257"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="xdx2ixbrl1265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1275"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1277"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1281"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1283"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1289"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1291"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1315"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1325"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1327"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1333"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1335"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1343"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="xdx2ixbrl1351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_ClassAWarrantMember"
      id="xdx2ixbrl1550"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_ClassAWarrantMember"
      id="xdx2ixbrl1554"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassAWarrantMember"
      id="xdx2ixbrl1558"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassAWarrantMember"
      id="xdx2ixbrl1564"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassAWarrantMember"
      id="xdx2ixbrl1566"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassAWarrantMember"
      id="xdx2ixbrl1568"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember_custom_ClassBWarrantMember"
      id="xdx2ixbrl1572"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_ClassBWarrantMember"
      id="xdx2ixbrl1576"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassBWarrantMember"
      id="xdx2ixbrl1580"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassBWarrantMember"
      id="xdx2ixbrl1586"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassBWarrantMember"
      id="xdx2ixbrl1588"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_ClassBWarrantMember"
      id="xdx2ixbrl1590"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1608"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1618"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1624"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1632"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1634"
      unitRef="USD"
      xsi:nil="true"/>
    <AIM:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl1707"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-09-30" id="Fact000014">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-01-01to2024-09-30" id="Fact000015">true</dei:DocumentQuarterlyReport>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-09-30" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-09-30" id="Fact000017">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-09-30" id="Fact000018">2024</dei:DocumentFiscalYearFocus>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-09-30" id="Fact000019">001-27072</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-09-30" id="Fact000020">AIM IMMUNOTECH INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-09-30" id="Fact000021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-09-30" id="Fact000022">52-0845822</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-09-30" id="Fact000023">2117 SW Highway 484</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-09-30" id="Fact000024">Ocala</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-09-30" id="Fact000025">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-09-30" id="Fact000026">34473</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-09-30" id="Fact000027">(352)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-09-30" id="Fact000028">448-7797</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-01-01to2024-09-30" id="Fact000029">Common     Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-01-01to2024-09-30" id="Fact000030">AIM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-01-01to2024-09-30" id="Fact000031">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-09-30" id="Fact000032">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-09-30" id="Fact000033">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-09-30" id="Fact000034">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-09-30" id="Fact000035">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-09-30" id="Fact000036">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-09-30" id="Fact000037">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-11-11"
      decimals="INF"
      id="Fact000038"
      unitRef="Shares">63706446</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000046"
      unitRef="USD">915000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000047"
      unitRef="USD">5439000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000049"
      unitRef="USD">6287000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000050"
      unitRef="USD">7631000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000053"
      unitRef="USD">1184000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000055"
      unitRef="USD">368000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000056"
      unitRef="USD">302000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000058"
      unitRef="USD">7570000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000059"
      unitRef="USD">14556000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000061"
      unitRef="USD">117000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000062"
      unitRef="USD">127000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000064"
      unitRef="USD">653000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000065"
      unitRef="USD">697000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000067"
      unitRef="USD">2532000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000068"
      unitRef="USD">2313000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000070"
      unitRef="USD">2716000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000071"
      unitRef="USD">1688000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000073"
      unitRef="USD">13588000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000074"
      unitRef="USD">19381000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">6264000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000083"
      unitRef="USD">6443000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000085"
      unitRef="USD">1011000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">1986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000088"
      unitRef="USD">232000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000089"
      unitRef="USD">223000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000091"
      unitRef="USD">2593000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000094"
      unitRef="USD">10100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000095"
      unitRef="USD">8652000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">437000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000101"
      unitRef="USD">495000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000103"
      unitRef="USD">139000</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000106"
      unitRef="USD">10676000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000107"
      unitRef="USD">9147000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000118"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000120"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000122"
      unitRef="Shares">4000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000124"
      unitRef="Shares">250000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000126"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000128"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000130"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact000132"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <AIM:PreferredStockStatedValuePerShare
      contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000137"
      unitRef="USDPShares">1000</AIM:PreferredStockStatedValuePerShare>
    <AIM:PreferredStockStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000139"
      unitRef="USDPShares">1000</AIM:PreferredStockStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">689</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000151"
      unitRef="Shares">689</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">689000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="-3"
      id="Fact000154"
      unitRef="USD">689000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000159"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000161"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000163"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000165"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000167"
      unitRef="Shares">58668647</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000169"
      unitRef="Shares">58668647</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000171"
      unitRef="Shares">49102484</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000173"
      unitRef="Shares">49102484</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000156"
      unitRef="USD">59000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000157"
      unitRef="USD">49000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000175"
      unitRef="USD">423714000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000176"
      unitRef="USD">419004000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000178"
      unitRef="USD">-420861000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000179"
      unitRef="USD">-409508000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000181"
      unitRef="USD">2912000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000182"
      unitRef="USD">10234000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000184"
      unitRef="USD">13588000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000185"
      unitRef="USD">19381000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000192"
      unitRef="USD">35000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000193"
      unitRef="USD">46000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000194"
      unitRef="USD">125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000195"
      unitRef="USD">137000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000197"
      unitRef="USD">35000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000198"
      unitRef="USD">46000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000199"
      unitRef="USD">125000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">137000</us-gaap:Revenues>
    <us-gaap:ManufacturingCosts
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000207"
      unitRef="USD">8000</us-gaap:ManufacturingCosts>
    <us-gaap:ManufacturingCosts
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000208"
      unitRef="USD">30000</us-gaap:ManufacturingCosts>
    <us-gaap:ManufacturingCosts
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000209"
      unitRef="USD">24000</us-gaap:ManufacturingCosts>
    <us-gaap:ManufacturingCosts
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000210"
      unitRef="USD">30000</us-gaap:ManufacturingCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000212"
      unitRef="USD">1437000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000213"
      unitRef="USD">2734000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000214"
      unitRef="USD">4533000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000215"
      unitRef="USD">7739000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000217"
      unitRef="USD">3079000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000218"
      unitRef="USD">5439000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000219"
      unitRef="USD">9485000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000220"
      unitRef="USD">10280000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000222"
      unitRef="USD">4524000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000223"
      unitRef="USD">8203000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">14042000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000225"
      unitRef="USD">18049000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000227"
      unitRef="USD">-4489000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000228"
      unitRef="USD">-8157000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000229"
      unitRef="USD">-13917000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">-17912000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000232"
      unitRef="USD">273000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">-310000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000234"
      unitRef="USD">96000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000235"
      unitRef="USD">-201000</us-gaap:GainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000237"
      unitRef="USD">718000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000238"
      unitRef="USD">294000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000239"
      unitRef="USD">3379000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">811000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">202000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000244"
      unitRef="USD">453000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000248"
      unitRef="USD">39000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000250"
      unitRef="USD">16000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <AIM:GainLossOnWarrantIssuance
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">-458000</AIM:GainLossOnWarrantIssuance>
    <AIM:GainFromSaleOfIncomeTaxOperatingLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000258"
      unitRef="USD">-318000</AIM:GainFromSaleOfIncomeTaxOperatingLoss>
    <AIM:GainFromSaleOfIncomeTaxOperatingLoss
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000260"
      unitRef="USD">-900000</AIM:GainFromSaleOfIncomeTaxOperatingLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000262"
      unitRef="USD">-3700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000263"
      unitRef="USD">-7816000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">-11353000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000265"
      unitRef="USD">-16386000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000267"
      unitRef="USDPShares">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000269"
      unitRef="USDPShares">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000271"
      unitRef="USDPShares">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000273"
      unitRef="USDPShares">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000275"
      unitRef="USDPShares">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000277"
      unitRef="USDPShares">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact000279"
      unitRef="USDPShares">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact000281"
      unitRef="USDPShares">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000283"
      unitRef="Shares">57677016</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000285"
      unitRef="Shares">57677016</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000287"
      unitRef="Shares">48635165</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000289"
      unitRef="Shares">48635165</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">53351467</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact000293"
      unitRef="Shares">53351467</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact000295"
      unitRef="Shares">48483802</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact000297"
      unitRef="Shares">48483802</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000299"
      unitRef="USD">689000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000306"
      unitRef="Shares">49102484</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000301"
      unitRef="USD">419004000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000303"
      unitRef="USD">-409508000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">10234000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000315"
      unitRef="Shares">807577</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000309"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000310"
      unitRef="USD">328000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000313"
      unitRef="USD">329000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <AIM:StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000324"
      unitRef="Shares">3272</AIM:StockIssuedDuringPeriodShareCsashlessExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000328"
      unitRef="USD">80000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000331"
      unitRef="USD">80000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <AIM:StockIssuedDuringPeriodSharesCommittedShares
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000340"
      unitRef="Shares">338600</AIM:StockIssuedDuringPeriodSharesCommittedShares>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000346"
      unitRef="USD">-5817000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-03-31"
      decimals="-3"
      id="Fact000347"
      unitRef="USD">-5817000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000349"
      unitRef="USD">689000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000356"
      unitRef="Shares">50251933</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000350"
      unitRef="USD">50000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000351"
      unitRef="USD">419412000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000353"
      unitRef="USD">-415325000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000354"
      unitRef="USD">4826000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000365"
      unitRef="Shares">6884747</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000359"
      unitRef="USD">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000360"
      unitRef="USD">525000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-04-012024-06-30"
      decimals="-3"
      id="Fact000363"
      unitRef="USD">532000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000369"
      unitRef="USD">2500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2024-04-012024-06-30"
      decimals="-3"
      id="Fact000372"
      unitRef="USD">2500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">80000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30"
      decimals="-3"
      id="Fact000379"
      unitRef="USD">80000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <AIM:StockIssuedDuringPeriodValuePreferredSharesExpired
      contextRef="From2024-04-012024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000381"
      unitRef="USD">-689000</AIM:StockIssuedDuringPeriodValuePreferredSharesExpired>
    <AIM:StockIssuedDuringPeriodValuePreferredSharesExpired
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000383"
      unitRef="USD">689000</AIM:StockIssuedDuringPeriodValuePreferredSharesExpired>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000392"
      unitRef="USD">-1836000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-04-012024-06-30"
      decimals="-3"
      id="Fact000393"
      unitRef="USD">-1836000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000402"
      unitRef="Shares">57136680</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000396"
      unitRef="USD">57000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000397"
      unitRef="USD">423206000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000399"
      unitRef="USD">-417161000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="-3"
      id="Fact000400"
      unitRef="USD">6102000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000411"
      unitRef="Shares">653430</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000405"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000406"
      unitRef="USD">179000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000409"
      unitRef="USD">180000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000427"
      unitRef="Shares">878537</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000421"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000422"
      unitRef="USD">329000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000425"
      unitRef="USD">330000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000440"
      unitRef="USD">-3700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">-3700000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000450"
      unitRef="Shares">58668647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000444"
      unitRef="USD">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">423714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000447"
      unitRef="USD">-420861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000448"
      unitRef="USD">2912000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000452"
      unitRef="USD">696000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000459"
      unitRef="Shares">48084287</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000454"
      unitRef="USD">418270000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000456"
      unitRef="USD">-380546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000457"
      unitRef="USD">38468000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000468"
      unitRef="Shares">322583</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000463"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000466"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000472"
      unitRef="USD">82000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000475"
      unitRef="USD">82000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">-4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000484"
      unitRef="Shares">456</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000479"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000490"
      unitRef="USD">-3661000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-03-31"
      decimals="-3"
      id="Fact000491"
      unitRef="USD">-3661000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000493"
      unitRef="USD">692000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000500"
      unitRef="Shares">48407326</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000494"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000495"
      unitRef="USD">418456000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000497"
      unitRef="USD">-384207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000498"
      unitRef="USD">34989000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000509"
      unitRef="Shares">11937</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000504"
      unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      id="Fact000507"
      unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      id="Fact000516"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000518"
      unitRef="USD">-2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000525"
      unitRef="Shares">228</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000520"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000531"
      unitRef="USD">-4909000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-04-012023-06-30"
      decimals="-3"
      id="Fact000532"
      unitRef="USD">-4909000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000534"
      unitRef="USD">690000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000541"
      unitRef="Shares">48419491</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000536"
      unitRef="USD">418513000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000538"
      unitRef="USD">-389116000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="Fact000539"
      unitRef="USD">30135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000543"
      unitRef="USD">690000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000550"
      unitRef="Shares">48419491</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000544"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000545"
      unitRef="USD">418513000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000547"
      unitRef="USD">-389116000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="-3"
      id="Fact000548"
      unitRef="USD">30135000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000559"
      unitRef="Shares">377959</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000554"
      unitRef="USD">233000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000557"
      unitRef="USD">233000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000563"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000566"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000579"
      unitRef="USD">-7816000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000580"
      unitRef="USD">-7816000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000582"
      unitRef="USD">690000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000589"
      unitRef="Shares">48797450</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000583"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000584"
      unitRef="USD">418796000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000586"
      unitRef="USD">-396932000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000587"
      unitRef="USD">22602000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesBPreferredStockMember"
      decimals="-3"
      id="Fact000591"
      unitRef="USD">690000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000598"
      unitRef="Shares">48797450</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000592"
      unitRef="USD">48000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000593"
      unitRef="USD">418796000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000595"
      unitRef="USD">-396932000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000596"
      unitRef="USD">22602000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000603"
      unitRef="USD">-11353000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000604"
      unitRef="USD">-16386000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000609"
      unitRef="USD">28000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000610"
      unitRef="USD">30000</us-gaap:Depreciation>
    <AIM:AbandonmentOfPatentAndTrademarkRights
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000612"
      unitRef="USD">46000</AIM:AbandonmentOfPatentAndTrademarkRights>
    <AIM:AbandonmentOfPatentAndTrademarkRights
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000613"
      unitRef="USD">14000</AIM:AbandonmentOfPatentAndTrademarkRights>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000615"
      unitRef="USD">154000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000616"
      unitRef="USD">150000</us-gaap:AmortizationOfIntangibleAssets>
    <AIM:ChangesInRouAssets
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000618"
      unitRef="USD">226000</AIM:ChangesInRouAssets>
    <AIM:ChangesInRouAssets
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000619"
      unitRef="USD">151000</AIM:ChangesInRouAssets>
    <AIM:GainFromSaleOfIncomeTaxOperatingLoss
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000622"
      unitRef="USD">-900000</AIM:GainFromSaleOfIncomeTaxOperatingLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000624"
      unitRef="USD">490000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000625"
      unitRef="USD">182000</us-gaap:ShareBasedCompensation>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000627"
      unitRef="USD">95000</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000628"
      unitRef="USD">-201000</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000630"
      unitRef="USD">-458000</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000633"
      unitRef="USD">232000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000640"
      unitRef="USD">9000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000642"
      unitRef="USD">-1181000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000643"
      unitRef="USD">-1676000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000645"
      unitRef="USD">63000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000646"
      unitRef="USD">-192000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000648"
      unitRef="USD">-231000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000649"
      unitRef="USD">-136000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000651"
      unitRef="USD">1028000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000654"
      unitRef="USD">-179000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000655"
      unitRef="USD">2411000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000657"
      unitRef="USD">-799000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000658"
      unitRef="USD">915000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000660"
      unitRef="USD">-10933000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000661"
      unitRef="USD">-11509000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfInvestmentProjects
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000666"
      unitRef="USD">1597000</us-gaap:ProceedsFromSaleOfInvestmentProjects>
    <us-gaap:ProceedsFromSaleOfInvestmentProjects
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000667"
      unitRef="USD">924000</us-gaap:ProceedsFromSaleOfInvestmentProjects>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000669"
      unitRef="USD">158000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000670"
      unitRef="USD">1155000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000672"
      unitRef="USD">18000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000673"
      unitRef="USD">10000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000675"
      unitRef="USD">419000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000676"
      unitRef="USD">377000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000678"
      unitRef="USD">1002000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000679"
      unitRef="USD">-618000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000684"
      unitRef="USD">860000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000685"
      unitRef="USD">338000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000687"
      unitRef="USD">2500000</us-gaap:ProceedsFromNotesPayable>
    <AIM:ProceedsFromIssuanceOfEquityWarrants
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000690"
      unitRef="USD">2047000</AIM:ProceedsFromIssuanceOfEquityWarrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000693"
      unitRef="USD">5407000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000694"
      unitRef="USD">338000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000696"
      unitRef="USD">-4524000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000697"
      unitRef="USD">-11789000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000699"
      unitRef="USD">5439000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000700"
      unitRef="USD">27053000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000702"
      unitRef="USD">915000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000703"
      unitRef="USD">15264000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <AIM:OperatingLeaserightOfUseAssets
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000708"
      unitRef="USD">-3000</AIM:OperatingLeaserightOfUseAssets>
    <AIM:OperatingLeaserightOfUseAssets
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000709"
      unitRef="USD">49000</AIM:OperatingLeaserightOfUseAssets>
    <AIM:UnrealizedGainLossOnMarketableInvestments
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000711"
      unitRef="USD">373000</AIM:UnrealizedGainLossOnMarketableInvestments>
    <AIM:UnrealizedGainLossOnMarketableInvestments
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000712"
      unitRef="USD">-71000</AIM:UnrealizedGainLossOnMarketableInvestments>
    <AIM:ConversionOfSeriesBPreferred
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact000715"
      unitRef="USD">6000</AIM:ConversionOfSeriesBPreferred>
    <AIM:ConversionOfNotePayableInterestIntoShares
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000717"
      unitRef="USD">175000</AIM:ConversionOfNotePayableInterestIntoShares>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000720">&lt;p id="xdx_808_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zvXrSbojjZ67" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1: &lt;span id="xdx_825_znFavMe4BT99"&gt;Business and Basis of Presentation&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AIM
ImmunoTech Inc. and its subsidiaries (collectively, &#x201c;AIM&#x201d;, &#x201c;Company&#x201d;, &#x201c;we&#x201d; or &#x201c;us&#x201d;) are
an immuno-pharma company headquartered in Ocala, Florida,  focused on the research and development of therapeutics to treat multiple
types of cancers, viral diseases and immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical
and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system
of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AIM&#x2019;s
flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (&#x201c;dsRNA&#x201d;)
molecule being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has not been approved
by the FDA or marketed in the United States but is approved for commercial sale in the Argentine Republic for the treatment of severe
Chronic Fatigue Syndrome (&#x201c;CFS&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is currently proceeding primarily in four areas:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conducting
                                            clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic
                                            cancer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Evaluating
                                            Ampligen across multiple cancers as a potential therapy that modifies the tumor microenvironment
                                            with the goal of increasing anti-tumor responses to checkpoint inhibitors.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exploring
                                            Ampligen&#x2019;s antiviral activities and potential use as a prophylactic or treatment for
                                            existing viruses, new viruses and mutated viruses thereof.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Evaluating
                                            Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (&#x201c;ME/CFS&#x201d;)
                                            and fatigue and/or the Post-COVID condition of fatigue.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic
cancer, ME/CFS and Post-COVID conditions having priority over antiviral experimentation. The Company intends that priority clinical work
be conducted in trials authorized by the FDA or European Medicines Agency (&#x201c;EMA&#x201d;), which trials support a potential future
NDA. However, AIM&#x2019;s antiviral experimentation is designed to accumulate additional preliminary data supporting their hypothesis
that Ampligen is a powerful, broad-spectrum prophylaxis and early-onset therapeutic that may confer enhanced immunity and cross-protection.
Accordingly, AIM will conduct antiviral programs in those venues most readily available and able to generate valid proof-of-concept data,
including foreign venues.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AIM&#x2019;s
business plan requires one or more Contract Manufacturing Organizations (&#x201c;CMO&#x201d;) to produce Ampligen and its Active Pharmaceutical
Ingredients (APIs). This includes utilizing Jubilant HollisterStier and Sterling for the manufacture of Ampligen and our Poly I and Poly
C12U polynucleotides, respectively. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the opinion of management, all adjustments necessary for a fair presentation of its consolidated financial statements have been included.
Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (&#x201c;SEC&#x201d;),
and do not contain certain information which will be included in the Company&#x2019;s annual consolidated financial statements and notes
thereto.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
consolidated financial statements should be read in conjunction with the Company&#x2019;s consolidated financial statements for the years
ended December 31, 2023, and 2022, contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023,
filed on April 1, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use
of Estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure (&#x201c;GAAP&#x201d;)
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the
reporting period. Actual results could differ from those estimates, and those differences may be material. Accounts requiring the use
of significant estimates include determination of other-than-temporary impairment on securities, valuation of deferred taxes, patent
and trademark valuations, stock-based compensation calculations, fair value of warrants, and contingency accruals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity
and Going Concern&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern.
The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements
are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the requirements of the Financial Accounting Standards Board&#x2019;s (the &#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 205-40, Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern, management must evaluate whether
there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue
as a going concern for one year from the date these financial statements are issued. This evaluation does not take into consideration
the potential mitigating effect of management&#x2019;s plans that have not been fully implemented or are not within control of the Company
as of the date the financial statements are issued. When substantial doubt about the Company&#x2019;s ability to continue as a going concern
exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt. The mitigating
effect of management&#x2019;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented
within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will
mitigate the relevant conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern
within one year after the date that the financial statements are issued. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s principal source of liquidity is its cash and cash equivalents, marketable securities, and proceeds from financing
activities to provide the necessary funding to meet our obligations as they become due. The Company has suffered losses from
operations and net cash used on operating activities for the nine-month period ended September 30, 2024, and has a working capital
deficit as of September 30, 2024. Additionally, the Company&#x2019;s stockholders&#x2019; equity was below the minimum requirements
for continued listing on the New York Stock Exchange American (&#x201c;NYSE American&#x201d;). These conditions raise substantial
doubt regarding the Company&#x2019;s ability to continue as a going concern for a period of at least one year from the date of
issuance of these unaudited condensed consolidated financial statements. Management evaluated the conditions, and the significance
of these conditions related to the Company&#x2019;s ability to meet its obligations and determined that the primary cause of the
deficit was related to certain accounts payable which the Company is currently in negotiations with the vendor. These negotiations
are ongoing and could result in significant amounts which could partially alleviate the negative working capital. There is no assurance as to the timing or outcome of these efforts. If the Company is unable to implement
sufficient mitigation efforts, the Company may be forced to limit its business activities or be unable to continue as a going
concern, which would have a material adverse effect on its results of operations and financial condition.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000722">&lt;p id="xdx_80C_eus-gaap--CashAndCashEquivalentsDisclosureTextBlock_zSSHZ6DUZhN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2&lt;/b&gt;: &lt;b&gt;&lt;span id="xdx_829_z2nryRywse58"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
includes bank deposits maintained at several financial institutions. The Company considers highly liquid instruments with an original
maturity of three months or less to be cash equivalents. At various times throughout the nine months ended September 30, 2024, some accounts
held at financial institutions were in excess of the federally insured limit of $&lt;span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20240930_ze3nab0wDKN1" title="Federlly insured limit"&gt;250,000&lt;/span&gt;. The Company has not experienced any losses
on these accounts and believes credit risk to be minimal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000724"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000726">&lt;p id="xdx_80E_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zFfeajKKv4L6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3: &lt;span id="xdx_829_zM8Uaj60oD13"&gt;Marketable Securities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable
securities consist of mutual funds. At September 30, 2024 and December
31, 2023, it was determined that none of the marketable securities had an other-than-temporary impairment. At September 30, 2024 and December
31, 2023, all securities were measured as Level 1 instruments of the fair value measurements standard (See Note 12: Fair Value). At September
30, 2024, and December 31, 2023 the Company held $&lt;span id="xdx_902_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_c20240930_zGPiXdFoGmFd" title="Held value of marketable securities"&gt;6,287,000&lt;/span&gt;
and $&lt;span id="xdx_906_eus-gaap--HeldToMaturitySecuritiesFairValue_iI_c20231231_zSQimBV7QZEd" title="Held value of marketable securities"&gt;7,631,000&lt;/span&gt; respectively, in mutual funds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mutual Funds classified as available for sale consisted of $&lt;span id="xdx_902_eus-gaap--MarketableSecuritiesCurrent_iI_c20240930_zBmGron1f3Si" title="Marketable securities"&gt;6,287,000&lt;/span&gt; at September 30, 2024. &lt;span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleTypeOfEquitySecurity_c20240101__20240930_zFGH0MtdGcjg" title="Equity securities description"&gt;The net gain recognized for the three-month
period ended September 30, 2024 on equity securities was $273,000. The net losses recognized for the three-month period ended September
30, 2024 on equity securities sold during the period were ($59,000). The unrealized gains recognized for the three-month period
ended September 30, 2024 on equity securities still held was $332,000. The net gain recognized for the nine-month period ended September
30, 2024 on equity securities was $96,000. The net losses recognized for the nine-month period ended September 30, 2024 on equity
securities sold during the period were ($277,000). The unrealized gains recognized for the nine-month period ended September 30,
2024 on equity securities still held was $373,000.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mutual Funds classified as available for sale consisted of $&lt;span id="xdx_900_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_z6a3a5ZWvIY2" title="Marketable securities"&gt;7,631,000&lt;/span&gt; at December 31, 2023. &lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleTypeOfEquitySecurity_c20230101__20231231_z6EMBUekZ2D3" title="Equity securities description"&gt;The net loss recognized for the three-month
period ended September 30, 2023 on equity securities was ($309,000).&#160; The net losses recognized for the three-month period ended
September 30, 2023 on equity securities sold during the period were ($42,000). The unrealized losses recognized during the three-month
period ended September 30, 2023 on equity securities still held was ($267,000). The net losses recognized for the nine-month
period ended September 30, 2023 on equity securities was ($201,000). The net losses recognized for the nine-month period ended
September 30, 2023 on equity securities sold during the period were ($130,000). The unrealized losses recognized during the nine-month
period ended September 30, 2023 on equity securities still held was ($71,000).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000728"
      unitRef="USD">6287000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000730"
      unitRef="USD">7631000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000732"
      unitRef="USD">6287000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:DebtInstrumentConvertibleTypeOfEquitySecurity contextRef="From2024-01-01to2024-09-30" id="Fact000734">The net gain recognized for the three-month
period ended September 30, 2024 on equity securities was $273,000. The net losses recognized for the three-month period ended September
30, 2024 on equity securities sold during the period were ($59,000). The unrealized gains recognized for the three-month period
ended September 30, 2024 on equity securities still held was $332,000. The net gain recognized for the nine-month period ended September
30, 2024 on equity securities was $96,000. The net losses recognized for the nine-month period ended September 30, 2024 on equity
securities sold during the period were ($277,000). The unrealized gains recognized for the nine-month period ended September 30,
2024 on equity securities still held was $373,000.</us-gaap:DebtInstrumentConvertibleTypeOfEquitySecurity>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000736"
      unitRef="USD">7631000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:DebtInstrumentConvertibleTypeOfEquitySecurity contextRef="From2023-01-012023-12-31" id="Fact000738">The net loss recognized for the three-month
period ended September 30, 2023 on equity securities was ($309,000).&#160; The net losses recognized for the three-month period ended
September 30, 2023 on equity securities sold during the period were ($42,000). The unrealized losses recognized during the three-month
period ended September 30, 2023 on equity securities still held was ($267,000). The net losses recognized for the nine-month
period ended September 30, 2023 on equity securities was ($201,000). The net losses recognized for the nine-month period ended
September 30, 2023 on equity securities sold during the period were ($130,000). The unrealized losses recognized during the nine-month
period ended September 30, 2023 on equity securities still held was ($71,000).</us-gaap:DebtInstrumentConvertibleTypeOfEquitySecurity>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000740">&lt;p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zCggWfUlxyhg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4: &lt;span id="xdx_826_zuXooo4pXdGc"&gt;Property and Equipment, net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zRGGwIRYWFyb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B1_zCYYYn4y7eL1"&gt;Schedule
of Property and Equipment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20240930_z5hFwuCCDQ9f" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20231231_zBpvQnD47La7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENztUG_zMy3sLzXGS6g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Furniture, fixtures, and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,466&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENztUG_zQo49N7TPXn1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,349&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,321&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENztUG_zFFesyhVHXMa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;117&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;127&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z4fpO1sgVRZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful
lives of the respective assets, ranging from &lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20240930__srt--RangeAxis__srt--MinimumMember_z7CckCeoYvx8" title="Estimated useful life::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0753"&gt;three&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20240930__srt--RangeAxis__srt--MaximumMember_zZJtA53jY7E3" title="Estimated useful life"&gt;ten years&lt;/span&gt;. Depreciation expense for the nine months ending September 30, 2024 and
September 30, 2023 was $&lt;span id="xdx_902_eus-gaap--Depreciation_c20240101__20240930_zfY7dvT8xSP6" title="Depreciation expense"&gt;28,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--Depreciation_c20230101__20230930_zOpQXeIXQdDb" title="Depreciation expense"&gt;30,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000742">&lt;p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zRGGwIRYWFyb" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B1_zCYYYn4y7eL1"&gt;Schedule
of Property and Equipment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_494_20240930_z5hFwuCCDQ9f" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20231231_zBpvQnD47La7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENztUG_zMy3sLzXGS6g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Furniture, fixtures, and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,466&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,448&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENztUG_zQo49N7TPXn1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,349&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,321&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENztUG_zFFesyhVHXMa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;117&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;127&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000744"
      unitRef="USD">1466000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000745"
      unitRef="USD">1448000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000747"
      unitRef="USD">1349000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000748"
      unitRef="USD">1321000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000750"
      unitRef="USD">117000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000751"
      unitRef="USD">127000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-09-30_srt_MaximumMember"
      id="Fact000755">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact000757"
      unitRef="USD">28000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact000759"
      unitRef="USD">30000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000761">&lt;p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_z4UG7EhRAl92" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5: &lt;span id="xdx_826_zXFFyQk49l5d"&gt;Patents, and Trademark Rights, Net&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zBCDvBpBjFmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patent
and trademark rights consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt"&gt;&lt;span id="xdx_8BB_zAa7JNWy89tb"&gt;Schedule
of Patent and Trademark Rights&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Gross Carrying Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Net Carrying Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Gross Carrying Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Net Carrying Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zbUICxw1Xj8c" style="width: 8%; text-align: right" title="Gross carrying value"&gt;3,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zpwzsHMhXvG4" style="width: 8%; text-align: right" title="Accumulated amortization"&gt;(887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zEPpi2tMxpDa" style="width: 8%; text-align: right" title="Net carrying value"&gt;2,428&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzxSZR35aLli" style="width: 8%; text-align: right" title="Gross carrying value"&gt;2,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8J54CytraFk" style="width: 8%; text-align: right" title="Accumulated amortization"&gt;(750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAGxijkjvRf" style="width: 8%; text-align: right" title="Net carrying value"&gt;2,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Trademarks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zvfvEdCm6oY3" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value"&gt;232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z33LHiL2D1bg" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization"&gt;(128&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zQvo28Jaoe61" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zjJM7f8pmrPd" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value"&gt;229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zoBAV3VSrXfk" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization"&gt;(113&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSX6Kv6qQrbl" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net amortizable patents and trademarks rights&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930_zwH2Yy8CWW62" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value"&gt;3,547&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930_zxHNsNce0g53" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;(1,015&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930_zUBZJdMlSL8b" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value"&gt;2,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zXvptjERIbih" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value"&gt;3,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zheFoTKFHNB6" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;(863&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zL8AbrNZtT67" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value"&gt;2,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zhTQpzAtb0vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zGqBFECNpEW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patent
and trademark rights acquisitions, abandonments and amortization:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B7_zkcpxAOiTA8"&gt;Schedule of Changes in
Patents, Trademark Rights&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20240101__20240930_zYazcw4FAWm1" style="width: 20%; text-align: right" title="Balance"&gt;2,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Acquisitions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20240930_zQkkLOeVr6Pl" style="text-align: right" title="Acquisitions"&gt;419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Abandonments and expirations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20240101__20240930_z1PWeAKfCbvg" style="text-align: right" title="Abandonments"&gt;(46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20240101__20240930_zbcdeHtCc1fd" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Amortization"&gt;(154&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20240101__20240930_zCEi51a2i4Qc" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance"&gt;2,532&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zp0yeFhg8wCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patents
and trademarks are stated at cost (primarily legal fees) and are amortized using the straight-line method over an estimated useful life
of &lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zqy5tcBpRkbc" title="Finite lived intangible assets, estimated useful life"&gt;17 years&lt;/span&gt; for patents and &lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zbUxrGLdmBZa" title="Finite lived intangible assets, estimated useful life"&gt;10 years&lt;/span&gt; for trademarks. The weighted remaining average amortization period is approximately &lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_c20240101__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvpKWnMvDxb4" title="Finite lived intangible assets, weighted average amortization"&gt;12 years&lt;/span&gt; for
patents and &lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension_c20240101__20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zVS9hQqXWWUe" title="Finite lived intangible assets, weighted average amortization"&gt;6 years&lt;/span&gt; for trademarks, respectively. The company expenses annuity costs related to its trademarks and patents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zFn3Ia1SZmGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
of patents and trademarks for each of the next five years and thereafter is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BF_zgAqJXpNuYmj"&gt;Schedule
of Amortization of Patents and Trademarks&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Year Ending December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240930_z1tIYpVuM4Xe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzzOp_zwjhISSXC6c7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 72%; text-align: justify"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 24%; text-align: right"&gt;72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zTsNY3ua6BM7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zoOVx8HtnVqi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zd5hADRcvfP4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zrSd1XdSTIfk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzzOp_zJfUCy3CpjH1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,469&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zWhqaolA3oN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,532&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z68D5vV7JGv" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000763">&lt;p id="xdx_891_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zBCDvBpBjFmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patent
and trademark rights consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt"&gt;&lt;span id="xdx_8BB_zAa7JNWy89tb"&gt;Schedule
of Patent and Trademark Rights&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Gross Carrying Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Net Carrying Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Gross Carrying Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Net Carrying Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zbUICxw1Xj8c" style="width: 8%; text-align: right" title="Gross carrying value"&gt;3,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zpwzsHMhXvG4" style="width: 8%; text-align: right" title="Accumulated amortization"&gt;(887&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zEPpi2tMxpDa" style="width: 8%; text-align: right" title="Net carrying value"&gt;2,428&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zzxSZR35aLli" style="width: 8%; text-align: right" title="Gross carrying value"&gt;2,947&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z8J54CytraFk" style="width: 8%; text-align: right" title="Accumulated amortization"&gt;(750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAGxijkjvRf" style="width: 8%; text-align: right" title="Net carrying value"&gt;2,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Trademarks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zvfvEdCm6oY3" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value"&gt;232&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z33LHiL2D1bg" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization"&gt;(128&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zQvo28Jaoe61" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zjJM7f8pmrPd" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying value"&gt;229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zoBAV3VSrXfk" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization"&gt;(113&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zSX6Kv6qQrbl" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying value"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net amortizable patents and trademarks rights&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20240930_zwH2Yy8CWW62" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value"&gt;3,547&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20240930_zxHNsNce0g53" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;(1,015&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20240930_zUBZJdMlSL8b" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value"&gt;2,532&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zXvptjERIbih" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying value"&gt;3,176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zheFoTKFHNB6" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;(863&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zL8AbrNZtT67" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying value"&gt;2,313&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-09-30_us-gaap_PatentsMember"
      decimals="-3"
      id="Fact000765"
      unitRef="USD">3315000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-09-30_us-gaap_PatentsMember"
      decimals="-3"
      id="Fact000767"
      unitRef="USD">-887000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-09-30_us-gaap_PatentsMember"
      decimals="-3"
      id="Fact000769"
      unitRef="USD">2428000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="-3"
      id="Fact000771"
      unitRef="USD">2947000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="-3"
      id="Fact000773"
      unitRef="USD">-750000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="-3"
      id="Fact000775"
      unitRef="USD">2197000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-09-30_us-gaap_TrademarksMember"
      decimals="-3"
      id="Fact000777"
      unitRef="USD">232000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-09-30_us-gaap_TrademarksMember"
      decimals="-3"
      id="Fact000779"
      unitRef="USD">-128000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-09-30_us-gaap_TrademarksMember"
      decimals="-3"
      id="Fact000781"
      unitRef="USD">104000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      id="Fact000783"
      unitRef="USD">229000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      id="Fact000785"
      unitRef="USD">-113000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      id="Fact000787"
      unitRef="USD">116000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000789"
      unitRef="USD">3547000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000791"
      unitRef="USD">-1015000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000793"
      unitRef="USD">2532000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000795"
      unitRef="USD">3176000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000797"
      unitRef="USD">-863000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000799"
      unitRef="USD">2313000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000801">&lt;p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zGqBFECNpEW9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Patent
and trademark rights acquisitions, abandonments and amortization:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B7_zkcpxAOiTA8"&gt;Schedule of Changes in
Patents, Trademark Rights&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pn3n3_c20240101__20240930_zYazcw4FAWm1" style="width: 20%; text-align: right" title="Balance"&gt;2,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Acquisitions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FinitelivedIntangibleAssetsAcquired1_pn3n3_c20240101__20240930_zQkkLOeVr6Pl" style="text-align: right" title="Acquisitions"&gt;419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Abandonments and expirations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--FinitelivedIntangibleAssetsAbandonments_iN_pn3n3_di_c20240101__20240930_z1PWeAKfCbvg" style="text-align: right" title="Abandonments"&gt;(46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_iN_pn3n3_di_c20240101__20240930_zbcdeHtCc1fd" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Amortization"&gt;(154&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pn3n3_c20240101__20240930_zCEi51a2i4Qc" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance"&gt;2,532&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000803"
      unitRef="USD">2313000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000805"
      unitRef="USD">419000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <AIM:FinitelivedIntangibleAssetsAbandonments
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000807"
      unitRef="USD">46000</AIM:FinitelivedIntangibleAssetsAbandonments>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact000809"
      unitRef="USD">154000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000811"
      unitRef="USD">2532000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-09-30_us-gaap_PatentsMember"
      id="Fact000813">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-09-30_us-gaap_TrademarksMember"
      id="Fact000815">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="From2024-01-012024-09-30_us-gaap_PatentsMember"
      id="Fact000817">P12Y</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
      contextRef="From2024-01-012024-09-30_us-gaap_TrademarksMember"
      id="Fact000819">P6Y</us-gaap:FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000821">&lt;p id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zFn3Ia1SZmGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
of patents and trademarks for each of the next five years and thereafter is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BF_zgAqJXpNuYmj"&gt;Schedule
of Amortization of Patents and Trademarks&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Year Ending December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240930_z1tIYpVuM4Xe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzzOp_zwjhISSXC6c7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 72%; text-align: justify"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 24%; text-align: right"&gt;72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzzOp_zTsNY3ua6BM7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzzOp_zoOVx8HtnVqi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzzOp_zd5hADRcvfP4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzzOp_zrSd1XdSTIfk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzzOp_zJfUCy3CpjH1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,469&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzzOp_zWhqaolA3oN5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,532&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000823"
      unitRef="USD">72000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000825"
      unitRef="USD">268000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000827"
      unitRef="USD">265000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000829"
      unitRef="USD">239000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000831"
      unitRef="USD">219000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <AIM:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000833"
      unitRef="USD">1469000</AIM:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000835"
      unitRef="USD">2532000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000837">&lt;p id="xdx_805_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zDu3gHvXqICe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6: &lt;span id="xdx_82F_zcgvTu96dolf"&gt;Accrued Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zQi5554CwUCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B1_zCZ86rKhvOt7"&gt;Schedule
of Accrued Expenses&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20240930_zpvTaGPeAyEl" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20231231_zyfNm3w9hjBi" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zxZUuEaIXWSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;414&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zErRAiIuwHzd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;790&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,352&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_z8kZCQ7m4g52" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Clinical trial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzYmu_zxpeMg9SgGIi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0851"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ziLMURobsHek" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zFlkF5q6M6L8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,011&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,986&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zs0RdJN0aHGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000839">&lt;p id="xdx_890_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zQi5554CwUCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B1_zCZ86rKhvOt7"&gt;Schedule
of Accrued Expenses&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20240930_zpvTaGPeAyEl" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20231231_zyfNm3w9hjBi" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_zxZUuEaIXWSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;Compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;414&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzYmu_zErRAiIuwHzd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;790&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,352&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AccruedClinicalTrialExpensesCurrent_iI_pn3n3_maALCzYmu_z8kZCQ7m4g52" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Clinical trial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzYmu_zxpeMg9SgGIi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0851"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzYmu_ziLMURobsHek" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzYmu_zFlkF5q6M6L8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,011&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,986&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000841"
      unitRef="USD">1000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000842"
      unitRef="USD">414000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000844"
      unitRef="USD">790000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000845"
      unitRef="USD">1352000</us-gaap:AccruedProfessionalFeesCurrent>
    <AIM:AccruedClinicalTrialExpensesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000847"
      unitRef="USD">132000</AIM:AccruedClinicalTrialExpensesCurrent>
    <AIM:AccruedClinicalTrialExpensesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000848"
      unitRef="USD">184000</AIM:AccruedClinicalTrialExpensesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000850"
      unitRef="USD">51000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000853"
      unitRef="USD">37000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000854"
      unitRef="USD">36000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000856"
      unitRef="USD">1011000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000857"
      unitRef="USD">1986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000859">&lt;p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_zYKkX7jA2XU" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7: &lt;span id="xdx_820_z1itmEsEwwC5"&gt;Unsecured Promissory Note&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2024, the Company (&#x201c;Borrower&#x201d;) entered into a Note Purchase Agreement with Streeterville Capital LLC
(&#x201c;Streeterville&#x201d; or the &#x201c;Lender&#x201d;). Under the terms of the agreement, Streeterville paid the Company $&lt;span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zWAjx8pvr3e9" title="Exchange of unsecured promissory notes"&gt;2,500,000&lt;/span&gt;
in exchange for an unsecured promissory Note with an Original Issue Discount of $&lt;span id="xdx_900_eus-gaap--DebtConversionOriginalDebtAmount1_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zSDdVIlvnB4a" title="Unsecured debt original issue discount"&gt;781,250&lt;/span&gt;.
The Company will pay $&lt;span id="xdx_90C_eus-gaap--LongTermDebt_iI_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zJpVZkQMLegi" title="Long term debt"&gt;3,301,250&lt;/span&gt;
consisting of the principal amount of the Note, together with the original issue discount and $&lt;span id="xdx_901_eus-gaap--DeferredFinanceCostsGross_iI_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zqKMVPANOnc3" title="Debt issuance costs"&gt;20,000&lt;/span&gt;
of lender transaction fees, no later than February 16, 2026. The stated interest rate of the note is &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_z7D8T6ZrVfm3" title="Debt instrument stated interest rate"&gt;10&lt;/span&gt;%.&lt;/span&gt;
There was &lt;span id="xdx_905_eus-gaap--UnsecuredDebt_iI_do_c20231231_zZMrBphQAdud" title="Unsecured debt"&gt;no&lt;/span&gt; debt at December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_z8qR51yTaila" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span&gt;&lt;span id="xdx_8B3_zzL1KXT6vYW6"&gt;Schedule of Long Term Debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240930_znIPEbSifguf" style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Debt schedule at September 30, 2024 (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LongTermDebt_iI_pn3n3_z5Qzrbi8hhlh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 77%; text-align: left"&gt;Long-term debt&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;3,301&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_zme2jc2Cl9lc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unamortized Original issue discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(555&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_zEzzylzYJd6g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Unamortized Financing fees&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn3n3_z1sjpi9zFbp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unamortized discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_z3tDTtSH1sf1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less current portion of long-term debt, net &lt;span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,593&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zfrhvPyY2899" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Long-term debt, net &lt;span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;139&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A0_zNlZ4r61hy0a" style="text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Interest expense related to long-term debt was $&lt;span id="xdx_906_eus-gaap--InterestExpenseDebtExcludingAmortization_c20240101__20240930_zPBg5i4epKn" title="Interest expense debt excluding amortization"&gt;226,000&lt;/span&gt; at
September 30, 2024. Amortization expenses related to long-term debt was $&lt;span id="xdx_905_eus-gaap--AdjustmentForAmortization_c20240101__20240930_zYRX6B9Jm1b6" title="Amortization expenses of long term debt"&gt;232,000&lt;/span&gt; at September 30, 2024. This consisted of $&lt;span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20240101__20240930_zL3PbyesAp83" title="Original issue discount"&gt;226,000&lt;/span&gt; in
original issue discount and $&lt;span id="xdx_900_eus-gaap--LoanProcessingFee_c20240101__20240930_z2VnrXySTJX" title="Loan fee amortization"&gt;6,000&lt;/span&gt; for loan fee amortization. Future maturities of long-term debt at September 30, 2024 were $&lt;span id="xdx_90C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_c20240930_zZweHYSlJ3j5" title="Future maturities of long term debt"&gt;750,000&lt;/span&gt;
for fiscal years ending December 31, 2024 and $&lt;span id="xdx_90E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20240930_zPHus6N6Alqd" title="Future maturities of long term debt"&gt;2,551,000&lt;/span&gt; for fiscal years ending December 31, 2025.&lt;/p&gt;

&lt;p style="display: none; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
                                            portion of long-term debt of approximately $3,000,000 is net of the current portion of debt
                                            discount of approximately $397,000 and the current portion of debt origination costs of approximately
                                            $10,000 as of September 30, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term
                                            portion of debt of approximately $301,000 is net of the long-term portion of debt discount
                                            of approximately $159,000 and the unamortized debt origination costs of approximately $3,000
                                            as of September 30, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current portion of long-term debt of approximately $&lt;span id="xdx_90F_eus-gaap--DeferredFinanceCostsCurrentGross_iI_c20240930_zNYv0YVPyoB9" title="Long-term debt, current"&gt;3,000,000&lt;/span&gt; is net of the current portion of debt discount of approximately $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20240930_zBDxCiJYsPK2" title="Debt discount, current"&gt;397,000&lt;/span&gt; and the current portion of debt origination costs of approximately $&lt;span id="xdx_904_eus-gaap--DeferredFinanceCostsCurrentNet_iI_c20240930_zNKvXoyp7qsg" title="Debt origination costs, current"&gt;10,000&lt;/span&gt; as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term portion of debt of approximately $&lt;span id="xdx_904_eus-gaap--DeferredFinanceCostsNoncurrentGross_iI_c20240930_zEs4B5YzXbf9" title="Long-term debt, non current"&gt;301,000&lt;/span&gt; is net of the long-term portion of debt discount of approximately $&lt;span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_c20240930_zC0vbMLiyli1" title="Debt discount, non current"&gt;159,000&lt;/span&gt; and the unamortized debt origination costs of approximately $&lt;span id="xdx_909_eus-gaap--DeferredFinanceCostsNoncurrentNet_iI_c20240930_zaA5Ts4qZz5c" title="Debt origination costs, non current"&gt;3,000&lt;/span&gt; as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentRedemptionDescription_c20240216__20240216__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember__us-gaap--CreditFacilityAxis__custom--StreetervilleCapitalLlcMember_zdzkBdvHSll3" title="Redemption description"&gt;The
agreement allows the Lender to redeem up to $250,000 per calendar month beginning in August 2024, upon providing written notice to Borrower.&lt;/span&gt;
The Note further contains triggering events which can be remedied by the Lender requiring the Borrower to correct the triggering event,
increasing the outstanding balance by applying the triggering effect, or making the Note immediately due and payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2024-02-162024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember"
      decimals="0"
      id="Fact000861"
      unitRef="USD">2500000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2024-02-162024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember"
      decimals="0"
      id="Fact000863"
      unitRef="USD">781250</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:LongTermDebt
      contextRef="AsOf2024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember"
      decimals="0"
      id="Fact000865"
      unitRef="USD">3301250</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="AsOf2024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember"
      decimals="0"
      id="Fact000867"
      unitRef="USD">20000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember"
      decimals="INF"
      id="Fact000869"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:UnsecuredDebt
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000871"
      unitRef="USD">0</us-gaap:UnsecuredDebt>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000873">&lt;p id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_z8qR51yTaila" style="font: 10pt Times New Roman, Times, Serif; display: none; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span&gt;&lt;span id="xdx_8B3_zzL1KXT6vYW6"&gt;Schedule of Long Term Debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240930_znIPEbSifguf" style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Debt schedule at September 30, 2024 (in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LongTermDebt_iI_pn3n3_z5Qzrbi8hhlh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 77%; text-align: left"&gt;Long-term debt&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;3,301&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn3n3_zme2jc2Cl9lc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unamortized Original issue discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(555&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_zEzzylzYJd6g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Unamortized Financing fees&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn3n3_z1sjpi9zFbp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unamortized discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LongTermDebtCurrent_iNI_pn3n3_di_z3tDTtSH1sf1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less current portion of long-term debt, net &lt;span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,593&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zfrhvPyY2899" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Long-term debt, net &lt;span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;139&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000875"
      unitRef="USD">3301000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000877"
      unitRef="USD">-555000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000879"
      unitRef="USD">14000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000881"
      unitRef="USD">2732000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000883"
      unitRef="USD">2593000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000885"
      unitRef="USD">139000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact000887"
      unitRef="USD">226000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact000889"
      unitRef="USD">232000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact000891"
      unitRef="USD">226000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:LoanProcessingFee
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact000893"
      unitRef="USD">6000</us-gaap:LoanProcessingFee>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000895"
      unitRef="USD">750000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000897"
      unitRef="USD">2551000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:DeferredFinanceCostsCurrentGross
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000899"
      unitRef="USD">3000000</us-gaap:DeferredFinanceCostsCurrentGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000901"
      unitRef="USD">397000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000903"
      unitRef="USD">10000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentGross
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000905"
      unitRef="USD">301000</us-gaap:DeferredFinanceCostsNoncurrentGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000907"
      unitRef="USD">159000</us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000909"
      unitRef="USD">3000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DebtInstrumentRedemptionDescription
      contextRef="From2024-02-162024-02-16_custom_NotePurchaseAgreementMember_custom_StreetervilleCapitalLlcMember"
      id="Fact000911">The
agreement allows the Lender to redeem up to $250,000 per calendar month beginning in August 2024, upon providing written notice to Borrower.</us-gaap:DebtInstrumentRedemptionDescription>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact000913">&lt;p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zh3Get3u1WJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8: &lt;span id="xdx_826_zl4NLBGUAcmb"&gt;Equity-Based Compensation &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
2018 Equity Incentive Plan, effective September 12, 2018, as amended and restated on August 19, 2019 (the &#x201c;2018 Equity
Incentive Plan&#x201d;) authorizes the grant of (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock
Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii)
Performance Cash Awards, and (viii) Other Stock Awards. After taking into account the &lt;span id="xdx_90F_eus-gaap--StockholdersEquityReverseStockSplit_c20180912__20180912__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z5Ns7upVg8jl" title="Stockholders equity reverse stock split"&gt;44:1 reverse stock split&lt;/span&gt; which was effected in
June 2019, initially, a maximum of &lt;span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20180912__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zM5eWYs3gOz9" title="Number of stock is reserved for potential issuance"&gt;230,390&lt;/span&gt;
shares of common stock were reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan. When the plan
was amended and restated, an additional &lt;span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20180912__us-gaap--PlanNameAxis__custom--RestatedTwoThousandEighteenEquityIncentivePlanMember_zepBZ2X2JJ91" title="Number of stock is reserved for potential issuance"&gt;250,000&lt;/span&gt;
shares were reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan. The number of shares of the
Company&#x2019;s common stock available for grant and issuance under the 2018 Equity Incentive Plan is subject to an annual increase
on July 1 of each calendar year, by an amount equal to two percent (2%) of the then outstanding shares of the Company&#x2019;s common
stock (the &#x201c;2018 Plan Evergreen Provision&#x201d;). On August 3, 2020, and July 1, 2021, 2022, 2023 and 2024, the number of
shares of the Company&#x2019;s common stock available for grant and issuance under the 2018 Equity Incentive Plan increased by &lt;span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20200803__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zSpUj2Db4E4b" title="Number of stock is reserved for potential issuance"&gt;685,012&lt;/span&gt;
shares, &lt;span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zf33XvYiGk97" title="Number of stock is reserved for potential issuance"&gt;956,660&lt;/span&gt;
shares, &lt;span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zBbAwwsEjpd5" title="Number of stock is reserved for potential issuance"&gt;960,976&lt;/span&gt;
shares, &lt;span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKsli0FMfluf" title="Number of stock is reserved for potential issuance"&gt;968,389&lt;/span&gt;
and &lt;span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240701__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zBPGcH9fZNL5" title="Number of stock is reserved for potential issuance"&gt;1,142,733&lt;/span&gt;
shares, respectively. As a result of the 2018 Plan Evergreen Provisions, a maximum of &lt;span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zVScmBNLTND9" title="Number of stock is reserved for potential issuance"&gt;5,167,160&lt;/span&gt;
shares of common stock is reserved for potential issuance pursuant to awards under the 2018 Equity Incentive Plan as of September
30, 2024. Unless sooner terminated, the 2018 Equity Incentive Plan will continue in effect for a period of &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20180912__20180912__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_znPFYVH4i0Sa" title="Option vested years"&gt;10&lt;/span&gt;
years from its effective date. During the fiscal year ended December 31, 2018, the Board of Directors issued &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20180101__20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zWJLKt2DDjY2" title="Number of options issued"&gt;1,189,284&lt;/span&gt;
options to each employee, the officers and directors at the exercise price of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20180101__20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zCcvL9Kb4Xnb" title="Exercise price"&gt;9.68&lt;/span&gt;
expiring in &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20180101__20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zGI9O7TGMhKe" title="Expiration period"&gt;10&lt;/span&gt;
years &lt;span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20180101__20181231_znVg4dNtEGU5" title="Stockholders equity reverse stock split"&gt;(27,028 options post reverse split)&lt;/span&gt;. During the fiscal year ending December 31, 2019, &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zeW3j5Ztk5Cj" title="Number of options issued"&gt;1,727,756&lt;/span&gt;
options were issued to each of these officers with an exercise price of $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20190101__20191231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zcUoNv9gWtJ8" title="Exercise price"&gt;9.68&lt;/span&gt;
for a period of &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20190101__20191231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zPXJcKkMOhde" title="Expiration period"&gt;ten
years&lt;/span&gt; with a vesting period of &lt;span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20190101__20191231_z2xit69fxrcb" title="Stockholders equity reverse stock split"&gt;one year (39,266 options post reverse split).&lt;/span&gt; During the fiscal year ending December 31, 2020, &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20200101__20201231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--TitleOfIndividualAxis__srt--OfficerMember_zmeg4dVDRNm3" title="Number of options issued"&gt;1,025,000&lt;/span&gt;
options were issued to each of these officers and directors with an exercise price range of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zTVwL4ez8rTl" title="Exercise price range"&gt;2.77&lt;/span&gt;
to $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z713DIxSEuT3" title="Option exercise price per share"&gt;3.07&lt;/span&gt;
for a period of &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20200101__20201231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_z5uk8Bere3nb" title="Expiration period"&gt;ten
years&lt;/span&gt; with a vesting period of one year. During the fiscal year ending December 31, 2021, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zsCDxuA8GMLg" title="Number of options granted"&gt;613,512&lt;/span&gt;
options were issued to officers, directors and consultants with an exercise price range of $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_z4RfXftsVTMi" title="Exercise price range"&gt;1.11&lt;/span&gt;
to $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zxTnbndBT9Gj" title="Option exercise price per share"&gt;1.71&lt;/span&gt;
for a period of &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210101__20211231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKybHGnE7cKh" title="Expiration period"&gt;ten
years&lt;/span&gt; with a vesting period of one year. During the fiscal year ending December 31, 2022, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zzlmhdaSrfYh" title="Number of options granted"&gt;850,000&lt;/span&gt;
options were issued to officers, directors and consultants with an exercise price range of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MinimumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zKAhZBMvT4m4" title="Option exercise price per share"&gt;0.31&lt;/span&gt;
to $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__srt--RangeAxis__srt--MaximumMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zSdfv7msygx6" title="Option exercise price per share"&gt;0.71&lt;/span&gt;
for a period of &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220101__20221231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zA0GtgA6Paga" title="Expiration period"&gt;ten
years&lt;/span&gt; with a vesting period of one year. During the fiscal year ending December 31, 2023, &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zbza9FnqKFl9" title="Number of options granted"&gt;400,000&lt;/span&gt;
options were issued to officers with an exercise price of $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zTLR2sRmaCzc" title="Exercise price range"&gt;0.47&lt;/span&gt;
for a period of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230101__20231231__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zIvzsvbAwMue" title="Expiration period"&gt;ten
years&lt;/span&gt; with a vesting period of one year. During the nine months ended September 30, 2024 there were &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20240101__20240930__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zY288SslhGRk" title="Number of options granted"&gt;no&lt;/span&gt;
options issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of each option and equity warrant award is estimated on the date of grant using a Black-Scholes-Merton option pricing valuation
model. Expected volatility is based on the historical volatility of the price of the Company&#x2019;s stock. The risk-free interest rate
is based on U.S. Treasury issues with a term equal to the expected life of the option and equity warrant. The Company uses historical
data to estimate expected dividend yield, expected life and forfeiture rates. During the nine months ended September 30, 2024, and 2023,
there were &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20240101__20240930__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zJZRsp0gA9hk" title="Number of options granted"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_do_c20230101__20230930__srt--TitleOfIndividualAxis__srt--OfficerMember__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zxe4UkvTeVB1" title="Number of options granted"&gt;no&lt;/span&gt;&lt;/span&gt; options granted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
options activity during the three months ended September 30, 2024, was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SOSBCSOASA-KMP_zh7fODkBMfI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
option activity for employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zELmZh9E6l79" style="display: none"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term &lt;br/&gt;(Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding June 30, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjyD49yckon5" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year"&gt;2,407,775&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUDZ6B9tPuhk" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zA6WtLyZASid" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsI90ptM0jv6" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0997"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlJOUT20gvv" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0999"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHLE9He70K7f" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUqxUDPKGHFg" style="text-align: right" title="Aggregate Intrinsic Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9AaJcEwgYJh" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1005"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7JJEhxpI8t1" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zH3aSRizWyMk" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1009"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIJ6I7oTvk64" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7AT3mlVDgFa" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1013"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zaxovopTHiic" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1015"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSb3FI5Sl4P9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period"&gt;2,407,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziURHvTtM7Wk" title="Weighted Average Exercise Price Outstanding, End of Period"&gt;2.44&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7nelISYhCrd" title="Weighted Average Remaining Contracted Term (years)"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zqhlUrLQeYt5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1023"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vested and expected to vest September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoXN9PEJ5iLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest"&gt;2,407,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCF6ICTITSrg" title="Weighted Average Exercise Price, Vested and Expected to Vest"&gt;2.44&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjEemedfkDJ3" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNwglLCnLnB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1031"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbhf65Q8YFt7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period"&gt;2,341,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl7Tc0AMcUah" title="Weighted Average Exercise Price Exercisable, Ending of Period"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSKGKa98BCnd" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;7.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zb7jfHMAqa5e" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1039"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zrU2qa2FTRGk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SONSATTB-QOTKSOK_zQj05qtEmQE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unvested
stock option activity for employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z9DxytPfegse" style="display: none"&gt;Schedule
of Unvested Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of &lt;br/&gt;Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt; Exercise &lt;br/&gt;Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term &lt;br/&gt;(Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Unvested June 30, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z84haaRrIaI6" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period"&gt;166,666&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOPx0OQtrqJb" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period"&gt;4.11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhcjV7bPlK7e" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;18.87&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbJjxQA7vjk4" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1052"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMg0PpIF6h3c" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1054"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOG76PIF5jX9" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1056"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zytehApLdBq6" style="text-align: right" title="Aggregate Intrinsic Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1058"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl4AwqJtOUXg" style="text-align: right" title="Number of Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVvGzMWc26n8" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z702F2nVWw5l" style="text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1064"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRGMkXjIjQIh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested"&gt;(99,905&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z5W5LUTZBwu2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zGhlSXfeXe6d" title="Weighted Average Remaining Contracted Term (years) Vested"&gt;7.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTPUpqtwN4og" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjiOohm1j9rd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period"&gt;66,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbnRsZ3Zcdk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period"&gt;9.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV3ToK6T3u89" title="Average Remaining Contractual Term (years) Unvested, End of Period"&gt;36.22&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUafxgzWlok5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1080"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zuH4ZGrHpM0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SOSBCSOASA-DNQVA_zuXh3tppq76j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
option activity for non-employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zx8D0sBXYWv9" style="display: none"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term (Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding June 30, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaF5yDYcOZA7" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning of Period"&gt;885,055&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z7kZUofcgBYe" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;2.02&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zftq24OTTlz7" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcJElAxfvgD6" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1092"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdySOjgFrc5a" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1094"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCvgHS82Mkwi" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1096"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z2s1Nfh7zpJe" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1098"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMpaDHJEvhw2" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1100"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeKE3oa92K1f" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhjdzz3wNJak" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1104"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z710pkk0K0uh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabMb2JSrqdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1108"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztqKFXx2XeCd" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1110"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeAutH3C3k71" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period"&gt;884,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z30GS8sFl1ak" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period"&gt;1.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9ABWbeWmxz3" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfXx2BNnCGS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vested and expected to vest September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zz9QdZSHTZuj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest"&gt;884,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhLvrb2naeBe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest"&gt;1.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXLoaRrf9Nvi" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAnWbQZRLmYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRESdE1Et5lh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period"&gt;729,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zl9srwqwk9kc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period"&gt;1.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zu2ni2MpRR0a" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;10.06&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFkhX2aFesW2" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1134"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zNrthgPuYDXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SONSATTB-BWM_z7TXuu6oUU0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unvested
stock option activity for non-employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zXrhTt3hW8sd" style="display: none"&gt;Schedule
of Unvested Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of &lt;br/&gt;Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term &lt;br/&gt;(Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt;Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Unvested June 30, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjsXfy3G7EIc" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period"&gt;155,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zng86shSyV5i" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period"&gt;3.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zyzkdqaqA9La" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;11.30&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUSMNti8XCE7" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1147"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZW30cPwV71a" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1149"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFNQl2tfVz83" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1151"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zo7fYGT9D579" style="text-align: right" title="Aggregate Intrinsic Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1153"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0n4X6iePLti" style="text-align: right" title="Number of Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zr8ObjoHO3b4" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1157"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRzwbedcMbrf" style="text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1159"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYIPol713VB9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested"&gt;95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcCNSfs1wMbi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested"&gt;0.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwaIDvMMIrt5" title="Average Remaining Contractual Term Vested"&gt;10.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMTvchDc45Of" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zE2w3bbv2uFl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period"&gt;155,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zyZlk7DeOZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period"&gt;3.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUOg3jQg6uz8" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;11.31&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBQ8EF5Zv8ui" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1175"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zQqB44N6O36d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation expense was approximately $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_c20240701__20240930_zlWx30wz2pFi" title="Share based compensation expense"&gt;80,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_c20230701__20230930_zBP7qd56yUj8" title="Share based compensation expense"&gt;50,000&lt;/span&gt; for the three months ended September 30, 2024, and 2023, resulting in an increase
in general and administrative expenses, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Employee
stock option activity during the nine months ended September 30, 2024, was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
option activity for employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C06_gL3SOSBCSOASA-KMP_zFYpVLRmIcz5"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30B_134_zbpFI8KrQIwe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt; Term &lt;br/&gt;(Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWsKzf9ySWcd" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year"&gt;2,408,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrvicYzwmdP5" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zN11clVZ5eVd" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zS9HesshdjB8" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zy6V6T5rRRN" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1189"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWJ8tezMnSG9" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1191"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhNtAfhE9CKc" style="text-align: right" title="Aggregate Intrinsic Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1193"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUJy01uAGkja" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1195"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z4k29IU5MeS8" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1197"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZ3INBtll8s8" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3RLPP1Z58l5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired"&gt;(758&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z5a9p87y7Nvl" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1203"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7rBX5pcldNj" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1205"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9PiyYO55108" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period"&gt;2,407,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zgiaI51Yf8Ud" title="Weighted Average Exercise Price Outstanding, End of Period"&gt;2.44&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV7PHskuC1te" title="Weighted Average Remaining Contracted Term (years)"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziTI4BvTbXZd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1213"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vested and expected to vest September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9jbdJ1UeeN2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest"&gt;2,407,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrwk3sPKL9r7" title="Weighted Average Exercise Price, Vested and Expected to Vest"&gt;2.44&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zISzyz1ExvRd" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8k63vScsNze" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1221"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8jCkn80oLDd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period"&gt;2,341,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zm7FjiaJ5nX1" title="Weighted Average Exercise Price Exercisable, Ending of Period"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlpZTqTiXH5" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;7.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNuy0VHkTDIi" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_C0E_gL3SOSBCSOASA-KMP_zZkor6JBlWQd"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unvested
stock option activity for employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_C0A_gL3SONSATTB-QOTKSOK_zBTuXomo6wV6"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C06_gL3SONSATTB-QOTKSOK_zZpy4ve80s04"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_308_134_zAZ64rbchUKi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of &lt;br/&gt;Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt; Contractual &lt;br/&gt;Term &lt;br/&gt;(Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt;Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Unvested January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrsbidNc06B2" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period"&gt;366,666&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zStSkwQd2cG2" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period"&gt;2.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zheVkcZA5wN6" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;12.44&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0qY0UsmBYE8" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1237"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zudH9uJhIe6a" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSLDdwvQEmd1" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z27QE6z6S5j5" style="text-align: right" title="Aggregate Intrinsic Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1243"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zorokXUxmwrj" style="text-align: right" title="Number of Options, Expired"&gt;(758&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zKpUHgKinFYd" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRFXpXaqQykh" style="text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1249"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zu3UHcuxfiG2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested"&gt;(299,242&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXQeItkxToq4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zh9JpIprSBu" title="Weighted Average Remaining Contracted Term (years) Vested"&gt;7.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zucRbwQeqIJg" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1257"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zouqYb3AJvB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period"&gt;66,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziPvgbO0hBaa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period"&gt;9.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJpG8ywn1Zi" title="Average Remaining Contractual Term (years) Unvested, End of Period"&gt;36.22&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRctqqO8TGzl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_C0C_gL3SONSATTB-QOTKSOK_zgDqFqbCeDhd"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
option activity for non-employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C04_gL3SOSBCSOASA-DNQVA_z9pVz8jZzuFk"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_306_134_z5EIUSL00SQj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term (Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAx9aZk5OJy1" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning of Period"&gt;885,055&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8Yy6kGEQ4gb" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;2.02&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zveAC0DMk4z8" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWf50mYIhqz3" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1273"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWvZ5bQsiAw5" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1275"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfVgCh1XgInb" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1277"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGBxQLenuel9" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1279"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zLhHJxFeAAWb" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1281"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIBK4GHzRX4" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1283"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPHXTzz1QA24" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1285"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMBcS49SknKb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUTYNo2XeF6b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwxBMmTX69k8" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1291"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zg8oTRGTPnQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period"&gt;884,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMuWMj8NH6ef" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period"&gt;1.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzu1hl5CNjUc" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztMrm84L0PBa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1299"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vested and expected to vest September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpinr46l4aYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest"&gt;884,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zM7xY4RRunc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest"&gt;1.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsq7ABwkucle" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUPo1PxB47Df" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1307"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpXb0qGCGuW6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period"&gt;729,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHk8CF75wanf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period"&gt;1.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuXm6S64XwJj" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;10.06&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZvKwcanEdFa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1315"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_C08_gL3SOSBCSOASA-DNQVA_zzy3q39sC92l"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unvested
stock option activity for non-employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_C0B_gL3SONSATTB-BWM_zfB4RMT3VGs"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C01_gL3SONSATTB-BWM_zOhQk7WcFAvi"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_305_134_zi3j29Bqb4l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of &lt;br/&gt;Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term &lt;br/&gt;(Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt;Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Unvested January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztMKYaa2HcQ7" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period"&gt;335,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwWwzRJl4Fs4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period"&gt;1.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvt3P0Xidfej" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;10.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoypW4H5aJF" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1323"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKQZKbADmTGg" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1325"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIn40faYM6ml" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1327"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zedKPVdPJhJb" style="text-align: right" title="Aggregate Intrinsic Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1329"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z1CmUEv6YRF2" style="text-align: right" title="Number of Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zItSoXu7NGHb" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1333"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zN47RSNjmyNe" style="text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1335"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTJT17NtE8M4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested"&gt;(179,905&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zbPwr0p8XMQ" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested"&gt;0.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhOprlOO2tMk" title="Average Remaining Contractual Term Vested"&gt;10.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcKVg4IKRwBk" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1343"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqPrUzeBm0jc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period"&gt;155,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVCsCim7RUvc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period"&gt;3.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeugZ61eatxh" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;11.31&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzEf8hRTmQY7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1351"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_C09_gL3SONSATTB-BWM_z5foyejtwwn7"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation expense was approximately $&lt;span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240930_zl13KkQhH6r1" title="Share based compensation expense"&gt;490,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930_z40MJp1EWLu5" title="Share based compensation expense"&gt;182,000&lt;/span&gt; for the nine months ended September 30, 2024, and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the Company&#x2019;s cash conservation strategy, the Company issued common stock as a substitute for cash salaries to certain
executives. For the three and nine months ended September 30, 2024, stock issued as payroll totaled $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20240701__20240930_z2yi3uNrBDij" title="Stock issued as payroll, value"&gt;&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20240101__20240930_zaXVnXiACW1l" title="Stock issued as payroll, value"&gt;250,000&lt;/span&gt;&lt;/span&gt;, which is included in the
overall equity-based compensation expense. There was no stock issued as payroll for the three and nine months ended September 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 30, 2024, and 2023, respectively, there was approximately $&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20240930_zKS25oHb6946"&gt;53,400
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20230930_zgb2CZZ4zs42"&gt;35,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of unrecognized equity-based compensation cost
related to options granted under the Equity Incentive Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2018-09-122018-09-12_custom_TwoThousandEighteenEquityIncentivePlanMember"
      id="Fact000915">44:1 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-09-12_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000917"
      unitRef="Shares">230390</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-09-12_custom_RestatedTwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000919"
      unitRef="Shares">250000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-08-03_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000921"
      unitRef="Shares">685012</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000923"
      unitRef="Shares">956660</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000925"
      unitRef="Shares">960976</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000927"
      unitRef="Shares">968389</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-07-01_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000929"
      unitRef="Shares">1142733</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-09-30_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000931"
      unitRef="Shares">5167160</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2018-09-122018-09-12_custom_TwoThousandEighteenEquityIncentivePlanMember"
      id="Fact000933">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2018-01-012018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember"
      decimals="INF"
      id="Fact000935"
      unitRef="Shares">1189284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2018-01-012018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember"
      decimals="INF"
      id="Fact000937"
      unitRef="USDPShares">9.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2018-01-012018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember"
      id="Fact000939">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2018-01-012018-12-31" id="Fact000941">(27,028 options post reverse split)</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-01-012019-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember"
      decimals="INF"
      id="Fact000943"
      unitRef="Shares">1727756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember"
      decimals="INF"
      id="Fact000945"
      unitRef="USDPShares">9.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2019-01-012019-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember"
      id="Fact000947">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2019-01-012019-12-31" id="Fact000949">one year (39,266 options post reverse split).</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember"
      decimals="INF"
      id="Fact000951"
      unitRef="Shares">1025000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000953"
      unitRef="USDPShares">2.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_srt_OfficerMember_srt_MaximumMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000955"
      unitRef="USDPShares">3.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2020-01-012020-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_OfficerMember"
      id="Fact000957">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000959"
      unitRef="Shares">613512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000961"
      unitRef="USDPShares">1.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-12-31_srt_OfficerMember_srt_MaximumMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000963"
      unitRef="USDPShares">1.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2021-01-012021-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      id="Fact000965">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000967"
      unitRef="Shares">850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_srt_OfficerMember_srt_MinimumMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000969"
      unitRef="USDPShares">0.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_srt_OfficerMember_srt_MaximumMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000971"
      unitRef="USDPShares">0.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2022-01-012022-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      id="Fact000973">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000975"
      unitRef="Shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000977"
      unitRef="USDPShares">0.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2023-01-012023-12-31_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      id="Fact000979">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-09-30_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000981"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-09-30_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000983"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-09-30_srt_OfficerMember_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact000985"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact000989">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SOSBCSOASA-KMP_zh7fODkBMfI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
option activity for employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zELmZh9E6l79" style="display: none"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term &lt;br/&gt;(Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding June 30, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjyD49yckon5" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year"&gt;2,407,775&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUDZ6B9tPuhk" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zA6WtLyZASid" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zsI90ptM0jv6" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0997"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlJOUT20gvv" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0999"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zHLE9He70K7f" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUqxUDPKGHFg" style="text-align: right" title="Aggregate Intrinsic Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1003"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9AaJcEwgYJh" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1005"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7JJEhxpI8t1" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zH3aSRizWyMk" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1009"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zIJ6I7oTvk64" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7AT3mlVDgFa" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1013"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zaxovopTHiic" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1015"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSb3FI5Sl4P9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period"&gt;2,407,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziURHvTtM7Wk" title="Weighted Average Exercise Price Outstanding, End of Period"&gt;2.44&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7nelISYhCrd" title="Weighted Average Remaining Contracted Term (years)"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zqhlUrLQeYt5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1023"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vested and expected to vest September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zoXN9PEJ5iLk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest"&gt;2,407,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zCF6ICTITSrg" title="Weighted Average Exercise Price, Vested and Expected to Vest"&gt;2.44&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjEemedfkDJ3" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNwglLCnLnB1" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1031"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbhf65Q8YFt7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period"&gt;2,341,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl7Tc0AMcUah" title="Weighted Average Exercise Price Exercisable, Ending of Period"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSKGKa98BCnd" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;7.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zb7jfHMAqa5e" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1039"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30B_134_zbpFI8KrQIwe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt; Term &lt;br/&gt;(Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWsKzf9ySWcd" style="width: 12%; text-align: right" title="Number of options outstanding, beginning of year"&gt;2,408,438&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrvicYzwmdP5" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zN11clVZ5eVd" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zS9HesshdjB8" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zy6V6T5rRRN" style="text-align: right" title="Number of options, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1189"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zWJ8tezMnSG9" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1191"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhNtAfhE9CKc" style="text-align: right" title="Aggregate Intrinsic Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1193"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUJy01uAGkja" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1195"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z4k29IU5MeS8" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1197"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zZ3INBtll8s8" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z3RLPP1Z58l5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired"&gt;(758&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z5a9p87y7Nvl" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1203"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirednPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7rBX5pcldNj" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1205"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9PiyYO55108" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period"&gt;2,407,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zgiaI51Yf8Ud" title="Weighted Average Exercise Price Outstanding, End of Period"&gt;2.44&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV7PHskuC1te" title="Weighted Average Remaining Contracted Term (years)"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziTI4BvTbXZd" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, Ending of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1213"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vested and expected to vest September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z9jbdJ1UeeN2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest"&gt;2,407,680&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrwk3sPKL9r7" title="Weighted Average Exercise Price, Vested and Expected to Vest"&gt;2.44&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zISzyz1ExvRd" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8k63vScsNze" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1221"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z8jCkn80oLDd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period"&gt;2,341,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zm7FjiaJ5nX1" title="Weighted Average Exercise Price Exercisable, Ending of Period"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zlpZTqTiXH5" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;7.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNuy0VHkTDIi" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Exercisable at End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&#160;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact000991"
      unitRef="Shares">2407775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact000993"
      unitRef="USDPShares">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact000995">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001011"
      unitRef="Shares">95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001017"
      unitRef="Shares">2407680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001019"
      unitRef="USDPShares">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001021">P8Y8M12D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001025"
      unitRef="Shares">2407680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001027"
      unitRef="USDPShares">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001029">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001033"
      unitRef="Shares">2341014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001035"
      unitRef="USDPShares">1.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001037">P7Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001044">&lt;p id="xdx_891_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_gL3SONSATTB-QOTKSOK_zQj05qtEmQE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unvested
stock option activity for employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z9DxytPfegse" style="display: none"&gt;Schedule
of Unvested Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of &lt;br/&gt;Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt; Exercise &lt;br/&gt;Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term &lt;br/&gt;(Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt; Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Unvested June 30, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z84haaRrIaI6" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period"&gt;166,666&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOPx0OQtrqJb" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period"&gt;4.11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zhcjV7bPlK7e" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;18.87&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbJjxQA7vjk4" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1052"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zMg0PpIF6h3c" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1054"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zOG76PIF5jX9" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1056"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zytehApLdBq6" style="text-align: right" title="Aggregate Intrinsic Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1058"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zl4AwqJtOUXg" style="text-align: right" title="Number of Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zVvGzMWc26n8" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z702F2nVWw5l" style="text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1064"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRGMkXjIjQIh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested"&gt;(99,905&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z5W5LUTZBwu2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zGhlSXfeXe6d" title="Weighted Average Remaining Contracted Term (years) Vested"&gt;7.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zTPUpqtwN4og" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zjiOohm1j9rd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period"&gt;66,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zbnRsZ3Zcdk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period"&gt;9.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV3ToK6T3u89" title="Average Remaining Contractual Term (years) Unvested, End of Period"&gt;36.22&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUafxgzWlok5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1080"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_308_134_zAZ64rbchUKi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of &lt;br/&gt;Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt; Contractual &lt;br/&gt;Term &lt;br/&gt;(Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt;Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Unvested January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrsbidNc06B2" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period"&gt;366,666&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zStSkwQd2cG2" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period"&gt;2.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zheVkcZA5wN6" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;12.44&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z0qY0UsmBYE8" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1237"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zudH9uJhIe6a" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSLDdwvQEmd1" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z27QE6z6S5j5" style="text-align: right" title="Aggregate Intrinsic Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1243"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zorokXUxmwrj" style="text-align: right" title="Number of Options, Expired"&gt;(758&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zKpUHgKinFYd" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRFXpXaqQykh" style="text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1249"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zu3UHcuxfiG2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested"&gt;(299,242&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zXQeItkxToq4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zh9JpIprSBu" title="Weighted Average Remaining Contracted Term (years) Vested"&gt;7.17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zucRbwQeqIJg" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1257"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zouqYb3AJvB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period"&gt;66,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ziPvgbO0hBaa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period"&gt;9.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zJpG8ywn1Zi" title="Average Remaining Contractual Term (years) Unvested, End of Period"&gt;36.22&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zRctqqO8TGzl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&#160;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001046"
      unitRef="Shares">166666</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001048"
      unitRef="USDPShares">4.11</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001050">P18Y10M13D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001060"
      unitRef="Shares">95</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001066"
      unitRef="Shares">99905</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001068"
      unitRef="USDPShares">0.47</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001070">P7Y2M1D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001074"
      unitRef="Shares">66666</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001076"
      unitRef="USDPShares">9.61</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001078">P36Y2M19D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001084">&lt;p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SOSBCSOASA-DNQVA_zuXh3tppq76j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
option activity for non-employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zx8D0sBXYWv9" style="display: none"&gt;Schedule
of Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term (Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding June 30, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaF5yDYcOZA7" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning of Period"&gt;885,055&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z7kZUofcgBYe" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;2.02&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zftq24OTTlz7" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcJElAxfvgD6" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1092"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zdySOjgFrc5a" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1094"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zCvgHS82Mkwi" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1096"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z2s1Nfh7zpJe" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1098"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMpaDHJEvhw2" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1100"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeKE3oa92K1f" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhjdzz3wNJak" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1104"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z710pkk0K0uh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zabMb2JSrqdd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1108"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztqKFXx2XeCd" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1110"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeAutH3C3k71" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period"&gt;884,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z30GS8sFl1ak" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period"&gt;1.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z9ABWbeWmxz3" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfXx2BNnCGS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vested and expected to vest September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zz9QdZSHTZuj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest"&gt;884,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhLvrb2naeBe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest"&gt;1.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zXLoaRrf9Nvi" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAnWbQZRLmYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRESdE1Et5lh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period"&gt;729,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zl9srwqwk9kc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period"&gt;1.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zu2ni2MpRR0a" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;10.06&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFkhX2aFesW2" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1134"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_306_134_z5EIUSL00SQj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Stock Option Activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term (Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zAx9aZk5OJy1" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning of Period"&gt;885,055&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z8Yy6kGEQ4gb" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning of Period"&gt;2.02&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zveAC0DMk4z8" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWf50mYIhqz3" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1273"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zWvZ5bQsiAw5" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1275"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zfVgCh1XgInb" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1277"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGBxQLenuel9" style="text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1279"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zLhHJxFeAAWb" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1281"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIBK4GHzRX4" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1283"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zPHXTzz1QA24" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1285"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMBcS49SknKb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUTYNo2XeF6b" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwxBMmTX69k8" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1291"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zg8oTRGTPnQh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending of Period"&gt;884,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMuWMj8NH6ef" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, End of Period"&gt;1.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzu1hl5CNjUc" title="Weighted Average Remaining Contracted Term (years) Outstanding"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodTotalIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztMrm84L0PBa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1299"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Vested and expected to vest September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpinr46l4aYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, Vested and Expected to Vest"&gt;884,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zM7xY4RRunc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Vested and Expected to Vest"&gt;1.88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zsq7ABwkucle" title="Weighted Average Remaining Contracted Term (years), Vested and Expected to Vest"&gt;9.23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUPo1PxB47Df" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1307"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zpXb0qGCGuW6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable, End of Period"&gt;729,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zHk8CF75wanf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable, Ending of Period"&gt;1.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zuXm6S64XwJj" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;10.06&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZvKwcanEdFa" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested and Expected to Vest"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1315"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&#160;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001086"
      unitRef="Shares">885055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001088"
      unitRef="USDPShares">2.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001090">P9Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001106"
      unitRef="Shares">95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001112"
      unitRef="Shares">884960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001114"
      unitRef="USDPShares">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001116">P9Y2M23D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001120"
      unitRef="Shares">884960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001122"
      unitRef="USDPShares">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001124">P9Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001128"
      unitRef="Shares">729960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001130"
      unitRef="USDPShares">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001132">P10Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001139">&lt;p id="xdx_893_eus-gaap--ScheduleOfNonvestedShareActivityTableTextBlock_hus-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_gL3SONSATTB-BWM_z7TXuu6oUU0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unvested
stock option activity for non-employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zXrhTt3hW8sd" style="display: none"&gt;Schedule
of Unvested Stock Option Activity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of &lt;br/&gt;Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term &lt;br/&gt;(Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt;Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Unvested June 30, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjsXfy3G7EIc" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period"&gt;155,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zng86shSyV5i" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period"&gt;3.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zyzkdqaqA9La" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;11.30&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUSMNti8XCE7" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1147"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zZW30cPwV71a" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1149"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zFNQl2tfVz83" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1151"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zo7fYGT9D579" style="text-align: right" title="Aggregate Intrinsic Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1153"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z0n4X6iePLti" style="text-align: right" title="Number of Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zr8ObjoHO3b4" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1157"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zRzwbedcMbrf" style="text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1159"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zYIPol713VB9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested"&gt;95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcCNSfs1wMbi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested"&gt;0.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwaIDvMMIrt5" title="Average Remaining Contractual Term Vested"&gt;10.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zMTvchDc45Of" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zE2w3bbv2uFl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period"&gt;155,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zyZlk7DeOZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period"&gt;3.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zUOg3jQg6uz8" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;11.31&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240701__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBQ8EF5Zv8ui" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1175"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&#160;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_305_134_zi3j29Bqb4l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Unvested Stock Option Activity (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of &lt;br/&gt;Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Term &lt;br/&gt;(Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate &lt;br/&gt; Intrinsic &lt;br/&gt;Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Unvested January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_ztMKYaa2HcQ7" style="width: 12%; text-align: right" title="Number of Options Unvested, Beginning of Period"&gt;335,001&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zwWwzRJl4Fs4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Unvested, Beginning of Period"&gt;1.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zvt3P0Xidfej" title="Average Remaining Contractual Term (years) Unvested, Beginning of Period"&gt;10.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iS_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zoypW4H5aJF" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value Unvested, Beginning of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1323"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zKQZKbADmTGg" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1325"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zIn40faYM6ml" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1327"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantsInPeriodAggregateIntrinsicValue_pdp0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zedKPVdPJhJb" style="text-align: right" title="Aggregate Intrinsic Value, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1329"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z1CmUEv6YRF2" style="text-align: right" title="Number of Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zItSoXu7NGHb" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1333"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zN47RSNjmyNe" style="text-align: right" title="Aggregate Intrinsic Value, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1335"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zTJT17NtE8M4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Vested"&gt;(179,905&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zbPwr0p8XMQ" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested"&gt;0.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zhOprlOO2tMk" title="Average Remaining Contractual Term Vested"&gt;10.18&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAggregateIntrinsicValue_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zcKVg4IKRwBk" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1343"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Unvested September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqPrUzeBm0jc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Unvested, End of Period"&gt;155,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVCsCim7RUvc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Unvested, Ending of Period"&gt;3.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeugZ61eatxh" title="Weighted Average Remaining Contracted Term (years), Exercisable at End of Period"&gt;11.31&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedAggregateIntrinsicValue_iE_pp0p0_c20240101__20240930__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zzEf8hRTmQY7" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Unvested, End of Period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1351"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001141"
      unitRef="Shares">155001</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-06-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001143"
      unitRef="USDPShares">3.42</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001145">P11Y3M18D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001155"
      unitRef="Shares">95</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001161"
      unitRef="Shares">95</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001163"
      unitRef="USDPShares">0.46</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001165">P10Y2M4D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001169"
      unitRef="Shares">155001</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001171"
      unitRef="USDPShares">3.42</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001173">P11Y3M21D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001177"
      unitRef="USD">80000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact001179"
      unitRef="USD">50000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001181"
      unitRef="Shares">2408438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001183"
      unitRef="USDPShares">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001185">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001201"
      unitRef="Shares">758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001207"
      unitRef="Shares">2407680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001209"
      unitRef="USDPShares">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001211">P8Y8M12D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001215"
      unitRef="Shares">2407680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001217"
      unitRef="USDPShares">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001219">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001223"
      unitRef="Shares">2341014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001225"
      unitRef="USDPShares">1.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001227">P7Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001231"
      unitRef="Shares">366666</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001233"
      unitRef="USDPShares">2.13</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001235">P12Y5M8D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001245"
      unitRef="Shares">758</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001251"
      unitRef="Shares">299242</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001253"
      unitRef="USDPShares">0.47</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001255">P7Y2M1D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001259"
      unitRef="Shares">66666</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      decimals="INF"
      id="Fact001261"
      unitRef="USDPShares">9.61</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementEmployeeMember"
      id="Fact001263">P36Y2M19D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001267"
      unitRef="Shares">885055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001269"
      unitRef="USDPShares">2.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001271">P9Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001287"
      unitRef="Shares">95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001293"
      unitRef="Shares">884960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001295"
      unitRef="USDPShares">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001297">P9Y2M23D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001301"
      unitRef="Shares">884960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001303"
      unitRef="USDPShares">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001305">P9Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001309"
      unitRef="Shares">729960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001311"
      unitRef="USDPShares">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001313">P10Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001317"
      unitRef="Shares">335001</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001319"
      unitRef="USDPShares">1.83</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001321">P10Y8M12D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001331"
      unitRef="Shares">95</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001337"
      unitRef="Shares">179905</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001339"
      unitRef="USDPShares">0.46</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001341">P10Y2M4D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001345"
      unitRef="Shares">155001</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      decimals="INF"
      id="Fact001347"
      unitRef="USDPShares">3.42</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-09-30_us-gaap_ShareBasedPaymentArrangementNonemployeeMember"
      id="Fact001349">P11Y3M21D</AIM:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm2>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact001353"
      unitRef="USD">490000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact001355"
      unitRef="USD">182000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001357"
      unitRef="USD">250000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact001359"
      unitRef="USD">250000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001360"
      unitRef="USD">53400</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact001361"
      unitRef="USD">35000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001363">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgmcER7ZoG6c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9: &lt;span id="xdx_825_zvWLU1z6KInl"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)
Preferred Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue &lt;span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930_zOqRZT6lrsj3" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt; shares of $&lt;span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240930_zyGSvb1nsSxi" title="Preferred stock stated value"&gt;0.01&lt;/span&gt; par value preferred stock with such designations, rights and preferences as
may be determined by the Board. Of our authorized preferred stock, &lt;span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zRTeQtHLu6kk" title="Preferred stock, shares authorized"&gt;4,000,000&lt;/span&gt; shares have been designated as Series A Junior Participating
Preferred Stock and &lt;span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zhMAyH0nNXuk" title="Preferred stock, shares authorized"&gt;10,000&lt;/span&gt; shares have been designated as Series B Convertible Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
A Junior Participating Preferred Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 10, 2023, the Company filed a Certificate of Increase in Delaware, increasing the number of preferred stock designated as Series
A Junior Participating Preferred Stock to &lt;span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230509__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zfxXoYbt2Aqj" title="Preferred stock, shares authorized"&gt;4,000,000&lt;/span&gt; from &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230510__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_zKWhsVN7Y272" title="Preferred stock, shares authorized"&gt;250,000&lt;/span&gt; shares. As of September 30, 2024, there were no Series A Junior Participating
Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Series
B Convertible Preferred Stock &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has designated &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zI3n7ruFUJ8d"&gt;10,000&lt;/span&gt; shares of its preferred stock as Series B Convertible Preferred Stock (the &#x201c;Preferred Stock&#x201d;).
Each share of Preferred Stock has a par value of $&lt;span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zs73uTZx61vb" title="Preferred stock, par value"&gt;0.01&lt;/span&gt; per share and a stated value equal to $&lt;span id="xdx_90C_ecustom--PreferredStockStatedValuePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zA0Fuo8Eh4c" title="Preferred stock, stated value"&gt;1,000&lt;/span&gt; (the &#x201c;Stated Value&#x201d;).
The shares of Preferred Stock shall initially be issued and maintained in the form of securities held in book-entry form and the Depository
Trust Company or its nominee (&#x201c;DTC&#x201d;) shall initially be the sole registered holder of the shares of Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option
of the Holder thereof or at any time and from time to time on or after the second anniversary of the Original Issue Date at the option
of the Corporation, into that number of shares of common stock (subject in each case to the limitations determined by dividing the Stated
Value of such share of Preferred Stock by the Conversion Price). The conversion price for the Preferred Stock shall be equal to $&lt;span id="xdx_90C_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20240930_zR3DqConzAKj" title="Preferred stock conversion price"&gt;0.20&lt;/span&gt;,
subject to adjustment herein (the &#x201c;Conversion Price&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to a registration statement relating to a rights offering (the &#x201c;Rights Offering&#x201d;) declared effective by the SEC on February
14, 2019, AIM distributed to its holders of common stock and to holders of certain options and redeemable warrants as of February 14,
2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date. Each
right entitled the holder to purchase one unit, at a subscription price of $&lt;span id="xdx_906_eus-gaap--CommonStockSharesSubscriptions_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zKFSenSQuSh3" title="Subscription price"&gt;1,000&lt;/span&gt; per unit, consisting of one share of Series B Convertible
Preferred Stock with a face value of $&lt;span id="xdx_909_ecustom--ConvertiblePreferredStockFaceValue_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zqxI7z5v5fZ6" title="Convertible preferred stock face value"&gt;1,000 &lt;/span&gt;(and immediately convertible into common stock at an assumed conversion price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN3mPLUCoTSa" title="Conversion price"&gt;8.80&lt;/span&gt;) and
&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240930_zmqXhS7lPcxe" title="Number of warrants"&gt;114&lt;/span&gt; warrants with an assumed exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930_zCFqUw37Tfm9" title="Subscription/exercise price"&gt;8.80&lt;/span&gt;. The redeemable warrants are exercisable for five years after the date of issuance.
The net proceeds realized from the rights offering were approximately $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RightsMember_zJ5uCOPkTQP4" title="Net proceeds from warrants"&gt;4,700,000&lt;/span&gt;. As of September 30, 2024, &lt;span id="xdx_90B_eus-gaap--ConversionOfStockSharesIssued1_pid_c20240101__20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zAzKca2mMK04" title="Conversion of shares issued"&gt;689&lt;/span&gt; shares of Series B Convertible
Preferred Stock had expired, and none were converted prior to expiration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)
Common Stock and Equity Finances&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has authorized shares of &lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_zKV0ggF1L197" title="Common stock, shares authorized"&gt;350,000,000&lt;/span&gt; with specific limitations and restrictions on the usage of &lt;span id="xdx_90D_ecustom--CommonStockSharesWithLimitationsAndRestrictionsOnUsage_iI_pid_c20240930_zHeSxRoLoD11" title="Common stock specific limitations and restrictions on usage"&gt;8,000,000&lt;/span&gt; of the &lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240930_zOLECR8Uf3c8" title="Common stock, shares authorized"&gt;350,000,000&lt;/span&gt;
authorized shares. &lt;span style="background-color: white"&gt;As of September 30, 2024, and December 31, 2023, there were &lt;span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20240930_z5s2RDcpK1Ng" title="Common stock, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20240930_z3VuKo6Z0eh3" title="Common stock, shares outstanding"&gt;58,668,647&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zLy7uy3idNR7" title="Common stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zGzCzttgT758" title="Common stock, shares outstanding"&gt;49,102,484&lt;/span&gt;&lt;/span&gt;
shares of common stock issued and outstanding, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Employee
Stock Purchase Plan (Not equity compensation)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 7, 2020, the Board approved a plan pursuant to which all directors, officers, and employees could purchase from the Company up to
an aggregate of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200707__20200707__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorsOfficersAndEmployeesMember_zpDOzkNs9kNe" title="Common stock shares issued, value"&gt;500,000&lt;/span&gt; worth of shares at the market price (including subsequent plans, the &#x201c;Employee Stock Purchase Plan&#x201d;).
Pursuant to NYSE American rules, this plan was effective for a sixty-day period commencing upon the date that the NYSE American approved
the Company&#x2019;s Supplemental Listing Application. The Company created successive new plans following the expiration of the July 7,
2020 plan. The latest plan was approved by the Board on October 21, 2024 and expires in December 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2024, the Company did &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_do_c20240701__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zJNGUQY8NQi3" title="Number of shares issued upon transaction"&gt;no&lt;/span&gt;t issue any shares of its common stock as part of the employee stock purchase
plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2024, the Company issued a total of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_za44fl9EQlw8" title="Number of shares issued upon transaction"&gt;335,603&lt;/span&gt; shares of its common stock at a price ranging from $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zixXXzTxGMTa" title="Shares issued price per share"&gt;0.33&lt;/span&gt;
to $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zd2pavd939oa" title="Shares issued price per share"&gt;0.41&lt;/span&gt; for total proceeds of approximately $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zPotQyhb5qZ7" title="Proceeds from issuance of common stock"&gt;120,000&lt;/span&gt; as part of the employee stock purchase plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2023, the Company issued a total of &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zBJQFnmATZ73" title="Number of shares issued upon transaction"&gt;62,841&lt;/span&gt; shares of its common stock at a price ranging from $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zEP0jVJQ2aF5" title="Shares issued price per share"&gt;0.44&lt;/span&gt;
to $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zQ6VeuTyZU68" title="Shares issued price per share"&gt;0.67&lt;/span&gt; for total proceeds of approximately $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zeyu7mvaf40i" title="Proceeds from issuance of common stock"&gt;35,500&lt;/span&gt; as part of the employee stock purchase plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;During the nine months ended September
30, 2023, the Company issued a total of &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zzN3cXNuqCf" title="Number of shares issued upon transaction"&gt;385,424&lt;/span&gt; shares of its common stock at a price ranging from $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_zy0tzmCUB1i6" title="Shares issued price per share"&gt;0.31&lt;/span&gt; to $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_z6XHYrdt27K3" title="Shares issued price per share"&gt;0.67&lt;/span&gt; for total proceeds of
approximately $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zgJMA0cJubDi" title="Proceeds from issuance of common stock"&gt;135,000&lt;/span&gt; as part of the employee stock purchase plan.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Rights
Plan&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 12, 2023, the Company amended and restated its November 14, 2017 Rights Plan with American Stock Transfer &amp;amp; Trust Company as
Rights Agent (the &#x201c;Rights Plan&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Warrants
(Rights offering)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;On
September 27, 2019, the Company closed a public offering underwritten by A.G.P./Alliance Global Partners, LLC (the &#x201c;Offering&#x201d;)
of (i) &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20190926__20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zBg7vwwbMv06" title="Number of shares issued upon transaction"&gt;1,740,550&lt;/span&gt; shares of common stock; (ii) pre-funded warrants exercisable for &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_zzFUxZG6TFE9" title="Warrants issued"&gt;7,148,310&lt;/span&gt; shares of common stock (the &#x201c;Pre-funded
Warrants&#x201d;), and (iii) warrants to purchase up to an aggregate of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zk06vIxeMAvj" title="Number of warrant to purchase shares of common stock"&gt;8,888,860&lt;/span&gt; shares of common stock (the &#x201c;Warrants&#x201d;).
In conjunction with the Offering, we issued &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a Representative&#x2019;s
Warrant to purchase up to an aggregate of &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zpn7ey1dppSj" title="Number of warrant to purchase shares of common stock"&gt;266,665&lt;/span&gt; shares of common stock (the &#x201c;Representative&#x2019;s Warrant&#x201d;)&lt;span style="background-color: white"&gt;.
The shares of common stock and Warrants were sold at a combined Offering price of $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zxpcFYlkmU31" title="Shares issued price per share"&gt;0.90&lt;/span&gt;, less underwriting discounts and commissions.
Each Warrant sold with the shares of common stock represents the right to purchase one share of common stock at an exercise price of
$&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Ahw2qUTV0f" title="Warrant exercise price"&gt;0.99&lt;/span&gt; per share. The Pre-Funded Warrants and Warrants were sold at a combined Offering price of $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zr7VaKtovb9i" title="Shares issued price per share"&gt;0.899&lt;/span&gt;, less underwriting discounts and
commissions. The Pre-Funded Warrants were sold to purchasers whose purchase of shares of common stock in the Offering would otherwise
result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than &lt;span id="xdx_90B_ecustom--PercentageOfOutstandingStock_iI_pid_dp_uPure_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zedz8pMBZfjc" title="Percentage of outstanding stock"&gt;4.99&lt;/span&gt;% of the Company&#x2019;s
outstanding common stock immediately following the consummation of the Offering, in lieu of shares of common stock. Each Pre-Funded Warrant
represents the right to purchase one share of common stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20190927__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zz4bJv3T8bt8" title="Exercise price"&gt;0.001&lt;/span&gt; per share. The Pre-Funded Warrants are exercisable
immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full. A registration statement on Form S-1,
relating to the Offering was filed with the SEC and was declared effective on September 25, 2019, the net proceeds were approximately
$&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190925__20190925__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember_z0ASZUL2lSYa" title="Proceeds from issuance or sale of equity"&gt;7,200,000&lt;/span&gt;. During the year ended &lt;/span&gt;December 31&lt;span style="background-color: white"&gt;, 2020, &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesOther_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zYmSzHIwGVuj" title="Stock issued during period shares other"&gt;1,870,000&lt;/span&gt; of the Pre-funded Warrants
were exercised and &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zctQaPregbB1" title="Pre-funded warrants exercised"&gt;8,873,960&lt;/span&gt; Warrants were exercised. &lt;/span&gt;In addition, on March 25, 2020, the Representative&#x2019;s Warrant was amended
to permit exercise of such warrant to commence on March 30, 2020. These warrants were exercised on March 31, 2020, and an aggregate of
&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200331__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zLqkg4B09CUi" title="Warrants exercised aggregate"&gt;266,665&lt;/span&gt; shares were issued upon exercise of this warrant for gross proceeds of approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200330__20200331_zh9jjVbDpWwg" title="Warrant gross proceeds"&gt;264,000&lt;/span&gt; and a $&lt;span id="xdx_907_ecustom--WarrantModifications_pp0p0_c20200330__20200331_zhlfJIMnyV66" title="Warrant modification"&gt;46,000&lt;/span&gt; expense for the warrant
modification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2024, there were &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_do_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMLHdojv32bi"&gt;no&lt;/span&gt; warrants exercised and &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240701__20240930__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember_zHNu2Pq7YRr7" title="Warrants expired"&gt;15,000&lt;/span&gt; warrants expired unexercised. During the nine
months ended September 30, 2024, &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh9Mlm1aHhB"&gt;205,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants were exercised, and &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20240101__20240930__dei--LegalEntityAxis__custom--AllianceGlobalPartnersLLCMember__us-gaap--StatementEquityComponentsAxis__custom--RepresentativeWarrantsMember_zoUWDRKMyD7l" title="Warrants expired"&gt;5,830,028
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants expired unexercised. As of September
30, 2024 there were &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_do_c20240930_z89reMuARwi6"&gt;no&lt;/span&gt; warrants outstanding and December 31, 2023 there were &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_zX4TJjnw8aLe"&gt;152,160&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;post-split
warrants outstanding, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Equity
Distribution Agreement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 19, 2023, the Company entered into an Equity Distribution Agreement (the &#x201c;EDA&#x201d;) with Maxim Group LLC (&#x201c;Maxim&#x201d;),
pursuant to which the Company may sell, from time to time, shares of its common stock having an aggregate offering price of up to $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20230419__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zMEtwbeO6O05" title="Issuance of common stoc, value"&gt;8,500,000&lt;/span&gt; through Maxim, as agent (the &#x201c;Offering&#x201d;). Sales under the EDA were registered under the S-3 Shelf Registration Statement.
Under the terms of the EDA, Maxim will be entitled to a transaction fee at a fixed rate of &lt;span id="xdx_908_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230419__20230419__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zGKFVuUhU4M1"&gt;3.0&lt;/span&gt;% of the gross sales price of shares sold
under the EDA. During the year ended December 31, 2023, the Company sold &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zOJlSDZcgXu4" title="Sale of stock, number of shares issued in transaction"&gt;598,114&lt;/span&gt; shares under the EDA for total gross proceeds of approximately
$&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z3ggv6RmBjze"&gt;344,000&lt;/span&gt;, which includes a &lt;span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zhWfTBAG9ojb"&gt;3.0&lt;/span&gt;% fee to Maxim of $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230101__20231231__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zMIXKv7gdpsi"&gt;10,326&lt;/span&gt;. For the three months ended September 30, 2024, the Company sold &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zCHh2hYi6Ji5" title="Sale of stock, number of shares issued in transaction"&gt;10,975&lt;/span&gt; shares
under the EDA for total gross proceeds of approximately $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zr2xUwumO2Yd"&gt;4,110&lt;/span&gt;, which includes a &lt;span id="xdx_901_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zhodRipzm8lg"&gt;3.0&lt;/span&gt;% fee to Maxim of $&lt;span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240701__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zFuh0L88Yfz9"&gt;123&lt;/span&gt;. For the nine months ended
September 30, 2024, the Company sold &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z8NOpmnjpGOa" title="Sale of stock, number of shares issued in transaction"&gt;1,305,653&lt;/span&gt; shares under the EDA for total gross proceeds of approximately $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z90Up4udVZB9"&gt;630,204 &lt;/span&gt;which includes
a &lt;span id="xdx_90D_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z61pkh309uQi"&gt;3.0&lt;/span&gt;% fee to Maxim of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240101__20240930__dei--LegalEntityAxis__custom--MaximGroupLLCMember__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zy8xvhzKMFqd"&gt;18,906&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Equity
Purchase Agreement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 28, 2024, the Company entered into a purchase agreement and a registration rights agreement with Atlas Sciences, LLC (&#x201c;Atlas&#x201d;),
pursuant to which Atlas committed to purchase up to $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240328__20240328__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAndRegistrationRightsAgreementMember_z6Qmmo76xiK6" title="Issuance of common stock"&gt;15,000,000 &lt;/span&gt;of common stock of the Company for a period of 24 months from the date
of the purchase agreement. No assurance can be given as to the actual amount that will be raised pursuant to the purchase agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms of the purchase agreement, the Company, at its sole discretion, shall have the right to issue Put shares to the Investor
at &lt;span id="xdx_90B_ecustom--MarketPricePercentage_iI_pid_dp_uPure_c20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zd08R2QALC9e" title="Market price, percentage"&gt;95&lt;/span&gt;%
of the Market Price of the shares on the day of trade. Sales under the purchase agreement are limited to a daily maximum of the
lessor of: $&lt;span id="xdx_902_ecustom--TradingDailyMaximumLessorAmount_c20240328__20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z3GK5yc5iheb" title="Trading maximum lessor amount"&gt;500,000&lt;/span&gt;,
the Median Daily Trading volume, and a beneficial ownership limitation of &lt;span id="xdx_90C_ecustom--BeneficialOwnershipPercentage_iI_dp_uPure_c20240328__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zc2r96719jHl" title="Beneficial ownership percentage"&gt;4.99&lt;/span&gt;%
and a maximum of &lt;span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20240328__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z8iLdsFcRGO7" title="Equity investment ownership percentage"&gt;19.99&lt;/span&gt;%
of the outstanding shares at the time of the purchase agreement. In April 2024, the Company filed a registration statement with the
SEC on Form S-1 registering a total of &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240401__20240430__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z0e2Ittf2D41" title="Number of stock sold"&gt;9,975,000&lt;/span&gt;
shares for resale pursuant to the Atlas Agreements, consisting of &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240401__20240430__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zpx0vsEx6u2j" title="Stock sold by the company"&gt;9,636,400&lt;/span&gt;
shares that can be sold by the Company to Atlas and &lt;span id="xdx_906_ecustom--StockIssuedDuringPeriodValueCommitmentShares_pid_c20240401__20240430__dei--LegalEntityAxis__custom--AtlasSciencesLlcMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_ze5ADbNSqO0c" title="Commitment shares issued"&gt;338,600&lt;/span&gt;
shares that were issued to Atlas as Commitment Shares. The registration statement was declared effective on May 1, 2024. There were
no shares issued for the three months ended September 30, 2024. As of September 30, 2024, a total of &lt;span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_znhEJEEFbAF4" title="Number of stock sold"&gt;759,685&lt;/span&gt;
shares have been issued pursuant to the purchase agreement for a total of approximately $&lt;span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pid_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z0YJkGyaGQYf" title="Amount of stock sold"&gt;128,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Securities
Purchase Agreement&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 31, 2024, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) to complete an offering
(the &#x201c;Transactions&#x201d;) with a single accredited investor (the &#x201c;Purchaser&#x201d;), pursuant to which, on June 3, 2024, the Company
issued to the Purchaser, (i) in a registered direct offering, &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zvsNQakMz1Dk" title="Number of shares issued upon transaction"&gt;5,640,958&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;Shares&#x201d;),
par value $&lt;span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zjHrPc0hk8Df" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share (&#x201c;common stock&#x201d;) and (ii) in a concurrent private placement, the Company  issued to the Purchaser
Class A common warrants to purchase an aggregate of up to &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_z0WsGfhJuftl" title="Number of shares issued upon transaction"&gt;5,640,958&lt;/span&gt; shares of its common stock (the &#x201c;A Warrants&#x201d;) at an exercise
price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zvOT7C0I7JFf" title="Exercise price"&gt;0.363&lt;/span&gt; per share and Class B common warrants to purchase an aggregate of up to &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonWarrantMember_zEJtUG87iYxd" title="Number of shares issued upon transaction"&gt;5,640,958&lt;/span&gt; shares of its common stock (the &#x201c;B
&#x201c;Warrants&#x201d; and, along with the A Warrants, the &#x201c;Common Warrants&#x201d;) at an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240603__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassBCommonWarrantMember_zwuJnVqAau9e" title="Exercise price"&gt;0.363&lt;/span&gt; per share. The
A Warrants and B Warrants are  not  exercisable for six months after the issuance date and  expire, respectively, 24 months and
five years and six months after the issuance date. The Common Warrants and the shares of common stock issuable upon the exercise of such
warrants are offered pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of
the Securities Act and Rule 506(b) promulgated thereunder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Shares were  offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared
effective on February 4, 2022 (as amended from time to time, the &#x201c;Registration Statement&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the terms of the Purchase Agreement, subject to certain exceptions, the Company could not issue any equity securities for 60 days following
the issuance date, provided that the Company was able to utilize its at-the-market offering program with the Placement Agent after
30 days. Additionally, the Company cannot enter into a variable rate transaction (other than the ATM program with the Placement Agent)
for 120 days after the issuance date. In addition, the Company&#x2019;s executive officers and each of the Company&#x2019;s directors have
entered into lock-up agreements with the Company pursuant to which each of them has agreed not to, for a period of 90 days from the closing
of the Transactions, offer, sell, transfer or otherwise dispose of the Company&#x2019;s securities, subject to certain exceptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The exercise price of the Common Warrants, and the number of Common Warrant
Shares, are subject to adjustment in the event of any stock dividend or split, reverse stock split, recapitalization, reorganization or
similar transaction, as described in the Common Warrants. If a Fundamental Transaction (as defined in the Common Warrants) occurs, then
the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the Company may
exercise and will assume all of its obligations under the Common Warrants with the same effect as if such successor entity had been named
in the warrant itself. Common Warrant Holders will have additional rights defined in the Common Warrants. The Common Warrants are exercisable
on a &#x201c;cashless&#x201d; basis only if there is not a current registration statement permitting public resale. In this regard, the Company
filed a registration statement to register the resale of the Common Warrant Shares providing for the resale of the Shares issued and issuable
upon exercise of the Common Warrants. That registration statement was declared effective by the SEC on July 11, 2024. The Company has
agreed to use commercially reasonable efforts to cause such registration statement to keep such registration statement effective at all
times until no Purchaser owns any Warrants or Warrant Shares issuable upon exercise thereof.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Maxim
Group LLC acted as the placement agent (the &#x201c;Placement Agent&#x201d;) on a &#x201c;commercially reasonable best efforts&#x201d; basis,
in connection with the Transactions pursuant to the Placement Agency Agreement, dated May 31, 2024 (the &#x201c;Placement Agency Agreement&#x201d;),
by and between the Company and the Placement Agent. Pursuant to the Placement Agency Agreement, the Placement Agent was paid a cash fee of &lt;span id="xdx_900_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20240501__20240531__us-gaap--SubsidiarySaleOfStockAxis__custom--PlacementAgentMember_znAyC7lznWWi" title="Aggregate gross proceeds, percentage"&gt;8&lt;/span&gt;% of the aggregate gross proceeds paid to the Company for the securities sold in the Transactions and reimbursement
of certain out-of-pocket expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluated the Common Warrants under the guidance of ASC 480 &#x2013; Distinguishing Liabilities from Equity and determined that
they were in scope under the guidance as freestanding financial instruments but did not meet the criteria for liability classification
and are classified as equity within the condensed consolidated financial statements. Proceeds allocated to such warrants totaled approximately
$&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20240930_zRbP2wp9At8k" title="Proceeds from warrants"&gt;2.5&lt;/span&gt; million. For the nine months ended September 30,2024, no Common Warrants were exercised, and all remain outstanding on September
30, 2024 related to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 30, 2024, the Company entered into a Securities Purchase Agreement to complete an offering with a single accredited investor.
For more information see Note 15: Subsequent Events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001365"
      unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001367"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact001369"
      unitRef="Shares">4000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001371"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-05-09_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact001373"
      unitRef="Shares">4000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-05-10_custom_SeriesAJuniorParticipatingPreferredStockMember"
      decimals="INF"
      id="Fact001375"
      unitRef="Shares">250000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001376"
      unitRef="Shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001378"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <AIM:PreferredStockStatedValuePerShare
      contextRef="AsOf2024-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001380"
      unitRef="USDPShares">1000</AIM:PreferredStockStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001382"
      unitRef="USDPShares">0.20</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="AsOf2024-09-30_us-gaap_RightsMember"
      decimals="0"
      id="Fact001384"
      unitRef="USD">1000</us-gaap:CommonStockSharesSubscriptions>
    <AIM:ConvertiblePreferredStockFaceValue
      contextRef="AsOf2024-09-30_us-gaap_RightsMember"
      decimals="0"
      id="Fact001386"
      unitRef="USD">1000</AIM:ConvertiblePreferredStockFaceValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001388"
      unitRef="USDPShares">8.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001390"
      unitRef="Shares">114</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001392"
      unitRef="USDPShares">8.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-09-30_us-gaap_RightsMember"
      decimals="0"
      id="Fact001394"
      unitRef="USD">4700000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2024-01-012024-09-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001396"
      unitRef="Shares">689</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001398"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <AIM:CommonStockSharesWithLimitationsAndRestrictionsOnUsage
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001400"
      unitRef="Shares">8000000</AIM:CommonStockSharesWithLimitationsAndRestrictionsOnUsage>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001402"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001404"
      unitRef="Shares">58668647</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001406"
      unitRef="Shares">58668647</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001408"
      unitRef="Shares">49102484</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001410"
      unitRef="Shares">49102484</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-07-072020-07-07_custom_DirectorsOfficersAndEmployeesMember"
      decimals="0"
      id="Fact001412"
      unitRef="USD">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember62774140"
      decimals="INF"
      id="Fact001414"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001416"
      unitRef="Shares">335603</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001418"
      unitRef="USDPShares">0.33</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001420"
      unitRef="USDPShares">0.41</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001422"
      unitRef="USD">120000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember62774171"
      decimals="INF"
      id="Fact001424"
      unitRef="Shares">62841</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001426"
      unitRef="USDPShares">0.44</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001428"
      unitRef="USDPShares">0.67</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember62774171"
      decimals="0"
      id="Fact001430"
      unitRef="USD">35500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001432"
      unitRef="Shares">385424</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001434"
      unitRef="USDPShares">0.31</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001436"
      unitRef="USDPShares">0.67</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001438"
      unitRef="USD">135000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-09-262019-09-27_custom_AllianceGlobalPartnersLLCMember"
      decimals="INF"
      id="Fact001440"
      unitRef="Shares">1740550</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember"
      decimals="INF"
      id="Fact001442"
      unitRef="Shares">7148310</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_WarrantsMember"
      decimals="INF"
      id="Fact001444"
      unitRef="Shares">8888860</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001446"
      unitRef="Shares">266665</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-09-27_custom_AllianceGlobalPartnersLLCMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001448"
      unitRef="USDPShares">0.90</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-09-27_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001450"
      unitRef="USDPShares">0.99</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001452"
      unitRef="USDPShares">0.899</us-gaap:SharesIssuedPricePerShare>
    <AIM:PercentageOfOutstandingStock
      contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001454"
      unitRef="Pure">0.0499</AIM:PercentageOfOutstandingStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-09-27_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001456"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2019-09-252019-09-25_custom_AllianceGlobalPartnersLLCMember"
      decimals="0"
      id="Fact001458"
      unitRef="USD">7200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-01-012020-12-31_custom_PreFundedWarrantsMember"
      decimals="0"
      id="Fact001460"
      unitRef="Shares">1870000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001462"
      unitRef="Shares">8873960</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-03-31_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001464"
      unitRef="Shares">266665</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-03-302020-03-31"
      decimals="0"
      id="Fact001466"
      unitRef="USD">264000</us-gaap:ProceedsFromWarrantExercises>
    <AIM:WarrantModifications
      contextRef="From2020-03-302020-03-31"
      decimals="0"
      id="Fact001468"
      unitRef="USD">46000</AIM:WarrantModifications>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-07-012024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001469"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-07-012024-09-30_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember"
      decimals="INF"
      id="Fact001471"
      unitRef="Shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001472"
      unitRef="Shares">205000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-01-012024-09-30_custom_AllianceGlobalPartnersLLCMember_custom_RepresentativeWarrantsMember"
      decimals="INF"
      id="Fact001474"
      unitRef="Shares">5830028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001475"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001476"
      unitRef="Shares">152160</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-192023-04-19_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="0"
      id="Fact001478"
      unitRef="USD">8500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2023-04-192023-04-19_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="INF"
      id="Fact001479"
      unitRef="Pure">0.030</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="INF"
      id="Fact001481"
      unitRef="Shares">598114</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="0"
      id="Fact001482"
      unitRef="USD">344000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="INF"
      id="Fact001483"
      unitRef="Pure">0.030</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-01-012023-12-31_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="0"
      id="Fact001484"
      unitRef="USD">10326</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-07-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="INF"
      id="Fact001486"
      unitRef="Shares">10975</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-07-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="0"
      id="Fact001487"
      unitRef="USD">4110</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2024-07-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="INF"
      id="Fact001488"
      unitRef="Pure">0.030</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-07-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="0"
      id="Fact001489"
      unitRef="USD">123</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="INF"
      id="Fact001491"
      unitRef="Shares">1305653</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="0"
      id="Fact001492"
      unitRef="USD">630204</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2024-01-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="INF"
      id="Fact001493"
      unitRef="Pure">0.030</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-01-012024-09-30_custom_MaximGroupLLCMember_custom_EquityDistributionAgreementMember"
      decimals="0"
      id="Fact001494"
      unitRef="USD">18906</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-03-282024-03-28_us-gaap_CommonStockMember_custom_AtlasSciencesLlcMember_custom_PurchaseAndRegistrationRightsAgreementMember"
      decimals="0"
      id="Fact001496"
      unitRef="USD">15000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <AIM:MarketPricePercentage
      contextRef="AsOf2024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001498"
      unitRef="Pure">0.95</AIM:MarketPricePercentage>
    <AIM:TradingDailyMaximumLessorAmount
      contextRef="From2024-03-282024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001500"
      unitRef="USD">500000</AIM:TradingDailyMaximumLessorAmount>
    <AIM:BeneficialOwnershipPercentage
      contextRef="AsOf2024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001502"
      unitRef="Pure">0.0499</AIM:BeneficialOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2024-03-28_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember62774609"
      decimals="INF"
      id="Fact001504"
      unitRef="Pure">0.1999</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-04-012024-04-30_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001506"
      unitRef="Shares">9975000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-04-012024-04-30_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001508"
      unitRef="Shares">9636400</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <AIM:StockIssuedDuringPeriodValueCommitmentShares
      contextRef="From2024-04-012024-04-30_custom_AtlasSciencesLlcMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001510"
      unitRef="USD">338600</AIM:StockIssuedDuringPeriodValueCommitmentShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-012024-09-30_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001512"
      unitRef="Shares">759685</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-01-012024-09-30_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001514"
      unitRef="USD">128000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-06-032024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001516"
      unitRef="Shares">5640958</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001518"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-06-032024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001520"
      unitRef="Shares">5640958</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-03_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001522"
      unitRef="USDPShares">0.363</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-06-032024-06-03_custom_SecuritiesPurchaseAgreementMember_custom_ClassBCommonWarrantMember"
      decimals="INF"
      id="Fact001524"
      unitRef="Shares">5640958</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-03_custom_SecuritiesPurchaseAgreementMember_custom_ClassBCommonWarrantMember"
      decimals="INF"
      id="Fact001526"
      unitRef="USDPShares">0.363</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2024-05-012024-05-31_custom_PlacementAgentMember"
      decimals="INF"
      id="Fact001528"
      unitRef="Pure">0.08</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact001530"
      unitRef="USD">2500000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001532">&lt;p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zQ16CfIusnze" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10: &lt;span id="xdx_822_zMey225KA1Dd"&gt;Net Loss Per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period.
Equivalent common shares, consisting of stock options and warrants which amounted to &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z0jmiCxJTYMe" title="Net loss per share, antidilutive"&gt;14,574,557&lt;/span&gt; and &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z7URUNwRkmuh" title="Net loss per share, antidilutive"&gt;2,763,020&lt;/span&gt; shares for the nine months
ended September 30, 2024 and 2023, respectively, are excluded from the calculation of diluted net loss per share since their effect is
anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001534"
      unitRef="Shares">14574557</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001536"
      unitRef="Shares">2763020</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001538">&lt;p id="xdx_80A_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zqKxGYvluOn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
11: &lt;span id="xdx_82F_zzidmEODBJMb"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on
the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements
that have been issued that might have a material impact on its financial position or results of operations. Accounting pronouncements
issued by the FASB since filing the &lt;span style="text-decoration: underline"&gt;Annual Report on Form 10-K for the year ended December 31, 2023&lt;/span&gt; did not or are not believed
by management to have a material impact on the Company&#x2019;s present or future financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001540">&lt;p id="xdx_80C_eus-gaap--FairValueDisclosuresTextBlock_zWqt4sq0Z5s5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
12: &lt;span id="xdx_828_zF9MURIPxiUh"&gt;Fair Value&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
Value&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the provisions of FASB ASC 820 &#x201c;Fair Value Measurements&#x201d; for its financial and non-financial assets
and liabilities. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosure for each major asset
and liability category measured at fair value on either a recurring or nonrecurring basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair values of cash and cash equivalents, other assets, accounts payable and accrued expenses approximate their carrying values due to
the short-term maturities of these items and are considered a Level 1 instrument of the fair value measurements standard. The Company
also has certain warrants with a cash settlement feature in the occurrence of a Fundamental Transaction. The fair value of the warrants
(&#x201c;June 2024 Warrants&#x201d;) related to the Company&#x2019;s June 2024 common stock and warrant issuance, are calculated using a
Monte Carlo Simulation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also had certain redeemable warrants in the Rights Offering with a cash settlement feature in the occurrence of a Fundamental
Transaction. No Fundamental Transaction occurred. In March 2024, &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240331_zpLyvAzh0wVj" title="Conversion of warrants"&gt;205,000&lt;/span&gt; of these warrants converted on a cashless basis and &lt;span id="xdx_902_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired_iI_pid_c20240331_zEh3F7bf07v7" title="Cashless basis, expired"&gt;5,830,028&lt;/span&gt;
expired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimated the fair value of the June 2024 Warrants using the Black-Scholes Model, which uses multiple inputs including the Company&#x2019;s
stock price, the exercise price of the warrant, volatility of the Company&#x2019;s stock price, the risk-free interest rate and the expected
term of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock_zDgvahFw0swl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilized the following assumptions to estimate the fair value of the Class A Warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zsQidJVgfr37" style="display: none"&gt;Schedule of Assumptions to
Estimate the Fair Value&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Underlying price per share&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zD97ws5Uj1Gf" title="Underlying price per share"&gt;0.350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zehpniDao4D1" title="Underlying price per share"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1550"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zjz2yccjPuc7" title="Exercise price per share"&gt;0.363&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zsLb2u8NbOT4" title="Exercise price per share"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1554"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z7chJrnIJQE7" title="Risk-free interest rate"&gt;4.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zPjaVxg5CK5d" title="Risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1558"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expected holding period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zKeOpE0BWuQ6" title="Expected holding period"&gt;5.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zNudCoGdbWBf" title="Expected volatility"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zGaYNRsqxF3i" title="Expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1564"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z1vSOtTunSqa" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1566"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zsbSz68ay1yc" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1568"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilized the following assumptions to estimate the fair value of the Class B Warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Underlying price per share&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zY6l4IrI6hpg" title="Underlying price per share"&gt;0.350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zGWPwsoNbCb3" title="Underlying price per share"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1572"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zHle8bqMekBg" title="Exercise price per share"&gt;0.363&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zvs0Pb7XXGH6" title="Exercise price per share"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1576"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zO3kY87vtQM1" title="Risk-free interest rate"&gt;4.82&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zZS7CsO8Cih7" title="Risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1580"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expected holding period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zRFXnPoLRT89" title="Expected holding period"&gt;2&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zhSJz61mkdKd" title="Expected volatility"&gt;89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zczDmWDxJonc" title="Expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1586"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_z4dFcP95gwc" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1588"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zBmcWKIhTX0l" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1590"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zcMvkDWRsSjj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
significant assumptions using the Monte Carlo Simulation approach for valuation of the Warrants are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-Free
                                            Interest Rate&lt;/i&gt;. The risk-free interest rates for the Warrants are based on U.S. Treasury
                                            constant maturities for periods commensurate with the remaining expected holding periods
                                            of the warrants.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
                                            Holding Period&lt;/i&gt;. The expected holding period represents the period of time that the Warrants
                                            are expected to be outstanding until they are exercised. The Company utilizes the remaining
                                            contractual term of the Warrants at each valuation date as the expected holding period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
                                            Volatility&lt;/i&gt;. Expected stock volatility is based on daily observations of the Company&#x2019;s
                                            historical stock values for a period commensurate with the remaining expected holding period
                                            on the last day of the period for which the computation is made.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
                                            Dividend Yield&lt;/i&gt;. The expected dividend yield is based on the Company&#x2019;s anticipated
                                            dividend payments over the remaining expected holding period. As the Company has never issued
                                            dividends, the expected dividend yield is 0% and this assumption will be continued in future
                                            calculations unless the Company changes its dividend policy.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(v)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
                                            Probability of a Fundamental Transaction.&lt;/i&gt; Put rights arise if a Fundamental Transaction
                                            1) is an all cash transaction; (2) results in the Company going private; or (3) is a transaction
                                            involving a person or entity not traded on a national securities exchange. The Company believes
                                            such an occurrence is unlikely because:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -22.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Company only has one product that is FDA approved but is currently not available for commercial
                                            sales.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Company will have to perform additional clinical trials for FDA approval of its flagship
                                            product.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Industry
                                            and market conditions continue to include uncertainty, adding risk to any transaction.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            nature of a life sciences company is heavily dependent on future funding and high fixed costs,
                                            including Research &amp;amp; Development.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Company has minimal revenues streams which are insufficient to meet the funding needs for
                                            the cost of operations or construction at their manufacturing facility; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
                                            Company&#x2019;s Rights Agreement and Executive Agreements make it less attractive to a potential
                                            buyer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_z1oSiJHN4Lh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
the above factors utilized in analysis of the likelihood of the Put&#x2019;s potential Liability, the Company estimated the range of probabilities
related to a Put right being triggered as:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zh1FKqV7mGub" style="display: none"&gt;Schedule of Potential
Liability&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Range of Probability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Probability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; text-align: center; padding-left: 3pt"&gt;Low&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--LowRangeOfProbability_pid_dp_uPure_c20240101__20240930_zkvLgwu2uHej" title="Low range, rate"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 3pt"&gt;Medium&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--MediumRangeOfProbability_pid_dp_uPure_c20240101__20240930_zATLeRfk5Hnf" title="Medium range, rate"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 3pt"&gt;High&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--HighRangeOfProbability_pid_dp_uPure_c20240101__20240930_zVtQC9DS1mZj" title="High range, rate"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zyFa61NFGg14" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Monte Carlo Simulation has incorporated a &lt;span id="xdx_903_ecustom--HighRangeOfProbability_pid_dp_uPure_c20240101__20240930_zK5LHEzjENPa" title="Probability, rate"&gt;5.0&lt;/span&gt;% probability of a Fundamental Transaction to date for the life of the securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(vi)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
                                            Timing of Announcement of a Fundamental Transaction.&lt;/i&gt; As the Company has no specific expectation
                                            of a Fundamental Transaction, for reasons elucidated above, the Company utilized a discrete
                                            uniform probability distribution over the Expected Holding Period to model in the potential
                                            announcement of a Fundamental Transaction occurring during the Expected Holding Period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(vii)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
                                            100 Day Volatility at Announcement of a Fundamental Transaction&lt;/i&gt;. An estimate of future
                                            volatility is necessary as there is no mechanism for directly measuring future stock price
                                            movements. Daily observations of the Company&#x2019;s historical stock values for the 100
                                            days immediately prior to the Warrants&#x2019; grant dates, with a floor of 100%, were utilized
                                            as a proxy for future volatility estimates.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(viii)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
                                            Risk-Free Interest Rate at Announcement of a Fundamental Transaction&lt;/i&gt;. The Company utilized
                                            a risk-free interest rate corresponding to the forward U.S. Treasury rate for the period
                                            equal to the time between the date forecast for the public announcement of a Fundamental
                                            Transaction and the Warrant expiration date for each simulation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ix)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
                                            Time Between Announcement and Consummation of a Fundamental Transaction.&lt;/i&gt; The expected
                                            time between the announcement and the consummation of a Fundamental Transaction is based
                                            on the Company&#x2019;s experience with the due diligence process performed by acquirers and
                                            is estimated to be six months. The Monte Carlo Simulation approach incorporates this additional
                                            period to reflect the delay Warrant Holders would experience in receiving the proceeds of
                                            the Put.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -27pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the assumptions remain consistent from period to period (e.g., utilizing historical stock prices), the actual historical prices input
for the relevant period input change.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for certain assets and liabilities at fair value. The hierarchy below lists three levels of fair value based on the
extent to which inputs used in measuring fair value are observable in the market. AIM categorizes each of its fair value measurements
in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These
levels are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1 &#x2013; Quoted prices are available in active markets for identical assets or liabilities
                                            at the reporting date. Generally, this includes debt and equity securities that are traded
                                            in an active market.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2 &#x2013; Observable inputs other than Level 1 prices such as quote prices for similar assets
                                            or liabilities; quoted prices in markets that are not active; or other inputs that are observable
                                            or can be corroborated by observable market data for substantially the full term of the assets
                                            or liabilities. Generally, this includes debt and equity securities that are not traded in
                                            an active market.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3 &#x2013; Unobservable inputs that are supported by little or no market activity and that
                                            are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities
                                            include financial instruments whose value is determined using pricing models, discounted
                                            cash flow methodologies, or other valuation techniques, as well as instruments for which
                                            the determination of fair value requires significant management judgment or estimation. As
                                            of September 30, 2024, the Company has classified the warrants with cash settlement features as
                                            Level 3. Management evaluates a variety of inputs and then estimates fair value based on
                                            those inputs. As discussed above, the Company utilized the Monte Carlo Simulation Model in
                                            valuing the warrants.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3JfoMmGwGK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy
as (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_z9N8VFqklMWa" style="display: none"&gt;Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;As of September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxI1fwhW7vZh" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;67&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zo0YJhRvvtb9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;67&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYjPFy5GJxAk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1608"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2eiI3hcGQT3" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1610"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Marketable securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQt1FjptGw6" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;6,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziVXcJcvj0gl" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;6,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zBULbOALFRw8" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1616"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8u55ydix3j5" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1618"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left; padding-bottom: 1pt"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zP7N3paE1grj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;4,805&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zW1g7juGpFkb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;4,805&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeQ27myYYqe5" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1624"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVkicbnuFTJj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1626"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCfaO7iLt9a6" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;7,631&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zf9yCE8hz1x2" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;7,631&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zOKyfcRFHeS7" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1632"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zN7gLJdiHbEa" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1634"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z6H1m7PmFMPk" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001542"
      unitRef="Shares">205000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <AIM:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact001544"
      unitRef="Shares">5830028</AIM:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantExpired>
    <AIM:ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001546">&lt;p id="xdx_89B_ecustom--ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock_zDgvahFw0swl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilized the following assumptions to estimate the fair value of the Class A Warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BC_zsQidJVgfr37" style="display: none"&gt;Schedule of Assumptions to
Estimate the Fair Value&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Underlying price per share&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zD97ws5Uj1Gf" title="Underlying price per share"&gt;0.350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zehpniDao4D1" title="Underlying price per share"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1550"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zjz2yccjPuc7" title="Exercise price per share"&gt;0.363&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zsLb2u8NbOT4" title="Exercise price per share"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1554"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z7chJrnIJQE7" title="Risk-free interest rate"&gt;4.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zPjaVxg5CK5d" title="Risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1558"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expected holding period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zKeOpE0BWuQ6" title="Expected holding period"&gt;5.5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zNudCoGdbWBf" title="Expected volatility"&gt;110&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dp_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zGaYNRsqxF3i" title="Expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1564"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_z1vSOtTunSqa" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1566"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassAWarrantMember_zsbSz68ay1yc" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1568"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilized the following assumptions to estimate the fair value of the Class B Warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;September 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;December 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Underlying price per share&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zY6l4IrI6hpg" title="Underlying price per share"&gt;0.350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zGWPwsoNbCb3" title="Underlying price per share"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1572"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zHle8bqMekBg" title="Exercise price per share"&gt;0.363&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zvs0Pb7XXGH6" title="Exercise price per share"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1576"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zO3kY87vtQM1" title="Risk-free interest rate"&gt;4.82&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zZS7CsO8Cih7" title="Risk-free interest rate"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1580"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expected holding period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zRFXnPoLRT89" title="Expected holding period"&gt;2&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zhSJz61mkdKd" title="Expected volatility"&gt;89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zczDmWDxJonc" title="Expected volatility"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1586"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20240930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_z4dFcP95gwc" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1588"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--ClassBWarrantMember_zBmcWKIhTX0l" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1590"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</AIM:ScheduleOfAssumptionsToEstimateTheFairValueTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-09-30_us-gaap_MeasurementInputSharePriceMember_custom_ClassAWarrantMember"
      decimals="INF"
      id="Fact001548"
      unitRef="Pure">0.350</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-09-30_us-gaap_MeasurementInputExercisePriceMember_custom_ClassAWarrantMember"
      decimals="INF"
      id="Fact001552"
      unitRef="Pure">0.363</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassAWarrantMember"
      decimals="INF"
      id="Fact001556"
      unitRef="Pure">4.42</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_ClassAWarrantMember"
      id="Fact001560">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassAWarrantMember"
      decimals="INF"
      id="Fact001562"
      unitRef="Pure">1.10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-09-30_us-gaap_MeasurementInputSharePriceMember_custom_ClassBWarrantMember"
      decimals="INF"
      id="Fact001570"
      unitRef="Pure">0.350</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-09-30_us-gaap_MeasurementInputExercisePriceMember_custom_ClassBWarrantMember"
      decimals="INF"
      id="Fact001574"
      unitRef="Pure">0.363</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ClassBWarrantMember"
      decimals="INF"
      id="Fact001578"
      unitRef="Pure">4.82</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-09-30_us-gaap_MeasurementInputExpectedTermMember_custom_ClassBWarrantMember"
      id="Fact001582">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_ClassBWarrantMember"
      decimals="INF"
      id="Fact001584"
      unitRef="Pure">0.89</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <AIM:ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001592">&lt;p id="xdx_899_ecustom--ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock_z1oSiJHN4Lh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;With
the above factors utilized in analysis of the likelihood of the Put&#x2019;s potential Liability, the Company estimated the range of probabilities
related to a Put right being triggered as:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zh1FKqV7mGub" style="display: none"&gt;Schedule of Potential
Liability&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;Range of Probability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Probability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; text-align: center; padding-left: 3pt"&gt;Low&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--LowRangeOfProbability_pid_dp_uPure_c20240101__20240930_zkvLgwu2uHej" title="Low range, rate"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-left: 3pt"&gt;Medium&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--MediumRangeOfProbability_pid_dp_uPure_c20240101__20240930_zATLeRfk5Hnf" title="Medium range, rate"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-left: 3pt"&gt;High&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--HighRangeOfProbability_pid_dp_uPure_c20240101__20240930_zVtQC9DS1mZj" title="High range, rate"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</AIM:ScheduleOfPotentialLiabilityEstimatedTheRangeOfProbabilitiesTableTextBlock>
    <AIM:LowRangeOfProbability
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact001594"
      unitRef="Pure">0.005</AIM:LowRangeOfProbability>
    <AIM:MediumRangeOfProbability
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact001596"
      unitRef="Pure">0.010</AIM:MediumRangeOfProbability>
    <AIM:HighRangeOfProbability
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact001598"
      unitRef="Pure">0.050</AIM:HighRangeOfProbability>
    <AIM:HighRangeOfProbability
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact001600"
      unitRef="Pure">0.050</AIM:HighRangeOfProbability>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001602">&lt;p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z3JfoMmGwGK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents the balances of assets and liabilities measured at fair value on a recurring basis by level within the hierarchy
as (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_z9N8VFqklMWa" style="display: none"&gt;Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;As of September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxI1fwhW7vZh" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;67&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zo0YJhRvvtb9" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;67&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zYjPFy5GJxAk" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1608"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z2eiI3hcGQT3" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1610"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Marketable securities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQt1FjptGw6" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;6,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziVXcJcvj0gl" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;6,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zBULbOALFRw8" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1616"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20240930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8u55ydix3j5" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1618"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left; padding-bottom: 1pt"&gt;Cash equivalents&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zP7N3paE1grj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;4,805&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zW1g7juGpFkb" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;4,805&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeQ27myYYqe5" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1624"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zVkicbnuFTJj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Cash equivalents-Marketable investments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1626"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCfaO7iLt9a6" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;7,631&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zf9yCE8hz1x2" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;7,631&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zOKyfcRFHeS7" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1632"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zN7gLJdiHbEa" style="border-bottom: Black 1pt solid; text-align: right" title="Marketable securities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1634"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2024-09-30_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001604"
      unitRef="USD">67000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001606"
      unitRef="USD">67000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-09-30_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001612"
      unitRef="USD">6287000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2024-09-30_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001614"
      unitRef="USD">6287000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001620"
      unitRef="USD">4805000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001622"
      unitRef="USD">4805000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001628"
      unitRef="USD">7631000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001630"
      unitRef="USD">7631000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001636">&lt;p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zgKnSyBHpoMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
13: &lt;span id="xdx_821_zOwjbGkph6b8"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases office and lab facilities and other equipment under non-cancellable operating leases with initial terms typically ranging
from &lt;span id="xdx_906_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20240930__srt--RangeAxis__srt--MinimumMember_zqwBK1mnUDV8" title="Operating lease term"&gt;1&lt;/span&gt; to &lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20240930__srt--RangeAxis__srt--MaximumMember_zDUrzhch49s4" title="Operating lease term"&gt;5&lt;/span&gt; years, expiring at various dates during 2024 through 2027, and requiring monthly payments ranging from less than $&lt;span id="xdx_90B_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_z0n4pZ8k0RBi" title="Operating lease Payment"&gt;1,000&lt;/span&gt; to
$&lt;span id="xdx_904_eus-gaap--OperatingLeasePayments_pp0p0_c20240101__20240930__srt--RangeAxis__srt--MaximumMember_zn6gAKjYwXZa" title="Operating lease Payment"&gt;17,000&lt;/span&gt;. Certain leases include additional renewal options ranging from &lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20240930__srt--RangeAxis__srt--MinimumMember_zLNbeWAp0ADe" title="Operating lease term"&gt;1&lt;/span&gt; to &lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtY_c20240930__srt--RangeAxis__srt--MaximumMember_z7z7Q1pL5c9f" title="Operating lease term"&gt;5&lt;/span&gt; years. AIM has classified all of its leases as operating
leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
September 30, 2024 and December 31, 2023, the balance of the right of use assets was $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20240930_zRALP3AZf36j" title="Right of use asset"&gt;653,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20231231_zFPuPCMI2857" title="Right of use asset"&gt;697,000&lt;/span&gt;, respectively, and the corresponding
operating lease liability balance was $&lt;span id="xdx_906_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20240930_zEzgo2kCuqyb" title="Lease liability"&gt;669,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20231231_zXwnqwpVXCwc" title="Lease liability"&gt;718,000&lt;/span&gt;, respectively. Right of use assets are recorded net of accumulated amortization
of $&lt;span id="xdx_90D_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_pp0p0_c20240930_zWZmwuKDzSwh" title="Accumulated amortization"&gt;404,000&lt;/span&gt; and $&lt;span id="xdx_907_ecustom--OperationLeaseRightOfUseAssetAccumulatedAmortization_iI_pp0p0_c20231231_z8FNm7i71c9i" title="Accumulated amortization"&gt;363,000 &lt;/span&gt;as of September 30, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zjz1PFbiezc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AIM
recognized rent expense associated with these leases are follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zun1HQhN8Be1" style="display: none"&gt;Schedule of AIM Recognized Rent Expense Associated with Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240930_zTI3OTTC3hs3" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230930_zDEerU0nJsUd" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_z4nmxel6skb3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease costs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseCost_pn3n3_maLCzBan_zsdk9W45uZG6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;226&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;214&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzBan_zvageJeGouK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Short-term and variable lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_mtLCzBan_zZ6TvucId2ae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;467&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Classification of lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3pRw35uNfzi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Research &amp;amp; development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0Zk0RR1SeEd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_zpv8JbELhHWh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;467&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zP1336Ol7TIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s leases have remaining lease terms between &lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20240930__srt--RangeAxis__srt--MinimumMember_zHehfpZopOj9" title="Lessee, operating lease, remaining lease term"&gt;6&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20240930__srt--RangeAxis__srt--MaximumMember_zXMllmtef8j9" title="Lessee, operating lease, remaining lease term"&gt;35&lt;/span&gt; months. At September 30, 2024, the weighted-average remaining term
was &lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240930_zduiQC1TIYp4" title="Operating lease, weighted average remaining lease term"&gt;32&lt;/span&gt; months. At December 31, 2023, the weighted-average remaining term was &lt;span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20231231_ze6WAzQMLW97" title="Lessee, operating lease, remaining lease term"&gt;41&lt;/span&gt; months. The Company&#x2019;s weighted average incremental
borrowing rate for its leases was &lt;span id="xdx_90B_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20240930_zvandRUOlQn7" title="Debt, weighted average interest rate"&gt;10.2&lt;/span&gt;% at September 30, 2024 and &lt;span id="xdx_90B_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_dp_uPure_c20231231_zaCkvHD1PB38" title="Debt, weighted average interest rate"&gt;10&lt;/span&gt;% at December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zK8RbzJr9QNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments as of September 30, 2024, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zttuDYqICJa1" style="display: none"&gt;Schedule of Operating Lease Future Payments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Year Ending December 31, &lt;br/&gt;
(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240930_zfOCBbh5b624" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_zo2ACskIj2Qi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zS98VF0BHrU2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zdqBlEQ5CUp8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_zNiQ2sSMMXGg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pn3n3_zCshRWIxwxm3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1707"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_di_z50YeeiL5h9e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(88&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zCm8nqEVfErg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;669&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AB_zAxPU8YUGbll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="AsOf2024-09-30_srt_MinimumMember"
      id="Fact001638">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="AsOf2024-09-30_srt_MaximumMember"
      id="Fact001640">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-012024-09-30_srt_MinimumMember"
      decimals="0"
      id="Fact001642"
      unitRef="USD">1000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-012024-09-30_srt_MaximumMember"
      decimals="0"
      id="Fact001644"
      unitRef="USD">17000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="AsOf2024-09-30_srt_MinimumMember"
      id="Fact001646">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="AsOf2024-09-30_srt_MaximumMember"
      id="Fact001648">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001650"
      unitRef="USD">653000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001652"
      unitRef="USD">697000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001654"
      unitRef="USD">669000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001656"
      unitRef="USD">718000</us-gaap:OperatingLeaseLiability>
    <AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001658"
      unitRef="USD">404000</AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization>
    <AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001660"
      unitRef="USD">363000</AIM:OperationLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001662">&lt;p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zjz1PFbiezc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AIM
recognized rent expense associated with these leases are follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zun1HQhN8Be1" style="display: none"&gt;Schedule of AIM Recognized Rent Expense Associated with Operating Lease&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20240930_zTI3OTTC3hs3" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230930_zDEerU0nJsUd" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LeaseCostAbstract_iB_z4nmxel6skb3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease costs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseCost_pn3n3_maLCzBan_zsdk9W45uZG6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;226&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;214&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ShortTermLeaseCost_pn3n3_maLCzBan_zvageJeGouK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Short-term and variable lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_mtLCzBan_zZ6TvucId2ae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Total lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;467&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Classification of lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z3pRw35uNfzi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Research &amp;amp; development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z0Zk0RR1SeEd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_zpv8JbELhHWh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;467&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001667"
      unitRef="USD">226000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact001668"
      unitRef="USD">214000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001670"
      unitRef="USD">205000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact001671"
      unitRef="USD">253000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001673"
      unitRef="USD">431000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact001674"
      unitRef="USD">467000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact001676"
      unitRef="USD">358000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact001677"
      unitRef="USD">400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001679"
      unitRef="USD">73000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001680"
      unitRef="USD">67000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-09-30"
      decimals="-3"
      id="Fact001682"
      unitRef="USD">431000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-09-30"
      decimals="-3"
      id="Fact001683"
      unitRef="USD">467000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2024-09-30_srt_MinimumMember"
      id="Fact001685">P6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2024-09-30_srt_MaximumMember"
      id="Fact001687">P35M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-09-30" id="Fact001689">P32M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2023-12-31" id="Fact001691">P41M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001693"
      unitRef="Pure">0.102</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001695"
      unitRef="Pure">0.10</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001697">&lt;p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zK8RbzJr9QNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
minimum payments as of September 30, 2024, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zttuDYqICJa1" style="display: none"&gt;Schedule of Operating Lease Future Payments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Year Ending December 31, &lt;br/&gt;
(in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240930_zfOCBbh5b624" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_zo2ACskIj2Qi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;78&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_zS98VF0BHrU2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_zdqBlEQ5CUp8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_zNiQ2sSMMXGg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pn3n3_zCshRWIxwxm3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1707"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_di_z50YeeiL5h9e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(88&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zCm8nqEVfErg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;669&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001699"
      unitRef="USD">78000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001701"
      unitRef="USD">276000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001703"
      unitRef="USD">244000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001705"
      unitRef="USD">159000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001709"
      unitRef="USD">88000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001711"
      unitRef="USD">669000</us-gaap:OperatingLeaseLiability>
    <AIM:ResearchConsultingAndSupplyAgreementsTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001713">&lt;p id="xdx_80F_ecustom--ResearchConsultingAndSupplyAgreementsTextBlock_z4IcQw1sEmy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
14: &lt;span id="xdx_829_zWLDangXpff6"&gt;Research, Consulting and Supply Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into research, consulting and supply agreements with third party service providers to perform research and development
activities on therapeutics, including clinical trials. The identification of research and development costs involves reviewing open contracts
and purchase orders, communicating with applicable company and third-party personnel to identify services that have been performed, and
corroborating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced
or otherwise notified of actual expenses. The Company expenses these research and development costs when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2024, research and development expenses were comprised of: clinical studies ($&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zTk3z4c27k03" title="Research and development expense"&gt;582,000&lt;/span&gt;), manufacturing
and engineering ($&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zACVIeWesRCb" title="Research and development expense"&gt;306,000&lt;/span&gt;), quality control ($&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__srt--ProductOrServiceAxis__custom--QualityControlMember_zivZgJJgb9ob" title="Research and development expense"&gt;398,000&lt;/span&gt;) and regulatory ($&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20240701__20240930__srt--ProductOrServiceAxis__custom--RegulatoryMember_zkQFYesVWaq6" title="Research and development expense"&gt;151,000&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three months ended September 30, 2023, research and development expenses were comprised of: clinical studies ($&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zQNh5kq4Z2e7" title="Research and development expense"&gt;1,916,000&lt;/span&gt;), manufacturing
and engineering ($&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zupUCNY2Trl5" title="Research and development expense"&gt;396,000&lt;/span&gt;), quality control ($&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__srt--ProductOrServiceAxis__custom--QualityControlMember_z8P3FwA2w4Gh" title="Research and development expense"&gt;251,000&lt;/span&gt;) and regulatory ($&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__srt--ProductOrServiceAxis__custom--RegulatoryMember_zpuXm6pGKq38" title="Research and development expense"&gt;170,000&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2024, research and development expenses were comprised of: clinical studies ($&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_z2D4Vsoc5GVb" title="Research and development expense"&gt;1,880,000&lt;/span&gt;), manufacturing
and engineering ($&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zQpvr0yAVnCl" title="Research and development expense"&gt;882,000&lt;/span&gt;), quality control ($&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__srt--ProductOrServiceAxis__custom--QualityControlMember_zR24LXVpVcKd" title="Research and development expense"&gt;1,232,000&lt;/span&gt;) and regulatory ($&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__srt--ProductOrServiceAxis__custom--RegulatoryMember_znM5pgBoWe8g" title="Research and development expense"&gt;540,000&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2023, research and development expenses were comprised of: clinical studies ($&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__srt--ProductOrServiceAxis__custom--ClinicalStudiesMember_zFVEJM3kuco8" title="Research and development expense"&gt;3,845,000&lt;/span&gt;), manufacturing
and engineering ($&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__srt--ProductOrServiceAxis__custom--ManufacturingAndEngineeringMember_zMC20vz8K0Hb" title="Research and development expense"&gt;2,783,000&lt;/span&gt;), quality control ($&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__srt--ProductOrServiceAxis__custom--QualityControlMember_zaikd6VzLOz3" title="Research and development expense"&gt;752,000&lt;/span&gt;) and regulatory ($&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__srt--ProductOrServiceAxis__custom--RegulatoryMember_zXXJOCSDxS4a" title="Research and development expense"&gt;359,000&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes the most substantial of our contracts relating to research, consulting, and supply costs for AIM as they related
to research and development costs for the nine months ended September 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Amarex
Clinical Research LLC&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amarex
is the principal administrator of several of AIM&#x2019;s largest clinical studies. AIM has multiple contracts with Amarex Clinical Research
LLC (&#x201c;Amarex&#x201d;). During the three months ended September 30, 2024 and 2023, the Company incurred approximately $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zJTgqcLWvxHc" title="Research and development expense"&gt;275,400&lt;/span&gt; and
$&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zNE78m7aQYr6" title="Research and development expense"&gt;516,284&lt;/span&gt;, respectively, related to these ongoing agreements. During the nine months ended September 30, 2024 and 2023, the Company
incurred approximately $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zXqFOIS9xQR3" title="Research and development expense"&gt;881,987&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zj1X3YFg2Lyg" title="Research and development expense"&gt;1,294,265&lt;/span&gt;, respectively, related to these ongoing agreements:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pancreatic
                                            Cancer - In April 2022, AIM executed a work order with Amarex pursuant to which Amarex is
                                            managing a Phase 2 clinical trial in locally advanced pancreatic cancer patients designated
                                            AMP-270. Per the work order, AIM anticipates that Amarex&#x2019;s management of the study
                                            will cost approximately $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pp0p0_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_z5DzZbNvoecl" title="Research and development expense excluding acquired in process cost"&gt;8,400,000&lt;/span&gt;. This estimate includes pass-through costs of approximately
                                            $&lt;span id="xdx_902_eus-gaap--DevelopmentCosts_pp0p0_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zLIDOqZK9X77" title="Development cost"&gt;1,000,000&lt;/span&gt; and excludes certain third-party and investigator costs and escalations necessary
                                            for study completion. AIM anticipates that the study will take approximately &lt;span id="xdx_904_ecustom--ResearchAndDevelopmentExpenseCostEstimatedLives_dtY_c20220401__20220430__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zzyuOSUiuroh" title="Estimated lives"&gt;4.6&lt;/span&gt; years to
                                            complete.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the three months ended September 30, 2024, the Company incurred approximately $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_zPMxjNbFMZJh" title="Research and development expense"&gt;129,000&lt;/span&gt; related
                                            to this agreement. &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the three months ended September 30, 2023, the Company incurred approximately $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_zfeeqhHOLYG5" title="Research and development expense"&gt;82,600&lt;/span&gt; related
                                            to this agreement.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the nine months ended September 30, 2024, the Company incurred approximately $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_zG31AwmZq5P3" title="Research and development expense"&gt;141,100&lt;/span&gt; related
                                            to this agreement. &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the nine months ended September 30, 2023, the Company incurred approximately $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--AdvancedPancreaticCancerStudyAgreementMember_z1q1nkd6jsp5" title="Research and development expense"&gt;350,600&lt;/span&gt; related
                                            to this agreement.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Post-COVID
                                            Conditions - In September 2022, AIM executed a work order with Amarex, pursuant to which
                                            Amarex is managing a Phase 2 trial in patients with Post-COVID Conditions. AIM is sponsoring
                                            the study. AIM anticipates that the study will cost approximately $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pp0p0_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zfZAe3tyMpIh"&gt;6,400,000&lt;/span&gt;, which includes
                                            pass through costs of approximately $&lt;span id="xdx_900_eus-gaap--DevelopmentCosts_pp0p0_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zEBQi3GwnBJ7" title="Development cost"&gt;125,000&lt;/span&gt;, investigator costs estimated at about $&lt;span id="xdx_902_eus-gaap--CostMaintenance_pp0p0_c20220901__20220930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zxvPX41gZc06" title="Invigilators cost"&gt;4,400,000&lt;/span&gt;
                                            and excludes certain other third-party costs and escalations. During 2023, the original work
                                            order increased to approximately $&lt;span id="xdx_90C_eus-gaap--DevelopmentCosts_pp0p0_c20230101__20231231__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember_zqNQf0sVXvN7" title="Development cost"&gt;6,600,000&lt;/span&gt; for the addition of patient reported outcome
                                            (PRO) electronic questionnaires (devices/tablets for patients to complete); services associated
                                            with the ePRO system and additional safety monitoring services as well as changes to study
                                            documentation (such as protocol amendments) which resulted in additional IND submissions
                                            to FDA. This study was completed in 2023, although certain activities are still ongoing.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the three months ended September 30, 2024, the Company incurred approximately $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zzwC0omYI5Fk" title="Research and development expense"&gt;27,500&lt;/span&gt; related
                                            to this agreement. During
                                            the three months ended September 30, 2023, the Company incurred approximately $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zKfmtSA1QyB7" title="Research and development expense"&gt;447,600&lt;/span&gt; related
                                            to this agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the nine months ended September 30, 2024, the Company incurred approximately $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zUAvqKyWhV9d" title="Research and development expense"&gt;195,800&lt;/span&gt; related
                                            to this agreement. During
                                            the nine months ended September 30, 2023, the Company incurred approximately $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AmarexClinicalResearchLLCMember__us-gaap--TypeOfArrangementAxis__custom--PostCOVIDStudyAgreementMember_zkZx6pQrBXF9" title="Research and development expense"&gt;783,400&lt;/span&gt; related
                                            to this agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Jubilant HollisterStier&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Jubilant HollisterStier (&#x201c;Jubilant&#x201d;)
is AIM&#x2019;s authorized CMO for Ampligen for the approval in Argentina. In 2017, the Company entered into an agreement with Jubilant
pursuant to which Jubilant will manufacture batches of Ampligen&#xae; for the Company. Since the 2017 engagement of Jubilant, two lots
of Ampligen consisting of more than &lt;span id="xdx_906_ecustom--UnitsManufactured_uInteger_c20170101__20171231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_zUcdr5GVZmk8" title="Number of units manufactured"&gt;16,000&lt;/span&gt; units were manufactured and released in the year 2018. The first lot was designated for human
use in the United States in the cost recovery CFS program and for expanded oncology clinical trials. The second lot has been designated
for these programs in addition to commercial distribution in Argentina for the treatment of CFS. Jubilant manufactured additional two
lots of Ampligen in December 2019 and January 2020. In December 2023, Jubilant completed manufacturing of &lt;span id="xdx_901_ecustom--NumberOfVials_uInteger_c20230101__20231231__dei--LegalEntityAxis__custom--JubilantHollisterStierMember_z4T5Sy2GSRu4" title="Additional number of vials"&gt;9,042&lt;/span&gt; vials of Ampligen for
clinical use.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the three months ended September 30, 2024, the Company did &lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20240701__20240930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zd7Xy1vOyrR6" title="Research and development expense"&gt;no&lt;/span&gt;t incur any expense related
                                            to this agreement. During
                                            the three months ended September 30, 2023, the Company did &lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zT4YJsfc8UBf" title="Research and development expense"&gt;no&lt;/span&gt;t incur any expense related
                                            to this agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the nine months ended September 30, 2024, the Company incurred approximately $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zr5aN8UyKlA2" title="Research and development expense"&gt;1,200&lt;/span&gt; related
                                            to this agreement.&lt;/span&gt; During
                                            the nine months ended September 30, 2023, the Company incurred approximately $&lt;span id="xdx_901_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--JubilantHollisterStierMember__us-gaap--TypeOfArrangementAxis__custom--AmpligenManufacturingAgreementMember_zA9ohgAhx0ck" title="Research and development expense"&gt;1,432,000&lt;/span&gt; related
                                            to this agreement.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Sterling
Pharma Solutions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2022, the Company entered into a Master Service Agreement and a Quality Agreement with Sterling Pharma Solutions (&#x201c;Sterling&#x201d;)
for the manufacture of the Company&#x2019;s Poly I and Poly C12U polynucleotides and transfer of associated test methods at Sterling&#x2019;s
Dudley, UK location to produce the polymer precursors to manufacture the drug Ampligen.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the three months ended September 30, 2024, the Company incurred approximately $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_z7DbKXwdCOX4" title="Research and development expense"&gt;133,000&lt;/span&gt; related
                                            to this agreement. During
                                            the three months ended September 30, 2023, the Company did &lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zE56Y1J9FBpf" title="Research and development expense"&gt;no&lt;/span&gt;t incur any expense related
                                            to this agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the nine months ended September 30, 2024, the Company incurred approximately $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_z5JuugVYuFfk" title="Research and development expense"&gt;261,600&lt;/span&gt; related
                                            to this agreement. During
                                            the nine months ended September 30, 2023, the Company incurred approximately $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--SterlingPharmaSolutionsMember__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementAndQualityAgreementMember_zuA6kpr77eg2" title="Research and development expense"&gt;357,000&lt;/span&gt; related
                                            to this agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Erasmus&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2022, the Company entered into a joint clinical study agreement with Erasmus University Medical Center Rotterdam to conduct
a Phase II study: Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic
pancreatic ductal adenocarcinoma for therapy efficacy. This is a study in collaboration with AstraZeneca. AIM&#x2019;s limited responsibilities
are limited to providing Ampligen. Additionally, in April 2023 AIM agreed to provide to Erasmus MC an unrestricted grant of $&lt;span id="xdx_903_eus-gaap--SuppliesExpense_pp0p0_c20230401__20230430__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_z7O3hYhkXxHk" title="Unrestricted grants"&gt;200,000&lt;/span&gt;
for immune monitoring in pancreatic cancer patients.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the three months ended September 30, 2024, the Company did &lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20240701__20240930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_ziXn8oDJb23l" title="Research and development expense"&gt;no&lt;/span&gt;t incur any expense related
                                            to this agreement. &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the three months ended September 30, 2023, the Company did &lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zaxmqBcY8vRl" title="Research and development expense"&gt;no&lt;/span&gt;t incur any expense related
                                            to this agreement.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the nine months ended September 30, 2024, the Company incurred approximately $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zk7nDOkwB5Zg" title="Research and development expense"&gt;79,000&lt;/span&gt; related
                                            to this agreement. &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the nine months ended September 30, 2023, the Company incurred approximately $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--ErasmusUniversityMedicalCenterMember__us-gaap--TypeOfArrangementAxis__custom--JointClinicalStudyAgreementMember_zajwWSFsXS9g" title="Research and development expense"&gt;100,000&lt;/span&gt; related
                                            to this agreement.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Azenova
Sales International&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2023, the Company entered into a consulting agreement with Azenova, LLC whereas Azenova will provide business development
services for AIM&#x2019;s Ampligen product for solid tumors for a 12-month term that is extendable upon the agreement of the parties.
In exchange for its services, Azenova will receive a fixed monthly retainer of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pp0p0_c20231031__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zERemEyApHXh" title="Stock options, aggregate intrinsic value"&gt;30,000&lt;/span&gt;
per month in addition to &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pp0p0_c20231031__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z5z9qgncyonk" title="Stock options, vested"&gt;360,000&lt;/span&gt;
stock options that vest monthly. In August 2024, an agreement was made to reduce the fixed monthly retainer fee to $&lt;span id="xdx_906_ecustom--MonthlyRetainerFee_pp0p0_c20240801__20240831__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zIfgDHoAayy7" title="Monthly retainer fee"&gt;10,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the three months ended September 30, 2024, the Company incurred approximately $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zw3TeYRvVbif" title="Research and development expense"&gt;50,000&lt;/span&gt; related
                                            to this agreement. During
                                            the three months ended September 30, 2023, the Company did &lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230701__20230930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zHDu2ilh8y6l" title="Research and development expense"&gt;no&lt;/span&gt;t incur any expense related
                                            to this agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the nine months ended September 30, 2024, the Company incurred approximately $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zyLJ2J5JZ1sg" title="Research and development expense"&gt;230,000&lt;/span&gt; related
                                            to this agreement. During
                                            the nine months ended September 30, 2023, the Company did &lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_do_c20230101__20230930__dei--LegalEntityAxis__custom--AzenovaLLCMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zPsV8praX1a3" title="Research and development expense"&gt;no&lt;/span&gt;t incur any expense related to
                                            this agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Alcami&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2023, the Company entered into an agreement with Alcami Corporation to perform an extractables study for a primary packaging
component. The agreement called for fixed costs of approximately $&lt;span id="xdx_903_eus-gaap--ProductionCosts_pp0p0_c20230901__20230930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_zWWl9oaMHjB7" title="Research and development expense"&gt;30,000&lt;/span&gt; upon completion of the study and issue of the final report,
along with solvent costs, and pass through items to be billed on a per activity basis. The final bill for the initial study was received
in December 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#x25cb;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;During
the three months ended September 30, 2024, the Company did &lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20240930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_zJ6NGjhJCKs6"&gt;no&lt;/span&gt;t
incur any expense for lab services from Alcami. &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the three months ended September 30, 2023, the Company incurred approximately $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20230930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_zjdPb2zWY2n7" title="Research and development expense"&gt;8,800&lt;/span&gt; of lab
                                            services from Alcami.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
                                                                                  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cb;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
                                            the nine months ended September 30, 2024, the Company incurred approximately $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240101__20240930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_ztSYpQQ3uOOc" title="Research and development expense"&gt;14,000&lt;/span&gt; of lab
                                            services from Alcami. During
                                            the nine months ended September 30, 2023, the Company incurred approximately $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930__dei--LegalEntityAxis__custom--AlcamiCorporationMember_zo2yiiwwdb8g" title="Research and development expense"&gt;25,000&lt;/span&gt; of lab
                                            services from Alcami.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: -0.25in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

</AIM:ResearchConsultingAndSupplyAgreementsTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_ClinicalStudiesMember"
      decimals="0"
      id="Fact001715"
      unitRef="USD">582000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_ManufacturingAndEngineeringMember"
      decimals="0"
      id="Fact001717"
      unitRef="USD">306000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_QualityControlMember"
      decimals="0"
      id="Fact001719"
      unitRef="USD">398000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_RegulatoryMember"
      decimals="0"
      id="Fact001721"
      unitRef="USD">151000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_ClinicalStudiesMember"
      decimals="0"
      id="Fact001723"
      unitRef="USD">1916000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_ManufacturingAndEngineeringMember"
      decimals="0"
      id="Fact001725"
      unitRef="USD">396000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_QualityControlMember"
      decimals="0"
      id="Fact001727"
      unitRef="USD">251000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_RegulatoryMember"
      decimals="0"
      id="Fact001729"
      unitRef="USD">170000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_ClinicalStudiesMember"
      decimals="0"
      id="Fact001731"
      unitRef="USD">1880000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_ManufacturingAndEngineeringMember"
      decimals="0"
      id="Fact001733"
      unitRef="USD">882000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_QualityControlMember"
      decimals="0"
      id="Fact001735"
      unitRef="USD">1232000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_RegulatoryMember"
      decimals="0"
      id="Fact001737"
      unitRef="USD">540000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_ClinicalStudiesMember"
      decimals="0"
      id="Fact001739"
      unitRef="USD">3845000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_ManufacturingAndEngineeringMember"
      decimals="0"
      id="Fact001741"
      unitRef="USD">2783000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_QualityControlMember"
      decimals="0"
      id="Fact001743"
      unitRef="USD">752000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_RegulatoryMember"
      decimals="0"
      id="Fact001745"
      unitRef="USD">359000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001747"
      unitRef="USD">275400</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001749"
      unitRef="USD">516284</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001751"
      unitRef="USD">881987</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001753"
      unitRef="USD">1294265</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001755"
      unitRef="USD">8400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:DevelopmentCosts
      contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001757"
      unitRef="USD">1000000</us-gaap:DevelopmentCosts>
    <AIM:ResearchAndDevelopmentExpenseCostEstimatedLives
      contextRef="From2022-04-012022-04-30_custom_AmarexClinicalResearchLLCMember"
      id="Fact001759">P4Y7M6D</AIM:ResearchAndDevelopmentExpenseCostEstimatedLives>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember"
      decimals="0"
      id="Fact001761"
      unitRef="USD">129000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember"
      decimals="0"
      id="Fact001763"
      unitRef="USD">82600</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember"
      decimals="0"
      id="Fact001765"
      unitRef="USD">141100</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_AdvancedPancreaticCancerStudyAgreementMember"
      decimals="0"
      id="Fact001767"
      unitRef="USD">350600</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001768"
      unitRef="USD">6400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:DevelopmentCosts
      contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001770"
      unitRef="USD">125000</us-gaap:DevelopmentCosts>
    <us-gaap:CostMaintenance
      contextRef="From2022-09-012022-09-30_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001772"
      unitRef="USD">4400000</us-gaap:CostMaintenance>
    <us-gaap:DevelopmentCosts
      contextRef="From2023-01-012023-12-31_custom_AmarexClinicalResearchLLCMember"
      decimals="0"
      id="Fact001774"
      unitRef="USD">6600000</us-gaap:DevelopmentCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember"
      decimals="0"
      id="Fact001776"
      unitRef="USD">27500</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember"
      decimals="0"
      id="Fact001778"
      unitRef="USD">447600</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember"
      decimals="0"
      id="Fact001780"
      unitRef="USD">195800</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_AmarexClinicalResearchLLCMember_custom_PostCOVIDStudyAgreementMember"
      decimals="0"
      id="Fact001782"
      unitRef="USD">783400</us-gaap:ResearchAndDevelopmentExpense>
    <AIM:UnitsManufactured
      contextRef="From2017-01-012017-12-31_custom_JubilantHollisterStierMember"
      decimals="INF"
      id="Fact001784"
      unitRef="Integer">16000</AIM:UnitsManufactured>
    <AIM:NumberOfVials
      contextRef="From2023-01-012023-12-31_custom_JubilantHollisterStierMember"
      decimals="INF"
      id="Fact001786"
      unitRef="Integer">9042</AIM:NumberOfVials>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember"
      decimals="0"
      id="Fact001788"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember"
      decimals="0"
      id="Fact001790"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember"
      decimals="0"
      id="Fact001792"
      unitRef="USD">1200</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_JubilantHollisterStierMember_custom_AmpligenManufacturingAgreementMember"
      decimals="0"
      id="Fact001794"
      unitRef="USD">1432000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember"
      decimals="0"
      id="Fact001796"
      unitRef="USD">133000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember"
      decimals="0"
      id="Fact001798"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember"
      decimals="0"
      id="Fact001800"
      unitRef="USD">261600</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_SterlingPharmaSolutionsMember_custom_MasterServiceAgreementAndQualityAgreementMember"
      decimals="0"
      id="Fact001802"
      unitRef="USD">357000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SuppliesExpense
      contextRef="From2023-04-012023-04-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember"
      decimals="0"
      id="Fact001804"
      unitRef="USD">200000</us-gaap:SuppliesExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember"
      decimals="0"
      id="Fact001806"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember"
      decimals="0"
      id="Fact001808"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember"
      decimals="0"
      id="Fact001810"
      unitRef="USD">79000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_ErasmusUniversityMedicalCenterMember_custom_JointClinicalStudyAgreementMember"
      decimals="0"
      id="Fact001812"
      unitRef="USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2023-10-31_custom_AzenovaLLCMember_custom_ConsultingAgreementMember"
      decimals="0"
      id="Fact001814"
      unitRef="USD">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-10-31_custom_AzenovaLLCMember_custom_ConsultingAgreementMember"
      decimals="0"
      id="Fact001816"
      unitRef="Shares">360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <AIM:MonthlyRetainerFee
      contextRef="From2024-08-012024-08-31_custom_AzenovaLLCMember_custom_ConsultingAgreementMember"
      decimals="0"
      id="Fact001818"
      unitRef="USD">10000</AIM:MonthlyRetainerFee>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember"
      decimals="0"
      id="Fact001820"
      unitRef="USD">50000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember"
      decimals="0"
      id="Fact001822"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember"
      decimals="0"
      id="Fact001824"
      unitRef="USD">230000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_AzenovaLLCMember_custom_ConsultingAgreementMember"
      decimals="0"
      id="Fact001826"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProductionCosts
      contextRef="From2023-09-012023-09-30_custom_AlcamiCorporationMember"
      decimals="0"
      id="Fact001828"
      unitRef="USD">30000</us-gaap:ProductionCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_AlcamiCorporationMember"
      decimals="0"
      id="Fact001831"
      unitRef="USD">8800</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_AlcamiCorporationMember"
      decimals="0"
      id="Fact001833"
      unitRef="USD">14000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_AlcamiCorporationMember"
      decimals="0"
      id="Fact001835"
      unitRef="USD">25000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact001837">&lt;p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zaJ6SoNeqCx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
15: &lt;span id="xdx_82B_zbBx8nigwpTe"&gt;Subsequent Events&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 30, 2024, the Company entered into a Securities Purchase Agreement (the &#x201c;&lt;span style="text-decoration: underline"&gt;Purchase Agreement&lt;/span&gt;&#x201d;) to complete
an offering (the &#x201c;&lt;span style="text-decoration: underline"&gt;Transactions&lt;/span&gt;&#x201d;) with a single accredited investor (the &#x201c;&lt;span style="text-decoration: underline"&gt;Purchaser&lt;/span&gt;&#x201d;). The Transactions
closed on October 1, 2024. Pursuant to the Purchase Agreement, at closing, the Company issued to the Purchaser, (i) in a registered
direct offering, &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zx00GvBaYtf8" title="Number of shares issued upon transaction"&gt;4,653,036&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;&lt;span style="text-decoration: underline"&gt;Shares&lt;/span&gt;&#x201d;), par value $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoVgIkZB8Qn1" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share (&#x201c;&lt;span style="text-decoration: underline"&gt;Common
Stock&lt;/span&gt;&#x201d;); and (ii) in a concurrent private placement, the Company issued to the Purchaser Class C common warrants to purchase
an aggregate of up to &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2scs6y8z3O1" title="Number of shares issued upon transaction"&gt;4,653,036&lt;/span&gt; shares of its Common Stock (the &#x201c;&lt;span style="text-decoration: underline"&gt;C Warrants&lt;/span&gt;&#x201d;) at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGzc24PkOgwj" title="Exercise price"&gt;0.28&lt;/span&gt; per share
and Class D common warrants to purchase an aggregate of up to &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassDCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOmoY0HHQ79h" title="Number of shares issued upon transaction"&gt;4,653,036&lt;/span&gt; shares of its Common Stock (the &#x201c;&lt;span style="text-decoration: underline"&gt;D Warrants&lt;/span&gt;&#x201d;
and, along with the C Warrants, the &#x201c;&lt;span style="text-decoration: underline"&gt;Common Warrants&lt;/span&gt;&#x201d;) at an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--ClassDCommonWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpvPwH27tzRc" title="Exercise price"&gt;0.28&lt;/span&gt; per share. The C Warrants and
D Warrants will not be exercisable for six months after the issuance date and will expire, respectively, 24 months and five years and
six months after the issuance date. The Common Warrants and the shares of Common Stock issuable upon the exercise of such warrants were
offered pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the &#x201c;&lt;span style="text-decoration: underline"&gt;Securities
Act&lt;/span&gt;&#x201d;), provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company received aggregate gross proceeds from the Transactions of approximately $&lt;span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_pn4n6_c20241001__20241001__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhwL3YQEkmcf" title="Grosss proceeds"&gt;1.26&lt;/span&gt; million, before deducting fees to the Placement
Agent and other estimated offering expenses payable by the Company. The shares underlying the Common Warrants are being offered by the
Company pursuant to a shelf registration statement on Form S-3 (File No. 333-262280), which was declared effective on February 4, 2022
(as amended from time to time, the &#x201c;&lt;span style="text-decoration: underline"&gt;Registration Statement&lt;/span&gt;&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the terms of the Purchase Agreement, subject to certain exceptions, the Company cannot issue any equity securities for 60 days following
the closing of the Transactions (the &#x201c;&lt;span style="text-decoration: underline"&gt;Closing Date&lt;/span&gt;&#x201d;), provided that the Company will be able to utilize it&#x2019;s
at-the-market offering (the &#x201c;&lt;span style="text-decoration: underline"&gt;ATM&lt;/span&gt;&#x201d;) program with the Placement Agent after 30 days. Additionally, the Company cannot
enter into a variable rate transaction (other than the ATM program with the Placement Agent) for 120 days after the Closing Date. In
addition, the Company&#x2019;s executive officers and each of the Company&#x2019;s directors have entered into lock-up agreements with
the Company pursuant to which each of them has agreed not to, for a period of 90 days from the Closing Date, offer, sell, transfer or
otherwise dispose of the Company&#x2019;s securities, subject to certain exceptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise price of the Common Warrants, and the number of shares of Common Stock underling the Common Warrant (the &#x201c;&lt;span style="text-decoration: underline"&gt;Common Warrant
Shares&lt;/span&gt;&#x201d;) will be subject to adjustment in the event of any stock dividend or split, reverse stock split, recapitalization,
reorganization or similar transaction, as described in the Common Warrants. If a Fundamental Transaction (as defined in the Common Warrants)
occurs, then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the
Company may exercise and will assume all of its obligations under the Common Warrants with the same effect as if such successor entity
had been named in the warrant itself. Common Warrant Holders will have additional rights defined in the Common Warrants. The Common Warrants
will be exercisable on a &#x201c;cashless&#x201d; basis only if there is not a current registration statement permitting public resale.
In this regard, the Company has agreed to file a registration statement to register the resale of the Common Warrant Shares as soon as
practicable (and in any event within 45 calendar days of the date of the Purchase Agreement) providing for the resale of the Shares issued
and issuable upon exercise of the Common Warrants. The Company has agreed to use commercially reasonable efforts to cause such registration statement to become effective within 181 days
following the Closing Date and to keep such registration statement effective at all times
until no Purchaser owns any Common Warrants or Common Warrant Shares issuable upon exercise thereof.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is currently evaluating the Common Warrants under the guidance of ASC 480 &#x2013; Distinguishing Liabilities from Equity&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-012024-10-01_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001839"
      unitRef="Shares">4653036</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-10-01_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001841"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-012024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassCCommonWarrantMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001843"
      unitRef="Shares">4653036</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassCCommonWarrantMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001845"
      unitRef="USDPShares">0.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-012024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassDCommonWarrantMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001847"
      unitRef="Shares">4653036</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-10-01_custom_SecuritiesPurchaseAgreementMember_custom_ClassDCommonWarrantMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001849"
      unitRef="USDPShares">0.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-10-012024-10-01_us-gaap_SubsequentEventMember"
      decimals="-4"
      id="Fact001851"
      unitRef="USD">1260000</us-gaap:ProceedsFromWarrantExercises>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
